Torsade	2	B-Disease
de	2	I-Disease
pointes	5	I-Disease
ventricular	5	B-Disease
tachycardia	5	I-Disease
during	5	O
low	9	O
dose	9	O
intermittent	5	O
dobutamine	5	B-Chemical
treatment	9	O
in	5	O
a	5	O
patient	5	O
with	5	O
dilated	5	B-Disease
cardiomyopathy	5	I-Disease
and	5	O
congestive	5	B-Disease
heart	5	I-Disease
failure	5	I-Disease
.	9	O

The	5	O
authors	5	O
describe	5	O
the	5	O
case	5	O
of	5	O
a	5	O
56	7	O
-	7	O
year	5	O
-	7	O
old	5	O
woman	5	O
with	5	O
chronic	5	O
,	9	O
severe	5	O
heart	5	B-Disease
failure	5	I-Disease
secondary	9	O
to	5	O
dilated	5	B-Disease
cardiomyopathy	5	I-Disease
and	5	O
absence	3	O
of	5	O
significant	9	O
ventricular	5	B-Disease
arrhythmias	5	I-Disease
who	5	O
developed	5	O
QT	5	B-Disease
prolongation	9	I-Disease
and	5	O
torsade	5	B-Disease
de	2	I-Disease
pointes	5	I-Disease
ventricular	5	B-Disease
tachycardia	5	I-Disease
during	5	O
one	5	O
cycle	9	O
of	5	O
intermittent	5	O
low	9	O
dose	9	O
(	9	O
2	9	O
.	9	O
5	9	O
mcg	0	O
/	9	O
kg	0	O
per	9	O
min	0	O
)	9	O
dobutamine	5	B-Chemical
.	9	O

This	5	O
report	5	O
of	5	O
torsade	5	B-Disease
de	2	I-Disease
pointes	5	I-Disease
ventricular	5	B-Disease
tachycardia	5	I-Disease
during	5	O
intermittent	5	O
dobutamine	5	B-Chemical
supports	9	O
the	5	O
hypothesis	9	O
that	5	O
unpredictable	5	O
fatal	5	O
arrhythmias	5	B-Disease
may	5	O
occur	5	O
even	5	O
with	5	O
low	9	O
doses	0	O
and	5	O
in	5	O
patients	5	O
with	5	O
no	9	O
history	5	O
of	5	O
significant	9	O
rhythm	5	O
disturbances	5	O
.	9	O

The	5	O
mechanisms	9	O
of	5	O
proarrhythmic	5	O
effects	9	O
of	5	O
Dubutamine	_	B-Chemical
are	5	O
discussed	5	O
.	9	O

Positive	7	O
skin	5	O
tests	5	O
in	5	O
late	9	O
reactions	9	O
to	5	O
radiographic	5	O
contrast	9	B-Chemical
media	9	I-Chemical
.	9	O

In	9	O
the	5	O
last	5	O
few	5	O
years	5	O
delayed	9	O
reactions	9	O
several	9	O
hours	9	O
after	9	O
the	5	O
injection	9	O
of	5	O
radiographic	5	O
and	5	O
contrast	9	B-Chemical
materials	5	I-Chemical
(	9	O
PRC	9	B-Chemical
)	9	O
have	5	O
been	9	O
described	9	O
with	5	O
increasing	9	O
frequency	5	O
.	9	O

The	5	O
authors	5	O
report	5	O
two	5	O
observations	9	O
on	5	O
patients	5	O
with	5	O
delayed	9	O
reactions	9	O
in	5	O
whom	5	O
intradermoreactions	_	O
(	9	O
IDR	5	O
)	9	O
and	5	O
patch	5	O
tests	5	O
to	5	O
a	5	O
series	5	O
of	5	O
ionic	0	O
and	5	O
non	9	O
ionic	0	O
PRC	9	B-Chemical
were	9	O
studied	9	O
.	9	O

After	9	O
angiography	5	O
by	9	O
the	5	O
venous	5	O
route	5	O
in	5	O
patient	5	O
n	9	O
degree	5	O
1	9	O
a	5	O
biphasic	9	O
reaction	9	O
with	5	O
an	5	O
immediate	5	O
reaction	9	O
(	9	O
dyspnea	5	B-Disease
,	9	O
loss	9	B-Disease
of	5	I-Disease
consciousness	5	I-Disease
)	9	O
and	5	O
delayed	9	O
macro	5	B-Disease
-	7	I-Disease
papular	5	I-Disease
rash	5	I-Disease
appeared	9	O
,	9	O
whilst	9	O
patient	5	O
n	9	O
degree	5	O
2	9	O
developed	5	O
a	5	O
generalised	5	O
sensation	5	O
of	5	O
heat	9	O
,	9	O
persistent	5	O
pain	5	B-Disease
at	9	O
the	5	O
site	9	O
of	5	O
injection	9	O
immediately	9	O
and	5	O
a	5	O
generalised	5	O
macro	5	O
-	7	O
papular	5	O
reaction	9	O
after	9	O
24	9	O
hours	9	O
.	9	O

The	5	O
skin	5	O
tests	5	O
revealed	9	O
positive	9	O
delayed	9	O
reactions	9	O
of	5	O
24	9	O
hours	9	O
and	5	O
48	9	O
hours	9	O
by	9	O
IDR	5	O
and	5	O
patch	5	O
tests	5	O
to	5	O
only	9	O
some	5	O
PRC	9	B-Chemical
with	5	O
common	5	O
chains	9	O
in	5	O
their	5	O
structures	9	O
.	9	O

The	5	O
positive	9	O
skin	5	O
tests	5	O
are	5	O
in	5	O
favour	5	O
of	5	O
immunological	9	O
reactions	9	O
and	5	O
may	5	O
help	5	O
in	5	O
diagnosis	5	O
of	5	O
allergy	9	B-Disease
in	5	O
the	5	O
patients	5	O
.	9	O

Risk	5	O
of	5	O
transient	9	O
hyperammonemic	5	B-Disease
encephalopathy	5	I-Disease
in	5	O
cancer	3	B-Disease
patients	5	O
who	5	O
received	9	O
continuous	5	O
infusion	0	O
of	5	O
5	9	B-Chemical
-	7	I-Chemical
fluorouracil	0	I-Chemical
with	5	O
the	5	O
complication	5	O
of	5	O
dehydration	9	B-Disease
and	5	O
infection	9	B-Disease
.	9	O

From	5	O
1986	2	O
to	5	O
1998	2	O
,	9	O
29	7	O
cancer	3	B-Disease
patients	5	O
who	5	O
had	9	O
32	7	O
episodes	5	O
of	5	O
transient	9	O
hyperammonemic	5	B-Disease
encephalopathy	5	I-Disease
related	9	O
to	5	O
continuous	5	O
infusion	0	O
of	5	O
5	9	B-Chemical
-	7	I-Chemical
fluorouracil	0	I-Chemical
(	9	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
)	9	O
were	9	O
identified	9	O
.	9	O

None	9	O
of	5	O
the	5	O
patients	5	O
had	9	O
decompensated	5	O
liver	9	B-Disease
disease	5	I-Disease
.	9	O

Onset	9	O
of	5	O
hyperammonemic	5	B-Disease
encephalopathy	5	I-Disease
varied	9	O
from	9	O
0	7	O
.	9	O
5	9	O
to	5	O
5	9	O
days	9	O
(	9	O
mean	5	O
:	9	O
2	9	O
.	9	O
6	9	O
+	9	O
/	9	O
-	7	O
1	9	O
.	9	O
3	9	O
days	9	O
)	9	O
after	9	O
the	5	O
initiation	9	O
of	5	O
chemotherapy	5	O
.	9	O

Plasma	0	O
ammonium	0	B-Chemical
level	9	O
ranged	9	O
from	9	O
248	7	O
to	5	O
2387	7	O
microg	0	O
%	9	O
(	9	O
mean	5	O
:	9	O
626	7	O
+	9	O
/	9	O
-	7	O
431	7	O
microg	0	O
%	9	O
)	9	O
.	9	O

Among	9	O
the	5	O
32	7	O
episodes	5	O
,	9	O
26	7	O
(	9	O
81	7	O
%	9	O
)	9	O
had	9	O
various	9	O
degrees	5	O
of	5	O
azotemia	5	B-Disease
,	9	O
18	7	O
(	9	O
56	7	O
%	9	O
)	9	O
occurred	9	O
during	5	O
bacterial	9	B-Disease
infections	5	I-Disease
and	5	O
14	7	O
(	9	O
44	7	O
%	9	O
)	9	O
without	9	O
infection	9	B-Disease
occurred	9	O
during	5	O
periods	5	O
of	5	O
dehydration	9	B-Disease
.	9	O

Higher	9	O
plasma	9	O
ammonium	0	B-Chemical
levels	3	O
and	5	O
more	5	O
rapid	5	O
onset	5	O
of	5	O
hyperammonemia	5	B-Disease
were	9	O
seen	9	O
in	5	O
18	7	O
patients	5	O
with	5	O
bacterial	9	B-Disease
infections	5	I-Disease
(	9	O
p	7	O
=	7	O
0	7	O
.	9	O
003	2	O
and	5	O
0	7	O
.	9	O
0006	7	O
,	9	O
respectively	9	O
)	9	O
and	5	O
in	5	O
nine	9	O
patients	5	O
receiving	9	O
high	9	O
daily	5	O
doses	0	O
(	9	O
2600	2	O
or	5	O
1800	9	O
mg	0	O
/	9	O
m2	7	O
)	9	O
of	5	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
(	9	O
p	7	O
=	7	O
0	7	O
.	9	O
0001	7	O
and	5	O
<	0	O
0	7	O
.	9	O
0001	7	O
,	9	O
respectively	9	O
)	9	O
.	9	O

In	9	O
25	9	O
out	9	O
of	5	O
32	7	O
episodes	5	O
(	9	O
78	7	O
%	9	O
)	9	O
,	9	O
plasma	9	O
ammonium	0	B-Chemical
levels	3	O
and	5	O
mental	5	O
status	9	O
returned	5	O
to	5	O
normal	9	O
within	9	O
2	9	O
days	9	O
after	9	O
adequate	5	O
management	5	O
.	9	O

In	9	O
conclusion	9	O
,	9	O
hyperammonemic	5	B-Disease
encephalopathy	5	I-Disease
can	5	O
occur	5	O
in	5	O
patients	5	O
receiving	9	O
continuous	5	O
infusion	0	O
of	5	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
.	9	O

Azotemia	7	B-Disease
,	9	O
body	5	O
fluid	5	O
insufficiency	9	O
and	5	O
bacterial	9	B-Disease
infections	5	I-Disease
were	9	O
frequently	5	O
found	9	O
in	5	O
these	5	O
patients	5	O
.	9	O

It	5	O
is	5	O
therefore	5	O
important	9	O
to	5	O
recognize	9	O
this	5	O
condition	5	O
in	5	O
patients	5	O
receiving	9	O
continuous	5	O
infusion	0	O
of	5	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
.	9	O

The	5	O
effects	9	O
of	5	O
quinine	0	B-Chemical
and	5	O
4	9	B-Chemical
-	7	I-Chemical
aminopyridine	0	I-Chemical
on	5	O
conditioned	9	O
place	5	O
preference	5	O
and	5	O
changes	9	O
in	5	O
motor	5	O
activity	9	O
induced	3	O
by	9	O
morphine	0	B-Chemical
in	5	O
rats	9	O
.	9	O

1	9	O
.	9	O

The	5	O
effects	9	O
of	5	O
two	5	O
unselective	0	O
potassium	0	B-Chemical
(	9	O
K	9	B-Chemical
(	9	O
+	9	O
)	9	O
-	7	O
)	9	O
channel	9	O
blockers	9	O
,	9	O
quinine	0	B-Chemical
(	9	O
12	9	O
.	9	O
5	9	O
,	9	O
25	9	O
and	5	O
50	0	O
mg	0	O
/	9	O
kg	0	O
)	9	O
and	5	O
4	9	B-Chemical
-	7	I-Chemical
aminopyridine	0	I-Chemical
(	9	O
1	9	O
and	5	O
2	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
,	9	O
on	5	O
conditioned	9	O
place	5	O
preference	5	O
and	5	O
biphasic	9	O
changes	9	O
in	5	O
motor	5	O
activity	9	O
induced	3	O
by	9	O
morphine	0	B-Chemical
(	9	O
10	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
were	9	O
tested	9	O
in	5	O
Wistar	9	O
rats	9	O
.	9	O

Quinine	0	B-Chemical
is	5	O
known	9	O
to	5	O
block	9	O
voltage	5	O
-	7	O
,	9	O
calcium	0	B-Chemical
-	7	O
and	5	O
ATP	0	B-Chemical
-	7	O
sensitive	9	O
K	9	B-Chemical
(	9	O
+	9	O
)	9	O
-	7	O
channels	9	O
while	9	O
4	9	B-Chemical
-	7	I-Chemical
aminopyridine	0	I-Chemical
is	5	O
known	9	O
to	5	O
block	9	O
voltage	5	O
-	7	O
sensitive	9	O
K	9	B-Chemical
(	9	O
+	9	O
)	9	O
-	7	O
channels	9	O
.	9	O

2	9	O
.	9	O

In	9	O
the	5	O
counterbalanced	5	O
method	5	O
,	9	O
quinine	0	B-Chemical
attenuated	3	O
morphine	0	B-Chemical
-	7	O
induced	3	O
place	5	O
preference	5	O
,	9	O
whereas	9	O
4	9	B-Chemical
-	7	I-Chemical
aminopyridine	0	I-Chemical
was	9	O
ineffective	9	O
.	9	O

In	9	O
the	5	O
motor	5	O
activity	9	O
test	5	O
measured	9	O
with	5	O
an	5	O
Animex	9	O
-	7	O
activity	9	O
meter	0	O
neither	9	O
of	5	O
the	5	O
K	9	B-Chemical
(	9	O
+	9	O
)	9	O
-	7	O
channel	9	O
blockers	9	O
affected	9	O
morphine	0	B-Chemical
-	7	O
induced	3	O
hypoactivity	5	B-Disease
,	9	O
but	9	O
both	9	O
K	9	B-Chemical
(	9	O
+	9	O
)	9	O
-	7	O
channel	9	O
blockers	9	O
prevented	9	O
morphine	0	B-Chemical
-	7	O
induced	3	O
secondary	9	O
hyperactivity	5	B-Disease
.	9	O

3	9	O
.	9	O

These	5	O
results	9	O
suggest	9	O
the	5	O
involvement	9	O
of	5	O
quinine	0	B-Chemical
-	7	O
sensitive	9	O
but	9	O
not	5	O
4	9	B-Chemical
-	7	I-Chemical
aminopyridine	0	I-Chemical
-	7	O
sensitive	9	O
K	9	B-Chemical
(	9	O
+	9	O
)	9	O
-	7	O
channels	9	O
in	5	O
morphine	0	B-Chemical
reward	5	O
.	9	O

It	5	O
is	5	O
also	9	O
suggested	9	O
that	5	O
the	5	O
blockade	3	O
of	5	O
K	9	B-Chemical
(	9	O
+	9	O
)	9	O
-	7	O
channels	9	O
sensitive	9	O
to	5	O
these	5	O
blockers	9	O
is	5	O
not	5	O
sufficient	9	O
to	5	O
prevent	5	O
morphine	0	B-Chemical
-	7	O
induced	3	O
hypoactivity	5	B-Disease
whereas	9	O
morphine	0	B-Chemical
-	7	O
induced	3	O
hyperactivity	5	B-Disease
seems	5	O
to	5	O
be	5	O
connected	5	O
to	5	O
both	9	O
quinine	0	B-Chemical
-	7	O
and	5	O
4	9	B-Chemical
-	7	I-Chemical
aminopyridine	0	I-Chemical
-	7	O
sensitive	9	O
K	9	B-Chemical
(	9	O
+	9	O
)	9	O
-	7	O
channels	9	O
.	9	O

Nociceptin	7	B-Chemical
/	9	O
orphanin	3	B-Chemical
FQ	9	I-Chemical
and	5	O
nocistatin	9	B-Chemical
on	5	O
learning	5	B-Disease
and	5	I-Disease
memory	5	I-Disease
impairment	5	I-Disease
induced	3	O
by	9	O
scopolamine	0	B-Chemical
in	5	O
mice	3	O
.	9	O

1	9	O
.	9	O

Nociceptin	7	B-Chemical
,	9	O
also	9	O
known	9	O
as	5	O
orphanin	3	B-Chemical
FQ	9	I-Chemical
,	9	O
is	5	O
an	5	O
endogenous	3	O
ligand	3	O
for	5	O
the	5	O
orphan	9	O
opioid	5	O
receptor	3	O
-	7	O
like	9	O
receptor	3	O
1	9	O
(	9	O
ORL1	3	O
)	9	O
and	5	O
involves	5	O
in	5	O
various	9	O
functions	9	O
in	5	O
the	5	O
central	5	O
nervous	5	O
system	5	O
(	9	O
CNS	9	O
)	9	O
.	9	O

On	5	O
the	5	O
other	5	O
hand	5	O
,	9	O
nocistatin	9	B-Chemical
is	5	O
recently	9	O
isolated	9	O
from	9	O
the	5	O
same	9	O
precursor	9	O
as	5	O
nociceptin	3	B-Chemical
and	5	O
blocks	9	O
nociceptin	3	B-Chemical
-	7	O
induced	3	O
allodynia	5	B-Disease
and	5	O
hyperalgesia	3	B-Disease
.	9	O

2	9	O
.	9	O

Although	9	O
ORL1	3	O
receptors	3	O
which	5	O
display	9	O
a	5	O
high	9	O
degree	5	O
of	5	O
sequence	1	O
homology	1	O
with	5	O
classical	9	O
opioid	5	O
receptors	3	O
are	5	O
abundant	9	O
in	5	O
the	5	O
hippocampus	9	O
,	9	O
little	9	O
is	5	O
known	9	O
regarding	5	O
their	5	O
role	9	O
in	5	O
learning	5	O
and	5	O
memory	5	O
.	9	O

3	9	O
.	9	O

The	5	O
present	9	O
study	9	O
was	9	O
designed	9	O
to	5	O
investigate	9	O
whether	9	O
nociceptin	3	B-Chemical
/	9	O
orphanin	3	B-Chemical
FQ	9	I-Chemical
and	5	O
nocistatin	9	B-Chemical
could	9	O
modulate	9	O
impairment	5	B-Disease
of	5	I-Disease
learning	5	I-Disease
and	5	I-Disease
memory	5	I-Disease
induced	3	O
by	9	O
scopolamine	0	B-Chemical
,	9	O
a	5	O
muscarinic	3	O
cholinergic	3	O
receptor	3	O
antagonist	3	O
,	9	O
using	9	O
spontaneous	5	O
alternation	5	O
of	5	O
Y	9	O
-	7	O
maze	5	O
and	5	O
step	9	O
-	7	O
down	9	O
type	9	O
passive	5	O
avoidance	5	O
tasks	5	O
in	5	O
mice	3	O
.	9	O

4	9	O
.	9	O

While	9	O
nocistatin	9	B-Chemical
(	9	O
0	7	O
.	9	O
5	9	O
-	7	O
5	9	O
.	9	O
0	7	O
nmol	0	O
mouse	3	O
-	7	O
1	9	O
,	9	O
i	9	O
.	9	O
c	9	O
.	9	O
v	0	O
.	9	O
)	9	O
administered	9	O
30	9	O
min	0	O
before	9	O
spontaneous	5	O
alternation	5	O
performance	5	O
or	5	O
the	5	O
training	5	O
session	5	O
of	5	O
the	5	O
passive	5	O
avoidance	5	O
task	5	O
,	9	O
had	9	O
no	9	O
effect	9	O
on	5	O
spontaneous	5	O
alternation	5	O
or	5	O
passive	5	O
avoidance	5	O
behaviours	5	O
,	9	O
a	5	O
lower	9	O
per	9	O
cent	5	O
alternation	5	O
and	5	O
shorter	9	O
median	9	O
step	9	O
-	7	O
down	9	O
latency	5	O
in	5	O
the	5	O
retention	9	O
test	5	O
were	9	O
obtained	9	O
in	5	O
nociceptin	3	B-Chemical
(	9	O
1	9	O
.	9	O
5	9	O
and	5	O
/	9	O
or	5	O
5	9	O
.	9	O
0	7	O
nmol	0	O
mouse	3	O
-	7	O
1	9	O
,	9	O
i	9	O
.	9	O
c	9	O
.	9	O
v	0	O
.	9	O
)	9	O
-	7	O
treated	3	O
normal	9	O
mice	3	O
.	9	O

5	9	O
.	9	O

Administration	2	O
of	5	O
nocistatin	9	B-Chemical
(	9	O
1	9	O
.	9	O
5	9	O
and	5	O
/	9	O
or	5	O
5	9	O
.	9	O
0	7	O
nmol	0	O
mouse	3	O
-	7	O
1	9	O
,	9	O
i	9	O
.	9	O
c	9	O
.	9	O
v	0	O
.	9	O
)	9	O
30	9	O
min	0	O
before	9	O
spontaneous	5	O
alternation	5	O
performance	5	O
or	5	O
the	5	O
training	5	O
session	5	O
of	5	O
the	5	O
passive	5	O
avoidance	5	O
task	5	O
,	9	O
attenuated	3	O
the	5	O
scopolamine	0	B-Chemical
-	7	O
induced	3	O
impairment	5	O
of	5	O
spontaneous	5	O
alternation	5	O
and	5	O
passive	5	O
avoidance	5	O
behaviours	5	O
.	9	O

6	9	O
.	9	O

These	5	O
results	9	O
indicated	9	O
that	5	O
nocistatin	9	B-Chemical
,	9	O
a	5	O
new	5	O
biologically	9	O
active	9	O
peptide	9	O
,	9	O
ameliorates	3	O
impairments	5	O
of	5	O
spontaneous	5	O
alternation	5	O
and	5	O
passive	5	O
avoidance	5	O
induced	3	O
by	9	O
scopolamine	0	B-Chemical
,	9	O
and	5	O
suggested	9	O
that	5	O
these	5	O
peptides	9	O
play	9	O
opposite	9	O
roles	9	O
in	5	O
learning	5	O
and	5	O
memory	5	O
.	9	O

Meloxicam	0	B-Chemical
-	7	O
induced	3	O
liver	9	B-Disease
toxicity	9	I-Disease
.	9	O

We	9	O
report	5	O
the	5	O
case	5	O
of	5	O
a	5	O
female	9	O
patient	5	O
with	5	O
rheumatoid	9	B-Disease
arthritis	9	I-Disease
who	5	O
developed	5	O
acute	9	O
cytolytic	3	O
hepatitis	9	B-Disease
due	5	O
to	5	O
meloxicam	0	B-Chemical
.	9	O

Recently	9	O
introduced	9	O
in	5	O
Belgium	2	O
,	9	O
meloxicam	0	B-Chemical
is	5	O
the	5	O
first	9	O
nonsteroidal	5	O
antiinflammatory	9	O
drug	5	O
with	5	O
selective	9	O
action	5	O
on	5	O
the	5	O
inducible	3	O
form	9	O
of	5	O
cyclooxygenase	0	O
2	9	O
.	9	O

The	5	O
acute	9	O
cytolytic	3	O
hepatitis	9	B-Disease
occurred	9	O
rapidly	9	O
after	9	O
meloxicam	0	B-Chemical
administration	9	O
and	5	O
was	9	O
associated	9	O
with	5	O
the	5	O
development	9	O
of	5	O
antinuclear	3	O
antibodies	3	O
suggesting	9	O
a	5	O
hypersensitivity	9	B-Disease
mechanism	9	O
.	9	O

This	5	O
first	9	O
case	5	O
of	5	O
meloxicam	0	B-Chemical
related	9	O
liver	9	B-Disease
toxicity	9	I-Disease
demonstrates	9	O
the	5	O
potential	9	O
of	5	O
this	5	O
drug	5	O
to	5	O
induce	3	O
hepatic	9	B-Disease
damage	9	I-Disease
.	9	O

Induction	3	O
of	5	O
apoptosis	3	O
by	9	O
remoxipride	5	B-Chemical
metabolites	0	O
in	5	O
HL60	3	O
and	5	O
CD34	3	O
+	9	O
/	9	O
CD19	3	O
-	7	O
human	3	O
bone	5	O
marrow	3	O
progenitor	3	O
cells	3	O
:	9	O
potential	9	O
relevance	9	O
to	5	O
remoxipride	5	B-Chemical
-	7	O
induced	3	O
aplastic	5	B-Disease
anemia	9	I-Disease
.	9	O

The	5	O
antipsychotic	5	O
agent	9	O
,	9	O
remoxipride	5	B-Chemical
[	9	O
(	9	B-Chemical
S	9	I-Chemical
)	9	I-Chemical
-	7	I-Chemical
(	9	I-Chemical
-	7	I-Chemical
)	9	I-Chemical
-	7	I-Chemical
3	9	I-Chemical
-	7	I-Chemical
bromo	0	I-Chemical
-	7	I-Chemical
N	9	I-Chemical
-	7	I-Chemical
[	9	I-Chemical
(	9	I-Chemical
1	9	I-Chemical
-	7	I-Chemical
ethyl	0	I-Chemical
-	7	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
pyrrolidinyl	0	I-Chemical
)	9	I-Chemical
methyl	0	I-Chemical
]	9	I-Chemical
-	7	I-Chemical
2	9	I-Chemical
,	9	I-Chemical
6	9	I-Chemical
-	7	I-Chemical
dimethoxybenz	_	I-Chemical
amide	0	I-Chemical
]	9	O
has	9	O
been	9	O
associated	9	O
with	5	O
acquired	5	O
aplastic	5	B-Disease
anemia	9	I-Disease
.	9	O

We	9	O
have	5	O
examined	9	O
the	5	O
ability	9	O
of	5	O
remoxipride	5	B-Chemical
,	9	O
three	9	O
pyrrolidine	0	B-Chemical
ring	0	O
metabolites	0	O
and	5	O
five	9	O
aromatic	0	O
ring	0	O
metabolites	0	O
of	5	O
the	5	O
parent	9	O
compound	0	O
to	5	O
induce	3	O
apoptosis	3	O
in	5	O
HL60	3	O
cells	3	O
and	5	O
human	3	O
bone	5	O
marrow	3	O
progenitor	3	O
(	9	O
HBMP	_	O
)	9	O
cells	3	O
.	9	O

Cells	3	O
were	9	O
treated	3	O
for	5	O
0	7	O
-	7	O
24	9	O
h	0	O
with	5	O
each	5	O
compound	0	O
(	9	O
0	7	O
-	7	O
200	0	O
microM	0	O
)	9	O
.	9	O

Apoptosis	3	O
was	9	O
assessed	9	O
by	9	O
fluorescence	0	O
microscopy	9	O
in	5	O
Hoechst	3	B-Chemical
33342	3	I-Chemical
-	7	O
and	5	O
propidium	0	B-Chemical
iodide	0	I-Chemical
stained	3	O
cell	3	O
samples	9	O
.	9	O

Results	9	O
were	9	O
confirmed	9	O
by	9	O
determination	9	O
of	5	O
internucleosomal	3	O
DNA	9	O
fragmentation	9	O
using	9	O
gel	0	O
electrophoresis	0	O
for	5	O
HL60	3	O
cell	3	O
samples	9	O
and	5	O
terminal	9	O
deoxynucleotidyl	3	O
transferase	1	O
assay	3	O
in	5	O
HBMP	_	O
cells	3	O
.	9	O

The	5	O
catechol	0	B-Chemical
and	5	O
hydroquinone	0	B-Chemical
metabolites	0	O
,	9	O
NCQ436	_	B-Chemical
and	5	O
NCQ344	_	B-Chemical
,	9	O
induced	3	O
apoptosis	3	O
in	5	O
HL60	3	O
and	5	O
HBMP	_	O
cells	3	O
in	5	O
a	5	O
time	5	O
-	7	O
and	5	O
concentration	0	O
dependent	9	O
manner	9	O
,	9	O
while	9	O
the	5	O
phenols	0	B-Chemical
,	9	O
NCR181	_	O
,	9	O
FLA873	_	O
,	9	O
and	5	O
FLA797	_	B-Chemical
,	9	O
and	5	O
the	5	O
derivatives	0	O
formed	9	O
by	9	O
oxidation	0	O
of	5	O
the	5	O
pyrrolidine	0	B-Chemical
ring	0	O
,	9	O
FLA838	_	O
,	9	O
NCM001	_	O
,	9	O
and	5	O
NCL118	_	O
,	9	O
had	9	O
no	9	O
effect	9	O
.	9	O

No	9	O
necrosis	9	B-Disease
was	9	O
observed	9	O
in	5	O
cells	3	O
treated	3	O
with	5	O
NCQ436	_	B-Chemical
but	9	O
NCQ344	_	B-Chemical
had	9	O
a	5	O
biphasic	9	O
effect	9	O
in	5	O
both	9	O
cell	3	O
types	9	O
,	9	O
inducing	3	O
apoptosis	3	O
at	9	O
lower	9	O
concentrations	0	O
and	5	O
necrosis	9	B-Disease
at	9	O
higher	9	O
concentrations	0	O
.	9	O

These	5	O
data	5	O
show	9	O
that	5	O
the	5	O
catechol	0	B-Chemical
and	5	O
hydroquinone	0	B-Chemical
metabolites	0	O
of	5	O
remoxipride	5	B-Chemical
have	5	O
direct	9	O
toxic	0	O
effects	9	O
in	5	O
HL60	3	O
and	5	O
HBMP	_	O
cells	3	O
,	9	O
leading	9	O
to	5	O
apoptosis	3	O
,	9	O
while	9	O
the	5	O
phenol	0	B-Chemical
metabolites	0	O
were	9	O
inactive	9	O
.	9	O

Similarly	9	O
,	9	O
benzene	0	B-Chemical
-	7	O
derived	9	O
catechol	0	B-Chemical
and	5	O
hydroquinone	0	B-Chemical
,	9	O
but	9	O
not	5	O
phenol	0	B-Chemical
,	9	O
induce	3	O
apoptosis	3	O
in	5	O
HBMP	_	O
cells	3	O
[	9	O
Moran	6	O
et	6	O
al	6	O
.	9	O
,	9	O
Mol	2	O
.	9	O
Pharmacol	2	O
.	9	O
,	9	O
50	0	O
(	9	O
1996	2	O
)	9	O
610	7	O
-	7	O
615	7	O
]	9	O
.	9	O

We	9	O
propose	9	O
that	5	O
remoxipride	5	B-Chemical
and	5	O
benzene	0	B-Chemical
may	5	O
induce	3	O
aplastic	5	B-Disease
anemia	9	I-Disease
via	9	O
production	9	O
of	5	O
similar	9	O
reactive	9	O
metabolites	0	O
and	5	O
that	5	O
the	5	O
ability	9	O
of	5	O
NCQ436	_	B-Chemical
and	5	O
NCQ344	_	B-Chemical
to	5	O
induce	3	O
apoptosis	3	O
in	5	O
HBMP	_	O
cells	3	O
may	5	O
contribute	9	O
to	5	O
the	5	O
mechanism	9	O
underlying	5	O
acquired	5	O
aplastic	5	B-Disease
anemia	9	I-Disease
that	5	O
has	9	O
been	9	O
associated	9	O
with	5	O
remoxipride	5	B-Chemical
.	9	O

Synthesis	0	O
and	5	O
preliminary	9	O
pharmacological	9	O
investigations	9	O
of	5	O
1	9	B-Chemical
-	7	I-Chemical
(	9	I-Chemical
1	9	I-Chemical
,	9	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
dihydro	0	I-Chemical
-	7	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
acenaphthylenyl	_	I-Chemical
)	9	I-Chemical
piperazine	0	I-Chemical
derivatives	0	O
as	5	O
potential	9	O
atypical	5	O
antipsychotic	5	O
agents	5	O
in	5	O
mice	3	O
.	9	O

In	9	O
research	5	O
towards	5	O
the	5	O
development	9	O
of	5	O
new	5	O
atypical	5	O
antipsychotic	5	O
agents	5	O
,	9	O
one	5	O
strategy	5	O
is	5	O
that	5	O
the	5	O
dopaminergic	5	O
system	5	O
can	5	O
be	5	O
modulated	9	O
through	9	O
manipulation	5	O
of	5	O
the	5	O
serotonergic	5	O
system	5	O
.	9	O

The	5	O
synthesis	9	O
and	5	O
preliminary	9	O
pharmacological	9	O
evaluation	5	O
of	5	O
a	5	O
series	5	O
of	5	O
potential	9	O
atypical	5	O
antipsychotic	5	O
agents	5	O
based	5	O
on	5	O
the	5	O
structure	9	O
of	5	O
1	9	B-Chemical
-	7	I-Chemical
(	9	I-Chemical
1	9	I-Chemical
,	9	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
dihydro	0	I-Chemical
-	7	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
acenaphthylenyl	_	I-Chemical
)	9	I-Chemical
piperazine	0	I-Chemical
(	9	O
7	9	O
)	9	O
is	5	O
described	9	O
.	9	O

Compound	0	O
7e	7	O
,	9	O
5	9	B-Chemical
-	7	I-Chemical
{	9	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
[	9	I-Chemical
4	9	I-Chemical
-	7	I-Chemical
(	9	I-Chemical
1	9	I-Chemical
,	9	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
dihydro	0	I-Chemical
-	7	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
acenaphthylenyl	_	I-Chemical
)	9	I-Chemical
piperazinyl	0	I-Chemical
]	9	I-Chemical
ethyl	0	I-Chemical
}	9	I-Chemical
-	7	I-Chemical
2	9	I-Chemical
,	9	I-Chemical
3	9	I-Chemical
-	7	I-Chemical
dihy	9	I-Chemical
dro	2	I-Chemical
-	7	I-Chemical
1H	0	I-Chemical
-	7	I-Chemical
indol	0	I-Chemical
-	7	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
one	5	I-Chemical
,	9	O
from	9	O
this	5	O
series	5	O
showed	9	O
significant	9	O
affinities	9	O
at	9	O
the	5	O
5	9	O
-	7	O
HT1A	3	O
and	5	O
5	9	O
-	7	O
HT2A	1	O
receptors	3	O
and	5	O
moderate	9	O
affinity	0	O
at	9	O
the	5	O
D2	9	O
receptor	3	O
.	9	O

7e	7	O
exhibits	9	O
a	5	O
high	9	O
reversal	9	O
of	5	O
catalepsy	5	B-Disease
induced	3	O
by	9	O
haloperidol	5	B-Chemical
indicating	9	O
its	9	O
atypical	5	O
antipsychotic	5	O
nature	5	O
.	9	O

Sub	9	O
-	7	O
chronic	5	O
inhibition	3	O
of	5	O
nitric	0	B-Chemical
-	7	I-Chemical
oxide	0	I-Chemical
synthesis	9	O
modifies	9	O
haloperidol	5	B-Chemical
-	7	O
induced	3	O
catalepsy	5	B-Disease
and	5	O
the	5	O
number	9	O
of	5	O
NADPH	0	B-Chemical
-	7	O
diaphorase	0	O
neurons	3	O
in	5	O
mice	3	O
.	9	O

RATIONALE	2	O
:	9	O
NG	9	B-Chemical
-	7	I-Chemical
nitro	0	I-Chemical
-	7	I-Chemical
L	0	I-Chemical
-	7	I-Chemical
arginine	0	I-Chemical
(	9	O
L	0	B-Chemical
-	7	I-Chemical
NOARG	9	I-Chemical
)	9	O
,	9	O
an	5	O
inhibitor	3	O
of	5	O
nitric	0	B-Chemical
-	7	I-Chemical
oxide	0	I-Chemical
synthase	1	O
(	9	O
NOS	9	O
)	9	O
,	9	O
induces	3	O
catalepsy	5	B-Disease
in	5	O
mice	3	O
.	9	O

This	5	O
effect	9	O
undergoes	9	O
rapid	5	O
tolerance	9	O
,	9	O
showing	9	O
a	5	O
significant	9	O
decrease	9	O
after	9	O
2	9	O
days	9	O
of	5	O
sub	9	O
-	7	O
chronic	5	O
L	0	B-Chemical
-	7	I-Chemical
NOARG	9	I-Chemical
treatment	9	O
.	9	O

Nitric	0	B-Chemical
oxide	0	I-Chemical
(	9	O
NO	9	B-Chemical
)	9	O
has	9	O
been	9	O
shown	9	O
to	5	O
influence	5	O
dopaminergic	5	O
neurotransmission	5	O
in	5	O
the	5	O
striatum	9	O
.	9	O

Neuroleptic	2	O
drugs	5	O
such	5	O
as	5	O
haloperidol	5	B-Chemical
,	9	O
which	5	O
block	9	O
dopamine	5	B-Chemical
receptors	3	O
,	9	O
also	9	O
cause	5	O
catalepsy	5	B-Disease
in	5	O
rodents	9	O
.	9	O

OBJECTIVES	2	O
:	9	O
To	9	O
investigate	9	O
the	5	O
effects	9	O
of	5	O
subchronic	0	O
L	0	B-Chemical
-	7	I-Chemical
NOARG	9	I-Chemical
treatment	9	O
in	5	O
haloperidol	5	B-Chemical
-	7	O
induced	3	O
catalepsy	5	B-Disease
and	5	O
the	5	O
number	9	O
of	5	O
NOS	9	O
neurons	3	O
in	5	O
areas	5	O
related	9	O
to	5	O
motor	5	O
control	9	O
.	9	O

METHODS	2	O
:	9	O
Male	7	O
albino	3	O
Swiss	2	O
mice	3	O
were	9	O
treated	3	O
sub	9	O
-	7	O
chronically	9	O
(	9	O
twice	9	O
a	5	O
day	9	O
for	5	O
4	9	O
days	9	O
)	9	O
with	5	O
L	0	B-Chemical
-	7	I-Chemical
NOARG	9	I-Chemical
(	9	O
40	9	O
mg	0	O
/	9	O
kg	0	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
or	5	O
haloperidol	5	B-Chemical
(	9	O
1	9	O
mg	0	O
/	9	O
kg	0	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
.	9	O

Catalepsy	0	B-Disease
was	9	O
evaluated	9	O
at	9	O
the	5	O
beginning	5	O
and	5	O
the	5	O
end	9	O
of	5	O
the	5	O
treatments	9	O
.	9	O

Reduced	9	O
nicotinamide	0	B-Chemical
adenine	0	I-Chemical
dinucleotide	1	I-Chemical
phosphate	0	I-Chemical
-	7	O
diaphorase	0	O
(	9	O
NADPH	0	B-Chemical
-	7	O
d	9	O
)	9	O
histochemistry	9	O
was	9	O
also	9	O
employed	5	O
to	5	O
visualize	9	O
NOS	9	O
as	5	O
an	5	O
index	5	O
of	5	O
enzyme	0	O
expression	3	O
in	5	O
mice	3	O
brain	5	O
regions	9	O
related	9	O
to	5	O
motor	5	O
control	9	O
.	9	O

RESULTS	9	O
:	9	O
L	0	B-Chemical
-	7	I-Chemical
NOARG	9	I-Chemical
sub	9	O
-	7	O
chronic	5	O
administration	9	O
produced	9	O
tolerance	9	O
of	5	O
L	0	B-Chemical
-	7	I-Chemical
NOARG	9	I-Chemical
and	5	O
of	5	O
haloperidol	5	B-Chemical
-	7	O
induced	3	O
catalepsy	5	B-Disease
.	9	O

It	5	O
also	9	O
induced	3	O
an	5	O
increase	9	O
in	5	O
the	5	O
number	9	O
of	5	O
NADPH	0	B-Chemical
-	7	O
d	9	O
-	7	O
positive	9	O
cells	3	O
in	5	O
the	5	O
dorsal	5	O
part	9	O
of	5	O
the	5	O
caudate	5	O
and	5	O
accumbens	5	O
nuclei	3	O
compared	9	O
with	5	O
haloperidol	5	B-Chemical
and	5	O
in	5	O
the	5	O
pedunculopontine	5	O
tegmental	5	O
nucleus	9	O
compared	9	O
with	5	O
saline	0	O
.	9	O

In	9	O
contrast	9	O
,	9	O
there	5	O
was	9	O
a	5	O
decrease	9	O
in	5	O
NADPH	0	B-Chemical
-	7	O
d	9	O
neuron	5	O
number	9	O
in	5	O
the	5	O
substantia	9	O
nigra	4	O
,	9	O
pars	4	O
compacta	4	O
in	5	O
both	9	O
haloperidol	5	B-Chemical
-	7	O
treated	3	O
and	5	O
L	0	B-Chemical
-	7	I-Chemical
NOARG	9	I-Chemical
-	7	O
treated	3	O
animals	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
The	5	O
results	9	O
give	5	O
further	9	O
support	5	O
to	5	O
the	5	O
hypothesis	9	O
that	5	O
NO	9	B-Chemical
plays	9	O
a	5	O
role	9	O
in	5	O
motor	5	O
behavior	5	O
control	9	O
and	5	O
suggest	9	O
that	5	O
it	5	O
may	5	O
take	5	O
part	9	O
in	5	O
the	5	O
synaptic	5	O
changes	9	O
produced	9	O
by	9	O
antipsychotic	5	O
treatment	9	O
.	9	O

Prolonged	9	O
left	5	B-Disease
ventricular	5	I-Disease
dysfunction	9	I-Disease
occurs	9	O
in	5	O
patients	5	O
with	5	O
coronary	5	B-Disease
artery	5	I-Disease
disease	5	I-Disease
after	9	O
both	9	O
dobutamine	5	B-Chemical
and	5	O
exercise	5	O
induced	3	O
myocardial	9	B-Disease
ischaemia	9	I-Disease
.	9	O

OBJECTIVE	2	O
:	9	O
To	9	O
determine	9	O
whether	9	O
pharmacological	9	O
stress	9	O
leads	9	O
to	5	O
prolonged	9	O
but	9	O
reversible	9	O
left	5	B-Disease
ventricular	5	I-Disease
dysfunction	9	I-Disease
in	5	O
patients	5	O
with	5	O
coronary	5	B-Disease
artery	5	I-Disease
disease	5	I-Disease
,	9	O
similar	9	O
to	5	O
that	5	O
seen	9	O
after	9	O
exercise	5	O
.	9	O

DESIGN	2	O
:	9	O
A	9	O
randomised	5	O
crossover	5	O
study	9	O
of	5	O
recovery	9	O
time	5	O
of	5	O
systolic	5	O
and	5	O
diastolic	5	O
left	5	O
ventricular	5	O
function	9	O
after	9	O
exercise	5	O
and	5	O
dobutamine	5	B-Chemical
induced	3	O
ischaemia	9	B-Disease
.	9	O

SUBJECTS	2	O
:	9	O
10	9	O
patients	5	O
with	5	O
stable	9	B-Disease
angina	5	I-Disease
,	9	O
angiographically	5	O
proven	5	O
coronary	5	B-Disease
artery	5	I-Disease
disease	5	I-Disease
,	9	O
and	5	O
normal	9	O
left	5	O
ventricular	5	O
function	9	O
.	9	O

INTERVENTIONS	2	O
:	9	O
Treadmill	5	O
exercise	5	O
and	5	O
dobutamine	5	B-Chemical
stress	9	O
were	9	O
performed	9	O
on	5	O
different	9	O
days	9	O
.	9	O

Quantitative	9	O
assessment	5	O
of	5	O
systolic	5	O
and	5	O
diastolic	5	O
left	5	O
ventricular	5	O
function	9	O
was	9	O
performed	9	O
using	9	O
transthoracic	5	O
echocardiography	5	O
at	9	O
baseline	5	O
and	5	O
at	9	O
regular	5	O
intervals	5	O
after	9	O
each	5	O
test	5	O
.	9	O

RESULTS	9	O
:	9	O
Both	9	O
forms	9	O
of	5	O
stress	9	O
led	9	O
to	5	O
prolonged	9	O
but	9	O
reversible	9	O
systolic	5	O
and	5	O
diastolic	5	O
dysfunction	9	O
.	9	O

There	5	O
was	9	O
no	9	O
difference	9	O
in	5	O
the	5	O
maximum	5	O
double	9	O
product	9	O
(	9	O
p	7	O
=	7	O
0	7	O
.	9	O
53	7	O
)	9	O
or	5	O
ST	9	O
depression	5	B-Disease
(	9	O
p	7	O
=	7	O
0	7	O
.	9	O
63	7	O
)	9	O
with	5	O
either	9	O
form	9	O
of	5	O
stress	9	O
.	9	O

After	9	O
exercise	5	O
,	9	O
ejection	5	O
fraction	9	O
was	9	O
reduced	9	O
at	9	O
15	9	O
and	5	O
30	9	O
minutes	0	O
compared	9	O
with	5	O
baseline	5	O
(	9	O
mean	5	O
(	9	O
SEM	9	O
)	9	O
,	9	O
-	7	O
5	9	O
.	9	O
6	9	O
(	9	O
1	9	O
.	9	O
5	9	O
)	9	O
%	9	O
,	9	O
p	7	O
<	0	O
0	7	O
.	9	O
05	7	O
;	9	O
and	5	O
-	7	O
6	9	O
.	9	O
1	9	O
(	9	O
2	9	O
.	9	O
2	9	O
)	9	O
%	9	O
,	9	O
p	7	O
<	0	O
0	7	O
.	9	O
01	7	O
)	9	O
,	9	O
and	5	O
at	9	O
30	9	O
and	5	O
45	9	O
minutes	0	O
after	9	O
dobutamine	5	B-Chemical
(	9	O
-	7	O
10	9	O
.	9	O
8	9	O
(	9	O
1	9	O
.	9	O
8	9	O
)	9	O
%	9	O
and	5	O
-	7	O
5	9	O
.	9	O
5	9	O
(	9	O
1	9	O
.	9	O
8	9	O
)	9	O
%	9	O
,	9	O
both	9	O
p	7	O
<	0	O
0	7	O
.	9	O
01	7	O
)	9	O
.	9	O

Regional	2	O
analysis	9	O
showed	9	O
a	5	O
reduction	9	O
in	5	O
the	5	O
worst	5	O
affected	9	O
segment	9	O
15	9	O
and	5	O
30	9	O
minutes	0	O
after	9	O
exercise	5	O
(	9	O
-	7	O
27	7	O
.	9	O
9	7	O
(	9	O
7	9	O
.	9	O
2	9	O
)	9	O
%	9	O
and	5	O
-	7	O
28	7	O
.	9	O
6	9	O
(	9	O
5	9	O
.	9	O
7	9	O
)	9	O
%	9	O
,	9	O
both	9	O
p	7	O
<	0	O
0	7	O
.	9	O
01	7	O
)	9	O
,	9	O
and	5	O
at	9	O
30	9	O
minutes	0	O
after	9	O
dobutamine	5	B-Chemical
(	9	O
-	7	O
32	7	O
(	9	O
5	9	O
.	9	O
3	9	O
)	9	O
%	9	O
,	9	O
p	7	O
<	0	O
0	7	O
.	9	O
01	7	O
)	9	O
.	9	O

The	5	O
isovolumic	5	O
relaxation	5	O
period	5	O
was	9	O
prolonged	9	O
45	9	O
minutes	0	O
after	9	O
each	5	O
form	9	O
of	5	O
stress	9	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
In	9	O
patients	5	O
with	5	O
coronary	5	B-Disease
artery	5	I-Disease
disease	5	I-Disease
,	9	O
dobutamine	5	B-Chemical
induced	3	O
ischaemia	9	B-Disease
results	9	O
in	5	O
prolonged	9	O
reversible	9	O
left	5	B-Disease
ventricular	5	I-Disease
dysfunction	9	I-Disease
,	9	O
presumed	9	O
to	5	O
be	5	O
myocardial	9	B-Disease
stunning	5	I-Disease
,	9	O
similar	9	O
to	5	O
that	5	O
seen	9	O
after	9	O
exercise	5	O
.	9	O

Dobutamine	0	B-Chemical
induced	3	O
ischaemia	9	B-Disease
could	9	O
therefore	5	O
be	5	O
used	5	O
to	5	O
study	9	O
the	5	O
pathophysiology	9	O
of	5	O
this	5	O
phenomenon	5	O
further	9	O
in	5	O
patients	5	O
with	5	O
coronary	5	B-Disease
artery	5	I-Disease
disease	5	I-Disease
.	9	O

Anorexigens	9	O
and	5	O
pulmonary	5	B-Disease
hypertension	5	I-Disease
in	5	O
the	5	O
United	9	O
States	9	O
:	9	O
results	9	O
from	9	O
the	5	O
surveillance	5	O
of	5	O
North	4	O
American	9	O
pulmonary	5	B-Disease
hypertension	5	I-Disease
.	9	O

BACKGROUND	2	O
:	9	O
The	5	O
use	5	O
of	5	O
appetite	5	O
suppressants	5	O
in	5	O
Europe	4	O
has	9	O
been	9	O
associated	9	O
with	5	O
the	5	O
development	9	O
of	5	O
primary	9	B-Disease
pulmonary	5	I-Disease
hypertension	5	I-Disease
(	9	O
PPH	5	B-Disease
)	9	O
.	9	O

Recently	9	O
,	9	O
fenfluramine	5	B-Chemical
appetite	5	O
suppressants	5	O
became	9	O
widely	5	O
used	5	O
in	5	O
the	5	O
United	9	O
States	9	O
but	9	O
were	9	O
withdrawn	9	O
in	5	O
September	2	O
1997	2	O
because	5	O
of	5	O
concerns	5	O
over	5	O
adverse	5	O
effects	9	O
.	9	O

MATERIALS	2	O
AND	2	O
METHODS	2	O
:	9	O
We	9	O
conducted	9	O
a	5	O
prospective	5	O
surveillance	5	O
study	9	O
on	5	O
patients	5	O
diagnosed	5	O
with	5	O
pulmonary	5	B-Disease
hypertension	5	I-Disease
at	9	O
12	9	O
large	5	O
referral	5	O
centers	5	O
in	5	O
North	4	O
America	4	O
.	9	O

Data	5	O
collected	9	O
on	5	O
patients	5	O
seen	9	O
from	9	O
September	2	O
1	9	O
,	9	O
1996	2	O
,	9	O
to	5	O
December	2	O
31	7	O
,	9	O
1997	2	O
,	9	O
included	5	O
the	5	O
cause	5	O
of	5	O
the	5	O
pulmonary	5	B-Disease
hypertension	5	I-Disease
and	5	O
its	9	O
severity	5	O
.	9	O

Patients	5	O
with	5	O
no	9	O
identifiable	5	O
cause	5	O
of	5	O
pulmonary	5	B-Disease
hypertension	5	I-Disease
were	9	O
classed	5	O
as	5	O
PPH	5	B-Disease
.	9	O

A	9	O
history	5	O
of	5	O
drug	5	O
exposure	9	O
also	9	O
was	9	O
taken	5	O
with	5	O
special	5	O
attention	5	O
on	5	O
the	5	O
use	5	O
of	5	O
antidepressants	5	O
,	9	O
anorexigens	5	O
,	9	O
and	5	O
amphetamines	5	B-Chemical
.	9	O

RESULTS	9	O
:	9	O
Five	9	O
hundred	5	O
seventy	5	O
-	7	O
nine	9	O
patients	5	O
were	9	O
studied	9	O
,	9	O
205	7	O
with	5	O
PPH	5	B-Disease
and	5	O
374	7	O
with	5	O
pulmonary	5	B-Disease
hypertension	5	I-Disease
from	9	O
other	5	O
causes	9	O
(	9	O
secondary	9	O
pulmonary	5	B-Disease
hypertension	5	I-Disease
[	9	O
SPH	0	O
]	9	O
)	9	O
.	9	O

The	5	O
use	5	O
of	5	O
anorexigens	5	O
was	9	O
common	5	O
in	5	O
both	9	O
groups	9	O
.	9	O

However	9	O
,	9	O
of	5	O
the	5	O
medications	5	O
surveyed	5	O
,	9	O
only	9	O
the	5	O
fenfluramines	5	B-Chemical
had	9	O
a	5	O
significant	9	O
preferential	9	O
association	9	O
with	5	O
PPH	5	B-Disease
as	5	O
compared	9	O
with	5	O
SPH	0	O
(	9	O
adjusted	9	O
odds	5	O
ratio	9	O
for	5	O
use	5	O
>	0	O
6	9	O
months	5	O
,	9	O
7	9	O
.	9	O
5	9	O
;	9	O
95	7	O
%	9	O
confidence	5	O
interval	5	O
,	9	O
1	9	O
.	9	O
7	9	O
to	5	O
32	7	O
.	9	O
4	9	O
)	9	O
.	9	O

The	5	O
association	9	O
was	9	O
stronger	9	O
with	5	O
longer	5	O
duration	5	O
of	5	O
use	5	O
when	5	O
compared	9	O
to	5	O
shorter	9	O
duration	5	O
of	5	O
use	5	O
and	5	O
was	9	O
more	5	O
pronounced	9	O
in	5	O
recent	5	O
users	5	O
than	5	O
in	5	O
remote	5	O
users	5	O
.	9	O

An	5	O
unexpectedly	9	O
high	9	O
(	9	O
11	7	O
.	9	O
4	9	O
%	9	O
)	9	O
number	9	O
of	5	O
patients	5	O
with	5	O
SPH	0	O
had	9	O
used	5	O
anorexigens	5	O
.	9	O

CONCLUSION	5	O
:	9	O
The	5	O
magnitude	5	O
of	5	O
the	5	O
association	9	O
with	5	O
PPH	5	B-Disease
,	9	O
the	5	O
increase	9	O
of	5	O
association	9	O
with	5	O
increasing	9	O
duration	5	O
of	5	O
use	5	O
,	9	O
and	5	O
the	5	O
specificity	9	O
for	5	O
fenfluramines	5	B-Chemical
are	5	O
consistent	9	O
with	5	O
previous	9	O
studies	9	O
indicating	9	O
that	5	O
fenfluramines	5	B-Chemical
are	5	O
causally	9	O
related	9	O
to	5	O
PPH	5	B-Disease
.	9	O

The	5	O
high	9	O
prevalence	5	O
of	5	O
anorexigen	5	O
use	5	O
in	5	O
patients	5	O
with	5	O
SPH	0	O
also	9	O
raises	9	O
the	5	O
possibility	9	O
that	5	O
these	5	O
drugs	5	O
precipitate	0	O
pulmonary	5	B-Disease
hypertension	5	I-Disease
in	5	O
patients	5	O
with	5	O
underlying	5	O
conditions	9	O
associated	9	O
with	5	O
SPH	0	O
.	9	O

Clinical	5	O
aspects	5	O
of	5	O
heparin	0	B-Chemical
-	7	O
induced	3	O
thrombocytopenia	9	B-Disease
and	5	O
thrombosis	5	B-Disease
and	5	O
other	5	O
side	5	O
effects	9	O
of	5	O
heparin	0	B-Chemical
therapy	5	O
.	9	O

Heparin	0	B-Chemical
,	9	O
first	9	O
used	5	O
to	5	O
prevent	5	O
the	5	O
clotting	5	O
of	5	O
blood	9	O
in	5	O
vitro	3	O
,	9	O
has	9	O
been	9	O
clinically	5	O
used	5	O
to	5	O
treat	5	O
thrombosis	5	B-Disease
for	5	O
more	5	O
than	5	O
50	0	O
years	5	O
.	9	O

Although	9	O
several	9	O
new	5	O
anticoagulant	9	O
drugs	5	O
are	5	O
in	5	O
development	9	O
,	9	O
heparin	0	B-Chemical
remains	9	O
the	5	O
anticoagulant	9	O
of	5	O
choice	5	O
to	5	O
treat	5	O
acute	9	O
thrombotic	5	B-Disease
episodes	5	O
.	9	O

The	5	O
clinical	5	O
effects	9	O
of	5	O
heparin	0	B-Chemical
are	5	O
meritorious	5	O
,	9	O
but	9	O
side	5	O
effects	9	O
do	5	O
exist	9	O
.	9	O

Bleeding	5	B-Disease
is	5	O
the	5	O
primary	9	O
untoward	5	O
effect	9	O
of	5	O
heparin	0	B-Chemical
.	9	O

Major	9	O
bleeding	5	B-Disease
is	5	O
of	5	O
primary	9	O
concern	5	O
in	5	O
patients	5	O
receiving	9	O
heparin	0	B-Chemical
therapy	5	O
.	9	O

However	9	O
,	9	O
additional	9	O
important	9	O
untoward	5	O
effects	9	O
of	5	O
heparin	0	B-Chemical
therapy	5	O
include	5	O
heparin	0	B-Chemical
-	7	O
induced	3	O
thrombocytopenia	9	B-Disease
,	9	O
heparin	0	B-Chemical
-	7	O
associated	9	O
osteoporosis	5	B-Disease
,	9	O
eosinophilia	3	B-Disease
,	9	O
skin	5	B-Disease
reactions	9	I-Disease
,	9	O
allergic	9	B-Disease
reactions	9	I-Disease
other	5	O
than	5	O
thrombocytopenia	9	B-Disease
,	9	O
alopecia	5	B-Disease
,	9	O
transaminasemia	5	O
,	9	O
hyperkalemia	5	B-Disease
,	9	O
hypoaldosteronism	5	B-Disease
,	9	O
and	5	O
priapism	5	B-Disease
.	9	O

These	5	O
side	5	O
effects	9	O
are	5	O
relatively	5	O
rare	5	O
in	5	O
a	5	O
given	5	O
individual	5	O
,	9	O
but	9	O
given	5	O
the	5	O
extremely	5	O
widespread	5	O
use	5	O
of	5	O
heparin	0	B-Chemical
,	9	O
some	5	O
are	5	O
quite	5	O
common	5	O
,	9	O
particularly	5	O
HITT	5	B-Disease
and	5	O
osteoporosis	5	B-Disease
.	9	O

Although	9	O
reasonable	5	O
incidences	5	O
of	5	O
many	5	O
of	5	O
these	5	O
side	5	O
effects	9	O
can	5	O
be	5	O
"	5	O
softly	5	O
"	5	O
deduced	9	O
from	9	O
current	5	O
reports	9	O
dealing	5	O
with	5	O
unfractionated	9	O
heparin	0	B-Chemical
,	9	O
at	9	O
present	9	O
the	5	O
incidences	5	O
of	5	O
these	5	O
side	5	O
effects	9	O
with	5	O
newer	5	O
low	9	O
molecular	9	O
weight	9	O
heparins	0	B-Chemical
appear	9	O
to	5	O
be	5	O
much	5	O
less	5	O
common	5	O
.	9	O

However	9	O
,	9	O
only	9	O
longer	5	O
experience	5	O
will	5	O
more	5	O
clearly	9	O
define	5	O
the	5	O
incidence	5	O
of	5	O
each	5	O
side	5	O
effect	9	O
with	5	O
low	9	O
molecular	9	O
weight	9	O
preparations	9	O
.	9	O

A	9	O
case	5	O
of	5	O
bilateral	5	O
optic	5	B-Disease
neuropathy	5	I-Disease
in	5	O
a	5	O
patient	5	O
on	5	O
tacrolimus	0	B-Chemical
(	9	O
FK506	3	B-Chemical
)	9	O
therapy	5	O
after	9	O
liver	9	O
transplantation	9	O
.	9	O

PURPOSE	2	O
:	9	O
To	9	O
report	5	O
a	5	O
case	5	O
of	5	O
bilateral	5	O
optic	5	B-Disease
neuropathy	5	I-Disease
in	5	O
a	5	O
patient	5	O
receiving	9	O
tacrolimus	0	B-Chemical
(	9	O
FK	9	B-Chemical
506	7	I-Chemical
,	9	O
Prograf	0	O
;	9	O
Fujisawa	6	O
USA	0	O
,	9	O
Inc	2	O
,	9	O
Deerfield	0	O
,	9	O
Illinois	2	O
)	9	O
for	5	O
immunosuppression	5	O
after	9	O
orthotropic	5	O
liver	9	O
transplantation	9	O
.	9	O

METHOD	2	O
:	9	O
Case	5	O
report	5	O
.	9	O

In	9	O
a	5	O
58	7	O
-	7	O
year	5	O
-	7	O
old	5	O
man	5	O
receiving	9	O
tacrolimus	0	B-Chemical
after	9	O
orthotropic	5	O
liver	9	O
transplantation	9	O
,	9	O
serial	9	O
neuro	9	O
-	7	O
ophthalmologic	5	O
examinations	5	O
and	5	O
laboratory	9	O
studies	9	O
were	9	O
performed	9	O
.	9	O

RESULTS	9	O
:	9	O
The	5	O
patient	5	O
had	9	O
episodic	5	O
deterioration	5	O
of	5	O
vision	5	O
in	5	O
both	9	O
eyes	5	O
,	9	O
with	5	O
clinical	5	O
features	5	O
resembling	9	O
ischemic	9	B-Disease
optic	5	I-Disease
neuropathies	5	I-Disease
.	9	O

Deterioration	5	B-Disease
of	5	I-Disease
vision	5	I-Disease
occurred	9	O
despite	9	O
discontinuation	5	O
of	5	O
the	5	O
tacrolimus	0	B-Chemical
.	9	O

CONCLUSION	5	O
:	9	O
Tacrolimus	0	B-Chemical
and	5	O
other	5	O
immunosuppressive	9	O
agents	5	O
may	5	O
be	5	O
associated	9	O
with	5	O
optic	5	B-Disease
nerve	5	I-Disease
toxicity	9	I-Disease
.	9	O

Hypercalcemia	9	B-Disease
,	9	O
arrhythmia	5	B-Disease
,	9	O
and	5	O
mood	5	O
stabilizers	0	O
.	9	O

Recent	9	O
findings	9	O
in	5	O
a	5	O
bipolar	5	B-Disease
patient	5	O
receiving	9	O
maintenance	9	O
lithium	0	B-Chemical
therapy	5	O
who	5	O
developed	5	O
hypercalcemia	5	B-Disease
and	5	O
severe	5	O
bradyarrhythmia	5	B-Disease
prompted	9	O
the	5	O
authors	5	O
to	5	O
conduct	5	O
a	5	O
retrospective	5	O
study	9	O
of	5	O
bipolar	5	B-Disease
patients	5	O
with	5	O
lithium	0	B-Chemical
-	7	O
associated	9	O
hypercalcemia	5	B-Disease
.	9	O

A	9	O
printout	5	O
of	5	O
all	5	O
cases	5	O
of	5	O
hypercalcemia	5	B-Disease
that	5	O
presented	5	O
during	5	O
a	5	O
1	9	O
-	7	O
year	5	O
period	5	O
was	9	O
generated	9	O
.	9	O

After	9	O
eliminating	5	O
spurious	5	O
hypercalcemias	_	B-Disease
or	5	O
those	5	O
associated	9	O
with	5	O
intravenous	0	O
fluids	5	O
,	9	O
the	5	O
authors	5	O
identified	9	O
18	7	O
non	9	O
-	7	O
lithium	0	B-Chemical
-	7	O
treated	3	O
patients	5	O
with	5	O
hypercalcemias	_	B-Disease
related	9	O
to	5	O
malignancies	5	B-Disease
and	5	O
other	5	O
medical	5	O
conditions	9	O
(	9	O
group	9	O
A	9	O
)	9	O
and	5	O
12	9	O
patients	5	O
with	5	O
lithium	0	B-Chemical
-	7	O
associated	9	O
hypercalcemia	5	B-Disease
(	9	O
group	9	O
B	9	O
)	9	O
.	9	O

Patients	5	O
in	5	O
group	9	O
B	9	O
were	9	O
not	5	O
comparable	9	O
to	5	O
those	5	O
in	5	O
group	9	O
A	9	O
,	9	O
as	5	O
the	5	O
latter	9	O
were	9	O
medically	5	O
compromised	9	O
and	5	O
were	9	O
receiving	9	O
multiple	5	O
pharmacotherapies	5	O
.	9	O

Thus	9	O
,	9	O
two	5	O
control	9	O
groups	9	O
were	9	O
generated	9	O
:	9	O
group	9	O
C1	9	O
,	9	O
which	5	O
included	5	O
age	5	O
-	7	O
and	5	O
sex	5	O
-	7	O
comparable	9	O
lithium	0	B-Chemical
-	7	O
treated	3	O
bipolar	5	B-Disease
normocalcemic	5	O
patients	5	O
,	9	O
and	5	O
group	9	O
C2	9	O
,	9	O
which	5	O
included	5	O
bipolar	5	B-Disease
normocalcemic	5	O
patients	5	O
treated	3	O
with	5	O
anticonvulsant	5	O
mood	5	O
stabilizers	0	O
.	9	O

The	5	O
electrocardiographic	5	O
(	9	O
ECG	5	O
)	9	O
findings	9	O
for	5	O
patients	5	O
in	5	O
group	9	O
B	9	O
were	9	O
compared	9	O
with	5	O
those	5	O
of	5	O
patients	5	O
in	5	O
groups	9	O
C1	9	O
and	5	O
C2	9	O
.	9	O

It	5	O
was	9	O
found	9	O
that	5	O
these	5	O
groups	9	O
did	9	O
not	5	O
differ	9	O
in	5	O
their	5	O
overall	5	O
frequency	5	O
of	5	O
ECG	5	O
abnormalities	9	O
;	9	O
however	9	O
,	9	O
there	5	O
were	9	O
significant	9	O
differences	9	O
in	5	O
the	5	O
frequency	5	O
of	5	O
conduction	5	O
defects	9	O
.	9	O

Patients	5	O
with	5	O
hypercalcemia	5	B-Disease
resulting	9	O
from	9	O
medical	5	O
diseases	5	O
and	5	O
bipolar	5	B-Disease
patients	5	O
with	5	O
lithium	0	B-Chemical
-	7	O
associated	9	O
hypercalcemia	5	B-Disease
had	9	O
significantly	9	O
higher	9	O
frequencies	9	O
of	5	O
conduction	5	O
defects	9	O
.	9	O

Patients	5	O
in	5	O
group	9	O
A	9	O
had	9	O
significant	9	O
mortality	5	O
at	9	O
2	9	O
-	7	O
year	5	O
follow	5	O
-	7	O
up	5	O
(	9	O
28	7	O
%	9	O
)	9	O
,	9	O
in	5	O
contrast	9	O
to	5	O
zero	5	O
mortality	5	O
in	5	O
the	5	O
other	5	O
three	9	O
groups	9	O
.	9	O

The	5	O
clinical	5	O
implications	5	O
of	5	O
these	5	O
findings	9	O
are	5	O
discussed	5	O
.	9	O

Attenuation	9	O
of	5	O
nephrotoxicity	9	B-Disease
by	9	O
a	5	O
novel	9	O
lipid	0	O
nanosphere	0	O
(	9	O
NS	7	O
-	7	O
718	7	O
)	9	O
incorporating	5	O
amphotericin	0	B-Chemical
B	9	I-Chemical
.	9	O

NS	7	O
-	7	O
718	7	O
,	9	O
a	5	O
lipid	0	O
nanosphere	0	O
incorporating	5	O
amphotericin	0	B-Chemical
B	9	I-Chemical
,	9	O
is	5	O
effective	5	O
against	9	O
pathogenic	9	O
fungi	4	O
and	5	O
has	9	O
low	9	O
toxicity	9	B-Disease
.	9	O

We	9	O
compared	9	O
the	5	O
toxicity	9	B-Disease
of	5	O
NS	7	O
-	7	O
718	7	O
with	5	O
that	5	O
of	5	O
Fungizone	0	B-Chemical
(	9	O
amphotericin	0	B-Chemical
B	9	I-Chemical
-	7	I-Chemical
sodium	0	I-Chemical
deoxycholate	0	I-Chemical
;	9	O
D	9	B-Chemical
-	7	I-Chemical
AmB	0	I-Chemical
)	9	O
in	5	O
vitro	3	O
using	9	O
renal	9	O
cell	3	O
cultures	3	O
and	5	O
in	5	O
vivo	3	O
by	9	O
biochemical	9	O
analysis	9	O
,	9	O
histopathological	9	O
study	9	O
of	5	O
the	5	O
kidney	9	O
and	5	O
pharmacokinetic	5	O
study	9	O
of	5	O
amphotericin	0	B-Chemical
B	9	I-Chemical
following	9	O
intravenous	0	O
infusion	0	O
of	5	O
the	5	O
formulation	5	O
in	5	O
rats	9	O
.	9	O

Incubation	0	O
with	5	O
NS	7	O
-	7	O
718	7	O
resulted	9	O
in	5	O
significantly	9	O
less	5	O
damage	9	O
of	5	O
cultured	3	O
human	3	O
renal	9	O
proximal	9	O
tubular	9	O
epithelial	3	O
cells	3	O
compared	9	O
with	5	O
D	9	B-Chemical
-	7	I-Chemical
AmB	0	I-Chemical
.	9	O

Serum	9	O
blood	9	O
urea	0	B-Chemical
and	5	O
creatinine	0	B-Chemical
concentrations	0	O
increased	9	O
significantly	9	O
in	5	O
rats	9	O
given	5	O
an	5	O
iv	9	O
infusion	0	O
of	5	O
D	9	B-Chemical
-	7	I-Chemical
AmB	0	I-Chemical
3	9	O
mg	0	O
/	9	O
kg	0	O
but	9	O
not	5	O
in	5	O
those	5	O
given	5	O
the	5	O
same	9	O
dose	9	O
of	5	O
NS	7	O
-	7	O
718	7	O
.	9	O

Histopathological	9	O
examination	5	O
of	5	O
the	5	O
kidney	9	O
showed	9	O
tubular	9	B-Disease
necrosis	9	I-Disease
in	5	O
D	9	B-Chemical
-	7	I-Chemical
AmB	0	I-Chemical
-	7	O
treated	3	O
rats	9	O
but	9	O
no	9	O
change	9	O
in	5	O
NS	7	O
-	7	O
718	7	O
-	7	O
treated	3	O
rats	9	O
.	9	O

Amphotericin	0	B-Chemical
B	9	I-Chemical
concentrations	0	O
in	5	O
the	5	O
kidney	9	O
in	5	O
NS	7	O
-	7	O
718	7	O
-	7	O
treated	3	O
rats	9	O
were	9	O
higher	9	O
than	5	O
those	5	O
in	5	O
D	9	B-Chemical
-	7	I-Chemical
AmB	0	I-Chemical
-	7	O
treated	3	O
rats	9	O
.	9	O

Our	9	O
in	5	O
vitro	3	O
and	5	O
in	5	O
vivo	3	O
results	9	O
suggest	9	O
that	5	O
incorporation	0	O
of	5	O
amphotericin	0	B-Chemical
B	9	I-Chemical
into	9	O
lipid	0	O
nanospheres	0	O
of	5	O
NS	7	O
-	7	O
718	7	O
attenuates	3	O
the	5	O
nephrotoxicity	9	B-Disease
of	5	O
amphotericin	0	B-Chemical
B	9	I-Chemical
.	9	O

Patterns	5	O
of	5	O
sulfadiazine	0	B-Chemical
acute	9	B-Disease
nephrotoxicity	9	I-Disease
.	9	O

Sulfadiazine	7	B-Chemical
acute	9	B-Disease
nephrotoxicity	9	I-Disease
is	5	O
reviving	5	O
specially	5	O
because	5	O
of	5	O
its	9	O
use	5	O
in	5	O
toxoplasmosis	5	B-Disease
in	5	O
HIV	5	O
-	7	O
positive	9	O
patients	5	O
.	9	O

We	9	O
report	5	O
4	9	O
cases	5	O
,	9	O
one	5	O
of	5	O
them	5	O
in	5	O
a	5	O
previously	9	O
healthy	5	O
person	5	O
.	9	O

Under	9	O
treatment	9	O
with	5	O
sulfadiazine	0	B-Chemical
they	5	O
developed	5	O
oliguria	5	B-Disease
,	9	O
abdominal	5	B-Disease
pain	5	I-Disease
,	9	O
renal	9	B-Disease
failure	5	I-Disease
and	5	O
showed	9	O
multiple	5	O
radiolucent	5	O
renal	9	B-Disease
calculi	5	I-Disease
in	5	O
echography	5	O
.	9	O

All	9	O
patients	5	O
recovered	9	O
their	5	O
previous	9	O
normal	9	O
renal	9	O
function	9	O
after	9	O
adequate	5	O
hydration	0	O
and	5	O
alcalinization	9	O
.	9	O

A	9	O
nephrostomy	5	O
tube	9	O
had	9	O
to	5	O
be	5	O
placed	5	O
in	5	O
one	5	O
of	5	O
the	5	O
patients	5	O
for	5	O
ureteral	5	B-Disease
lithiasis	5	I-Disease
in	5	O
a	5	O
single	9	O
functional	9	O
kidney	9	O
.	9	O

None	9	O
of	5	O
them	5	O
needed	5	O
dialysis	5	O
or	5	O
a	5	O
renal	9	O
biopsy	5	O
because	5	O
of	5	O
a	5	O
typical	9	O
benign	5	O
course	5	O
.	9	O

Treatment	9	O
with	5	O
sulfadiazine	0	B-Chemical
requires	5	O
exquisite	5	O
control	9	O
of	5	O
renal	9	O
function	9	O
,	9	O
an	5	O
increase	9	O
in	5	O
water	0	O
ingestion	9	O
and	5	O
possibly	9	O
the	5	O
alcalinization	9	O
of	5	O
the	5	O
urine	9	O
.	9	O

We	9	O
communicate	5	O
a	5	O
case	5	O
in	5	O
a	5	O
previously	9	O
healthy	5	O
person	5	O
,	9	O
a	5	O
fact	9	O
not	5	O
found	9	O
in	5	O
the	5	O
recent	5	O
literature	5	O
.	9	O

Probably	9	O
many	5	O
more	5	O
cases	5	O
are	5	O
not	5	O
detected	9	O
.	9	O

We	9	O
think	5	O
that	5	O
a	5	O
prospective	5	O
study	9	O
would	5	O
be	5	O
useful	5	O
.	9	O

Downbeat	5	B-Disease
nystagmus	5	I-Disease
associated	9	O
with	5	O
intravenous	0	O
patient	5	O
-	7	O
controlled	5	O
administration	9	O
of	5	O
morphine	0	B-Chemical
.	9	O

IMPLICATIONS	2	O
:	9	O
This	5	O
case	5	O
documents	5	O
a	5	O
patient	5	O
who	5	O
developed	5	O
dizziness	5	B-Disease
with	5	O
downbeating	5	B-Disease
nystagmus	5	I-Disease
while	9	O
receiving	9	O
a	5	O
relatively	5	O
large	5	O
dose	9	O
of	5	O
IV	9	O
patient	5	O
-	7	O
controlled	5	O
analgesia	5	O
morphine	0	B-Chemical
.	9	O

Although	9	O
there	5	O
have	5	O
been	9	O
case	5	O
reports	9	O
of	5	O
epidural	5	O
morphine	0	B-Chemical
with	5	O
these	5	O
symptoms	5	O
and	5	O
signs	5	O
,	9	O
this	5	O
has	9	O
not	5	O
been	9	O
previously	9	O
documented	9	O
with	5	O
IV	9	O
or	5	O
patient	5	O
-	7	O
controlled	5	O
analgesia	5	O
morphine	0	B-Chemical
.	9	O

Hemodynamic	5	O
and	5	O
antiadrenergic	5	O
effects	9	O
of	5	O
dronedarone	5	B-Chemical
and	5	O
amiodarone	0	B-Chemical
in	5	O
animals	9	O
with	5	O
a	5	O
healed	5	O
myocardial	9	B-Disease
infarction	5	I-Disease
.	9	O

The	5	O
hemodynamic	5	O
and	5	O
antiadrenergic	5	O
effects	9	O
of	5	O
dronedarone	5	B-Chemical
,	9	O
a	5	O
noniodinated	0	O
compound	0	O
structurally	9	O
related	9	O
to	5	O
amiodarone	0	B-Chemical
,	9	O
were	9	O
compared	9	O
with	5	O
those	5	O
of	5	O
amiodarone	0	B-Chemical
after	9	O
prolonged	9	O
oral	9	O
administration	9	O
,	9	O
both	9	O
at	9	O
rest	5	O
and	5	O
during	5	O
sympathetic	5	O
stimulation	3	O
in	5	O
conscious	5	O
dogs	5	O
with	5	O
a	5	O
healed	5	O
myocardial	9	B-Disease
infarction	5	I-Disease
.	9	O

All	9	O
dogs	5	O
(	9	O
n	9	O
=	7	O
6	9	O
)	9	O
randomly	5	O
received	9	O
orally	0	O
dronedarone	5	B-Chemical
(	9	O
10	9	O
and	5	O
30	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
,	9	O
amiodarone	0	B-Chemical
(	9	O
10	9	O
and	5	O
30	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
,	9	O
and	5	O
placebo	9	O
twice	9	O
daily	5	O
for	5	O
7	9	O
days	9	O
,	9	O
with	5	O
a	5	O
3	9	O
-	7	O
week	9	O
washout	0	O
between	5	O
consecutive	5	O
treatments	9	O
.	9	O

Heart	2	O
rate	9	O
(	9	O
HR	9	O
)	9	O
,	9	O
mean	5	O
arterial	5	O
pressure	5	O
(	9	O
MBP	3	O
)	9	O
,	9	O
positive	9	O
rate	9	O
of	5	O
increase	9	O
of	5	O
left	5	O
ventricular	5	O
pressure	5	O
(	9	O
+	9	O
LVdP	7	O
/	9	O
dt	9	O
)	9	O
,	9	O
echocardiographically	5	O
assessed	9	O
left	5	O
ventricular	5	O
ejection	5	O
fraction	9	O
(	9	O
LVEF	5	O
)	9	O
,	9	O
and	5	O
fractional	5	O
shortening	9	O
(	9	O
FS	9	O
)	9	O
,	9	O
as	5	O
well	9	O
as	5	O
chronotropic	5	O
response	9	O
to	5	O
isoproterenol	0	B-Chemical
and	5	O
exercise	5	O
-	7	O
induced	3	O
sympathetic	5	O
stimulation	3	O
were	9	O
evaluated	9	O
under	9	O
baseline	5	O
and	5	O
posttreatment	9	O
conditions	9	O
.	9	O

Resting	9	O
values	5	O
of	5	O
LVEF	5	O
,	9	O
FS	9	O
,	9	O
+	9	O
LVdP	7	O
/	9	O
dt	9	O
,	9	O
and	5	O
MBP	3	O
remained	9	O
unchanged	9	O
whatever	5	O
the	5	O
drug	5	O
and	5	O
the	5	O
dosing	9	O
regimen	5	O
,	9	O
whereas	9	O
resting	5	O
HR	9	O
was	9	O
significantly	9	O
and	5	O
dose	9	O
-	7	O
dependently	3	O
lowered	9	O
after	9	O
dronedarone	5	B-Chemical
and	5	O
to	5	O
a	5	O
lesser	9	O
extent	9	O
after	9	O
amiodarone	0	B-Chemical
.	9	O

Both	9	O
dronedarone	5	B-Chemical
and	5	O
amiodarone	0	B-Chemical
significantly	9	O
reduced	9	O
the	5	O
exercise	5	O
-	7	O
induced	3	O
tachycardia	5	B-Disease
and	5	O
,	9	O
at	9	O
the	5	O
highest	9	O
dose	9	O
,	9	O
decreased	9	O
the	5	O
isoproterenol	0	B-Chemical
-	7	O
induced	3	O
tachycardia	5	B-Disease
.	9	O

Thus	9	O
,	9	O
dronedarone	5	B-Chemical
and	5	O
amiodarone	0	B-Chemical
displayed	9	O
a	5	O
similar	9	O
level	9	O
of	5	O
antiadrenergic	5	O
effect	9	O
and	5	O
did	9	O
not	5	O
impair	9	O
the	5	O
resting	5	O
left	5	O
ventricular	5	O
function	9	O
.	9	O

Consequently	9	O
,	9	O
dronedarone	5	B-Chemical
might	9	O
be	5	O
particularly	5	O
suitable	5	O
for	5	O
the	5	O
treatment	9	O
and	5	O
prevention	5	O
of	5	O
various	9	O
clinical	5	O
arrhythmias	5	B-Disease
,	9	O
without	9	O
compromising	5	O
the	5	O
left	5	O
ventricular	5	O
function	9	O
.	9	O

Phase	9	O
2	9	O
trial	5	O
of	5	O
liposomal	0	O
doxorubicin	0	B-Chemical
(	9	O
40	9	O
mg	0	O
/	9	O
m	9	O
(	9	O
2	9	O
)	9	O
)	9	O
in	5	O
platinum	0	B-Chemical
/	9	O
paclitaxel	0	B-Chemical
-	7	O
refractory	9	O
ovarian	9	B-Disease
and	5	I-Disease
fallopian	5	I-Disease
tube	9	I-Disease
cancers	9	I-Disease
and	5	O
primary	9	O
carcinoma	3	B-Disease
of	5	I-Disease
the	5	I-Disease
peritoneum	9	I-Disease
.	9	O

BACKGROUND	2	O
:	9	O
Several	9	O
studies	9	O
have	5	O
demonstrated	9	O
liposomal	0	O
doxorubicin	0	B-Chemical
(	9	O
Doxil	0	B-Chemical
)	9	O
to	5	O
be	5	O
an	5	O
active	9	O
antineoplastic	9	O
agent	9	O
in	5	O
platinum	0	B-Chemical
-	7	O
resistant	9	O
ovarian	9	B-Disease
cancer	3	I-Disease
,	9	O
with	5	O
dose	9	O
limiting	9	O
toxicity	9	B-Disease
of	5	O
the	5	O
standard	5	O
dosing	9	O
regimen	5	O
(	9	O
50	0	O
mg	0	O
/	9	O
m	9	O
(	9	O
2	9	O
)	9	O
q	9	O
4	9	O
weeks	9	O
)	9	O
being	5	O
severe	5	O
erythrodysesthesia	5	B-Disease
(	9	O
"	5	O
hand	5	B-Disease
-	7	I-Disease
foot	5	I-Disease
syndrome	5	I-Disease
"	5	O
)	9	O
and	5	O
stomatitis	9	B-Disease
.	9	O

We	9	O
wished	9	O
to	5	O
develop	5	O
a	5	O
more	5	O
tolerable	5	O
liposomal	0	O
doxorubicin	0	B-Chemical
treatment	9	O
regimen	5	O
and	5	O
document	5	O
its	9	O
level	9	O
of	5	O
activity	9	O
in	5	O
a	5	O
well	9	O
-	7	O
defined	5	O
patient	5	O
population	5	O
with	5	O
platinum	0	B-Chemical
/	9	O
paclitaxel	0	B-Chemical
-	7	O
refractory	9	O
disease	5	O
.	9	O

METHODS	2	O
AND	2	O
MATERIALS	2	O
:	9	O
Patients	5	O
with	5	O
ovarian	9	B-Disease
or	5	I-Disease
fallopian	5	I-Disease
tube	9	I-Disease
cancers	9	I-Disease
or	5	O
primary	9	O
peritoneal	3	B-Disease
carcinoma	3	I-Disease
with	5	O
platinum	0	B-Chemical
/	9	O
paclitaxel	0	B-Chemical
-	7	O
refractory	9	O
disease	5	O
(	9	O
stable	9	O
or	5	O
progressive	5	O
disease	5	O
following	9	O
treatment	9	O
with	5	O
these	5	O
agents	5	O
or	5	O
previous	9	O
objective	5	O
response	9	O
<	0	O
3	9	O
months	5	O
in	5	O
duration	5	O
)	9	O
were	9	O
treated	3	O
with	5	O
liposomal	0	O
doxorubicin	0	B-Chemical
at	9	O
a	5	O
dose	9	O
of	5	O
40	9	O
mg	0	O
/	9	O
m	9	O
(	9	O
2	9	O
)	9	O
q	9	O
4	9	O
weeks	9	O
.	9	O

RESULTS	9	O
:	9	O
A	9	O
total	9	O
of	5	O
49	7	O
patients	5	O
(	9	O
median	9	O
age	5	O
:	9	O
60	9	O
;	9	O
range	9	O
41	7	O
-	7	O
81	7	O
)	9	O
entered	5	O
this	5	O
phase	5	O
2	9	O
trial	5	O
.	9	O

The	5	O
median	9	O
number	9	O
of	5	O
prior	9	O
regimens	5	O
was	9	O
2	9	O
(	9	O
range	9	O
:	9	O
1	9	O
-	7	O
6	9	O
)	9	O
.	9	O

Six	9	O
(	9	O
12	9	O
%	9	O
)	9	O
and	5	O
4	9	O
(	9	O
8	9	O
%	9	O
)	9	O
patients	5	O
experienced	5	O
grade	9	O
2	9	O
hand	5	B-Disease
-	7	I-Disease
foot	5	I-Disease
syndrome	5	I-Disease
and	5	O
stomatitis	9	B-Disease
,	9	O
respectively	9	O
(	9	O
no	9	O
episodes	5	O
of	5	O
grade	9	O
3	9	O
)	9	O
.	9	O

One	5	O
patient	5	O
developed	5	O
grade	9	O
3	9	O
diarrhea	5	B-Disease
requiring	5	O
hospitalization	5	O
for	5	O
hydration	0	O
.	9	O

Six	9	O
(	9	O
12	9	O
%	9	O
)	9	O
individuals	5	O
required	9	O
dose	9	O
reductions	9	O
.	9	O

The	5	O
median	9	O
number	9	O
of	5	O
courses	5	O
of	5	O
liposomal	0	O
doxorubicin	0	B-Chemical
administered	9	O
on	5	O
this	5	O
protocol	9	O
was	9	O
2	9	O
(	9	O
range	9	O
:	9	O
1	9	O
-	7	O
12	9	O
)	9	O
.	9	O

Four	9	O
of	5	O
44	7	O
patients	5	O
(	9	O
9	7	O
%	9	O
)	9	O
evaluable	9	O
for	5	O
response	9	O
exhibited	9	O
objective	5	O
and	5	O
subjective	5	O
evidence	9	O
of	5	O
an	5	O
antineoplastic	9	O
effect	9	O
of	5	O
therapy	5	O
.	9	O

CONCLUSION	5	O
:	9	O
This	5	O
modified	9	O
liposomal	0	O
doxorubicin	0	B-Chemical
regimen	5	O
results	9	O
in	5	O
less	5	O
toxicity	9	B-Disease
(	9	O
stomatitis	9	B-Disease
,	9	O
hand	5	B-Disease
-	7	I-Disease
foot	5	I-Disease
syndrome	5	I-Disease
)	9	O
than	5	O
the	5	O
standard	5	O
FDA	5	O
-	7	O
approved	2	O
dose	9	O
schedule	5	O
.	9	O

Definite	5	O
,	9	O
although	9	O
limited	5	O
,	9	O
antineoplastic	9	O
activity	9	O
is	5	O
observed	9	O
in	5	O
patients	5	O
with	5	O
well	9	O
-	7	O
defined	5	O
platinum	0	B-Chemical
-	7	O
and	5	O
paclitaxel	0	B-Chemical
-	7	O
refractory	9	O
ovarian	9	B-Disease
cancer	3	I-Disease
.	9	O

Efficacy	5	O
of	5	O
olanzapine	5	B-Chemical
in	5	O
acute	9	O
bipolar	5	B-Disease
mania	5	I-Disease
:	9	O
a	5	O
double	9	O
-	7	O
blind	5	O
,	9	O
placebo	9	O
-	7	O
controlled	5	O
study	9	O
.	9	O

The	5	O
Olanzipine	_	B-Chemical
HGGW	_	O
Study	5	O
Group	9	O
.	9	O

BACKGROUND	2	O
:	9	O
We	9	O
compared	9	O
the	5	O
efficacy	9	O
and	5	O
safety	5	O
of	5	O
olanzapine	5	B-Chemical
vs	7	O
placebo	9	O
for	5	O
the	5	O
treatment	9	O
of	5	O
acute	9	O
bipolar	5	B-Disease
mania	5	I-Disease
.	9	O

METHODS	2	O
:	9	O
Four	9	O
-	7	O
week	9	O
,	9	O
randomized	5	O
,	9	O
double	9	O
-	7	O
blind	5	O
,	9	O
parallel	5	O
study	9	O
.	9	O

A	9	O
total	9	O
of	5	O
115	7	O
patients	5	O
with	5	O
a	5	O
DSM	4	O
-	7	O
IV	9	O
diagnosis	5	O
of	5	O
bipolar	5	B-Disease
disorder	5	I-Disease
,	9	O
manic	5	B-Disease
or	5	O
mixed	9	O
,	9	O
were	9	O
randomized	5	O
to	5	O
olanzapine	5	B-Chemical
,	9	O
5	9	O
to	5	O
20	9	O
mg	0	O
/	9	O
d	9	O
(	9	O
n	9	O
=	7	O
55	7	O
)	9	O
,	9	O
or	5	O
placebo	9	O
(	9	O
n	9	O
=	7	O
60	9	O
)	9	O
.	9	O

The	5	O
primary	9	O
efficacy	9	O
measure	5	O
was	9	O
the	5	O
Young	6	O
-	7	O
Mania	5	B-Disease
Rating	5	O
Scale	5	O
(	9	O
Y	9	O
-	7	O
MRS	9	O
)	9	O
total	9	O
score	5	O
.	9	O

Response	5	O
and	5	O
euthymia	5	O
were	9	O
defined	5	O
,	9	O
a	5	O
priori	5	O
,	9	O
as	5	O
at	9	O
least	9	O
a	5	O
50	0	O
%	9	O
improvement	5	O
from	9	O
baseline	5	O
to	5	O
end	9	O
point	5	O
and	5	O
as	5	O
a	5	O
score	5	O
of	5	O
no	9	O
less	5	O
than	5	O
12	9	O
at	9	O
end	9	O
point	5	O
in	5	O
the	5	O
Y	9	O
-	7	O
MRS	9	O
total	9	O
score	5	O
,	9	O
respectively	9	O
.	9	O

Safety	5	O
was	9	O
assessed	9	O
using	9	O
adverse	5	O
events	5	O
,	9	O
Extrapyramidal	5	B-Disease
Symptom	5	I-Disease
(	9	O
EPS	9	B-Disease
)	9	O
rating	5	O
scales	5	O
,	9	O
laboratory	9	O
values	5	O
,	9	O
electrocardiograms	5	O
,	9	O
vital	5	O
signs	5	O
,	9	O
and	5	O
weight	9	O
change	9	O
.	9	O

RESULTS	9	O
:	9	O
Olanzapine	7	B-Chemical
-	7	O
treated	3	O
patients	5	O
demonstrated	9	O
a	5	O
statistically	9	O
significant	9	O
greater	5	O
mean	5	O
(	9	O
+	9	O
/	9	O
-	7	O
SD	7	O
)	9	O
improvement	5	O
in	5	O
Y	9	O
-	7	O
MRS	9	O
total	9	O
score	5	O
than	5	O
placebo	9	O
-	7	O
treated	3	O
patients	5	O
(	9	O
-	7	O
14	7	O
.	9	O
8	9	O
+	9	O
/	9	O
-	7	O
12	9	O
.	9	O
5	9	O
and	5	O
-	7	O
8	9	O
.	9	O
1	9	O
+	9	O
/	9	O
-	7	O
12	9	O
.	9	O
7	9	O
,	9	O
respectively	9	O
;	9	O
P	9	O
<	0	O
.	9	O
001	9	O
)	9	O
,	9	O
which	5	O
was	9	O
evident	9	O
at	9	O
the	5	O
first	9	O
postbaseline	5	O
observation	9	O
1	9	O
week	9	O
after	9	O
randomization	5	O
and	5	O
was	9	O
maintained	9	O
throughout	9	O
the	5	O
study	9	O
(	9	O
last	5	O
observation	9	O
carried	9	O
forward	9	O
)	9	O
.	9	O

Olanzapine	7	B-Chemical
-	7	O
treated	3	O
patients	5	O
demonstrated	9	O
a	5	O
higher	9	O
rate	9	O
of	5	O
response	9	O
(	9	O
65	7	O
%	9	O
vs	7	O
43	7	O
%	9	O
,	9	O
respectively	9	O
;	9	O
P	9	O
=	7	O
.	9	O
02	7	O
)	9	O
and	5	O
euthymia	5	O
(	9	O
61	7	O
%	9	O
vs	7	O
36	9	O
%	9	O
,	9	O
respectively	9	O
;	9	O
P	9	O
=	7	O
.	9	O
01	7	O
)	9	O
than	5	O
placebo	9	O
-	7	O
treated	3	O
patients	5	O
.	9	O

There	5	O
were	9	O
no	9	O
statistically	9	O
significant	9	O
differences	9	O
in	5	O
EPSs	0	B-Disease
between	5	O
groups	9	O
.	9	O

However	9	O
,	9	O
olanzapine	5	B-Chemical
-	7	O
treated	3	O
patients	5	O
had	9	O
a	5	O
statistically	9	O
significant	9	O
greater	5	O
mean	5	O
(	9	O
+	9	O
/	9	O
-	7	O
SD	7	O
)	9	O
weight	9	B-Disease
gain	5	I-Disease
than	5	O
placebo	9	O
-	7	O
treated	3	O
patients	5	O
(	9	O
2	9	O
.	9	O
1	9	O
+	9	O
/	9	O
-	7	O
2	9	O
.	9	O
8	9	O
vs	7	O
0	7	O
.	9	O
45	9	O
+	9	O
/	9	O
-	7	O
2	9	O
.	9	O
3	9	O
kg	0	O
,	9	O
respectively	9	O
)	9	O
and	5	O
also	9	O
experienced	5	O
more	5	O
treatment	9	O
-	7	O
emergent	5	O
somnolence	5	B-Disease
(	9	O
21	7	O
patients	5	O
[	9	O
38	7	O
.	9	O
2	9	O
%	9	O
]	9	O
vs	7	O
5	9	O
[	9	O
8	9	O
.	9	O
3	9	O
%	9	O
]	9	O
,	9	O
respectively	9	O
)	9	O
.	9	O

CONCLUSION	5	O
:	9	O
Olanzapine	7	B-Chemical
demonstrated	9	O
greater	5	O
efficacy	9	O
than	5	O
placebo	9	O
in	5	O
the	5	O
treatment	9	O
of	5	O
acute	9	O
bipolar	5	B-Disease
mania	5	I-Disease
and	5	O
was	9	O
generally	5	O
well	9	O
tolerated	9	O
.	9	O

The	5	O
effect	9	O
of	5	O
pupil	5	B-Disease
dilation	5	I-Disease
with	5	O
tropicamide	0	B-Chemical
on	5	O
vision	5	O
and	5	O
driving	5	O
simulator	5	O
performance	5	O
.	9	O

PURPOSE	2	O
:	9	O
To	9	O
assess	5	O
the	5	O
effect	9	O
of	5	O
pupil	5	B-Disease
dilation	5	I-Disease
on	5	O
vision	5	O
and	5	O
driving	5	O
ability	9	O
.	9	O

METHODS	2	O
:	9	O
A	9	O
series	5	O
of	5	O
tests	5	O
on	5	O
various	9	O
parameters	5	O
of	5	O
visual	5	O
function	9	O
and	5	O
driving	5	O
simulator	5	O
performance	5	O
were	9	O
performed	9	O
on	5	O
12	9	O
healthy	5	O
drivers	5	O
,	9	O
before	9	O
and	5	O
after	9	O
pupil	5	B-Disease
dilation	5	I-Disease
using	9	O
guttae	5	O
tropicamide	0	B-Chemical
1	9	O
%	9	O
.	9	O

A	9	O
driving	5	O
simulator	5	O
(	9	O
Transport	9	O
Research	2	O
Laboratory	2	O
)	9	O
was	9	O
used	5	O
to	5	O
measure	5	O
reaction	9	O
time	5	O
(	9	O
RT	9	O
)	9	O
,	9	O
speed	5	O
maintenance	9	O
and	5	O
steering	5	O
accuracy	5	O
.	9	O

Tests	5	O
of	5	O
basic	5	O
visual	5	O
function	9	O
included	5	O
high	9	O
-	7	O
and	5	O
low	9	O
-	7	O
contrast	9	O
visual	5	O
acuity	5	O
(	9	O
HCVA	7	O
and	5	O
LCVA	7	O
)	9	O
,	9	O
Pelli	6	O
-	7	O
Robson	6	O
contrast	9	O
threshold	5	O
(	9	O
CT	9	O
)	9	O
and	5	O
Goldmann	6	O
perimetry	5	O
(	9	O
FIELDS	2	O
)	9	O
.	9	O

Useful	5	O
Field	9	O
of	5	O
View	9	O
(	9	O
UFOV	5	O
-	7	O
-	7	O
a	5	O
test	5	O
of	5	O
visual	5	O
attention	5	O
)	9	O
was	9	O
also	9	O
undertaken	5	O
.	9	O

The	5	O
mean	5	O
differences	9	O
in	5	O
the	5	O
pre	9	O
-	7	O
and	5	O
post	9	O
-	7	O
dilatation	5	O
measurements	5	O
were	9	O
tested	9	O
for	5	O
statistical	5	O
significance	9	O
at	9	O
the	5	O
95	7	O
%	9	O
level	9	O
using	9	O
one	5	O
-	7	O
tail	9	O
paired	9	O
t	5	O
-	7	O
tests	5	O
.	9	O

RESULTS	9	O
:	9	O
Pupillary	5	B-Disease
dilation	5	I-Disease
resulted	9	O
in	5	O
a	5	O
statistically	9	O
significant	9	O
deterioration	5	O
in	5	O
CT	9	O
and	5	O
HCVA	7	O
only	9	O
.	9	O

Five	9	O
of	5	O
12	9	O
drivers	5	O
also	9	O
exhibited	9	O
deterioration	5	O
in	5	O
LCVA	7	O
,	9	O
CT	9	O
and	5	O
RT	9	O
.	9	O

Little	9	O
evidence	9	O
emerged	9	O
for	5	O
deterioration	5	O
in	5	O
FIELDS	2	O
and	5	O
UFOV	5	O
.	9	O

Also	9	O
,	9	O
7	9	O
of	5	O
12	9	O
drivers	5	O
appeared	9	O
to	5	O
adjust	5	O
their	5	O
driving	5	O
behaviour	5	O
by	9	O
reducing	9	O
their	5	O
speed	5	O
on	5	O
the	5	O
driving	5	O
simulator	5	O
,	9	O
leading	9	O
to	5	O
improved	5	O
steering	5	O
accuracy	5	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Pupillary	5	B-Disease
dilation	5	I-Disease
may	5	O
lead	5	O
to	5	O
a	5	O
decrease	9	O
in	5	O
vision	5	O
and	5	O
daylight	5	O
driving	5	O
performance	5	O
in	5	O
young	5	O
people	5	O
.	9	O

A	9	O
larger	5	O
study	9	O
,	9	O
including	9	O
a	5	O
broader	5	O
spectrum	9	O
of	5	O
subjects	5	O
,	9	O
is	5	O
warranted	9	O
before	9	O
guidelines	5	O
can	5	O
be	5	O
recommended	5	O
.	9	O

A	9	O
case	5	O
of	5	O
isotretinoin	5	B-Disease
embryopathy	5	I-Disease
with	5	O
bilateral	5	O
anotia	5	B-Disease
and	5	O
Taussig	6	B-Disease
-	7	I-Disease
Bing	6	I-Disease
malformation	5	I-Disease
.	9	O

We	9	O
report	5	O
a	5	O
newborn	9	O
infant	5	O
with	5	O
multiple	5	O
congenital	5	O
anomalies	5	O
(	9	O
anotia	5	B-Disease
and	5	O
Taussig	6	B-Disease
-	7	I-Disease
Bing	6	I-Disease
malformation	5	I-Disease
)	9	O
due	5	O
to	5	O
exposure	9	O
to	5	O
isotretinoin	5	B-Chemical
within	9	O
the	5	O
first	9	O
trimester	5	O
.	9	O

In	9	O
this	5	O
paper	5	O
we	5	O
aim	5	O
to	5	O
draw	5	O
to	5	O
the	5	O
fact	9	O
that	5	O
caution	5	O
is	5	O
needed	5	O
when	5	O
prescribing	5	O
vitamin	0	B-Chemical
A	9	I-Chemical
-	7	O
containing	0	O
drugs	5	O
to	5	O
women	5	O
of	5	O
childbearing	5	O
years	5	O
.	9	O

Effect	0	O
of	5	O
methoxamine	0	B-Chemical
on	5	O
maximum	5	O
urethral	5	O
pressure	5	O
in	5	O
women	5	O
with	5	O
genuine	5	O
stress	9	B-Disease
incontinence	5	I-Disease
:	9	O
a	5	O
placebo	9	O
-	7	O
controlled	5	O
,	9	O
double	9	O
-	7	O
blind	5	O
crossover	5	O
study	9	O
.	9	O

The	5	O
aim	5	O
of	5	O
the	5	O
study	9	O
was	9	O
to	5	O
evaluate	9	O
the	5	O
potential	9	O
role	9	O
for	5	O
a	5	O
selective	9	O
alpha1	9	O
-	7	O
adrenoceptor	5	O
agonist	3	O
in	5	O
the	5	O
treatment	9	O
of	5	O
urinary	9	B-Disease
stress	9	I-Disease
incontinence	5	I-Disease
.	9	O

A	9	O
randomised	5	O
,	9	O
double	9	O
-	7	O
blind	5	O
,	9	O
placebo	9	O
-	7	O
controlled	5	O
,	9	O
crossover	5	O
study	9	O
design	5	O
was	9	O
employed	5	O
.	9	O

Half	9	O
log	9	O
incremental	5	O
doses	0	O
of	5	O
intravenous	0	O
methoxamine	0	B-Chemical
or	5	O
placebo	9	O
(	9	O
saline	0	O
)	9	O
were	9	O
administered	9	O
to	5	O
a	5	O
group	9	O
of	5	O
women	5	O
with	5	O
genuine	5	O
stress	9	B-Disease
incontinence	5	I-Disease
while	9	O
measuring	9	O
maximum	5	O
urethral	5	O
pressure	5	O
(	9	O
MUP	9	O
)	9	O
,	9	O
blood	9	O
pressure	5	O
,	9	O
heart	5	O
rate	9	O
,	9	O
and	5	O
symptomatic	5	O
side	5	O
effects	9	O
.	9	O

Methoxamine	0	B-Chemical
evoked	5	O
non	9	O
-	7	O
significant	9	O
increases	9	O
in	5	O
MUP	9	O
and	5	O
diastolic	5	O
blood	9	O
pressure	5	O
but	9	O
caused	9	O
a	5	B-Disease
significant	9	I-Disease
rise	9	I-Disease
in	5	I-Disease
systolic	5	I-Disease
blood	9	I-Disease
pressure	5	I-Disease
and	5	O
significant	9	O
fall	5	O
in	5	O
heart	5	O
rate	9	O
at	9	O
maximum	5	O
dosage	9	O
.	9	O

Systemic	9	O
side	5	O
effects	9	O
including	9	O
piloerection	5	O
,	9	O
headache	5	B-Disease
,	9	O
and	5	O
cold	9	O
extremities	5	O
were	9	O
experienced	5	O
in	5	O
all	5	O
subjects	5	O
.	9	O

The	5	O
results	9	O
indicate	9	O
that	5	O
the	5	O
clinical	5	O
usefulness	5	O
of	5	O
direct	9	O
,	9	O
peripherally	9	O
acting	9	O
sub	9	O
-	7	O
type	9	O
-	7	O
selective	9	O
alpha1	9	O
-	7	O
adrenoceptor	5	O
agonists	3	O
in	5	O
the	5	O
medical	5	O
treatment	9	O
of	5	O
stress	9	B-Disease
incontinence	5	I-Disease
may	5	O
be	5	O
limited	5	O
by	9	O
associated	9	O
piloerection	5	O
and	5	O
cardiovascular	5	O
side	5	O
effects	9	O
.	9	O

Hyperglycemic	3	B-Disease
effect	9	O
of	5	O
amino	1	B-Chemical
compounds	0	O
structurally	9	O
related	9	O
to	5	O
caproate	0	B-Chemical
in	5	O
rats	9	O
.	9	O

The	5	O
chronic	5	O
feeding	5	O
of	5	O
small	9	O
amounts	9	O
(	9	O
0	7	O
.	9	O
3	9	O
-	7	O
3	9	O
%	9	O
of	5	O
diet	9	O
weight	9	O
)	9	O
of	5	O
certain	5	O
amino	1	B-Chemical
derivatives	0	O
of	5	O
caproate	0	B-Chemical
resulted	9	O
in	5	O
hyperglycemia	9	B-Disease
,	9	O
an	5	O
elevated	9	O
glucose	0	B-Chemical
tolerance	9	O
curve	9	O
and	5	O
,	9	O
occasionally	5	O
,	9	O
glucosuria	5	B-Disease
.	9	O

Effective	5	O
compounds	0	O
included	5	O
norleucine	0	B-Chemical
,	9	O
norvaline	0	B-Chemical
,	9	O
glutamate	0	B-Chemical
,	9	O
epsilon	9	B-Chemical
-	7	I-Chemical
aminocaproate	0	I-Chemical
,	9	O
methionine	0	B-Chemical
,	9	O
and	5	O
leucine	0	B-Chemical
.	9	O

Toleration	9	O
of	5	O
high	9	O
doses	0	O
of	5	O
angiotensin	9	B-Chemical
-	7	I-Chemical
converting	9	I-Chemical
enzyme	0	I-Chemical
inhibitors	3	I-Chemical
in	5	O
patients	5	O
with	5	O
chronic	5	O
heart	5	B-Disease
failure	5	I-Disease
:	9	O
results	9	O
from	9	O
the	5	O
ATLAS	2	O
trial	5	O
.	9	O

The	5	O
Assessment	5	O
of	5	O
Treatment	9	O
with	5	O
Lisinopril	0	B-Chemical
and	5	O
Survival	9	O
.	9	O

BACKGROUND	2	O
:	9	O
Treatment	9	O
with	5	O
angiotensin	9	B-Chemical
-	7	I-Chemical
converting	9	I-Chemical
enzyme	0	I-Chemical
(	9	I-Chemical
ACE	9	I-Chemical
)	9	I-Chemical
inhibitors	3	I-Chemical
reduces	9	O
mortality	5	O
and	5	O
morbidity	5	O
in	5	O
patients	5	O
with	5	O
chronic	5	O
heart	5	B-Disease
failure	5	I-Disease
(	9	O
CHF	9	B-Disease
)	9	O
,	9	O
but	9	O
most	9	O
affected	9	O
patients	5	O
are	5	O
not	5	O
receiving	9	O
these	5	O
agents	5	O
or	5	O
are	5	O
being	5	O
treated	3	O
with	5	O
doses	0	O
lower	9	O
than	5	O
those	5	O
found	9	O
to	5	O
be	5	O
efficacious	5	O
in	5	O
trials	5	O
,	9	O
primarily	9	O
because	5	O
of	5	O
concerns	5	O
about	5	O
the	5	O
safety	5	O
and	5	O
tolerability	5	O
of	5	O
these	5	O
agents	5	O
,	9	O
especially	5	O
at	9	O
the	5	O
recommended	5	O
doses	0	O
.	9	O

The	5	O
present	9	O
study	9	O
examines	5	O
the	5	O
safety	5	O
and	5	O
tolerability	5	O
of	5	O
high	9	O
-	7	O
compared	9	O
with	5	O
low	9	O
-	7	O
dose	9	O
lisinopril	0	B-Chemical
in	5	O
CHF	9	B-Disease
.	9	O

METHODS	2	O
:	9	O
The	5	O
Assessment	5	O
of	5	O
Lisinopril	0	B-Chemical
and	5	O
Survival	9	O
study	9	O
was	9	O
a	5	O
multicenter	5	O
,	9	O
randomized	5	O
,	9	O
double	9	O
-	7	O
blind	5	O
trial	5	O
in	5	O
which	5	O
patients	5	O
with	5	O
or	5	O
without	9	O
previous	9	O
ACE	9	B-Chemical
inhibitor	3	I-Chemical
treatment	9	O
were	9	O
stabilized	9	O
receiving	9	O
medium	0	O
-	7	O
dose	9	O
lisinopril	0	B-Chemical
(	9	O
12	9	O
.	9	O
5	9	O
or	5	O
15	9	O
.	9	O
0	7	O
mg	0	O
once	5	O
daily	5	O
[	9	O
OD	9	O
]	9	O
)	9	O
for	5	O
2	9	O
to	5	O
4	9	O
weeks	9	O
and	5	O
then	9	O
randomized	5	O
to	5	O
high	9	O
-	7	O
(	9	O
35	9	O
.	9	O
0	7	O
or	5	O
32	7	O
.	9	O
5	9	O
mg	0	O
OD	9	O
)	9	O
or	5	O
low	9	O
-	7	O
dose	9	O
(	9	O
5	9	O
.	9	O
0	7	O
or	5	O
2	9	O
.	9	O
5	9	O
mg	0	O
OD	9	O
)	9	O
groups	9	O
.	9	O

Patients	5	O
with	5	O
New	2	O
York	2	O
Heart	2	O
Association	2	O
classes	5	O
II	9	O
to	5	O
IV	9	O
CHF	9	B-Disease
and	5	O
left	5	O
ventricular	5	O
ejection	5	O
fractions	0	O
of	5	O
no	9	O
greater	5	O
than	5	O
0	7	O
.	9	O
30	9	O
(	9	O
n	9	O
=	7	O
3164	7	O
)	9	O
were	9	O
randomized	5	O
and	5	O
followed	9	O
up	5	O
for	5	O
a	5	O
median	9	O
of	5	O
46	7	O
months	5	O
.	9	O

We	9	O
examined	9	O
the	5	O
occurrence	5	O
of	5	O
adverse	5	O
events	5	O
and	5	O
the	5	O
need	5	O
for	5	O
discontinuation	5	O
and	5	O
dose	9	O
reduction	9	O
during	5	O
treatment	9	O
,	9	O
with	5	O
a	5	O
focus	5	O
on	5	O
hypotension	5	B-Disease
and	5	O
renal	9	B-Disease
dysfunction	9	I-Disease
.	9	O

RESULTS	9	O
:	9	O
Of	9	O
405	9	O
patients	5	O
not	5	O
previously	9	O
receiving	9	O
an	5	O
ACE	9	B-Chemical
inhibitor	3	I-Chemical
,	9	O
doses	0	O
in	5	O
only	9	O
4	9	O
.	9	O
2	9	O
%	9	O
could	9	O
not	5	O
be	5	O
titrated	0	O
to	5	O
the	5	O
medium	0	O
doses	0	O
required	9	O
for	5	O
randomization	5	O
because	5	O
of	5	O
symptoms	5	O
possibly	9	O
related	9	O
to	5	O
hypotension	5	B-Disease
(	9	O
2	9	O
.	9	O
0	7	O
%	9	O
)	9	O
or	5	O
because	5	O
of	5	O
renal	9	B-Disease
dysfunction	9	I-Disease
or	5	O
hyperkalemia	5	B-Disease
(	9	O
2	9	O
.	9	O
3	9	O
%	9	O
)	9	O
.	9	O

Doses	0	O
in	5	O
more	5	O
than	5	O
90	9	O
%	9	O
of	5	O
randomized	5	O
patients	5	O
in	5	O
the	5	O
high	9	O
-	7	O
and	5	O
low	9	O
-	7	O
dose	9	O
groups	9	O
were	9	O
titrated	0	O
to	5	O
their	5	O
assigned	5	O
target	9	O
,	9	O
and	5	O
the	5	O
mean	5	O
doses	0	O
of	5	O
blinded	5	O
medication	5	O
in	5	O
both	9	O
groups	9	O
remained	9	O
similar	9	O
throughout	9	O
the	5	O
study	9	O
.	9	O

Withdrawals	5	O
occurred	9	O
in	5	O
27	7	O
.	9	O
1	9	O
%	9	O
of	5	O
the	5	O
high	9	O
-	7	O
and	5	O
30	9	O
.	9	O
7	9	O
%	9	O
of	5	O
the	5	O
low	9	O
-	7	O
dose	9	O
groups	9	O
.	9	O

Subgroups	5	O
presumed	9	O
to	5	O
be	5	O
at	9	O
higher	9	O
risk	5	O
for	5	O
ACE	9	B-Chemical
inhibitor	3	I-Chemical
intolerance	5	O
(	9	O
blood	9	O
pressure	5	O
,	9	O
<	0	O
120	9	O
mm	9	O
Hg	0	O
;	9	O
creatinine	0	B-Chemical
,	9	O
>	0	O
or	5	O
=	7	O
132	7	O
.	9	O
6	9	O
micromol	0	O
/	9	O
L	0	O
[	9	O
>	0	O
or	5	O
=	7	O
1	9	O
.	9	O
5	9	O
mg	0	O
/	9	O
dL	7	O
]	9	O
;	9	O
age	5	O
,	9	O
>	0	O
or	5	O
=	7	O
70	9	O
years	5	O
;	9	O
and	5	O
patients	5	O
with	5	O
diabetes	5	B-Disease
)	9	O
generally	5	O
tolerated	9	O
the	5	O
high	9	O
-	7	O
dose	9	O
strategy	5	O
.	9	O

CONCLUSIONS	5	O
:	9	O
These	5	O
findings	9	O
demonstrate	9	O
that	5	O
ACE	9	B-Chemical
inhibitor	3	I-Chemical
therapy	5	O
in	5	O
most	9	O
patients	5	O
with	5	O
CHF	9	B-Disease
can	5	O
be	5	O
successfully	5	O
titrated	0	O
to	5	O
and	5	O
maintained	9	O
at	9	O
high	9	O
doses	0	O
,	9	O
and	5	O
that	5	O
more	5	O
aggressive	5	O
use	5	O
of	5	O
these	5	O
agents	5	O
is	5	O
warranted	9	O
.	9	O

Cocaine	5	B-Chemical
,	9	O
ethanol	0	B-Chemical
,	9	O
and	5	O
cocaethylene	0	B-Chemical
cardiotoxity	9	B-Disease
in	5	O
an	5	O
animal	5	O
model	5	O
of	5	O
cocaine	5	B-Disease
and	5	I-Disease
ethanol	0	I-Disease
abuse	5	I-Disease
.	9	O

OBJECTIVES	2	O
:	9	O
Simultaneous	9	O
abuse	5	B-Disease
of	5	I-Disease
cocaine	5	I-Disease
and	5	I-Disease
ethanol	0	I-Disease
affects	9	O
12	9	O
million	5	O
Americans	5	O
annually	5	O
.	9	O

In	9	O
combination	9	O
,	9	O
these	5	O
substances	0	O
are	5	O
substantially	9	O
more	5	O
toxic	0	O
than	5	O
either	9	O
drug	5	O
alone	9	O
.	9	O

Their	5	O
combined	9	O
cardiac	5	B-Disease
toxicity	9	I-Disease
may	5	O
be	5	O
due	5	O
to	5	O
independent	9	O
effects	9	O
of	5	O
each	5	O
drug	5	O
;	9	O
however	9	O
,	9	O
they	5	O
may	5	O
also	9	O
be	5	O
due	5	O
to	5	O
cocaethylene	0	B-Chemical
(	9	O
CE	9	B-Chemical
)	9	O
,	9	O
a	5	O
cocaine	5	B-Chemical
metabolite	0	O
formed	9	O
only	9	O
in	5	O
the	5	O
presence	9	O
of	5	O
ethanol	0	B-Chemical
.	9	O

The	5	O
purpose	5	O
of	5	O
this	5	O
study	9	O
was	9	O
to	5	O
delineate	9	O
the	5	O
role	9	O
of	5	O
CE	9	B-Chemical
in	5	O
the	5	O
combined	9	O
cardiotoxicity	9	B-Disease
of	5	O
cocaine	5	B-Chemical
and	5	O
ethanol	0	B-Chemical
in	5	O
a	5	O
model	5	O
simulating	5	O
their	5	O
abuse	5	O
.	9	O

METHODS	2	O
:	9	O
Twenty	9	O
-	7	O
three	9	O
dogs	5	O
were	9	O
randomized	5	O
to	5	O
receive	5	O
either	9	O
1	9	O
)	9	O
three	9	O
intravenous	0	O
(	9	O
IV	9	O
)	9	O
boluses	5	O
of	5	O
cocaine	5	B-Chemical
7	9	O
.	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
with	5	O
ethanol	0	B-Chemical
(	9	O
1	9	O
g	0	O
/	9	O
kg	0	O
)	9	O
as	5	O
an	5	O
IV	9	O
infusion	0	O
(	9	O
C	9	O
+	9	O
E	9	O
,	9	O
n	9	O
=	7	O
8	9	O
)	9	O
,	9	O
2	9	O
)	9	O
three	9	O
cocaine	5	B-Chemical
boluses	5	O
only	9	O
(	9	O
C	9	O
,	9	O
n	9	O
=	7	O
6	9	O
)	9	O
,	9	O
3	9	O
)	9	O
ethanol	0	B-Chemical
infusion	0	O
only	9	O
(	9	O
E	9	O
,	9	O
n	9	O
=	7	O
5	9	O
)	9	O
,	9	O
or	5	O
4	9	O
)	9	O
placebo	9	O
boluses	5	O
and	5	O
infusion	0	O
(	9	O
n	9	O
=	7	O
4	9	O
)	9	O
.	9	O

Hemodynamic	5	O
measurements	5	O
,	9	O
electrocardiograms	5	O
,	9	O
and	5	O
serum	9	O
drug	5	O
concentrations	0	O
were	9	O
obtained	9	O
at	9	O
baseline	5	O
,	9	O
and	5	O
then	9	O
at	9	O
fixed	9	O
time	5	O
intervals	5	O
after	9	O
each	5	O
drug	5	O
was	9	O
administered	9	O
.	9	O

RESULTS	9	O
:	9	O
Two	9	O
of	5	O
eight	9	O
dogs	5	O
in	5	O
the	5	O
C	9	O
+	9	O
E	9	O
group	9	O
experienced	5	O
cardiovascular	5	B-Disease
collapse	5	I-Disease
.	9	O

The	5	O
most	9	O
dramatic	9	O
hemodynamic	5	O
changes	9	O
occurred	9	O
after	9	O
each	5	O
cocaine	5	B-Chemical
bolus	0	O
in	5	O
the	5	O
C	9	O
+	9	O
E	9	O
and	5	O
C	9	O
only	9	O
groups	9	O
;	9	O
however	9	O
,	9	O
persistent	5	O
hemodynamic	5	O
changes	9	O
occurred	9	O
in	5	O
the	5	O
C	9	O
+	9	O
E	9	O
group	9	O
.	9	O

Peak	9	O
CE	9	B-Chemical
levels	3	O
were	9	O
associated	9	O
with	5	O
a	5	O
45	9	O
%	9	O
(	9	O
SD	7	O
+	9	O
/	9	O
-	7	O
22	7	O
%	9	O
,	9	O
95	7	O
%	9	O
CI	7	O
=	7	O
22	7	O
%	9	O
to	5	O
69	7	O
%	9	O
)	9	O
decrease	9	B-Disease
in	5	I-Disease
cardiac	5	I-Disease
output	5	I-Disease
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
,	9	O
a	5	O
56	7	O
%	9	O
(	9	O
SD	7	O
+	9	O
/	9	O
-	7	O
23	7	O
%	9	O
,	9	O
95	7	O
%	9	O
CI	7	O
=	7	O
32	7	O
%	9	O
to	5	O
80	9	O
%	9	O
)	9	O
decrease	9	O
in	5	O
dP	5	O
/	9	O
dt	9	O
(	9	O
max	9	O
)	9	O
(	9	O
p	7	O
<	0	O
.	9	O
006	7	O
)	9	O
,	9	O
and	5	O
a	5	O
23	7	O
%	9	O
(	9	O
SD	7	O
+	9	O
/	9	O
-	7	O
15	9	O
%	9	O
,	9	O
95	7	O
%	9	O
CI	7	O
=	7	O
7	9	O
%	9	O
to	5	O
49	7	O
%	9	O
)	9	O
decrease	9	O
in	5	O
SVO	5	O
(	9	O
2	9	O
)	9	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
025	7	O
)	9	O
.	9	O

Ventricular	5	B-Disease
arrhythmias	5	I-Disease
were	9	O
primarily	9	O
observed	9	O
in	5	O
the	5	O
C	9	O
+	9	O
E	9	O
group	9	O
,	9	O
in	5	O
which	5	O
four	9	O
of	5	O
eight	9	O
dogs	5	O
experienced	5	O
ventricular	5	B-Disease
tachycardia	5	I-Disease
.	9	O

CONCLUSIONS	5	O
:	9	O
Cocaine	5	B-Chemical
and	5	O
ethanol	0	B-Chemical
in	5	O
combination	9	O
were	9	O
more	5	O
toxic	0	O
than	5	O
either	9	O
substance	5	O
alone	9	O
.	9	O

Co	0	O
-	7	O
administration	9	O
resulted	9	O
in	5	O
prolonged	9	O
cardiac	5	B-Disease
toxicity	9	I-Disease
and	5	O
was	9	O
dysrhythmogenic	9	O
.	9	O

Peak	9	O
serum	9	O
cocaethylene	0	B-Chemical
concentrations	0	O
were	9	O
associated	9	O
with	5	O
prolonged	9	O
myocardial	9	B-Disease
depression	5	I-Disease
.	9	O

Worsening	5	O
of	5	O
Parkinsonism	5	B-Disease
after	9	O
the	5	O
use	5	O
of	5	O
veralipride	5	B-Chemical
for	5	O
treatment	9	O
of	5	O
menopause	5	O
:	9	O
case	5	O
report	5	O
.	9	O

We	9	O
describe	5	O
a	5	O
female	9	O
patient	5	O
with	5	O
stable	9	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
who	5	O
has	9	O
shown	9	O
a	5	O
marked	9	O
worsening	5	O
of	5	O
her	5	O
motor	5	O
functions	9	O
following	9	O
therapy	5	O
of	5	O
menopause	5	O
related	9	O
symptoms	5	O
with	5	O
veralipride	5	B-Chemical
,	9	O
as	5	O
well	9	O
as	5	O
the	5	O
improvement	5	O
of	5	O
her	5	O
symptoms	5	O
back	5	O
to	5	O
baseline	5	O
after	9	O
discontinuation	5	O
of	5	O
the	5	O
drug	5	O
.	9	O

We	9	O
emphasize	5	O
the	5	O
anti	3	O
-	7	O
dopaminergic	5	O
effect	9	O
of	5	O
veralipride	5	B-Chemical
.	9	O

Viracept	7	B-Chemical
and	5	O
irregular	5	B-Disease
heartbeat	5	I-Disease
warning	5	O
.	9	O

A	9	O
group	9	O
of	5	O
doctors	5	O
in	5	O
Boston	2	O
warn	5	O
that	5	O
the	5	O
protease	0	O
inhibitor	3	O
Viracept	7	B-Chemical
may	5	O
cause	5	O
an	5	O
irregular	5	B-Disease
heart	5	I-Disease
beat	5	I-Disease
,	9	O
known	9	O
as	5	O
bradycardia	5	B-Disease
,	9	O
in	5	O
people	5	O
with	5	O
HIV	5	O
.	9	O

Bradycardia	7	B-Disease
occurred	9	O
in	5	O
a	5	O
45	9	O
-	7	O
year	5	O
-	7	O
old	5	O
male	9	O
patient	5	O
who	5	O
was	9	O
Viracept	7	B-Chemical
in	5	O
combination	9	O
with	5	O
other	5	O
anti	3	O
-	7	O
HIV	5	O
drugs	5	O
.	9	O

The	5	O
symptoms	5	O
ceased	5	O
after	9	O
switching	5	O
to	5	O
another	9	O
drug	5	O
combination	9	O
.	9	O

Frequency	5	O
of	5	O
appearance	9	O
of	5	O
myeloperoxidase	0	O
-	7	O
antineutrophil	3	O
cytoplasmic	3	O
antibody	3	O
(	9	O
MPO	0	O
-	7	O
ANCA	3	O
)	9	O
in	5	O
Graves	5	B-Disease
'	9	I-Disease
disease	5	I-Disease
patients	5	O
treated	3	O
with	5	O
propylthiouracil	0	B-Chemical
and	5	O
the	5	O
relationship	5	O
between	5	O
MPO	0	O
-	7	O
ANCA	3	O
and	5	O
clinical	5	O
manifestations	5	O
.	9	O

OBJECTIVE	2	O
:	9	O
Myeloperoxidase	0	O
antineutrophil	3	O
cytoplasmic	3	O
antibody	3	O
(	9	O
MPO	0	O
-	7	O
ANCA	3	O
)	9	O
-	7	O
positive	9	O
vasculitis	5	B-Disease
has	9	O
been	9	O
reported	9	O
in	5	O
patients	5	O
with	5	O
Graves	5	B-Disease
'	9	I-Disease
disease	5	I-Disease
who	5	O
were	9	O
treated	3	O
with	5	O
propylthiouracil	0	B-Chemical
(	9	O
PTU	0	B-Chemical
)	9	O
.	9	O

The	5	O
appearance	9	O
of	5	O
MPO	0	O
-	7	O
ANCA	3	O
in	5	O
these	5	O
cases	5	O
was	9	O
suspected	5	O
of	5	O
being	5	O
related	9	O
to	5	O
PTU	0	B-Chemical
because	5	O
the	5	O
titres	9	O
of	5	O
MPO	0	O
-	7	O
ANCA	3	O
decreased	9	O
when	5	O
PTU	0	B-Chemical
was	9	O
stopped	9	O
.	9	O

Nevertheless	9	O
,	9	O
there	5	O
have	5	O
been	9	O
no	9	O
studies	9	O
on	5	O
the	5	O
temporal	5	O
relationship	5	O
between	5	O
the	5	O
appearance	9	O
of	5	O
MPO	0	O
-	7	O
ANCA	3	O
and	5	O
vasculitis	5	B-Disease
during	5	O
PTU	0	B-Chemical
therapy	5	O
,	9	O
or	5	O
on	5	O
the	5	O
incidence	5	O
of	5	O
MPO	0	O
-	7	O
ANCA	3	O
in	5	O
untreated	3	O
Graves	5	B-Disease
'	9	I-Disease
disease	5	I-Disease
patients	5	O
.	9	O

Therefore	9	O
,	9	O
we	5	O
sought	9	O
to	5	O
address	5	O
these	5	O
parameters	5	O
in	5	O
patients	5	O
with	5	O
Graves	5	B-Disease
'	9	I-Disease
disease	5	I-Disease
.	9	O

PATIENTS	2	O
:	9	O
We	9	O
investigated	9	O
102	7	O
untreated	3	O
patients	5	O
with	5	O
hyperthyroidism	5	B-Disease
due	5	O
to	5	O
Graves	5	B-Disease
'	9	I-Disease
disease	5	I-Disease
for	5	O
the	5	O
presence	9	O
of	5	O
MPO	0	O
-	7	O
ANCA	3	O
,	9	O
and	5	O
for	5	O
the	5	O
development	9	O
vasculitis	5	B-Disease
after	9	O
starting	9	O
PTU	0	B-Chemical
therapy	5	O
.	9	O

Twenty	9	O
-	7	O
nine	9	O
of	5	O
them	5	O
were	9	O
later	9	O
excluded	9	O
because	5	O
of	5	O
adverse	5	O
effects	9	O
of	5	O
PTU	0	B-Chemical
or	5	O
because	5	O
the	5	O
observation	9	O
period	5	O
was	9	O
less	5	O
than	5	O
3	9	O
months	5	O
.	9	O

The	5	O
remaining	9	O
73	7	O
patients	5	O
(	9	O
55	7	O
women	5	O
and	5	O
18	7	O
men	5	O
)	9	O
,	9	O
all	5	O
of	5	O
whom	5	O
were	9	O
examined	9	O
for	5	O
more	5	O
than	5	O
3	9	O
months	5	O
,	9	O
were	9	O
adopted	5	O
as	5	O
the	5	O
subjects	5	O
of	5	O
the	5	O
investigation	9	O
.	9	O

The	5	O
median	9	O
observation	9	O
period	5	O
was	9	O
23	7	O
.	9	O
6	9	O
months	5	O
(	9	O
range	9	O
:	9	O
3	9	O
-	7	O
37	9	O
months	5	O
)	9	O
.	9	O

MEASUREMENTS	2	O
:	9	O
MPO	0	O
-	7	O
ANCA	3	O
was	9	O
measured	9	O
at	9	O
intervals	5	O
of	5	O
2	9	O
-	7	O
6	9	O
months	5	O
.	9	O

RESULTS	9	O
:	9	O
Before	9	O
treatment	9	O
,	9	O
the	5	O
MPO	0	O
-	7	O
ANCA	3	O
titres	9	O
of	5	O
all	5	O
102	7	O
untreated	3	O
Graves	5	B-Disease
'	9	I-Disease
disease	5	I-Disease
patients	5	O
were	9	O
within	9	O
the	5	O
reference	9	O
range	9	O
(	9	O
below	9	O
10	9	O
U	9	O
/	9	O
ml	0	O
)	9	O
.	9	O

Three	9	O
(	9	O
4	9	O
.	9	O
1	9	O
%	9	O
)	9	O
of	5	O
the	5	O
73	7	O
patients	5	O
were	9	O
positive	9	O
for	5	O
MPO	0	O
-	7	O
ANCA	3	O
at	9	O
13	7	O
,	9	O
16	9	O
and	5	O
17	7	O
months	5	O
,	9	O
respectively	9	O
,	9	O
after	9	O
the	5	O
start	9	O
of	5	O
PTU	0	B-Chemical
therapy	5	O
.	9	O

In	9	O
two	5	O
of	5	O
them	5	O
,	9	O
the	5	O
MPO	0	O
-	7	O
ANCA	3	O
titres	9	O
transiently	3	O
increased	9	O
to	5	O
12	9	O
.	9	O
8	9	O
and	5	O
15	9	O
.	9	O
0	7	O
U	9	O
/	9	O
ml	0	O
,	9	O
respectively	9	O
,	9	O
despite	9	O
continued	9	O
PTU	0	B-Chemical
therapy	5	O
,	9	O
but	9	O
no	9	O
vasculitic	5	B-Disease
disorders	5	I-Disease
developed	5	O
.	9	O

In	9	O
the	5	O
third	9	O
patient	5	O
,	9	O
the	5	O
MPO	0	O
-	7	O
ANCA	3	O
titre	9	O
increased	9	O
to	5	O
204	7	O
U	9	O
/	9	O
ml	0	O
and	5	O
she	5	O
developed	5	O
a	5	O
higher	9	O
fever	5	B-Disease
,	9	O
oral	9	B-Disease
ulcers	5	I-Disease
and	5	O
polyarthralgia	5	B-Disease
,	9	O
but	9	O
the	5	O
symptoms	5	O
resolved	9	O
2	9	O
weeks	9	O
after	9	O
stopping	5	O
PTU	0	B-Chemical
therapy	5	O
,	9	O
and	5	O
the	5	O
MPO	0	O
-	7	O
ANCA	3	O
titre	9	O
decreased	9	O
to	5	O
20	9	O
.	9	O
7	9	O
U	9	O
/	9	O
ml	0	O
by	9	O
4	9	O
months	5	O
after	9	O
discontinuing	5	O
PTU	0	B-Chemical
.	9	O

CONCLUSIONS	5	O
:	9	O
PTU	0	B-Chemical
therapy	5	O
may	5	O
be	5	O
related	9	O
to	5	O
the	5	O
appearance	9	O
of	5	O
MPO	0	O
-	7	O
ANCA	3	O
,	9	O
but	9	O
MPO	0	O
-	7	O
ANCA	3	O
does	9	O
not	5	O
appear	9	O
to	5	O
be	5	O
closely	9	O
related	9	O
to	5	O
vasculitis	5	B-Disease
.	9	O

Prevalence	9	O
of	5	O
heart	5	B-Disease
disease	5	I-Disease
in	5	O
asymptomatic	5	O
chronic	5	O
cocaine	5	B-Chemical
users	5	O
.	9	O

To	9	O
determine	9	O
the	5	O
prevalence	5	O
of	5	O
heart	5	B-Disease
disease	5	I-Disease
in	5	O
outpatient	5	O
young	5	O
asymptomatic	5	O
chronic	5	O
cocaine	5	B-Chemical
users	5	O
,	9	O
35	9	O
cocaine	5	B-Chemical
users	5	O
and	5	O
32	7	O
age	5	O
-	7	O
matched	9	O
controls	9	O
underwent	5	O
resting	5	O
and	5	O
exercise	5	O
electrocardiography	5	O
(	9	O
ECG	5	O
)	9	O
and	5	O
Doppler	5	O
echocardiography	5	O
.	9	O

Findings	5	O
consistent	9	O
with	5	O
coronary	5	B-Disease
artery	5	I-Disease
disease	5	I-Disease
were	9	O
detected	9	O
in	5	O
12	9	O
(	9	O
34	7	O
%	9	O
)	9	O
patients	5	O
and	5	O
3	9	O
(	9	O
9	7	O
%	9	O
)	9	O
controls	9	O
(	9	O
p	7	O
=	7	O
0	7	O
.	9	O
01	7	O
)	9	O
.	9	O

Decreased	9	O
left	5	O
ventricular	5	O
systolic	5	O
function	9	O
was	9	O
demonstrated	9	O
in	5	O
5	9	O
(	9	O
14	7	O
%	9	O
)	9	O
patients	5	O
,	9	O
but	9	O
in	5	O
none	9	O
of	5	O
the	5	O
controls	9	O
(	9	O
p	7	O
=	7	O
0	7	O
.	9	O
055	2	O
)	9	O
.	9	O

Finally	9	O
,	9	O
resting	5	O
and	5	O
peak	9	O
exercise	5	O
abnormal	9	B-Disease
left	5	I-Disease
ventricular	5	I-Disease
filling	5	I-Disease
was	9	O
detected	9	O
in	5	O
38	7	O
and	5	O
35	9	O
%	9	O
of	5	O
patients	5	O
as	5	O
compared	9	O
to	5	O
19	7	O
and	5	O
9	7	O
%	9	O
of	5	O
controls	9	O
,	9	O
respectively	9	O
(	9	O
p	7	O
=	7	O
0	7	O
.	9	O
11	7	O
and	5	O
0	7	O
.	9	O
02	7	O
,	9	O
respectively	9	O
)	9	O
.	9	O

We	9	O
conclude	9	O
that	5	O
coronary	5	B-Disease
artery	5	I-Disease
or	5	I-Disease
myocardial	9	I-Disease
disease	5	I-Disease
is	5	O
common	5	O
(	9	O
38	7	O
%	9	O
)	9	O
in	5	O
young	5	O
asymptomatic	5	O
chronic	5	O
cocaine	5	B-Chemical
users	5	O
.	9	O

Therefore	9	O
,	9	O
screening	5	O
ECG	5	O
and	5	O
echocardiography	5	O
may	5	O
be	5	O
warranted	9	O
in	5	O
these	5	O
patients	5	O
.	9	O

Cardioprotective	0	O
effects	9	O
of	5	O
Picrorrhiza	4	O
kurroa	4	O
against	9	O
isoproterenol	0	B-Chemical
-	7	O
induced	3	O
myocardial	9	O
stress	9	O
in	5	O
rats	9	O
.	9	O

The	5	O
cardioprotective	9	O
effect	9	O
of	5	O
the	5	O
ethanol	0	B-Chemical
extract	0	O
of	5	O
Picrorrhiza	4	O
kurroa	4	O
rhizomes	4	O
and	5	O
roots	4	O
(	9	O
PK	9	O
)	9	O
on	5	O
isoproterenol	0	B-Chemical
-	7	O
induced	3	O
myocardial	9	B-Disease
infarction	5	I-Disease
in	5	O
rats	9	O
with	5	O
respect	9	O
to	5	O
lipid	0	O
metabolism	9	O
in	5	O
serum	9	O
and	5	O
heart	5	O
tissue	9	O
has	9	O
been	9	O
investigated	9	O
.	9	O

Oral	9	O
pre	9	O
-	7	O
treatment	9	O
with	5	O
PK	9	O
(	9	O
80	9	O
mg	0	O
kg	0	O
(	9	O
-	7	O
1	9	O
)	9	O
day	9	O
(	9	O
-	7	O
1	9	O
)	9	O
for	5	O
15	9	O
days	9	O
)	9	O
significantly	9	O
prevented	9	O
the	5	O
isoproterenol	0	B-Chemical
-	7	O
induced	3	O
myocardial	9	B-Disease
infarction	5	I-Disease
and	5	O
maintained	9	O
the	5	O
rats	9	O
at	9	O
near	9	O
normal	9	O
status	9	O
.	9	O

Phase	9	O
2	9	O
early	9	O
afterdepolarization	5	O
as	5	O
a	5	O
trigger	9	O
of	5	O
polymorphic	9	O
ventricular	5	B-Disease
tachycardia	5	I-Disease
in	5	O
acquired	5	O
long	5	B-Disease
-	7	I-Disease
QT	5	I-Disease
syndrome	5	I-Disease
:	9	O
direct	9	O
evidence	9	O
from	9	O
intracellular	3	O
recordings	5	O
in	5	O
the	5	O
intact	9	O
left	5	O
ventricular	5	O
wall	5	O
.	9	O

BACKGROUND	2	O
:	9	O
This	5	O
study	9	O
examined	9	O
the	5	O
role	9	O
of	5	O
phase	5	O
2	9	O
early	9	O
afterdepolarization	5	O
(	9	O
EAD	5	O
)	9	O
in	5	O
producing	9	O
a	5	O
trigger	9	O
to	5	O
initiate	9	O
torsade	5	B-Disease
de	2	I-Disease
pointes	5	I-Disease
(	9	O
TdP	5	B-Disease
)	9	O
with	5	O
QT	5	B-Disease
prolongation	9	I-Disease
induced	3	O
by	9	O
dl	7	O
-	7	O
sotalol	5	B-Chemical
and	5	O
azimilide	9	B-Chemical
.	9	O

The	5	O
contribution	9	O
of	5	O
transmural	5	O
dispersion	5	O
of	5	O
repolarization	5	O
(	9	O
TDR	5	O
)	9	O
to	5	O
transmural	5	O
propagation	5	O
of	5	O
EAD	5	O
and	5	O
the	5	O
maintenance	9	O
of	5	O
TdP	5	B-Disease
was	9	O
also	9	O
evaluated	9	O
.	9	O

METHODS	2	O
AND	2	O
RESULTS	9	O
:	9	O
Transmembrane	7	O
action	5	O
potentials	5	O
from	9	O
epicardium	5	O
,	9	O
midmyocardium	5	O
,	9	O
and	5	O
endocardium	5	O
were	9	O
recorded	5	O
simultaneously	5	O
,	9	O
together	9	O
with	5	O
a	5	O
transmural	5	O
ECG	5	O
,	9	O
in	5	O
arterially	0	O
perfused	0	O
canine	9	O
and	5	O
rabbit	3	O
left	5	O
ventricular	5	O
preparations	9	O
.	9	O

dl	7	O
-	7	O
Sotalol	7	B-Chemical
preferentially	9	O
prolonged	9	O
action	5	O
potential	9	O
duration	5	O
(	9	O
APD	5	O
)	9	O
in	5	O
M	9	O
cells	3	O
dose	9	O
-	7	O
dependently	3	O
(	9	O
1	9	O
to	5	O
100	0	O
micromol	0	O
/	9	O
L	0	O
)	9	O
,	9	O
leading	9	O
to	5	O
QT	5	B-Disease
prolongation	9	I-Disease
and	5	O
an	5	O
increase	9	O
in	5	O
TDR	5	O
.	9	O

Azimilide	9	B-Chemical
,	9	O
however	9	O
,	9	O
significantly	9	O
prolonged	9	O
APD	5	O
and	5	O
QT	5	O
interval	5	O
at	9	O
concentrations	0	O
from	9	O
0	7	O
.	9	O
1	9	O
to	5	O
10	9	O
micromol	0	O
/	9	O
L	0	O
but	9	O
shortened	9	O
them	5	O
at	9	O
30	9	O
micromol	0	O
/	9	O
L	0	O
.	9	O

Unlike	9	O
dl	7	O
-	7	O
sotalol	5	B-Chemical
,	9	O
azimilide	9	B-Chemical
(	9	O
>	0	O
3	9	O
micromol	0	O
/	9	O
L	0	O
)	9	O
increased	9	O
epicardial	5	O
APD	5	O
markedly	9	O
,	9	O
causing	9	O
a	5	O
diminished	9	O
TDR	5	O
.	9	O

Although	9	O
both	9	O
dl	7	O
-	7	O
sotalol	5	B-Chemical
and	5	O
azimilide	9	B-Chemical
rarely	5	O
induced	3	O
EADs	3	O
in	5	O
canine	9	O
left	5	O
ventricles	5	O
,	9	O
they	5	O
produced	9	O
frequent	5	O
EADs	3	O
in	5	O
rabbits	9	O
,	9	O
in	5	O
which	5	O
more	5	O
pronounced	9	O
QT	5	B-Disease
prolongation	9	I-Disease
was	9	O
seen	9	O
.	9	O

An	5	O
increase	9	O
in	5	O
TDR	5	O
by	9	O
dl	7	O
-	7	O
sotalol	5	B-Chemical
facilitated	5	O
transmural	5	O
propagation	5	O
of	5	O
EADs	3	O
that	5	O
initiated	9	O
multiple	5	O
episodes	5	O
of	5	O
spontaneous	5	O
TdP	5	B-Disease
in	5	O
3	9	O
of	5	O
6	9	O
rabbit	3	O
left	5	O
ventricles	5	O
.	9	O

Of	9	O
note	9	O
,	9	O
although	9	O
azimilide	9	B-Chemical
(	9	O
3	9	O
to	5	O
10	9	O
micromol	0	O
/	9	O
L	0	O
)	9	O
increased	9	O
APD	5	O
more	5	O
than	5	O
dl	7	O
-	7	O
sotalol	5	B-Chemical
,	9	O
its	9	O
EADs	3	O
often	5	O
failed	9	O
to	5	O
propagate	5	O
transmurally	5	O
,	9	O
probably	9	O
because	5	O
of	5	O
a	5	O
diminished	9	O
TDR	5	O
.	9	O

CONCLUSIONS	5	O
:	9	O
This	5	O
study	9	O
provides	5	O
the	5	O
first	9	O
direct	9	O
evidence	9	O
from	9	O
intracellular	3	O
action	5	O
potential	9	O
recordings	5	O
that	5	O
phase	5	O
2	9	O
EAD	5	O
can	5	O
be	5	O
generated	9	O
from	9	O
intact	9	O
ventricular	5	O
wall	5	O
and	5	O
produce	9	O
a	5	O
trigger	9	O
to	5	O
initiate	9	O
the	5	O
onset	5	O
of	5	O
TdP	5	B-Disease
under	9	O
QT	5	B-Disease
prolongation	9	I-Disease
.	9	O

A	9	O
pilot	5	O
study	9	O
to	5	O
assess	5	O
the	5	O
safety	5	O
of	5	O
dobutamine	5	B-Chemical
stress	9	O
echocardiography	5	O
in	5	O
the	5	O
emergency	5	O
department	5	O
evaluation	5	O
of	5	O
cocaine	5	B-Chemical
-	7	O
associated	9	O
chest	5	B-Disease
pain	5	I-Disease
.	9	O

STUDY	2	O
OBJECTIVE	2	O
:	9	O
Chest	5	B-Disease
pain	5	I-Disease
in	5	O
the	5	O
setting	5	O
of	5	O
cocaine	5	B-Chemical
use	5	O
poses	5	O
a	5	O
diagnostic	5	O
dilemma	5	O
.	9	O

Dobutamine	0	B-Chemical
stress	9	O
echocardiography	5	O
(	9	O
DSE	9	O
)	9	O
is	5	O
a	5	O
widely	5	O
available	5	O
and	5	O
sensitive	9	O
test	5	O
for	5	O
evaluating	5	O
cardiac	5	O
ischemia	9	B-Disease
.	9	O

Because	9	O
of	5	O
the	5	O
theoretical	5	O
concern	5	O
regarding	5	O
administration	9	O
of	5	O
dobutamine	5	B-Chemical
in	5	O
the	5	O
setting	5	O
of	5	O
cocaine	5	B-Chemical
use	5	O
,	9	O
we	5	O
conducted	9	O
a	5	O
pilot	5	O
study	9	O
to	5	O
assess	5	O
the	5	O
safety	5	O
of	5	O
DSE	9	O
in	5	O
emergency	5	O
department	5	O
patients	5	O
with	5	O
cocaine	5	B-Chemical
-	7	O
associated	9	O
chest	5	B-Disease
pain	5	I-Disease
.	9	O

METHODS	2	O
:	9	O
A	9	O
prospective	5	O
case	5	O
series	5	O
was	9	O
conducted	9	O
in	5	O
the	5	O
intensive	5	O
diagnostic	5	O
and	5	O
treatment	9	O
unit	5	O
in	5	O
the	5	O
ED	5	O
of	5	O
an	5	O
urban	5	O
tertiary	9	O
-	7	O
care	5	O
teaching	5	O
hospital	5	O
.	9	O

Patients	5	O
were	9	O
eligible	5	O
for	5	O
DSE	9	O
if	5	O
they	5	O
had	9	O
used	5	O
cocaine	5	B-Chemical
within	9	O
24	9	O
hours	9	O
preceding	5	O
the	5	O
onset	5	O
of	5	O
chest	5	B-Disease
pain	5	I-Disease
and	5	O
had	9	O
a	5	O
normal	9	O
ECG	5	O
and	5	O
tropinin	9	O
I	9	O
level	9	O
.	9	O

Patients	5	O
exhibiting	9	O
signs	5	O
of	5	O
continuing	5	O
cocaine	5	B-Chemical
toxicity	9	B-Disease
were	9	O
excluded	9	O
from	9	O
the	5	O
study	9	O
.	9	O

All	9	O
patients	5	O
were	9	O
admitted	5	O
to	5	O
the	5	O
hospital	5	O
for	5	O
serial	9	O
testing	5	O
after	9	O
the	5	O
DSE	9	O
testing	5	O
in	5	O
the	5	O
intensive	5	O
diagnostic	5	O
and	5	O
treatment	9	O
unit	5	O
.	9	O

RESULTS	9	O
:	9	O
Twenty	9	O
-	7	O
four	9	O
patients	5	O
were	9	O
enrolled	5	O
.	9	O

Two	9	O
patients	5	O
had	9	O
inadequate	5	O
resting	5	O
images	5	O
,	9	O
one	5	O
DSE	9	O
was	9	O
terminated	9	O
because	5	O
of	5	O
inferior	5	O
hypokinesis	5	B-Disease
,	9	O
another	9	O
DSE	9	O
was	9	O
terminated	9	O
because	5	O
of	5	O
a	5	O
rate	9	O
-	7	O
related	9	O
atrial	5	O
conduction	5	O
deficit	5	O
,	9	O
and	5	O
1	9	O
patient	5	O
did	9	O
not	5	O
reach	5	O
the	5	O
target	9	O
heart	5	O
rate	9	O
.	9	O

Thus	9	O
,	9	O
19	7	O
patients	5	O
completed	5	O
a	5	O
DSE	9	O
and	5	O
reached	9	O
their	5	O
target	9	O
heart	5	O
rates	5	O
.	9	O

None	9	O
of	5	O
the	5	O
patients	5	O
experienced	5	O
signs	5	O
of	5	O
exaggerated	5	O
adrenergic	9	O
response	9	O
,	9	O
which	5	O
was	9	O
defined	5	O
as	5	O
a	5	O
systolic	5	O
blood	9	O
pressure	5	O
of	5	O
greater	5	O
than	5	O
200	0	O
mm	9	O
Hg	0	O
or	5	O
the	5	O
occurrence	5	O
of	5	O
tachydysrhythmias	5	B-Disease
(	9	O
excluding	9	O
sinus	5	B-Disease
tachycardia	5	I-Disease
)	9	O
.	9	O

Further	9	O
suggesting	9	O
lack	9	O
of	5	O
exaggerated	5	O
adrenergic	9	O
response	9	O
,	9	O
13	7	O
(	9	O
65	7	O
%	9	O
)	9	O
of	5	O
20	9	O
patients	5	O
required	9	O
supplemental	9	O
atropine	0	B-Chemical
to	5	O
reach	5	O
their	5	O
target	9	O
heart	5	O
rates	5	O
.	9	O

CONCLUSION	5	O
:	9	O
No	9	O
exaggerated	5	O
adrenergic	9	O
response	9	O
was	9	O
detected	9	O
when	5	O
dobutamine	5	B-Chemical
was	9	O
administered	9	O
to	5	O
patients	5	O
with	5	O
cocaine	5	B-Chemical
-	7	O
related	9	O
chest	5	B-Disease
pain	5	I-Disease
.	9	O

Prenatal	5	O
cocaine	5	B-Chemical
exposure	9	O
and	5	O
cranial	5	O
sonographic	5	O
findings	9	O
in	5	O
preterm	5	B-Disease
infants	5	I-Disease
.	9	O

PURPOSE	2	O
:	9	O
Prenatal	5	O
cocaine	5	B-Chemical
exposure	9	O
has	9	O
been	9	O
linked	9	O
with	5	O
subependymal	3	O
hemorrhage	5	B-Disease
and	5	O
the	5	O
formation	9	O
of	5	O
cysts	5	B-Disease
that	5	O
are	5	O
detectable	9	O
on	5	O
cranial	5	O
sonography	5	O
in	5	O
neonates	9	O
born	5	O
at	9	O
term	5	O
.	9	O

We	9	O
sought	9	O
to	5	O
determine	9	O
if	5	O
prenatal	5	O
cocaine	5	B-Chemical
exposure	9	O
increases	9	O
the	5	O
incidence	5	O
of	5	O
subependymal	3	B-Disease
cysts	5	I-Disease
in	5	O
preterm	5	B-Disease
infants	5	I-Disease
.	9	O

METHODS	2	O
:	9	O
We	9	O
retrospectively	5	O
reviewed	9	O
the	5	O
medical	5	O
records	5	O
and	5	O
cranial	5	O
sonograms	5	O
obtained	9	O
during	5	O
a	5	O
1	9	O
-	7	O
year	5	O
period	5	O
on	5	O
122	7	O
premature	9	B-Disease
(	9	I-Disease
<	0	I-Disease
36	9	I-Disease
weeks	9	I-Disease
of	5	I-Disease
gestation	9	I-Disease
)	9	I-Disease
infants	5	I-Disease
.	9	O

Infants	5	O
were	9	O
categorized	5	O
into	9	O
1	9	O
of	5	O
2	9	O
groups	9	O
:	9	O
those	5	O
exposed	9	O
to	5	O
cocaine	5	B-Chemical
and	5	O
those	5	O
not	5	O
exposed	9	O
to	5	O
cocaine	5	B-Chemical
.	9	O

Infants	5	O
were	9	O
assigned	5	O
to	5	O
the	5	O
cocaine	5	B-Chemical
-	7	O
exposed	9	O
group	9	O
if	5	O
there	5	O
was	9	O
a	5	O
maternal	9	O
history	5	O
of	5	O
cocaine	5	B-Disease
abuse	5	I-Disease
during	5	O
pregnancy	5	O
or	5	O
if	5	O
maternal	9	O
or	5	O
neonatal	9	O
urine	9	O
toxicology	5	O
results	9	O
were	9	O
positive	9	O
at	9	O
the	5	O
time	5	O
of	5	O
delivery	5	O
.	9	O

RESULTS	9	O
:	9	O
Five	9	O
of	5	O
the	5	O
122	7	O
infants	5	O
were	9	O
excluded	9	O
from	9	O
the	5	O
study	9	O
because	5	O
of	5	O
insufficient	5	O
medical	5	O
and	5	O
drug	5	O
histories	5	O
.	9	O

The	5	O
incidence	5	O
of	5	O
subependymal	3	B-Disease
cysts	5	I-Disease
in	5	O
the	5	O
117	7	O
remaining	9	O
infants	5	O
was	9	O
14	7	O
%	9	O
(	9	O
16	9	O
of	5	O
117	7	O
)	9	O
.	9	O

The	5	O
incidence	5	O
of	5	O
subependymal	3	B-Disease
cysts	5	I-Disease
in	5	O
infants	5	O
exposed	9	O
to	5	O
cocaine	5	B-Chemical
prenatally	5	O
was	9	O
44	7	O
%	9	O
(	9	O
8	9	O
of	5	O
18	7	O
)	9	O
compared	9	O
with	5	O
8	9	O
%	9	O
(	9	O
8	9	O
of	5	O
99	7	O
)	9	O
in	5	O
the	5	O
unexposed	9	O
group	9	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
01	7	O
)	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
We	9	O
found	9	O
an	5	O
increased	9	O
incidence	5	O
of	5	O
subependymal	3	B-Disease
cyst	5	I-Disease
formation	9	O
in	5	O
preterm	5	B-Disease
infants	5	I-Disease
who	5	O
were	9	O
exposed	9	O
to	5	O
cocaine	5	B-Chemical
prenatally	5	O
.	9	O

This	5	O
result	9	O
is	5	O
consistent	9	O
with	5	O
results	9	O
of	5	O
similar	9	O
studies	9	O
in	5	O
term	5	O
infants	5	O
.	9	O

Thalidomide	0	B-Chemical
neuropathy	5	B-Disease
in	5	O
patients	5	O
treated	3	O
for	5	O
metastatic	3	O
prostate	3	B-Disease
cancer	3	I-Disease
.	9	O

We	9	O
prospectively	5	O
evaluated	9	O
thalidomide	0	B-Chemical
-	7	O
induced	3	O
neuropathy	5	B-Disease
using	9	O
electrodiagnostic	5	O
studies	9	O
.	9	O

Sixty	5	O
-	7	O
seven	9	O
men	5	O
with	5	O
metastatic	3	O
androgen	3	B-Chemical
-	7	O
independent	9	O
prostate	3	B-Disease
cancer	3	I-Disease
in	5	O
an	5	O
open	5	O
-	7	O
label	9	O
trial	5	O
of	5	O
oral	9	O
thalidomide	0	B-Chemical
underwent	5	O
neurologic	5	O
examinations	5	O
and	5	O
nerve	5	O
conduction	5	O
studies	9	O
(	9	O
NCS	9	O
)	9	O
prior	9	O
to	5	O
and	5	O
at	9	O
3	9	O
-	7	O
month	5	O
intervals	5	O
during	5	O
treatment	9	O
.	9	O

NCS	9	O
included	5	O
recording	5	O
of	5	O
sensory	5	O
nerve	5	O
action	5	O
potentials	5	O
(	9	O
SNAPs	5	O
)	9	O
from	9	O
median	9	O
,	9	O
radial	5	O
,	9	O
ulnar	5	O
,	9	O
and	5	O
sural	5	O
nerves	5	O
.	9	O

SNAP	9	O
amplitudes	5	O
for	5	O
each	5	O
nerve	5	O
were	9	O
expressed	3	O
as	5	O
the	5	O
percentage	9	O
of	5	O
its	9	O
baseline	5	O
,	9	O
and	5	O
the	5	O
mean	5	O
of	5	O
the	5	O
four	9	O
was	9	O
termed	9	O
the	5	O
SNAP	9	O
index	5	O
.	9	O

A	9	O
40	9	O
%	9	O
decline	9	O
in	5	O
the	5	O
SNAP	9	O
index	5	O
was	9	O
considered	5	O
clinically	5	O
significant	9	O
.	9	O

Thalidomide	0	B-Chemical
was	9	O
discontinued	5	O
in	5	O
55	7	O
patients	5	O
for	5	O
lack	9	O
of	5	O
therapeutic	5	O
response	9	O
.	9	O

Of	9	O
67	7	O
patients	5	O
initially	9	O
enrolled	5	O
,	9	O
24	9	O
remained	9	O
on	5	O
thalidomide	0	B-Chemical
for	5	O
3	9	O
months	5	O
,	9	O
8	9	O
remained	9	O
at	9	O
6	9	O
months	5	O
,	9	O
and	5	O
3	9	O
remained	9	O
at	9	O
9	7	O
months	5	O
.	9	O

Six	9	O
patients	5	O
developed	5	O
neuropathy	5	B-Disease
.	9	O

Clinical	5	O
symptoms	5	O
and	5	O
a	5	O
decline	9	O
in	5	O
the	5	O
SNAP	9	O
index	5	O
occurred	9	O
concurrently	9	O
.	9	O

Older	5	O
age	5	O
and	5	O
cumulative	5	O
dose	9	O
were	9	O
possible	5	O
contributing	9	O
factors	9	O
.	9	O

Neuropathy	7	B-Disease
may	5	O
thus	9	O
be	5	O
a	5	O
common	5	O
complication	5	O
of	5	O
thalidomide	0	B-Chemical
in	5	O
older	5	O
patients	5	O
.	9	O

The	5	O
SNAP	9	O
index	5	O
can	5	O
be	5	O
used	5	O
to	5	O
monitor	5	O
peripheral	9	B-Disease
neuropathy	5	I-Disease
,	9	O
but	9	O
not	5	O
for	5	O
early	9	O
detection	9	O
.	9	O

Overexpression	3	O
of	5	O
copper	0	B-Chemical
/	9	O
zinc	9	B-Chemical
-	7	O
superoxide	0	B-Chemical
dismutase	0	O
protects	3	O
from	9	O
kanamycin	1	B-Chemical
-	7	O
induced	3	O
hearing	5	B-Disease
loss	9	I-Disease
.	9	O

The	5	O
participation	5	O
of	5	O
reactive	9	O
oxygen	0	B-Chemical
species	4	O
in	5	O
aminoglycoside	9	B-Chemical
-	7	O
induced	3	O
ototoxicity	5	B-Disease
has	9	O
been	9	O
deduced	9	O
from	9	O
observations	9	O
that	5	O
aminoglycoside	9	B-Chemical
-	7	O
iron	0	B-Chemical
complexes	9	O
catalyze	0	O
the	5	O
formation	9	O
of	5	O
superoxide	0	B-Chemical
radicals	0	O
in	5	O
vitro	3	O
and	5	O
that	5	O
antioxidants	0	O
attenuate	9	O
ototoxicity	5	B-Disease
in	5	O
vivo	3	O
.	9	O

We	9	O
therefore	5	O
hypothesized	9	O
that	5	O
overexpression	3	O
of	5	O
Cu	0	B-Chemical
/	9	O
Zn	0	B-Chemical
-	7	O
superoxide	0	B-Chemical
dismutase	0	O
(	9	O
h	0	O
-	7	O
SOD1	3	O
)	9	O
should	5	O
protect	9	O
transgenic	3	O
mice	3	O
from	9	O
ototoxicity	5	B-Disease
.	9	O

Immunocytochemistry	3	O
confirmed	9	O
expression	3	O
of	5	O
h	0	O
-	7	O
SOD1	3	O
in	5	O
inner	9	O
ear	5	O
tissues	9	O
of	5	O
transgenic	3	O
C57BL	3	O
/	9	O
6	9	O
-	7	O
TgN	3	O
[	9	O
SOD1	3	O
]	9	O
3Cje	_	O
mice	3	O
.	9	O

Transgenic	3	O
and	5	O
nontransgenic	3	O
littermates	3	O
received	9	O
kanamycin	1	B-Chemical
(	9	O
400	0	O
mg	0	O
/	9	O
kg	0	O
body	5	O
weight	9	O
/	9	O
day	9	O
)	9	O
for	5	O
10	9	O
days	9	O
beginning	5	O
on	5	O
day	9	O
10	9	O
after	9	O
birth	5	O
.	9	O

Auditory	5	O
thresholds	5	O
were	9	O
tested	9	O
by	9	O
evoked	5	O
auditory	5	O
brain	5	O
stem	3	O
responses	5	O
at	9	O
1	9	O
month	5	O
after	9	O
birth	5	O
.	9	O

In	9	O
nontransgenic	3	O
animals	9	O
,	9	O
the	5	O
threshold	5	O
in	5	O
the	5	O
kanamycin	1	B-Chemical
-	7	O
treated	3	O
group	9	O
was	9	O
45	9	O
-	7	O
50	0	O
dB	5	O
higher	9	O
than	5	O
in	5	O
saline	0	O
-	7	O
injected	3	O
controls	9	O
.	9	O

In	9	O
the	5	O
transgenic	3	O
group	9	O
,	9	O
kanamycin	1	B-Chemical
increased	9	O
the	5	O
threshold	5	O
by	9	O
only	9	O
15	9	O
dB	5	O
over	5	O
the	5	O
respective	9	O
controls	9	O
.	9	O

The	5	O
effects	9	O
were	9	O
similar	9	O
at	9	O
12	9	O
and	5	O
24	9	O
kHz	5	O
.	9	O

The	5	O
protection	9	O
by	9	O
overexpression	3	O
of	5	O
superoxide	0	B-Chemical
dismutase	0	O
supports	9	O
the	5	O
hypothesis	9	O
that	5	O
oxidant	0	O
stress	9	O
plays	9	O
a	5	O
significant	9	O
role	9	O
in	5	O
aminoglycoside	9	B-Chemical
-	7	O
induced	3	O
ototoxicity	5	B-Disease
.	9	O

The	5	O
results	9	O
also	9	O
suggest	9	O
transgenic	3	O
animals	9	O
as	5	O
suitable	5	O
models	5	O
to	5	O
investigate	9	O
the	5	O
underlying	5	O
mechanisms	9	O
and	5	O
possible	5	O
strategies	5	O
for	5	O
prevention	5	O
.	9	O

Fatty	0	B-Disease
liver	9	I-Disease
induced	3	O
by	9	O
tetracycline	0	B-Chemical
in	5	O
the	5	O
rat	3	O
.	9	O

Dose	0	O
-	7	O
response	9	O
relationships	5	O
and	5	O
effect	9	O
of	5	O
sex	5	O
.	9	O

Dose	0	O
-	7	O
response	9	O
relationships	5	O
,	9	O
biochemical	9	O
mechanisms	9	O
,	9	O
and	5	O
sex	5	O
differences	9	O
in	5	O
the	5	O
experimental	5	O
fatty	0	B-Disease
liver	9	I-Disease
induced	3	O
by	9	O
tetracycline	0	B-Chemical
were	9	O
studied	9	O
in	5	O
the	5	O
intact	9	O
rat	3	O
and	5	O
with	5	O
the	5	O
isolated	9	O
perfused	0	O
rat	3	O
liver	9	O
in	5	O
vitro	3	O
.	9	O

In	9	O
the	5	O
intact	9	O
male	9	O
and	5	O
female	9	O
rat	3	O
,	9	O
no	9	O
direct	9	O
relationship	5	O
was	9	O
observed	9	O
between	5	O
dose	9	O
of	5	O
tetracycline	0	B-Chemical
and	5	O
hepatic	9	O
accumulation	9	O
of	5	O
triglyceride	0	B-Chemical
.	9	O

With	5	O
provision	5	O
of	5	O
adequate	5	O
oleic	0	B-Chemical
acid	0	I-Chemical
as	5	O
a	5	O
substrate	0	O
for	5	O
the	5	O
isolated	9	O
perfused	0	O
liver	9	O
,	9	O
a	5	O
direct	9	O
relationship	5	O
was	9	O
observed	9	O
between	5	O
dose	9	O
of	5	O
tetracycline	0	B-Chemical
and	5	O
both	9	O
accumulation	9	O
of	5	O
triglyceride	0	B-Chemical
in	5	O
the	5	O
liver	9	O
and	5	O
depression	5	B-Disease
of	5	O
output	5	O
of	5	O
triglyceride	0	B-Chemical
by	9	O
livers	3	O
from	9	O
male	9	O
and	5	O
female	9	O
rats	9	O
.	9	O

Marked	9	O
differences	9	O
were	9	O
observed	9	O
between	5	O
female	9	O
and	5	O
male	9	O
rats	9	O
with	5	O
regard	5	O
to	5	O
base	5	O
line	9	O
(	9	O
control	9	O
)	9	O
hepatic	9	O
concentration	0	O
of	5	O
triglyceride	0	B-Chemical
and	5	O
output	5	O
of	5	O
triglyceride	0	B-Chemical
.	9	O

Accumulation	9	O
of	5	O
hepatic	9	O
triglyceride	0	B-Chemical
,	9	O
as	5	O
a	5	O
per	9	O
cent	5	O
of	5	O
control	9	O
values	5	O
,	9	O
in	5	O
response	9	O
to	5	O
graded	5	O
doses	0	O
of	5	O
tetracycline	0	B-Chemical
,	9	O
did	9	O
not	5	O
differ	9	O
significantly	9	O
between	5	O
male	9	O
,	9	O
female	9	O
and	5	O
pregnant	5	O
rat	3	O
livers	3	O
.	9	O

However	9	O
,	9	O
livers	3	O
from	9	O
female	9	O
,	9	O
and	5	O
especially	5	O
pregnant	5	O
female	9	O
rats	9	O
,	9	O
were	9	O
strikingly	9	O
resistant	9	O
to	5	O
the	5	O
effects	9	O
of	5	O
tetracycline	0	B-Chemical
on	5	O
depression	5	B-Disease
of	5	O
output	5	O
of	5	O
triglyceride	0	B-Chemical
under	9	O
these	5	O
experimental	5	O
conditions	9	O
.	9	O

These	5	O
differences	9	O
between	5	O
the	5	O
sexes	9	O
could	9	O
not	5	O
be	5	O
related	9	O
to	5	O
altered	9	O
disposition	5	O
of	5	O
tetracycline	0	B-Chemical
or	5	O
altered	9	O
uptake	0	O
of	5	O
oleic	0	B-Chemical
acid	0	I-Chemical
.	9	O

Depressed	5	O
hepatic	9	O
secretion	3	O
of	5	O
triglyceride	0	B-Chemical
accounted	5	O
only	9	O
for	5	O
30	9	O
to	5	O
50	0	O
%	9	O
of	5	O
accumulated	9	O
hepatic	9	O
triglyceride	0	B-Chemical
,	9	O
indicating	9	O
that	5	O
additional	9	O
mechanisms	9	O
must	5	O
be	5	O
involved	9	O
in	5	O
the	5	O
production	9	O
of	5	O
the	5	O
triglyceride	0	B-Chemical
-	7	O
rich	9	O
fatty	0	B-Disease
liver	9	I-Disease
in	5	O
response	9	O
to	5	O
tetracycline	0	B-Chemical
.	9	O

Prednisone	0	B-Chemical
induces	3	O
anxiety	5	B-Disease
and	5	O
glial	3	O
cerebral	5	O
changes	9	O
in	5	O
rats	9	O
.	9	O

OBJECTIVE	2	O
:	9	O
To	9	O
assess	5	O
whether	9	O
prednisone	0	B-Chemical
(	9	O
PDN	0	B-Chemical
)	9	O
produces	9	O
anxiety	5	B-Disease
and	5	O
/	9	O
or	5	O
cerebral	5	O
glial	3	O
changes	9	O
in	5	O
rats	9	O
.	9	O

METHODS	2	O
:	9	O
Male	7	O
Wistar	9	O
rats	9	O
were	9	O
studied	9	O
and	5	O
3	9	O
groups	9	O
were	9	O
formed	9	O
(	9	O
8	9	O
rats	9	O
per	9	O
group	9	O
)	9	O
.	9	O

The	5	O
moderate	9	O
-	7	O
dose	9	O
group	9	O
received	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
/	9	O
day	9	O
PDN	0	B-Chemical
released	9	O
from	9	O
a	5	O
subcutaneous	9	O
implant	5	O
.	9	O

In	9	O
the	5	O
high	9	O
-	7	O
dose	9	O
group	9	O
,	9	O
implants	5	O
containing	0	O
PDN	0	B-Chemical
equivalent	9	O
to	5	O
60	9	O
mg	0	O
/	9	O
kg	0	O
/	9	O
day	9	O
were	9	O
applied	5	O
.	9	O

In	9	O
the	5	O
control	9	O
group	9	O
implants	5	O
contained	9	O
no	9	O
PDN	0	B-Chemical
.	9	O

Anxiety	5	B-Disease
was	9	O
assessed	9	O
using	9	O
an	5	O
open	5	O
field	5	O
and	5	O
elevated	9	O
plus	9	O
-	7	O
maze	5	O
devices	5	O
.	9	O

The	5	O
number	9	O
of	5	O
cells	3	O
and	5	O
cytoplasmic	3	O
transformation	9	O
of	5	O
astrocytes	3	O
and	5	O
microglia	3	O
cells	3	O
were	9	O
assessed	9	O
by	9	O
immunohistochemical	3	O
analyses	9	O
.	9	O

RESULTS	9	O
:	9	O
Anxiety	5	B-Disease
was	9	O
documented	9	O
in	5	O
both	9	O
groups	9	O
of	5	O
PDN	0	B-Chemical
treated	3	O
rats	9	O
compared	9	O
with	5	O
controls	9	O
.	9	O

The	5	O
magnitude	5	O
of	5	O
transformation	9	O
of	5	O
the	5	O
microglia	3	O
assessed	9	O
by	9	O
the	5	O
number	9	O
of	5	O
intersections	5	O
was	9	O
significantly	9	O
higher	9	O
in	5	O
the	5	O
PDN	0	B-Chemical
groups	9	O
than	5	O
in	5	O
controls	9	O
in	5	O
the	5	O
prefrontal	5	O
cortex	5	O
(	9	O
moderate	9	O
-	7	O
dose	9	O
,	9	O
24	9	O
.	9	O
1	9	O
;	9	O
high	9	O
-	7	O
dose	9	O
,	9	O
23	7	O
.	9	O
6	9	O
;	9	O
controls	9	O
18	7	O
.	9	O
7	9	O
;	9	O
p	7	O
<	0	O
0	7	O
.	9	O
01	7	O
)	9	O
and	5	O
striatum	9	O
(	9	O
moderate	9	O
-	7	O
dose	9	O
25	9	O
.	9	O
6	9	O
;	9	O
high	9	O
-	7	O
dose	9	O
26	7	O
.	9	O
3	9	O
;	9	O
controls	9	O
18	7	O
.	9	O
9	7	O
;	9	O
p	7	O
<	0	O
0	7	O
.	9	O
01	7	O
)	9	O
,	9	O
but	9	O
not	5	O
in	5	O
hippocampus	9	O
.	9	O

The	5	O
number	9	O
of	5	O
stained	3	O
microglia	3	O
cells	3	O
was	9	O
significantly	9	O
higher	9	O
in	5	O
the	5	O
PDN	0	B-Chemical
treated	3	O
groups	9	O
in	5	O
the	5	O
prefrontal	5	O
cortex	5	O
than	5	O
in	5	O
controls	9	O
(	9	O
moderate	9	O
-	7	O
dose	9	O
,	9	O
29	7	O
.	9	O
1	9	O
;	9	O
high	9	O
-	7	O
dose	9	O
,	9	O
28	7	O
.	9	O
4	9	O
;	9	O
control	9	O
,	9	O
17	7	O
.	9	O
7	9	O
cells	3	O
per	9	O
field	5	O
;	9	O
p	7	O
<	0	O
0	7	O
.	9	O
01	7	O
)	9	O
.	9	O

Stained	3	O
microglia	3	O
cells	3	O
were	9	O
significantly	9	O
more	5	O
numerous	9	O
striatum	9	O
and	5	O
hippocampus	9	O
in	5	O
the	5	O
high	9	O
-	7	O
dose	9	O
group	9	O
compared	9	O
to	5	O
controls	9	O
.	9	O

CONCLUSION	5	O
:	9	O
Subacute	5	O
exposure	9	O
to	5	O
PDN	0	B-Chemical
induced	3	O
anxiety	5	B-Disease
and	5	O
reactivity	9	O
of	5	O
microglia	3	O
.	9	O

The	5	O
relevance	9	O
of	5	O
these	5	O
features	5	O
for	5	O
patients	5	O
using	9	O
PDN	0	B-Chemical
remains	9	O
to	5	O
be	5	O
elucidated	9	O
.	9	O

Phase	9	O
II	9	O
study	9	O
of	5	O
carboplatin	0	B-Chemical
and	5	O
liposomal	0	O
doxorubicin	0	B-Chemical
in	5	O
patients	5	O
with	5	O
recurrent	5	O
squamous	5	B-Disease
cell	3	I-Disease
carcinoma	3	I-Disease
of	5	I-Disease
the	5	I-Disease
cervix	5	I-Disease
.	9	O

BACKGROUND	2	O
:	9	O
The	5	O
activity	9	O
of	5	O
the	5	O
combination	9	O
of	5	O
carboplatin	0	B-Chemical
and	5	O
liposomal	0	O
doxorubicin	0	B-Chemical
was	9	O
tested	9	O
in	5	O
a	5	O
Phase	9	O
II	9	O
study	9	O
of	5	O
patients	5	O
with	5	O
recurrent	5	O
cervical	5	B-Disease
carcinoma	3	I-Disease
.	9	O

METHODS	2	O
:	9	O
The	5	O
combination	9	O
of	5	O
carboplatin	0	B-Chemical
(	9	O
area	5	O
under	9	O
the	5	O
concentration	0	O
curve	9	O
[	9	O
AUC	9	O
]	9	O
,	9	O
5	9	O
)	9	O
and	5	O
liposomal	0	O
doxorubicin	0	B-Chemical
(	9	O
Doxil	0	B-Chemical
;	9	O
starting	9	O
dose	9	O
,	9	O
40	9	O
mg	0	O
/	9	O
m	9	O
(	9	O
2	9	O
)	9	O
)	9	O
was	9	O
administered	9	O
intravenously	0	O
every	5	O
28	7	O
days	9	O
to	5	O
37	9	O
patients	5	O
with	5	O
recurrent	5	O
squamous	5	B-Disease
cell	3	I-Disease
cervical	5	I-Disease
carcinoma	3	I-Disease
to	5	O
determine	9	O
antitumor	3	O
activity	9	O
and	5	O
toxicity	9	B-Disease
profile	9	O
.	9	O

RESULTS	9	O
:	9	O
Twenty	9	O
-	7	O
nine	9	O
patients	5	O
were	9	O
assessable	5	O
for	5	O
response	9	O
,	9	O
and	5	O
35	9	O
patients	5	O
were	9	O
assessable	5	O
for	5	O
toxicity	9	B-Disease
.	9	O

The	5	O
overall	5	O
response	9	O
rate	9	O
was	9	O
38	7	O
%	9	O
,	9	O
the	5	O
median	9	O
time	5	O
to	5	O
response	9	O
was	9	O
10	9	O
weeks	9	O
,	9	O
the	5	O
median	9	O
duration	5	O
of	5	O
response	9	O
was	9	O
26	7	O
weeks	9	O
,	9	O
and	5	O
the	5	O
median	9	O
survival	9	O
was	9	O
37	9	O
weeks	9	O
.	9	O

The	5	O
main	5	O
toxic	0	O
effect	9	O
was	9	O
myelosuppression	5	B-Disease
,	9	O
with	5	O
Grade	9	O
3	9	O
and	5	O
4	9	O
neutropenia	5	B-Disease
in	5	O
16	9	O
patients	5	O
,	9	O
anemia	9	B-Disease
in	5	O
12	9	O
patients	5	O
,	9	O
thrombocytopenia	9	B-Disease
in	5	O
11	7	O
patients	5	O
,	9	O
and	5	O
neutropenic	5	B-Disease
fever	5	I-Disease
in	5	O
3	9	O
patients	5	O
.	9	O

Four	9	O
patients	5	O
had	9	O
five	9	O
infusion	0	O
-	7	O
related	9	O
reactions	9	O
during	5	O
the	5	O
infusion	0	O
of	5	O
liposomal	0	O
doxorubicin	0	B-Chemical
,	9	O
leading	9	O
to	5	O
treatment	9	O
discontinuation	5	O
in	5	O
three	9	O
patients	5	O
.	9	O

Grade	9	O
>	0	O
or	5	O
=	7	O
2	9	O
nonhematologic	5	O
toxicity	9	B-Disease
included	5	O
nausea	5	B-Disease
in	5	O
17	7	O
patients	5	O
,	9	O
emesis	5	B-Disease
in	5	O
14	7	O
patients	5	O
,	9	O
fatigue	5	B-Disease
in	5	O
9	7	O
patients	5	O
,	9	O
mucositis	5	B-Disease
and	5	O
/	9	O
or	5	O
stomatitis	9	B-Disease
in	5	O
8	9	O
patients	5	O
,	9	O
constipation	5	B-Disease
in	5	O
6	9	O
patients	5	O
,	9	O
weight	9	B-Disease
loss	9	I-Disease
in	5	O
5	9	O
patients	5	O
,	9	O
hand	5	B-Disease
-	7	I-Disease
foot	5	I-Disease
syndrome	5	I-Disease
in	5	O
2	9	O
patients	5	O
,	9	O
and	5	O
skin	5	B-Disease
reactions	9	I-Disease
in	5	O
3	9	O
patients	5	O
.	9	O

CONCLUSIONS	5	O
:	9	O
The	5	O
combination	9	O
of	5	O
carboplatin	0	B-Chemical
and	5	O
liposomal	0	O
doxorubicin	0	B-Chemical
has	9	O
modest	9	O
activity	9	O
in	5	O
patients	5	O
with	5	O
recurrent	5	O
cervical	5	B-Disease
carcinoma	3	I-Disease
.	9	O

Antimicrobial	9	O
-	7	O
induced	3	O
mania	5	B-Disease
(	9	O
antibiomania	_	B-Disease
)	9	O
:	9	O
a	5	O
review	5	O
of	5	O
spontaneous	5	O
reports	9	O
.	9	O

The	5	O
authors	5	O
reviewed	9	O
reported	9	O
cases	5	O
of	5	O
antibiotic	5	O
-	7	O
induced	3	O
manic	5	B-Disease
episodes	5	O
by	9	O
means	5	O
of	5	O
a	5	O
MEDLINE	5	O
and	5	O
PsychLit	9	O
search	5	O
for	5	O
reports	9	O
of	5	O
antibiotic	5	O
-	7	O
induced	3	O
mania	5	B-Disease
.	9	O

Unpublished	2	O
reports	9	O
were	9	O
requested	5	O
from	9	O
the	5	O
World	5	O
Health	2	O
Organization	2	O
(	9	O
WHO	5	O
)	9	O
and	5	O
the	5	O
Food	5	O
and	5	O
Drug	5	O
Administration	2	O
(	9	O
FDA	5	O
)	9	O
.	9	O

Twenty	9	O
-	7	O
one	5	O
reports	9	O
of	5	O
antimicrobial	9	O
-	7	O
induced	3	O
mania	5	B-Disease
were	9	O
found	9	O
in	5	O
the	5	O
literature	5	O
.	9	O

There	5	O
were	9	O
6	9	O
cases	5	O
implicating	9	O
clarithromycin	0	B-Chemical
,	9	O
13	7	O
implicating	9	O
isoniazid	0	B-Chemical
,	9	O
and	5	O
1	9	O
case	5	O
each	5	O
implicating	9	O
erythromycin	0	B-Chemical
and	5	O
amoxicillin	0	B-Chemical
.	9	O

The	5	O
WHO	5	O
reported	9	O
82	7	O
cases	5	O
.	9	O

Of	9	O
these	5	O
,	9	O
clarithromycin	0	B-Chemical
was	9	O
implicated	9	O
in	5	O
23	7	O
(	9	O
27	7	O
.	9	O
6	9	O
%	9	O
)	9	O
cases	5	O
,	9	O
ciprofloxacin	0	B-Chemical
in	5	O
12	9	O
(	9	O
14	7	O
.	9	O
4	9	O
%	9	O
)	9	O
cases	5	O
,	9	O
and	5	O
ofloxacin	0	B-Chemical
in	5	O
10	9	O
(	9	O
12	9	O
%	9	O
)	9	O
cases	5	O
.	9	O

Cotrimoxazole	7	B-Chemical
,	9	O
metronidazole	0	B-Chemical
,	9	O
and	5	O
erythromycin	0	B-Chemical
were	9	O
involved	9	O
in	5	O
15	9	O
reported	9	O
manic	5	B-Disease
episodes	5	O
.	9	O

Cases	9	O
reported	9	O
by	9	O
the	5	O
FDA	5	O
showed	9	O
clarithromycin	0	B-Chemical
and	5	O
ciprofloxacin	0	B-Chemical
to	5	O
be	5	O
the	5	O
most	9	O
frequently	5	O
associated	9	O
with	5	O
the	5	O
development	9	O
of	5	O
mania	5	B-Disease
.	9	O

Statistical	5	O
analysis	9	O
of	5	O
the	5	O
data	5	O
would	5	O
not	5	O
have	5	O
demonstrated	9	O
a	5	O
significant	9	O
statistical	5	O
correlative	5	O
risk	5	O
and	5	O
was	9	O
therefore	5	O
not	5	O
undertaken	5	O
.	9	O

Patients	5	O
have	5	O
an	5	O
increased	9	O
risk	5	O
of	5	O
developing	5	O
mania	5	B-Disease
while	9	O
being	5	O
treated	3	O
with	5	O
antimicrobials	5	O
.	9	O

Although	9	O
this	5	O
is	5	O
not	5	O
a	5	O
statistically	9	O
significant	9	O
risk	5	O
,	9	O
physicians	5	O
must	5	O
be	5	O
aware	5	O
of	5	O
the	5	O
effect	9	O
and	5	O
reversibility	9	O
.	9	O

Further	9	O
research	5	O
clearly	9	O
is	5	O
required	9	O
to	5	O
determine	9	O
the	5	O
incidence	5	O
of	5	O
antimicrobial	9	O
-	7	O
induced	3	O
mania	5	B-Disease
,	9	O
the	5	O
relative	9	O
risk	5	O
factors	9	O
of	5	O
developing	5	O
an	5	O
antimicrobial	9	O
-	7	O
induced	3	O
manic	5	B-Disease
episode	5	O
among	5	O
various	9	O
demographic	5	O
populations	9	O
,	9	O
and	5	O
the	5	O
incidence	5	O
of	5	O
patients	5	O
who	5	O
continue	5	O
to	5	O
have	5	O
persistent	5	O
affective	5	O
disorders	5	O
once	5	O
the	5	O
initial	9	O
episode	5	O
,	9	O
which	5	O
occurs	9	O
while	9	O
the	5	O
patient	5	O
is	5	O
taking	5	O
antibiotics	5	O
,	9	O
subsides	5	O
.	9	O

The	5	O
authors	5	O
elected	5	O
to	5	O
name	5	O
this	5	O
syndrome	5	O
"	5	O
antibiomania	_	B-Disease
.	9	O
"	5	O

Levodopa	0	B-Chemical
-	7	O
induced	3	O
ocular	5	B-Disease
dyskinesias	5	I-Disease
in	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
.	9	O

Levodopa	0	B-Chemical
-	7	O
induced	3	O
ocular	5	B-Disease
dyskinesias	5	I-Disease
are	5	O
very	5	O
uncommon	5	O
.	9	O

Usually	5	O
they	5	O
occur	5	O
simultaneously	5	O
with	5	O
limb	5	O
peak	9	O
-	7	O
dose	9	O
choreatic	5	B-Disease
dyskinesias	5	I-Disease
.	9	O

We	9	O
report	5	O
on	5	O
a	5	O
patient	5	O
with	5	O
leftward	5	O
and	5	O
upward	5	O
deviations	5	O
of	5	O
gaze	5	O
during	5	O
the	5	O
peak	9	O
effect	9	O
of	5	O
levodopa	5	B-Chemical
,	9	O
and	5	O
hypothesize	9	O
that	5	O
a	5	O
severe	5	O
dopaminergic	5	O
denervation	5	O
in	5	O
the	5	O
caudate	5	O
nucleus	9	O
is	5	O
needed	5	O
for	5	O
the	5	O
appearance	9	O
of	5	O
these	5	O
levodopa	5	B-Chemical
-	7	O
induce	3	O
ocular	5	B-Disease
dyskinesias	5	I-Disease
.	9	O

A	9	O
comparison	9	O
of	5	O
glyceryl	0	B-Chemical
trinitrate	0	I-Chemical
with	5	O
diclofenac	0	B-Chemical
for	5	O
the	5	O
treatment	9	O
of	5	O
primary	9	O
dysmenorrhea	5	B-Disease
:	9	O
an	5	O
open	5	O
,	9	O
randomized	5	O
,	9	O
cross	5	O
-	7	O
over	5	O
trial	5	O
.	9	O

Primary	9	O
dysmenorrhea	5	B-Disease
is	5	O
a	5	O
syndrome	5	O
characterized	9	O
by	9	O
painful	5	O
uterine	5	O
contractility	9	O
caused	9	O
by	9	O
a	5	O
hypersecretion	9	O
of	5	O
endometrial	9	O
prostaglandins	0	B-Chemical
;	9	O
non	9	O
-	7	O
steroidal	0	O
anti	3	O
-	7	O
inflammatory	3	O
drugs	5	O
are	5	O
the	5	O
first	9	O
choice	5	O
for	5	O
its	9	O
treatment	9	O
.	9	O

However	9	O
,	9	O
in	5	O
vivo	3	O
and	5	O
in	5	O
vitro	3	O
studies	9	O
have	5	O
demonstrated	9	O
that	5	O
myometrial	3	O
cells	3	O
are	5	O
also	9	O
targets	9	O
of	5	O
the	5	O
relaxant	0	O
effects	9	O
of	5	O
nitric	0	B-Chemical
oxide	0	I-Chemical
(	9	O
NO	9	B-Chemical
)	9	O
.	9	O

The	5	O
aim	5	O
of	5	O
the	5	O
present	9	O
study	9	O
was	9	O
to	5	O
determine	9	O
the	5	O
efficacy	9	O
of	5	O
glyceryl	0	B-Chemical
trinitrate	0	I-Chemical
(	9	O
GTN	0	B-Chemical
)	9	O
,	9	O
an	5	O
NO	9	B-Chemical
donor	9	O
,	9	O
in	5	O
the	5	O
resolution	5	O
of	5	O
primary	9	O
dysmenorrhea	5	B-Disease
in	5	O
comparison	9	O
with	5	O
diclofenac	0	B-Chemical
(	9	O
DCF	0	B-Chemical
)	9	O
.	9	O

A	9	O
total	9	O
of	5	O
24	9	O
patients	5	O
with	5	O
the	5	O
diagnosis	5	O
of	5	O
severe	5	O
primary	9	O
dysmenorrhea	5	B-Disease
were	9	O
studied	9	O
during	5	O
two	5	O
consecutive	5	O
menstrual	5	O
cycles	9	O
.	9	O

In	9	O
an	5	O
open	5	O
,	9	O
cross	5	O
-	7	O
over	5	O
,	9	O
controlled	5	O
design	5	O
,	9	O
patients	5	O
were	9	O
randomized	5	O
to	5	O
receive	5	O
either	9	O
DCF	0	B-Chemical
per	9	O
os	9	O
or	5	O
GTN	0	B-Chemical
patches	5	O
the	5	O
first	9	O
days	9	O
of	5	O
menses	5	O
,	9	O
when	5	O
menstrual	5	O
cramps	5	O
became	9	O
unendurable	5	O
.	9	O

In	9	O
the	5	O
subsequent	9	O
cycle	9	O
the	5	O
other	5	O
treatment	9	O
was	9	O
used	5	O
.	9	O

Patients	5	O
received	9	O
up	5	O
to	5	O
3	9	O
doses	0	O
/	9	O
day	9	O
of	5	O
50	0	O
mg	0	O
DCF	0	B-Chemical
or	5	O
2	9	O
.	9	O
5	9	O
mg	0	O
/	9	O
24	9	O
h	0	O
transdermal	0	O
GTN	0	B-Chemical
for	5	O
the	5	O
first	9	O
3	9	O
days	9	O
of	5	O
the	5	O
cycle	9	O
,	9	O
according	9	O
to	5	O
their	5	O
needs	5	O
.	9	O

The	5	O
participants	5	O
recorded	5	O
menstrual	5	O
symptoms	5	O
and	5	O
possible	5	O
side	5	O
-	7	O
effects	9	O
at	9	O
different	9	O
times	5	O
(	9	O
0	7	O
,	9	O
30	9	O
,	9	O
60	9	O
,	9	O
120	9	O
minutes	0	O
)	9	O
after	9	O
the	5	O
first	9	O
dose	9	O
of	5	O
medication	5	O
on	5	O
the	5	O
first	9	O
day	9	O
of	5	O
the	5	O
cycle	9	O
,	9	O
with	5	O
both	9	O
drugs	5	O
.	9	O

The	5	O
difference	9	O
in	5	O
pain	5	B-Disease
intensity	5	O
score	5	O
(	9	O
DPI	0	O
)	9	O
was	9	O
the	5	O
main	5	O
outcome	5	O
variable	5	O
.	9	O

Both	9	O
treatments	9	O
significantly	9	O
reduced	9	O
DPI	0	O
by	9	O
the	5	O
30th	9	O
minute	5	O
(	9	O
GTN	0	B-Chemical
,	9	O
-	7	O
12	9	O
.	9	O
8	9	O
+	9	O
/	9	O
-	7	O
17	7	O
.	9	O
9	7	O
;	9	O
DCF	0	B-Chemical
,	9	O
-	7	O
18	7	O
.	9	O
9	7	O
+	9	O
/	9	O
-	7	O
16	9	O
.	9	O
6	9	O
)	9	O
.	9	O

However	9	O
,	9	O
DCF	0	B-Chemical
continued	9	O
to	5	O
be	5	O
effective	5	O
in	5	O
reducing	9	O
pelvic	5	B-Disease
pain	5	I-Disease
for	5	O
two	5	O
hours	9	O
,	9	O
whereas	9	O
GTN	0	B-Chemical
scores	5	O
remained	9	O
more	5	O
or	5	O
less	5	O
stable	9	O
after	9	O
30	9	O
min	0	O
and	5	O
significantly	9	O
higher	9	O
than	5	O
those	5	O
for	5	O
DFC	0	O
(	9	O
after	9	O
one	5	O
hour	0	O
:	9	O
GTN	0	B-Chemical
,	9	O
-	7	O
12	9	O
.	9	O
8	9	O
+	9	O
/	9	O
-	7	O
17	7	O
.	9	O
9	7	O
;	9	O
DFC	0	O
,	9	O
-	7	O
18	7	O
.	9	O
9	7	O
+	9	O
/	9	O
-	7	O
16	9	O
.	9	O
6	9	O
and	5	O
after	9	O
two	5	O
hours	9	O
:	9	O
GTN	0	B-Chemical
,	9	O
-	7	O
23	7	O
.	9	O
7	9	O
+	9	O
/	9	O
-	7	O
20	9	O
.	9	O
5	9	O
;	9	O
DFC	0	O
,	9	O
-	7	O
59	7	O
.	9	O
7	9	O
+	9	O
/	9	O
-	7	O
17	7	O
.	9	O
9	7	O
,	9	O
p	7	O
=	7	O
0	7	O
.	9	O
0001	7	O
)	9	O
.	9	O

Low	9	B-Disease
back	5	I-Disease
pain	5	I-Disease
was	9	O
also	9	O
relieved	5	O
by	9	O
both	9	O
drugs	5	O
.	9	O

Headache	7	B-Disease
was	9	O
significantly	9	O
increased	9	O
by	9	O
GTN	0	B-Chemical
but	9	O
not	5	O
by	9	O
DCF	0	B-Chemical
.	9	O

Eight	9	O
patients	5	O
stopped	9	O
using	9	O
GTN	0	B-Chemical
because	5	O
headache	5	B-Disease
-	7	O
-	7	O
attributed	9	O
to	5	O
its	9	O
use	5	O
-	7	O
-	7	O
became	9	O
intolerable	5	O
.	9	O

These	5	O
findings	9	O
indicate	9	O
that	5	O
GTN	0	B-Chemical
has	9	O
a	5	O
reduced	9	O
efficacy	9	O
and	5	O
tolerability	5	O
by	9	O
comparison	9	O
with	5	O
DCF	0	B-Chemical
in	5	O
the	5	O
treatment	9	O
of	5	O
primary	9	O
dysmenorrhea	5	B-Disease
.	9	O

Temocapril	9	B-Chemical
,	9	O
a	5	O
long	5	O
-	7	O
acting	9	O
non	9	O
-	7	O
SH	9	O
group	9	O
angiotensin	9	B-Chemical
converting	9	O
enzyme	0	O
inhibitor	3	O
,	9	O
modulates	9	O
glomerular	5	B-Disease
injury	9	I-Disease
in	5	O
chronic	5	O
puromycin	3	B-Chemical
aminonucleoside	0	I-Chemical
nephrosis	0	B-Disease
.	9	O

The	5	O
purpose	5	O
of	5	O
the	5	O
present	9	O
study	9	O
was	9	O
to	5	O
determine	9	O
whether	9	O
chronic	5	O
administration	9	O
of	5	O
temocapril	0	B-Chemical
,	9	O
a	5	O
long	5	O
-	7	O
acting	9	O
non	9	O
-	7	O
SH	9	O
group	9	O
angiotensin	9	B-Chemical
converting	9	O
enzyme	0	O
(	9	O
ACE	9	O
)	9	O
inhibitor	3	O
,	9	O
reduced	9	O
proteinuria	9	B-Disease
,	9	O
inhibited	3	O
glomerular	5	O
hypertrophy	9	B-Disease
and	5	O
prevented	9	O
glomerulosclerosis	3	B-Disease
in	5	O
chronic	5	O
puromycin	3	B-Chemical
aminonucleoside	0	I-Chemical
(	9	O
PAN	0	B-Chemical
)	9	O
-	7	O
induced	3	O
nephrotic	5	B-Disease
rats	9	O
.	9	O

Nephrosis	2	B-Disease
was	9	O
induced	3	O
by	9	O
injection	9	O
of	5	O
PAN	0	B-Chemical
(	9	O
15mg	0	O
/	9	O
100g	0	O
body	5	O
weight	9	O
)	9	O
in	5	O
male	9	O
Sprague	9	O
-	7	O
Dawley	0	O
(	9	O
SD	7	O
)	9	O
rats	9	O
.	9	O

Four	9	O
groups	9	O
were	9	O
used	5	O
,	9	O
i	9	O
)	9	O
the	5	O
PAN	0	B-Chemical
group	9	O
(	9	O
14	7	O
)	9	O
,	9	O
ii	9	O
)	9	O
PAN	0	B-Chemical
/	9	O
temocapril	0	B-Chemical
(	9	O
13	7	O
)	9	O
,	9	O
iii	9	O
)	9	O
temocapril	0	B-Chemical
(	9	O
14	7	O
)	9	O
and	5	O
iv	9	O
)	9	O
untreated	3	O
controls	9	O
(	9	O
15	9	O
)	9	O
.	9	O

Temocapril	9	B-Chemical
(	9	O
8	9	O
mg	0	O
/	9	O
kg	0	O
/	9	O
day	9	O
)	9	O
was	9	O
administered	9	O
to	5	O
the	5	O
rats	9	O
which	5	O
were	9	O
killed	9	O
at	9	O
weeks	9	O
4	9	O
,	9	O
14	7	O
or	5	O
20	9	O
.	9	O

At	9	O
each	5	O
time	5	O
point	5	O
,	9	O
systolic	5	O
blood	9	O
pressure	5	O
(	9	O
BP	9	O
)	9	O
,	9	O
urinary	9	O
protein	1	O
excretion	0	O
and	5	O
renal	9	O
histopathological	9	O
findings	9	O
were	9	O
evaluated	9	O
,	9	O
and	5	O
morphometric	5	O
image	5	O
analysis	9	O
was	9	O
done	9	O
.	9	O

Systolic	7	O
BP	9	O
in	5	O
the	5	O
PAN	0	B-Chemical
group	9	O
was	9	O
significantly	9	O
high	9	O
at	9	O
4	9	O
,	9	O
14	7	O
and	5	O
20	9	O
weeks	9	O
,	9	O
but	9	O
was	9	O
normal	9	O
in	5	O
the	5	O
PAN	0	B-Chemical
/	9	O
temocapril	0	B-Chemical
group	9	O
.	9	O

Urinary	9	O
protein	1	O
excretion	0	O
in	5	O
the	5	O
PAN	0	B-Chemical
group	9	O
increased	9	O
significantly	9	O
,	9	O
peaking	9	O
at	9	O
8	9	O
days	9	O
,	9	O
then	9	O
decreased	9	O
at	9	O
4	9	O
weeks	9	O
,	9	O
but	9	O
rose	9	O
again	9	O
significantly	9	O
at	9	O
14	7	O
and	5	O
20	9	O
weeks	9	O
.	9	O

Temocapril	9	B-Chemical
did	9	O
not	5	O
attenuate	9	O
proteinuria	9	B-Disease
at	9	O
8	9	O
days	9	O
,	9	O
but	9	O
it	5	O
did	9	O
markedly	9	O
lower	9	O
it	5	O
from	9	O
weeks	9	O
4	9	O
to	5	O
20	9	O
.	9	O

The	5	O
glomerulosclerosis	3	B-Disease
index	5	O
(	9	O
GSI	9	O
)	9	O
was	9	O
6	9	O
.	9	O
21	7	O
%	9	O
at	9	O
4	9	O
weeks	9	O
and	5	O
respectively	9	O
25	9	O
.	9	O
35	9	O
%	9	O
and	5	O
30	9	O
.	9	O
49	7	O
%	9	O
at	9	O
14	7	O
and	5	O
20	9	O
weeks	9	O
in	5	O
the	5	O
PAN	0	B-Chemical
group	9	O
.	9	O

There	5	O
was	9	O
a	5	O
significant	9	O
correlation	9	O
between	5	O
urinary	9	O
protein	1	O
excretion	0	O
and	5	O
GSI	9	O
(	9	O
r	9	O
=	7	O
0	7	O
.	9	O
808	7	O
,	9	O
p	7	O
<	0	O
0	7	O
.	9	O
0001	7	O
)	9	O
.	9	O

The	5	O
ratio	9	O
of	5	O
glomerular	5	O
tuft	4	O
area	5	O
to	5	O
the	5	O
area	5	O
of	5	O
Bowman	6	O
'	9	O
s	9	O
capsules	0	O
(	9	O
GT	9	O
/	9	O
BC	9	O
)	9	O
in	5	O
the	5	O
PAN	0	B-Chemical
group	9	O
was	9	O
significantly	9	O
increased	9	O
,	9	O
but	9	O
it	5	O
was	9	O
significantly	9	O
lower	9	O
in	5	O
the	5	O
PAN	0	B-Chemical
/	9	O
temocapril	0	B-Chemical
group	9	O
.	9	O

It	5	O
appears	9	O
that	5	O
temocapril	0	B-Chemical
was	9	O
effective	5	O
in	5	O
retarding	9	O
renal	9	O
progression	9	O
and	5	O
protected	9	O
renal	9	O
function	9	O
in	5	O
PAN	0	B-Chemical
neprotic	_	B-Disease
rats	9	O
.	9	O

Pulmonary	9	B-Disease
hypertension	5	I-Disease
after	9	O
ibuprofen	0	B-Chemical
prophylaxis	5	O
in	5	O
very	5	O
preterm	5	O
infants	5	O
.	9	O

We	9	O
report	5	O
three	9	O
cases	5	O
of	5	O
severe	5	O
hypoxaemia	5	B-Disease
after	9	O
ibuprofen	0	B-Chemical
administration	9	O
during	5	O
a	5	O
randomised	5	O
controlled	5	O
trial	5	O
of	5	O
prophylactic	5	O
treatment	9	O
of	5	O
patent	5	B-Disease
ductus	5	I-Disease
arteriosus	5	I-Disease
with	5	O
ibuprofen	0	B-Chemical
in	5	O
premature	9	O
infants	5	O
born	5	O
at	9	O
less	5	O
than	5	O
28	7	O
weeks	9	O
of	5	O
gestation	9	O
.	9	O

Echocardiography	5	O
showed	9	O
severely	9	O
decreased	9	O
pulmonary	5	O
blood	9	O
flow	5	O
.	9	O

Hypoxaemia	5	B-Disease
resolved	9	O
quickly	5	O
on	5	O
inhaled	5	O
nitric	0	B-Chemical
oxide	0	I-Chemical
therapy	5	O
.	9	O

We	9	O
suggest	9	O
that	5	O
investigators	5	O
involved	9	O
in	5	O
similar	9	O
trials	5	O
pay	5	O
close	5	O
attention	5	O
to	5	O
pulmonary	5	O
pressure	5	O
if	5	O
hypoxaemia	5	B-Disease
occurs	9	O
after	9	O
prophylactic	5	O
administration	9	O
of	5	O
ibuprofen	0	B-Chemical
.	9	O

Hyponatremia	5	B-Disease
and	5	O
syndrome	5	B-Disease
of	5	I-Disease
inappropriate	5	I-Disease
anti	3	I-Disease
-	7	I-Disease
diuretic	5	I-Disease
hormone	9	I-Disease
reported	9	O
with	5	O
the	5	O
use	5	O
of	5	O
Vincristine	0	B-Chemical
:	9	O
an	5	O
over	5	O
-	7	O
representation	5	O
of	5	O
Asians	5	O
?	5	O

PURPOSE	2	O
:	9	O
This	5	O
retrospective	5	O
study	9	O
used	5	O
a	5	O
pharmaceutical	5	O
company	5	O
'	9	O
s	9	O
global	5	O
safety	5	O
database	5	O
to	5	O
determine	9	O
the	5	O
reporting	5	O
rate	9	O
of	5	O
hyponatremia	5	B-Disease
and	5	O
/	9	O
or	5	O
syndrome	5	B-Disease
of	5	I-Disease
inappropriate	5	I-Disease
secretion	3	I-Disease
of	5	I-Disease
anti	3	I-Disease
-	7	I-Disease
diuretic	5	I-Disease
hormone	9	I-Disease
(	9	O
SIADH	5	B-Disease
)	9	O
among	5	O
vincristine	0	B-Chemical
-	7	O
treated	3	O
patients	5	O
and	5	O
to	5	O
explore	5	O
the	5	O
possibility	9	O
of	5	O
at	9	O
-	7	O
risk	5	O
population	5	O
subgroups	9	O
.	9	O

METHOD	2	O
:	9	O
We	9	O
searched	9	O
the	5	O
Eli	2	O
Lilly	2	O
and	5	O
Company	2	O
'	9	O
s	9	O
computerized	5	O
adverse	5	O
event	5	O
database	5	O
for	5	O
all	5	O
reported	9	O
cases	5	O
of	5	O
hyponatremia	5	B-Disease
and	5	O
/	9	O
or	5	O
SIADH	5	B-Disease
as	5	O
of	5	O
1	9	O
November	2	O
1999	2	O
that	5	O
had	9	O
been	9	O
reported	9	O
during	5	O
the	5	O
use	5	O
of	5	O
vincristine	0	B-Chemical
.	9	O

RESULTS	9	O
:	9	O
A	9	O
total	9	O
of	5	O
76	7	O
cases	5	O
of	5	O
hyponatremia	5	B-Disease
and	5	O
/	9	O
or	5	O
SIADH	5	B-Disease
associated	9	O
with	5	O
vincristine	0	B-Chemical
use	5	O
were	9	O
identified	9	O
.	9	O

The	5	O
overall	5	O
reporting	5	O
rate	9	O
was	9	O
estimated	5	O
to	5	O
be	5	O
1	9	O
.	9	O
3	9	O
/	9	O
100	0	O
,	9	O
000	9	O
treated	3	O
patients	5	O
.	9	O

The	5	O
average	5	O
age	5	O
of	5	O
patients	5	O
was	9	O
35	9	O
.	9	O
6	9	O
+	9	O
/	9	O
-	7	O
28	7	O
.	9	O
3	9	O
years	5	O
,	9	O
and	5	O
62	7	O
%	9	O
were	9	O
males	9	O
.	9	O

Approximately	9	O
75	9	O
%	9	O
of	5	O
the	5	O
patients	5	O
were	9	O
receiving	9	O
treatment	9	O
for	5	O
leukemia	3	B-Disease
or	5	O
lymphoma	9	B-Disease
.	9	O

Among	9	O
the	5	O
39	7	O
reports	9	O
that	5	O
included	5	O
information	5	O
on	5	O
race	5	O
,	9	O
the	5	O
racial	5	O
distribution	9	O
was	9	O
:	9	O
1	9	O
Black	9	O
,	9	O
3	9	O
Caucasian	9	O
,	9	O
and	5	O
35	9	O
Asian	4	O
.	9	O

CONCLUSION	5	O
:	9	O
Our	9	O
data	5	O
suggest	9	O
that	5	O
Asian	4	O
patients	5	O
may	5	O
be	5	O
at	9	O
increased	9	O
risk	5	O
of	5	O
hyponatremia	5	B-Disease
and	5	O
/	9	O
or	5	O
SIADH	5	B-Disease
associated	9	O
with	5	O
vincristine	0	B-Chemical
use	5	O
.	9	O

Although	9	O
the	5	O
overall	5	O
reported	9	O
rate	9	O
of	5	O
SIADH	5	B-Disease
associated	9	O
with	5	O
vincristine	0	B-Chemical
is	5	O
very	5	O
low	9	O
,	9	O
physicians	5	O
caring	5	O
for	5	O
Asian	4	O
oncology	5	O
patients	5	O
should	5	O
be	5	O
aware	5	O
of	5	O
this	5	O
potential	9	O
serious	5	O
but	9	O
reversible	9	O
adverse	5	O
event	5	O
.	9	O

Delayed	5	O
toxicity	9	B-Disease
of	5	O
cyclophosphamide	0	B-Chemical
on	5	O
the	5	O
bladder	9	O
of	5	O
DBA	3	O
/	9	O
2	9	O
and	5	O
C57BL	3	O
/	9	O
6	9	O
female	9	O
mouse	3	O
.	9	O

The	5	O
present	9	O
study	9	O
describes	5	O
the	5	O
delayed	9	O
development	9	O
of	5	O
a	5	O
severe	5	O
bladder	9	O
pathology	5	O
in	5	O
a	5	O
susceptible	9	O
strain	1	O
of	5	O
mice	3	O
(	9	O
DBA	3	O
/	9	O
2	9	O
)	9	O
but	9	O
not	5	O
in	5	O
a	5	O
resistant	9	O
strain	1	O
(	9	O
C57BL	3	O
/	9	O
6	9	O
)	9	O
when	5	O
both	9	O
were	9	O
treated	3	O
with	5	O
a	5	O
single	9	O
300	0	O
mg	0	O
/	9	O
kg	0	O
dose	9	O
of	5	O
cyclophosphamide	0	B-Chemical
(	9	O
CY	9	B-Chemical
)	9	O
.	9	O

Inbred	3	O
DBA	3	O
/	9	O
2	9	O
and	5	O
C57BL	3	O
/	9	O
6	9	O
female	9	O
mice	3	O
were	9	O
injected	3	O
with	5	O
CY	9	B-Chemical
,	9	O
and	5	O
the	5	O
effect	9	O
of	5	O
the	5	O
drug	5	O
on	5	O
the	5	O
bladder	9	O
was	9	O
assessed	9	O
during	5	O
100	0	O
days	9	O
by	9	O
light	9	O
microscopy	9	O
using	9	O
different	9	O
staining	3	O
procedures	5	O
,	9	O
and	5	O
after	9	O
30	9	O
days	9	O
by	9	O
conventional	5	O
electron	0	O
microscopy	9	O
.	9	O

Early	9	O
CY	9	B-Chemical
toxicity	9	B-Disease
caused	9	O
a	5	O
typical	9	O
haemorrhagic	5	B-Disease
cystitis	9	B-Disease
in	5	O
both	9	O
strains	1	O
that	5	O
was	9	O
completely	9	O
repaired	5	O
in	5	O
about	5	O
7	9	O
-	7	O
10	9	O
days	9	O
.	9	O

After	9	O
30	9	O
days	9	O
of	5	O
CY	9	B-Chemical
injection	9	O
ulcerous	5	O
and	5	O
non	9	O
-	7	O
ulcerous	5	O
forms	9	O
of	5	O
chronic	5	O
cystitis	9	B-Disease
appeared	9	O
in	5	O
86	7	O
%	9	O
of	5	O
DBA	3	O
/	9	O
2	9	O
mice	3	O
but	9	O
only	9	O
in	5	O
4	9	O
%	9	O
of	5	O
C57BL	3	O
/	9	O
6	9	O
mice	3	O
.	9	O

Delayed	5	O
cystitis	9	B-Disease
was	9	O
characterized	9	O
by	9	O
infiltration	3	O
and	5	O
transepithelial	0	O
passage	9	O
into	9	O
the	5	O
lumen	9	O
of	5	O
inflammatory	3	O
cells	3	O
and	5	O
by	9	O
frequent	5	O
exfoliation	0	O
of	5	O
the	5	O
urothelium	3	O
.	9	O

Mast	3	O
cells	3	O
appeared	9	O
in	5	O
the	5	O
connective	5	O
and	5	O
muscular	5	O
layers	5	O
of	5	O
the	5	O
bladder	9	O
at	9	O
a	5	O
much	5	O
higher	9	O
number	9	O
in	5	O
DBA	3	O
/	9	O
2	9	O
mice	3	O
than	5	O
in	5	O
C57BL	3	O
/	9	O
6	9	O
mice	3	O
or	5	O
untreated	3	O
controls	9	O
.	9	O

Electron	0	O
microscopy	9	O
disclosed	9	O
the	5	O
absence	3	O
of	5	O
the	5	O
typical	9	O
discoidal	4	O
vesicles	9	O
normally	9	O
present	9	O
in	5	O
the	5	O
cytoplasm	3	O
of	5	O
surface	9	O
cells	3	O
.	9	O

Instead	5	O
,	9	O
numerous	9	O
abnormal	9	O
vesicles	9	O
containing	0	O
one	5	O
or	5	O
several	9	O
dark	9	O
granules	9	O
were	9	O
observed	9	O
in	5	O
the	5	O
cytoplasm	3	O
of	5	O
cells	3	O
from	9	O
all	5	O
the	5	O
epithelial	3	O
layers	5	O
.	9	O

Delayed	5	O
cystitis	9	B-Disease
still	5	O
persisted	9	O
in	5	O
DBA	3	O
/	9	O
2	9	O
mice	3	O
100	0	O
days	9	O
after	9	O
treatment	9	O
.	9	O

These	5	O
results	9	O
indicate	9	O
that	5	O
delayed	9	O
toxicity	9	B-Disease
of	5	O
CY	9	B-Chemical
in	5	O
female	9	O
DBA	3	O
/	9	O
2	9	O
mice	3	O
causes	9	O
a	5	O
bladder	9	O
pathology	5	O
that	5	O
is	5	O
not	5	O
observed	9	O
in	5	O
C57BL	3	O
/	9	O
6	9	O
mice	3	O
.	9	O

This	5	O
pathology	5	O
resembles	9	O
interstitial	9	B-Disease
cystitis	9	I-Disease
in	5	O
humans	9	O
and	5	O
could	9	O
perhaps	5	O
be	5	O
used	5	O
as	5	O
an	5	O
animal	5	O
model	5	O
for	5	O
studies	9	O
on	5	O
the	5	O
disease	5	O
.	9	O

High	9	O
-	7	O
dose	9	O
5	9	B-Chemical
-	7	I-Chemical
fluorouracil	0	I-Chemical
/	9	O
folinic	0	B-Chemical
acid	0	I-Chemical
in	5	O
combination	9	O
with	5	O
three	9	O
-	7	O
weekly	5	O
mitomycin	3	B-Chemical
C	9	I-Chemical
in	5	O
the	5	O
treatment	9	O
of	5	O
advanced	5	O
gastric	9	B-Disease
cancer	3	I-Disease
.	9	O

A	9	O
phase	5	O
II	9	O
study	9	O
.	9	O

BACKGROUND	2	O
:	9	O
The	5	O
24	9	O
-	7	O
hour	0	O
continuous	5	O
infusion	0	O
of	5	O
5	9	B-Chemical
-	7	I-Chemical
fluorouracil	0	I-Chemical
(	9	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
)	9	O
and	5	O
folinic	0	B-Chemical
acid	0	I-Chemical
(	9	O
FA	9	B-Chemical
)	9	O
as	5	O
part	9	O
of	5	O
several	9	O
new	5	O
multidrug	9	O
chemotherapy	5	O
regimens	5	O
in	5	O
advanced	5	O
gastric	9	B-Disease
cancer	3	I-Disease
(	9	O
AGC	9	B-Disease
)	9	O
has	9	O
shown	9	O
to	5	O
be	5	O
effective	5	O
,	9	O
with	5	O
low	9	O
toxicity	9	B-Disease
.	9	O

In	9	O
a	5	O
previous	9	O
phase	5	O
II	9	O
study	9	O
with	5	O
3	9	O
-	7	O
weekly	5	O
bolus	0	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
,	9	O
FA	9	B-Chemical
and	5	O
mitomycin	3	B-Chemical
C	9	I-Chemical
(	9	O
MMC	9	B-Chemical
)	9	O
we	5	O
found	9	O
a	5	O
low	9	O
toxicity	9	B-Disease
rate	9	O
and	5	O
response	9	O
rates	5	O
comparable	9	O
to	5	O
those	5	O
of	5	O
regimens	5	O
such	5	O
as	5	O
ELF	9	O
,	9	O
FAM	0	O
or	5	O
FAMTX	5	O
,	9	O
and	5	O
a	5	O
promising	5	O
median	9	O
overall	5	O
survival	9	O
.	9	O

In	9	O
order	5	O
to	5	O
improve	5	O
this	5	O
MMC	9	B-Chemical
-	7	O
dependent	9	O
schedule	5	O
we	5	O
initiated	9	O
a	5	O
phase	5	O
II	9	O
study	9	O
with	5	O
high	9	O
-	7	O
dose	9	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
/	9	O
FA	9	B-Chemical
and	5	O
3	9	O
-	7	O
weekly	5	O
bolus	0	O
MMC	9	B-Chemical
.	9	O

PATIENTS	2	O
AND	2	O
METHODS	2	O
:	9	O
From	5	O
February	2	O
,	9	O
1998	2	O
to	5	O
September	2	O
,	9	O
2000	9	O
we	5	O
recruited	9	O
33	7	O
patients	5	O
with	5	O
AGC	9	B-Disease
to	5	O
receive	5	O
weekly	5	O
24	9	O
-	7	O
hour	0	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
2	9	O
,	9	O
600	0	O
mg	0	O
/	9	O
m	9	O
(	9	O
2	9	O
)	9	O
preceded	9	O
by	9	O
2	9	O
-	7	O
hour	0	O
FA	9	B-Chemical
500	0	O
mg	0	O
/	9	O
m	9	O
(	9	O
2	9	O
)	9	O
for	5	O
6	9	O
weeks	9	O
,	9	O
followed	9	O
by	9	O
a	5	O
2	9	O
-	7	O
week	9	O
rest	5	O
period	5	O
.	9	O

Bolus	0	O
MMC	9	B-Chemical
10	9	O
mg	0	O
/	9	O
m	9	O
(	9	O
2	9	O
)	9	O
was	9	O
added	0	O
in	5	O
3	9	O
-	7	O
weekly	5	O
intervals	5	O
.	9	O

Treatment	9	O
given	5	O
on	5	O
an	5	O
outpatient	5	O
basis	5	O
,	9	O
using	9	O
portable	5	O
pump	0	O
systems	5	O
,	9	O
was	9	O
repeated	5	O
on	5	O
day	9	O
57	7	O
.	9	O

Patients	5	O
'	9	O
characteristics	5	O
were	9	O
:	9	O
male	9	O
/	9	O
female	9	O
ratio	9	O
20	9	O
/	9	O
13	7	O
;	9	O
median	9	O
age	5	O
57	7	O
(	9	O
27	7	O
-	7	O
75	9	O
)	9	O
years	5	O
;	9	O
median	9	O
WHO	5	O
status	9	O
1	9	O
(	9	O
0	7	O
-	7	O
2	9	O
)	9	O
.	9	O

18	7	O
patients	5	O
had	9	O
a	5	O
primary	9	O
AGC	9	B-Disease
,	9	O
and	5	O
15	9	O
showed	9	O
a	5	O
relapsed	5	O
AGC	9	B-Disease
.	9	O

Median	7	O
follow	5	O
-	7	O
up	5	O
was	9	O
11	7	O
.	9	O
8	9	O
months	5	O
(	9	O
range	9	O
of	5	O
those	5	O
surviving	9	O
:	9	O
2	9	O
.	9	O
7	9	O
-	7	O
11	7	O
.	9	O
8	9	O
months	5	O
)	9	O
.	9	O

RESULTS	9	O
:	9	O
32	7	O
patients	5	O
were	9	O
evaluable	9	O
for	5	O
response	9	O
-	7	O
complete	9	O
remission	5	O
9	7	O
.	9	O
1	9	O
%	9	O
(	9	O
n	9	O
=	7	O
3	9	O
)	9	O
,	9	O
partial	9	O
remission	5	O
45	9	O
.	9	O
5	9	O
%	9	O
(	9	O
n	9	O
=	7	O
15	9	O
)	9	O
,	9	O
no	9	O
change	9	O
27	7	O
.	9	O
3	9	O
%	9	O
(	9	O
n	9	O
=	7	O
9	7	O
)	9	O
,	9	O
progressive	5	O
disease	5	O
15	9	O
.	9	O
1	9	O
%	9	O
(	9	O
n	9	O
=	7	O
5	9	O
)	9	O
.	9	O

Median	7	O
overall	5	O
survival	9	O
time	5	O
was	9	O
10	9	O
.	9	O
2	9	O
months	5	O
[	9	O
95	7	O
%	9	O
confidence	5	O
interval	5	O
(	9	O
CI	7	O
)	9	O
:	9	O
8	9	O
.	9	O
7	9	O
-	7	O
11	7	O
.	9	O
6	9	O
]	9	O
,	9	O
and	5	O
median	9	O
progression	9	O
-	7	O
free	9	O
survival	9	O
time	5	O
was	9	O
7	9	O
.	9	O
6	9	O
months	5	O
(	9	O
95	7	O
%	9	O
CI	7	O
:	9	O
4	9	O
.	9	O
4	9	O
-	7	O
10	9	O
.	9	O
9	7	O
)	9	O
.	9	O

The	5	O
worst	5	O
toxicities	5	B-Disease
(	9	O
%	9	O
)	9	O
observed	9	O
were	9	O
(	9	O
CTC	9	O
-	7	O
NCI	2	O
1	9	O
/	9	O
2	9	O
/	9	O
3	9	O
)	9	O
:	9	O
leukopenia	9	B-Disease
45	9	O
.	9	O
5	9	O
/	9	O
18	7	O
.	9	O
2	9	O
/	9	O
6	9	O
.	9	O
1	9	O
,	9	O
thrombocytopenia	9	B-Disease
33	7	O
.	9	O
3	9	O
/	9	O
9	7	O
.	9	O
1	9	O
/	9	O
6	9	O
.	9	O
1	9	O
,	9	O
vomitus	5	B-Disease
24	9	O
.	9	O
2	9	O
/	9	O
9	7	O
.	9	O
1	9	O
/	9	O
0	7	O
,	9	O
diarrhea	5	B-Disease
36	9	O
.	9	O
4	9	O
/	9	O
6	9	O
.	9	O
1	9	O
/	9	O
3	9	O
.	9	O
0	7	O
,	9	O
stomatitis	9	B-Disease
18	7	O
.	9	O
2	9	O
/	9	O
9	7	O
.	9	O
1	9	O
/	9	O
0	7	O
,	9	O
hand	5	B-Disease
-	7	I-Disease
foot	5	I-Disease
syndrome	5	I-Disease
12	9	O
.	9	O
1	9	O
/	9	O
0	7	O
/	9	O
0	7	O
.	9	O

Two	9	O
patients	5	O
developed	5	O
hemolytic	0	B-Disease
-	7	I-Disease
uremic	9	I-Disease
syndrome	5	I-Disease
(	9	O
HUS	9	B-Disease
)	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
High	9	O
-	7	O
dose	9	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
/	9	O
FA	9	B-Chemical
/	9	O
MMC	9	B-Chemical
is	5	O
an	5	O
effective	5	O
and	5	O
well	9	O
-	7	O
tolerated	9	O
outpatient	5	O
regimen	5	O
for	5	O
AGC	9	B-Disease
(	9	O
objective	5	O
response	9	O
rate	9	O
54	7	O
.	9	O
6	9	O
%	9	O
)	9	O
.	9	O

It	5	O
may	5	O
serve	5	O
as	5	O
an	5	O
alternative	5	O
to	5	O
cisplatin	3	B-Chemical
-	7	O
containing	0	O
regimens	5	O
;	9	O
however	9	O
,	9	O
it	5	O
has	9	O
to	5	O
be	5	O
considered	5	O
that	5	O
possibly	9	O
HUS	9	B-Disease
may	5	O
occur	5	O
.	9	O

Persistent	9	O
sterile	0	O
leukocyturia	5	B-Disease
is	5	O
associated	9	O
with	5	O
impaired	9	B-Disease
renal	9	I-Disease
function	9	I-Disease
in	5	O
human	3	B-Disease
immunodeficiency	9	I-Disease
virus	9	I-Disease
type	9	I-Disease
1	9	I-Disease
-	7	I-Disease
infected	3	I-Disease
children	5	O
treated	3	O
with	5	O
indinavir	0	B-Chemical
.	9	O

BACKGROUND	2	O
:	9	O
Prolonged	9	O
administration	9	O
of	5	O
indinavir	0	B-Chemical
is	5	O
associated	9	O
with	5	O
the	5	O
occurrence	5	O
of	5	O
a	5	O
variety	5	O
of	5	O
renal	9	O
complications	5	O
in	5	O
adults	5	O
.	9	O

These	5	O
well	9	O
-	7	O
documented	9	O
side	5	O
effects	9	O
have	5	O
restricted	9	O
the	5	O
use	5	O
of	5	O
this	5	O
potent	3	O
protease	0	O
inhibitor	3	O
in	5	O
children	5	O
.	9	O

DESIGN	2	O
:	9	O
A	9	O
prospective	5	O
study	9	O
to	5	O
monitor	5	O
indinavir	0	B-Chemical
-	7	O
related	9	O
nephrotoxicity	9	B-Disease
in	5	O
a	5	O
cohort	9	O
of	5	O
30	9	O
human	3	B-Disease
immunodeficiency	9	I-Disease
virus	9	I-Disease
type	9	I-Disease
1	9	I-Disease
-	7	I-Disease
infected	3	I-Disease
children	5	O
treated	3	O
with	5	O
indinavir	0	B-Chemical
.	9	O

METHODS	2	O
:	9	O
Urinary	9	O
pH	0	O
,	9	O
albumin	0	O
,	9	O
creatinine	0	B-Chemical
,	9	O
the	5	O
presence	9	O
of	5	O
erythrocytes	9	O
,	9	O
leukocytes	3	O
,	9	O
bacteria	9	O
and	5	O
crystals	0	O
,	9	O
and	5	O
culture	9	O
were	9	O
analyzed	9	O
every	5	O
3	9	O
months	5	O
for	5	O
96	9	O
weeks	9	O
.	9	O

Serum	9	O
creatinine	0	B-Chemical
levels	3	O
were	9	O
routinely	9	O
determined	9	O
at	9	O
the	5	O
same	9	O
time	5	O
points	5	O
.	9	O

Steady	9	O
-	7	O
state	5	O
pharmacokinetics	9	O
of	5	O
indinavir	0	B-Chemical
were	9	O
done	9	O
at	9	O
week	9	O
4	9	O
after	9	O
the	5	O
initiation	9	O
of	5	O
indinavir	0	B-Chemical
.	9	O

RESULTS	9	O
:	9	O
The	5	O
cumulative	5	O
incidence	5	O
of	5	O
persistent	5	O
sterile	0	O
leukocyturia	5	B-Disease
(	9	O
>	0	O
or	5	O
=	7	O
75	9	O
cells	3	O
/	9	O
micro	0	O
L	0	O
in	5	O
at	9	O
least	9	O
2	9	O
consecutive	5	O
visits	5	O
)	9	O
after	9	O
96	9	O
weeks	9	O
was	9	O
53	7	O
%	9	O
.	9	O

Persistent	9	O
sterile	0	O
leukocyturia	5	B-Disease
was	9	O
frequently	5	O
associated	9	O
with	5	O
a	5	O
mild	9	O
increase	9	O
in	5	O
the	5	O
urine	9	O
albumin	0	O
/	9	O
creatinine	0	B-Chemical
ratio	9	O
and	5	O
by	9	O
microscopic	9	O
hematuria	5	B-Disease
.	9	O

The	5	O
cumulative	5	O
incidence	5	O
of	5	O
serum	9	O
creatinine	0	B-Chemical
levels	3	O
>	0	O
50	0	O
%	9	O
above	9	O
normal	9	O
was	9	O
33	7	O
%	9	O
after	9	O
96	9	O
weeks	9	O
.	9	O

Children	5	O
with	5	O
persistent	5	O
sterile	0	O
leukocyturia	5	B-Disease
more	5	O
frequently	5	O
had	9	O
serum	9	O
creatinine	0	B-Chemical
levels	3	O
of	5	O
50	0	O
%	9	O
above	9	O
normal	9	O
than	5	O
those	5	O
children	5	O
without	9	O
persistent	5	O
sterile	0	O
leukocyturia	5	B-Disease
.	9	O

In	9	O
children	5	O
younger	5	O
than	5	O
5	9	O
.	9	O
6	9	O
years	5	O
,	9	O
persistent	5	O
sterile	0	O
leukocyturia	5	B-Disease
was	9	O
significantly	9	O
more	5	O
frequent	5	O
than	5	O
in	5	O
older	5	O
children	5	O
.	9	O

A	9	O
higher	9	O
cumulative	5	O
incidence	5	O
of	5	O
persistent	5	O
leukocyturia	5	B-Disease
was	9	O
found	9	O
in	5	O
children	5	O
with	5	O
an	5	O
area	5	O
under	9	O
the	5	O
curve	9	O
>	0	O
19	7	O
mg	0	O
/	9	O
L	0	O
x	9	O
h	0	O
or	5	O
a	5	O
peak	9	O
serum	9	O
level	9	O
of	5	O
indinavir	0	B-Chemical
>	0	O
12	9	O
mg	0	O
/	9	O
L	0	O
.	9	O

In	9	O
4	9	O
children	5	O
,	9	O
indinavir	0	B-Chemical
was	9	O
discontinued	5	O
because	5	O
of	5	O
nephrotoxicity	9	B-Disease
.	9	O

Subsequently	9	O
,	9	O
the	5	O
serum	9	O
creatinine	0	B-Chemical
levels	3	O
decreased	9	O
,	9	O
the	5	O
urine	9	O
albumin	0	O
/	9	O
creatinine	0	B-Chemical
ratios	9	O
returned	5	O
to	5	O
zero	5	O
,	9	O
and	5	O
the	5	O
leukocyturia	5	B-Disease
disappeared	9	O
within	9	O
3	9	O
months	5	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Children	5	O
treated	3	O
with	5	O
indinavir	0	B-Chemical
have	5	O
a	5	O
high	9	O
cumulative	5	O
incidence	5	O
of	5	O
persistent	5	O
sterile	0	O
leukocyturia	5	B-Disease
.	9	O

Children	5	O
with	5	O
persistent	5	O
sterile	0	O
leukocyturia	5	B-Disease
more	5	O
frequently	5	O
had	9	O
an	5	O
increase	9	O
in	5	O
serum	9	O
creatinine	0	B-Chemical
levels	3	O
of	5	O
>	0	O
50	0	O
%	9	O
above	9	O
normal	9	O
.	9	O

Younger	5	O
children	5	O
have	5	O
an	5	O
additional	9	O
risk	5	O
for	5	O
renal	9	O
complications	5	O
.	9	O

The	5	O
impairment	5	B-Disease
of	5	I-Disease
the	5	I-Disease
renal	9	I-Disease
function	9	I-Disease
in	5	O
these	5	O
children	5	O
occurred	9	O
in	5	O
the	5	O
absence	3	O
of	5	O
clinical	5	O
symptoms	5	O
of	5	O
nephrolithiasis	5	B-Disease
.	9	O

Indinavir	7	B-Chemical
-	7	O
associated	9	O
nephrotoxicity	9	B-Disease
must	5	O
be	5	O
monitored	9	O
closely	9	O
,	9	O
especially	5	O
in	5	O
children	5	O
with	5	O
risk	5	O
factors	9	O
such	5	O
as	5	O
persistent	5	O
sterile	0	O
leukocyturia	5	B-Disease
,	9	O
age	5	O
<	0	O
5	9	O
.	9	O
6	9	O
years	5	O
,	9	O
an	5	O
area	5	O
under	9	O
the	5	O
curve	9	O
of	5	O
indinavir	0	B-Chemical
>	0	O
19	7	O
mg	0	O
/	9	O
L	0	O
x	9	O
h	0	O
,	9	O
and	5	O
a	5	O
C	9	O
(	9	O
max	9	O
)	9	O
>	0	O
12	9	O
mg	0	O
/	9	O
L	0	O
.	9	O

Utility	5	O
of	5	O
troponin	9	O
I	9	O
in	5	O
patients	5	O
with	5	O
cocaine	5	B-Chemical
-	7	O
associated	9	O
chest	5	B-Disease
pain	5	I-Disease
.	9	O

Baseline	9	O
electrocardiogram	5	O
abnormalities	9	O
and	5	O
market	5	O
elevations	9	O
not	5	O
associated	9	O
with	5	O
myocardial	9	B-Disease
necrosis	9	I-Disease
make	5	O
accurate	5	O
diagnosis	5	O
of	5	O
myocardial	9	B-Disease
infarction	5	I-Disease
(	9	O
MI	9	B-Disease
)	9	O
difficult	5	O
in	5	O
patients	5	O
with	5	O
cocaine	5	B-Chemical
-	7	O
associated	9	O
chest	5	B-Disease
pain	5	I-Disease
.	9	O

Troponin	7	O
sampling	5	O
may	5	O
offer	5	O
greater	5	O
diagnostic	5	O
utility	5	O
in	5	O
these	5	O
patients	5	O
.	9	O

OBJECTIVE	2	O
:	9	O
To	9	O
assess	5	O
outcomes	5	O
based	5	O
on	5	O
troponin	9	O
positivity	9	O
in	5	O
patients	5	O
with	5	O
cocaine	5	B-Chemical
chest	5	B-Disease
pain	5	I-Disease
admitted	5	O
for	5	O
exclusion	5	O
of	5	O
MI	9	B-Disease
.	9	O

METHODS	2	O
:	9	O
Outcomes	5	O
were	9	O
examined	9	O
in	5	O
patients	5	O
admitted	5	O
for	5	O
possible	5	O
MI	9	B-Disease
after	9	O
cocaine	5	B-Chemical
use	5	O
.	9	O

All	9	O
patients	5	O
underwent	5	O
a	5	O
rapid	5	O
rule	5	O
-	7	O
in	5	O
protocol	9	O
that	5	O
included	5	O
serial	9	O
sampling	5	O
of	5	O
creatine	0	B-Chemical
kinase	3	O
(	9	O
CK	9	O
)	9	O
,	9	O
CK	9	O
-	7	O
MB	0	O
,	9	O
and	5	O
cardiac	5	O
troponin	9	O
I	9	O
(	9	O
cTnI	9	O
)	9	O
over	5	O
eight	9	O
hours	9	O
.	9	O

Outcomes	5	O
included	5	O
CK	9	O
-	7	O
MB	0	O
MI	9	B-Disease
(	9	O
CK	9	O
-	7	O
MB	0	O
>	0	O
or	5	O
=	7	O
8	9	O
ng	0	O
/	9	O
mL	0	O
with	5	O
a	5	O
relative	9	O
index	5	O
[	9	O
(	9	O
CK	9	O
-	7	O
MB	0	O
x	9	O
100	0	O
)	9	O
/	9	O
total	9	O
CK	9	O
]	9	O
>	0	O
or	5	O
=	7	O
4	9	O
,	9	O
cardiac	5	B-Disease
death	9	I-Disease
,	9	O
and	5	O
significant	9	O
coronary	5	B-Disease
disease	5	I-Disease
(	9	O
>	0	O
or	5	O
=	7	O
50	0	O
%	9	O
)	9	O
.	9	O

RESULTS	9	O
:	9	O
Of	9	O
the	5	O
246	7	O
admitted	5	O
patients	5	O
,	9	O
34	7	O
(	9	O
14	7	O
%	9	O
)	9	O
met	5	O
CK	9	O
-	7	O
MB	0	O
criteria	5	O
for	5	O
MI	9	B-Disease
and	5	O
38	7	O
(	9	O
16	9	O
%	9	O
)	9	O
had	9	O
cTnI	9	O
elevations	9	O
.	9	O

Angiography	5	O
was	9	O
performed	9	O
in	5	O
29	7	O
of	5	O
38	7	O
patients	5	O
who	5	O
were	9	O
cTnI	9	O
-	7	O
positive	9	O
,	9	O
with	5	O
significant	9	O
disease	5	O
present	9	O
in	5	O
25	9	O
(	9	O
86	7	O
%	9	O
)	9	O
.	9	O

Three	9	O
of	5	O
the	5	O
four	9	O
patients	5	O
without	9	O
significant	9	O
disease	5	O
who	5	O
had	9	O
cTnI	9	O
elevations	9	O
met	5	O
CK	9	O
-	7	O
MB	0	O
criteria	5	O
for	5	O
MI	9	B-Disease
,	9	O
and	5	O
the	5	O
other	5	O
had	9	O
a	5	O
peak	9	O
CK	9	O
-	7	O
MB	0	O
level	9	O
of	5	O
13	7	O
ng	0	O
/	9	O
mL	0	O
.	9	O

Sensitivities	9	O
,	9	O
specificities	9	O
,	9	O
and	5	O
positive	9	O
and	5	O
negative	9	O
likelihood	5	O
ratios	9	O
for	5	O
predicting	5	O
cardiac	5	B-Disease
death	9	I-Disease
or	5	O
significant	9	O
disease	5	O
were	9	O
high	9	O
for	5	O
both	9	O
CK	9	O
-	7	O
MB	0	O
MI	9	B-Disease
and	5	O
cTnI	9	O
and	5	O
were	9	O
not	5	O
significantly	9	O
different	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Most	5	O
patients	5	O
with	5	O
cTnI	9	O
elevations	9	O
meet	5	O
CK	9	O
-	7	O
MB	0	O
criteria	5	O
for	5	O
MI	9	B-Disease
,	9	O
as	5	O
well	9	O
as	5	O
have	5	O
a	5	O
high	9	O
incidence	5	O
of	5	O
underlying	5	O
significant	9	O
disease	5	O
.	9	O

Troponin	7	O
appears	9	O
to	5	O
have	5	O
an	5	O
equivalent	9	O
diagnostic	5	O
accuracy	5	O
compared	9	O
with	5	O
CK	9	O
-	7	O
MB	0	O
for	5	O
diagnosing	5	O
necrosis	9	B-Disease
in	5	O
patients	5	O
with	5	O
cocaine	5	B-Chemical
-	7	O
associated	9	O
chest	5	B-Disease
pain	5	I-Disease
and	5	O
suspected	5	O
MI	9	B-Disease
.	9	O

Acute	5	O
interstitial	9	B-Disease
nephritis	9	I-Disease
due	5	O
to	5	O
nicergoline	0	B-Chemical
(	9	O
Sermion	_	B-Chemical
)	9	O
.	9	O

We	9	O
report	5	O
a	5	O
case	5	O
of	5	O
acute	9	O
interstitial	9	B-Disease
nephritis	9	I-Disease
(	9	O
AIN	9	B-Disease
)	9	O
due	5	O
to	5	O
nicergoline	0	B-Chemical
(	9	O
Sermion	_	B-Chemical
)	9	O
.	9	O

A	9	O
50	0	O
-	7	O
year	5	O
-	7	O
old	5	O
patient	5	O
admitted	5	O
to	5	O
our	5	O
hospital	5	O
for	5	O
fever	5	B-Disease
and	5	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
.	9	O

Before	9	O
admission	5	O
,	9	O
he	5	O
had	9	O
been	9	O
taking	5	O
nicergoline	0	B-Chemical
and	5	O
bendazac	_	B-Chemical
lysine	0	I-Chemical
due	5	O
to	5	O
retinal	5	B-Disease
vein	5	I-Disease
occlusion	5	I-Disease
at	9	O
ophthalmologic	5	O
department	5	O
.	9	O

Thereafter	9	O
,	9	O
he	5	O
experienced	5	O
intermittent	5	O
fever	5	B-Disease
and	5	O
skin	5	B-Disease
rash	5	I-Disease
.	9	O

On	5	O
admission	5	O
,	9	O
clinical	5	O
symptoms	5	O
(	9	O
i	9	O
.	9	O
e	9	O
.	9	O
arthralgia	5	B-Disease
and	5	O
fever	5	B-Disease
)	9	O
and	5	O
laboratory	9	O
findings	9	O
(	9	O
i	9	O
.	9	O
e	9	O
.	9	O
eosinophilia	3	B-Disease
and	5	O
renal	9	B-Disease
failure	5	I-Disease
)	9	O
suggested	9	O
AIN	9	B-Disease
,	9	O
and	5	O
which	5	O
was	9	O
confirmed	9	O
by	9	O
pathologic	5	O
findings	9	O
on	5	O
renal	9	O
biopsy	5	O
.	9	O

A	9	O
lymphocyte	3	O
transformation	9	O
test	5	O
demonstrated	9	O
a	5	O
positive	9	O
result	9	O
against	9	O
nicergoline	0	B-Chemical
.	9	O

Treatment	9	O
was	9	O
consisted	5	O
of	5	O
withdrawal	5	O
of	5	O
nicergoline	0	B-Chemical
and	5	O
intravenous	0	O
methylprednisolone	0	B-Chemical
,	9	O
and	5	O
his	5	O
renal	9	O
function	9	O
was	9	O
completely	9	O
recovered	9	O
.	9	O

To	9	O
our	5	O
knowledge	5	O
,	9	O
this	5	O
is	5	O
the	5	O
first	9	O
report	5	O
of	5	O
nicergoline	0	B-Chemical
-	7	O
associated	9	O
AIN	9	B-Disease
.	9	O

Neuroleptic	2	B-Disease
malignant	3	I-Disease
syndrome	5	I-Disease
complicated	5	O
by	9	O
massive	9	O
intestinal	9	O
bleeding	5	B-Disease
in	5	O
a	5	O
patient	5	O
with	5	O
chronic	5	B-Disease
renal	9	I-Disease
failure	5	I-Disease
.	9	O

A	9	O
patient	5	O
with	5	O
chronic	5	B-Disease
renal	9	I-Disease
failure	5	I-Disease
(	9	O
CRF	9	B-Disease
)	9	O
developed	5	O
neuroleptic	5	B-Disease
malignant	3	I-Disease
syndrome	5	I-Disease
(	9	O
NMS	9	B-Disease
)	9	O
after	9	O
administration	9	O
of	5	O
risperidone	5	B-Chemical
and	5	O
levomepromazine	5	B-Chemical
.	9	O

In	9	O
addition	9	O
to	5	O
the	5	O
typical	9	O
symptoms	5	O
of	5	O
NMS	9	B-Disease
,	9	O
massive	9	O
intestinal	9	O
bleeding	5	B-Disease
was	9	O
observed	9	O
during	5	O
the	5	O
episode	5	O
.	9	O

This	5	O
report	5	O
suggests	9	O
that	5	O
NMS	9	B-Disease
in	5	O
a	5	O
patient	5	O
with	5	O
CRF	9	B-Disease
may	5	O
be	5	O
complicated	5	O
by	9	O
intestinal	9	O
bleeding	5	B-Disease
and	5	O
needs	5	O
special	5	O
caution	5	O
for	5	O
this	5	O
complication	5	O
.	9	O

Blood	9	O
brain	5	O
barrier	5	O
in	5	O
right	5	O
-	7	O
and	5	O
left	5	O
-	7	O
pawed	9	O
female	9	O
rats	9	O
assessed	9	O
by	9	O
a	5	O
new	5	O
staining	3	O
method	5	O
.	9	O

The	5	O
asymmetrical	5	O
breakdown	9	O
of	5	O
the	5	O
blood	9	O
-	7	O
brain	5	O
barrier	5	O
(	9	O
BBB	9	O
)	9	O
was	9	O
studied	9	O
in	5	O
female	9	O
rats	9	O
.	9	O

Paw	5	O
preference	5	O
was	9	O
assessed	9	O
by	9	O
a	5	O
food	5	O
reaching	5	O
test	5	O
.	9	O

Adrenaline	0	B-Chemical
-	7	O
induced	3	O
hypertension	5	B-Disease
was	9	O
used	5	O
to	5	O
destroy	9	O
the	5	O
BBB	9	O
,	9	O
which	5	O
was	9	O
evaluated	9	O
using	9	O
triphenyltetrazolium	0	B-Chemical
(	9	O
TTC	9	B-Chemical
)	9	O
staining	3	O
of	5	O
the	5	O
brain	5	O
slices	9	O
just	5	O
after	9	O
giving	5	O
adrenaline	0	B-Chemical
for	5	O
30	9	O
s	9	O
.	9	O

In	9	O
normal	9	O
rats	9	O
,	9	O
the	5	O
whole	9	O
brain	5	O
sections	9	O
exhibited	9	O
complete	9	O
staining	3	O
with	5	O
TTC	9	B-Chemical
.	9	O

After	9	O
adrenaline	0	B-Chemical
infusion	0	O
for	5	O
30	9	O
s	9	O
,	9	O
there	5	O
were	9	O
large	5	O
unstained	3	O
areas	5	O
in	5	O
the	5	O
left	5	O
brain	5	O
in	5	O
right	5	O
-	7	O
pawed	9	O
animals	9	O
,	9	O
and	5	O
vice	9	O
versa	9	O
in	5	O
left	5	O
-	7	O
pawed	9	O
animals	9	O
.	9	O

Similar	9	O
results	9	O
were	9	O
obtained	9	O
in	5	O
seizure	5	B-Disease
-	7	O
induced	3	O
breakdown	9	O
of	5	O
BBB	9	O
.	9	O

These	5	O
results	9	O
were	9	O
explained	5	O
by	9	O
an	5	O
asymmetric	9	O
cerebral	5	O
blood	9	O
flow	5	O
depending	5	O
upon	9	O
the	5	O
paw	5	O
preference	5	O
in	5	O
rats	9	O
.	9	O

It	5	O
was	9	O
suggested	9	O
that	5	O
this	5	O
new	5	O
method	5	O
and	5	O
the	5	O
results	9	O
are	5	O
consistent	9	O
with	5	O
contralateral	5	O
motor	5	O
control	9	O
that	5	O
may	5	O
be	5	O
important	9	O
in	5	O
determining	9	O
the	5	O
dominant	9	O
cerebral	5	O
hemisphere	5	O
in	5	O
animals	9	O
.	9	O

Carvedilol	0	B-Chemical
protects	3	O
against	9	O
doxorubicin	0	B-Chemical
-	7	O
induced	3	O
mitochondrial	9	O
cardiomyopathy	5	B-Disease
.	9	O

Several	9	O
cytopathic	3	O
mechanisms	9	O
have	5	O
been	9	O
suggested	9	O
to	5	O
mediate	3	O
the	5	O
dose	9	O
-	7	O
limiting	9	O
cumulative	5	O
and	5	O
irreversible	9	O
cardiomyopathy	5	B-Disease
caused	9	O
by	9	O
doxorubicin	0	B-Chemical
.	9	O

Recent	9	O
evidence	9	O
indicates	9	O
that	5	O
oxidative	9	O
stress	9	O
and	5	O
mitochondrial	9	B-Disease
dysfunction	9	I-Disease
are	5	O
key	9	O
factors	9	O
in	5	O
the	5	O
pathogenic	9	O
process	5	O
.	9	O

The	5	O
objective	5	O
of	5	O
this	5	O
investigation	9	O
was	9	O
to	5	O
test	5	O
the	5	O
hypothesis	9	O
that	5	O
carvedilol	0	B-Chemical
,	9	O
a	5	O
nonselective	0	O
beta	9	O
-	7	O
adrenergic	9	O
receptor	3	O
antagonist	3	O
with	5	O
potent	3	O
antioxidant	0	O
properties	9	O
,	9	O
protects	3	O
against	9	O
the	5	O
cardiac	5	O
and	5	O
hepatic	9	O
mitochondrial	9	O
bioenergetic	9	O
dysfunction	9	O
associated	9	O
with	5	O
subchronic	0	O
doxorubicin	0	B-Chemical
toxicity	9	B-Disease
.	9	O

Heart	2	O
and	5	O
liver	9	O
mitochondria	3	O
were	9	O
isolated	9	O
from	9	O
rats	9	O
treated	3	O
for	5	O
7	9	O
weeks	9	O
with	5	O
doxorubicin	0	B-Chemical
(	9	O
2	9	O
mg	0	O
/	9	O
kg	0	O
sc	9	O
/	9	O
week	9	O
)	9	O
,	9	O
carvedilol	0	B-Chemical
(	9	O
1	9	O
mg	0	O
/	9	O
kg	0	O
ip	0	O
/	9	O
week	9	O
)	9	O
,	9	O
or	5	O
the	5	O
combination	9	O
of	5	O
the	5	O
two	5	O
drugs	5	O
.	9	O

Heart	2	O
mitochondria	3	O
isolated	9	O
from	9	O
doxorubicin	0	B-Chemical
-	7	O
treated	3	O
rats	9	O
exhibited	9	O
depressed	5	O
rates	5	O
for	5	O
state	5	O
3	9	O
respiration	9	O
(	9	O
336	7	O
+	9	O
/	9	O
-	7	O
26	7	O
versus	9	O
425	7	O
+	9	O
/	9	O
-	7	O
53	7	O
natom	9	O
O	9	O
/	9	O
min	0	O
/	9	O
mg	0	O
protein	1	O
)	9	O
and	5	O
a	5	O
lower	9	O
respiratory	5	O
control	9	O
ratio	9	O
(	9	O
RCR	5	O
)	9	O
(	9	O
4	9	O
.	9	O
3	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
6	9	O
versus	9	O
5	9	O
.	9	O
8	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
4	9	O
)	9	O
compared	9	O
with	5	O
cardiac	5	O
mitochondria	3	O
isolated	9	O
from	9	O
saline	0	O
-	7	O
treated	3	O
rats	9	O
.	9	O

Mitochondrial	9	O
calcium	0	B-Chemical
-	7	O
loading	9	O
capacity	9	O
and	5	O
the	5	O
activity	9	O
of	5	O
NADH	0	O
-	7	O
dehydrogenase	1	O
were	9	O
also	9	O
suppressed	3	O
in	5	O
cardiac	5	O
mitochondria	3	O
from	9	O
doxorubicin	0	B-Chemical
-	7	O
treated	3	O
rats	9	O
.	9	O

Doxorubicin	0	B-Chemical
treatment	9	O
also	9	O
caused	9	O
a	5	O
decrease	9	O
in	5	O
RCR	5	O
for	5	O
liver	9	O
mitochondria	3	O
(	9	O
3	9	O
.	9	O
9	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
9	7	O
versus	9	O
5	9	O
.	9	O
6	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
7	9	O
for	5	O
control	9	O
rats	9	O
)	9	O
and	5	O
inhibition	3	O
of	5	O
hepatic	9	O
cytochrome	0	O
oxidase	0	O
activity	9	O
.	9	O

Coadministration	0	O
of	5	O
carvedilol	0	B-Chemical
decreased	9	O
the	5	O
extent	9	O
of	5	O
cellular	3	O
vacuolization	3	O
in	5	O
cardiac	5	O
myocytes	3	O
and	5	O
prevented	9	O
the	5	O
inhibitory	3	O
effect	9	O
of	5	O
doxorubicin	0	B-Chemical
on	5	O
mitochondrial	9	O
respiration	9	O
in	5	O
both	9	O
heart	5	O
and	5	O
liver	9	O
.	9	O

Carvedilol	0	B-Chemical
also	9	O
prevented	9	O
the	5	O
decrease	9	O
in	5	O
mitochondrial	9	O
Ca	0	B-Chemical
(	9	O
2	9	O
+	9	O
)	9	O
loading	9	O
capacity	9	O
and	5	O
the	5	O
inhibition	3	O
of	5	O
the	5	O
respiratory	5	O
complexes	9	O
of	5	O
heart	5	O
mitochondria	3	O
caused	9	O
by	9	O
doxorubicin	0	B-Chemical
.	9	O

Carvedilol	0	B-Chemical
by	9	O
itself	9	O
did	9	O
not	5	O
affect	9	O
any	5	O
of	5	O
the	5	O
parameters	5	O
measured	9	O
for	5	O
heart	5	O
or	5	O
liver	9	O
mitochondria	3	O
.	9	O

It	5	O
is	5	O
concluded	9	O
that	5	O
this	5	O
protection	9	O
by	9	O
carvedilol	0	B-Chemical
against	9	O
both	9	O
the	5	O
structural	9	O
and	5	O
functional	9	O
cardiac	5	O
tissue	9	O
damage	9	O
may	5	O
afford	5	O
significant	9	O
clinical	5	O
advantage	5	O
in	5	O
minimizing	5	O
the	5	O
dose	9	O
-	7	O
limiting	9	O
mitochondrial	9	B-Disease
dysfunction	9	I-Disease
and	5	O
cardiomyopathy	5	B-Disease
that	5	O
accompanies	9	O
long	5	O
-	7	O
term	5	O
doxorubicin	0	B-Chemical
therapy	5	O
in	5	O
cancer	3	B-Disease
patients	5	O
.	9	O

Cocaine	5	B-Chemical
-	7	O
induced	3	O
hyperactivity	5	B-Disease
is	5	O
more	5	O
influenced	5	O
by	9	O
adenosine	0	B-Chemical
receptor	3	O
agonists	3	O
than	5	O
amphetamine	5	B-Chemical
-	7	O
induced	3	O
hyperactivity	5	B-Disease
.	9	O

The	5	O
influence	5	O
of	5	O
adenosine	0	B-Chemical
receptor	3	O
agonists	3	O
and	5	O
antagonists	3	O
on	5	O
cocaine	5	B-Chemical
-	7	O
and	5	O
amphetamine	5	B-Chemical
-	7	O
induced	3	O
hyperactivity	5	B-Disease
was	9	O
examined	9	O
in	5	O
mice	3	O
.	9	O

All	9	O
adenosine	0	B-Chemical
receptor	3	O
agonists	3	O
significantly	9	O
decreased	9	B-Disease
the	5	I-Disease
locomotor	5	I-Disease
activity	9	I-Disease
in	5	O
mice	3	O
,	9	O
and	5	O
the	5	O
effects	9	O
were	9	O
dose	9	O
-	7	O
dependent	9	O
.	9	O

It	5	O
seems	5	O
that	5	O
adenosine	0	B-Chemical
A1	9	O
and	5	O
A2	9	O
receptors	3	O
might	9	O
be	5	O
involved	9	O
in	5	O
this	5	O
reaction	9	O
.	9	O

Moreover	9	O
,	9	O
all	5	O
adenosine	0	B-Chemical
receptor	3	O
agonists	3	O
:	9	O
2	9	B-Chemical
-	7	I-Chemical
p	7	I-Chemical
-	7	I-Chemical
(	9	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
carboxyethyl	0	I-Chemical
)	9	I-Chemical
phenethylamino	0	I-Chemical
-	7	I-Chemical
5	9	I-Chemical
'	9	I-Chemical
-	7	I-Chemical
N	9	I-Chemical
-	7	I-Chemical
ethylcarboxamidoadenosine	_	I-Chemical
(	9	O
CGS	9	B-Chemical
21680	3	I-Chemical
)	9	O
,	9	O
A2A	3	O
receptor	3	O
agonist	3	O
,	9	O
N6	8	B-Chemical
-	7	I-Chemical
cyclopentyladenosine	0	I-Chemical
(	9	O
CPA	9	B-Chemical
)	9	O
,	9	O
A1	9	O
receptor	3	O
agonist	3	O
,	9	O
and	5	O
5	9	B-Chemical
'	9	I-Chemical
-	7	I-Chemical
N	9	I-Chemical
-	7	I-Chemical
ethylcarboxamidoadenosine	_	I-Chemical
(	9	O
NECA	0	B-Chemical
)	9	O
,	9	O
A2	9	O
/	9	O
A1	9	O
receptor	3	O
agonist	3	O
significantly	9	O
and	5	O
dose	9	O
-	7	O
dependently	3	O
decreased	9	O
cocaine	5	B-Chemical
-	7	O
induced	3	O
locomotor	5	O
activity	9	O
.	9	O

CPA	9	B-Chemical
reduced	9	O
cocaine	5	B-Chemical
action	5	O
at	9	O
the	5	O
doses	0	O
which	5	O
,	9	O
given	5	O
alone	9	O
,	9	O
did	9	O
not	5	O
influence	5	O
motility	9	O
,	9	O
while	9	O
CGS	9	B-Chemical
21680	3	I-Chemical
and	5	O
NECA	0	B-Chemical
decreased	9	O
the	5	O
action	5	O
of	5	O
cocaine	5	B-Chemical
at	9	O
the	5	O
doses	0	O
which	5	O
,	9	O
given	5	O
alone	9	O
,	9	O
decreased	9	O
locomotor	5	O
activity	9	O
in	5	O
animals	9	O
.	9	O

These	5	O
results	9	O
suggest	9	O
the	5	O
involvement	9	O
of	5	O
both	9	O
adenosine	0	B-Chemical
receptors	3	O
in	5	O
the	5	O
action	5	O
of	5	O
cocaine	5	B-Chemical
although	9	O
agonists	3	O
of	5	O
A1	9	O
receptors	3	O
seem	5	O
to	5	O
have	5	O
stronger	9	O
influence	5	O
on	5	O
it	5	O
.	9	O

The	5	O
selective	9	O
blockade	3	O
of	5	O
A2	9	O
adenosine	0	B-Chemical
receptor	3	O
by	9	O
DMPX	0	B-Chemical
(	9	O
3	9	B-Chemical
,	9	I-Chemical
7	9	I-Chemical
-	7	I-Chemical
dimethyl	0	I-Chemical
-	7	I-Chemical
1	9	I-Chemical
-	7	I-Chemical
propargylxanthine	_	I-Chemical
)	9	O
significantly	9	O
enhanced	3	O
cocaine	5	B-Chemical
-	7	O
induced	3	O
locomotor	5	O
activity	9	O
of	5	O
animals	9	O
.	9	O

Caffeine	0	B-Chemical
had	9	O
similar	9	O
action	5	O
but	9	O
the	5	O
effect	9	O
was	9	O
not	5	O
significant	9	O
.	9	O

CPT	9	B-Chemical
(	9	O
8	9	B-Chemical
-	7	I-Chemical
cyclopentyltheophylline	_	I-Chemical
)	9	O
-	7	O
-	7	O
A1	9	O
receptor	3	O
antagonist	3	O
,	9	O
did	9	O
not	5	O
show	9	O
any	5	O
influence	5	O
in	5	O
this	5	O
test	5	O
.	9	O

Similarly	9	O
,	9	O
all	5	O
adenosine	0	B-Chemical
receptor	3	O
agonists	3	O
decreased	9	O
amphetamine	5	B-Chemical
-	7	O
induced	3	O
hyperactivity	5	B-Disease
,	9	O
but	9	O
at	9	O
the	5	O
higher	9	O
doses	0	O
than	5	O
those	5	O
which	5	O
were	9	O
active	9	O
in	5	O
cocaine	5	B-Chemical
-	7	O
induced	3	O
hyperactivity	5	B-Disease
.	9	O

The	5	O
selective	9	O
blockade	3	O
of	5	O
A2	9	O
adenosine	0	B-Chemical
receptors	3	O
(	9	O
DMPX	0	B-Chemical
)	9	O
and	5	O
non	9	O
-	7	O
selective	9	O
blockade	3	O
of	5	O
adenosine	0	B-Chemical
receptors	3	O
(	9	O
caffeine	0	B-Chemical
)	9	O
significantly	9	O
increased	9	O
the	5	O
action	5	O
of	5	O
amphetamine	5	B-Chemical
in	5	O
the	5	O
locomotor	5	O
activity	9	O
test	5	O
.	9	O

Our	9	O
results	9	O
have	5	O
shown	9	O
that	5	O
all	5	O
adenosine	0	B-Chemical
receptor	3	O
agonists	3	O
(	9	O
A1	9	O
and	5	O
A2	9	O
)	9	O
reduce	5	O
cocaine	5	B-Chemical
-	7	O
and	5	O
amphetamine	5	B-Chemical
-	7	O
induced	3	O
locomotor	5	O
activity	9	O
and	5	O
indicate	9	O
that	5	O
cocaine	5	B-Chemical
-	7	O
induced	3	O
hyperactivity	5	B-Disease
is	5	O
more	5	O
influenced	5	O
by	9	O
adenosine	0	B-Chemical
receptor	3	O
agonists	3	O
(	9	O
particularly	5	O
A1	9	O
receptors	3	O
)	9	O
than	5	O
amphetamine	5	B-Chemical
-	7	O
induced	3	O
hyperactivity	5	B-Disease
.	9	O

Amiodarone	7	B-Chemical
and	5	O
the	5	O
risk	5	O
of	5	O
bradyarrhythmia	5	B-Disease
requiring	5	O
permanent	5	O
pacemaker	5	O
in	5	O
elderly	5	O
patients	5	O
with	5	O
atrial	5	B-Disease
fibrillation	5	I-Disease
and	5	O
prior	9	O
myocardial	9	B-Disease
infarction	5	I-Disease
.	9	O

OBJECTIVES	2	O
:	9	O
The	5	O
aim	5	O
of	5	O
this	5	O
study	9	O
was	9	O
to	5	O
determine	9	O
whether	9	O
the	5	O
use	5	O
of	5	O
amiodarone	0	B-Chemical
in	5	O
patients	5	O
with	5	O
atrial	5	B-Disease
fibrillation	5	I-Disease
(	9	O
AF	9	B-Disease
)	9	O
increases	9	O
the	5	O
risk	5	O
of	5	O
bradyarrhythmia	5	B-Disease
requiring	5	O
a	5	O
permanent	5	O
pacemaker	5	O
.	9	O

BACKGROUND	2	O
:	9	O
Reports	5	O
of	5	O
severe	5	O
bradyarrhythmia	5	B-Disease
during	5	O
amiodarone	0	B-Chemical
therapy	5	O
are	5	O
infrequent	5	O
and	5	O
limited	5	O
to	5	O
studies	9	O
assessing	5	O
the	5	O
therapy	5	O
'	9	O
s	9	O
use	5	O
in	5	O
the	5	O
management	5	O
of	5	O
patients	5	O
with	5	O
ventricular	5	B-Disease
arrhythmias	5	I-Disease
.	9	O

METHODS	2	O
:	9	O
A	9	O
study	9	O
cohort	9	O
of	5	O
8	9	O
,	9	O
770	9	O
patients	5	O
age	5	O
>	0	O
or	5	O
=	7	O
65	7	O
years	5	O
with	5	O
a	5	O
new	5	O
diagnosis	5	O
of	5	O
AF	9	B-Disease
was	9	O
identified	9	O
from	9	O
a	5	O
provincewide	5	O
database	5	O
of	5	O
Quebec	2	O
residents	5	O
with	5	O
a	5	O
myocardial	9	B-Disease
infarction	5	I-Disease
(	9	O
MI	9	B-Disease
)	9	O
between	5	O
1991	2	O
and	5	O
1999	2	O
.	9	O

Using	9	O
a	5	O
nested	9	O
case	5	O
-	7	O
control	9	O
design	5	O
,	9	O
477	7	O
cases	5	O
of	5	O
bradyarrhythmia	5	B-Disease
requiring	5	O
a	5	O
permanent	5	O
pacemaker	5	O
were	9	O
matched	9	O
(	9	O
1	9	O
:	9	O
4	9	O
)	9	O
to	5	O
1	9	O
,	9	O
908	7	O
controls	9	O
.	9	O

Multivariable	5	O
logistic	5	O
regression	5	O
was	9	O
used	5	O
to	5	O
estimate	5	O
the	5	O
odds	5	O
ratio	9	O
(	9	O
OR	9	O
)	9	O
of	5	O
pacemaker	5	O
insertion	1	O
associated	9	O
with	5	O
amiodarone	0	B-Chemical
use	5	O
,	9	O
controlling	9	O
for	5	O
baseline	5	O
risk	5	O
factors	9	O
and	5	O
exposure	9	O
to	5	O
sotalol	5	B-Chemical
,	9	O
Class	9	O
I	9	O
antiarrhythmic	5	O
agents	5	O
,	9	O
beta	9	O
-	7	O
blockers	9	O
,	9	O
calcium	0	B-Chemical
channel	9	O
blockers	9	O
,	9	O
and	5	O
digoxin	0	B-Chemical
.	9	O

RESULTS	9	O
:	9	O
amiodarone	0	B-Chemical
use	5	O
was	9	O
associated	9	O
with	5	O
an	5	O
increased	9	O
risk	5	O
of	5	O
pacemaker	5	O
insertion	1	O
(	9	O
OR	9	O
:	9	O
2	9	O
.	9	O
14	7	O
,	9	O
95	7	O
%	9	O
confidence	5	O
interval	5	O
[	9	O
CI	7	O
]	9	O
:	9	O
1	9	O
.	9	O
30	9	O
to	5	O
3	9	O
.	9	O
54	7	O
)	9	O
.	9	O

This	5	O
effect	9	O
was	9	O
modified	9	O
by	9	O
gender	5	O
,	9	O
with	5	O
a	5	O
greater	5	O
risk	5	O
in	5	O
women	5	O
versus	9	O
men	5	O
(	9	O
OR	9	O
:	9	O
3	9	O
.	9	O
86	7	O
,	9	O
95	7	O
%	9	O
CI	7	O
:	9	O
1	9	O
.	9	O
70	9	O
to	5	O
8	9	O
.	9	O
75	9	O
vs	7	O
.	9	O
OR	9	O
:	9	O
1	9	O
.	9	O
52	7	O
,	9	O
95	7	O
%	9	O
CI	7	O
:	9	O
0	7	O
.	9	O
80	9	O
to	5	O
2	9	O
.	9	O
89	7	O
)	9	O
.	9	O

Digoxin	7	B-Chemical
was	9	O
the	5	O
only	9	O
other	5	O
medication	5	O
associated	9	O
with	5	O
an	5	O
increased	9	O
risk	5	O
of	5	O
pacemaker	5	O
insertion	1	O
(	9	O
OR	9	O
:	9	O
1	9	O
.	9	O
78	7	O
,	9	O
95	7	O
%	9	O
CI	7	O
:	9	O
1	9	O
.	9	O
37	9	O
to	5	O
2	9	O
.	9	O
31	7	O
)	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
This	5	O
study	9	O
suggests	9	O
that	5	O
the	5	O
use	5	O
of	5	O
amiodarone	0	B-Chemical
in	5	O
elderly	5	O
patients	5	O
with	5	O
AF	9	B-Disease
and	5	O
a	5	O
previous	9	O
MI	9	B-Disease
increases	9	O
the	5	O
risk	5	O
of	5	O
bradyarrhythmia	5	B-Disease
requiring	5	O
a	5	O
permanent	5	O
pacemaker	5	O
.	9	O

The	5	O
finding	9	O
of	5	O
an	5	O
augmented	9	O
risk	5	O
of	5	O
pacemaker	5	O
insertion	1	O
in	5	O
elderly	5	O
women	5	O
receiving	9	O
amiodarone	0	B-Chemical
requires	5	O
further	9	O
investigation	9	O
.	9	O

Indomethacin	0	B-Chemical
-	7	O
induced	3	O
morphologic	9	O
changes	9	O
in	5	O
the	5	O
rat	3	O
urinary	9	O
bladder	9	O
epithelium	3	O
.	9	O

OBJECTIVES	2	O
:	9	O
To	9	O
evaluate	9	O
the	5	O
morphologic	9	O
changes	9	O
in	5	O
rat	3	O
urothelium	3	O
induced	3	O
by	9	O
indomethacin	0	B-Chemical
.	9	O

Nonsteroidal	2	O
anti	3	O
-	7	O
inflammatory	3	O
drug	5	O
-	7	O
induced	3	O
cystitis	9	B-Disease
is	5	O
a	5	O
poorly	9	O
recognized	9	O
and	5	O
under	9	O
-	7	O
reported	9	O
condition	5	O
.	9	O

In	9	O
addition	9	O
to	5	O
tiaprofenic	0	B-Chemical
acid	0	I-Chemical
,	9	O
indomethacin	0	B-Chemical
has	9	O
been	9	O
reported	9	O
to	5	O
be	5	O
associated	9	O
with	5	O
this	5	O
condition	5	O
.	9	O

METHODS	2	O
:	9	O
Three	9	O
groups	9	O
were	9	O
established	9	O
:	9	O
a	5	O
control	9	O
group	9	O
(	9	O
n	9	O
=	7	O
10	9	O
)	9	O
,	9	O
a	5	O
high	9	O
-	7	O
dose	9	O
group	9	O
(	9	O
n	9	O
=	7	O
10	9	O
)	9	O
,	9	O
treated	3	O
with	5	O
one	5	O
intraperitoneal	0	O
injection	9	O
of	5	O
indomethacin	0	B-Chemical
20	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
and	5	O
a	5	O
therapeutic	5	O
dose	9	O
group	9	O
(	9	O
n	9	O
=	7	O
10	9	O
)	9	O
in	5	O
which	5	O
oral	9	O
indomethacin	0	B-Chemical
was	9	O
administered	9	O
3	9	O
.	9	O
25	9	O
mg	0	O
/	9	O
kg	0	O
body	5	O
weight	9	O
daily	5	O
for	5	O
3	9	O
weeks	9	O
.	9	O

The	5	O
animals	9	O
were	9	O
then	9	O
killed	9	O
and	5	O
the	5	O
bladders	9	O
removed	9	O
for	5	O
light	9	O
and	5	O
electron	0	O
microscopic	9	O
studies	9	O
.	9	O

RESULTS	9	O
:	9	O
The	5	O
light	9	O
microscopic	9	O
findings	9	O
showed	9	O
some	5	O
focal	5	O
epithelial	3	O
degeneration	9	O
that	5	O
was	9	O
more	5	O
prominent	9	O
in	5	O
the	5	O
high	9	O
-	7	O
dose	9	O
group	9	O
.	9	O

When	9	O
compared	9	O
with	5	O
the	5	O
control	9	O
group	9	O
,	9	O
both	9	O
indomethacin	0	B-Chemical
groups	9	O
revealed	9	O
statistically	9	O
increased	9	O
numbers	9	O
of	5	O
mast	3	O
cells	3	O
in	5	O
the	5	O
mucosa	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
0001	7	O
)	9	O
and	5	O
penetration	5	O
of	5	O
lanthanum	0	B-Chemical
nitrate	0	I-Chemical
through	9	O
intercellular	3	O
areas	5	O
of	5	O
the	5	O
epithelium	3	O
.	9	O

Furthermore	9	O
,	9	O
the	5	O
difference	9	O
in	5	O
mast	3	O
cell	3	O
counts	9	O
between	5	O
the	5	O
high	9	O
and	5	O
therapeutic	5	O
dose	9	O
groups	9	O
was	9	O
also	9	O
statistically	9	O
significant	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
0001	7	O
)	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Indomethacin	0	B-Chemical
resulted	9	O
in	5	O
histopathologic	9	O
findings	9	O
typical	9	O
of	5	O
interstitial	9	B-Disease
cystitis	9	I-Disease
,	9	O
such	5	O
as	5	O
leaky	5	O
bladder	9	O
epithelium	3	O
and	5	O
mucosal	9	O
mastocytosis	5	B-Disease
.	9	O

The	5	O
true	5	O
incidence	5	O
of	5	O
nonsteroidal	5	O
anti	3	O
-	7	O
inflammatory	3	O
drug	5	O
-	7	O
induced	3	O
cystitis	9	B-Disease
in	5	O
humans	9	O
must	5	O
be	5	O
clarified	9	O
by	9	O
prospective	5	O
clinical	5	O
trials	5	O
.	9	O

An	5	O
open	5	O
-	7	O
label	9	O
phase	5	O
II	9	O
study	9	O
of	5	O
low	9	O
-	7	O
dose	9	O
thalidomide	0	B-Chemical
in	5	O
androgen	3	B-Chemical
-	7	O
independent	9	O
prostate	3	B-Disease
cancer	3	I-Disease
.	9	O

The	5	O
antiangiogenic	3	O
effects	9	O
of	5	O
thalidomide	0	B-Chemical
have	5	O
been	9	O
assessed	9	O
in	5	O
clinical	5	O
trials	5	O
in	5	O
patients	5	O
with	5	O
various	9	O
solid	9	O
and	5	O
haematological	5	B-Disease
malignancies	5	I-Disease
.	9	O

Thalidomide	0	B-Chemical
blocks	9	O
the	5	O
activity	9	O
of	5	O
angiogenic	3	O
agents	5	O
including	9	O
bFGF	3	O
,	9	O
VEGF	3	O
and	5	O
IL	0	O
-	7	O
6	9	O
.	9	O

We	9	O
undertook	9	O
an	5	O
open	5	O
-	7	O
label	9	O
study	9	O
using	9	O
thalidomide	0	B-Chemical
100	0	O
mg	0	O
once	5	O
daily	5	O
for	5	O
up	5	O
to	5	O
6	9	O
months	5	O
in	5	O
20	9	O
men	5	O
with	5	O
androgen	3	B-Chemical
-	7	O
independent	9	O
prostate	3	B-Disease
cancer	3	I-Disease
.	9	O

The	5	O
mean	5	O
time	5	O
of	5	O
study	9	O
was	9	O
109	7	O
days	9	O
(	9	O
median	9	O
107	9	O
,	9	O
range	9	O
4	9	O
-	7	O
184	7	O
days	9	O
)	9	O
.	9	O

Patients	5	O
underwent	5	O
regular	5	O
measurement	5	O
of	5	O
prostate	3	O
-	7	O
specific	9	O
antigen	3	O
(	9	O
PSA	9	O
)	9	O
,	9	O
urea	0	B-Chemical
and	5	O
electrolytes	0	O
,	9	O
serum	9	O
bFGF	3	O
and	5	O
VEGF	3	O
.	9	O

Three	9	O
men	5	O
(	9	O
15	9	O
%	9	O
)	9	O
showed	9	O
a	5	O
decline	9	O
in	5	O
serum	9	O
PSA	9	O
of	5	O
at	9	O
least	9	O
50	0	O
%	9	O
,	9	O
sustained	5	O
throughout	9	O
treatment	9	O
.	9	O

Of	9	O
16	9	O
men	5	O
treated	3	O
for	5	O
at	9	O
least	9	O
2	9	O
months	5	O
,	9	O
six	9	O
(	9	O
37	9	O
.	9	O
5	9	O
%	9	O
)	9	O
showed	9	O
a	5	O
fall	5	O
in	5	O
absolute	5	O
PSA	9	O
by	9	O
a	5	O
median	9	O
of	5	O
48	9	O
%	9	O
.	9	O

Increasing	9	O
levels	3	O
of	5	O
serum	9	O
bFGF	3	O
and	5	O
VEGF	3	O
were	9	O
associated	9	O
with	5	O
progressive	5	O
disease	5	O
;	9	O
five	9	O
of	5	O
six	9	O
men	5	O
who	5	O
demonstrated	9	O
a	5	O
fall	5	O
in	5	O
PSA	9	O
also	9	O
showed	9	O
a	5	O
decline	9	O
in	5	O
bFGF	3	O
and	5	O
VEGF	3	O
levels	3	O
,	9	O
and	5	O
three	9	O
of	5	O
four	9	O
men	5	O
with	5	O
a	5	O
rising	5	O
PSA	9	O
showed	9	O
an	5	O
increase	9	O
in	5	O
both	9	O
growth	3	O
factors	9	O
.	9	O

Adverse	5	O
effects	9	O
included	5	O
constipation	5	B-Disease
,	9	O
morning	5	O
drowsiness	5	B-Disease
,	9	O
dizziness	5	B-Disease
and	5	O
rash	5	B-Disease
,	9	O
and	5	O
resulted	9	O
in	5	O
withdrawal	5	O
from	9	O
the	5	O
study	9	O
by	9	O
three	9	O
men	5	O
.	9	O

Evidence	9	O
of	5	O
peripheral	9	B-Disease
sensory	5	I-Disease
neuropathy	5	I-Disease
was	9	O
found	9	O
in	5	O
nine	9	O
of	5	O
13	7	O
men	5	O
before	9	O
treatment	9	O
.	9	O

In	9	O
the	5	O
seven	9	O
men	5	O
who	5	O
completed	5	O
six	9	O
months	5	O
on	5	O
thalidomide	0	B-Chemical
,	9	O
subclinical	5	O
evidence	9	O
of	5	O
peripheral	9	B-Disease
neuropathy	5	I-Disease
was	9	O
found	9	O
in	5	O
four	9	O
before	9	O
treatment	9	O
,	9	O
but	9	O
in	5	O
all	5	O
seven	9	O
at	9	O
repeat	9	O
testing	5	O
.	9	O

The	5	O
findings	9	O
indicate	9	O
that	5	O
thalidomide	0	B-Chemical
may	5	O
be	5	O
an	5	O
option	5	O
for	5	O
patients	5	O
who	5	O
have	5	O
failed	9	O
other	5	O
forms	9	O
of	5	O
therapy	5	O
,	9	O
provided	9	O
close	5	O
follow	5	O
-	7	O
up	5	O
is	5	O
maintained	9	O
for	5	O
development	9	O
of	5	O
peripheral	9	B-Disease
neuropathy	5	I-Disease
.	9	O

Central	4	B-Disease
nervous	5	I-Disease
system	5	I-Disease
toxicity	9	I-Disease
following	9	O
the	5	O
administration	9	O
of	5	O
levobupivacaine	0	B-Chemical
for	5	O
lumbar	5	O
plexus	9	O
block	9	O
:	9	O
A	9	O
report	5	O
of	5	O
two	5	O
cases	5	O
.	9	O

BACKGROUND	2	O
AND	2	O
OBJECTIVES	2	O
:	9	O
Central	4	B-Disease
nervous	5	I-Disease
system	5	I-Disease
and	5	I-Disease
cardiac	5	I-Disease
toxicity	9	I-Disease
following	9	O
the	5	O
administration	9	O
of	5	O
local	5	O
anesthetics	5	O
is	5	O
a	5	O
recognized	9	O
complication	5	O
of	5	O
regional	5	O
anesthesia	5	O
.	9	O

Levobupivacaine	0	B-Chemical
,	9	O
the	5	O
pure	9	O
S	9	O
(	9	O
-	7	O
)	9	O
enantiomer	0	O
of	5	O
bupivacaine	0	B-Chemical
,	9	O
was	9	O
developed	5	O
to	5	O
improve	5	O
the	5	O
cardiac	5	O
safety	5	O
profile	9	O
of	5	O
bupivacaine	0	B-Chemical
.	9	O

We	9	O
describe	5	O
2	9	O
cases	5	O
of	5	O
grand	5	B-Disease
mal	2	I-Disease
seizures	5	I-Disease
following	9	O
accidental	5	O
intravascular	5	O
injection	9	O
of	5	O
levobupivacaine	0	B-Chemical
.	9	O

CASE	2	O
REPORT	5	O
:	9	O
Two	9	O
patients	5	O
presenting	5	O
for	5	O
elective	5	O
orthopedic	5	O
surgery	5	O
of	5	O
the	5	O
lower	9	O
limb	5	O
underwent	5	O
blockade	3	O
of	5	O
the	5	O
lumbar	5	O
plexus	9	O
via	9	O
the	5	O
posterior	5	O
approach	5	O
.	9	O

Immediately	9	O
after	9	O
the	5	O
administration	9	O
of	5	O
levobupivacaine	0	B-Chemical
0	7	O
.	9	O
5	9	O
%	9	O
with	5	O
epinephrine	0	B-Chemical
2	9	O
.	9	O
5	9	O
microgram	0	O
/	9	O
mL	0	O
,	9	O
the	5	O
patients	5	O
developed	5	O
grand	5	B-Disease
mal	2	I-Disease
seizures	5	I-Disease
,	9	O
despite	9	O
negative	9	O
aspiration	5	O
for	5	O
blood	9	O
and	5	O
no	9	O
clinical	5	O
signs	5	O
of	5	O
intravenous	0	O
epinephrine	0	B-Chemical
administration	9	O
.	9	O

The	5	O
seizures	5	B-Disease
were	9	O
successfully	5	O
treated	3	O
with	5	O
sodium	0	B-Chemical
thiopental	0	I-Chemical
in	5	O
addition	9	O
to	5	O
succinylcholine	5	B-Chemical
in	5	O
1	9	O
patient	5	O
.	9	O

Neither	9	O
patient	5	O
developed	5	O
signs	5	O
of	5	O
cardiovascular	5	B-Disease
toxicity	9	I-Disease
.	9	O

Both	9	O
patients	5	O
were	9	O
treated	3	O
preoperatively	5	O
with	5	O
beta	9	O
-	7	O
adrenergic	9	O
antagonist	3	O
medications	5	O
,	9	O
which	5	O
may	5	O
have	5	O
masked	5	O
the	5	O
cardiovascular	5	O
signs	5	O
of	5	O
the	5	O
unintentional	5	O
intravascular	5	O
administration	9	O
of	5	O
levobupivacaine	0	B-Chemical
with	5	O
epinephrine	0	B-Chemical
.	9	O

CONCLUSIONS	5	O
:	9	O
Although	9	O
levobupivacaine	0	B-Chemical
may	5	O
have	5	O
a	5	O
safer	5	O
cardiac	5	B-Disease
toxicity	9	I-Disease
profile	9	O
than	5	O
racemic	0	O
bupivacaine	0	B-Chemical
,	9	O
if	5	O
adequate	5	O
amounts	9	O
of	5	O
levobupivacaine	0	B-Chemical
reach	5	O
the	5	O
circulation	9	O
,	9	O
it	5	O
will	5	O
result	9	O
in	5	O
convulsions	5	B-Disease
.	9	O

Plasma	0	O
concentrations	0	O
sufficient	9	O
to	5	O
result	9	O
in	5	O
central	5	B-Disease
nervous	5	I-Disease
system	5	I-Disease
toxicity	9	I-Disease
did	9	O
not	5	O
produce	9	O
manifestations	5	O
of	5	O
cardiac	5	B-Disease
toxicity	9	I-Disease
in	5	O
these	5	O
2	9	O
patients	5	O
.	9	O

Amiodarone	7	B-Chemical
-	7	O
induced	3	O
torsade	5	B-Disease
de	2	I-Disease
pointes	5	I-Disease
during	5	O
bladder	9	O
irrigation	5	O
:	9	O
an	5	O
unusual	9	O
presentation	5	O
-	7	O
-	7	O
a	5	O
case	5	O
report	5	O
.	9	O

The	5	O
authors	5	O
present	9	O
a	5	O
case	5	O
of	5	O
early	9	O
(	9	O
within	9	O
4	9	O
days	9	O
)	9	O
development	9	O
of	5	O
torsade	5	B-Disease
de	2	I-Disease
pointes	5	I-Disease
(	9	O
TdP	5	B-Disease
)	9	O
associated	9	O
with	5	O
oral	9	O
amiodarone	0	B-Chemical
therapy	5	O
.	9	O

Consistent	9	O
with	5	O
other	5	O
reports	9	O
this	5	O
case	5	O
of	5	O
TdP	5	B-Disease
occurred	9	O
in	5	O
the	5	O
context	5	O
of	5	O
multiple	5	O
exacerbating	5	O
factors	9	O
including	9	O
hypokalemia	5	B-Disease
and	5	O
digoxin	0	B-Chemical
excess	9	O
.	9	O

Transient	9	O
prolongation	9	O
of	5	O
the	5	O
QT	5	O
during	5	O
bladder	9	O
irrigation	5	O
prompted	9	O
the	5	O
episode	5	O
of	5	O
TdP	5	B-Disease
.	9	O

It	5	O
is	5	O
well	9	O
known	9	O
that	5	O
bradycardia	5	B-Disease
exacerbates	9	O
acquired	5	O
TdP	5	B-Disease
.	9	O

The	5	O
authors	5	O
speculate	9	O
that	5	O
the	5	O
increased	9	O
vagal	5	O
tone	5	O
during	5	O
bladder	9	O
irrigation	5	O
,	9	O
a	5	O
vagal	5	O
maneuver	5	O
,	9	O
in	5	O
the	5	O
context	5	O
of	5	O
amiodarone	0	B-Chemical
therapy	5	O
resulted	9	O
in	5	O
amiodarone	0	B-Chemical
-	7	O
induced	3	O
proarrhythmia	5	B-Disease
.	9	O

In	9	O
the	5	O
absence	3	O
of	5	O
amiodarone	0	B-Chemical
therapy	5	O
,	9	O
a	5	O
second	9	O
bladder	9	O
irrigation	5	O
did	9	O
not	5	O
induce	3	O
TdP	5	B-Disease
despite	9	O
hypokalemia	5	B-Disease
and	5	O
hypomagnesemia	5	B-Disease
.	9	O

Anaesthetic	5	O
complications	5	O
associated	9	O
with	5	O
myotonia	5	B-Disease
congenita	5	I-Disease
:	9	O
case	5	O
study	9	O
and	5	O
comparison	9	O
with	5	O
other	5	O
myotonic	5	B-Disease
disorders	5	I-Disease
.	9	O

Myotonia	2	B-Disease
congenita	5	I-Disease
(	9	O
MC	9	B-Disease
)	9	O
is	5	O
caused	9	O
by	9	O
a	5	O
defect	9	O
in	5	O
the	5	O
skeletal	9	O
muscle	9	O
chloride	0	B-Chemical
channel	9	O
function	9	O
,	9	O
which	5	O
may	5	O
cause	5	O
sustained	5	B-Disease
membrane	9	I-Disease
depolarisation	3	I-Disease
.	9	O

We	9	O
describe	5	O
a	5	O
previously	9	O
healthy	5	O
32	7	O
-	7	O
year	5	O
-	7	O
old	5	O
woman	5	O
who	5	O
developed	5	O
a	5	O
life	5	O
-	7	O
threatening	5	O
muscle	9	B-Disease
spasm	5	I-Disease
and	5	O
secondary	9	O
ventilation	5	O
difficulties	5	O
following	9	O
a	5	O
preoperative	5	O
injection	9	O
of	5	O
suxamethonium	5	B-Chemical
.	9	O

The	5	O
muscle	9	B-Disease
spasms	5	I-Disease
disappeared	9	O
spontaneously	5	O
and	5	O
the	5	O
surgery	5	O
proceeded	9	O
without	9	O
further	9	O
problems	5	O
.	9	O

When	9	O
subsequently	9	O
questioned	5	O
,	9	O
she	5	O
reported	9	O
minor	9	O
symptoms	5	O
suggesting	9	O
a	5	O
myotonic	5	B-Disease
condition	5	I-Disease
.	9	O

Myotonia	2	B-Disease
was	9	O
found	9	O
on	5	O
clinical	5	O
examination	5	O
and	5	O
EMG	5	O
.	9	O

The	5	O
diagnosis	5	O
MC	9	B-Disease
was	9	O
confirmed	9	O
genetically	9	O
.	9	O

Neither	9	O
the	5	O
patient	5	O
nor	9	O
the	5	O
anaesthetist	5	O
were	9	O
aware	5	O
of	5	O
the	5	O
diagnosis	5	O
before	9	O
this	5	O
potentially	5	O
lethal	9	O
complication	5	O
occurred	9	O
.	9	O

We	9	O
give	5	O
a	5	O
brief	5	O
overview	5	O
of	5	O
ion	0	B-Disease
channel	9	I-Disease
disorders	5	I-Disease
including	9	O
malignant	3	B-Disease
hyperthermia	5	I-Disease
and	5	O
their	5	O
anaesthetic	5	O
considerations	5	O
.	9	O

Respiratory	9	O
pattern	9	O
in	5	O
a	5	O
rat	3	O
model	5	O
of	5	O
epilepsy	5	B-Disease
.	9	O

PURPOSE	2	O
:	9	O
Apnea	5	B-Disease
is	5	O
known	9	O
to	5	O
occur	5	O
during	5	O
seizures	5	B-Disease
,	9	O
but	9	O
systematic	5	O
studies	9	O
of	5	O
ictal	5	O
respiratory	5	O
changes	9	O
in	5	O
adults	5	O
are	5	O
few	5	O
.	9	O

Data	5	O
regarding	5	O
respiratory	5	O
pattern	9	O
defects	9	O
during	5	O
interictal	5	O
periods	5	O
also	9	O
are	5	O
scarce	5	O
.	9	O

Here	9	O
we	5	O
sought	9	O
to	5	O
generate	9	O
information	5	O
with	5	O
regard	5	O
to	5	O
the	5	O
interictal	5	O
period	5	O
in	5	O
animals	9	O
with	5	O
pilocarpine	0	B-Chemical
-	7	O
induced	3	O
epilepsy	5	B-Disease
.	9	O

METHODS	2	O
:	9	O
Twelve	9	O
rats	9	O
(	9	O
six	9	O
chronically	9	O
epileptic	5	B-Disease
animals	9	O
and	5	O
six	9	O
controls	9	O
)	9	O
were	9	O
anesthetized	0	O
,	9	O
given	5	O
tracheotomies	5	O
,	9	O
and	5	O
subjected	9	O
to	5	O
hyperventilation	5	B-Disease
or	5	O
hypoventilation	5	O
conditions	9	O
.	9	O

Breathing	5	O
movements	5	O
caused	9	O
changes	9	O
in	5	O
thoracic	5	O
volume	9	O
and	5	O
forced	5	O
air	5	O
to	5	O
flow	5	O
tidally	5	O
through	9	O
a	5	O
pneumotachograph	5	O
.	9	O

This	5	O
flow	5	O
was	9	O
measured	9	O
by	9	O
using	9	O
a	5	O
differential	9	O
pressure	5	O
transducer	5	O
,	9	O
passed	5	O
through	9	O
a	5	O
polygraph	5	O
,	9	O
and	5	O
from	9	O
this	5	O
to	5	O
a	5	O
computer	5	O
with	5	O
custom	5	O
software	5	O
that	5	O
derived	9	O
ventilation	5	O
(	9	O
VE	9	O
)	9	O
,	9	O
tidal	5	O
volume	9	O
(	9	O
VT	9	O
)	9	O
,	9	O
inspiratory	5	O
time	5	O
(	9	O
TI	9	O
)	9	O
,	9	O
expiratory	5	O
time	5	O
(	9	O
TE	9	O
)	9	O
,	9	O
breathing	5	O
frequency	5	O
(	9	O
f	9	O
)	9	O
,	9	O
and	5	O
mean	5	O
inspiratory	5	O
flow	5	O
(	9	O
VT	9	O
/	9	O
TI	9	O
)	9	O
on	5	O
a	5	O
breath	5	O
-	7	O
by	9	O
-	7	O
breath	5	O
basis	5	O
.	9	O

RESULTS	9	O
:	9	O
The	5	O
hyperventilation	5	B-Disease
maneuver	5	O
caused	9	O
a	5	O
decrease	9	O
in	5	O
spontaneous	5	O
ventilation	5	O
in	5	O
pilocarpine	0	B-Chemical
-	7	O
treated	3	O
and	5	O
control	9	O
rats	9	O
.	9	O

Although	9	O
VE	9	O
had	9	O
a	5	O
similar	9	O
decrease	9	O
in	5	O
both	9	O
groups	9	O
,	9	O
in	5	O
the	5	O
epileptic	5	B-Disease
group	9	O
,	9	O
the	5	O
decrease	9	O
in	5	O
VE	9	O
was	9	O
due	5	O
to	5	O
a	5	O
significant	9	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
increase	9	O
in	5	O
TE	9	O
peak	9	O
in	5	O
relation	5	O
to	5	O
that	5	O
of	5	O
the	5	O
control	9	O
animals	9	O
.	9	O

The	5	O
hypoventilation	5	O
maneuver	5	O
led	9	O
to	5	O
an	5	O
increase	9	O
in	5	O
the	5	O
arterial	5	O
Paco2	0	O
,	9	O
followed	9	O
by	9	O
an	5	O
increase	9	O
in	5	O
VE	9	O
.	9	O

In	9	O
the	5	O
epileptic	5	B-Disease
group	9	O
,	9	O
the	5	O
increase	9	O
in	5	O
VE	9	O
was	9	O
mediated	3	O
by	9	O
a	5	O
significant	9	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
decrease	9	O
in	5	O
TE	9	O
peak	9	O
compared	9	O
with	5	O
the	5	O
control	9	O
group	9	O
.	9	O

Systemic	9	O
application	5	O
of	5	O
KCN	0	O
,	9	O
to	5	O
evaluate	9	O
the	5	O
effects	9	O
of	5	O
peripheral	9	O
chemoreception	5	O
activation	3	O
on	5	O
ventilation	5	O
,	9	O
led	9	O
to	5	O
a	5	O
similar	9	O
increase	9	O
in	5	O
VE	9	O
for	5	O
both	9	O
groups	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
The	5	O
data	5	O
indicate	9	O
that	5	O
pilocarpine	0	B-Chemical
-	7	O
treated	3	O
animals	9	O
have	5	O
an	5	O
altered	9	O
ability	9	O
to	5	O
react	9	O
to	5	O
(	9	O
or	5	O
compensate	5	O
for	5	O
)	9	O
blood	9	O
gas	0	O
changes	9	O
with	5	O
changes	9	O
in	5	O
ventilation	5	O
and	5	O
suggest	9	O
that	5	O
it	5	O
is	5	O
centrally	5	O
determined	9	O
.	9	O

We	9	O
speculate	9	O
on	5	O
the	5	O
possible	5	O
relation	5	O
of	5	O
the	5	O
current	5	O
findings	9	O
on	5	O
treating	5	O
different	9	O
epilepsy	5	B-Disease
-	7	O
associated	9	O
conditions	9	O
.	9	O

Fatal	5	O
myeloencephalopathy	9	B-Disease
due	5	O
to	5	O
intrathecal	3	O
vincristine	0	B-Chemical
administration	9	O
.	9	O

Vincristine	0	B-Chemical
was	9	O
accidentally	5	O
given	5	O
intrathecally	3	O
to	5	O
a	5	O
child	5	O
with	5	O
leukaemia	3	B-Disease
,	9	O
producing	9	O
sensory	5	B-Disease
and	5	I-Disease
motor	5	I-Disease
dysfunction	9	I-Disease
followed	9	O
by	9	O
encephalopathy	5	B-Disease
and	5	O
death	9	O
.	9	O

Separate	5	O
times	5	O
for	5	O
administering	9	O
vincristine	0	B-Chemical
and	5	O
intrathecal	3	O
therapy	5	O
is	5	O
recommended	5	O
.	9	O

Progesterone	9	B-Chemical
potentiation	3	O
of	5	O
bupivacaine	0	B-Chemical
arrhythmogenicity	5	O
in	5	O
pentobarbital	0	B-Chemical
-	7	O
anesthetized	0	O
rats	9	O
and	5	O
beating	5	O
rat	3	O
heart	5	O
cell	3	O
cultures	3	O
.	9	O

The	5	O
effects	9	O
of	5	O
progesterone	3	B-Chemical
treatment	9	O
on	5	O
bupivacaine	0	B-Chemical
arrhythmogenicity	5	O
in	5	O
beating	5	O
rat	3	O
heart	5	O
myocyte	3	O
cultures	3	O
and	5	O
on	5	O
anesthetized	0	O
rats	9	O
were	9	O
determined	9	O
.	9	O

After	9	O
determining	9	O
the	5	O
bupivacaine	0	B-Chemical
AD50	0	O
(	9	O
the	5	O
concentration	0	O
of	5	O
bupivacaine	0	B-Chemical
that	5	O
caused	9	O
50	0	O
%	9	O
of	5	O
all	5	O
beating	5	O
rat	3	O
heart	5	O
myocyte	3	O
cultures	3	O
to	5	O
become	5	O
arrhythmic	5	B-Disease
)	9	O
,	9	O
we	5	O
determined	9	O
the	5	O
effect	9	O
of	5	O
1	9	O
-	7	O
hour	0	O
progesterone	3	B-Chemical
HCl	0	B-Chemical
exposure	9	O
on	5	O
myocyte	3	O
contractile	9	O
rhythm	5	O
.	9	O

Each	5	O
concentration	0	O
of	5	O
progesterone	3	B-Chemical
(	9	O
6	9	O
.	9	O
25	9	O
,	9	O
12	9	O
.	9	O
5	9	O
,	9	O
25	9	O
,	9	O
and	5	O
50	0	O
micrograms	0	O
/	9	O
ml	0	O
)	9	O
caused	9	O
a	5	O
significant	9	O
and	5	O
concentration	0	O
-	7	O
dependent	9	O
reduction	9	O
in	5	O
the	5	O
AD50	0	O
for	5	O
bupivacaine	0	B-Chemical
.	9	O

Estradiol	0	B-Chemical
treatment	9	O
also	9	O
increased	9	O
the	5	O
arrhythmogenicity	5	O
of	5	O
bupivacaine	0	B-Chemical
in	5	O
myocyte	3	O
cultures	3	O
,	9	O
but	9	O
was	9	O
only	9	O
one	5	O
fourth	9	O
as	5	O
potent	3	O
as	5	O
progesterone	3	B-Chemical
.	9	O

Neither	9	O
progesterone	3	B-Chemical
nor	9	O
estradiol	0	B-Chemical
effects	9	O
on	5	O
bupivacaine	0	B-Chemical
arrhythmogenicity	5	O
were	9	O
potentiated	3	O
by	9	O
epinephrine	0	B-Chemical
.	9	O

Chronic	9	O
progesterone	3	B-Chemical
pretreatment	0	O
(	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
/	9	O
day	9	O
for	5	O
21	7	O
days	9	O
)	9	O
caused	9	O
a	5	O
significant	9	O
increase	9	O
in	5	O
bupivacaine	0	B-Chemical
arrhythmogenicity	5	O
in	5	O
intact	9	O
pentobarbital	0	B-Chemical
-	7	O
anesthetized	0	O
rats	9	O
.	9	O

There	5	O
was	9	O
a	5	O
significant	9	O
decrease	9	O
in	5	O
the	5	O
time	5	O
to	5	O
onset	5	O
of	5	O
arrhythmia	5	B-Disease
as	5	O
compared	9	O
with	5	O
control	9	O
nonprogesterone	_	O
-	7	O
treated	3	O
rats	9	O
(	9	O
6	9	O
.	9	O
2	9	O
+	9	O
/	9	O
-	7	O
1	9	O
.	9	O
3	9	O
vs	7	O
.	9	O
30	9	O
.	9	O
8	9	O
+	9	O
/	9	O
-	7	O
2	9	O
.	9	O
5	9	O
min	0	O
,	9	O
mean	5	O
+	9	O
/	9	O
-	7	O
SE	9	O
)	9	O
.	9	O

The	5	O
results	9	O
of	5	O
this	5	O
study	9	O
indicate	9	O
that	5	O
progesterone	3	B-Chemical
can	5	O
potentiate	3	O
bupivacaine	0	B-Chemical
arrhythmogenicity	5	O
both	9	O
in	5	O
vivo	3	O
and	5	O
in	5	O
vitro	3	O
.	9	O

Potentiation	3	O
of	5	O
bupivacaine	0	B-Chemical
arrhythmia	5	B-Disease
in	5	O
myocyte	3	O
cultures	3	O
suggests	9	O
that	5	O
this	5	O
effect	9	O
is	5	O
at	9	O
least	9	O
partly	9	O
mediated	3	O
at	9	O
the	5	O
myocyte	3	O
level	9	O
.	9	O

Increased	9	O
serum	9	O
soluble	0	O
Fas	3	O
in	5	O
patients	5	O
with	5	O
acute	9	B-Disease
liver	9	I-Disease
failure	5	I-Disease
due	5	O
to	5	O
paracetamol	0	B-Chemical
overdose	0	B-Disease
.	9	O

BACKGROUND	2	O
/	9	O
AIMS	5	O
:	9	O
Experimental	9	O
studies	9	O
have	5	O
suggested	9	O
that	5	O
apoptosis	3	O
via	9	O
the	5	O
Fas	3	O
/	9	O
Fas	3	O
Ligand	9	O
signaling	3	O
system	5	O
may	5	O
play	9	O
an	5	O
important	9	O
role	9	O
in	5	O
the	5	O
development	9	O
of	5	O
acute	9	B-Disease
liver	9	I-Disease
failure	5	I-Disease
.	9	O

The	5	O
aim	5	O
of	5	O
the	5	O
study	9	O
was	9	O
to	5	O
investigate	9	O
the	5	O
soluble	0	O
form	9	O
of	5	O
Fas	3	O
in	5	O
patients	5	O
with	5	O
acute	9	B-Disease
liver	9	I-Disease
failure	5	I-Disease
.	9	O

METHODOLOGY	2	O
:	9	O
Serum	9	O
levels	3	O
of	5	O
sFas	3	O
(	9	O
soluble	0	O
Fas	3	O
)	9	O
were	9	O
measured	9	O
by	9	O
ELISA	3	O
in	5	O
24	9	O
patients	5	O
with	5	O
acute	9	B-Disease
liver	9	I-Disease
failure	5	I-Disease
and	5	O
10	9	O
normal	9	O
control	9	O
subjects	5	O
.	9	O

Serum	9	O
levels	3	O
of	5	O
tumor	3	B-Disease
necrosis	9	B-Disease
factor	9	O
-	7	O
alpha	9	O
and	5	O
interferon	3	O
-	7	O
gamma	9	O
were	9	O
also	9	O
determined	9	O
by	9	O
ELISA	3	O
.	9	O

RESULTS	9	O
:	9	O
Serum	9	O
sFas	3	O
was	9	O
significantly	9	O
increased	9	O
in	5	O
patients	5	O
with	5	O
acute	9	B-Disease
liver	9	I-Disease
failure	5	I-Disease
(	9	O
median	9	O
,	9	O
26	7	O
.	9	O
8	9	O
U	9	O
/	9	O
mL	0	O
;	9	O
range	9	O
,	9	O
6	9	O
.	9	O
9	7	O
-	7	O
52	7	O
.	9	O
7	9	O
U	9	O
/	9	O
mL	0	O
)	9	O
compared	9	O
to	5	O
the	5	O
normal	9	O
controls	9	O
(	9	O
median	9	O
,	9	O
8	9	O
.	9	O
6	9	O
U	9	O
/	9	O
mL	0	O
;	9	O
range	9	O
,	9	O
6	9	O
.	9	O
5	9	O
-	7	O
12	9	O
.	9	O
0	7	O
U	9	O
/	9	O
mL	0	O
,	9	O
P	9	O
<	0	O
0	7	O
.	9	O
0001	7	O
)	9	O
.	9	O

Levels	9	O
were	9	O
significantly	9	O
greater	5	O
in	5	O
patients	5	O
with	5	O
acute	9	B-Disease
liver	9	I-Disease
failure	5	I-Disease
due	5	O
to	5	O
paracetamol	0	B-Chemical
overdose	0	B-Disease
(	9	O
median	9	O
,	9	O
28	7	O
.	9	O
7	9	O
U	9	O
/	9	O
mL	0	O
;	9	O
range	9	O
,	9	O
12	9	O
.	9	O
8	9	O
-	7	O
52	7	O
.	9	O
7	9	O
U	9	O
/	9	O
mL	0	O
,	9	O
n	9	O
=	7	O
17	7	O
)	9	O
than	5	O
those	5	O
due	5	O
to	5	O
non	9	O
-	7	O
A	9	O
to	5	O
E	9	O
hepatitis	9	B-Disease
(	9	O
median	9	O
,	9	O
12	9	O
.	9	O
5	9	O
U	9	O
/	9	O
mL	0	O
;	9	O
range	9	O
,	9	O
6	9	O
.	9	O
9	7	O
-	7	O
46	7	O
.	9	O
0	7	O
U	9	O
/	9	O
mL	0	O
,	9	O
n	9	O
=	7	O
7	9	O
,	9	O
P	9	O
<	0	O
0	7	O
.	9	O
01	7	O
)	9	O
.	9	O

There	5	O
was	9	O
no	9	O
relationship	5	O
of	5	O
sFas	3	O
to	5	O
eventual	5	O
outcome	5	O
in	5	O
the	5	O
patients	5	O
.	9	O

A	9	O
significant	9	O
correlation	9	O
was	9	O
observed	9	O
between	5	O
serum	9	O
sFas	3	O
levels	3	O
and	5	O
aspartate	1	B-Chemical
aminotransferase	7	O
(	9	O
r	9	O
=	7	O
0	7	O
.	9	O
613	7	O
,	9	O
P	9	O
<	0	O
0	7	O
.	9	O
01	7	O
)	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
The	5	O
increased	9	O
concentration	0	O
of	5	O
sFas	3	O
in	5	O
serum	9	O
of	5	O
patients	5	O
with	5	O
acute	9	B-Disease
liver	9	I-Disease
failure	5	I-Disease
may	5	O
reflect	5	O
activation	3	O
of	5	O
Fas	3	O
-	7	O
mediated	3	O
apoptosis	3	O
in	5	O
the	5	O
liver	9	O
and	5	O
this	5	O
together	9	O
with	5	O
increased	9	O
tumor	3	B-Disease
necrosis	9	B-Disease
factor	9	O
-	7	O
alpha	9	O
may	5	O
be	5	O
an	5	O
important	9	O
factor	9	O
in	5	O
liver	9	O
cell	3	O
loss	9	O
.	9	O

Bilateral	5	O
subthalamic	5	O
nucleus	9	O
stimulation	3	O
for	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
.	9	O

High	9	O
frequency	5	O
stimulation	3	O
of	5	O
the	5	O
subthalamic	5	O
nucleus	9	O
(	9	O
STN	5	O
)	9	O
is	5	O
known	9	O
to	5	O
ameliorate	9	O
the	5	O
signs	5	O
and	5	O
symptoms	5	O
of	5	O
advanced	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
.	9	O

AIM	9	O
:	9	O
We	9	O
studied	9	O
the	5	O
effect	9	O
of	5	O
high	9	O
frequency	5	O
STN	5	O
stimulation	3	O
in	5	O
23	7	O
patients	5	O
.	9	O

METHOD	2	O
:	9	O
Twenty	9	O
-	7	O
three	9	O
patients	5	O
suffering	5	O
from	9	O
severe	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
(	9	O
Stages	5	O
III	9	O
-	7	O
V	9	O
on	5	O
Hoehn	5	O
and	5	O
Yahr	5	O
scale	5	O
)	9	O
and	5	O
,	9	O
particularly	5	O
bradykinesia	5	B-Disease
,	9	O
rigidity	5	B-Disease
,	9	O
and	5	O
levodopa	5	B-Chemical
-	7	O
induced	3	O
dyskinesias	5	B-Disease
underwent	5	O
bilateral	5	O
implantation	5	O
of	5	O
electrodes	5	O
in	5	O
the	5	O
STN	5	O
.	9	O

Preoperative	5	O
and	5	O
postoperative	5	O
assessments	5	O
of	5	O
these	5	O
patients	5	O
at	9	O
1	9	O
,	9	O
3	9	O
,	9	O
6	9	O
and	5	O
12	9	O
months	5	O
follow	5	O
-	7	O
up	5	O
,	9	O
in	5	O
"	5	O
on	5	O
"	5	O
and	5	O
"	5	O
off	5	O
"	5	O
drug	5	O
conditions	9	O
,	9	O
was	9	O
carried	9	O
out	9	O
using	9	O
Unified	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
Disease	2	I-Disease
Rating	5	O
Scale	5	O
,	9	O
Hoehn	5	O
and	5	O
Yahr	5	O
staging	5	O
,	9	O
England	2	O
activities	9	O
of	5	O
daily	5	O
living	5	O
score	5	O
and	5	O
video	5	O
recordings	5	O
.	9	O

RESULTS	9	O
:	9	O
After	9	O
one	5	O
year	5	O
of	5	O
electrical	5	O
stimulation	3	O
of	5	O
the	5	O
STN	5	O
,	9	O
the	5	O
patients	5	O
'	9	O
scores	5	O
for	5	O
activities	9	O
of	5	O
daily	5	O
living	5	O
and	5	O
motor	5	O
examination	5	O
scores	5	O
(	9	O
Unified	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
Disease	2	I-Disease
Rating	5	O
Scale	5	O
parts	5	O
II	9	O
and	5	O
III	9	O
)	9	O
off	5	O
medication	5	O
improved	5	O
by	9	O
62	7	O
%	9	O
and	5	O
61	7	O
%	9	O
respectively	9	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
0005	7	O
)	9	O
.	9	O

The	5	O
subscores	5	O
for	5	O
the	5	O
akinesia	5	B-Disease
,	9	O
rigidity	5	B-Disease
,	9	O
tremor	5	B-Disease
and	5	O
gait	5	O
also	9	O
improved	5	O
.	9	O

(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
0005	7	O
)	9	O
.	9	O

The	5	O
average	5	O
levodopa	5	B-Chemical
dose	9	O
decreased	9	O
from	9	O
813	7	O
mg	0	O
to	5	O
359	7	O
mg	0	O
.	9	O

The	5	O
cognitive	5	O
functions	9	O
remained	9	O
unchanged	9	O
.	9	O

Two	9	O
patients	5	O
developed	5	O
device	5	O
-	7	O
related	9	O
complications	5	O
and	5	O
two	5	O
patients	5	O
experienced	5	O
abnormal	9	O
weight	9	O
gain	5	O
.	9	O

CONCLUSION	5	O
:	9	O
Bilateral	5	O
subthalamic	5	O
nucleus	9	O
stimulation	3	O
is	5	O
an	5	O
effective	5	O
treatment	9	O
for	5	O
advanced	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
.	9	O

It	5	O
reduces	9	O
the	5	O
severity	5	O
of	5	O
"	5	O
off	5	O
"	5	O
phase	5	O
symptoms	5	O
,	9	O
improves	5	O
the	5	O
axial	5	O
symptoms	5	O
and	5	O
reduces	9	O
levodopa	5	B-Chemical
requirements	5	O
.	9	O

The	5	O
reduction	9	O
in	5	O
the	5	O
levodopa	5	B-Chemical
dose	9	O
is	5	O
useful	5	O
in	5	O
controlling	9	O
drug	5	B-Disease
-	7	I-Disease
induced	3	I-Disease
dyskinesias	5	I-Disease
.	9	O

Acute	5	B-Disease
renal	9	I-Disease
failure	5	I-Disease
occurring	9	O
during	5	O
intravenous	0	O
desferrioxamine	0	B-Chemical
therapy	5	O
:	9	O
recovery	9	O
after	9	O
haemodialysis	5	O
.	9	O

A	9	O
patient	5	O
with	5	O
transfusion	5	O
-	7	O
dependent	9	O
thalassemia	9	B-Disease
was	9	O
undergoing	9	O
home	5	O
intravenous	0	O
desferrioxamine	0	B-Chemical
(	9	O
DFX	0	B-Chemical
)	9	O
treatment	9	O
by	9	O
means	5	O
of	5	O
a	5	O
totally	9	O
implanted	9	O
system	5	O
because	5	O
of	5	O
his	5	O
poor	5	O
compliance	5	O
with	5	O
the	5	O
nightly	5	O
subcutaneous	9	O
therapy	5	O
.	9	O

Due	5	O
to	5	O
an	5	O
accidental	5	O
malfunctioning	5	O
of	5	O
the	5	O
infusion	0	O
pump	0	O
,	9	O
the	5	O
patient	5	O
was	9	O
inadvertently	5	O
administered	9	O
a	5	O
toxic	0	O
dosage	9	O
of	5	O
the	5	O
drug	5	O
which	5	O
caused	9	O
renal	9	B-Disease
insufficiency	9	I-Disease
.	9	O

Given	9	O
the	5	O
progressive	5	O
deterioration	5	O
of	5	O
the	5	O
symptoms	5	O
and	5	O
of	5	O
the	5	O
laboratory	9	O
values	5	O
,	9	O
despite	9	O
adequate	5	O
medical	5	O
treatment	9	O
,	9	O
a	5	O
decision	5	O
was	9	O
made	5	O
to	5	O
introduce	5	O
haemodialytical	_	O
therapy	5	O
in	5	O
order	5	O
to	5	O
remove	9	O
the	5	O
drug	5	O
and	5	O
therapy	5	O
reduce	5	O
the	5	O
nephrotoxicity	9	B-Disease
.	9	O

From	5	O
the	5	O
results	9	O
obtained	9	O
,	9	O
haemodialysis	5	O
can	5	O
therefore	5	O
be	5	O
suggested	9	O
as	5	O
a	5	O
useful	5	O
therapy	5	O
in	5	O
rare	5	O
cases	5	O
of	5	O
progressive	5	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
caused	9	O
by	9	O
desferrioxamine	0	B-Chemical
.	9	O

Ocular	5	O
motility	9	O
changes	9	O
after	9	O
subtenon	5	O
carboplatin	0	B-Chemical
chemotherapy	5	O
for	5	O
retinoblastoma	3	B-Disease
.	9	O

BACKGROUND	2	O
:	9	O
Focal	9	O
subtenon	5	O
carboplatin	0	B-Chemical
injections	9	O
have	5	O
recently	9	O
been	9	O
used	5	O
as	5	O
a	5	O
presumably	9	O
toxicity	9	B-Disease
-	7	O
free	9	O
adjunct	5	O
to	5	O
systemic	9	O
chemotherapy	5	O
for	5	O
intraocular	5	O
retinoblastoma	3	B-Disease
.	9	O

OBJECTIVE	2	O
:	9	O
To	9	O
report	5	O
our	5	O
clinical	5	O
experience	5	O
with	5	O
abnormal	9	B-Disease
ocular	5	I-Disease
motility	9	I-Disease
in	5	O
patients	5	O
treated	3	O
with	5	O
subtenon	5	O
carboplatin	0	B-Chemical
chemotherapy	5	O
.	9	O

METHODS	2	O
:	9	O
We	9	O
noted	9	O
abnormal	9	B-Disease
ocular	5	I-Disease
motility	9	I-Disease
in	5	O
10	9	O
consecutive	5	O
patients	5	O
with	5	O
retinoblastoma	3	B-Disease
who	5	O
had	9	O
received	9	O
subtenon	5	O
carboplatin	0	B-Chemical
.	9	O

During	5	O
ocular	5	O
manipulation	5	O
under	9	O
general	5	O
anesthesia	5	O
,	9	O
we	5	O
assessed	9	O
their	5	O
eyes	5	O
by	9	O
forced	5	O
duction	0	O
testing	5	O
,	9	O
comparing	9	O
ocular	5	O
motility	9	O
after	9	O
tumor	3	B-Disease
control	9	O
with	5	O
ocular	5	O
motility	9	O
at	9	O
diagnosis	5	O
.	9	O

Eyes	5	O
subsequently	9	O
enucleated	9	O
because	5	O
of	5	O
treatment	9	O
failure	5	O
(	9	O
n	9	O
=	7	O
4	9	O
)	9	O
were	9	O
examined	9	O
histologically	9	O
.	9	O

RESULTS	9	O
:	9	O
Limitation	5	O
of	5	O
ocular	5	O
motility	9	O
was	9	O
detected	9	O
in	5	O
all	5	O
12	9	O
eyes	5	O
of	5	O
10	9	O
patients	5	O
treated	3	O
for	5	O
intraocular	5	O
retinoblastoma	3	B-Disease
with	5	O
1	9	O
to	5	O
6	9	O
injections	9	O
of	5	O
subtenon	5	O
carboplatin	0	B-Chemical
as	5	O
part	9	O
of	5	O
multimodality	5	O
therapy	5	O
.	9	O

Histopathological	9	O
examination	5	O
revealed	9	O
many	5	O
lipophages	9	O
in	5	O
the	5	O
periorbital	5	O
fat	9	O
surrounding	9	O
the	5	O
optic	5	O
nerve	5	O
in	5	O
1	9	O
eye	5	O
,	9	O
indicative	9	O
of	5	O
phagocytosis	3	O
of	5	O
previously	9	O
existing	5	O
fat	9	O
cells	3	O
and	5	O
suggesting	9	O
prior	9	O
fat	9	O
necrosis	9	B-Disease
.	9	O

The	5	O
enucleations	5	O
were	9	O
technically	5	O
difficult	5	O
and	5	O
hazardous	5	O
for	5	O
globe	5	O
rupture	5	B-Disease
because	5	O
of	5	O
extensive	5	O
orbital	5	O
soft	5	O
tissue	9	O
adhesions	3	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Subtenon	5	O
carboplatin	0	B-Chemical
chemotherapy	5	O
is	5	O
associated	9	O
with	5	O
significant	9	O
fibrosis	9	B-Disease
of	5	O
orbital	5	O
soft	5	O
tissues	9	O
,	9	O
leading	9	O
to	5	O
mechanical	5	O
restriction	9	O
of	5	O
eye	5	O
movements	5	O
and	5	O
making	5	O
subsequent	9	O
enucleation	5	O
difficult	5	O
.	9	O

Subtenon	5	O
carboplatin	0	B-Chemical
is	5	O
not	5	O
free	9	O
of	5	O
toxicity	9	B-Disease
,	9	O
and	5	O
its	9	O
use	5	O
is	5	O
best	5	O
restricted	9	O
to	5	O
specific	9	O
indications	5	O
.	9	O

Ethambutol	0	B-Chemical
and	5	O
optic	5	B-Disease
neuropathy	5	I-Disease
.	9	O

PURPOSE	2	O
:	9	O
To	9	O
demonstrate	9	O
the	5	O
association	9	O
between	5	O
ethambutol	0	B-Chemical
and	5	O
optic	5	B-Disease
neuropathy	5	I-Disease
.	9	O

METHOD	2	O
:	9	O
Thirteen	9	O
patients	5	O
who	5	O
developed	5	O
optic	5	B-Disease
neuropathy	5	I-Disease
after	9	O
being	5	O
treated	3	O
with	5	O
ethambutol	0	B-Chemical
for	5	O
tuberculosis	9	B-Disease
of	5	I-Disease
the	5	I-Disease
lung	9	I-Disease
or	5	I-Disease
lymph	9	I-Disease
node	5	I-Disease
at	9	O
Siriraj	2	O
Hospital	2	O
between	5	O
1997	2	O
and	5	O
2001	2	O
were	9	O
retrospectively	5	O
reviewed	9	O
.	9	O

The	5	O
clinical	5	O
characteristics	5	O
and	5	O
initial	9	O
and	5	O
final	9	O
visual	5	O
acuity	5	O
were	9	O
analyzed	9	O
to	5	O
determine	9	O
visual	5	O
outcome	5	O
.	9	O

RESULTS	9	O
:	9	O
All	9	O
patients	5	O
had	9	O
optic	5	B-Disease
neuropathy	5	I-Disease
between	5	O
1	9	O
to	5	O
6	9	O
months	5	O
(	9	O
mean	5	O
=	7	O
2	9	O
.	9	O
9	7	O
months	5	O
)	9	O
after	9	O
starting	9	O
ethambutol	0	B-Chemical
therapy	5	O
at	9	O
a	5	O
dosage	9	O
ranging	9	O
from	9	O
13	7	O
to	5	O
20	9	O
mg	0	O
/	9	O
kg	0	O
/	9	O
day	9	O
(	9	O
mean	5	O
=	7	O
17	7	O
mg	0	O
/	9	O
kg	0	O
/	9	O
day	9	O
)	9	O
.	9	O

Seven	9	O
(	9	O
54	7	O
%	9	O
)	9	O
of	5	O
the	5	O
13	7	O
patients	5	O
experienced	5	O
visual	5	O
recovery	9	O
after	9	O
stopping	5	O
the	5	O
drug	5	O
.	9	O

Of	9	O
6	9	O
patients	5	O
with	5	O
irreversible	9	O
visual	5	B-Disease
impairment	5	I-Disease
,	9	O
4	9	O
patients	5	O
had	9	O
diabetes	5	B-Disease
mellitus	9	I-Disease
,	9	O
glaucoma	5	B-Disease
and	5	O
a	5	O
history	5	O
of	5	O
heavy	9	O
smoking	5	O
.	9	O

CONCLUSION	5	O
:	9	O
Early	9	O
recognition	5	O
of	5	O
optic	5	B-Disease
neuropathy	5	I-Disease
should	5	O
be	5	O
considered	5	O
in	5	O
patients	5	O
with	5	O
ethambutol	0	B-Chemical
therapy	5	O
.	9	O

A	9	O
low	9	O
dose	9	O
and	5	O
prompt	5	O
discontinuation	5	O
of	5	O
the	5	O
drug	5	O
is	5	O
recommended	5	O
particularly	5	O
in	5	O
individuals	5	O
with	5	O
diabetes	5	B-Disease
mellitus	9	I-Disease
,	9	O
glaucoma	5	B-Disease
or	5	O
who	5	O
are	5	O
heavy	9	O
smokers	5	O
.	9	O

Treatment	9	O
of	5	O
compensatory	5	O
gustatory	5	B-Disease
hyperhidrosis	5	I-Disease
with	5	O
topical	0	O
glycopyrrolate	0	B-Chemical
.	9	O

Gustatory	5	B-Disease
hyperhidrosis	5	I-Disease
is	5	O
facial	5	O
sweating	5	B-Disease
usually	5	O
associated	9	O
with	5	O
the	5	O
eating	5	O
of	5	O
hot	5	O
spicy	5	O
food	5	O
or	5	O
even	5	O
smelling	5	O
this	5	O
food	5	O
.	9	O

Current	9	O
options	5	O
of	5	O
treatment	9	O
include	5	O
oral	9	O
anticholinergic	5	O
drugs	5	O
,	9	O
the	5	O
topical	0	O
application	5	O
of	5	O
anticholinergics	5	O
or	5	O
aluminum	0	B-Chemical
chloride	0	I-Chemical
,	9	O
and	5	O
the	5	O
injection	9	O
of	5	O
botulinum	9	O
toxin	1	O
.	9	O

Thirteen	9	O
patients	5	O
have	5	O
been	9	O
treated	3	O
to	5	O
date	5	O
with	5	O
1	9	O
.	9	O
5	9	O
%	9	O
or	5	O
2	9	O
%	9	O
topical	0	O
glycopyrrolate	0	B-Chemical
.	9	O

All	9	O
patients	5	O
had	9	O
gustatory	5	B-Disease
hyperhidrosis	5	I-Disease
,	9	O
which	5	O
interfered	9	O
with	5	O
their	5	O
social	5	O
activities	9	O
,	9	O
after	9	O
transthroacic	_	O
endoscopic	5	O
sympathectomy	5	O
,	9	O
and	5	O
which	5	O
was	9	O
associated	9	O
with	5	O
compensatory	5	O
focal	5	O
hyperhidrosis	5	B-Disease
.	9	O

After	9	O
applying	5	O
topical	0	O
glycopyrrolate	0	B-Chemical
,	9	O
the	5	O
subjective	5	O
effect	9	O
was	9	O
excellent	5	O
(	9	O
no	9	O
sweating	5	B-Disease
after	9	O
eating	5	O
hot	5	O
spicy	5	O
food	5	O
)	9	O
in	5	O
10	9	O
patients	5	O
(	9	O
77	7	O
%	9	O
)	9	O
,	9	O
and	5	O
fair	5	O
(	9	O
clearly	9	O
reduced	9	O
sweating	5	B-Disease
)	9	O
in	5	O
3	9	O
patients	5	O
(	9	O
23	7	O
%	9	O
)	9	O
.	9	O

All	9	O
had	9	O
reported	9	O
incidents	5	O
of	5	O
being	5	O
very	5	O
embarrassed	5	O
whilst	9	O
eating	5	O
hot	5	O
spicy	5	O
foods	5	O
.	9	O

Adverse	5	O
effects	9	O
included	5	O
a	5	O
mildly	9	O
dry	0	B-Disease
mouth	5	I-Disease
and	5	O
a	5	O
sore	5	B-Disease
throat	5	I-Disease
in	5	O
2	9	O
patients	5	O
(	9	O
2	9	O
%	9	O
glycopyrrolate	0	B-Chemical
)	9	O
,	9	O
a	5	O
light	9	O
headache	5	B-Disease
in	5	O
1	9	O
patient	5	O
(	9	O
1	9	O
.	9	O
5	9	O
%	9	O
glycopyrrolate	0	B-Chemical
)	9	O
.	9	O

The	5	O
topical	0	O
application	5	O
of	5	O
a	5	O
glycopyrrolate	0	B-Chemical
pad	5	O
appeared	9	O
to	5	O
be	5	O
safe	5	O
,	9	O
efficacious	5	O
,	9	O
well	9	O
tolerated	9	O
,	9	O
and	5	O
a	5	O
convenient	5	O
method	5	O
of	5	O
treatment	9	O
for	5	O
moderate	9	O
to	5	O
severe	5	O
symptoms	5	O
of	5	O
gustatory	5	B-Disease
hyperhidrosis	5	I-Disease
in	5	O
post	9	O
transthoracic	5	O
endoscopic	5	O
sympathectomy	5	O
or	5	O
sympathicotomy	5	O
patients	5	O
,	9	O
with	5	O
few	5	O
side	5	O
effects	9	O
.	9	O

Neuroleptic	2	B-Chemical
-	7	O
associated	9	O
hyperprolactinemia	5	B-Disease
.	9	O

Can	5	O
it	5	O
be	5	O
treated	3	O
with	5	O
bromocriptine	0	B-Chemical
?	5	O

Six	9	O
stable	9	O
psychiatric	5	O
outpatients	5	O
with	5	O
hyperprolactinemia	5	B-Disease
and	5	O
amenorrhea	5	B-Disease
/	9	O
oligomenorrhea	5	B-Disease
associated	9	O
with	5	O
their	5	O
neuroleptic	5	B-Chemical
medications	5	I-Chemical
were	9	O
treated	3	O
with	5	O
bromocriptine	0	B-Chemical
.	9	O

Daily	5	O
dosages	9	O
of	5	O
5	9	O
-	7	O
10	9	O
mg	0	O
corrected	5	O
the	5	O
hyperprolactinemia	5	B-Disease
and	5	O
restored	3	O
menstruation	5	O
in	5	O
four	9	O
of	5	O
the	5	O
six	9	O
patients	5	O
.	9	O

One	5	O
woman	5	O
,	9	O
however	9	O
,	9	O
developed	5	O
worsened	5	O
psychiatric	5	B-Disease
symptoms	5	I-Disease
while	9	O
taking	5	O
bromocriptine	0	B-Chemical
,	9	O
and	5	O
it	5	O
was	9	O
discontinued	5	O
.	9	O

Thus	9	O
,	9	O
three	9	O
of	5	O
six	9	O
patients	5	O
had	9	O
their	5	O
menstrual	5	O
irregularity	5	O
successfully	5	O
corrected	5	O
with	5	O
bromocriptine	0	B-Chemical
.	9	O

This	5	O
suggests	9	O
that	5	O
bromocriptine	0	B-Chemical
should	5	O
be	5	O
further	9	O
evaluated	9	O
as	5	O
potential	9	O
therapy	5	O
for	5	O
neuroleptic	5	B-Chemical
-	7	O
associated	9	O
hyperprolactinemia	5	B-Disease
and	5	O
amenorrhea	5	B-Disease
/	9	O
galactorrhea	5	B-Disease
.	9	O

Ethacrynic	0	B-Chemical
acid	0	I-Chemical
-	7	O
induced	3	O
convulsions	5	B-Disease
and	5	O
brain	5	O
neurotransmitters	9	O
in	5	O
mice	3	O
.	9	O

Intracerebroventricular	3	O
injection	9	O
of	5	O
ethacrynic	0	B-Chemical
acid	0	I-Chemical
(	9	O
50	0	O
%	9	O
convulsive	5	B-Disease
dose	9	O
;	9	O
50	0	O
micrograms	0	O
/	9	O
mouse	3	O
)	9	O
accelerated	9	O
the	5	O
synthesis	9	O
/	9	O
turnover	9	O
of	5	O
5	9	B-Chemical
-	7	I-Chemical
hydroxytryptamine	0	I-Chemical
(	9	O
5	9	B-Chemical
-	7	I-Chemical
HT	9	I-Chemical
)	9	O
but	9	O
suppressed	3	O
the	5	O
synthesis	9	O
of	5	O
gamma	9	B-Chemical
-	7	I-Chemical
aminobutyric	0	I-Chemical
acid	0	I-Chemical
and	5	O
acetylcholine	0	B-Chemical
in	5	O
mouse	3	O
brain	5	O
.	9	O

These	5	O
effects	9	O
were	9	O
completely	9	O
antagonized	3	O
by	9	O
pretreatment	0	O
with	5	O
a	5	O
glutamate	0	B-Chemical
/	9	O
N	9	B-Chemical
-	7	I-Chemical
methyl	0	I-Chemical
-	7	I-Chemical
D	9	I-Chemical
-	7	I-Chemical
aspartate	1	I-Chemical
antagonist	3	O
,	9	O
aminophosphonovaleric	9	B-Chemical
acid	0	I-Chemical
.	9	O

In	9	O
ethacrynic	0	B-Chemical
acid	0	I-Chemical
-	7	O
induced	3	O
convulsions	5	B-Disease
,	9	O
these	5	O
neurotransmitter	9	O
systems	5	O
may	5	O
be	5	O
differentially	9	O
modulated	9	O
,	9	O
probably	9	O
through	9	O
activation	3	O
of	5	O
glutaminergic	5	O
neurons	3	O
in	5	O
the	5	O
brain	5	O
.	9	O

Pharmacology	2	O
of	5	O
gamma	9	B-Chemical
-	7	I-Chemical
aminobutyric	0	I-Chemical
acidA	7	I-Chemical
receptor	3	O
complex	9	O
after	9	O
the	5	O
in	5	O
vivo	3	O
administration	9	O
of	5	O
the	5	O
anxioselective	9	O
and	5	O
anticonvulsant	5	O
beta	9	B-Chemical
-	7	I-Chemical
carboline	0	I-Chemical
derivative	0	O
abecarnil	9	B-Chemical
.	9	O

In	9	O
rodents	9	O
,	9	O
the	5	O
effect	9	O
of	5	O
the	5	O
beta	9	B-Chemical
-	7	I-Chemical
carboline	0	I-Chemical
derivative	0	O
isopropyl	0	B-Chemical
-	7	I-Chemical
6	9	I-Chemical
-	7	I-Chemical
benzyloxy	0	I-Chemical
-	7	I-Chemical
4	9	I-Chemical
-	7	I-Chemical
methoxymethyl	0	I-Chemical
-	7	I-Chemical
beta	9	I-Chemical
-	7	I-Chemical
carboline	0	I-Chemical
-	7	I-Chemical
3	9	I-Chemical
-	7	I-Chemical
carboxylate	0	I-Chemical
(	9	O
abecarrnil	_	B-Chemical
)	9	O
,	9	O
a	5	O
new	5	O
ligand	3	O
for	5	O
benzodiazepine	5	B-Chemical
receptors	3	O
possessing	9	O
anxiolytic	5	O
and	5	O
anticonvulsant	5	O
properties	9	O
,	9	O
was	9	O
evaluated	9	O
on	5	O
the	5	O
function	9	O
of	5	O
central	5	O
gamma	9	B-Chemical
-	7	I-Chemical
aminobutyric	0	I-Chemical
acid	0	I-Chemical
(	9	O
GABA	0	B-Chemical
)	9	O
A	9	O
receptor	3	O
complex	9	O
,	9	O
both	9	O
in	5	O
vitro	3	O
and	5	O
in	5	O
vivo	3	O
.	9	O

Added	9	O
in	5	O
vitro	3	O
to	5	O
rat	3	O
cortical	5	O
membrane	9	O
preparation	9	O
,	9	O
abecarnil	9	B-Chemical
increased	9	O
[	9	O
3H	0	O
]	9	O
GABA	0	B-Chemical
binding	1	O
,	9	O
enhanced	3	O
muscimol	0	B-Chemical
-	7	O
stimulated	3	O
36Cl	0	O
-	7	O
uptake	0	O
and	5	O
reduced	9	O
the	5	O
binding	1	O
of	5	O
t	5	B-Chemical
-	7	I-Chemical
[	9	I-Chemical
35S	1	I-Chemical
]	9	I-Chemical
butylbicyclophosphorothionate	_	I-Chemical
(	9	O
[	9	B-Chemical
35S	1	I-Chemical
]	9	I-Chemical
TBPS	0	I-Chemical
)	9	O
.	9	O

These	5	O
effects	9	O
were	9	O
similar	9	O
to	5	O
those	5	O
induced	3	O
by	9	O
diazepam	0	B-Chemical
,	9	O
whereas	9	O
the	5	O
partial	9	O
agonist	3	O
Ro	0	B-Chemical
16	9	I-Chemical
-	7	I-Chemical
6028	7	I-Chemical
(	9	O
tert	1	B-Chemical
-	7	I-Chemical
butyl	0	I-Chemical
-	7	I-Chemical
(	9	I-Chemical
S	9	I-Chemical
)	9	I-Chemical
-	7	I-Chemical
8	9	I-Chemical
-	7	I-Chemical
bromo	0	I-Chemical
-	7	I-Chemical
11	7	I-Chemical
,	9	I-Chemical
12	9	I-Chemical
,	9	I-Chemical
13	7	I-Chemical
,	9	I-Chemical
13a	0	I-Chemical
-	7	I-Chemical
tetrahydro	0	I-Chemical
-	7	I-Chemical
9	7	I-Chemical
-	7	I-Chemical
oxo	0	I-Chemical
-	7	I-Chemical
9H	7	I-Chemical
-	7	I-Chemical
imidazo	0	I-Chemical
[	9	I-Chemical
1	9	I-Chemical
,	9	I-Chemical
5	9	I-Chemical
-	7	I-Chemical
a	5	I-Chemical
]	9	I-Chemical
-	7	I-Chemical
pyrrolo	0	I-Chemical
-	7	I-Chemical
[	9	I-Chemical
2	9	I-Chemical
,	9	I-Chemical
1	9	I-Chemical
-	7	I-Chemical
c	9	I-Chemical
]	9	I-Chemical
[	9	I-Chemical
1	9	I-Chemical
,	9	I-Chemical
4	9	I-Chemical
]	9	I-Chemical
benzodiazepine	5	I-Chemical
-	7	I-Chemical
1	9	I-Chemical
-	7	I-Chemical
carboxylate	0	I-Chemical
)	9	O
showed	9	O
very	5	O
weak	9	O
efficacy	9	O
in	5	O
these	5	O
biochemical	9	O
tests	5	O
.	9	O

After	9	O
i	9	O
.	9	O
p	7	O
.	9	O
injection	9	O
to	5	O
rats	9	O
,	9	O
abecarnil	9	B-Chemical
and	5	O
diazepam	0	B-Chemical
decreased	9	O
in	5	O
a	5	O
time	5	O
-	7	O
dependent	9	O
and	5	O
dose	9	O
-	7	O
related	9	O
(	9	O
0	7	O
.	9	O
25	9	O
-	7	O
20	9	O
mg	0	O
/	9	O
kg	0	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
manner	9	O
[	9	B-Chemical
35S	1	I-Chemical
]	9	I-Chemical
TBPS	0	I-Chemical
binding	1	O
measured	9	O
ex	9	O
vivo	3	O
in	5	O
the	5	O
cerebral	5	O
cortex	5	O
.	9	O

Moreover	9	O
,	9	O
both	9	O
drugs	5	O
at	9	O
the	5	O
dose	9	O
of	5	O
0	7	O
.	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
antagonized	3	O
completely	9	O
the	5	O
convulsant	0	O
activity	9	O
and	5	O
the	5	O
increase	9	O
of	5	O
[	9	B-Chemical
35S	1	I-Chemical
]	9	I-Chemical
TBPS	0	I-Chemical
binding	1	O
induced	3	O
by	9	O
isoniazide	0	B-Chemical
(	9	O
350	9	O
mg	0	O
/	9	O
kg	0	O
s	9	O
.	9	O
c	9	O
.	9	O
)	9	O
as	5	O
well	9	O
as	5	O
the	5	O
increase	9	O
of	5	O
[	9	B-Chemical
35S	1	I-Chemical
]	9	I-Chemical
TBPS	0	I-Chemical
binding	1	O
induced	3	O
by	9	O
foot	5	O
-	7	O
shock	9	O
stress	9	O
.	9	O

To	9	O
better	5	O
correlate	9	O
the	5	O
biochemical	9	O
and	5	O
the	5	O
pharmacological	9	O
effects	9	O
,	9	O
we	5	O
studied	9	O
the	5	O
action	5	O
of	5	O
abecarnil	9	B-Chemical
on	5	O
[	9	B-Chemical
35S	1	I-Chemical
]	9	I-Chemical
TBPS	0	I-Chemical
binding	1	O
,	9	O
exploratory	5	O
motility	9	O
and	5	O
on	5	O
isoniazid	0	B-Chemical
-	7	O
induced	3	O
biochemical	9	O
and	5	O
pharmacological	9	O
effects	9	O
in	5	O
mice	3	O
.	9	O

In	9	O
these	5	O
animals	9	O
,	9	O
abecarnil	9	B-Chemical
produced	9	O
a	5	O
paralleled	9	O
dose	9	O
-	7	O
dependent	9	O
(	9	O
0	7	O
.	9	O
05	7	O
-	7	O
1	9	O
mg	0	O
/	9	O
kg	0	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
reduction	9	O
of	5	O
both	9	O
motor	5	O
behavior	5	O
and	5	O
cortical	5	O
[	9	O
35S	1	O
]	9	O
TBPS	0	O
binding	1	O
.	9	O

Moreover	9	O
,	9	O
0	7	O
.	9	O
05	7	O
mg	0	O
/	9	O
kg	0	O
of	5	O
this	5	O
beta	9	B-Chemical
-	7	I-Chemical
carboline	0	I-Chemical
reduced	9	O
markedly	9	O
the	5	O
increase	9	O
of	5	O
[	9	B-Chemical
35S	1	I-Chemical
]	9	I-Chemical
TBPS	0	I-Chemical
binding	1	O
and	5	O
the	5	O
convulsions	5	B-Disease
induced	3	O
by	9	O
isoniazid	0	B-Chemical
(	9	O
200	0	O
mg	0	O
/	9	O
kg	0	O
s	9	O
.	9	O
c	9	O
.	9	O
)	9	O
.	9	O
(	9	O
ABSTRACT	2	O
TRUNCATED	2	O
AT	9	O
250	0	O
WORDS	3	O
)	9	O

Recurrent	5	O
myocardial	9	B-Disease
infarction	5	I-Disease
in	5	O
a	5	O
postpartum	5	O
patient	5	O
receiving	9	O
bromocriptine	0	B-Chemical
.	9	O

Myocardial	9	B-Disease
infarction	5	I-Disease
in	5	O
puerperium	5	O
is	5	O
infrequently	5	O
reported	9	O
.	9	O

Spasm	5	B-Disease
,	9	O
coronary	5	O
dissection	5	O
,	9	O
or	5	O
atheromatous	5	O
etiology	9	O
has	9	O
been	9	O
described	9	O
.	9	O

Bromocriptine	0	B-Chemical
has	9	O
been	9	O
implicated	9	O
in	5	O
several	9	O
previous	9	O
case	5	O
reports	9	O
of	5	O
myocardial	9	B-Disease
infarction	5	I-Disease
in	5	O
the	5	O
puerperium	5	O
.	9	O

Our	9	O
case	5	O
(	9	O
including	9	O
an	5	O
inadvertent	5	O
rechallenge	3	O
)	9	O
suggests	9	O
such	5	O
a	5	O
relationship	5	O
.	9	O

Although	9	O
generally	5	O
regarded	5	O
as	5	O
"	5	O
safe	5	O
,	9	O
"	5	O
possible	5	O
serious	5	O
cardiac	5	O
effects	9	O
of	5	O
bromocriptine	0	B-Chemical
should	5	O
be	5	O
acknowledged	5	O
.	9	O

Asterixis	9	B-Disease
induced	3	O
by	9	O
carbamazepine	0	B-Chemical
therapy	5	O
.	9	O

There	5	O
are	5	O
very	5	O
few	5	O
reports	9	O
about	5	O
asterixis	5	B-Disease
as	5	O
a	5	O
side	5	O
effect	9	O
of	5	O
treatment	9	O
with	5	O
psychopharmacologic	5	O
agents	5	O
.	9	O

In	9	O
this	5	O
report	5	O
we	5	O
present	9	O
four	9	O
patients	5	O
treated	3	O
with	5	O
a	5	O
combination	9	O
of	5	O
different	9	O
psychotropic	5	O
drugs	5	O
,	9	O
in	5	O
whom	5	O
asterixis	5	B-Disease
was	9	O
triggered	9	O
either	9	O
by	9	O
adding	0	O
carbamazepine	0	B-Chemical
(	9	O
CBZ	0	B-Chemical
)	9	O
to	5	O
a	5	O
treatment	9	O
regimen	5	O
,	9	O
or	5	O
by	9	O
increasing	9	O
its	9	O
dosage	9	O
.	9	O

Neither	9	O
dosage	9	O
nor	9	O
serum	9	O
levels	3	O
of	5	O
CBZ	0	B-Chemical
were	9	O
in	5	O
a	5	O
higher	9	O
range	9	O
.	9	O

We	9	O
consider	5	O
asterixis	5	B-Disease
to	5	O
be	5	O
an	5	O
easily	5	O
overlooked	5	O
sign	5	O
of	5	O
neurotoxicity	9	B-Disease
,	9	O
which	5	O
may	5	O
occur	5	O
even	5	O
at	9	O
low	9	O
or	5	O
moderate	9	O
dosage	9	O
levels	3	O
,	9	O
if	5	O
certain	5	O
drugs	5	O
as	5	O
lithium	0	B-Chemical
or	5	O
clozapine	5	B-Chemical
are	5	O
used	5	O
in	5	O
combination	9	O
with	5	O
CBZ	0	B-Chemical
.	9	O

Pharmacodynamics	0	O
of	5	O
the	5	O
hypotensive	5	B-Disease
effect	9	O
of	5	O
levodopa	5	B-Chemical
in	5	O
parkinsonian	5	B-Disease
patients	5	O
.	9	O

Blood	9	O
pressure	5	O
effects	9	O
of	5	O
i	9	O
.	9	O
v	0	O
.	9	O
levodopa	5	B-Chemical
were	9	O
examined	9	O
in	5	O
parkinsonian	5	B-Disease
patients	5	O
with	5	O
stable	9	O
and	5	O
fluctuating	5	O
responses	5	O
to	5	O
levodopa	5	B-Chemical
.	9	O

The	5	O
magnitude	5	O
of	5	O
the	5	O
hypotensive	5	B-Disease
effect	9	O
of	5	O
levodopa	5	B-Chemical
was	9	O
concentration	0	O
dependent	9	O
and	5	O
was	9	O
fit	5	O
to	5	O
an	5	O
Emax	0	O
model	5	O
in	5	O
fluctuating	5	O
responders	5	O
.	9	O

Stable	9	O
responders	5	O
demonstrated	9	O
a	5	O
small	9	O
hypotensive	5	B-Disease
response	9	O
.	9	O

Baseline	9	O
blood	9	O
pressures	5	O
were	9	O
higher	9	O
in	5	O
fluctuating	5	O
patients	5	O
;	9	O
a	5	O
higher	9	O
baseline	5	O
blood	9	O
pressure	5	O
correlated	9	O
with	5	O
greater	5	O
hypotensive	5	B-Disease
effects	9	O
.	9	O

Antiparkinsonian	7	O
effects	9	O
of	5	O
levodopa	5	B-Chemical
temporally	5	O
correlated	9	O
with	5	O
blood	9	O
pressure	5	O
changes	9	O
.	9	O

Phenylalanine	7	B-Chemical
,	9	O
a	5	O
large	5	O
neutral	5	O
amino	1	B-Chemical
acid	0	I-Chemical
(	9	O
LNAA	0	O
)	9	O
competing	5	O
with	5	O
levodopa	5	B-Chemical
for	5	O
transport	9	O
across	5	O
the	5	O
blood	9	O
-	7	O
brain	5	O
barrier	5	O
,	9	O
reduced	9	O
the	5	O
hypotensive	5	B-Disease
and	5	O
antiparkinsonian	5	O
effects	9	O
of	5	O
levodopa	5	B-Chemical
.	9	O

We	9	O
conclude	9	O
that	5	O
levodopa	5	B-Chemical
has	9	O
a	5	O
central	5	O
hypotensive	5	B-Disease
action	5	O
that	5	O
parallels	9	O
the	5	O
motor	5	O
effects	9	O
in	5	O
fluctuating	5	O
patients	5	O
.	9	O

The	5	O
hypotensive	5	B-Disease
effect	9	O
appears	9	O
to	5	O
be	5	O
related	9	O
to	5	O
the	5	O
higher	9	O
baseline	5	O
blood	9	O
pressure	5	O
we	5	O
observed	9	O
in	5	O
fluctuating	5	O
patients	5	O
relative	9	O
to	5	O
stable	9	O
patients	5	O
.	9	O

Syndrome	5	B-Disease
of	5	I-Disease
inappropriate	5	I-Disease
secretion	3	I-Disease
of	5	I-Disease
antidiuretic	5	I-Disease
hormone	9	I-Disease
after	9	O
infusional	5	O
vincristine	0	B-Chemical
.	9	O

A	9	O
77	7	O
-	7	O
year	5	O
-	7	O
old	5	O
woman	5	O
with	5	O
refractory	9	O
multiple	5	B-Disease
myeloma	3	I-Disease
was	9	O
treated	3	O
with	5	O
a	5	O
4	9	O
-	7	O
day	9	O
continuous	5	O
intravenous	0	O
infusion	0	O
of	5	O
vincristine	0	B-Chemical
and	5	O
doxorubicin	0	B-Chemical
and	5	O
4	9	O
days	9	O
of	5	O
oral	9	O
dexamethasone	0	B-Chemical
.	9	O

Nine	9	O
days	9	O
after	9	O
her	5	O
second	9	O
cycle	9	O
she	5	O
presented	5	O
with	5	O
lethargy	5	B-Disease
and	5	O
weakness	5	B-Disease
associated	9	O
with	5	O
hyponatremia	5	B-Disease
.	9	O

Evaluation	5	O
revealed	9	O
the	5	O
syndrome	5	B-Disease
of	5	I-Disease
inappropriate	5	I-Disease
secretion	3	I-Disease
of	5	I-Disease
antidiuretic	5	I-Disease
hormone	9	I-Disease
,	9	O
which	5	O
was	9	O
attributed	9	O
to	5	O
the	5	O
vincristine	0	B-Chemical
infusion	0	O
.	9	O

After	9	O
normal	9	O
serum	9	O
sodium	0	B-Chemical
levels	3	O
returned	5	O
,	9	O
further	9	O
doxorubicin	0	B-Chemical
and	5	O
dexamethasone	0	B-Chemical
chemotherapy	5	O
without	9	O
vincristine	0	B-Chemical
did	9	O
not	5	O
produce	9	O
this	5	O
complication	5	O
.	9	O

Heart	2	B-Disease
failure	5	I-Disease
:	9	O
to	5	O
digitalise	9	O
or	5	O
not	5	O
?	5	O

The	5	O
view	5	O
against	9	O
.	9	O

Despite	5	O
extensive	5	O
clinical	5	O
experience	5	O
the	5	O
role	9	O
of	5	O
digoxin	0	B-Chemical
is	5	O
still	5	O
not	5	O
well	9	O
defined	5	O
.	9	O

In	9	O
patients	5	O
with	5	O
atrial	5	B-Disease
fibrillation	5	I-Disease
digoxin	0	B-Chemical
is	5	O
beneficial	9	O
for	5	O
ventricular	5	O
rate	9	O
control	9	O
.	9	O

For	9	O
patients	5	O
in	5	O
sinus	5	O
rhythm	5	O
and	5	O
heart	5	B-Disease
failure	5	I-Disease
the	5	O
situation	5	O
is	5	O
less	5	O
clear	9	O
.	9	O

Digoxin	7	B-Chemical
has	9	O
a	5	O
narrow	5	O
therapeutic	5	O
:	9	O
toxic	0	O
ratio	9	O
and	5	O
concentrations	0	O
are	5	O
affected	9	O
by	9	O
a	5	O
number	9	O
of	5	O
drugs	5	O
.	9	O

Also	9	O
,	9	O
digoxin	0	B-Chemical
has	9	O
undesirable	5	O
effects	9	O
such	5	O
as	5	O
increasing	9	O
peripheral	9	O
resistance	9	O
and	5	O
myocardial	9	O
demands	5	O
,	9	O
and	5	O
causing	9	O
arrhythmias	5	B-Disease
.	9	O

There	5	O
is	5	O
a	5	O
paucity	9	O
of	5	O
data	5	O
from	9	O
well	9	O
-	7	O
designed	9	O
trials	5	O
.	9	O

The	5	O
trials	5	O
that	5	O
are	5	O
available	5	O
are	5	O
generally	5	O
small	9	O
with	5	O
limitations	5	O
in	5	O
design	5	O
and	5	O
these	5	O
show	9	O
variation	5	O
in	5	O
patient	5	O
benefit	5	O
.	9	O

More	5	O
convincing	9	O
evidence	9	O
is	5	O
required	9	O
showing	9	O
that	5	O
digoxin	0	B-Chemical
improves	5	O
symptoms	5	O
or	5	O
exercise	5	O
capacity	9	O
.	9	O

Furthermore	9	O
,	9	O
no	9	O
trial	5	O
has	9	O
had	9	O
sufficient	9	O
power	5	O
to	5	O
evaluate	9	O
mortality	5	O
.	9	O

Pooled	9	O
analysis	9	O
of	5	O
the	5	O
effects	9	O
of	5	O
other	5	O
inotropic	5	O
drugs	5	O
shows	9	O
an	5	O
excess	9	O
mortality	5	O
and	5	O
there	5	O
is	5	O
a	5	O
possibility	9	O
that	5	O
digoxin	0	B-Chemical
may	5	O
increase	9	O
mortality	5	O
after	9	O
myocardial	9	B-Disease
infarction	5	I-Disease
(	9	O
MI	9	B-Disease
)	9	O
.	9	O

Angiotensin	0	B-Chemical
-	7	O
converting	9	O
enzyme	0	O
(	9	O
ACE	9	O
)	9	O
inhibitors	3	O
should	5	O
be	5	O
used	5	O
first	9	O
as	5	O
they	5	O
are	5	O
safer	5	O
,	9	O
do	5	O
not	5	O
require	5	O
blood	9	O
level	9	O
monitoring	5	O
,	9	O
modify	9	O
progression	9	O
of	5	O
disease	5	O
,	9	O
relieve	5	O
symptoms	5	O
,	9	O
improve	5	O
exercise	5	O
tolerance	9	O
and	5	O
reduce	5	O
mortality	5	O
.	9	O

Caution	5	O
should	5	O
be	5	O
exercised	5	O
in	5	O
using	9	O
digoxin	0	B-Chemical
until	5	O
large	5	O
mortality	5	O
trials	5	O
are	5	O
completed	5	O
showing	9	O
either	9	O
benefit	5	O
or	5	O
harm	5	O
.	9	O

Until	5	O
then	9	O
digoxin	0	B-Chemical
should	5	O
be	5	O
considered	5	O
a	5	O
third	9	O
-	7	O
line	9	O
therapy	5	O
.	9	O

Isradipine	7	B-Chemical
treatment	9	O
for	5	O
hypertension	5	B-Disease
in	5	O
general	5	O
practice	5	O
in	5	O
Hong	2	O
Kong	2	O
.	9	O

A	9	O
6	9	O
-	7	O
week	9	O
open	5	O
study	9	O
of	5	O
the	5	O
introduction	9	O
of	5	O
isradipine	0	B-Chemical
treatment	9	O
was	9	O
conducted	9	O
in	5	O
general	5	O
practice	5	O
in	5	O
Hong	2	O
Kong	2	O
.	9	O

303	7	O
Chinese	9	O
patients	5	O
with	5	O
mild	9	O
to	5	O
moderate	9	O
hypertension	5	B-Disease
entered	5	O
the	5	O
study	9	O
.	9	O

Side	5	O
effects	9	O
were	9	O
reported	9	O
in	5	O
21	7	O
%	9	O
of	5	O
patients	5	O
and	5	O
caused	9	O
withdrawal	5	O
from	9	O
the	5	O
study	9	O
in	5	O
3	9	O
patients	5	O
.	9	O

The	5	O
main	5	O
side	5	O
-	7	O
effects	9	O
were	9	O
headache	5	B-Disease
,	9	O
dizziness	5	B-Disease
,	9	O
palpitation	5	B-Disease
and	5	O
flushing	5	B-Disease
and	5	O
these	5	O
were	9	O
not	5	O
more	5	O
frequent	5	O
than	5	O
reported	9	O
in	5	O
other	5	O
studies	9	O
with	5	O
isradipine	0	B-Chemical
or	5	O
with	5	O
placebo	9	O
.	9	O

Supine	7	O
blood	9	O
pressure	5	O
was	9	O
reduced	9	O
(	9	O
P	9	O
less	5	O
than	5	O
0	7	O
.	9	O
01	7	O
)	9	O
from	9	O
170	9	O
+	9	O
/	9	O
-	7	O
20	9	O
/	9	O
102	7	O
+	9	O
/	9	O
-	7	O
6	9	O
mmHg	7	O
to	5	O
153	7	O
+	9	O
/	9	O
-	7	O
19	7	O
/	9	O
92	7	O
+	9	O
/	9	O
-	7	O
8	9	O
,	9	O
147	7	O
+	9	O
/	9	O
-	7	O
18	7	O
/	9	O
88	7	O
+	9	O
/	9	O
-	7	O
7	9	O
and	5	O
144	7	O
+	9	O
/	9	O
-	7	O
14	7	O
/	9	O
87	7	O
+	9	O
/	9	O
-	7	O
6	9	O
mmHg	7	O
at	9	O
2	9	O
,	9	O
4	9	O
and	5	O
6	9	O
weeks	9	O
respectively	9	O
in	5	O
evaluable	9	O
patients	5	O
.	9	O

Similar	9	O
reductions	9	O
occurred	9	O
in	5	O
standing	5	O
blood	9	O
pressure	5	O
and	5	O
there	5	O
was	9	O
no	9	O
evidence	9	O
of	5	O
postural	5	B-Disease
hypotension	5	I-Disease
.	9	O

Normalization	5	O
and	5	O
responder	9	O
rates	5	O
at	9	O
6	9	O
weeks	9	O
were	9	O
86	7	O
%	9	O
and	5	O
69	7	O
%	9	O
respectively	9	O
.	9	O

Dosage	0	O
was	9	O
increased	9	O
from	9	O
2	9	O
.	9	O
5	9	O
mg	0	O
b	9	O
.	9	O
d	9	O
.	9	O
to	5	O
5	9	O
mg	0	O
b	9	O
.	9	O
d	9	O
.	9	O
at	9	O
4	9	O
weeks	9	O
in	5	O
patients	5	O
with	5	O
diastolic	5	O
blood	9	O
pressure	5	O
greater	5	O
than	5	O
90	9	O
mmHg	7	O
and	5	O
their	5	O
further	9	O
response	9	O
was	9	O
greater	5	O
than	5	O
those	5	O
remaining	9	O
on	5	O
2	9	O
.	9	O
5	9	O
mg	0	O
b	9	O
.	9	O
d	9	O
.	9	O

Pharmacological	9	O
characteristics	5	O
and	5	O
side	5	O
effects	9	O
of	5	O
a	5	O
new	5	O
galenic	5	O
formulation	5	O
of	5	O
propofol	0	B-Chemical
without	9	O
soyabean	0	O
oil	0	O
.	9	O

We	9	O
compared	9	O
the	5	O
pharmacokinetics	9	O
,	9	O
pharmacodynamics	5	O
and	5	O
safety	5	O
profile	9	O
of	5	O
a	5	O
new	5	O
galenic	5	O
formulation	5	O
of	5	O
propofol	0	B-Chemical
(	9	O
AM149	_	O
1	9	O
%	9	O
)	9	O
,	9	O
which	5	O
does	9	O
not	5	O
contain	9	O
soyabean	0	O
oil	0	O
,	9	O
with	5	O
a	5	O
standard	5	O
formulation	5	O
of	5	O
propofol	0	B-Chemical
(	9	O
Disoprivan	9	B-Chemical
1	9	O
%	9	O
)	9	O
.	9	O

In	9	O
a	5	O
randomised	5	O
,	9	O
double	9	O
-	7	O
blind	5	O
,	9	O
cross	5	O
-	7	O
over	5	O
study	9	O
,	9	O
30	9	O
healthy	5	O
volunteers	5	O
received	9	O
a	5	O
single	9	O
intravenous	0	O
bolus	0	O
injection	9	O
of	5	O
2	9	O
.	9	O
5	9	O
mg	0	O
.	9	O
kg	0	O
-	7	O
1	9	O
propofol	0	B-Chemical
.	9	O

Plasma	0	O
propofol	0	B-Chemical
levels	3	O
were	9	O
measured	9	O
for	5	O
48	9	O
h	0	O
following	9	O
drug	5	O
administration	9	O
and	5	O
evaluated	9	O
according	9	O
to	5	O
a	5	O
three	9	O
-	7	O
compartment	9	O
model	5	O
.	9	O

The	5	O
pharmacodynamic	5	O
parameters	5	O
assessed	9	O
included	5	O
induction	3	O
and	5	O
emergence	9	O
times	5	O
,	9	O
respiratory	5	O
and	5	O
cardiovascular	5	O
effects	9	O
,	9	O
and	5	O
pain	5	B-Disease
on	5	O
injection	9	O
.	9	O

Patients	5	O
were	9	O
monitored	9	O
for	5	O
side	5	O
effects	9	O
over	5	O
48	9	O
h	0	O
.	9	O

Owing	5	O
to	5	O
a	5	O
high	9	O
incidence	5	O
of	5	O
thrombophlebitis	5	B-Disease
,	9	O
the	5	O
study	9	O
was	9	O
terminated	9	O
prematurely	5	O
and	5	O
only	9	O
the	5	O
data	5	O
of	5	O
the	5	O
two	5	O
parallel	5	O
treatment	9	O
groups	9	O
(	9	O
15	9	O
patients	5	O
in	5	O
each	5	O
group	9	O
)	9	O
were	9	O
analysed	9	O
.	9	O

Plasma	0	O
concentrations	0	O
did	9	O
not	5	O
differ	9	O
significantly	9	O
between	5	O
the	5	O
two	5	O
formulations	0	O
.	9	O

Anaesthesia	2	O
induction	3	O
and	5	O
emergence	9	O
times	5	O
,	9	O
respiratory	5	O
and	5	O
cardiovascular	5	O
variables	5	O
showed	9	O
no	9	O
significant	9	O
differences	9	O
between	5	O
the	5	O
two	5	O
treatment	9	O
groups	9	O
.	9	O

Pain	5	B-Disease
on	5	O
injection	9	O
(	9	O
80	9	O
vs	7	O
.	9	O
20	9	O
%	9	O
,	9	O
p	7	O
<	0	O
0	7	O
.	9	O
01	7	O
)	9	O
and	5	O
thrombophlebitis	5	B-Disease
(	9	O
93	7	O
.	9	O
3	9	O
vs	7	O
.	9	O
6	9	O
.	9	O
6	9	O
%	9	O
,	9	O
p	7	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
occurred	9	O
more	5	O
frequently	5	O
with	5	O
AM149	_	O
than	5	O
with	5	O
Disoprivan	9	B-Chemical
.	9	O

Although	9	O
both	9	O
formulations	0	O
had	9	O
similar	9	O
pharmacokinetic	5	O
and	5	O
pharmacodynamic	5	O
profiles	9	O
the	5	O
new	5	O
formulation	5	O
is	5	O
not	5	O
suitable	5	O
for	5	O
clinical	5	O
use	5	O
due	5	O
to	5	O
the	5	O
high	9	O
incidence	5	O
of	5	O
thrombophlebitis	5	B-Disease
produced	9	O
.	9	O

Pure	0	B-Disease
red	9	I-Disease
cell	3	I-Disease
aplasia	5	I-Disease
,	9	O
toxic	0	B-Disease
dermatitis	5	I-Disease
and	5	O
lymphadenopathy	5	B-Disease
in	5	O
a	5	O
patient	5	O
taking	5	O
diphenylhydantoin	0	B-Chemical
.	9	O

A	9	O
patient	5	O
taking	5	O
diphenylhydantoin	0	B-Chemical
for	5	O
3	9	O
weeks	9	O
developed	5	O
a	5	O
generalized	5	O
skin	5	B-Disease
rash	5	I-Disease
,	9	O
lymphadenopathy	5	B-Disease
and	5	O
pure	9	B-Disease
red	9	I-Disease
cell	3	I-Disease
aplasia	5	I-Disease
.	9	O

After	9	O
withdrawal	5	O
of	5	O
the	5	O
pharmacon	0	O
all	5	O
symptoms	5	O
disappeared	9	O
spontaneously	5	O
.	9	O

Skin	9	B-Disease
rash	5	I-Disease
is	5	O
a	5	O
well	9	O
-	7	O
known	9	O
complication	5	O
of	5	O
diphenylhydantoin	0	B-Chemical
treatment	9	O
as	5	O
is	5	O
benign	5	O
and	5	O
malignant	3	O
lymphadenopathy	5	B-Disease
.	9	O

Pure	0	B-Disease
red	9	I-Disease
cell	3	I-Disease
aplasia	5	I-Disease
associated	9	O
with	5	O
diphenylhydantoin	0	B-Chemical
medication	5	O
has	9	O
been	9	O
reported	9	O
in	5	O
3	9	O
patients	5	O
.	9	O

The	5	O
exact	5	O
mechanism	9	O
by	9	O
which	5	O
diphenylhydantoin	0	B-Chemical
exerts	9	O
its	9	O
toxic	0	O
effects	9	O
is	5	O
not	5	O
known	9	O
.	9	O

In	9	O
this	5	O
patient	5	O
the	5	O
time	5	O
relation	5	O
between	5	O
the	5	O
ingestion	9	O
of	5	O
diphenylhydantoin	0	B-Chemical
and	5	O
the	5	O
occurrence	5	O
of	5	O
the	5	O
skin	5	B-Disease
rash	5	I-Disease
,	9	O
lymphadenopathy	5	B-Disease
and	5	O
pure	9	B-Disease
red	9	I-Disease
cell	3	I-Disease
aplasia	5	I-Disease
is	5	O
very	5	O
suggestive	9	O
of	5	O
a	5	O
direct	9	O
connection	5	O
.	9	O

Vinorelbine	0	B-Chemical
-	7	O
related	9	O
cardiac	5	O
events	5	O
:	9	O
a	5	O
meta	9	O
-	7	O
analysis	9	O
of	5	O
randomized	5	O
clinical	5	O
trials	5	O
.	9	O

Several	9	O
cases	5	O
of	5	O
cardiac	5	O
adverse	5	O
reactions	9	O
related	9	O
to	5	O
vinorelbine	0	B-Chemical
(	9	O
VNR	3	B-Chemical
)	9	O
have	5	O
been	9	O
reported	9	O
in	5	O
the	5	O
literature	5	O
.	9	O

In	9	O
order	5	O
to	5	O
quantify	9	O
the	5	O
incidence	5	O
of	5	O
these	5	O
cardiac	5	O
events	5	O
,	9	O
we	5	O
performed	9	O
a	5	O
meta	9	O
-	7	O
analysis	9	O
of	5	O
clinical	5	O
trials	5	O
comparing	9	O
VNR	3	B-Chemical
with	5	O
other	5	O
chemotherapeutic	3	O
agents	5	O
in	5	O
the	5	O
treatment	9	O
of	5	O
various	9	O
malignancies	5	B-Disease
.	9	O

Randomized	5	O
clinical	5	O
trials	5	O
comparing	9	O
VNR	3	B-Chemical
with	5	O
other	5	O
drugs	5	O
in	5	O
the	5	O
treatment	9	O
of	5	O
cancer	3	B-Disease
were	9	O
searched	9	O
in	5	O
Medline	5	O
,	9	O
Embase	5	O
,	9	O
Evidence	9	O
-	7	O
based	5	O
Medicine	2	O
Reviews	5	O
databases	5	O
and	5	O
the	5	O
Cochrane	5	O
library	9	O
from	9	O
1987	2	O
to	5	O
2002	2	O
.	9	O

Outcomes	5	O
of	5	O
interest	5	O
were	9	O
severe	5	O
cardiac	5	O
events	5	O
,	9	O
toxic	0	O
deaths	5	O
and	5	O
cardiac	5	O
event	5	O
-	7	O
related	9	O
deaths	5	O
reported	9	O
in	5	O
each	5	O
publication	5	O
.	9	O

We	9	O
found	9	O
19	7	O
trials	5	O
,	9	O
involving	5	O
2441	7	O
patients	5	O
treated	3	O
by	9	O
VNR	3	B-Chemical
and	5	O
2050	5	O
control	9	O
patients	5	O
.	9	O

The	5	O
incidence	5	O
of	5	O
cardiac	5	O
events	5	O
with	5	O
VNR	3	B-Chemical
was	9	O
1	9	O
.	9	O
19	7	O
%	9	O
[	9	O
95	7	O
%	9	O
confidence	5	O
interval	5	O
(	9	O
CI	7	O
)	9	O
(	9	O
0	7	O
.	9	O
75	9	O
;	9	O
1	9	O
.	9	O
67	7	O
)	9	O
]	9	O
.	9	O

There	5	O
was	9	O
no	9	O
difference	9	O
in	5	O
the	5	O
risk	5	O
of	5	O
cardiac	5	O
events	5	O
between	5	O
VNR	3	B-Chemical
and	5	O
other	5	O
drugs	5	O
[	9	O
odds	5	O
ratio	9	O
:	9	O
0	7	O
.	9	O
92	7	O
,	9	O
95	7	O
%	9	O
CI	7	O
(	9	O
0	7	O
.	9	O
54	7	O
;	9	O
1	9	O
.	9	O
55	7	O
)	9	O
]	9	O
.	9	O

The	5	O
risk	5	O
of	5	O
VNR	3	B-Chemical
cardiac	5	O
events	5	O
was	9	O
similar	9	O
to	5	O
vindesine	0	B-Chemical
(	9	O
VDS	5	B-Chemical
)	9	O
and	5	O
other	5	O
cardiotoxic	5	B-Disease
drugs	5	O
[	9	O
fluorouracil	0	B-Chemical
,	9	O
anthracyclines	0	B-Chemical
,	9	O
gemcitabine	3	B-Chemical
(	9	O
GEM	9	B-Chemical
)	9	O
em	2	O
leader	9	O
]	9	O
.	9	O

Even	5	O
if	5	O
it	5	O
did	9	O
not	5	O
reach	5	O
statistical	5	O
significance	9	O
because	5	O
of	5	O
a	5	O
few	5	O
number	9	O
of	5	O
cases	5	O
,	9	O
the	5	O
risk	5	O
was	9	O
lower	9	O
in	5	O
trials	5	O
excluding	9	O
patients	5	O
with	5	O
cardiac	5	O
history	5	O
,	9	O
and	5	O
seemed	9	O
to	5	O
be	5	O
higher	9	O
in	5	O
trials	5	O
including	9	O
patients	5	O
with	5	O
pre	9	O
-	7	O
existing	5	O
cardiac	5	B-Disease
diseases	5	I-Disease
.	9	O

Vinorelbine	0	B-Chemical
-	7	O
related	9	O
cardiac	5	O
events	5	O
concern	5	O
about	5	O
1	9	O
%	9	O
of	5	O
treated	3	O
patients	5	O
in	5	O
clinical	5	O
trials	5	O
.	9	O

However	9	O
,	9	O
the	5	O
risk	5	O
associated	9	O
with	5	O
VNR	3	B-Chemical
seems	5	O
to	5	O
be	5	O
similar	9	O
to	5	O
that	5	O
of	5	O
other	5	O
chemotherapeutic	3	O
agents	5	O
in	5	O
the	5	O
same	9	O
indications	5	O
.	9	O

MRI	5	O
findings	9	O
of	5	O
hypoxic	3	O
cortical	5	O
laminar	5	O
necrosis	9	B-Disease
in	5	O
a	5	O
child	5	O
with	5	O
hemolytic	0	B-Disease
anemia	9	I-Disease
crisis	5	O
.	9	O

We	9	O
present	9	O
magnetic	0	O
resonance	5	O
imaging	5	O
findings	9	O
of	5	O
a	5	O
5	9	O
-	7	O
year	5	O
-	7	O
old	5	O
girl	5	O
who	5	O
had	9	O
a	5	O
rapidly	9	O
installing	5	O
hemolytic	0	B-Disease
anemia	9	I-Disease
crisis	5	O
induced	3	O
by	9	O
trimethoprim	0	B-Chemical
-	7	I-Chemical
sulfomethoxazole	0	I-Chemical
,	9	O
resulting	9	O
in	5	O
cerebral	5	B-Disease
anoxia	9	I-Disease
leading	9	O
to	5	O
permanent	5	O
damage	9	O
.	9	O

Magnetic	5	O
Resonance	5	O
imaging	5	O
revealed	9	O
cortical	5	O
laminar	5	O
necrosis	9	B-Disease
in	5	O
arterial	5	O
border	9	O
zones	5	O
in	5	O
both	9	O
cerebral	5	O
hemispheres	5	O
,	9	O
ischemic	9	O
changes	9	O
in	5	O
subcortical	5	O
white	9	O
matter	5	O
of	5	O
left	5	O
cerebral	5	O
hemisphere	5	O
,	9	O
and	5	O
in	5	O
the	5	O
left	5	O
putamen	5	O
.	9	O

Although	9	O
cortical	5	O
laminar	5	O
necrosis	9	B-Disease
is	5	O
a	5	O
classic	5	O
entity	5	O
in	5	O
adulthood	5	O
related	9	O
to	5	O
conditions	9	O
of	5	O
energy	5	O
depletions	3	O
,	9	O
there	5	O
are	5	O
few	5	O
reports	9	O
available	5	O
in	5	O
children	5	O
.	9	O

A	9	O
wide	5	O
review	5	O
of	5	O
the	5	O
literature	5	O
is	5	O
also	9	O
presented	5	O
.	9	O

The	5	O
natural	5	O
history	5	O
of	5	O
Vigabatrin	0	B-Chemical
associated	9	O
visual	5	B-Disease
field	5	I-Disease
defects	9	I-Disease
in	5	O
patients	5	O
electing	5	O
to	5	O
continue	5	O
their	5	O
medication	5	O
.	9	O

PURPOSE	2	O
:	9	O
To	9	O
determine	9	O
the	5	O
natural	5	O
history	5	O
of	5	O
visual	5	B-Disease
field	5	I-Disease
defects	9	I-Disease
in	5	O
a	5	O
group	9	O
of	5	O
patients	5	O
known	9	O
to	5	O
have	5	O
Vigabatrin	0	B-Chemical
-	7	O
associated	9	O
changes	9	O
who	5	O
elected	5	O
to	5	O
continue	5	O
the	5	O
medication	5	O
because	5	O
of	5	O
good	5	O
seizure	5	B-Disease
control	9	O
.	9	O

METHODS	2	O
:	9	O
All	9	O
patients	5	O
taking	5	O
Vigabatrin	0	B-Chemical
alone	9	O
or	5	O
in	5	O
combination	9	O
with	5	O
other	5	O
antiepileptic	5	O
drugs	5	O
for	5	O
at	9	O
least	9	O
5	9	O
years	5	O
(	9	O
range	9	O
5	9	O
-	7	O
12	9	O
years	5	O
)	9	O
were	9	O
entered	5	O
into	9	O
a	5	O
visual	5	O
surveillance	5	O
programme	5	O
.	9	O

Patients	5	O
were	9	O
followed	9	O
up	5	O
at	9	O
6	9	O
-	7	O
monthly	5	O
intervals	5	O
for	5	O
not	5	O
less	5	O
than	5	O
18	7	O
months	5	O
(	9	O
range	9	O
18	7	O
-	7	O
43	7	O
months	5	O
)	9	O
.	9	O

In	9	O
all	5	O
,	9	O
16	9	O
patients	5	O
with	5	O
unequivocal	9	O
defects	9	O
continued	9	O
the	5	O
medication	5	O
.	9	O

Following	9	O
already	5	O
published	9	O
methodology	5	O
(	9	O
Eye	2	O
2002	2	O
;	9	O
16	9	O
;	9	O
567	7	O
-	7	O
571	7	O
)	9	O
monocular	5	O
mean	5	O
radial	5	O
degrees	5	O
(	9	O
MRDs	5	O
)	9	O
to	5	O
the	5	O
I	9	O
/	9	O
4e	0	O
isopter	5	O
on	5	O
Goldmann	6	O
perimetry	5	O
was	9	O
calculated	5	O
for	5	O
the	5	O
right	5	O
eye	5	O
at	9	O
the	5	O
time	5	O
of	5	O
discovery	9	O
of	5	O
a	5	O
visual	5	B-Disease
field	5	I-Disease
defect	9	I-Disease
and	5	O
again	9	O
after	9	O
not	5	O
less	5	O
than	5	O
18	7	O
months	5	O
follow	5	O
-	7	O
up	5	O
.	9	O

RESULTS	9	O
:	9	O
Mean	9	O
right	5	O
eye	5	O
MRD	9	O
at	9	O
presentation	5	O
was	9	O
36	9	O
.	9	O
98	7	O
degrees	5	O
(	9	O
range	9	O
22	7	O
.	9	O
25	9	O
-	7	O
51	7	O
.	9	O
0	7	O
)	9	O
,	9	O
compared	9	O
to	5	O
38	7	O
.	9	O
40	9	O
degrees	5	O
(	9	O
range	9	O
22	7	O
.	9	O
5	9	O
-	7	O
49	7	O
.	9	O
75	9	O
)	9	O
after	9	O
follow	5	O
-	7	O
up	5	O
;	9	O
P	9	O
=	7	O
0	7	O
.	9	O
338	7	O
unpaired	9	O
t	5	O
-	7	O
test	5	O
.	9	O

Only	9	O
one	5	O
patient	5	O
demonstrated	9	O
a	5	O
deterioration	5	B-Disease
in	5	I-Disease
visual	5	I-Disease
field	5	I-Disease
during	5	O
the	5	O
study	9	O
period	5	O
and	5	O
discontinued	5	O
treatment	9	O
.	9	O

CONCLUSION	5	O
:	9	O
Established	9	O
visual	5	B-Disease
field	5	I-Disease
defects	9	I-Disease
presumed	9	O
to	5	O
be	5	O
due	5	O
to	5	O
Vigabatrin	0	B-Chemical
therapy	5	O
did	9	O
not	5	O
usually	5	O
progress	5	O
in	5	O
spite	9	O
of	5	O
continuing	5	O
use	5	O
of	5	O
the	5	O
medication	5	O
.	9	O

These	5	O
data	5	O
give	5	O
support	5	O
to	5	O
the	5	O
hypothesis	9	O
that	5	O
the	5	O
pathogenesis	9	O
of	5	O
Vigabatrin	0	B-Chemical
-	7	O
associated	9	O
visual	5	B-Disease
field	5	I-Disease
defects	9	I-Disease
may	5	O
be	5	O
an	5	O
idiosyncratic	5	O
adverse	5	O
drug	5	O
reaction	9	O
rather	5	O
than	5	O
dose	9	O
-	7	O
dependent	9	O
toxicity	9	B-Disease
.	9	O

Induction	3	O
of	5	O
rosaceiform	_	O
dermatitis	5	B-Disease
during	5	O
treatment	9	O
of	5	O
facial	5	B-Disease
inflammatory	3	I-Disease
dermatoses	5	I-Disease
with	5	O
tacrolimus	0	B-Chemical
ointment	0	O
.	9	O

BACKGROUND	2	O
:	9	O
Tacrolimus	0	B-Chemical
ointment	0	O
is	5	O
increasingly	5	O
used	5	O
for	5	O
anti	3	O
-	7	O
inflammatory	3	O
treatment	9	O
of	5	O
sensitive	9	O
areas	5	O
such	5	O
as	5	O
the	5	O
face	5	O
,	9	O
and	5	O
recent	5	O
observations	9	O
indicate	9	O
that	5	O
the	5	O
treatment	9	O
is	5	O
effective	5	O
in	5	O
steroid	9	B-Chemical
-	7	O
aggravated	9	O
rosacea	5	B-Disease
and	5	O
perioral	5	B-Disease
dermatitis	5	I-Disease
.	9	O

We	9	O
report	5	O
on	5	O
rosaceiform	_	O
dermatitis	5	B-Disease
as	5	O
a	5	O
complication	5	O
of	5	O
treatment	9	O
with	5	O
tacrolimus	0	B-Chemical
ointment	0	O
.	9	O

OBSERVATIONS	2	O
:	9	O
Six	9	O
adult	9	O
patients	5	O
with	5	O
inflammatory	3	B-Disease
facial	5	I-Disease
dermatoses	5	I-Disease
were	9	O
treated	3	O
with	5	O
tacrolimus	0	B-Chemical
ointment	0	O
because	5	O
of	5	O
the	5	O
ineffectiveness	5	O
of	5	O
standard	5	O
treatments	9	O
.	9	O

Within	9	O
2	9	O
to	5	O
3	9	O
weeks	9	O
of	5	O
initially	9	O
effective	5	O
and	5	O
well	9	O
-	7	O
tolerated	9	O
treatment	9	O
,	9	O
3	9	O
patients	5	O
with	5	O
a	5	O
history	5	O
of	5	O
rosacea	5	B-Disease
and	5	O
1	9	O
with	5	O
a	5	O
history	5	O
of	5	O
acne	5	B-Disease
experienced	5	O
sudden	5	O
worsening	5	O
with	5	O
pustular	5	O
rosaceiform	_	O
lesions	5	O
.	9	O

Biopsy	9	O
revealed	9	O
an	5	O
abundance	9	O
of	5	O
Demodex	4	O
mites	4	O
in	5	O
2	9	O
of	5	O
these	5	O
patients	5	O
.	9	O

In	9	O
1	9	O
patient	5	O
with	5	O
eyelid	5	O
eczema	5	B-Disease
,	9	O
rosaceiform	_	O
periocular	5	B-Disease
dermatitis	5	I-Disease
gradually	9	O
appeared	9	O
after	9	O
3	9	O
weeks	9	O
of	5	O
treatment	9	O
.	9	O

In	9	O
1	9	O
patient	5	O
with	5	O
atopic	5	B-Disease
dermatitis	5	I-Disease
,	9	O
telangiectatic	5	O
and	5	O
papular	5	B-Disease
rosacea	5	I-Disease
insidiously	5	O
appeared	9	O
after	9	O
5	9	O
months	5	O
of	5	O
treatment	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Our	9	O
observations	9	O
suggest	9	O
that	5	O
the	5	O
spectrum	9	O
of	5	O
rosaceiform	_	O
dermatitis	5	B-Disease
as	5	O
a	5	O
complication	5	O
of	5	O
treatment	9	O
with	5	O
tacrolimus	0	B-Chemical
ointment	0	O
is	5	O
heterogeneous	5	O
.	9	O

A	9	O
variety	5	O
of	5	O
factors	9	O
,	9	O
such	5	O
as	5	O
vasoactive	5	O
properties	9	O
of	5	O
tacrolimus	0	B-Chemical
,	9	O
proliferation	3	O
of	5	O
Demodex	4	O
due	5	O
to	5	O
local	5	O
immunosuppression	5	O
,	9	O
and	5	O
the	5	O
occlusive	5	O
properties	9	O
of	5	O
the	5	O
ointment	0	O
,	9	O
may	5	O
be	5	O
involved	9	O
in	5	O
the	5	O
observed	9	O
phenomena	5	O
.	9	O

Future	5	O
studies	9	O
are	5	O
needed	5	O
to	5	O
identify	9	O
individual	5	O
risk	5	O
factors	9	O
.	9	O

Intravascular	5	O
hemolysis	9	B-Disease
and	5	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
following	9	O
intermittent	5	O
rifampin	0	B-Chemical
therapy	5	O
.	9	O

Renal	9	B-Disease
failure	5	I-Disease
is	5	O
a	5	O
rare	5	O
complication	5	O
associated	9	O
with	5	O
the	5	O
use	5	O
of	5	O
rifampin	0	B-Chemical
.	9	O

Intravascular	5	O
hemolysis	9	B-Disease
leading	9	O
to	5	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
following	9	O
rifampin	0	B-Chemical
therapy	5	O
is	5	O
extremely	5	O
rare	5	O
.	9	O

Two	9	O
patients	5	O
with	5	O
leprosy	5	B-Disease
who	5	O
developed	5	O
hemolysis	9	B-Disease
and	5	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
following	9	O
rifampin	0	B-Chemical
are	5	O
reported	9	O
.	9	O

Structural	9	O
abnormalities	9	O
in	5	O
the	5	O
brains	9	O
of	5	O
human	3	O
subjects	5	O
who	5	O
use	5	O
methamphetamine	5	B-Chemical
.	9	O

We	9	O
visualize	9	O
,	9	O
for	5	O
the	5	O
first	9	O
time	5	O
,	9	O
the	5	O
profile	9	O
of	5	O
structural	9	B-Disease
deficits	5	I-Disease
in	5	I-Disease
the	5	I-Disease
human	3	I-Disease
brain	5	I-Disease
associated	9	O
with	5	O
chronic	5	O
methamphetamine	5	B-Chemical
(	9	O
MA	2	B-Chemical
)	9	O
abuse	5	O
.	9	O

Studies	9	O
of	5	O
human	3	O
subjects	5	O
who	5	O
have	5	O
used	5	O
MA	2	B-Chemical
chronically	9	O
have	5	O
revealed	9	O
deficits	5	O
in	5	O
dopaminergic	5	O
and	5	O
serotonergic	5	O
systems	5	O
and	5	O
cerebral	5	O
metabolic	9	B-Disease
abnormalities	9	I-Disease
.	9	O

Using	9	O
magnetic	0	O
resonance	5	O
imaging	5	O
(	9	O
MRI	5	O
)	9	O
and	5	O
new	5	O
computational	5	O
brain	5	O
-	7	O
mapping	5	O
techniques	5	O
,	9	O
we	5	O
determined	9	O
the	5	O
pattern	9	O
of	5	O
structural	9	O
brain	5	O
alterations	9	O
associated	9	O
with	5	O
chronic	5	O
MA	2	B-Chemical
abuse	5	O
in	5	O
human	3	O
subjects	5	O
and	5	O
related	9	O
these	5	O
deficits	5	O
to	5	O
cognitive	5	B-Disease
impairment	5	I-Disease
.	9	O

We	9	O
used	5	O
high	9	O
-	7	O
resolution	5	O
MRI	5	O
and	5	O
surface	9	O
-	7	O
based	5	O
computational	5	O
image	5	O
analyses	9	O
to	5	O
map	5	O
regional	5	O
abnormalities	9	B-Disease
in	5	I-Disease
the	5	I-Disease
cortex	5	I-Disease
,	9	I-Disease
hippocampus	9	I-Disease
,	9	I-Disease
white	9	I-Disease
matter	5	I-Disease
,	9	I-Disease
and	5	I-Disease
ventricles	5	I-Disease
in	5	O
22	7	O
human	3	O
subjects	5	O
who	5	O
used	5	O
MA	2	B-Chemical
and	5	O
21	7	O
age	5	O
-	7	O
matched	9	O
,	9	O
healthy	5	O
controls	9	O
.	9	O

Cortical	5	O
maps	5	O
revealed	9	O
severe	5	O
gray	9	O
-	7	O
matter	5	O
deficits	5	O
in	5	O
the	5	O
cingulate	5	O
,	9	O
limbic	5	O
,	9	O
and	5	O
paralimbic	5	O
cortices	5	O
of	5	O
MA	2	B-Chemical
abusers	5	O
(	9	O
averaging	5	O
11	7	O
.	9	O
3	9	O
%	9	O
below	9	O
control	9	O
;	9	O
p	7	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

On	5	O
average	5	O
,	9	O
MA	2	B-Chemical
abusers	5	O
had	9	O
7	9	O
.	9	O
8	9	O
%	9	O
smaller	5	O
hippocampal	3	O
volumes	5	O
than	5	O
control	9	O
subjects	5	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
01	7	O
;	9	O
left	5	O
,	9	O
p	7	O
=	7	O
0	7	O
.	9	O
01	7	O
;	9	O
right	5	O
,	9	O
p	7	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
and	5	O
significant	9	O
white	9	O
-	7	O
matter	5	O
hypertrophy	9	B-Disease
(	9	O
7	9	O
.	9	O
0	7	O
%	9	O
;	9	O
p	7	O
<	0	O
0	7	O
.	9	O
01	7	O
)	9	O
.	9	O

Hippocampal	3	O
deficits	5	O
were	9	O
mapped	9	O
and	5	O
correlated	9	O
with	5	O
memory	5	O
performance	5	O
on	5	O
a	5	O
word	5	O
-	7	O
recall	5	O
test	5	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

MRI	5	O
-	7	O
based	5	O
maps	5	O
suggest	9	O
that	5	O
chronic	5	O
methamphetamine	5	B-Chemical
abuse	5	O
causes	9	O
a	5	O
selective	9	O
pattern	9	O
of	5	O
cerebral	5	O
deterioration	5	O
that	5	O
contributes	9	O
to	5	O
impaired	9	B-Disease
memory	5	I-Disease
performance	5	I-Disease
.	9	O

MA	2	B-Chemical
may	5	O
selectively	3	O
damage	9	O
the	5	O
medial	5	O
temporal	5	O
lobe	5	O
and	5	O
,	9	O
consistent	9	O
with	5	O
metabolic	9	O
studies	9	O
,	9	O
the	5	O
cingulate	5	O
-	7	O
limbic	5	O
cortex	5	O
,	9	O
inducing	3	O
neuroadaptation	5	O
,	9	O
neuropil	5	O
reduction	9	O
,	9	O
or	5	O
cell	3	O
death	9	O
.	9	O

Prominent	5	O
white	9	O
-	7	O
matter	5	O
hypertrophy	9	B-Disease
may	5	O
result	9	O
from	9	O
altered	9	O
myelination	3	O
and	5	O
adaptive	5	O
glial	3	O
changes	9	O
,	9	O
including	9	O
gliosis	3	B-Disease
secondary	9	O
to	5	O
neuronal	3	B-Disease
damage	9	I-Disease
.	9	O

These	5	O
brain	5	O
substrates	0	O
may	5	O
help	5	O
account	5	O
for	5	O
the	5	O
symptoms	5	O
of	5	O
MA	2	B-Chemical
abuse	5	O
,	9	O
providing	9	O
therapeutic	5	O
targets	9	O
for	5	O
drug	5	O
-	7	O
induced	3	O
brain	5	B-Disease
injury	9	I-Disease
.	9	O

Disruption	9	O
of	5	O
hepatic	9	O
lipid	0	O
homeostasis	9	O
in	5	O
mice	3	O
after	9	O
amiodarone	0	B-Chemical
treatment	9	O
is	5	O
associated	9	O
with	5	O
peroxisome	3	O
proliferator	3	O
-	7	O
activated	3	O
receptor	3	O
-	7	O
alpha	9	O
target	9	O
gene	1	O
activation	3	O
.	9	O

Amiodarone	7	B-Chemical
,	9	O
an	5	O
efficacious	5	O
and	5	O
widely	5	O
used	5	O
antiarrhythmic	5	O
agent	9	O
,	9	O
has	9	O
been	9	O
reported	9	O
to	5	O
cause	5	O
hepatotoxicity	9	B-Disease
in	5	O
some	5	O
patients	5	O
.	9	O

To	9	O
gain	5	O
insight	5	O
into	9	O
the	5	O
mechanism	9	O
of	5	O
this	5	O
unwanted	5	O
effect	9	O
,	9	O
mice	3	O
were	9	O
administered	9	O
various	9	O
doses	0	O
of	5	O
amiodarone	0	B-Chemical
and	5	O
examined	9	O
for	5	O
changes	9	O
in	5	O
hepatic	9	O
histology	9	O
and	5	O
gene	1	O
regulation	9	O
.	9	O

Amiodarone	7	B-Chemical
induced	3	O
hepatomegaly	5	B-Disease
,	9	O
hepatocyte	3	O
microvesicular	3	O
lipid	0	O
accumulation	9	O
,	9	O
and	5	O
a	5	O
significant	9	O
decrease	9	O
in	5	O
serum	9	O
triglycerides	9	B-Chemical
and	5	O
glucose	0	B-Chemical
.	9	O

Northern	4	O
blot	3	O
analysis	9	O
of	5	O
hepatic	9	O
RNA	9	O
revealed	9	O
a	5	O
dose	9	O
-	7	O
dependent	9	O
increase	9	O
in	5	O
the	5	O
expression	3	O
of	5	O
a	5	O
number	9	O
of	5	O
genes	1	O
critical	9	O
for	5	O
fatty	0	B-Chemical
acid	0	I-Chemical
oxidation	0	O
,	9	O
lipoprotein	9	O
assembly	9	O
,	9	O
and	5	O
lipid	0	O
transport	9	O
.	9	O

Many	5	O
of	5	O
these	5	O
genes	1	O
are	5	O
regulated	3	O
by	9	O
the	5	O
peroxisome	3	O
proliferator	3	O
-	7	O
activated	3	O
receptor	3	O
-	7	O
alpha	9	O
(	9	O
PPARalpha	3	O
)	9	O
,	9	O
a	5	O
ligand	3	O
-	7	O
activated	3	O
nuclear	3	O
hormone	9	O
receptor	3	O
transcription	1	O
factor	9	O
.	9	O

The	5	O
absence	3	O
of	5	O
induction	3	O
of	5	O
these	5	O
genes	1	O
as	5	O
well	9	O
as	5	O
hepatomegaly	5	B-Disease
in	5	O
PPARalpha	3	O
knockout	3	O
[	9	O
PPARalpha	3	O
-	7	O
/	9	O
-	7	O
]	9	O
mice	3	O
indicated	9	O
that	5	O
the	5	O
effects	9	O
of	5	O
amiodarone	0	B-Chemical
were	9	O
dependent	9	O
upon	9	O
the	5	O
presence	9	O
of	5	O
a	5	O
functional	9	O
PPARalpha	3	O
gene	1	O
.	9	O

Compared	9	O
to	5	O
wild	1	O
-	7	O
type	9	O
mice	3	O
,	9	O
treatment	9	O
of	5	O
PPARalpha	3	O
-	7	O
/	9	O
-	7	O
mice	3	O
with	5	O
amiodarone	0	B-Chemical
resulted	9	O
in	5	O
an	5	O
increased	9	O
rate	9	O
and	5	O
extent	9	O
of	5	O
total	9	O
body	5	O
weight	9	B-Disease
loss	9	I-Disease
.	9	O

The	5	O
inability	9	O
of	5	O
amiodarone	0	B-Chemical
to	5	O
directly	9	O
activate	3	O
either	9	O
human	3	O
or	5	O
mouse	3	O
PPARalpha	3	O
transiently	3	O
expressed	3	O
in	5	O
human	3	O
HepG2	3	O
hepatoma	3	B-Disease
cells	3	O
indicates	9	O
that	5	O
the	5	O
effects	9	O
of	5	O
amiodarone	0	B-Chemical
on	5	O
the	5	O
function	9	O
of	5	O
this	5	O
receptor	3	O
were	9	O
indirect	5	O
.	9	O

Based	9	O
upon	9	O
these	5	O
results	9	O
,	9	O
we	5	O
conclude	9	O
that	5	O
amiodarone	0	B-Chemical
disrupts	9	O
hepatic	9	O
lipid	0	O
homeostasis	9	O
and	5	O
that	5	O
the	5	O
increased	9	O
expression	3	O
of	5	O
PPARalpha	3	O
target	9	O
genes	1	O
is	5	O
secondary	9	O
to	5	O
this	5	O
toxic	0	O
effect	9	O
.	9	O

These	5	O
results	9	O
provide	5	O
important	9	O
new	5	O
mechanistic	9	O
information	5	O
regarding	5	O
the	5	O
hepatotoxic	0	B-Disease
effects	9	O
of	5	O
amiodarone	0	B-Chemical
and	5	O
indicate	9	O
that	5	O
PPARalpha	3	O
protects	3	O
against	9	O
amiodarone	0	B-Chemical
-	7	O
induced	3	O
hepatotoxicity	9	B-Disease
.	9	O

Safety	5	O
and	5	O
compliance	5	O
with	5	O
once	5	O
-	7	O
daily	5	O
niacin	0	B-Chemical
extended	5	I-Chemical
-	7	I-Chemical
release	9	I-Chemical
/	9	I-Chemical
lovastatin	0	I-Chemical
as	5	O
initial	9	O
therapy	5	O
in	5	O
the	5	O
Impact	5	O
of	5	O
Medical	2	O
Subspecialty	2	O
on	5	O
Patient	5	O
Compliance	5	O
to	5	O
Treatment	9	O
(	9	O
IMPACT	5	O
)	9	O
study	9	O
.	9	O

Niacin	0	B-Chemical
extended	5	I-Chemical
-	7	I-Chemical
release	9	I-Chemical
/	9	I-Chemical
lovastatin	0	I-Chemical
is	5	O
a	5	O
new	5	O
combination	9	O
product	9	O
approved	2	O
for	5	O
treatment	9	O
of	5	O
primary	9	O
hypercholesterolemia	9	B-Disease
and	5	O
mixed	9	O
dyslipidemia	5	B-Disease
.	9	O

This	5	O
open	5	O
-	7	O
labeled	3	O
,	9	O
multicenter	5	O
study	9	O
evaluated	9	O
the	5	O
safety	5	O
of	5	O
bedtime	5	O
niacin	0	B-Chemical
extended	5	I-Chemical
-	7	I-Chemical
release	9	I-Chemical
/	9	I-Chemical
lovastatin	0	I-Chemical
when	5	O
dosed	0	O
as	5	O
initial	9	O
therapy	5	O
and	5	O
patient	5	O
compliance	5	O
to	5	O
treatment	9	O
in	5	O
various	9	O
clinical	5	O
practice	5	O
settings	5	O
.	9	O

A	9	O
total	9	O
of	5	O
4	9	O
,	9	O
499	7	O
patients	5	O
with	5	O
dyslipidemia	5	B-Disease
requiring	5	O
drug	5	O
intervention	5	O
was	9	O
enrolled	5	O
at	9	O
1	9	O
,	9	O
081	7	O
sites	9	O
.	9	O

Patients	5	O
were	9	O
treated	3	O
with	5	O
1	9	O
tablet	0	O
(	9	O
500	0	O
mg	0	O
of	5	O
niacin	0	B-Chemical
extended	5	O
-	7	O
release	9	O
/	9	O
20	9	O
mg	0	O
of	5	O
lovastatin	0	B-Chemical
)	9	O
once	5	O
nightly	5	O
for	5	O
4	9	O
weeks	9	O
and	5	O
then	9	O
2	9	O
tablets	0	O
for	5	O
8	9	O
weeks	9	O
.	9	O

Patients	5	O
also	9	O
received	9	O
dietary	5	O
counseling	5	O
,	9	O
educational	5	O
materials	5	O
,	9	O
and	5	O
reminders	5	O
to	5	O
call	5	O
a	5	O
toll	5	O
-	7	O
free	9	O
number	9	O
that	5	O
provided	9	O
further	9	O
education	5	O
about	5	O
dyslipidemia	5	B-Disease
and	5	O
niacin	0	B-Chemical
extended	5	I-Chemical
-	7	I-Chemical
release	9	I-Chemical
/	9	I-Chemical
lovastatin	0	I-Chemical
.	9	O

Primary	9	O
end	9	O
points	5	O
were	9	O
study	9	O
compliance	5	O
,	9	O
increases	9	O
in	5	O
liver	9	O
transaminases	9	O
to	5	O
>	0	O
3	9	O
times	5	O
the	5	O
upper	9	O
limit	5	O
of	5	O
normal	9	O
,	9	O
and	5	O
clinical	5	O
myopathy	9	B-Disease
.	9	O

Final	9	O
study	9	O
status	9	O
was	9	O
available	5	O
for	5	O
4	9	O
,	9	O
217	7	O
patients	5	O
(	9	O
94	7	O
%	9	O
)	9	O
.	9	O

Compliance	5	O
to	5	O
niacin	0	B-Chemical
extended	5	I-Chemical
-	7	I-Chemical
release	9	I-Chemical
/	9	I-Chemical
lovastatin	0	I-Chemical
was	9	O
77	7	O
%	9	O
,	9	O
with	5	O
3	9	O
,	9	O
245	7	O
patients	5	O
completing	5	O
the	5	O
study	9	O
.	9	O

Patients	5	O
in	5	O
the	5	O
southeast	4	O
and	5	O
those	5	O
enrolled	5	O
by	9	O
endocrinologists	5	O
had	9	O
the	5	O
lowest	9	O
compliance	5	O
and	5	O
highest	9	O
adverse	5	O
event	5	O
rates	5	O
.	9	O

Flushing	5	B-Disease
was	9	O
the	5	O
most	9	O
common	5	O
adverse	5	O
event	5	O
,	9	O
reported	9	O
by	9	O
18	7	O
%	9	O
of	5	O
patients	5	O
and	5	O
leading	9	O
to	5	O
discontinuation	5	O
by	9	O
6	9	O
%	9	O
.	9	O

Incidence	9	O
of	5	O
increased	9	O
aspartate	1	B-Chemical
aminotransferase	7	O
and	5	O
/	9	O
or	5	O
alanine	1	B-Chemical
aminotransferase	7	O
>	0	O
3	9	O
times	5	O
the	5	O
upper	9	O
limit	5	O
of	5	O
normal	9	O
was	9	O
<	0	O
0	7	O
.	9	O
3	9	O
%	9	O
.	9	O

An	5	O
increase	9	O
of	5	O
creatine	0	B-Chemical
phosphokinase	0	O
to	5	O
>	0	O
5	9	O
times	5	O
the	5	O
upper	9	O
limit	5	O
of	5	O
normal	9	O
occurred	9	O
in	5	O
0	7	O
.	9	O
24	9	O
%	9	O
of	5	O
patients	5	O
,	9	O
and	5	O
no	9	O
cases	5	O
of	5	O
drug	5	O
-	7	O
induced	3	O
myopathy	9	B-Disease
were	9	O
observed	9	O
.	9	O

Niacin	0	B-Chemical
extended	5	I-Chemical
-	7	I-Chemical
release	9	I-Chemical
/	9	I-Chemical
lovastatin	0	I-Chemical
1	9	O
,	9	O
000	9	O
/	9	O
40	9	O
mg	0	O
,	9	O
dosed	0	O
as	5	O
initial	9	O
therapy	5	O
,	9	O
was	9	O
associated	9	O
with	5	O
good	5	O
compliance	5	O
and	5	O
safety	5	O
and	5	O
had	9	O
very	5	O
low	9	O
incidences	5	O
of	5	O
increased	9	O
liver	9	O
and	5	O
muscle	9	O
enzymes	1	O
.	9	O

Protective	9	O
effect	9	O
of	5	O
Terminalia	4	B-Chemical
chebula	4	I-Chemical
against	9	O
experimental	5	O
myocardial	9	B-Disease
injury	9	I-Disease
induced	3	O
by	9	O
isoproterenol	0	B-Chemical
.	9	O

Cardioprotective	0	O
effect	9	O
of	5	O
ethanolic	0	B-Chemical
extract	0	I-Chemical
of	5	I-Chemical
Terminalia	4	I-Chemical
chebula	4	I-Chemical
fruits	4	I-Chemical
(	9	O
500	0	O
mg	0	O
/	9	O
kg	0	O
body	5	O
wt	3	O
)	9	O
was	9	O
examined	9	O
in	5	O
isoproterenol	0	B-Chemical
(	9	O
200	0	O
mg	0	O
/	9	O
kg	0	O
body	5	O
wt	3	O
)	9	O
induced	3	O
myocardial	9	B-Disease
damage	9	I-Disease
in	5	O
rats	9	O
.	9	O

In	9	O
isoproterenol	0	B-Chemical
administered	9	O
rats	9	O
,	9	O
the	5	O
level	9	O
of	5	O
lipid	0	O
peroxides	0	B-Chemical
increased	9	O
significantly	9	O
in	5	O
the	5	O
serum	9	O
and	5	O
heart	5	O
.	9	O

A	9	O
significant	9	O
decrease	9	O
was	9	O
observed	9	O
in	5	O
the	5	O
activity	9	O
of	5	O
the	5	O
myocardial	9	O
marker	3	O
enzymes	1	O
with	5	O
a	5	O
concomitant	9	O
increase	9	O
in	5	O
their	5	O
activity	9	O
in	5	O
serum	9	O
.	9	O

Histopathological	9	O
examination	5	O
was	9	O
carried	9	O
out	9	O
to	5	O
confirm	9	O
the	5	O
myocardial	9	O
necrosis	9	B-Disease
.	9	O

T	3	B-Chemical
.	9	I-Chemical
chebula	4	I-Chemical
extract	0	I-Chemical
pretreatment	0	O
was	9	O
found	9	O
to	5	O
ameliorate	9	O
the	5	O
effect	9	O
of	5	O
isoproterenol	0	B-Chemical
on	5	O
lipid	0	O
peroxide	0	B-Chemical
formation	9	O
and	5	O
retained	9	O
the	5	O
activities	9	O
of	5	O
the	5	O
diagnostic	5	O
marker	3	O
enzymes	1	O
.	9	O

A	9	O
case	5	O
of	5	O
postoperative	5	O
anxiety	5	B-Disease
due	5	O
to	5	O
low	9	O
dose	9	O
droperidol	0	B-Chemical
used	5	O
with	5	O
patient	5	O
-	7	O
controlled	5	O
analgesia	5	O
.	9	O

A	9	O
multiparous	5	O
woman	5	O
in	5	O
good	5	O
psychological	5	O
health	5	O
underwent	5	O
urgent	5	O
caesarean	5	O
section	5	O
in	5	O
labour	5	O
.	9	O

Postoperatively	5	O
,	9	O
she	5	O
was	9	O
given	5	O
a	5	O
patient	5	O
-	7	O
controlled	5	O
analgesia	5	O
device	5	O
delivering	5	O
boluses	5	O
of	5	O
diamorphine	5	B-Chemical
0	7	O
.	9	O
5	9	O
mg	0	O
and	5	O
droperidol	0	B-Chemical
0	7	O
.	9	O
025	7	O
mg	0	O
.	9	O

Whilst	5	O
using	9	O
the	5	O
device	5	O
she	5	O
gradually	9	O
became	9	O
anxious	5	O
,	9	O
the	5	O
feeling	5	O
worsening	5	O
after	9	O
each	5	O
bolus	0	O
.	9	O

The	5	O
diagnosis	5	O
of	5	O
droperidol	0	B-Chemical
-	7	O
induced	3	O
psychological	5	B-Disease
disturbance	5	I-Disease
was	9	O
not	5	O
made	5	O
straight	5	O
away	5	O
although	9	O
on	5	O
subsequent	9	O
close	5	O
questioning	5	O
the	5	O
patient	5	O
gave	9	O
a	5	O
very	5	O
clear	9	O
history	5	O
.	9	O

After	9	O
she	5	O
had	9	O
received	9	O
a	5	O
total	9	O
of	5	O
only	9	O
0	7	O
.	9	O
9	7	O
mg	0	O
droperidol	0	B-Chemical
,	9	O
a	5	O
syringe	0	O
containing	0	O
diamorphine	5	B-Chemical
only	9	O
was	9	O
substituted	0	O
and	5	O
her	5	O
unease	5	O
resolved	9	O
completely	9	O
.	9	O

We	9	O
feel	5	O
that	5	O
,	9	O
although	9	O
the	5	O
dramatic	9	O
extrapyramidal	5	O
side	5	O
effects	9	O
of	5	O
dopaminergic	5	O
antiemetics	5	O
are	5	O
well	9	O
known	9	O
,	9	O
more	5	O
subtle	5	O
manifestations	5	O
may	5	O
easily	5	O
be	5	O
overlooked	5	O
.	9	O

Accurate	5	O
patient	5	O
history	5	O
contributes	9	O
to	5	O
differentiating	9	O
diabetes	5	B-Disease
insipidus	5	I-Disease
:	9	O
a	5	O
case	5	O
study	9	O
.	9	O

This	5	O
case	5	O
study	9	O
highlights	5	O
the	5	O
important	9	O
contribution	9	O
of	5	O
nursing	5	O
in	5	O
obtaining	5	O
an	5	O
accurate	5	O
health	5	O
history	5	O
.	9	O

The	5	O
case	5	O
discussed	5	O
herein	9	O
initially	9	O
appeared	9	O
to	5	O
be	5	O
neurogenic	5	B-Disease
diabetes	5	I-Disease
insipidus	5	I-Disease
(	9	O
DI	9	B-Disease
)	9	O
secondary	9	O
to	5	O
a	5	O
traumatic	5	B-Disease
brain	5	I-Disease
injury	9	I-Disease
.	9	O

The	5	O
nursing	5	O
staff	5	O
,	9	O
by	9	O
reviewing	5	O
the	5	O
patient	5	O
'	9	O
s	9	O
health	5	O
history	5	O
with	5	O
his	5	O
family	9	O
,	9	O
discovered	9	O
a	5	O
history	5	O
of	5	O
polydipsia	5	B-Disease
and	5	O
long	5	O
-	7	O
standing	5	O
lithium	0	B-Chemical
use	5	O
.	9	O

Lithium	0	B-Chemical
is	5	O
implicated	9	O
in	5	O
drug	5	O
-	7	O
induced	3	O
nephrogenic	5	B-Disease
DI	9	I-Disease
,	9	O
and	5	O
because	5	O
the	5	O
patient	5	O
had	9	O
not	5	O
received	9	O
lithium	0	B-Chemical
since	9	O
being	5	O
admitted	5	O
to	5	O
the	5	O
hospital	5	O
,	9	O
his	5	O
treatment	9	O
changed	9	O
to	5	O
focus	5	O
on	5	O
nephrogenic	5	B-Disease
DI	9	I-Disease
.	9	O

By	5	O
combining	5	O
information	5	O
from	9	O
the	5	O
patient	5	O
history	5	O
,	9	O
the	5	O
physical	5	O
examination	5	O
,	9	O
and	5	O
radiologic	5	O
and	5	O
laboratory	9	O
studies	9	O
,	9	O
the	5	O
critical	9	O
care	5	O
team	5	O
demonstrated	9	O
that	5	O
the	5	O
patient	5	O
had	9	O
been	9	O
self	5	O
-	7	O
treating	5	O
his	5	O
lithium	0	B-Chemical
-	7	O
induced	3	O
nephrogenic	5	B-Disease
DI	9	I-Disease
and	5	O
developed	5	O
neurogenic	5	B-Disease
DI	9	I-Disease
secondary	9	O
to	5	O
brain	5	B-Disease
trauma	5	I-Disease
.	9	O

Thus	9	O
successful	5	O
treatment	9	O
required	9	O
that	5	O
nephrogenic	5	O
and	5	O
neurogenic	5	B-Disease
DI	9	I-Disease
be	5	O
treated	3	O
concomitantly	9	O
.	9	O

Factors	5	O
contributing	9	O
to	5	O
ribavirin	9	B-Chemical
-	7	O
induced	3	O
anemia	9	B-Disease
.	9	O

BACKGROUND	2	O
AND	2	O
AIM	9	O
:	9	O
Interferon	3	B-Chemical
and	5	O
ribavirin	9	B-Chemical
combination	9	O
therapy	5	O
for	5	O
chronic	5	B-Disease
hepatitis	9	I-Disease
C	9	I-Disease
produces	9	O
hemolytic	0	B-Disease
anemia	9	I-Disease
.	9	O

This	5	O
study	9	O
was	9	O
conducted	9	O
to	5	O
identify	9	O
the	5	O
factors	9	O
contributing	9	O
to	5	O
ribavirin	9	B-Chemical
-	7	O
induced	3	O
anemia	9	B-Disease
.	9	O

METHODS	2	O
:	9	O
Eighty	5	O
-	7	O
eight	9	O
patients	5	O
with	5	O
chronic	5	B-Disease
hepatitis	9	I-Disease
C	9	I-Disease
who	5	O
received	9	O
interferon	3	B-Chemical
-	7	I-Chemical
alpha	9	I-Chemical
-	7	I-Chemical
2b	9	I-Chemical
at	9	O
a	5	O
dose	9	O
of	5	O
6	9	O
MU	9	O
administered	9	O
intramuscularly	0	O
for	5	O
24	9	O
weeks	9	O
in	5	O
combination	9	O
with	5	O
ribavirin	9	B-Chemical
administered	9	O
orally	0	O
at	9	O
a	5	O
dose	9	O
of	5	O
600	0	O
mg	0	O
or	5	O
800	0	O
mg	0	O
participated	5	O
in	5	O
the	5	O
study	9	O
.	9	O

A	9	O
hemoglobin	0	O
concentration	0	O
of	5	O
<	0	O
10	9	O
g	0	O
/	9	O
dL	7	O
was	9	O
defined	5	O
as	5	O
ribavirin	9	B-Chemical
-	7	O
induced	3	O
anemia	9	B-Disease
.	9	O

RESULTS	9	O
:	9	O
Ribavirin	0	B-Chemical
-	7	O
induced	3	O
anemia	9	B-Disease
occurred	9	O
in	5	O
18	7	O
(	9	O
20	9	O
.	9	O
5	9	O
%	9	O
)	9	O
patients	5	O
during	5	O
treatment	9	O
.	9	O

A	9	O
2	9	O
g	0	O
/	9	O
dL	7	O
decrease	9	O
in	5	O
hemoglobin	0	O
concentrations	0	O
in	5	O
patients	5	O
with	5	O
anemia	9	B-Disease
was	9	O
observed	9	O
at	9	O
week	9	O
2	9	O
after	9	O
the	5	O
start	9	O
of	5	O
treatment	9	O
.	9	O

The	5	O
hemoglobin	0	O
concentration	0	O
in	5	O
patients	5	O
with	5	O
>	0	O
or	5	O
=	7	O
2	9	O
g	0	O
/	9	O
dL	7	O
decrease	9	O
at	9	O
week	9	O
2	9	O
was	9	O
observed	9	O
to	5	O
be	5	O
significantly	9	O
lower	9	O
even	5	O
after	9	O
week	9	O
2	9	O
than	5	O
in	5	O
patients	5	O
with	5	O
<	0	O
2	9	O
g	0	O
/	9	O
dL	7	O
decrease	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
01	7	O
)	9	O
.	9	O

A	9	O
significant	9	O
relationship	5	O
was	9	O
observed	9	O
between	5	O
the	5	O
rate	9	O
of	5	O
reduction	9	O
of	5	O
hemoglobin	0	O
concentrations	0	O
at	9	O
week	9	O
2	9	O
and	5	O
the	5	O
severity	5	O
of	5	O
anemia	9	B-Disease
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
01	7	O
)	9	O
.	9	O

Such	5	O
factors	9	O
as	5	O
sex	5	O
(	9	O
female	9	O
)	9	O
,	9	O
age	5	O
(	9	O
>	0	O
or	5	O
=	7	O
60	9	O
years	5	O
old	5	O
)	9	O
,	9	O
and	5	O
the	5	O
ribavirin	9	B-Chemical
dose	9	O
by	9	O
body	5	O
weight	9	O
(	9	O
12	9	O
mg	0	O
/	9	O
kg	0	O
or	5	O
more	5	O
)	9	O
were	9	O
significant	9	O
by	9	O
univariate	5	O
analysis	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Careful	5	O
administration	9	O
is	5	O
necessary	5	O
in	5	O
patients	5	O
>	0	O
or	5	O
=	7	O
60	9	O
years	5	O
old	5	O
,	9	O
in	5	O
female	9	O
patients	5	O
,	9	O
and	5	O
in	5	O
patients	5	O
receiving	9	O
a	5	O
ribavirin	9	B-Chemical
dose	9	O
of	5	O
12	9	O
mg	0	O
/	9	O
kg	0	O
or	5	O
more	5	O
.	9	O

Patients	5	O
who	5	O
experience	5	O
a	5	O
fall	5	O
in	5	O
hemoglobin	0	O
concentrations	0	O
of	5	O
2	9	O
g	0	O
/	9	O
dL	7	O
or	5	O
more	5	O
at	9	O
week	9	O
2	9	O
after	9	O
the	5	O
start	9	O
of	5	O
treatment	9	O
should	5	O
be	5	O
monitored	9	O
with	5	O
particular	5	O
care	5	O
.	9	O

Zidovudine	0	B-Chemical
-	7	O
induced	3	O
hepatitis	9	B-Disease
.	9	O

A	9	O
case	5	O
of	5	O
acute	9	O
hepatitis	9	B-Disease
induced	3	O
by	9	O
zidovudine	5	B-Chemical
in	5	O
a	5	O
38	7	O
-	7	O
year	5	O
-	7	O
old	5	O
patient	5	O
with	5	O
AIDS	5	B-Disease
is	5	O
presented	5	O
.	9	O

The	5	O
mechanism	9	O
whereby	5	O
the	5	O
hepatitis	9	B-Disease
was	9	O
induced	3	O
is	5	O
not	5	O
known	9	O
.	9	O

However	9	O
,	9	O
the	5	O
patient	5	O
tolerated	9	O
well	9	O
an	5	O
alternative	5	O
reverse	9	O
transcriptase	9	O
inhibitor	3	O
,	9	O
2	9	B-Chemical
'	9	I-Chemical
3	9	I-Chemical
'	9	I-Chemical
dideoxyinosine	0	I-Chemical
.	9	O

Physicians	5	O
caring	5	O
for	5	O
patients	5	O
with	5	O
AIDS	5	B-Disease
should	5	O
be	5	O
aware	5	O
of	5	O
this	5	O
hitherto	9	O
rarely	5	O
reported	9	O
complication	5	O
.	9	O

Oxidative	9	O
damage	9	O
precedes	9	O
nitrative	3	O
damage	9	O
in	5	O
adriamycin	3	B-Chemical
-	7	O
induced	3	O
cardiac	5	O
mitochondrial	9	B-Disease
injury	9	I-Disease
.	9	O

The	5	O
purpose	5	O
of	5	O
the	5	O
present	9	O
study	9	O
was	9	O
to	5	O
determine	9	O
if	5	O
elevated	9	O
reactive	9	O
oxygen	0	B-Chemical
(	9	O
ROS	3	O
)	9	O
/	9	O
nitrogen	0	B-Chemical
species	4	O
(	9	O
RNS	3	O
)	9	O
reported	9	O
to	5	O
be	5	O
present	9	O
in	5	O
adriamycin	3	B-Chemical
(	9	O
ADR	9	B-Chemical
)	9	O
-	7	O
induced	3	O
cardiotoxicity	9	B-Disease
actually	5	O
resulted	9	O
in	5	O
cardiomyocyte	3	O
oxidative	9	O
/	9	O
nitrative	3	O
damage	9	O
,	9	O
and	5	O
to	5	O
quantitatively	9	O
determine	9	O
the	5	O
time	5	O
course	5	O
and	5	O
subcellular	3	O
localization	3	O
of	5	O
these	5	O
postulated	9	O
damage	9	O
products	9	O
using	9	O
an	5	O
in	5	O
vivo	3	O
approach	5	O
.	9	O

B6C3	3	O
mice	3	O
were	9	O
treated	3	O
with	5	O
a	5	O
single	9	O
dose	9	O
of	5	O
20	9	O
mg	0	O
/	9	O
kg	0	O
ADR	9	B-Chemical
.	9	O

Ultrastructural	9	O
damage	9	O
and	5	O
levels	3	O
of	5	O
4	9	B-Chemical
-	7	I-Chemical
hydroxy	0	I-Chemical
-	7	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
nonenal	0	I-Chemical
(	9	O
4HNE	0	B-Chemical
)	9	O
-	7	O
protein	1	O
adducts	0	O
and	5	O
3	9	B-Chemical
-	7	I-Chemical
nitrotyrosine	3	I-Chemical
(	9	O
3NT	3	B-Chemical
)	9	O
were	9	O
analyzed	9	O
.	9	O

Quantitative	9	O
ultrastructural	9	O
damage	9	O
using	9	O
computerized	5	O
image	5	O
techniques	5	O
showed	9	O
cardiomyocyte	3	O
injury	9	O
as	5	O
early	9	O
as	5	O
3	9	O
hours	9	O
,	9	O
with	5	O
mitochondria	3	O
being	5	O
the	5	O
most	9	O
extensively	9	O
and	5	O
progressively	9	O
injured	5	O
subcellular	3	O
organelle	9	O
.	9	O

Analysis	9	O
of	5	O
4HNE	0	B-Chemical
protein	1	O
adducts	0	O
by	9	O
immunogold	3	O
electron	0	O
microscopy	9	O
showed	9	O
appearance	9	O
of	5	O
4HNE	0	B-Chemical
protein	1	O
adducts	0	O
in	5	O
mitochondria	3	O
as	5	O
early	9	O
as	5	O
3	9	O
hours	9	O
,	9	O
with	5	O
a	5	O
peak	9	O
at	9	O
6	9	O
hours	9	O
and	5	O
subsequent	9	O
decline	9	O
at	9	O
24	9	O
hours	9	O
.	9	O

3NT	3	B-Chemical
levels	3	O
were	9	O
significantly	9	O
increased	9	O
in	5	O
all	5	O
subcellular	3	O
compartments	9	O
at	9	O
6	9	O
hours	9	O
and	5	O
subsequently	9	O
declined	9	O
at	9	O
24	9	O
hours	9	O
.	9	O

Our	9	O
data	5	O
showed	9	O
ADR	9	B-Chemical
induced	3	O
4HNE	0	B-Chemical
-	7	O
protein	1	O
adducts	0	O
in	5	O
mitochondria	3	O
at	9	O
the	5	O
same	9	O
time	5	O
point	5	O
as	5	O
when	5	O
mitochondrial	9	B-Disease
injury	9	I-Disease
initially	9	O
appeared	9	O
.	9	O

These	5	O
results	9	O
document	5	O
for	5	O
the	5	O
first	9	O
time	5	O
in	5	O
vivo	3	O
that	5	O
mitochondrial	9	B-Disease
oxidative	9	I-Disease
damage	9	I-Disease
precedes	9	O
nitrative	3	O
damage	9	O
.	9	O

The	5	O
progressive	5	O
nature	5	O
of	5	O
mitochondrial	9	B-Disease
injury	9	I-Disease
suggests	9	O
that	5	O
mitochondria	3	O
,	9	O
not	5	O
other	5	O
subcellular	3	O
organelles	9	O
,	9	O
are	5	O
the	5	O
major	9	O
site	9	O
of	5	O
intracellular	3	O
injury	9	O
.	9	O

Sotalol	7	B-Chemical
-	7	O
induced	3	O
coronary	5	B-Disease
spasm	5	I-Disease
in	5	O
a	5	O
patient	5	O
with	5	O
dilated	5	B-Disease
cardiomyopathy	5	I-Disease
associated	9	O
with	5	O
sustained	5	O
ventricular	5	B-Disease
tachycardia	5	I-Disease
.	9	O

A	9	O
54	7	O
-	7	O
year	5	O
-	7	O
old	5	O
man	5	O
with	5	O
severe	5	O
left	5	O
ventricular	5	B-Disease
dysfunction	9	I-Disease
due	5	O
to	5	O
dilated	5	B-Disease
cardiomyopathy	5	I-Disease
was	9	O
referred	5	O
to	5	O
our	5	O
hospital	5	O
for	5	O
symptomatic	5	O
incessant	5	O
sustained	5	O
ventricular	5	B-Disease
tachycardia	5	I-Disease
(	9	O
VT	9	B-Disease
)	9	O
.	9	O

After	9	O
the	5	O
administration	9	O
of	5	O
nifekalant	5	B-Chemical
hydrochloride	0	I-Chemical
,	9	O
sustained	5	O
VT	9	B-Disease
was	9	O
terminated	9	O
.	9	O

An	5	O
alternate	9	O
class	9	O
III	9	O
agent	9	O
,	9	O
sotalol	5	B-Chemical
,	9	O
was	9	O
also	9	O
effective	5	O
for	5	O
the	5	O
prevention	5	O
of	5	O
VT	9	B-Disease
.	9	O

However	9	O
,	9	O
one	5	O
month	5	O
after	9	O
switching	5	O
over	5	O
nifekalant	5	B-Chemical
to	5	O
sotalol	5	B-Chemical
,	9	O
a	5	O
short	5	O
duration	5	O
of	5	O
ST	9	O
elevation	9	O
was	9	O
documented	9	O
in	5	O
ECG	5	O
monitoring	5	O
at	9	O
almost	9	O
the	5	O
same	9	O
time	5	O
for	5	O
three	9	O
consecutive	5	O
days	9	O
.	9	O

ST	9	O
elevation	9	O
with	5	O
chest	5	O
discomfort	5	O
disappeared	9	O
since	9	O
he	5	O
began	5	O
taking	5	O
long	5	O
-	7	O
acting	9	O
diltiazem	0	B-Chemical
.	9	O

Coronary	5	B-Disease
vasospasm	5	I-Disease
may	5	O
be	5	O
induced	3	O
by	9	O
the	5	O
non	9	O
-	7	O
selective	9	O
beta	9	O
-	7	O
blocking	3	O
properties	9	O
of	5	O
sotalol	5	B-Chemical
.	9	O

Effects	9	O
of	5	O
the	5	O
antidepressant	5	O
trazodone	0	B-Chemical
,	9	O
a	5	O
5	9	B-Chemical
-	7	I-Chemical
HT	9	I-Chemical
2A	9	O
/	9	O
2C	9	O
receptor	3	O
antagonist	3	O
,	9	O
on	5	O
dopamine	5	B-Chemical
-	7	O
dependent	9	O
behaviors	5	O
in	5	O
rats	9	O
.	9	O

RATIONALE	2	O
:	9	O
5	9	B-Chemical
-	7	I-Chemical
Hydroxytryptamine	9	I-Chemical
,	9	O
via	9	O
stimulation	3	O
of	5	O
5	9	B-Chemical
-	7	I-Chemical
HT	9	I-Chemical
2C	9	O
receptors	3	O
,	9	O
exerts	9	O
a	5	O
tonic	5	O
inhibitory	3	O
influence	5	O
on	5	O
dopaminergic	5	O
neurotransmission	5	O
,	9	O
whereas	9	O
activation	3	O
of	5	O
5	9	B-Chemical
-	7	I-Chemical
HT	9	I-Chemical
2A	9	O
receptors	3	O
enhances	3	O
stimulated	3	O
DAergic	3	O
neurotransmission	5	O
.	9	O

The	5	O
antidepressant	5	O
trazodone	0	B-Chemical
is	5	O
a	5	O
5	9	B-Chemical
-	7	I-Chemical
HT	9	I-Chemical
2A	9	O
/	9	O
2C	9	O
receptor	3	O
antagonist	3	O
.	9	O

OBJECTIVES	2	O
:	9	O
To	9	O
evaluate	9	O
the	5	O
effect	9	O
of	5	O
trazodone	0	B-Chemical
treatment	9	O
on	5	O
behaviors	5	O
dependent	9	O
on	5	O
the	5	O
functional	9	O
status	9	O
of	5	O
the	5	O
nigrostriatal	3	O
DAergic	3	O
system	5	O
.	9	O

METHODS	2	O
:	9	O
The	5	O
effect	9	O
of	5	O
pretreatment	0	O
with	5	O
trazodone	0	B-Chemical
on	5	O
dexamphetamine	5	B-Chemical
-	7	O
and	5	O
apomorphine	0	B-Chemical
-	7	O
induced	3	O
oral	9	B-Disease
stereotypies	5	I-Disease
,	9	O
on	5	O
catalepsy	5	B-Disease
induced	3	O
by	9	O
haloperidol	5	B-Chemical
and	5	O
apomorphine	0	B-Chemical
(	9	O
0	7	O
.	9	O
05	7	O
mg	0	O
/	9	O
kg	0	O
,	9	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
,	9	O
on	5	O
ergometrine	0	B-Chemical
-	7	O
induced	3	O
wet	5	O
dog	5	O
shake	5	O
(	9	O
WDS	5	O
)	9	O
behavior	5	O
and	5	O
fluoxetine	0	B-Chemical
-	7	O
induced	3	O
penile	5	O
erections	5	O
was	9	O
studied	9	O
in	5	O
rats	9	O
.	9	O

We	9	O
also	9	O
investigated	9	O
whether	9	O
trazodone	0	B-Chemical
induces	3	O
catalepsy	5	B-Disease
in	5	O
rats	9	O
.	9	O

RESULTS	9	O
:	9	O
Trazodone	7	B-Chemical
at	9	O
2	9	O
.	9	O
5	9	O
-	7	O
20	9	O
mg	0	O
/	9	O
kg	0	O
i	9	O
.	9	O
p	7	O
.	9	O
did	9	O
not	5	O
induce	3	O
catalepsy	5	B-Disease
,	9	O
and	5	O
did	9	O
not	5	O
antagonize	3	O
apomorphine	0	B-Chemical
(	9	O
1	9	O
.	9	O
5	9	O
and	5	O
3	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
stereotypy	5	O
and	5	O
apomorphine	0	B-Chemical
(	9	O
0	7	O
.	9	O
05	7	O
mg	0	O
/	9	O
kg	0	O
)	9	O
-	7	O
induced	3	O
catalepsy	5	B-Disease
.	9	O

However	9	O
,	9	O
pretreatment	0	O
with	5	O
5	9	O
,	9	O
10	9	O
and	5	O
20	9	O
mg	0	O
/	9	O
kg	0	O
i	9	O
.	9	O
p	7	O
.	9	O
trazodone	0	B-Chemical
enhanced	3	O
dexamphetamine	5	B-Chemical
stereotypy	5	O
,	9	O
and	5	O
antagonized	3	O
haloperidol	5	B-Chemical
catalepsy	5	B-Disease
,	9	O
ergometrine	0	B-Chemical
-	7	O
induced	3	O
WDS	5	O
behavior	5	O
and	5	O
fluoxetine	0	B-Chemical
-	7	O
induced	3	O
penile	5	O
erections	5	O
.	9	O

Trazodone	7	B-Chemical
at	9	O
30	9	O
,	9	O
40	9	O
and	5	O
50	0	O
mg	0	O
/	9	O
kg	0	O
i	9	O
.	9	O
p	7	O
.	9	O
induced	3	O
catalepsy	5	B-Disease
and	5	O
antagonized	3	O
apomorphine	0	B-Chemical
and	5	O
dexamphetamine	5	B-Chemical
stereotypies	5	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Our	9	O
results	9	O
indicate	9	O
that	5	O
trazodone	0	B-Chemical
at	9	O
2	9	O
.	9	O
5	9	O
-	7	O
20	9	O
mg	0	O
/	9	O
kg	0	O
does	9	O
not	5	O
block	9	O
pre	9	O
-	7	O
and	5	O
postsynaptic	3	O
striatal	3	O
D2	9	O
DA	9	O
receptors	3	O
,	9	O
while	9	O
at	9	O
30	9	O
,	9	O
40	9	O
and	5	O
50	0	O
mg	0	O
/	9	O
kg	0	O
it	5	O
blocks	9	O
postsynaptic	3	O
striatal	3	O
D2	9	O
DA	9	O
receptors	3	O
.	9	O

Furthermore	9	O
,	9	O
at	9	O
5	9	O
,	9	O
10	9	O
and	5	O
20	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
trazodone	0	B-Chemical
blocks	9	O
5	9	B-Chemical
-	7	I-Chemical
HT	9	I-Chemical
2A	9	O
and	5	O
5	9	B-Chemical
-	7	I-Chemical
HT	9	I-Chemical
2C	9	O
receptors	3	O
.	9	O

We	9	O
suggest	9	O
that	5	O
trazodone	0	B-Chemical
(	9	O
5	9	O
,	9	O
10	9	O
and	5	O
20	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
,	9	O
by	9	O
blocking	3	O
the	5	O
5	9	B-Chemical
-	7	I-Chemical
HT	9	I-Chemical
2C	9	O
receptors	3	O
,	9	O
releases	9	O
the	5	O
nigrostriatal	3	O
DAergic	3	O
neurons	3	O
from	9	O
tonic	5	O
inhibition	3	O
caused	9	O
by	9	O
5	9	B-Chemical
-	7	I-Chemical
HT	9	I-Chemical
,	9	O
and	5	O
thereby	9	O
potentiates	3	O
dexamphetamine	5	B-Chemical
stereotypy	5	O
and	5	O
antagonizes	3	O
haloperidol	5	B-Chemical
catalepsy	5	B-Disease
.	9	O

Swallowing	5	B-Disease
abnormalities	9	I-Disease
and	5	O
dyskinesia	5	B-Disease
in	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
.	9	O

Gastrointestinal	9	B-Disease
abnormalities	9	I-Disease
in	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
(	9	O
PD	9	B-Disease
)	9	O
have	5	O
been	9	O
known	9	O
for	5	O
almost	9	O
two	5	O
centuries	5	O
,	9	O
but	9	O
many	5	O
aspects	5	O
concerning	5	O
their	5	O
pathophysiology	9	O
have	5	O
not	5	O
been	9	O
completely	9	O
clarified	9	O
.	9	O

The	5	O
aim	5	O
of	5	O
this	5	O
study	9	O
was	9	O
to	5	O
characterize	9	O
the	5	O
oropharyngeal	5	O
dynamics	5	O
in	5	O
PD	9	B-Disease
patients	5	O
with	5	O
and	5	O
without	9	O
levodopa	5	B-Chemical
-	7	O
induced	3	O
dyskinesia	5	B-Disease
.	9	O

Fifteen	9	O
dyskinetic	5	B-Disease
,	9	O
12	9	O
nondyskinetic	5	O
patients	5	O
,	9	O
and	5	O
a	5	O
control	9	O
group	9	O
were	9	O
included	5	O
.	9	O

Patients	5	O
were	9	O
asked	5	O
about	5	O
dysphagia	5	B-Disease
and	5	O
evaluated	9	O
with	5	O
the	5	O
Unified	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
Disease	2	I-Disease
Rating	5	O
Scale	5	O
Parts	9	O
II	9	O
and	5	O
III	9	O
and	5	O
the	5	O
Hoehn	5	O
and	5	O
Yahr	5	O
scale	5	O
.	9	O

Deglutition	5	O
was	9	O
assessed	9	O
using	9	O
modified	9	O
barium	0	B-Chemical
swallow	5	O
with	5	O
videofluoroscopy	5	O
.	9	O

Nondyskinetic	_	O
patients	5	O
,	9	O
but	9	O
not	5	O
the	5	O
dyskinetic	5	B-Disease
ones	5	O
,	9	O
showed	9	O
less	5	O
oropharyngeal	5	O
swallowing	5	O
efficiency	9	O
(	9	O
OPSE	5	O
)	9	O
for	5	O
liquid	0	O
food	5	O
than	5	O
controls	9	O
(	9	O
Dunnett	9	O
,	9	O
P	9	O
=	7	O
0	7	O
.	9	O
02	7	O
)	9	O
.	9	O

Dyskinetic	7	B-Disease
patients	5	O
tended	5	O
to	5	O
have	5	O
a	5	O
greater	5	O
OPSE	5	O
than	5	O
nondyskinetic	5	O
(	9	O
Dunnett	9	O
,	9	O
P	9	O
=	7	O
0	7	O
.	9	O
06	7	O
)	9	O
.	9	O

Patients	5	O
who	5	O
were	9	O
using	9	O
a	5	O
higher	9	O
dose	9	O
of	5	O
levodopa	5	B-Chemical
had	9	O
a	5	O
greater	5	O
OPSE	5	O
and	5	O
a	5	O
trend	9	O
toward	5	O
a	5	O
smaller	5	O
oral	9	O
transit	9	O
time	5	O
(	9	O
Pearson	5	O
'	9	O
s	9	O
correlation	9	O
,	9	O
P	9	O
=	7	O
0	7	O
.	9	O
01	7	O
and	5	O
0	7	O
.	9	O
08	7	O
,	9	O
respectively	9	O
)	9	O
.	9	O

Neither	9	O
the	5	O
report	5	O
of	5	O
dysphagia	5	B-Disease
nor	9	O
any	5	O
of	5	O
the	5	O
PD	9	B-Disease
severity	5	O
parameters	5	O
correlated	9	O
to	5	O
the	5	O
videofluoroscopic	5	O
variables	5	O
.	9	O

In	9	O
the	5	O
current	5	O
study	9	O
,	9	O
dyskinetic	5	B-Disease
patients	5	O
performed	9	O
better	5	O
in	5	O
swallowing	5	O
function	9	O
,	9	O
which	5	O
could	9	O
be	5	O
explained	5	O
on	5	O
the	5	O
basis	5	O
of	5	O
a	5	O
greater	5	O
levodopa	5	B-Chemical
dose	9	O
.	9	O

Our	9	O
results	9	O
suggest	9	O
a	5	O
role	9	O
for	5	O
levodopa	5	B-Chemical
in	5	O
the	5	O
oral	9	O
phase	5	O
of	5	O
deglutition	5	O
and	5	O
confirm	9	O
that	5	O
dysphagia	5	B-Disease
is	5	O
not	5	O
a	5	O
good	5	O
predictor	5	O
of	5	O
deglutition	5	O
alterations	9	O
in	5	O
PD	9	B-Disease
.	9	O

Inhibition	3	O
of	5	O
nuclear	3	O
factor	9	O
-	7	O
kappaB	3	O
activation	3	O
attenuates	3	O
tubulointerstitial	3	B-Disease
nephritis	9	I-Disease
induced	3	O
by	9	O
gentamicin	0	B-Chemical
.	9	O

BACKGROUND	2	O
:	9	O
Animals	9	O
treated	3	O
with	5	O
gentamicin	0	B-Chemical
can	5	O
show	9	O
residual	9	O
areas	5	O
of	5	O
interstitial	9	O
fibrosis	9	B-Disease
in	5	O
the	5	O
renal	9	O
cortex	5	O
.	9	O

This	5	O
study	9	O
investigated	9	O
the	5	O
expression	3	O
of	5	O
nuclear	3	O
factor	9	O
-	7	O
kappaB	3	O
(	9	O
NF	9	O
-	7	O
kappaB	3	O
)	9	O
,	9	O
mitogen	3	O
-	7	O
activated	3	O
protein	1	O
(	9	O
MAP	9	O
)	9	O
kinases	3	O
and	5	O
macrophages	3	O
in	5	O
the	5	O
renal	9	O
cortex	5	O
and	5	O
structural	9	O
and	5	O
functional	9	O
renal	9	O
changes	9	O
of	5	O
rats	9	O
treated	3	O
with	5	O
gentamicin	0	B-Chemical
or	5	O
gentamicin	0	B-Chemical
+	9	O
pyrrolidine	0	B-Chemical
dithiocarbamate	0	I-Chemical
(	9	O
PDTC	3	B-Chemical
)	9	O
,	9	O
an	5	O
NF	9	O
-	7	O
kappaB	3	O
inhibitor	3	O
.	9	O

METHODS	2	O
:	9	O
38	7	O
female	9	O
Wistar	9	O
rats	9	O
were	9	O
injected	3	O
with	5	O
gentamicin	0	B-Chemical
,	9	O
40	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
twice	9	O
a	5	O
day	9	O
for	5	O
9	7	O
days	9	O
,	9	O
38	7	O
with	5	O
gentamicin	0	B-Chemical
+	9	O
PDTC	3	B-Chemical
,	9	O
and	5	O
28	7	O
with	5	O
0	7	O
.	9	O
15	9	O
M	9	O
NaCl	0	B-Chemical
solution	0	O
.	9	O

The	5	O
animals	9	O
were	9	O
killed	9	O
5	9	O
and	5	O
30	9	O
days	9	O
after	9	O
these	5	O
injections	9	O
and	5	O
the	5	O
kidneys	9	O
were	9	O
removed	9	O
for	5	O
histological	9	O
and	5	O
immunohistochemical	3	O
studies	9	O
.	9	O

The	5	O
results	9	O
of	5	O
the	5	O
immunohistochemical	3	O
studies	9	O
were	9	O
scored	5	O
according	9	O
to	5	O
the	5	O
extent	9	O
of	5	O
staining	3	O
.	9	O

The	5	O
fractional	5	O
interstitial	9	O
area	5	O
was	9	O
determined	9	O
by	9	O
morphometry	5	O
.	9	O

RESULTS	9	O
:	9	O
Gentamicin	0	B-Chemical
-	7	O
treated	3	O
rats	9	O
presented	5	O
a	5	O
transitory	5	O
increase	9	O
in	5	O
plasma	9	O
creatinine	0	B-Chemical
levels	3	O
.	9	O

Increased	9	O
ED	5	O
-	7	O
1	9	O
,	9	O
MAP	9	O
kinases	3	O
and	5	O
NF	9	O
-	7	O
kappaB	3	O
staining	3	O
were	9	O
also	9	O
observed	9	O
in	5	O
the	5	O
renal	9	O
cortex	5	O
from	9	O
all	5	O
gentamicin	0	B-Chemical
-	7	O
treated	3	O
rats	9	O
compared	9	O
to	5	O
control	9	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

The	5	O
animals	9	O
killed	9	O
on	5	O
day	9	O
30	9	O
also	9	O
presented	5	O
fibrosis	9	B-Disease
in	5	O
the	5	O
renal	9	O
cortex	5	O
despite	9	O
the	5	O
recovery	9	O
of	5	O
renal	9	O
function	9	O
.	9	O

Treatment	9	O
with	5	O
PDTC	3	B-Chemical
reduced	9	O
the	5	O
functional	9	O
and	5	O
structural	9	O
changes	9	O
induced	3	O
by	9	O
gentamicin	0	B-Chemical
.	9	O

CONCLUSIONS	5	O
:	9	O
These	5	O
data	5	O
show	9	O
that	5	O
inhibition	3	O
of	5	O
NF	9	O
-	7	O
kappaB	3	O
activation	3	O
attenuates	3	O
tubulointerstitial	3	B-Disease
nephritis	9	I-Disease
induced	3	O
by	9	O
gentamicin	0	B-Chemical
.	9	O

Glucose	0	B-Chemical
metabolism	9	O
in	5	O
patients	5	O
with	5	O
schizophrenia	5	B-Disease
treated	3	O
with	5	O
atypical	5	O
antipsychotic	5	O
agents	5	O
:	9	O
a	5	O
frequently	5	O
sampled	5	O
intravenous	0	O
glucose	0	B-Chemical
tolerance	9	O
test	5	O
and	5	O
minimal	9	O
model	5	O
analysis	9	O
.	9	O

BACKGROUND	2	O
:	9	O
While	9	O
the	5	O
incidence	5	O
of	5	O
new	5	O
-	7	O
onset	5	O
diabetes	5	B-Disease
mellitus	9	I-Disease
may	5	O
be	5	O
increasing	9	O
in	5	O
patients	5	O
with	5	O
schizophrenia	5	B-Disease
treated	3	O
with	5	O
certain	5	O
atypical	5	O
antipsychotic	5	O
agents	5	O
,	9	O
it	5	O
remains	9	O
unclear	9	O
whether	9	O
atypical	5	O
agents	5	O
are	5	O
directly	9	O
affecting	9	O
glucose	0	B-Chemical
metabolism	9	O
or	5	O
simply	5	O
increasing	9	O
known	9	O
risk	5	O
factors	9	O
for	5	O
diabetes	5	B-Disease
.	9	O

OBJECTIVE	2	O
:	9	O
To	9	O
study	9	O
the	5	O
2	9	O
drugs	5	O
most	9	O
clearly	9	O
implicated	9	O
(	9	O
clozapine	5	B-Chemical
and	5	O
olanzapine	5	B-Chemical
)	9	O
and	5	O
risperidone	5	B-Chemical
using	9	O
a	5	O
frequently	5	O
sampled	5	O
intravenous	0	O
glucose	0	B-Chemical
tolerance	9	O
test	5	O
.	9	O

DESIGN	2	O
:	9	O
A	9	O
cross	5	O
-	7	O
sectional	5	O
design	5	O
in	5	O
stable	9	O
,	9	O
treated	3	O
patients	5	O
with	5	O
schizophrenia	5	B-Disease
evaluated	9	O
using	9	O
a	5	O
frequently	5	O
sampled	5	O
intravenous	0	O
glucose	0	B-Chemical
tolerance	9	O
test	5	O
and	5	O
the	5	O
Bergman	6	O
minimal	9	O
model	5	O
analysis	9	O
.	9	O

SETTING	2	O
:	9	O
Subjects	5	O
were	9	O
recruited	9	O
from	9	O
an	5	O
urban	5	O
community	5	O
mental	5	O
health	5	O
clinic	5	O
and	5	O
were	9	O
studied	9	O
at	9	O
a	5	O
general	5	O
clinical	5	O
research	5	O
center	5	O
.	9	O

Patients	5	O
Fifty	9	O
subjects	5	O
signed	5	O
informed	5	O
consent	5	O
and	5	O
41	7	O
underwent	5	O
the	5	O
frequently	5	O
sampled	5	O
intravenous	0	O
glucose	0	B-Chemical
tolerance	9	O
test	5	O
.	9	O

Thirty	9	O
-	7	O
six	9	O
nonobese	9	O
subjects	5	O
with	5	O
schizophrenia	5	B-Disease
or	5	O
schizoaffective	5	B-Disease
disorder	5	I-Disease
,	9	O
matched	9	O
by	9	O
body	5	O
mass	9	O
index	5	O
and	5	O
treated	3	O
with	5	O
either	9	O
clozapine	5	B-Chemical
,	9	O
olanzapine	5	B-Chemical
,	9	O
or	5	O
risperidone	5	B-Chemical
,	9	O
were	9	O
included	5	O
in	5	O
the	5	O
analysis	9	O
.	9	O

MAIN	2	O
OUTCOME	2	O
MEASURES	2	O
:	9	O
Fasting	7	O
plasma	9	O
glucose	0	B-Chemical
and	5	O
fasting	9	O
serum	9	O
insulin	3	O
levels	3	O
,	9	O
insulin	3	B-Disease
sensitivity	9	I-Disease
index	5	O
,	9	O
homeostasis	9	O
model	5	O
assessment	5	O
of	5	O
insulin	3	B-Disease
resistance	9	I-Disease
,	9	O
and	5	O
glucose	0	B-Chemical
effectiveness	5	O
.	9	O

RESULTS	9	O
:	9	O
The	5	O
mean	5	O
+	9	O
/	9	O
-	7	O
SD	7	O
duration	5	O
of	5	O
treatment	9	O
with	5	O
the	5	O
identified	9	O
atypical	5	O
antipsychotic	5	O
agent	9	O
was	9	O
68	7	O
.	9	O
3	9	O
+	9	O
/	9	O
-	7	O
28	7	O
.	9	O
9	7	O
months	5	O
(	9	O
clozapine	5	B-Chemical
)	9	O
,	9	O
29	7	O
.	9	O
5	9	O
+	9	O
/	9	O
-	7	O
17	7	O
.	9	O
5	9	O
months	5	O
(	9	O
olanzapine	5	B-Chemical
)	9	O
,	9	O
and	5	O
40	9	O
.	9	O
9	7	O
+	9	O
/	9	O
-	7	O
33	7	O
.	9	O
7	9	O
(	9	O
risperidone	5	B-Chemical
)	9	O
.	9	O

Fasting	7	O
serum	9	O
insulin	3	O
concentrations	0	O
differed	9	O
among	5	O
groups	9	O
(	9	O
F	7	O
(	9	O
33	7	O
)	9	O
=	7	O
3	9	O
.	9	O
35	9	O
;	9	O
P	9	O
=	7	O
.	9	O
047	7	O
)	9	O
(	9	O
clozapine	5	B-Chemical
>	0	O
olanzapine	5	B-Chemical
>	0	O
risperidone	5	B-Chemical
)	9	O
with	5	O
significant	9	O
differences	9	O
between	5	O
clozapine	5	B-Chemical
and	5	O
risperidone	5	B-Chemical
(	9	O
t	5	O
(	9	O
33	7	O
)	9	O
=	7	O
2	9	O
.	9	O
32	7	O
;	9	O
P	9	O
=	7	O
.	9	O
03	7	O
)	9	O
and	5	O
olanzapine	5	B-Chemical
and	5	O
risperidone	5	B-Chemical
(	9	O
t	5	O
(	9	O
33	7	O
)	9	O
=	7	O
2	9	O
.	9	O
15	9	O
;	9	O
P	9	O
=	7	O
.	9	O
04	7	O
)	9	O
.	9	O

There	5	O
was	9	O
a	5	O
significant	9	O
difference	9	O
in	5	O
insulin	3	B-Disease
sensitivity	9	I-Disease
index	5	O
among	5	O
groups	9	O
(	9	O
F	7	O
(	9	O
33	7	O
)	9	O
=	7	O
10	9	O
.	9	O
66	7	O
;	9	O
P	9	O
<	0	O
.	9	O
001	9	O
)	9	O
(	9	O
clozapine	5	B-Chemical
<	0	O
olanzapine	5	B-Chemical
<	0	O
risperidone	5	B-Chemical
)	9	O
,	9	O
with	5	O
subjects	5	O
who	5	O
received	9	O
clozapine	5	B-Chemical
and	5	O
olanzapine	5	B-Chemical
exhibiting	9	O
significant	9	O
insulin	3	B-Disease
resistance	9	I-Disease
compared	9	O
with	5	O
subjects	5	O
who	5	O
were	9	O
treated	3	O
with	5	O
risperidone	5	B-Chemical
(	9	O
clozapine	5	B-Chemical
vs	7	O
risperidone	5	B-Chemical
,	9	O
t	5	O
(	9	O
33	7	O
)	9	O
=	7	O
-	7	O
4	9	O
.	9	O
29	7	O
;	9	O
P	9	O
<	0	O
.	9	O
001	9	O
;	9	O
olanzapine	5	B-Chemical
vs	7	O
risperidone	5	B-Chemical
,	9	O
t	5	O
(	9	O
33	7	O
)	9	O
=	7	O
-	7	O
3	9	O
.	9	O
62	7	O
;	9	O
P	9	O
=	7	O
.	9	O
001	9	O
[	9	O
P	9	O
<	0	O
.	9	O
001	9	O
]	9	O
)	9	O
.	9	O

The	5	O
homeostasis	9	O
model	5	O
assessment	5	O
of	5	O
insulin	3	B-Disease
resistance	9	I-Disease
also	9	O
differed	9	O
significantly	9	O
among	5	O
groups	9	O
(	9	O
F	7	O
(	9	O
33	7	O
)	9	O
=	7	O
4	9	O
.	9	O
92	7	O
;	9	O
P	9	O
=	7	O
.	9	O
01	7	O
)	9	O
(	9	O
clozapine	5	B-Chemical
>	0	O
olanzapine	5	B-Chemical
>	0	O
risperidone	5	B-Chemical
)	9	O
(	9	O
clozapine	5	B-Chemical
vs	7	O
risperidone	5	B-Chemical
,	9	O
t	5	O
(	9	O
33	7	O
)	9	O
=	7	O
2	9	O
.	9	O
94	7	O
;	9	O
P	9	O
=	7	O
.	9	O
006	7	O
;	9	O
olanzapine	5	B-Chemical
vs	7	O
risperidone	5	B-Chemical
,	9	O
t	5	O
(	9	O
33	7	O
)	9	O
=	7	O
2	9	O
.	9	O
42	7	O
;	9	O
P	9	O
=	7	O
.	9	O
02	7	O
)	9	O
.	9	O

There	5	O
was	9	O
a	5	O
significant	9	O
difference	9	O
among	5	O
groups	9	O
in	5	O
glucose	0	B-Chemical
effectiveness	5	O
(	9	O
F	7	O
(	9	O
30	9	O
)	9	O
=	7	O
4	9	O
.	9	O
18	7	O
;	9	O
P	9	O
=	7	O
.	9	O
02	7	O
)	9	O
(	9	O
clozapine	5	B-Chemical
<	0	O
olanzapine	5	B-Chemical
<	0	O
risperidone	5	B-Chemical
)	9	O
with	5	O
significant	9	O
differences	9	O
between	5	O
clozapine	5	B-Chemical
and	5	O
risperidone	5	B-Chemical
(	9	O
t	5	O
(	9	O
30	9	O
)	9	O
=	7	O
-	7	O
2	9	O
.	9	O
59	7	O
;	9	O
P	9	O
=	7	O
.	9	O
02	7	O
)	9	O
and	5	O
olanzapine	5	B-Chemical
and	5	O
risperidone	5	B-Chemical
(	9	O
t	5	O
(	9	O
30	9	O
)	9	O
=	7	O
-	7	O
2	9	O
.	9	O
34	7	O
,	9	O
P	9	O
=	7	O
.	9	O
03	7	O
)	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Both	9	O
nonobese	9	O
clozapine	5	B-Chemical
-	7	O
and	5	O
olanzapine	5	B-Chemical
-	7	O
treated	3	O
groups	9	O
displayed	9	O
significant	9	O
insulin	3	B-Disease
resistance	9	I-Disease
and	5	O
impairment	5	O
of	5	O
glucose	0	B-Chemical
effectiveness	5	O
compared	9	O
with	5	O
risperidone	5	B-Chemical
-	7	O
treated	3	O
subjects	5	O
.	9	O

Patients	5	O
taking	5	O
clozapine	5	B-Chemical
and	5	O
olanzapine	5	B-Chemical
must	5	O
be	5	O
examined	9	O
for	5	O
insulin	3	B-Disease
resistance	9	I-Disease
and	5	O
its	9	O
consequences	5	O
.	9	O

Thoracic	5	B-Disease
hematomyelia	5	I-Disease
secondary	9	O
to	5	O
coumadin	5	B-Chemical
anticoagulant	9	O
therapy	5	O
:	9	O
a	5	O
case	5	O
report	5	O
.	9	O

A	9	O
case	5	O
of	5	O
thoracic	5	B-Disease
hematomyelia	5	I-Disease
secondary	9	O
to	5	O
anticoagulant	9	O
therapy	5	O
is	5	O
presented	5	O
.	9	O

Clinical	5	O
features	5	O
,	9	O
similar	9	O
to	5	O
2	9	O
other	5	O
previously	9	O
reported	9	O
cases	5	O
,	9	O
are	5	O
discussed	5	O
.	9	O

A	9	O
high	9	O
index	5	O
of	5	O
suspicion	5	O
may	5	O
lead	5	O
to	5	O
a	5	O
quick	5	O
diagnostic	5	O
procedure	5	O
and	5	O
successful	5	O
decompressive	5	O
surgery	5	O
.	9	O

Mania	5	B-Disease
associated	9	O
with	5	O
fluoxetine	0	B-Chemical
treatment	9	O
in	5	O
adolescents	5	O
.	9	O

Fluoxetine	0	B-Chemical
,	9	O
a	5	O
selective	9	O
serotonin	9	B-Chemical
reuptake	0	O
inhibitor	3	O
,	9	O
is	5	O
gaining	5	O
increased	9	O
acceptance	5	O
in	5	O
the	5	O
treatment	9	O
of	5	O
adolescent	5	O
depression	5	B-Disease
.	9	O

Generally	5	O
safe	5	O
and	5	O
well	9	O
tolerated	9	O
by	9	O
adults	5	O
,	9	O
fluoxetine	0	B-Chemical
has	9	O
been	9	O
reported	9	O
to	5	O
induce	3	O
mania	5	B-Disease
.	9	O

The	5	O
cases	5	O
of	5	O
five	9	O
depressed	5	B-Disease
adolescents	5	O
,	9	O
14	7	O
-	7	O
16	9	O
years	5	O
of	5	O
age	5	O
,	9	O
who	5	O
developed	5	O
mania	5	B-Disease
during	5	O
pharmacotherapy	5	O
with	5	O
fluoxetine	0	B-Chemical
,	9	O
are	5	O
reported	9	O
here	5	O
.	9	O

Apparent	9	O
risk	5	O
factors	9	O
for	5	O
the	5	O
development	9	O
of	5	O
mania	5	B-Disease
or	5	O
hypomania	5	B-Disease
during	5	O
fluoxetine	0	B-Chemical
pharmacotherapy	5	O
in	5	O
this	5	O
population	5	O
were	9	O
the	5	O
combination	9	O
of	5	O
attention	5	B-Disease
-	7	I-Disease
deficit	5	I-Disease
hyperactivity	5	I-Disease
disorder	5	I-Disease
and	5	O
affective	5	O
instability	5	O
;	9	O
major	9	O
depression	5	B-Disease
with	5	O
psychotic	5	B-Disease
features	5	O
;	9	O
a	5	O
family	9	O
history	5	O
of	5	O
affective	5	B-Disease
disorder	5	I-Disease
,	9	O
especially	5	O
bipolar	5	B-Disease
disorder	5	I-Disease
;	9	O
and	5	O
a	5	O
diagnosis	5	O
of	5	O
bipolar	5	B-Disease
disorder	5	I-Disease
.	9	O

Further	9	O
study	9	O
is	5	O
needed	5	O
to	5	O
determine	9	O
the	5	O
optimal	5	O
dosage	9	O
and	5	O
to	5	O
identify	9	O
risk	5	O
factors	9	O
that	5	O
increase	9	O
individual	5	O
vulnerability	5	O
to	5	O
fluoxetine	0	B-Chemical
induced	3	O
mania	5	B-Disease
in	5	O
adolescents	5	O
.	9	O

Acute	5	B-Disease
renal	9	I-Disease
insufficiency	9	I-Disease
after	9	O
high	9	O
-	7	O
dose	9	O
melphalan	0	B-Chemical
in	5	O
patients	5	O
with	5	O
primary	9	B-Disease
systemic	9	I-Disease
amyloidosis	5	I-Disease
during	5	O
stem	3	O
cell	3	O
transplantation	9	O
.	9	O

BACKGROUND	2	O
:	9	O
Patients	5	O
with	5	O
primary	9	B-Disease
systemic	9	I-Disease
amyloidosis	5	I-Disease
(	9	O
AL	2	B-Disease
)	9	O
have	5	O
a	5	O
poor	5	O
prognosis	5	O
.	9	O

Median	7	O
survival	9	O
time	5	O
from	9	O
standard	5	O
treatments	9	O
is	5	O
only	9	O
17	7	O
months	5	O
.	9	O

High	9	O
-	7	O
dose	9	O
intravenous	0	O
melphalan	0	B-Chemical
followed	9	O
by	9	O
peripheral	9	O
blood	9	O
stem	3	O
cell	3	O
transplant	9	O
(	9	O
PBSCT	5	O
)	9	O
appears	9	O
to	5	O
be	5	O
the	5	O
most	9	O
promising	5	O
therapy	5	O
,	9	O
but	9	O
treatment	9	O
mortality	5	O
can	5	O
be	5	O
high	9	O
.	9	O

The	5	O
authors	5	O
have	5	O
noted	9	O
the	5	O
development	9	O
of	5	O
acute	9	B-Disease
renal	9	I-Disease
insufficiency	9	I-Disease
immediately	9	O
after	9	O
melphalan	0	B-Chemical
conditioning	5	O
.	9	O

This	5	O
study	9	O
was	9	O
undertaken	5	O
to	5	O
further	9	O
examine	9	O
its	9	O
risk	5	O
factors	9	O
and	5	O
impact	5	O
on	5	O
posttransplant	5	O
mortality	5	O
.	9	O

METHODS	2	O
:	9	O
Consecutive	5	O
AL	2	B-Disease
patients	5	O
who	5	O
underwent	5	O
PBSCT	5	O
were	9	O
studied	9	O
retrospectively	5	O
.	9	O

Acute	5	B-Disease
renal	9	I-Disease
insufficiency	9	I-Disease
(	9	O
ARI	5	B-Disease
)	9	O
after	9	O
high	9	O
-	7	O
dose	9	O
melphalan	0	B-Chemical
was	9	O
defined	5	O
by	9	O
a	5	O
minimum	5	O
increase	9	O
of	5	O
0	7	O
.	9	O
5	9	O
mg	0	O
/	9	O
dL	7	O
(	9	O
44	7	O
micromol	0	O
/	9	O
L	0	O
)	9	O
in	5	O
the	5	O
serum	9	O
creatinine	0	B-Chemical
level	9	O
that	5	O
is	5	O
greater	5	O
than	5	O
50	0	O
%	9	O
of	5	O
baseline	5	O
immediately	9	O
after	9	O
conditioning	5	O
.	9	O

Urine	9	O
sediment	0	O
score	5	O
was	9	O
the	5	O
sum	5	O
of	5	O
the	5	O
individual	5	O
types	9	O
of	5	O
sediment	0	O
identified	9	O
on	5	O
urine	9	O
microscopy	9	O
.	9	O

RESULTS	9	O
:	9	O
Of	9	O
the	5	O
80	9	O
patients	5	O
studied	9	O
,	9	O
ARI	5	B-Disease
developed	5	O
in	5	O
18	7	O
.	9	O
8	9	O
%	9	O
of	5	O
the	5	O
patients	5	O
after	9	O
high	9	O
-	7	O
dose	9	O
melphalan	0	B-Chemical
.	9	O

Univariate	5	O
analysis	9	O
identified	9	O
age	5	O
,	9	O
hypoalbuminemia	5	B-Disease
,	9	O
heavy	9	O
proteinuria	9	B-Disease
,	9	O
diuretic	5	O
use	5	O
,	9	O
and	5	O
urine	9	O
sediment	0	O
score	5	O
(	9	O
>	0	O
3	9	O
)	9	O
as	5	O
risk	5	O
factors	9	O
.	9	O

Age	7	O
and	5	O
urine	9	O
sediment	0	O
score	5	O
remained	9	O
independently	9	O
significant	9	O
risk	5	O
factors	9	O
in	5	O
the	5	O
multivariate	5	O
analysis	9	O
.	9	O

Patients	5	O
who	5	O
had	9	O
ARI	5	B-Disease
after	9	O
high	9	O
-	7	O
dose	9	O
melphalan	0	B-Chemical
underwent	5	O
dialysis	5	O
more	5	O
often	5	O
(	9	O
P	9	O
=	7	O
0	7	O
.	9	O
007	2	O
)	9	O
,	9	O
and	5	O
had	9	O
a	5	O
worse	5	O
1	9	O
-	7	O
year	5	O
survival	9	O
(	9	O
P	9	O
=	7	O
0	7	O
.	9	O
03	7	O
)	9	O
.	9	O

CONCLUSION	5	O
:	9	O
The	5	O
timing	5	O
of	5	O
renal	9	B-Disease
injury	9	I-Disease
strongly	9	O
suggests	9	O
melphalan	0	B-Chemical
as	5	O
the	5	O
causative	9	O
agent	9	O
.	9	O

Ongoing	5	O
tubular	9	B-Disease
injury	9	I-Disease
may	5	O
be	5	O
a	5	O
prerequisite	9	O
for	5	O
renal	9	B-Disease
injury	9	I-Disease
by	9	O
melphalan	0	B-Chemical
as	5	O
evidenced	9	O
by	9	O
the	5	O
active	9	O
urinary	9	O
sediment	0	O
.	9	O

Development	2	O
of	5	O
ARI	5	B-Disease
adversely	5	O
affected	9	O
the	5	O
outcome	5	O
after	9	O
PBSCT	5	O
.	9	O

Effective	5	O
preventive	5	O
measures	5	O
may	5	O
help	5	O
decrease	9	O
the	5	O
treatment	9	O
mortality	5	O
of	5	O
PBSCT	5	O
in	5	O
AL	2	B-Disease
patients	5	O
.	9	O

Focal	9	O
cerebral	5	B-Disease
ischemia	9	I-Disease
in	5	O
rats	9	O
:	9	O
effect	9	O
of	5	O
phenylephrine	0	B-Chemical
-	7	O
induced	3	O
hypertension	5	B-Disease
during	5	O
reperfusion	9	O
.	9	O

After	9	O
180	9	O
min	0	O
of	5	O
temporary	5	O
middle	9	B-Disease
cerebral	5	I-Disease
artery	5	I-Disease
occlusion	5	I-Disease
in	5	O
spontaneously	5	O
hypertensive	5	B-Disease
rats	9	O
,	9	O
the	5	O
effect	9	O
of	5	O
phenylephrine	0	B-Chemical
-	7	O
induced	3	O
hypertension	5	B-Disease
on	5	O
ischemic	9	B-Disease
brain	5	I-Disease
injury	9	I-Disease
and	5	O
blood	9	O
-	7	O
brain	5	O
barrier	5	O
permeability	0	O
was	9	O
determined	9	O
.	9	O

Blood	9	O
pressure	5	O
was	9	O
manipulated	5	O
by	9	O
one	5	O
of	5	O
the	5	O
following	9	O
schedules	5	O
during	5	O
120	9	O
min	0	O
of	5	O
reperfusion	9	O
:	9	O
Control	9	O
,	9	O
normotensive	9	O
reperfusion	9	O
;	9	O
90	9	O
/	9	O
hypertension	5	B-Disease
(	9	O
90	9	O
/	9	O
HTN	9	B-Disease
)	9	O
,	9	O
blood	9	O
pressure	5	O
was	9	O
increased	9	O
by	9	O
35	9	O
mm	9	O
Hg	0	O
during	5	O
the	5	O
initial	9	O
90	9	O
min	0	O
of	5	O
reperfusion	9	O
only	9	O
;	9	O
15	9	O
/	9	O
hypertension	5	B-Disease
(	9	O
15	9	O
/	9	O
HTN	9	B-Disease
)	9	O
,	9	O
normotensive	9	O
reperfusion	9	O
for	5	O
30	9	O
min	0	O
followed	9	O
by	9	O
15	9	O
min	0	O
of	5	O
hypertension	5	B-Disease
and	5	O
75	9	O
min	0	O
of	5	O
normotension	5	O
.	9	O

Part	9	O
A	9	O
,	9	O
for	5	O
eight	9	O
rats	9	O
in	5	O
each	5	O
group	9	O
brain	5	B-Disease
injury	9	I-Disease
was	9	O
evaluated	9	O
by	9	O
staining	3	O
tissue	9	O
using	9	O
2	9	B-Chemical
,	9	I-Chemical
3	9	I-Chemical
,	9	I-Chemical
5	9	I-Chemical
-	7	I-Chemical
triphenyltetrazolium	0	I-Chemical
chloride	0	I-Chemical
and	5	O
edema	5	B-Disease
was	9	O
evaluated	9	O
by	9	O
microgravimetry	9	O
.	9	O

Part	9	O
B	9	O
,	9	O
for	5	O
eight	9	O
different	9	O
rats	9	O
in	5	O
each	5	O
group	9	O
blood	9	O
-	7	O
brain	5	O
barrier	5	O
permeability	0	O
was	9	O
evaluated	9	O
by	9	O
measuring	9	O
the	5	O
amount	9	O
and	5	O
extent	9	O
of	5	O
extravasation	3	O
of	5	O
Evans	6	O
Blue	0	O
dye	0	O
.	9	O

Brain	9	B-Disease
injury	9	I-Disease
(	9	O
percentage	9	O
of	5	O
the	5	O
ischemic	9	B-Disease
hemisphere	5	I-Disease
)	9	O
was	9	O
less	5	O
in	5	O
the	5	O
15	9	O
/	9	O
HTN	9	B-Disease
group	9	O
(	9	O
16	9	O
+	9	O
/	9	O
-	7	O
6	9	O
,	9	O
mean	5	O
+	9	O
/	9	O
-	7	O
SD	7	O
)	9	O
versus	9	O
the	5	O
90	9	O
/	9	O
HTN	9	B-Disease
group	9	O
(	9	O
30	9	O
+	9	O
/	9	O
-	7	O
6	9	O
)	9	O
,	9	O
which	5	O
was	9	O
in	5	O
turn	9	O
less	5	O
than	5	O
the	5	O
control	9	O
group	9	O
(	9	O
42	7	O
+	9	O
/	9	O
-	7	O
5	9	O
)	9	O
.	9	O

Specific	9	O
gravity	5	O
was	9	O
greater	5	O
in	5	O
the	5	O
15	9	O
/	9	O
HTN	9	B-Disease
group	9	O
(	9	O
1	9	O
.	9	O
043	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
002	7	O
)	9	O
versus	9	O
the	5	O
90	9	O
/	9	O
HTN	9	B-Disease
(	9	O
1	9	O
.	9	O
036	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
003	2	O
)	9	O
and	5	O
control	9	O
(	9	O
1	9	O
.	9	O
037	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
003	2	O
)	9	O
groups	9	O
.	9	O

Evans	6	B-Chemical
Blue	0	I-Chemical
(	9	O
mug	5	O
g	0	O
-	7	O
1	9	O
of	5	O
brain	5	O
tissue	9	O
)	9	O
was	9	O
greater	5	O
in	5	O
the	5	O
90	9	O
/	9	O
HTN	9	B-Disease
group	9	O
(	9	O
24	9	O
.	9	O
4	9	O
+	9	O
/	9	O
-	7	O
6	9	O
.	9	O
0	7	O
)	9	O
versus	9	O
the	5	O
control	9	O
group	9	O
(	9	O
12	9	O
.	9	O
3	9	O
+	9	O
/	9	O
-	7	O
4	9	O
.	9	O
1	9	O
)	9	O
,	9	O
which	5	O
was	9	O
in	5	O
turn	9	O
greater	5	O
than	5	O
the	5	O
15	9	O
/	9	O
HTN	9	B-Disease
group	9	O
(	9	O
7	9	O
.	9	O
3	9	O
+	9	O
/	9	O
-	7	O
3	9	O
.	9	O
2	9	O
)	9	O
.	9	O

This	5	O
study	9	O
supports	9	O
a	5	O
hypothesis	9	O
that	5	O
during	5	O
reperfusion	9	O
,	9	O
a	5	O
short	5	O
interval	5	O
of	5	O
hypertension	5	B-Disease
decreases	9	O
brain	5	B-Disease
injury	9	I-Disease
and	5	O
edema	5	B-Disease
;	9	O
and	5	O
that	5	O
sustained	5	O
hypertension	5	B-Disease
increases	9	O
the	5	O
risk	5	O
of	5	O
vasogenic	5	B-Disease
edema	5	I-Disease
.	9	O

People	5	O
aged	9	O
over	5	O
75	9	O
in	5	O
atrial	5	B-Disease
fibrillation	5	I-Disease
on	5	O
warfarin	5	B-Chemical
:	9	O
the	5	O
rate	9	O
of	5	O
major	9	O
hemorrhage	5	B-Disease
and	5	O
stroke	5	B-Disease
in	5	O
more	5	O
than	5	O
500	0	O
patient	5	O
-	7	O
years	5	O
of	5	O
follow	5	O
-	7	O
up	5	O
.	9	O

OBJECTIVES	2	O
:	9	O
To	9	O
determine	9	O
the	5	O
incidence	5	O
of	5	O
major	9	O
hemorrhage	5	B-Disease
and	5	O
stroke	5	B-Disease
in	5	O
people	5	O
aged	9	O
76	7	O
and	5	O
older	5	O
with	5	O
atrial	5	B-Disease
fibrillation	5	I-Disease
on	5	O
adjusted	9	O
-	7	O
dose	9	O
warfarin	5	B-Chemical
who	5	O
had	9	O
been	9	O
recently	9	O
been	9	O
admitted	5	O
to	5	O
hospital	5	O
.	9	O

DESIGN	2	O
:	9	O
A	9	O
retrospective	5	O
observational	5	O
cohort	9	O
study	9	O
.	9	O

SETTING	2	O
:	9	O
A	9	O
major	9	O
healthcare	5	O
network	5	O
involving	5	O
four	9	O
tertiary	9	O
hospitals	5	O
.	9	O

PARTICIPANTS	2	O
:	9	O
Two	9	O
hundred	5	O
thirty	5	O
-	7	O
five	9	O
patients	5	O
aged	9	O
76	7	O
and	5	O
older	5	O
admitted	5	O
to	5	O
a	5	O
major	9	O
healthcare	5	O
network	5	O
between	5	O
July	2	O
1	9	O
,	9	O
2001	2	O
,	9	O
and	5	O
June	2	O
30	9	O
,	9	O
2002	2	O
,	9	O
with	5	O
atrial	5	B-Disease
fibrillation	5	I-Disease
on	5	O
warfarin	5	B-Chemical
were	9	O
enrolled	5	O
.	9	O

MEASUREMENTS	2	O
:	9	O
Information	5	O
regarding	5	O
major	9	O
bleeding	5	B-Disease
episodes	5	O
,	9	O
strokes	5	B-Disease
,	9	O
and	5	O
warfarin	5	B-Chemical
use	5	O
was	9	O
obtained	9	O
from	9	O
patients	5	O
,	9	O
relatives	5	O
,	9	O
primary	9	O
physicians	5	O
,	9	O
and	5	O
medical	5	O
records	5	O
.	9	O

RESULTS	9	O
:	9	O
Two	9	O
hundred	5	O
twenty	5	O
-	7	O
eight	9	O
patients	5	O
(	9	O
42	7	O
%	9	O
men	5	O
)	9	O
with	5	O
a	5	O
mean	5	O
age	5	O
of	5	O
81	7	O
.	9	O
1	9	O
(	9	O
range	9	O
76	7	O
-	7	O
94	7	O
)	9	O
were	9	O
included	5	O
in	5	O
the	5	O
analysis	9	O
.	9	O

Total	7	O
follow	5	O
-	7	O
up	5	O
on	5	O
warfarin	5	B-Chemical
was	9	O
530	9	O
years	5	O
(	9	O
mean	5	O
28	7	O
months	5	O
)	9	O
.	9	O

There	5	O
were	9	O
53	7	O
major	9	O
hemorrhages	5	B-Disease
,	9	O
for	5	O
an	5	O
annual	5	O
rate	9	O
of	5	O
10	9	O
.	9	O
0	7	O
%	9	O
,	9	O
including	9	O
24	9	O
(	9	O
45	9	O
.	9	O
3	9	O
%	9	O
)	9	O
life	5	O
-	7	O
threatening	5	O
and	5	O
five	9	O
(	9	O
9	7	O
.	9	O
4	9	O
%	9	O
)	9	O
fatal	5	O
bleeds	5	O
.	9	O

The	5	O
annual	5	O
stroke	5	B-Disease
rate	9	O
after	9	O
initiation	9	O
of	5	O
warfarin	5	B-Chemical
was	9	O
2	9	O
.	9	O
6	9	O
%	9	O
.	9	O

CONCLUSION	5	O
:	9	O
The	5	O
rate	9	O
of	5	O
major	9	O
hemorrhage	5	B-Disease
was	9	O
high	9	O
in	5	O
this	5	O
old	5	O
,	9	O
frail	5	O
group	9	O
,	9	O
but	9	O
excluding	9	O
fatalities	5	O
,	9	O
resulted	9	O
in	5	O
no	9	O
long	5	O
-	7	O
term	5	O
sequelae	5	O
,	9	O
and	5	O
the	5	O
stroke	5	B-Disease
rate	9	O
on	5	O
warfarin	5	B-Chemical
was	9	O
low	9	O
,	9	O
demonstrating	9	O
how	5	O
effective	5	O
warfarin	5	B-Chemical
treatment	9	O
is	5	O
.	9	O

Safety	5	O
of	5	O
celecoxib	3	B-Chemical
in	5	O
patients	5	O
with	5	O
adverse	5	O
skin	5	B-Disease
reactions	9	I-Disease
to	5	O
acetaminophen	0	B-Chemical
(	9	O
paracetamol	0	B-Chemical
)	9	O
and	5	O
nimesulide	0	B-Chemical
associated	9	O
or	5	O
not	5	O
with	5	O
common	5	O
non	9	O
-	7	O
steroidal	0	O
anti	3	O
-	7	O
inflammatory	3	O
drugs	5	O
.	9	O

BACKGROUND	2	O
:	9	O
Acetaminophen	0	B-Chemical
(	9	O
paracetamol	0	B-Chemical
-	7	O
-	7	O
P	9	B-Chemical
)	9	O
and	5	O
Nimesulide	0	B-Chemical
(	9	O
N	9	B-Chemical
)	9	O
are	5	O
widely	5	O
used	5	O
analgesic	5	O
-	7	O
antipyretic	0	O
/	9	O
anti	3	O
-	7	O
inflammatory	3	O
drugs	5	O
.	9	O

The	5	O
rate	9	O
of	5	O
adverse	5	O
hypersensitivity	9	B-Disease
reactions	9	O
to	5	O
these	5	O
agents	5	O
is	5	O
generally	5	O
low	9	O
.	9	O

On	5	O
the	5	O
contrary	9	O
non	9	O
-	7	O
steroidal	0	O
anti	3	O
-	7	O
inflammatory	3	O
drugs	5	O
(	9	O
NSAIDs	5	O
)	9	O
are	5	O
commonly	5	O
involved	9	O
in	5	O
such	5	O
reactions	9	O
.	9	O

Celecoxib	0	B-Chemical
(	9	O
CE	9	B-Chemical
)	9	O
is	5	O
a	5	O
novel	9	O
drug	5	O
,	9	O
with	5	O
high	9	O
selectivity	9	O
and	5	O
affinity	0	O
for	5	O
COX	9	O
-	7	O
2	9	O
enzyme	0	O
.	9	O

OBJECTIVE	2	O
:	9	O
We	9	O
evaluated	9	O
the	5	O
tolerability	5	O
of	5	O
CE	9	B-Chemical
in	5	O
a	5	O
group	9	O
of	5	O
patients	5	O
with	5	O
documented	9	O
history	5	O
of	5	O
adverse	5	O
cutaneous	5	B-Disease
reactions	9	I-Disease
to	5	O
P	9	B-Chemical
and	5	O
N	9	B-Chemical
associated	9	O
or	5	O
not	5	O
to	5	O
classic	5	O
NSAIDs	5	O
.	9	O

METHODS	2	O
:	9	O
We	9	O
studied	9	O
9	7	O
patients	5	O
with	5	O
hypersensitivity	9	B-Disease
to	5	O
P	9	B-Chemical
and	5	O
N	9	B-Chemical
with	5	O
or	5	O
without	9	O
associated	9	O
reactions	9	O
to	5	O
classic	5	O
NSAIDs	5	O
.	9	O

The	5	O
diagnosis	5	O
of	5	O
P	9	B-Chemical
and	5	O
N	9	B-Chemical
-	7	O
induced	3	O
skin	5	B-Disease
reactions	9	I-Disease
was	9	O
based	5	O
in	5	O
vivo	3	O
challenge	9	O
.	9	O

The	5	O
placebo	9	O
was	9	O
blindly	5	O
administered	9	O
at	9	O
the	5	O
beginning	5	O
of	5	O
each	5	O
challenge	9	O
.	9	O

After	9	O
three	9	O
days	9	O
,	9	O
a	5	O
cumulative	5	O
dosage	9	O
of	5	O
200	0	O
mg	0	O
of	5	O
CE	9	B-Chemical
in	5	O
refracted	5	O
doses	0	O
were	9	O
given	5	O
.	9	O

After	9	O
2	9	O
-	7	O
3	9	O
days	9	O
,	9	O
a	5	O
single	9	O
dose	9	O
of	5	O
200	0	O
mg	0	O
was	9	O
administered	9	O
.	9	O

All	9	O
patients	5	O
were	9	O
observed	9	O
for	5	O
6	9	O
hours	9	O
after	9	O
each	5	O
challenge	9	O
,	9	O
and	5	O
controlled	5	O
again	9	O
after	9	O
24	9	O
hours	9	O
to	5	O
exclude	9	O
delayed	9	O
reactions	9	O
.	9	O

The	5	O
challenge	9	O
was	9	O
considered	5	O
positive	9	O
if	5	O
one	5	O
or	5	O
more	5	O
of	5	O
the	5	O
following	9	O
appeared	9	O
:	9	O
erythema	5	B-Disease
,	9	O
rush	5	O
or	5	O
urticaria	5	B-Disease
-	7	O
angioedema	5	B-Disease
.	9	O

RESULTS	9	O
:	9	O
No	9	O
reaction	9	O
was	9	O
observed	9	O
with	5	O
placebo	9	O
and	5	O
eight	9	O
patients	5	O
(	9	O
88	7	O
.	9	O
8	9	O
%	9	O
)	9	O
tolerated	9	O
CE	9	B-Chemical
.	9	O

Only	9	O
one	5	O
patient	5	O
developed	5	O
a	5	O
moderate	9	O
angioedema	5	B-Disease
of	5	O
the	5	O
lips	5	O
.	9	O

CONCLUSION	5	O
:	9	O
Only	9	O
one	5	O
hypersensitivity	9	B-Disease
reaction	9	O
to	5	O
CE	9	B-Chemical
was	9	O
documented	9	O
among	5	O
9	7	O
P	9	B-Chemical
and	5	O
N	9	B-Chemical
-	7	O
highly	9	O
NSAIDs	5	O
intolerant	9	O
patients	5	O
.	9	O

Thus	9	O
,	9	O
we	5	O
conclude	9	O
that	5	O
CE	9	B-Chemical
is	5	O
a	5	O
reasonably	5	O
safe	5	O
alternative	5	O
to	5	O
be	5	O
used	5	O
in	5	O
subjects	5	O
who	5	O
do	5	O
not	5	O
tolerate	5	O
P	9	B-Chemical
and	5	O
N	9	B-Chemical
.	9	O

Case	5	O
-	7	O
control	9	O
study	9	O
of	5	O
regular	5	O
analgesic	5	O
and	5	O
nonsteroidal	5	O
anti	3	O
-	7	O
inflammatory	3	O
use	5	O
and	5	O
end	9	B-Disease
-	7	I-Disease
stage	9	I-Disease
renal	9	I-Disease
disease	5	I-Disease
.	9	O

BACKGROUND	2	O
:	9	O
Studies	9	O
on	5	O
the	5	O
association	9	O
between	5	O
the	5	O
long	5	O
-	7	O
term	5	O
use	5	O
of	5	O
aspirin	9	B-Chemical
and	5	O
other	5	O
analgesic	5	O
and	5	O
nonsteroidal	5	O
anti	3	O
-	7	O
inflammatory	3	O
drugs	5	O
(	9	O
NSAIDs	5	O
)	9	O
and	5	O
end	9	B-Disease
-	7	I-Disease
stage	9	I-Disease
renal	9	I-Disease
disease	5	I-Disease
(	9	O
ESRD	5	B-Disease
)	9	O
have	5	O
given	5	O
conflicting	5	O
results	9	O
.	9	O

In	9	O
order	5	O
to	5	O
examine	9	O
this	5	O
association	9	O
,	9	O
a	5	O
case	5	O
-	7	O
control	9	O
study	9	O
with	5	O
incident	5	O
cases	5	O
of	5	O
ESRD	5	B-Disease
was	9	O
carried	9	O
out	9	O
.	9	O

METHODS	2	O
:	9	O
The	5	O
cases	5	O
were	9	O
all	5	O
patients	5	O
entering	5	O
the	5	O
local	5	O
dialysis	5	O
program	5	O
because	5	O
of	5	O
ESRD	5	B-Disease
in	5	O
the	5	O
study	9	O
area	5	O
between	5	O
June	2	O
1	9	O
,	9	O
1995	2	O
and	5	O
November	2	O
30	9	O
,	9	O
1997	2	O
.	9	O

They	5	O
were	9	O
classified	5	O
according	9	O
to	5	O
the	5	O
underlying	5	O
disease	5	O
,	9	O
which	5	O
had	9	O
presumably	9	O
led	9	O
them	5	O
to	5	O
ESRD	5	B-Disease
.	9	O

Controls	9	O
were	9	O
patients	5	O
admitted	5	O
to	5	O
the	5	O
same	9	O
hospitals	5	O
from	9	O
where	5	O
the	5	O
cases	5	O
arose	9	O
,	9	O
also	9	O
matched	9	O
by	9	O
age	5	O
and	5	O
sex	5	O
.	9	O

Odds	5	O
ratios	9	O
were	9	O
calculated	5	O
using	9	O
a	5	O
conditional	9	O
logistic	5	O
model	5	O
,	9	O
including	9	O
potential	9	O
confounding	5	O
factors	9	O
,	9	O
both	9	O
for	5	O
the	5	O
whole	9	O
study	9	O
population	5	O
and	5	O
for	5	O
the	5	O
various	9	O
underlying	5	O
diseases	5	O
.	9	O

RESULTS	9	O
:	9	O
Five	9	O
hundred	5	O
and	5	O
eighty	5	O
-	7	O
three	9	O
cases	5	O
and	5	O
1190	7	O
controls	9	O
were	9	O
included	5	O
in	5	O
the	5	O
analysis	9	O
.	9	O

Long	9	O
-	7	O
term	5	O
use	5	O
of	5	O
any	5	O
analgesic	5	O
was	9	O
associated	9	O
with	5	O
an	5	O
overall	5	O
odds	5	O
ratio	9	O
of	5	O
1	9	O
.	9	O
22	7	O
(	9	O
95	7	O
%	9	O
CI	7	O
,	9	O
0	7	O
.	9	O
89	7	O
-	7	O
1	9	O
.	9	O
66	7	O
)	9	O
.	9	O

For	9	O
specific	9	O
groups	9	O
of	5	O
drugs	5	O
,	9	O
the	5	O
risks	5	O
were	9	O
1	9	O
.	9	O
56	7	O
(	9	O
1	9	O
.	9	O
05	7	O
-	7	O
2	9	O
.	9	O
30	9	O
)	9	O
for	5	O
aspirin	9	B-Chemical
,	9	O
1	9	O
.	9	O
03	7	O
(	9	O
0	7	O
.	9	O
60	9	O
-	7	O
1	9	O
.	9	O
76	7	O
)	9	O
for	5	O
pyrazolones	0	B-Chemical
,	9	O
0	7	O
.	9	O
80	9	O
(	9	O
0	7	O
.	9	O
39	7	O
-	7	O
1	9	O
.	9	O
63	7	O
)	9	O
for	5	O
paracetamol	0	B-Chemical
,	9	O
and	5	O
0	7	O
.	9	O
94	7	O
(	9	O
0	7	O
.	9	O
57	7	O
-	7	O
1	9	O
.	9	O
56	7	O
)	9	O
for	5	O
nonaspirin	5	O
NSAIDs	5	O
.	9	O

The	5	O
risk	5	O
of	5	O
ESRD	5	B-Disease
associated	9	O
with	5	O
aspirin	9	B-Chemical
was	9	O
related	9	O
to	5	O
the	5	O
cumulated	5	O
dose	9	O
and	5	O
duration	5	O
of	5	O
use	5	O
,	9	O
and	5	O
it	5	O
was	9	O
particularly	5	O
high	9	O
among	5	O
the	5	O
subset	9	O
of	5	O
patients	5	O
with	5	O
vascular	5	O
nephropathy	9	B-Disease
as	5	O
underlying	5	O
disease	5	O
[	9	O
2	9	O
.	9	O
35	9	O
(	9	O
1	9	O
.	9	O
17	7	O
-	7	O
4	9	O
.	9	O
72	9	O
)	9	O
]	9	O
.	9	O

CONCLUSION	5	O
:	9	O
Our	9	O
data	5	O
indicate	9	O
that	5	O
long	5	O
-	7	O
term	5	O
use	5	O
of	5	O
nonaspirin	5	O
analgesic	5	O
drugs	5	O
and	5	O
NSAIDs	5	O
is	5	O
not	5	O
associated	9	O
with	5	O
an	5	O
increased	9	O
risk	5	O
of	5	O
ESRD	5	B-Disease
.	9	O

However	9	O
,	9	O
the	5	O
chronic	5	O
use	5	O
of	5	O
aspirin	9	B-Chemical
may	5	O
increase	9	O
the	5	O
risk	5	O
of	5	O
ESRD	5	B-Disease
.	9	O

Two	9	O
cases	5	O
of	5	O
amisulpride	5	B-Chemical
overdose	0	B-Disease
:	9	O
a	5	O
cause	5	O
for	5	O
prolonged	9	B-Disease
QT	5	I-Disease
syndrome	5	I-Disease
.	9	O

Two	9	O
cases	5	O
of	5	O
deliberate	5	O
self	5	O
-	7	O
poisoning	5	B-Disease
with	5	O
5	9	O
g	0	O
and	5	O
3	9	O
.	9	O
6	9	O
g	0	O
of	5	O
amisulpride	5	B-Chemical
,	9	O
respectively	9	O
,	9	O
are	5	O
reported	9	O
.	9	O

In	9	O
both	9	O
cases	5	O
,	9	O
QT	5	B-Disease
prolongation	9	I-Disease
and	5	O
hypocalcaemia	5	B-Disease
were	9	O
noted	9	O
.	9	O

The	5	O
QT	5	B-Disease
prolongation	9	I-Disease
appeared	9	O
to	5	O
respond	5	O
to	5	O
administration	9	O
of	5	O
i	9	O
.	9	O
v	0	O
.	9	O
calcium	0	B-Chemical
gluconate	0	I-Chemical
.	9	O

Growth	9	O
-	7	O
associated	9	O
protein	1	O
43	7	O
expression	3	O
in	5	O
hippocampal	3	O
molecular	9	O
layer	9	O
of	5	O
chronic	5	O
epileptic	5	B-Disease
rats	9	O
treated	3	O
with	5	O
cycloheximide	3	B-Chemical
.	9	O

PURPOSE	2	O
:	9	O
GAP43	3	O
has	9	O
been	9	O
thought	5	O
to	5	O
be	5	O
linked	9	O
with	5	O
mossy	5	O
fiber	5	O
sprouting	3	O
(	9	O
MFS	9	O
)	9	O
in	5	O
various	9	O
experimental	5	O
models	5	O
of	5	O
epilepsy	5	B-Disease
.	9	O

To	9	O
investigate	9	O
how	5	O
GAP43	3	O
expression	3	O
(	9	O
GAP43	3	O
-	7	O
ir	9	O
)	9	O
correlates	9	O
with	5	O
MFS	9	O
,	9	O
we	5	O
assessed	9	O
the	5	O
intensity	5	O
(	9	O
densitometry	3	O
)	9	O
and	5	O
extension	9	O
(	9	O
width	5	O
)	9	O
of	5	O
GAP43	3	O
-	7	O
ir	9	O
in	5	O
the	5	O
inner	9	O
molecular	9	O
layer	9	O
of	5	O
the	5	O
dentate	3	O
gyrus	5	O
(	9	O
IML	5	O
)	9	O
of	5	O
rats	9	O
subject	5	O
to	5	O
status	9	B-Disease
epilepticus	5	I-Disease
induced	3	O
by	9	O
pilocarpine	0	B-Chemical
(	9	O
Pilo	6	B-Chemical
)	9	O
,	9	O
previously	9	O
injected	3	O
or	5	O
not	5	O
with	5	O
cycloheximide	3	B-Chemical
(	9	O
CHX	0	B-Chemical
)	9	O
,	9	O
which	5	O
has	9	O
been	9	O
shown	9	O
to	5	O
inhibit	3	O
MFS	9	O
.	9	O

METHODS	2	O
:	9	O
CHX	0	B-Chemical
was	9	O
injected	3	O
before	9	O
the	5	O
Pilo	6	B-Chemical
injection	9	O
in	5	O
adult	9	O
Wistar	9	O
rats	9	O
.	9	O

The	5	O
Pilo	6	B-Chemical
group	9	O
was	9	O
injected	3	O
with	5	O
the	5	O
same	9	O
drugs	5	O
,	9	O
except	9	O
for	5	O
CHX	0	B-Chemical
.	9	O

Animals	9	O
were	9	O
killed	9	O
between	5	O
30	9	O
and	5	O
60	9	O
days	9	O
later	9	O
,	9	O
and	5	O
brain	5	O
sections	9	O
were	9	O
processed	9	O
for	5	O
GAP43	3	O
immunohistochemistry	3	O
.	9	O

RESULTS	9	O
:	9	O
Densitometry	3	O
showed	9	O
no	9	O
significant	9	O
difference	9	O
regarding	5	O
GAP43	3	O
-	7	O
ir	9	O
in	5	O
the	5	O
IML	5	O
between	5	O
Pilo	6	B-Chemical
,	9	O
CHX	0	B-Chemical
+	9	O
Pilo	6	B-Chemical
,	9	O
and	5	O
control	9	O
groups	9	O
.	9	O

However	9	O
,	9	O
the	5	O
results	9	O
of	5	O
the	5	O
width	5	O
of	5	O
the	5	O
GAP43	3	O
-	7	O
ir	9	O
band	9	O
in	5	O
the	5	O
IML	5	O
showed	9	O
that	5	O
CHX	0	B-Chemical
+	9	O
Pilo	6	B-Chemical
and	5	O
control	9	O
animals	9	O
had	9	O
a	5	O
significantly	9	O
larger	5	O
band	9	O
(	9	O
p	7	O
=	7	O
0	7	O
.	9	O
03	7	O
)	9	O
as	5	O
compared	9	O
with	5	O
that	5	O
in	5	O
the	5	O
Pilo	6	B-Chemical
group	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Our	9	O
current	5	O
finding	9	O
that	5	O
animals	9	O
in	5	O
the	5	O
CHX	0	B-Chemical
+	9	O
Pilo	6	B-Chemical
group	9	O
have	5	O
a	5	O
GAP43	3	O
-	7	O
ir	9	O
band	9	O
in	5	O
the	5	O
IML	5	O
,	9	O
similar	9	O
to	5	O
that	5	O
of	5	O
controls	9	O
,	9	O
reinforces	9	O
prior	9	O
data	5	O
on	5	O
the	5	O
blockade	3	O
of	5	O
MFS	9	O
in	5	O
these	5	O
animals	9	O
.	9	O

The	5	O
change	9	O
in	5	O
GAP43	3	O
-	7	O
ir	9	O
present	9	O
in	5	O
Pilo	6	B-Chemical
-	7	O
treated	3	O
animals	9	O
was	9	O
a	5	O
thinning	5	O
of	5	O
the	5	O
band	9	O
to	5	O
a	5	O
very	5	O
narrow	5	O
layer	9	O
just	5	O
above	9	O
the	5	O
granule	3	O
cell	3	O
layer	9	O
that	5	O
is	5	O
likely	5	O
to	5	O
be	5	O
associated	9	O
with	5	O
the	5	O
loss	9	O
of	5	O
hilar	5	O
cell	3	O
projections	5	O
that	5	O
express	3	O
GAP	9	O
-	7	O
43	7	O
.	9	O

Nicotine	0	B-Chemical
antagonizes	3	O
caffeine	0	B-Chemical
-	7	O
but	9	O
not	5	O
pentylenetetrazole	0	B-Chemical
-	7	O
induced	3	O
anxiogenic	5	O
effect	9	O
in	5	O
mice	3	O
.	9	O

RATIONALE	2	O
:	9	O
Nicotine	0	B-Chemical
and	5	O
caffeine	0	B-Chemical
are	5	O
widely	5	O
consumed	5	O
licit	5	O
psychoactive	5	O
drugs	5	O
worldwide	5	O
.	9	O

Epidemiological	5	O
studies	9	O
showed	9	O
that	5	O
they	5	O
were	9	O
generally	5	O
used	5	O
concurrently	9	O
.	9	O

Although	9	O
some	5	O
studies	9	O
in	5	O
experimental	5	O
animals	9	O
indicate	9	O
clear	9	O
pharmacological	9	O
interactions	9	O
between	5	O
them	5	O
,	9	O
no	9	O
studies	9	O
have	5	O
shown	9	O
a	5	O
specific	9	O
interaction	9	O
on	5	O
anxiety	5	B-Disease
responses	5	O
.	9	O

OBJECTIVES	2	O
:	9	O
The	5	O
present	9	O
study	9	O
investigates	5	O
the	5	O
effects	9	O
of	5	O
nicotine	0	B-Chemical
on	5	O
anxiety	5	B-Disease
induced	3	O
by	9	O
caffeine	0	B-Chemical
and	5	O
another	9	O
anxiogenic	5	O
drug	5	O
,	9	O
pentylenetetrazole	0	B-Chemical
,	9	O
in	5	O
mice	3	O
.	9	O

The	5	O
elevated	9	O
plus	9	O
-	7	O
maze	5	O
(	9	O
EPM	9	O
)	9	O
test	5	O
was	9	O
used	5	O
to	5	O
evaluate	9	O
the	5	O
effects	9	O
of	5	O
drugs	5	O
on	5	O
anxiety	5	B-Disease
.	9	O

METHODS	2	O
:	9	O
Adult	9	O
male	9	O
Swiss	2	O
Webster	6	O
mice	3	O
(	9	O
25	9	O
-	7	O
32	7	O
g	0	O
)	9	O
were	9	O
given	5	O
nicotine	0	B-Chemical
(	9	O
0	7	O
.	9	O
05	7	O
-	7	O
0	7	O
.	9	O
25	9	O
mg	0	O
/	9	O
kg	0	O
s	9	O
.	9	O
c	9	O
.	9	O
)	9	O
or	5	O
saline	0	O
10	9	O
min	0	O
before	9	O
caffeine	0	B-Chemical
(	9	O
70	9	O
mg	0	O
/	9	O
kg	0	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
or	5	O
pentylenetetrazole	0	B-Chemical
(	9	O
15	9	O
and	5	O
30	9	O
mg	0	O
/	9	O
kg	0	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
injections	9	O
.	9	O

After	9	O
15	9	O
min	0	O
,	9	O
mice	3	O
were	9	O
evaluated	9	O
for	5	O
their	5	O
open	5	O
-	7	O
and	5	O
closed	5	O
-	7	O
arm	5	O
time	5	O
and	5	O
entries	5	O
on	5	O
the	5	O
EPM	9	O
for	5	O
a	5	O
10	9	O
-	7	O
min	0	O
session	5	O
.	9	O

Locomotor	5	O
activity	9	O
was	9	O
recorded	5	O
for	5	O
individual	5	O
groups	9	O
by	9	O
using	9	O
the	5	O
same	9	O
treatment	9	O
protocol	9	O
with	5	O
the	5	O
EPM	9	O
test	5	O
.	9	O

RESULTS	9	O
:	9	O
Nicotine	0	B-Chemical
(	9	O
0	7	O
.	9	O
05	7	O
-	7	O
0	7	O
.	9	O
25	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
itself	9	O
did	9	O
not	5	O
produce	9	O
any	5	O
significant	9	O
effect	9	O
in	5	O
the	5	O
EPM	9	O
test	5	O
,	9	O
whereas	9	O
caffeine	0	B-Chemical
(	9	O
70	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
and	5	O
pentylenetetrazole	0	B-Chemical
(	9	O
30	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
produced	9	O
an	5	O
anxiogenic	5	O
effect	9	O
,	9	O
apparent	9	O
with	5	O
decreases	9	O
in	5	O
open	5	O
-	7	O
arm	5	O
time	5	O
and	5	O
entry	9	O
.	9	O

Nicotine	0	B-Chemical
(	9	O
0	7	O
.	9	O
25	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
pretreatment	0	O
blocked	3	O
the	5	O
caffeine	0	B-Chemical
-	7	O
but	9	O
not	5	O
pentylenetetrazole	0	B-Chemical
-	7	O
induced	3	O
anxiety	5	B-Disease
.	9	O

Administration	2	O
of	5	O
each	5	O
drug	5	O
and	5	O
their	5	O
combinations	9	O
did	9	O
not	5	O
produce	9	O
any	5	O
effect	9	O
on	5	O
locomotor	5	O
activity	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Our	9	O
results	9	O
suggest	9	O
that	5	O
the	5	O
antagonistic	9	O
effect	9	O
of	5	O
nicotine	0	B-Chemical
on	5	O
caffeine	0	B-Chemical
-	7	O
induced	3	O
anxiety	5	B-Disease
is	5	O
specific	9	O
to	5	O
caffeine	0	B-Chemical
,	9	O
instead	5	O
of	5	O
a	5	O
non	9	O
-	7	O
specific	9	O
anxiolytic	5	O
effect	9	O
.	9	O

Thus	9	O
,	9	O
it	5	O
may	5	O
extend	9	O
the	5	O
current	5	O
findings	9	O
on	5	O
the	5	O
interaction	9	O
between	5	O
nicotine	0	B-Chemical
and	5	O
caffeine	0	B-Chemical
.	9	O

Long	9	O
term	5	O
hormone	9	O
therapy	5	O
for	5	O
perimenopausal	5	O
and	5	O
postmenopausal	5	O
women	5	O
.	9	O

BACKGROUND	2	O
:	9	O
Hormone	9	O
therapy	5	O
(	9	O
HT	9	O
)	9	O
is	5	O
widely	5	O
used	5	O
for	5	O
controlling	9	O
menopausal	5	B-Disease
symptoms	5	I-Disease
.	9	O

It	5	O
has	9	O
also	9	O
been	9	O
used	5	O
for	5	O
the	5	O
management	5	O
and	5	O
prevention	5	O
of	5	O
cardiovascular	5	B-Disease
disease	5	I-Disease
,	9	O
osteoporosis	5	B-Disease
and	5	O
dementia	5	B-Disease
in	5	O
older	5	O
women	5	O
but	9	O
the	5	O
evidence	9	O
supporting	9	O
its	9	O
use	5	O
for	5	O
these	5	O
indications	5	O
is	5	O
largely	9	O
observational	5	O
.	9	O

OBJECTIVES	2	O
:	9	O
To	9	O
assess	5	O
the	5	O
effect	9	O
of	5	O
long	5	O
-	7	O
term	5	O
HT	9	O
on	5	O
mortality	5	O
,	9	O
heart	5	B-Disease
disease	5	I-Disease
,	9	O
venous	5	B-Disease
thromboembolism	5	I-Disease
,	9	O
stroke	5	B-Disease
,	9	O
transient	9	B-Disease
ischaemic	5	I-Disease
attacks	5	I-Disease
,	9	O
breast	3	B-Disease
cancer	3	I-Disease
,	9	O
colorectal	9	B-Disease
cancer	3	I-Disease
,	9	O
ovarian	9	B-Disease
cancer	3	I-Disease
,	9	O
endometrial	9	B-Disease
cancer	3	I-Disease
,	9	O
gallbladder	5	B-Disease
disease	5	I-Disease
,	9	O
cognitive	5	O
function	9	O
,	9	O
dementia	5	B-Disease
,	9	O
fractures	5	B-Disease
and	5	O
quality	5	O
of	5	O
life	5	O
.	9	O

SEARCH	2	O
STRATEGY	2	O
:	9	O
We	9	O
searched	9	O
the	5	O
following	9	O
databases	5	O
up	5	O
to	5	O
November	2	O
2004	2	O
:	9	O
the	5	O
Cochrane	5	O
Menstrual	5	O
Disorders	2	O
and	5	O
Subfertility	5	O
Group	9	O
Trials	5	O
Register	5	O
,	9	O
Cochrane	5	O
Central	4	O
Register	5	O
of	5	O
Controlled	5	O
Trials	5	O
(	9	O
CENTRAL	2	O
)	9	O
,	9	O
MEDLINE	5	O
,	9	O
EMBASE	2	O
,	9	O
Biological	2	O
Abstracts	2	O
.	9	O

Relevant	5	O
non	9	O
-	7	O
indexed	5	O
journals	5	O
and	5	O
conference	5	O
abstracts	5	O
were	9	O
also	9	O
searched	9	O
.	9	O

SELECTION	2	O
CRITERIA	2	O
:	9	O
Randomised	5	O
double	9	O
-	7	O
blind	5	O
trials	5	O
of	5	O
HT	9	O
(	9	O
oestrogens	5	B-Chemical
with	5	O
or	5	O
without	9	O
progestogens	5	B-Chemical
)	9	O
versus	9	O
placebo	9	O
,	9	O
taken	5	O
for	5	O
at	9	O
least	9	O
one	5	O
year	5	O
by	9	O
perimenopausal	5	O
or	5	O
postmenopausal	5	O
women	5	O
.	9	O

DATA	2	O
COLLECTION	2	O
AND	2	O
ANALYSIS	2	O
:	9	O
Fifteen	9	O
RCTs	5	O
were	9	O
included	5	O
.	9	O

Trials	5	O
were	9	O
assessed	9	O
for	5	O
quality	5	O
and	5	O
two	5	O
review	5	O
authors	5	O
extracted	9	O
data	5	O
independently	9	O
.	9	O

They	5	O
calculated	5	O
risk	5	O
ratios	9	O
for	5	O
dichotomous	5	O
outcomes	5	O
and	5	O
weighted	5	O
mean	5	O
differences	9	O
for	5	O
continuous	5	O
outcomes	5	O
.	9	O

Clinical	5	O
heterogeneity	9	O
precluded	5	O
meta	9	O
-	7	O
analysis	9	O
for	5	O
most	9	O
outcomes	5	O
.	9	O

MAIN	2	O
RESULTS	9	O
:	9	O
All	9	O
the	5	O
statistically	9	O
significant	9	O
results	9	O
were	9	O
derived	9	O
from	9	O
the	5	O
two	5	O
biggest	5	O
trials	5	O
.	9	O

In	9	O
relatively	5	O
healthy	5	O
women	5	O
,	9	O
combined	9	O
continuous	5	O
HT	9	O
significantly	9	O
increased	9	O
the	5	O
risk	5	O
of	5	O
venous	5	B-Disease
thromboembolism	5	I-Disease
or	5	O
coronary	5	O
event	5	O
(	9	O
after	9	O
one	5	O
year	5	O
'	9	O
s	9	O
use	5	O
)	9	O
,	9	O
stroke	5	B-Disease
(	9	O
after	9	O
3	9	O
years	5	O
)	9	O
,	9	O
breast	3	B-Disease
cancer	3	I-Disease
(	9	O
after	9	O
5	9	O
years	5	O
)	9	O
and	5	O
gallbladder	5	B-Disease
disease	5	I-Disease
.	9	O

Long	9	O
-	7	O
term	5	O
oestrogen	3	B-Chemical
-	7	O
only	9	O
HT	9	O
also	9	O
significantly	9	O
increased	9	O
the	5	O
risk	5	O
of	5	O
stroke	5	B-Disease
and	5	O
gallbladder	5	B-Disease
disease	5	I-Disease
.	9	O

Overall	9	O
,	9	O
the	5	O
only	9	O
statistically	9	O
significant	9	O
benefits	5	O
of	5	O
HT	9	O
were	9	O
a	5	O
decreased	9	O
incidence	5	O
of	5	O
fractures	5	B-Disease
and	5	O
colon	9	B-Disease
cancer	3	I-Disease
with	5	O
long	5	O
-	7	O
term	5	O
use	5	O
.	9	O

Among	9	O
relatively	5	O
healthy	5	O
women	5	O
over	5	O
65	7	O
years	5	O
taking	5	O
continuous	5	O
combined	9	O
HT	9	O
,	9	O
there	5	O
was	9	O
a	5	O
statistically	9	O
significant	9	O
increase	9	O
in	5	O
the	5	O
incidence	5	O
of	5	O
dementia	5	B-Disease
.	9	O

Among	9	O
women	5	O
with	5	O
cardiovascular	5	B-Disease
disease	5	I-Disease
,	9	O
long	5	O
-	7	O
term	5	O
use	5	O
of	5	O
combined	9	O
continuous	5	O
HT	9	O
significantly	9	O
increased	9	O
the	5	O
risk	5	O
of	5	O
venous	5	B-Disease
thromboembolism	5	I-Disease
.	9	O

No	9	O
trials	5	O
focussed	5	O
specifically	9	O
on	5	O
younger	5	O
women	5	O
.	9	O

However	9	O
,	9	O
one	5	O
trial	5	O
analysed	9	O
subgroups	9	O
of	5	O
2839	7	O
relatively	5	O
healthy	5	O
50	0	O
to	5	O
59	7	O
year	5	O
-	7	O
old	5	O
women	5	O
taking	5	O
combined	9	O
continuous	5	O
HT	9	O
and	5	O
1637	7	O
taking	5	O
oestrogen	3	B-Chemical
-	7	O
only	9	O
HT	9	O
,	9	O
versus	9	O
similar	9	O
-	7	O
sized	5	O
placebo	9	O
groups	9	O
.	9	O

The	5	O
only	9	O
significantly	9	O
increased	9	O
risk	5	O
reported	9	O
was	9	O
for	5	O
venous	5	B-Disease
thromboembolism	5	I-Disease
in	5	O
women	5	O
taking	5	O
combined	9	O
continuous	5	O
HT	9	O
;	9	O
their	5	O
absolute	5	O
risk	5	O
remained	9	O
very	5	O
low	9	O
.	9	O

AUTHORS	2	O
'	9	O
CONCLUSIONS	5	O
:	9	O
HT	9	O
is	5	O
not	5	O
indicated	9	O
for	5	O
the	5	O
routine	5	O
management	5	O
of	5	O
chronic	5	B-Disease
disease	5	I-Disease
.	9	O

We	9	O
need	5	O
more	5	O
evidence	9	O
on	5	O
the	5	O
safety	5	O
of	5	O
HT	9	O
for	5	O
menopausal	5	O
symptom	5	O
control	9	O
,	9	O
though	9	O
short	5	O
-	7	O
term	5	O
use	5	O
appears	9	O
to	5	O
be	5	O
relatively	5	O
safe	5	O
for	5	O
healthy	5	O
younger	5	O
women	5	O
.	9	O

Drug	5	B-Disease
-	7	I-Disease
induced	3	I-Disease
liver	9	I-Disease
injury	9	I-Disease
:	9	O
an	5	O
analysis	9	O
of	5	O
461	7	O
incidences	5	O
submitted	9	O
to	5	O
the	5	O
Spanish	5	O
registry	5	O
over	5	O
a	5	O
10	9	O
-	7	O
year	5	O
period	5	O
.	9	O

BACKGROUND	2	O
&	7	O
AIMS	5	O
:	9	O
Progress	5	O
in	5	O
the	5	O
understanding	5	O
of	5	O
susceptibility	9	O
factors	9	O
to	5	O
drug	5	B-Disease
-	7	I-Disease
induced	3	I-Disease
liver	9	I-Disease
injury	9	I-Disease
(	9	O
DILI	5	B-Disease
)	9	O
and	5	O
outcome	5	O
predictability	5	O
are	5	O
hampered	5	O
by	9	O
the	5	O
lack	9	O
of	5	O
systematic	5	O
programs	5	O
to	5	O
detect	9	O
bona	1	O
fide	9	O
cases	5	O
.	9	O

METHODS	2	O
:	9	O
A	9	O
cooperative	5	O
network	5	O
was	9	O
created	5	O
in	5	O
1994	2	O
in	5	O
Spain	2	O
to	5	O
identify	9	O
all	5	O
suspicions	5	O
of	5	O
DILI	5	B-Disease
following	9	O
a	5	O
prospective	5	O
structured	5	O
report	5	O
form	9	O
.	9	O

The	5	O
liver	9	B-Disease
damage	9	I-Disease
was	9	O
characterized	9	O
according	9	O
to	5	O
hepatocellular	9	O
,	9	O
cholestatic	5	B-Disease
,	9	O
and	5	O
mixed	9	O
laboratory	9	O
criteria	5	O
and	5	O
to	5	O
histologic	9	O
criteria	5	O
when	5	O
available	5	O
.	9	O

Further	9	O
evaluation	5	O
of	5	O
causality	5	O
assessment	5	O
was	9	O
centrally	5	O
performed	9	O
.	9	O

RESULTS	9	O
:	9	O
Since	9	O
April	2	O
1994	2	O
to	5	O
August	2	O
2004	2	O
,	9	O
461	7	O
out	9	O
of	5	O
570	9	O
submitted	9	O
cases	5	O
,	9	O
involving	5	O
505	7	O
drugs	5	O
,	9	O
were	9	O
deemed	5	O
to	5	O
be	5	O
related	9	O
to	5	O
DILI	5	B-Disease
.	9	O

The	5	O
antiinfective	5	O
group	9	O
of	5	O
drugs	5	O
was	9	O
the	5	O
more	5	O
frequently	5	O
incriminated	5	O
,	9	O
amoxicillin	0	B-Chemical
-	7	I-Chemical
clavulanate	0	I-Chemical
accounting	5	O
for	5	O
the	5	O
12	9	O
.	9	O
8	9	O
%	9	O
of	5	O
the	5	O
whole	9	O
series	5	O
.	9	O

The	5	O
hepatocellular	9	O
pattern	9	O
of	5	O
damage	9	O
was	9	O
the	5	O
most	9	O
common	5	O
(	9	O
58	7	O
%	9	O
)	9	O
,	9	O
was	9	O
inversely	9	O
correlated	9	O
with	5	O
age	5	O
(	9	O
P	9	O
<	0	O
.	9	O
0001	7	O
)	9	O
,	9	O
and	5	O
had	9	O
the	5	O
worst	5	O
outcome	5	O
(	9	O
Cox	9	O
regression	5	O
,	9	O
P	9	O
<	0	O
.	9	O
034	7	O
)	9	O
.	9	O

Indeed	9	O
,	9	O
the	5	O
incidence	5	O
of	5	O
liver	9	O
transplantation	9	O
and	5	O
death	9	O
in	5	O
this	5	O
group	9	O
was	9	O
11	7	O
.	9	O
7	9	O
%	9	O
if	5	O
patients	5	O
had	9	O
jaundice	5	B-Disease
at	9	O
presentation	5	O
,	9	O
whereas	9	O
the	5	O
corresponding	9	O
figure	9	O
was	9	O
3	9	O
.	9	O
8	9	O
%	9	O
in	5	O
nonjaundiced	5	O
patients	5	O
(	9	O
P	9	O
<	0	O
.	9	O
04	7	O
)	9	O
.	9	O

Factors	5	O
associated	9	O
with	5	O
the	5	O
development	9	O
of	5	O
fulminant	5	B-Disease
hepatic	9	I-Disease
failure	5	I-Disease
were	9	O
female	9	O
sex	5	O
(	9	O
OR	9	O
=	7	O
25	9	O
;	9	O
95	7	O
%	9	O
CI	7	O
:	9	O
4	9	O
.	9	O
1	9	O
-	7	O
151	7	O
;	9	O
P	9	O
<	0	O
.	9	O
0001	7	O
)	9	O
,	9	O
hepatocellular	9	O
damage	9	O
(	9	O
OR	9	O
=	7	O
7	9	O
.	9	O
9	7	O
;	9	O
95	7	O
%	9	O
CI	7	O
:	9	O
1	9	O
.	9	O
6	9	O
-	7	O
37	9	O
;	9	O
P	9	O
<	0	O
.	9	O
009	2	O
)	9	O
,	9	O
and	5	O
higher	9	O
baseline	5	O
plasma	9	O
bilirubin	0	B-Chemical
value	9	O
(	9	O
OR	9	O
=	7	O
1	9	O
.	9	O
15	9	O
;	9	O
95	7	O
%	9	O
CI	7	O
:	9	O
1	9	O
.	9	O
09	7	O
-	7	O
1	9	O
.	9	O
22	7	O
;	9	O
P	9	O
<	0	O
.	9	O
0001	7	O
)	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Patients	5	O
with	5	O
drug	5	O
-	7	O
induced	3	O
hepatocellular	9	O
jaundice	5	B-Disease
have	5	O
11	7	O
.	9	O
7	9	O
%	9	O
chance	5	O
of	5	O
progressing	5	O
to	5	O
death	9	O
or	5	O
transplantation	9	O
.	9	O

Amoxicillin	0	B-Chemical
-	7	I-Chemical
clavulanate	0	I-Chemical
stands	5	O
out	9	O
as	5	O
the	5	O
most	9	O
common	5	O
drug	5	O
related	9	O
to	5	O
DILI	5	B-Disease
.	9	O

Morphological	9	O
evaluation	5	O
of	5	O
the	5	O
effect	9	O
of	5	O
d	9	B-Chemical
-	7	I-Chemical
ribose	0	I-Chemical
on	5	O
adriamycin	3	B-Chemical
-	7	O
evoked	5	O
cardiotoxicity	9	B-Disease
in	5	O
rats	9	O
.	9	O

The	5	O
influence	5	O
of	5	O
d	9	B-Chemical
-	7	I-Chemical
ribose	0	I-Chemical
on	5	O
adriamycin	3	B-Chemical
-	7	O
induced	3	O
myocardiopathy	5	B-Disease
in	5	O
rats	9	O
was	9	O
studied	9	O
.	9	O

Adriamycin	0	B-Chemical
in	5	O
the	5	O
cumulative	5	O
dose	9	O
of	5	O
25	9	O
mg	0	O
/	9	O
kg	0	O
evoked	5	O
fully	9	O
developed	5	O
cardiac	5	B-Disease
toxicity	9	I-Disease
.	9	O

D	9	B-Chemical
-	7	I-Chemical
ribose	0	I-Chemical
in	5	O
the	5	O
multiple	5	O
doses	0	O
of	5	O
200	0	O
mg	0	O
/	9	O
kg	0	O
did	9	O
not	5	O
influence	5	O
ADR	9	B-Chemical
cardiotoxicity	9	B-Disease
.	9	O

In	9	O
vivo	3	O
evidences	9	O
suggesting	9	O
the	5	O
role	9	O
of	5	O
oxidative	9	O
stress	9	O
in	5	O
pathogenesis	9	O
of	5	O
vancomycin	9	B-Chemical
-	7	O
induced	3	O
nephrotoxicity	9	B-Disease
:	9	O
protection	9	O
by	9	O
erdosteine	0	B-Chemical
.	9	O

The	5	O
aims	5	O
of	5	O
this	5	O
study	9	O
were	9	O
to	5	O
examine	9	O
vancomycin	9	B-Chemical
(	9	O
VCM	5	B-Chemical
)	9	O
-	7	O
induced	3	O
oxidative	9	O
stress	9	O
that	5	O
promotes	3	O
production	9	O
of	5	O
reactive	9	O
oxygen	0	B-Chemical
species	4	O
(	9	O
ROS	3	O
)	9	O
and	5	O
to	5	O
investigate	9	O
the	5	O
role	9	O
of	5	O
erdosteine	0	B-Chemical
,	9	O
an	5	O
expectorant	4	O
agent	9	O
,	9	O
which	5	O
has	9	O
also	9	O
antioxidant	0	O
properties	9	O
,	9	O
on	5	O
kidney	9	O
tissue	9	O
against	9	O
the	5	O
possible	5	O
VCM	5	B-Chemical
-	7	O
induced	3	O
renal	9	B-Disease
impairment	5	I-Disease
in	5	O
rats	9	O
.	9	O

Rats	9	O
were	9	O
divided	5	O
into	9	O
three	9	O
groups	9	O
:	9	O
sham	9	O
,	9	O
VCM	5	B-Chemical
and	5	O
VCM	5	B-Chemical
plus	9	O
erdosteine	0	B-Chemical
.	9	O

VCM	5	B-Chemical
was	9	O
administrated	0	O
intraperitoneally	0	O
(	9	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
with	5	O
200mgkg	0	O
(	9	O
-	7	O
1	9	O
)	9	O
twice	9	O
daily	5	O
for	5	O
7	9	O
days	9	O
.	9	O

Erdosteine	0	B-Chemical
was	9	O
administered	9	O
orally	0	O
.	9	O

VCM	5	B-Chemical
administration	9	O
to	5	O
control	9	O
rats	9	O
significantly	9	O
increased	9	O
renal	9	O
malondialdehyde	0	B-Chemical
(	9	O
MDA	9	B-Chemical
)	9	O
and	5	O
urinary	9	O
N	9	O
-	7	O
acetyl	0	O
-	7	O
beta	9	O
-	7	O
d	9	O
-	7	O
glucosaminidase	0	O
(	9	O
NAG	0	O
,	9	O
a	5	O
marker	3	O
of	5	O
renal	9	B-Disease
tubular	9	I-Disease
injury	9	I-Disease
)	9	O
excretion	0	O
but	9	O
decreased	9	O
superoxide	0	B-Chemical
dismutase	0	O
(	9	O
SOD	0	O
)	9	O
and	5	O
catalase	0	O
(	9	O
CAT	9	O
)	9	O
activities	9	O
.	9	O

Erdosteine	0	B-Chemical
administration	9	O
with	5	O
VCM	5	B-Chemical
injections	9	O
caused	9	O
significantly	9	O
decreased	9	O
renal	9	O
MDA	9	B-Chemical
and	5	O
urinary	9	O
NAG	0	O
excretion	0	O
,	9	O
and	5	O
increased	9	O
SOD	0	O
activity	9	O
,	9	O
but	9	O
not	5	O
CAT	9	O
activity	9	O
in	5	O
renal	9	O
tissue	9	O
when	5	O
compared	9	O
with	5	O
VCM	5	B-Chemical
alone	9	O
.	9	O

Erdosteine	0	B-Chemical
showed	9	O
histopathological	9	O
protection	9	O
against	9	O
VCM	5	B-Chemical
-	7	O
induced	3	O
nephrotoxicity	9	B-Disease
.	9	O

There	5	O
were	9	O
a	5	O
significant	9	O
dilatation	5	O
of	5	O
tubular	9	O
lumens	5	O
,	9	O
extensive	5	O
epithelial	3	O
cell	3	O
vacuolization	3	O
,	9	O
atrophy	5	B-Disease
,	9	O
desquamation	5	B-Disease
,	9	O
and	5	O
necrosis	9	B-Disease
in	5	O
VCM	5	B-Chemical
-	7	O
treated	3	O
rats	9	O
more	5	O
than	5	O
those	5	O
of	5	O
the	5	O
control	9	O
and	5	O
the	5	O
erdosteine	0	B-Chemical
groups	9	O
.	9	O

Erdosteine	0	B-Chemical
caused	9	O
a	5	O
marked	9	O
reduction	9	O
in	5	O
the	5	O
extent	9	O
of	5	O
tubular	9	O
damage	9	O
.	9	O

It	5	O
is	5	O
concluded	9	O
that	5	O
oxidative	9	O
tubular	9	O
damage	9	O
plays	9	O
an	5	O
important	9	O
role	9	O
in	5	O
the	5	O
VCM	5	B-Chemical
-	7	O
induced	3	O
nephrotoxicity	9	B-Disease
and	5	O
the	5	O
modulation	9	O
of	5	O
oxidative	9	O
stress	9	O
with	5	O
erdosteine	0	B-Chemical
reduces	9	O
the	5	O
VCM	5	B-Chemical
-	7	O
induced	3	O
kidney	9	B-Disease
damage	9	I-Disease
both	9	O
at	9	O
the	5	O
biochemical	9	O
and	5	O
histological	9	O
levels	3	O
.	9	O

Gemfibrozil	0	B-Chemical
-	7	O
lovastatin	0	B-Chemical
therapy	5	O
for	5	O
primary	9	O
hyperlipoproteinemias	9	B-Disease
.	9	O

The	5	O
specific	9	O
aim	5	O
of	5	O
this	5	O
retrospective	5	O
,	9	O
observational	5	O
study	9	O
was	9	O
to	5	O
assess	5	O
safety	5	O
and	5	O
efficacy	9	O
of	5	O
long	5	O
-	7	O
term	5	O
(	9	O
21	7	O
months	5	O
/	9	O
patient	5	O
)	9	O
,	9	O
open	5	O
-	7	O
label	9	O
,	9	O
gemfibrozil	0	B-Chemical
-	7	O
lovastatin	0	B-Chemical
treatment	9	O
in	5	O
80	9	O
patients	5	O
with	5	O
primary	9	O
mixed	9	O
hyperlipidemia	9	B-Disease
(	9	O
68	7	O
%	9	O
of	5	O
whom	5	O
had	9	O
atherosclerotic	3	B-Disease
vascular	5	I-Disease
disease	5	I-Disease
)	9	O
.	9	O

Because	9	O
ideal	5	O
lipid	0	O
targets	9	O
were	9	O
not	5	O
reached	9	O
(	9	O
low	9	O
-	7	O
density	9	O
lipoprotein	9	O
(	9	O
LDL	0	O
)	9	O
cholesterol	0	B-Chemical
less	5	O
than	5	O
130	9	O
mg	0	O
/	9	O
dl	7	O
,	9	O
high	9	O
-	7	O
density	9	O
lipoprotein	9	O
(	9	O
HDL	9	O
)	9	O
cholesterol	0	B-Chemical
greater	5	O
than	5	O
35	9	O
mg	0	O
/	9	O
dl	7	O
,	9	O
or	5	O
total	9	O
cholesterol	0	B-Chemical
/	9	O
HDL	9	O
cholesterol	0	B-Chemical
less	5	O
than	5	O
4	9	O
.	9	O
5	9	O
mg	0	O
/	9	O
dl	7	O
)	9	O
with	5	O
diet	9	O
plus	9	O
a	5	O
single	9	O
drug	5	O
,	9	O
gemfibrozil	0	B-Chemical
(	9	O
1	9	O
.	9	O
2	9	O
g	0	O
/	9	O
day	9	O
)	9	O
-	7	O
lovastatin	0	B-Chemical
(	9	O
primarily	9	O
20	9	O
or	5	O
40	9	O
mg	0	O
)	9	O
treatment	9	O
was	9	O
given	5	O
.	9	O

Follow	5	O
-	7	O
up	5	O
visits	5	O
were	9	O
scheduled	5	O
with	5	O
2	9	O
-	7	O
drug	5	O
therapy	5	O
every	5	O
6	9	O
to	5	O
8	9	O
weeks	9	O
,	9	O
an	5	O
average	5	O
of	5	O
10	9	O
.	9	O
3	9	O
visits	5	O
per	9	O
patient	5	O
,	9	O
with	5	O
741	7	O
batteries	5	O
of	5	O
6	9	O
liver	9	O
function	9	O
tests	5	O
and	5	O
714	7	O
creatine	0	B-Chemical
phosphokinase	0	O
levels	3	O
measured	9	O
.	9	O

Only	9	O
1	9	O
of	5	O
the	5	O
4	9	O
,	9	O
446	7	O
liver	9	O
function	9	O
tests	5	O
(	9	O
0	7	O
.	9	O
02	7	O
%	9	O
)	9	O
,	9	O
a	5	O
gamma	9	O
glutamyl	0	O
transferase	1	O
,	9	O
was	9	O
greater	5	O
than	5	O
or	5	O
equal	9	O
to	5	O
3	9	O
times	5	O
the	5	O
upper	9	O
normal	9	O
limit	5	O
.	9	O

Of	9	O
the	5	O
714	7	O
creatine	0	B-Chemical
phosphokinase	0	O
levels	3	O
,	9	O
9	7	O
%	9	O
were	9	O
high	9	O
;	9	O
only	9	O
1	9	O
(	9	O
0	7	O
.	9	O
1	9	O
%	9	O
)	9	O
was	9	O
greater	5	O
than	5	O
or	5	O
equal	9	O
to	5	O
3	9	O
times	5	O
the	5	O
upper	9	O
normal	9	O
limit	5	O
.	9	O

With	5	O
2	9	O
-	7	O
drug	5	O
therapy	5	O
,	9	O
mean	5	O
total	9	O
cholesterol	0	B-Chemical
decreased	9	O
22	7	O
%	9	O
from	9	O
255	7	O
to	5	O
200	0	O
mg	0	O
/	9	O
dl	7	O
,	9	O
triglyceride	0	B-Chemical
levels	3	O
decreased	9	O
35	9	O
%	9	O
from	9	O
236	7	O
to	5	O
154	7	O
mg	0	O
/	9	O
dl	7	O
,	9	O
LDL	0	O
cholesterol	0	B-Chemical
decreased	9	O
26	7	O
%	9	O
from	9	O
176	7	O
to	5	O
131	7	O
mg	0	O
/	9	O
dl	7	O
,	9	O
and	5	O
the	5	O
total	9	O
cholesterol	0	B-Chemical
/	9	O
HDL	9	O
cholesterol	0	B-Chemical
ratio	9	O
decreased	9	O
24	9	O
%	9	O
from	9	O
7	9	O
.	9	O
1	9	O
to	5	O
5	9	O
.	9	O
4	9	O
,	9	O
all	5	O
p	7	O
less	5	O
than	5	O
or	5	O
equal	9	O
to	5	O
0	7	O
.	9	O
0001	7	O
.	9	O

Myositis	2	B-Disease
,	9	O
attributable	9	O
to	5	O
the	5	O
drug	5	O
combination	9	O
and	5	O
symptomatic	5	O
enough	5	O
to	5	O
discontinue	5	O
it	5	O
,	9	O
occurred	9	O
in	5	O
3	9	O
%	9	O
of	5	O
patients	5	O
,	9	O
and	5	O
in	5	O
1	9	O
%	9	O
with	5	O
concurrent	5	O
high	9	O
creatine	0	B-Chemical
phosphokinase	0	O
(	9	O
769	7	O
U	9	O
/	9	O
liter	0	O
)	9	O
;	9	O
no	9	O
patients	5	O
had	9	O
rhabdomyolysis	5	B-Disease
or	5	O
myoglobinuria	5	B-Disease
.	9	O
(	9	O
ABSTRACT	2	O
TRUNCATED	2	O
AT	9	O
250	0	O
WORDS	3	O
)	9	O

Does	5	O
domperidone	0	B-Chemical
potentiate	3	O
mirtazapine	5	B-Chemical
-	7	O
associated	9	O
restless	5	B-Disease
legs	5	I-Disease
syndrome	5	I-Disease
?	5	O

There	5	O
is	5	O
now	5	O
evidence	9	O
to	5	O
suggest	9	O
a	5	O
central	5	O
role	9	O
for	5	O
the	5	O
dopaminergic	5	O
system	5	O
in	5	O
restless	5	B-Disease
legs	5	I-Disease
syndrome	5	I-Disease
(	9	O
RLS	5	B-Disease
)	9	O
.	9	O

For	9	O
example	5	O
,	9	O
the	5	O
symptoms	5	O
of	5	O
RLS	5	B-Disease
can	5	O
be	5	O
dramatically	9	O
improved	5	O
by	9	O
levodopa	5	B-Chemical
and	5	O
dopamine	5	B-Chemical
agonists	3	O
,	9	O
whereas	9	O
central	5	O
dopamine	5	B-Chemical
D2	9	O
receptor	3	O
antagonists	3	O
can	5	O
induce	3	O
or	5	O
aggravate	9	O
RLS	5	B-Disease
symptoms	5	O
.	9	O

To	9	O
our	5	O
knowledge	5	O
,	9	O
there	5	O
is	5	O
no	9	O
previous	9	O
report	5	O
regarding	5	O
whether	9	O
domperidone	0	B-Chemical
,	9	O
a	5	O
peripheral	9	O
dopamine	5	B-Chemical
D2	9	O
receptor	3	O
antagonist	3	O
,	9	O
can	5	O
also	9	O
induce	3	O
or	5	O
aggravate	9	O
symptoms	5	O
of	5	O
RLS	5	B-Disease
.	9	O

Mirtazapine	7	B-Chemical
,	9	O
the	5	O
first	9	O
noradrenergic	5	O
and	5	O
specific	9	O
serotonergic	5	O
antidepressant	5	O
(	9	O
NaSSA	7	O
)	9	O
,	9	O
has	9	O
been	9	O
associated	9	O
with	5	O
RLS	5	B-Disease
in	5	O
several	9	O
recent	5	O
publications	5	O
.	9	O

The	5	O
authors	5	O
report	5	O
here	5	O
a	5	O
depressed	5	O
patient	5	O
comorbid	5	O
with	5	O
postprandial	5	B-Disease
dyspepsia	5	I-Disease
who	5	O
developed	5	O
RLS	5	B-Disease
after	9	O
mirtazapine	5	B-Chemical
had	9	O
been	9	O
added	0	O
to	5	O
his	5	O
domperidone	0	B-Chemical
therapy	5	O
.	9	O

Our	9	O
patient	5	O
started	5	O
to	5	O
have	5	O
symptoms	5	O
of	5	O
RLS	5	B-Disease
only	9	O
after	9	O
he	5	O
had	9	O
been	9	O
treated	3	O
with	5	O
mirtazapine	5	B-Chemical
,	9	O
and	5	O
his	5	O
RLS	5	B-Disease
symptoms	5	O
resolved	9	O
completely	9	O
upon	9	O
discontinuation	5	O
of	5	O
his	5	O
mirtazapine	5	B-Chemical
.	9	O

Such	5	O
a	5	O
temporal	5	O
relationship	5	O
between	5	O
the	5	O
use	5	O
of	5	O
mirtazapine	5	B-Chemical
and	5	O
the	5	O
symptoms	5	O
of	5	O
RLS	5	B-Disease
in	5	O
our	5	O
patient	5	O
did	9	O
not	5	O
support	5	O
a	5	O
potentiating	3	O
effect	9	O
of	5	O
domperione	_	B-Chemical
on	5	O
mirtazapine	5	B-Chemical
-	7	O
associated	9	O
RLS	5	B-Disease
.	9	O

However	9	O
,	9	O
physicians	5	O
should	5	O
be	5	O
aware	5	O
of	5	O
the	5	O
possibility	9	O
that	5	O
mirtazapine	5	B-Chemical
can	5	O
be	5	O
associated	9	O
with	5	O
RLS	5	B-Disease
in	5	O
some	5	O
individuals	5	O
,	9	O
especially	5	O
those	5	O
receiving	9	O
concomitant	9	O
dopamine	5	B-Chemical
D2	9	O
receptor	3	O
antagonists	3	O
.	9	O

Antiandrogenic	0	O
therapy	5	O
can	5	O
cause	5	O
coronary	5	B-Disease
arterial	5	I-Disease
disease	5	I-Disease
.	9	O

AIM	9	O
:	9	O
To	9	O
study	9	O
the	5	O
change	9	O
of	5	O
lipid	0	O
metabolism	9	O
by	9	O
antiandrogen	0	O
therapy	5	O
in	5	O
patients	5	O
with	5	O
prostate	3	B-Disease
cancer	3	I-Disease
.	9	O

MATERIALS	2	O
AND	2	O
METHODS	2	O
:	9	O
We	9	O
studied	9	O
with	5	O
a	5	O
2	9	O
.	9	O
5	9	O
years	5	O
follow	5	O
-	7	O
up	5	O
the	5	O
changes	9	O
in	5	O
plasma	9	O
cholesterols	0	B-Chemical
(	9	O
C	9	B-Chemical
)	9	O
,	9	O
triglycerides	9	B-Chemical
(	9	O
TG	9	B-Chemical
)	9	O
,	9	O
lipoproteins	0	O
(	9	O
LP	9	O
)	9	O
,	9	O
and	5	O
apolipoproteins	0	O
(	9	O
Apo	9	O
)	9	O
B	9	O
-	7	O
100	0	O
,	9	O
A	9	O
-	7	O
I	9	O
,	9	O
and	5	O
A	9	O
-	7	O
II	9	O
pro	9	O
fi	9	O
les	2	O
in	5	O
24	9	O
patients	5	O
of	5	O
mean	5	O
age	5	O
60	9	O
years	5	O
with	5	O
low	9	O
risk	5	O
prostate	3	B-Disease
cancer	3	I-Disease
(	9	O
stage	9	O
:	9	O
T1cN0M0	7	O
,	9	O
Gleason	9	O
score	5	O
:	9	O
2	9	O
-	7	O
5	9	O
)	9	O
during	5	O
treatment	9	O
with	5	O
cyproterone	0	B-Chemical
acetate	0	I-Chemical
(	9	O
CPA	9	B-Chemical
)	9	O
without	9	O
surgical	5	O
management	5	O
or	5	O
radiation	9	O
therapy	5	O
.	9	O

RESULTS	9	O
:	9	O
Significant	9	O
decreases	9	O
of	5	O
HDL	9	O
-	7	O
C	9	O
,	9	O
Apo	9	O
A	9	O
-	7	O
I	9	O
and	5	O
Apo	9	O
A	9	O
-	7	O
II	9	O
and	5	O
an	5	O
increase	9	O
of	5	O
triglyceride	0	B-Chemical
levels	3	O
in	5	O
VLDL	0	O
were	9	O
induced	3	O
by	9	O
CPA	9	B-Chemical
.	9	O

After	9	O
a	5	O
period	5	O
of	5	O
2	9	O
.	9	O
5	9	O
years	5	O
on	5	O
CPA	9	B-Chemical
treatment	9	O
,	9	O
four	9	O
patients	5	O
out	9	O
of	5	O
twenty	5	O
-	7	O
four	9	O
were	9	O
found	9	O
to	5	O
be	5	O
affected	9	O
by	9	O
coronary	5	B-Disease
heart	5	I-Disease
disease	5	I-Disease
.	9	O

CONCLUSIONS	5	O
:	9	O
Ischaemic	7	O
coronary	5	B-Disease
arteriosclerosis	5	I-Disease
with	5	O
an	5	O
incidence	5	O
rate	9	O
of	5	O
16	9	O
.	9	O
6	9	O
%	9	O
as	5	O
caused	9	O
by	9	O
prolonged	9	O
CPA	9	B-Chemical
therapy	5	O
is	5	O
mediated	3	O
through	9	O
changes	9	O
in	5	O
HDL	9	O
cholesterol	0	B-Chemical
,	9	O
Apo	9	O
A	9	O
-	7	O
I	9	O
and	5	O
Apo	9	O
A	9	O
-	7	O
II	9	O
pro	9	O
fi	9	O
les	2	O
,	9	O
other	5	O
than	5	O
the	5	O
well	9	O
-	7	O
known	9	O
hyperglyceridemic	_	B-Disease
effect	9	I-Disease
caused	9	O
by	9	O
estrogen	3	B-Chemical
.	9	O

5	9	B-Chemical
-	7	I-Chemical
Fluorouracil	0	I-Chemical
cardiotoxicity	9	B-Disease
induced	3	O
by	9	O
alpha	9	B-Chemical
-	7	I-Chemical
fluoro	0	I-Chemical
-	7	I-Chemical
beta	9	I-Chemical
-	7	I-Chemical
alanine	1	I-Chemical
.	9	O

Cardiotoxicity	9	B-Disease
is	5	O
a	5	O
rare	5	O
complication	5	O
occurring	9	O
during	5	O
5	9	B-Chemical
-	7	I-Chemical
fluorouracil	0	I-Chemical
(	9	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
)	9	O
treatment	9	O
for	5	O
malignancies	5	B-Disease
.	9	O

We	9	O
herein	9	O
report	5	O
the	5	O
case	5	O
of	5	O
a	5	O
70	9	O
-	7	O
year	5	O
-	7	O
old	5	O
man	5	O
with	5	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
-	7	O
induced	3	O
cardiotoxicity	9	B-Disease
,	9	O
in	5	O
whom	5	O
a	5	O
high	9	O
serum	9	O
level	9	O
of	5	O
alpha	9	B-Chemical
-	7	I-Chemical
fluoro	0	I-Chemical
-	7	I-Chemical
beta	9	I-Chemical
-	7	I-Chemical
alanine	1	I-Chemical
(	9	O
FBAL	0	B-Chemical
)	9	O
was	9	O
observed	9	O
.	9	O

The	5	O
patient	5	O
,	9	O
who	5	O
had	9	O
unresectable	5	O
colon	9	B-Disease
cancer	3	I-Disease
metastases	5	O
to	5	O
the	5	O
liver	9	O
and	5	O
lung	9	O
,	9	O
was	9	O
referred	5	O
to	5	O
us	5	O
for	5	O
chemotherapy	5	O
from	9	O
an	5	O
affiliated	2	O
hospital	5	O
;	9	O
he	5	O
had	9	O
no	9	O
cardiac	5	O
history	5	O
.	9	O

After	9	O
admission	5	O
,	9	O
the	5	O
patient	5	O
received	9	O
a	5	O
continuous	5	O
intravenous	0	O
infusion	0	O
of	5	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
(	9	O
1000	9	O
mg	0	O
/	9	O
day	9	O
)	9	O
,	9	O
during	5	O
which	5	O
precordial	5	B-Disease
pain	5	I-Disease
with	5	O
right	5	B-Disease
bundle	5	I-Disease
branch	5	I-Disease
block	9	I-Disease
occurred	9	O
concomitantly	9	O
with	5	O
a	5	O
high	9	O
serum	9	O
FBAL	0	B-Chemical
concentration	0	O
of	5	O
1955	2	O
ng	0	O
/	9	O
ml	0	O
.	9	O

Both	9	O
the	5	O
precordial	5	B-Disease
pain	5	I-Disease
and	5	O
the	5	O
electrocardiographic	5	O
changes	9	O
disappeared	9	O
spontaneously	5	O
after	9	O
the	5	O
discontinuation	5	O
of	5	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
.	9	O

As	9	O
the	5	O
precordial	5	B-Disease
pain	5	I-Disease
in	5	O
this	5	O
patient	5	O
was	9	O
considered	5	O
to	5	O
have	5	O
been	9	O
due	5	O
to	5	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
-	7	O
induced	3	O
cardiotoxicity	9	B-Disease
,	9	O
the	5	O
administration	9	O
of	5	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
was	9	O
abandoned	5	O
.	9	O

Instead	5	O
,	9	O
oral	9	O
administration	9	O
of	5	O
S	9	O
-	7	O
1	9	O
(	9	O
a	5	O
derivative	0	O
of	5	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
)	9	O
,	9	O
at	9	O
200	0	O
mg	0	O
/	9	O
day	9	O
twice	9	O
a	5	O
week	9	O
,	9	O
was	9	O
instituted	5	O
,	9	O
because	5	O
S	9	O
-	7	O
1	9	O
has	9	O
a	5	O
strong	9	O
inhibitory	3	O
effect	9	O
on	5	O
dihydropyrimidine	0	B-Chemical
dehydrogenase	1	O
,	9	O
which	5	O
catalyzes	0	O
the	5	O
degradative	3	O
of	5	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
into	9	O
FBAL	0	B-Chemical
.	9	O

The	5	O
serum	9	O
FBAL	0	B-Chemical
concentration	0	O
subsequently	9	O
decreased	9	O
to	5	O
352	7	O
ng	0	O
/	9	O
ml	0	O
,	9	O
the	5	O
same	9	O
as	5	O
the	5	O
value	9	O
measured	9	O
on	5	O
the	5	O
first	9	O
day	9	O
of	5	O
S	9	O
-	7	O
1	9	O
administration	9	O
.	9	O

Thereafter	9	O
,	9	O
no	9	O
cardiac	5	B-Disease
symptoms	5	I-Disease
were	9	O
observed	9	O
.	9	O

The	5	O
patient	5	O
achieved	5	O
a	5	O
partial	9	O
response	9	O
6	9	O
months	5	O
after	9	O
the	5	O
initiation	9	O
of	5	O
the	5	O
S	9	O
-	7	O
1	9	O
treatment	9	O
.	9	O

The	5	O
experience	5	O
of	5	O
this	5	O
case	5	O
,	9	O
together	9	O
with	5	O
a	5	O
review	5	O
of	5	O
the	5	O
literature	5	O
,	9	O
suggests	9	O
that	5	O
FBAL	0	B-Chemical
is	5	O
related	9	O
to	5	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
-	7	O
induced	3	O
cardiotoxicity	9	B-Disease
.	9	O

S	9	O
-	7	O
1	9	O
may	5	O
be	5	O
administered	9	O
safely	5	O
to	5	O
patients	5	O
with	5	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
-	7	O
induced	3	O
cardiotoxicity	9	B-Disease
.	9	O

Hepatocellular	9	B-Disease
carcinoma	3	I-Disease
in	5	O
Fanconi	9	B-Disease
'	9	I-Disease
s	9	I-Disease
anemia	9	I-Disease
treated	3	O
with	5	O
androgen	3	B-Chemical
and	5	O
corticosteroid	5	B-Chemical
.	9	O

The	5	O
case	5	O
of	5	O
an	5	O
11	7	O
-	7	O
year	5	O
-	7	O
old	5	O
boy	5	O
is	5	O
reported	9	O
who	5	O
was	9	O
known	9	O
to	5	O
have	5	O
Fanconi	9	B-Disease
'	9	I-Disease
s	9	I-Disease
anemia	9	I-Disease
for	5	O
3	9	O
years	5	O
and	5	O
was	9	O
treated	3	O
with	5	O
androgens	9	B-Chemical
,	9	O
corticosteroids	5	B-Chemical
and	5	O
transfusions	5	O
.	9	O

Two	9	O
weeks	9	O
before	9	O
his	5	O
death	9	O
he	5	O
was	9	O
readmitted	5	O
because	5	O
of	5	O
aplastic	5	O
crisis	5	O
with	5	O
septicemia	5	B-Disease
and	5	O
marked	9	O
abnormalities	9	O
in	5	O
liver	9	O
function	9	O
and	5	O
died	9	O
of	5	O
hemorrhagic	5	B-Disease
bronchopneumonia	5	I-Disease
.	9	O

At	9	O
autopsy	5	O
peliosis	5	B-Disease
and	5	O
multiple	5	O
hepatic	9	B-Disease
tumors	3	I-Disease
were	9	O
found	9	O
which	5	O
histologically	9	O
proved	9	O
to	5	O
be	5	O
well	9	O
-	7	O
differentiated	3	O
hepatocellular	9	B-Disease
carcinoma	3	I-Disease
.	9	O

This	5	O
case	5	O
contributes	9	O
to	5	O
the	5	O
previous	9	O
observations	9	O
that	5	O
non	9	O
-	7	O
metastasizing	5	O
hepatic	9	B-Disease
neoplasms	5	I-Disease
and	5	O
peliosis	5	B-Disease
can	5	O
develop	5	O
in	5	O
patients	5	O
with	5	O
androgen	3	B-Chemical
-	7	O
and	5	O
corticosteroid	5	B-Chemical
-	7	O
treated	3	O
Fanconi	9	B-Disease
'	9	I-Disease
s	9	I-Disease
anemia	9	I-Disease
.	9	O

The	5	O
influence	5	O
of	5	O
the	5	O
time	5	O
interval	5	O
between	5	O
monoHER	0	B-Chemical
and	5	O
doxorubicin	0	B-Chemical
administration	9	O
on	5	O
the	5	O
protection	9	O
against	9	O
doxorubicin	0	B-Chemical
-	7	O
induced	3	O
cardiotoxicity	9	B-Disease
in	5	O
mice	3	O
.	9	O

PURPOSE	2	O
:	9	O
Despite	5	O
its	9	O
well	9	O
-	7	O
known	9	O
cardiotoxicity	9	B-Disease
,	9	O
the	5	O
anthracyclin	0	O
doxorubicin	0	B-Chemical
(	9	O
DOX	0	B-Chemical
)	9	O
continues	5	O
to	5	O
be	5	O
an	5	O
effective	5	O
and	5	O
widely	5	O
used	5	O
chemotherapeutic	3	O
agent	9	O
.	9	O

DOX	0	B-Chemical
-	7	O
induced	3	O
cardiac	5	B-Disease
damage	9	I-Disease
presumably	9	O
results	9	O
from	9	O
the	5	O
formation	9	O
of	5	O
free	9	O
radicals	0	O
by	9	O
DOX	0	B-Chemical
.	9	O

Reactive	0	O
oxygen	0	B-Chemical
species	4	O
particularly	5	O
affect	9	O
the	5	O
cardiac	5	O
myocytes	3	O
because	5	O
these	5	O
cells	3	O
seem	5	O
to	5	O
have	5	O
a	5	O
relatively	5	O
poor	5	O
antioxidant	0	O
defense	5	O
system	5	O
.	9	O

The	5	O
semisynthetic	0	O
flavonoid	0	B-Chemical
monohydroxyethylrutoside	_	B-Chemical
(	9	O
monoHER	0	B-Chemical
)	9	O
showed	9	O
cardioprotection	3	O
against	9	O
DOX	0	B-Chemical
-	7	O
induced	3	O
cardiotoxicity	9	B-Disease
through	9	O
its	9	O
radical	0	O
scavenging	0	O
and	5	O
iron	0	B-Chemical
chelating	0	O
properties	9	O
.	9	O

Because	9	O
of	5	O
the	5	O
relatively	5	O
short	5	O
final	9	O
half	5	O
-	7	O
life	5	O
of	5	O
monoHER	0	B-Chemical
(	9	O
about	5	O
30	9	O
min	0	O
)	9	O
,	9	O
it	5	O
is	5	O
expected	9	O
that	5	O
the	5	O
time	5	O
interval	5	O
between	5	O
monoHER	0	B-Chemical
and	5	O
DOX	0	B-Chemical
might	9	O
be	5	O
of	5	O
influence	5	O
on	5	O
the	5	O
cardioprotective	9	O
effect	9	O
of	5	O
monoHER	0	B-Chemical
.	9	O

Therefore	9	O
,	9	O
the	5	O
aim	5	O
of	5	O
the	5	O
present	9	O
study	9	O
was	9	O
to	5	O
investigate	9	O
this	5	O
possible	5	O
effect	9	O
.	9	O

METHODS	2	O
:	9	O
Six	9	O
groups	9	O
of	5	O
6	9	O
BALB	3	O
/	9	O
c	9	O
mice	3	O
were	9	O
treated	3	O
with	5	O
saline	0	O
,	9	O
DOX	0	B-Chemical
alone	9	O
or	5	O
DOX	0	B-Chemical
(	9	O
4	9	O
mg	0	O
/	9	O
kg	0	O
i	9	O
.	9	O
v	0	O
.	9	O
)	9	O
preceded	9	O
by	9	O
monoHER	0	B-Chemical
(	9	O
500	0	O
mg	0	O
/	9	O
kg	0	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
with	5	O
an	5	O
interval	5	O
of	5	O
10	9	O
,	9	O
30	9	O
,	9	O
60	9	O
or	5	O
120	9	O
min	0	O
.	9	O

After	9	O
a	5	O
6	9	O
-	7	O
week	9	O
treatment	9	O
period	5	O
and	5	O
additional	9	O
observation	9	O
for	5	O
2	9	O
weeks	9	O
,	9	O
the	5	O
mice	3	O
were	9	O
sacrificed	3	O
.	9	O

Their	5	O
cardiac	5	O
tissues	9	O
were	9	O
processed	9	O
for	5	O
light	9	O
microscopy	9	O
,	9	O
after	9	O
which	5	O
cardiomyocyte	3	B-Disease
damage	9	I-Disease
was	9	O
evaluated	9	O
according	9	O
to	5	O
Billingham	6	O
(	9	O
in	5	O
Cancer	2	B-Disease
Treat	9	O
Rep	2	O
62	7	O
(	9	O
6	9	O
)	9	O
:	9	O
865	7	O
-	7	O
872	7	O
,	9	O
1978	2	O
)	9	O
.	9	O

Microscopic	9	O
evaluation	5	O
revealed	9	O
that	5	O
treatment	9	O
with	5	O
DOX	0	B-Chemical
alone	9	O
induced	3	O
significant	9	O
cardiac	5	B-Disease
damage	9	I-Disease
in	5	O
comparison	9	O
to	5	O
the	5	O
saline	0	O
control	9	O
group	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
.	9	O

RESULTS	9	O
:	9	O
The	5	O
number	9	O
of	5	O
damaged	9	O
cardiomyocytes	3	O
was	9	O
9	7	O
.	9	O
6	9	O
-	7	O
fold	9	O
(	9	O
95	7	O
%	9	O
CI	7	O
4	9	O
.	9	O
4	9	O
-	7	O
21	7	O
.	9	O
0	7	O
)	9	O
higher	9	O
in	5	O
mice	3	O
treated	3	O
with	5	O
DOX	0	B-Chemical
alone	9	O
than	5	O
that	5	O
in	5	O
animals	9	O
of	5	O
the	5	O
control	9	O
group	9	O
.	9	O

The	5	O
ratio	9	O
of	5	O
aberrant	3	O
cardiomyocytes	3	O
in	5	O
mice	3	O
treated	3	O
with	5	O
DOX	0	B-Chemical
preceded	9	O
by	9	O
monoHER	0	B-Chemical
and	5	O
those	5	O
in	5	O
mice	3	O
treated	3	O
with	5	O
saline	0	O
ranged	9	O
from	9	O
1	9	O
.	9	O
6	9	O
to	5	O
2	9	O
.	9	O
8	9	O
(	9	O
mean	5	O
2	9	O
.	9	O
2	9	O
,	9	O
95	7	O
%	9	O
CI	7	O
1	9	O
.	9	O
2	9	O
-	7	O
4	9	O
.	9	O
1	9	O
,	9	O
P	9	O
=	7	O
0	7	O
.	9	O
019	7	O
)	9	O
.	9	O

The	5	O
mean	5	O
protective	9	O
effect	9	O
by	9	O
adding	0	O
monoHER	0	B-Chemical
before	9	O
DOX	0	B-Chemical
led	9	O
to	5	O
a	5	O
significant	9	O
4	9	O
.	9	O
4	9	O
-	7	O
fold	9	O
reduction	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
001	9	O
,	9	O
95	7	O
%	9	O
CI	7	O
2	9	O
.	9	O
3	9	O
-	7	O
8	9	O
.	9	O
2	9	O
)	9	O
of	5	O
abnormal	9	O
cardiomyocytes	3	O
.	9	O

This	5	O
protective	9	O
effect	9	O
did	9	O
not	5	O
depend	5	O
on	5	O
the	5	O
time	5	O
interval	5	O
between	5	O
monoHER	0	B-Chemical
and	5	O
DOX	0	B-Chemical
administration	9	O
(	9	O
P	9	O
=	7	O
0	7	O
.	9	O
345	7	O
)	9	O
.	9	O

CONCLUSION	5	O
:	9	O
The	5	O
results	9	O
indicate	9	O
that	5	O
in	5	O
an	5	O
outpatient	5	O
clinical	5	O
setting	5	O
monoHER	0	B-Chemical
may	5	O
be	5	O
administered	9	O
shortly	9	O
before	9	O
DOX	0	B-Chemical
.	9	O

Clinical	5	O
evaluation	5	O
of	5	O
adverse	5	O
effects	9	O
during	5	O
bepridil	0	B-Chemical
administration	9	O
for	5	O
atrial	5	B-Disease
fibrillation	5	I-Disease
and	5	I-Disease
flutter	5	I-Disease
.	9	O

BACKGROUND	2	O
:	9	O
Bepridil	0	B-Chemical
hydrochloride	0	I-Chemical
(	9	O
Bpd	_	B-Chemical
)	9	O
has	9	O
attracted	5	O
attention	5	O
as	5	O
an	5	O
effective	5	O
drug	5	O
for	5	O
atrial	5	B-Disease
fibrillation	5	I-Disease
(	9	O
AF	9	B-Disease
)	9	O
and	5	O
atrial	5	B-Disease
flutter	5	I-Disease
(	9	O
AFL	5	B-Disease
)	9	O
.	9	O

However	9	O
,	9	O
serious	5	O
adverse	5	O
effects	9	O
,	9	O
including	9	O
torsade	5	B-Disease
de	2	I-Disease
pointes	5	I-Disease
(	9	O
Tdp	9	B-Disease
)	9	O
,	9	O
have	5	O
been	9	O
reported	9	O
.	9	O

METHODS	2	O
AND	2	O
RESULTS	9	O
:	9	O
Adverse	5	O
effects	9	O
of	5	O
Bpd	_	B-Chemical
requiring	5	O
discontinuation	5	O
of	5	O
treatment	9	O
were	9	O
evaluated	9	O
.	9	O

Bpd	_	B-Chemical
was	9	O
administered	9	O
to	5	O
459	7	O
patients	5	O
(	9	O
361	7	O
males	9	O
,	9	O
63	7	O
+	9	O
/	9	O
-	7	O
12	9	O
years	5	O
old	5	O
)	9	O
comprising	9	O
378	7	O
AF	9	B-Disease
and	5	O
81	7	O
AFL	5	B-Disease
cases	5	O
.	9	O

Mean	9	O
left	5	O
ventricular	5	O
ejection	5	O
fraction	9	O
and	5	O
atrial	5	O
dimension	5	O
(	9	O
LAD	9	O
)	9	O
were	9	O
66	7	O
+	9	O
/	9	O
-	7	O
11	7	O
%	9	O
and	5	O
40	9	O
+	9	O
/	9	O
-	7	O
6	9	O
mm	9	O
,	9	O
respectively	9	O
.	9	O

Adverse	5	O
effects	9	O
were	9	O
observed	9	O
in	5	O
19	7	O
patients	5	O
(	9	O
4	9	O
%	9	O
)	9	O
during	5	O
an	5	O
average	5	O
follow	5	O
-	7	O
up	5	O
of	5	O
20	9	O
months	5	O
.	9	O

There	5	O
was	9	O
marked	9	O
QT	5	B-Disease
prolongation	9	I-Disease
greater	5	O
than	5	O
0	7	O
.	9	O
55	7	O
s	9	O
in	5	O
13	7	O
patients	5	O
,	9	O
bradycardia	5	B-Disease
less	5	O
than	5	O
40	9	O
beats	5	O
/	9	O
min	0	O
in	5	O
6	9	O
patients	5	O
,	9	O
dizziness	5	B-Disease
and	5	O
general	5	O
fatigue	5	B-Disease
in	5	O
1	9	O
patient	5	O
each	5	O
.	9	O

In	9	O
4	9	O
of	5	O
13	7	O
patients	5	O
with	5	O
QT	5	B-Disease
prolongation	9	I-Disease
,	9	O
Tdp	9	B-Disease
occurred	9	O
.	9	O

The	5	O
major	9	O
triggering	9	O
factors	9	O
of	5	O
Tdp	9	B-Disease
were	9	O
hypokalemia	5	B-Disease
and	5	O
sudden	5	O
decrease	9	O
in	5	O
heart	5	O
rate	9	O
.	9	O

There	5	O
were	9	O
no	9	O
differences	9	O
in	5	O
the	5	O
clinical	5	O
backgrounds	9	O
of	5	O
the	5	O
patients	5	O
with	5	O
and	5	O
without	9	O
Tdp	9	B-Disease
other	5	O
than	5	O
LAD	9	O
and	5	O
age	5	O
,	9	O
which	5	O
were	9	O
larger	5	O
and	5	O
older	5	O
in	5	O
the	5	O
patients	5	O
with	5	O
Tdp	9	B-Disease
.	9	O

CONCLUSION	5	O
:	9	O
Careful	5	O
observation	9	O
of	5	O
serum	9	O
potassium	0	B-Chemical
concentration	0	O
and	5	O
the	5	O
ECG	5	O
should	5	O
always	5	O
be	5	O
done	9	O
during	5	O
Bpd	_	B-Chemical
administration	9	O
,	9	O
particularly	5	O
in	5	O
elderly	5	O
patients	5	O
.	9	O

Enhanced	9	O
isoproterenol	0	B-Chemical
-	7	O
induced	3	O
cardiac	5	B-Disease
hypertrophy	9	I-Disease
in	5	O
transgenic	3	O
rats	9	O
with	5	O
low	9	O
brain	5	O
angiotensinogen	3	O
.	9	O

We	9	O
have	5	O
previously	9	O
shown	9	O
that	5	O
a	5	O
permanent	5	O
deficiency	9	O
in	5	O
the	5	O
brain	5	O
renin	9	O
-	7	O
angiotensin	9	B-Chemical
system	5	O
(	9	O
RAS	9	O
)	9	O
may	5	O
increase	9	O
the	5	O
sensitivity	9	O
of	5	O
the	5	O
baroreflex	5	O
control	9	O
of	5	O
heart	5	O
rate	9	O
.	9	O

In	9	O
this	5	O
study	9	O
we	5	O
aimed	5	O
at	9	O
studying	5	O
the	5	O
involvement	9	O
of	5	O
the	5	O
brain	5	O
RAS	9	O
in	5	O
the	5	O
cardiac	5	O
reactivity	9	O
to	5	O
the	5	O
beta	9	O
-	7	O
adrenoceptor	5	O
(	9	O
beta	9	O
-	7	O
AR	9	O
)	9	O
agonist	3	O
isoproterenol	0	B-Chemical
(	9	O
Iso	0	B-Chemical
)	9	O
.	9	O

Transgenic	3	O
rats	9	O
with	5	O
low	9	O
brain	5	O
angiotensinogen	3	O
(	9	O
TGR	9	O
)	9	O
were	9	O
used	5	O
.	9	O

In	9	O
isolated	9	O
hearts	3	O
,	9	O
Iso	0	B-Chemical
induced	3	O
a	5	O
significantly	9	O
greater	5	O
increase	9	O
in	5	O
left	5	O
ventricular	5	O
(	9	O
LV	9	O
)	9	O
pressure	5	O
and	5	O
maximal	9	O
contraction	9	O
(	9	O
+	9	O
dP	5	O
/	9	O
dt	9	O
(	9	O
max	9	O
)	9	O
)	9	O
in	5	O
the	5	O
TGR	9	O
than	5	O
in	5	O
the	5	O
Sprague	9	O
-	7	O
Dawley	0	O
(	9	O
SD	7	O
)	9	O
rats	9	O
.	9	O

LV	9	B-Disease
hypertrophy	9	I-Disease
induced	3	O
by	9	O
Iso	0	B-Chemical
treatment	9	O
was	9	O
significantly	9	O
higher	9	O
in	5	O
TGR	9	O
than	5	O
in	5	O
SD	7	O
rats	9	O
(	9	O
in	5	O
g	0	O
LV	9	O
wt	3	O
/	9	O
100	0	O
g	0	O
body	5	O
wt	3	O
,	9	O
0	7	O
.	9	O
28	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
004	7	O
vs	7	O
.	9	O
0	7	O
.	9	O
24	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
004	7	O
,	9	O
respectively	9	O
)	9	O
.	9	O

The	5	O
greater	5	O
LV	9	B-Disease
hypertrophy	9	I-Disease
in	5	O
TGR	9	O
rats	9	O
was	9	O
associated	9	O
with	5	O
more	5	O
pronounced	9	O
downregulation	3	O
of	5	O
beta	9	O
-	7	O
AR	9	O
and	5	O
upregulation	3	O
of	5	O
LV	9	O
beta	9	O
-	7	O
AR	9	O
kinase	3	O
-	7	O
1	9	O
mRNA	3	O
levels	3	O
compared	9	O
with	5	O
those	5	O
in	5	O
SD	7	O
rats	9	O
.	9	O

The	5	O
decrease	9	O
in	5	O
the	5	O
heart	5	O
rate	9	O
(	9	O
HR	9	O
)	9	O
induced	3	O
by	9	O
the	5	O
beta	9	O
-	7	O
AR	9	O
antagonist	3	O
metoprolol	0	B-Chemical
in	5	O
conscious	5	O
rats	9	O
was	9	O
significantly	9	O
attenuated	3	O
in	5	O
TGR	9	O
compared	9	O
with	5	O
SD	7	O
rats	9	O
(	9	O
-	7	O
9	7	O
.	9	O
9	7	O
+	9	O
/	9	O
-	7	O
1	9	O
.	9	O
7	9	O
%	9	O
vs	7	O
.	9	O
-	7	O
18	7	O
.	9	O
1	9	O
+	9	O
/	9	O
-	7	O
1	9	O
.	9	O
5	9	O
%	9	O
)	9	O
,	9	O
whereas	9	O
the	5	O
effect	9	O
of	5	O
parasympathetic	5	O
blockade	3	O
by	9	O
atropine	0	B-Chemical
on	5	O
HR	9	O
was	9	O
similar	9	O
in	5	O
both	9	O
strains	1	O
.	9	O

These	5	O
results	9	O
indicate	9	O
that	5	O
TGR	9	O
are	5	O
more	5	O
sensitive	9	O
to	5	O
beta	9	O
-	7	O
AR	9	O
agonist	3	O
-	7	O
induced	3	O
cardiac	5	B-Disease
inotropic	5	I-Disease
response	9	O
and	5	O
hypertrophy	9	B-Disease
,	9	O
possibly	9	O
due	5	O
to	5	O
chronically	9	O
low	9	O
sympathetic	5	O
outflow	5	O
directed	9	O
to	5	O
the	5	O
heart	5	O
.	9	O

Drug	5	O
-	7	O
induced	3	O
long	5	B-Disease
QT	5	I-Disease
syndrome	5	I-Disease
in	5	O
injection	9	O
drug	5	O
users	5	O
receiving	9	O
methadone	5	B-Chemical
:	9	O
high	9	O
frequency	5	O
in	5	O
hospitalized	5	O
patients	5	O
and	5	O
risk	5	O
factors	9	O
.	9	O

BACKGROUND	2	O
:	9	O
Drug	5	O
-	7	O
induced	3	O
long	5	B-Disease
QT	5	I-Disease
syndrome	5	I-Disease
is	5	O
a	5	O
serious	5	O
adverse	5	O
drug	5	O
reaction	9	O
.	9	O

Methadone	7	B-Chemical
prolongs	9	O
the	5	O
QT	5	O
interval	5	O
in	5	O
vitro	3	O
in	5	O
a	5	O
dose	9	O
-	7	O
dependent	9	O
manner	9	O
.	9	O

In	9	O
the	5	O
inpatient	5	O
setting	5	O
,	9	O
the	5	O
frequency	5	O
of	5	O
QT	5	B-Disease
interval	5	I-Disease
prolongation	9	I-Disease
with	5	O
methadone	5	B-Chemical
treatment	9	O
,	9	O
its	9	O
dose	9	O
dependence	5	O
,	9	O
and	5	O
the	5	O
importance	5	O
of	5	O
cofactors	9	O
such	5	O
as	5	O
drug	5	O
-	7	O
drug	5	O
interactions	9	O
remain	9	O
unknown	9	O
.	9	O

METHODS	2	O
:	9	O
We	9	O
performed	9	O
a	5	O
systematic	5	O
,	9	O
retrospective	5	O
study	9	O
comparing	9	O
active	9	O
or	5	O
former	5	O
intravenous	0	O
drug	5	O
users	5	O
receiving	9	O
methadone	5	B-Chemical
and	5	O
those	5	O
not	5	O
receiving	9	O
methadone	5	B-Chemical
among	5	O
all	5	O
patients	5	O
hospitalized	5	O
over	5	O
a	5	O
5	9	O
-	7	O
year	5	O
period	5	O
in	5	O
a	5	O
tertiary	9	O
care	5	O
hospital	5	O
.	9	O

A	9	O
total	9	O
of	5	O
167	7	O
patients	5	O
receiving	9	O
methadone	5	B-Chemical
fulfilled	5	O
the	5	O
inclusion	5	O
criteria	5	O
and	5	O
were	9	O
compared	9	O
with	5	O
a	5	O
control	9	O
group	9	O
of	5	O
80	9	O
injection	9	O
drug	5	O
users	5	O
not	5	O
receiving	9	O
methadone	5	B-Chemical
.	9	O

In	9	O
addition	9	O
to	5	O
methadone	5	B-Chemical
dose	9	O
,	9	O
15	9	O
demographic	5	O
,	9	O
biological	5	O
,	9	O
and	5	O
pharmacological	9	O
variables	5	O
were	9	O
considered	5	O
as	5	O
potential	9	O
risk	5	O
factors	9	O
for	5	O
QT	5	B-Disease
prolongation	9	I-Disease
.	9	O

RESULTS	9	O
:	9	O
Among	9	O
167	7	O
methadone	5	B-Chemical
maintenance	9	O
patients	5	O
,	9	O
the	5	O
prevalence	5	O
of	5	O
QTc	5	O
prolongation	9	O
to	5	O
0	7	O
.	9	O
50	0	O
second	9	O
(	9	O
(	9	O
1	9	O
/	9	O
2	9	O
)	9	O
)	9	O
or	5	O
longer	5	O
was	9	O
16	9	O
.	9	O
2	9	O
%	9	O
compared	9	O
with	5	O
0	7	O
%	9	O
in	5	O
80	9	O
control	9	O
subjects	5	O
.	9	O

Six	9	O
patients	5	O
(	9	O
3	9	O
.	9	O
6	9	O
%	9	O
)	9	O
in	5	O
the	5	O
methadone	5	B-Chemical
group	9	O
presented	5	O
torsades	5	B-Disease
de	2	I-Disease
pointes	5	I-Disease
.	9	O

QTc	5	O
length	9	O
was	9	O
weakly	9	O
but	9	O
significantly	9	O
associated	9	O
with	5	O
methadone	5	B-Chemical
daily	5	O
dose	9	O
(	9	O
Spearman	5	O
rank	5	O
correlation	9	O
coefficient	5	O
,	9	O
0	7	O
.	9	O
20	9	O
;	9	O
P	9	O
<	0	O
.	9	O
01	7	O
)	9	O
.	9	O

Multivariate	5	O
regression	5	O
analysis	9	O
allowed	9	O
attribution	5	O
of	5	O
31	7	O
.	9	O
8	9	O
%	9	O
of	5	O
QTc	5	O
variability	5	O
to	5	O
methadone	5	B-Chemical
dose	9	O
,	9	O
cytochrome	0	O
P	9	O
-	7	O
450	9	O
3A4	0	O
drug	5	O
-	7	O
drug	5	O
interactions	9	O
,	9	O
hypokalemia	5	B-Disease
,	9	O
and	5	O
altered	9	O
liver	9	O
function	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
QT	5	B-Disease
interval	5	I-Disease
prolongation	9	I-Disease
in	5	O
methadone	5	B-Chemical
maintenance	9	O
patients	5	O
hospitalized	5	O
in	5	O
a	5	O
tertiary	9	O
care	5	O
center	5	O
is	5	O
a	5	O
frequent	5	O
finding	9	O
.	9	O

Methadone	7	B-Chemical
dose	9	O
,	9	O
presence	9	O
of	5	O
cytochrome	0	O
P	9	O
-	7	O
450	9	O
3A4	0	O
inhibitors	3	O
,	9	O
potassium	0	B-Chemical
level	9	O
,	9	O
and	5	O
liver	9	O
function	9	O
contribute	9	O
to	5	O
QT	5	B-Disease
prolongation	9	I-Disease
.	9	O

Long	9	B-Disease
QT	5	I-Disease
syndrome	5	I-Disease
can	5	O
occur	5	O
with	5	O
low	9	O
doses	0	O
of	5	O
methadone	5	B-Chemical
.	9	O

Mechanisms	9	O
of	5	O
hypertension	5	B-Disease
induced	3	O
by	9	O
nitric	0	B-Chemical
oxide	0	I-Chemical
(	9	O
NO	9	B-Chemical
)	9	O
deficiency	9	O
:	9	O
focus	5	O
on	5	O
venous	5	O
function	9	O
.	9	O

Loss	9	O
of	5	O
endothelial	3	O
cell	3	O
-	7	O
derived	9	O
nitric	0	B-Chemical
oxide	0	I-Chemical
(	9	O
NO	9	B-Chemical
)	9	O
in	5	O
hypertension	5	B-Disease
is	5	O
a	5	O
hallmark	9	O
of	5	O
arterial	5	B-Disease
dysfunction	9	I-Disease
.	9	O

Experimental	9	O
hypertension	5	B-Disease
created	5	O
by	9	O
the	5	O
removal	9	O
of	5	O
NO	9	B-Chemical
,	9	O
however	9	O
,	9	O
involves	5	O
mechanisms	9	O
in	5	O
addition	9	O
to	5	O
decreased	9	O
arterial	5	O
vasodilator	0	O
activity	9	O
.	9	O

These	5	O
include	5	O
augmented	9	O
endothelin	3	O
-	7	O
1	9	O
(	9	O
ET	9	O
-	7	O
1	9	O
)	9	O
release	9	O
,	9	O
increased	9	O
sympathetic	5	O
nervous	5	O
system	5	O
activity	9	O
,	9	O
and	5	O
elevated	9	O
tissue	9	O
oxidative	9	O
stress	9	O
.	9	O

We	9	O
hypothesized	9	O
that	5	O
increased	9	O
venous	5	O
smooth	5	O
muscle	9	O
(	9	O
venomotor	9	O
)	9	O
tone	5	O
plays	9	O
a	5	O
role	9	O
in	5	O
Nomega	_	B-Chemical
-	7	I-Chemical
nitro	0	I-Chemical
-	7	I-Chemical
L	0	I-Chemical
-	7	I-Chemical
arginine	0	I-Chemical
(	9	O
LNNA	0	B-Chemical
)	9	O
hypertension	5	B-Disease
through	9	O
these	5	O
mechanisms	9	O
.	9	O

Rats	9	O
were	9	O
treated	3	O
with	5	O
the	5	O
NO	9	B-Chemical
synthase	1	O
inhibitor	3	O
LNNA	0	B-Chemical
(	9	O
0	7	O
.	9	O
5	9	O
g	0	O
/	9	O
L	0	O
in	5	O
drinking	5	O
water	0	O
)	9	O
for	5	O
2	9	O
weeks	9	O
.	9	O

Mean	9	O
arterial	5	O
pressure	5	O
of	5	O
conscious	5	O
rats	9	O
was	9	O
119	7	O
+	9	O
/	9	O
-	7	O
2	9	O
mm	9	O
Hg	0	O
in	5	O
control	9	O
and	5	O
194	7	O
+	9	O
/	9	O
-	7	O
5	9	O
mm	9	O
Hg	0	O
in	5	O
LNNA	0	B-Chemical
rats	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

Carotid	5	O
arteries	5	O
and	5	O
vena	5	O
cava	5	O
were	9	O
removed	9	O
for	5	O
measurement	5	O
of	5	O
isometric	5	O
contraction	9	O
.	9	O

Maximal	9	O
contraction	9	O
to	5	O
norepinephrine	9	B-Chemical
was	9	O
modestly	9	O
reduced	9	O
in	5	O
arteries	5	O
from	9	O
LNNA	0	B-Chemical
compared	9	O
with	5	O
control	9	O
rats	9	O
whereas	9	O
the	5	O
maximum	5	O
contraction	9	O
to	5	O
ET	9	O
-	7	O
1	9	O
was	9	O
significantly	9	O
reduced	9	O
(	9	O
54	7	O
%	9	O
control	9	O
)	9	O
.	9	O

Maximum	9	O
contraction	9	O
of	5	O
vena	5	O
cava	5	O
to	5	O
norepinephrine	9	B-Chemical
(	9	O
37	9	O
%	9	O
control	9	O
)	9	O
also	9	O
was	9	O
reduced	9	O
but	9	O
no	9	O
change	9	O
in	5	O
response	9	O
to	5	O
ET	9	O
-	7	O
1	9	O
was	9	O
observed	9	O
.	9	O

Mean	9	O
circulatory	5	O
filling	5	O
pressure	5	O
,	9	O
an	5	O
in	5	O
vivo	3	O
measure	5	O
of	5	O
venomotor	9	O
tone	5	O
,	9	O
was	9	O
not	5	O
elevated	9	O
in	5	O
LNNA	0	B-Chemical
hypertension	5	B-Disease
at	9	O
1	9	O
or	5	O
2	9	O
weeks	9	O
after	9	O
LNNA	0	B-Chemical
.	9	O

The	5	O
superoxide	0	B-Chemical
scavenger	0	O
tempol	0	B-Chemical
(	9	O
30	9	O
,	9	O
100	0	O
,	9	O
and	5	O
300	0	O
micromol	0	O
kg	0	O
(	9	O
-	7	O
1	9	O
)	9	O
,	9	O
IV	9	O
)	9	O
did	9	O
not	5	O
change	9	O
arterial	5	O
pressure	5	O
in	5	O
control	9	O
rats	9	O
but	9	O
caused	9	O
a	5	O
dose	9	O
-	7	O
dependent	9	O
decrease	9	O
in	5	O
LNNA	0	B-Chemical
rats	9	O
(	9	O
-	7	O
18	7	O
+	9	O
/	9	O
-	7	O
8	9	O
,	9	O
-	7	O
26	7	O
+	9	O
/	9	O
-	7	O
15	9	O
,	9	O
and	5	O
-	7	O
54	7	O
+	9	O
/	9	O
-	7	O
11	7	O
mm	9	O
Hg	0	O
)	9	O
.	9	O

Similarly	9	O
,	9	O
ganglionic	3	O
blockade	3	O
with	5	O
hexamethonium	0	B-Chemical
caused	9	O
a	5	O
significantly	9	O
greater	5	O
fall	5	O
in	5	O
LNNA	0	B-Chemical
hypertensive	5	B-Disease
rats	9	O
(	9	O
76	7	O
+	9	O
/	9	O
-	7	O
9	7	O
mm	9	O
Hg	0	O
)	9	O
compared	9	O
with	5	O
control	9	O
rats	9	O
(	9	O
35	9	O
+	9	O
/	9	O
-	7	O
10	9	O
mm	9	O
Hg	0	O
)	9	O
.	9	O

Carotid	5	O
arteries	5	O
,	9	O
vena	5	O
cava	5	O
,	9	O
and	5	O
sympathetic	5	O
ganglia	5	O
from	9	O
LNNA	0	B-Chemical
rats	9	O
had	9	O
higher	9	O
basal	3	O
levels	3	O
of	5	O
superoxide	0	B-Chemical
compared	9	O
with	5	O
those	5	O
from	9	O
control	9	O
rats	9	O
.	9	O

These	5	O
data	5	O
suggest	9	O
that	5	O
while	9	O
NO	9	B-Chemical
deficiency	9	O
increases	9	O
oxidative	9	O
stress	9	O
and	5	O
sympathetic	5	O
activity	9	O
in	5	O
both	9	O
arterial	5	O
and	5	O
venous	5	O
vessels	5	O
,	9	O
the	5	O
impact	5	O
on	5	O
veins	5	O
does	9	O
not	5	O
make	5	O
a	5	O
major	9	O
contribution	9	O
to	5	O
this	5	O
form	9	O
of	5	O
hypertension	5	B-Disease
.	9	O

Association	2	O
of	5	O
DRD2	1	O
polymorphisms	9	O
and	5	O
chlorpromazine	0	B-Chemical
-	7	O
induced	3	O
extrapyramidal	5	B-Disease
syndrome	5	I-Disease
in	5	O
Chinese	9	O
schizophrenic	5	B-Disease
patients	5	O
.	9	O

AIM	9	O
:	9	O
Extrapyramidal	5	B-Disease
syndrome	5	I-Disease
(	9	O
EPS	9	B-Disease
)	9	O
is	5	O
most	9	O
commonly	5	O
affected	9	O
by	9	O
typical	9	O
antipsychotic	5	O
drugs	5	O
that	5	O
have	5	O
a	5	O
high	9	O
affinity	0	O
with	5	O
the	5	O
D2	9	O
receptor	3	O
.	9	O

Recently	9	O
,	9	O
many	5	O
research	5	O
groups	9	O
have	5	O
reported	9	O
on	5	O
the	5	O
positive	9	O
relationship	5	O
between	5	O
the	5	O
genetic	5	O
variations	5	O
in	5	O
the	5	O
DRD2	1	O
gene	1	O
and	5	O
the	5	O
therapeutic	5	O
response	9	O
in	5	O
schizophrenia	5	B-Disease
patients	5	O
as	5	O
a	5	O
result	9	O
of	5	O
the	5	O
role	9	O
of	5	O
variations	5	O
in	5	O
the	5	O
receptor	3	O
in	5	O
modulating	9	O
receptor	3	O
expression	3	O
.	9	O

In	9	O
this	5	O
study	9	O
,	9	O
we	5	O
evaluate	9	O
the	5	O
role	9	O
DRD2	1	O
plays	9	O
in	5	O
chlorpromazine	0	B-Chemical
-	7	O
induced	3	O
EPS	9	B-Disease
in	5	O
schizophrenic	5	B-Disease
patients	5	O
.	9	O

METHODS	2	O
:	9	O
We	9	O
identified	9	O
seven	9	O
SNP	9	O
(	9	O
single	9	O
nucleotide	1	O
polymorphism	9	O
)	9	O
(	9	O
-	7	O
141Cins	_	O
>	0	O
del	2	O
,	9	O
TaqIB	7	O
,	9	O
TaqID	7	O
,	9	O
Ser311Cys	1	O
,	9	O
rs6275	7	O
,	9	O
rs6277	7	O
and	5	O
TaqIA	1	O
)	9	O
in	5	O
the	5	O
DRD2	1	O
gene	1	O
in	5	O
146	7	O
schizophrenic	5	B-Disease
inpatients	5	O
(	9	O
59	7	O
with	5	O
EPS	9	B-Disease
and	5	O
87	7	O
without	9	O
EPS	9	B-Disease
according	9	O
to	5	O
the	5	O
Simpson	6	O
-	7	O
Angus	6	O
Scale	5	O
)	9	O
treated	3	O
with	5	O
chlorpromazine	0	B-Chemical
after	9	O
8	9	O
weeks	9	O
.	9	O

The	5	O
alleles	1	O
of	5	O
all	5	O
loci	9	O
were	9	O
determined	9	O
by	9	O
PCR	9	O
(	9	O
polymerase	1	O
chain	9	O
reaction	9	O
)	9	O
.	9	O

RESULTS	9	O
:	9	O
Polymorphisms	9	O
TaqID	7	O
,	9	O
Ser311Cys	1	O
and	5	O
rs6277	7	O
were	9	O
not	5	O
polymorphic	9	O
in	5	O
the	5	O
population	5	O
recruited	9	O
in	5	O
the	5	O
present	9	O
study	9	O
.	9	O

No	9	O
statistical	5	O
significance	9	O
was	9	O
found	9	O
in	5	O
the	5	O
allele	1	O
distribution	9	O
of	5	O
-	7	O
141Cins	_	O
>	0	O
del	2	O
,	9	O
TaqIB	7	O
,	9	O
rs6275	7	O
and	5	O
TaqIA	1	O
or	5	O
in	5	O
the	5	O
estimated	5	O
haplotypes	9	O
(	9	O
constituted	9	O
by	9	O
TaqIB	7	O
,	9	O
rs6275	7	O
and	5	O
TaqIA	1	O
)	9	O
in	5	O
linkage	9	O
disequilibrium	5	O
between	5	O
the	5	O
two	5	O
groups	9	O
.	9	O

CONCLUSION	5	O
:	9	O
Our	9	O
results	9	O
did	9	O
not	5	O
lend	5	O
strong	9	O
support	5	O
to	5	O
the	5	O
view	5	O
that	5	O
the	5	O
genetic	5	O
variation	5	O
of	5	O
the	5	O
DRD2	1	O
gene	1	O
plays	9	O
a	5	O
major	9	O
role	9	O
in	5	O
the	5	O
individually	9	O
variable	5	O
adverse	5	O
effect	9	O
induced	3	O
by	9	O
chlorpromazine	0	B-Chemical
,	9	O
at	9	O
least	9	O
in	5	O
Chinese	9	O
patients	5	O
with	5	O
schizophrenia	5	B-Disease
.	9	O

Our	9	O
results	9	O
confirmed	9	O
a	5	O
previous	9	O
study	9	O
on	5	O
the	5	O
relationship	5	O
between	5	O
DRD2	1	O
and	5	O
EPS	9	B-Disease
in	5	O
Caucasians	9	O
.	9	O

Physical	5	O
training	5	O
decreases	9	O
susceptibility	9	O
to	5	O
subsequent	9	O
pilocarpine	0	B-Chemical
-	7	O
induced	3	O
seizures	5	B-Disease
in	5	O
the	5	O
rat	3	O
.	9	O

Regular	5	O
motor	5	O
activity	9	O
has	9	O
many	5	O
benefits	5	O
for	5	O
mental	5	O
and	5	O
physical	5	O
condition	5	O
but	9	O
its	9	O
implications	5	O
for	5	O
epilepsy	5	B-Disease
are	5	O
still	5	O
controversial	9	O
.	9	O

In	9	O
order	5	O
to	5	O
elucidate	9	O
this	5	O
problem	5	O
,	9	O
we	5	O
have	5	O
studied	9	O
the	5	O
effect	9	O
of	5	O
long	5	O
-	7	O
term	5	O
physical	5	O
activity	9	O
on	5	O
susceptibility	9	O
to	5	O
subsequent	9	O
seizures	5	B-Disease
.	9	O

Male	7	O
Wistar	9	O
rats	9	O
were	9	O
subjected	9	O
to	5	O
repeated	5	O
training	5	O
sessions	5	O
in	5	O
a	5	O
treadmill	5	O
and	5	O
swimming	5	O
pool	9	O
.	9	O

Thereafter	9	O
,	9	O
seizures	5	B-Disease
were	9	O
induced	3	O
by	9	O
pilocarpine	0	B-Chemical
injections	9	O
in	5	O
trained	5	O
and	5	O
non	9	O
-	7	O
trained	5	O
control	9	O
groups	9	O
.	9	O

During	5	O
the	5	O
acute	9	O
period	5	O
of	5	O
status	9	B-Disease
epilepticus	5	I-Disease
,	9	O
we	5	O
measured	9	O
:	9	O
(	9	O
1	9	O
)	9	O
the	5	O
latency	5	O
of	5	O
the	5	O
first	9	O
motor	5	O
sign	5	O
,	9	O
(	9	O
2	9	O
)	9	O
the	5	O
intensity	5	O
of	5	O
seizures	5	B-Disease
,	9	O
(	9	O
3	9	O
)	9	O
the	5	O
time	5	O
when	5	O
it	5	O
occurred	9	O
within	9	O
the	5	O
6	9	O
-	7	O
h	0	O
observation	9	O
period	5	O
,	9	O
and	5	O
(	9	O
4	9	O
)	9	O
the	5	O
time	5	O
when	5	O
the	5	O
acute	9	O
period	5	O
ended	5	O
.	9	O

All	9	O
these	5	O
behavioral	5	O
parameters	5	O
showed	9	O
statistically	9	O
significant	9	O
changes	9	O
suggesting	9	O
that	5	O
regular	5	O
physical	5	O
exercises	5	O
decrease	9	O
susceptibility	9	O
to	5	O
subsequently	9	O
induced	3	O
seizures	5	B-Disease
and	5	O
ameliorate	9	O
the	5	O
course	5	O
of	5	O
experimentally	9	O
induced	3	O
status	9	B-Disease
epilepticus	5	I-Disease
.	9	O

Tonic	5	O
dopaminergic	5	O
stimulation	3	O
impairs	9	B-Disease
associative	5	I-Disease
learning	5	I-Disease
in	5	O
healthy	5	O
subjects	5	O
.	9	O

Endogenous	3	O
dopamine	5	B-Chemical
plays	9	O
a	5	O
central	5	O
role	9	O
in	5	O
salience	5	O
coding	1	O
during	5	O
associative	5	O
learning	5	O
.	9	O

Administration	2	O
of	5	O
the	5	O
dopamine	5	B-Chemical
precursor	9	O
levodopa	5	B-Chemical
enhances	3	O
learning	5	O
in	5	O
healthy	5	O
subjects	5	O
and	5	O
stroke	5	B-Disease
patients	5	O
.	9	O

Because	9	O
levodopa	5	B-Chemical
increases	9	O
both	9	O
phasic	5	O
and	5	O
tonic	5	O
dopaminergic	5	O
neurotransmission	5	O
,	9	O
the	5	O
critical	9	O
mechanism	9	O
mediating	9	O
the	5	O
enhancement	9	O
of	5	O
learning	5	O
is	5	O
unresolved	9	O
.	9	O

We	9	O
here	5	O
probed	3	O
how	5	O
selective	9	O
tonic	5	O
dopaminergic	5	O
stimulation	3	O
affects	9	O
associative	5	O
learning	5	O
.	9	O

Forty	9	O
healthy	5	O
subjects	5	O
were	9	O
trained	5	O
in	5	O
a	5	O
novel	9	O
vocabulary	5	O
of	5	O
45	9	O
concrete	5	O
nouns	5	O
over	5	O
the	5	O
course	5	O
of	5	O
5	9	O
consecutive	5	O
training	5	O
days	9	O
in	5	O
a	5	O
prospective	5	O
,	9	O
randomized	5	O
,	9	O
double	9	O
-	7	O
blind	5	O
,	9	O
placebo	9	O
-	7	O
controlled	5	O
design	5	O
.	9	O

Subjects	5	O
received	9	O
the	5	O
tonically	5	O
stimulating	9	O
dopamine	5	B-Chemical
-	7	O
receptor	3	O
agonist	3	O
pergolide	0	B-Chemical
(	9	O
0	7	O
.	9	O
1	9	O
mg	0	O
)	9	O
vs	7	O
placebo	9	O
120	9	O
min	0	O
before	9	O
training	5	O
on	5	O
each	5	O
training	5	O
day	9	O
.	9	O

The	5	O
dopamine	5	B-Chemical
agonist	3	O
significantly	9	O
impaired	9	B-Disease
novel	9	I-Disease
word	5	I-Disease
learning	5	I-Disease
compared	9	O
to	5	O
placebo	9	O
.	9	O

This	5	O
learning	5	O
decrement	5	O
persisted	9	O
up	5	O
to	5	O
the	5	O
last	5	O
follow	5	O
-	7	O
up	5	O
4	9	O
weeks	9	O
post	9	O
-	7	O
training	5	O
.	9	O

Subjects	5	O
treated	3	O
with	5	O
pergolide	0	B-Chemical
also	9	O
showed	9	O
restricted	9	O
emotional	5	O
responses	5	O
compared	9	O
to	5	O
the	5	O
PLACEBO	2	O
group	9	O
.	9	O

The	5	O
extent	9	O
of	5	O
'	9	O
flattened	5	O
'	9	O
affect	9	O
with	5	O
pergolide	0	B-Chemical
was	9	O
related	9	O
to	5	O
the	5	O
degree	5	O
of	5	O
learning	5	O
inhibition	3	O
.	9	O

These	5	O
findings	9	O
suggest	9	O
that	5	O
tonic	5	O
occupation	5	O
of	5	O
dopamine	5	B-Chemical
receptors	3	O
impairs	9	O
learning	5	O
by	9	O
competition	5	O
with	5	O
phasic	5	O
dopamine	5	B-Chemical
signals	9	O
.	9	O

Thus	9	O
,	9	O
phasic	5	O
signaling	3	O
seems	5	O
to	5	O
be	5	O
the	5	O
critical	9	O
mechanism	9	O
by	9	O
which	5	O
dopamine	5	B-Chemical
enhances	3	O
associative	5	O
learning	5	O
in	5	O
healthy	5	O
subjects	5	O
and	5	O
stroke	5	B-Disease
patients	5	O
.	9	O

Minocycline	0	B-Chemical
-	7	O
induced	3	O
vasculitis	5	B-Disease
fulfilling	5	O
the	5	O
criteria	5	O
of	5	O
polyarteritis	5	B-Disease
nodosa	4	I-Disease
.	9	O

A	9	O
47	7	O
-	7	O
year	5	O
-	7	O
old	5	O
man	5	O
who	5	O
had	9	O
been	9	O
taking	5	O
minocycline	0	B-Chemical
for	5	O
palmoplantar	5	B-Disease
pustulosis	5	I-Disease
developed	5	O
fever	5	B-Disease
,	9	O
myalgias	5	B-Disease
,	9	O
polyneuropathy	5	B-Disease
,	9	O
and	5	O
testicular	9	B-Disease
pain	5	I-Disease
,	9	O
with	5	O
elevated	9	O
C	9	O
-	7	O
reactive	9	O
protein	1	O
(	9	O
CRP	9	O
)	9	O
.	9	O

Neither	9	O
myeloperoxidase	0	O
-	7	O
nor	9	O
proteinase	0	O
-	7	O
3	9	O
-	7	O
antineutrophil	3	O
cytoplasmic	3	O
antibody	3	O
was	9	O
positive	9	O
.	9	O

These	5	O
manifestations	5	O
met	5	O
the	5	O
American	9	O
College	2	O
of	5	O
Rheumatology	2	O
1990	2	O
criteria	5	O
for	5	O
the	5	O
classification	5	O
of	5	O
polyarteritis	5	B-Disease
nodosa	4	I-Disease
.	9	O

Stopping	5	O
minocycline	0	B-Chemical
led	9	O
to	5	O
amelioration	9	O
of	5	O
symptoms	5	O
and	5	O
normalization	5	O
of	5	O
CRP	9	O
level	9	O
.	9	O

To	9	O
our	5	O
knowledge	5	O
,	9	O
this	5	O
is	5	O
the	5	O
second	9	O
case	5	O
of	5	O
minocycline	0	B-Chemical
-	7	O
induced	3	O
vasculitis	5	B-Disease
satisfying	5	O
the	5	O
criteria	5	O
.	9	O

Differential	9	O
diagnosis	5	O
for	5	O
drug	5	O
-	7	O
induced	3	O
disease	5	O
is	5	O
invaluable	6	O
even	5	O
for	5	O
patients	5	O
with	5	O
classical	9	O
polyarteritis	5	B-Disease
nodosa	4	I-Disease
.	9	O

Intramuscular	0	O
hepatitis	9	B-Disease
B	9	I-Disease
immune	3	O
globulin	9	O
combined	9	O
with	5	O
lamivudine	5	B-Chemical
in	5	O
prevention	5	O
of	5	O
hepatitis	9	B-Disease
B	9	I-Disease
recurrence	5	O
after	9	O
liver	9	O
transplantation	9	O
.	9	O

BACKGROUND	2	O
:	9	O
Combined	9	O
hepatitis	9	B-Disease
B	9	I-Disease
immune	3	O
globulin	9	O
(	9	O
HBIg	3	O
)	9	O
and	5	O
lamivudine	5	B-Chemical
in	5	O
prophylaxis	5	O
of	5	O
the	5	O
recurrence	5	O
of	5	O
hepatitis	9	B-Disease
B	9	I-Disease
after	9	O
liver	9	O
transplantation	9	O
has	9	O
significantly	9	O
improved	5	O
the	5	O
survival	9	O
of	5	O
HBsAg	9	B-Chemical
positive	9	O
patients	5	O
.	9	O

This	5	O
study	9	O
was	9	O
undertaken	5	O
to	5	O
evaluate	9	O
the	5	O
outcomes	5	O
of	5	O
liver	9	O
transplantation	9	O
for	5	O
patients	5	O
with	5	O
hepatitis	9	B-Disease
B	9	I-Disease
virus	9	O
(	9	O
HBV	9	O
)	9	O
.	9	O

METHODS	2	O
:	9	O
A	9	O
retrospective	5	O
chart	5	O
analysis	9	O
and	5	O
a	5	O
review	5	O
of	5	O
the	5	O
organ	5	O
transplant	9	O
database	5	O
identified	9	O
51	7	O
patients	5	O
(	9	O
43	7	O
men	5	O
and	5	O
8	9	O
women	5	O
)	9	O
transplanted	3	O
for	5	O
benign	5	O
HBV	9	O
-	7	O
related	9	O
cirrhotic	5	B-Disease
diseases	5	I-Disease
between	5	O
June	2	O
2002	2	O
and	5	O
December	2	O
2004	2	O
who	5	O
had	9	O
survived	9	O
more	5	O
than	5	O
3	9	O
months	5	O
.	9	O

HBIg	3	O
was	9	O
administered	9	O
intravenously	0	O
during	5	O
the	5	O
first	9	O
week	9	O
and	5	O
intramuscularly	0	O
thereafter	9	O
.	9	O

RESULTS	9	O
:	9	O
At	9	O
a	5	O
median	9	O
follow	5	O
-	7	O
up	5	O
of	5	O
14	7	O
.	9	O
1	9	O
months	5	O
,	9	O
the	5	O
overall	5	O
recurrence	5	O
rate	9	O
in	5	O
the	5	O
51	7	O
patients	5	O
was	9	O
3	9	O
.	9	O
9	7	O
%	9	O
(	9	O
2	9	O
/	9	O
51	7	O
)	9	O
.	9	O

The	5	O
overall	5	O
patient	5	O
survival	9	O
was	9	O
88	7	O
.	9	O
3	9	O
%	9	O
,	9	O
and	5	O
82	7	O
.	9	O
4	9	O
%	9	O
after	9	O
1	9	O
and	5	O
2	9	O
years	5	O
,	9	O
respectively	9	O
.	9	O

A	9	O
daily	5	O
oral	9	O
dose	9	O
of	5	O
100	0	O
mg	0	O
lamivudine	5	B-Chemical
for	5	O
2	9	O
weeks	9	O
before	9	O
transplantation	9	O
for	5	O
10	9	O
patients	5	O
enabled	5	O
57	7	O
.	9	O
1	9	O
%	9	O
(	9	O
4	9	O
/	9	O
7	9	O
)	9	O
and	5	O
62	7	O
.	9	O
5	9	O
%	9	O
(	9	O
5	9	O
/	9	O
8	9	O
)	9	O
of	5	O
HBV	9	O
-	7	O
DNA	9	O
and	5	O
HBeAg	9	B-Chemical
positive	9	O
patients	5	O
respectively	9	O
to	5	O
convert	9	O
to	5	O
be	5	O
negative	9	O
.	9	O

Intramuscular	0	O
HBIg	3	O
was	9	O
well	9	O
tolerated	9	O
in	5	O
all	5	O
patients	5	O
.	9	O

CONCLUSION	5	O
:	9	O
Lamivudine	7	B-Chemical
combined	9	O
with	5	O
intramuscular	9	O
HBIg	3	O
can	5	O
effectively	5	O
prevent	5	O
allograft	5	O
from	9	O
the	5	O
recurrence	5	O
of	5	O
HBV	9	O
after	9	O
liver	9	O
transplantation	9	O
.	9	O

Anticonvulsant	0	O
effect	9	O
of	5	O
eslicarbazepine	0	B-Chemical
acetate	0	I-Chemical
(	9	O
BIA	5	B-Chemical
2	9	I-Chemical
-	7	I-Chemical
093	7	I-Chemical
)	9	O
on	5	O
seizures	5	B-Disease
induced	3	O
by	9	O
microperfusion	5	O
of	5	O
picrotoxin	0	B-Chemical
in	5	O
the	5	O
hippocampus	9	O
of	5	O
freely	5	O
moving	5	O
rats	9	O
.	9	O

Eslicarbazepine	0	B-Chemical
acetate	0	I-Chemical
(	9	O
BIA	5	B-Chemical
2	9	I-Chemical
-	7	I-Chemical
093	7	I-Chemical
,	9	O
S	9	B-Chemical
-	7	I-Chemical
(	9	I-Chemical
-	7	I-Chemical
)	9	I-Chemical
-	7	I-Chemical
10	9	I-Chemical
-	7	I-Chemical
acetoxy	0	I-Chemical
-	7	I-Chemical
10	9	I-Chemical
,	9	I-Chemical
11	7	I-Chemical
-	7	I-Chemical
dihydro	0	I-Chemical
-	7	I-Chemical
5H	0	I-Chemical
-	7	I-Chemical
dibenzo	0	I-Chemical
/	9	I-Chemical
b	9	I-Chemical
,	9	I-Chemical
f	9	I-Chemical
/	9	I-Chemical
azepine	0	I-Chemical
-	7	I-Chemical
5	9	I-Chemical
-	7	I-Chemical
carboxamide	0	I-Chemical
)	9	O
is	5	O
a	5	O
novel	9	O
antiepileptic	5	O
drug	5	O
,	9	O
now	5	O
in	5	O
Phase	9	O
III	9	O
clinical	5	O
trials	5	O
,	9	O
designed	9	O
with	5	O
the	5	O
aim	5	O
of	5	O
improving	5	O
efficacy	9	O
and	5	O
safety	5	O
in	5	O
comparison	9	O
with	5	O
the	5	O
structurally	9	O
related	9	O
drugs	5	O
carbamazepine	0	B-Chemical
(	9	O
CBZ	0	B-Chemical
)	9	O
and	5	O
oxcarbazepine	0	B-Chemical
(	9	O
OXC	0	B-Chemical
)	9	O
.	9	O

We	9	O
have	5	O
studied	9	O
the	5	O
effects	9	O
of	5	O
oral	9	O
treatment	9	O
with	5	O
eslicarbazepine	0	B-Chemical
acetate	0	I-Chemical
on	5	O
a	5	O
whole	9	O
-	7	O
animal	5	O
model	5	O
in	5	O
which	5	O
partial	9	O
seizures	5	B-Disease
can	5	O
be	5	O
elicited	9	O
repeatedly	5	O
on	5	O
different	9	O
days	9	O
without	9	O
changes	9	O
in	5	O
threshold	5	O
or	5	O
seizure	5	B-Disease
patterns	5	O
.	9	O

In	9	O
the	5	O
animals	9	O
treated	3	O
with	5	O
threshold	5	O
doses	0	O
of	5	O
picrotoxin	0	B-Chemical
,	9	O
the	5	O
average	5	O
number	9	O
of	5	O
seizures	5	B-Disease
was	9	O
2	9	O
.	9	O
3	9	O
+	9	O
/	9	O
-	7	O
1	9	O
.	9	O
2	9	O
,	9	O
and	5	O
average	5	O
seizure	5	B-Disease
duration	5	O
was	9	O
39	7	O
.	9	O
5	9	O
+	9	O
/	9	O
-	7	O
8	9	O
.	9	O
4s	0	O
.	9	O

Pre	9	O
-	7	O
treatment	9	O
with	5	O
a	5	O
dose	9	O
of	5	O
30	9	O
mg	0	O
/	9	O
kg	0	O
2h	0	O
before	9	O
picrotoxin	0	B-Chemical
microperfusion	5	O
prevented	9	O
seizures	5	B-Disease
in	5	O
the	5	O
75	9	O
%	9	O
of	5	O
the	5	O
rats	9	O
.	9	O

Lower	9	O
doses	0	O
(	9	O
3	9	O
and	5	O
10mg	0	O
/	9	O
kg	0	O
)	9	O
did	9	O
not	5	O
suppress	3	O
seizures	5	B-Disease
,	9	O
however	9	O
,	9	O
after	9	O
administration	9	O
of	5	O
10mg	0	O
/	9	O
kg	0	O
,	9	O
significant	9	O
reductions	9	O
in	5	O
seizures	5	B-Disease
duration	5	O
(	9	O
24	9	O
.	9	O
3	9	O
+	9	O
/	9	O
-	7	O
6	9	O
.	9	O
8s	0	O
)	9	O
and	5	O
seizure	5	B-Disease
number	9	O
(	9	O
1	9	O
.	9	O
6	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
34	7	O
)	9	O
were	9	O
found	9	O
.	9	O

No	9	O
adverse	5	O
effects	9	O
of	5	O
eslicarbazepine	0	B-Chemical
acetate	0	I-Chemical
were	9	O
observed	9	O
in	5	O
the	5	O
behavioral	5	O
/	9	O
EEG	5	O
patterns	5	O
studied	9	O
,	9	O
including	9	O
sleep	5	O
/	9	O
wakefulness	5	O
cycle	9	O
,	9	O
at	9	O
the	5	O
doses	0	O
studied	9	O
.	9	O

Acute	5	B-Disease
renal	9	I-Disease
failure	5	I-Disease
associated	9	O
with	5	O
prolonged	9	O
intake	5	O
of	5	O
slimming	5	O
pills	5	O
containing	0	O
anthraquinones	0	B-Chemical
.	9	O

Chinese	9	B-Chemical
herbal	5	I-Chemical
medicine	5	O
preparations	9	O
are	5	O
widely	5	O
available	5	O
and	5	O
often	5	O
regarded	5	O
by	9	O
the	5	O
public	5	O
as	5	O
natural	5	O
and	5	O
safe	5	O
remedies	5	O
for	5	O
a	5	O
variety	5	O
of	5	O
medical	5	O
conditions	9	O
.	9	O

Nephropathy	7	B-Disease
caused	9	O
by	9	O
Chinese	9	B-Chemical
herbs	5	I-Chemical
has	9	O
previously	9	O
been	9	O
reported	9	O
,	9	O
usually	5	O
involving	5	O
the	5	O
use	5	O
of	5	O
aristolochic	0	B-Chemical
acids	0	I-Chemical
.	9	O

We	9	O
report	5	O
a	5	O
23	7	O
-	7	O
year	5	O
-	7	O
old	5	O
woman	5	O
who	5	O
developed	5	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
following	9	O
prolonged	9	O
use	5	O
of	5	O
a	5	O
proprietary	5	O
Chinese	9	B-Chemical
herbal	5	I-Chemical
slimming	5	O
pill	5	O
that	5	O
contained	9	O
anthraquinone	0	B-Chemical
derivatives	0	O
,	9	O
extracted	9	O
from	9	O
Rhizoma	4	O
Rhei	4	O
(	9	O
rhubarb	4	O
)	9	O
.	9	O

The	5	O
renal	9	B-Disease
injury	9	I-Disease
was	9	O
probably	9	O
aggravated	9	O
by	9	O
the	5	O
concomitant	9	O
intake	5	O
of	5	O
a	5	O
non	9	O
-	7	O
steroidal	0	O
anti	3	O
-	7	O
inflammatory	3	O
drug	5	O
,	9	O
diclofenac	0	B-Chemical
.	9	O

Renal	9	O
pathology	5	O
was	9	O
that	5	O
of	5	O
hypocellular	5	O
interstitial	9	O
fibrosis	9	B-Disease
.	9	O

Spontaneous	9	O
renal	9	O
recovery	9	O
occurred	9	O
upon	9	O
cessation	5	O
of	5	O
the	5	O
slimming	5	O
pills	5	O
,	9	O
but	9	O
mild	9	O
interstitial	9	O
fibrosis	9	B-Disease
and	5	O
tubular	9	O
atrophy	5	B-Disease
was	9	O
still	5	O
evident	9	O
histologically	9	O
4	9	O
months	5	O
later	9	O
.	9	O

Although	9	O
a	5	O
causal	5	O
relationship	5	O
between	5	O
the	5	O
use	5	O
of	5	O
an	5	O
anthraquinone	0	B-Chemical
-	7	O
containing	0	O
herbal	5	O
agent	9	O
and	5	O
renal	9	B-Disease
injury	9	I-Disease
remains	9	O
to	5	O
be	5	O
proven	5	O
,	9	O
phytotherapy	5	O
-	7	O
associated	9	O
interstitial	9	O
nephropathy	9	B-Disease
should	5	O
be	5	O
considered	5	O
in	5	O
patients	5	O
who	5	O
present	9	O
with	5	O
unexplained	5	O
renal	9	B-Disease
failure	5	I-Disease
.	9	O

Chloroacetaldehyde	7	B-Chemical
as	5	O
a	5	O
sulfhydryl	0	B-Chemical
reagent	0	O
:	9	O
the	5	O
role	9	O
of	5	O
critical	9	O
thiol	0	B-Chemical
groups	9	O
in	5	O
ifosfamide	0	B-Chemical
nephropathy	9	B-Disease
.	9	O

Chloroacetaldehyde	7	B-Chemical
(	9	O
CAA	9	B-Chemical
)	9	O
is	5	O
a	5	O
metabolite	0	O
of	5	O
the	5	O
alkylating	0	O
agent	9	O
ifosfamide	0	B-Chemical
(	9	O
IFO	7	B-Chemical
)	9	O
and	5	O
putatively	9	O
responsible	9	O
for	5	O
renal	9	B-Disease
damage	9	I-Disease
following	9	O
anti	3	O
-	7	O
tumor	3	B-Disease
therapy	5	O
with	5	O
IFO	7	B-Chemical
.	9	O

Depletion	3	O
of	5	O
sulfhydryl	0	B-Chemical
(	9	O
SH	9	B-Chemical
)	9	O
groups	9	O
has	9	O
been	9	O
reported	9	O
from	9	O
cell	3	O
culture	9	O
,	9	O
animal	5	O
and	5	O
clinical	5	O
studies	9	O
.	9	O

In	9	O
this	5	O
work	5	O
the	5	O
effect	9	O
of	5	O
CAA	9	B-Chemical
on	5	O
human	3	O
proximal	9	O
tubule	9	O
cells	3	O
in	5	O
primary	9	O
culture	9	O
(	9	O
hRPTEC	_	O
)	9	O
was	9	O
investigated	9	O
.	9	O

Toxicity	9	B-Disease
of	5	O
CAA	9	B-Chemical
was	9	O
determined	9	O
by	9	O
protein	1	O
content	9	O
,	9	O
cell	3	O
number	9	O
,	9	O
LDH	0	O
release	9	O
,	9	O
trypan	3	B-Chemical
blue	9	I-Chemical
exclusion	5	O
assay	3	O
and	5	O
caspase	3	O
-	7	O
3	9	O
activity	9	O
.	9	O

Free	9	O
thiols	0	B-Chemical
were	9	O
measured	9	O
by	9	O
the	5	O
method	5	O
of	5	O
Ellman	0	O
.	9	O

CAA	9	B-Chemical
reduced	9	O
hRPTEC	_	O
cell	3	O
number	9	O
and	5	O
protein	1	O
,	9	O
induced	3	O
a	5	O
loss	9	O
in	5	O
free	9	O
intracellular	3	O
thiols	0	B-Chemical
and	5	O
an	5	O
increase	9	O
in	5	O
necrosis	9	B-Disease
markers	3	O
.	9	O

CAA	9	B-Chemical
but	9	O
not	5	O
acrolein	0	B-Chemical
inhibited	3	O
the	5	O
cysteine	1	B-Chemical
proteases	9	O
caspase	3	O
-	7	O
3	9	O
,	9	O
caspase	3	O
-	7	O
8	9	O
and	5	O
cathepsin	3	O
B	9	O
.	9	O

Caspase	3	O
activation	3	O
by	9	O
cisplatin	3	B-Chemical
was	9	O
inhibited	3	O
by	9	O
CAA	9	B-Chemical
.	9	O

In	9	O
cells	3	O
stained	3	O
with	5	O
fluorescent	3	O
dyes	0	O
targeting	3	O
lysosomes	3	O
,	9	O
CAA	9	B-Chemical
induced	3	O
an	5	O
increase	9	O
in	5	O
lysosomal	3	O
size	9	O
and	5	O
lysosomal	3	O
leakage	9	O
.	9	O

The	5	O
effects	9	O
of	5	O
CAA	9	B-Chemical
on	5	O
cysteine	1	B-Chemical
protease	0	O
activities	9	O
and	5	O
thiols	0	B-Chemical
could	9	O
be	5	O
reproduced	9	O
in	5	O
cell	3	O
lysate	3	O
.	9	O

Acidification	0	O
,	9	O
which	5	O
slowed	9	O
the	5	O
reaction	9	O
of	5	O
CAA	9	B-Chemical
with	5	O
thiol	0	B-Chemical
donors	9	O
,	9	O
could	9	O
also	9	O
attenuate	9	O
effects	9	O
of	5	O
CAA	9	B-Chemical
on	5	O
necrosis	9	B-Disease
markers	3	O
,	9	O
thiol	0	B-Chemical
depletion	3	O
and	5	O
cysteine	1	B-Chemical
protease	0	O
inhibition	3	O
in	5	O
living	5	O
cells	3	O
.	9	O

Thus	9	O
,	9	O
CAA	9	B-Chemical
directly	9	O
reacts	0	O
with	5	O
cellular	3	O
protein	1	O
and	5	O
non	9	O
-	7	O
protein	1	O
thiols	0	B-Chemical
,	9	O
mediating	9	O
its	9	O
toxicity	9	B-Disease
on	5	O
hRPTEC	_	O
.	9	O

This	5	O
effect	9	O
can	5	O
be	5	O
reduced	9	O
by	9	O
acidification	9	O
.	9	O

Therefore	9	O
,	9	O
urinary	9	O
acidification	9	O
could	9	O
be	5	O
an	5	O
option	5	O
to	5	O
prevent	5	O
IFO	7	B-Chemical
nephropathy	9	B-Disease
in	5	O
patients	5	O
.	9	O

Stereological	5	O
methods	5	O
reveal	9	O
the	5	O
robust	5	O
size	9	O
and	5	O
stability	9	O
of	5	O
ectopic	3	O
hilar	5	O
granule	3	O
cells	3	O
after	9	O
pilocarpine	0	B-Chemical
-	7	O
induced	3	O
status	9	B-Disease
epilepticus	5	I-Disease
in	5	O
the	5	O
adult	9	O
rat	3	O
.	9	O

Following	9	O
status	9	B-Disease
epilepticus	5	I-Disease
in	5	O
the	5	O
rat	3	O
,	9	O
dentate	3	O
granule	3	O
cell	3	O
neurogenesis	3	O
increases	9	O
greatly	9	O
,	9	O
and	5	O
many	5	O
of	5	O
the	5	O
new	5	O
neurons	3	O
appear	9	O
to	5	O
develop	5	O
ectopically	3	O
,	9	O
in	5	O
the	5	O
hilar	5	O
region	9	O
of	5	O
the	5	O
hippocampal	3	O
formation	9	O
.	9	O

It	5	O
has	9	O
been	9	O
suggested	9	O
that	5	O
the	5	O
ectopic	3	O
hilar	5	O
granule	3	O
cells	3	O
could	9	O
contribute	9	O
to	5	O
the	5	O
spontaneous	5	O
seizures	5	B-Disease
that	5	O
ultimately	5	O
develop	5	O
after	9	O
status	9	B-Disease
epilepticus	5	I-Disease
.	9	O

However	9	O
,	9	O
the	5	O
population	5	O
has	9	O
never	5	O
been	9	O
quantified	9	O
,	9	O
so	5	O
it	5	O
is	5	O
unclear	9	O
whether	9	O
it	5	O
is	5	O
substantial	9	O
enough	5	O
to	5	O
have	5	O
a	5	O
strong	9	O
influence	5	O
on	5	O
epileptogenesis	5	O
.	9	O

To	9	O
quantify	9	O
this	5	O
population	5	O
,	9	O
the	5	O
total	9	O
number	9	O
of	5	O
ectopic	3	O
hilar	5	O
granule	3	O
cells	3	O
was	9	O
estimated	5	O
using	9	O
unbiased	5	O
stereology	5	O
at	9	O
different	9	O
times	5	O
after	9	O
pilocarpine	0	B-Chemical
-	7	O
induced	3	O
status	9	B-Disease
epilepticus	5	I-Disease
.	9	O

The	5	O
number	9	O
of	5	O
hilar	5	O
neurons	3	O
immunoreactive	3	O
for	5	O
Prox	7	O
-	7	O
1	9	O
,	9	O
a	5	O
granule	3	O
-	7	O
cell	3	O
-	7	O
specific	9	O
marker	3	O
,	9	O
was	9	O
estimated	5	O
using	9	O
the	5	O
optical	5	O
fractionator	5	O
method	5	O
.	9	O

The	5	O
results	9	O
indicate	9	O
that	5	O
the	5	O
size	9	O
of	5	O
the	5	O
hilar	5	O
ectopic	3	O
granule	3	O
cell	3	O
population	5	O
after	9	O
status	9	B-Disease
epilepticus	5	I-Disease
is	5	O
substantial	9	O
,	9	O
and	5	O
stable	9	O
over	5	O
time	5	O
.	9	O

Interestingly	9	O
,	9	O
the	5	O
size	9	O
of	5	O
the	5	O
population	5	O
appears	9	O
to	5	O
be	5	O
correlated	9	O
with	5	O
the	5	O
frequency	5	O
of	5	O
behavioral	5	O
seizures	5	B-Disease
,	9	O
because	5	O
animals	9	O
with	5	O
more	5	O
ectopic	3	O
granule	3	O
cells	3	O
in	5	O
the	5	O
hilus	3	O
have	5	O
more	5	O
frequent	5	O
behavioral	5	O
seizures	5	B-Disease
.	9	O

The	5	O
hilar	5	O
ectopic	3	O
granule	3	O
cell	3	O
population	5	O
does	9	O
not	5	O
appear	9	O
to	5	O
vary	5	O
systematically	5	O
across	5	O
the	5	O
septotemporal	5	O
axis	5	O
,	9	O
although	9	O
it	5	O
is	5	O
associated	9	O
with	5	O
an	5	O
increase	9	O
in	5	O
volume	9	O
of	5	O
the	5	O
hilus	3	O
.	9	O

The	5	O
results	9	O
provide	5	O
new	5	O
insight	5	O
into	9	O
the	5	O
potential	9	O
role	9	O
of	5	O
ectopic	3	O
hilar	5	O
granule	3	O
cells	3	O
in	5	O
the	5	O
pilocarpine	0	B-Chemical
model	5	O
of	5	O
temporal	5	B-Disease
lobe	5	I-Disease
epilepsy	5	I-Disease
.	9	O

A	9	O
prospective	5	O
,	9	O
open	5	O
-	7	O
label	9	O
trial	5	O
of	5	O
galantamine	0	B-Chemical
in	5	O
autistic	5	B-Disease
disorder	5	I-Disease
.	9	O

OBJECTIVE	2	O
:	9	O
Post	9	O
-	7	O
mortem	5	O
studies	9	O
have	5	O
reported	9	O
abnormalities	9	O
of	5	O
the	5	O
cholinergic	3	O
system	5	O
in	5	O
autism	5	B-Disease
.	9	O

The	5	O
purpose	5	O
of	5	O
this	5	O
study	9	O
was	9	O
to	5	O
assess	5	O
the	5	O
use	5	O
of	5	O
galantamine	0	B-Chemical
,	9	O
an	5	O
acetylcholinesterase	0	O
inhibitor	3	O
and	5	O
nicotinic	0	O
receptor	3	O
modulator	9	O
,	9	O
in	5	O
the	5	O
treatment	9	O
of	5	O
interfering	3	O
behaviors	5	O
in	5	O
children	5	O
with	5	O
autism	5	B-Disease
.	9	O

METHODS	2	O
:	9	O
Thirteen	9	O
medication	5	O
-	7	O
free	9	O
children	5	O
with	5	O
autism	5	B-Disease
(	9	O
mean	5	O
age	5	O
,	9	O
8	9	O
.	9	O
8	9	O
+	9	O
/	9	O
-	7	O
3	9	O
.	9	O
5	9	O
years	5	O
)	9	O
participated	5	O
in	5	O
a	5	O
12	9	O
-	7	O
week	9	O
,	9	O
open	5	O
-	7	O
label	9	O
trial	5	O
of	5	O
galantamine	0	B-Chemical
.	9	O

Patients	5	O
were	9	O
rated	5	O
monthly	5	O
by	9	O
parents	5	O
on	5	O
the	5	O
Aberrant	3	O
Behavior	5	O
Checklist	5	O
(	9	O
ABC	9	O
)	9	O
and	5	O
the	5	O
Conners	5	O
'	9	O
Parent	5	O
Rating	5	O
Scale	5	O
-	7	O
Revised	5	O
,	9	O
and	5	O
by	9	O
a	5	O
physician	5	O
using	9	O
the	5	O
Children	5	O
'	9	O
s	9	O
Psychiatric	5	O
Rating	5	O
Scale	5	O
and	5	O
the	5	O
Clinical	5	O
Global	5	O
Impressions	5	O
scale	5	O
.	9	O

RESULTS	9	O
:	9	O
Patients	5	O
showed	9	O
a	5	O
significant	9	O
reduction	9	O
in	5	O
parent	9	O
-	7	O
rated	5	O
irritability	5	B-Disease
and	5	O
social	5	O
withdrawal	5	O
on	5	O
the	5	O
ABC	9	O
as	5	O
well	9	O
as	5	O
significant	9	O
improvements	5	O
in	5	O
emotional	5	O
lability	9	O
and	5	O
inattention	5	O
on	5	O
the	5	O
Conners	5	O
'	9	O
Parent	5	O
Rating	5	O
Scale	5	O
-	7	O
-	7	O
Revised	5	O
.	9	O

Similarly	9	O
,	9	O
clinician	5	O
ratings	5	O
showed	9	O
reductions	9	O
in	5	O
the	5	O
anger	5	O
subscale	5	O
of	5	O
the	5	O
Children	5	O
'	9	O
s	9	O
Psychiatric	5	O
Rating	5	O
Scale	5	O
.	9	O

Eight	9	O
of	5	O
13	7	O
participants	5	O
were	9	O
rated	5	O
as	5	O
responders	5	O
on	5	O
the	5	O
basis	5	O
of	5	O
their	5	O
improvement	5	O
scores	5	O
on	5	O
the	5	O
Clinical	5	O
Global	5	O
Impressions	5	O
scale	5	O
.	9	O

Overall	9	O
,	9	O
galantamine	0	B-Chemical
was	9	O
well	9	O
-	7	O
tolerated	9	O
,	9	O
with	5	O
no	9	O
significant	9	O
adverse	5	O
effects	9	O
apart	9	O
from	9	O
headaches	5	B-Disease
in	5	O
one	5	O
patient	5	O
.	9	O

CONCLUSION	5	O
:	9	O
In	9	O
this	5	O
open	5	O
trial	5	O
,	9	O
galantamine	0	B-Chemical
was	9	O
well	9	O
-	7	O
tolerated	9	O
and	5	O
appeared	9	O
to	5	O
be	5	O
beneficial	9	O
for	5	O
the	5	O
treatment	9	O
of	5	O
interfering	3	O
behaviors	5	O
in	5	O
children	5	O
with	5	O
autism	5	B-Disease
,	9	O
particularly	5	O
aggression	5	B-Disease
,	9	O
behavioral	5	B-Disease
dyscontrol	5	I-Disease
,	9	O
and	5	O
inattention	5	B-Disease
.	9	O

Further	9	O
controlled	5	O
trials	5	O
are	5	O
warranted	9	O
.	9	O

Randomized	5	O
comparison	9	O
of	5	O
olanzapine	5	B-Chemical
versus	9	O
risperidone	5	B-Chemical
for	5	O
the	5	O
treatment	9	O
of	5	O
first	9	O
-	7	O
episode	5	O
schizophrenia	5	B-Disease
:	9	O
4	9	O
-	7	O
month	5	O
outcomes	5	O
.	9	O

OBJECTIVE	2	O
:	9	O
The	5	O
authors	5	O
compared	9	O
4	9	O
-	7	O
month	5	O
treatment	9	O
outcomes	5	O
for	5	O
olanzapine	5	B-Chemical
versus	9	O
risperidone	5	B-Chemical
in	5	O
patients	5	O
with	5	O
first	9	O
-	7	O
episode	5	O
schizophrenia	5	B-Disease
spectrum	9	O
disorders	5	O
.	9	O

METHOD	2	O
:	9	O
One	5	O
hundred	5	O
twelve	9	O
subjects	5	O
(	9	O
70	9	O
%	9	O
male	9	O
;	9	O
mean	5	O
age	5	O
=	7	O
23	7	O
.	9	O
3	9	O
years	5	O
[	9	O
SD	7	O
=	7	O
5	9	O
.	9	O
1	9	O
]	9	O
)	9	O
with	5	O
first	9	O
-	7	O
episode	5	O
schizophrenia	5	B-Disease
(	9	O
75	9	O
%	9	O
)	9	O
,	9	O
schizophreniform	5	B-Disease
disorder	5	I-Disease
(	9	O
17	7	O
%	9	O
)	9	O
,	9	O
or	5	O
schizoaffective	5	B-Disease
disorder	5	I-Disease
(	9	O
8	9	O
%	9	O
)	9	O
were	9	O
randomly	5	O
assigned	5	O
to	5	O
treatment	9	O
with	5	O
olanzapine	5	B-Chemical
(	9	O
2	9	O
.	9	O
5	9	O
-	7	O
20	9	O
mg	0	O
/	9	O
day	9	O
)	9	O
or	5	O
risperidone	5	B-Chemical
(	9	O
1	9	O
-	7	O
6	9	O
mg	0	O
/	9	O
day	9	O
)	9	O
.	9	O

RESULTS	9	O
:	9	O
Response	5	O
rates	5	O
did	9	O
not	5	O
significantly	9	O
differ	9	O
between	5	O
olanzapine	5	B-Chemical
(	9	O
43	7	O
.	9	O
7	9	O
%	9	O
,	9	O
95	7	O
%	9	O
CI	7	O
=	7	O
28	7	O
.	9	O
8	9	O
%	9	O
-	7	O
58	7	O
.	9	O
6	9	O
%	9	O
)	9	O
and	5	O
risperidone	5	B-Chemical
(	9	O
54	7	O
.	9	O
3	9	O
%	9	O
,	9	O
95	7	O
%	9	O
CI	7	O
=	7	O
39	7	O
.	9	O
9	7	O
%	9	O
-	7	O
68	7	O
.	9	O
7	9	O
%	9	O
)	9	O
.	9	O

Among	9	O
those	5	O
responding	5	O
to	5	O
treatment	9	O
,	9	O
more	5	O
subjects	5	O
in	5	O
the	5	O
olanzapine	5	B-Chemical
group	9	O
(	9	O
40	9	O
.	9	O
9	7	O
%	9	O
,	9	O
95	7	O
%	9	O
CI	7	O
=	7	O
16	9	O
.	9	O
8	9	O
%	9	O
-	7	O
65	7	O
.	9	O
0	7	O
%	9	O
)	9	O
than	5	O
in	5	O
the	5	O
risperidone	5	B-Chemical
group	9	O
(	9	O
18	7	O
.	9	O
9	7	O
%	9	O
,	9	O
95	7	O
%	9	O
CI	7	O
=	7	O
0	7	O
%	9	O
-	7	O
39	7	O
.	9	O
2	9	O
%	9	O
)	9	O
had	9	O
subsequent	9	O
ratings	5	O
not	5	O
meeting	5	O
response	9	O
criteria	5	O
.	9	O

Negative	7	O
symptom	5	O
outcomes	5	O
and	5	O
measures	5	O
of	5	O
parkinsonism	5	B-Disease
and	5	O
akathisia	5	B-Disease
did	9	O
not	5	O
differ	9	O
between	5	O
medications	5	O
.	9	O

Extrapyramidal	5	B-Disease
symptom	5	I-Disease
severity	5	O
scores	5	O
were	9	O
1	9	O
.	9	O
4	9	O
(	9	O
95	7	O
%	9	O
CI	7	O
=	7	O
1	9	O
.	9	O
2	9	O
-	7	O
1	9	O
.	9	O
6	9	O
)	9	O
with	5	O
risperidone	5	B-Chemical
and	5	O
1	9	O
.	9	O
2	9	O
(	9	O
95	7	O
%	9	O
CI	7	O
=	7	O
1	9	O
.	9	O
0	7	O
-	7	O
1	9	O
.	9	O
4	9	O
)	9	O
with	5	O
olanzapine	5	B-Chemical
.	9	O

Significantly	9	O
more	5	O
weight	9	B-Disease
gain	5	I-Disease
occurred	9	O
with	5	O
olanzapine	5	B-Chemical
than	5	O
with	5	O
risperidone	5	B-Chemical
:	9	O
the	5	O
increase	9	O
in	5	O
weight	9	O
at	9	O
4	9	O
months	5	O
relative	9	O
to	5	O
baseline	5	O
weight	9	O
was	9	O
17	7	O
.	9	O
3	9	O
%	9	O
(	9	O
95	7	O
%	9	O
CI	7	O
=	7	O
14	7	O
.	9	O
2	9	O
%	9	O
-	7	O
20	9	O
.	9	O
5	9	O
%	9	O
)	9	O
with	5	O
olanzapine	5	B-Chemical
and	5	O
11	7	O
.	9	O
3	9	O
%	9	O
(	9	O
95	7	O
%	9	O
CI	7	O
=	7	O
8	9	O
.	9	O
4	9	O
%	9	O
-	7	O
14	7	O
.	9	O
3	9	O
%	9	O
)	9	O
with	5	O
risperidone	5	B-Chemical
.	9	O

Body	9	O
mass	9	O
index	5	O
at	9	O
baseline	5	O
and	5	O
at	9	O
4	9	O
months	5	O
was	9	O
24	9	O
.	9	O
3	9	O
(	9	O
95	7	O
%	9	O
CI	7	O
=	7	O
22	7	O
.	9	O
8	9	O
-	7	O
25	9	O
.	9	O
7	9	O
)	9	O
versus	9	O
28	7	O
.	9	O
2	9	O
(	9	O
95	7	O
%	9	O
CI	7	O
=	7	O
26	7	O
.	9	O
7	9	O
-	7	O
29	7	O
.	9	O
7	9	O
)	9	O
with	5	O
olanzapine	5	B-Chemical
and	5	O
23	7	O
.	9	O
9	7	O
(	9	O
95	7	O
%	9	O
CI	7	O
=	7	O
22	7	O
.	9	O
5	9	O
-	7	O
25	9	O
.	9	O
3	9	O
)	9	O
versus	9	O
26	7	O
.	9	O
7	9	O
(	9	O
95	7	O
%	9	O
CI	7	O
=	7	O
25	9	O
.	9	O
2	9	O
-	7	O
28	7	O
.	9	O
2	9	O
)	9	O
with	5	O
risperidone	5	B-Chemical
.	9	O

CONCLUSIONS	5	O
:	9	O
Clinical	5	O
outcomes	5	O
with	5	O
risperidone	5	B-Chemical
were	9	O
equal	9	O
to	5	O
those	5	O
with	5	O
olanzapine	5	B-Chemical
,	9	O
and	5	O
response	9	O
may	5	O
be	5	O
more	5	O
stable	9	O
.	9	O

Olanzapine	7	B-Chemical
may	5	O
have	5	O
an	5	O
advantage	5	O
for	5	O
motor	5	O
side	5	O
effects	9	O
.	9	O

Both	9	O
medications	5	O
caused	9	O
substantial	9	O
rapid	5	O
weight	9	B-Disease
gain	5	I-Disease
,	9	O
but	9	O
weight	9	B-Disease
gain	5	I-Disease
was	9	O
greater	5	O
with	5	O
olanzapine	5	B-Chemical
.	9	O

Early	9	O
paracentral	5	O
visual	5	B-Disease
field	5	I-Disease
loss	9	I-Disease
in	5	O
patients	5	O
taking	5	O
hydroxychloroquine	0	B-Chemical
.	9	O

OBJECTIVE	2	O
:	9	O
To	9	O
review	5	O
the	5	O
natural	5	O
history	5	O
and	5	O
ocular	5	O
and	5	O
systemic	9	O
adverse	5	O
effects	9	O
of	5	O
patients	5	O
taking	5	O
hydroxychloroquine	0	B-Chemical
sulfate	0	I-Chemical
who	5	O
attended	5	O
an	5	O
ophthalmic	5	O
screening	5	O
program	5	O
.	9	O

DESIGN	2	O
:	9	O
Retrospective	9	O
study	9	O
.	9	O

RESULTS	9	O
:	9	O
Records	2	O
of	5	O
262	7	O
patients	5	O
who	5	O
were	9	O
taking	5	O
hydroxychloroquine	0	B-Chemical
and	5	O
screened	9	O
in	5	O
the	5	O
Department	2	O
of	5	O
Ophthalmology	2	O
were	9	O
reviewed	9	O
.	9	O

Of	9	O
the	5	O
262	7	O
patients	5	O
,	9	O
14	7	O
(	9	O
18	7	O
%	9	O
)	9	O
of	5	O
76	7	O
who	5	O
had	9	O
stopped	9	O
treatment	9	O
at	9	O
the	5	O
time	5	O
of	5	O
the	5	O
study	9	O
experienced	5	O
documented	9	O
adverse	5	O
effects	9	O
.	9	O

Systemic	9	O
adverse	5	O
effects	9	O
occurred	9	O
in	5	O
8	9	O
patients	5	O
(	9	O
10	9	O
.	9	O
5	9	O
%	9	O
)	9	O
and	5	O
ocular	5	O
adverse	5	O
effects	9	O
,	9	O
in	5	O
5	9	O
(	9	O
6	9	O
.	9	O
5	9	O
%	9	O
)	9	O
.	9	O

Thirty	9	O
-	7	O
five	9	O
patients	5	O
(	9	O
13	7	O
.	9	O
4	9	O
%	9	O
)	9	O
had	9	O
visual	5	B-Disease
field	5	I-Disease
abnormalities	9	I-Disease
,	9	O
which	5	O
were	9	O
attributed	9	O
to	5	O
hydroxychloroquine	0	B-Chemical
treatment	9	O
in	5	O
4	9	O
patients	5	O
(	9	O
1	9	O
.	9	O
5	9	O
%	9	O
)	9	O
.	9	O

Three	9	O
of	5	O
the	5	O
4	9	O
patients	5	O
were	9	O
taking	5	O
less	5	O
than	5	O
6	9	O
.	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
per	9	O
day	9	O
and	5	O
all	5	O
patients	5	O
had	9	O
normal	9	O
renal	9	O
and	5	O
liver	9	O
function	9	O
test	5	O
results	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
The	5	O
current	5	O
study	9	O
used	5	O
a	5	O
protocol	9	O
of	5	O
visual	5	O
acuity	5	O
and	5	O
color	5	O
vision	5	O
assessment	5	O
,	9	O
funduscopy	5	O
,	9	O
and	5	O
Humphrey	6	O
10	9	O
-	7	O
2	9	O
visual	5	O
field	5	O
testing	5	O
and	5	O
shows	9	O
that	5	O
visual	5	B-Disease
field	5	I-Disease
defects	9	I-Disease
appeared	9	O
before	9	O
any	5	O
corresponding	9	O
changes	9	O
in	5	O
any	5	O
other	5	O
tested	9	O
clinical	5	O
parameters	5	O
;	9	O
the	5	O
defects	9	O
were	9	O
reproducible	5	O
and	5	O
the	5	O
test	5	O
parameters	5	O
were	9	O
reliable	5	O
.	9	O

Patients	5	O
taking	5	O
hydroxychloroquine	0	B-Chemical
can	5	O
demonstrate	9	O
a	5	O
toxic	0	O
reaction	9	O
in	5	O
the	5	O
retina	9	O
despite	9	O
the	5	O
absence	3	O
of	5	O
known	9	O
risk	5	O
factors	9	O
.	9	O

Screening	9	O
,	9	O
including	9	O
Humphrey	6	O
10	9	O
-	7	O
2	9	O
visual	5	O
field	5	O
assessment	5	O
,	9	O
is	5	O
recommended	5	O
2	9	O
years	5	O
after	9	O
the	5	O
initial	9	O
baseline	5	O
and	5	O
yearly	5	O
thereafter	9	O
.	9	O

Peri	6	O
-	7	O
operative	5	O
atrioventricular	5	B-Disease
block	9	I-Disease
as	5	O
a	5	O
result	9	O
of	5	O
chemotherapy	5	O
with	5	O
epirubicin	0	B-Chemical
and	5	O
paclitaxel	0	B-Chemical
.	9	O

A	9	O
47	7	O
-	7	O
year	5	O
-	7	O
old	5	O
woman	5	O
presented	5	O
for	5	O
mastectomy	5	O
and	5	O
immediate	5	O
latissimus	5	O
dorsi	5	O
flap	5	O
reconstruction	5	O
having	5	O
been	9	O
diagnosed	5	O
with	5	O
carcinoma	3	B-Disease
of	5	I-Disease
the	5	I-Disease
breast	3	I-Disease
6	9	O
months	5	O
previously	9	O
.	9	O

In	9	O
the	5	O
preceding	5	O
months	5	O
she	5	O
had	9	O
received	9	O
neo	1	O
-	7	O
adjuvant	9	O
chemotherapy	5	O
with	5	O
epirubicin	0	B-Chemical
,	9	O
paclitaxel	0	B-Chemical
(	9	O
Taxol	0	B-Chemical
)	9	O
and	5	O
cyclophosphamide	0	B-Chemical
.	9	O

This	5	O
had	9	O
been	9	O
apparently	9	O
uncomplicated	5	O
and	5	O
she	5	O
had	9	O
maintained	9	O
a	5	O
remarkably	9	O
high	9	O
level	9	O
of	5	O
physical	5	O
activity	9	O
.	9	O

She	5	O
was	9	O
found	9	O
to	5	O
be	5	O
bradycardic	5	B-Disease
at	9	O
pre	9	O
-	7	O
operative	5	O
assessment	5	O
but	9	O
had	9	O
no	9	O
cardiac	5	O
symptoms	5	O
.	9	O

Second	9	O
degree	5	O
Mobitz	5	O
type	9	O
II	9	O
atrioventricular	5	B-Disease
block	9	I-Disease
was	9	O
diagnosed	5	O
on	5	O
electrocardiogram	5	O
,	9	O
and	5	O
temporary	5	O
transvenous	5	O
ventricular	5	O
pacing	5	O
instituted	5	O
in	5	O
the	5	O
peri	5	O
-	7	O
operative	5	O
period	5	O
.	9	O

We	9	O
discuss	5	O
how	5	O
evidence	9	O
-	7	O
based	5	O
guidelines	5	O
would	5	O
not	5	O
have	5	O
been	9	O
helpful	6	O
in	5	O
this	5	O
case	5	O
,	9	O
and	5	O
how	5	O
chemotherapy	5	O
can	5	O
exhibit	9	O
substantial	9	O
cardiotoxicity	9	B-Disease
that	5	O
may	5	O
develop	5	O
over	5	O
many	5	O
years	5	O
.	9	O

We	9	O
suggest	9	O
that	5	O
patients	5	O
who	5	O
have	5	O
received	9	O
chemotherapy	5	O
at	9	O
any	5	O
time	5	O
should	5	O
have	5	O
a	5	O
pre	9	O
-	7	O
operative	5	O
electrocardiogram	5	O
even	5	O
if	5	O
they	5	O
are	5	O
asymptomatic	5	O
.	9	O

Risks	5	O
and	5	O
benefits	5	O
of	5	O
COX	9	B-Chemical
-	7	I-Chemical
2	9	I-Chemical
inhibitors	3	I-Chemical
vs	7	O
non	9	O
-	7	O
selective	9	O
NSAIDs	5	O
:	9	O
does	9	O
their	5	O
cardiovascular	5	O
risk	5	O
exceed	5	O
their	5	O
gastrointestinal	9	O
benefit	5	O
?	5	O

A	9	O
retrospective	5	O
cohort	9	O
study	9	O
.	9	O

OBJECTIVES	2	O
:	9	O
The	5	O
risk	5	O
of	5	O
acute	9	B-Disease
myocardial	9	I-Disease
infarction	5	I-Disease
(	9	O
AMI	9	B-Disease
)	9	O
with	5	O
COX	9	B-Chemical
-	7	I-Chemical
2	9	I-Chemical
inhibitors	3	I-Chemical
may	5	O
offset	5	O
their	5	O
gastrointestinal	9	O
(	9	O
GI	9	O
)	9	O
benefit	5	O
compared	9	O
with	5	O
non	9	O
-	7	O
selective	9	O
(	9	O
NS	7	O
)	9	O
non	9	B-Chemical
-	7	I-Chemical
steroidal	0	I-Chemical
anti	3	I-Chemical
-	7	I-Chemical
inflammatory	3	I-Chemical
drugs	5	I-Chemical
(	9	O
NSAIDs	5	O
)	9	O
.	9	O

We	9	O
aimed	5	O
to	5	O
compare	9	O
the	5	O
risks	5	O
of	5	O
hospitalization	5	O
for	5	O
AMI	9	B-Disease
and	5	O
GI	9	B-Disease
bleeding	5	I-Disease
among	5	O
elderly	5	O
patients	5	O
using	9	O
COX	9	B-Chemical
-	7	I-Chemical
2	9	I-Chemical
inhibitors	3	I-Chemical
,	9	O
NS	7	O
-	7	O
NSAIDs	5	O
and	5	O
acetaminophen	0	B-Chemical
.	9	O

METHODS	2	O
:	9	O
We	9	O
conducted	9	O
a	5	O
retrospective	5	O
cohort	9	O
study	9	O
using	9	O
administrative	5	O
data	5	O
of	5	O
patients	5	O
>	0	O
or	5	O
=	7	O
65	7	O
years	5	O
of	5	O
age	5	O
who	5	O
filled	9	O
a	5	O
prescription	5	O
for	5	O
NSAID	5	O
or	5	O
acetaminophen	0	B-Chemical
during	5	O
1999	2	O
-	7	O
2002	2	O
.	9	O

Outcomes	5	O
were	9	O
compared	9	O
using	9	O
Cox	9	O
regression	5	O
models	5	O
with	5	O
time	5	O
-	7	O
dependent	9	O
exposures	5	O
.	9	O

RESULTS	9	O
:	9	O
Person	5	O
-	7	O
years	5	O
of	5	O
exposure	9	O
among	5	O
non	9	O
-	7	O
users	5	O
of	5	O
aspirin	9	B-Chemical
were	9	O
:	9	O
75	9	O
,	9	O
761	7	O
to	5	O
acetaminophen	0	B-Chemical
,	9	O
42	7	O
,	9	O
671	7	O
to	5	O
rofecoxib	5	B-Chemical
65	7	O
,	9	O
860	9	O
to	5	O
celecoxib	3	B-Chemical
,	9	O
and	5	O
37	9	O
,	9	O
495	7	O
to	5	O
NS	7	O
-	7	O
NSAIDs	5	O
.	9	O

Among	9	O
users	5	O
of	5	O
aspirin	9	B-Chemical
,	9	O
they	5	O
were	9	O
:	9	O
14	7	O
,	9	O
671	7	O
to	5	O
rofecoxib	5	B-Chemical
,	9	O
22	7	O
,	9	O
875	7	O
to	5	O
celecoxib	3	B-Chemical
,	9	O
9	7	O
,	9	O
832	7	O
to	5	O
NS	7	O
-	7	O
NSAIDs	5	O
and	5	O
38	7	O
,	9	O
048	7	O
to	5	O
acetaminophen	0	B-Chemical
.	9	O

Among	9	O
non	9	O
-	7	O
users	5	O
of	5	O
aspirin	9	B-Chemical
,	9	O
the	5	O
adjusted	9	O
hazard	5	O
ratios	9	O
(	9	O
95	7	O
%	9	O
confidence	5	O
interval	5	O
)	9	O
of	5	O
hospitalization	5	O
for	5	O
AMI	9	B-Disease
/	9	O
GI	9	O
vs	7	O
the	5	O
acetaminophen	0	B-Chemical
(	9	O
with	5	O
no	9	O
aspirin	9	B-Chemical
)	9	O
group	9	O
were	9	O
:	9	O
rofecoxib	5	B-Chemical
1	9	O
.	9	O
27	7	O
(	9	O
1	9	O
.	9	O
13	7	O
,	9	O
1	9	O
.	9	O
42	7	O
)	9	O
,	9	O
celecoxib	3	B-Chemical
0	7	O
.	9	O
93	7	O
(	9	O
0	7	O
.	9	O
83	7	O
,	9	O
1	9	O
.	9	O
03	7	O
)	9	O
,	9	O
naproxen	0	B-Chemical
1	9	O
.	9	O
59	7	O
(	9	O
1	9	O
.	9	O
31	7	O
,	9	O
1	9	O
.	9	O
93	7	O
)	9	O
,	9	O
diclofenac	0	B-Chemical
1	9	O
.	9	O
17	7	O
(	9	O
0	7	O
.	9	O
99	7	O
,	9	O
1	9	O
.	9	O
38	7	O
)	9	O
and	5	O
ibuprofen	0	B-Chemical
1	9	O
.	9	O
05	7	O
(	9	O
0	7	O
.	9	O
74	7	O
,	9	O
1	9	O
.	9	O
51	7	O
)	9	O
.	9	O

Among	9	O
users	5	O
of	5	O
aspirin	9	B-Chemical
,	9	O
they	5	O
were	9	O
:	9	O
rofecoxib	5	B-Chemical
1	9	O
.	9	O
73	7	O
(	9	O
1	9	O
.	9	O
52	7	O
,	9	O
1	9	O
.	9	O
98	7	O
)	9	O
,	9	O
celecoxib	3	B-Chemical
1	9	O
.	9	O
34	7	O
(	9	O
1	9	O
.	9	O
19	7	O
,	9	O
1	9	O
.	9	O
52	7	O
)	9	O
,	9	O
ibuprofen	0	B-Chemical
1	9	O
.	9	O
51	7	O
(	9	O
0	7	O
.	9	O
95	7	O
,	9	O
2	9	O
.	9	O
41	7	O
)	9	O
,	9	O
diclofenac	0	B-Chemical
1	9	O
.	9	O
69	7	O
(	9	O
1	9	O
.	9	O
35	9	O
,	9	O
2	9	O
.	9	O
10	9	O
)	9	O
,	9	O
naproxen	0	B-Chemical
1	9	O
.	9	O
35	9	O
(	9	O
0	7	O
.	9	O
97	7	O
,	9	O
1	9	O
.	9	O
88	7	O
)	9	O
and	5	O
acetaminophen	0	B-Chemical
1	9	O
.	9	O
29	7	O
(	9	O
1	9	O
.	9	O
17	7	O
,	9	O
1	9	O
.	9	O
42	7	O
)	9	O
.	9	O

CONCLUSION	5	O
:	9	O
Among	9	O
non	9	O
-	7	O
users	5	O
of	5	O
aspirin	9	B-Chemical
,	9	O
naproxen	0	B-Chemical
seemed	9	O
to	5	O
carry	9	O
the	5	O
highest	9	O
risk	5	O
for	5	O
AMI	9	B-Disease
/	9	O
GI	9	B-Disease
bleeding	5	I-Disease
.	9	O

The	5	O
AMI	9	B-Disease
/	9	O
GI	9	O
toxicity	9	B-Disease
of	5	O
celecoxib	3	B-Chemical
was	9	O
similar	9	O
to	5	O
that	5	O
of	5	O
acetaminophen	0	B-Chemical
and	5	O
seemed	9	O
to	5	O
be	5	O
better	5	O
than	5	O
those	5	O
of	5	O
rofecoxib	5	B-Chemical
and	5	O
NS	7	O
-	7	O
NSAIDs	5	O
.	9	O

Among	9	O
users	5	O
of	5	O
aspirin	9	B-Chemical
,	9	O
both	9	O
celecoxib	3	B-Chemical
and	5	O
naproxen	0	B-Chemical
seemed	9	O
to	5	O
be	5	O
the	5	O
least	9	O
toxic	0	O
.	9	O

Quinine	0	B-Chemical
-	7	O
induced	3	O
arrhythmia	5	B-Disease
in	5	O
a	5	O
patient	5	O
with	5	O
severe	5	B-Disease
malaria	5	I-Disease
.	9	O

It	5	O
was	9	O
reported	9	O
that	5	O
there	5	O
was	9	O
a	5	O
case	5	O
of	5	O
severe	5	B-Disease
malaria	5	I-Disease
patient	5	O
with	5	O
jaundice	5	B-Disease
who	5	O
presented	5	O
with	5	O
arrhythmia	5	B-Disease
(	9	O
premature	9	B-Disease
ventricular	5	I-Disease
contraction	9	I-Disease
)	9	O
while	9	O
getting	5	O
quinine	0	B-Chemical
infusion	0	O
was	9	O
reported	9	O
.	9	O

A	9	O
man	5	O
,	9	O
25	9	O
years	5	O
old	5	O
,	9	O
was	9	O
admitted	5	O
to	5	O
hospital	5	O
with	5	O
high	9	O
fever	5	B-Disease
,	9	O
chill	5	B-Disease
,	9	O
vomiting	5	B-Disease
,	9	O
jaundice	5	B-Disease
.	9	O

The	5	O
patient	5	O
was	9	O
fully	9	O
conscious	5	O
,	9	O
blood	9	O
pressure	5	O
120	9	O
/	9	O
80	9	O
mmHg	7	O
,	9	O
pulse	5	O
rate	9	O
100	0	O
x	9	O
/	9	O
minute	5	O
,	9	O
regular	5	O
.	9	O

On	5	O
admission	5	O
,	9	O
laboratory	9	O
examination	5	O
showed	9	O
Plasmodium	4	O
falciparum	9	O
(	9	O
+	9	O
+	9	O
+	9	O
+	9	O
)	9	O
,	9	O
total	9	O
bilirubin	0	B-Chemical
8	9	O
.	9	O
25	9	O
mg	0	O
/	9	O
dL	7	O
,	9	O
conjugated	0	O
bilirubin	0	B-Chemical
4	9	O
.	9	O
36	9	O
mg	0	O
/	9	O
dL	7	O
,	9	O
unconjugated	3	O
bilirubin	0	B-Chemical
3	9	O
.	9	O
89	7	O
mg	0	O
/	9	O
dL	7	O
,	9	O
potassium	0	B-Chemical
3	9	O
.	9	O
52	7	O
meq	0	O
/	9	O
L	0	O
Patient	5	O
was	9	O
diagnosed	5	O
as	5	O
severe	5	B-Disease
malaria	5	I-Disease
with	5	O
jaundice	5	B-Disease
and	5	O
got	5	O
quinine	0	B-Chemical
infusion	0	O
in	5	O
dextrose	0	B-Chemical
5	9	O
%	9	O
500	0	O
mg	0	O
/	9	O
8	9	O
hour	0	O
.	9	O

On	5	O
the	5	O
second	9	O
day	9	O
the	5	O
patient	5	O
had	9	O
vomitus	5	B-Disease
,	9	O
diarrhea	5	B-Disease
,	9	O
tinnitus	5	B-Disease
,	9	O
loss	9	B-Disease
of	5	I-Disease
hearing	5	I-Disease
.	9	O

After	9	O
30	9	O
hours	9	O
of	5	O
quinine	0	B-Chemical
infusion	0	O
the	5	O
patient	5	O
felt	5	O
palpitation	5	B-Disease
and	5	O
electrocardiography	5	O
(	9	O
ECG	5	O
)	9	O
recording	5	O
showed	9	O
premature	9	B-Disease
ventricular	5	I-Disease
contraction	9	I-Disease
(	9	O
PVC	5	B-Disease
)	9	O
>	0	O
5	9	O
x	9	O
/	9	O
minute	5	O
,	9	O
trigemini	4	O
,	9	O
constant	9	O
type	9	O
-	7	O
-	7	O
sinoatrial	5	B-Disease
block	9	I-Disease
,	9	O
positive	9	O
U	9	O
wave	5	O
.	9	O

He	5	O
was	9	O
treated	3	O
with	5	O
lidocaine	0	B-Chemical
50	0	O
mg	0	O
intravenously	0	O
followed	9	O
by	9	O
infusion	0	O
1500	9	O
mg	0	O
in	5	O
dextrose	0	B-Chemical
5	9	O
%	9	O
/	9	O
24	9	O
hour	0	O
and	5	O
potassium	0	B-Chemical
aspartate	1	I-Chemical
tablet	0	O
.	9	O

Quinine	0	B-Chemical
infusion	0	O
was	9	O
discontinued	5	O
and	5	O
changed	9	O
with	5	O
sulfate	0	O
quinine	0	B-Chemical
tablets	0	O
.	9	O

Three	9	O
hours	9	O
later	9	O
the	5	O
patient	5	O
felt	5	O
better	5	O
,	9	O
the	5	O
frequency	5	O
of	5	O
PVC	5	B-Disease
reduced	9	O
to	5	O
4	9	O
-	7	O
5	9	O
x	9	O
/	9	O
minute	5	O
and	5	O
on	5	O
the	5	O
third	9	O
day	9	O
ECG	5	O
was	9	O
normal	9	O
,	9	O
potassium	0	B-Chemical
level	9	O
was	9	O
3	9	O
.	9	O
34	7	O
meq	0	O
/	9	O
L	0	O
.	9	O

He	5	O
was	9	O
discharged	5	O
on	5	O
7th	9	O
day	9	O
in	5	O
good	5	O
condition	5	O
.	9	O

Quinine	0	B-Chemical
,	9	O
like	9	O
quinidine	0	B-Chemical
,	9	O
is	5	O
a	5	O
chincona	_	O
alkaloid	0	O
that	5	O
has	9	O
anti	3	O
-	7	O
arrhythmic	5	B-Disease
property	5	O
,	9	O
although	9	O
it	5	O
also	9	O
pro	9	O
-	7	O
arrhythmic	5	B-Disease
that	5	O
can	5	O
cause	5	O
various	9	O
arrhythmias	5	B-Disease
,	9	O
including	9	O
severe	5	O
arrhythmia	5	B-Disease
such	5	O
as	5	O
multiple	5	O
PVC	5	B-Disease
.	9	O

Administration	2	O
of	5	O
parenteral	5	O
quinine	0	B-Chemical
must	5	O
be	5	O
done	9	O
carefully	5	O
and	5	O
with	5	O
good	5	O
observation	9	O
because	5	O
of	5	O
its	9	O
pro	9	O
-	7	O
arrhythmic	5	B-Disease
effect	9	O
,	9	O
especially	5	O
in	5	O
older	5	O
patients	5	O
who	5	O
have	5	O
heart	5	B-Disease
diseases	5	I-Disease
or	5	O
patients	5	O
with	5	O
electrolyte	0	B-Disease
disorder	5	I-Disease
(	9	O
hypokalemia	5	B-Disease
)	9	O
which	5	O
frequently	5	O
occurs	9	O
due	5	O
to	5	O
vomiting	5	B-Disease
and	5	O
or	5	O
diarrhea	5	B-Disease
in	5	O
malaria	5	B-Disease
cases	5	O
.	9	O

Penicillamine	0	B-Chemical
-	7	O
related	9	O
lichenoid	5	B-Disease
dermatitis	5	I-Disease
and	5	O
utility	5	O
of	5	O
zinc	9	B-Chemical
acetate	0	I-Chemical
in	5	O
a	5	O
Wilson	6	B-Disease
disease	5	I-Disease
patient	5	O
with	5	O
hepatic	9	O
presentation	5	O
,	9	O
anxiety	5	B-Disease
and	5	O
SPECT	5	O
abnormalities	9	O
.	9	O

Wilson	6	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
is	5	O
an	5	O
autosomal	9	O
recessive	9	O
disorder	5	O
of	5	O
hepatic	9	O
copper	0	B-Chemical
metabolism	9	O
with	5	O
consequent	9	O
copper	0	B-Chemical
accumulation	9	O
and	5	O
toxicity	9	B-Disease
in	5	O
many	5	O
tissues	9	O
and	5	O
consequent	9	O
hepatic	9	B-Disease
,	9	I-Disease
neurologic	5	I-Disease
and	5	I-Disease
psychiatric	5	I-Disease
disorders	5	I-Disease
.	9	O

We	9	O
report	5	O
a	5	O
case	5	O
of	5	O
Wilson	6	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
with	5	O
chronic	5	B-Disease
liver	9	I-Disease
disease	5	I-Disease
;	9	O
moreover	9	O
,	9	O
in	5	O
our	5	O
patient	5	O
,	9	O
presenting	5	O
also	9	O
with	5	O
high	9	O
levels	3	O
of	5	O
state	5	O
anxiety	5	B-Disease
without	9	O
depression	5	B-Disease
,	9	O
99mTc	0	O
-	7	O
ECD	9	O
-	7	O
SPECT	5	O
showed	9	O
cortical	5	O
hypoperfusion	5	O
in	5	O
frontal	5	O
lobes	5	O
,	9	O
more	5	O
marked	9	O
on	5	O
the	5	O
left	5	O
frontal	5	O
lobe	5	O
.	9	O

During	5	O
the	5	O
follow	5	O
-	7	O
up	5	O
of	5	O
our	5	O
patient	5	O
,	9	O
penicillamine	0	B-Chemical
was	9	O
interrupted	5	O
after	9	O
the	5	O
appearance	9	O
of	5	O
a	5	O
lichenoid	5	B-Disease
dermatitis	5	I-Disease
,	9	O
and	5	O
zinc	9	B-Chemical
acetate	0	I-Chemical
permitted	5	O
to	5	O
continue	5	O
the	5	O
successful	5	O
treatment	9	O
of	5	O
the	5	O
patient	5	O
without	9	O
side	5	O
-	7	O
effects	9	O
.	9	O

In	9	O
our	5	O
case	5	O
the	5	O
therapy	5	O
with	5	O
zinc	9	B-Chemical
acetate	0	I-Chemical
represented	9	O
an	5	O
effective	5	O
treatment	9	O
for	5	O
a	5	O
Wilson	6	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
patient	5	O
in	5	O
which	5	O
penicillamine	0	B-Chemical
-	7	O
related	9	O
side	5	O
effects	9	O
appeared	9	O
.	9	O

The	5	O
safety	5	O
of	5	O
the	5	O
zinc	9	B-Chemical
acetate	0	I-Chemical
allowed	9	O
us	5	O
to	5	O
avoid	5	O
other	5	O
potentially	5	O
toxic	0	O
chelating	0	O
drugs	5	O
;	9	O
this	5	O
observation	9	O
is	5	O
in	5	O
line	9	O
with	5	O
the	5	O
growing	9	O
evidence	9	O
on	5	O
the	5	O
efficacy	9	O
of	5	O
the	5	O
drug	5	O
in	5	O
the	5	O
treatment	9	O
of	5	O
Wilson	6	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
.	9	O

Since	9	O
most	9	O
of	5	O
Wilson	6	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
penicillamine	0	B-Chemical
-	7	O
treated	3	O
patients	5	O
do	5	O
not	5	O
seem	5	O
to	5	O
develop	5	O
this	5	O
skin	5	B-Disease
lesion	5	I-Disease
,	9	O
it	5	O
could	9	O
be	5	O
conceivable	9	O
that	5	O
a	5	O
specific	9	O
genetic	5	O
factor	9	O
is	5	O
involved	9	O
in	5	O
drug	5	O
response	9	O
.	9	O

Further	9	O
studies	9	O
are	5	O
needed	5	O
for	5	O
a	5	O
better	5	O
clarification	5	O
of	5	O
Wilson	6	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
therapy	5	O
,	9	O
and	5	O
in	5	O
particular	5	O
to	5	O
differentiate	9	O
specific	9	O
therapies	5	O
for	5	O
different	9	O
Wilson	6	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
phenotypes	9	O
.	9	O

A	9	O
dramatic	9	O
drop	9	B-Disease
in	5	I-Disease
blood	9	I-Disease
pressure	5	I-Disease
following	9	O
prehospital	5	O
GTN	0	B-Chemical
administration	9	O
.	9	O

A	9	O
male	9	O
in	5	O
his	5	O
sixties	5	O
with	5	O
no	9	O
history	5	O
of	5	O
cardiac	5	O
chest	5	B-Disease
pain	5	I-Disease
awoke	5	O
with	5	O
chest	5	B-Disease
pain	5	I-Disease
following	9	O
an	5	O
afternoon	5	O
sleep	5	O
.	9	O

The	5	O
patient	5	O
did	9	O
not	5	O
self	5	O
medicate	5	O
.	9	O

The	5	O
patient	5	O
'	9	O
s	9	O
observations	9	O
were	9	O
within	9	O
normal	9	O
limits	5	O
,	9	O
he	5	O
was	9	O
administered	9	O
oxygen	0	B-Chemical
via	9	O
a	5	O
face	5	O
mask	5	O
and	5	O
glyceryl	0	B-Chemical
trinitrate	0	I-Chemical
(	9	O
GTN	0	B-Chemical
)	9	O
.	9	O

Several	9	O
minutes	0	O
after	9	O
the	5	O
GTN	0	B-Chemical
the	5	O
patient	5	O
experienced	5	O
a	5	O
sudden	5	O
drop	9	B-Disease
in	5	I-Disease
blood	9	I-Disease
pressure	5	I-Disease
and	5	O
heart	5	O
rate	9	O
,	9	O
this	5	O
was	9	O
rectified	5	O
by	9	O
atropine	0	B-Chemical
sulphate	0	I-Chemical
and	5	O
a	5	O
fluid	5	O
challenge	9	O
.	9	O

There	5	O
was	9	O
no	9	O
further	9	O
deterioration	5	O
in	5	O
the	5	O
patient	5	O
'	9	O
s	9	O
condition	5	O
during	5	O
transport	9	O
to	5	O
hospital	5	O
.	9	O

There	5	O
are	5	O
very	5	O
few	5	O
documented	9	O
case	5	O
like	9	O
this	5	O
in	5	O
the	5	O
prehospital	5	O
scientific	5	O
literature	5	O
.	9	O

The	5	O
cause	5	O
appears	9	O
to	5	O
be	5	O
the	5	O
Bezold	6	O
-	7	O
Jarish	2	O
reflex	5	O
,	9	O
stimulation	3	O
of	5	O
the	5	O
ventricular	5	O
walls	5	O
which	5	O
in	5	O
turn	9	O
decreases	9	O
sympathetic	5	O
outflow	5	O
from	9	O
the	5	O
vasomotor	5	O
centre	5	O
.	9	O

Prehospital	5	O
care	5	O
providers	5	O
who	5	O
are	5	O
managing	5	O
any	5	O
patient	5	O
with	5	O
a	5	O
syncopal	5	B-Disease
episode	5	I-Disease
that	5	O
fails	9	O
to	5	O
recover	9	O
within	9	O
a	5	O
reasonable	5	O
time	5	O
frame	5	O
should	5	O
consider	5	O
the	5	O
Bezold	6	O
-	7	O
Jarisch	6	O
reflex	5	O
as	5	O
the	5	O
cause	5	O
and	5	O
manage	5	O
the	5	O
patient	5	O
accordingly	9	O
.	9	O

Chronic	9	O
lesion	5	O
of	5	O
rostral	5	O
ventrolateral	5	O
medulla	9	O
in	5	O
spontaneously	5	O
hypertensive	5	B-Disease
rats	9	O
.	9	O

We	9	O
studied	9	O
the	5	O
effects	9	O
of	5	O
chronic	5	O
selective	9	O
neuronal	3	O
lesion	5	O
of	5	O
rostral	5	O
ventrolateral	5	O
medulla	9	O
on	5	O
mean	5	O
arterial	5	O
pressure	5	O
,	9	O
heart	5	O
rate	9	O
,	9	O
and	5	O
neurogenic	5	O
tone	5	O
in	5	O
conscious	5	O
,	9	O
unrestrained	5	O
spontaneously	5	O
hypertensive	5	B-Disease
rats	9	O
.	9	O

The	5	O
lesions	5	O
were	9	O
placed	5	O
via	9	O
bilateral	5	O
microinjections	9	O
of	5	O
30	9	O
nmol	0	O
/	9	O
200	0	O
nl	0	O
N	9	B-Chemical
-	7	I-Chemical
methyl	0	I-Chemical
-	7	I-Chemical
D	9	I-Chemical
-	7	I-Chemical
aspartic	1	I-Chemical
acid	0	I-Chemical
.	9	O

The	5	O
restimulation	3	O
of	5	O
this	5	O
area	5	O
with	5	O
N	9	B-Chemical
-	7	I-Chemical
methyl	0	I-Chemical
-	7	I-Chemical
D	9	I-Chemical
-	7	I-Chemical
aspartic	1	I-Chemical
acid	0	I-Chemical
15	9	O
days	9	O
postlesion	5	O
failed	9	O
to	5	O
produce	9	O
a	5	O
pressor	5	O
response	9	O
.	9	O

One	5	O
day	9	O
postlesion	5	O
,	9	O
the	5	O
resting	5	O
mean	5	O
arterial	5	O
pressure	5	O
was	9	O
significantly	9	O
decreased	9	O
in	5	O
lesioned	3	O
rats	9	O
when	5	O
compared	9	O
with	5	O
sham	9	O
rats	9	O
(	9	O
100	0	O
+	9	O
/	9	O
-	7	O
7	9	O
versus	9	O
173	7	O
+	9	O
/	9	O
-	7	O
4	9	O
mm	9	O
Hg	0	O
,	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

Fifteen	9	O
days	9	O
later	9	O
,	9	O
the	5	O
lesioned	3	O
group	9	O
still	5	O
showed	9	O
values	5	O
significantly	9	O
lower	9	O
than	5	O
the	5	O
sham	9	O
group	9	O
(	9	O
150	0	O
+	9	O
/	9	O
-	7	O
6	9	O
versus	9	O
167	7	O
+	9	O
/	9	O
-	7	O
5	9	O
mm	9	O
Hg	0	O
,	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

No	9	O
significant	9	O
heart	5	O
rate	9	O
differences	9	O
were	9	O
observed	9	O
between	5	O
the	5	O
sham	9	O
and	5	O
lesioned	3	O
groups	9	O
.	9	O

The	5	O
ganglionic	3	O
blocker	0	O
trimethaphan	9	B-Chemical
(	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
i	9	O
.	9	O
v	0	O
.	9	O
)	9	O
caused	9	O
similar	9	O
reductions	9	O
in	5	O
mean	5	O
arterial	5	O
pressure	5	O
in	5	O
both	9	O
lesioned	3	O
and	5	O
sham	9	O
groups	9	O
.	9	O

The	5	O
trimethaphan	9	B-Chemical
-	7	O
induced	3	O
hypotension	5	B-Disease
was	9	O
accompanied	9	O
by	9	O
a	5	O
significant	9	O
bradycardia	5	B-Disease
in	5	O
lesioned	3	O
rats	9	O
(	9	O
-	7	O
32	7	O
+	9	O
/	9	O
-	7	O
13	7	O
beats	5	O
per	9	O
minute	5	O
)	9	O
but	9	O
a	5	O
tachycardia	5	B-Disease
in	5	O
sham	9	O
rats	9	O
(	9	O
+	9	O
33	7	O
+	9	O
/	9	O
-	7	O
12	9	O
beats	5	O
per	9	O
minute	5	O
)	9	O
1	9	O
day	9	O
postlesion	5	O
.	9	O

Therefore	9	O
,	9	O
rostral	5	O
ventrolateral	5	O
medulla	9	O
neurons	3	O
appear	9	O
to	5	O
play	9	O
a	5	O
significant	9	O
role	9	O
in	5	O
maintaining	9	O
hypertension	5	B-Disease
in	5	O
conscious	5	O
spontaneously	5	O
hypertensive	5	B-Disease
rats	9	O
.	9	O

Spinal	9	O
or	5	O
suprabulbar	5	O
structures	9	O
could	9	O
be	5	O
responsible	9	O
for	5	O
the	5	O
gradual	9	O
recovery	9	O
of	5	O
the	5	O
hypertension	5	B-Disease
in	5	O
the	5	O
lesioned	3	O
rats	9	O
.	9	O

Acute	5	B-Disease
encephalopathy	5	I-Disease
and	5	O
cerebral	5	B-Disease
vasospasm	5	I-Disease
after	9	O
multiagent	5	O
chemotherapy	5	O
including	9	O
PEG	0	B-Chemical
-	7	I-Chemical
asparaginase	0	I-Chemical
and	5	O
intrathecal	3	O
cytarabine	0	B-Chemical
for	5	O
the	5	O
treatment	9	O
of	5	O
acute	9	B-Disease
lymphoblastic	3	I-Disease
leukemia	3	I-Disease
.	9	O

A	9	O
7	9	O
-	7	O
year	5	O
-	7	O
old	5	O
girl	5	O
with	5	O
an	5	O
unusual	9	O
reaction	9	O
to	5	O
induction	3	O
chemotherapy	5	O
for	5	O
precursor	9	O
B	9	O
-	7	O
cell	3	O
acute	9	B-Disease
lymphoblastic	3	I-Disease
leukemia	3	I-Disease
(	9	O
ALL	9	B-Disease
)	9	O
is	5	O
described	9	O
.	9	O

The	5	O
patient	5	O
developed	5	O
acute	9	B-Disease
encephalopathy	5	I-Disease
evidenced	9	O
by	9	O
behavioral	5	O
changes	9	O
,	9	O
aphasia	5	B-Disease
,	9	O
incontinence	5	B-Disease
,	9	O
visual	5	B-Disease
hallucinations	5	I-Disease
,	9	O
and	5	O
right	5	O
-	7	O
sided	5	O
weakness	5	B-Disease
with	5	O
diffuse	5	O
cerebral	5	B-Disease
vasospasm	5	I-Disease
on	5	O
magnetic	0	O
resonance	5	O
angiography	5	O
after	9	O
the	5	O
administration	9	O
of	5	O
intrathecal	3	O
cytarabine	0	B-Chemical
.	9	O

Vincristine	0	B-Chemical
,	9	O
dexamethasone	0	B-Chemical
,	9	O
and	5	O
polyethylene	0	B-Chemical
glycol	0	I-Chemical
-	7	I-Chemical
asparaginase	0	I-Chemical
were	9	O
also	9	O
administered	9	O
before	9	O
the	5	O
episode	5	O
as	5	O
part	9	O
of	5	O
induction	3	O
therapy	5	O
.	9	O

Neurologic	5	O
status	9	O
returned	5	O
to	5	O
baseline	5	O
within	9	O
10	9	O
days	9	O
of	5	O
the	5	O
acute	9	O
event	5	O
,	9	O
and	5	O
magnetic	0	O
resonance	5	O
angiography	5	O
findings	9	O
returned	5	O
to	5	O
normal	9	O
4	9	O
months	5	O
later	9	O
.	9	O

Comparison	9	O
of	5	O
valsartan	0	B-Chemical
/	9	O
hydrochlorothiazide	0	B-Chemical
combination	9	O
therapy	5	O
at	9	O
doses	0	O
up	5	O
to	5	O
320	9	O
/	9	O
25	9	O
mg	0	O
versus	9	O
monotherapy	5	O
:	9	O
a	5	O
double	9	O
-	7	O
blind	5	O
,	9	O
placebo	9	O
-	7	O
controlled	5	O
study	9	O
followed	9	O
by	9	O
long	5	O
-	7	O
term	5	O
combination	9	O
therapy	5	O
in	5	O
hypertensive	5	B-Disease
adults	5	O
.	9	O

BACKGROUND	2	O
:	9	O
One	5	O
third	9	O
of	5	O
patients	5	O
treated	3	O
for	5	O
hypertension	5	B-Disease
attain	5	O
adequate	5	O
blood	9	O
pressure	5	O
(	9	O
BP	9	O
)	9	O
control	9	O
,	9	O
and	5	O
multidrug	9	O
regimens	5	O
are	5	O
often	5	O
required	9	O
.	9	O

Given	9	O
the	5	O
lifelong	5	O
nature	5	O
of	5	O
hypertension	5	B-Disease
,	9	O
there	5	O
is	5	O
a	5	O
need	5	O
to	5	O
evaluate	9	O
the	5	O
long	5	O
-	7	O
term	5	O
efficacy	9	O
and	5	O
tolerability	5	O
of	5	O
higher	9	O
doses	0	O
of	5	O
combination	9	O
anti	3	O
-	7	O
hypertensive	5	B-Disease
therapies	5	O
.	9	O

OBJECTIVE	2	O
:	9	O
This	5	O
study	9	O
investigated	9	O
the	5	O
efficacy	9	O
and	5	O
tolerability	5	O
of	5	O
valsartan	0	B-Chemical
(	9	O
VAL	9	B-Chemical
)	9	O
or	5	O
hydrochlorothiazide	0	B-Chemical
(	9	O
HCTZ	0	B-Chemical
)	9	O
-	7	O
monotherapy	5	O
and	5	O
higher	9	O
-	7	O
dose	9	O
combinations	9	O
in	5	O
patients	5	O
with	5	O
essential	9	B-Disease
hypertension	5	I-Disease
.	9	O

METHODS	2	O
:	9	O
The	5	O
first	9	O
part	9	O
of	5	O
this	5	O
study	9	O
was	9	O
an	5	O
8	9	O
-	7	O
week	9	O
,	9	O
multicenter	5	O
,	9	O
randomized	5	O
,	9	O
double	9	O
-	7	O
blind	5	O
,	9	O
placebo	9	O
controlled	5	O
,	9	O
parallel	5	O
-	7	O
group	9	O
trial	5	O
.	9	O

Patients	5	O
with	5	O
essential	9	B-Disease
hypertension	5	I-Disease
(	9	O
mean	5	O
sitting	5	O
diastolic	5	O
BP	9	O
[	9	O
MSDBP	7	O
]	9	O
,	9	O
>	0	O
or	5	O
=	7	O
95	7	O
mm	9	O
Hg	0	O
and	5	O
<	0	O
110	9	O
mm	9	O
Hg	0	O
)	9	O
were	9	O
randomized	5	O
to	5	O
1	9	O
of	5	O
8	9	O
treatment	9	O
groups	9	O
:	9	O
VAL	9	B-Chemical
160	9	O
or	5	O
320	9	O
mg	0	O
;	9	O
HCTZ	0	B-Chemical
12	9	O
.	9	O
5	9	O
or	5	O
25	9	O
mg	0	O
;	9	O
VAL	9	B-Chemical
/	9	O
HCTZ	0	B-Chemical
160	9	O
/	9	O
12	9	O
.	9	O
5	9	O
,	9	O
320	9	O
/	9	O
12	9	O
.	9	O
5	9	O
,	9	O
or	5	O
320	9	O
/	9	O
25	9	O
mg	0	O
;	9	O
or	5	O
placebo	9	O
.	9	O

Mean	9	O
changes	9	O
in	5	O
MSDBP	7	O
and	5	O
mean	5	O
sitting	5	O
systolic	5	O
BP	9	O
(	9	O
MSSBP	5	O
)	9	O
were	9	O
analyzed	9	O
at	9	O
the	5	O
8	9	O
-	7	O
week	9	O
core	9	O
study	9	O
end	9	O
point	5	O
.	9	O

VAL	9	B-Chemical
/	9	O
HCTZ	0	B-Chemical
320	9	O
/	9	O
12	9	O
.	9	O
5	9	O
and	5	O
320	9	O
/	9	O
25	9	O
mg	0	O
were	9	O
further	9	O
investigated	9	O
in	5	O
a	5	O
54	7	O
-	7	O
week	9	O
,	9	O
open	5	O
-	7	O
label	9	O
extension	9	O
.	9	O

Response	5	O
was	9	O
defined	5	O
as	5	O
MSDBP	7	O
<	0	O
90	9	O
mm	9	O
Hg	0	O
or	5	O
a	5	O
>	0	O
or	5	O
=	7	O
10	9	O
mm	9	O
Hg	0	O
decrease	9	O
compared	9	O
to	5	O
baseline	5	O
.	9	O

Control	9	O
was	9	O
defined	5	O
as	5	O
MSDBP	7	O
<	0	O
90	9	O
mm	9	O
Hg	0	O
compared	9	O
with	5	O
baseline	5	O
.	9	O

Tolerability	5	O
was	9	O
assessed	9	O
by	9	O
monitoring	5	O
adverse	5	O
events	5	O
at	9	O
randomization	5	O
and	5	O
all	5	O
subsequent	9	O
study	9	O
visits	5	O
and	5	O
regular	5	O
evaluation	5	O
of	5	O
hematology	5	O
and	5	O
blood	9	O
chemistry	0	O
.	9	O

RESULTS	9	O
:	9	O
A	9	O
total	9	O
of	5	O
1346	7	O
patients	5	O
were	9	O
randomized	5	O
into	9	O
the	5	O
8	9	O
-	7	O
week	9	O
core	9	O
study	9	O
(	9	O
734	7	O
men	5	O
,	9	O
612	7	O
women	5	O
;	9	O
924	7	O
white	9	O
,	9	O
291	7	O
black	9	O
,	9	O
23	7	O
Asian	4	O
,	9	O
108	9	O
other	5	O
;	9	O
mean	5	O
age	5	O
,	9	O
52	7	O
.	9	O
7	9	O
years	5	O
;	9	O
mean	5	O
weight	9	O
,	9	O
92	7	O
.	9	O
6	9	O
kg	0	O
)	9	O
.	9	O

All	9	O
active	9	O
treatments	9	O
were	9	O
associated	9	O
with	5	O
significantly	9	O
reduced	9	O
MSSBP	5	O
and	5	O
MSDBP	7	O
during	5	O
the	5	O
core	9	O
8	9	O
-	7	O
week	9	O
study	9	O
,	9	O
with	5	O
each	5	O
monotherapy	5	O
significantly	9	O
contributing	9	O
to	5	O
the	5	O
overall	5	O
effect	9	O
of	5	O
combination	9	O
therapy	5	O
(	9	O
VAL	9	B-Chemical
and	5	O
HCTZ	0	B-Chemical
,	9	O
P	9	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
.	9	O

Each	5	O
combination	9	O
was	9	O
associated	9	O
with	5	O
significantly	9	O
greater	5	O
reductions	9	O
in	5	O
MSSBP	5	O
and	5	O
MSDBP	7	O
compared	9	O
with	5	O
the	5	O
monotherapies	5	O
and	5	O
placebo	9	O
(	9	O
all	5	O
,	9	O
P	9	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
.	9	O

The	5	O
mean	5	O
reduction	9	O
in	5	O
MSSBP	5	O
/	9	O
MSDBP	7	O
with	5	O
VAL	9	B-Chemical
/	9	O
HCTZ	0	B-Chemical
320	9	O
/	9	O
25	9	O
mg	0	O
was	9	O
24	9	O
.	9	O
7	9	O
/	9	O
16	9	O
.	9	O
6	9	O
mm	9	O
Hg	0	O
,	9	O
compared	9	O
with	5	O
5	9	O
.	9	O
9	7	O
/	9	O
7	9	O
.	9	O
0	7	O
mm	9	O
Hg	0	O
with	5	O
placebo	9	O
.	9	O

The	5	O
reduction	9	O
in	5	O
MSSBP	5	O
was	9	O
significantly	9	O
greater	5	O
with	5	O
VAL	9	B-Chemical
/	9	O
HCTZ	0	B-Chemical
320	9	O
/	9	O
25	9	O
mg	0	O
compared	9	O
with	5	O
VAL	9	B-Chemical
/	9	O
HCTZ	0	B-Chemical
160	9	O
/	9	O
12	9	O
.	9	O
5	9	O
mg	0	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
002	7	O
)	9	O
.	9	O

Rates	5	O
of	5	O
response	9	O
and	5	O
BP	9	O
control	9	O
were	9	O
significantly	9	O
higher	9	O
in	5	O
the	5	O
groups	9	O
that	5	O
received	9	O
combination	9	O
treatment	9	O
compared	9	O
with	5	O
those	5	O
that	5	O
received	9	O
monotherapy	5	O
.	9	O

The	5	O
incidence	5	O
of	5	O
hypokalemia	5	B-Disease
was	9	O
lower	9	O
with	5	O
VAL	9	B-Chemical
/	9	O
HCTZ	0	B-Chemical
combinations	9	O
(	9	O
1	9	O
.	9	O
8	9	O
%	9	O
-	7	O
6	9	O
.	9	O
1	9	O
%	9	O
)	9	O
than	5	O
with	5	O
HCTZ	0	B-Chemical
monotherapies	5	O
(	9	O
7	9	O
.	9	O
1	9	O
%	9	O
-	7	O
13	7	O
.	9	O
3	9	O
%	9	O
)	9	O
.	9	O

The	5	O
majority	9	O
of	5	O
adverse	5	O
events	5	O
in	5	O
the	5	O
core	9	O
study	9	O
were	9	O
of	5	O
mild	9	O
to	5	O
moderate	9	O
severity	5	O
.	9	O

The	5	O
efficacy	9	O
and	5	O
tolerability	5	O
of	5	O
VAL	9	B-Chemical
/	9	O
HCTZ	0	B-Chemical
combinations	9	O
were	9	O
maintained	9	O
during	5	O
the	5	O
extension	9	O
(	9	O
797	7	O
patients	5	O
)	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
In	9	O
this	5	O
study	9	O
population	5	O
,	9	O
combination	9	O
therapies	5	O
with	5	O
VAL	9	B-Chemical
/	9	O
HCTZ	0	B-Chemical
were	9	O
associated	9	O
with	5	O
significantly	9	O
greater	5	O
BP	9	O
reductions	9	O
compared	9	O
with	5	O
either	9	O
monotherapy	5	O
,	9	O
were	9	O
well	9	O
tolerated	9	O
,	9	O
and	5	O
were	9	O
associated	9	O
with	5	O
less	5	O
hypokalemia	5	B-Disease
than	5	O
HCTZ	0	B-Chemical
alone	9	O
.	9	O

Succimer	0	B-Chemical
chelation	0	O
improves	5	O
learning	5	O
,	9	O
attention	5	O
,	9	O
and	5	O
arousal	5	O
regulation	9	O
in	5	O
lead	5	B-Chemical
-	7	O
exposed	9	O
rats	9	O
but	9	O
produces	9	O
lasting	5	O
cognitive	5	B-Disease
impairment	5	I-Disease
in	5	O
the	5	O
absence	3	O
of	5	O
lead	5	B-Chemical
exposure	9	O
.	9	O

BACKGROUND	2	O
:	9	O
There	5	O
is	5	O
growing	9	O
pressure	5	O
for	5	O
clinicians	5	O
to	5	O
prescribe	5	O
chelation	0	O
therapy	5	O
at	9	O
only	9	O
slightly	9	O
elevated	9	O
blood	9	O
lead	5	B-Chemical
levels	3	O
.	9	O

However	9	O
,	9	O
very	5	O
few	5	O
studies	9	O
have	5	O
evaluated	9	O
whether	9	O
chelation	0	O
improves	5	O
cognitive	5	O
outcomes	5	O
in	5	O
Pb	0	B-Chemical
-	7	O
exposed	9	O
children	5	O
,	9	O
or	5	O
whether	9	O
these	5	O
agents	5	O
have	5	O
adverse	5	O
effects	9	O
that	5	O
may	5	O
affect	9	O
brain	5	O
development	9	O
in	5	O
the	5	O
absence	3	O
of	5	O
Pb	0	B-Chemical
exposure	9	O
.	9	O

OBJECTIVES	2	O
:	9	O
The	5	O
present	9	O
study	9	O
was	9	O
designed	9	O
to	5	O
answer	5	O
these	5	O
questions	5	O
,	9	O
using	9	O
a	5	O
rodent	9	O
model	5	O
of	5	O
early	9	O
childhood	5	O
Pb	0	B-Chemical
exposure	9	O
and	5	O
treatment	9	O
with	5	O
succimer	0	B-Chemical
,	9	O
a	5	O
widely	5	O
used	5	O
chelating	0	O
agent	9	O
for	5	O
the	5	O
treatment	9	O
of	5	O
Pb	0	B-Disease
poisoning	5	I-Disease
.	9	O

RESULTS	9	O
:	9	O
Pb	0	B-Chemical
exposure	9	O
produced	9	O
lasting	5	O
impairments	5	B-Disease
in	5	I-Disease
learning	5	I-Disease
,	9	I-Disease
attention	5	I-Disease
,	9	I-Disease
inhibitory	3	I-Disease
control	9	I-Disease
,	9	I-Disease
and	5	I-Disease
arousal	5	I-Disease
regulation	9	I-Disease
,	9	O
paralleling	9	O
the	5	O
areas	5	O
of	5	O
dysfunction	9	O
seen	9	O
in	5	O
Pb	0	B-Chemical
-	7	O
exposed	9	O
children	5	O
.	9	O

Succimer	0	B-Chemical
treatment	9	O
of	5	O
the	5	O
Pb	0	B-Chemical
-	7	O
exposed	9	O
rats	9	O
significantly	9	O
improved	5	O
learning	5	O
,	9	O
attention	5	O
,	9	O
and	5	O
arousal	5	O
regulation	9	O
,	9	O
although	9	O
the	5	O
efficacy	9	O
of	5	O
the	5	O
treatment	9	O
varied	9	O
as	5	O
a	5	O
function	9	O
of	5	O
the	5	O
Pb	0	B-Chemical
exposure	9	O
level	9	O
and	5	O
the	5	O
specific	9	O
functional	9	O
deficit	5	O
.	9	O

In	9	O
contrast	9	O
,	9	O
succimer	0	B-Chemical
treatment	9	O
of	5	O
rats	9	O
not	5	O
previously	9	O
exposed	9	O
to	5	O
Pb	0	B-Chemical
produced	9	O
lasting	5	O
and	5	O
pervasive	5	O
cognitive	5	B-Disease
and	5	I-Disease
affective	5	I-Disease
dysfunction	9	I-Disease
comparable	9	O
in	5	O
magnitude	5	O
to	5	O
that	5	O
produced	9	O
by	9	O
the	5	O
higher	9	O
Pb	0	B-Chemical
exposure	9	O
regimen	5	O
.	9	O

CONCLUSIONS	5	O
:	9	O
These	5	O
are	5	O
the	5	O
first	9	O
data	5	O
,	9	O
to	5	O
our	5	O
knowledge	5	O
,	9	O
to	5	O
show	9	O
that	5	O
treatment	9	O
with	5	O
any	5	O
chelating	0	O
agent	9	O
can	5	O
alleviate	5	O
cognitive	5	B-Disease
deficits	5	I-Disease
due	5	O
to	5	O
Pb	0	B-Chemical
exposure	9	O
.	9	O

These	5	O
findings	9	O
suggest	9	O
that	5	O
it	5	O
may	5	O
be	5	O
possible	5	O
to	5	O
identify	9	O
a	5	O
succimer	0	B-Chemical
treatment	9	O
protocol	9	O
that	5	O
improves	5	O
cognitive	5	O
outcomes	5	O
in	5	O
Pb	0	B-Chemical
-	7	O
exposed	9	O
children	5	O
.	9	O

However	9	O
,	9	O
they	5	O
also	9	O
suggest	9	O
that	5	O
succimer	0	B-Chemical
treatment	9	O
should	5	O
be	5	O
strongly	9	O
discouraged	5	O
for	5	O
children	5	O
who	5	O
do	5	O
not	5	O
have	5	O
elevated	9	O
tissue	9	O
levels	3	O
of	5	O
Pb	0	B-Chemical
or	5	O
other	5	O
heavy	9	O
metals	0	O
.	9	O

Caffeine	0	B-Chemical
challenge	9	O
test	5	O
in	5	O
panic	5	B-Disease
disorder	5	I-Disease
and	5	O
depression	5	B-Disease
with	5	O
panic	5	B-Disease
attacks	5	I-Disease
.	9	O

Our	9	O
aim	5	O
was	9	O
to	5	O
observe	9	O
if	5	O
patients	5	O
with	5	O
panic	5	B-Disease
disorder	5	I-Disease
(	9	O
PD	9	B-Disease
)	9	O
and	5	O
patients	5	O
with	5	O
major	9	B-Disease
depression	5	I-Disease
with	5	O
panic	5	B-Disease
attacks	5	I-Disease
(	9	O
MDP	9	B-Disease
)	9	O
(	9	O
Diagnostic	5	O
and	5	O
Statistical	5	O
Manual	5	O
of	5	O
Mental	5	B-Disease
Disorders	2	I-Disease
,	9	O
Fourth	9	O
Edition	2	O
criteria	5	O
)	9	O
respond	5	O
in	5	O
a	5	O
similar	9	O
way	5	O
to	5	O
the	5	O
induction	3	O
of	5	O
panic	5	B-Disease
attacks	5	I-Disease
by	9	O
an	5	O
oral	9	O
caffeine	0	B-Chemical
challenge	9	O
test	5	O
.	9	O

We	9	O
randomly	5	O
selected	9	O
29	7	O
patients	5	O
with	5	O
PD	9	B-Disease
,	9	O
27	7	O
with	5	O
MDP	9	B-Disease
,	9	O
25	9	O
with	5	O
major	9	B-Disease
depression	5	I-Disease
without	9	O
panic	5	B-Disease
attacks	5	I-Disease
(	9	O
MD	9	B-Disease
)	9	O
,	9	O
and	5	O
28	7	O
healthy	5	O
volunteers	5	O
.	9	O

The	5	O
patients	5	O
had	9	O
no	9	O
psychotropic	5	O
drug	5	O
for	5	O
at	9	O
least	9	O
a	5	O
4	9	O
-	7	O
week	9	O
period	5	O
.	9	O

In	9	O
a	5	O
randomized	5	O
double	9	O
-	7	O
blind	5	O
experiment	9	O
performed	9	O
in	5	O
2	9	O
occasions	5	O
7	9	O
days	9	O
apart	9	O
,	9	O
480	9	O
mg	0	O
caffeine	0	B-Chemical
and	5	O
a	5	O
caffeine	0	B-Chemical
-	7	O
free	9	O
(	9	O
placebo	9	O
)	9	O
solution	0	O
were	9	O
administered	9	O
in	5	O
a	5	O
coffee	5	O
form	9	O
and	5	O
anxiety	5	B-Disease
scales	5	O
were	9	O
applied	5	O
before	9	O
and	5	O
after	9	O
each	5	O
test	5	O
.	9	O

A	9	O
total	9	O
of	5	O
58	7	O
.	9	O
6	9	O
%	9	O
(	9	O
n	9	O
=	7	O
17	7	O
)	9	O
of	5	O
patients	5	O
with	5	O
PD	9	B-Disease
,	9	O
44	7	O
.	9	O
4	9	O
%	9	O
(	9	O
n	9	O
=	7	O
12	9	O
)	9	O
of	5	O
patients	5	O
with	5	O
MDP	9	B-Disease
,	9	O
12	9	O
.	9	O
0	7	O
%	9	O
(	9	O
n	9	O
=	7	O
3	9	O
)	9	O
of	5	O
patients	5	O
with	5	O
MD	9	B-Disease
,	9	O
and	5	O
7	9	O
.	9	O
1	9	O
%	9	O
(	9	O
n	9	O
=	7	O
2	9	O
)	9	O
of	5	O
control	9	O
subjects	5	O
had	9	O
a	5	O
panic	5	B-Disease
attack	5	I-Disease
after	9	O
the	5	O
480	9	O
-	7	O
mg	0	O
caffeine	0	B-Chemical
challenge	9	O
test	5	O
(	9	O
chi	5	O
(	9	O
2	9	O
)	9	O
(	9	O
3	9	O
)	9	O
=	7	O
16	9	O
.	9	O
22	7	O
,	9	O
P	9	O
=	7	O
.	9	O
001	9	O
)	9	O
.	9	O

The	5	O
patients	5	O
with	5	O
PD	9	B-Disease
and	5	O
MDP	9	B-Disease
were	9	O
more	5	O
sensitive	9	O
to	5	O
caffeine	0	B-Chemical
than	5	O
were	9	O
patients	5	O
with	5	O
MD	9	B-Disease
and	5	O
healthy	5	O
volunteers	5	O
.	9	O

No	9	O
panic	5	B-Disease
attack	5	I-Disease
was	9	O
observed	9	O
after	9	O
the	5	O
caffeine	0	B-Chemical
-	7	O
free	9	O
solution	0	O
intake	5	O
.	9	O

The	5	O
patients	5	O
with	5	O
MD	9	B-Disease
had	9	O
a	5	O
lower	9	O
heart	5	O
rate	9	O
response	9	O
to	5	O
the	5	O
test	5	O
than	5	O
all	5	O
the	5	O
other	5	O
groups	9	O
(	9	O
2	9	O
-	7	O
way	5	O
analysis	9	O
of	5	O
variance	5	O
,	9	O
group	9	O
by	9	O
time	5	O
interaction	9	O
with	5	O
Greenhouse	2	O
-	7	O
Geisser	5	O
correction	5	O
:	9	O
F	7	O
(	9	O
3	9	O
,	9	O
762	7	O
)	9	O
=	7	O
2	9	O
.	9	O
85	9	O
,	9	O
P	9	O
=	7	O
.	9	O
026	2	O
)	9	O
.	9	O

Our	9	O
data	5	O
suggest	9	O
that	5	O
there	5	O
is	5	O
an	5	O
association	9	O
between	5	O
panic	5	B-Disease
attacks	5	I-Disease
,	9	O
no	9	O
matter	5	O
if	5	O
associated	9	O
with	5	O
PD	9	B-Disease
or	5	O
MDP	9	B-Disease
,	9	O
and	5	O
hyperreactivity	5	O
to	5	O
an	5	O
oral	9	O
caffeine	0	B-Chemical
challenge	9	O
test	5	O
.	9	O

Mitral	7	O
annuloplasty	5	O
as	5	O
a	5	O
ventricular	5	O
restoration	5	O
method	5	O
for	5	O
the	5	O
failing	5	B-Disease
left	5	I-Disease
ventricle	5	I-Disease
:	9	O
a	5	O
pilot	5	O
study	9	O
.	9	O

BACKGROUND	2	O
AND	2	O
AIM	9	O
OF	2	O
THE	2	O
STUDY	2	O
:	9	O
Undersized	5	O
mitral	5	O
annuloplasty	5	O
(	9	O
MAP	9	O
)	9	O
is	5	O
effective	5	O
in	5	O
patients	5	O
with	5	O
dilated	5	B-Disease
cardiomyopathy	5	I-Disease
and	5	O
functional	9	O
mitral	5	B-Disease
regurgitation	5	I-Disease
(	9	O
MR	9	B-Disease
)	9	O
since	9	O
,	9	O
as	5	O
well	9	O
as	5	O
addressing	5	O
the	5	O
MR	9	B-Disease
,	9	O
the	5	O
MAP	9	O
may	5	O
also	9	O
reshape	5	O
the	5	O
dilated	5	O
left	5	O
ventricular	5	O
(	9	O
LV	9	O
)	9	O
base	5	O
.	9	O

However	9	O
,	9	O
the	5	O
direct	9	O
benefits	5	O
of	5	O
this	5	O
possible	5	O
reshaping	5	O
on	5	O
LV	9	O
function	9	O
in	5	O
the	5	O
absence	3	O
of	5	O
underlying	5	O
MR	9	B-Disease
remain	9	O
incompletely	9	O
understood	5	O
.	9	O

The	5	O
study	9	O
aim	5	O
was	9	O
to	5	O
identify	9	O
these	5	O
benefits	5	O
in	5	O
a	5	O
canine	9	O
model	5	O
of	5	O
acute	9	O
heart	5	B-Disease
failure	5	I-Disease
.	9	O

METHODS	2	O
:	9	O
Six	9	O
dogs	5	O
underwent	5	O
MAP	9	O
with	5	O
a	5	O
prosthetic	5	O
band	9	O
on	5	O
the	5	O
posterior	5	O
mitral	5	O
annulus	5	O
,	9	O
using	9	O
four	9	O
mattress	5	O
sutures	5	O
.	9	O

The	5	O
sutures	5	O
were	9	O
passed	5	O
individually	9	O
through	9	O
four	9	O
tourniquets	5	O
and	5	O
exteriorized	5	O
untied	5	O
via	9	O
the	5	O
left	5	O
atriotomy	5	O
.	9	O

Sonomicrometry	9	O
crystals	0	O
were	9	O
implanted	9	O
around	5	O
the	5	O
mitral	5	O
annulus	5	O
and	5	O
left	5	O
ventricle	5	O
to	5	O
measure	5	O
geometry	5	O
and	5	O
regional	5	O
function	9	O
.	9	O

Acute	5	O
heart	5	B-Disease
failure	5	I-Disease
was	9	O
induced	3	O
by	9	O
propranolol	0	B-Chemical
and	5	O
volume	9	O
loading	9	O
after	9	O
weaning	5	O
from	9	O
cardiopulmonary	5	O
bypass	5	O
;	9	O
an	5	O
absence	3	O
of	5	O
MR	9	B-Disease
was	9	O
confirmed	9	O
by	9	O
echocardiography	5	O
.	9	O

MAP	9	O
was	9	O
accomplished	5	O
by	9	O
cinching	5	O
the	5	O
tourniquets	5	O
.	9	O

Data	5	O
were	9	O
acquired	5	O
at	9	O
baseline	5	O
,	9	O
after	9	O
induction	3	O
of	5	O
acute	9	O
heart	5	B-Disease
failure	5	I-Disease
,	9	O
and	5	O
after	9	O
MAP	9	O
.	9	O

RESULTS	9	O
:	9	O
MAP	9	O
decreased	9	O
mitral	5	O
annular	5	O
dimensions	5	O
in	5	O
both	9	O
commissure	5	O
-	7	O
commissure	5	O
and	5	O
septal	5	O
-	7	O
lateral	5	O
directions	5	O
.	9	O

Concomitantly	9	O
,	9	O
the	5	O
diastolic	5	O
diameter	9	O
of	5	O
the	5	O
LV	9	O
base	5	O
and	5	O
LV	9	O
sphericity	5	O
decreased	9	O
(	9	O
i	9	O
.	9	O
e	9	O
.	9	O
,	9	O
improved	5	O
)	9	O
from	9	O
37	9	O
.	9	O
4	9	O
+	9	O
/	9	O
-	7	O
9	7	O
.	9	O
3	9	O
to	5	O
35	9	O
.	9	O
9	7	O
+	9	O
/	9	O
-	7	O
10	9	O
mm	9	O
(	9	O
p	7	O
=	7	O
0	7	O
.	9	O
063	7	O
)	9	O
,	9	O
and	5	O
from	9	O
67	7	O
.	9	O
9	7	O
+	9	O
/	9	O
-	7	O
18	7	O
.	9	O
6	9	O
%	9	O
to	5	O
65	7	O
.	9	O
3	9	O
+	9	O
/	9	O
-	7	O
18	7	O
.	9	O
9	7	O
%	9	O
(	9	O
p	7	O
=	7	O
0	7	O
.	9	O
016	2	O
)	9	O
,	9	O
respectively	9	O
.	9	O

Decreases	9	O
were	9	O
evident	9	O
in	5	O
both	9	O
LV	9	O
end	9	O
-	7	O
diastolic	5	O
pressure	5	O
(	9	O
from	9	O
17	7	O
+	9	O
/	9	O
-	7	O
7	9	O
to	5	O
15	9	O
+	9	O
/	9	O
-	7	O
6	9	O
mmHg	7	O
,	9	O
p	7	O
=	7	O
0	7	O
.	9	O
0480	7	O
and	5	O
Tau	3	O
(	9	O
from	9	O
48	9	O
+	9	O
/	9	O
-	7	O
8	9	O
to	5	O
45	9	O
+	9	O
/	9	O
-	7	O
8	9	O
ms	5	O
,	9	O
p	7	O
<	0	O
0	7	O
.	9	O
01	7	O
)	9	O
,	9	O
while	9	O
fractional	5	O
shortening	9	O
at	9	O
the	5	O
LV	9	O
base	5	O
increased	9	O
from	9	O
7	9	O
.	9	O
7	9	O
+	9	O
/	9	O
-	7	O
4	9	O
.	9	O
5	9	O
%	9	O
to	5	O
9	7	O
.	9	O
4	9	O
+	9	O
/	9	O
-	7	O
4	9	O
.	9	O
5	9	O
%	9	O
(	9	O
p	7	O
=	7	O
0	7	O
.	9	O
045	7	O
)	9	O
.	9	O

After	9	O
MAP	9	O
,	9	O
increases	9	O
were	9	O
identified	9	O
in	5	O
both	9	O
cardiac	5	O
output	5	O
(	9	O
from	9	O
1	9	O
.	9	O
54	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
57	7	O
to	5	O
1	9	O
.	9	O
65	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
57	7	O
1	9	O
/	9	O
min	0	O
)	9	O
and	5	O
Emax	0	O
(	9	O
from	9	O
1	9	O
.	9	O
86	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
9	7	O
to	5	O
2	9	O
.	9	O
41	7	O
+	9	O
/	9	O
-	7	O
1	9	O
.	9	O
31	7	O
mmHg	7	O
/	9	O
ml	0	O
)	9	O
.	9	O

CONCLUSION	5	O
:	9	O
The	5	O
data	5	O
acquired	5	O
suggest	9	O
that	5	O
isolated	9	O
MAP	9	O
may	5	O
have	5	O
certain	5	O
benefits	5	O
on	5	O
LV	9	O
dimension	5	O
/	9	O
function	9	O
in	5	O
acute	9	O
heart	5	B-Disease
failure	5	I-Disease
,	9	O
even	5	O
in	5	O
the	5	O
absence	3	O
of	5	O
MR	9	B-Disease
.	9	O

However	9	O
,	9	O
further	9	O
investigations	9	O
are	5	O
warranted	9	O
in	5	O
a	5	O
model	5	O
of	5	O
chronic	5	O
heart	5	B-Disease
failure	5	I-Disease
.	9	O

Piperacillin	7	B-Chemical
/	9	I-Chemical
tazobactam	0	I-Chemical
-	7	O
induced	3	O
seizure	5	B-Disease
rapidly	9	O
reversed	9	O
by	9	O
high	9	O
flux	9	O
hemodialysis	5	O
in	5	O
a	5	O
patient	5	O
on	5	O
peritoneal	3	O
dialysis	5	O
.	9	O

Despite	5	O
popular	5	O
use	5	O
of	5	O
piperacillin	0	B-Chemical
,	9	O
the	5	O
dire	5	O
neurotoxicity	9	B-Disease
associated	9	O
with	5	O
piperacillin	0	B-Chemical
still	5	O
goes	5	O
unrecognized	9	O
,	9	O
leading	9	O
to	5	O
a	5	O
delay	5	O
in	5	O
appropriate	5	O
management	5	O
.	9	O

We	9	O
report	5	O
a	5	O
57	7	O
-	7	O
year	5	O
-	7	O
old	5	O
woman	5	O
with	5	O
end	9	B-Disease
-	7	I-Disease
stage	9	I-Disease
renal	9	I-Disease
disease	5	I-Disease
receiving	9	O
continuous	5	O
ambulatory	5	O
peritoneal	3	O
dialysis	5	O
(	9	O
CAPD	5	O
)	9	O
,	9	O
who	5	O
developed	5	O
slurred	5	O
speech	5	O
,	9	O
tremor	5	B-Disease
,	9	O
bizarre	5	O
behavior	5	O
,	9	O
progressive	5	O
mental	5	O
confusion	5	B-Disease
,	9	O
and	5	O
2	9	O
episodes	5	O
of	5	O
generalized	5	O
tonic	5	B-Disease
-	7	I-Disease
clonic	5	I-Disease
seizure	5	I-Disease
(	9	O
GTCS	5	B-Disease
)	9	O
after	9	O
5	9	O
doses	0	O
of	5	O
piperacillin	0	B-Chemical
/	9	I-Chemical
tazobactam	0	I-Chemical
(	9	O
2	9	O
g	0	O
/	9	O
250	0	O
mg	0	O
)	9	O
were	9	O
given	5	O
for	5	O
bronchiectasis	5	B-Disease
with	5	O
secondary	9	B-Disease
infection	9	I-Disease
.	9	O

The	5	O
laboratory	9	O
data	5	O
revealed	9	O
normal	9	O
plasma	9	O
electrolyte	0	O
and	5	O
ammonia	0	B-Chemical
levels	3	O
but	9	O
leukocytosis	9	B-Disease
.	9	O

Neurologic	5	O
examinations	5	O
showed	9	O
dysarthria	5	B-Disease
and	5	O
bilateral	5	O
Babinski	5	O
sign	5	O
.	9	O

Computed	5	O
tomography	5	O
of	5	O
brain	5	O
and	5	O
electroencephalogram	5	O
were	9	O
unremarkable	5	O
.	9	O

Despite	5	O
the	5	O
use	5	O
of	5	O
antiepileptic	5	O
agents	5	O
,	9	O
another	9	O
GTCS	5	B-Disease
episode	5	O
recurred	5	O
after	9	O
the	5	O
sixth	9	O
dose	9	O
of	5	O
piperacillin	0	B-Chemical
/	9	I-Chemical
tazobactam	0	I-Chemical
.	9	O

Brain	9	O
magnetic	0	O
resonance	5	O
imaging	5	O
did	9	O
not	5	O
demonstrate	9	O
acute	9	O
infarction	5	B-Disease
and	5	O
organic	0	B-Disease
brain	5	I-Disease
lesions	5	I-Disease
.	9	O

Initiation	9	O
of	5	O
high	9	O
-	7	O
flux	9	O
hemodialysis	5	O
rapidly	9	O
reversed	9	O
the	5	O
neurologic	5	O
symptoms	5	O
within	9	O
4	9	O
hours	9	O
.	9	O

Piperacillin	7	B-Chemical
-	7	O
induced	3	O
encephalopathy	5	B-Disease
should	5	O
be	5	O
considered	5	O
in	5	O
any	5	O
uremic	9	B-Disease
patients	5	O
with	5	O
unexplained	5	O
neurological	5	O
manifestations	5	O
.	9	O

CAPD	5	O
is	5	O
inefficient	9	O
in	5	O
removing	5	O
piperacillin	0	B-Chemical
,	9	O
whereas	9	O
hemodialysis	5	O
can	5	O
rapidly	9	O
terminate	9	O
the	5	O
piperacillin	0	B-Chemical
-	7	O
induced	3	O
encephalopathy	5	B-Disease
.	9	O

Frequency	5	O
of	5	O
transient	9	O
ipsilateral	5	O
vocal	5	B-Disease
cord	9	I-Disease
paralysis	5	I-Disease
in	5	O
patients	5	O
undergoing	9	O
carotid	5	O
endarterectomy	5	O
under	9	O
local	5	O
anesthesia	5	O
.	9	O

BACKGROUND	2	O
:	9	O
Especially	9	O
because	5	O
of	5	O
improvements	5	O
in	5	O
clinical	5	O
neurologic	5	O
monitoring	5	O
,	9	O
carotid	5	O
endarterectomy	5	O
done	9	O
under	9	O
local	5	O
anesthesia	5	O
has	9	O
become	5	O
the	5	O
technique	5	O
of	5	O
choice	5	O
in	5	O
several	9	O
centers	5	O
.	9	O

Temporary	5	O
ipsilateral	5	O
vocal	5	B-Disease
nerve	5	I-Disease
palsies	5	I-Disease
due	5	O
to	5	O
local	5	O
anesthetics	5	O
have	5	O
been	9	O
described	9	O
,	9	O
however	9	O
.	9	O

Such	5	O
complications	5	O
are	5	O
most	9	O
important	9	O
in	5	O
situations	5	O
where	5	O
there	5	O
is	5	O
a	5	O
pre	9	O
-	7	O
existing	5	O
contralateral	5	O
paralysis	5	B-Disease
.	9	O

We	9	O
therefore	5	O
examined	9	O
the	5	O
effect	9	O
of	5	O
local	5	O
anesthesia	5	O
on	5	O
vocal	5	O
cord	9	O
function	9	O
to	5	O
better	5	O
understand	5	O
its	9	O
possible	5	O
consequences	5	O
.	9	O

METHODS	2	O
:	9	O
This	5	O
prospective	5	O
study	9	O
included	5	O
28	7	O
patients	5	O
undergoing	9	O
carotid	5	O
endarterectomy	5	O
under	9	O
local	5	O
anesthesia	5	O
.	9	O

Vocal	5	O
cord	9	O
function	9	O
was	9	O
evaluated	9	O
before	9	O
,	9	O
during	5	O
,	9	O
and	5	O
after	9	O
surgery	5	O
(	9	O
postoperative	5	O
day	9	O
1	9	O
)	9	O
using	9	O
flexible	5	O
laryngoscopy	5	O
.	9	O

Anesthesia	2	O
was	9	O
performed	9	O
by	9	O
injecting	9	O
20	9	O
to	5	O
40	9	O
mL	0	O
of	5	O
a	5	O
mixture	0	O
of	5	O
long	5	O
-	7	O
acting	9	O
(	9	O
ropivacaine	0	B-Chemical
)	9	O
and	5	O
short	5	O
-	7	O
acting	9	O
(	9	O
prilocaine	0	B-Chemical
)	9	O
anesthetic	5	O
.	9	O

RESULTS	9	O
:	9	O
All	9	O
patients	5	O
had	9	O
normal	9	O
vocal	5	O
cord	9	O
function	9	O
preoperatively	5	O
.	9	O

Twelve	9	O
patients	5	O
(	9	O
43	7	O
%	9	O
)	9	O
were	9	O
found	9	O
to	5	O
have	5	O
intraoperative	5	O
ipsilateral	5	O
vocal	5	B-Disease
cord	9	I-Disease
paralysis	5	I-Disease
.	9	O

It	5	O
resolved	9	O
in	5	O
all	5	O
cases	5	O
<	0	O
or	5	O
=	7	O
24	9	O
hours	9	O
.	9	O

There	5	O
were	9	O
no	9	O
significant	9	O
differences	9	O
in	5	O
operating	5	O
time	5	O
or	5	O
volume	9	O
or	5	O
frequency	5	O
of	5	O
anesthetic	5	O
administration	9	O
in	5	O
patients	5	O
with	5	O
temporary	5	O
vocal	5	B-Disease
cord	9	I-Disease
paralysis	5	I-Disease
compared	9	O
with	5	O
those	5	O
without	9	O
.	9	O

CONCLUSION	5	O
:	9	O
Local	5	O
anesthesia	5	O
led	9	O
to	5	O
temporary	5	O
ipsilateral	5	O
vocal	5	B-Disease
cord	9	I-Disease
paralysis	5	I-Disease
in	5	O
almost	9	O
half	5	O
of	5	O
these	5	O
patients	5	O
.	9	O

Because	9	O
pre	9	O
-	7	O
existing	5	O
paralysis	5	B-Disease
is	5	O
of	5	O
a	5	O
relevant	5	O
frequency	5	O
(	9	O
up	5	O
to	5	O
3	9	O
%	9	O
)	9	O
,	9	O
a	5	O
preoperative	5	O
evaluation	5	O
of	5	O
vocal	5	O
cord	9	O
function	9	O
before	9	O
carotid	5	O
endarterectomy	5	O
under	9	O
local	5	O
anesthesia	5	O
is	5	O
recommended	5	O
to	5	O
avoid	5	O
intraoperative	5	O
bilateral	5	O
paralysis	5	B-Disease
.	9	O

In	9	O
patients	5	O
with	5	O
preoperative	5	O
contralateral	5	O
vocal	5	B-Disease
cord	9	I-Disease
paralysis	5	I-Disease
,	9	O
surgery	5	O
under	9	O
general	5	O
anesthesia	5	O
should	5	O
be	5	O
considered	5	O
.	9	O

Impaired	9	B-Disease
fear	5	I-Disease
recognition	5	I-Disease
in	5	O
regular	5	O
recreational	5	O
cocaine	5	B-Chemical
users	5	O
.	9	O

INTRODUCTION	5	O
:	9	O
The	5	O
ability	9	O
to	5	O
read	5	O
facial	5	O
expressions	9	O
is	5	O
essential	9	O
for	5	O
normal	9	O
human	3	O
social	5	O
interaction	9	O
.	9	O

The	5	O
aim	5	O
of	5	O
the	5	O
present	9	O
study	9	O
was	9	O
to	5	O
conduct	5	O
the	5	O
first	9	O
investigation	9	O
of	5	O
facial	5	O
expression	3	O
recognition	5	O
performance	5	O
in	5	O
recreational	5	O
cocaine	5	B-Chemical
users	5	O
.	9	O

MATERIALS	2	O
AND	2	O
METHODS	2	O
:	9	O
Three	9	O
groups	9	O
,	9	O
comprised	9	O
of	5	O
21	7	O
cocaine	5	B-Chemical
naive	3	O
participants	5	O
(	9	O
CN	9	O
)	9	O
,	9	O
30	9	O
occasional	5	O
cocaine	5	B-Chemical
(	9	O
OC	9	O
)	9	O
,	9	O
and	5	O
48	9	O
regular	5	O
recreational	5	O
cocaine	5	B-Chemical
(	9	O
RC	9	O
)	9	O
users	5	O
,	9	O
were	9	O
compared	9	O
.	9	O

An	5	O
emotional	5	O
facial	5	O
expression	3	O
(	9	O
EFE	0	O
)	9	O
task	5	O
consisting	9	O
of	5	O
a	5	O
male	9	O
and	5	O
female	9	O
face	5	O
expressing	3	O
six	9	O
basic	5	O
emotions	5	O
(	9	O
happiness	5	O
,	9	O
surprise	5	O
,	9	O
sadness	5	O
,	9	O
anger	5	O
,	9	O
fear	5	O
,	9	O
and	5	O
disgust	5	O
)	9	O
was	9	O
administered	9	O
.	9	O

Mean	9	O
percent	5	O
accuracy	5	O
and	5	O
latencies	5	O
for	5	O
correct	5	O
responses	5	O
across	5	O
eight	9	O
presentations	5	O
of	5	O
each	5	O
basic	5	O
emotion	5	O
were	9	O
derived	9	O
.	9	O

Participants	5	O
were	9	O
also	9	O
assessed	9	O
with	5	O
the	5	O
"	5	O
Eyes	5	O
task	5	O
"	5	O
to	5	O
investigate	9	O
their	5	O
ability	9	O
to	5	O
recognize	9	O
more	5	O
complex	9	O
emotional	5	O
states	5	O
and	5	O
the	5	O
Symptom	5	O
CheckList	2	O
-	7	O
90	9	O
-	7	O
Revised	5	O
to	5	O
measure	5	O
psychopathology	5	O
.	9	O

RESULTS	9	O
:	9	O
There	5	O
were	9	O
no	9	O
group	9	O
differences	9	O
in	5	O
psychopathology	5	O
or	5	O
"	5	O
eyes	5	O
task	5	O
"	5	O
performance	5	O
,	9	O
but	9	O
the	5	O
RC	9	O
group	9	O
,	9	O
who	5	O
otherwise	9	O
had	9	O
similar	9	O
illicit	5	O
substance	5	O
use	5	O
histories	5	O
to	5	O
the	5	O
OC	9	O
group	9	O
,	9	O
exhibited	9	O
impaired	9	B-Disease
fear	5	I-Disease
recognition	5	I-Disease
accuracy	5	O
compared	9	O
to	5	O
the	5	O
OC	9	O
and	5	O
CN	9	O
groups	9	O
.	9	O

The	5	O
RC	9	O
group	9	O
also	9	O
correctly	5	O
identified	9	O
anger	5	O
,	9	O
fear	5	O
,	9	O
happiness	5	O
,	9	O
and	5	O
surprise	5	O
,	9	O
more	5	O
slowly	5	O
than	5	O
CN	9	O
,	9	O
but	9	O
not	5	O
OC	9	O
participants	5	O
.	9	O

The	5	O
OC	9	O
group	9	O
was	9	O
slower	9	O
than	5	O
CN	9	O
when	5	O
correctly	5	O
identifying	5	O
disgust	5	O
.	9	O

The	5	O
selective	9	O
deficit	5	B-Disease
in	5	I-Disease
fear	5	I-Disease
recognition	5	I-Disease
accuracy	5	O
manifested	9	O
by	9	O
the	5	O
RC	9	O
group	9	O
cannot	5	O
be	5	O
explained	5	O
by	9	O
the	5	O
subacute	5	O
effects	9	O
of	5	O
cocaine	5	B-Chemical
,	9	O
or	5	O
ecstasy	5	B-Chemical
,	9	O
because	5	O
recent	5	O
and	5	O
less	5	O
recent	5	O
users	5	O
of	5	O
these	5	O
drugs	5	O
within	9	O
this	5	O
group	9	O
were	9	O
similarly	9	O
impaired	9	O
.	9	O

Possible	9	O
parallels	9	O
between	5	O
RC	9	O
users	5	O
and	5	O
psychopaths	5	B-Disease
with	5	O
respect	9	O
to	5	O
impaired	9	B-Disease
fear	5	I-Disease
recognition	5	I-Disease
,	9	O
amygdala	5	B-Disease
dysfunction	9	I-Disease
,	9	O
and	5	O
etiology	9	O
are	5	O
discussed	5	O
.	9	O

Damage	5	B-Disease
of	5	I-Disease
substantia	9	I-Disease
nigra	4	I-Disease
pars	4	I-Disease
reticulata	4	I-Disease
during	5	O
pilocarpine	0	B-Chemical
-	7	O
induced	3	O
status	9	B-Disease
epilepticus	5	I-Disease
in	5	O
the	5	O
rat	3	O
:	9	O
immunohistochemical	3	O
study	9	O
of	5	O
neurons	3	O
,	9	O
astrocytes	3	O
and	5	O
serum	9	O
-	7	O
protein	1	O
extravasation	3	O
.	9	O

The	5	O
substantia	9	O
nigra	4	O
has	9	O
a	5	O
gating	5	O
function	9	O
controlling	9	O
the	5	O
spread	5	O
of	5	O
epileptic	5	B-Disease
seizure	5	I-Disease
activity	9	O
.	9	O

Additionally	9	O
,	9	O
in	5	O
models	5	O
of	5	O
prolonged	9	B-Disease
status	9	I-Disease
epilepticus	5	I-Disease
the	5	O
pars	4	O
reticulata	4	O
of	5	O
substantia	9	O
nigra	4	O
(	9	O
SNR	5	O
)	9	O
suffers	5	O
from	9	O
a	5	O
massive	9	O
lesion	5	O
which	5	O
may	5	O
arise	5	O
from	9	O
a	5	O
massive	9	O
metabolic	9	B-Disease
derangement	5	I-Disease
and	5	O
hyperexcitation	5	O
developing	5	O
in	5	O
the	5	O
activated	3	O
SNR	5	O
.	9	O

In	9	O
this	5	O
study	9	O
,	9	O
status	9	B-Disease
epilepticus	5	I-Disease
was	9	O
induced	3	O
by	9	O
systemic	9	O
injection	9	O
of	5	O
pilocarpine	0	B-Chemical
in	5	O
rats	9	O
.	9	O

The	5	O
neuropathology	5	O
of	5	O
SNR	5	O
was	9	O
investigated	9	O
using	9	O
immunohistochemical	3	O
techniques	5	O
with	5	O
the	5	O
major	9	O
emphasis	5	O
on	5	O
the	5	O
time	5	O
-	7	O
course	5	O
of	5	O
changes	9	O
in	5	O
neurons	3	O
and	5	O
astrocytes	3	O
.	9	O

Animals	9	O
surviving	9	O
20	9	O
,	9	O
30	9	O
,	9	O
40	9	O
,	9	O
60	9	O
min	0	O
,	9	O
2	9	O
,	9	O
3	9	O
,	9	O
6	9	O
hours	9	O
,	9	O
1	9	O
,	9	O
2	9	O
,	9	O
and	5	O
3	9	O
days	9	O
after	9	O
induction	3	O
of	5	O
status	9	B-Disease
epilepticus	5	I-Disease
were	9	O
perfusion	5	O
-	7	O
fixed	9	O
,	9	O
and	5	O
brains	9	O
processed	9	O
for	5	O
immunohistochemical	3	O
staining	3	O
of	5	O
SNR	5	O
.	9	O

Nissl	3	O
-	7	O
staining	3	O
and	5	O
antibodies	3	O
against	9	O
the	5	O
neuron	5	O
-	7	O
specific	9	O
calcium	0	B-Chemical
-	7	O
binding	1	O
protein	1	O
,	9	O
parvalbumin	3	O
,	9	O
served	9	O
to	5	O
detect	9	O
neuronal	3	B-Disease
damage	9	I-Disease
in	5	O
SNR	5	O
.	9	O

Antibodies	3	O
against	9	O
the	5	O
astroglia	3	O
-	7	O
specific	9	O
cytoskeletal	3	O
protein	1	O
,	9	O
glial	3	O
fibrillary	3	O
acidic	0	O
protein	1	O
(	9	O
GFAP	3	O
)	9	O
,	9	O
and	5	O
against	9	O
the	5	O
glial	3	O
calcium	0	B-Chemical
-	7	O
binding	1	O
protein	1	O
,	9	O
S	9	O
-	7	O
100	0	O
protein	1	O
,	9	O
were	9	O
used	5	O
to	5	O
assess	5	O
the	5	O
status	9	O
of	5	O
astrocytes	3	O
.	9	O

Immunohistochemical	3	O
staining	3	O
for	5	O
serum	9	O
-	7	O
albumin	0	O
and	5	O
immunoglobulins	3	O
in	5	O
brain	5	O
tissue	9	O
was	9	O
taken	5	O
as	5	O
indicator	9	O
of	5	O
blood	9	O
-	7	O
brain	5	O
barrier	5	O
disturbances	5	O
and	5	O
vasogenic	5	B-Disease
edema	5	I-Disease
formation	9	O
.	9	O

Immunohistochemical	3	O
staining	3	O
indicated	9	O
loss	9	O
of	5	O
GFAP	3	O
-	7	O
staining	3	O
already	5	O
at	9	O
30	9	O
min	0	O
after	9	O
induction	3	O
of	5	O
seizures	5	B-Disease
in	5	O
an	5	O
oval	5	O
focus	5	O
situated	5	O
in	5	O
the	5	O
center	5	O
of	5	O
SNR	5	O
while	9	O
sparing	5	O
medial	5	O
and	5	O
lateral	5	O
aspects	5	O
.	9	O

At	9	O
1	9	O
h	0	O
there	5	O
was	9	O
additional	9	O
vacuolation	3	O
in	5	O
S	9	O
-	7	O
100	0	O
protein	1	O
staining	3	O
.	9	O

By	5	O
2	9	O
hours	9	O
,	9	O
parvalbumin	3	O
-	7	O
staining	3	O
changed	9	O
in	5	O
the	5	O
central	5	O
SNR	5	O
indicating	9	O
neuronal	3	B-Disease
damage	9	I-Disease
,	9	O
and	5	O
Nissl	3	O
-	7	O
staining	3	O
visualized	9	O
some	5	O
neuronal	3	O
distortion	5	O
.	9	O

Staining	3	O
for	5	O
serum	9	O
-	7	O
proteins	1	O
occurred	9	O
in	5	O
a	5	O
patchy	5	O
manner	9	O
throughout	9	O
the	5	O
forebrain	3	O
during	5	O
the	5	O
first	9	O
hours	9	O
.	9	O

By	5	O
6	9	O
h	0	O
,	9	O
vasogenic	5	B-Disease
edema	5	I-Disease
covered	5	O
the	5	O
lesioned	3	B-Disease
SNR	5	I-Disease
.	9	O

By	5	O
24	9	O
h	0	O
,	9	O
glial	3	O
and	5	O
neuronal	3	O
markers	3	O
indicated	9	O
a	5	O
massive	9	O
lesion	5	O
in	5	O
the	5	O
center	5	O
of	5	O
SNR	5	O
.	9	O

By	5	O
48	9	O
-	7	O
72	9	O
h	0	O
,	9	O
astrocytes	3	O
surrounding	9	O
the	5	O
lesion	5	O
increased	9	O
in	5	O
size	9	O
,	9	O
and	5	O
polymorphic	9	O
phagocytotic	3	O
cells	3	O
invaded	4	O
the	5	O
damaged	9	O
area	5	O
.	9	O

In	9	O
a	5	O
further	9	O
group	9	O
of	5	O
animals	9	O
surviving	9	O
1	9	O
to	5	O
5	9	O
days	9	O
,	9	O
conventional	5	O
paraffin	0	O
-	7	O
sections	9	O
confirmed	9	O
the	5	O
neuronal	3	O
and	5	O
glial	3	O
damage	9	B-Disease
of	5	I-Disease
SNR	5	I-Disease
.	9	O

Additional	9	O
pathology	5	O
of	5	O
similar	9	O
quality	5	O
was	9	O
found	9	O
in	5	O
the	5	O
globus	5	O
pallidus	4	O
.	9	O

Since	9	O
astrocytes	3	O
were	9	O
always	5	O
damaged	9	O
in	5	O
parallel	5	O
with	5	O
neurons	3	O
in	5	O
SNR	5	O
it	5	O
is	5	O
proposed	5	O
that	5	O
the	5	O
anatomical	5	O
and	5	O
functional	9	O
interrelationship	9	O
between	5	O
neurons	3	O
and	5	O
astrocytes	3	O
is	5	O
particularly	5	O
tight	9	O
in	5	O
SNR	5	O
.	9	O

Both	9	O
cell	3	O
elements	5	O
may	5	O
suffer	5	O
in	5	O
common	5	O
from	9	O
metabolic	9	O
disturbance	5	O
and	5	O
neurotransmitter	9	B-Disease
dysfunction	9	I-Disease
as	5	O
occur	5	O
during	5	O
massive	9	O
status	9	B-Disease
epilepticus	5	I-Disease
.	9	O

Neuroprotective	0	O
effects	9	O
of	5	O
melatonin	9	B-Chemical
upon	9	O
the	5	O
offspring	9	O
cerebellar	5	O
cortex	5	O
in	5	O
the	5	O
rat	3	O
model	5	O
of	5	O
BCNU	0	B-Chemical
-	7	O
induced	3	O
cortical	5	B-Disease
dysplasia	5	I-Disease
.	9	O

Cortical	5	B-Disease
dysplasia	5	I-Disease
is	5	O
a	5	O
malformation	5	O
characterized	9	O
by	9	O
defects	9	O
in	5	O
proliferation	3	O
,	9	O
migration	3	O
and	5	O
maturation	3	O
.	9	O

This	5	O
study	9	O
was	9	O
designed	9	O
to	5	O
evaluate	9	O
the	5	O
alterations	9	O
in	5	O
offspring	9	O
rat	3	O
cerebellum	9	O
induced	3	O
by	9	O
maternal	9	O
exposure	9	O
to	5	O
carmustine	0	B-Chemical
-	7	O
[	9	O
1	9	B-Chemical
,	9	I-Chemical
3	9	I-Chemical
-	7	I-Chemical
bis	0	I-Chemical
(	9	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
chloroethyl	0	I-Chemical
)	9	I-Chemical
-	7	I-Chemical
1	9	I-Chemical
-	7	I-Chemical
nitrosoure	_	I-Chemical
]	9	O
(	9	O
BCNU	0	B-Chemical
)	9	O
and	5	O
to	5	O
investigate	9	O
the	5	O
effects	9	O
of	5	O
exogenous	3	O
melatonin	9	B-Chemical
upon	9	O
cerebellar	5	O
BCNU	0	B-Chemical
-	7	O
induced	3	O
cortical	5	B-Disease
dysplasia	5	I-Disease
,	9	O
using	9	O
histological	9	O
and	5	O
biochemical	9	O
analyses	9	O
.	9	O

Pregnant	5	O
Wistar	9	O
rats	9	O
were	9	O
assigned	5	O
to	5	O
five	9	O
groups	9	O
:	9	O
intact	9	O
-	7	O
control	9	O
,	9	O
saline	0	O
-	7	O
control	9	O
,	9	O
melatonin	9	B-Chemical
-	7	O
treated	3	O
,	9	O
BCNU	0	B-Chemical
-	7	O
exposed	9	O
and	5	O
BCNU	0	B-Chemical
-	7	O
exposed	9	O
plus	9	O
melatonin	9	B-Chemical
.	9	O

Rats	9	O
were	9	O
exposed	9	O
to	5	O
BCNU	0	B-Chemical
on	5	O
embryonic	3	O
day	9	O
15	9	O
and	5	O
melatonin	9	B-Chemical
was	9	O
given	5	O
until	5	O
delivery	5	O
.	9	O

Immuno	0	O
/	9	O
histochemistry	9	O
and	5	O
electron	0	O
microscopy	9	O
were	9	O
carried	9	O
out	9	O
on	5	O
the	5	O
offspring	9	O
cerebellum	9	O
,	9	O
and	5	O
levels	3	O
of	5	O
malondialdehyde	0	B-Chemical
and	5	O
superoxide	0	B-Chemical
dismutase	0	O
were	9	O
determined	9	O
.	9	O

Histopathologically	5	O
,	9	O
typical	9	O
findings	9	O
were	9	O
observed	9	O
in	5	O
the	5	O
cerebella	3	O
from	9	O
the	5	O
control	9	O
groups	9	O
,	9	O
but	9	O
the	5	O
findings	9	O
consistent	9	O
with	5	O
early	9	O
embryonic	3	O
development	9	O
were	9	O
noted	9	O
in	5	O
BCNU	0	B-Chemical
-	7	O
exposed	9	O
cortical	5	B-Disease
dysplasia	5	I-Disease
group	9	O
.	9	O

There	5	O
was	9	O
a	5	O
marked	9	O
increase	9	O
in	5	O
the	5	O
number	9	O
of	5	O
TUNEL	3	O
positive	9	O
cells	3	O
and	5	O
nestin	3	O
positive	9	O
cells	3	O
in	5	O
BCNU	0	B-Chemical
-	7	O
exposed	9	O
group	9	O
,	9	O
but	9	O
a	5	O
decreased	9	O
immunoreactivity	3	O
to	5	O
glial	3	O
fibrillary	3	O
acidic	0	O
protein	1	O
,	9	O
synaptophysin	3	O
and	5	O
transforming	9	O
growth	3	O
factor	9	O
beta1	3	O
was	9	O
observed	9	O
,	9	O
indicating	9	O
a	5	O
delayed	9	O
maturation	3	O
,	9	O
and	5	O
melatonin	9	B-Chemical
significantly	9	O
reversed	9	O
these	5	O
changes	9	O
.	9	O

Malondialdehyde	0	B-Chemical
level	9	O
in	5	O
BCNU	0	B-Chemical
-	7	O
exposed	9	O
group	9	O
was	9	O
higher	9	O
than	5	O
those	5	O
in	5	O
control	9	O
groups	9	O
and	5	O
melatonin	9	B-Chemical
decreased	9	O
malondialdehyde	0	B-Chemical
levels	3	O
in	5	O
BCNU	0	B-Chemical
group	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
01	7	O
)	9	O
,	9	O
while	9	O
there	5	O
were	9	O
no	9	O
significant	9	O
differences	9	O
in	5	O
the	5	O
superoxide	0	B-Chemical
dismutase	0	O
levels	3	O
between	5	O
these	5	O
groups	9	O
.	9	O

These	5	O
data	5	O
suggest	9	O
that	5	O
exposure	9	O
of	5	O
animals	9	O
to	5	O
BCNU	0	B-Chemical
during	5	O
pregnancy	5	O
leads	9	O
to	5	O
delayed	9	O
maturation	3	O
of	5	O
offspring	9	O
cerebellum	9	O
and	5	O
melatonin	9	B-Chemical
protects	3	O
the	5	O
cerebellum	9	O
against	9	O
the	5	O
effects	9	O
of	5	O
BCNU	0	B-Chemical
.	9	O

Reduced	9	O
cardiotoxicity	9	B-Disease
of	5	O
doxorubicin	0	B-Chemical
given	5	O
in	5	O
the	5	O
form	9	O
of	5	O
N	9	B-Chemical
-	7	I-Chemical
(	9	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
hydroxypropyl	0	I-Chemical
)	9	I-Chemical
methacrylamide	0	I-Chemical
conjugates	0	O
:	9	O
and	5	O
experimental	5	O
study	9	O
in	5	O
the	5	O
rat	3	O
.	9	O

A	9	O
rat	3	O
model	5	O
was	9	O
used	5	O
to	5	O
evaluate	9	O
the	5	O
general	5	O
acute	9	O
toxicity	9	B-Disease
and	5	O
the	5	O
late	9	O
cardiotoxicity	9	B-Disease
of	5	O
4	9	O
mg	0	O
/	9	O
kg	0	O
doxorubicin	0	B-Chemical
(	9	O
DOX	0	B-Chemical
)	9	O
given	5	O
either	9	O
as	5	O
free	9	O
drug	5	O
or	5	O
in	5	O
the	5	O
form	9	O
of	5	O
three	9	O
N	9	B-Chemical
-	7	I-Chemical
(	9	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
hydroxypropyl	0	I-Chemical
)	9	I-Chemical
methacrylamide	0	I-Chemical
(	9	O
HPMA	0	B-Chemical
)	9	O
copolymer	0	O
conjugates	0	O
.	9	O

In	9	O
these	5	O
HPMA	0	B-Chemical
copolymers	0	O
,	9	O
DOX	0	B-Chemical
was	9	O
covalently	0	O
bound	9	O
via	9	O
peptide	9	O
linkages	9	O
that	5	O
were	9	O
either	9	O
non	9	O
-	7	O
biodegradable	0	O
(	9	O
Gly	1	O
-	7	O
Gly	1	O
)	9	O
or	5	O
degradable	0	O
by	9	O
lysosomal	3	O
proteinases	9	O
(	9	O
Gly	1	B-Chemical
-	7	I-Chemical
Phe	0	I-Chemical
-	7	I-Chemical
Leu	1	I-Chemical
-	7	I-Chemical
Gly	1	I-Chemical
)	9	O
.	9	O

In	9	O
addition	9	O
,	9	O
one	5	O
biodegradable	0	O
conjugate	0	O
containing	0	O
galactosamine	0	B-Chemical
was	9	O
used	5	O
;	9	O
this	5	O
residue	1	O
was	9	O
targeted	9	O
to	5	O
the	5	O
liver	9	O
.	9	O

Over	5	O
the	5	O
first	9	O
3	9	O
weeks	9	O
after	9	O
the	5	O
i	9	O
.	9	O
v	0	O
.	9	O
administration	9	O
of	5	O
free	9	O
and	5	O
polymer	0	O
-	7	O
bound	9	O
DOX	0	B-Chemical
,	9	O
all	5	O
animals	9	O
showed	9	O
a	5	O
transient	9	O
reduction	9	O
in	5	O
body	5	O
weight	9	O
.	9	O

However	9	O
,	9	O
the	5	O
maximal	9	O
reduction	9	O
in	5	O
body	5	O
weight	9	O
seen	9	O
in	5	O
animals	9	O
that	5	O
received	9	O
polymer	0	O
-	7	O
bound	9	O
DOX	0	B-Chemical
(	9	O
4	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
was	9	O
significantly	9	O
lower	9	O
than	5	O
that	5	O
observed	9	O
in	5	O
those	5	O
that	5	O
received	9	O
free	9	O
DOX	0	B-Chemical
(	9	O
4	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
or	5	O
a	5	O
mixture	0	O
of	5	O
the	5	O
unmodified	9	O
parent	9	O
HPMA	0	B-Chemical
copolymer	0	O
and	5	O
free	9	O
DOX	0	B-Chemical
(	9	O
4	9	O
mg	0	O
/	9	O
kg	0	O
;	9	O
P	9	O
less	5	O
than	5	O
0	7	O
.	9	O
01	7	O
)	9	O
.	9	O

Throughout	5	O
the	5	O
study	9	O
(	9	O
20	9	O
weeks	9	O
)	9	O
,	9	O
deaths	5	O
related	9	O
to	5	O
cardiotoxicity	9	B-Disease
were	9	O
observed	9	O
only	9	O
in	5	O
animals	9	O
that	5	O
received	9	O
either	9	O
free	9	O
DOX	0	B-Chemical
or	5	O
the	5	O
mixture	0	O
of	5	O
HPMA	0	B-Chemical
copolymer	0	O
and	5	O
free	9	O
DOX	0	B-Chemical
;	9	O
in	5	O
these	5	O
cases	5	O
,	9	O
histological	9	O
investigations	9	O
revealed	9	O
marked	9	O
changes	9	O
in	5	O
the	5	O
heart	5	O
that	5	O
were	9	O
consistent	9	O
with	5	O
DOX	0	B-Chemical
-	7	O
induced	3	O
cardiotoxicity	9	B-Disease
.	9	O

Sequential	5	O
measurements	5	O
of	5	O
cardiac	5	O
output	5	O
in	5	O
surviving	9	O
animals	9	O
that	5	O
received	9	O
either	9	O
free	9	O
DOX	0	B-Chemical
or	5	O
the	5	O
mixture	0	O
of	5	O
HPMA	0	B-Chemical
copolymer	0	O
and	5	O
free	9	O
DOX	0	B-Chemical
showed	9	O
a	5	O
reduction	9	O
of	5	O
approximately	9	O
30	9	O
%	9	O
in	5	O
function	9	O
beginning	5	O
at	9	O
the	5	O
4th	9	O
week	9	O
after	9	O
drug	5	O
administration	9	O
.	9	O

The	5	O
heart	5	O
rate	9	O
in	5	O
these	5	O
animals	9	O
was	9	O
approximately	9	O
12	9	O
%	9	O
lower	9	O
than	5	O
that	5	O
measured	9	O
in	5	O
age	5	O
-	7	O
matched	9	O
control	9	O
rats	9	O
(	9	O
P	9	O
less	5	O
than	5	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

Animals	9	O
that	5	O
were	9	O
given	5	O
the	5	O
HPMA	0	B-Chemical
copolymer	0	O
conjugates	0	O
containing	0	O
DOX	0	B-Chemical
exhibited	9	O
no	9	O
significant	9	O
change	9	O
in	5	O
cardiac	5	O
output	5	O
throughout	9	O
the	5	O
study	9	O
(	9	O
P	9	O
less	5	O
than	5	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

In	9	O
addition	9	O
,	9	O
no	9	O
significant	9	O
histological	9	O
change	9	O
was	9	O
observed	9	O
in	5	O
the	5	O
heart	5	O
of	5	O
animals	9	O
that	5	O
received	9	O
DOX	0	B-Chemical
in	5	O
the	5	O
form	9	O
of	5	O
HPMA	0	B-Chemical
copolymer	0	O
conjugates	0	O
and	5	O
were	9	O
killed	9	O
at	9	O
the	5	O
end	9	O
of	5	O
the	5	O
study	9	O
.	9	O

However	9	O
,	9	O
these	5	O
animals	9	O
had	9	O
shown	9	O
a	5	O
significant	9	O
increase	9	O
in	5	O
heart	5	O
rate	9	O
beginning	5	O
at	9	O
8	9	O
weeks	9	O
after	9	O
drug	5	O
administration	9	O
(	9	O
P	9	O
less	5	O
than	5	O
0	7	O
.	9	O
01	7	O
)	9	O
.	9	O
(	9	O
ABSTRACT	2	O
TRUNCATED	2	O
AT	9	O
400	0	O
WORDS	3	O
)	9	O

Corneal	5	B-Disease
ulcers	5	I-Disease
associated	9	O
with	5	O
aerosolized	0	O
crack	5	B-Chemical
cocaine	5	I-Chemical
use	5	O
.	9	O

PURPOSE	2	O
:	9	O
We	9	O
report	5	O
4	9	O
cases	5	O
of	5	O
corneal	5	B-Disease
ulcers	5	I-Disease
associated	9	O
with	5	O
drug	5	B-Disease
abuse	5	I-Disease
.	9	O

The	5	O
pathogenesis	9	O
of	5	O
these	5	O
ulcers	5	B-Disease
and	5	O
management	5	O
of	5	O
these	5	O
patients	5	O
are	5	O
also	9	O
reviewed	9	O
.	9	O

METHODS	2	O
:	9	O
Review	2	O
of	5	O
all	5	O
cases	5	O
of	5	O
corneal	5	B-Disease
ulcers	5	I-Disease
associated	9	O
with	5	O
drug	5	B-Disease
abuse	5	I-Disease
seen	9	O
at	9	O
our	5	O
institution	5	O
from	9	O
July	2	O
2006	2	O
to	5	O
December	2	O
2006	2	O
.	9	O

RESULTS	9	O
:	9	O
Four	9	O
patients	5	O
with	5	O
corneal	5	B-Disease
ulcers	5	I-Disease
associated	9	O
with	5	O
crack	5	B-Chemical
cocaine	5	I-Chemical
use	5	O
were	9	O
reviewed	9	O
.	9	O

All	9	O
corneal	5	B-Disease
ulcers	5	I-Disease
were	9	O
cultured	3	O
,	9	O
and	5	O
the	5	O
patients	5	O
were	9	O
admitted	5	O
to	5	O
the	5	O
hospital	5	O
for	5	O
intensive	5	O
topical	0	O
antibiotic	5	O
treatment	9	O
.	9	O

Each	5	O
patient	5	O
received	9	O
comprehensive	5	O
health	5	O
care	5	O
,	9	O
including	9	O
medical	5	O
and	5	O
substance	5	B-Disease
abuse	5	I-Disease
consultations	5	O
.	9	O

Streptococcal	2	O
organisms	9	O
were	9	O
found	9	O
in	5	O
3	9	O
cases	5	O
and	5	O
Capnocytophaga	4	O
and	5	O
Brevibacterium	4	O
casei	4	O
in	5	O
1	9	O
patient	5	O
.	9	O

The	5	O
infections	5	B-Disease
responded	9	O
to	5	O
antibiotic	5	O
treatment	9	O
.	9	O

Two	9	O
patients	5	O
needed	5	O
a	5	O
lateral	5	O
tarsorrhaphy	5	O
for	5	O
persistent	5	O
epithelial	3	B-Disease
defects	9	I-Disease
.	9	O

CONCLUSIONS	5	O
:	9	O
Aerosolized	0	O
crack	5	B-Chemical
cocaine	5	I-Chemical
use	5	O
can	5	O
be	5	O
associated	9	O
with	5	O
the	5	O
development	9	O
of	5	O
corneal	5	B-Disease
ulcers	5	I-Disease
.	9	O

Drug	5	B-Disease
abuse	5	I-Disease
provides	5	O
additional	9	O
challenges	5	O
for	5	O
management	5	O
.	9	O

Not	9	O
only	9	O
treatment	9	O
of	5	O
their	5	O
infections	5	B-Disease
but	9	O
also	9	O
the	5	O
overall	5	O
poor	5	O
health	5	O
of	5	O
the	5	O
patients	5	O
and	5	O
increased	9	O
risk	5	O
of	5	O
noncompliance	5	O
need	5	O
to	5	O
be	5	O
addressed	5	O
.	9	O

Comprehensive	2	O
care	5	O
may	5	O
provide	5	O
the	5	O
patient	5	O
the	5	O
opportunity	5	O
to	5	O
discontinue	5	O
their	5	O
substance	5	B-Disease
abuse	5	I-Disease
,	9	O
improve	5	O
their	5	O
overall	5	O
health	5	O
,	9	O
and	5	O
prevent	5	O
future	5	O
corneal	5	O
complications	5	O
.	9	O

Topical	0	O
0	7	O
.	9	O
025	7	O
%	9	O
capsaicin	0	B-Chemical
in	5	O
chronic	5	O
post	9	B-Disease
-	7	I-Disease
herpetic	5	I-Disease
neuralgia	5	I-Disease
:	9	O
efficacy	9	O
,	9	O
predictors	5	O
of	5	O
response	9	O
and	5	O
long	5	O
-	7	O
term	5	O
course	5	O
.	9	O

In	9	O
order	5	O
to	5	O
evaluate	9	O
the	5	O
efficacy	9	O
,	9	O
time	5	O
-	7	O
course	5	O
of	5	O
action	5	O
and	5	O
predictors	5	O
of	5	O
response	9	O
to	5	O
topical	0	O
capsaicin	0	B-Chemical
,	9	O
39	7	O
patients	5	O
with	5	O
chronic	5	O
post	9	B-Disease
-	7	I-Disease
herpetic	5	I-Disease
neuralgia	5	I-Disease
(	9	O
PHN	5	B-Disease
)	9	O
,	9	O
median	9	O
duration	5	O
24	9	O
months	5	O
,	9	O
were	9	O
treated	3	O
with	5	O
0	7	O
.	9	O
025	7	O
%	9	O
capsaicin	0	B-Chemical
cream	0	O
for	5	O
8	9	O
weeks	9	O
.	9	O

During	5	O
therapy	5	O
the	5	O
patients	5	O
rated	5	O
their	5	O
pain	5	B-Disease
on	5	O
a	5	O
visual	5	O
analogue	0	O
scale	5	O
(	9	O
VAS	5	O
)	9	O
and	5	O
a	5	O
verbal	5	O
outcome	5	O
scale	5	O
.	9	O

A	9	O
follow	5	O
-	7	O
up	5	O
investigation	9	O
was	9	O
performed	9	O
10	9	O
-	7	O
12	9	O
months	5	O
after	9	O
study	9	O
onset	5	O
on	5	O
the	5	O
patients	5	O
who	5	O
had	9	O
improved	5	O
.	9	O

Nineteen	9	O
patients	5	O
(	9	O
48	9	O
.	9	O
7	9	O
%	9	O
)	9	O
substantially	9	O
improved	5	O
after	9	O
the	5	O
8	9	O
-	7	O
week	9	O
trial	5	O
;	9	O
5	9	O
(	9	O
12	9	O
.	9	O
8	9	O
%	9	O
)	9	O
discontinued	5	O
therapy	5	O
due	5	O
to	5	O
side	5	O
-	7	O
effects	9	O
such	5	O
as	5	O
intolerable	5	O
capsaicin	0	B-Chemical
-	7	O
induced	3	O
burning	5	O
sensations	5	O
(	9	O
4	9	O
)	9	O
or	5	O
mastitis	5	B-Disease
(	9	O
1	9	O
)	9	O
;	9	O
15	9	O
(	9	O
38	7	O
.	9	O
5	9	O
%	9	O
)	9	O
reported	9	O
no	9	O
benefit	5	O
.	9	O

The	5	O
decrease	9	O
in	5	O
VAS	5	O
ratings	5	O
was	9	O
significant	9	O
after	9	O
2	9	O
weeks	9	O
of	5	O
continuous	5	O
application	5	O
.	9	O

Of	9	O
the	5	O
responders	5	O
72	9	O
.	9	O
2	9	O
%	9	O
were	9	O
still	5	O
improved	5	O
at	9	O
the	5	O
follow	5	O
-	7	O
up	5	O
;	9	O
only	9	O
one	5	O
-	7	O
third	9	O
of	5	O
them	5	O
had	9	O
continued	9	O
application	5	O
irregularly	5	O
.	9	O

Treatment	9	O
effect	9	O
was	9	O
not	5	O
dependent	9	O
on	5	O
patient	5	O
'	9	O
s	9	O
age	5	O
,	9	O
duration	5	O
or	5	O
localization	3	O
of	5	O
PHN	5	B-Disease
(	9	O
trigeminal	5	O
involvement	9	O
was	9	O
excluded	9	O
)	9	O
,	9	O
sensory	5	B-Disease
disturbance	5	I-Disease
or	5	O
pain	5	B-Disease
character	5	O
.	9	O

Treatment	9	O
response	9	O
was	9	O
not	5	O
correlated	9	O
with	5	O
the	5	O
incidence	5	O
,	9	O
time	5	O
-	7	O
course	5	O
or	5	O
severity	5	O
of	5	O
capsaicin	0	B-Chemical
-	7	O
induced	3	O
burning	5	O
.	9	O

If	5	O
confirmed	9	O
in	5	O
controlled	5	O
trials	5	O
,	9	O
the	5	O
long	5	O
-	7	O
term	5	O
results	9	O
of	5	O
this	5	O
open	5	O
,	9	O
non	9	O
-	7	O
randomized	5	O
study	9	O
might	9	O
indicate	9	O
that	5	O
the	5	O
analgesic	5	O
effect	9	O
of	5	O
capsaicin	0	B-Chemical
in	5	O
PHN	5	B-Disease
is	5	O
mediated	3	O
by	9	O
both	9	O
interference	9	O
with	5	O
neuropeptide	9	O
metabolism	9	O
and	5	O
morphological	9	O
changes	9	O
(	9	O
perhaps	5	O
degeneration	9	O
)	9	O
of	5	O
nociceptive	5	O
afferents	5	O
.	9	O

Myo	0	B-Chemical
-	7	I-Chemical
inositol	0	I-Chemical
-	7	I-Chemical
1	9	I-Chemical
-	7	I-Chemical
phosphate	0	I-Chemical
(	9	O
MIP	9	B-Chemical
)	9	O
synthase	1	O
inhibition	3	O
:	9	O
in	5	O
-	7	O
vivo	3	O
study	9	O
in	5	O
rats	9	O
.	9	O

Lithium	0	B-Chemical
and	5	O
valproate	0	B-Chemical
are	5	O
the	5	O
prototypic	9	O
mood	5	O
stabilizers	0	O
and	5	O
have	5	O
diverse	9	O
structures	9	O
and	5	O
targets	9	O
.	9	O

Both	9	O
drugs	5	O
influence	5	O
inositol	0	B-Chemical
metabolism	9	O
.	9	O

Lithium	0	B-Chemical
inhibits	3	O
IMPase	1	O
and	5	O
valproate	0	B-Chemical
inhibits	3	O
MIP	9	B-Chemical
synthase	1	O
.	9	O

This	5	O
study	9	O
shows	9	O
that	5	O
MIP	9	B-Chemical
synthase	1	O
inhibition	3	O
does	9	O
not	5	O
replicate	9	O
or	5	O
augment	9	O
the	5	O
effects	9	O
of	5	O
lithium	0	B-Chemical
in	5	O
the	5	O
inositol	0	B-Chemical
sensitive	9	O
pilocarpine	0	B-Chemical
-	7	O
induced	3	O
seizures	5	B-Disease
model	5	O
.	9	O

This	5	O
lack	9	O
of	5	O
effects	9	O
may	5	O
stem	3	O
from	9	O
the	5	O
low	9	O
contribution	9	O
of	5	O
de	2	O
-	7	O
novo	9	O
synthesis	9	O
to	5	O
cellular	3	O
inositol	0	B-Chemical
supply	5	O
or	5	O
to	5	O
the	5	O
inhibition	3	O
of	5	O
the	5	O
de	2	O
-	7	O
novo	9	O
synthesis	9	O
by	9	O
lithium	0	B-Chemical
itself	9	O
.	9	O

Non	9	O
-	7	O
steroidal	0	O
anti	3	O
-	7	O
inflammatory	3	O
drugs	5	O
-	7	O
associated	9	O
acute	9	O
interstitial	9	B-Disease
nephritis	9	I-Disease
with	5	O
granular	9	O
tubular	9	O
basement	3	O
membrane	9	O
deposits	9	O
.	9	O

Acute	5	B-Disease
tubulo	2	I-Disease
-	7	I-Disease
interstitial	9	I-Disease
nephritis	9	I-Disease
(	9	O
ATIN	5	B-Disease
)	9	O
is	5	O
an	5	O
important	9	O
cause	5	O
of	5	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
resulting	9	O
from	9	O
a	5	O
variety	5	O
of	5	O
insults	9	O
,	9	O
including	9	O
immune	3	O
complex	9	O
-	7	O
mediated	3	O
tubulo	2	B-Disease
-	7	I-Disease
interstitial	9	I-Disease
injury	9	I-Disease
,	9	O
but	9	O
drugs	5	O
such	5	O
as	5	O
non	9	O
-	7	O
steroidal	0	O
anti	3	O
-	7	O
inflammatory	3	O
drugs	5	O
(	9	O
NSAIDs	5	O
)	9	O
are	5	O
a	5	O
far	5	O
more	5	O
frequent	5	O
cause	5	O
.	9	O

Overall	9	O
,	9	O
as	5	O
an	5	O
entity	5	O
,	9	O
ATIN	5	B-Disease
remains	9	O
under	9	O
-	7	O
diagnosed	5	O
,	9	O
as	5	O
symptoms	5	O
resolve	5	O
spontaneously	5	O
if	5	O
the	5	O
medication	5	O
is	5	O
stopped	9	O
.	9	O

We	9	O
report	5	O
on	5	O
a	5	O
14	7	O
-	7	O
year	5	O
-	7	O
old	5	O
boy	5	O
who	5	O
developed	5	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
2	9	O
weeks	9	O
after	9	O
aortic	9	O
valve	5	O
surgery	5	O
.	9	O

He	5	O
was	9	O
put	5	O
on	5	O
aspirin	9	B-Chemical
following	9	O
surgery	5	O
and	5	O
took	5	O
ibuprofen	0	B-Chemical
for	5	O
fever	5	B-Disease
for	5	O
nearly	9	O
a	5	O
week	9	O
prior	9	O
to	5	O
presentation	5	O
.	9	O

He	5	O
then	9	O
presented	5	O
to	5	O
the	5	O
emergency	5	O
department	5	O
feeling	5	O
quite	5	O
ill	5	O
and	5	O
was	9	O
found	9	O
to	5	O
have	5	O
a	5	O
blood	9	B-Chemical
urea	0	I-Chemical
nitrogen	0	I-Chemical
(	9	O
BUN	0	B-Chemical
)	9	O
concentration	0	O
of	5	O
of	5	O
147	7	O
mg	0	O
/	9	O
dl	7	O
,	9	O
creatinine	0	B-Chemical
of	5	O
15	9	O
.	9	O
3	9	O
mg	0	O
/	9	O
dl	7	O
and	5	O
serum	9	O
potassium	0	B-Chemical
of	5	O
8	9	O
.	9	O
7	9	O
mEq	0	O
/	9	O
l	0	O
.	9	O

Dialysis	9	O
was	9	O
immediately	9	O
initiated	9	O
.	9	O

A	9	O
kidney	9	O
biopsy	5	O
showed	9	O
inflammatory	3	O
infiltrate	9	O
consistent	9	O
with	5	O
ATIN	5	B-Disease
.	9	O

However	9	O
,	9	O
in	5	O
the	5	O
tubular	9	O
basement	3	O
membrane	9	O
(	9	O
TBM	5	O
)	9	O
,	9	O
very	5	O
intense	9	O
granular	9	O
deposits	9	O
of	5	O
polyclonal	3	O
IgG	3	O
and	5	O
C3	9	O
were	9	O
noted	9	O
.	9	O

He	5	O
needed	5	O
dialysis	5	O
for	5	O
2	9	O
weeks	9	O
and	5	O
was	9	O
treated	3	O
successfully	5	O
with	5	O
steroids	9	B-Chemical
for	5	O
6	9	O
months	5	O
.	9	O

His	9	O
renal	9	O
recovery	9	O
and	5	O
disappearance	9	O
of	5	O
proteinuria	9	B-Disease
took	5	O
a	5	O
year	5	O
.	9	O

In	9	O
conclusion	9	O
,	9	O
this	5	O
is	5	O
a	5	O
first	9	O
report	5	O
of	5	O
NSAIDs	5	O
-	7	O
associated	9	O
ATIN	5	B-Disease
,	9	O
showing	9	O
deposits	9	O
of	5	O
granular	9	O
immune	3	O
complex	9	O
present	9	O
only	9	O
in	5	O
the	5	O
TBM	5	O
and	5	O
not	5	O
in	5	O
the	5	O
glomeruli	9	O
.	9	O

Rifampicin	0	B-Chemical
-	7	O
associated	9	O
segmental	5	O
necrotizing	5	O
glomerulonephritis	3	B-Disease
in	5	O
staphylococcal	9	B-Disease
endocarditis	5	I-Disease
.	9	O

Segmental	5	O
necrotising	5	O
glomerulonephritis	3	B-Disease
has	9	O
been	9	O
reported	9	O
as	5	O
complication	5	O
of	5	O
rifampicin	0	B-Chemical
therapy	5	O
in	5	O
patients	5	O
receiving	9	O
treatment	9	O
for	5	O
tuberculosis	9	B-Disease
.	9	O

Changing	5	O
epidemiology	5	O
of	5	O
infections	5	B-Disease
such	5	O
as	5	O
infective	9	B-Disease
endocarditis	5	I-Disease
(	9	O
IE	9	B-Disease
)	9	O
has	9	O
led	9	O
to	5	O
an	5	O
increase	9	O
in	5	O
the	5	O
use	5	O
of	5	O
rifampicin	0	B-Chemical
for	5	O
Staphylococcal	9	B-Disease
infections	5	I-Disease
.	9	O

We	9	O
describe	5	O
a	5	O
case	5	O
of	5	O
a	5	O
patient	5	O
with	5	O
Staphylococcal	9	B-Disease
IE	9	I-Disease
who	5	O
developed	5	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
secondary	9	O
to	5	O
a	5	O
segmental	5	O
necrotising	5	O
glomerulonephritis	3	B-Disease
while	9	O
being	5	O
treated	3	O
with	5	O
rifampicin	0	B-Chemical
,	9	O
and	5	O
review	5	O
the	5	O
literature	5	O
regarding	5	O
this	5	O
complication	5	O
of	5	O
rifampicin	0	B-Chemical
therapy	5	O
.	9	O

Rate	5	O
of	5	O
YMDD	1	O
motif	1	O
mutants	1	O
in	5	O
lamivudine	5	B-Chemical
-	7	O
untreated	3	O
Iranian	5	O
patients	5	O
with	5	O
chronic	5	B-Disease
hepatitis	9	I-Disease
B	9	I-Disease
virus	9	I-Disease
infection	9	I-Disease
.	9	O

BACKGROUND	2	O
:	9	O
Lamivudine	7	B-Chemical
is	5	O
used	5	O
for	5	O
the	5	O
treatment	9	O
of	5	O
chronic	5	B-Disease
hepatitis	9	I-Disease
B	9	I-Disease
patients	5	O
.	9	O

Recent	9	O
studies	9	O
show	9	O
that	5	O
the	5	O
YMDD	1	O
motif	1	O
mutants	1	O
(	9	O
resistant	9	O
hepatitis	9	B-Disease
B	9	I-Disease
virus	9	O
)	9	O
occur	5	O
as	5	O
natural	5	O
genome	9	O
variability	5	O
in	5	O
lamivudine	5	B-Chemical
-	7	O
untreated	3	O
chronic	5	B-Disease
hepatitis	9	I-Disease
B	9	I-Disease
patients	5	O
.	9	O

In	9	O
this	5	O
study	9	O
we	5	O
aimed	5	O
to	5	O
determine	9	O
the	5	O
rate	9	O
of	5	O
YMDD	1	O
motif	1	O
mutants	1	O
in	5	O
lamivudine	5	B-Chemical
-	7	O
untreated	3	O
chronic	5	B-Disease
hepatitis	9	I-Disease
B	9	I-Disease
patients	5	O
in	5	O
Iran	2	O
.	9	O

PATIENTS	2	O
AND	2	O
METHODS	2	O
:	9	O
A	9	O
total	9	O
of	5	O
77	7	O
chronic	5	B-Disease
hepatitis	9	I-Disease
B	9	I-Disease
patients	5	O
who	5	O
had	9	O
not	5	O
been	9	O
treated	3	O
with	5	O
lamivudine	5	B-Chemical
were	9	O
included	5	O
in	5	O
the	5	O
study	9	O
.	9	O

Serum	9	O
samples	9	O
from	9	O
patients	5	O
were	9	O
tested	9	O
by	9	O
polymerase	1	O
chain	9	O
reaction	9	O
-	7	O
restriction	9	O
fragment	1	O
length	9	O
polymorphism	9	O
(	9	O
PCR	9	O
-	7	O
RFLP	9	O
)	9	O
for	5	O
detection	9	O
of	5	O
YMDD	1	O
motif	1	O
mutants	1	O
.	9	O

All	9	O
patients	5	O
were	9	O
also	9	O
tested	9	O
for	5	O
liver	9	O
enzymes	1	O
,	9	O
anti	3	O
-	7	O
HCV	9	O
,	9	O
HBeAg	9	B-Chemical
,	9	O
and	5	O
anti	3	O
-	7	O
HBe	3	O
.	9	O

RESULTS	9	O
:	9	O
Of	9	O
the	5	O
77	7	O
patients	5	O
enrolled	5	O
in	5	O
the	5	O
study	9	O
,	9	O
73	7	O
%	9	O
were	9	O
male	9	O
and	5	O
27	7	O
%	9	O
were	9	O
female	9	O
.	9	O

Mean	9	O
ALT	9	O
and	5	O
AST	9	O
levels	3	O
were	9	O
124	7	O
.	9	O
4	9	O
+	9	O
/	9	O
-	7	O
73	7	O
.	9	O
4	9	O
and	5	O
103	7	O
.	9	O
1	9	O
+	9	O
/	9	O
-	7	O
81	7	O
IU	0	O
/	9	O
l	0	O
,	9	O
respectively	9	O
.	9	O

HBeAg	9	B-Chemical
was	9	O
positive	9	O
in	5	O
40	9	O
%	9	O
and	5	O
anti	3	O
-	7	O
HBe	3	O
in	5	O
60	9	O
%	9	O
of	5	O
the	5	O
patients	5	O
.	9	O

Anti	3	O
-	7	O
HCV	9	O
was	9	O
negative	9	O
in	5	O
all	5	O
of	5	O
them	5	O
.	9	O

YMDD	1	O
motif	1	O
mutants	1	O
were	9	O
not	5	O
detected	9	O
in	5	O
any	5	O
of	5	O
the	5	O
patients	5	O
despite	9	O
the	5	O
liver	9	O
enzyme	0	O
levels	3	O
and	5	O
the	5	O
presence	9	O
of	5	O
HBeAg	9	B-Chemical
or	5	O
anti	3	O
-	7	O
HBe	3	O
.	9	O

CONCLUSION	5	O
:	9	O
Although	9	O
the	5	O
natural	5	O
occurrence	5	O
of	5	O
YMDD	1	O
motif	1	O
mutants	1	O
in	5	O
lamivudine	5	B-Chemical
-	7	O
untreated	3	O
patients	5	O
with	5	O
chronic	5	B-Disease
hepatitis	9	I-Disease
B	9	I-Disease
has	9	O
been	9	O
reported	9	O
,	9	O
these	5	O
mutants	1	O
were	9	O
not	5	O
detected	9	O
in	5	O
Iranian	5	O
lamivudine	5	B-Chemical
-	7	O
untreated	3	O
chronic	5	B-Disease
hepatitis	9	I-Disease
B	9	I-Disease
patients	5	O
.	9	O

Branch	2	O
retinal	5	B-Disease
vein	5	I-Disease
occlusion	5	I-Disease
and	5	O
fluoxetine	0	B-Chemical
.	9	O

A	9	O
case	5	O
of	5	O
branch	5	O
retinal	5	B-Disease
vein	5	I-Disease
occlusion	5	I-Disease
associated	9	O
with	5	O
fluoxetine	0	B-Chemical
-	7	O
induced	3	O
secondary	9	O
hypertension	5	B-Disease
is	5	O
described	9	O
.	9	O

Although	9	O
an	5	O
infrequent	5	O
complication	5	O
of	5	O
selective	9	O
serotonin	9	B-Chemical
reuptake	0	O
inhibitor	3	O
therapy	5	O
,	9	O
it	5	O
is	5	O
important	9	O
that	5	O
ophthalmologists	5	O
are	5	O
aware	5	O
that	5	O
these	5	O
agents	5	O
can	5	O
cause	5	O
hypertension	5	B-Disease
because	5	O
this	5	O
class	9	O
of	5	O
drugs	5	O
is	5	O
widely	5	O
prescribed	5	O
.	9	O

The	5	O
differential	9	O
effects	9	O
of	5	O
bupivacaine	0	B-Chemical
and	5	O
lidocaine	0	B-Chemical
on	5	O
prostaglandin	0	B-Chemical
E2	3	I-Chemical
release	9	O
,	9	O
cyclooxygenase	0	O
gene	1	O
expression	3	O
and	5	O
pain	5	B-Disease
in	5	O
a	5	O
clinical	5	O
pain	5	B-Disease
model	5	O
.	9	O

BACKGROUND	2	O
:	9	O
In	9	O
addition	9	O
to	5	O
blocking	3	O
nociceptive	5	O
input	5	O
from	9	O
surgical	5	O
sites	9	O
,	9	O
long	5	O
-	7	O
acting	9	O
local	5	O
anesthetics	5	O
might	9	O
directly	9	O
modulate	9	O
inflammation	9	B-Disease
.	9	O

In	9	O
the	5	O
present	9	O
study	9	O
,	9	O
we	5	O
describe	5	O
the	5	O
proinflammatory	3	O
effects	9	O
of	5	O
bupivacaine	0	B-Chemical
on	5	O
local	5	O
prostaglandin	0	B-Chemical
E2	3	I-Chemical
(	9	O
PGE2	3	B-Chemical
)	9	O
production	9	O
and	5	O
cyclooxygenase	0	O
(	9	O
COX	9	O
)	9	O
gene	1	O
expression	3	O
that	5	O
increases	9	O
postoperative	5	B-Disease
pain	5	I-Disease
in	5	O
human	3	O
subjects	5	O
.	9	O

METHODS	2	O
:	9	O
Subjects	5	O
(	9	O
n	9	O
=	7	O
114	7	O
)	9	O
undergoing	9	O
extraction	9	O
of	5	O
impacted	5	O
third	9	O
molars	5	O
received	9	O
either	9	O
2	9	O
%	9	O
lidocaine	0	B-Chemical
or	5	O
0	7	O
.	9	O
5	9	O
%	9	O
bupivacaine	0	B-Chemical
before	9	O
surgery	5	O
and	5	O
either	9	O
rofecoxib	5	B-Chemical
50	0	O
mg	0	O
or	5	O
placebo	9	O
orally	0	O
90	9	O
min	0	O
before	9	O
surgery	5	O
and	5	O
for	5	O
the	5	O
following	9	O
48	9	O
h	0	O
.	9	O

Oral	9	O
mucosal	9	O
biopsies	9	O
were	9	O
taken	5	O
before	9	O
surgery	5	O
and	5	O
48	9	O
h	0	O
after	9	O
surgery	5	O
.	9	O

After	9	O
extraction	9	O
,	9	O
a	5	O
microdialysis	5	O
probe	9	O
was	9	O
placed	5	O
at	9	O
the	5	O
surgical	5	O
site	9	O
for	5	O
PGE2	3	B-Chemical
and	5	O
thromboxane	0	B-Chemical
B2	9	I-Chemical
(	9	O
TXB2	0	B-Chemical
)	9	O
measurements	5	O
.	9	O

RESULTS	9	O
:	9	O
The	5	O
bupivacaine	0	B-Chemical
/	9	O
rofecoxib	5	B-Chemical
group	9	O
reported	9	O
significantly	9	O
less	5	O
pain	5	B-Disease
,	9	O
as	5	O
assessed	9	O
by	9	O
a	5	O
visual	5	O
analog	0	O
scale	5	O
,	9	O
compared	9	O
with	5	O
the	5	O
other	5	O
three	9	O
treatment	9	O
groups	9	O
over	5	O
the	5	O
first	9	O
4	9	O
h	0	O
.	9	O

However	9	O
,	9	O
the	5	O
bupivacaine	0	B-Chemical
/	9	O
placebo	9	O
group	9	O
reported	9	O
significantly	9	O
more	5	O
pain	5	B-Disease
at	9	O
24	9	O
h	0	O
and	5	O
PGE2	3	B-Chemical
levels	3	O
during	5	O
the	5	O
first	9	O
4	9	O
h	0	O
were	9	O
significantly	9	O
higher	9	O
than	5	O
the	5	O
other	5	O
three	9	O
treatment	9	O
groups	9	O
.	9	O

Moreover	9	O
,	9	O
bupivacaine	0	B-Chemical
significantly	9	O
increased	9	O
COX	9	O
-	7	O
2	9	O
gene	1	O
expression	3	O
at	9	O
48	9	O
h	0	O
as	5	O
compared	9	O
with	5	O
the	5	O
lidocaine	0	B-Chemical
/	9	O
placebo	9	O
group	9	O
.	9	O

Thromboxane	2	B-Chemical
levels	3	O
were	9	O
not	5	O
significantly	9	O
affected	9	O
by	9	O
any	5	O
of	5	O
the	5	O
treatments	9	O
,	9	O
indicating	9	O
that	5	O
the	5	O
effects	9	O
seen	9	O
were	9	O
attributable	9	O
to	5	O
inhibition	3	O
of	5	O
COX	9	O
-	7	O
2	9	O
,	9	O
but	9	O
not	5	O
COX	9	O
-	7	O
1	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
These	5	O
results	9	O
suggest	9	O
that	5	O
bupivacaine	0	B-Chemical
stimulates	3	O
COX	9	O
-	7	O
2	9	O
gene	1	O
expression	3	O
after	9	O
tissue	9	B-Disease
injury	9	I-Disease
,	9	O
which	5	O
is	5	O
associated	9	O
with	5	O
higher	9	O
PGE2	3	B-Chemical
production	9	O
and	5	O
pain	5	B-Disease
after	9	O
the	5	O
local	5	O
anesthetic	5	O
effect	9	O
dissipates	5	O
.	9	O

p75NTR	3	O
expression	3	O
in	5	O
rat	3	O
urinary	9	O
bladder	9	O
sensory	5	O
neurons	3	O
and	5	O
spinal	5	O
cord	9	O
with	5	O
cyclophosphamide	0	B-Chemical
-	7	O
induced	3	O
cystitis	9	B-Disease
.	9	O

A	9	O
role	9	O
for	5	O
nerve	5	O
growth	3	O
factor	9	O
(	9	O
NGF	3	O
)	9	O
in	5	O
contributing	9	O
to	5	O
increased	9	O
voiding	5	O
frequency	5	O
and	5	O
altered	9	O
sensation	5	O
from	9	O
the	5	O
urinary	9	O
bladder	9	O
has	9	O
been	9	O
suggested	9	O
.	9	O

Previous	9	O
studies	9	O
have	5	O
examined	9	O
the	5	O
expression	3	O
and	5	O
regulation	9	O
of	5	O
tyrosine	3	B-Chemical
kinase	3	O
receptors	3	O
(	9	O
Trks	3	O
)	9	O
in	5	O
micturition	5	O
reflexes	5	O
with	5	O
urinary	9	B-Disease
bladder	9	I-Disease
inflammation	9	I-Disease
.	9	O

The	5	O
present	9	O
studies	9	O
examine	9	O
the	5	O
expression	3	O
and	5	O
regulation	9	O
of	5	O
another	9	O
receptor	3	O
known	9	O
to	5	O
bind	1	O
NGF	3	O
,	9	O
p75	3	O
(	9	O
NTR	9	O
)	9	O
,	9	O
after	9	O
various	9	O
durations	5	O
of	5	O
bladder	9	B-Disease
inflammation	9	I-Disease
induced	3	O
by	9	O
cyclophosphamide	0	B-Chemical
(	9	O
CYP	0	B-Chemical
)	9	O
.	9	O

CYP	0	B-Chemical
-	7	O
induced	3	O
cystitis	9	B-Disease
increased	9	O
(	9	O
P	9	O
<	0	O
or	5	O
=	7	O
0	7	O
.	9	O
001	9	O
)	9	O
p75	3	O
(	9	O
NTR	9	O
)	9	O
expression	3	O
in	5	O
the	5	O
superficial	5	O
lateral	5	O
and	5	O
medial	5	O
dorsal	5	O
horn	5	O
in	5	O
L1	9	O
-	7	O
L2	9	O
and	5	O
L6	3	O
-	7	O
S1	9	O
spinal	5	O
segments	9	O
.	9	O

The	5	O
number	9	O
of	5	O
p75	3	O
(	9	O
NTR	9	O
)	9	O
-	7	O
immunoreactive	3	O
(	9	O
-	7	O
IR	9	O
)	9	O
cells	3	O
in	5	O
the	5	O
lumbosacral	5	O
dorsal	5	O
root	5	O
ganglia	5	O
(	9	O
DRG	3	O
)	9	O
also	9	O
increased	9	O
(	9	O
P	9	O
<	0	O
or	5	O
=	7	O
0	7	O
.	9	O
05	7	O
)	9	O
with	5	O
CYP	0	B-Chemical
-	7	O
induced	3	O
cystitis	9	B-Disease
(	9	O
acute	9	O
,	9	O
intermediate	9	O
,	9	O
and	5	O
chronic	5	O
)	9	O
.	9	O

Quantitative	9	O
,	9	O
real	5	O
-	7	O
time	5	O
polymerase	1	O
chain	9	O
reaction	9	O
also	9	O
demonstrated	9	O
significant	9	O
increases	9	O
(	9	O
P	9	O
<	0	O
or	5	O
=	7	O
0	7	O
.	9	O
01	7	O
)	9	O
in	5	O
p75	3	O
(	9	O
NTR	9	O
)	9	O
mRNA	3	O
in	5	O
DRG	3	O
with	5	O
intermediate	9	O
and	5	O
chronic	5	O
CYP	0	B-Chemical
-	7	O
induced	3	O
cystitis	9	B-Disease
.	9	O

Retrograde	5	O
dye	0	O
-	7	O
tracing	5	O
techniques	5	O
with	5	O
Fastblue	_	O
were	9	O
used	5	O
to	5	O
identify	9	O
presumptive	9	O
bladder	9	O
afferent	5	O
cells	3	O
in	5	O
the	5	O
lumbosacral	5	O
DRG	3	O
.	9	O

In	9	O
bladder	9	O
afferent	5	O
cells	3	O
in	5	O
DRG	3	O
,	9	O
p75	3	O
(	9	O
NTR	9	O
)	9	O
-	7	O
IR	9	O
was	9	O
also	9	O
increased	9	O
(	9	O
P	9	O
<	0	O
or	5	O
=	7	O
0	7	O
.	9	O
01	7	O
)	9	O
with	5	O
cystitis	9	B-Disease
.	9	O

In	9	O
addition	9	O
to	5	O
increases	9	O
in	5	O
p75	3	O
(	9	O
NTR	9	O
)	9	O
-	7	O
IR	9	O
in	5	O
DRG	3	O
cell	3	O
bodies	9	O
,	9	O
increases	9	O
(	9	O
P	9	O
<	0	O
or	5	O
=	7	O
0	7	O
.	9	O
001	9	O
)	9	O
in	5	O
pericellular	3	O
(	9	O
encircling	5	O
DRG	3	O
cells	3	O
)	9	O
p75	3	O
(	9	O
NTR	9	O
)	9	O
-	7	O
IR	9	O
in	5	O
DRG	3	O
also	9	O
increased	9	O
.	9	O

Confocal	3	O
analyses	9	O
demonstrated	9	O
that	5	O
pericellular	3	O
p75	3	O
(	9	O
NTR	9	O
)	9	O
-	7	O
IR	9	O
was	9	O
not	5	O
colocalized	3	O
with	5	O
the	5	O
glial	3	O
marker	3	O
,	9	O
glial	3	O
fibrillary	3	O
acidic	0	O
protein	1	O
(	9	O
GFAP	3	O
)	9	O
.	9	O

These	5	O
studies	9	O
demonstrate	9	O
that	5	O
p75	3	O
(	9	O
NTR	9	O
)	9	O
expression	3	O
in	5	O
micturition	5	O
reflexes	5	O
is	5	O
present	9	O
constitutively	3	O
and	5	O
modified	9	O
by	9	O
bladder	9	B-Disease
inflammation	9	I-Disease
.	9	O

The	5	O
functional	9	O
significance	9	O
of	5	O
p75	3	O
(	9	O
NTR	9	O
)	9	O
expression	3	O
in	5	O
micturition	5	O
reflexes	5	O
remains	9	O
to	5	O
be	5	O
determined	9	O
.	9	O

Azathioprine	0	B-Chemical
-	7	O
induced	3	O
suicidal	5	O
erythrocyte	9	O
death	9	O
.	9	O

BACKGROUND	2	O
:	9	O
Azathioprine	0	B-Chemical
is	5	O
widely	5	O
used	5	O
as	5	O
an	5	O
immunosuppressive	9	O
drug	5	O
.	9	O

The	5	O
side	5	O
effects	9	O
of	5	O
azathioprine	5	B-Chemical
include	5	O
anemia	9	B-Disease
,	9	O
which	5	O
has	9	O
been	9	O
attributed	9	O
to	5	O
bone	5	O
marrow	3	O
suppression	9	O
.	9	O

Alternatively	9	O
,	9	O
anemia	9	B-Disease
could	9	O
result	9	O
from	9	O
accelerated	9	O
suicidal	5	O
erythrocyte	9	O
death	9	O
or	5	O
eryptosis	3	O
,	9	O
which	5	O
is	5	O
characterized	9	O
by	9	O
exposure	9	O
of	5	O
phosphatidylserine	0	B-Chemical
(	9	O
PS	9	B-Chemical
)	9	O
at	9	O
the	5	O
erythrocyte	9	O
surface	9	O
and	5	O
by	9	O
cell	3	O
shrinkage	5	O
.	9	O

METHODS	2	O
:	9	O
The	5	O
present	9	O
experiments	9	O
explored	9	O
whether	9	O
azathioprine	5	B-Chemical
influences	5	O
eryptosis	3	O
.	9	O

According	5	O
to	5	O
annexin	3	O
V	9	O
binding	1	O
,	9	O
erythrocytes	9	O
from	9	O
patients	5	O
indeed	9	O
showed	9	O
a	5	O
significant	9	O
increase	9	O
of	5	O
PS	9	B-Chemical
exposure	9	O
within	9	O
1	9	O
week	9	O
of	5	O
treatment	9	O
with	5	O
azathioprine	5	B-Chemical
.	9	O

In	9	O
a	5	O
second	9	O
series	5	O
,	9	O
cytosolic	3	O
Ca2	0	B-Chemical
+	9	O
activity	9	O
(	9	O
Fluo3	0	B-Chemical
fluorescence	0	O
)	9	O
,	9	O
cell	3	O
volume	9	O
(	9	O
forward	9	O
scatter	5	O
)	9	O
,	9	O
and	5	O
PS	9	B-Chemical
-	7	O
exposure	9	O
(	9	O
annexin	3	O
V	9	O
binding	1	O
)	9	O
were	9	O
determined	9	O
by	9	O
FACS	3	O
analysis	9	O
in	5	O
erythrocytes	9	O
from	9	O
healthy	5	O
volunteers	5	O
.	9	O

RESULTS	9	O
:	9	O
Exposure	9	O
to	5	O
azathioprine	5	B-Chemical
(	9	O
>	0	O
or	5	O
=	7	O
2	9	O
microg	0	O
/	9	O
mL	0	O
)	9	O
for	5	O
48	9	O
hours	9	O
increased	9	O
cytosolic	3	O
Ca2	0	B-Chemical
+	9	O
activity	9	O
and	5	O
annexin	3	O
V	9	O
binding	1	O
and	5	O
decreased	9	O
forward	9	O
scatter	5	O
.	9	O

The	5	O
effect	9	O
of	5	O
azathioprine	5	B-Chemical
on	5	O
both	9	O
annexin	3	O
V	9	O
binding	1	O
and	5	O
forward	9	O
scatter	5	O
was	9	O
significantly	9	O
blunted	9	O
in	5	O
the	5	O
nominal	9	O
absence	3	O
of	5	O
extracellular	9	O
Ca2	0	B-Chemical
+	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Azathioprine	0	B-Chemical
triggers	9	O
suicidal	5	O
erythrocyte	9	O
death	9	O
,	9	O
an	5	O
effect	9	O
presumably	9	O
contributing	9	O
to	5	O
azathioprine	5	B-Chemical
-	7	O
induced	3	O
anemia	9	B-Disease
.	9	O

Levetiracetam	0	B-Chemical
as	5	O
an	5	O
adjunct	5	O
to	5	O
phenobarbital	0	B-Chemical
treatment	9	O
in	5	O
cats	9	O
with	5	O
suspected	5	O
idiopathic	5	B-Disease
epilepsy	5	I-Disease
.	9	O

OBJECTIVE	2	O
:	9	O
To	9	O
assess	5	O
pharmacokinetics	9	O
,	9	O
efficacy	9	O
,	9	O
and	5	O
tolerability	5	O
of	5	O
oral	9	O
levetiracetam	5	B-Chemical
administered	9	O
as	5	O
an	5	O
adjunct	5	O
to	5	O
phenobarbital	0	B-Chemical
treatment	9	O
in	5	O
cats	9	O
with	5	O
poorly	9	O
controlled	5	O
suspected	5	O
idiopathic	5	B-Disease
epilepsy	5	I-Disease
.	9	O

DESIGN	2	O
-	7	O
Open	5	O
-	7	O
label	9	O
,	9	O
noncomparative	5	O
clinical	5	O
trial	5	O
.	9	O

ANIMALS	2	O
:	9	O
12	9	O
cats	9	O
suspected	5	O
to	5	O
have	5	O
idiopathic	5	B-Disease
epilepsy	5	I-Disease
that	5	O
was	9	O
poorly	9	O
controlled	5	O
with	5	O
phenobarbital	0	B-Chemical
or	5	O
that	5	O
had	9	O
unacceptable	5	O
adverse	5	O
effects	9	O
when	5	O
treated	3	O
with	5	O
phenobarbital	0	B-Chemical
.	9	O

PROCEDURES	2	O
:	9	O
Cats	9	O
were	9	O
treated	3	O
with	5	O
levetiracetam	5	B-Chemical
(	9	O
20	9	O
mg	0	O
/	9	O
kg	0	O
[	9	O
9	7	O
.	9	O
1	9	O
mg	0	O
/	9	O
lb	9	O
]	9	O
,	9	O
PO	9	O
,	9	O
q	9	O
8	9	O
h	0	O
)	9	O
.	9	O

After	9	O
a	5	O
minimum	5	O
of	5	O
1	9	O
week	9	O
of	5	O
treatment	9	O
,	9	O
serum	9	O
levetiracetam	5	B-Chemical
concentrations	0	O
were	9	O
measured	9	O
before	9	O
and	5	O
2	9	O
,	9	O
4	9	O
,	9	O
and	5	O
6	9	O
hours	9	O
after	9	O
drug	5	O
administration	9	O
,	9	O
and	5	O
maximum	5	O
and	5	O
minimum	5	O
serum	9	O
concentrations	0	O
and	5	O
elimination	9	O
half	5	O
-	7	O
life	5	O
were	9	O
calculated	5	O
.	9	O

Seizure	5	B-Disease
frequencies	9	O
before	9	O
and	5	O
after	9	O
initiation	9	O
of	5	O
levetiracetam	5	B-Chemical
treatment	9	O
were	9	O
compared	9	O
,	9	O
and	5	O
adverse	5	O
effects	9	O
were	9	O
recorded	5	O
.	9	O

RESULTS	9	O
:	9	O
Median	7	O
maximum	5	O
serum	9	O
levetiracetam	5	B-Chemical
concentration	0	O
was	9	O
25	9	O
.	9	O
5	9	O
microg	0	O
/	9	O
mL	0	O
,	9	O
median	9	O
minimum	5	O
serum	9	O
levetiracetam	5	B-Chemical
concentration	0	O
was	9	O
8	9	O
.	9	O
3	9	O
microg	0	O
/	9	O
mL	0	O
,	9	O
and	5	O
median	9	O
elimination	9	O
half	5	O
-	7	O
life	5	O
was	9	O
2	9	O
.	9	O
9	7	O
hours	9	O
.	9	O

Median	7	O
seizure	5	B-Disease
frequency	5	O
prior	9	O
to	5	O
treatment	9	O
with	5	O
levetiracetam	5	B-Chemical
(	9	O
2	9	O
.	9	O
1	9	O
seizures	5	B-Disease
/	9	O
mo	9	O
)	9	O
was	9	O
significantly	9	O
higher	9	O
than	5	O
median	9	O
seizure	5	B-Disease
frequency	5	O
after	9	O
initiation	9	O
of	5	O
levetiracetam	5	B-Chemical
treatment	9	O
(	9	O
0	7	O
.	9	O
42	7	O
seizures	5	B-Disease
/	9	O
mo	9	O
)	9	O
,	9	O
and	5	O
7	9	O
of	5	O
10	9	O
cats	9	O
were	9	O
classified	5	O
as	5	O
having	5	O
responded	9	O
to	5	O
levetiracetam	5	B-Chemical
treatment	9	O
(	9	O
ie	5	O
,	9	O
reduction	9	O
in	5	O
seizure	5	B-Disease
frequency	5	O
of	5	O
>	0	O
or	5	O
=	7	O
50	0	O
%	9	O
)	9	O
.	9	O

Two	9	O
cats	9	O
had	9	O
transient	9	O
lethargy	5	B-Disease
and	5	O
inappetence	5	B-Disease
.	9	O

CONCLUSIONS	5	O
AND	2	O
CLINICAL	2	O
RELEVANCE	2	O
:	9	O
Results	9	O
suggested	9	O
that	5	O
levetiracetam	5	B-Chemical
is	5	O
well	9	O
tolerated	9	O
in	5	O
cats	9	O
and	5	O
may	5	O
be	5	O
useful	5	O
as	5	O
an	5	O
adjunct	5	O
to	5	O
phenobarbital	0	B-Chemical
treatment	9	O
in	5	O
cats	9	O
with	5	O
idiopathic	5	B-Disease
epilepsy	5	I-Disease
.	9	O

Serotonin	0	B-Chemical
reuptake	0	O
inhibitors	3	O
,	9	O
paranoia	5	B-Disease
,	9	O
and	5	O
the	5	O
ventral	5	O
basal	3	O
ganglia	5	O
.	9	O

Antidepressants	7	O
have	5	O
previously	9	O
been	9	O
associated	9	O
with	5	O
paranoid	5	B-Disease
reactions	9	O
in	5	O
psychiatric	5	O
patients	5	O
.	9	O

Five	9	O
cases	5	O
of	5	O
paranoid	5	B-Disease
exacerbation	5	O
with	5	O
the	5	O
serotonin	9	B-Chemical
reuptake	0	O
inhibitors	3	O
fluoxetine	0	B-Chemical
and	5	O
amitriptyline	0	B-Chemical
are	5	O
reported	9	O
here	5	O
.	9	O

Elements	9	O
common	5	O
to	5	O
these	5	O
cases	5	O
included	5	O
a	5	O
history	5	O
of	5	O
paranoid	5	B-Disease
symptomatology	5	O
and	5	O
the	5	O
concomitant	9	O
occurrence	5	O
of	5	O
depressive	5	B-Disease
and	5	I-Disease
psychotic	5	I-Disease
symptoms	5	I-Disease
.	9	O

Complicated	5	O
depressive	5	B-Disease
disorders	5	I-Disease
(	9	O
including	9	O
atypicality	5	O
of	5	O
course	5	O
and	5	O
symptomatology	5	O
,	9	O
chronicity	5	O
,	9	O
psychosis	5	B-Disease
,	9	O
bipolarity	5	O
,	9	O
and	5	O
secondary	9	O
onset	5	O
in	5	O
the	5	O
course	5	O
of	5	O
a	5	O
primary	9	O
psychosis	5	B-Disease
)	9	O
may	5	O
present	9	O
particular	5	O
vulnerability	5	O
to	5	O
paranoid	5	B-Disease
exacerbations	5	O
associated	9	O
with	5	O
serotonin	9	B-Chemical
reuptake	0	O
inhibitors	3	O
.	9	O

Although	9	O
the	5	O
pharmacology	5	O
and	5	O
neurobiology	5	O
of	5	O
paranoia	5	B-Disease
remain	9	O
cryptic	4	O
,	9	O
several	9	O
mechanisms	9	O
,	9	O
including	9	O
5HT3	0	O
receptor	3	O
-	7	O
mediated	3	O
dopamine	5	B-Chemical
release	9	O
,	9	O
beta	9	O
-	7	O
noradrenergic	5	O
receptor	3	O
downregulation	3	O
,	9	O
or	5	O
GABAB	3	O
receptor	3	O
upregulation	3	O
acting	9	O
in	5	O
the	5	O
vicinity	9	O
of	5	O
the	5	O
ventral	5	O
basal	3	O
ganglia	5	O
(	9	O
possibly	9	O
in	5	O
lateral	5	O
orbitofrontal	5	O
or	5	O
anterior	5	O
cingulate	5	O
circuits	5	O
)	9	O
,	9	O
might	9	O
apply	5	O
to	5	O
this	5	O
phenomenon	5	O
.	9	O

These	5	O
cases	5	O
call	5	O
attention	5	O
to	5	O
possible	5	O
paranoid	5	B-Disease
exacerbations	5	O
with	5	O
serotonin	9	B-Chemical
reuptake	0	O
blockers	9	O
in	5	O
select	5	O
patients	5	O
and	5	O
raise	9	O
neurobiological	5	O
considerations	5	O
regarding	5	O
paranoia	5	B-Disease
.	9	O

Clinical	5	O
comparison	9	O
of	5	O
cardiorespiratory	5	O
effects	9	O
during	5	O
unilateral	5	O
and	5	O
conventional	5	O
spinal	5	O
anaesthesia	5	O
.	9	O

BACKGROUND	2	O
:	9	O
Spinal	9	O
anaesthesia	5	O
is	5	O
widely	5	O
employed	5	O
in	5	O
clinical	5	O
practice	5	O
but	9	O
has	9	O
the	5	O
main	5	O
drawback	5	O
of	5	O
post	9	O
-	7	O
spinal	5	O
block	9	O
hypotension	5	B-Disease
.	9	O

Efforts	5	O
must	5	O
therefore	5	O
continue	5	O
to	5	O
be	5	O
made	5	O
to	5	O
obviate	5	O
this	5	O
setback	5	O
OBJECTIVE	2	O
:	9	O
To	9	O
evaluate	9	O
the	5	O
cardiovascular	5	O
and	5	O
respiratory	5	O
changes	9	O
during	5	O
unilateral	5	O
and	5	O
conventional	5	O
spinal	5	O
anaesthesia	5	O
.	9	O

METHODS	2	O
:	9	O
With	5	O
ethical	5	O
approval	5	O
,	9	O
we	5	O
studied	9	O
74	7	O
American	9	O
Society	2	O
of	5	O
Anesthesiologists	5	O
(	9	O
ASA	9	O
)	9	O
,	9	O
physical	5	O
status	9	O
class	9	O
1	9	O
and	5	O
2	9	O
patients	5	O
scheduled	5	O
for	5	O
elective	5	O
unilateral	5	O
lower	9	O
limb	5	O
surgery	5	O
.	9	O

Patients	5	O
were	9	O
randomly	5	O
allocated	5	O
into	9	O
one	5	O
of	5	O
two	5	O
groups	9	O
:	9	O
lateral	5	O
and	5	O
conventional	5	O
spinal	5	O
anaesthesia	5	O
groups	9	O
.	9	O

In	9	O
the	5	O
lateral	5	O
position	9	O
with	5	O
operative	5	O
side	5	O
down	9	O
,	9	O
patients	5	O
recived	5	O
10	9	O
mg	0	O
(	9	O
2mls	0	O
)	9	O
of	5	O
0	7	O
.	9	O
5	9	O
%	9	O
hyperbaric	5	O
bupivacaine	0	B-Chemical
through	9	O
a	5	O
25	9	O
-	7	O
gauge	5	O
spinal	5	O
needle	5	O
.	9	O

Patients	5	O
in	5	O
the	5	O
unilateral	5	O
group	9	O
were	9	O
maintained	9	O
in	5	O
the	5	O
lateral	5	O
position	9	O
for	5	O
15	9	O
minutes	0	O
following	9	O
spinal	5	O
injection	9	O
while	9	O
those	5	O
in	5	O
the	5	O
conventional	5	O
group	9	O
were	9	O
turned	5	O
supine	5	O
immediately	9	O
after	9	O
injection	9	O
.	9	O

Blood	9	O
pressure	5	O
,	9	O
heart	5	O
rate	9	O
,	9	O
respiratory	5	O
rate	9	O
and	5	O
oxygen	0	B-Chemical
saturation	9	O
were	9	O
monitored	9	O
over	5	O
1	9	O
hour	0	O
.	9	O

RESULTS	9	O
:	9	O
Three	9	O
patients	5	O
(	9	O
8	9	O
.	9	O
1	9	O
%	9	O
)	9	O
in	5	O
the	5	O
unilateral	5	O
group	9	O
and	5	O
5	9	O
(	9	O
13	7	O
.	9	O
5	9	O
%	9	O
)	9	O
in	5	O
the	5	O
conventional	5	O
group	9	O
developed	5	O
hypotension	5	B-Disease
,	9	O
P	9	O
=	7	O
0	7	O
.	9	O
71	7	O
.	9	O

Four	9	O
(	9	O
10	9	O
.	9	O
8	9	O
%	9	O
)	9	O
patients	5	O
in	5	O
the	5	O
conventional	5	O
group	9	O
and	5	O
1	9	O
(	9	O
2	9	O
.	9	O
7	9	O
%	9	O
)	9	O
in	5	O
the	5	O
unilateral	5	O
group	9	O
,	9	O
P	9	O
=	7	O
0	7	O
.	9	O
17	7	O
required	9	O
epinephrine	0	B-Chemical
infusion	0	O
to	5	O
treat	5	O
hypotension	5	B-Disease
.	9	O

Patients	5	O
in	5	O
the	5	O
conventional	5	O
group	9	O
had	9	O
statistically	9	O
significant	9	O
greater	5	O
fall	5	O
in	5	O
the	5	O
systolic	5	O
blood	9	O
pressures	5	O
at	9	O
15	9	O
,	9	O
30	9	O
and	5	O
45	9	O
minutes	0	O
when	5	O
compared	9	O
to	5	O
the	5	O
baseline	5	O
(	9	O
P	9	O
=	7	O
0	7	O
.	9	O
003	2	O
,	9	O
0	7	O
.	9	O
001	9	O
and	5	O
0	7	O
.	9	O
004	7	O
)	9	O
.	9	O

The	5	O
mean	5	O
respiratory	5	O
rate	9	O
and	5	O
oxygen	0	B-Chemical
saturations	5	O
in	5	O
the	5	O
two	5	O
groups	9	O
were	9	O
similar	9	O
.	9	O

CONCLUSION	5	O
:	9	O
Compared	9	O
to	5	O
conventional	5	O
spinal	5	O
anaesthesia	5	O
,	9	O
unilateral	5	O
spinal	5	O
anaesthesia	5	O
was	9	O
associated	9	O
with	5	O
fewer	5	O
cardiovascular	5	O
perturbations	5	O
.	9	O

Also	9	O
,	9	O
the	5	O
type	9	O
of	5	O
spinal	5	O
block	9	O
instituted	5	O
affected	9	O
neither	9	O
the	5	O
respiratory	5	O
rate	9	O
nor	9	O
the	5	O
arterial	5	O
oxygen	0	B-Chemical
saturation	9	O
.	9	O

Spectrum	5	O
of	5	O
adverse	5	O
events	5	O
after	9	O
generic	5	O
HAART	5	O
in	5	O
southern	4	O
Indian	4	O
HIV	5	B-Disease
-	7	I-Disease
infected	3	I-Disease
patients	5	O
.	9	O

To	9	O
determine	9	O
the	5	O
incidence	5	O
of	5	O
clinically	5	O
significant	9	O
adverse	5	O
events	5	O
after	9	O
long	5	O
-	7	O
term	5	O
,	9	O
fixed	9	O
-	7	O
dose	9	O
,	9	O
generic	5	O
highly	9	O
active	9	O
antiretroviral	5	O
therapy	5	O
(	9	O
HAART	5	O
)	9	O
use	5	O
among	5	O
HIV	5	B-Disease
-	7	I-Disease
infected	3	I-Disease
individuals	5	O
in	5	O
South	4	O
India	2	O
,	9	O
we	5	O
examined	9	O
the	5	O
experiences	5	O
of	5	O
3154	7	O
HIV	5	B-Disease
-	7	I-Disease
infected	3	I-Disease
individuals	5	O
who	5	O
received	9	O
a	5	O
minimum	5	O
of	5	O
3	9	O
months	5	O
of	5	O
generic	5	O
HAART	5	O
between	5	O
February	2	O
1996	2	O
and	5	O
December	2	O
2006	2	O
at	9	O
a	5	O
tertiary	9	O
HIV	5	O
care	5	O
referral	5	O
center	5	O
in	5	O
South	4	O
India	2	O
.	9	O

The	5	O
most	9	O
common	5	O
regimens	5	O
were	9	O
3TC	0	B-Chemical
+	9	O
d4T	7	B-Chemical
+	9	O
nevirapine	5	B-Chemical
(	9	O
NVP	5	B-Chemical
)	9	O
(	9	O
54	7	O
.	9	O
8	9	O
%	9	O
)	9	O
,	9	O
zidovudine	5	B-Chemical
(	9	O
AZT	0	B-Chemical
)	9	O
+	9	O
3TC	0	B-Chemical
+	9	O
NVP	5	B-Chemical
(	9	O
14	7	O
.	9	O
5	9	O
%	9	O
)	9	O
,	9	O
3TC	0	B-Chemical
+	9	O
d4T	7	B-Chemical
+	9	O
efavirenz	0	B-Chemical
(	9	O
EFV	0	B-Chemical
)	9	O
(	9	O
20	9	O
.	9	O
1	9	O
%	9	O
)	9	O
,	9	O
and	5	O
AZT	0	B-Chemical
+	9	O
3TC	0	B-Chemical
+	9	O
EFV	0	B-Chemical
(	9	O
5	9	O
.	9	O
4	9	O
%	9	O
)	9	O
.	9	O

The	5	O
most	9	O
common	5	O
adverse	5	O
events	5	O
and	5	O
median	9	O
CD4	3	O
at	9	O
time	5	O
of	5	O
event	5	O
were	9	O
rash	5	B-Disease
(	9	O
15	9	O
.	9	O
2	9	O
%	9	O
;	9	O
CD4	3	O
,	9	O
285	7	O
cells	3	O
/	9	O
microL	0	O
)	9	O
and	5	O
peripheral	9	B-Disease
neuropathy	5	I-Disease
(	9	O
9	7	O
.	9	O
0	7	O
%	9	O
and	5	O
348	7	O
cells	3	O
/	9	O
microL	0	O
)	9	O
.	9	O

Clinically	5	O
significant	9	O
anemia	9	B-Disease
(	9	O
hemoglobin	0	O
<	0	O
7	9	O
g	0	O
/	9	O
dL	7	O
)	9	O
was	9	O
observed	9	O
in	5	O
5	9	O
.	9	O
4	9	O
%	9	O
of	5	O
patients	5	O
(	9	O
CD4	3	O
,	9	O
165	7	O
cells	3	O
/	9	O
microL	0	O
)	9	O
and	5	O
hepatitis	9	B-Disease
(	9	O
clinical	5	O
jaundice	5	B-Disease
with	5	O
alanine	1	B-Chemical
aminotransferase	7	O
>	0	O
5	9	O
times	5	O
upper	9	O
limits	5	O
of	5	O
normal	9	O
)	9	O
in	5	O
3	9	O
.	9	O
5	9	O
%	9	O
of	5	O
patients	5	O
(	9	O
CD4	3	O
,	9	O
260	9	O
cells	3	O
/	9	O
microL	0	O
)	9	O
.	9	O

Women	5	O
were	9	O
significantly	9	O
more	5	O
likely	5	O
to	5	O
experience	5	O
lactic	0	B-Disease
acidosis	5	I-Disease
,	9	O
while	9	O
men	5	O
were	9	O
significantly	9	O
more	5	O
likely	5	O
to	5	O
experience	5	O
immune	3	B-Disease
reconstitution	3	I-Disease
syndrome	5	I-Disease
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

Among	9	O
the	5	O
patients	5	O
with	5	O
1	9	O
year	5	O
of	5	O
follow	5	O
-	7	O
up	5	O
,	9	O
NVP	5	B-Chemical
therapy	5	O
was	9	O
significantly	9	O
associated	9	O
with	5	O
developing	5	O
rash	5	B-Disease
and	5	O
d4T	7	B-Chemical
therapy	5	O
with	5	O
developing	5	O
peripheral	9	B-Disease
neuropathy	5	I-Disease
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

Anemia	7	B-Disease
and	5	O
hepatitis	9	B-Disease
often	5	O
occur	5	O
within	9	O
12	9	O
weeks	9	O
of	5	O
initiating	9	O
generic	5	O
HAART	5	O
.	9	O

Frequent	5	O
and	5	O
early	9	O
monitoring	5	O
for	5	O
these	5	O
toxicities	5	B-Disease
is	5	O
warranted	9	O
in	5	O
developing	5	O
countries	5	O
where	5	O
generic	5	O
HAART	5	O
is	5	O
increasingly	5	O
available	5	O
.	9	O

Thalidomide	0	B-Chemical
and	5	O
sensory	5	B-Disease
neurotoxicity	9	I-Disease
:	9	O
a	5	O
neurophysiological	5	O
study	9	O
.	9	O

BACKGROUND	2	O
:	9	O
Recent	9	O
studies	9	O
confirmed	9	O
a	5	O
high	9	O
incidence	5	O
of	5	O
sensory	5	B-Disease
axonal	3	I-Disease
neuropathy	5	I-Disease
in	5	O
patients	5	O
treated	3	O
with	5	O
different	9	O
doses	0	O
of	5	O
thalidomide	0	B-Chemical
.	9	O

The	5	O
study	9	O
'	9	O
s	9	O
aims	5	O
were	9	O
to	5	O
measure	5	O
variations	5	O
in	5	O
sural	5	O
nerve	5	O
sensory	5	O
action	5	O
potential	9	O
(	9	O
SAP	9	O
)	9	O
amplitude	5	O
in	5	O
patients	5	O
with	5	O
refractory	9	O
cutaneous	5	B-Disease
lupus	9	I-Disease
erythematosus	9	I-Disease
(	9	O
CLE	9	B-Disease
)	9	O
treated	3	O
with	5	O
thalidomide	0	B-Chemical
and	5	O
use	5	O
these	5	O
findings	9	O
to	5	O
identify	9	O
the	5	O
neurotoxic	9	B-Disease
potential	9	O
of	5	O
thalidomide	0	B-Chemical
and	5	O
the	5	O
recovery	9	O
capacity	9	O
of	5	O
sensory	5	O
fibres	9	O
after	9	O
discontinuation	5	O
of	5	O
treatment	9	O
.	9	O

PATIENTS	2	O
AND	2	O
METHODS	2	O
:	9	O
Clinical	5	O
and	5	O
electrophysiological	5	O
data	5	O
in	5	O
12	9	O
female	9	O
patients	5	O
with	5	O
CLE	9	B-Disease
during	5	O
treatment	9	O
with	5	O
thalidomide	0	B-Chemical
and	5	O
up	5	O
to	5	O
47	7	O
months	5	O
after	9	O
discontinuation	5	O
of	5	O
treatment	9	O
were	9	O
analysed	9	O
.	9	O

Sural	7	O
nerve	5	O
SAP	9	O
amplitude	5	O
reduction	9	O
>	0	O
or	5	O
=	7	O
40	9	O
%	9	O
was	9	O
the	5	O
criteria	5	O
for	5	O
discontinuing	5	O
therapy	5	O
.	9	O

RESULTS	9	O
:	9	O
During	5	O
treatment	9	O
,	9	O
11	7	O
patients	5	O
showed	9	O
a	5	O
reduction	9	O
in	5	O
sural	5	O
nerve	5	O
SAP	9	O
amplitude	5	O
compared	9	O
to	5	O
baseline	5	O
values	5	O
(	9	O
9	7	O
with	5	O
a	5	O
reduction	9	O
>	0	O
or	5	O
=	7	O
50	0	O
%	9	O
and	5	O
2	9	O
<	0	O
50	0	O
%	9	O
)	9	O
.	9	O

One	5	O
patient	5	O
showed	9	O
no	9	O
changes	9	O
in	5	O
SAP	9	O
amplitude	5	O
.	9	O

Five	9	O
patients	5	O
complained	5	O
of	5	O
paresthesias	5	B-Disease
and	5	O
leg	5	O
cramps	5	B-Disease
.	9	O

After	9	O
thalidomide	0	B-Chemical
treatment	9	O
,	9	O
sural	5	O
SAP	9	O
amplitude	5	O
recovered	9	O
in	5	O
3	9	O
patients	5	O
.	9	O

At	9	O
detection	9	O
of	5	O
reduction	9	O
in	5	O
sural	5	O
nerve	5	O
SAP	9	O
amplitude	5	O
,	9	O
the	5	O
median	9	O
thalidomide	0	B-Chemical
cumulative	5	O
dose	9	O
was	9	O
21	7	O
.	9	O
4	9	O
g	0	O
.	9	O

The	5	O
threshold	5	O
neurotoxic	9	B-Disease
dosage	9	O
is	5	O
lower	9	O
than	5	O
previously	9	O
reported	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Sural	7	O
nerve	5	O
SAP	9	O
amplitude	5	O
reduction	9	O
is	5	O
a	5	O
reliable	5	O
and	5	O
sensitive	9	O
marker	3	O
of	5	O
degeneration	9	O
and	5	O
recovery	9	O
of	5	O
sensory	5	O
fibres	9	O
.	9	O

This	5	O
electrophysiological	5	O
parameter	5	O
provides	5	O
information	5	O
about	5	O
subclinical	5	O
neurotoxic	9	B-Disease
potential	9	O
of	5	O
thalidomide	0	B-Chemical
but	9	O
is	5	O
not	5	O
helpful	6	O
in	5	O
predicting	5	O
the	5	O
appearance	9	O
of	5	O
sensory	5	O
symptoms	5	O
.	9	O

Five	9	O
cases	5	O
of	5	O
encephalitis	5	B-Disease
during	5	O
treatment	9	O
of	5	O
loiasis	5	B-Disease
with	5	O
diethylcarbamazine	0	B-Chemical
.	9	O

Five	9	O
cases	5	O
of	5	O
encephalitis	5	B-Disease
following	9	O
treatment	9	O
with	5	O
diethylcarbamazine	0	B-Chemical
(	9	O
DEC	9	B-Chemical
)	9	O
were	9	O
observed	9	O
in	5	O
Congolese	5	O
patients	5	O
with	5	O
Loa	4	O
loa	4	O
filariasis	5	B-Disease
.	9	O

Two	9	O
cases	5	O
had	9	O
a	5	O
fatal	5	O
outcome	5	O
and	5	O
one	5	O
resulted	9	O
in	5	O
severe	5	O
sequelae	5	O
.	9	O

The	5	O
notable	9	O
fact	9	O
was	9	O
that	5	O
this	5	O
complication	5	O
occurred	9	O
in	5	O
three	9	O
patients	5	O
hospitalized	5	O
before	9	O
treatment	9	O
began	5	O
,	9	O
with	5	O
whom	5	O
particularly	5	O
strict	5	O
therapeutic	5	O
precautions	5	O
were	9	O
taken	5	O
,	9	O
i	9	O
.	9	O
e	9	O
.	9	O
,	9	O
initial	9	O
dose	9	O
less	5	O
than	5	O
10	9	O
mg	0	O
of	5	O
DEC	9	B-Chemical
,	9	O
very	5	O
gradual	9	O
dose	9	O
increases	9	O
,	9	O
and	5	O
associated	9	O
anti	3	O
-	7	O
allergic	9	O
treatment	9	O
.	9	O

This	5	O
type	9	O
of	5	O
drug	5	O
-	7	O
induced	3	O
complication	5	O
may	5	O
not	5	O
be	5	O
that	5	O
uncommon	5	O
in	5	O
highly	9	O
endemic	4	O
regions	9	O
.	9	O

It	5	O
occurs	9	O
primarily	9	O
,	9	O
but	9	O
not	5	O
exclusively	9	O
,	9	O
in	5	O
subjects	5	O
presenting	5	O
with	5	O
a	5	O
high	9	O
microfilarial	5	O
load	5	O
.	9	O

The	5	O
relationship	5	O
between	5	O
the	5	O
occurrence	5	O
of	5	O
encephalitis	5	B-Disease
and	5	O
the	5	O
decrease	9	O
in	5	O
microfilaremia	5	B-Disease
is	5	O
evident	9	O
.	9	O

The	5	O
pathophysiological	5	O
mechanisms	9	O
are	5	O
discussed	5	O
in	5	O
the	5	O
light	9	O
of	5	O
these	5	O
observations	9	O
and	5	O
the	5	O
few	5	O
other	5	O
comments	6	O
on	5	O
this	5	O
subject	5	O
published	9	O
in	5	O
the	5	O
literature	5	O
.	9	O

Amiodarone	7	B-Chemical
-	7	O
related	9	O
pulmonary	5	B-Disease
mass	9	I-Disease
and	5	O
unique	9	O
membranous	9	B-Disease
glomerulonephritis	3	I-Disease
in	5	O
a	5	O
patient	5	O
with	5	O
valvular	5	B-Disease
heart	5	I-Disease
disease	5	I-Disease
:	9	O
Diagnostic	5	O
pitfall	4	O
and	5	O
new	5	O
findings	9	O
.	9	O

Amiodarone	7	B-Chemical
is	5	O
an	5	O
anti	3	O
-	7	O
arrhythmic	5	B-Disease
drug	5	O
for	5	O
life	5	O
-	7	O
threatening	5	O
tachycardia	5	B-Disease
,	9	O
but	9	O
various	9	O
adverse	5	O
effects	9	O
have	5	O
been	9	O
reported	9	O
.	9	O

Reported	5	O
herein	9	O
is	5	O
an	5	O
autopsy	5	O
case	5	O
of	5	O
valvular	5	B-Disease
heart	5	I-Disease
disease	5	I-Disease
,	9	O
in	5	O
a	5	O
patient	5	O
who	5	O
developed	5	O
a	5	O
lung	9	B-Disease
mass	9	I-Disease
(	9	O
1	9	O
.	9	O
5	9	O
cm	9	O
in	5	O
diameter	9	O
)	9	O
and	5	O
proteinuria	9	B-Disease
(	9	O
2	9	O
.	9	O
76	7	O
g	0	O
/	9	O
day	9	O
)	9	O
after	9	O
treatment	9	O
with	5	O
amiodarone	0	B-Chemical
for	5	O
a	5	O
long	5	O
time	5	O
.	9	O

The	5	O
lung	9	B-Disease
mass	9	I-Disease
was	9	O
highly	9	O
suspected	5	O
to	5	O
be	5	O
lung	9	B-Disease
cancer	3	I-Disease
on	5	O
CT	9	O
and	5	O
positron	5	O
emission	0	O
tomography	5	O
,	9	O
but	9	O
histologically	9	O
the	5	O
lesion	5	O
was	9	O
composed	9	O
of	5	O
lymphoplasmacytic	5	O
infiltrates	9	O
in	5	O
alveolar	3	O
walls	5	O
and	5	O
intra	5	O
-	7	O
alveolar	3	O
accumulation	9	O
of	5	O
foamy	3	O
macrophages	3	O
containing	0	O
characteristic	9	O
myelinoid	0	O
bodies	9	O
,	9	O
indicating	9	O
that	5	O
it	5	O
was	9	O
an	5	O
amiodarone	0	B-Chemical
-	7	O
related	9	O
lesion	5	O
.	9	O

In	9	O
addition	9	O
,	9	O
the	5	O
lung	9	O
tissue	9	O
had	9	O
unevenly	5	O
distributed	5	O
hemosiderin	5	B-Disease
deposition	9	O
,	9	O
and	5	O
abnormally	9	O
tortuous	5	O
capillaries	5	O
were	9	O
seen	9	O
in	5	O
the	5	O
mass	9	O
and	5	O
in	5	O
heavily	5	O
hemosiderotic	5	B-Disease
lung	9	O
portions	9	O
outside	5	O
the	5	O
mass	9	O
.	9	O

In	9	O
the	5	O
kidneys	9	O
,	9	O
glomeruli	9	O
had	9	O
membrane	9	O
spikes	5	O
,	9	O
prominent	9	O
swelling	5	O
of	5	O
podocytes	3	O
and	5	O
subepithelial	5	O
deposits	9	O
,	9	O
which	5	O
were	9	O
sometimes	5	O
large	5	O
and	5	O
hump	5	O
-	7	O
like	9	O
.	9	O

Autoimmune	9	B-Disease
diseases	5	I-Disease
,	9	O
viral	9	B-Disease
hepatitis	9	I-Disease
,	9	O
malignant	3	O
neoplasms	5	B-Disease
or	5	O
other	5	O
diseases	5	O
with	5	O
a	5	O
known	9	O
relationship	5	O
to	5	O
membranous	9	B-Disease
glomerulonephritis	3	I-Disease
were	9	O
not	5	O
found	9	O
.	9	O

The	5	O
present	9	O
case	5	O
highlights	5	O
the	5	O
possibility	9	O
that	5	O
differential	9	O
diagnosis	5	O
between	5	O
an	5	O
amiodarone	0	B-Chemical
-	7	O
related	9	O
pulmonary	5	B-Disease
lesion	5	I-Disease
and	5	O
a	5	O
neoplasm	5	B-Disease
can	5	O
be	5	O
very	5	O
difficult	5	O
radiologically	5	O
,	9	O
and	5	O
suggests	9	O
that	5	O
membranous	9	B-Disease
glomerulonephritis	3	I-Disease
might	9	O
be	5	O
another	9	O
possible	5	O
complication	5	O
of	5	O
amiodarone	0	B-Chemical
treatment	9	O
.	9	O

Risk	5	O
of	5	O
coronary	5	B-Disease
artery	5	I-Disease
disease	5	I-Disease
associated	9	O
with	5	O
initial	9	O
sulphonylurea	0	B-Chemical
treatment	9	O
of	5	O
patients	5	O
with	5	O
type	9	B-Disease
2	9	I-Disease
diabetes	5	I-Disease
:	9	O
a	5	O
matched	9	O
case	5	O
-	7	O
control	9	O
study	9	O
.	9	O

AIMS	5	O
:	9	O
This	5	O
study	9	O
sought	9	O
to	5	O
assess	5	O
the	5	O
risk	5	O
of	5	O
developing	5	O
coronary	5	B-Disease
artery	5	I-Disease
disease	5	I-Disease
(	9	O
CAD	5	B-Disease
)	9	O
associated	9	O
with	5	O
initial	9	O
treatment	9	O
of	5	O
type	9	B-Disease
2	9	I-Disease
diabetes	5	I-Disease
with	5	O
different	9	O
sulphonylureas	5	B-Chemical
.	9	O

METHODS	2	O
:	9	O
In	9	O
type	9	B-Disease
2	9	I-Disease
diabetic	9	I-Disease
patients	5	O
,	9	O
cases	5	O
who	5	O
developed	5	O
CAD	5	B-Disease
were	9	O
compared	9	O
retrospectively	5	O
with	5	O
controls	9	O
that	5	O
did	9	O
not	5	O
.	9	O

The	5	O
20	9	O
-	7	O
year	5	O
risk	5	O
of	5	O
CAD	5	B-Disease
at	9	O
diagnosis	5	O
of	5	O
diabetes	5	B-Disease
,	9	O
using	9	O
the	5	O
UKPDS	5	O
risk	5	O
engine	5	O
,	9	O
was	9	O
used	5	O
to	5	O
match	5	O
cases	5	O
with	5	O
controls	9	O
.	9	O

RESULTS	9	O
:	9	O
The	5	O
76	7	O
cases	5	O
of	5	O
CAD	5	B-Disease
were	9	O
compared	9	O
with	5	O
152	7	O
controls	9	O
.	9	O

The	5	O
hazard	5	O
of	5	O
developing	5	O
CAD	5	B-Disease
(	9	O
95	7	O
%	9	O
CI	7	O
)	9	O
associated	9	O
with	5	O
initial	9	O
treatment	9	O
increased	9	O
by	9	O
2	9	O
.	9	O
4	9	O
-	7	O
fold	9	O
(	9	O
1	9	O
.	9	O
3	9	O
-	7	O
4	9	O
.	9	O
3	9	O
,	9	O
P	9	O
=	7	O
0	7	O
.	9	O
004	7	O
)	9	O
with	5	O
glibenclamide	0	B-Chemical
;	9	O
2	9	O
-	7	O
fold	9	O
(	9	O
0	7	O
.	9	O
9	7	O
-	7	O
4	9	O
.	9	O
6	9	O
,	9	O
P	9	O
=	7	O
0	7	O
.	9	O
099	7	O
)	9	O
with	5	O
glipizide	0	B-Chemical
;	9	O
2	9	O
.	9	O
9	7	O
-	7	O
fold	9	O
(	9	O
1	9	O
.	9	O
6	9	O
-	7	O
5	9	O
.	9	O
1	9	O
,	9	O
P	9	O
=	7	O
0	7	O
.	9	O
000	9	O
)	9	O
with	5	O
either	9	O
,	9	O
and	5	O
was	9	O
unchanged	9	O
with	5	O
metformin	3	B-Chemical
.	9	O

The	5	O
hazard	5	O
decreased	9	O
0	7	O
.	9	O
3	9	O
-	7	O
fold	9	O
(	9	O
0	7	O
.	9	O
7	9	O
-	7	O
1	9	O
.	9	O
7	9	O
,	9	O
P	9	O
=	7	O
0	7	O
.	9	O
385	7	O
)	9	O
with	5	O
glimepiride	0	B-Chemical
,	9	O
0	7	O
.	9	O
4	9	O
-	7	O
fold	9	O
(	9	O
0	7	O
.	9	O
7	9	O
-	7	O
1	9	O
.	9	O
3	9	O
,	9	O
P	9	O
=	7	O
0	7	O
.	9	O
192	9	O
)	9	O
with	5	O
gliclazide	0	B-Chemical
,	9	O
and	5	O
0	7	O
.	9	O
4	9	O
-	7	O
fold	9	O
(	9	O
0	7	O
.	9	O
7	9	O
-	7	O
1	9	O
.	9	O
1	9	O
,	9	O
P	9	O
=	7	O
0	7	O
.	9	O
09	7	O
)	9	O
with	5	O
either	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Initiating	5	O
treatment	9	O
of	5	O
type	9	B-Disease
2	9	I-Disease
diabetes	5	I-Disease
with	5	O
glibenclamide	0	B-Chemical
or	5	O
glipizide	0	B-Chemical
is	5	O
associated	9	O
with	5	O
increased	9	O
risk	5	O
of	5	O
CAD	5	B-Disease
in	5	O
comparison	9	O
to	5	O
gliclazide	0	B-Chemical
or	5	O
glimepiride	0	B-Chemical
.	9	O

If	5	O
confirmed	9	O
,	9	O
this	5	O
may	5	O
be	5	O
important	9	O
because	5	O
most	9	O
Indian	4	O
patients	5	O
receive	5	O
the	5	O
cheaper	5	O
older	5	O
sulphonylureas	5	B-Chemical
,	9	O
and	5	O
present	9	O
guidelines	5	O
do	5	O
not	5	O
distinguish	9	O
between	5	O
individual	5	O
agents	5	O
.	9	O

Reduced	9	O
progression	9	O
of	5	O
adriamycin	3	B-Chemical
nephropathy	9	B-Disease
in	5	O
spontaneously	5	O
hypertensive	5	B-Disease
rats	9	O
treated	3	O
by	9	O
losartan	0	B-Chemical
.	9	O

BACKGROUND	2	O
:	9	O
The	5	O
aim	5	O
of	5	O
the	5	O
study	9	O
was	9	O
to	5	O
investigate	9	O
the	5	O
antihypertensive	5	O
effects	9	O
of	5	O
angiotensin	9	B-Chemical
II	9	I-Chemical
type	9	O
-	7	O
1	9	O
receptor	3	O
blocker	0	O
,	9	O
losartan	0	B-Chemical
,	9	O
and	5	O
its	9	O
potential	9	O
in	5	O
slowing	5	O
down	9	O
renal	9	B-Disease
disease	5	I-Disease
progression	9	O
in	5	O
spontaneously	5	O
hypertensive	5	B-Disease
rats	9	O
(	9	O
SHR	9	O
)	9	O
with	5	O
adriamycin	3	B-Chemical
(	9	O
ADR	9	B-Chemical
)	9	O
nephropathy	9	B-Disease
.	9	O

METHODS	2	O
:	9	O
Six	9	O
-	7	O
month	5	O
-	7	O
old	5	O
female	9	O
SHR	9	O
were	9	O
randomly	5	O
selected	9	O
in	5	O
six	9	O
groups	9	O
.	9	O

Two	9	O
control	9	O
groups	9	O
(	9	O
SH	9	O
(	9	O
6	9	O
)	9	O
,	9	O
SH	9	O
(	9	O
12	9	O
)	9	O
)	9	O
received	9	O
vehicle	3	O
.	9	O

Groups	9	O
ADR	9	B-Chemical
(	9	O
6	9	O
)	9	O
,	9	O
ADR	9	B-Chemical
+	9	O
LOS	9	B-Chemical
(	9	O
6	9	O
)	9	O
and	5	O
ADR	9	B-Chemical
(	9	O
12	9	O
)	9	O
,	9	O
and	5	O
ADR	9	B-Chemical
+	9	O
LOS	9	B-Chemical
(	9	O
12	9	O
)	9	O
received	9	O
ADR	9	B-Chemical
(	9	O
2	9	O
mg	0	O
/	9	O
kg	0	O
/	9	O
b	9	O
.	9	O
w	0	O
.	9	O
i	9	O
.	9	O
v	0	O
.	9	O
)	9	O
twice	9	O
in	5	O
a	5	O
3	9	O
-	7	O
week	9	O
interval	5	O
.	9	O

Group	9	O
ADR	9	B-Chemical
+	9	O
LOS	9	B-Chemical
(	9	O
6	9	O
)	9	O
received	9	O
losartan	0	B-Chemical
(	9	O
10	9	O
mg	0	O
/	9	O
kg	0	O
/	9	O
b	9	O
.	9	O
w	0	O
.	9	O
/	9	O
day	9	O
by	9	O
gavages	0	O
)	9	O
for	5	O
6	9	O
weeks	9	O
and	5	O
group	9	O
ADR	9	B-Chemical
+	9	O
LOS	9	B-Chemical
(	9	O
12	9	O
)	9	O
for	5	O
12	9	O
weeks	9	O
after	9	O
second	9	O
injection	9	O
of	5	O
ADR	9	B-Chemical
.	9	O

Animals	9	O
were	9	O
killed	9	O
after	9	O
6	9	O
or	5	O
12	9	O
weeks	9	O
,	9	O
respectively	9	O
.	9	O

Haemodynamic	5	O
measurements	5	O
were	9	O
performed	9	O
on	5	O
anaesthetized	0	O
animals	9	O
,	9	O
blood	9	O
and	5	O
urine	9	O
samples	9	O
were	9	O
taken	5	O
for	5	O
biochemical	9	O
analysis	9	O
and	5	O
the	5	O
left	5	O
kidney	9	O
was	9	O
processed	9	O
for	5	O
morphological	9	O
studies	9	O
.	9	O

RESULTS	9	O
:	9	O
Short	5	O
-	7	O
term	5	O
losartan	0	B-Chemical
treatment	9	O
,	9	O
besides	9	O
antihypertensive	5	O
effect	9	O
,	9	O
improved	5	O
glomerular	5	O
filtration	0	O
rate	9	O
and	5	O
ameliorated	9	O
glomerulosclerosis	3	B-Disease
resulting	9	O
in	5	O
decreased	9	O
proteinuria	9	B-Disease
.	9	O

Prolonged	9	O
treatment	9	O
with	5	O
losartan	0	B-Chemical
showed	9	O
further	9	O
reduction	9	O
of	5	O
glomerulosclerosis	3	B-Disease
associated	9	O
with	5	O
reduced	9	O
progression	9	O
of	5	O
tubular	9	O
atrophy	5	B-Disease
and	5	O
interstitial	9	B-Disease
fibrosis	9	I-Disease
,	9	O
thus	9	O
preventing	9	O
heavy	9	O
proteinuria	9	B-Disease
and	5	O
chronic	5	B-Disease
renal	9	I-Disease
failure	5	I-Disease
.	9	O

Losartan	0	B-Chemical
reduced	9	O
uraemia	5	B-Disease
and	5	O
increased	9	O
urea	0	B-Chemical
clearance	9	O
in	5	O
advanced	5	O
ADR	9	B-Chemical
nephropathy	9	B-Disease
in	5	O
SHR	9	O
.	9	O

Histological	9	O
examination	5	O
showed	9	O
that	5	O
losartan	0	B-Chemical
could	9	O
prevent	5	O
tubular	9	O
atrophy	5	B-Disease
,	9	O
interstitial	9	O
infiltration	3	O
and	5	O
fibrosis	9	B-Disease
in	5	O
ADR	9	B-Chemical
nephropathy	9	B-Disease
.	9	O

CONCLUSION	5	O
:	9	O
Losartan	0	B-Chemical
reduces	9	O
the	5	O
rate	9	O
of	5	O
progression	9	O
of	5	O
ADR	9	B-Chemical
-	7	O
induced	3	O
focal	5	B-Disease
segmental	5	I-Disease
glomerulosclerosis	3	I-Disease
to	5	O
end	9	B-Disease
-	7	I-Disease
stage	9	I-Disease
renal	9	I-Disease
disease	5	I-Disease
in	5	O
SHR	9	O
.	9	O

The	5	O
risks	5	O
of	5	O
aprotinin	0	O
and	5	O
tranexamic	0	B-Chemical
acid	0	I-Chemical
in	5	O
cardiac	5	O
surgery	5	O
:	9	O
a	5	O
one	5	O
-	7	O
year	5	O
follow	5	O
-	7	O
up	5	O
of	5	O
1188	7	O
consecutive	5	O
patients	5	O
.	9	O

BACKGROUND	2	O
:	9	O
Our	9	O
aim	5	O
was	9	O
to	5	O
investigate	9	O
postoperative	5	O
complications	5	O
and	5	O
mortality	5	O
after	9	O
administration	9	O
of	5	O
aprotinin	0	O
compared	9	O
to	5	O
tranexamic	0	B-Chemical
acid	0	I-Chemical
in	5	O
an	5	O
unselected	9	O
,	9	O
consecutive	5	O
cohort	9	O
.	9	O

METHODS	2	O
:	9	O
Perioperative	5	O
data	5	O
from	9	O
consecutive	5	O
cardiac	5	O
surgery	5	O
patients	5	O
were	9	O
prospectively	5	O
collected	9	O
between	5	O
September	2	O
2005	2	O
and	5	O
June	2	O
2006	2	O
in	5	O
a	5	O
university	5	O
-	7	O
affiliated	2	O
clinic	5	O
(	9	O
n	9	O
=	7	O
1188	7	O
)	9	O
.	9	O

During	5	O
the	5	O
first	9	O
5	9	O
mo	9	O
,	9	O
596	7	O
patients	5	O
received	9	O
aprotinin	0	O
(	9	O
Group	9	O
A	9	O
)	9	O
;	9	O
in	5	O
the	5	O
next	9	O
5	9	O
mo	9	O
,	9	O
592	7	O
patients	5	O
were	9	O
treated	3	O
with	5	O
tranexamic	0	B-Chemical
acid	0	I-Chemical
(	9	O
Group	9	O
T	3	O
)	9	O
.	9	O

Except	9	O
for	5	O
antifibrinolytic	5	O
therapy	5	O
,	9	O
the	5	O
anesthetic	5	O
and	5	O
surgical	5	O
protocols	5	O
remained	9	O
unchanged	9	O
.	9	O

RESULTS	9	O
:	9	O
The	5	O
pre	9	O
-	7	O
and	5	O
intraoperative	5	O
variables	5	O
were	9	O
comparable	9	O
between	5	O
the	5	O
treatment	9	O
groups	9	O
.	9	O

Postoperatively	5	O
,	9	O
a	5	O
significantly	9	O
higher	9	O
incidence	5	O
of	5	O
seizures	5	B-Disease
was	9	O
found	9	O
in	5	O
Group	9	O
T	3	O
(	9	O
4	9	O
.	9	O
6	9	O
%	9	O
vs	7	O
1	9	O
.	9	O
2	9	O
%	9	O
,	9	O
P	9	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
.	9	O

This	5	O
difference	9	O
was	9	O
also	9	O
significant	9	O
in	5	O
the	5	O
primary	9	O
valve	5	O
surgery	5	O
and	5	O
the	5	O
high	9	O
risk	5	O
surgery	5	O
subgroups	9	O
(	9	O
7	9	O
.	9	O
9	7	O
%	9	O
vs	7	O
1	9	O
.	9	O
2	9	O
%	9	O
,	9	O
P	9	O
=	7	O
0	7	O
.	9	O
003	2	O
;	9	O
7	9	O
.	9	O
3	9	O
%	9	O
vs	7	O
2	9	O
.	9	O
4	9	O
%	9	O
,	9	O
P	9	O
=	7	O
0	7	O
.	9	O
035	7	O
,	9	O
respectively	9	O
)	9	O
.	9	O

Persistent	9	O
atrial	5	O
fibrillation	5	O
(	9	O
7	9	O
.	9	O
9	7	O
%	9	O
vs	7	O
2	9	O
.	9	O
3	9	O
%	9	O
,	9	O
P	9	O
=	7	O
0	7	O
.	9	O
020	2	O
)	9	O
and	5	O
renal	9	B-Disease
failure	5	I-Disease
(	9	O
9	7	O
.	9	O
7	9	O
%	9	O
vs	7	O
1	9	O
.	9	O
7	9	O
%	9	O
,	9	O
P	9	O
=	7	O
0	7	O
.	9	O
002	7	O
)	9	O
were	9	O
also	9	O
more	5	O
common	5	O
in	5	O
Group	9	O
T	3	O
,	9	O
in	5	O
the	5	O
primary	9	O
valve	5	O
surgery	5	O
subgroup	9	O
.	9	O

On	5	O
the	5	O
contrary	9	O
,	9	O
among	5	O
primary	9	O
coronary	5	O
artery	5	O
bypass	5	O
surgery	5	O
patients	5	O
,	9	O
there	5	O
were	9	O
more	5	O
acute	9	O
myocardial	9	B-Disease
infarctions	5	I-Disease
and	5	O
renal	9	B-Disease
dysfunction	9	I-Disease
in	5	O
Group	9	O
A	9	O
(	9	O
5	9	O
.	9	O
8	9	O
%	9	O
vs	7	O
2	9	O
.	9	O
0	7	O
%	9	O
,	9	O
P	9	O
=	7	O
0	7	O
.	9	O
027	9	O
;	9	O
22	7	O
.	9	O
5	9	O
%	9	O
vs	7	O
15	9	O
.	9	O
2	9	O
%	9	O
,	9	O
P	9	O
=	7	O
0	7	O
.	9	O
036	7	O
,	9	O
respectively	9	O
)	9	O
.	9	O

The	5	O
1	9	O
-	7	O
yr	7	O
mortality	5	O
was	9	O
significantly	9	O
higher	9	O
after	9	O
aprotinin	0	O
treatment	9	O
in	5	O
the	5	O
high	9	O
risk	5	O
surgery	5	O
group	9	O
(	9	O
17	7	O
.	9	O
7	9	O
%	9	O
vs	7	O
9	7	O
.	9	O
8	9	O
%	9	O
,	9	O
P	9	O
=	7	O
0	7	O
.	9	O
034	7	O
)	9	O
.	9	O

CONCLUSION	5	O
:	9	O
Both	9	O
antifibrinolytic	5	O
drugs	5	O
bear	9	O
the	5	O
risk	5	O
of	5	O
adverse	5	O
outcome	5	O
depending	5	O
on	5	O
the	5	O
type	9	O
of	5	O
cardiac	5	O
surgery	5	O
.	9	O

Administration	2	O
of	5	O
aprotinin	0	O
should	5	O
be	5	O
avoided	5	O
in	5	O
coronary	5	O
artery	5	O
bypass	5	O
graft	5	O
and	5	O
high	9	O
risk	5	O
patients	5	O
,	9	O
whereas	9	O
administration	9	O
of	5	O
tranexamic	0	B-Chemical
acid	0	I-Chemical
is	5	O
not	5	O
recommended	5	O
in	5	O
valve	5	O
surgery	5	O
.	9	O

Delirium	5	B-Disease
in	5	O
an	5	O
elderly	5	O
woman	5	O
possibly	9	O
associated	9	O
with	5	O
administration	9	O
of	5	O
misoprostol	5	B-Chemical
.	9	O

Misoprostol	5	B-Chemical
has	9	O
been	9	O
associated	9	O
with	5	O
adverse	5	O
reactions	9	O
,	9	O
including	9	O
gastrointestinal	9	O
symptoms	5	O
,	9	O
gynecologic	5	O
problems	5	O
,	9	O
and	5	O
headache	5	B-Disease
.	9	O

Changes	9	O
in	5	O
mental	5	O
status	9	O
,	9	O
however	9	O
,	9	O
have	5	O
not	5	O
been	9	O
reported	9	O
.	9	O

We	9	O
present	9	O
a	5	O
case	5	O
in	5	O
which	5	O
an	5	O
89	7	O
-	7	O
year	5	O
-	7	O
old	5	O
woman	5	O
in	5	O
a	5	O
long	5	O
-	7	O
term	5	O
care	5	O
facility	5	O
became	9	O
confused	4	O
after	9	O
the	5	O
initiation	9	O
of	5	O
misoprostol	5	B-Chemical
therapy	5	O
.	9	O

The	5	O
patient	5	O
'	9	O
s	9	O
change	9	O
in	5	O
mental	5	O
status	9	O
was	9	O
first	9	O
reported	9	O
nine	9	O
days	9	O
after	9	O
the	5	O
initiation	9	O
of	5	O
therapy	5	O
.	9	O

Her	5	O
delirium	5	B-Disease
significantly	9	O
improved	5	O
after	9	O
misoprostol	5	B-Chemical
was	9	O
discontinued	5	O
and	5	O
her	5	O
mental	5	O
status	9	O
returned	5	O
to	5	O
normal	9	O
within	9	O
a	5	O
week	9	O
.	9	O

Because	9	O
no	9	O
other	5	O
factors	9	O
related	9	O
to	5	O
this	5	O
patient	5	O
changed	9	O
significantly	9	O
,	9	O
the	5	O
delirium	5	B-Disease
experienced	5	O
by	9	O
this	5	O
patient	5	O
possibly	9	O
resulted	9	O
from	9	O
misoprostol	5	B-Chemical
therapy	5	O
.	9	O

The	5	O
biological	5	O
properties	9	O
of	5	O
the	5	O
optical	5	O
isomers	0	O
of	5	O
propranolol	0	B-Chemical
and	5	O
their	5	O
effects	9	O
on	5	O
cardiac	5	B-Disease
arrhythmias	5	I-Disease
.	9	O

1	9	O
.	9	O

The	5	O
optical	5	O
isomers	0	O
of	5	O
propranolol	0	B-Chemical
have	5	O
been	9	O
compared	9	O
for	5	O
their	5	O
beta	9	O
-	7	O
blocking	3	O
and	5	O
antiarrhythmic	5	O
activities	9	O
.	9	O
2	9	O
.	9	O

In	9	O
blocking	3	O
the	5	O
positive	9	O
inotropic	5	O
and	5	O
chronotropic	5	O
responses	5	O
to	5	O
isoprenaline	0	B-Chemical
,	9	O
(	9	O
+	9	O
)	9	O
-	7	O
propranolol	0	B-Chemical
had	9	O
less	5	O
than	5	O
one	5	O
hundredth	5	O
the	5	O
potency	9	O
of	5	O
(	9	O
-	7	O
)	9	O
-	7	O
propranolol	0	B-Chemical
.	9	O

At	9	O
dose	9	O
levels	3	O
of	5	O
(	9	O
+	9	O
)	9	O
-	7	O
propranolol	0	B-Chemical
which	5	O
attenuated	3	O
the	5	O
responses	5	O
to	5	O
isoprenaline	0	B-Chemical
,	9	O
there	5	O
was	9	O
a	5	O
significant	9	O
prolongation	9	O
of	5	O
the	5	O
PR	9	O
interval	5	O
of	5	O
the	5	O
electrocardiogram	5	O
.	9	O
3	9	O
.	9	O

The	5	O
metabolic	9	O
responses	5	O
to	5	O
isoprenaline	0	B-Chemical
in	5	O
dogs	5	O
(	9	O
an	5	O
increase	9	O
in	5	O
circulating	9	O
glucose	0	B-Chemical
,	9	O
lactate	0	B-Chemical
and	5	O
free	9	O
fatty	0	B-Chemical
acids	0	I-Chemical
)	9	O
were	9	O
all	5	O
blocked	3	O
by	9	O
(	9	O
-	7	O
)	9	O
-	7	O
propranolol	0	B-Chemical
.	9	O

(	9	O
+	9	O
)	9	O
-	7	O
Propranolol	0	B-Chemical
had	9	O
no	9	O
effect	9	O
on	5	O
fatty	0	B-Chemical
acid	0	I-Chemical
mobilization	9	O
but	9	O
significantly	9	O
reduced	9	O
the	5	O
increments	9	O
in	5	O
both	9	O
lactate	0	B-Chemical
and	5	O
glucose	0	B-Chemical
.	9	O
4	9	O
.	9	O

Both	9	O
isomers	0	O
of	5	O
propranolol	0	B-Chemical
possessed	9	O
similar	9	O
depressant	5	O
potency	9	O
on	5	O
isolated	9	O
atrial	5	O
muscle	9	O
taken	5	O
from	9	O
guinea	9	O
-	7	O
pigs	9	O
.	9	O
5	9	O
.	9	O

The	5	O
isomers	0	O
of	5	O
propranolol	0	B-Chemical
exhibited	9	O
similar	9	O
local	5	O
anaesthetic	5	O
potencies	0	O
on	5	O
an	5	O
isolated	9	O
frog	9	O
nerve	5	O
preparation	9	O
at	9	O
a	5	O
level	9	O
approximately	9	O
three	9	O
times	5	O
that	5	O
of	5	O
procaine	0	B-Chemical
.	9	O

The	5	O
racemic	0	O
compound	0	O
was	9	O
significantly	9	O
less	5	O
potent	3	O
than	5	O
either	9	O
isomer	0	O
.	9	O
6	9	O
.	9	O

Both	9	O
isomers	0	O
of	5	O
propranolol	0	B-Chemical
were	9	O
capable	9	O
of	5	O
preventing	9	O
adrenaline	0	B-Chemical
-	7	O
induced	3	O
cardiac	5	B-Disease
arrhythmias	5	I-Disease
in	5	O
cats	9	O
anaesthetized	0	O
with	5	O
halothane	0	B-Chemical
,	9	O
but	9	O
the	5	O
mean	5	O
dose	9	O
of	5	O
(	9	O
-	7	O
)	9	O
-	7	O
propranolol	0	B-Chemical
was	9	O
0	7	O
.	9	O
09	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
02	7	O
mg	0	O
/	9	O
kg	0	O
whereas	9	O
that	5	O
of	5	O
(	9	O
+	9	O
)	9	O
-	7	O
propranolol	0	B-Chemical
was	9	O
4	9	O
.	9	O
2	9	O
+	9	O
/	9	O
-	7	O
1	9	O
.	9	O
2	9	O
mg	0	O
/	9	O
kg	0	O
.	9	O

At	9	O
the	5	O
effective	5	O
dose	9	O
level	9	O
of	5	O
(	9	O
+	9	O
)	9	O
-	7	O
propranolol	0	B-Chemical
there	5	O
was	9	O
a	5	O
significant	9	O
prolongation	9	O
of	5	O
the	5	O
PR	9	O
interval	5	O
of	5	O
the	5	O
electrocardiogram	5	O
.	9	O

Blockade	3	O
of	5	O
arrhythmias	5	B-Disease
with	5	O
both	9	O
isomers	0	O
was	9	O
surmountable	5	O
by	9	O
increasing	9	O
the	5	O
dose	9	O
of	5	O
adrenaline	0	B-Chemical
.	9	O
7	9	O
.	9	O

Both	9	O
isomers	0	O
of	5	O
propranolol	0	B-Chemical
were	9	O
also	9	O
capable	9	O
of	5	O
reversing	5	O
ventricular	5	B-Disease
tachycardia	5	I-Disease
caused	9	O
by	9	O
ouabain	0	B-Chemical
in	5	O
anaesthetized	0	O
cats	9	O
and	5	O
dogs	5	O
.	9	O

The	5	O
dose	9	O
of	5	O
(	9	O
-	7	O
)	9	O
-	7	O
propranolol	0	B-Chemical
was	9	O
significantly	9	O
smaller	5	O
than	5	O
that	5	O
of	5	O
(	9	O
+	9	O
)	9	O
-	7	O
propranolol	0	B-Chemical
in	5	O
both	9	O
species	4	O
but	9	O
much	5	O
higher	9	O
than	5	O
that	5	O
required	9	O
to	5	O
produce	9	O
evidence	9	O
of	5	O
beta	9	O
-	7	O
blockade	3	O
.	9	O
8	9	O
.	9	O

The	5	O
implications	5	O
of	5	O
these	5	O
results	9	O
are	5	O
discussed	5	O
.	9	O

Topotecan	0	B-Chemical
in	5	O
combination	9	O
with	5	O
radiotherapy	5	O
in	5	O
unresectable	5	O
glioblastoma	3	B-Disease
:	9	O
a	5	O
phase	5	O
2	9	O
study	9	O
.	9	O

Improving	5	O
glioblastoma	3	B-Disease
multiforme	9	I-Disease
(	9	O
GBM	9	B-Disease
)	9	O
treatment	9	O
with	5	O
radio	5	O
-	7	O
chemotherapy	5	O
remains	9	O
a	5	O
challenge	9	O
.	9	O

Topotecan	0	B-Chemical
is	5	O
an	5	O
attractive	5	O
option	5	O
as	5	O
it	5	O
exhibits	9	O
growth	3	O
inhibition	3	O
of	5	O
human	3	O
glioma	3	B-Disease
as	5	O
well	9	O
as	5	O
brain	5	O
penetration	5	O
.	9	O

The	5	O
present	9	O
study	9	O
assessed	9	O
the	5	O
combination	9	O
of	5	O
radiotherapy	5	O
(	9	O
60	9	O
Gy	9	O
/	9	O
30	9	O
fractions	0	O
/	9	O
40	9	O
days	9	O
)	9	O
and	5	O
topotecan	0	B-Chemical
(	9	O
0	7	O
.	9	O
9	7	O
mg	0	O
/	9	O
m	9	O
(	9	O
2	9	O
)	9	O
/	9	O
day	9	O
on	5	O
days	9	O
1	9	O
-	7	O
5	9	O
on	5	O
weeks	9	O
1	9	O
,	9	O
3	9	O
and	5	O
5	9	O
)	9	O
in	5	O
50	0	O
adults	5	O
with	5	O
histologically	9	O
proven	5	O
and	5	O
untreated	3	O
GBM	9	B-Disease
.	9	O

The	5	O
incidence	5	O
of	5	O
non	9	O
-	7	O
hematological	9	O
toxicities	5	B-Disease
was	9	O
low	9	O
and	5	O
grade	9	O
3	9	O
-	7	O
4	9	O
hematological	9	O
toxicities	5	B-Disease
were	9	O
reported	9	O
in	5	O
20	9	O
patients	5	O
(	9	O
mainly	9	O
lymphopenia	3	B-Disease
and	5	O
neutropenia	5	B-Disease
)	9	O
.	9	O

Partial	9	O
response	9	O
and	5	O
stabilization	9	O
rates	5	O
were	9	O
2	9	O
%	9	O
and	5	O
32	7	O
%	9	O
,	9	O
respectively	9	O
,	9	O
with	5	O
an	5	O
overall	5	O
time	5	O
to	5	O
progression	9	O
of	5	O
12	9	O
weeks	9	O
.	9	O

One	5	O
-	7	O
year	5	O
overall	5	O
survival	9	O
(	9	O
OS	9	O
)	9	O
rate	9	O
was	9	O
42	7	O
%	9	O
,	9	O
with	5	O
a	5	O
median	9	O
OS	9	O
of	5	O
40	9	O
weeks	9	O
.	9	O

Topotecan	0	B-Chemical
in	5	O
combination	9	O
with	5	O
radiotherapy	5	O
was	9	O
well	9	O
tolerated	9	O
.	9	O

However	9	O
,	9	O
while	9	O
response	9	O
and	5	O
stabilization	9	O
concerned	5	O
one	5	O
-	7	O
third	9	O
of	5	O
the	5	O
patients	5	O
,	9	O
the	5	O
study	9	O
did	9	O
not	5	O
show	9	O
increased	9	O
benefits	5	O
in	5	O
terms	5	O
of	5	O
survival	9	O
in	5	O
patients	5	O
with	5	O
unresectable	5	O
GBM	9	B-Disease
.	9	O

Long	9	O
-	7	O
term	5	O
lithium	0	B-Chemical
therapy	5	O
leading	9	O
to	5	O
hyperparathyroidism	5	B-Disease
:	9	O
a	5	O
case	5	O
report	5	O
.	9	O

PURPOSE	2	O
:	9	O
This	5	O
paper	5	O
reviews	5	O
the	5	O
effect	9	O
of	5	O
chronic	5	O
lithium	0	B-Chemical
therapy	5	O
on	5	O
serum	9	O
calcium	0	B-Chemical
level	9	O
and	5	O
parathyroid	9	O
glands	3	O
,	9	O
its	9	O
pathogenesis	9	O
,	9	O
and	5	O
treatment	9	O
options	5	O
.	9	O

We	9	O
examined	9	O
the	5	O
case	5	O
of	5	O
a	5	O
lithium	0	B-Chemical
-	7	O
treated	3	O
patient	5	O
who	5	O
had	9	O
recurrent	5	O
hypercalcemia	5	B-Disease
to	5	O
better	5	O
understand	5	O
the	5	O
disease	5	O
process	5	O
.	9	O

CONCLUSION	5	O
:	9	O
Primary	9	B-Disease
hyperparathyroidism	5	I-Disease
is	5	O
a	5	O
rare	5	O
but	9	O
potentially	5	O
life	5	O
-	7	O
threatening	5	O
side	5	O
effect	9	O
of	5	O
long	5	O
-	7	O
term	5	O
lithium	0	B-Chemical
therapy	5	O
.	9	O

Careful	5	O
patient	5	O
selection	5	O
and	5	O
long	5	O
-	7	O
term	5	O
follow	5	O
-	7	O
up	5	O
can	5	O
reduce	5	O
morbidity	5	O
.	9	O

PRACTICAL	2	O
IMPLICATIONS	2	O
:	9	O
As	9	O
much	5	O
as	5	O
15	9	O
%	9	O
of	5	O
lithium	0	B-Chemical
-	7	O
treated	3	O
patients	5	O
become	5	O
hypercalcemic	5	B-Disease
.	9	O

By	5	O
routinely	9	O
monitoring	5	O
serum	9	O
calcium	0	B-Chemical
levels	3	O
,	9	O
healthcare	5	O
providers	5	O
can	5	O
improve	5	O
the	5	O
quality	5	O
of	5	O
life	5	O
of	5	O
this	5	O
patient	5	O
group	9	O
.	9	O

Comparison	9	O
of	5	O
laryngeal	5	O
mask	5	O
with	5	O
endotracheal	5	O
tube	9	O
for	5	O
anesthesia	5	O
in	5	O
endoscopic	5	O
sinus	5	O
surgery	5	O
.	9	O

BACKGROUND	2	O
:	9	O
The	5	O
purpose	5	O
of	5	O
this	5	O
study	9	O
was	9	O
to	5	O
compare	9	O
surgical	5	O
conditions	9	O
,	9	O
including	9	O
the	5	O
amount	9	O
of	5	O
intraoperative	5	O
bleeding	5	B-Disease
as	5	O
well	9	O
as	5	O
intraoperative	5	O
blood	9	O
pressure	5	O
,	9	O
during	5	O
functional	9	O
endoscopic	5	O
sinus	5	O
surgery	5	O
(	9	O
FESS	5	O
)	9	O
using	9	O
flexible	5	O
reinforced	5	O
laryngeal	5	O
mask	5	O
airway	5	O
(	9	O
FRLMA	_	O
)	9	O
versus	9	O
endotracheal	5	O
tube	9	O
(	9	O
ETT	5	O
)	9	O
in	5	O
maintaining	9	O
controlled	5	O
hypotension	5	B-Disease
anesthesia	5	O
induced	3	O
by	9	O
propofol	0	B-Chemical
-	7	O
remifentanil	5	B-Chemical
total	9	O
i	9	O
.	9	O
v	0	O
.	9	O
anesthesia	5	O
(	9	O
TIVA	5	O
)	9	O
.	9	O

METHODS	2	O
:	9	O
Sixty	5	O
normotensive	9	O
American	9	O
Society	2	O
of	5	O
Anesthesiologists	5	O
I	9	O
-	7	O
II	9	O
adult	9	O
patients	5	O
undergoing	9	O
FESS	5	O
under	9	O
controlled	5	O
hypotension	5	B-Disease
anesthesia	5	O
caused	9	O
by	9	O
propofol	0	B-Chemical
-	7	O
remifentanil	5	B-Chemical
-	7	O
TIVA	5	O
were	9	O
randomly	5	O
assigned	5	O
into	9	O
two	5	O
groups	9	O
:	9	O
group	9	O
I	9	O
,	9	O
FRLMA	_	O
;	9	O
group	9	O
II	9	O
,	9	O
ETT	5	O
.	9	O

Hemorrhage	5	B-Disease
was	9	O
measured	9	O
and	5	O
the	5	O
visibility	5	O
of	5	O
the	5	O
operative	5	O
field	5	O
was	9	O
evaluated	9	O
according	9	O
to	5	O
a	5	O
six	9	O
-	7	O
point	5	O
scale	5	O
.	9	O

RESULTS	9	O
:	9	O
Controlled	5	O
hypotension	5	B-Disease
was	9	O
achieved	5	O
within	9	O
a	5	O
shorter	9	O
period	5	O
using	9	O
laryngeal	5	O
mask	5	O
using	9	O
lower	9	O
rates	5	O
of	5	O
remifentanil	5	B-Chemical
infusion	0	O
and	5	O
lower	9	O
total	9	O
dose	9	O
of	5	O
remifentanil	5	B-Chemical
.	9	O

CONCLUSION	5	O
:	9	O
In	9	O
summary	9	O
,	9	O
our	5	O
results	9	O
indicate	9	O
that	5	O
airway	5	O
management	5	O
using	9	O
FRLMA	_	O
during	5	O
controlled	5	O
hypotension	5	B-Disease
anesthesia	5	O
provided	9	O
better	5	O
surgical	5	O
conditions	9	O
in	5	O
terms	5	O
of	5	O
quality	5	O
of	5	O
operative	5	O
field	5	O
and	5	O
blood	9	O
loss	9	O
and	5	O
allowed	9	O
for	5	O
convenient	5	O
induced	3	O
hypotension	5	B-Disease
with	5	O
low	9	O
doses	0	O
of	5	O
remifentanil	5	B-Chemical
during	5	O
TIVA	5	O
in	5	O
patients	5	O
undergoing	9	O
FESS	5	O
.	9	O

Nonalcoholic	2	B-Disease
fatty	0	I-Disease
liver	9	I-Disease
disease	5	I-Disease
during	5	O
valproate	0	B-Chemical
therapy	5	O
.	9	O

Valproic	0	B-Chemical
acid	0	I-Chemical
(	9	O
VPA	9	B-Chemical
)	9	O
is	5	O
effective	5	O
for	5	O
the	5	O
treatment	9	O
of	5	O
many	5	O
types	9	O
of	5	O
epilepsy	5	B-Disease
,	9	O
but	9	O
its	9	O
use	5	O
can	5	O
be	5	O
associated	9	O
with	5	O
an	5	O
increase	9	O
in	5	O
body	5	O
weight	9	O
.	9	O

We	9	O
report	5	O
a	5	O
case	5	O
of	5	O
nonalcoholic	5	B-Disease
fatty	0	I-Disease
liver	9	I-Disease
disease	5	I-Disease
(	9	O
NAFLD	9	B-Disease
)	9	O
arising	5	O
in	5	O
a	5	O
child	5	O
who	5	O
developed	5	O
obesity	5	B-Disease
during	5	O
VPA	9	B-Chemical
treatment	9	O
.	9	O

Laboratory	2	O
data	5	O
revealed	9	O
hyperinsulinemia	5	B-Disease
with	5	O
insulin	3	B-Disease
resistance	9	I-Disease
.	9	O

After	9	O
the	5	O
withdrawal	5	O
of	5	O
VPA	9	B-Chemical
therapy	5	O
,	9	O
our	5	O
patient	5	O
showed	9	O
a	5	O
significant	9	O
weight	9	B-Disease
loss	9	I-Disease
,	9	O
a	5	O
decrease	9	O
of	5	O
body	5	O
mass	9	O
index	5	O
,	9	O
and	5	O
normalization	5	O
of	5	O
metabolic	9	O
and	5	O
endocrine	9	O
parameters	5	O
;	9	O
moreover	9	O
,	9	O
ultrasound	5	O
measurements	5	O
showed	9	O
a	5	O
complete	9	O
normalization	5	O
.	9	O

The	5	O
present	9	O
case	5	O
suggests	9	O
that	5	O
obesity	5	B-Disease
,	9	O
hyperinsulinemia	5	B-Disease
,	9	O
insulin	3	B-Disease
resistance	9	I-Disease
,	9	O
and	5	O
long	5	O
-	7	O
term	5	O
treatment	9	O
with	5	O
VPA	9	B-Chemical
may	5	O
be	5	O
all	5	O
associated	9	O
with	5	O
the	5	O
development	9	O
of	5	O
NAFLD	9	B-Disease
;	9	O
this	5	O
side	5	O
effect	9	O
is	5	O
reversible	9	O
after	9	O
VPA	9	B-Chemical
withdrawal	5	O
.	9	O

Carbimazole	0	B-Chemical
induced	3	O
ANCA	3	B-Disease
positive	9	I-Disease
vasculitis	5	I-Disease
.	9	O

Anti	3	B-Chemical
-	7	I-Chemical
thyroid	9	I-Chemical
drugs	5	I-Chemical
,	9	O
like	9	O
carbimazole	5	B-Chemical
and	5	O
propylthiouracil	0	B-Chemical
(	9	O
PTU	0	B-Chemical
)	9	O
are	5	O
commonly	5	O
prescribed	5	O
for	5	O
the	5	O
treatment	9	O
of	5	O
hyperthyroidism	5	B-Disease
.	9	O

One	5	O
should	5	O
be	5	O
aware	5	O
of	5	O
the	5	O
side	5	O
effects	9	O
of	5	O
antithyroid	0	B-Chemical
medications	5	I-Chemical
.	9	O

Antineutrophil	3	B-Disease
cytoplasmic	3	I-Disease
antibody	3	I-Disease
(	9	I-Disease
ANCA	3	I-Disease
)	9	I-Disease
-	7	I-Disease
-	7	I-Disease
associated	9	I-Disease
vasculitis	5	I-Disease
is	5	O
a	5	O
potentially	5	O
life	5	O
-	7	O
threatening	5	O
adverse	5	O
effect	9	O
of	5	O
antithyroidmedications	_	B-Chemical
.	9	O

We	9	O
report	5	O
a	5	O
patient	5	O
with	5	O
Graves	5	B-Disease
'	9	I-Disease
disease	5	I-Disease
who	5	O
developed	5	O
ANCA	3	O
positive	9	O
carbimazole	5	B-Chemical
induced	3	O
vasculitis	5	B-Disease
.	9	O

The	5	O
episode	5	O
was	9	O
characterized	9	O
by	9	O
a	5	O
vasculitic	5	B-Disease
skin	5	B-Disease
rash	5	I-Disease
associated	9	O
with	5	O
large	5	O
joint	5	O
arthritis	9	B-Disease
,	9	O
pyrexia	5	B-Disease
and	5	O
parotiditis	5	B-Disease
but	9	O
no	9	O
renal	9	O
or	5	O
pulmonary	5	O
involvement	9	O
.	9	O

He	5	O
was	9	O
referred	5	O
to	5	O
us	5	O
for	5	O
neurological	5	O
evaluation	5	O
because	5	O
he	5	O
had	9	O
difficulty	5	O
in	5	O
getting	5	O
up	5	O
from	9	O
squatting	5	O
position	9	O
and	5	O
was	9	O
suspected	5	O
to	5	O
have	5	O
myositis	9	B-Disease
.	9	O

Carbimazole	0	B-Chemical
and	5	O
methimazole	0	B-Chemical
have	5	O
a	5	O
lower	9	O
incidence	5	O
of	5	O
reported	9	O
ANCA	3	O
positive	9	O
side	5	O
effects	9	O
than	5	O
PUT	9	O
.	9	O

To	9	O
the	5	O
best	5	O
of	5	O
our	5	O
knowledge	5	O
this	5	O
is	5	O
the	5	O
first	9	O
ANCA	3	O
positive	9	O
carbimazole	5	B-Chemical
induced	3	O
vasculitis	5	B-Disease
case	5	O
reported	9	O
from	9	O
India	2	O
.	9	O

Aspirin	0	B-Chemical
for	5	O
the	5	O
primary	9	O
prevention	5	O
of	5	O
cardiovascular	5	O
events	5	O
:	9	O
an	5	O
update	5	O
of	5	O
the	5	O
evidence	9	O
for	5	O
the	5	O
U	9	O
.	9	O
S	9	O
.	9	O

Preventive	2	O
Services	2	O
Task	5	O
Force	5	O
.	9	O

BACKGROUND	2	O
:	9	O
Coronary	5	B-Disease
heart	5	I-Disease
disease	5	I-Disease
and	5	O
cerebrovascular	5	B-Disease
disease	5	I-Disease
are	5	O
leading	9	O
causes	9	O
of	5	O
death	9	O
in	5	O
the	5	O
United	9	O
States	9	O
.	9	O

In	9	O
2002	2	O
,	9	O
the	5	O
U	9	O
.	9	O
S	9	O
.	9	O

Preventive	2	O
Services	2	O
Task	5	O
Force	5	O
(	9	O
USPSTF	5	O
)	9	O
strongly	9	O
recommended	5	O
that	5	O
clinicians	5	O
discuss	5	O
aspirin	9	B-Chemical
with	5	O
adults	5	O
who	5	O
are	5	O
at	9	O
increased	9	O
risk	5	O
for	5	O
coronary	5	B-Disease
heart	5	I-Disease
disease	5	I-Disease
.	9	O

PURPOSE	2	O
:	9	O
To	9	O
determine	9	O
the	5	O
benefits	5	O
and	5	O
harms	5	O
of	5	O
taking	5	O
aspirin	9	B-Chemical
for	5	O
the	5	O
primary	9	O
prevention	5	O
of	5	O
myocardial	9	B-Disease
infarctions	5	I-Disease
,	9	O
strokes	5	B-Disease
,	9	O
and	5	O
death	9	O
.	9	O

DATA	2	O
SOURCES	2	O
:	9	O
MEDLINE	5	O
and	5	O
Cochrane	5	O
Library	2	O
(	9	O
search	5	O
dates	5	O
,	9	O
1	9	O
January	2	O
2001	2	O
to	5	O
28	7	O
August	2	O
2008	2	O
)	9	O
,	9	O
recent	5	O
systematic	5	O
reviews	5	O
,	9	O
reference	9	O
lists	5	O
of	5	O
retrieved	9	O
articles	5	O
,	9	O
and	5	O
suggestions	6	O
from	9	O
experts	5	O
.	9	O

STUDY	2	O
SELECTION	2	O
:	9	O
English	5	O
-	7	O
language	5	O
randomized	5	O
,	9	O
controlled	5	O
trials	5	O
(	9	O
RCTs	5	O
)	9	O
;	9	O
case	5	O
-	7	O
control	9	O
studies	9	O
;	9	O
meta	9	O
-	7	O
analyses	9	O
;	9	O
and	5	O
systematic	5	O
reviews	5	O
of	5	O
aspirin	9	B-Chemical
versus	9	O
control	9	O
for	5	O
the	5	O
primary	9	O
prevention	5	O
of	5	O
cardiovascular	5	B-Disease
disease	5	I-Disease
(	9	O
CVD	5	B-Disease
)	9	O
were	9	O
selected	9	O
to	5	O
answer	5	O
the	5	O
following	9	O
questions	5	O
:	9	O
Does	5	O
aspirin	9	B-Chemical
decrease	9	O
coronary	5	O
heart	5	O
events	5	O
,	9	O
strokes	5	B-Disease
,	9	O
death	9	O
from	9	O
coronary	5	O
heart	5	O
events	5	O
or	5	O
stroke	5	B-Disease
,	9	O
or	5	O
all	5	O
-	7	O
cause	5	O
mortality	5	O
in	5	O
adults	5	O
without	9	O
known	9	O
CVD	5	B-Disease
?	5	O

Does	5	O
aspirin	9	B-Chemical
increase	9	O
gastrointestinal	9	B-Disease
bleeding	5	I-Disease
or	5	O
hemorrhagic	5	B-Disease
strokes	5	I-Disease
?	5	O

DATA	2	O
EXTRACTION	2	O
:	9	O
All	9	O
studies	9	O
were	9	O
reviewed	9	O
,	9	O
abstracted	5	O
,	9	O
and	5	O
rated	5	O
for	5	O
quality	5	O
by	9	O
using	9	O
predefined	5	O
USPSTF	5	O
criteria	5	O
.	9	O

DATA	2	O
SYNTHESIS	2	O
:	9	O
New	2	O
evidence	9	O
from	9	O
1	9	O
good	5	O
-	7	O
quality	5	O
RCT	5	O
,	9	O
1	9	O
good	5	O
-	7	O
quality	5	O
meta	9	O
-	7	O
analysis	9	O
,	9	O
and	5	O
2	9	O
fair	5	O
-	7	O
quality	5	O
subanalyses	5	O
of	5	O
RCTs	5	O
demonstrates	9	O
that	5	O
aspirin	9	B-Chemical
use	5	O
reduces	9	O
the	5	O
number	9	O
of	5	O
CVD	5	B-Disease
events	5	O
in	5	O
patients	5	O
without	9	O
known	9	O
CVD	5	B-Disease
.	9	O

Men	7	O
in	5	O
these	5	O
studies	9	O
experienced	5	O
fewer	5	O
myocardial	9	B-Disease
infarctions	5	I-Disease
and	5	O
women	5	O
experienced	5	O
fewer	5	O
ischemic	9	O
strokes	5	B-Disease
.	9	O

Aspirin	0	B-Chemical
does	9	O
not	5	O
seem	5	O
to	5	O
affect	9	O
CVD	5	B-Disease
mortality	5	O
or	5	O
all	5	O
-	7	O
cause	5	O
mortality	5	O
in	5	O
either	9	O
men	5	O
or	5	O
women	5	O
.	9	O

The	5	O
use	5	O
of	5	O
aspirin	9	B-Chemical
for	5	O
primary	9	O
prevention	5	O
increases	9	O
the	5	O
risk	5	O
for	5	O
major	9	O
bleeding	5	B-Disease
events	5	O
,	9	O
primarily	9	O
gastrointestinal	9	B-Disease
bleeding	5	I-Disease
events	5	O
,	9	O
in	5	O
both	9	O
men	5	O
and	5	O
women	5	O
.	9	O

Men	7	O
have	5	O
an	5	O
increased	9	O
risk	5	O
for	5	O
hemorrhagic	5	B-Disease
strokes	5	I-Disease
with	5	O
aspirin	9	B-Chemical
use	5	O
.	9	O

A	9	O
new	5	O
RCT	5	O
and	5	O
meta	9	O
-	7	O
analysis	9	O
suggest	9	O
that	5	O
the	5	O
risk	5	O
for	5	O
hemorrhagic	5	B-Disease
strokes	5	I-Disease
in	5	O
women	5	O
is	5	O
not	5	O
statistically	9	O
significantly	9	O
increased	9	O
.	9	O

LIMITATIONS	2	O
:	9	O
New	2	O
evidence	9	O
on	5	O
aspirin	9	B-Chemical
for	5	O
the	5	O
primary	9	O
prevention	5	O
of	5	O
CVD	5	B-Disease
is	5	O
limited	5	O
.	9	O

The	5	O
dose	9	O
of	5	O
aspirin	9	B-Chemical
used	5	O
in	5	O
the	5	O
RCTs	5	O
varied	9	O
,	9	O
which	5	O
prevented	9	O
the	5	O
estimation	5	O
of	5	O
the	5	O
most	9	O
appropriate	5	O
dose	9	O
for	5	O
primary	9	O
prevention	5	O
.	9	O

Several	9	O
of	5	O
the	5	O
RCTs	5	O
were	9	O
conducted	9	O
within	9	O
populations	9	O
of	5	O
health	5	O
professionals	5	O
,	9	O
which	5	O
potentially	5	O
limits	5	O
generalizability	5	O
.	9	O

CONCLUSION	5	O
:	9	O
Aspirin	0	B-Chemical
reduces	9	O
the	5	O
risk	5	O
for	5	O
myocardial	9	B-Disease
infarction	5	I-Disease
in	5	O
men	5	O
and	5	O
strokes	5	B-Disease
in	5	O
women	5	O
.	9	O

Aspirin	0	B-Chemical
use	5	O
increases	9	O
the	5	O
risk	5	O
for	5	O
serious	5	O
bleeding	5	B-Disease
events	5	O
.	9	O

Reducing	9	O
harm	5	O
associated	9	O
with	5	O
anticoagulation	5	O
:	9	O
practical	5	O
considerations	5	O
of	5	O
argatroban	5	B-Chemical
therapy	5	O
in	5	O
heparin	0	B-Chemical
-	7	O
induced	3	O
thrombocytopenia	9	B-Disease
.	9	O

Argatroban	0	B-Chemical
is	5	O
a	5	O
hepatically	0	O
metabolized	0	O
,	9	O
direct	9	O
thrombin	0	O
inhibitor	3	O
used	5	O
for	5	O
prophylaxis	5	O
or	5	O
treatment	9	O
of	5	O
thrombosis	5	B-Disease
in	5	O
heparin	0	B-Chemical
-	7	O
induced	3	O
thrombocytopenia	9	B-Disease
(	9	O
HIT	5	B-Disease
)	9	O
and	5	O
for	5	O
patients	5	O
with	5	O
or	5	O
at	9	O
risk	5	O
of	5	O
HIT	5	B-Disease
undergoing	9	O
percutaneous	5	O
coronary	5	O
intervention	5	O
(	9	O
PCI	5	O
)	9	O
.	9	O

The	5	O
objective	5	O
of	5	O
this	5	O
review	5	O
is	5	O
to	5	O
summarize	5	O
practical	5	O
considerations	5	O
of	5	O
argatroban	5	B-Chemical
therapy	5	O
in	5	O
HIT	5	B-Disease
.	9	O

The	5	O
US	5	O
FDA	5	O
-	7	O
recommended	5	O
argatroban	5	B-Chemical
dose	9	O
in	5	O
HIT	5	B-Disease
is	5	O
2	9	O
microg	0	O
/	9	O
kg	0	O
/	9	O
min	0	O
(	9	O
reduced	9	O
in	5	O
patients	5	O
with	5	O
hepatic	9	B-Disease
impairment	5	I-Disease
and	5	O
in	5	O
paediatric	5	O
patients	5	O
)	9	O
,	9	O
adjusted	9	O
to	5	O
achieve	5	O
activated	3	O
partial	9	O
thromboplastin	5	O
times	5	O
(	9	O
aPTTs	5	O
)	9	O
1	9	O
.	9	O
5	9	O
-	7	O
3	9	O
times	5	O
baseline	5	O
(	9	O
not	5	O
>	0	O
100	0	O
seconds	5	O
)	9	O
.	9	O

Contemporary	5	O
experiences	5	O
indicate	9	O
that	5	O
reduced	9	O
doses	0	O
are	5	O
also	9	O
needed	5	O
in	5	O
patients	5	O
with	5	O
conditions	9	O
associated	9	O
with	5	O
hepatic	9	O
hypoperfusion	5	O
,	9	O
e	9	O
.	9	O
g	0	O
.	9	O
heart	5	B-Disease
failure	5	I-Disease
,	9	O
yet	9	O
are	5	O
unnecessary	5	O
for	5	O
renal	9	B-Disease
dysfunction	9	I-Disease
,	9	O
adult	9	O
age	5	O
,	9	O
sex	5	O
,	9	O
race	5	O
/	9	O
ethnicity	5	O
or	5	O
obesity	5	B-Disease
.	9	O

Argatroban	0	B-Chemical
0	7	O
.	9	O
5	9	O
-	7	O
1	9	O
.	9	O
2	9	O
microg	0	O
/	9	O
kg	0	O
/	9	O
min	0	O
typically	5	O
supports	9	O
therapeutic	5	O
aPTTs	5	O
.	9	O

The	5	O
FDA	5	O
-	7	O
recommended	5	O
dose	9	O
during	5	O
PCI	5	O
is	5	O
25	9	O
microg	0	O
/	9	O
kg	0	O
/	9	O
min	0	O
(	9	O
350	9	O
microg	0	O
/	9	O
kg	0	O
initial	9	O
bolus	0	O
)	9	O
,	9	O
adjusted	9	O
to	5	O
achieve	5	O
activated	3	O
clotting	5	O
times	5	O
(	9	O
ACTs	5	O
)	9	O
of	5	O
300	0	O
-	7	O
450	9	O
sec	9	O
.	9	O

For	9	O
PCI	5	O
,	9	O
argatroban	5	B-Chemical
has	9	O
not	5	O
been	9	O
investigated	9	O
in	5	O
hepatically	0	O
impaired	9	O
patients	5	O
;	9	O
dose	9	O
adjustment	5	O
is	5	O
unnecessary	5	O
for	5	O
adult	9	O
age	5	O
,	9	O
sex	5	O
,	9	O
race	5	O
/	9	O
ethnicity	5	O
or	5	O
obesity	5	B-Disease
,	9	O
and	5	O
lesser	9	O
doses	0	O
may	5	O
be	5	O
adequate	5	O
with	5	O
concurrent	5	O
glycoprotein	3	O
IIb	9	O
/	9	O
IIIa	9	O
inhibition	3	O
.	9	O

Argatroban	0	B-Chemical
prolongs	9	O
the	5	O
International	2	O
Normalized	9	O
Ratio	9	O
,	9	O
and	5	O
published	9	O
approaches	5	O
for	5	O
monitoring	5	O
the	5	O
argatroban	5	B-Chemical
-	7	O
to	5	O
-	7	O
warfarin	5	B-Chemical
transition	9	O
should	5	O
be	5	O
followed	9	O
.	9	O

Major	9	O
bleeding	5	B-Disease
with	5	O
argatroban	5	B-Chemical
is	5	O
0	7	O
-	7	O
10	9	O
%	9	O
in	5	O
the	5	O
non	9	O
-	7	O
interventional	5	O
setting	5	O
and	5	O
0	7	O
-	7	O
5	9	O
.	9	O
8	9	O
%	9	O
periprocedurally	5	O
.	9	O

Argatroban	0	B-Chemical
has	9	O
no	9	O
specific	9	O
antidote	5	O
,	9	O
and	5	O
if	5	O
excessive	5	O
anticoagulation	5	O
occurs	9	O
,	9	O
argatroban	5	B-Chemical
infusion	0	O
should	5	O
be	5	O
stopped	9	O
or	5	O
reduced	9	O
.	9	O

Improved	9	O
familiarity	5	O
of	5	O
healthcare	5	O
professionals	5	O
with	5	O
argatroban	5	B-Chemical
therapy	5	O
in	5	O
HIT	5	B-Disease
,	9	O
including	9	O
in	5	O
special	5	O
populations	9	O
and	5	O
during	5	O
PCI	5	O
,	9	O
may	5	O
facilitate	5	O
reduction	9	O
of	5	O
harm	5	O
associated	9	O
with	5	O
HIT	5	B-Disease
(	9	O
e	9	O
.	9	O
g	0	O
.	9	O
fewer	5	O
thromboses	5	O
)	9	O
or	5	O
its	9	O
treatment	9	O
(	9	O
e	9	O
.	9	O
g	0	O
.	9	O
fewer	5	O
argatroban	5	B-Chemical
medication	5	O
errors	5	O
)	9	O
.	9	O

Rhabdomyolysis	5	B-Disease
and	5	O
brain	5	O
ischemic	9	B-Disease
stroke	5	I-Disease
in	5	O
a	5	O
heroin	5	B-Chemical
-	7	O
dependent	9	O
male	9	O
under	9	O
methadone	5	B-Chemical
maintenance	9	O
therapy	5	O
.	9	O

OBJECTIVE	2	O
:	9	O
There	5	O
are	5	O
several	9	O
complications	5	O
associated	9	O
with	5	O
heroin	5	B-Disease
abuse	5	I-Disease
,	9	O
some	5	O
of	5	O
which	5	O
are	5	O
life	5	O
-	7	O
threatening	5	O
.	9	O

Methadone	7	B-Chemical
may	5	O
aggravate	9	O
this	5	O
problem	5	O
.	9	O

METHOD	2	O
:	9	O
A	9	O
clinical	5	O
case	5	O
description	5	O
.	9	O

RESULTS	9	O
:	9	O
A	9	O
33	7	O
-	7	O
year	5	O
-	7	O
old	5	O
man	5	O
presented	5	O
with	5	O
rhabdomyolysis	5	B-Disease
and	5	O
cerebral	5	O
ischemic	9	B-Disease
stroke	5	I-Disease
after	9	O
intravenous	0	O
heroin	5	B-Chemical
.	9	O

He	5	O
had	9	O
used	5	O
heroin	5	B-Chemical
since	9	O
age	5	O
20	9	O
,	9	O
and	5	O
had	9	O
used	5	O
150	0	O
mg	0	O
methadone	5	B-Chemical
daily	5	O
for	5	O
6	9	O
months	5	O
.	9	O

He	5	O
was	9	O
found	9	O
unconsciousness	5	B-Disease
at	9	O
home	5	O
and	5	O
was	9	O
sent	5	O
to	5	O
our	5	O
hospital	5	O
.	9	O

In	9	O
the	5	O
ER	3	O
,	9	O
his	5	O
opiate	5	O
level	9	O
was	9	O
4497	7	O
ng	0	O
/	9	O
ml	0	O
.	9	O

In	9	O
the	5	O
ICU	5	O
,	9	O
we	5	O
found	9	O
rhabdomyolysis	5	B-Disease
,	9	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
and	5	O
acute	9	O
respiratory	5	B-Disease
failure	5	I-Disease
.	9	O

After	9	O
transfer	9	O
to	5	O
an	5	O
internal	5	O
ward	5	O
,	9	O
we	5	O
noted	9	O
aphasia	5	B-Disease
and	5	O
weakness	5	B-Disease
of	5	O
his	5	O
left	5	O
limbs	5	O
.	9	O

After	9	O
MRI	5	O
,	9	O
we	5	O
found	9	O
cerebral	5	B-Disease
ischemic	9	I-Disease
infarction	5	I-Disease
.	9	O

CONCLUSION	5	O
:	9	O
Those	5	O
using	9	O
methadone	5	B-Chemical
and	5	O
heroin	5	B-Chemical
simultaneously	5	O
may	5	O
increase	9	O
risk	5	O
of	5	O
rhabdomyolysis	5	B-Disease
and	5	O
ischemic	9	B-Disease
stroke	5	I-Disease
.	9	O

Patients	5	O
under	9	O
methadone	5	B-Chemical
maintenance	9	O
therapy	5	O
should	5	O
be	5	O
warned	5	O
regarding	5	O
these	5	O
serious	5	O
adverse	5	O
events	5	O
.	9	O

Hypotheses	5	O
of	5	O
heroin	5	B-Chemical
-	7	O
related	9	O
rhabdomyolysis	5	B-Disease
and	5	O
stroke	5	B-Disease
in	5	O
heroin	5	B-Chemical
abusers	5	O
are	5	O
discussed	5	O
.	9	O

Increased	9	O
vulnerability	5	O
to	5	O
6	9	B-Chemical
-	7	I-Chemical
hydroxydopamine	0	I-Chemical
lesion	5	O
and	5	O
reduced	9	O
development	9	O
of	5	O
dyskinesias	5	B-Disease
in	5	O
mice	3	O
lacking	1	O
CB1	3	O
cannabinoid	3	O
receptors	3	O
.	9	O

Motor	5	O
impairment	5	O
,	9	O
dopamine	5	B-Chemical
(	9	O
DA	9	B-Chemical
)	9	O
neuronal	3	O
activity	9	O
and	5	O
proenkephalin	3	B-Chemical
(	9	O
PENK	7	B-Chemical
)	9	O
gene	1	O
expression	3	O
in	5	O
the	5	O
caudate	5	O
-	7	O
putamen	5	O
(	9	O
CPu	3	O
)	9	O
were	9	O
measured	9	O
in	5	O
6	9	B-Chemical
-	7	I-Chemical
OHDA	0	I-Chemical
-	7	O
lesioned	3	O
and	5	O
treated	3	O
(	9	O
L	0	B-Chemical
-	7	I-Chemical
DOPA	0	I-Chemical
+	9	I-Chemical
benserazide	0	I-Chemical
)	9	O
CB1	3	O
KO	3	O
and	5	O
WT	3	O
mice	3	O
.	9	O

A	9	O
lesion	5	O
induced	3	O
by	9	O
6	9	B-Chemical
-	7	I-Chemical
OHDA	0	I-Chemical
produced	9	O
more	5	O
severe	5	O
motor	5	O
deterioration	5	O
in	5	O
CB1	3	O
KO	3	O
mice	3	O
accompanied	9	O
by	9	O
more	5	O
loss	9	O
of	5	O
DA	9	B-Chemical
neurons	3	O
and	5	O
increased	9	O
PENK	7	B-Chemical
gene	1	O
expression	3	O
in	5	O
the	5	O
CPu	3	O
.	9	O

Oxidative	9	O
/	9	O
nitrosative	3	O
and	5	O
neuroinflammatory	3	O
parameters	5	O
were	9	O
estimated	5	O
in	5	O
the	5	O
CPu	3	O
and	5	O
cingulate	5	O
cortex	5	O
(	9	O
Cg	9	O
)	9	O
.	9	O

CB1	3	O
KO	3	O
mice	3	O
exhibited	9	O
higher	9	O
MDA	9	B-Chemical
levels	3	O
and	5	O
iNOS	3	O
protein	1	O
expression	3	O
in	5	O
the	5	O
CPu	3	O
and	5	O
Cg	9	O
compared	9	O
to	5	O
WT	3	O
mice	3	O
.	9	O

Treatment	9	O
with	5	O
L	0	B-Chemical
-	7	I-Chemical
DOPA	0	I-Chemical
+	9	I-Chemical
benserazide	0	I-Chemical
(	9	O
12	9	O
weeks	9	O
)	9	O
resulted	9	O
in	5	O
less	5	O
severe	5	O
dyskinesias	5	B-Disease
in	5	O
CB1	3	O
KO	3	O
than	5	O
in	5	O
WT	3	O
mice	3	O
.	9	O

The	5	O
results	9	O
revealed	9	O
that	5	O
the	5	O
lack	9	O
of	5	O
cannabinoid	3	O
CB1	3	O
receptors	3	O
increased	9	O
the	5	O
severity	5	O
of	5	O
motor	5	O
impairment	5	O
and	5	O
DA	9	B-Chemical
lesion	5	O
,	9	O
and	5	O
reduced	9	O
L	0	B-Chemical
-	7	I-Chemical
DOPA	0	I-Chemical
-	7	O
induced	3	O
dyskinesias	5	B-Disease
.	9	O

These	5	O
results	9	O
suggest	9	O
that	5	O
activation	3	O
of	5	O
CB1	3	O
receptors	3	O
offers	5	O
neuroprotection	3	O
against	9	O
dopaminergic	5	O
lesion	5	O
and	5	O
the	5	O
development	9	O
of	5	O
L	0	B-Chemical
-	7	I-Chemical
DOPA	0	I-Chemical
-	7	O
induced	3	O
dyskinesias	5	B-Disease
.	9	O

Hepatocellular	9	O
oxidant	0	O
stress	9	O
following	9	O
intestinal	9	O
ischemia	9	B-Disease
-	7	O
reperfusion	9	B-Disease
injury	9	I-Disease
.	9	O

Reperfusion	9	O
of	5	O
ischemic	9	B-Disease
intestine	9	O
results	9	O
in	5	O
acute	9	O
liver	9	B-Disease
dysfunction	9	I-Disease
characterized	9	O
by	9	O
hepatocellular	9	O
enzyme	0	O
release	9	O
into	9	O
plasma	9	O
,	9	O
reduction	9	O
in	5	O
bile	0	O
flow	5	O
rate	9	O
,	9	O
and	5	O
neutrophil	3	O
sequestration	9	O
within	9	O
the	5	O
liver	9	O
.	9	O

The	5	O
pathophysiology	9	O
underlying	5	O
this	5	O
acute	9	O
hepatic	9	B-Disease
injury	9	I-Disease
is	5	O
unknown	9	O
.	9	O

This	5	O
study	9	O
was	9	O
undertaken	5	O
to	5	O
determine	9	O
whether	9	O
oxidants	0	O
are	5	O
associated	9	O
with	5	O
the	5	O
hepatic	9	B-Disease
injury	9	I-Disease
and	5	O
to	5	O
determine	9	O
the	5	O
relative	9	O
value	9	O
of	5	O
several	9	O
indirect	5	O
methods	5	O
of	5	O
assessing	5	O
oxidant	0	O
exposure	9	O
in	5	O
vivo	3	O
.	9	O

Rats	9	O
were	9	O
subjected	9	O
to	5	O
a	5	O
standardized	5	O
intestinal	9	O
ischemia	9	B-Disease
-	7	O
reperfusion	9	B-Disease
injury	9	I-Disease
.	9	O

Hepatic	9	O
tissue	9	O
was	9	O
assayed	3	O
for	5	O
lipid	0	O
peroxidation	0	O
products	9	O
and	5	O
oxidized	0	B-Chemical
and	5	I-Chemical
reduced	9	I-Chemical
glutathione	0	I-Chemical
.	9	O

There	5	O
was	9	O
no	9	O
change	9	O
in	5	O
hepatic	9	O
tissue	9	O
total	9	O
glutathione	0	B-Chemical
following	9	O
intestinal	9	O
ischemia	9	B-Disease
-	7	O
reperfusion	9	B-Disease
injury	9	I-Disease
.	9	O

Oxidized	0	B-Chemical
glutathione	0	I-Chemical
(	9	O
GSSG	0	B-Chemical
)	9	O
increased	9	O
significantly	9	O
following	9	O
30	9	O
and	5	O
60	9	O
min	0	O
of	5	O
reperfusion	9	O
.	9	O

There	5	O
was	9	O
no	9	O
increase	9	O
in	5	O
any	5	O
of	5	O
the	5	O
products	9	O
of	5	O
lipid	0	O
peroxidation	0	O
associated	9	O
with	5	O
this	5	O
injury	9	O
.	9	O

An	5	O
increase	9	O
in	5	O
GSSG	0	B-Chemical
within	9	O
hepatic	9	O
tissue	9	O
during	5	O
intestinal	9	O
reperfusion	9	O
suggests	9	O
exposure	9	O
of	5	O
hepatocytes	3	O
to	5	O
an	5	O
oxidant	0	O
stress	9	O
.	9	O

The	5	O
lack	9	O
of	5	O
a	5	O
significant	9	O
increase	9	O
in	5	O
products	9	O
of	5	O
lipid	0	O
peroxidation	0	O
suggests	9	O
that	5	O
the	5	O
oxidant	0	O
stress	9	O
is	5	O
of	5	O
insufficient	5	O
magnitude	5	O
to	5	O
result	9	O
in	5	O
irreversible	9	O
injury	9	O
to	5	O
hepatocyte	3	O
cell	3	O
membranes	0	O
.	9	O

These	5	O
data	5	O
also	9	O
suggest	9	O
that	5	O
the	5	O
measurement	5	O
of	5	O
tissue	9	O
GSSG	0	B-Chemical
may	5	O
be	5	O
a	5	O
more	5	O
sensitive	9	O
indicator	9	O
of	5	O
oxidant	0	O
stress	9	O
than	5	O
measurement	5	O
of	5	O
products	9	O
of	5	O
lipid	0	O
peroxidation	0	O
.	9	O

Animal	2	O
model	5	O
of	5	O
mania	5	B-Disease
induced	3	O
by	9	O
ouabain	0	B-Chemical
:	9	O
Evidence	9	O
of	5	O
oxidative	9	O
stress	9	O
in	5	O
submitochondrial	0	O
particles	0	O
of	5	O
the	5	O
rat	3	O
brain	5	O
.	9	O

The	5	O
intracerebroventricular	3	O
(	9	O
ICV	9	O
)	9	O
administration	9	O
of	5	O
ouabain	0	B-Chemical
(	9	O
a	5	O
Na	0	B-Chemical
(	9	O
+	9	O
)	9	O
/	9	O
K	9	B-Chemical
(	9	O
+	9	O
)	9	O
-	7	O
ATPase	1	O
inhibitor	3	O
)	9	O
in	5	O
rats	9	O
has	9	O
been	9	O
suggested	9	O
to	5	O
mimic	9	O
some	5	O
symptoms	5	O
of	5	O
human	3	O
bipolar	5	B-Disease
mania	5	I-Disease
.	9	O

Clinical	5	O
studies	9	O
have	5	O
shown	9	O
that	5	O
bipolar	5	B-Disease
disorder	5	I-Disease
may	5	O
be	5	O
related	9	O
to	5	O
mitochondrial	9	B-Disease
dysfunction	9	I-Disease
.	9	O

Herein	9	O
,	9	O
we	5	O
investigated	9	O
the	5	O
behavioral	5	O
and	5	O
biochemical	9	O
effects	9	O
induced	3	O
by	9	O
the	5	O
ICV	9	O
administration	9	O
of	5	O
ouabain	0	B-Chemical
in	5	O
rats	9	O
.	9	O

To	9	O
achieve	5	O
this	5	O
aim	5	O
,	9	O
the	5	O
effects	9	O
of	5	O
ouabain	0	B-Chemical
injection	9	O
immediately	9	O
after	9	O
and	5	O
7	9	O
days	9	O
following	9	O
a	5	O
single	9	O
ICV	9	O
administration	9	O
(	9	O
at	9	O
concentrations	0	O
of	5	O
10	9	O
(	9	O
-	7	O
2	9	O
)	9	O
and	5	O
10	9	O
(	9	O
-	7	O
3	9	O
)	9	O
M	9	O
)	9	O
on	5	O
locomotion	5	O
was	9	O
measured	9	O
using	9	O
the	5	O
open	5	O
-	7	O
field	5	O
test	5	O
.	9	O

Additionally	9	O
,	9	O
thiobarbituric	0	B-Chemical
acid	0	I-Chemical
reactive	9	O
substances	0	O
(	9	O
TBARSs	0	O
)	9	O
and	5	O
superoxide	0	B-Chemical
production	9	O
were	9	O
measured	9	O
in	5	O
submitochondrial	0	O
particles	0	O
of	5	O
the	5	O
prefrontal	5	O
cortex	5	O
,	9	O
hippocampus	9	O
,	9	O
striatum	9	O
and	5	O
amygdala	5	O
.	9	O

Our	9	O
findings	9	O
demonstrated	9	O
that	5	O
ouabain	0	B-Chemical
at	9	O
10	9	O
(	9	O
-	7	O
2	9	O
)	9	O
and	5	O
10	9	O
(	9	O
-	7	O
3	9	O
)	9	O
M	9	O
induced	3	O
hyperlocomotion	3	B-Disease
in	5	O
rats	9	O
,	9	O
and	5	O
this	5	O
response	9	O
remained	9	O
up	5	O
to	5	O
7	9	O
days	9	O
following	9	O
a	5	O
single	9	O
ICV	9	O
injection	9	O
.	9	O

In	9	O
addition	9	O
,	9	O
we	5	O
observed	9	O
that	5	O
the	5	O
persistent	5	O
increase	9	O
in	5	O
the	5	O
rat	3	O
spontaneous	5	O
locomotion	5	O
is	5	O
associated	9	O
with	5	O
increased	9	O
TBARS	0	O
levels	3	O
and	5	O
superoxide	0	B-Chemical
generation	9	O
in	5	O
submitochondrial	0	O
particles	0	O
in	5	O
the	5	O
prefrontal	5	O
cortex	5	O
,	9	O
striatum	9	O
and	5	O
amygdala	5	O
.	9	O

In	9	O
conclusion	9	O
,	9	O
ouabain	0	B-Chemical
-	7	O
induced	3	O
mania	5	B-Disease
-	7	O
like	9	O
behavior	5	O
may	5	O
provide	5	O
a	5	O
useful	5	O
animal	5	O
model	5	O
to	5	O
test	5	O
the	5	O
hypothesis	9	O
of	5	O
the	5	O
involvement	9	O
of	5	O
oxidative	9	O
stress	9	O
in	5	O
bipolar	5	B-Disease
disorder	5	I-Disease
.	9	O

Intraoperative	5	O
dialysis	5	O
during	5	O
liver	9	O
transplantation	9	O
with	5	O
citrate	0	B-Chemical
dialysate	0	O
.	9	O

Liver	9	O
transplantation	9	O
for	5	O
acutely	9	O
ill	5	O
patients	5	O
with	5	O
fulminant	5	B-Disease
liver	9	I-Disease
failure	5	I-Disease
carries	9	O
high	9	O
intraoperative	5	O
and	5	O
immediate	5	O
postoperative	5	O
risks	5	O
.	9	O

These	5	O
are	5	O
increased	9	O
with	5	O
the	5	O
presence	9	O
of	5	O
concomitant	9	O
acute	9	B-Disease
kidney	9	I-Disease
injury	9	I-Disease
(	9	O
AKI	5	B-Disease
)	9	O
and	5	O
intraoperative	5	O
dialysis	5	O
is	5	O
sometimes	5	O
required	9	O
to	5	O
allow	5	O
the	5	O
transplant	9	O
to	5	O
proceed	9	O
.	9	O

The	5	O
derangements	5	O
in	5	O
the	5	O
procoagulant	9	O
and	5	O
anticoagulant	9	O
pathways	9	O
during	5	O
fulminant	5	B-Disease
liver	9	I-Disease
failure	5	I-Disease
can	5	O
lead	5	O
to	5	O
difficulties	5	O
with	5	O
anticoagulation	5	O
during	5	O
dialysis	5	O
,	9	O
especially	5	O
when	5	O
continued	9	O
in	5	O
the	5	O
operating	5	O
room	9	O
.	9	O

Systemic	9	O
anticoagulation	5	O
is	5	O
unsafe	5	O
and	5	O
regional	5	O
citrate	0	B-Chemical
anticoagulation	5	O
in	5	O
the	5	O
absence	3	O
of	5	O
a	5	O
functional	9	O
liver	9	O
carries	9	O
the	5	O
risk	5	O
of	5	O
citrate	0	B-Chemical
toxicity	9	B-Disease
.	9	O

Citrate	0	B-Chemical
dialysate	0	O
,	9	O
a	5	O
new	5	O
dialysate	0	O
with	5	O
citric	0	B-Chemical
acid	0	I-Chemical
can	5	O
be	5	O
used	5	O
for	5	O
anticoagulation	5	O
in	5	O
patients	5	O
who	5	O
cannot	5	O
tolerate	5	O
heparin	0	B-Chemical
or	5	O
regional	5	O
citrate	0	B-Chemical
.	9	O

We	9	O
report	5	O
a	5	O
case	5	O
of	5	O
a	5	O
40	9	O
-	7	O
year	5	O
-	7	O
old	5	O
female	9	O
with	5	O
acetaminophen	0	B-Chemical
-	7	O
induced	3	O
fulminant	5	B-Disease
liver	9	I-Disease
failure	5	I-Disease
with	5	O
associated	9	O
AKI	5	B-Disease
who	5	O
underwent	5	O
intraoperative	5	O
dialytic	5	O
support	5	O
during	5	O
liver	9	O
transplantation	9	O
anticoagulated	5	O
with	5	O
citrate	0	B-Chemical
dialysate	0	O
during	5	O
the	5	O
entire	9	O
procedure	5	O
.	9	O

The	5	O
patient	5	O
tolerated	9	O
the	5	O
procedure	5	O
well	9	O
without	9	O
any	5	O
signs	5	O
of	5	O
citrate	0	B-Chemical
toxicity	9	B-Disease
and	5	O
maintained	9	O
adequate	5	O
anticoagulation	5	O
for	5	O
patency	5	O
of	5	O
the	5	O
dialysis	5	O
circuit	5	O
.	9	O

Citrate	0	B-Chemical
dialysate	0	O
is	5	O
a	5	O
safe	5	O
alternative	5	O
for	5	O
intradialytic	5	O
support	5	O
of	5	O
liver	9	O
transplantation	9	O
in	5	O
fulminant	5	B-Disease
liver	9	I-Disease
failure	5	I-Disease
.	9	O

Delirium	5	B-Disease
in	5	O
a	5	O
patient	5	O
with	5	O
toxic	0	O
flecainide	0	B-Chemical
plasma	9	O
concentrations	0	O
:	9	O
the	5	O
role	9	O
of	5	O
a	5	O
pharmacokinetic	5	O
drug	5	O
interaction	9	O
with	5	O
paroxetine	0	B-Chemical
.	9	O

OBJECTIVE	2	O
:	9	O
To	9	O
describe	5	O
a	5	O
case	5	O
of	5	O
flecainide	0	B-Chemical
-	7	O
induced	3	O
delirium	5	B-Disease
associated	9	O
with	5	O
a	5	O
pharmacokinetic	5	O
drug	5	O
interaction	9	O
with	5	O
paroxetine	0	B-Chemical
.	9	O

CASE	2	O
SUMMARY	9	O
:	9	O
A	9	O
69	7	O
-	7	O
year	5	O
-	7	O
old	5	O
white	9	O
female	9	O
presented	5	O
to	5	O
the	5	O
emergency	5	O
department	5	O
with	5	O
a	5	O
history	5	O
of	5	O
confusion	5	B-Disease
and	5	O
paranoia	5	B-Disease
over	5	O
the	5	O
past	5	O
several	9	O
days	9	O
.	9	O

On	5	O
admission	5	O
the	5	O
patient	5	O
was	9	O
taking	5	O
carvedilol	0	B-Chemical
12	9	O
mg	0	O
twice	9	O
daily	5	O
,	9	O
warfarin	5	B-Chemical
2	9	O
mg	0	O
/	9	O
day	9	O
,	9	O
folic	0	B-Chemical
acid	0	I-Chemical
1	9	O
mg	0	O
/	9	O
day	9	O
,	9	O
levothyroxine	5	B-Chemical
100	0	O
microg	0	O
/	9	O
day	9	O
,	9	O
pantoprazole	0	B-Chemical
40	9	O
mg	0	O
/	9	O
day	9	O
,	9	O
paroxetine	0	B-Chemical
40	9	O
mg	0	O
/	9	O
day	9	O
,	9	O
and	5	O
flecainide	0	B-Chemical
100	0	O
mg	0	O
twice	9	O
daily	5	O
.	9	O

Flecainide	0	B-Chemical
had	9	O
been	9	O
started	5	O
2	9	O
weeks	9	O
prior	9	O
for	5	O
atrial	5	B-Disease
fibrillation	5	I-Disease
.	9	O

Laboratory	2	O
test	5	O
findings	9	O
on	5	O
admission	5	O
were	9	O
notable	9	O
only	9	O
for	5	O
a	5	O
flecainide	0	B-Chemical
plasma	9	O
concentration	0	O
of	5	O
1360	7	O
microg	0	O
/	9	O
L	0	O
(	9	O
reference	9	O
range	9	O
200	0	O
-	7	O
1000	9	O
)	9	O
.	9	O

A	9	O
metabolic	9	O
drug	5	O
interaction	9	O
between	5	O
flecainide	0	B-Chemical
and	5	O
paroxetine	0	B-Chemical
,	9	O
which	5	O
the	5	O
patient	5	O
had	9	O
been	9	O
taking	5	O
for	5	O
more	5	O
than	5	O
5	9	O
years	5	O
,	9	O
was	9	O
considered	5	O
.	9	O

Paroxetine	7	B-Chemical
was	9	O
discontinued	5	O
and	5	O
the	5	O
dose	9	O
of	5	O
flecainide	0	B-Chemical
was	9	O
reduced	9	O
to	5	O
50	0	O
mg	0	O
twice	9	O
daily	5	O
.	9	O

Her	5	O
delirium	5	B-Disease
resolved	9	O
3	9	O
days	9	O
later	9	O
.	9	O

DISCUSSION	9	O
:	9	O
Flecainide	0	B-Chemical
and	5	O
pharmacologically	9	O
similar	9	O
agents	5	O
that	5	O
interact	9	O
with	5	O
sodium	0	B-Chemical
channels	9	O
may	5	O
cause	5	O
delirium	5	B-Disease
in	5	O
susceptible	9	O
patients	5	O
.	9	O

A	9	O
MEDLINE	5	O
search	5	O
(	9	O
1966	2	O
-	7	O
January	2	O
2009	2	O
)	9	O
revealed	9	O
one	5	O
in	5	O
vivo	3	O
pharmacokinetic	5	O
study	9	O
on	5	O
the	5	O
interaction	9	O
between	5	O
flecainide	0	B-Chemical
,	9	O
a	5	O
CYP2D6	9	O
substrate	0	O
,	9	O
and	5	O
paroxetine	0	B-Chemical
,	9	O
a	5	O
CYP2D6	9	O
inhibitor	3	O
,	9	O
as	5	O
well	9	O
as	5	O
3	9	O
case	5	O
reports	9	O
of	5	O
flecainide	0	B-Chemical
-	7	O
induced	3	O
delirium	5	B-Disease
.	9	O

According	5	O
to	5	O
the	5	O
Naranjo	6	O
probability	5	O
scale	5	O
,	9	O
flecainide	0	B-Chemical
was	9	O
the	5	O
probable	9	O
cause	5	O
of	5	O
the	5	O
patient	5	O
'	9	O
s	9	O
delirium	5	B-Disease
;	9	O
the	5	O
Horn	4	O
Drug	5	O
Interaction	9	O
Probability	5	O
Scale	5	O
indicates	9	O
a	5	O
possible	5	O
pharmacokinetic	5	O
drug	5	O
interaction	9	O
between	5	O
flecainide	0	B-Chemical
and	5	O
paroxetine	0	B-Chemical
.	9	O

CONCLUSIONS	5	O
:	9	O
Supratherapeutic	9	O
flecainide	0	B-Chemical
plasma	9	O
concentrations	0	O
may	5	O
cause	5	O
delirium	5	B-Disease
.	9	O

Because	9	O
toxicity	9	B-Disease
may	5	O
occur	5	O
when	5	O
flecainide	0	B-Chemical
is	5	O
prescribed	5	O
with	5	O
paroxetine	0	B-Chemical
and	5	O
other	5	O
potent	3	O
CYP2D6	9	O
inhibitors	3	O
,	9	O
flecainide	0	B-Chemical
plasma	9	O
concentrations	0	O
should	5	O
be	5	O
monitored	9	O
closely	9	O
with	5	O
commencement	5	O
of	5	O
CYP2D6	9	O
inhibitors	3	O
.	9	O

Efficacy	5	O
of	5	O
everolimus	0	B-Chemical
(	9	O
RAD001	3	B-Chemical
)	9	O
in	5	O
patients	5	O
with	5	O
advanced	5	O
NSCLC	3	B-Disease
previously	9	O
treated	3	O
with	5	O
chemotherapy	5	O
alone	9	O
or	5	O
with	5	O
chemotherapy	5	O
and	5	O
EGFR	3	O
inhibitors	3	O
.	9	O

BACKGROUND	2	O
:	9	O
Treatment	9	O
options	5	O
are	5	O
scarce	5	O
in	5	O
pretreated	3	O
advanced	5	O
non	9	B-Disease
-	7	I-Disease
small	9	I-Disease
-	7	I-Disease
cell	3	I-Disease
lung	9	I-Disease
cancer	3	I-Disease
(	9	O
NSCLC	3	B-Disease
)	9	O
patients	5	O
.	9	O

RAD001	3	B-Chemical
,	9	O
an	5	O
oral	9	O
inhibitor	3	O
of	5	O
the	5	O
mammalian	9	O
target	9	O
of	5	O
rapamycin	3	B-Chemical
(	9	O
mTOR	3	O
)	9	O
,	9	O
has	9	O
shown	9	O
phase	5	O
I	9	O
efficacy	9	O
in	5	O
NSCLC	3	B-Disease
.	9	O

METHODS	2	O
:	9	O
Stage	9	O
IIIb	9	O
or	5	O
IV	9	O
NSCLC	3	B-Disease
patients	5	O
,	9	O
with	5	O
two	5	O
or	5	O
fewer	5	O
prior	9	O
chemotherapy	5	O
regimens	5	O
,	9	O
one	5	O
platinum	0	B-Chemical
based	5	O
(	9	O
stratum	9	O
1	9	O
)	9	O
or	5	O
both	9	O
chemotherapy	5	O
and	5	O
epidermal	3	O
growth	3	O
factor	9	O
receptor	3	O
tyrosine	3	B-Chemical
kinase	3	O
inhibitors	3	O
(	9	O
stratum	9	O
2	9	O
)	9	O
,	9	O
received	9	O
RAD001	3	B-Chemical
10	9	O
mg	0	O
/	9	O
day	9	O
until	5	O
progression	9	O
or	5	O
unacceptable	5	O
toxicity	9	B-Disease
.	9	O

Primary	9	O
objective	5	O
was	9	O
overall	5	O
response	9	O
rate	9	O
(	9	O
ORR	9	O
)	9	O
.	9	O

Analyses	9	O
of	5	O
markers	3	O
associated	9	O
with	5	O
the	5	O
mTOR	3	O
pathway	3	O
were	9	O
carried	9	O
out	9	O
on	5	O
archival	5	O
tumor	3	B-Disease
from	9	O
a	5	O
subgroup	9	O
using	9	O
immunohistochemistry	3	O
(	9	O
IHC	9	O
)	9	O
and	5	O
direct	9	O
mutation	1	O
sequencing	9	O
.	9	O

RESULTS	9	O
:	9	O
Eighty	5	O
-	7	O
five	9	O
patients	5	O
were	9	O
enrolled	5	O
,	9	O
42	7	O
in	5	O
stratum	9	O
1	9	O
and	5	O
43	7	O
in	5	O
stratum	9	O
.	9	O

ORR	9	O
was	9	O
4	9	O
.	9	O
7	9	O
%	9	O
(	9	O
7	9	O
.	9	O
1	9	O
%	9	O
stratum	9	O
1	9	O
;	9	O
2	9	O
.	9	O
3	9	O
%	9	O
stratum	9	O
2	9	O
)	9	O
.	9	O

Overall	9	O
disease	5	O
control	9	O
rate	9	O
was	9	O
47	7	O
.	9	O
1	9	O
%	9	O
.	9	O

Median	7	O
progression	9	O
-	7	O
free	9	O
survivals	5	O
(	9	O
PFSs	5	O
)	9	O
were	9	O
2	9	O
.	9	O
6	9	O
(	9	O
stratum	9	O
1	9	O
)	9	O
and	5	O
2	9	O
.	9	O
7	9	O
months	5	O
(	9	O
stratum	9	O
2	9	O
)	9	O
.	9	O

Common	9	O
>	0	O
or	5	O
=	7	O
grade	9	O
3	9	O
events	5	O
were	9	O
fatigue	5	B-Disease
,	9	O
dyspnea	5	B-Disease
,	9	O
stomatitis	9	B-Disease
,	9	O
anemia	9	B-Disease
,	9	O
and	5	O
thrombocytopenia	9	B-Disease
.	9	O

Pneumonitis	7	B-Disease
,	9	O
probably	9	O
or	5	O
possibly	9	O
related	9	O
,	9	O
mainly	9	O
grade	9	O
1	9	O
/	9	O
2	9	O
,	9	O
occurred	9	O
in	5	O
25	9	O
%	9	O
.	9	O

Cox	9	O
regression	5	O
analysis	9	O
of	5	O
IHC	9	O
scores	5	O
found	9	O
that	5	O
only	9	O
phospho	3	O
AKT	3	O
(	9	O
pAKT	3	O
)	9	O
was	9	O
a	5	O
significant	9	O
independent	9	O
predictor	5	O
of	5	O
worse	5	O
PFS	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
RAD001	3	B-Chemical
10	9	O
mg	0	O
/	9	O
day	9	O
was	9	O
well	9	O
tolerated	9	O
,	9	O
showing	9	O
modest	9	O
clinical	5	O
activity	9	O
in	5	O
pretreated	3	O
NSCLC	3	B-Disease
.	9	O

Evaluation	5	O
of	5	O
RAD001	3	B-Chemical
plus	9	O
standard	5	O
therapy	5	O
for	5	O
metastatic	3	O
NSCLC	3	B-Disease
continues	5	O
.	9	O

Posttransplant	5	O
anemia	9	B-Disease
:	9	O
the	5	O
role	9	O
of	5	O
sirolimus	0	B-Chemical
.	9	O

Posttransplant	5	O
anemia	9	B-Disease
is	5	O
a	5	O
common	5	O
problem	5	O
that	5	O
may	5	O
hinder	5	O
patients	5	O
'	9	O
quality	5	O
of	5	O
life	5	O
.	9	O

It	5	O
occurs	9	O
in	5	O
12	9	O
to	5	O
76	7	O
%	9	O
of	5	O
patients	5	O
,	9	O
and	5	O
is	5	O
most	9	O
common	5	O
in	5	O
the	5	O
immediate	5	O
posttransplant	5	O
period	5	O
.	9	O

A	9	O
variety	5	O
of	5	O
factors	9	O
have	5	O
been	9	O
identified	9	O
that	5	O
increase	9	O
the	5	O
risk	5	O
of	5	O
posttransplant	5	O
anemia	9	B-Disease
,	9	O
of	5	O
which	5	O
the	5	O
level	9	O
of	5	O
renal	9	O
function	9	O
is	5	O
most	9	O
important	9	O
.	9	O

Sirolimus	0	B-Chemical
,	9	O
a	5	O
mammalian	9	O
target	9	O
of	5	O
rapamycin	3	B-Chemical
inhibitor	3	O
,	9	O
has	9	O
been	9	O
implicated	9	O
as	5	O
playing	5	O
a	5	O
special	5	O
role	9	O
in	5	O
posttransplant	5	O
anemia	9	B-Disease
.	9	O

This	5	O
review	5	O
considers	5	O
anemia	9	B-Disease
associated	9	O
with	5	O
sirolimus	0	B-Chemical
,	9	O
including	9	O
its	9	O
presentation	5	O
,	9	O
mechanisms	9	O
,	9	O
and	5	O
management	5	O
.	9	O

Coronary	5	O
computerized	5	O
tomography	5	O
angiography	5	O
for	5	O
rapid	5	O
discharge	5	O
of	5	O
low	9	O
-	7	O
risk	5	O
patients	5	O
with	5	O
cocaine	5	B-Chemical
-	7	O
associated	9	O
chest	5	B-Disease
pain	5	I-Disease
.	9	O

BACKGROUND	2	O
:	9	O
Most	5	O
patients	5	O
presenting	5	O
to	5	O
emergency	5	O
departments	5	O
(	9	O
EDs	5	O
)	9	O
with	5	O
cocaine	5	B-Chemical
-	7	O
associated	9	O
chest	5	B-Disease
pain	5	I-Disease
are	5	O
admitted	5	O
for	5	O
at	9	O
least	9	O
12	9	O
hours	9	O
and	5	O
receive	5	O
a	5	O
"	5	O
rule	5	O
out	9	O
acute	9	B-Disease
coronary	5	I-Disease
syndrome	5	I-Disease
"	5	O
protocol	9	O
,	9	O
often	5	O
with	5	O
noninvasive	5	O
testing	5	O
prior	9	O
to	5	O
discharge	5	O
.	9	O

In	9	O
patients	5	O
without	9	O
cocaine	5	B-Chemical
use	5	O
,	9	O
coronary	5	O
computerized	5	O
tomography	5	O
angiography	5	O
(	9	O
CTA	9	O
)	9	O
has	9	O
been	9	O
shown	9	O
to	5	O
be	5	O
useful	5	O
for	5	O
identifying	5	O
a	5	O
group	9	O
of	5	O
patients	5	O
at	9	O
low	9	O
risk	5	O
for	5	O
cardiac	5	O
events	5	O
who	5	O
can	5	O
be	5	O
safely	5	O
discharged	5	O
.	9	O

It	5	O
is	5	O
unclear	9	O
whether	9	O
a	5	O
coronary	5	O
CTA	9	O
strategy	5	O
would	5	O
be	5	O
efficacious	5	O
in	5	O
cocaine	5	B-Chemical
-	7	O
associated	9	O
chest	5	B-Disease
pain	5	I-Disease
,	9	O
as	5	O
coronary	5	B-Disease
vasospasm	5	I-Disease
may	5	O
account	5	O
for	5	O
some	5	O
of	5	O
the	5	O
ischemia	9	B-Disease
.	9	O

We	9	O
studied	9	O
whether	9	O
a	5	O
negative	9	O
coronary	5	O
CTA	9	O
in	5	O
patients	5	O
with	5	O
cocaine	5	B-Chemical
-	7	O
associated	9	O
chest	5	B-Disease
pain	5	I-Disease
could	9	O
identify	9	O
a	5	O
subset	9	O
safe	5	O
for	5	O
discharge	5	O
.	9	O

METHODS	2	O
:	9	O
We	9	O
prospectively	5	O
evaluated	9	O
the	5	O
safety	5	O
of	5	O
coronary	5	O
CTA	9	O
for	5	O
low	9	O
-	7	O
risk	5	O
patients	5	O
who	5	O
presented	5	O
to	5	O
the	5	O
ED	5	O
with	5	O
cocaineassociated	_	O
chest	5	B-Disease
pain	5	I-Disease
(	9	O
self	5	O
-	7	O
reported	9	O
or	5	O
positive	9	O
urine	9	O
test	5	O
)	9	O
.	9	O

Consecutive	5	O
patients	5	O
received	9	O
either	9	O
immediate	5	O
coronary	5	O
CTA	9	O
in	5	O
the	5	O
ED	5	O
(	9	O
without	9	O
serial	9	O
markers	3	O
)	9	O
or	5	O
underwent	5	O
coronary	5	O
CTA	9	O
after	9	O
a	5	O
brief	5	O
observation	9	O
period	5	O
with	5	O
serial	9	O
cardiac	5	O
marker	3	O
measurements	5	O
.	9	O

Patients	5	O
with	5	O
negative	9	O
coronary	5	O
CTA	9	O
(	9	O
maximal	9	O
stenosis	5	B-Disease
less	5	O
than	5	O
50	0	O
%	9	O
)	9	O
were	9	O
discharged	5	O
.	9	O

The	5	O
main	5	O
outcome	5	O
was	9	O
30	9	O
-	7	O
day	9	O
cardiovascular	5	O
death	9	O
or	5	O
myocardial	9	B-Disease
infarction	5	I-Disease
.	9	O

RESULTS	9	O
:	9	O
A	9	O
total	9	O
of	5	O
59	7	O
patients	5	O
with	5	O
cocaine	5	B-Chemical
-	7	O
associated	9	O
chest	5	B-Disease
pain	5	I-Disease
were	9	O
evaluated	9	O
.	9	O

Patients	5	O
had	9	O
a	5	O
mean	5	O
age	5	O
of	5	O
45	9	O
.	9	O
6	9	O
+	9	O
/	9	O
-	7	O
6	9	O
.	9	O
6	9	O
yrs	7	O
and	5	O
were	9	O
86	7	O
%	9	O
black	9	O
,	9	O
66	7	O
%	9	O
male	9	O
.	9	O

Seventy	5	O
-	7	O
nine	9	O
percent	5	O
had	9	O
a	5	O
normal	9	O
or	5	O
nonspecific	3	O
ECG	5	O
and	5	O
85	9	O
%	9	O
had	9	O
a	5	O
TIMI	5	O
score	5	O
<	0	O
2	9	O
.	9	O

Twenty	9	O
patients	5	O
received	9	O
coronary	5	O
CTA	9	O
immediately	9	O
in	5	O
the	5	O
ED	5	O
,	9	O
18	7	O
of	5	O
whom	5	O
were	9	O
discharged	5	O
following	9	O
CTA	9	O
(	9	O
90	9	O
%	9	O
)	9	O
.	9	O

Thirty	9	O
-	7	O
nine	9	O
received	9	O
coronary	5	O
CTA	9	O
after	9	O
a	5	O
brief	5	O
observation	9	O
period	5	O
,	9	O
with	5	O
37	9	O
discharged	5	O
home	5	O
following	9	O
CTA	9	O
(	9	O
95	7	O
%	9	O
)	9	O
.	9	O

Six	9	O
patients	5	O
had	9	O
coronary	5	B-Disease
stenosis	5	I-Disease
>	0	O
or	5	O
=	7	O
50	0	O
%	9	O
.	9	O

During	5	O
the	5	O
30	9	O
-	7	O
day	9	O
follow	5	O
-	7	O
up	5	O
period	5	O
,	9	O
no	9	O
patients	5	O
died	9	O
of	5	O
a	5	O
cardiovascular	5	O
event	5	O
(	9	O
0	7	O
%	9	O
;	9	O
95	7	O
%	9	O
CI	7	O
,	9	O
0	7	O
-	7	O
6	9	O
.	9	O
1	9	O
%	9	O
)	9	O
and	5	O
no	9	O
patient	5	O
sustained	5	O
a	5	O
nonfatal	5	O
myocardial	9	B-Disease
infarction	5	I-Disease
(	9	O
0	7	O
%	9	O
;	9	O
95	7	O
%	9	O
CI	7	O
,	9	O
0	7	O
-	7	O
6	9	O
.	9	O
1	9	O
%	9	O
)	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Although	9	O
cocaine	5	B-Chemical
-	7	O
associated	9	O
myocardial	9	B-Disease
ischemia	9	I-Disease
can	5	O
result	9	O
from	9	O
coronary	5	O
vasoconstriction	9	O
,	9	O
patients	5	O
with	5	O
cocaine	5	B-Chemical
associated	9	O
chest	5	B-Disease
pain	5	I-Disease
,	9	O
a	5	O
non	9	O
-	7	O
ischemic	9	B-Disease
ECG	5	O
,	9	O
and	5	O
a	5	O
TIMI	5	O
risk	5	O
score	5	O
<	0	O
2	9	O
may	5	O
be	5	O
safely	5	O
discharged	5	O
from	9	O
the	5	O
ED	5	O
after	9	O
a	5	O
negative	9	O
coronary	5	O
CTA	9	O
with	5	O
a	5	O
low	9	O
risk	5	O
of	5	O
30	9	O
-	7	O
day	9	O
adverse	5	O
events	5	O
.	9	O

Bilateral	5	O
haemorrhagic	5	B-Disease
infarction	5	I-Disease
of	5	I-Disease
the	5	I-Disease
globus	5	I-Disease
pallidus	4	I-Disease
after	9	O
cocaine	5	B-Chemical
and	5	O
alcohol	5	B-Chemical
intoxication	9	O
.	9	O

Cocaine	5	B-Chemical
is	5	O
a	5	O
risk	5	O
factor	9	O
for	5	O
both	9	O
ischemic	9	B-Disease
and	5	I-Disease
haemorrhagic	5	I-Disease
stroke	5	I-Disease
.	9	O

We	9	O
present	9	O
the	5	O
case	5	O
of	5	O
a	5	O
31	7	O
-	7	O
year	5	O
-	7	O
old	5	O
man	5	O
with	5	O
bilateral	5	O
ischemia	9	B-Disease
of	5	I-Disease
the	5	I-Disease
globus	5	I-Disease
pallidus	4	I-Disease
after	9	O
excessive	5	O
alcohol	5	B-Chemical
and	5	O
intranasal	9	O
cocaine	5	B-Chemical
use	5	O
.	9	O

Drug	5	O
-	7	O
related	9	O
globus	5	B-Disease
pallidus	4	I-Disease
infarctions	5	I-Disease
are	5	O
most	9	O
often	5	O
associated	9	O
with	5	O
heroin	5	B-Chemical
.	9	O

Bilateral	5	O
basal	3	B-Disease
ganglia	5	I-Disease
infarcts	5	I-Disease
after	9	O
the	5	O
use	5	O
of	5	O
cocaine	5	B-Chemical
,	9	O
without	9	O
concurrent	5	O
heroin	5	B-Chemical
use	5	O
,	9	O
have	5	O
never	5	O
been	9	O
reported	9	O
.	9	O

In	9	O
our	5	O
patient	5	O
,	9	O
transient	9	O
cardiac	5	B-Disease
arrhythmia	5	I-Disease
or	5	O
respiratory	5	B-Disease
dysfunction	9	I-Disease
related	9	O
to	5	O
cocaine	5	B-Chemical
and	5	O
/	9	O
or	5	O
ethanol	0	B-Chemical
use	5	O
were	9	O
the	5	O
most	9	O
likely	5	O
causes	9	O
of	5	O
cerebral	5	B-Disease
hypoperfusion	5	I-Disease
.	9	O

Late	9	O
fulminant	5	O
posterior	5	B-Disease
reversible	9	I-Disease
encephalopathy	5	I-Disease
syndrome	5	I-Disease
after	9	O
liver	9	O
transplant	9	O
.	9	O

OBJECTIVES	2	O
:	9	O
Posterior	5	B-Disease
leukoencephalopathy	5	I-Disease
due	5	O
to	5	O
calcineurin	3	O
-	7	O
inhibitor	3	O
-	7	O
related	9	O
neurotoxicity	9	B-Disease
is	5	O
a	5	O
rare	5	O
but	9	O
severe	5	O
complication	5	O
that	5	O
results	9	O
from	9	O
treatment	9	O
with	5	O
immunosuppressive	9	O
agents	5	O
(	9	O
primarily	9	O
those	5	O
administered	9	O
after	9	O
a	5	O
liver	9	O
or	5	O
kidney	9	O
transplant	9	O
)	9	O
.	9	O

The	5	O
pathophysiologic	5	O
mechanisms	9	O
of	5	O
that	5	O
disorder	5	O
remain	9	O
unknown	9	O
.	9	O

CASE	2	O
:	9	O
We	9	O
report	5	O
the	5	O
case	5	O
of	5	O
a	5	O
46	7	O
-	7	O
year	5	O
-	7	O
old	5	O
woman	5	O
who	5	O
received	9	O
a	5	O
liver	9	O
transplant	9	O
in	5	O
our	5	O
center	5	O
as	5	O
treatment	9	O
for	5	O
alcoholic	5	B-Disease
cirrhosis	5	I-Disease
and	5	O
in	5	O
whom	5	O
either	9	O
a	5	O
fulminant	5	O
course	5	O
of	5	O
posterior	5	B-Disease
leukoencephalopathy	5	I-Disease
or	5	O
posterior	5	B-Disease
reversible	9	I-Disease
encephalopathy	5	I-Disease
syndrome	5	I-Disease
developed	5	O
110	9	O
days	9	O
after	9	O
transplant	9	O
.	9	O

After	9	O
an	5	O
initially	9	O
uneventful	5	O
course	5	O
after	9	O
the	5	O
transplant	9	O
,	9	O
the	5	O
patient	5	O
rapidly	9	O
fell	5	O
into	9	O
deep	5	O
coma	5	O
.	9	O

RESULTS	9	O
:	9	O
Cerebral	5	O
MRI	5	O
scan	5	O
showed	9	O
typical	9	O
signs	5	O
of	5	O
enhancement	9	O
in	5	O
the	5	O
pontine	5	O
and	5	O
posterior	5	O
regions	9	O
.	9	O

Switching	5	O
the	5	O
immunosuppressive	9	O
regimen	5	O
from	9	O
tacrolimus	0	B-Chemical
to	5	O
cyclosporine	0	B-Chemical
did	9	O
not	5	O
improve	5	O
the	5	O
clinical	5	O
situation	5	O
.	9	O

The	5	O
termination	9	O
of	5	O
treatment	9	O
with	5	O
any	5	O
calcineurin	3	O
inhibitor	3	O
resulted	9	O
in	5	O
a	5	O
complete	9	O
resolution	5	O
of	5	O
that	5	O
complication	5	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Posterior	5	B-Disease
reversible	9	I-Disease
encephalopathy	5	I-Disease
syndrome	5	I-Disease
after	9	O
liver	9	O
transplant	9	O
is	5	O
rare	5	O
.	9	O

We	9	O
recommend	5	O
a	5	O
complete	9	O
cessation	5	O
of	5	O
any	5	O
calcineurin	3	O
inhibitor	3	O
rather	5	O
than	5	O
a	5	O
dose	9	O
reduction	9	O
.	9	O

Prolonged	9	O
hypothermia	5	B-Disease
as	5	O
a	5	O
bridge	5	O
to	5	O
recovery	9	O
for	5	O
cerebral	5	B-Disease
edema	5	I-Disease
and	5	O
intracranial	5	B-Disease
hypertension	5	I-Disease
associated	9	O
with	5	O
fulminant	5	B-Disease
hepatic	9	I-Disease
failure	5	I-Disease
.	9	O

BACKGROUND	2	O
:	9	O
To	9	O
review	5	O
evidence	9	O
-	7	O
based	5	O
treatment	9	O
options	5	O
in	5	O
patients	5	O
with	5	O
cerebral	5	B-Disease
edema	5	I-Disease
complicating	5	O
fulminant	5	B-Disease
hepatic	9	I-Disease
failure	5	I-Disease
(	9	O
FHF	5	B-Disease
)	9	O
and	5	O
discuss	5	O
the	5	O
potential	9	O
applications	5	O
of	5	O
hypothermia	5	B-Disease
.	9	O

METHOD	2	O
:	9	O
Case	5	O
-	7	O
based	5	O
observations	9	O
from	9	O
a	5	O
medical	5	O
intensive	5	O
care	5	O
unit	5	O
(	9	O
MICU	5	O
)	9	O
in	5	O
a	5	O
tertiary	9	O
care	5	O
facility	5	O
in	5	O
a	5	O
27	7	O
-	7	O
year	5	O
-	7	O
old	5	O
female	9	O
with	5	O
FHF	5	B-Disease
from	9	O
acetaminophen	0	B-Chemical
and	5	O
resultant	9	O
cerebral	5	B-Disease
edema	5	I-Disease
.	9	O

RESULTS	9	O
:	9	O
Our	9	O
patient	5	O
was	9	O
admitted	5	O
to	5	O
the	5	O
MICU	5	O
after	9	O
being	5	O
found	9	O
unresponsive	9	O
with	5	O
presumed	9	O
toxicity	9	B-Disease
from	9	O
acetaminophen	0	B-Chemical
which	5	O
was	9	O
ingested	0	O
over	5	O
a	5	O
2	9	O
-	7	O
day	9	O
period	5	O
.	9	O

The	5	O
patient	5	O
had	9	O
depressed	5	O
of	5	O
mental	5	O
status	9	O
lasting	5	O
at	9	O
least	9	O
24	9	O
h	0	O
prior	9	O
to	5	O
admission	5	O
.	9	O

Initial	9	O
evaluation	5	O
confirmed	9	O
FHF	5	B-Disease
from	9	O
acetaminophen	0	B-Chemical
and	5	O
cerebral	5	B-Disease
edema	5	I-Disease
.	9	O

The	5	O
patient	5	O
was	9	O
treated	3	O
with	5	O
hyperosmolar	5	O
therapy	5	O
,	9	O
hyperventilation	5	B-Disease
,	9	O
sedation	5	O
,	9	O
and	5	O
chemical	0	O
paralysis	5	B-Disease
.	9	O

Her	5	O
intracranial	5	O
pressure	5	O
remained	9	O
elevated	9	O
despite	9	O
maximal	9	O
medical	5	O
therapy	5	O
.	9	O

We	9	O
then	9	O
initiated	9	O
therapeutic	5	O
hypothermia	5	B-Disease
which	5	O
was	9	O
continued	9	O
for	5	O
5	9	O
days	9	O
.	9	O

At	9	O
re	5	O
-	7	O
warming	5	O
,	9	O
patient	5	O
had	9	O
resolution	5	O
of	5	O
her	5	O
cerebral	5	B-Disease
edema	5	I-Disease
and	5	O
intracranial	5	B-Disease
hypertension	5	I-Disease
.	9	O

At	9	O
discharge	5	O
,	9	O
she	5	O
had	9	O
complete	9	O
recovery	9	O
of	5	O
neurological	5	O
and	5	O
hepatic	9	O
functions	9	O
.	9	O

CONCLUSION	5	O
:	9	O
In	9	O
patients	5	O
with	5	O
FHF	5	B-Disease
and	5	O
cerebral	5	B-Disease
edema	5	I-Disease
from	9	O
acetaminophen	0	B-Chemical
overdose	0	B-Disease
,	9	O
prolonged	9	O
therapeutic	5	O
hypothermia	5	B-Disease
could	9	O
potentially	5	O
be	5	O
used	5	O
as	5	O
a	5	O
life	5	O
saving	5	O
therapy	5	O
and	5	O
a	5	O
bridge	5	O
to	5	O
hepatic	9	O
and	5	O
neurological	5	O
recovery	9	O
.	9	O

A	9	O
clinical	5	O
trial	5	O
of	5	O
hypothermia	5	B-Disease
in	5	O
patients	5	O
with	5	O
this	5	O
condition	5	O
is	5	O
warranted	9	O
.	9	O

Binasal	_	B-Disease
visual	5	I-Disease
field	5	I-Disease
defects	9	I-Disease
are	5	O
not	5	O
specific	9	O
to	5	O
vigabatrin	0	B-Chemical
.	9	O

This	5	O
study	9	O
investigated	9	O
the	5	O
visual	5	B-Disease
defects	9	I-Disease
associated	9	O
with	5	O
the	5	O
antiepileptic	5	O
drug	5	O
vigabatrin	0	B-Chemical
(	9	O
VGB	0	B-Chemical
)	9	O
.	9	O

Two	9	O
hundred	5	O
four	9	O
people	5	O
with	5	O
epilepsy	5	B-Disease
were	9	O
grouped	9	O
on	5	O
the	5	O
basis	5	O
of	5	O
antiepileptic	5	O
drug	5	O
therapy	5	O
(	9	O
current	5	O
,	9	O
previous	9	O
,	9	O
or	5	O
no	9	O
exposure	9	O
to	5	O
VGB	0	B-Chemical
)	9	O
.	9	O

Groups	9	O
were	9	O
matched	9	O
with	5	O
respect	9	O
to	5	O
age	5	O
,	9	O
gender	5	O
,	9	O
and	5	O
seizure	5	B-Disease
frequency	5	O
.	9	O

All	9	O
patients	5	O
underwent	5	O
objective	5	O
assessment	5	O
of	5	O
electrophysiological	5	O
function	9	O
(	9	O
wide	5	O
-	7	O
field	5	O
multifocal	5	O
electroretinography	5	O
)	9	O
and	5	O
conventional	5	O
visual	5	O
field	5	O
testing	5	O
(	9	O
static	5	O
perimetry	5	O
)	9	O
.	9	O

Bilateral	5	O
visual	5	O
field	5	O
constriction	5	O
was	9	O
observed	9	O
in	5	O
59	7	O
%	9	O
of	5	O
patients	5	O
currently	5	O
taking	5	O
VGB	0	B-Chemical
,	9	O
43	7	O
%	9	O
of	5	O
patients	5	O
who	5	O
previously	9	O
took	5	O
VGB	0	B-Chemical
,	9	O
and	5	O
24	9	O
%	9	O
of	5	O
patients	5	O
with	5	O
no	9	O
exposure	9	O
to	5	O
VGB	0	B-Chemical
.	9	O

Assessment	5	O
of	5	O
retinal	5	O
function	9	O
revealed	9	O
abnormal	9	O
responses	5	O
in	5	O
48	9	O
%	9	O
of	5	O
current	5	O
VGB	0	B-Chemical
users	5	O
and	5	O
22	7	O
%	9	O
of	5	O
prior	9	O
VGB	0	B-Chemical
users	5	O
,	9	O
but	9	O
in	5	O
none	9	O
of	5	O
the	5	O
patients	5	O
without	9	O
previous	9	O
exposure	9	O
to	5	O
VGB	0	B-Chemical
.	9	O

Bilateral	5	B-Disease
visual	5	I-Disease
field	5	I-Disease
abnormalities	9	I-Disease
are	5	O
common	5	O
in	5	O
the	5	O
treated	3	O
epilepsy	5	B-Disease
population	5	O
,	9	O
irrespective	9	O
of	5	O
drug	5	O
history	5	O
.	9	O

Assessment	5	O
by	9	O
conventional	5	O
static	5	O
perimetry	5	O
may	5	O
neither	9	O
be	5	O
sufficiently	5	O
sensitive	9	O
nor	9	O
specific	9	O
to	5	O
reliably	5	O
identify	9	O
retinal	5	B-Disease
toxicity	9	I-Disease
associated	9	O
with	5	O
VGB	0	B-Chemical
.	9	O

Smoking	7	O
of	5	O
crack	5	B-Chemical
cocaine	5	I-Chemical
as	5	O
a	5	O
risk	5	O
factor	9	O
for	5	O
HIV	5	B-Disease
infection	9	I-Disease
among	5	O
people	5	O
who	5	O
use	5	O
injection	9	O
drugs	5	O
.	9	O

BACKGROUND	2	O
:	9	O
Little	9	O
is	5	O
known	9	O
about	5	O
the	5	O
possible	5	O
role	9	O
that	5	O
smoking	5	O
crack	5	B-Chemical
cocaine	5	I-Chemical
has	9	O
on	5	O
the	5	O
incidence	5	O
of	5	O
HIV	5	B-Disease
infection	9	I-Disease
.	9	O

Given	9	O
the	5	O
increasing	9	O
use	5	O
of	5	O
crack	5	B-Chemical
cocaine	5	I-Chemical
,	9	O
we	5	O
sought	9	O
to	5	O
examine	9	O
whether	9	O
use	5	O
of	5	O
this	5	O
illicit	5	O
drug	5	O
has	9	O
become	5	O
a	5	O
risk	5	O
factor	9	O
for	5	O
HIV	5	B-Disease
infection	9	I-Disease
.	9	O

METHODS	2	O
:	9	O
We	9	O
included	5	O
data	5	O
from	9	O
people	5	O
participating	5	O
in	5	O
the	5	O
Vancouver	2	O
Injection	9	O
Drug	5	O
Users	5	O
Study	5	O
who	5	O
reported	9	O
injecting	9	O
illicit	5	O
drugs	5	O
at	9	O
least	9	O
once	5	O
in	5	O
the	5	O
month	5	O
before	9	O
enrolment	5	O
,	9	O
lived	5	O
in	5	O
the	5	O
greater	5	O
Vancouver	2	O
area	5	O
,	9	O
were	9	O
HIV	5	O
-	7	O
negative	9	O
at	9	O
enrolment	5	O
and	5	O
completed	5	O
at	9	O
least	9	O
1	9	O
follow	5	O
-	7	O
up	5	O
study	9	O
visit	5	O
.	9	O

To	9	O
determine	9	O
whether	9	O
the	5	O
risk	5	O
of	5	O
HIV	5	B-Disease
seroconversion	5	I-Disease
among	5	O
daily	5	O
smokers	5	O
of	5	O
crack	5	B-Chemical
cocaine	5	I-Chemical
changed	9	O
over	5	O
time	5	O
,	9	O
we	5	O
used	5	O
Cox	9	O
proportional	5	O
hazards	5	O
regression	5	O
and	5	O
divided	5	O
the	5	O
study	9	O
into	9	O
3	9	O
periods	5	O
:	9	O
May	2	O
1	9	O
,	9	O
1996	2	O
-	7	O
Nov	2	O
.	9	O

30	9	O
,	9	O
1999	2	O
(	9	O
period	5	O
1	9	O
)	9	O
,	9	O
Dec	2	O
.	9	O

1	9	O
,	9	O
1999	2	O
-	7	O
Nov	2	O
.	9	O

30	9	O
,	9	O
2002	2	O
(	9	O
period	5	O
2	9	O
)	9	O
,	9	O
and	5	O
Dec	2	O
.	9	O

1	9	O
,	9	O
2002	2	O
-	7	O
Dec	2	O
.	9	O

30	9	O
,	9	O
2005	2	O
(	9	O
period	5	O
3	9	O
)	9	O
.	9	O

RESULTS	9	O
:	9	O
Overall	9	O
,	9	O
1048	7	O
eligible	5	O
injection	9	O
drug	5	O
users	5	O
were	9	O
included	5	O
in	5	O
our	5	O
study	9	O
.	9	O

Of	9	O
these	5	O
,	9	O
137	7	O
acquired	5	O
HIV	5	B-Disease
infection	9	I-Disease
during	5	O
follow	5	O
-	7	O
up	5	O
.	9	O

The	5	O
mean	5	O
proportion	9	O
of	5	O
participants	5	O
who	5	O
reported	9	O
daily	5	O
smoking	5	O
of	5	O
crack	5	B-Chemical
cocaine	5	I-Chemical
increased	9	O
from	9	O
11	7	O
.	9	O
6	9	O
%	9	O
in	5	O
period	5	O
1	9	O
to	5	O
39	7	O
.	9	O
7	9	O
%	9	O
in	5	O
period	5	O
3	9	O
.	9	O

After	9	O
adjusting	5	O
for	5	O
potential	9	O
confounders	5	O
,	9	O
we	5	O
found	9	O
that	5	O
the	5	O
risk	5	O
of	5	O
HIV	5	B-Disease
seroconversion	5	I-Disease
among	5	O
participants	5	O
who	5	O
were	9	O
daily	5	O
smokers	5	O
of	5	O
crack	5	B-Chemical
cocaine	5	I-Chemical
increased	9	O
over	5	O
time	5	O
(	9	O
period	5	O
1	9	O
:	9	O
hazard	5	O
ratio	9	O
[	9	O
HR	9	O
]	9	O
1	9	O
.	9	O
03	7	O
,	9	O
95	7	O
%	9	O
confidence	5	O
interval	5	O
[	9	O
CI	7	O
]	9	O
0	7	O
.	9	O
57	7	O
-	7	O
1	9	O
.	9	O
85	9	O
;	9	O
period	5	O
2	9	O
:	9	O
HR	9	O
1	9	O
.	9	O
68	7	O
,	9	O
95	7	O
%	9	O
CI	7	O
1	9	O
.	9	O
01	7	O
-	7	O
2	9	O
.	9	O
80	9	O
;	9	O
and	5	O
period	5	O
3	9	O
:	9	O
HR	9	O
2	9	O
.	9	O
74	7	O
,	9	O
95	7	O
%	9	O
CI	7	O
1	9	O
.	9	O
06	7	O
-	7	O
7	9	O
.	9	O
11	7	O
)	9	O
.	9	O

INTERPRETATION	2	O
:	9	O
Smoking	7	O
of	5	O
crack	5	B-Chemical
cocaine	5	I-Chemical
was	9	O
found	9	O
to	5	O
be	5	O
an	5	O
independent	9	O
risk	5	O
factor	9	O
for	5	O
HIV	5	B-Disease
seroconversion	5	I-Disease
among	5	O
people	5	O
who	5	O
were	9	O
injection	9	O
drug	5	O
users	5	O
.	9	O

This	5	O
finding	9	O
points	5	O
to	5	O
the	5	O
urgent	5	O
need	5	O
for	5	O
evidence	9	O
-	7	O
based	5	O
public	5	O
health	5	O
initiatives	5	O
targeted	9	O
at	9	O
people	5	O
who	5	O
smoke	5	O
crack	5	B-Chemical
cocaine	5	I-Chemical
.	9	O

Fluoxetine	0	B-Chemical
improves	5	O
the	5	O
memory	5	B-Disease
deficits	5	I-Disease
caused	9	O
by	9	O
the	5	O
chemotherapy	5	O
agent	9	O
5	9	B-Chemical
-	7	I-Chemical
fluorouracil	0	I-Chemical
.	9	O

Cancer	2	B-Disease
patients	5	O
who	5	O
have	5	O
been	9	O
treated	3	O
with	5	O
systemic	9	O
adjuvant	9	O
chemotherapy	5	O
have	5	O
described	9	O
experiencing	5	O
deteriorations	5	O
in	5	O
cognition	5	O
.	9	O

A	9	O
widely	5	O
used	5	O
chemotherapeutic	3	O
agent	9	O
,	9	O
5	9	B-Chemical
-	7	I-Chemical
fluorouracil	0	I-Chemical
(	9	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
)	9	O
,	9	O
readily	9	O
crosses	9	O
the	5	O
blood	9	O
-	7	O
brain	5	O
barrier	5	O
and	5	O
so	5	O
could	9	O
have	5	O
a	5	O
direct	9	O
effect	9	O
on	5	O
brain	5	O
function	9	O
.	9	O

In	9	O
particular	5	O
this	5	O
anti	3	O
mitotic	3	O
drug	5	O
could	9	O
reduce	5	O
cell	3	O
proliferation	3	O
in	5	O
the	5	O
neurogenic	5	O
regions	9	O
of	5	O
the	5	O
adult	9	O
brain	5	O
.	9	O

In	9	O
contrast	9	O
reports	9	O
indicate	9	O
that	5	O
hippocampal	3	O
dependent	9	O
neurogenesis	3	O
and	5	O
cognition	5	O
are	5	O
enhanced	3	O
by	9	O
the	5	O
SSRI	5	B-Chemical
antidepressant	5	O
Fluoxetine	0	B-Chemical
.	9	O

In	9	O
this	5	O
investigation	9	O
the	5	O
behavioural	5	O
effects	9	O
of	5	O
chronic	5	O
(	9	O
two	5	O
week	9	O
)	9	O
treatment	9	O
with	5	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
and	5	O
(	9	O
three	9	O
weeks	9	O
)	9	O
with	5	O
Fluoxetine	0	B-Chemical
either	9	O
separately	9	O
or	5	O
in	5	O
combination	9	O
with	5	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
were	9	O
tested	9	O
on	5	O
adult	9	O
Lister	6	O
hooded	4	O
rats	9	O
.	9	O

Behavioural	5	O
effects	9	O
were	9	O
tested	9	O
using	9	O
a	5	O
context	5	O
dependent	9	O
conditioned	9	O
emotional	5	O
response	9	O
test	5	O
(	9	O
CER	5	O
)	9	O
which	5	O
showed	9	O
that	5	O
animals	9	O
treated	3	O
with	5	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
had	9	O
a	5	O
significant	9	O
reduction	9	O
in	5	O
freezing	5	O
time	5	O
compared	9	O
to	5	O
controls	9	O
.	9	O

A	9	O
separate	9	O
group	9	O
of	5	O
animals	9	O
was	9	O
tested	9	O
using	9	O
a	5	O
hippocampal	3	O
dependent	9	O
spatial	5	O
working	5	O
memory	5	O
test	5	O
,	9	O
the	5	O
object	5	O
location	5	O
recognition	5	O
test	5	O
(	9	O
OLR	5	O
)	9	O
.	9	O

Animals	9	O
treated	3	O
only	9	O
with	5	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
showed	9	O
significant	9	O
deficits	5	O
in	5	O
their	5	O
ability	9	O
to	5	O
carry	9	O
out	9	O
the	5	O
OLR	5	O
task	5	O
but	9	O
co	9	O
administration	9	O
of	5	O
Fluoxetine	0	B-Chemical
improved	5	O
their	5	O
performance	5	O
.	9	O

5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
chemotherapy	5	O
caused	9	O
a	5	O
significant	9	O
reduction	9	O
in	5	O
the	5	O
number	9	O
of	5	O
proliferating	3	O
cells	3	O
in	5	O
the	5	O
sub	9	O
granular	9	O
zone	9	O
of	5	O
the	5	O
dentate	3	O
gyrus	5	O
compared	9	O
to	5	O
controls	9	O
.	9	O

This	5	O
reduction	9	O
was	9	O
eliminated	9	O
when	5	O
Fluoxetine	0	B-Chemical
was	9	O
co	9	O
administered	9	O
with	5	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
.	9	O

Fluoxetine	0	B-Chemical
on	5	O
its	9	O
own	5	O
had	9	O
no	9	O
effect	9	O
on	5	O
proliferating	3	O
cell	3	O
number	9	O
or	5	O
behaviour	5	O
.	9	O

These	5	O
findings	9	O
suggest	9	O
that	5	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
can	5	O
negatively	9	O
affect	9	O
both	9	O
cell	3	O
proliferation	3	O
and	5	O
hippocampal	3	O
dependent	9	O
working	5	O
memory	5	O
and	5	O
that	5	O
these	5	O
deficits	5	O
can	5	O
be	5	O
reversed	9	O
by	9	O
the	5	O
simultaneous	5	O
administration	9	O
of	5	O
the	5	O
antidepressant	5	O
Fluoxetine	0	B-Chemical
.	9	O

Liver	9	O
-	7	O
specific	9	O
ablation	9	O
of	5	O
integrin	3	O
-	7	O
linked	9	O
kinase	3	O
in	5	O
mice	3	O
results	9	O
in	5	O
enhanced	3	O
and	5	O
prolonged	9	O
cell	3	O
proliferation	3	O
and	5	O
hepatomegaly	5	B-Disease
after	9	O
phenobarbital	0	B-Chemical
administration	9	O
.	9	O

We	9	O
have	5	O
recently	9	O
demonstrated	9	O
that	5	O
disruption	9	O
of	5	O
extracellular	9	O
matrix	5	O
(	9	O
ECM	3	O
)	9	O
/	9	O
integrin	3	O
signaling	3	O
via	9	O
elimination	9	O
of	5	O
integrin	3	O
-	7	O
linked	9	O
kinase	3	O
(	9	O
ILK	3	O
)	9	O
in	5	O
hepatocytes	3	O
interferes	9	O
with	5	O
signals	9	O
leading	9	O
to	5	O
termination	9	O
of	5	O
liver	9	O
regeneration	9	O
.	9	O

This	5	O
study	9	O
investigates	5	O
the	5	O
role	9	O
of	5	O
ILK	3	O
in	5	O
liver	9	O
enlargement	5	O
induced	3	O
by	9	O
phenobarbital	0	B-Chemical
(	9	O
PB	9	B-Chemical
)	9	O
.	9	O

Wild	4	O
-	7	O
type	9	O
(	9	O
WT	3	O
)	9	O
and	5	O
ILK	3	O
:	9	O
liver	9	O
-	7	O
/	9	O
-	7	O
mice	3	O
were	9	O
given	5	O
PB	9	B-Chemical
(	9	O
0	7	O
.	9	O
1	9	O
%	9	O
in	5	O
drinking	5	O
water	0	O
)	9	O
for	5	O
10	9	O
days	9	O
.	9	O

Livers	3	O
were	9	O
harvested	3	O
on	5	O
2	9	O
,	9	O
5	9	O
,	9	O
and	5	O
10	9	O
days	9	O
during	5	O
PB	9	B-Chemical
administration	9	O
.	9	O

In	9	O
the	5	O
hepatocyte	3	O
-	7	O
specific	9	O
ILK	3	O
/	9	O
liver	9	O
-	7	O
/	9	O
-	7	O
mice	3	O
,	9	O
the	5	O
liver	9	O
:	9	O
body	5	O
weight	9	O
ratio	9	O
was	9	O
more	5	O
than	5	O
double	9	O
as	5	O
compared	9	O
to	5	O
0	7	O
h	0	O
at	9	O
day	9	O
2	9	O
(	9	O
2	9	O
.	9	O
5	9	O
times	5	O
)	9	O
,	9	O
while	9	O
at	9	O
days	9	O
5	9	O
and	5	O
10	9	O
,	9	O
it	5	O
was	9	O
enlarged	9	O
three	9	O
times	5	O
.	9	O

In	9	O
the	5	O
WT	3	O
mice	3	O
,	9	O
the	5	O
increase	9	O
was	9	O
as	5	O
expected	9	O
from	9	O
previous	9	O
literature	5	O
(	9	O
1	9	O
.	9	O
8	9	O
times	5	O
)	9	O
and	5	O
seems	5	O
to	5	O
have	5	O
leveled	5	O
off	5	O
after	9	O
day	9	O
2	9	O
.	9	O

There	5	O
were	9	O
slightly	9	O
increased	9	O
proliferating	3	O
cell	3	O
nuclear	3	O
antigen	3	O
-	7	O
positive	9	O
cells	3	O
in	5	O
the	5	O
ILK	3	O
/	9	O
liver	9	O
-	7	O
/	9	O
-	7	O
animals	9	O
at	9	O
day	9	O
2	9	O
as	5	O
compared	9	O
to	5	O
WT	3	O
after	9	O
PB	9	B-Chemical
administration	9	O
.	9	O

In	9	O
the	5	O
WT	3	O
animals	9	O
,	9	O
the	5	O
proliferative	3	O
response	9	O
had	9	O
come	5	O
back	5	O
to	5	O
normal	9	O
by	9	O
days	9	O
5	9	O
and	5	O
10	9	O
.	9	O

Hepatocytes	3	O
of	5	O
the	5	O
ILK	3	O
/	9	O
liver	9	O
-	7	O
/	9	O
-	7	O
mice	3	O
continued	9	O
to	5	O
proliferate	3	O
up	5	O
until	5	O
day	9	O
10	9	O
.	9	O

ILK	3	O
/	9	O
liver	9	O
-	7	O
/	9	O
-	7	O
mice	3	O
also	9	O
showed	9	O
increased	9	O
expression	3	O
of	5	O
key	9	O
genes	1	O
involved	9	O
in	5	O
hepatocyte	3	O
proliferation	3	O
at	9	O
different	9	O
time	5	O
points	5	O
during	5	O
PB	9	B-Chemical
administration	9	O
.	9	O

In	9	O
summary	9	O
,	9	O
ECM	3	O
proteins	1	O
communicate	5	O
with	5	O
the	5	O
signaling	3	O
machinery	9	O
of	5	O
dividing	9	O
cells	3	O
via	9	O
ILK	3	O
to	5	O
regulate	3	O
hepatocyte	3	O
proliferation	3	O
and	5	O
termination	9	O
of	5	O
the	5	O
proliferative	3	O
response	9	O
.	9	O

Lack	9	O
of	5	O
ILK	3	O
in	5	O
the	5	O
hepatocytes	3	O
imparts	9	O
prolonged	9	O
proliferative	3	O
response	9	O
not	5	O
only	9	O
to	5	O
stimuli	5	O
related	9	O
to	5	O
liver	9	O
regeneration	9	O
but	9	O
also	9	O
to	5	O
xenobiotic	0	O
chemical	0	O
mitogens	3	O
,	9	O
such	5	O
as	5	O
PB	9	B-Chemical
.	9	O

Decreased	9	O
Expression	3	O
of	5	O
Na	0	B-Chemical
/	9	O
K	9	B-Chemical
-	7	O
ATPase	1	O
,	9	O
NHE3	3	O
,	9	O
NBC1	3	O
,	9	O
AQP1	3	O
and	5	O
OAT	9	O
in	5	O
Gentamicin	0	B-Chemical
-	7	O
induced	3	O
Nephropathy	7	B-Disease
.	9	O

The	5	O
present	9	O
study	9	O
was	9	O
aimed	5	O
to	5	O
determine	9	O
whether	9	O
there	5	O
is	5	O
an	5	O
altered	9	O
regulation	9	O
of	5	O
tubular	9	O
transporters	1	O
in	5	O
gentamicin	0	B-Chemical
-	7	O
induced	3	O
nephropathy	9	B-Disease
.	9	O

Sprague	9	O
-	7	O
Dawley	0	O
male	9	O
rats	9	O
(	9	O
200	0	O
~	9	O
250	0	O
g	0	O
)	9	O
were	9	O
subcutaneously	3	O
injected	3	O
with	5	O
gentamicin	0	B-Chemical
(	9	O
100	0	O
mg	0	O
/	9	O
kg	0	O
per	9	O
day	9	O
)	9	O
for	5	O
7	9	O
days	9	O
,	9	O
and	5	O
the	5	O
expression	3	O
of	5	O
tubular	9	O
transporters	1	O
was	9	O
determined	9	O
by	9	O
immunoblotting	3	O
and	5	O
immunohistochemistry	3	O
.	9	O

The	5	O
mRNA	3	O
and	5	O
protein	1	O
expression	3	O
of	5	O
OAT	9	O
was	9	O
also	9	O
determined	9	O
.	9	O

Gentamicin	0	B-Chemical
-	7	O
treated	3	O
rats	9	O
exhibited	9	O
significantly	9	O
decreased	9	O
creatinine	0	B-Chemical
clearance	9	O
along	9	O
with	5	O
increased	9	O
plasma	9	O
creatinine	0	B-Chemical
levels	3	O
.	9	O

Accordingly	9	O
,	9	O
the	5	O
fractional	5	O
excretion	0	O
of	5	O
sodium	0	B-Chemical
increased	9	O
.	9	O

Urine	9	O
volume	9	O
was	9	O
increased	9	O
,	9	O
while	9	O
urine	9	O
osmolality	0	O
and	5	O
free	9	O
water	0	O
reabsorption	0	O
were	9	O
decreased	9	O
.	9	O

Immunoblotting	3	O
and	5	O
immunohistochemistry	3	O
revealed	9	O
decreased	9	O
expression	3	O
of	5	O
Na	0	B-Chemical
(	9	O
+	9	O
)	9	O
/	9	O
K	9	B-Chemical
(	9	O
+	9	O
)	9	O
-	7	O
ATPase	1	O
,	9	O
NHE3	3	O
,	9	O
NBC1	3	O
,	9	O
and	5	O
AQP1	3	O
in	5	O
the	5	O
kidney	9	O
of	5	O
gentamicin	0	B-Chemical
-	7	O
treated	3	O
rats	9	O
.	9	O

The	5	O
expression	3	O
of	5	O
OAT1	3	O
and	5	O
OAT3	3	O
was	9	O
also	9	O
decreased	9	O
.	9	O

Gentamicin	0	B-Chemical
-	7	O
induced	3	O
nephropathy	9	B-Disease
may	5	O
at	9	O
least	9	O
in	5	O
part	9	O
be	5	O
causally	9	O
related	9	O
with	5	O
a	5	O
decreased	9	O
expression	3	O
of	5	O
Na	0	B-Chemical
(	9	O
+	9	O
)	9	O
/	9	O
K	9	B-Chemical
(	9	O
+	9	O
)	9	O
-	7	O
ATPase	1	O
,	9	O
NHE3	3	O
,	9	O
NBC1	3	O
,	9	O
AQP1	3	O
and	5	O
OAT	9	O
.	9	O

Acute	5	B-Disease
renal	9	I-Disease
failure	5	I-Disease
after	9	O
high	9	O
-	7	O
dose	9	O
methotrexate	9	B-Chemical
therapy	5	O
in	5	O
a	5	O
patient	5	O
with	5	O
ileostomy	5	O
.	9	O

High	9	O
-	7	O
dose	9	O
methotrexate	9	B-Chemical
(	9	O
HD	9	O
-	7	O
MTX	0	B-Chemical
)	9	O
is	5	O
an	5	O
important	9	O
treatment	9	O
for	5	O
Burkitt	3	B-Disease
lymphoma	9	I-Disease
,	9	O
but	9	O
can	5	O
cause	5	O
hepatic	9	B-Disease
and	5	I-Disease
renal	9	I-Disease
toxicity	9	I-Disease
when	5	O
its	9	O
clearance	9	O
is	5	O
delayed	9	O
.	9	O

We	9	O
report	5	O
a	5	O
case	5	O
of	5	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
after	9	O
HD	9	O
-	7	O
MTX	0	B-Chemical
therapy	5	O
in	5	O
a	5	O
patient	5	O
with	5	O
ileostomy	5	O
,	9	O
The	5	O
patient	5	O
was	9	O
a	5	O
3	9	O
-	7	O
year	5	O
-	7	O
old	5	O
boy	5	O
who	5	O
had	9	O
received	9	O
a	5	O
living	5	O
-	7	O
related	9	O
liver	9	O
transplantation	9	O
for	5	O
congenital	5	O
biliary	5	B-Disease
atresia	5	I-Disease
.	9	O

At	9	O
day	9	O
833	7	O
after	9	O
the	5	O
transplantation	9	O
,	9	O
he	5	O
was	9	O
diagnosed	5	O
with	5	O
PTLD	5	B-Disease
(	9	O
post	9	B-Disease
-	7	I-Disease
transplantation	9	I-Disease
lymphoproliferative	3	I-Disease
disorder	5	I-Disease
,	9	O
Burkitt	3	B-Disease
-	7	I-Disease
type	9	I-Disease
malignant	3	I-Disease
lymphoma	9	I-Disease
)	9	O
.	9	O

During	5	O
induction	3	O
therapy	5	O
,	9	O
he	5	O
suffered	5	O
ileal	9	O
perforation	5	O
and	5	O
ileostomy	5	O
was	9	O
performed	9	O
.	9	O

Subsequent	9	O
HD	9	O
-	7	O
MTX	0	B-Chemical
therapy	5	O
caused	9	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
that	5	O
required	9	O
continuous	5	O
hemodialysis	5	O
.	9	O

We	9	O
supposed	5	O
that	5	O
intravascular	5	O
hypovolemia	5	B-Disease
due	5	O
to	5	O
substantial	9	O
drainage	5	O
from	9	O
the	5	O
ileostoma	5	O
caused	9	O
acute	9	B-Disease
prerenal	5	I-Disease
failure	5	I-Disease
.	9	O

After	9	O
recovery	9	O
of	5	O
his	5	O
renal	9	O
function	9	O
,	9	O
we	5	O
could	9	O
safely	5	O
treat	5	O
the	5	O
patient	5	O
with	5	O
HD	9	O
-	7	O
MTX	0	B-Chemical
therapy	5	O
by	9	O
controlling	9	O
drainage	5	O
from	9	O
ileostoma	5	O
with	5	O
total	9	O
parenteral	5	O
nutrition	5	O
.	9	O

Longitudinal	5	O
association	9	O
of	5	O
alcohol	5	B-Chemical
use	5	O
with	5	O
HIV	5	B-Disease
disease	5	I-Disease
progression	9	O
and	5	O
psychological	5	O
health	5	O
of	5	O
women	5	O
with	5	O
HIV	5	O
.	9	O

We	9	O
evaluated	9	O
the	5	O
association	9	O
of	5	O
alcohol	5	B-Chemical
consumption	5	O
and	5	O
depression	5	B-Disease
,	9	O
and	5	O
their	5	O
effects	9	O
on	5	O
HIV	5	B-Disease
disease	5	I-Disease
progression	9	O
among	5	O
women	5	O
with	5	O
HIV	5	O
.	9	O

The	5	O
study	9	O
included	5	O
871	7	O
women	5	O
with	5	O
HIV	5	O
who	5	O
were	9	O
recruited	9	O
from	9	O
1993	2	O
-	7	O
1995	2	O
in	5	O
four	9	O
US	5	O
cities	5	O
.	9	O

The	5	O
participants	5	O
had	9	O
physical	5	O
examination	5	O
,	9	O
medical	5	O
record	5	O
extraction	9	O
,	9	O
and	5	O
venipuncture	5	O
,	9	O
CD4	3	O
+	9	O
T	3	O
-	7	O
cell	3	O
counts	9	O
determination	9	O
,	9	O
measurement	5	O
of	5	O
depression	5	B-Disease
symptoms	5	O
(	9	O
using	9	O
the	5	O
self	5	O
-	7	O
report	5	O
Center	2	O
for	5	O
Epidemiological	5	O
Studies	9	O
-	7	O
Depression	5	B-Disease
Scale	5	O
)	9	O
,	9	O
and	5	O
alcohol	5	B-Chemical
use	5	O
assessment	5	O
at	9	O
enrollment	5	O
,	9	O
and	5	O
semiannually	5	O
until	5	O
March	2	O
2000	9	O
.	9	O

Multilevel	5	O
random	5	O
coefficient	5	O
ordinal	5	O
models	5	O
as	5	O
well	9	O
as	5	O
multilevel	5	O
models	5	O
with	5	O
joint	5	O
responses	5	O
were	9	O
used	5	O
in	5	O
the	5	O
analysis	9	O
.	9	O

There	5	O
was	9	O
no	9	O
significant	9	O
association	9	O
between	5	O
level	9	O
of	5	O
alcohol	5	B-Chemical
use	5	O
and	5	O
CD4	3	O
+	9	O
T	3	O
-	7	O
cell	3	O
counts	9	O
.	9	O

When	9	O
participants	5	O
were	9	O
stratified	5	O
by	9	O
antiretroviral	5	O
therapy	5	O
(	9	O
ART	5	O
)	9	O
use	5	O
,	9	O
the	5	O
association	9	O
between	5	O
alcohol	5	B-Chemical
and	5	O
CD4	3	O
+	9	O
T	3	O
-	7	O
cell	3	O
did	9	O
not	5	O
reach	5	O
statistical	5	O
significance	9	O
.	9	O

The	5	O
association	9	O
between	5	O
alcohol	5	B-Chemical
consumption	5	O
and	5	O
depression	5	B-Disease
was	9	O
significant	9	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
.	9	O

Depression	5	B-Disease
had	9	O
a	5	O
significant	9	O
negative	9	O
effect	9	O
on	5	O
CD4	3	O
+	9	O
T	3	O
-	7	O
cell	3	O
counts	9	O
over	5	O
time	5	O
regardless	9	O
of	5	O
ART	5	O
use	5	O
.	9	O

Our	9	O
findings	9	O
suggest	9	O
that	5	O
alcohol	5	B-Chemical
consumption	5	O
has	9	O
a	5	O
direct	9	O
association	9	O
with	5	O
depression	5	B-Disease
.	9	O

Moreover	9	O
,	9	O
depression	5	B-Disease
is	5	O
associated	9	O
with	5	O
HIV	5	B-Disease
disease	5	I-Disease
progression	9	O
.	9	O

Our	9	O
findings	9	O
have	5	O
implications	5	O
for	5	O
the	5	O
provision	5	O
of	5	O
alcohol	5	B-Chemical
use	5	O
interventions	5	O
and	5	O
psychological	5	O
resources	5	O
to	5	O
improve	5	O
the	5	O
health	5	O
of	5	O
women	5	O
with	5	O
HIV	5	O
.	9	O

Chemokine	3	O
CCL2	3	O
and	5	O
its	9	O
receptor	3	O
CCR2	3	O
are	5	O
increased	9	O
in	5	O
the	5	O
hippocampus	9	O
following	9	O
pilocarpine	0	B-Chemical
-	7	O
induced	3	O
status	9	B-Disease
epilepticus	5	I-Disease
.	9	O

BACKGROUND	2	O
:	9	O
Neuroinflammation	3	B-Disease
occurs	9	O
after	9	O
seizures	5	B-Disease
and	5	O
is	5	O
implicated	9	O
in	5	O
epileptogenesis	5	O
.	9	O

CCR2	3	O
is	5	O
a	5	O
chemokine	3	O
receptor	3	O
for	5	O
CCL2	3	O
and	5	O
their	5	O
interaction	9	O
mediates	3	O
monocyte	3	O
infiltration	3	O
in	5	O
the	5	O
neuroinflammatory	3	B-Disease
cascade	9	O
triggered	9	O
in	5	O
different	9	O
brain	5	O
pathologies	5	O
.	9	O

In	9	O
this	5	O
work	5	O
CCR2	3	O
and	5	O
CCL2	3	O
expression	3	O
were	9	O
examined	9	O
following	9	O
status	9	B-Disease
epilepticus	5	I-Disease
(	9	O
SE	9	B-Disease
)	9	O
induced	3	O
by	9	O
pilocarpine	0	B-Chemical
injection	9	O
.	9	O

METHODS	2	O
:	9	O
SE	9	B-Disease
was	9	O
induced	3	O
by	9	O
pilocarpine	0	B-Chemical
injection	9	O
.	9	O

Control	9	O
rats	9	O
were	9	O
injected	3	O
with	5	O
saline	0	O
instead	5	O
of	5	O
pilocarpine	0	B-Chemical
.	9	O

Five	9	O
days	9	O
after	9	O
SE	9	B-Disease
,	9	O
CCR2	3	O
staining	3	O
in	5	O
neurons	3	O
and	5	O
glial	3	O
cells	3	O
was	9	O
examined	9	O
using	9	O
imunohistochemical	3	O
analyses	9	O
.	9	O

The	5	O
number	9	O
of	5	O
CCR2	3	O
positive	9	O
cells	3	O
was	9	O
determined	9	O
using	9	O
stereology	5	O
probes	9	O
in	5	O
the	5	O
hippocampus	9	O
.	9	O

CCL2	3	O
expression	3	O
in	5	O
the	5	O
hippocampus	9	O
was	9	O
examined	9	O
by	9	O
molecular	9	O
assay	3	O
.	9	O

RESULTS	9	O
:	9	O
Increased	9	O
CCR2	3	O
was	9	O
observed	9	O
in	5	O
the	5	O
hippocampus	9	O
after	9	O
SE	9	B-Disease
.	9	O

Seizures	5	B-Disease
also	9	O
resulted	9	O
in	5	O
alterations	9	O
to	5	O
the	5	O
cell	3	O
types	9	O
expressing	3	O
CCR2	3	O
.	9	O

Increased	9	O
numbers	9	O
of	5	O
neurons	3	O
that	5	O
expressed	3	O
CCR2	3	O
was	9	O
observed	9	O
following	9	O
SE	9	B-Disease
.	9	O

Microglial	3	O
cells	3	O
were	9	O
more	5	O
closely	9	O
apposed	5	O
to	5	O
the	5	O
CCR2	3	O
-	7	O
labeled	3	O
cells	3	O
in	5	O
SE	9	B-Disease
rats	9	O
.	9	O

In	9	O
addition	9	O
,	9	O
rats	9	O
that	5	O
experienced	5	O
SE	9	B-Disease
exhibited	9	O
CCR2	3	O
-	7	O
labeling	3	O
in	5	O
populations	9	O
of	5	O
hypertrophied	9	B-Disease
astrocytes	3	O
,	9	O
especially	5	O
in	5	O
CA1	3	O
and	5	O
dentate	3	O
gyrus	5	O
.	9	O

These	5	O
CCR2	3	O
+	9	O
astroctytes	_	O
were	9	O
not	5	O
observed	9	O
in	5	O
control	9	O
rats	9	O
.	9	O

Examination	9	O
of	5	O
CCL2	3	O
expression	3	O
showed	9	O
that	5	O
it	5	O
was	9	O
elevated	9	O
in	5	O
the	5	O
hippocampus	9	O
following	9	O
SE	9	B-Disease
.	9	O

CONCLUSION	5	O
:	9	O
The	5	O
data	5	O
show	9	O
that	5	O
CCR2	3	O
and	5	O
CCL2	3	O
are	5	O
up	5	O
-	7	O
regulated	3	O
in	5	O
the	5	O
hippocampus	9	O
after	9	O
pilocarpine	0	B-Chemical
-	7	O
induced	3	O
SE	9	B-Disease
.	9	O

Seizures	5	B-Disease
also	9	O
result	9	O
in	5	O
changes	9	O
to	5	O
CCR2	3	O
receptor	3	O
expression	3	O
in	5	O
neurons	3	O
and	5	O
astrocytes	3	O
.	9	O

These	5	O
changes	9	O
might	9	O
be	5	O
involved	9	O
in	5	O
detrimental	9	O
neuroplasticity	5	O
and	5	O
neuroinflammatory	3	B-Disease
changes	9	O
that	5	O
occur	5	O
following	9	O
seizures	5	B-Disease
.	9	O

Metallothionein	7	B-Chemical
induction	3	O
reduces	9	O
caspase	3	O
-	7	O
3	9	O
activity	9	O
and	5	O
TNFalpha	3	O
levels	3	O
with	5	O
preservation	9	O
of	5	O
cognitive	5	O
function	9	O
and	5	O
intact	9	O
hippocampal	3	O
neurons	3	O
in	5	O
carmustine	0	B-Chemical
-	7	O
treated	3	O
rats	9	O
.	9	O

Hippocampal	3	O
integrity	9	O
is	5	O
essential	9	O
for	5	O
cognitive	5	O
functions	9	O
.	9	O

On	5	O
the	5	O
other	5	O
hand	5	O
,	9	O
induction	3	O
of	5	O
metallothionein	1	B-Chemical
(	9	O
MT	9	B-Chemical
)	9	O
by	9	O
ZnSO	0	B-Chemical
(	9	I-Chemical
4	9	I-Chemical
)	9	I-Chemical
and	5	O
its	9	O
role	9	O
in	5	O
neuroprotection	3	O
has	9	O
been	9	O
documented	9	O
.	9	O

The	5	O
present	9	O
study	9	O
aimed	5	O
to	5	O
explore	5	O
the	5	O
effect	9	O
of	5	O
MT	9	B-Chemical
induction	3	O
on	5	O
carmustine	0	B-Chemical
(	9	O
BCNU	0	B-Chemical
)	9	O
-	7	O
induced	3	O
hippocampal	3	O
cognitive	5	B-Disease
dysfunction	9	I-Disease
in	5	O
rats	9	O
.	9	O

A	9	O
total	9	O
of	5	O
60	9	O
male	9	O
Wistar	9	O
albino	3	O
rats	9	O
were	9	O
randomly	5	O
divided	5	O
into	9	O
four	9	O
groups	9	O
(	9	O
15	9	O
/	9	O
group	9	O
)	9	O
:	9	O
The	5	O
control	9	O
group	9	O
injected	3	O
with	5	O
single	9	O
doses	0	O
of	5	O
normal	9	O
saline	0	O
(	9	O
i	9	O
.	9	O
c	9	O
.	9	O
v	0	O
)	9	O
followed	9	O
24	9	O
h	0	O
later	9	O
by	9	O
BCNU	0	B-Chemical
solvent	0	O
(	9	O
i	9	O
.	9	O
v	0	O
)	9	O
.	9	O

The	5	O
second	9	O
group	9	O
administered	9	O
ZnSO	0	B-Chemical
(	9	I-Chemical
4	9	I-Chemical
)	9	I-Chemical
(	9	O
0	7	O
.	9	O
1	9	O
micromol	0	O
/	9	O
10	9	O
microl	0	O
normal	9	O
saline	0	O
,	9	O
i	9	O
.	9	O
c	9	O
.	9	O
v	0	O
,	9	O
once	5	O
)	9	O
then	9	O
BCNU	0	B-Chemical
solvent	0	O
(	9	O
i	9	O
.	9	O
v	0	O
)	9	O
after	9	O
24	9	O
h	0	O
.	9	O

Third	9	O
group	9	O
received	9	O
BCNU	0	B-Chemical
(	9	O
20	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
i	9	O
.	9	O
v	0	O
,	9	O
once	5	O
)	9	O
24	9	O
h	0	O
after	9	O
injection	9	O
with	5	O
normal	9	O
saline	0	O
(	9	O
i	9	O
.	9	O
c	9	O
.	9	O
v	0	O
)	9	O
.	9	O

Fourth	9	O
group	9	O
received	9	O
a	5	O
single	9	O
dose	9	O
of	5	O
ZnSO	0	B-Chemical
(	9	I-Chemical
4	9	I-Chemical
)	9	I-Chemical
(	9	O
0	7	O
.	9	O
1	9	O
micromol	0	O
/	9	O
10	9	O
microl	0	O
normal	9	O
saline	0	O
,	9	O
i	9	O
.	9	O
c	9	O
.	9	O
v	0	O
)	9	O
then	9	O
BCNU	0	B-Chemical
(	9	O
20	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
i	9	O
.	9	O
v	0	O
,	9	O
once	5	O
)	9	O
after	9	O
24	9	O
h	0	O
.	9	O

The	5	O
obtained	9	O
data	5	O
revealed	9	O
that	5	O
BCNU	0	B-Chemical
administration	9	O
resulted	9	O
in	5	O
deterioration	5	B-Disease
of	5	I-Disease
learning	5	I-Disease
and	5	I-Disease
short	5	I-Disease
-	7	I-Disease
term	5	I-Disease
memory	5	I-Disease
(	9	O
STM	9	O
)	9	O
,	9	O
as	5	O
measured	9	O
by	9	O
using	9	O
radial	5	O
arm	5	O
water	0	O
maze	5	O
,	9	O
accompanied	9	O
with	5	O
decreased	9	O
hippocampal	3	O
glutathione	0	B-Chemical
reductase	0	O
(	9	O
GR	9	O
)	9	O
activity	9	O
and	5	O
reduced	9	O
glutathione	0	B-Chemical
(	9	O
GSH	0	B-Chemical
)	9	O
content	9	O
.	9	O

Also	9	O
,	9	O
BCNU	0	B-Chemical
administration	9	O
increased	9	O
serum	9	O
tumor	3	B-Disease
necrosis	9	B-Disease
factor	9	O
-	7	O
alpha	9	O
(	9	O
TNFalpha	3	O
)	9	O
,	9	O
hippocampal	3	O
MT	9	B-Chemical
and	5	O
malondialdehyde	0	B-Chemical
(	9	O
MDA	9	B-Chemical
)	9	O
contents	9	O
as	5	O
well	9	O
as	5	O
caspase	3	O
-	7	O
3	9	O
activity	9	O
in	5	O
addition	9	O
to	5	O
histological	9	O
alterations	9	O
.	9	O

ZnSO	0	B-Chemical
(	9	I-Chemical
4	9	I-Chemical
)	9	I-Chemical
pretreatment	0	O
counteracted	9	O
BCNU	0	B-Chemical
-	7	O
induced	3	O
inhibition	3	O
of	5	O
GR	9	O
and	5	O
depletion	3	O
of	5	O
GSH	0	B-Chemical
and	5	O
resulted	9	O
in	5	O
significant	9	O
reduction	9	O
in	5	O
the	5	O
levels	3	O
of	5	O
MDA	9	B-Chemical
and	5	O
TNFalpha	3	O
as	5	O
well	9	O
as	5	O
the	5	O
activity	9	O
of	5	O
caspase	3	O
-	7	O
3	9	O
.	9	O

The	5	O
histological	9	O
features	5	O
were	9	O
improved	5	O
in	5	O
hippocampus	9	O
of	5	O
rats	9	O
treated	3	O
with	5	O
ZnSO	0	B-Chemical
(	9	I-Chemical
4	9	I-Chemical
)	9	I-Chemical
+	9	O
BCNU	0	B-Chemical
compared	9	O
to	5	O
only	9	O
BCNU	0	B-Chemical
-	7	O
treated	3	O
animals	9	O
.	9	O

In	9	O
conclusion	9	O
,	9	O
MT	9	B-Chemical
induction	3	O
halts	9	O
BCNU	0	B-Chemical
-	7	O
induced	3	O
hippocampal	3	O
toxicity	9	B-Disease
as	5	O
it	5	O
prevented	9	O
GR	9	O
inhibition	3	O
and	5	O
GSH	0	B-Chemical
depletion	3	O
and	5	O
counteracted	9	O
the	5	O
increased	9	O
levels	3	O
of	5	O
TNFalpha	3	O
,	9	O
MDA	9	B-Chemical
and	5	O
caspase	3	O
-	7	O
3	9	O
activity	9	O
with	5	O
subsequent	9	O
preservation	9	O
of	5	O
cognition	5	O
.	9	O

Fatal	5	O
carbamazepine	0	B-Chemical
induced	3	O
fulminant	5	B-Disease
eosinophilic	5	I-Disease
(	9	O
hypersensitivity	9	B-Disease
)	9	O
myocarditis	9	B-Disease
:	9	O
emphasis	5	O
on	5	O
anatomical	5	O
and	5	O
histological	9	O
characteristics	5	O
,	9	O
mechanisms	9	O
and	5	O
genetics	9	O
of	5	O
drug	5	B-Disease
hypersensitivity	9	I-Disease
and	5	O
differential	9	O
diagnosis	5	O
.	9	O

The	5	O
most	9	O
severe	5	O
adverse	5	O
reactions	9	O
to	5	O
carbamazepine	0	B-Chemical
have	5	O
been	9	O
observed	9	O
in	5	O
the	5	O
haemopoietic	3	O
system	5	O
,	9	O
the	5	O
liver	9	O
and	5	O
the	5	O
cardiovascular	5	O
system	5	O
.	9	O

A	9	O
frequently	5	O
fatal	5	O
,	9	O
although	9	O
exceptionally	5	O
rare	5	O
side	5	O
effect	9	O
of	5	O
carbamazepine	0	B-Chemical
is	5	O
necrotizing	5	O
eosinophilic	5	O
(	9	O
hypersensitivity	9	B-Disease
)	9	O
myocarditis	9	B-Disease
.	9	O

We	9	O
report	5	O
a	5	O
case	5	O
of	5	O
hypersensitivity	9	B-Disease
myocarditis	9	B-Disease
secondary	9	O
to	5	O
administration	9	O
of	5	O
carbamazepine	0	B-Chemical
.	9	O

Acute	5	O
hypersensitivity	9	B-Disease
myocarditis	9	B-Disease
was	9	O
not	5	O
suspected	5	O
clinically	5	O
,	9	O
and	5	O
the	5	O
diagnosis	5	O
was	9	O
made	5	O
post	9	O
-	7	O
mortem	5	O
.	9	O

Histology	9	O
revealed	9	O
diffuse	5	O
infiltration	3	O
of	5	O
the	5	O
myocardium	9	O
by	9	O
eosinophils	3	O
and	5	O
lymphocytes	3	O
with	5	O
myocyte	3	O
damage	9	O
.	9	O

Clinically	5	O
,	9	O
death	9	O
was	9	O
due	5	O
to	5	O
cardiogenic	5	B-Disease
shock	9	I-Disease
.	9	O

To	9	O
best	5	O
of	5	O
our	5	O
knowledge	5	O
this	5	O
is	5	O
the	5	O
second	9	O
case	5	O
of	5	O
fatal	5	O
carbamazepine	0	B-Chemical
induced	3	O
myocarditis	9	B-Disease
reported	9	O
in	5	O
English	5	O
literature	5	O
.	9	O

Neuropsychiatric	5	O
behaviors	5	O
in	5	O
the	5	O
MPTP	3	B-Chemical
marmoset	9	O
model	5	O
of	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
.	9	O

OBJECTIVES	2	O
:	9	O
Neuropsychiatric	5	O
symptoms	5	O
are	5	O
increasingly	5	O
recognised	5	O
as	5	O
a	5	O
significant	9	O
problem	5	O
in	5	O
patients	5	O
with	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
(	9	O
PD	9	B-Disease
)	9	O
.	9	O

These	5	O
symptoms	5	O
may	5	O
be	5	O
due	5	O
to	5	O
'	9	O
sensitisation	5	O
'	9	O
following	9	O
repeated	5	O
levodopa	5	B-Chemical
treatment	9	O
or	5	O
a	5	O
direct	9	O
effect	9	O
of	5	O
dopamine	5	B-Chemical
on	5	O
the	5	O
disease	5	O
state	5	O
.	9	O

The	5	O
levodopa	5	B-Chemical
-	7	O
treated	3	O
MPTP	3	B-Chemical
-	7	O
lesioned	3	O
marmoset	9	O
was	9	O
used	5	O
as	5	O
a	5	O
model	5	O
of	5	O
neuropsychiatric	5	B-Disease
symptoms	5	I-Disease
in	5	O
PD	9	B-Disease
patients	5	O
.	9	O

Here	9	O
we	5	O
compare	9	O
the	5	O
time	5	O
course	5	O
of	5	O
levodopa	5	B-Chemical
-	7	O
induced	3	O
motor	5	O
fluctuations	5	O
and	5	O
neuropsychiatric	5	B-Disease
-	7	I-Disease
like	9	I-Disease
behaviors	5	I-Disease
to	5	O
determine	9	O
the	5	O
relationship	5	O
between	5	O
duration	5	O
of	5	O
treatment	9	O
and	5	O
onset	5	O
of	5	O
symptoms	5	O
.	9	O

METHODS	2	O
:	9	O
Marmosets	3	O
were	9	O
administered	9	O
1	9	B-Chemical
-	7	I-Chemical
methyl	0	I-Chemical
-	7	I-Chemical
4	9	I-Chemical
-	7	I-Chemical
phenyl	0	I-Chemical
-	7	I-Chemical
1	9	I-Chemical
,	9	I-Chemical
2	9	I-Chemical
,	9	I-Chemical
3	9	I-Chemical
,	9	I-Chemical
6	9	I-Chemical
-	7	I-Chemical
tetrahydropyridine	0	I-Chemical
(	9	O
2	9	O
.	9	O
0	7	O
mg	0	O
/	9	O
kg	0	O
s	9	O
.	9	O
c	9	O
.	9	O
)	9	O
for	5	O
five	9	O
days	9	O
,	9	O
resulting	9	O
in	5	O
stable	9	O
parkinsonism	5	B-Disease
.	9	O

Levodopa	0	B-Chemical
(	9	O
15	9	O
mg	0	O
/	9	O
kg	0	O
and	5	O
benserazide	0	B-Chemical
,	9	O
3	9	O
.	9	O
75	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
p	7	O
.	9	O
o	9	O
.	9	O

b	9	O
.	9	O
i	9	O
.	9	O
d	9	O
,	9	O
was	9	O
administered	9	O
for	5	O
30	9	O
days	9	O
.	9	O

Animals	9	O
were	9	O
evaluated	9	O
for	5	O
parkinsonian	5	B-Disease
disability	5	I-Disease
,	9	O
dyskinesia	5	B-Disease
and	5	O
on	5	O
-	7	O
time	5	O
(	9	O
motor	5	O
fluctuations	5	O
)	9	O
and	5	O
neuropsychiatric	5	B-Disease
-	7	I-Disease
like	9	I-Disease
behaviors	5	I-Disease
on	5	O
Day	9	O
0	7	O
(	9	O
prior	9	O
to	5	O
levodopa	5	B-Chemical
)	9	O
and	5	O
on	5	O
Days	9	O
1	9	O
,	9	O
7	9	O
,	9	O
13	7	O
,	9	O
27	7	O
and	5	O
30	9	O
of	5	O
treatment	9	O
using	9	O
post	9	O
hoc	5	O
DVD	5	O
analysis	9	O
by	9	O
a	5	O
trained	5	O
rater	5	O
,	9	O
blind	5	O
to	5	O
the	5	O
treatment	9	O
day	9	O
.	9	O

RESULTS	9	O
:	9	O
The	5	O
neuropsychiatric	5	B-Disease
-	7	I-Disease
like	9	I-Disease
behavior	5	I-Disease
rating	5	O
scale	5	O
demonstrated	9	O
high	9	O
interrater	5	O
reliability	5	O
between	5	O
three	9	O
trained	5	O
raters	5	O
of	5	O
differing	9	O
professional	5	O
backgrounds	9	O
.	9	O

As	9	O
anticipated	5	O
,	9	O
animals	9	O
exhibited	9	O
a	5	O
progressive	5	O
increase	9	O
in	5	O
levodopa	5	B-Chemical
-	7	O
induced	3	O
motor	5	O
fluctuations	5	O
,	9	O
dyskinesia	5	B-Disease
and	5	O
wearing	5	O
-	7	O
off	5	O
,	9	O
that	5	O
correlated	9	O
with	5	O
the	5	O
duration	5	O
of	5	O
levodopa	5	B-Chemical
therapy	5	O
.	9	O

In	9	O
contrast	9	O
,	9	O
levodopa	5	B-Chemical
-	7	O
induced	3	O
neuropsychiatric	5	B-Disease
-	7	I-Disease
like	9	I-Disease
behaviors	5	I-Disease
were	9	O
present	9	O
on	5	O
Day	9	O
1	9	O
of	5	O
levodopa	5	B-Chemical
treatment	9	O
and	5	O
their	5	O
severity	5	O
did	9	O
not	5	O
correlate	9	O
with	5	O
duration	5	O
of	5	O
treatment	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
The	5	O
data	5	O
suggest	9	O
that	5	O
neuropsychiatric	5	B-Disease
disorders	5	I-Disease
in	5	O
PD	9	B-Disease
are	5	O
more	5	O
likely	5	O
an	5	O
interaction	9	O
between	5	O
levodopa	5	B-Chemical
and	5	O
the	5	O
disease	5	O
state	5	O
than	5	O
a	5	O
consequence	5	O
of	5	O
sensitisation	5	O
to	5	O
repeated	5	O
dopaminergic	5	O
therapy	5	O
.	9	O

Contrast	5	B-Chemical
medium	0	I-Chemical
nephrotoxicity	9	B-Disease
after	9	O
renal	9	O
artery	5	O
and	5	O
coronary	5	O
angioplasty	5	O
.	9	O

BACKGROUND	2	O
:	9	O
Renal	9	B-Disease
dysfunction	9	I-Disease
induced	3	O
by	9	O
iodinated	0	O
contrast	9	B-Chemical
medium	0	I-Chemical
(	9	O
CM	9	B-Chemical
)	9	O
administration	9	O
can	5	O
minimize	5	O
the	5	O
benefit	5	O
of	5	O
the	5	O
interventional	5	O
procedure	5	O
in	5	O
patients	5	O
undergoing	9	O
renal	9	O
angioplasty	5	O
(	9	O
PTRA	5	O
)	9	O
.	9	O

PURPOSE	2	O
:	9	O
To	9	O
compare	9	O
the	5	O
susceptibility	9	O
to	5	O
nephrotoxic	5	B-Disease
effect	9	O
of	5	O
CM	9	B-Chemical
in	5	O
patients	5	O
undergoing	9	O
PTRA	5	O
with	5	O
that	5	O
of	5	O
patients	5	O
submitted	9	O
to	5	O
percutaneous	5	O
coronary	5	O
intervention	5	O
(	9	O
PCI	5	O
)	9	O
.	9	O

MATERIAL	2	O
AND	2	O
METHODS	2	O
:	9	O
A	9	O
total	9	O
of	5	O
33	7	O
patients	5	O
successfully	5	O
treated	3	O
with	5	O
PTRA	5	O
(	9	O
PTRA	5	O
group	9	O
,	9	O
mean	5	O
age	5	O
70	9	O
+	9	O
/	9	O
-	7	O
12	9	O
years	5	O
,	9	O
23	7	O
female	9	O
,	9	O
basal	3	O
creatinine	0	B-Chemical
1	9	O
.	9	O
46	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
79	7	O
,	9	O
range	9	O
0	7	O
.	9	O
7	9	O
-	7	O
4	9	O
.	9	O
9	7	O
mg	0	O
/	9	O
dl	7	O
)	9	O
were	9	O
compared	9	O
with	5	O
33	7	O
patients	5	O
undergoing	9	O
successful	5	O
PCI	5	O
(	9	O
PCI	5	O
group	9	O
)	9	O
,	9	O
matched	9	O
for	5	O
basal	3	O
creatinine	0	B-Chemical
(	9	O
1	9	O
.	9	O
44	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
6	9	O
,	9	O
range	9	O
0	7	O
.	9	O
7	9	O
-	7	O
3	9	O
.	9	O
4	9	O
mg	0	O
/	9	O
dl	7	O
)	9	O
,	9	O
gender	5	O
,	9	O
and	5	O
age	5	O
.	9	O

In	9	O
both	9	O
groups	9	O
postprocedural	5	O
(	9	O
48	9	O
h	0	O
)	9	O
serum	9	O
creatinine	0	B-Chemical
was	9	O
measured	9	O
.	9	O

RESULTS	9	O
:	9	O
Postprocedural	5	O
creatinine	0	B-Chemical
level	9	O
decreased	9	O
nonsignificantly	5	O
in	5	O
the	5	O
PTRA	5	O
group	9	O
(	9	O
1	9	O
.	9	O
46	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
8	9	O
vs	7	O
.	9	O
1	9	O
.	9	O
34	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
5	9	O
mg	0	O
/	9	O
dl	7	O
,	9	O
P	9	O
=	7	O
NS	7	O
)	9	O
and	5	O
increased	9	O
significantly	9	O
in	5	O
the	5	O
PCI	5	O
group	9	O
(	9	O
1	9	O
.	9	O
44	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
6	9	O
vs	7	O
.	9	O
1	9	O
.	9	O
57	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
7	9	O
mg	0	O
/	9	O
dl	7	O
,	9	O
P	9	O
<	0	O
0	7	O
.	9	O
02	7	O
)	9	O
.	9	O

Changes	9	O
in	5	O
serum	9	O
creatinine	0	B-Chemical
after	9	O
intervention	5	O
(	9	O
after	9	O
-	7	O
before	9	O
)	9	O
were	9	O
significantly	9	O
different	9	O
between	5	O
the	5	O
PTRA	5	O
and	5	O
PCI	5	O
groups	9	O
(	9	O
-	7	O
0	7	O
.	9	O
12	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
5	9	O
vs	7	O
.	9	O
0	7	O
.	9	O
13	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
3	9	O
,	9	O
P	9	O
=	7	O
0	7	O
.	9	O
014	2	O
)	9	O
.	9	O

This	5	O
difference	9	O
was	9	O
not	5	O
related	9	O
to	5	O
either	9	O
a	5	O
different	9	O
clinical	5	O
risk	5	O
profile	9	O
or	5	O
to	5	O
the	5	O
volume	9	O
of	5	O
CM	9	B-Chemical
administered	9	O
.	9	O

CONCLUSION	5	O
:	9	O
In	9	O
this	5	O
preliminary	9	O
study	9	O
patients	5	O
submitted	9	O
to	5	O
PTRA	5	O
showed	9	O
a	5	O
lower	9	O
susceptibility	9	O
to	5	O
renal	9	B-Disease
damage	9	I-Disease
induced	3	O
by	9	O
CM	9	B-Chemical
administration	9	O
than	5	O
PCI	5	O
patients	5	O
.	9	O

The	5	O
effectiveness	5	O
of	5	O
PTRA	5	O
on	5	O
renal	9	O
function	9	O
seems	5	O
to	5	O
be	5	O
barely	9	O
influenced	5	O
by	9	O
CM	9	B-Chemical
toxicity	9	B-Disease
.	9	O

Diphenhydramine	0	B-Chemical
prevents	9	O
the	5	O
haemodynamic	5	O
changes	9	O
of	5	O
cimetidine	0	B-Chemical
in	5	O
ICU	5	O
patients	5	O
.	9	O

Cimetidine	0	B-Chemical
,	9	O
a	5	O
histamine	0	B-Chemical
2	9	O
(	9	O
H2	9	O
)	9	O
antagonist	3	O
,	9	O
produces	9	O
a	5	O
decrease	9	O
in	5	O
arterial	5	O
pressure	5	O
due	5	O
to	5	O
vasodilatation	5	O
,	9	O
especially	5	O
in	5	O
critically	9	O
ill	5	O
patients	5	O
.	9	O

This	5	O
may	5	O
be	5	O
because	5	O
cimetidine	0	B-Chemical
acts	9	O
as	5	O
a	5	O
histamine	0	B-Chemical
agonist	3	O
.	9	O

We	9	O
,	9	O
therefore	5	O
,	9	O
investigated	9	O
the	5	O
effects	9	O
of	5	O
the	5	O
histamine	0	B-Chemical
1	9	O
(	9	O
H1	9	O
)	9	O
receptor	3	O
antagonist	3	O
,	9	O
diphenhydramine	0	B-Chemical
,	9	O
on	5	O
the	5	O
haemodynamic	5	O
changes	9	O
observed	9	O
after	9	O
cimetidine	0	B-Chemical
in	5	O
ICU	5	O
patients	5	O
.	9	O

Each	5	O
patient	5	O
was	9	O
studied	9	O
on	5	O
two	5	O
separate	9	O
days	9	O
.	9	O

In	9	O
a	5	O
random	5	O
fashion	5	O
,	9	O
they	5	O
received	9	O
cimetidine	0	B-Chemical
200	0	O
mg	0	O
iv	9	O
on	5	O
one	5	O
day	9	O
,	9	O
and	5	O
on	5	O
the	5	O
other	5	O
,	9	O
a	5	O
pretreatment	0	O
of	5	O
diphenhydramine	0	B-Chemical
40	9	O
mg	0	O
iv	9	O
with	5	O
cimetidine	0	B-Chemical
200	0	O
mg	0	O
iv	9	O
.	9	O

In	9	O
the	5	O
non	9	O
-	7	O
pretreatment	0	O
group	9	O
,	9	O
mean	5	O
arterial	5	O
pressure	5	O
(	9	O
MAP	9	O
)	9	O
decreased	9	O
from	9	O
107	9	O
.	9	O
4	9	O
+	9	O
/	9	O
-	7	O
8	9	O
.	9	O
4	9	O
mmHg	7	O
to	5	O
86	7	O
.	9	O
7	9	O
+	9	O
/	9	O
-	7	O
11	7	O
.	9	O
4	9	O
mmHg	7	O
(	9	O
P	9	O
less	5	O
than	5	O
0	7	O
.	9	O
01	7	O
)	9	O
two	5	O
minutes	0	O
after	9	O
cimetidine	0	B-Chemical
.	9	O

Also	9	O
,	9	O
systemic	9	O
vascular	5	O
resistance	9	O
(	9	O
SVR	9	O
)	9	O
decreased	9	O
during	5	O
the	5	O
eight	9	O
-	7	O
minute	5	O
observation	9	O
period	5	O
(	9	O
P	9	O
less	5	O
than	5	O
0	7	O
.	9	O
01	7	O
)	9	O
.	9	O

In	9	O
contrast	9	O
,	9	O
in	5	O
the	5	O
pretreatment	0	O
group	9	O
,	9	O
little	9	O
haemodynamic	5	O
change	9	O
was	9	O
seen	9	O
.	9	O

We	9	O
conclude	9	O
that	5	O
an	5	O
H1	9	O
antagonist	3	O
may	5	O
be	5	O
useful	5	O
in	5	O
preventing	9	O
hypotension	5	B-Disease
caused	9	O
by	9	O
iv	9	O
cimetidine	0	B-Chemical
,	9	O
since	9	O
the	5	O
vasodilating	5	O
activity	9	O
of	5	O
cimetidine	0	B-Chemical
is	5	O
mediated	3	O
,	9	O
in	5	O
part	9	O
,	9	O
through	9	O
the	5	O
H1	9	O
receptor	3	O
.	9	O

Medical	2	O
and	5	O
psychiatric	5	O
outcomes	5	O
for	5	O
patients	5	O
transplanted	3	O
for	5	O
acetaminophen	0	B-Chemical
-	7	O
induced	3	O
acute	9	B-Disease
liver	9	I-Disease
failure	5	I-Disease
:	9	O
a	5	O
case	5	O
-	7	O
control	9	O
study	9	O
.	9	O

BACKGROUND	2	O
:	9	O
Acetaminophen	0	B-Chemical
-	7	O
induced	3	O
hepatotoxicity	9	B-Disease
is	5	O
the	5	O
most	9	O
common	5	O
cause	5	O
of	5	O
acute	9	B-Disease
liver	9	I-Disease
failure	5	I-Disease
(	9	O
ALF	9	B-Disease
)	9	O
in	5	O
the	5	O
UK	2	O
.	9	O

Patients	5	O
often	5	O
consume	5	O
the	5	O
drug	5	O
with	5	O
suicidal	5	O
intent	5	O
or	5	O
with	5	O
a	5	O
background	9	O
of	5	O
substance	5	O
dependence	5	O
.	9	O

AIMS	5	O
AND	2	O
METHODS	2	O
:	9	O
We	9	O
compared	9	O
the	5	O
severity	5	O
of	5	O
pretransplant	5	O
illness	5	O
,	9	O
psychiatric	5	O
co	9	O
-	7	O
morbidity	5	O
,	9	O
medical	5	O
and	5	O
psychosocial	5	O
outcomes	5	O
of	5	O
all	5	O
patients	5	O
who	5	O
had	9	O
undergone	5	O
liver	9	O
transplantation	9	O
(	9	O
LT	9	O
)	9	O
emergently	5	O
between	5	O
1999	2	O
-	7	O
2004	2	O
for	5	O
acetaminophen	0	B-Chemical
-	7	O
induced	3	O
ALF	9	B-Disease
(	9	O
n	9	O
=	7	O
36	9	O
)	9	O
with	5	O
age	5	O
-	7	O
and	5	O
sex	5	O
-	7	O
matched	9	O
patients	5	O
undergoing	9	O
emergent	5	O
LT	9	O
for	5	O
non	9	O
-	7	O
acetaminophen	0	B-Chemical
-	7	O
induced	3	O
ALF	9	B-Disease
(	9	O
n	9	O
=	7	O
35	9	O
)	9	O
and	5	O
elective	5	O
LT	9	O
for	5	O
chronic	5	B-Disease
liver	9	I-Disease
disease	5	I-Disease
(	9	O
CLD	9	B-Disease
,	9	O
n	9	O
=	7	O
34	7	O
)	9	O
.	9	O

RESULTS	9	O
:	9	O
Acetaminophen	0	B-Chemical
-	7	O
induced	3	O
ALF	9	B-Disease
patients	5	O
undergoing	9	O
LT	9	O
had	9	O
a	5	O
greater	5	O
severity	5	O
of	5	O
pre	9	O
-	7	O
LT	9	O
illness	5	O
reflected	5	O
by	9	O
higher	9	O
Acute	5	O
Physiology	2	O
and	5	O
Chronic	9	O
Health	2	O
Evaluation	5	O
II	9	O
scores	5	O
and	5	O
requirement	9	O
for	5	O
organ	5	O
support	5	O
compared	9	O
with	5	O
the	5	O
other	5	O
two	5	O
groups	9	O
.	9	O

Twenty	9	O
(	9	O
56	7	O
%	9	O
)	9	O
acetaminophen	0	B-Chemical
-	7	O
induced	3	O
ALF	9	B-Disease
patients	5	O
had	9	O
a	5	O
formal	5	O
psychiatric	5	O
diagnosis	5	O
before	9	O
LT	9	O
(	9	O
non	9	O
-	7	O
acetaminophen	0	B-Chemical
-	7	O
induced	3	O
ALF	9	B-Disease
=	7	O
0	7	O
/	9	O
35	9	O
,	9	O
CLD	9	B-Disease
=	7	O
2	9	O
/	9	O
34	7	O
;	9	O
P	9	O
<	0	O
0	7	O
.	9	O
01	7	O
for	5	O
all	5	O
)	9	O
and	5	O
nine	9	O
(	9	O
25	9	O
%	9	O
)	9	O
had	9	O
a	5	O
previous	9	O
suicide	5	O
attempt	5	O
.	9	O

During	5	O
follow	5	O
-	7	O
up	5	O
(	9	O
median	9	O
5	9	O
years	5	O
)	9	O
,	9	O
there	5	O
were	9	O
no	9	O
significant	9	O
differences	9	O
in	5	O
rejection	5	O
(	9	O
acute	9	O
and	5	O
chronic	5	O
)	9	O
,	9	O
graft	5	O
failure	5	O
or	5	O
survival	9	O
between	5	O
the	5	O
groups	9	O
(	9	O
acetaminophen	0	B-Chemical
-	7	O
induced	3	O
ALF	9	B-Disease
1	9	O
year	5	O
87	7	O
%	9	O
,	9	O
5	9	O
years	5	O
75	9	O
%	9	O
;	9	O
non	9	O
-	7	O
acetaminophen	0	B-Chemical
-	7	O
induced	3	O
ALF	9	B-Disease
88	7	O
%	9	O
,	9	O
78	7	O
%	9	O
;	9	O
CLD	9	B-Disease
93	7	O
%	9	O
,	9	O
82	7	O
%	9	O
:	9	O
P	9	O
>	0	O
0	7	O
.	9	O
6	9	O
log	9	O
rank	5	O
)	9	O
.	9	O

Two	9	O
acetaminophen	0	B-Chemical
-	7	O
induced	3	O
ALF	9	B-Disease
patients	5	O
reattempted	5	O
suicide	5	O
post	9	O
-	7	O
LT	9	O
(	9	O
one	5	O
died	9	O
8	9	O
years	5	O
post	9	O
-	7	O
LT	9	O
)	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Despite	5	O
a	5	O
high	9	O
prevalence	5	O
of	5	O
psychiatric	5	O
disturbance	5	O
,	9	O
outcomes	5	O
for	5	O
patients	5	O
transplanted	3	O
emergently	5	O
for	5	O
acetaminophen	0	B-Chemical
-	7	O
induced	3	O
ALF	9	B-Disease
were	9	O
comparable	9	O
to	5	O
those	5	O
transplanted	3	O
for	5	O
non	9	O
-	7	O
acetaminophen	0	B-Chemical
-	7	O
induced	3	O
ALF	9	B-Disease
and	5	O
electively	5	O
for	5	O
CLD	9	B-Disease
.	9	O

Multidisciplinary	5	O
approaches	5	O
with	5	O
long	5	O
-	7	O
term	5	O
psychiatric	5	O
follow	5	O
-	7	O
up	5	O
may	5	O
contribute	9	O
to	5	O
low	9	O
post	9	O
-	7	O
transplant	9	O
suicide	5	O
rates	5	O
seen	9	O
and	5	O
low	9	O
rates	5	O
of	5	O
graft	5	O
loss	9	O
because	5	O
of	5	O
non	9	O
-	7	O
compliance	5	O
.	9	O

Antithrombotic	7	O
drug	5	O
use	5	O
,	9	O
cerebral	5	B-Disease
microbleeds	5	I-Disease
,	9	O
and	5	O
intracerebral	5	B-Disease
hemorrhage	5	I-Disease
:	9	O
a	5	O
systematic	5	O
review	5	O
of	5	O
published	9	O
and	5	O
unpublished	6	O
studies	9	O
.	9	O

BACKGROUND	2	O
AND	2	O
PURPOSE	2	O
:	9	O
Cerebral	5	B-Disease
microbleeds	5	I-Disease
(	9	O
MB	0	B-Disease
)	9	O
are	5	O
potential	9	O
risk	5	O
factors	9	O
for	5	O
intracerebral	5	B-Disease
hemorrhage	5	I-Disease
(	9	O
ICH	5	B-Disease
)	9	O
,	9	O
but	9	O
it	5	O
is	5	O
unclear	9	O
if	5	O
they	5	O
are	5	O
a	5	O
contraindication	5	O
to	5	O
using	9	O
antithrombotic	5	O
drugs	5	O
.	9	O

Insights	5	O
could	9	O
be	5	O
gained	5	O
by	9	O
pooling	5	O
data	5	O
on	5	O
MB	0	B-Disease
frequency	5	O
stratified	5	O
by	9	O
antithrombotic	5	O
use	5	O
in	5	O
cohorts	9	O
with	5	O
ICH	5	B-Disease
and	5	O
ischemic	9	B-Disease
stroke	5	I-Disease
(	9	O
IS	9	B-Disease
)	9	O
/	9	O
transient	9	B-Disease
ischemic	9	I-Disease
attack	5	I-Disease
(	9	O
TIA	5	B-Disease
)	9	O
.	9	O

METHODS	2	O
:	9	O
We	9	O
performed	9	O
a	5	O
systematic	5	O
review	5	O
of	5	O
published	9	O
and	5	O
unpublished	6	O
data	5	O
from	9	O
cohorts	9	O
with	5	O
stroke	5	B-Disease
or	5	O
TIA	5	B-Disease
to	5	O
compare	9	O
the	5	O
presence	9	O
of	5	O
MB	0	B-Disease
in	5	O
:	9	O
(	9	O
1	9	O
)	9	O
antithrombotic	5	O
users	5	O
vs	7	O
nonantithrombotic	_	O
users	5	O
with	5	O
ICH	5	B-Disease
;	9	O
(	9	O
2	9	O
)	9	O
antithrombotic	5	O
users	5	O
vs	7	O
nonusers	5	O
with	5	O
IS	9	B-Disease
/	9	O
TIA	5	B-Disease
;	9	O
and	5	O
(	9	O
3	9	O
)	9	O
ICH	5	B-Disease
vs	7	O
ischemic	9	B-Disease
events	5	O
stratified	5	O
by	9	O
antithrombotic	5	O
use	5	O
.	9	O

We	9	O
also	9	O
analyzed	9	O
published	9	O
and	5	O
unpublished	6	O
follow	5	O
-	7	O
up	5	O
data	5	O
to	5	O
determine	9	O
the	5	O
risk	5	O
of	5	O
ICH	5	B-Disease
in	5	O
antithrombotic	5	O
users	5	O
with	5	O
MB	0	B-Disease
.	9	O

RESULTS	9	O
:	9	O
In	9	O
a	5	O
pooled	9	O
analysis	9	O
of	5	O
1460	7	O
ICH	5	B-Disease
and	5	O
3817	7	O
IS	9	B-Disease
/	9	O
TIA	5	B-Disease
,	9	O
MB	0	B-Disease
were	9	O
more	5	O
frequent	5	O
in	5	O
ICH	5	B-Disease
vs	7	O
IS	9	B-Disease
/	9	O
TIA	5	B-Disease
in	5	O
all	5	O
treatment	9	O
groups	9	O
,	9	O
but	9	O
the	5	O
excess	9	O
increased	9	O
from	9	O
2	9	O
.	9	O
8	9	O
(	9	O
odds	5	O
ratio	9	O
;	9	O
range	9	O
,	9	O
2	9	O
.	9	O
3	9	O
-	7	O
3	9	O
.	9	O
5	9	O
)	9	O
in	5	O
nonantithrombotic	_	O
users	5	O
to	5	O
5	9	O
.	9	O
7	9	O
(	9	O
range	9	O
,	9	O
3	9	O
.	9	O
4	9	O
-	7	O
9	7	O
.	9	O
7	9	O
)	9	O
in	5	O
antiplatelet	5	O
users	5	O
and	5	O
8	9	O
.	9	O
0	7	O
(	9	O
range	9	O
,	9	O
3	9	O
.	9	O
5	9	O
-	7	O
17	7	O
.	9	O
8	9	O
)	9	O
in	5	O
warfarin	5	B-Chemical
users	5	O
(	9	O
P	9	O
difference	9	O
=	7	O
0	7	O
.	9	O
01	7	O
)	9	O
.	9	O

There	5	O
was	9	O
also	9	O
an	5	O
excess	9	O
of	5	O
MB	0	B-Disease
in	5	O
warfarin	5	B-Chemical
users	5	O
vs	7	O
nonusers	5	O
with	5	O
ICH	5	B-Disease
(	9	O
OR	9	O
,	9	O
2	9	O
.	9	O
7	9	O
;	9	O
95	7	O
%	9	O
CI	7	O
,	9	O
1	9	O
.	9	O
6	9	O
-	7	O
4	9	O
.	9	O
4	9	O
;	9	O
P	9	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
but	9	O
none	9	O
in	5	O
warfarin	5	B-Chemical
users	5	O
with	5	O
IS	9	B-Disease
/	9	O
TIA	5	B-Disease
(	9	O
OR	9	O
,	9	O
1	9	O
.	9	O
3	9	O
;	9	O
95	7	O
%	9	O
CI	7	O
,	9	O
0	7	O
.	9	O
9	7	O
-	7	O
1	9	O
.	9	O
7	9	O
;	9	O
P	9	O
=	7	O
0	7	O
.	9	O
33	7	O
;	9	O
P	9	O
difference	9	O
=	7	O
0	7	O
.	9	O
01	7	O
)	9	O
.	9	O

There	5	O
was	9	O
a	5	O
smaller	5	O
excess	9	O
of	5	O
MB	0	B-Disease
in	5	O
antiplatelet	5	O
users	5	O
vs	7	O
nonusers	5	O
with	5	O
ICH	5	B-Disease
(	9	O
OR	9	O
,	9	O
1	9	O
.	9	O
7	9	O
;	9	O
95	7	O
%	9	O
CI	7	O
,	9	O
1	9	O
.	9	O
3	9	O
-	7	O
2	9	O
.	9	O
3	9	O
;	9	O
P	9	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
,	9	O
but	9	O
findings	9	O
were	9	O
similar	9	O
for	5	O
antiplatelet	5	O
users	5	O
with	5	O
IS	9	B-Disease
/	9	O
TIA	5	B-Disease
(	9	O
OR	9	O
,	9	O
1	9	O
.	9	O
4	9	O
;	9	O
95	7	O
%	9	O
CI	7	O
,	9	O
1	9	O
.	9	O
2	9	O
-	7	O
1	9	O
.	9	O
7	9	O
;	9	O
P	9	O
<	0	O
0	7	O
.	9	O
001	9	O
;	9	O
P	9	O
difference	9	O
=	7	O
0	7	O
.	9	O
25	9	O
)	9	O
.	9	O

In	9	O
pooled	9	O
follow	5	O
-	7	O
up	5	O
data	5	O
for	5	O
768	7	O
antithrombotic	5	O
users	5	O
,	9	O
presence	9	O
of	5	O
MB	0	B-Disease
at	9	O
baseline	5	O
was	9	O
associated	9	O
with	5	O
a	5	O
substantially	9	O
increased	9	O
risk	5	O
of	5	O
subsequent	9	O
ICH	5	B-Disease
(	9	O
OR	9	O
,	9	O
12	9	O
.	9	O
1	9	O
;	9	O
95	7	O
%	9	O
CI	7	O
,	9	O
3	9	O
.	9	O
4	9	O
-	7	O
42	7	O
.	9	O
5	9	O
;	9	O
P	9	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
The	5	O
excess	9	O
of	5	O
MB	0	B-Disease
in	5	O
warfarin	5	B-Chemical
users	5	O
with	5	O
ICH	5	B-Disease
compared	9	O
to	5	O
other	5	O
groups	9	O
suggests	9	O
that	5	O
MB	0	B-Disease
increase	9	O
the	5	O
risk	5	O
of	5	O
warfarin	5	B-Chemical
-	7	O
associated	9	O
ICH	5	B-Disease
.	9	O

Limited	9	O
prospective	5	O
data	5	O
corroborate	9	O
these	5	O
findings	9	O
,	9	O
but	9	O
larger	5	O
prospective	5	O
studies	9	O
are	5	O
urgently	5	O
required	9	O
.	9	O

Studies	9	O
of	5	O
synergy	9	O
between	5	O
morphine	0	B-Chemical
and	5	O
a	5	O
novel	9	O
sodium	0	B-Chemical
channel	9	O
blocker	0	O
,	9	O
CNSB002	_	B-Chemical
,	9	O
in	5	O
rat	3	O
models	5	O
of	5	O
inflammatory	3	O
and	5	O
neuropathic	5	B-Disease
pain	5	I-Disease
.	9	O

OBJECTIVE	2	O
:	9	O
This	5	O
study	9	O
determined	9	O
the	5	O
antihyperalgesic	0	O
effect	9	O
of	5	O
CNSB002	_	B-Chemical
,	9	O
a	5	O
sodium	0	B-Chemical
channel	9	O
blocker	0	O
with	5	O
antioxidant	0	O
properties	9	O
given	5	O
alone	9	O
and	5	O
in	5	O
combinations	9	O
with	5	O
morphine	0	B-Chemical
in	5	O
rat	3	O
models	5	O
of	5	O
inflammatory	3	O
and	5	O
neuropathic	5	B-Disease
pain	5	I-Disease
.	9	O

DESIGN	2	O
:	9	O
Dose	0	O
response	9	O
curves	5	O
for	5	O
nonsedating	5	O
doses	0	O
of	5	O
morphine	0	B-Chemical
and	5	O
CNSB002	_	B-Chemical
given	5	O
intraperitoneally	0	O
alone	9	O
and	5	O
together	9	O
in	5	O
combinations	9	O
were	9	O
constructed	9	O
for	5	O
antihyperalgesic	0	O
effect	9	O
using	9	O
paw	5	O
withdrawal	5	O
from	9	O
noxious	5	O
heat	9	O
in	5	O
two	5	O
rat	3	O
pain	5	B-Disease
models	5	O
:	9	O
carrageenan	0	B-Chemical
-	7	O
induced	3	O
paw	5	O
inflammation	9	B-Disease
and	5	O
streptozotocin	0	B-Chemical
(	9	O
STZ	0	B-Chemical
)	9	O
-	7	O
induced	3	O
diabetic	9	B-Disease
neuropathy	5	I-Disease
.	9	O

RESULTS	9	O
:	9	O
The	5	O
maximum	5	O
nonsedating	5	O
doses	0	O
were	9	O
:	9	O
morphine	0	B-Chemical
,	9	O
3	9	O
.	9	O
2	9	O
mg	0	O
/	9	O
kg	0	O
;	9	O
CNSB002	_	B-Chemical
10	9	O
.	9	O
0	7	O
mg	0	O
/	9	O
kg	0	O
;	9	O
5	9	O
.	9	O
0	7	O
mg	0	O
/	9	O
kg	0	O
CNSB002	_	B-Chemical
with	5	O
morphine	0	B-Chemical
3	9	O
.	9	O
2	9	O
mg	0	O
/	9	O
kg	0	O
in	5	O
combination	9	O
.	9	O

The	5	O
doses	0	O
calculated	5	O
to	5	O
cause	5	O
50	0	O
%	9	O
reversal	9	O
of	5	O
hyperalgesia	3	B-Disease
(	9	O
ED50	0	O
)	9	O
were	9	O
7	9	O
.	9	O
54	7	O
(	9	O
1	9	O
.	9	O
81	7	O
)	9	O
and	5	O
4	9	O
.	9	O
83	7	O
(	9	O
1	9	O
.	9	O
54	7	O
)	9	O
in	5	O
the	5	O
carrageenan	0	B-Chemical
model	5	O
and	5	O
44	7	O
.	9	O
18	7	O
(	9	O
1	9	O
.	9	O
37	9	O
)	9	O
and	5	O
9	7	O
.	9	O
14	7	O
(	9	O
1	9	O
.	9	O
24	9	O
)	9	O
in	5	O
the	5	O
STZ	0	B-Chemical
-	7	O
induced	3	O
neuropathy	5	B-Disease
model	5	O
for	5	O
CNSB002	_	B-Chemical
and	5	O
morphine	0	B-Chemical
,	9	O
respectively	9	O
(	9	O
mg	0	O
/	9	O
kg	0	O
;	9	O
mean	5	O
,	9	O
SEM	9	O
)	9	O
.	9	O

These	5	O
values	5	O
were	9	O
greater	5	O
than	5	O
the	5	O
maximum	5	O
nonsedating	5	O
doses	0	O
.	9	O

The	5	O
ED50	0	O
values	5	O
for	5	O
morphine	0	B-Chemical
when	5	O
given	5	O
in	5	O
combination	9	O
with	5	O
CNSB002	_	B-Chemical
(	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
were	9	O
less	5	O
than	5	O
the	5	O
maximum	5	O
nonsedating	5	O
dose	9	O
:	9	O
0	7	O
.	9	O
56	7	O
(	9	O
1	9	O
.	9	O
55	7	O
)	9	O
in	5	O
the	5	O
carrageenan	0	B-Chemical
model	5	O
and	5	O
1	9	O
.	9	O
37	9	O
(	9	O
1	9	O
.	9	O
23	7	O
)	9	O
in	5	O
the	5	O
neuropathy	5	B-Disease
model	5	O
(	9	O
mg	0	O
/	9	O
kg	0	O
;	9	O
mean	5	O
,	9	O
SEM	9	O
)	9	O
.	9	O

The	5	O
antinociception	3	O
after	9	O
morphine	0	B-Chemical
(	9	O
3	9	O
.	9	O
2	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
was	9	O
increased	9	O
by	9	O
co	9	O
-	7	O
administration	9	O
with	5	O
CNSB002	_	B-Chemical
from	9	O
28	7	O
.	9	O
0	7	O
and	5	O
31	7	O
.	9	O
7	9	O
%	9	O
to	5	O
114	7	O
.	9	O
6	9	O
and	5	O
56	7	O
.	9	O
9	7	O
%	9	O
reversal	9	O
of	5	O
hyperalgesia	3	B-Disease
in	5	O
the	5	O
inflammatory	3	O
and	5	O
neuropathic	5	B-Disease
models	5	O
,	9	O
respectively	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
01	7	O
;	9	O
one	5	O
-	7	O
way	5	O
analysis	9	O
of	5	O
variance	5	O
-	7	O
significantly	9	O
greater	5	O
than	5	O
either	9	O
drug	5	O
given	5	O
alone	9	O
)	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
The	5	O
maximum	5	O
antihyperalgesic	0	O
effect	9	O
achievable	5	O
with	5	O
nonsedating	5	O
doses	0	O
of	5	O
morphine	0	B-Chemical
may	5	O
be	5	O
increased	9	O
significantly	9	O
when	5	O
the	5	O
drug	5	O
is	5	O
used	5	O
in	5	O
combination	9	O
with	5	O
CNSB002	_	B-Chemical
.	9	O

Heparin	0	B-Chemical
-	7	O
induced	3	O
thrombocytopenia	9	B-Disease
:	9	O
a	5	O
practical	5	O
review	5	O
.	9	O

Heparin	0	B-Chemical
-	7	O
induced	3	O
thrombocytopenia	9	B-Disease
(	9	O
HIT	5	B-Disease
)	9	O
remains	9	O
under	9	O
-	7	O
recognized	9	O
despite	9	O
its	9	O
potentially	5	O
devastating	5	O
outcomes	5	O
.	9	O

It	5	O
begins	5	O
when	5	O
heparin	0	B-Chemical
exposure	9	O
stimulates	3	O
the	5	O
formation	9	O
of	5	O
heparin	0	B-Chemical
-	7	O
platelet	9	O
factor	9	O
4	9	O
antibodies	3	O
,	9	O
which	5	O
in	5	O
turn	9	O
triggers	9	O
the	5	O
release	9	O
of	5	O
procoagulant	9	O
platelet	9	O
particles	0	O
.	9	O

Thrombosis	2	B-Disease
and	5	O
thrombocytopenia	9	B-Disease
that	5	O
follow	5	O
comprise	9	O
the	5	O
2	9	O
hallmark	9	O
traits	5	O
of	5	O
HIT	5	B-Disease
,	9	O
with	5	O
the	5	O
former	5	O
largely	9	O
responsible	9	O
for	5	O
significant	9	O
vascular	5	O
complications	5	O
.	9	O

The	5	O
prevalence	5	O
of	5	O
HIT	5	B-Disease
varies	9	O
among	5	O
several	9	O
subgroups	9	O
,	9	O
with	5	O
greater	5	O
incidence	5	O
in	5	O
surgical	5	O
as	5	O
compared	9	O
with	5	O
medical	5	O
populations	9	O
.	9	O

HIT	5	B-Disease
must	5	O
be	5	O
acknowledged	5	O
for	5	O
its	9	O
intense	9	O
predilection	5	O
for	5	O
thrombosis	5	B-Disease
and	5	O
suspected	5	O
whenever	5	O
thrombosis	5	B-Disease
occurs	9	O
after	9	O
heparin	0	B-Chemical
exposure	9	O
.	9	O

Early	9	O
recognition	5	O
that	5	O
incorporates	5	O
the	5	O
clinical	5	O
and	5	O
serologic	9	O
clues	5	O
is	5	O
paramount	5	O
to	5	O
timely	5	O
institution	5	O
of	5	O
treatment	9	O
,	9	O
as	5	O
its	9	O
delay	5	O
may	5	O
result	9	O
in	5	O
catastrophic	5	O
outcomes	5	O
.	9	O

The	5	O
treatment	9	O
of	5	O
HIT	5	B-Disease
mandates	5	O
an	5	O
immediate	5	O
cessation	5	O
of	5	O
all	5	O
heparin	0	B-Chemical
exposure	9	O
and	5	O
the	5	O
institution	5	O
of	5	O
an	5	O
antithrombotic	5	O
therapy	5	O
,	9	O
most	9	O
commonly	5	O
using	9	O
a	5	O
direct	9	B-Chemical
thrombin	0	I-Chemical
inhibitor	3	I-Chemical
.	9	O

Current	9	O
"	5	O
diagnostic	5	O
"	5	O
tests	5	O
,	9	O
which	5	O
primarily	9	O
include	5	O
functional	9	O
and	5	O
antigenic	9	O
assays	3	O
,	9	O
have	5	O
more	5	O
of	5	O
a	5	O
confirmatory	5	O
than	5	O
diagnostic	5	O
role	9	O
in	5	O
the	5	O
management	5	O
of	5	O
HIT	5	B-Disease
.	9	O

Special	2	O
attention	5	O
must	5	O
be	5	O
paid	5	O
to	5	O
cardiac	5	O
patients	5	O
who	5	O
are	5	O
often	5	O
exposed	9	O
to	5	O
heparin	0	B-Chemical
multiple	5	O
times	5	O
during	5	O
their	5	O
course	5	O
of	5	O
treatment	9	O
.	9	O

Direct	9	B-Chemical
thrombin	0	I-Chemical
inhibitors	3	I-Chemical
are	5	O
appropriate	5	O
,	9	O
evidence	9	O
-	7	O
based	5	O
alternatives	5	O
to	5	O
heparin	0	B-Chemical
in	5	O
patients	5	O
with	5	O
a	5	O
history	5	O
of	5	O
HIT	5	B-Disease
,	9	O
who	5	O
need	5	O
to	5	O
undergo	9	O
percutaneous	5	O
coronary	5	O
intervention	5	O
.	9	O

As	9	O
heparin	0	B-Chemical
remains	9	O
one	5	O
of	5	O
the	5	O
most	9	O
frequently	5	O
used	5	O
medications	5	O
today	5	O
with	5	O
potential	9	O
for	5	O
HIT	5	B-Disease
with	5	O
every	5	O
heparin	0	B-Chemical
exposure	9	O
,	9	O
a	5	O
close	5	O
vigilance	5	O
of	5	O
platelet	9	O
counts	9	O
must	5	O
be	5	O
practiced	5	O
whenever	5	O
heparin	0	B-Chemical
is	5	O
initiated	9	O
.	9	O

Abductor	7	O
paralysis	5	B-Disease
after	9	O
botox	5	B-Chemical
injection	9	O
for	5	O
adductor	5	B-Disease
spasmodic	5	I-Disease
dysphonia	5	I-Disease
.	9	O

OBJECTIVES	2	O
/	9	O
HYPOTHESIS	2	O
:	9	O
Botulinum	5	O
toxin	1	O
(	9	O
Botox	5	B-Chemical
)	9	O
injections	9	O
into	9	O
the	5	O
thyroarytenoid	5	O
muscles	5	O
are	5	O
the	5	O
current	5	O
standard	5	O
of	5	O
care	5	O
for	5	O
adductor	5	B-Disease
spasmodic	5	I-Disease
dysphonia	5	I-Disease
(	9	O
ADSD	5	B-Disease
)	9	O
.	9	O

Reported	5	O
adverse	5	O
effects	9	O
include	5	O
a	5	O
period	5	O
of	5	O
breathiness	5	O
,	9	O
throat	5	B-Disease
pain	5	I-Disease
,	9	O
and	5	O
difficulty	5	O
with	5	O
swallowing	5	O
liquids	0	O
.	9	O

Here	9	O
we	5	O
report	5	O
multiple	5	O
cases	5	O
of	5	O
bilateral	5	O
abductor	5	O
paralysis	5	B-Disease
following	9	O
Botox	5	B-Chemical
injections	9	O
for	5	O
ADSD	5	B-Disease
,	9	O
a	5	O
complication	5	O
previously	9	O
unreported	9	O
.	9	O

STUDY	2	O
DESIGN	2	O
:	9	O
Retrospective	9	O
case	5	O
series	5	O
.	9	O

METHODS	2	O
:	9	O
Patients	5	O
that	5	O
received	9	O
Botox	5	B-Chemical
injections	9	O
for	5	O
spasmodic	5	B-Disease
dysphonia	5	I-Disease
between	5	O
January	2	O
2000	9	O
and	5	O
October	2	O
2009	2	O
were	9	O
evaluated	9	O
.	9	O

Patients	5	O
with	5	O
ADSD	5	B-Disease
were	9	O
identified	9	O
.	9	O

The	5	O
number	9	O
of	5	O
treatments	9	O
received	9	O
and	5	O
adverse	5	O
effects	9	O
were	9	O
noted	9	O
.	9	O

For	9	O
patients	5	O
with	5	O
bilateral	5	O
abductor	5	O
paralysis	5	B-Disease
,	9	O
age	5	O
,	9	O
sex	5	O
,	9	O
paralytic	5	O
Botox	5	B-Chemical
dose	9	O
,	9	O
prior	9	O
Botox	5	B-Chemical
dose	9	O
,	9	O
and	5	O
course	5	O
following	9	O
paralysis	5	B-Disease
were	9	O
noted	9	O
.	9	O

RESULTS	9	O
:	9	O
From	5	O
a	5	O
database	5	O
of	5	O
452	7	O
patients	5	O
receiving	9	O
Botox	5	B-Chemical
,	9	O
352	7	O
patients	5	O
had	9	O
been	9	O
diagnosed	5	O
with	5	O
ADSD	5	B-Disease
.	9	O

Of	9	O
these	5	O
352	7	O
patients	5	O
,	9	O
eight	9	O
patients	5	O
suffered	5	O
bilateral	5	O
abductor	5	O
paralysis	5	B-Disease
,	9	O
and	5	O
two	5	O
suffered	5	O
this	5	O
complication	5	O
twice	9	O
.	9	O

All	9	O
affected	9	O
patients	5	O
were	9	O
females	9	O
over	5	O
the	5	O
age	5	O
of	5	O
50	0	O
years	5	O
.	9	O

Most	5	O
patients	5	O
had	9	O
received	9	O
treatments	9	O
prior	9	O
to	5	O
abductor	5	O
paralysis	5	B-Disease
and	5	O
continued	9	O
receiving	9	O
after	9	O
paralysis	5	B-Disease
.	9	O

Seven	9	O
patients	5	O
recovered	9	O
after	9	O
a	5	O
brief	5	O
period	5	O
of	5	O
activity	9	O
restrictions	5	O
,	9	O
and	5	O
one	5	O
underwent	5	O
a	5	O
tracheotomy	5	O
.	9	O

The	5	O
incidence	5	O
of	5	O
abductor	5	O
paralysis	5	B-Disease
after	9	O
Botox	5	B-Chemical
injection	9	O
for	5	O
ADSD	5	B-Disease
was	9	O
0	7	O
.	9	O
34	7	O
%	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Bilateral	5	O
abductor	5	O
paralysis	5	B-Disease
is	5	O
a	5	O
rare	5	O
complication	5	O
of	5	O
Botox	5	B-Chemical
injections	9	O
for	5	O
ADSD	5	B-Disease
,	9	O
causing	9	O
difficulty	5	O
with	5	O
breathing	5	O
upon	9	O
exertion	5	O
.	9	O

The	5	O
likely	5	O
mechanism	9	O
of	5	O
paralysis	5	B-Disease
is	5	O
diffusion	5	O
of	5	O
Botox	5	B-Chemical
around	5	O
the	5	O
muscular	5	O
process	5	O
of	5	O
the	5	O
arytenoid	5	O
to	5	O
the	5	O
posterior	5	O
cricoarytenoid	5	O
muscles	5	O
.	9	O

The	5	O
paralysis	5	B-Disease
is	5	O
temporary	5	O
,	9	O
and	5	O
watchful	5	O
waiting	5	O
with	5	O
restriction	9	O
of	5	O
activity	9	O
is	5	O
the	5	O
recommended	5	O
management	5	O
.	9	O

Mitochondrial	9	B-Disease
impairment	5	I-Disease
contributes	9	O
to	5	O
cocaine	5	B-Chemical
-	7	O
induced	3	O
cardiac	5	B-Disease
dysfunction	9	I-Disease
:	9	O
Prevention	2	O
by	9	O
the	5	O
targeted	9	O
antioxidant	0	O
MitoQ	0	B-Chemical
.	9	O

The	5	O
goal	5	O
of	5	O
this	5	O
study	9	O
was	9	O
to	5	O
assess	5	O
mitochondrial	9	O
function	9	O
and	5	O
ROS	3	O
production	9	O
in	5	O
an	5	O
experimental	5	O
model	5	O
of	5	O
cocaine	5	B-Chemical
-	7	O
induced	3	O
cardiac	5	B-Disease
dysfunction	9	I-Disease
.	9	O

We	9	O
hypothesized	9	O
that	5	O
cocaine	5	B-Disease
abuse	5	I-Disease
may	5	O
lead	5	O
to	5	O
altered	9	O
mitochondrial	9	O
function	9	O
that	5	O
in	5	O
turn	9	O
may	5	O
cause	5	O
left	5	B-Disease
ventricular	5	I-Disease
dysfunction	9	I-Disease
.	9	O

Seven	9	O
days	9	O
of	5	O
cocaine	5	B-Chemical
administration	9	O
to	5	O
rats	9	O
led	9	O
to	5	O
an	5	O
increased	9	O
oxygen	0	B-Chemical
consumption	5	O
detected	9	O
in	5	O
cardiac	5	O
fibers	9	O
,	9	O
specifically	9	O
through	9	O
complex	9	O
I	9	O
and	5	O
complex	9	O
III	9	O
.	9	O

ROS	3	O
levels	3	O
were	9	O
increased	9	O
,	9	O
specifically	9	O
in	5	O
interfibrillar	5	O
mitochondria	3	O
.	9	O

In	9	O
parallel	5	O
there	5	O
was	9	O
a	5	O
decrease	9	O
in	5	O
ATP	0	B-Chemical
synthesis	9	O
,	9	O
whereas	9	O
no	9	O
difference	9	O
was	9	O
observed	9	O
in	5	O
subsarcolemmal	5	O
mitochondria	3	O
.	9	O

This	5	O
uncoupling	9	O
effect	9	O
on	5	O
oxidative	9	O
phosphorylation	3	O
was	9	O
not	5	O
detectable	9	O
after	9	O
short	5	O
-	7	O
term	5	O
exposure	9	O
to	5	O
cocaine	5	B-Chemical
,	9	O
suggesting	9	O
that	5	O
these	5	O
mitochondrial	9	B-Disease
abnormalities	9	I-Disease
were	9	O
a	5	O
late	9	O
rather	5	O
than	5	O
a	5	O
primary	9	O
event	5	O
in	5	O
the	5	O
pathological	5	O
response	9	O
to	5	O
cocaine	5	B-Chemical
.	9	O

MitoQ	0	B-Chemical
,	9	O
a	5	O
mitochondrial	9	O
-	7	O
targeted	9	O
antioxidant	0	O
,	9	O
was	9	O
shown	9	O
to	5	O
completely	9	O
prevent	5	O
these	5	O
mitochondrial	9	B-Disease
abnormalities	9	I-Disease
as	5	O
well	9	O
as	5	O
cardiac	5	B-Disease
dysfunction	9	I-Disease
characterized	9	O
here	5	O
by	9	O
a	5	O
diastolic	5	B-Disease
dysfunction	9	I-Disease
studied	9	O
with	5	O
a	5	O
conductance	5	O
catheter	5	O
to	5	O
obtain	5	O
pressure	5	O
-	7	O
volume	9	O
data	5	O
.	9	O

Taken	9	O
together	9	O
,	9	O
these	5	O
results	9	O
extend	9	O
previous	9	O
studies	9	O
and	5	O
demonstrate	9	O
that	5	O
cocaine	5	B-Chemical
-	7	O
induced	3	O
cardiac	5	B-Disease
dysfunction	9	I-Disease
may	5	O
be	5	O
due	5	O
to	5	O
a	5	O
mitochondrial	9	B-Disease
defect	9	I-Disease
.	9	O

Trimethoprim	0	B-Chemical
-	7	O
induced	3	O
immune	3	O
hemolytic	0	B-Disease
anemia	9	I-Disease
in	5	O
a	5	O
pediatric	5	O
oncology	5	O
patient	5	O
presenting	5	O
as	5	O
an	5	O
acute	9	O
hemolytic	0	O
transfusion	5	O
reaction	9	O
.	9	O

A	9	O
10	9	O
-	7	O
year	5	O
-	7	O
old	5	O
male	9	O
with	5	O
acute	9	B-Disease
leukemia	3	I-Disease
presented	5	O
with	5	O
post	9	O
-	7	O
chemotherapy	5	O
anemia	9	B-Disease
.	9	O

During	5	O
red	9	O
cell	3	O
transfusion	5	O
,	9	O
he	5	O
developed	5	O
hemoglobinuria	3	B-Disease
.	9	O

Transfusion	2	O
reaction	9	O
workup	5	O
was	9	O
negative	9	O
.	9	O

Drug	5	O
-	7	O
induced	3	O
immune	3	O
hemolytic	0	B-Disease
anemia	9	I-Disease
was	9	O
suspected	5	O
because	5	O
of	5	O
positive	9	O
direct	9	O
antiglobulin	3	O
test	5	O
,	9	O
negative	9	O
eluate	0	O
,	9	O
and	5	O
microspherocytes	9	O
on	5	O
smear	5	O
pre	9	O
-	7	O
and	5	O
post	9	O
-	7	O
transfusion	5	O
.	9	O

Drug	5	O
studies	9	O
using	9	O
the	5	O
indirect	5	O
antiglobulin	3	O
test	5	O
were	9	O
strongly	9	O
positive	9	O
with	5	O
trimethoprim	0	B-Chemical
and	5	O
trimethoprim	0	B-Chemical
-	7	I-Chemical
sulfamethoxazole	0	I-Chemical
but	9	O
negative	9	O
with	5	O
sulfamethoxazole	0	B-Chemical
.	9	O

The	5	O
patient	5	O
recovered	9	O
after	9	O
discontinuing	5	O
the	5	O
drug	5	O
,	9	O
with	5	O
no	9	O
recurrence	5	O
in	5	O
2	9	O
years	5	O
.	9	O

Other	9	O
causes	9	O
of	5	O
anemia	9	B-Disease
should	5	O
be	5	O
considered	5	O
in	5	O
patients	5	O
with	5	O
worse	5	O
-	7	O
than	5	O
-	7	O
expected	9	O
anemia	9	B-Disease
after	9	O
chemotherapy	5	O
.	9	O

Furthermore	9	O
,	9	O
hemolysis	9	B-Disease
during	5	O
transfusion	5	O
is	5	O
not	5	O
always	5	O
a	5	O
transfusion	5	O
reaction	9	O
.	9	O

Verapamil	0	B-Chemical
stimulation	3	O
test	5	O
in	5	O
hyperprolactinemia	5	B-Disease
:	9	O
loss	9	O
of	5	O
prolactin	3	O
response	9	O
in	5	O
anatomic	5	O
or	5	O
functional	9	O
stalk	9	O
effect	9	O
.	9	O

AIM	9	O
:	9	O
Verapamil	0	B-Chemical
stimulation	3	O
test	5	O
was	9	O
previously	9	O
investigated	9	O
as	5	O
a	5	O
tool	5	O
for	5	O
differential	9	O
diagnosis	5	O
of	5	O
hyperprolactinemia	5	B-Disease
,	9	O
but	9	O
with	5	O
conflicting	5	O
results	9	O
.	9	O

Macroprolactinemia	9	B-Disease
was	9	O
never	5	O
considered	5	O
in	5	O
those	5	O
previous	9	O
studies	9	O
.	9	O

Here	9	O
,	9	O
we	5	O
aimed	5	O
to	5	O
re	5	O
-	7	O
investigate	9	O
the	5	O
diagnostic	5	O
value	9	O
of	5	O
verapamil	0	B-Chemical
in	5	O
a	5	O
population	5	O
who	5	O
were	9	O
all	5	O
screened	9	O
for	5	O
macroprolactinemia	5	B-Disease
.	9	O

Prolactin	9	O
responses	5	O
to	5	O
verapamil	0	B-Chemical
in	5	O
65	7	O
female	9	O
patients	5	O
(	9	O
age	5	O
:	9	O
29	7	O
.	9	O
9	7	O
+	9	O
/	9	O
-	7	O
8	9	O
.	9	O
1	9	O
years	5	O
)	9	O
with	5	O
hyperprolactinemia	5	B-Disease
were	9	O
tested	9	O
in	5	O
a	5	O
descriptive	5	O
,	9	O
matched	9	O
case	5	O
-	7	O
control	9	O
study	9	O
.	9	O

METHODS	2	O
:	9	O
Verapamil	0	B-Chemical
80	9	O
mg	0	O
,	9	O
p	7	O
.	9	O
o	9	O
.	9	O
was	9	O
administered	9	O
,	9	O
and	5	O
then	9	O
PRL	3	O
levels	3	O
were	9	O
measured	9	O
at	9	O
8th	9	O
and	5	O
16th	5	O
hours	9	O
,	9	O
by	9	O
immunometric	0	O
chemiluminescence	0	O
.	9	O

Verapamil	0	B-Chemical
responsiveness	9	O
was	9	O
determined	9	O
by	9	O
peak	9	O
percent	5	O
change	9	O
in	5	O
basal	3	O
prolactin	3	O
levels	3	O
(	9	O
PRL	3	O
)	9	O
.	9	O

RESULTS	9	O
:	9	O
Verapamil	0	B-Chemical
significantly	9	O
increased	9	O
PRL	3	O
levels	3	O
in	5	O
healthy	5	O
controls	9	O
(	9	O
N	9	O
.	9	O
8	9	O
,	9	O
PRL	3	O
:	9	O
183	7	O
%	9	O
)	9	O
,	9	O
macroprolactinoma	5	B-Disease
(	9	O
N	9	O
.	9	O
8	9	O
,	9	O
PRL	3	O
:	9	O
7	9	O
%	9	O
)	9	O
,	9	O
microprolactinoma	5	B-Disease
(	9	O
N	9	O
.	9	O
19	7	O
,	9	O
PRL	3	O
:	9	O
21	7	O
%	9	O
)	9	O
,	9	O
macroprolactinemia	5	B-Disease
(	9	O
N	9	O
.	9	O
23	7	O
,	9	O
PRL	3	O
:	9	O
126	7	O
%	9	O
)	9	O
,	9	O
but	9	O
not	5	O
in	5	O
pseudoprolactinoma	_	B-Disease
(	9	O
N	9	O
.	9	O
8	9	O
,	9	O
PRL	3	O
:	9	O
0	7	O
.	9	O
8	9	O
%	9	O
)	9	O
,	9	O
and	5	O
risperidone	5	B-Chemical
-	7	O
induced	3	O
hyperprolactinemia	5	B-Disease
(	9	O
N	9	O
.	9	O
7	9	O
,	9	O
PRL	3	O
:	9	O
3	9	O
%	9	O
)	9	O
.	9	O

ROC	5	O
curve	9	O
analysis	9	O
revealed	9	O
that	5	O
unresponsiveness	3	O
to	5	O
verapamil	0	B-Chemical
defined	5	O
as	5	O
PRL	3	O
<	0	O
7	9	O
%	9	O
,	9	O
discriminated	5	O
anatomical	5	O
or	5	O
functional	9	O
stalk	9	O
effect	9	O
(	9	O
sensitivity	9	O
:	9	O
74	7	O
%	9	O
,	9	O
specificity	9	O
:	9	O
73	7	O
%	9	O
,	9	O
AUC	9	O
:	9	O
0	7	O
.	9	O
855	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
04	7	O
,	9	O
P	9	O
<	0	O
0	7	O
.	9	O
001	9	O
,	9	O
CI	7	O
:	9	O
0	7	O
.	9	O
768	7	O
-	7	O
0	7	O
.	9	O
942	7	O
)	9	O
associated	9	O
with	5	O
pseudoprolactinoma	_	B-Disease
or	5	O
risperidone	5	B-Chemical
-	7	O
induced	3	O
hyperprolactinemia	5	B-Disease
,	9	O
respectively	9	O
.	9	O

CONCLUSION	5	O
:	9	O
Verapamil	0	B-Chemical
responsiveness	9	O
is	5	O
not	5	O
a	5	O
reliable	5	O
finding	9	O
for	5	O
the	5	O
differential	9	O
diagnosis	5	O
of	5	O
hyperprolactinemia	5	B-Disease
.	9	O

However	9	O
,	9	O
verapamil	0	B-Chemical
unresponsiveness	3	O
discriminates	9	O
stalk	9	O
effect	9	O
(	9	O
i	9	O
.	9	O
e	9	O
.	9	O
,	9	O
anatomically	5	O
or	5	O
functionally	9	O
inhibited	3	O
dopaminergic	5	O
tonus	5	O
)	9	O
from	9	O
other	5	O
causes	9	O
of	5	O
hyperprolactinemia	5	B-Disease
with	5	O
varying	5	O
degrees	5	O
of	5	O
responsiveness	9	O
.	9	O

Blockade	3	O
of	5	O
endothelial	3	O
-	7	O
mesenchymal	3	O
transition	9	O
by	9	O
a	5	O
Smad3	3	O
inhibitor	3	O
delays	5	O
the	5	O
early	9	O
development	9	O
of	5	O
streptozotocin	0	B-Chemical
-	7	O
induced	3	O
diabetic	9	B-Disease
nephropathy	9	I-Disease
.	9	O

OBJECTIVE	2	O
:	9	O
A	9	O
multicenter	5	O
,	9	O
controlled	5	O
trial	5	O
showed	9	O
that	5	O
early	9	O
blockade	3	O
of	5	O
the	5	O
renin	9	O
-	7	O
angiotensin	9	B-Chemical
system	5	O
in	5	O
patients	5	O
with	5	O
type	9	B-Disease
1	9	I-Disease
diabetes	5	I-Disease
and	5	O
normoalbuminuria	5	O
did	9	O
not	5	O
retard	9	O
the	5	O
progression	9	O
of	5	O
nephropathy	9	B-Disease
,	9	O
suggesting	9	O
that	5	O
other	5	O
mechanism	9	O
(	9	O
s	9	O
)	9	O
are	5	O
involved	9	O
in	5	O
the	5	O
pathogenesis	9	O
of	5	O
early	9	O
diabetic	9	B-Disease
nephropathy	9	I-Disease
(	9	O
diabetic	9	B-Disease
nephropathy	9	I-Disease
)	9	O
.	9	O

We	9	O
have	5	O
previously	9	O
demonstrated	9	O
that	5	O
endothelial	3	O
-	7	O
mesenchymal	3	O
-	7	O
transition	9	O
(	9	O
EndoMT	3	O
)	9	O
contributes	9	O
to	5	O
the	5	O
early	9	O
development	9	O
of	5	O
renal	9	O
interstitial	9	O
fibrosis	9	B-Disease
independently	9	O
of	5	O
microalbuminuria	5	O
in	5	O
mice	3	O
with	5	O
streptozotocin	0	B-Chemical
(	9	O
STZ	0	B-Chemical
)	9	O
-	7	O
induced	3	O
diabetes	5	B-Disease
.	9	O

In	9	O
the	5	O
present	9	O
study	9	O
,	9	O
we	5	O
hypothesized	9	O
that	5	O
blocking	3	O
EndoMT	3	O
reduces	9	O
the	5	O
early	9	O
development	9	O
of	5	O
diabetic	9	B-Disease
nephropathy	9	I-Disease
.	9	O

RESEARCH	2	O
DESIGN	2	O
AND	2	O
METHODS	2	O
:	9	O
EndoMT	3	O
was	9	O
induced	3	O
in	5	O
a	5	O
mouse	3	O
pancreatic	3	O
microvascular	5	O
endothelial	3	O
cell	3	O
line	9	O
(	9	O
MMEC	3	O
)	9	O
in	5	O
the	5	O
presence	9	O
of	5	O
advanced	5	O
glycation	0	O
end	9	O
products	9	O
(	9	O
AGEs	3	O
)	9	O
and	5	O
in	5	O
the	5	O
endothelial	3	O
lineage	4	O
-	7	O
traceble	_	O
mouse	3	O
line	9	O
Tie2	3	O
-	7	O
Cre	3	O
;	9	O
Loxp	1	O
-	7	O
EGFP	3	O
by	9	O
administration	9	O
of	5	O
AGEs	3	O
,	9	O
with	5	O
nonglycated	0	O
mouse	3	O
albumin	0	O
serving	5	O
as	5	O
a	5	O
control	9	O
.	9	O

Phosphorylated	3	O
Smad3	3	O
was	9	O
detected	9	O
by	9	O
immunoprecipitation	3	O
/	9	O
Western	3	O
blotting	3	O
and	5	O
confocal	3	O
microscopy	9	O
.	9	O

Blocking	3	O
studies	9	O
using	9	O
receptor	3	O
for	5	O
AGE	9	O
siRNA	3	O
and	5	O
a	5	O
specific	9	O
inhibitor	3	O
of	5	O
Smad3	3	O
(	9	O
SIS3	3	O
)	9	O
were	9	O
performed	9	O
in	5	O
MMECs	3	O
and	5	O
in	5	O
STZ	0	B-Chemical
-	7	O
induced	3	O
diabetic	9	B-Disease
nephropathy	9	I-Disease
in	5	O
Tie2	3	O
-	7	O
Cre	3	O
;	9	O
Loxp	1	O
-	7	O
EGFP	3	O
mice	3	O
.	9	O

RESULTS	9	O
:	9	O
Confocal	3	O
microscopy	9	O
and	5	O
real	5	O
-	7	O
time	5	O
PCR	9	O
demonstrated	9	O
that	5	O
AGEs	3	O
induced	3	O
EndoMT	3	O
in	5	O
MMECs	3	O
and	5	O
in	5	O
Tie2	3	O
-	7	O
Cre	3	O
;	9	O
Loxp	1	O
-	7	O
EGFP	3	O
mice	3	O
.	9	O

Immunoprecipitation	3	O
/	9	O
Western	3	O
blotting	3	O
showed	9	O
that	5	O
Smad3	3	O
was	9	O
activated	3	O
by	9	O
AGEs	3	O
but	9	O
was	9	O
inhibited	3	O
by	9	O
SIS3	3	O
in	5	O
MMECs	3	O
and	5	O
in	5	O
STZ	0	B-Chemical
-	7	O
induced	3	O
diabetic	9	B-Disease
nephropathy	9	I-Disease
.	9	O

Confocal	3	O
microscopy	9	O
and	5	O
real	5	O
-	7	O
time	5	O
PCR	9	O
further	9	O
demonstrated	9	O
that	5	O
SIS3	3	O
abrogated	3	O
EndoMT	3	O
,	9	O
reduced	9	O
renal	9	O
fibrosis	9	B-Disease
,	9	O
and	5	O
retarded	9	O
progression	9	O
of	5	O
nephropathy	9	B-Disease
.	9	O

CONCLUSIONS	5	O
:	9	O
EndoMT	3	O
is	5	O
a	5	O
novel	9	O
pathway	3	O
leading	9	O
to	5	O
early	9	O
development	9	O
of	5	O
diabetic	9	B-Disease
nephropathy	9	I-Disease
.	9	O

Blockade	3	O
of	5	O
EndoMT	3	O
by	9	O
SIS3	3	O
may	5	O
provide	5	O
a	5	O
new	5	O
strategy	5	O
to	5	O
retard	9	O
the	5	O
progression	9	O
of	5	O
diabetic	9	B-Disease
nephropathy	9	I-Disease
and	5	O
other	5	O
diabetes	5	B-Disease
complications	5	I-Disease
.	9	O

Cytostatic	0	O
and	5	O
anti	3	O
-	7	O
angiogenic	3	O
effects	9	O
of	5	O
temsirolimus	3	B-Chemical
in	5	O
refractory	9	O
mantle	5	B-Disease
cell	3	I-Disease
lymphoma	9	I-Disease
.	9	O

Mantle	9	B-Disease
cell	3	I-Disease
lymphoma	9	I-Disease
(	9	O
MCL	9	B-Disease
)	9	O
is	5	O
a	5	O
rare	5	O
and	5	O
aggressive	5	O
type	9	O
of	5	O
B	9	B-Disease
-	7	I-Disease
cell	3	I-Disease
non	9	I-Disease
-	7	I-Disease
Hodgkin	5	I-Disease
'	9	I-Disease
s	9	I-Disease
lymphoma	9	I-Disease
.	9	O

Patients	5	O
become	5	O
progressively	9	O
refractory	9	O
to	5	O
conventional	5	O
chemotherapy	5	O
,	9	O
and	5	O
their	5	O
prognosis	5	O
is	5	O
poor	5	O
.	9	O

However	9	O
,	9	O
a	5	O
38	7	O
%	9	O
remission	5	O
rate	9	O
has	9	O
been	9	O
recently	9	O
reported	9	O
in	5	O
refractory	9	O
MCL	9	B-Disease
treated	3	O
with	5	O
temsirolimus	3	B-Chemical
,	9	O
a	5	O
mTOR	3	O
inhibitor	3	O
.	9	O
Here	9	O
we	5	O
had	9	O
the	5	O
opportunity	5	O
to	5	O
study	9	O
a	5	O
case	5	O
of	5	O
refractory	9	O
MCL	9	B-Disease
who	5	O
had	9	O
tumor	3	B-Disease
regression	5	O
two	5	O
months	5	O
after	9	O
temsirolimus	3	B-Chemical
treatment	9	O
,	9	O
and	5	O
a	5	O
progression	9	O
-	7	O
free	9	O
survival	9	O
of	5	O
10	9	O
months	5	O
.	9	O

In	9	O
this	5	O
case	5	O
,	9	O
lymph	9	O
node	5	O
biopsies	9	O
were	9	O
performed	9	O
before	9	O
and	5	O
six	9	O
months	5	O
after	9	O
temsirolimus	3	B-Chemical
therapy	5	O
.	9	O

Comparison	9	O
of	5	O
the	5	O
two	5	O
biopsies	9	O
showed	9	O
that	5	O
temsirolimus	3	B-Chemical
inhibited	3	O
tumor	3	B-Disease
cell	3	O
proliferation	3	O
through	9	O
cell	3	O
cycle	9	O
arrest	3	O
,	9	O
but	9	O
did	9	O
not	5	O
induce	3	O
any	5	O
change	9	O
in	5	O
the	5	O
number	9	O
of	5	O
apoptotic	3	O
tumor	3	B-Disease
cells	3	O
.	9	O

Apart	9	O
from	9	O
this	5	O
cytostatic	3	O
effect	9	O
,	9	O
temsirolimus	3	B-Chemical
had	9	O
an	5	O
antiangiogenic	3	O
effect	9	O
with	5	O
decrease	9	O
of	5	O
tumor	3	B-Disease
microvessel	3	O
density	9	O
and	5	O
of	5	O
VEGF	3	O
expression	3	O
.	9	O

Moreover	9	O
,	9	O
numerous	9	O
patchy	5	O
,	9	O
well	9	O
-	7	O
limited	5	O
fibrotic	5	O
areas	5	O
,	9	O
compatible	5	O
with	5	O
post	9	O
-	7	O
necrotic	3	B-Disease
tissue	9	O
repair	9	O
,	9	O
were	9	O
found	9	O
after	9	O
6	9	O
-	7	O
month	5	O
temsirolimus	3	B-Chemical
therapy	5	O
.	9	O

Thus	9	O
,	9	O
temsirolimus	3	B-Chemical
reduced	9	O
tumor	3	B-Disease
burden	5	O
through	9	O
associated	9	O
cytostatic	3	O
and	5	O
anti	3	O
-	7	O
angiogenic	3	O
effects	9	O
.	9	O
This	5	O
dual	9	O
effect	9	O
of	5	O
temsirolimus	3	B-Chemical
on	5	O
tumor	3	B-Disease
tissue	9	O
could	9	O
contribute	9	O
to	5	O
its	9	O
recently	9	O
reported	9	O
efficiency	9	O
in	5	O
refractory	9	O
MCL	9	B-Disease
resistant	9	O
to	5	O
conventional	5	O
chemotherapy	5	O
.	9	O

Acute	5	B-Disease
renal	9	I-Disease
failure	5	I-Disease
due	5	O
to	5	O
rifampicin	0	B-Chemical
.	9	O

A	9	O
23	7	O
-	7	O
year	5	O
-	7	O
old	5	O
male	9	O
patient	5	O
with	5	O
bacteriologically	5	O
proven	5	O
pulmonary	5	B-Disease
tuberculosis	9	I-Disease
was	9	O
treated	3	O
with	5	O
the	5	O
various	9	O
regimens	5	O
of	5	O
antituberculosis	5	O
drugs	5	O
for	5	O
nearly	9	O
15	9	O
months	5	O
.	9	O

Rifampicin	0	B-Chemical
was	9	O
administered	9	O
thrice	0	O
as	5	O
one	5	O
of	5	O
the	5	O
3	9	O
-	7	O
4	9	O
drug	5	O
regimen	5	O
and	5	O
each	5	O
time	5	O
he	5	O
developed	5	O
untoward	5	O
side	5	O
effects	9	O
like	9	O
nausea	5	B-Disease
,	9	O
vomiting	5	B-Disease
and	5	O
fever	5	B-Disease
with	5	O
chills	5	O
and	5	O
rigors	5	O
.	9	O

The	5	O
last	5	O
such	5	O
episode	5	O
was	9	O
of	5	O
acute	9	O
renal	9	O
failure	5	O
at	9	O
which	5	O
stage	9	O
the	5	O
patient	5	O
was	9	O
seen	9	O
by	9	O
the	5	O
authors	5	O
of	5	O
this	5	O
report	5	O
.	9	O

The	5	O
patient	5	O
,	9	O
however	9	O
,	9	O
made	5	O
a	5	O
full	5	O
recovery	9	O
.	9	O

Syncope	7	B-Disease
caused	9	O
by	9	O
hyperkalemia	5	B-Disease
during	5	O
use	5	O
of	5	O
a	5	O
combined	9	O
therapy	5	O
with	5	O
the	5	O
angiotensin	9	B-Chemical
-	7	O
converting	9	O
enzyme	0	O
inhibitor	3	O
and	5	O
spironolactone	0	B-Chemical
.	9	O

A	9	O
76	7	O
year	5	O
-	7	O
old	5	O
woman	5	O
with	5	O
a	5	O
history	5	O
of	5	O
coronary	5	O
artery	5	O
bypass	5	O
grafting	5	O
and	5	O
prior	9	O
myocardial	9	B-Disease
infarction	5	I-Disease
was	9	O
transferred	9	O
to	5	O
the	5	O
emergency	5	O
room	9	O
with	5	O
loss	9	B-Disease
of	5	I-Disease
consciousness	5	I-Disease
due	5	O
to	5	O
marked	9	O
bradycardia	5	B-Disease
caused	9	O
by	9	O
hyperkalemia	5	B-Disease
.	9	O

The	5	O
concentration	0	O
of	5	O
serum	9	O
potassium	0	B-Chemical
was	9	O
high	9	O
,	9	O
and	5	O
normal	9	O
sinus	5	O
rhythm	5	O
was	9	O
restored	3	O
after	9	O
correction	5	O
of	5	O
the	5	O
serum	9	O
potassium	0	B-Chemical
level	9	O
.	9	O

The	5	O
cause	5	O
of	5	O
hyperkalemia	5	B-Disease
was	9	O
considered	5	O
to	5	O
be	5	O
several	9	O
doses	0	O
of	5	O
spiranolactone	9	B-Chemical
,	9	O
an	5	O
aldosterone	9	B-Chemical
antagonist	3	O
,	9	O
in	5	O
addition	9	O
to	5	O
the	5	O
long	5	O
-	7	O
term	5	O
intake	5	O
of	5	O
ramipril	0	B-Chemical
,	9	O
an	5	O
ACE	9	O
inhibitor	3	O
.	9	O

This	5	O
case	5	O
is	5	O
a	5	O
good	5	O
example	5	O
of	5	O
electrolyte	0	O
imbalance	9	O
causing	9	O
acute	9	O
life	5	O
-	7	O
threatening	5	O
cardiac	5	O
events	5	O
.	9	O

Clinicians	5	O
should	5	O
be	5	O
alert	5	O
to	5	O
the	5	O
possibility	9	O
of	5	O
hyperkalemia	5	B-Disease
,	9	O
especially	5	O
in	5	O
elderly	5	O
patients	5	O
using	9	O
ACE	9	O
/	9	O
ARB	9	O
in	5	O
combination	9	O
with	5	O
potassium	0	B-Chemical
sparing	5	O
agents	5	O
and	5	O
who	5	O
have	5	O
mild	9	O
renal	9	B-Disease
disturbance	5	I-Disease
.	9	O

Diffuse	9	O
skeletal	9	O
pain	5	B-Disease
after	9	O
administration	9	O
of	5	O
alendronate	0	B-Chemical
.	9	O

BACKGROUND	2	O
:	9	O
Osteoporosis	5	B-Disease
is	5	O
caused	9	O
by	9	O
bone	5	O
resorption	5	O
in	5	O
excess	9	O
of	5	O
bone	5	O
formation	9	O
,	9	O
and	5	O
bisphosphonates	5	B-Chemical
,	9	O
are	5	O
used	5	O
to	5	O
inhibit	3	O
bone	5	O
resorption	5	O
.	9	O

Alendronate	0	B-Chemical
,	9	O
a	5	O
biphosphonate	0	B-Chemical
,	9	O
is	5	O
effective	5	O
for	5	O
both	9	O
the	5	O
treatment	9	O
and	5	O
prevention	5	O
of	5	O
osteoporosis	5	B-Disease
in	5	O
postmenopausal	5	O
women	5	O
.	9	O

Side	5	O
effects	9	O
are	5	O
relatively	5	O
few	5	O
and	5	O
prominently	9	O
gastrointestinal	9	O
.	9	O

Musculoskeletal	2	B-Disease
pain	5	I-Disease
may	5	O
be	5	O
an	5	O
important	9	O
side	5	O
effect	9	O
in	5	O
these	5	O
patients	5	O
.	9	O

We	9	O
presented	5	O
a	5	O
patient	5	O
admitted	5	O
to	5	O
our	5	O
out	9	O
-	7	O
patient	5	O
clinic	5	O
with	5	O
diffuse	5	O
skeletal	9	O
pain	5	B-Disease
after	9	O
three	9	O
consecutive	5	O
administration	9	O
of	5	O
alendronate	0	B-Chemical
.	9	O

CONCLUSION	5	O
:	9	O
We	9	O
conclude	9	O
that	5	O
patients	5	O
with	5	O
osteoporosis	5	B-Disease
can	5	O
report	5	O
pain	5	B-Disease
,	9	O
and	5	O
bisphosphonate	5	B-Chemical
-	7	O
related	9	O
pain	5	B-Disease
should	5	O
also	9	O
be	5	O
considered	5	O
before	9	O
ascribing	5	O
this	5	O
complaint	5	O
to	5	O
osteoporosis	5	B-Disease
.	9	O

Cerebrospinal	9	O
fluid	5	O
penetration	5	O
of	5	O
high	9	O
-	7	O
dose	9	O
daptomycin	0	B-Chemical
in	5	O
suspected	5	O
Staphylococcus	4	O
aureus	9	O
meningitis	5	B-Disease
.	9	O

OBJECTIVE	2	O
:	9	O
To	9	O
report	5	O
a	5	O
case	5	O
of	5	O
methicillin	9	B-Chemical
-	7	O
sensitive	9	O
Staphylococcus	4	O
aureus	9	O
(	9	O
MSSA	9	O
)	9	O
bacteremia	5	B-Disease
with	5	O
suspected	5	O
MSSA	9	O
meningitis	5	B-Disease
treated	3	O
with	5	O
high	9	O
-	7	O
dose	9	O
daptomycin	0	B-Chemical
assessed	9	O
with	5	O
concurrent	5	O
serum	9	O
and	5	O
cerebrospinal	9	O
fluid	5	O
(	9	O
CSF	9	O
)	9	O
concentrations	0	O
.	9	O

CASE	2	O
SUMMARY	9	O
:	9	O
A	9	O
54	7	O
-	7	O
year	5	O
-	7	O
old	5	O
male	9	O
presented	5	O
to	5	O
the	5	O
emergency	5	O
department	5	O
with	5	O
generalized	5	O
weakness	5	B-Disease
and	5	O
presumed	9	O
health	5	O
-	7	O
care	5	O
-	7	O
associated	9	O
pneumonia	5	B-Disease
shown	9	O
on	5	O
chest	5	O
radiograph	5	O
.	9	O

Treatment	9	O
was	9	O
empirically	5	O
initiated	9	O
with	5	O
vancomycin	9	B-Chemical
,	9	O
levofloxacin	0	B-Chemical
,	9	O
and	5	O
piperacillin	0	B-Chemical
/	9	O
tazobactam	0	B-Chemical
.	9	O

Blood	9	O
cultures	3	O
revealed	9	O
S	9	O
.	9	O
aureus	9	O
susceptible	9	O
to	5	O
oxacillin	0	B-Chemical
.	9	O

Empiric	5	O
antibiotic	5	O
treatment	9	O
was	9	O
narrowed	5	O
to	5	O
nafcillin	0	B-Chemical
on	5	O
day	9	O
4	9	O
.	9	O

On	5	O
day	9	O
8	9	O
,	9	O
the	5	O
patient	5	O
developed	5	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
(	9	O
serum	9	O
creatinine	0	B-Chemical
1	9	O
.	9	O
9	7	O
mg	0	O
/	9	O
dL	7	O
,	9	O
increased	9	O
from	9	O
1	9	O
.	9	O
2	9	O
mg	0	O
/	9	O
dL	7	O
the	5	O
previous	9	O
day	9	O
and	5	O
0	7	O
.	9	O
8	9	O
mg	0	O
/	9	O
dL	7	O
on	5	O
admission	5	O
)	9	O
.	9	O

The	5	O
patient	5	O
'	9	O
s	9	O
Glasgow	5	O
Coma	5	O
Score	5	O
was	9	O
3	9	O
,	9	O
with	5	O
normal	9	O
findings	9	O
shown	9	O
on	5	O
computed	5	O
tomography	5	O
scan	5	O
of	5	O
the	5	O
head	5	O
72	9	O
hours	9	O
following	9	O
an	5	O
episode	5	O
of	5	O
cardiac	5	B-Disease
arrest	3	I-Disease
on	5	O
day	9	O
10	9	O
.	9	O

The	5	O
patient	5	O
experienced	5	O
relapsing	5	O
MSSA	9	O
bacteremia	5	B-Disease
on	5	O
day	9	O
9	7	O
,	9	O
increasing	9	O
the	5	O
suspicion	5	O
for	5	O
a	5	O
central	5	O
nervous	5	O
system	5	O
(	9	O
CNS	9	O
)	9	O
infection	9	B-Disease
.	9	O

Nafcillin	7	B-Chemical
was	9	O
discontinued	5	O
and	5	O
daptomycin	0	B-Chemical
9	7	O
mg	0	O
/	9	O
kg	0	O
daily	5	O
was	9	O
initiated	9	O
for	5	O
suspected	5	O
meningitis	5	B-Disease
and	5	O
was	9	O
continued	9	O
until	5	O
the	5	O
patient	5	O
'	9	O
s	9	O
death	9	O
on	5	O
day	9	O
16	9	O
.	9	O

Daptomycin	0	B-Chemical
serum	9	O
and	5	O
CSF	9	O
trough	9	O
concentrations	0	O
were	9	O
11	7	O
.	9	O
21	7	O
ug	0	O
/	9	O
mL	0	O
and	5	O
0	7	O
.	9	O
52	7	O
ug	0	O
/	9	O
mL	0	O
,	9	O
respectively	9	O
,	9	O
prior	9	O
to	5	O
the	5	O
third	9	O
dose	9	O
.	9	O

Lumbar	5	O
puncture	5	O
results	9	O
were	9	O
inconclusive	9	O
and	5	O
no	9	O
further	9	O
blood	9	O
cultures	3	O
were	9	O
positive	9	O
for	5	O
MSSA	9	O
.	9	O

Creatine	7	B-Chemical
kinase	3	O
levels	3	O
were	9	O
normal	9	O
prior	9	O
to	5	O
daptomycin	0	B-Chemical
therapy	5	O
and	5	O
were	9	O
not	5	O
reassessed	5	O
.	9	O

DISCUSSION	9	O
:	9	O
Daptomycin	0	B-Chemical
was	9	O
initiated	9	O
in	5	O
our	5	O
patient	5	O
secondary	9	O
to	5	O
possible	5	O
nafcillin	0	B-Chemical
-	7	O
induced	3	O
acute	9	O
interstitial	9	B-Disease
nephritis	9	I-Disease
and	5	O
relapsing	5	O
bacteremia	5	B-Disease
.	9	O

At	9	O
a	5	O
dose	9	O
of	5	O
9	7	O
mg	0	O
/	9	O
kg	0	O
,	9	O
resultant	9	O
penetration	5	O
of	5	O
5	9	O
%	9	O
was	9	O
higher	9	O
than	5	O
in	5	O
previous	9	O
reports	9	O
,	9	O
more	5	O
consistent	9	O
with	5	O
inflamed	3	O
meninges	5	O
.	9	O

CONCLUSIONS	5	O
:	9	O
High	9	O
-	7	O
dose	9	O
daptomycin	0	B-Chemical
may	5	O
be	5	O
an	5	O
alternative	5	O
option	5	O
for	5	O
MSSA	9	O
bacteremia	5	B-Disease
with	5	O
or	5	O
without	9	O
a	5	O
CNS	9	O
source	5	O
in	5	O
patients	5	O
who	5	O
have	5	O
failed	9	O
or	5	O
cannot	5	O
tolerate	5	O
standard	5	O
therapy	5	O
.	9	O

Further	9	O
clinical	5	O
evaluation	5	O
in	5	O
patients	5	O
with	5	O
confirmed	9	O
meningitis	5	B-Disease
is	5	O
warranted	9	O
.	9	O

The	5	O
role	9	O
of	5	O
nitric	0	B-Chemical
oxide	0	I-Chemical
in	5	O
convulsions	5	B-Disease
induced	3	O
by	9	O
lindane	0	B-Chemical
in	5	O
rats	9	O
.	9	O

Lindane	0	B-Chemical
is	5	O
an	5	O
organochloride	0	O
pesticide	5	O
and	5	O
scabicide	9	O
.	9	O

It	5	O
evokes	5	O
convulsions	5	B-Disease
mainly	9	O
trough	9	O
the	5	O
blockage	9	O
of	5	O
GABA	0	B-Chemical
(	9	O
A	9	O
)	9	O
receptors	3	O
.	9	O

Nitric	0	B-Chemical
oxide	0	I-Chemical
(	9	O
NO	9	B-Chemical
)	9	O
,	9	O
gaseous	0	O
neurotransmitter	9	O
,	9	O
has	9	O
contradictor	_	O
role	9	O
in	5	O
epileptogenesis	5	O
due	5	O
to	5	O
opposite	9	O
effects	9	O
of	5	O
L	0	B-Chemical
-	7	I-Chemical
arginine	0	I-Chemical
,	9	O
precursor	9	O
of	5	O
NO	9	B-Chemical
syntheses	9	O
(	9	O
NOS	9	O
)	9	O
,	9	O
and	5	O
L	0	B-Chemical
-	7	I-Chemical
NAME	0	I-Chemical
(	9	O
NOS	9	O
inhibitor	3	O
)	9	O
observed	9	O
in	5	O
different	9	O
epilepsy	5	B-Disease
models	5	O
.	9	O

The	5	O
aim	5	O
of	5	O
the	5	O
current	5	O
study	9	O
was	9	O
to	5	O
determine	9	O
the	5	O
effects	9	O
of	5	O
NO	9	B-Chemical
on	5	O
the	5	O
behavioral	5	O
and	5	O
EEG	5	O
characteristics	5	O
of	5	O
lindane	0	B-Chemical
-	7	O
induced	3	O
epilepsy	5	B-Disease
in	5	O
male	9	O
Wistar	9	O
albino	3	O
rats	9	O
.	9	O

The	5	O
administration	9	O
of	5	O
L	0	B-Chemical
-	7	I-Chemical
arginine	0	I-Chemical
(	9	O
600	0	O
,	9	O
800	0	O
and	5	O
1000	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
in	5	O
dose	9	O
-	7	O
dependent	9	O
manner	9	O
significantly	9	O
increased	9	O
convulsion	5	B-Disease
incidence	5	O
and	5	O
severity	5	O
and	5	O
shortened	9	O
latency	5	O
time	5	O
to	5	O
first	9	O
convulsion	5	B-Disease
elicited	9	O
by	9	O
lower	9	O
lindane	0	B-Chemical
dose	9	O
(	9	O
4	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
.	9	O

On	5	O
the	5	O
contrary	9	O
,	9	O
pretreatment	0	O
with	5	O
L	0	B-Chemical
-	7	I-Chemical
NAME	0	I-Chemical
(	9	O
500	0	O
,	9	O
700	9	O
and	5	O
900	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
decreased	9	O
convulsion	5	B-Disease
incidence	5	O
and	5	O
severity	5	O
and	5	O
prolonged	9	O
latency	5	O
time	5	O
to	5	O
convulsion	5	B-Disease
following	9	O
injection	9	O
with	5	O
a	5	O
convulsive	5	B-Disease
dose	9	O
of	5	O
lindane	0	B-Chemical
(	9	O
8	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
.	9	O

EEG	5	O
analyses	9	O
showed	9	O
increase	9	O
of	5	O
number	9	O
and	5	O
duration	5	O
of	5	O
ictal	5	O
periods	5	O
in	5	O
EEG	5	O
of	5	O
rats	9	O
receiving	9	O
l	0	B-Chemical
-	7	I-Chemical
arginine	0	I-Chemical
prior	9	O
to	5	O
lindane	0	B-Chemical
and	5	O
decrease	9	O
of	5	O
this	5	O
number	9	O
in	5	O
rats	9	O
pretreated	3	O
with	5	O
L	0	B-Chemical
-	7	I-Chemical
NAME	0	I-Chemical
.	9	O

These	5	O
results	9	O
support	5	O
the	5	O
conclusion	9	O
that	5	O
NO	9	B-Chemical
plays	9	O
a	5	O
role	9	O
of	5	O
endogenous	3	O
convulsant	0	O
in	5	O
rat	3	O
model	5	O
of	5	O
lindane	0	B-Chemical
seizures	5	B-Disease
.	9	O

Severe	9	O
polyneuropathy	5	B-Disease
and	5	O
motor	5	O
loss	9	O
after	9	O
intrathecal	3	O
thiotepa	0	B-Chemical
combination	9	O
chemotherapy	5	O
:	9	O
description	5	O
of	5	O
two	5	O
cases	5	O
.	9	O

Two	9	O
cases	5	O
of	5	O
severe	5	O
delayed	9	O
neurologic	5	B-Disease
toxicity	9	I-Disease
related	9	O
to	5	O
the	5	O
administration	9	O
of	5	O
intrathecal	3	O
(	9	O
IT	9	O
)	9	O
combination	9	O
chemotherapy	5	O
including	9	O
thiotepa	0	B-Chemical
(	9	O
TSPA	0	B-Chemical
)	9	O
are	5	O
presented	5	O
.	9	O

Both	9	O
cases	5	O
developed	5	O
axonal	3	B-Disease
neuropathy	5	I-Disease
with	5	O
motor	5	O
predominance	9	O
in	5	O
the	5	O
lower	9	O
extremities	5	O
1	9	O
and	5	O
6	9	O
months	5	O
after	9	O
IT	9	O
chemotherapy	5	O
was	9	O
administered	9	O
.	9	O

Neurologic	5	B-Disease
toxicities	5	I-Disease
have	5	O
been	9	O
described	9	O
with	5	O
IT	9	O
-	7	O
methotrexate	9	B-Chemical
,	9	O
IT	9	O
-	7	O
cytosine	1	B-Chemical
arabinoside	0	I-Chemical
and	5	O
IT	9	O
-	7	O
TSPA	0	B-Chemical
.	9	O

To	9	O
our	5	O
knowledge	5	O
,	9	O
however	9	O
,	9	O
axonal	3	B-Disease
neuropathy	5	I-Disease
following	9	O
administration	9	O
of	5	O
these	5	O
three	9	O
agents	5	O
has	9	O
not	5	O
been	9	O
previously	9	O
described	9	O
.	9	O

In	9	O
spite	9	O
of	5	O
the	5	O
fact	9	O
that	5	O
TSPA	0	B-Chemical
is	5	O
a	5	O
useful	5	O
IT	9	O
agent	9	O
,	9	O
its	9	O
combination	9	O
with	5	O
MTX	0	B-Chemical
,	9	O
ara	1	B-Chemical
-	7	I-Chemical
C	9	I-Chemical
and	5	O
radiotherapy	5	O
could	9	O
cause	5	O
severe	5	O
neurotoxicity	9	B-Disease
.	9	O

This	5	O
unexpected	9	O
complication	5	O
indicates	9	O
the	5	O
need	5	O
for	5	O
further	9	O
toxicology	5	O
research	5	O
on	5	O
IT	9	O
-	7	O
TSPA	0	B-Chemical
.	9	O

Effects	9	O
of	5	O
cromakalim	0	B-Chemical
and	5	O
pinacidil	0	B-Chemical
on	5	O
large	5	O
epicardial	5	O
and	5	O
small	9	O
coronary	5	O
arteries	5	O
in	5	O
conscious	5	O
dogs	5	O
.	9	O

The	5	O
effects	9	O
of	5	O
i	9	O
.	9	O
v	0	O
.	9	O
bolus	0	O
administration	9	O
of	5	O
cromakalim	0	B-Chemical
(	9	O
1	9	O
-	7	O
10	9	O
micrograms	0	O
/	9	O
kg	0	O
)	9	O
and	5	O
pinacidil	0	B-Chemical
(	9	O
3	9	O
-	7	O
100	0	O
micrograms	0	O
/	9	O
kg	0	O
)	9	O
on	5	O
large	5	O
(	9	O
circumflex	5	O
artery	5	O
)	9	O
and	5	O
small	9	O
coronary	5	O
arteries	5	O
and	5	O
on	5	O
systemic	9	O
hemodynamics	5	O
were	9	O
investigated	9	O
in	5	O
chronically	9	O
instrumented	5	O
conscious	5	O
dogs	5	O
and	5	O
compared	9	O
to	5	O
those	5	O
of	5	O
nitroglycerin	5	B-Chemical
(	9	O
0	7	O
.	9	O
03	7	O
-	7	O
10	9	O
micrograms	0	O
/	9	O
kg	0	O
)	9	O
.	9	O

Nitroglycerin	0	B-Chemical
,	9	O
up	5	O
to	5	O
0	7	O
.	9	O
3	9	O
micrograms	0	O
/	9	O
kg	0	O
,	9	O
selectively	3	O
increased	9	O
circumflex	5	O
artery	5	O
diameter	9	O
(	9	O
CxAD	_	O
)	9	O
without	9	O
simultaneously	5	O
affecting	9	O
any	5	O
other	5	O
cardiac	5	O
or	5	O
systemic	9	O
hemodynamic	5	O
parameter	5	O
.	9	O

In	9	O
contrast	9	O
,	9	O
cromakalim	0	B-Chemical
and	5	O
pinacidil	0	B-Chemical
at	9	O
all	5	O
doses	0	O
and	5	O
nitroglycerin	5	B-Chemical
at	9	O
doses	0	O
higher	9	O
than	5	O
0	7	O
.	9	O
3	9	O
micrograms	0	O
/	9	O
kg	0	O
simultaneously	5	O
and	5	O
dose	9	O
-	7	O
dependently	3	O
increased	9	O
CxAD	_	O
,	9	O
coronary	5	O
blood	9	O
flow	5	O
and	5	O
heart	5	O
rate	9	O
and	5	O
decreased	9	O
coronary	5	O
vascular	5	O
resistance	9	O
and	5	O
aortic	9	O
pressure	5	O
.	9	O

Cromakalim	0	B-Chemical
was	9	O
approximately	9	O
8	9	O
-	7	O
to	5	O
9	7	O
.	9	O
5	9	O
-	7	O
fold	9	O
more	5	O
potent	3	O
than	5	O
pinacidil	0	B-Chemical
in	5	O
increasing	9	O
CxAD	_	O
.	9	O

Vasodilation	0	O
of	5	O
large	5	O
and	5	O
small	9	O
coronary	5	O
vessels	5	O
and	5	O
hypotension	5	B-Disease
induced	3	O
by	9	O
cromakalim	0	B-Chemical
and	5	O
pinacidil	0	B-Chemical
were	9	O
not	5	O
affected	9	O
by	9	O
prior	9	O
combined	9	O
beta	9	B-Chemical
adrenergic	9	I-Chemical
and	5	I-Chemical
muscarinic	3	I-Chemical
receptors	3	I-Chemical
blockade	3	I-Chemical
but	9	O
drug	5	O
-	7	O
induced	3	O
tachycardia	5	B-Disease
was	9	O
abolished	3	O
.	9	O

When	9	O
circumflex	5	O
artery	5	O
blood	9	O
flow	5	O
was	9	O
maintained	9	O
constant	9	O
,	9	O
the	5	O
increases	9	O
in	5	O
CxAD	_	O
induced	3	O
by	9	O
cromakalim	0	B-Chemical
(	9	O
10	9	O
micrograms	0	O
/	9	O
kg	0	O
)	9	O
,	9	O
pinacidil	0	B-Chemical
(	9	O
30	9	O
micrograms	0	O
/	9	O
kg	0	O
)	9	O
and	5	O
nitroglycerin	5	B-Chemical
(	9	O
10	9	O
micrograms	0	O
/	9	O
kg	0	O
)	9	O
were	9	O
reduced	9	O
by	9	O
68	7	O
+	9	O
/	9	O
-	7	O
7	9	O
,	9	O
54	7	O
+	9	O
/	9	O
-	7	O
9	7	O
and	5	O
1	9	O
+	9	O
/	9	O
-	7	O
1	9	O
%	9	O
,	9	O
respectively	9	O
.	9	O

Thus	9	O
,	9	O
whereas	9	O
nitroglycerin	5	B-Chemical
preferentially	9	O
and	5	O
flow	5	O
-	7	O
independently	9	O
dilates	5	O
large	5	O
coronary	5	O
arteries	5	O
,	9	O
cromakalim	0	B-Chemical
and	5	O
pinacidil	0	B-Chemical
dilate	5	O
both	9	O
large	5	O
and	5	O
small	9	O
coronary	5	O
arteries	5	O
and	5	O
this	5	O
effect	9	O
is	5	O
not	5	O
dependent	9	O
upon	9	O
the	5	O
simultaneous	5	O
beta	9	O
adrenoceptors	3	O
-	7	O
mediated	3	O
rise	9	O
in	5	O
myocardial	9	O
metabolic	9	O
demand	5	O
.	9	O

Finally	9	O
,	9	O
two	5	O
mechanisms	9	O
at	9	O
least	9	O
,	9	O
direct	9	O
vasodilation	9	O
and	5	O
flow	5	O
dependency	5	O
,	9	O
are	5	O
involved	9	O
in	5	O
the	5	O
cromakalim	0	B-Chemical
-	7	O
and	5	O
pinacidil	0	B-Chemical
-	7	O
induced	3	O
increase	9	O
in	5	O
CxAD	_	O
.	9	O

Mefenamic	0	B-Chemical
acid	0	I-Chemical
-	7	O
induced	3	O
neutropenia	5	B-Disease
and	5	O
renal	9	B-Disease
failure	5	I-Disease
in	5	O
elderly	5	O
females	9	O
with	5	O
hypothyroidism	5	B-Disease
.	9	O

We	9	O
report	5	O
mefenamic	0	B-Chemical
acid	0	I-Chemical
-	7	O
induced	3	O
non	9	O
-	7	O
oliguric	5	O
renal	9	B-Disease
failure	5	I-Disease
and	5	O
severe	5	O
neutropenia	5	B-Disease
occurring	9	O
simultaneously	5	O
in	5	O
two	5	O
elderly	5	O
females	9	O
.	9	O

The	5	O
neutropenia	5	B-Disease
was	9	O
due	5	O
to	5	O
maturation	3	O
arrest	3	O
of	5	O
the	5	O
myeloid	3	O
series	5	O
in	5	O
one	5	O
patient	5	O
.	9	O

Both	9	O
patients	5	O
were	9	O
also	9	O
hypothyroid	9	B-Disease
,	9	O
but	9	O
it	5	O
is	5	O
not	5	O
clear	9	O
whether	9	O
this	5	O
was	9	O
a	5	O
predisposing	5	O
factor	9	O
to	5	O
the	5	O
development	9	O
of	5	O
these	5	O
adverse	5	O
reactions	9	O
.	9	O

However	9	O
,	9	O
it	5	O
would	5	O
seem	5	O
prudent	5	O
not	5	O
to	5	O
use	5	O
mefenamic	0	B-Chemical
acid	0	I-Chemical
in	5	O
hypothyroid	9	B-Disease
patients	5	O
until	5	O
the	5	O
hypothyroidism	5	B-Disease
has	9	O
been	9	O
corrected	5	O
.	9	O

Etiology	5	O
of	5	O
hypercalcemia	5	B-Disease
in	5	O
hemodialysis	5	O
patients	5	O
on	5	O
calcium	0	B-Chemical
carbonate	0	I-Chemical
therapy	5	O
.	9	O

Fourteen	9	O
of	5	O
39	7	O
dialysis	5	O
patients	5	O
(	9	O
36	9	O
%	9	O
)	9	O
became	9	O
hypercalcemic	5	B-Disease
after	9	O
switching	5	O
to	5	O
calcium	0	B-Chemical
carbonate	0	I-Chemical
as	5	O
their	5	O
principal	5	O
phosphate	0	B-Chemical
binder	0	O
.	9	O

In	9	O
order	5	O
to	5	O
identify	9	O
risk	5	O
factors	9	O
associated	9	O
with	5	O
the	5	O
development	9	O
of	5	O
hypercalcemia	5	B-Disease
,	9	O
indirect	5	O
parameters	5	O
of	5	O
intestinal	9	O
calcium	0	B-Chemical
reabsorption	0	O
and	5	O
bone	5	O
turnover	9	O
rate	9	O
in	5	O
these	5	O
14	7	O
patients	5	O
were	9	O
compared	9	O
with	5	O
results	9	O
in	5	O
14	7	O
eucalcemic	5	O
patients	5	O
matched	9	O
for	5	O
age	5	O
,	9	O
sex	5	O
,	9	O
length	9	O
of	5	O
time	5	O
on	5	O
dialysis	5	O
,	9	O
and	5	O
etiology	9	O
of	5	O
renal	9	B-Disease
disease	5	I-Disease
.	9	O

In	9	O
addition	9	O
to	5	O
experiencing	5	O
hypercalcemic	5	B-Disease
episodes	5	O
with	5	O
peak	9	O
calcium	0	B-Chemical
values	5	O
of	5	O
2	9	O
.	9	O
7	9	O
to	5	O
3	9	O
.	9	O
8	9	O
mmol	0	O
/	9	O
L	0	O
(	9	O
10	9	O
.	9	O
7	9	O
to	5	O
15	9	O
.	9	O
0	7	O
mg	0	O
/	9	O
dL	7	O
)	9	O
,	9	O
patients	5	O
in	5	O
the	5	O
hypercalcemic	5	B-Disease
group	9	O
exhibited	9	O
a	5	O
significant	9	O
increase	9	O
in	5	O
the	5	O
mean	5	O
calcium	0	B-Chemical
concentration	0	O
obtained	9	O
during	5	O
6	9	O
months	5	O
before	9	O
the	5	O
switch	9	O
,	9	O
compared	9	O
with	5	O
the	5	O
mean	5	O
value	9	O
obtained	9	O
during	5	O
the	5	O
7	9	O
months	5	O
of	5	O
observation	9	O
after	9	O
the	5	O
switch	9	O
(	9	O
2	9	O
.	9	O
4	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
03	7	O
to	5	O
2	9	O
.	9	O
5	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
03	7	O
mmol	0	O
/	9	O
L	0	O
[	9	O
9	7	O
.	9	O
7	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
2	9	O
to	5	O
10	9	O
.	9	O
2	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
1	9	O
mg	0	O
/	9	O
dL	7	O
]	9	O
,	9	O
P	9	O
=	7	O
0	7	O
.	9	O
006	7	O
)	9	O
.	9	O

In	9	O
contrast	9	O
,	9	O
eucalcemic	5	O
patients	5	O
exhibited	9	O
no	9	O
change	9	O
in	5	O
mean	5	O
calcium	0	B-Chemical
values	5	O
over	5	O
the	5	O
same	9	O
time	5	O
period	5	O
(	9	O
2	9	O
.	9	O
3	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
05	7	O
to	5	O
2	9	O
.	9	O
3	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
05	7	O
mmol	0	O
/	9	O
L	0	O
[	9	O
9	7	O
.	9	O
2	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
2	9	O
to	5	O
9	7	O
.	9	O
2	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
2	9	O
mg	0	O
/	9	O
dL	7	O
]	9	O
)	9	O
.	9	O

CaCO3	0	B-Chemical
dosage	9	O
,	9	O
calculated	5	O
dietary	5	O
calcium	0	B-Chemical
intake	5	O
,	9	O
and	5	O
circulating	9	O
levels	3	O
of	5	O
vitamin	0	B-Chemical
D	9	I-Chemical
metabolites	0	O
were	9	O
similar	9	O
in	5	O
both	9	O
groups	9	O
.	9	O

Physical	5	O
activity	9	O
index	5	O
and	5	O
predialysis	5	O
serum	9	O
bicarbonate	0	B-Chemical
levels	3	O
also	9	O
were	9	O
similar	9	O
in	5	O
both	9	O
groups	9	O
.	9	O

However	9	O
,	9	O
there	5	O
was	9	O
a	5	O
significant	9	O
difference	9	O
in	5	O
parameters	5	O
reflecting	5	O
bone	5	O
turnover	9	O
rates	5	O
between	5	O
groups	9	O
.	9	O
(	9	O
ABSTRACT	2	O
TRUNCATED	2	O
AT	9	O
250	0	O
WORDS	3	O
)	9	O

Late	9	O
-	7	O
onset	5	O
scleroderma	9	B-Disease
renal	9	I-Disease
crisis	5	I-Disease
induced	3	O
by	9	O
tacrolimus	0	B-Chemical
and	5	O
prednisolone	0	B-Chemical
:	9	O
a	5	O
case	5	O
report	5	O
.	9	O

Scleroderma	2	B-Disease
renal	9	I-Disease
crisis	5	I-Disease
(	9	O
SRC	9	B-Disease
)	9	O
is	5	O
a	5	O
rare	5	O
complication	5	O
of	5	O
systemic	9	B-Disease
sclerosis	5	I-Disease
(	9	O
SSc	9	B-Disease
)	9	O
but	9	O
can	5	O
be	5	O
severe	5	O
enough	5	O
to	5	O
require	5	O
temporary	5	O
or	5	O
permanent	5	O
renal	9	O
replacement	9	O
therapy	5	O
.	9	O

Moderate	7	O
to	5	O
high	9	O
dose	9	O
corticosteroid	5	B-Chemical
use	5	O
is	5	O
recognized	9	O
as	5	O
a	5	O
major	9	O
risk	5	O
factor	9	O
for	5	O
SRC	9	B-Disease
.	9	O

Furthermore	9	O
,	9	O
there	5	O
have	5	O
been	9	O
reports	9	O
of	5	O
thrombotic	5	B-Disease
microangiopathy	5	I-Disease
precipitated	0	O
by	9	O
cyclosporine	0	B-Chemical
in	5	O
patients	5	O
with	5	O
SSc	9	B-Disease
.	9	O

In	9	O
this	5	O
article	6	O
,	9	O
we	5	O
report	5	O
a	5	O
patient	5	O
with	5	O
SRC	9	B-Disease
induced	3	O
by	9	O
tacrolimus	0	B-Chemical
and	5	O
corticosteroids	5	B-Chemical
.	9	O

The	5	O
aim	5	O
of	5	O
this	5	O
work	5	O
is	5	O
to	5	O
call	5	O
attention	5	O
to	5	O
the	5	O
risk	5	O
of	5	O
tacrolimus	0	B-Chemical
use	5	O
in	5	O
patients	5	O
with	5	O
SSc	9	B-Disease
.	9	O

Methyldopa	7	B-Chemical
-	7	O
induced	3	O
hemolytic	0	B-Disease
anemia	9	I-Disease
in	5	O
a	5	O
15	9	O
year	5	O
old	5	O
presenting	5	O
as	5	O
near	9	O
-	7	O
syncope	5	B-Disease
.	9	O

Methyldopa	7	B-Chemical
is	5	O
an	5	O
antihypertensive	5	O
medication	5	O
which	5	O
is	5	O
available	5	O
generically	5	O
and	5	O
under	9	O
the	5	O
trade	5	O
name	5	O
Aldomet	0	B-Chemical
that	5	O
is	5	O
widely	5	O
prescribed	5	O
in	5	O
the	5	O
adult	9	O
population	5	O
and	5	O
infrequently	5	O
used	5	O
in	5	O
children	5	O
.	9	O

Methyldopa	7	B-Chemical
causes	9	O
an	5	O
autoimmune	3	B-Disease
hemolytic	0	I-Disease
anemia	9	I-Disease
in	5	O
a	5	O
small	9	O
percentage	9	O
of	5	O
patients	5	O
who	5	O
take	5	O
the	5	O
drug	5	O
.	9	O

We	9	O
report	5	O
a	5	O
case	5	O
of	5	O
methyldopa	0	B-Chemical
-	7	O
induced	3	O
hemolytic	0	B-Disease
anemia	9	I-Disease
in	5	O
a	5	O
15	9	O
-	7	O
year	5	O
-	7	O
old	5	O
boy	5	O
who	5	O
presented	5	O
to	5	O
the	5	O
emergency	5	B-Disease
department	5	I-Disease
with	5	O
near	9	O
-	7	O
syncope	5	B-Disease
.	9	O

The	5	O
boy	5	O
had	9	O
been	9	O
treated	3	O
with	5	O
intravenous	0	O
methyldopa	0	B-Chemical
during	5	O
a	5	O
trauma	5	B-Disease
admission	5	O
seven	9	O
weeks	9	O
prior	9	O
to	5	O
presentation	5	O
.	9	O

Evaluation	5	O
revealed	9	O
a	5	O
hemoglobin	0	O
of	5	O
three	9	O
grams	0	O
,	9	O
3	9	O
+	9	O
Coombs	6	O
'	9	O
test	5	O
with	5	O
polyspecific	3	O
anti	3	O
-	7	O
human	3	O
globulin	9	O
and	5	O
monospecific	9	O
IgG	3	O
reagents	0	O
,	9	O
and	5	O
a	5	O
warm	5	O
reacting	0	O
autoantibody	3	O
.	9	O

Transfusion	2	O
and	5	O
corticosteroid	5	B-Chemical
therapy	5	O
resulted	9	O
in	5	O
a	5	O
complete	9	O
recovery	9	O
of	5	O
the	5	O
patient	5	O
.	9	O

Emergency	2	O
physicians	5	O
treating	5	O
children	5	O
must	5	O
be	5	O
aware	5	O
of	5	O
this	5	O
syndrome	5	O
in	5	O
order	5	O
to	5	O
diagnose	5	O
and	5	O
treat	5	O
it	5	O
correctly	5	O
.	9	O

A	9	O
brief	5	O
review	5	O
of	5	O
autoimmune	3	O
and	5	O
drug	5	O
-	7	O
induced	3	O
hemolytic	0	B-Disease
anemias	5	I-Disease
is	5	O
provided	9	O
.	9	O

The	5	O
risk	5	O
and	5	O
associated	9	O
factors	9	O
of	5	O
methamphetamine	5	B-Chemical
psychosis	5	B-Disease
in	5	O
methamphetamine	5	B-Chemical
-	7	O
dependent	9	O
patients	5	O
in	5	O
Malaysia	4	O
.	9	O

OBJECTIVE	2	O
:	9	O
The	5	O
objective	5	O
of	5	O
this	5	O
study	9	O
was	9	O
to	5	O
determine	9	O
the	5	O
risk	5	O
of	5	O
lifetime	5	O
and	5	O
current	5	O
methamphetamine	5	B-Chemical
-	7	O
induced	3	O
psychosis	5	B-Disease
in	5	O
patients	5	O
with	5	O
methamphetamine	5	B-Chemical
dependence	5	O
.	9	O

The	5	O
association	9	O
between	5	O
psychiatric	5	O
co	9	O
-	7	O
morbidity	5	O
and	5	O
methamphetamine	5	B-Chemical
-	7	O
induced	3	O
psychosis	5	B-Disease
was	9	O
also	9	O
studied	9	O
.	9	O

METHODS	2	O
:	9	O
This	5	O
was	9	O
a	5	O
cross	5	O
-	7	O
sectional	5	O
study	9	O
conducted	9	O
concurrently	9	O
at	9	O
a	5	O
teaching	5	O
hospital	5	O
and	5	O
a	5	O
drug	5	O
rehabilitation	5	O
center	5	O
in	5	O
Malaysia	4	O
.	9	O

Patients	5	O
with	5	O
the	5	O
diagnosis	5	O
of	5	O
methamphetamine	5	B-Chemical
based	5	O
on	5	O
DSM	4	O
-	7	O
IV	9	O
were	9	O
interviewed	5	O
using	9	O
the	5	O
Mini	0	O
International	2	O
Neuropsychiatric	5	O
Interview	5	O
(	9	O
M	9	O
.	9	O
I	9	O
.	9	O
N	9	O
.	9	O
I	9	O
.	9	O
)	9	O
for	5	O
methamphetamine	5	B-Chemical
-	7	O
induced	3	O
psychosis	5	B-Disease
and	5	O
other	5	O
Axis	5	O
I	9	O
psychiatric	5	B-Disease
disorders	5	I-Disease
.	9	O

The	5	O
information	5	O
on	5	O
sociodemographic	5	O
background	9	O
and	5	O
drug	5	O
use	5	O
history	5	O
was	9	O
obtained	9	O
from	9	O
interview	5	O
or	5	O
medical	5	O
records	5	O
.	9	O

RESULTS	9	O
:	9	O
Of	9	O
292	7	O
subjects	5	O
,	9	O
47	7	O
.	9	O
9	7	O
%	9	O
of	5	O
the	5	O
subjects	5	O
had	9	O
a	5	O
past	5	O
history	5	O
of	5	O
psychotic	5	B-Disease
symptoms	5	I-Disease
and	5	O
13	7	O
.	9	O
0	7	O
%	9	O
of	5	O
the	5	O
patients	5	O
were	9	O
having	5	O
current	5	O
psychotic	5	B-Disease
symptoms	5	I-Disease
.	9	O

Co	0	O
-	7	O
morbid	5	O
major	9	O
depressive	5	B-Disease
disorder	5	I-Disease
(	9	O
OR	9	O
=	7	O
7	9	O
.	9	O
18	7	O
,	9	O
95	7	O
CI	7	O
=	7	O
2	9	O
.	9	O
612	7	O
-	7	O
19	7	O
.	9	O
708	7	O
)	9	O
,	9	O
bipolar	5	B-Disease
disorder	5	I-Disease
(	9	O
OR	9	O
=	7	O
13	7	O
.	9	O
807	7	O
,	9	O
95	7	O
CI	7	O
=	7	O
5	9	O
.	9	O
194	7	O
-	7	O
36	9	O
.	9	O
706	7	O
)	9	O
,	9	O
antisocial	5	B-Disease
personality	5	I-Disease
disorder	5	I-Disease
(	9	O
OR	9	O
=	7	O
12	9	O
.	9	O
619	7	O
,	9	O
95	7	O
CI	7	O
=	7	O
6	9	O
.	9	O
702	7	O
-	7	O
23	7	O
.	9	O
759	7	O
)	9	O
and	5	O
heavy	9	O
methamphetamine	5	B-Chemical
uses	5	O
were	9	O
significantly	9	O
associated	9	O
with	5	O
lifetime	5	O
methamphetamine	5	B-Chemical
-	7	O
induced	3	O
psychosis	5	B-Disease
after	9	O
adjusted	9	O
for	5	O
other	5	O
factors	9	O
.	9	O

Major	9	B-Disease
depressive	5	I-Disease
disorder	5	I-Disease
(	9	O
OR	9	O
=	7	O
2	9	O
.	9	O
870	7	O
,	9	O
CI	7	O
=	7	O
1	9	O
.	9	O
154	7	O
-	7	O
7	9	O
.	9	O
142	7	O
)	9	O
and	5	O
antisocial	5	B-Disease
personality	5	I-Disease
disorder	5	I-Disease
(	9	O
OR	9	O
=	7	O
3	9	O
.	9	O
299	7	O
,	9	O
95	7	O
CI	7	O
=	7	O
1	9	O
.	9	O
375	9	O
-	7	O
7	9	O
.	9	O
914	7	O
)	9	O
were	9	O
the	5	O
only	9	O
factors	9	O
associated	9	O
with	5	O
current	5	O
psychosis	5	B-Disease
.	9	O

CONCLUSION	5	O
:	9	O
There	5	O
was	9	O
a	5	O
high	9	O
risk	5	O
of	5	O
psychosis	5	B-Disease
in	5	O
patients	5	O
with	5	O
methamphetamine	5	B-Chemical
dependence	5	O
.	9	O

It	5	O
was	9	O
associated	9	O
with	5	O
co	9	O
-	7	O
morbid	5	O
affective	5	B-Disease
disorder	5	I-Disease
,	9	O
antisocial	5	B-Disease
personality	5	I-Disease
,	9	O
and	5	O
heavy	9	O
methamphetamine	5	B-Chemical
use	5	O
.	9	O

It	5	O
is	5	O
recommended	5	O
that	5	O
all	5	O
cases	5	O
of	5	O
methamphetamine	5	B-Chemical
dependence	5	O
should	5	O
be	5	O
screened	9	O
for	5	O
psychotic	5	B-Disease
symptoms	5	I-Disease
.	9	O

Cerebellar	9	O
sensory	5	O
processing	5	O
alterations	9	O
impact	5	O
motor	5	O
cortical	5	O
plasticity	5	O
in	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
:	9	O
clues	5	O
from	9	O
dyskinetic	5	B-Disease
patients	5	O
.	9	O

The	5	O
plasticity	5	O
of	5	O
primary	9	O
motor	5	O
cortex	5	O
(	9	O
M1	9	O
)	9	O
in	5	O
patients	5	O
with	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
(	9	O
PD	9	B-Disease
)	9	O
and	5	O
levodopa	5	B-Chemical
-	7	O
induced	3	O
dyskinesias	5	B-Disease
(	9	O
LIDs	5	B-Disease
)	9	O
is	5	O
severely	9	O
impaired	9	O
.	9	O

We	9	O
recently	9	O
reported	9	O
in	5	O
young	5	O
healthy	5	O
subjects	5	O
that	5	O
inhibitory	3	O
cerebellar	5	O
stimulation	3	O
enhanced	3	O
the	5	O
sensorimotor	5	O
plasticity	5	O
of	5	O
M1	9	O
that	5	O
was	9	O
induced	3	O
by	9	O
paired	9	O
associative	5	O
stimulation	3	O
(	9	O
PAS	9	O
)	9	O
.	9	O

This	5	O
study	9	O
demonstrates	9	O
that	5	O
the	5	O
deficient	3	O
sensorimotor	5	O
M1	9	O
plasticity	5	O
in	5	O
16	9	O
patients	5	O
with	5	O
LIDs	5	B-Disease
could	9	O
be	5	O
reinstated	9	O
by	9	O
a	5	O
single	9	O
session	5	O
of	5	O
real	5	O
inhibitory	3	O
cerebellar	5	O
stimulation	3	O
but	9	O
not	5	O
sham	9	O
stimulation	3	O
.	9	O

This	5	O
was	9	O
evident	9	O
only	9	O
when	5	O
a	5	O
sensory	5	O
component	9	O
was	9	O
involved	9	O
in	5	O
the	5	O
induction	3	O
of	5	O
plasticity	5	O
,	9	O
indicating	9	O
that	5	O
cerebellar	5	O
sensory	5	O
processing	5	O
function	9	O
is	5	O
involved	9	O
in	5	O
the	5	O
resurgence	5	O
of	5	O
M1	9	O
plasticity	5	O
.	9	O

The	5	O
benefit	5	O
of	5	O
inhibitory	3	O
cerebellar	5	O
stimulation	3	O
on	5	O
LIDs	5	B-Disease
is	5	O
known	9	O
.	9	O

To	9	O
explore	5	O
whether	9	O
this	5	O
benefit	5	O
is	5	O
linked	9	O
to	5	O
the	5	O
restoration	5	O
of	5	O
sensorimotor	5	O
plasticity	5	O
of	5	O
M1	9	O
,	9	O
we	5	O
conducted	9	O
an	5	O
additional	9	O
study	9	O
looking	5	O
at	9	O
changes	9	O
in	5	O
LIDs	5	B-Disease
and	5	O
PAS	9	O
-	7	O
induced	3	O
plasticity	5	O
after	9	O
10	9	O
sessions	5	O
of	5	O
either	9	O
bilateral	5	O
,	9	O
real	5	O
inhibitory	3	O
cerebellar	5	O
stimulation	3	O
or	5	O
sham	9	O
stimulation	3	O
.	9	O

Only	9	O
real	5	O
and	5	O
not	5	O
sham	9	O
stimulation	3	O
had	9	O
an	5	O
antidyskinetic	5	O
effect	9	O
and	5	O
it	5	O
was	9	O
paralleled	9	O
by	9	O
a	5	O
resurgence	5	O
in	5	O
the	5	O
sensorimotor	5	O
plasticity	5	O
of	5	O
M1	9	O
.	9	O

These	5	O
results	9	O
suggest	9	O
that	5	O
alterations	9	O
in	5	O
cerebellar	5	O
sensory	5	O
processing	5	O
function	9	O
,	9	O
occurring	9	O
secondary	9	O
to	5	O
abnormal	9	O
basal	3	O
ganglia	5	O
signals	9	O
reaching	5	O
it	5	O
,	9	O
may	5	O
be	5	O
an	5	O
important	9	O
element	9	O
contributing	9	O
to	5	O
the	5	O
maladaptive	5	O
sensorimotor	5	O
plasticity	5	O
of	5	O
M1	9	O
and	5	O
the	5	O
emergence	9	O
of	5	O
abnormal	9	B-Disease
involuntary	5	I-Disease
movements	5	I-Disease
.	9	O

The	5	O
long	5	O
-	7	O
term	5	O
safety	5	O
of	5	O
danazol	0	B-Chemical
in	5	O
women	5	O
with	5	O
hereditary	5	B-Disease
angioedema	5	I-Disease
.	9	O

Although	9	O
the	5	O
short	5	O
-	7	O
term	5	O
safety	5	O
(	9	O
less	5	O
than	5	O
or	5	O
equal	9	O
to	5	O
6	9	O
months	5	O
)	9	O
of	5	O
danazol	0	B-Chemical
has	9	O
been	9	O
established	9	O
in	5	O
a	5	O
variety	5	O
of	5	O
settings	5	O
,	9	O
no	9	O
information	5	O
exists	9	O
as	5	O
to	5	O
its	9	O
long	5	O
-	7	O
term	5	O
safety	5	O
.	9	O

We	9	O
therefore	5	O
investigated	9	O
the	5	O
long	5	O
-	7	O
term	5	O
safety	5	O
of	5	O
danazol	0	B-Chemical
by	9	O
performing	5	O
a	5	O
retrospective	5	O
chart	5	O
review	5	O
of	5	O
60	9	O
female	9	O
patients	5	O
with	5	O
hereditary	5	B-Disease
angioedema	5	I-Disease
treated	3	O
with	5	O
danazol	0	B-Chemical
for	5	O
a	5	O
continuous	5	O
period	5	O
of	5	O
6	9	O
months	5	O
or	5	O
longer	5	O
.	9	O

The	5	O
mean	5	O
age	5	O
of	5	O
the	5	O
patients	5	O
was	9	O
35	9	O
.	9	O
2	9	O
years	5	O
and	5	O
the	5	O
mean	5	O
duration	5	O
of	5	O
therapy	5	O
was	9	O
59	7	O
.	9	O
7	9	O
months	5	O
.	9	O

Virtually	9	O
all	5	O
patients	5	O
experienced	5	O
one	5	O
or	5	O
more	5	O
adverse	5	O
reactions	9	O
.	9	O

Menstrual	5	B-Disease
abnormalities	9	I-Disease
(	9	O
79	7	O
%	9	O
)	9	O
,	9	O
weight	9	B-Disease
gain	5	I-Disease
(	9	O
60	9	O
%	9	O
)	9	O
,	9	O
muscle	9	B-Disease
cramps	5	I-Disease
/	9	O
myalgias	5	B-Disease
(	9	O
40	9	O
%	9	O
)	9	O
,	9	O
and	5	O
transaminase	0	O
elevations	9	O
(	9	O
40	9	O
%	9	O
)	9	O
were	9	O
the	5	O
most	9	O
common	5	O
adverse	5	O
reactions	9	O
.	9	O

The	5	O
drug	5	O
was	9	O
discontinued	5	O
due	5	O
to	5	O
adverse	5	O
reactions	9	O
in	5	O
8	9	O
patients	5	O
.	9	O

No	9	O
patient	5	O
has	9	O
died	9	O
or	5	O
suffered	5	O
any	5	O
apparent	9	O
long	5	O
-	7	O
term	5	O
sequelae	5	O
that	5	O
were	9	O
directly	9	O
attributable	9	O
to	5	O
the	5	O
drug	5	O
.	9	O

We	9	O
conclude	9	O
that	5	O
,	9	O
despite	9	O
a	5	O
relatively	5	O
high	9	O
incidence	5	O
of	5	O
adverse	5	O
reactions	9	O
,	9	O
danazol	0	B-Chemical
has	9	O
proven	5	O
to	5	O
be	5	O
remarkably	9	O
safe	5	O
over	5	O
the	5	O
long	5	O
-	7	O
term	5	O
in	5	O
this	5	O
group	9	O
of	5	O
patients	5	O
.	9	O

The	5	O
function	9	O
of	5	O
P2X3	3	O
receptor	3	O
and	5	O
NK1	3	O
receptor	3	O
antagonists	3	O
on	5	O
cyclophosphamide	0	B-Chemical
-	7	O
induced	3	O
cystitis	9	B-Disease
in	5	O
rats	9	O
.	9	O

PURPOSE	2	O
:	9	O
The	5	O
purpose	5	O
of	5	O
the	5	O
study	9	O
is	5	O
to	5	O
explore	5	O
the	5	O
function	9	O
of	5	O
P2X3	3	O
and	5	O
NK1	3	O
receptors	3	O
antagonists	3	O
on	5	O
cyclophosphamide	0	B-Chemical
(	9	O
CYP	0	B-Chemical
)	9	O
-	7	O
induced	3	O
cystitis	9	B-Disease
in	5	O
rats	9	O
.	9	O

METHODS	2	O
:	9	O
Sixty	5	O
female	9	O
Sprague	9	O
-	7	O
Dawley	0	O
(	9	O
SD	7	O
)	9	O
rats	9	O
were	9	O
randomly	5	O
divided	5	O
into	9	O
three	9	O
groups	9	O
.	9	O

The	5	O
rats	9	O
in	5	O
the	5	O
control	9	O
group	9	O
were	9	O
intraperitoneally	0	O
(	9	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
injected	3	O
with	5	O
0	7	O
.	9	O
9	7	O
%	9	O
saline	0	O
(	9	O
4	9	O
ml	0	O
/	9	O
kg	0	O
)	9	O
;	9	O
the	5	O
rats	9	O
in	5	O
the	5	O
model	5	O
group	9	O
were	9	O
i	9	O
.	9	O
p	7	O
.	9	O
injected	3	O
with	5	O
CYP	0	B-Chemical
(	9	O
150	0	O
mg	0	O
/	9	O
kg	0	O
)	9	O
;	9	O
and	5	O
the	5	O
rats	9	O
in	5	O
the	5	O
intervention	5	O
group	9	O
were	9	O
i	9	O
.	9	O
p	7	O
.	9	O
injected	3	O
with	5	O
CYP	0	B-Chemical
with	5	O
subsequently	9	O
perfusion	5	O
of	5	O
bladder	9	O
with	5	O
P2X3	3	O
and	5	O
NK1	3	O
receptors	3	O
'	9	O
antagonists	3	O
,	9	O
Suramin	0	B-Chemical
and	5	O
GR	9	B-Chemical
82334	_	I-Chemical
.	9	O

Spontaneous	9	O
pain	5	B-Disease
behaviors	5	O
following	9	O
the	5	O
administration	9	O
of	5	O
CYP	0	B-Chemical
were	9	O
observed	9	O
.	9	O

Urodynamic	5	O
parameters	5	O
,	9	O
bladder	9	O
pressure	5	O
-	7	O
volume	9	O
curve	9	O
,	9	O
maximum	5	O
voiding	5	O
pressure	5	O
(	9	O
MVP	5	O
)	9	O
,	9	O
and	5	O
maximum	5	O
cystometric	5	O
capacity	9	O
(	9	O
MCC	9	O
)	9	O
,	9	O
were	9	O
recorded	5	O
.	9	O

Pathological	9	O
changes	9	O
in	5	O
bladder	9	O
tissue	9	O
were	9	O
observed	9	O
.	9	O

Immunofluorescence	3	O
was	9	O
used	5	O
to	5	O
detect	9	O
the	5	O
expression	3	O
of	5	O
P2X3	3	O
and	5	O
NK1	3	O
receptors	3	O
in	5	O
bladder	9	O
.	9	O

RESULTS	9	O
:	9	O
Cyclophosphamide	0	B-Chemical
treatment	9	O
increased	9	O
the	5	O
spontaneous	5	O
pain	5	B-Disease
behaviors	5	O
scores	5	O
.	9	O

The	5	O
incidence	5	O
of	5	O
bladder	9	O
instability	5	O
during	5	O
urine	9	O
storage	9	O
period	5	O
of	5	O
model	5	O
group	9	O
was	9	O
significantly	9	O
higher	9	O
than	5	O
intervention	5	O
group	9	O
(	9	O
X	9	O
(	9	O
2	9	O
)	9	O
=	7	O
7	9	O
.	9	O
619	7	O
,	9	O
P	9	O
=	7	O
0	7	O
.	9	O
007	2	O
)	9	O
and	5	O
control	9	O
group	9	O
(	9	O
X	9	O
(	9	O
2	9	O
)	9	O
=	7	O
13	7	O
.	9	O
755	7	O
,	9	O
P	9	O
=	7	O
0	7	O
.	9	O
000	9	O
)	9	O
.	9	O

MCC	9	O
in	5	O
the	5	O
model	5	O
group	9	O
was	9	O
lower	9	O
than	5	O
the	5	O
control	9	O
and	5	O
intervention	5	O
groups	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
01	7	O
)	9	O
.	9	O

Histological	9	O
changes	9	O
evident	9	O
in	5	O
model	5	O
and	5	O
intervention	5	O
groups	9	O
rats	9	O
'	9	O
bladder	9	O
included	5	O
edema	5	B-Disease
,	9	O
vasodilation	9	O
,	9	O
and	5	O
infiltration	3	O
of	5	O
inflammatory	3	O
cells	3	O
.	9	O

In	9	O
model	5	O
group	9	O
,	9	O
the	5	O
expression	3	O
of	5	O
P2X3	3	O
receptor	3	O
increased	9	O
in	5	O
urothelium	3	O
and	5	O
suburothelium	3	O
,	9	O
and	5	O
NK1	3	O
receptor	3	O
increased	9	O
in	5	O
suburothelium	3	O
,	9	O
while	9	O
the	5	O
expression	3	O
of	5	O
them	5	O
in	5	O
intervention	5	O
group	9	O
was	9	O
lower	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
In	9	O
CYP	0	B-Chemical
-	7	O
induced	3	O
cystitis	9	B-Disease
,	9	O
the	5	O
expression	3	O
of	5	O
P2X3	3	O
and	5	O
NK1	3	O
receptors	3	O
increased	9	O
in	5	O
urothelium	3	O
and	5	O
/	9	O
or	5	O
suburothelium	3	O
.	9	O

Perfusion	0	O
of	5	O
bladder	9	O
with	5	O
P2X3	3	O
and	5	O
NK1	3	O
receptors	3	O
antagonists	3	O
ameliorated	9	O
the	5	O
bladder	9	O
function	9	O
.	9	O

Patient	5	O
tolerance	9	O
study	9	O
of	5	O
topical	0	O
chlorhexidine	0	B-Chemical
diphosphanilate	_	I-Chemical
:	9	O
a	5	O
new	5	O
topical	0	O
agent	9	O
for	5	O
burns	5	B-Disease
.	9	O

Effective	5	O
topical	0	O
antimicrobial	9	O
agents	5	O
decrease	9	O
infection	9	B-Disease
and	5	O
mortality	5	O
in	5	O
burn	5	B-Disease
patients	5	O
.	9	O

Chlorhexidine	0	B-Chemical
phosphanilate	_	I-Chemical
(	9	O
CHP	9	B-Chemical
)	9	O
,	9	O
a	5	O
new	5	O
broad	5	O
-	7	O
spectrum	9	O
antimicrobial	9	O
agent	9	O
,	9	O
has	9	O
been	9	O
evaluated	9	O
as	5	O
a	5	O
topical	0	O
burn	5	B-Disease
wound	5	O
dressing	5	O
in	5	O
cream	0	O
form	9	O
,	9	O
but	9	O
preliminary	9	O
clinical	5	O
trials	5	O
reported	9	O
that	5	O
it	5	O
was	9	O
painful	5	O
upon	9	O
application	5	O
.	9	O

This	5	O
study	9	O
compared	9	O
various	9	O
concentrations	0	O
of	5	O
CHP	9	B-Chemical
to	5	O
determine	9	O
if	5	O
a	5	O
tolerable	5	O
concentration	0	O
could	9	O
be	5	O
identified	9	O
with	5	O
retention	9	O
of	5	O
antimicrobial	9	O
efficacy	9	O
.	9	O

Twenty	9	O
-	7	O
nine	9	O
burn	5	B-Disease
patients	5	O
,	9	O
each	5	O
with	5	O
two	5	O
similar	9	O
burns	5	B-Disease
which	5	O
could	9	O
be	5	O
separately	9	O
treated	3	O
,	9	O
were	9	O
given	5	O
pairs	9	O
of	5	O
treatments	9	O
at	9	O
successive	5	O
12	9	O
-	7	O
h	0	O
intervals	5	O
over	5	O
a	5	O
3	9	O
-	7	O
day	9	O
period	5	O
.	9	O

One	5	O
burn	5	B-Disease
site	9	O
was	9	O
treated	3	O
with	5	O
each	5	O
of	5	O
four	9	O
different	9	O
CHP	9	B-Chemical
concentrations	0	O
,	9	O
from	9	O
0	7	O
.	9	O
25	9	O
per	9	O
cent	5	O
to	5	O
2	9	O
per	9	O
cent	5	O
,	9	O
their	5	O
vehicle	3	O
,	9	O
and	5	O
1	9	O
per	9	O
cent	5	O
silver	0	B-Chemical
sulphadiazine	0	I-Chemical
(	9	O
AgSD	0	B-Chemical
)	9	O
cream	0	O
,	9	O
an	5	O
antimicrobial	9	O
agent	9	O
frequently	5	O
used	5	O
for	5	O
topical	0	O
treatment	9	O
of	5	O
burn	5	B-Disease
wounds	5	O
.	9	O

The	5	O
other	5	O
site	9	O
was	9	O
always	5	O
treated	3	O
with	5	O
AgSD	0	B-Chemical
cream	0	O
.	9	O

There	5	O
was	9	O
a	5	O
direct	9	O
relationship	5	O
between	5	O
CHP	9	B-Chemical
concentration	0	O
and	5	O
patients	5	O
'	9	O
ratings	5	O
of	5	O
pain	5	B-Disease
on	5	O
an	5	O
analogue	0	O
scale	5	O
.	9	O

The	5	O
0	7	O
.	9	O
25	9	O
per	9	O
cent	5	O
CHP	9	B-Chemical
cream	0	O
was	9	O
closest	9	O
to	5	O
AgSD	0	B-Chemical
in	5	O
pain	5	B-Disease
tolerance	9	O
;	9	O
however	9	O
,	9	O
none	9	O
of	5	O
the	5	O
treatments	9	O
differed	9	O
statistically	9	O
from	9	O
AgSD	0	B-Chemical
or	5	O
from	9	O
each	5	O
other	5	O
.	9	O

In	9	O
addition	9	O
,	9	O
ease	5	O
of	5	O
application	5	O
of	5	O
CHP	9	B-Chemical
creams	0	O
was	9	O
less	5	O
satisfactory	5	O
than	5	O
that	5	O
of	5	O
AgSD	0	B-Chemical
.	9	O

It	5	O
was	9	O
concluded	9	O
that	5	O
formulations	0	O
at	9	O
or	5	O
below	9	O
0	7	O
.	9	O
5	9	O
per	9	O
cent	5	O
CHP	9	B-Chemical
may	5	O
prove	5	O
acceptable	5	O
for	5	O
wound	5	O
care	5	O
,	9	O
but	9	O
the	5	O
vehicle	3	O
system	5	O
needs	5	O
pharmaceutical	5	O
improvement	5	O
to	5	O
render	9	O
it	5	O
more	5	O
tolerable	5	O
and	5	O
easier	5	O
to	5	O
use	5	O
.	9	O

Acute	5	O
hepatitis	9	B-Disease
associated	9	O
with	5	O
clopidogrel	0	B-Chemical
:	9	O
a	5	O
case	5	O
report	5	O
and	5	O
review	5	O
of	5	O
the	5	O
literature	5	O
.	9	O

Drug	5	O
-	7	O
induced	3	O
hepatotoxicity	9	B-Disease
is	5	O
a	5	O
common	5	O
cause	5	O
of	5	O
acute	9	O
hepatitis	9	B-Disease
,	9	O
and	5	O
the	5	O
recognition	5	O
of	5	O
the	5	O
responsible	9	O
drug	5	O
may	5	O
be	5	O
difficult	5	O
.	9	O

We	9	O
describe	5	O
a	5	O
case	5	O
of	5	O
clopidogrel	0	B-Chemical
-	7	O
related	9	O
acute	9	O
hepatitis	9	B-Disease
.	9	O

The	5	O
diagnosis	5	O
is	5	O
strongly	9	O
suggested	9	O
by	9	O
an	5	O
accurate	5	O
medical	5	O
history	5	O
and	5	O
liver	9	O
biopsy	5	O
.	9	O

Reports	5	O
about	5	O
cases	5	O
of	5	O
hepatotoxicity	9	B-Disease
due	5	O
to	5	O
clopidogrel	0	B-Chemical
are	5	O
increasing	9	O
in	5	O
the	5	O
last	5	O
few	5	O
years	5	O
,	9	O
after	9	O
the	5	O
increased	9	O
use	5	O
of	5	O
this	5	O
drug	5	O
.	9	O

In	9	O
conclusion	9	O
,	9	O
we	5	O
believe	5	O
that	5	O
physicians	5	O
should	5	O
carefully	5	O
consider	5	O
the	5	O
risk	5	O
of	5	O
drug	5	O
-	7	O
induced	3	O
hepatic	9	B-Disease
injury	9	I-Disease
when	5	O
clopidogrel	0	B-Chemical
is	5	O
prescribed	5	O
.	9	O

Bortezomib	3	B-Chemical
and	5	O
dexamethasone	0	B-Chemical
as	5	O
salvage	5	O
therapy	5	O
in	5	O
patients	5	O
with	5	O
relapsed	5	O
/	9	O
refractory	9	O
multiple	5	B-Disease
myeloma	3	I-Disease
:	9	O
analysis	9	O
of	5	O
long	5	O
-	7	O
term	5	O
clinical	5	O
outcomes	5	O
.	9	O

Bortezomib	3	B-Chemical
(	9	O
bort	9	B-Chemical
)	9	O
-	7	O
dexamethasone	0	B-Chemical
(	9	O
dex	3	B-Chemical
)	9	O
is	5	O
an	5	O
effective	5	O
therapy	5	O
for	5	O
relapsed	5	O
/	9	O
refractory	9	O
(	9	O
R	9	O
/	9	O
R	9	O
)	9	O
multiple	5	B-Disease
myeloma	3	I-Disease
(	9	O
MM	9	B-Disease
)	9	O
.	9	O

This	5	O
retrospective	5	O
study	9	O
investigated	9	O
the	5	O
combination	9	O
of	5	O
bort	9	B-Chemical
(	9	O
1	9	O
.	9	O
3	9	O
mg	0	O
/	9	O
m	9	O
(	9	O
2	9	O
)	9	O
on	5	O
days	9	O
1	9	O
,	9	O
4	9	O
,	9	O
8	9	O
,	9	O
and	5	O
11	7	O
every	5	O
3	9	O
weeks	9	O
)	9	O
and	5	O
dex	3	B-Chemical
(	9	O
20	9	O
mg	0	O
on	5	O
the	5	O
day	9	O
of	5	O
and	5	O
the	5	O
day	9	O
after	9	O
bort	9	B-Chemical
)	9	O
as	5	O
salvage	5	O
treatment	9	O
in	5	O
85	9	O
patients	5	O
with	5	O
R	9	O
/	9	O
R	9	O
MM	9	B-Disease
after	9	O
prior	9	O
autologous	3	O
stem	3	O
cell	3	O
transplantation	9	O
or	5	O
conventional	5	O
chemotherapy	5	O
.	9	O

The	5	O
median	9	O
number	9	O
of	5	O
prior	9	O
lines	3	O
of	5	O
therapy	5	O
was	9	O
2	9	O
.	9	O

Eighty	5	O
-	7	O
seven	9	O
percent	5	O
of	5	O
the	5	O
patients	5	O
had	9	O
received	9	O
immunomodulatory	9	O
drugs	5	O
included	5	O
in	5	O
some	5	O
line	9	O
of	5	O
therapy	5	O
before	9	O
bort	9	B-Chemical
-	7	O
dex	3	B-Chemical
.	9	O

The	5	O
median	9	O
number	9	O
of	5	O
bort	9	B-Chemical
-	7	O
dex	3	B-Chemical
cycles	9	O
was	9	O
6	9	O
,	9	O
up	5	O
to	5	O
a	5	O
maximum	5	O
of	5	O
12	9	O
cycles	9	O
.	9	O

On	5	O
an	5	O
intention	5	O
-	7	O
to	5	O
-	7	O
treat	5	O
basis	5	O
,	9	O
55	7	O
%	9	O
of	5	O
the	5	O
patients	5	O
achieved	5	O
at	9	O
least	9	O
partial	9	O
response	9	O
,	9	O
including	9	O
19	7	O
%	9	O
CR	9	O
and	5	O
35	9	O
%	9	O
achieved	5	O
at	9	O
least	9	O
very	5	O
good	5	O
partial	9	O
response	9	O
.	9	O

Median	7	O
durations	5	O
of	5	O
response	9	O
,	9	O
time	5	O
to	5	O
next	9	O
therapy	5	O
and	5	O
treatment	9	O
-	7	O
free	9	O
interval	5	O
were	9	O
8	9	O
,	9	O
11	7	O
.	9	O
2	9	O
,	9	O
and	5	O
5	9	O
.	9	O
1	9	O
months	5	O
,	9	O
respectively	9	O
.	9	O

The	5	O
most	9	O
relevant	5	O
adverse	5	O
event	5	O
was	9	O
peripheral	9	B-Disease
neuropathy	5	I-Disease
,	9	O
which	5	O
occurred	9	O
in	5	O
78	7	O
%	9	O
of	5	O
the	5	O
patients	5	O
(	9	O
grade	9	O
II	9	O
,	9	O
38	7	O
%	9	O
;	9	O
grade	9	O
III	9	O
,	9	O
21	7	O
%	9	O
)	9	O
and	5	O
led	9	O
to	5	O
treatment	9	O
discontinuation	5	O
in	5	O
6	9	O
%	9	O
.	9	O

With	5	O
a	5	O
median	9	O
follow	5	O
up	5	O
of	5	O
22	7	O
months	5	O
,	9	O
median	9	O
time	5	O
to	5	O
progression	9	O
,	9	O
progression	9	O
-	7	O
free	9	O
survival	9	O
(	9	O
PFS	9	O
)	9	O
and	5	O
overall	5	O
survival	9	O
(	9	O
OS	9	O
)	9	O
were	9	O
8	9	O
.	9	O
9	7	O
,	9	O
8	9	O
.	9	O
7	9	O
,	9	O
and	5	O
22	7	O
months	5	O
,	9	O
respectively	9	O
.	9	O

Prolonged	9	O
PFS	9	O
and	5	O
OS	9	O
were	9	O
observed	9	O
in	5	O
patients	5	O
achieving	5	O
CR	9	O
and	5	O
receiving	9	O
bort	9	B-Chemical
-	7	O
dex	3	B-Chemical
a	5	O
single	9	O
line	9	O
of	5	O
prior	9	O
therapy	5	O
.	9	O

Bort	3	B-Chemical
-	7	O
dex	3	B-Chemical
was	9	O
an	5	O
effective	5	O
salvage	5	O
treatment	9	O
for	5	O
MM	9	B-Disease
patients	5	O
,	9	O
particularly	5	O
for	5	O
those	5	O
in	5	O
first	9	O
relapse	5	O
.	9	O

Pubertal	7	O
exposure	9	O
to	5	O
Bisphenol	0	B-Chemical
A	9	I-Chemical
increases	9	O
anxiety	5	B-Disease
-	7	O
like	9	O
behavior	5	O
and	5	O
decreases	9	O
acetylcholinesterase	0	O
activity	9	O
of	5	O
hippocampus	9	O
in	5	O
adult	9	O
male	9	O
mice	3	O
.	9	O

The	5	O
negative	9	O
effects	9	O
of	5	O
Bisphenol	0	B-Chemical
A	9	I-Chemical
(	9	O
BPA	9	B-Chemical
)	9	O
on	5	O
neurodevelopment	5	O
and	5	O
behaviors	5	O
have	5	O
been	9	O
well	9	O
established	9	O
.	9	O

Acetylcholinesterase	0	O
(	9	O
AChE	0	O
)	9	O
is	5	O
a	5	O
regulatory	1	O
enzyme	0	O
which	5	O
is	5	O
involved	9	O
in	5	O
anxiety	5	B-Disease
-	7	O
like	9	O
behavior	5	O
.	9	O

This	5	O
study	9	O
investigated	9	O
behavioral	5	O
phenotypes	9	O
and	5	O
AChE	0	O
activity	9	O
in	5	O
male	9	O
mice	3	O
following	9	O
BPA	9	B-Chemical
exposure	9	O
during	5	O
puberty	5	O
.	9	O

On	5	O
postnatal	9	O
day	9	O
(	9	O
PND	9	O
)	9	O
35	9	O
,	9	O
male	9	O
mice	3	O
were	9	O
exposed	9	O
to	5	O
50mg	0	O
BPA	9	B-Chemical
/	9	O
kg	0	O
diet	9	O
per	9	O
day	9	O
for	5	O
a	5	O
period	5	O
of	5	O
35	9	O
days	9	O
.	9	O

On	5	O
PND71	9	O
,	9	O
a	5	O
behavioral	5	O
assay	3	O
was	9	O
performed	9	O
using	9	O
the	5	O
elevated	9	O
plus	9	O
maze	5	O
(	9	O
EPM	9	O
)	9	O
and	5	O
the	5	O
light	9	O
/	9	O
dark	9	O
test	5	O
.	9	O

In	9	O
addition	9	O
,	9	O
AChE	0	O
activity	9	O
was	9	O
measured	9	O
in	5	O
the	5	O
prefrontal	5	O
cortex	5	O
,	9	O
hypothalamus	9	O
,	9	O
cerebellum	9	O
and	5	O
hippocampus	9	O
.	9	O

Results	9	O
from	9	O
our	5	O
behavioral	5	O
phenotyping	9	O
indicated	9	O
that	5	O
anxiety	5	B-Disease
-	7	O
like	9	O
behavior	5	O
was	9	O
increased	9	O
in	5	O
mice	3	O
exposed	9	O
to	5	O
BPA	9	B-Chemical
.	9	O

AChE	0	O
activity	9	O
was	9	O
significantly	9	O
decreased	9	O
in	5	O
the	5	O
hippocampus	9	O
of	5	O
mice	3	O
with	5	O
BPA	9	B-Chemical
compared	9	O
to	5	O
control	9	O
mice	3	O
,	9	O
whereas	9	O
no	9	O
difference	9	O
was	9	O
found	9	O
in	5	O
the	5	O
prefrontal	5	O
cortex	5	O
,	9	O
hypothalamus	9	O
and	5	O
cerebellum	9	O
.	9	O

Our	9	O
findings	9	O
showed	9	O
that	5	O
pubertal	5	O
BPA	9	B-Chemical
exposure	9	O
increased	9	O
anxiety	5	B-Disease
-	7	O
like	9	O
behavior	5	O
,	9	O
which	5	O
may	5	O
be	5	O
associated	9	O
with	5	O
decreased	9	O
AChE	0	O
activity	9	O
of	5	O
the	5	O
hippocampus	9	O
in	5	O
adult	9	O
male	9	O
mice	3	O
.	9	O

Further	9	O
studies	9	O
are	5	O
necessary	5	O
to	5	O
investigate	9	O
the	5	O
cholinergic	3	O
signaling	3	O
of	5	O
the	5	O
hippocampus	9	O
in	5	O
PBE	0	O
induced	3	O
anxiety	5	B-Disease
-	7	O
like	9	O
behaviors	5	O
.	9	O

Biochemical	9	O
effects	9	O
of	5	O
Solidago	4	O
virgaurea	4	O
extract	0	O
on	5	O
experimental	5	O
cardiotoxicity	9	B-Disease
.	9	O

Cardiovascular	2	B-Disease
diseases	5	I-Disease
(	9	O
CVDs	5	B-Disease
)	9	O
are	5	O
the	5	O
major	9	O
health	5	O
problem	5	O
of	5	O
advanced	5	O
as	5	O
well	9	O
as	5	O
developing	5	O
countries	5	O
of	5	O
the	5	O
world	5	O
.	9	O

The	5	O
aim	5	O
of	5	O
the	5	O
present	9	O
study	9	O
was	9	O
to	5	O
investigate	9	O
the	5	O
protective	9	O
effect	9	O
of	5	O
the	5	O
Solidago	4	O
virgaurea	4	O
extract	0	O
on	5	O
isoproterenol	0	B-Chemical
-	7	O
induced	3	O
cardiotoxicity	9	B-Disease
in	5	O
rats	9	O
.	9	O

The	5	O
subcutaneous	9	O
injection	9	O
of	5	O
isoproterenol	0	B-Chemical
(	9	O
30	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
into	9	O
rats	9	O
twice	9	O
at	9	O
an	5	O
interval	5	O
of	5	O
24	9	O
h	0	O
,	9	O
for	5	O
two	5	O
consecutive	5	O
days	9	O
,	9	O
led	9	O
to	5	O
a	5	O
significant	9	O
increase	9	O
in	5	O
serum	9	O
lactate	0	B-Chemical
dehydrogenase	1	O
,	9	O
creatine	0	B-Chemical
phosphokinase	0	O
,	9	O
alanine	1	B-Chemical
transaminase	0	O
,	9	O
aspartate	1	B-Chemical
transaminase	0	O
,	9	O
and	5	O
angiotensin	9	B-Chemical
-	7	O
converting	9	O
enzyme	0	O
activities	9	O
,	9	O
total	9	O
cholesterol	0	B-Chemical
,	9	O
triglycerides	9	B-Chemical
,	9	O
free	9	O
serum	9	O
fatty	0	B-Chemical
acid	0	I-Chemical
,	9	O
cardiac	5	O
tissue	9	O
malondialdehyde	0	B-Chemical
(	9	O
MDA	9	B-Chemical
)	9	O
,	9	O
and	5	O
nitric	0	B-Chemical
oxide	0	I-Chemical
levels	3	O
and	5	O
a	5	O
significant	9	O
decrease	9	O
in	5	O
levels	3	O
of	5	O
glutathione	0	B-Chemical
and	5	O
superoxide	0	B-Chemical
dismutase	0	O
in	5	O
cardiac	5	O
tissue	9	O
as	5	O
compared	9	O
to	5	O
the	5	O
normal	9	O
control	9	O
group	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

Pretreatment	3	O
with	5	O
S	9	O
.	9	O
virgaurea	4	O
extract	0	O
for	5	O
5	9	O
weeks	9	O
at	9	O
a	5	O
dose	9	O
of	5	O
250	0	O
mg	0	O
/	9	O
kg	0	O
followed	9	O
by	9	O
isoproterenol	0	B-Chemical
injection	9	O
significantly	9	O
prevented	9	O
the	5	O
observed	9	O
alterations	9	O
.	9	O

Captopril	0	B-Chemical
(	9	O
50	0	O
mg	0	O
/	9	O
kg	0	O
/	9	O
day	9	O
,	9	O
given	5	O
orally	0	O
)	9	O
,	9	O
an	5	O
inhibitor	3	O
of	5	O
angiotensin	9	B-Chemical
-	7	O
converting	9	O
enzyme	0	O
used	5	O
as	5	O
a	5	O
standard	5	O
cardioprotective	9	O
drug	5	O
,	9	O
was	9	O
used	5	O
as	5	O
a	5	O
positive	9	O
control	9	O
in	5	O
this	5	O
study	9	O
.	9	O

The	5	O
data	5	O
of	5	O
the	5	O
present	9	O
study	9	O
suggest	9	O
that	5	O
S	9	O
.	9	O
virgaurea	4	O
extract	0	O
exerts	9	O
its	9	O
protective	9	O
effect	9	O
by	9	O
decreasing	9	O
MDA	9	B-Chemical
level	9	O
and	5	O
increasing	9	O
the	5	O
antioxidant	0	O
status	9	O
in	5	O
isoproterenol	0	B-Chemical
-	7	O
treated	3	O
rats	9	O
.	9	O

The	5	O
study	9	O
emphasizes	5	O
the	5	O
beneficial	9	O
action	5	O
of	5	O
S	9	O
.	9	O
virgaurea	4	O
extract	0	O
as	5	O
a	5	O
cardioprotective	9	O
agent	9	O
.	9	O

"	5	O
Real	9	O
-	7	O
world	5	O
"	5	O
data	5	O
on	5	O
the	5	O
efficacy	9	O
and	5	O
safety	5	O
of	5	O
lenalidomide	0	B-Chemical
and	5	O
dexamethasone	0	B-Chemical
in	5	O
patients	5	O
with	5	O
relapsed	5	O
/	9	O
refractory	9	O
multiple	5	B-Disease
myeloma	3	I-Disease
who	5	O
were	9	O
treated	3	O
according	9	O
to	5	O
the	5	O
standard	5	O
clinical	5	O
practice	5	O
:	9	O
a	5	O
study	9	O
of	5	O
the	5	O
Greek	5	O
Myeloma	2	B-Disease
Study	5	O
Group	9	O
.	9	O

Lenalidomide	0	B-Chemical
and	5	O
dexamethasone	0	B-Chemical
(	9	O
RD	9	B-Chemical
)	9	O
is	5	O
a	5	O
standard	5	O
of	5	O
care	5	O
for	5	O
relapsed	5	O
/	9	O
refractory	9	O
multiple	5	B-Disease
myeloma	3	I-Disease
(	9	O
RRMM	5	B-Disease
)	9	O
,	9	O
but	9	O
there	5	O
is	5	O
limited	5	O
published	9	O
data	5	O
on	5	O
its	9	O
efficacy	9	O
and	5	O
safety	5	O
in	5	O
the	5	O
"	5	O
real	5	O
world	5	O
"	5	O
(	9	O
RW	9	O
)	9	O
,	9	O
according	9	O
to	5	O
the	5	O
International	2	O
Society	2	O
of	5	O
Pharmacoeconomics	2	O
and	5	O
Outcomes	5	O
Research	2	O
definition	5	O
.	9	O

We	9	O
studied	9	O
212	7	O
RRMM	5	B-Disease
patients	5	O
who	5	O
received	9	O
RD	9	B-Chemical
in	5	O
RW	9	O
.	9	O

Objective	5	O
response	9	O
(	9	O
>	0	O
PR	9	O
(	9	O
partial	9	O
response	9	O
)	9	O
)	9	O
rate	9	O
was	9	O
77	7	O
.	9	O
4	9	O
%	9	O
(	9	O
complete	9	O
response	9	O
(	9	O
CR	9	O
)	9	O
,	9	O
20	9	O
.	9	O
2	9	O
%	9	O
)	9	O
.	9	O

Median	7	O
time	5	O
to	5	O
first	9	O
and	5	O
best	5	O
response	9	O
was	9	O
2	9	O
and	5	O
5	9	O
months	5	O
,	9	O
respectively	9	O
.	9	O

Median	7	O
time	5	O
to	5	O
CR	9	O
when	5	O
RD	9	B-Chemical
was	9	O
given	5	O
as	5	O
2nd	9	O
or	5	O
>	0	O
2	9	O
(	9	O
nd	7	O
)	9	O
-	7	O
line	9	O
treatment	9	O
at	9	O
4	9	O
and	5	O
11	7	O
months	5	O
,	9	O
respectively	9	O
.	9	O

Quality	5	O
of	5	O
response	9	O
was	9	O
independent	9	O
of	5	O
previous	9	O
lines	3	O
of	5	O
therapies	5	O
or	5	O
previous	9	O
exposure	9	O
to	5	O
thalidomide	0	B-Chemical
or	5	O
bortezomib	3	B-Chemical
.	9	O

Median	7	O
duration	5	O
of	5	O
response	9	O
was	9	O
34	7	O
.	9	O
4	9	O
months	5	O
,	9	O
and	5	O
it	5	O
was	9	O
higher	9	O
in	5	O
patients	5	O
who	5	O
received	9	O
RD	9	B-Chemical
until	5	O
progression	9	O
(	9	O
not	5	O
reached	9	O
versus	9	O
19	7	O
months	5	O
,	9	O
p	7	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
.	9	O

Improvement	5	O
of	5	O
humoral	3	O
immunity	3	O
occurred	9	O
in	5	O
60	9	O
%	9	O
of	5	O
responders	5	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
and	5	O
in	5	O
the	5	O
majority	9	O
of	5	O
patients	5	O
who	5	O
achieved	5	O
stable	9	O
disease	5	O
.	9	O

Adverse	5	O
events	5	O
were	9	O
reported	9	O
in	5	O
68	7	O
.	9	O
9	7	O
%	9	O
of	5	O
patients	5	O
(	9	O
myelosuppression	5	B-Disease
in	5	O
49	7	O
.	9	O
4	9	O
%	9	O
)	9	O
and	5	O
12	9	O
.	9	O
7	9	O
%	9	O
of	5	O
patients	5	O
needed	5	O
hospitalization	5	O
.	9	O

Peripheral	9	B-Disease
neuropathy	5	I-Disease
was	9	O
observed	9	O
only	9	O
in	5	O
2	9	O
.	9	O
5	9	O
%	9	O
of	5	O
patients	5	O
and	5	O
deep	5	B-Disease
vein	5	I-Disease
thrombosis	5	I-Disease
in	5	O
5	9	O
.	9	O
7	9	O
%	9	O
.	9	O

Dose	0	O
reductions	9	O
were	9	O
needed	5	O
in	5	O
31	7	O
%	9	O
of	5	O
patients	5	O
and	5	O
permanent	5	O
discontinuation	5	O
in	5	O
38	7	O
.	9	O
9	7	O
%	9	O
.	9	O

Median	7	O
time	5	O
to	5	O
treatment	9	O
discontinuation	5	O
was	9	O
16	9	O
.	9	O
8	9	O
months	5	O
.	9	O

Performance	5	O
status	9	O
(	9	O
PS	9	O
)	9	O
and	5	O
initial	9	O
lenalidomide	0	B-Chemical
dose	9	O
predicted	9	O
for	5	O
treatment	9	O
discontinuation	5	O
.	9	O

Extra	9	O
-	7	O
medullary	5	O
relapses	5	O
occurred	9	O
in	5	O
3	9	O
.	9	O
8	9	O
%	9	O
of	5	O
patients	5	O
.	9	O

Our	9	O
study	9	O
confirms	9	O
that	5	O
RD	9	B-Chemical
is	5	O
effective	5	O
and	5	O
safe	5	O
in	5	O
RRMM	5	B-Disease
in	5	O
the	5	O
RW	9	O
;	9	O
it	5	O
produces	9	O
durable	5	O
responses	5	O
especially	5	O
in	5	O
patients	5	O
who	5	O
continue	5	O
on	5	O
treatment	9	O
till	9	O
progression	9	O
and	5	O
improves	5	O
humoral	3	O
immunity	3	O
even	5	O
in	5	O
patients	5	O
with	5	O
stable	9	O
disease	5	O
.	9	O

The	5	O
cytogenetic	9	O
action	5	O
of	5	O
ifosfamide	0	B-Chemical
,	9	O
mesna	0	B-Chemical
,	9	O
and	5	O
their	5	O
combination	9	O
on	5	O
peripheral	9	O
rabbit	3	O
lymphocytes	3	O
:	9	O
an	5	O
in	5	O
vivo	3	O
/	9	O
in	5	O
vitro	3	O
cytogenetic	9	O
study	9	O
.	9	O

Ifosfamide	0	B-Chemical
(	9	O
IFO	7	B-Chemical
)	9	O
is	5	O
an	5	O
alkylating	0	O
nitrogen	0	B-Chemical
mustard	0	O
,	9	O
administrated	0	O
as	5	O
an	5	O
antineoplasmic	_	O
agent	9	O
.	9	O

It	5	O
is	5	O
characterized	9	O
by	9	O
its	9	O
intense	9	O
urotoxic	0	O
action	5	O
,	9	O
leading	9	O
to	5	O
hemorrhagic	5	B-Disease
cystitis	9	I-Disease
.	9	O

This	5	O
side	5	O
effect	9	O
of	5	O
IFO	7	B-Chemical
raises	9	O
the	5	O
requirement	9	O
for	5	O
the	5	O
co	9	O
-	7	O
administration	9	O
with	5	O
sodium	0	B-Chemical
2	9	I-Chemical
-	7	I-Chemical
sulfanylethanesulfonate	_	I-Chemical
(	9	O
Mesna	0	B-Chemical
)	9	O
aiming	5	O
to	5	O
avoid	5	O
or	5	O
minimize	5	O
this	5	O
effect	9	O
.	9	O

IFO	7	B-Chemical
and	5	O
Mesna	0	B-Chemical
were	9	O
administrated	0	O
separately	9	O
on	5	O
rabbit	3	O
'	9	O
s	9	O
lymphocytes	3	O
in	5	O
vivo	3	O
,	9	O
which	5	O
were	9	O
later	9	O
developed	5	O
in	5	O
vitro	3	O
.	9	O

Cytogenetic	9	O
markers	3	O
for	5	O
sister	4	O
chromatid	1	O
exchanges	5	O
(	9	O
SCEs	3	O
)	9	O
,	9	O
proliferation	3	O
rate	9	O
index	5	O
(	9	O
PRI	9	O
)	9	O
and	5	O
Mitotic	9	O
Index	5	O
were	9	O
recorded	5	O
.	9	O

Mesna	0	B-Chemical
'	9	O
s	9	O
action	5	O
,	9	O
in	5	O
conjunction	9	O
with	5	O
IFO	7	B-Chemical
reduces	9	O
the	5	O
frequency	5	O
of	5	O
SCEs	3	O
,	9	O
in	5	O
comparison	9	O
with	5	O
the	5	O
SCEs	3	O
recordings	5	O
obtained	9	O
when	5	O
IFO	7	B-Chemical
is	5	O
administered	9	O
alone	9	O
.	9	O

In	9	O
addition	9	O
to	5	O
this	5	O
,	9	O
when	5	O
high	9	O
concentrations	0	O
of	5	O
Mesna	0	B-Chemical
were	9	O
administered	9	O
alone	9	O
significant	9	O
reductions	9	O
of	5	O
the	5	O
PRI	9	O
were	9	O
noted	9	O
,	9	O
than	5	O
with	5	O
IFO	7	B-Chemical
acting	9	O
at	9	O
the	5	O
same	9	O
concentration	0	O
on	5	O
the	5	O
lymphocytes	3	O
.	9	O

Mesna	0	B-Chemical
significantly	9	O
reduces	9	O
IFO	7	B-Chemical
'	9	O
s	9	O
genotoxicity	0	B-Disease
,	9	O
while	9	O
when	5	O
administered	9	O
in	5	O
high	9	O
concentrations	0	O
it	5	O
acts	9	O
in	5	O
an	5	O
inhibitory	3	O
fashion	5	O
on	5	O
the	5	O
cytostatic	3	O
action	5	O
of	5	O
the	5	O
drug	5	O
.	9	O

Risk	5	O
factors	9	O
and	5	O
predictors	5	O
of	5	O
levodopa	5	B-Chemical
-	7	O
induced	3	O
dyskinesia	5	B-Disease
among	5	O
multiethnic	5	O
Malaysians	5	O
with	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
.	9	O

Chronic	9	O
pulsatile	5	O
levodopa	5	B-Chemical
therapy	5	O
for	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
(	9	O
PD	9	B-Disease
)	9	O
leads	9	O
to	5	O
the	5	O
development	9	O
of	5	O
motor	5	O
fluctuations	5	O
and	5	O
dyskinesia	5	B-Disease
.	9	O

We	9	O
studied	9	O
the	5	O
prevalence	5	O
and	5	O
predictors	5	O
of	5	O
levodopa	5	B-Chemical
-	7	O
induced	3	O
dyskinesia	5	B-Disease
among	5	O
multiethnic	5	O
Malaysian	4	O
patients	5	O
with	5	O
PD	9	B-Disease
.	9	O

METHODS	2	O
:	9	O
This	5	O
is	5	O
a	5	O
cross	5	O
-	7	O
sectional	5	O
study	9	O
involving	5	O
95	7	O
patients	5	O
with	5	O
PD	9	B-Disease
on	5	O
uninterrupted	5	O
levodopa	5	B-Chemical
therapy	5	O
for	5	O
at	9	O
least	9	O
6	9	O
months	5	O
.	9	O

The	5	O
instrument	5	O
used	5	O
was	9	O
the	5	O
UPDRS	5	O
questionnaires	5	O
.	9	O

The	5	O
predictors	5	O
of	5	O
dyskinesia	5	B-Disease
were	9	O
determined	9	O
using	9	O
multivariate	5	O
logistic	5	O
regression	5	O
analysis	9	O
.	9	O

RESULTS	9	O
:	9	O
The	5	O
mean	5	O
age	5	O
was	9	O
65	7	O
.	9	O
6	9	O
+	9	O
8	9	O
.	9	O
5	9	O
years	5	O
.	9	O

The	5	O
mean	5	O
onset	5	O
age	5	O
was	9	O
58	7	O
.	9	O
5	9	O
+	9	O
9	7	O
.	9	O
8	9	O
years	5	O
.	9	O

The	5	O
median	9	O
disease	5	O
duration	5	O
was	9	O
6	9	O
(	9	O
7	9	O
)	9	O
years	5	O
.	9	O

Dyskinesia	5	B-Disease
was	9	O
present	9	O
in	5	O
44	7	O
%	9	O
(	9	O
n	9	O
=	7	O
42	7	O
)	9	O
with	5	O
median	9	O
levodopa	5	B-Chemical
therapy	5	O
of	5	O
3	9	O
years	5	O
.	9	O

There	5	O
were	9	O
64	7	O
.	9	O
3	9	O
%	9	O
Chinese	9	O
,	9	O
31	7	O
%	9	O
Malays	5	O
,	9	O
and	5	O
3	9	O
.	9	O
7	9	O
%	9	O
Indians	5	O
and	5	O
other	5	O
ethnic	5	O
groups	9	O
.	9	O

Eighty	5	O
-	7	O
one	5	O
percent	5	O
of	5	O
patients	5	O
with	5	O
dyskinesia	5	B-Disease
had	9	O
clinical	5	O
fluctuations	5	O
.	9	O

Patients	5	O
with	5	O
dyskinesia	5	B-Disease
had	9	O
lower	9	O
onset	5	O
age	5	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
,	9	O
longer	5	O
duration	5	O
of	5	O
levodopa	5	B-Chemical
therapy	5	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
,	9	O
longer	5	O
disease	5	O
duration	5	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
,	9	O
higher	9	O
total	9	O
daily	5	O
levodopa	5	B-Chemical
dose	9	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
,	9	O
and	5	O
higher	9	O
total	9	O
UPDRS	5	O
scores	5	O
(	9	O
p	7	O
=	7	O
0	7	O
.	9	O
005	7	O
)	9	O
than	5	O
patients	5	O
without	9	O
dyskinesia	5	B-Disease
.	9	O

The	5	O
three	9	O
significant	9	O
predictors	5	O
of	5	O
dyskinesia	5	B-Disease
were	9	O
duration	5	O
of	5	O
levodopa	5	B-Chemical
therapy	5	O
,	9	O
onset	5	O
age	5	O
,	9	O
and	5	O
total	9	O
daily	5	O
levodopa	5	B-Chemical
dose	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
The	5	O
prevalence	5	O
of	5	O
levodopa	5	B-Chemical
-	7	O
induced	3	O
dyskinesia	5	B-Disease
in	5	O
our	5	O
patients	5	O
was	9	O
44	7	O
%	9	O
.	9	O

The	5	O
most	9	O
significant	9	O
predictors	5	O
were	9	O
duration	5	O
of	5	O
levodopa	5	B-Chemical
therapy	5	O
,	9	O
total	9	O
daily	5	O
levodopa	5	B-Chemical
dose	9	O
,	9	O
and	5	O
onset	5	O
age	5	O
.	9	O

Dose	0	O
-	7	O
dependent	9	O
neurotoxicity	9	B-Disease
of	5	O
high	9	O
-	7	O
dose	9	O
busulfan	0	B-Chemical
in	5	O
children	5	O
:	9	O
a	5	O
clinical	5	O
and	5	O
pharmacological	9	O
study	9	O
.	9	O

Busulfan	0	B-Chemical
is	5	O
known	9	O
to	5	O
be	5	O
neurotoxic	9	B-Disease
in	5	O
animals	9	O
and	5	O
humans	9	O
,	9	O
but	9	O
its	9	O
acute	9	O
neurotoxicity	9	B-Disease
remains	9	O
poorly	9	O
characterized	9	O
in	5	O
children	5	O
.	9	O

We	9	O
report	5	O
here	5	O
a	5	O
retrospective	5	O
study	9	O
of	5	O
123	9	O
children	5	O
(	9	O
median	9	O
age	5	O
,	9	O
6	9	O
.	9	O
5	9	O
years	5	O
)	9	O
receiving	9	O
high	9	O
-	7	O
dose	9	O
busulfan	0	B-Chemical
in	5	O
combined	9	O
chemotherapy	5	O
before	9	O
bone	5	O
marrow	3	O
transplantation	9	O
for	5	O
malignant	3	O
solid	9	O
tumors	3	B-Disease
,	9	O
brain	5	B-Disease
tumors	3	I-Disease
excluded	9	O
.	9	O

Busulfan	0	B-Chemical
was	9	O
given	5	O
p	7	O
.	9	O
o	9	O
.	9	O
,	9	O
every	5	O
6	9	O
hours	9	O
for	5	O
16	9	O
doses	0	O
over	5	O
4	9	O
days	9	O
.	9	O

Two	9	O
total	9	O
doses	0	O
were	9	O
consecutively	5	O
used	5	O
:	9	O
16	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
then	9	O
600	0	O
mg	0	O
/	9	O
m2	7	O
.	9	O

The	5	O
dose	9	O
calculation	5	O
on	5	O
the	5	O
basis	5	O
of	5	O
body	5	O
surface	9	O
area	5	O
results	9	O
in	5	O
higher	9	O
doses	0	O
in	5	O
young	5	O
children	5	O
than	5	O
in	5	O
older	5	O
patients	5	O
(	9	O
16	9	O
to	5	O
28	7	O
mg	0	O
/	9	O
kg	0	O
)	9	O
.	9	O

Ninety	5	O
-	7	O
six	9	O
patients	5	O
were	9	O
not	5	O
given	5	O
anticonvulsive	5	O
prophylaxis	5	O
;	9	O
7	9	O
(	9	O
7	9	O
.	9	O
5	9	O
%	9	O
)	9	O
developed	5	O
seizures	5	B-Disease
during	5	O
the	5	O
4	9	O
days	9	O
of	5	O
the	5	O
busulfan	0	B-Chemical
course	5	O
or	5	O
within	9	O
24	9	O
h	0	O
after	9	O
the	5	O
last	5	O
dosing	9	O
.	9	O

When	9	O
the	5	O
total	9	O
busulfan	0	B-Chemical
dose	9	O
was	9	O
taken	5	O
into	9	O
account	5	O
,	9	O
there	5	O
was	9	O
a	5	O
significant	9	O
difference	9	O
in	5	O
terms	5	O
of	5	O
neurotoxicity	9	B-Disease
incidence	5	O
among	5	O
patients	5	O
under	9	O
16	9	O
mg	0	O
/	9	O
kg	0	O
(	9	O
1	9	O
of	5	O
57	7	O
,	9	O
1	9	O
.	9	O
7	9	O
%	9	O
)	9	O
and	5	O
patients	5	O
under	9	O
600	0	O
mg	0	O
/	9	O
m2	7	O
(	9	O
6	9	O
of	5	O
39	7	O
,	9	O
15	9	O
.	9	O
4	9	O
%	9	O
)	9	O
(	9	O
P	9	O
less	5	O
than	5	O
0	7	O
.	9	O
02	7	O
)	9	O
.	9	O

Twenty	9	O
-	7	O
seven	9	O
patients	5	O
were	9	O
given	5	O
a	5	O
600	0	O
-	7	O
mg	0	O
/	9	O
m2	7	O
busulfan	0	B-Chemical
total	9	O
dose	9	O
with	5	O
continuous	5	O
i	9	O
.	9	O
v	0	O
.	9	O
infusion	0	O
of	5	O
clonazepam	0	B-Chemical
;	9	O
none	9	O
had	9	O
any	5	O
neurological	5	B-Disease
symptoms	5	I-Disease
.	9	O

Busulfan	0	B-Chemical
levels	3	O
were	9	O
measured	9	O
by	9	O
a	5	O
gas	0	O
chromatographic	0	O
-	7	O
mass	9	O
spectrometry	0	O
assay	3	O
in	5	O
the	5	O
plasma	9	O
and	5	O
cerebrospinal	9	O
fluid	5	O
of	5	O
9	7	O
children	5	O
without	9	O
central	5	B-Disease
nervous	5	I-Disease
system	5	I-Disease
disease	5	I-Disease
under	9	O
600	0	O
mg	0	O
/	9	O
m2	7	O
busulfan	0	B-Chemical
with	5	O
clonazepam	0	B-Chemical
:	9	O
busulfan	0	B-Chemical
cerebrospinal	9	O
fluid	5	O
:	9	O
plasma	9	O
ratio	9	O
was	9	O
1	9	O
.	9	O
39	7	O
.	9	O

This	5	O
was	9	O
significantly	9	O
different	9	O
(	9	O
P	9	O
less	5	O
than	5	O
0	7	O
.	9	O
02	7	O
)	9	O
from	9	O
the	5	O
cerebrospinal	9	O
fluid	5	O
:	9	O
plasma	9	O
ratio	9	O
previously	9	O
defined	5	O
in	5	O
children	5	O
receiving	9	O
a	5	O
16	9	O
-	7	O
mg	0	O
/	9	O
kg	0	O
total	9	O
dose	9	O
of	5	O
busulfan	0	B-Chemical
.	9	O

This	5	O
study	9	O
shows	9	O
that	5	O
busulfan	0	B-Chemical
neurotoxicity	9	B-Disease
is	5	O
dose	9	O
-	7	O
dependent	9	O
in	5	O
children	5	O
and	5	O
efficiently	9	O
prevented	9	O
by	9	O
clonazepam	0	B-Chemical
.	9	O

A	9	O
busulfan	0	B-Chemical
dose	9	O
calculated	5	O
on	5	O
the	5	O
basis	5	O
of	5	O
body	5	O
surface	9	O
area	5	O
,	9	O
resulting	9	O
in	5	O
higher	9	O
doses	0	O
in	5	O
young	5	O
children	5	O
,	9	O
was	9	O
followed	9	O
by	9	O
increased	9	O
neurotoxicity	9	B-Disease
,	9	O
close	5	O
to	5	O
neurotoxicity	9	B-Disease
incidence	5	O
observed	9	O
in	5	O
adults	5	O
.	9	O

Since	9	O
plasma	9	O
pharmacokinetic	5	O
studies	9	O
showed	9	O
a	5	O
faster	5	O
busulfan	0	B-Chemical
clearance	9	O
in	5	O
children	5	O
than	5	O
in	5	O
adults	5	O
,	9	O
this	5	O
new	5	O
dose	9	O
may	5	O
approximate	5	O
more	5	O
closely	9	O
the	5	O
adult	9	O
systemic	9	O
exposure	9	O
obtained	9	O
after	9	O
the	5	O
usual	5	O
16	9	O
-	7	O
mg	0	O
/	9	O
kg	0	O
total	9	O
dose	9	O
,	9	O
with	5	O
potential	9	O
inferences	5	O
in	5	O
terms	5	O
of	5	O
anticancer	0	O
or	5	O
myeloablative	5	O
effects	9	O
.	9	O

The	5	O
busulfan	0	B-Chemical
dose	9	O
in	5	O
children	5	O
and	5	O
infants	5	O
undergoing	9	O
bone	5	O
marrow	3	O
transplantation	9	O
should	5	O
be	5	O
reconsidered	5	O
on	5	O
the	5	O
basis	5	O
of	5	O
pharmacokinetic	5	O
studies	9	O
.	9	O

An	5	O
unexpected	9	O
diagnosis	5	O
in	5	O
a	5	O
renal	9	O
-	7	O
transplant	9	O
patient	5	O
with	5	O
proteinuria	9	B-Disease
treated	3	O
with	5	O
everolimus	0	B-Chemical
:	9	O
AL	2	B-Disease
amyloidosis	5	B-Disease
.	9	O

Proteinuria	7	B-Disease
is	5	O
an	5	O
expected	9	O
complication	5	O
in	5	O
transplant	9	O
patients	5	O
treated	3	O
with	5	O
mammalian	9	O
target	9	O
of	5	O
rapamycin	3	B-Chemical
inhibitors	3	O
(	9	O
mTOR	3	O
-	7	O
i	9	O
)	9	O
.	9	O

However	9	O
,	9	O
clinical	5	O
suspicion	5	O
should	5	O
always	5	O
be	5	O
supported	9	O
by	9	O
histological	9	O
evidence	9	O
in	5	O
order	5	O
to	5	O
investigate	9	O
potential	9	O
alternate	9	O
diagnoses	5	O
such	5	O
as	5	O
acute	9	O
or	5	O
chronic	5	O
rejection	5	O
,	9	O
interstitial	9	O
fibrosis	9	B-Disease
and	5	O
tubular	9	O
atrophy	5	B-Disease
,	9	O
or	5	O
recurrent	5	O
or	5	O
de	2	O
novo	9	O
glomerulopathy	5	B-Disease
.	9	O

In	9	O
this	5	O
case	5	O
we	5	O
report	5	O
the	5	O
unexpected	9	O
diagnosis	5	O
of	5	O
amyloidosis	5	B-Disease
in	5	O
a	5	O
renal	9	O
-	7	O
transplant	9	O
patient	5	O
with	5	O
pre	9	O
-	7	O
transplant	9	O
monoclonal	3	O
gammapathy	3	O
of	5	O
undetermined	9	O
significance	9	O
who	5	O
developed	5	O
proteinuria	9	B-Disease
after	9	O
conversion	9	O
from	9	O
tacrolimus	0	B-Chemical
to	5	O
everolimus	0	B-Chemical
.	9	O

Long	9	O
-	7	O
term	5	O
oral	9	O
galactose	0	B-Chemical
treatment	9	O
prevents	9	O
cognitive	5	B-Disease
deficits	5	I-Disease
in	5	O
male	9	O
Wistar	9	O
rats	9	O
treated	3	O
intracerebroventricularly	3	O
with	5	O
streptozotocin	0	B-Chemical
.	9	O

Basic	9	O
and	5	O
clinical	5	O
research	5	O
has	9	O
demonstrated	9	O
that	5	O
dementia	5	B-Disease
of	5	O
sporadic	9	O
Alzheimer	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
(	9	O
sAD	5	O
)	9	O
type	9	O
is	5	O
associated	9	O
with	5	O
dysfunction	9	O
of	5	O
the	5	O
insulin	3	O
-	7	O
receptor	3	O
(	9	O
IR	9	O
)	9	O
system	5	O
followed	9	O
by	9	O
decreased	9	O
glucose	0	B-Chemical
transport	9	O
via	9	O
glucose	0	B-Chemical
transporter	1	O
GLUT4	3	O
and	5	O
decreased	9	O
glucose	0	B-Chemical
metabolism	9	O
in	5	O
brain	5	O
cells	3	O
.	9	O

An	5	O
alternative	5	O
source	5	O
of	5	O
energy	5	O
is	5	O
d	9	B-Chemical
-	7	I-Chemical
galactose	0	I-Chemical
(	9	O
the	5	O
C	9	O
-	7	O
4	9	O
-	7	O
epimer	0	O
of	5	O
d	9	B-Chemical
-	7	I-Chemical
glucose	0	I-Chemical
)	9	O
which	5	O
is	5	O
transported	9	O
into	9	O
the	5	O
brain	5	O
by	9	O
insulin	3	O
-	7	O
independent	9	O
GLUT3	3	O
transporter	1	O
where	5	O
it	5	O
might	9	O
be	5	O
metabolized	0	O
to	5	O
glucose	0	B-Chemical
via	9	O
the	5	O
Leloir	2	O
pathway	3	O
.	9	O

Exclusively	9	O
parenteral	5	O
daily	5	O
injections	9	O
of	5	O
galactose	0	B-Chemical
induce	3	O
memory	5	B-Disease
deterioration	5	I-Disease
in	5	O
rodents	9	O
and	5	O
are	5	O
used	5	O
to	5	O
generate	9	O
animal	5	O
aging	5	O
model	5	O
,	9	O
but	9	O
the	5	O
effects	9	O
of	5	O
oral	9	O
galactose	0	B-Chemical
treatment	9	O
on	5	O
cognitive	5	O
functions	9	O
have	5	O
never	5	O
been	9	O
tested	9	O
.	9	O

We	9	O
have	5	O
investigated	9	O
the	5	O
effects	9	O
of	5	O
continuous	5	O
daily	5	O
oral	9	O
galactose	0	B-Chemical
(	9	O
200	0	O
mg	0	O
/	9	O
kg	0	O
/	9	O
day	9	O
)	9	O
treatment	9	O
on	5	O
cognitive	5	B-Disease
deficits	5	I-Disease
in	5	O
streptozotocin	0	B-Chemical
-	7	O
induced	3	O
(	9	O
STZ	0	B-Chemical
-	7	O
icv	0	O
)	9	O
rat	3	O
model	5	O
of	5	O
sAD	5	O
,	9	O
tested	9	O
by	9	O
Morris	6	O
Water	0	O
Maze	5	O
and	5	O
Passive	5	O
Avoidance	5	O
test	5	O
,	9	O
respectively	9	O
.	9	O

One	5	O
month	5	O
of	5	O
oral	9	O
galactose	0	B-Chemical
treatment	9	O
initiated	9	O
immediately	9	O
after	9	O
the	5	O
STZ	0	B-Chemical
-	7	O
icv	0	O
administration	9	O
,	9	O
successfully	5	O
prevented	9	O
development	9	O
of	5	O
the	5	O
STZ	0	B-Chemical
-	7	O
icv	0	O
-	7	O
induced	3	O
cognitive	5	B-Disease
deficits	5	I-Disease
.	9	O

Beneficial	5	O
effect	9	O
of	5	O
oral	9	O
galactose	0	B-Chemical
was	9	O
independent	9	O
of	5	O
the	5	O
rat	3	O
age	5	O
and	5	O
of	5	O
the	5	O
galactose	0	B-Chemical
dose	9	O
ranging	9	O
from	9	O
100	0	O
to	5	O
300	0	O
mg	0	O
/	9	O
kg	0	O
/	9	O
day	9	O
.	9	O

Additionally	9	O
,	9	O
oral	9	O
galactose	0	B-Chemical
administration	9	O
led	9	O
to	5	O
the	5	O
appearance	9	O
of	5	O
galactose	0	B-Chemical
in	5	O
the	5	O
blood	9	O
.	9	O

The	5	O
increase	9	O
of	5	O
galactose	0	B-Chemical
concentration	0	O
in	5	O
the	5	O
cerebrospinal	9	O
fluid	5	O
was	9	O
several	9	O
times	5	O
lower	9	O
after	9	O
oral	9	O
than	5	O
after	9	O
parenteral	5	O
administration	9	O
of	5	O
the	5	O
same	9	O
galactose	0	B-Chemical
dose	9	O
.	9	O

Oral	9	O
galactose	0	B-Chemical
exposure	9	O
might	9	O
have	5	O
beneficial	9	O
effects	9	O
on	5	O
learning	5	O
and	5	O
memory	5	O
ability	9	O
and	5	O
could	9	O
be	5	O
worth	5	O
investigating	5	O
for	5	O
improvement	5	O
of	5	O
cognitive	5	B-Disease
deficits	5	I-Disease
associated	9	O
with	5	O
glucose	0	B-Disease
hypometabolism	5	I-Disease
in	5	O
AD	9	B-Disease
.	9	O

An	5	O
investigation	9	O
of	5	O
the	5	O
pattern	9	O
of	5	O
kidney	9	B-Disease
injury	9	I-Disease
in	5	O
HIV	5	O
-	7	O
positive	9	O
persons	5	O
exposed	9	O
to	5	O
tenofovir	0	B-Chemical
disoproxil	0	I-Chemical
fumarate	0	I-Chemical
:	9	O
an	5	O
examination	5	O
of	5	O
a	5	O
large	5	O
population	5	O
database	5	O
(	9	O
MHRA	5	O
database	5	O
)	9	O
.	9	O

The	5	O
potential	9	O
for	5	O
tenofovir	0	B-Chemical
to	5	O
cause	5	O
a	5	O
range	9	O
of	5	O
kidney	9	O
syndromes	5	O
has	9	O
been	9	O
established	9	O
from	9	O
mechanistic	9	O
and	5	O
randomised	5	O
clinical	5	O
trials	5	O
.	9	O

However	9	O
,	9	O
the	5	O
exact	5	O
pattern	9	O
of	5	O
kidney	9	O
involvement	9	O
is	5	O
still	5	O
uncertain	5	O
.	9	O

We	9	O
undertook	9	O
a	5	O
descriptive	5	O
analysis	9	O
of	5	O
Yellow	9	O
Card	5	O
records	5	O
of	5	O
407	7	O
HIV	5	O
-	7	O
positive	9	O
persons	5	O
taking	5	O
tenofovir	0	B-Chemical
disoproxil	0	I-Chemical
fumarate	0	I-Chemical
(	9	O
TDF	9	B-Chemical
)	9	O
as	5	O
part	9	O
of	5	O
their	5	O
antiretroviral	5	O
therapy	5	O
regimen	5	O
and	5	O
submitted	9	O
to	5	O
the	5	O
Medicines	5	O
and	5	O
Healthcare	0	O
Products	0	O
Regulatory	9	O
Agency	2	O
(	9	O
MHRA	5	O
)	9	O
with	5	O
suspected	5	O
kidney	9	O
adverse	5	O
effects	9	O
.	9	O

Reports	5	O
that	5	O
satisfy	5	O
defined	5	O
criteria	5	O
were	9	O
classified	5	O
as	5	O
acute	9	B-Disease
kidney	9	I-Disease
injury	9	I-Disease
,	9	O
kidney	9	B-Disease
tubular	9	I-Disease
dysfunction	9	I-Disease
and	5	O
Fanconi	9	B-Disease
syndrome	5	I-Disease
.	9	O

Of	9	O
the	5	O
407	7	O
Yellow	9	O
Card	5	O
records	5	O
analysed	9	O
,	9	O
106	9	O
satisfied	5	O
criteria	5	O
for	5	O
TDF	9	B-Chemical
-	7	O
related	9	O
kidney	9	B-Disease
disease	5	I-Disease
,	9	O
of	5	O
which	5	O
53	7	O
(	9	O
50	0	O
%	9	O
)	9	O
had	9	O
features	5	O
of	5	O
kidney	9	B-Disease
tubular	9	I-Disease
dysfunction	9	I-Disease
,	9	O
35	9	O
(	9	O
33	7	O
%	9	O
)	9	O
were	9	O
found	9	O
to	5	O
have	5	O
features	5	O
of	5	O
glomerular	5	B-Disease
dysfunction	9	I-Disease
and	5	O
18	7	O
(	9	O
17	7	O
%	9	O
)	9	O
had	9	O
Fanconi	9	B-Disease
syndrome	5	I-Disease
.	9	O

The	5	O
median	9	O
TDF	9	B-Chemical
exposure	9	O
was	9	O
316	7	O
days	9	O
(	9	O
interquartile	9	O
range	9	O
120	9	O
-	7	O
740	9	O
)	9	O
.	9	O

The	5	O
incidence	5	O
of	5	O
hospitalisation	5	O
for	5	O
TDF	9	B-Chemical
kidney	9	O
adverse	5	O
effects	9	O
was	9	O
high	9	O
,	9	O
particularly	5	O
amongst	5	O
patients	5	O
with	5	O
features	5	O
of	5	O
Fanconi	9	B-Disease
syndrome	5	I-Disease
.	9	O

The	5	O
pattern	9	O
of	5	O
kidney	9	O
syndromes	5	O
in	5	O
this	5	O
population	5	O
series	5	O
mirrors	5	O
that	5	O
reported	9	O
in	5	O
randomised	5	O
clinical	5	O
trials	5	O
.	9	O

Cessation	5	O
of	5	O
TDF	9	B-Chemical
was	9	O
associated	9	O
with	5	O
complete	9	O
restoration	5	O
of	5	O
kidney	9	O
function	9	O
in	5	O
up	5	O
half	5	O
of	5	O
the	5	O
patients	5	O
in	5	O
this	5	O
report	5	O
.	9	O

Incidence	9	O
of	5	O
postoperative	5	B-Disease
delirium	5	I-Disease
is	5	O
high	9	O
even	5	O
in	5	O
a	5	O
population	5	O
without	9	O
known	9	O
risk	5	O
factors	9	O
.	9	O

PURPOSE	2	O
:	9	O
Postoperative	5	B-Disease
delirium	5	I-Disease
is	5	O
a	5	O
recognized	9	O
complication	5	O
in	5	O
populations	9	O
at	9	O
risk	5	O
.	9	O

The	5	O
aim	5	O
of	5	O
this	5	O
study	9	O
is	5	O
to	5	O
assess	5	O
the	5	O
prevalence	5	O
of	5	O
early	9	O
postoperative	5	B-Disease
delirium	5	I-Disease
in	5	O
a	5	O
population	5	O
without	9	O
known	9	O
risk	5	O
factors	9	O
admitted	5	O
to	5	O
the	5	O
ICU	5	O
for	5	O
postoperative	5	O
monitoring	5	O
after	9	O
elective	5	O
major	9	O
surgery	5	O
.	9	O

The	5	O
secondary	9	O
outcome	5	O
investigated	9	O
is	5	O
to	5	O
identify	9	O
eventual	5	O
independent	9	O
risk	5	O
factors	9	O
among	5	O
demographic	5	O
data	5	O
and	5	O
anesthetic	5	O
drugs	5	O
used	5	O
.	9	O

METHODS	2	O
:	9	O
An	5	O
observational	5	O
,	9	O
prospective	5	O
study	9	O
was	9	O
conducted	9	O
on	5	O
a	5	O
consecutive	5	O
cohort	9	O
of	5	O
patients	5	O
admitted	5	O
to	5	O
our	5	O
ICU	5	O
within	9	O
and	5	O
for	5	O
at	9	O
least	9	O
24	9	O
h	0	O
after	9	O
major	9	O
surgical	5	O
procedures	5	O
.	9	O

Exclusion	5	O
criteria	5	O
were	9	O
any	5	O
preexisting	9	O
predisposing	5	O
factor	9	O
for	5	O
delirium	5	B-Disease
or	5	O
other	5	O
potentially	5	O
confounding	5	O
neurological	5	B-Disease
dysfunctions	5	I-Disease
.	9	O

Patients	5	O
were	9	O
assessed	9	O
daily	5	O
using	9	O
the	5	O
confusion	5	B-Disease
assessment	5	O
method	5	O
for	5	O
the	5	O
ICU	5	O
scale	5	O
for	5	O
3	9	O
days	9	O
after	9	O
the	5	O
surgical	5	O
procedure	5	O
.	9	O

Early	9	O
postoperative	5	B-Disease
delirium	5	I-Disease
incidence	5	O
risk	5	O
factors	9	O
were	9	O
then	9	O
assessed	9	O
through	9	O
three	9	O
different	9	O
multiple	5	O
regression	5	O
models	5	O
.	9	O

RESULTS	9	O
:	9	O
According	5	O
to	5	O
the	5	O
confusion	5	O
assessment	5	O
method	5	O
for	5	O
the	5	O
ICU	5	O
scale	5	O
,	9	O
28	7	O
%	9	O
of	5	O
patients	5	O
were	9	O
diagnosed	5	O
with	5	O
early	9	O
postoperative	5	B-Disease
delirium	5	I-Disease
.	9	O

The	5	O
use	5	O
of	5	O
thiopentone	0	B-Chemical
was	9	O
significantly	9	O
associated	9	O
with	5	O
an	5	O
eight	9	O
-	7	O
fold	9	O
-	7	O
higher	9	O
risk	5	O
for	5	O
delirium	5	B-Disease
compared	9	O
to	5	O
propofol	0	B-Chemical
(	9	O
57	7	O
.	9	O
1	9	O
%	9	O
vs	7	O
.	9	O
7	9	O
.	9	O
1	9	O
%	9	O
,	9	O
RR	9	O
=	7	O
8	9	O
.	9	O
0	7	O
,	9	O
X2	9	O
=	7	O
4	9	O
.	9	O
256	9	O
;	9	O
df	7	O
=	7	O
1	9	O
;	9	O
0	7	O
.	9	O
05	7	O
<	0	O
p	7	O
<	0	O
0	7	O
.	9	O
02	7	O
)	9	O
.	9	O

CONCLUSION	5	O
:	9	O
In	9	O
this	5	O
study	9	O
early	9	O
postoperative	5	B-Disease
delirium	5	I-Disease
was	9	O
found	9	O
to	5	O
be	5	O
a	5	O
very	5	O
common	5	O
complication	5	O
after	9	O
major	9	O
surgery	5	O
,	9	O
even	5	O
in	5	O
a	5	O
population	5	O
without	9	O
known	9	O
risk	5	O
factors	9	O
.	9	O

Thiopentone	0	B-Chemical
was	9	O
independently	9	O
associated	9	O
with	5	O
an	5	O
increase	9	O
in	5	O
its	9	O
relative	9	O
risk	5	O
.	9	O

A	9	O
single	9	O
neurotoxic	9	B-Disease
dose	9	O
of	5	O
methamphetamine	5	B-Chemical
induces	3	O
a	5	O
long	5	O
-	7	O
lasting	5	O
depressive	5	B-Disease
-	7	O
like	9	O
behaviour	5	O
in	5	O
mice	3	O
.	9	O

Methamphetamine	7	B-Chemical
(	9	O
METH	9	B-Chemical
)	9	O
triggers	9	O
a	5	O
disruption	9	O
of	5	O
the	5	O
monoaminergic	5	O
system	5	O
and	5	O
METH	9	B-Chemical
abuse	5	O
leads	9	O
to	5	O
negative	9	O
emotional	5	O
states	5	O
including	9	O
depressive	5	B-Disease
symptoms	5	I-Disease
during	5	O
drug	5	O
withdrawal	5	O
.	9	O

However	9	O
,	9	O
it	5	O
is	5	O
currently	5	O
unknown	9	O
if	5	O
the	5	O
acute	9	O
toxic	0	O
dosage	9	O
of	5	O
METH	9	B-Chemical
also	9	O
causes	9	O
a	5	O
long	5	O
-	7	O
lasting	5	O
depressive	5	B-Disease
phenotype	3	O
and	5	O
persistent	5	O
monoaminergic	5	O
deficits	5	O
.	9	O

Thus	9	O
,	9	O
we	5	O
now	5	O
assessed	9	O
the	5	O
depressive	5	B-Disease
-	7	O
like	9	O
behaviour	5	O
in	5	O
mice	3	O
at	9	O
early	9	O
and	5	O
long	5	O
-	7	O
term	5	O
periods	5	O
following	9	O
a	5	O
single	9	O
high	9	O
METH	9	B-Chemical
dose	9	O
(	9	O
30	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
.	9	O

METH	9	B-Chemical
did	9	O
not	5	O
alter	9	O
the	5	O
motor	5	O
function	9	O
and	5	O
procedural	5	O
memory	5	O
of	5	O
mice	3	O
as	5	O
assessed	9	O
by	9	O
swimming	5	O
speed	5	O
and	5	O
escape	5	O
latency	5	O
to	5	O
find	5	O
the	5	O
platform	5	O
in	5	O
a	5	O
cued	5	O
version	5	O
of	5	O
the	5	O
water	0	O
maze	5	O
task	5	O
.	9	O

However	9	O
,	9	O
METH	9	B-Chemical
significantly	9	O
increased	9	O
the	5	O
immobility	5	O
time	5	O
in	5	O
the	5	O
tail	9	O
suspension	0	O
test	5	O
at	9	O
3	9	O
and	5	O
49	7	O
days	9	O
post	9	O
-	7	O
administration	9	O
.	9	O

This	5	O
depressive	5	B-Disease
-	7	O
like	9	O
profile	9	O
induced	3	O
by	9	O
METH	9	B-Chemical
was	9	O
accompanied	9	O
by	9	O
a	5	O
marked	9	O
depletion	3	O
of	5	O
frontostriatal	5	O
dopaminergic	5	O
and	5	O
serotonergic	5	O
neurotransmission	5	O
,	9	O
indicated	9	O
by	9	O
a	5	O
reduction	9	O
in	5	O
the	5	O
levels	3	O
of	5	O
dopamine	5	B-Chemical
,	9	O
DOPAC	0	B-Chemical
and	5	O
HVA	0	B-Chemical
,	9	O
tyrosine	3	B-Chemical
hydroxylase	1	O
and	5	O
serotonin	9	B-Chemical
,	9	O
observed	9	O
at	9	O
both	9	O
3	9	O
and	5	O
49	7	O
days	9	O
post	9	O
-	7	O
administration	9	O
.	9	O

In	9	O
parallel	5	O
,	9	O
another	9	O
neurochemical	5	O
feature	5	O
of	5	O
depression	5	B-Disease
-	7	O
-	7	O
astroglial	3	O
dysfunction	9	O
-	7	O
-	7	O
was	9	O
unaffected	9	O
in	5	O
the	5	O
cortex	5	O
and	5	O
the	5	O
striatal	3	O
levels	3	O
of	5	O
the	5	O
astrocytic	3	O
protein	1	O
marker	3	O
,	9	O
glial	3	O
fibrillary	3	O
acidic	0	O
protein	1	O
,	9	O
were	9	O
only	9	O
transiently	3	O
increased	9	O
at	9	O
3	9	O
days	9	O
.	9	O

These	5	O
findings	9	O
demonstrate	9	O
for	5	O
the	5	O
first	9	O
time	5	O
that	5	O
a	5	O
single	9	O
high	9	O
dose	9	O
of	5	O
METH	9	B-Chemical
induces	3	O
long	5	O
-	7	O
lasting	5	O
depressive	5	B-Disease
-	7	O
like	9	O
behaviour	5	O
in	5	O
mice	3	O
associated	9	O
with	5	O
a	5	O
persistent	5	O
disruption	9	O
of	5	O
frontostriatal	5	O
dopaminergic	5	O
and	5	O
serotonergic	5	O
homoeostasis	9	O
.	9	O

Linezolid	0	B-Chemical
-	7	O
induced	3	O
optic	5	B-Disease
neuropathy	5	I-Disease
.	9	O

Many	5	O
systemic	9	O
antimicrobials	5	O
have	5	O
been	9	O
implicated	9	O
to	5	O
cause	5	O
ocular	5	O
adverse	5	O
effects	9	O
.	9	O

This	5	O
is	5	O
especially	5	O
relevant	5	O
in	5	O
multidrug	9	O
therapy	5	O
where	5	O
more	5	O
than	5	O
one	5	O
drug	5	O
can	5	O
cause	5	O
a	5	O
similar	9	O
ocular	5	O
adverse	5	O
effect	9	O
.	9	O

We	9	O
describe	5	O
a	5	O
case	5	O
of	5	O
progressive	5	O
loss	9	B-Disease
of	5	I-Disease
vision	5	I-Disease
associated	9	O
with	5	O
linezolid	0	B-Chemical
therapy	5	O
.	9	O

A	9	O
45	9	O
-	7	O
year	5	O
-	7	O
old	5	O
male	9	O
patient	5	O
who	5	O
was	9	O
on	5	O
treatment	9	O
with	5	O
multiple	5	O
second	9	O
-	7	O
line	9	O
anti	3	O
-	7	O
tuberculous	5	O
drugs	5	O
including	9	O
linezolid	0	B-Chemical
and	5	O
ethambutol	0	B-Chemical
for	5	O
extensively	9	B-Disease
drug	5	I-Disease
-	7	I-Disease
resistant	9	I-Disease
tuberculosis	9	I-Disease
(	9	O
XDR	5	B-Disease
-	7	I-Disease
TB	5	I-Disease
)	9	O
presented	5	O
to	5	O
us	5	O
with	5	O
painless	5	O
progressive	5	O
loss	9	B-Disease
of	5	I-Disease
vision	5	I-Disease
in	5	O
both	9	O
eyes	5	O
.	9	O

Color	5	O
vision	5	O
was	9	O
defective	1	O
and	5	O
fundus	5	O
examination	5	O
revealed	9	O
optic	5	B-Disease
disc	5	I-Disease
edema	5	I-Disease
in	5	O
both	9	O
eyes	5	O
.	9	O

Ethambutol	0	B-Chemical
-	7	O
induced	3	O
toxic	0	B-Disease
optic	5	I-Disease
neuropathy	5	I-Disease
was	9	O
suspected	5	O
and	5	O
tablet	0	O
ethambutol	0	B-Chemical
was	9	O
withdrawn	9	O
.	9	O

Deterioration	5	B-Disease
of	5	I-Disease
vision	5	I-Disease
occurred	9	O
despite	9	O
withdrawal	5	O
of	5	O
ethambutol	0	B-Chemical
.	9	O

Discontinuation	5	O
of	5	O
linezolid	0	B-Chemical
resulted	9	O
in	5	O
marked	9	O
improvement	5	O
of	5	O
vision	5	O
.	9	O

Our	9	O
report	5	O
emphasizes	5	O
the	5	O
need	5	O
for	5	O
monitoring	5	O
of	5	O
visual	5	O
function	9	O
in	5	O
patients	5	O
on	5	O
long	5	O
-	7	O
term	5	O
linezolid	0	B-Chemical
treatment	9	O
.	9	O

Resuscitation	5	O
with	5	O
lipid	0	O
,	9	O
epinephrine	0	B-Chemical
,	9	O
or	5	O
both	9	O
in	5	O
levobupivacaine	0	B-Chemical
-	7	O
induced	3	O
cardiac	5	B-Disease
toxicity	9	I-Disease
in	5	O
newborn	9	O
piglets	9	O
.	9	O

BACKGROUND	2	O
:	9	O
The	5	O
optimal	5	O
dosing	9	O
regimens	5	O
of	5	O
lipid	0	O
emulsion	0	O
,	9	O
epinephrine	0	B-Chemical
,	9	O
or	5	O
both	9	O
are	5	O
not	5	O
yet	9	O
determined	9	O
in	5	O
neonates	9	O
in	5	O
cases	5	O
of	5	O
local	5	O
anaesthetic	5	O
systemic	9	O
toxicity	9	B-Disease
(	9	O
LAST	2	O
)	9	O
.	9	O

METHODS	2	O
:	9	O
Newborn	9	O
piglets	9	O
received	9	O
levobupivacaine	0	B-Chemical
until	5	O
cardiovascular	5	B-Disease
collapse	5	I-Disease
occurred	9	O
.	9	O

Standard	9	O
cardiopulmonary	5	O
resuscitation	5	O
was	9	O
started	5	O
and	5	O
electrocardiogram	5	O
(	9	O
ECG	5	O
)	9	O
was	9	O
monitored	9	O
for	5	O
ventricular	5	B-Disease
tachycardia	5	I-Disease
,	9	O
fibrillation	5	B-Disease
,	9	O
or	5	O
QRS	5	O
prolongation	9	O
.	9	O

Piglets	5	O
were	9	O
then	9	O
randomly	5	O
allocated	5	O
to	5	O
four	9	O
groups	9	O
:	9	O
control	9	O
(	9	O
saline	0	O
)	9	O
,	9	O
Intralipid	0	O
(	9	O
)	9	O
alone	9	O
,	9	O
epinephrine	0	B-Chemical
alone	9	O
,	9	O
or	5	O
a	5	O
combination	9	O
of	5	O
Intralipd	_	O
plus	9	O
epinephrine	0	B-Chemical
.	9	O

Resuscitation	5	O
continued	9	O
for	5	O
30	9	O
min	0	O
or	5	O
until	5	O
there	5	O
was	9	O
a	5	O
return	5	O
of	5	O
spontaneous	5	O
circulation	9	O
(	9	O
ROSC	5	O
)	9	O
accompanied	9	O
by	9	O
a	5	O
mean	5	O
arterial	5	O
pressure	5	O
at	9	O
or	5	O
superior	5	O
to	5	O
the	5	O
baseline	5	O
pressure	5	O
and	5	O
normal	9	O
sinus	5	O
rhythm	5	O
for	5	O
a	5	O
period	5	O
of	5	O
30	9	O
min	0	O
.	9	O

RESULTS	9	O
:	9	O
ROSC	5	O
was	9	O
achieved	5	O
in	5	O
only	9	O
one	5	O
of	5	O
the	5	O
control	9	O
piglets	9	O
compared	9	O
with	5	O
most	9	O
of	5	O
the	5	O
treated	3	O
piglets	9	O
.	9	O

Mortality	5	O
was	9	O
not	5	O
significantly	9	O
different	9	O
between	5	O
the	5	O
three	9	O
treatment	9	O
groups	9	O
,	9	O
but	9	O
was	9	O
significantly	9	O
lower	9	O
in	5	O
all	5	O
the	5	O
treatment	9	O
groups	9	O
compared	9	O
with	5	O
control	9	O
.	9	O

The	5	O
number	9	O
of	5	O
ECG	5	O
abnormalities	9	O
was	9	O
zero	5	O
in	5	O
the	5	O
Intralipid	0	O
only	9	O
group	9	O
,	9	O
but	9	O
14	7	O
and	5	O
17	7	O
,	9	O
respectively	9	O
,	9	O
in	5	O
the	5	O
epinephrine	0	B-Chemical
and	5	O
epinephrine	0	B-Chemical
plus	9	O
lipid	0	O
groups	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Lipid	0	O
emulsion	0	O
with	5	O
or	5	O
without	9	O
epinephrine	0	B-Chemical
,	9	O
or	5	O
epinephrine	0	B-Chemical
alone	9	O
were	9	O
equally	9	O
effective	5	O
in	5	O
achieving	5	O
a	5	O
return	5	O
to	5	O
spontaneous	5	O
circulation	9	O
in	5	O
this	5	O
model	5	O
of	5	O
LAST	2	O
.	9	O

Epinephrine	0	B-Chemical
alone	9	O
or	5	O
in	5	O
combination	9	O
with	5	O
lipid	0	O
was	9	O
associated	9	O
with	5	O
an	5	O
increased	9	O
number	9	O
of	5	O
ECG	5	O
abnormalities	9	O
compared	9	O
with	5	O
lipid	0	O
emulsion	0	O
alone	9	O
.	9	O

Incidence	9	O
of	5	O
heparin	0	B-Chemical
-	7	O
induced	3	O
thrombocytopenia	9	B-Disease
type	9	I-Disease
II	9	I-Disease
and	5	O
postoperative	5	O
recovery	9	O
of	5	O
platelet	9	O
count	9	O
in	5	O
liver	9	O
graft	5	O
recipients	9	O
:	9	O
a	5	O
retrospective	5	O
cohort	9	O
analysis	9	O
.	9	O

BACKGROUND	2	O
:	9	O
Thrombocytopenia	7	B-Disease
in	5	O
patients	5	O
with	5	O
end	9	B-Disease
-	7	I-Disease
stage	9	I-Disease
liver	9	I-Disease
disease	5	I-Disease
is	5	O
a	5	O
common	5	O
disorder	5	O
caused	9	O
mainly	9	O
by	9	O
portal	5	B-Disease
hypertension	5	I-Disease
,	9	O
low	9	O
levels	3	O
of	5	O
thrombopoetin	3	O
,	9	O
and	5	O
endotoxemia	9	B-Disease
.	9	O

The	5	O
impact	5	O
of	5	O
immune	3	O
-	7	O
mediated	3	O
heparin	0	B-Chemical
-	7	O
induced	3	O
thrombocytopenia	9	B-Disease
type	9	I-Disease
II	9	I-Disease
(	9	O
HIT	5	B-Disease
type	9	I-Disease
II	9	I-Disease
)	9	O
as	5	O
a	5	O
cause	5	O
of	5	O
thrombocytopenia	9	B-Disease
after	9	O
liver	9	O
transplantation	9	O
is	5	O
not	5	O
yet	9	O
understood	5	O
,	9	O
with	5	O
few	5	O
literature	5	O
citations	5	O
reporting	5	O
contradictory	5	O
results	9	O
.	9	O

The	5	O
aim	5	O
of	5	O
our	5	O
study	9	O
was	9	O
to	5	O
demonstrate	9	O
the	5	O
perioperative	5	O
course	5	O
of	5	O
thrombocytopenia	9	B-Disease
after	9	O
liver	9	O
transplantation	9	O
and	5	O
determine	9	O
the	5	O
occurrence	5	O
of	5	O
clinical	5	O
HIT	5	B-Disease
type	9	I-Disease
II	9	I-Disease
.	9	O

METHOD	2	O
:	9	O
We	9	O
retrospectively	5	O
evaluated	9	O
the	5	O
medical	5	O
records	5	O
of	5	O
205	7	O
consecutive	5	O
adult	9	O
patients	5	O
who	5	O
underwent	5	O
full	5	O
-	7	O
size	9	O
liver	9	O
transplantation	9	O
between	5	O
January	2	O
2006	2	O
and	5	O
December	2	O
2010	2	O
due	5	O
to	5	O
end	9	B-Disease
-	7	I-Disease
stage	9	I-Disease
or	5	I-Disease
malignant	3	I-Disease
liver	9	I-Disease
disease	5	I-Disease
.	9	O

Preoperative	5	O
platelet	9	O
count	9	O
,	9	O
postoperative	5	O
course	5	O
of	5	O
platelets	3	O
,	9	O
and	5	O
clinical	5	O
signs	5	O
of	5	O
HIT	5	B-Disease
type	9	I-Disease
II	9	I-Disease
were	9	O
analyzed	9	O
.	9	O

RESULTS	9	O
:	9	O
A	9	O
total	9	O
of	5	O
155	7	O
(	9	O
75	9	O
.	9	O
6	9	O
%	9	O
)	9	O
of	5	O
205	7	O
patients	5	O
had	9	O
thrombocytopenia	9	B-Disease
before	9	O
transplantation	9	O
,	9	O
significantly	9	O
influenced	5	O
by	9	O
Model	5	O
of	5	O
End	9	B-Disease
-	7	I-Disease
Stage	9	I-Disease
Liver	9	I-Disease
Disease	2	I-Disease
score	5	O
and	5	O
liver	9	B-Disease
cirrhosis	5	I-Disease
.	9	O

The	5	O
platelet	9	O
count	9	O
exceeded	9	O
100	0	O
,	9	O
000	9	O
/	9	O
uL	0	O
in	5	O
most	9	O
of	5	O
the	5	O
patients	5	O
(	9	O
n	9	O
=	7	O
193	7	O
)	9	O
at	9	O
a	5	O
medium	0	O
of	5	O
7	9	O
d	9	O
.	9	O

Regarding	9	O
HIT	5	B-Disease
II	9	I-Disease
,	9	O
there	5	O
were	9	O
four	9	O
(	9	O
1	9	O
.	9	O
95	7	O
%	9	O
)	9	O
patients	5	O
with	5	O
a	5	O
background	9	O
of	5	O
HIT	5	B-Disease
type	9	I-Disease
II	9	I-Disease
.	9	O

CONCLUSIONS	5	O
:	9	O
The	5	O
incidence	5	O
of	5	O
HIT	5	B-Disease
in	5	O
patients	5	O
with	5	O
end	9	B-Disease
-	7	I-Disease
stage	9	I-Disease
hepatic	9	I-Disease
failure	5	I-Disease
is	5	O
,	9	O
with	5	O
about	5	O
1	9	O
.	9	O
95	7	O
%	9	O
,	9	O
rare	5	O
.	9	O

For	9	O
further	9	O
reduction	9	O
of	5	O
HIT	5	B-Disease
type	9	I-Disease
II	9	I-Disease
,	9	O
the	5	O
use	5	O
of	5	O
intravenous	0	O
heparin	0	B-Chemical
should	5	O
be	5	O
avoided	5	O
and	5	O
the	5	O
prophylactic	5	O
anticoagulation	5	O
should	5	O
be	5	O
performed	9	O
with	5	O
low	9	O
-	7	O
molecular	9	O
-	7	O
weight	9	O
heparin	0	B-Chemical
after	9	O
normalization	5	O
of	5	O
platelet	9	O
count	9	O
.	9	O

Takotsubo	5	B-Disease
syndrome	5	I-Disease
(	9	O
or	5	O
apical	9	B-Disease
ballooning	5	I-Disease
syndrome	5	I-Disease
)	9	O
secondary	9	O
to	5	O
Zolmitriptan	0	B-Chemical
.	9	O

Takotsubo	5	B-Disease
syndrome	5	I-Disease
(	9	O
TS	9	B-Disease
)	9	O
,	9	O
also	9	O
known	9	O
as	5	O
broken	5	B-Disease
heart	5	I-Disease
syndrome	5	I-Disease
,	9	O
is	5	O
characterized	9	O
by	9	O
left	5	O
ventricle	5	O
apical	9	O
ballooning	5	O
with	5	O
elevated	9	O
cardiac	5	O
biomarkers	9	O
and	5	O
electrocardiographic	5	O
changes	9	O
suggestive	9	O
of	5	O
an	5	O
acute	9	B-Disease
coronary	5	I-Disease
syndrome	5	I-Disease
(	9	O
ie	5	O
,	9	O
ST	9	O
-	7	O
segment	9	O
elevation	9	O
,	9	O
T	3	O
wave	5	O
inversions	5	O
,	9	O
and	5	O
pathologic	5	O
Q	9	O
waves	5	O
)	9	O
.	9	O

We	9	O
report	5	O
a	5	O
case	5	O
of	5	O
54	7	O
-	7	O
year	5	O
-	7	O
old	5	O
woman	5	O
with	5	O
medical	5	O
history	5	O
of	5	O
mitral	5	B-Disease
valve	5	I-Disease
prolapse	5	I-Disease
and	5	O
migraines	5	B-Disease
,	9	O
who	5	O
was	9	O
admitted	5	O
to	5	O
the	5	O
hospital	5	O
for	5	O
substernal	5	O
chest	5	B-Disease
pain	5	I-Disease
and	5	O
electrocardiogram	5	O
demonstrated	9	O
1	9	O
/	9	O
2	9	O
mm	9	O
ST	9	O
-	7	O
segment	9	O
elevation	9	O
in	5	O
leads	9	O
II	9	O
,	9	O
III	9	O
,	9	O
aVF	5	O
,	9	O
V5	9	O
,	9	O
and	5	O
V6	9	O
and	5	O
positive	9	O
troponin	9	O
I	9	O
.	9	O

Emergent	5	O
coronary	5	O
angiogram	5	O
revealed	9	O
normal	9	O
coronary	5	O
arteries	5	O
with	5	O
moderately	9	O
reduced	9	O
left	5	O
ventricular	5	O
ejection	5	O
fraction	9	O
with	5	O
wall	5	O
motion	5	O
abnormalities	9	O
consistent	9	O
with	5	O
TS	9	B-Disease
.	9	O

Detailed	5	O
history	5	O
obtained	9	O
retrospectively	5	O
revealed	9	O
that	5	O
the	5	O
patient	5	O
took	5	O
zolmitriptan	0	B-Chemical
sparingly	0	O
only	9	O
when	5	O
she	5	O
had	9	O
migraines	5	B-Disease
.	9	O

But	5	O
before	9	O
this	5	O
event	5	O
,	9	O
she	5	O
was	9	O
taking	5	O
zolmitriptan	0	B-Chemical
2	9	O
-	7	O
3	9	O
times	5	O
daily	5	O
for	5	O
several	9	O
days	9	O
because	5	O
of	5	O
a	5	O
persistent	5	O
migraine	5	B-Disease
headache	5	I-Disease
.	9	O

She	5	O
otherwise	9	O
reported	9	O
that	5	O
she	5	O
is	5	O
quite	5	O
active	9	O
,	9	O
rides	5	O
horses	5	O
,	9	O
and	5	O
does	9	O
show	9	O
jumping	5	O
without	9	O
any	5	O
limitations	5	O
in	5	O
her	5	O
physical	5	O
activity	9	O
.	9	O

There	5	O
was	9	O
no	9	O
evidence	9	O
of	5	O
any	5	O
recent	5	O
stress	9	O
or	5	O
status	9	B-Disease
migrainosus	5	I-Disease
.	9	O

Extensive	9	O
literature	5	O
search	5	O
revealed	9	O
multiple	5	O
cases	5	O
of	5	O
coronary	5	B-Disease
artery	5	I-Disease
vasospasm	5	I-Disease
secondary	9	O
to	5	O
zolmitriptan	0	B-Chemical
,	9	O
but	9	O
none	9	O
of	5	O
the	5	O
cases	5	O
were	9	O
associated	9	O
with	5	O
TS	9	B-Disease
.	9	O

Depression	5	B-Disease
,	9	O
impulsiveness	5	B-Disease
,	9	O
sleep	5	O
,	9	O
and	5	O
memory	5	O
in	5	O
past	5	O
and	5	O
present	9	O
polydrug	5	O
users	5	O
of	5	O
3	9	B-Chemical
,	9	I-Chemical
4	9	I-Chemical
-	7	I-Chemical
methylenedioxymethamphetamine	0	I-Chemical
(	9	O
MDMA	5	B-Chemical
,	9	O
ecstasy	5	B-Chemical
)	9	O
.	9	O

RATIONALE	2	O
:	9	O
Ecstasy	7	B-Chemical
(	9	O
3	9	B-Chemical
,	9	I-Chemical
4	9	I-Chemical
-	7	I-Chemical
methylenedioxymethamphetamine	0	I-Chemical
,	9	O
MDMA	5	B-Chemical
)	9	O
is	5	O
a	5	O
worldwide	5	O
recreational	5	O
drug	5	O
of	5	O
abuse	5	O
.	9	O

Unfortunately	5	O
,	9	O
the	5	O
results	9	O
from	9	O
human	3	O
research	5	O
investigating	5	O
its	9	O
psychological	5	O
effects	9	O
have	5	O
been	9	O
inconsistent	5	O
.	9	O

OBJECTIVES	2	O
:	9	O
The	5	O
present	9	O
study	9	O
aimed	5	O
to	5	O
be	5	O
the	5	O
largest	5	O
to	5	O
date	5	O
in	5	O
sample	9	O
size	9	O
and	5	O
5HT	0	O
-	7	O
related	9	O
behaviors	5	O
;	9	O
the	5	O
first	9	O
to	5	O
compare	9	O
present	9	O
ecstasy	5	B-Chemical
users	5	O
with	5	O
past	5	O
users	5	O
after	9	O
an	5	O
abstinence	5	O
of	5	O
4	9	O
or	5	O
more	5	O
years	5	O
,	9	O
and	5	O
the	5	O
first	9	O
to	5	O
include	5	O
robust	5	O
controls	9	O
for	5	O
other	5	O
recreational	5	O
substances	0	O
.	9	O

METHODS	2	O
:	9	O
A	9	O
sample	9	O
of	5	O
997	7	O
participants	5	O
(	9	O
52	7	O
%	9	O
male	9	O
)	9	O
was	9	O
recruited	9	O
to	5	O
four	9	O
control	9	O
groups	9	O
(	9	O
non	9	O
-	7	O
drug	5	O
(	9	O
ND	7	O
)	9	O
,	9	O
alcohol	5	B-Chemical
/	9	O
nicotine	0	B-Chemical
(	9	O
AN	9	B-Chemical
)	9	O
,	9	O
cannabis	5	B-Chemical
/	9	O
alcohol	5	B-Chemical
/	9	O
nicotine	0	B-Chemical
(	9	O
CAN	9	B-Chemical
)	9	O
,	9	O
non	9	O
-	7	O
ecstasy	5	B-Chemical
polydrug	5	O
(	9	O
PD	9	O
)	9	O
)	9	O
,	9	O
and	5	O
two	5	O
ecstasy	5	B-Chemical
polydrug	5	O
groups	9	O
(	9	O
present	9	O
(	9	O
MDMA	5	B-Chemical
)	9	O
and	5	O
past	5	O
users	5	O
(	9	O
EX	9	O
-	7	O
MDMA	5	B-Chemical
)	9	O
.	9	O

Participants	5	O
completed	5	O
a	5	O
drug	5	O
history	5	O
questionnaire	5	O
,	9	O
Beck	6	O
Depression	5	B-Disease
Inventory	5	O
,	9	O
Barratt	6	O
Impulsiveness	5	B-Disease
Scale	5	O
,	9	O
Pittsburgh	2	O
Sleep	5	O
Quality	5	O
Index	5	O
,	9	O
and	5	O
Wechsler	5	O
Memory	5	O
Scale	5	O
-	7	O
Revised	5	O
which	5	O
,	9	O
in	5	O
total	9	O
,	9	O
provided	9	O
13	7	O
psychometric	5	O
measures	5	O
.	9	O

RESULTS	9	O
:	9	O
While	9	O
the	5	O
CAN	9	B-Chemical
and	5	O
PD	9	O
groups	9	O
tended	5	O
to	5	O
record	5	O
greater	5	O
deficits	5	O
than	5	O
the	5	O
non	9	O
-	7	O
drug	5	O
controls	9	O
,	9	O
the	5	O
MDMA	5	B-Chemical
and	5	O
EX	9	O
-	7	O
MDMA	5	B-Chemical
groups	9	O
recorded	5	O
greater	5	O
deficits	5	O
than	5	O
all	5	O
the	5	O
control	9	O
groups	9	O
on	5	O
ten	9	O
of	5	O
the	5	O
13	7	O
psychometric	5	O
measures	5	O
.	9	O

Strikingly	3	O
,	9	O
despite	9	O
prolonged	9	O
abstinence	5	O
(	9	O
mean	5	O
,	9	O
4	9	O
.	9	O
98	7	O
;	9	O
range	9	O
,	9	O
4	9	O
-	7	O
9	7	O
years	5	O
)	9	O
,	9	O
past	5	O
ecstasy	5	B-Chemical
users	5	O
showed	9	O
few	5	O
signs	5	O
of	5	O
recovery	9	O
.	9	O

Compared	9	O
with	5	O
present	9	O
ecstasy	5	B-Chemical
users	5	O
,	9	O
the	5	O
past	5	O
users	5	O
showed	9	O
no	9	O
change	9	O
for	5	O
ten	9	O
measures	5	O
,	9	O
increased	9	O
impairment	5	O
for	5	O
two	5	O
measures	5	O
,	9	O
and	5	O
improvement	5	O
on	5	O
just	5	O
one	5	O
measure	5	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Given	9	O
this	5	O
record	5	O
of	5	O
impaired	9	B-Disease
memory	5	I-Disease
and	5	O
clinically	5	O
significant	9	O
levels	3	O
of	5	O
depression	5	B-Disease
,	9	O
impulsiveness	5	B-Disease
,	9	O
and	5	O
sleep	5	B-Disease
disturbance	5	I-Disease
,	9	O
the	5	O
prognosis	5	O
for	5	O
the	5	O
current	5	O
generation	9	O
of	5	O
ecstasy	5	B-Chemical
users	5	O
is	5	O
a	5	O
major	9	O
cause	5	O
for	5	O
concern	5	O
.	9	O

Association	2	O
of	5	O
common	5	O
genetic	5	O
variants	1	O
of	5	O
HOMER1	7	O
gene	1	O
with	5	O
levodopa	5	B-Chemical
adverse	5	O
effects	9	O
in	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
patients	5	O
.	9	O

Levodopa	0	B-Chemical
is	5	O
the	5	O
most	9	O
effective	5	O
symptomatic	5	O
therapy	5	O
for	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
,	9	O
but	9	O
its	9	O
chronic	5	O
use	5	O
could	9	O
lead	5	O
to	5	O
chronic	5	O
adverse	5	O
outcomes	5	O
,	9	O
such	5	O
as	5	O
motor	5	O
fluctuations	5	O
,	9	O
dyskinesia	5	B-Disease
and	5	O
visual	5	B-Disease
hallucinations	5	I-Disease
.	9	O

HOMER1	7	O
is	5	O
a	5	O
protein	1	O
with	5	O
pivotal	9	O
function	9	O
in	5	O
glutamate	0	B-Chemical
transmission	5	O
,	9	O
which	5	O
has	9	O
been	9	O
related	9	O
to	5	O
the	5	O
pathogenesis	9	O
of	5	O
these	5	O
complications	5	O
.	9	O

This	5	O
study	9	O
investigates	5	O
whether	9	O
polymorphisms	9	O
in	5	O
the	5	O
HOMER1	7	O
gene	1	O
promoter	1	O
region	9	O
are	5	O
associated	9	O
with	5	O
the	5	O
occurrence	5	O
of	5	O
the	5	O
chronic	5	O
complications	5	O
of	5	O
levodopa	5	B-Chemical
therapy	5	O
.	9	O

A	9	O
total	9	O
of	5	O
205	7	O
patients	5	O
with	5	O
idiopathic	5	B-Disease
Parkinson	5	I-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
were	9	O
investigated	9	O
.	9	O

Patients	5	O
were	9	O
genotyped	9	O
for	5	O
rs4704559	_	O
,	9	O
rs10942891	_	O
and	5	O
rs4704560	_	O
by	9	O
allelic	9	O
discrimination	5	O
with	5	O
Taqman	9	O
assays	3	O
.	9	O

The	5	O
rs4704559	_	O
G	9	O
allele	1	O
was	9	O
associated	9	O
with	5	O
a	5	O
lower	9	O
prevalence	5	O
of	5	O
dyskinesia	5	B-Disease
(	9	O
prevalence	5	O
ratio	9	O
(	9	O
PR	9	O
)	9	O
=	7	O
0	7	O
.	9	O
615	7	O
,	9	O
95	7	O
%	9	O
confidence	5	O
interval	5	O
(	9	O
CI	7	O
)	9	O
0	7	O
.	9	O
426	7	O
-	7	O
0	7	O
.	9	O
887	7	O
,	9	O
P	9	O
=	7	O
0	7	O
.	9	O
009	2	O
)	9	O
and	5	O
visual	5	B-Disease
hallucinations	5	I-Disease
(	9	O
PR	9	O
=	7	O
0	7	O
.	9	O
515	7	O
,	9	O
95	7	O
%	9	O
CI	7	O
0	7	O
.	9	O
295	7	O
-	7	O
0	7	O
.	9	O
899	7	O
,	9	O
P	9	O
=	7	O
0	7	O
.	9	O
020	2	O
)	9	O
.	9	O

Our	9	O
data	5	O
suggest	9	O
that	5	O
HOMER1	7	O
rs4704559	_	O
G	9	O
allele	1	O
has	9	O
a	5	O
protective	9	O
role	9	O
for	5	O
the	5	O
development	9	O
of	5	O
levodopa	5	B-Chemical
adverse	5	O
effects	9	O
.	9	O

Crocin	0	B-Chemical
improves	5	O
lipid	0	O
dysregulation	9	O
in	5	O
subacute	5	O
diazinon	0	B-Chemical
exposure	9	O
through	9	O
ERK1	3	O
/	9	O
2	9	O
pathway	3	O
in	5	O
rat	3	O
liver	9	O
.	9	O

INTRODUCTION	5	O
:	9	O
Diazinon	7	B-Chemical
Yis	5	O
one	5	O
of	5	O
the	5	O
most	9	O
broadly	5	O
used	5	O
organophosphorus	0	B-Chemical
insecticides	5	O
in	5	O
agriculture	5	O
.	9	O

It	5	O
has	9	O
been	9	O
shown	9	O
that	5	O
exposure	9	O
to	5	O
diazinon	0	B-Chemical
may	5	O
interfere	9	O
with	5	O
lipid	0	O
metabolism	9	O
.	9	O

Moreover	9	O
,	9	O
the	5	O
hypolipidemic	0	O
effect	9	O
of	5	O
crocin	0	B-Chemical
has	9	O
been	9	O
established	9	O
.	9	O

Earlier	9	O
studies	9	O
revealed	9	O
the	5	O
major	9	O
role	9	O
of	5	O
Extracellular	0	O
signal	9	O
-	7	O
regulated	3	O
kinase	3	O
(	9	O
ERK	3	O
)	9	O
pathways	9	O
in	5	O
low	9	O
-	7	O
density	9	O
lipoprotein	9	O
receptor	3	O
(	9	O
LDLr	3	O
)	9	O
expression	3	O
.	9	O

The	5	O
aim	5	O
of	5	O
this	5	O
study	9	O
was	9	O
to	5	O
evaluate	9	O
changes	9	O
in	5	O
the	5	O
regulation	9	O
of	5	O
lipid	0	O
metabolism	9	O
,	9	O
ERK	3	O
and	5	O
LDLr	3	O
expression	3	O
in	5	O
the	5	O
liver	9	O
of	5	O
rats	9	O
exposed	9	O
to	5	O
subacute	5	O
diazinon	0	B-Chemical
.	9	O

Furthermore	9	O
ameliorating	9	O
effect	9	O
of	5	O
crocin	0	B-Chemical
on	5	O
diazinon	0	B-Chemical
induced	3	O
disturbed	5	O
cholesterol	0	B-Chemical
homeostasis	9	O
was	9	O
studied	9	O
.	9	O

METHODS	2	O
:	9	O
24	9	O
Rats	9	O
were	9	O
divided	5	O
into	9	O
4	9	O
groups	9	O
and	5	O
received	9	O
following	9	O
treatments	9	O
for	5	O
4	9	O
weeks	9	O
;	9	O
Corn	0	O
oil	0	O
(	9	O
control	9	O
)	9	O
,	9	O
diazinon	0	B-Chemical
(	9	O
15mg	0	O
/	9	O
kg	0	O
per	9	O
day	9	O
,	9	O
orally	0	O
)	9	O
and	5	O
crocin	0	B-Chemical
(	9	O
12	9	O
.	9	O
5	9	O
and	5	O
25mg	0	O
/	9	O
kg	0	O
per	9	O
day	9	O
,	9	O
intraperitoneally	0	O
)	9	O
in	5	O
combination	9	O
with	5	O
diazinon	0	B-Chemical
(	9	O
15	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
.	9	O

The	5	O
levels	3	O
of	5	O
cholesterol	0	B-Chemical
,	9	O
triglyceride	0	B-Chemical
and	5	O
LDL	0	O
in	5	O
blood	9	O
of	5	O
rats	9	O
were	9	O
analyzed	9	O
.	9	O

Moreover	9	O
mRNA	3	O
levels	3	O
of	5	O
LDLr	3	O
and	5	O
ERK1	3	O
/	9	O
2	9	O
as	5	O
well	9	O
as	5	O
protein	1	O
levels	3	O
of	5	O
total	9	O
and	5	O
activated	3	O
forms	9	O
of	5	O
ERK1	3	O
/	9	O
2	9	O
in	5	O
rat	3	O
liver	9	O
were	9	O
evaluated	9	O
by	9	O
Western	3	O
blotting	3	O
and	5	O
quantitative	9	O
real	5	O
time	5	O
polymerase	1	O
chain	9	O
reaction	9	O
analysis	9	O
.	9	O

RESULTS	9	O
:	9	O
Our	9	O
data	5	O
showed	9	O
that	5	O
subacute	5	O
exposure	9	O
to	5	O
diazinon	0	B-Chemical
significantly	9	O
increased	9	O
concentrations	0	O
of	5	O
cholesterol	0	B-Chemical
,	9	O
triglyceride	0	B-Chemical
and	5	O
LDL	0	O
.	9	O

Moreover	9	O
diazinon	0	B-Chemical
decreased	9	O
ERK1	3	O
/	9	O
2	9	O
protein	1	O
phosphorylation	3	O
and	5	O
LDLr	3	O
transcript	1	O
.	9	O

Crocin	0	B-Chemical
reduced	9	O
inhibition	3	O
of	5	O
ERK	3	O
activation	3	O
and	5	O
diazinon	0	B-Chemical
-	7	O
induced	3	O
hyperlipemia	9	B-Disease
and	5	O
increased	9	O
levels	3	O
of	5	O
LDLr	3	O
transcript	1	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Crocin	0	B-Chemical
may	5	O
be	5	O
considered	5	O
as	5	O
a	5	O
novel	9	O
protective	9	O
agent	9	O
in	5	O
diazinon	0	B-Chemical
-	7	O
induced	3	O
hyperlipemia	9	B-Disease
through	9	O
modulating	9	O
of	5	O
ERK	3	O
pathway	3	O
and	5	O
increase	9	O
of	5	O
LDLr	3	O
expression	3	O
.	9	O

GEM	9	B-Chemical
-	7	O
P	9	O
chemotherapy	5	O
is	5	O
active	9	O
in	5	O
the	5	O
treatment	9	O
of	5	O
relapsed	5	O
Hodgkin	5	B-Disease
lymphoma	9	I-Disease
.	9	O

Hodgkin	5	B-Disease
lymphoma	9	I-Disease
(	9	O
HL	9	B-Disease
)	9	O
is	5	O
a	5	O
relatively	5	O
chemosensitive	5	O
malignancy	5	B-Disease
.	9	O

However	9	O
,	9	O
for	5	O
those	5	O
who	5	O
relapse	5	O
,	9	O
high	9	O
-	7	O
dose	9	O
chemotherapy	5	O
with	5	O
autologous	3	O
stem	3	O
cell	3	O
transplant	9	O
is	5	O
the	5	O
treatment	9	O
of	5	O
choice	5	O
which	5	O
relies	5	O
on	5	O
adequate	5	O
disease	5	O
control	9	O
with	5	O
salvage	5	O
chemotherapy	5	O
.	9	O

Regimens	5	O
commonly	5	O
used	5	O
often	5	O
require	5	O
inpatient	5	O
administration	9	O
and	5	O
can	5	O
be	5	O
difficult	5	O
to	5	O
deliver	5	O
due	5	O
to	5	O
toxicity	9	B-Disease
.	9	O

Gemcitabine	0	B-Chemical
and	5	O
cisplatin	3	B-Chemical
have	5	O
activity	9	O
in	5	O
HL	9	B-Disease
,	9	O
non	9	O
-	7	O
overlapping	9	O
toxicity	9	B-Disease
with	5	O
first	9	O
-	7	O
line	9	O
chemotherapeutics	3	O
,	9	O
and	5	O
may	5	O
be	5	O
delivered	5	O
in	5	O
an	5	O
outpatient	5	O
setting	5	O
.	9	O

In	9	O
this	5	O
retrospective	5	O
single	9	O
-	7	O
centre	5	O
analysis	9	O
,	9	O
patients	5	O
with	5	O
relapsed	5	O
or	5	O
refractory	9	O
HL	9	B-Disease
treated	3	O
with	5	O
gemcitabine	3	B-Chemical
1	9	O
,	9	O
000	9	O
mg	0	O
/	9	O
m	9	O
(	9	O
2	9	O
)	9	O
day	9	O
(	9	O
D	9	O
)	9	O
1	9	O
,	9	O
D8	9	O
and	5	O
D15	7	O
;	9	O
methylprednisolone	0	B-Chemical
1	9	O
,	9	O
000	9	O
mg	0	O
D1	3	O
-	7	O
5	9	O
;	9	O
and	5	O
cisplatin	3	B-Chemical
100	0	O
mg	0	O
/	9	O
m	9	O
(	9	O
2	9	O
)	9	O
D15	7	O
,	9	O
every	5	O
28	7	O
days	9	O
(	9	O
GEM	9	B-Chemical
-	7	O
P	9	O
)	9	O
were	9	O
included	5	O
.	9	O

Demographic	5	O
,	9	O
survival	9	O
,	9	O
response	9	O
and	5	O
toxicity	9	B-Disease
data	5	O
were	9	O
recorded	5	O
.	9	O

Forty	9	O
-	7	O
one	5	O
eligible	5	O
patients	5	O
were	9	O
identified	9	O
:	9	O
median	9	O
age	5	O
27	7	O
.	9	O

One	5	O
hundred	5	O
and	5	O
twenty	5	O
-	7	O
two	5	O
cycles	9	O
of	5	O
GEM	9	B-Chemical
-	7	O
P	9	O
were	9	O
administered	9	O
in	5	O
total	9	O
(	9	O
median	9	O
3	9	O
cycles	9	O
;	9	O
range	9	O
1	9	O
-	7	O
6	9	O
)	9	O
.	9	O

Twenty	9	O
of	5	O
41	7	O
(	9	O
48	9	O
%	9	O
)	9	O
patients	5	O
received	9	O
GEM	9	B-Chemical
-	7	O
P	9	O
as	5	O
second	9	O
-	7	O
line	9	O
treatment	9	O
and	5	O
11	7	O
/	9	O
41	7	O
(	9	O
27	7	O
%	9	O
)	9	O
as	5	O
third	9	O
-	7	O
line	9	O
therapy	5	O
.	9	O

Overall	9	O
response	9	O
rate	9	O
(	9	O
ORR	9	O
)	9	O
to	5	O
GEM	9	B-Chemical
-	7	O
P	9	O
in	5	O
the	5	O
entire	9	O
cohort	9	O
was	9	O
80	9	O
%	9	O
(	9	O
complete	9	O
response	9	O
(	9	O
CR	9	O
)	9	O
37	9	O
%	9	O
,	9	O
partial	9	O
response	9	O
44	7	O
%	9	O
)	9	O
with	5	O
14	7	O
/	9	O
15	9	O
CR	9	O
confirmed	9	O
as	5	O
a	5	O
metabolic	9	O
CR	9	O
on	5	O
PET	5	O
and	5	O
ORR	9	O
of	5	O
85	9	O
%	9	O
in	5	O
the	5	O
20	9	O
second	9	O
-	7	O
line	9	O
patients	5	O
.	9	O

The	5	O
most	9	O
common	5	O
grade	9	O
3	9	O
/	9	O
4	9	O
toxicities	5	B-Disease
were	9	O
haematological	5	O
:	9	O
neutropenia	5	B-Disease
54	7	O
%	9	O
and	5	O
thrombocytopenia	9	B-Disease
51	7	O
%	9	O
.	9	O

Median	7	O
follow	5	O
-	7	O
up	5	O
from	9	O
the	5	O
start	9	O
of	5	O
GEM	9	B-Chemical
-	7	O
P	9	O
was	9	O
4	9	O
.	9	O
5	9	O
years	5	O
.	9	O

Following	9	O
GEM	9	B-Chemical
-	7	O
P	9	O
,	9	O
5	9	O
-	7	O
year	5	O
progression	9	O
-	7	O
free	9	O
survival	9	O
was	9	O
46	7	O
%	9	O
(	9	O
95	7	O
%	9	O
confidence	5	O
interval	5	O
(	9	O
CI	7	O
)	9	O
,	9	O
30	9	O
-	7	O
62	7	O
%	9	O
)	9	O
and	5	O
5	9	O
-	7	O
year	5	O
overall	5	O
survival	9	O
was	9	O
59	7	O
%	9	O
(	9	O
95	7	O
%	9	O
CI	7	O
,	9	O
43	7	O
-	7	O
74	7	O
%	9	O
)	9	O
.	9	O

Fourteen	9	O
of	5	O
41	7	O
patients	5	O
proceeded	9	O
directly	9	O
to	5	O
autologous	3	O
transplant	9	O
.	9	O

GEM	9	B-Chemical
-	7	O
P	9	O
is	5	O
a	5	O
salvage	5	O
chemotherapy	5	O
with	5	O
relatively	5	O
high	9	O
response	9	O
rates	5	O
,	9	O
leading	9	O
to	5	O
successful	5	O
transplantation	9	O
in	5	O
appropriate	5	O
patients	5	O
,	9	O
in	5	O
the	5	O
treatment	9	O
of	5	O
relapsed	5	O
or	5	O
refractory	9	O
HL	9	B-Disease
.	9	O

Basal	9	O
functioning	5	O
of	5	O
the	5	O
hypothalamic	3	O
-	7	O
pituitary	3	O
-	7	O
adrenal	9	O
(	9	O
HPA	9	O
)	9	O
axis	5	O
and	5	O
psychological	5	O
distress	5	O
in	5	O
recreational	5	O
ecstasy	5	B-Chemical
polydrug	5	O
users	5	O
.	9	O

RATIONALE	2	O
:	9	O
Ecstasy	7	B-Chemical
(	9	O
MDMA	5	B-Chemical
)	9	O
is	5	O
a	5	O
psychostimulant	5	O
drug	5	O
which	5	O
is	5	O
increasingly	5	O
associated	9	O
with	5	O
psychobiological	5	B-Disease
dysfunction	9	I-Disease
.	9	O

While	9	O
some	5	O
recent	5	O
studies	9	O
suggest	9	O
acute	9	O
changes	9	O
in	5	O
neuroendocrine	5	O
function	9	O
,	9	O
less	5	O
is	5	O
known	9	O
about	5	O
long	5	O
-	7	O
term	5	O
changes	9	O
in	5	O
HPA	9	O
functionality	9	O
in	5	O
recreational	5	O
users	5	O
.	9	O

OBJECTIVES	2	O
:	9	O
The	5	O
current	5	O
study	9	O
is	5	O
the	5	O
first	9	O
to	5	O
explore	5	O
the	5	O
effects	9	O
of	5	O
ecstasy	5	B-Chemical
-	7	O
polydrug	5	O
use	5	O
on	5	O
psychological	5	O
distress	5	O
and	5	O
basal	3	O
functioning	5	O
of	5	O
the	5	O
HPA	9	O
axis	5	O
through	9	O
assessing	5	O
the	5	O
secretion	3	O
of	5	O
cortisol	5	B-Chemical
across	5	O
the	5	O
diurnal	9	O
period	5	O
.	9	O

METHOD	2	O
:	9	O
Seventy	5	O
-	7	O
six	9	O
participants	5	O
(	9	O
21	7	O
nonusers	5	O
,	9	O
29	7	O
light	9	O
ecstasy	5	B-Chemical
-	7	O
polydrug	5	O
users	5	O
,	9	O
26	7	O
heavy	9	O
ecstasy	5	B-Chemical
-	7	O
polydrug	5	O
users	5	O
)	9	O
completed	5	O
a	5	O
substance	5	O
use	5	O
inventory	5	O
and	5	O
measures	5	O
of	5	O
psychological	5	O
distress	5	O
at	9	O
baseline	5	O
,	9	O
then	9	O
two	5	O
consecutive	5	O
days	9	O
of	5	O
cortisol	5	B-Chemical
sampling	5	O
(	9	O
on	5	O
awakening	5	O
,	9	O
30	9	O
min	0	O
post	9	O
awakening	5	O
,	9	O
between	5	O
1400	9	O
and	5	O
1600	9	O
hours	9	O
and	5	O
pre	9	O
bedtime	5	O
)	9	O
.	9	O

On	5	O
day	9	O
2	9	O
,	9	O
participants	5	O
also	9	O
attended	5	O
the	5	O
laboratory	9	O
to	5	O
complete	9	O
a	5	O
20	9	O
-	7	O
min	0	O
multitasking	5	O
stressor	5	O
.	9	O

RESULTS	9	O
:	9	O
Both	9	O
user	5	O
groups	9	O
exhibited	9	O
significantly	9	O
greater	5	O
levels	3	O
of	5	O
anxiety	5	B-Disease
and	5	O
depression	5	B-Disease
than	5	O
nonusers	5	O
.	9	O

On	5	O
day	9	O
1	9	O
,	9	O
all	5	O
participants	5	O
exhibited	9	O
a	5	O
typical	9	O
cortisol	5	B-Chemical
profile	9	O
,	9	O
though	9	O
light	9	O
users	5	O
had	9	O
significantly	9	O
elevated	9	O
levels	3	O
pre	9	O
-	7	O
bed	5	O
.	9	O

On	5	O
day	9	O
2	9	O
,	9	O
heavy	9	O
users	5	O
demonstrated	9	O
elevated	9	O
levels	3	O
upon	9	O
awakening	5	O
and	5	O
all	5	O
ecstasy	5	B-Chemical
-	7	O
polydrug	5	O
users	5	O
demonstrated	9	O
elevated	9	O
pre	9	O
-	7	O
bed	5	O
levels	3	O
compared	9	O
to	5	O
non	9	O
-	7	O
users	5	O
.	9	O

Significant	9	O
between	5	O
group	9	O
differences	9	O
were	9	O
also	9	O
observed	9	O
in	5	O
afternoon	5	O
cortisol	5	B-Chemical
levels	3	O
and	5	O
in	5	O
overall	5	O
cortisol	5	B-Chemical
secretion	3	O
across	5	O
the	5	O
day	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
The	5	O
increases	9	O
in	5	O
anxiety	5	B-Disease
and	5	O
depression	5	B-Disease
are	5	O
in	5	O
line	9	O
with	5	O
previous	9	O
observations	9	O
in	5	O
recreational	5	O
ecstasy	5	B-Chemical
-	7	O
polydrug	5	O
users	5	O
.	9	O

Dysregulated	3	O
diurnal	9	O
cortisol	5	B-Chemical
may	5	O
be	5	O
indicative	9	O
of	5	O
inappropriate	5	O
anticipation	5	O
of	5	O
forthcoming	5	O
demands	5	O
and	5	O
hypersecretion	9	O
may	5	O
lead	5	O
to	5	O
the	5	O
increased	9	O
psychological	5	O
and	5	O
physical	5	O
morbidity	5	O
associated	9	O
with	5	O
heavy	9	O
recreational	5	O
use	5	O
of	5	O
ecstasy	5	B-Chemical
.	9	O

Ifosfamide	0	B-Chemical
related	9	O
encephalopathy	5	B-Disease
:	9	O
the	5	O
need	5	O
for	5	O
a	5	O
timely	5	O
EEG	5	O
evaluation	5	O
.	9	O

BACKGROUND	2	O
:	9	O
Ifosfamide	0	B-Chemical
is	5	O
an	5	O
alkylating	0	O
agent	9	O
useful	5	O
in	5	O
the	5	O
treatment	9	O
of	5	O
a	5	O
wide	5	O
range	9	O
of	5	O
cancers	9	B-Disease
including	9	O
sarcomas	5	B-Disease
,	9	O
lymphoma	9	B-Disease
,	9	O
gynecologic	5	B-Disease
and	5	I-Disease
testicular	9	I-Disease
cancers	9	I-Disease
.	9	O

Encephalopathy	5	B-Disease
has	9	O
been	9	O
reported	9	O
in	5	O
10	9	O
-	7	O
40	9	O
%	9	O
of	5	O
patients	5	O
receiving	9	O
high	9	O
-	7	O
dose	9	O
IV	9	O
ifosfamide	0	B-Chemical
.	9	O

OBJECTIVE	2	O
:	9	O
To	9	O
highlight	5	O
the	5	O
role	9	O
of	5	O
electroencephalogram	5	O
(	9	O
EEG	5	O
)	9	O
in	5	O
the	5	O
early	9	O
detection	9	O
and	5	O
management	5	O
of	5	O
ifosfamide	0	B-Chemical
related	9	O
encephalopathy	5	B-Disease
.	9	O

METHODS	2	O
:	9	O
Retrospective	9	O
chart	5	O
review	5	O
including	9	O
clinical	5	O
data	5	O
and	5	O
EEG	5	O
recordings	5	O
was	9	O
done	9	O
on	5	O
five	9	O
patients	5	O
,	9	O
admitted	5	O
to	5	O
MD	9	O
Anderson	6	O
Cancer	2	B-Disease
Center	2	O
between	5	O
years	5	O
2009	2	O
and	5	O
2012	2	O
,	9	O
who	5	O
developed	5	O
ifosfamide	0	B-Chemical
related	9	O
acute	9	O
encephalopathy	5	B-Disease
.	9	O

RESULTS	9	O
:	9	O
All	9	O
five	9	O
patients	5	O
experienced	5	O
symptoms	5	O
of	5	O
encephalopathy	5	B-Disease
soon	5	O
after	9	O
(	9	O
within	9	O
12	9	O
h	0	O
-	7	O
2	9	O
days	9	O
)	9	O
receiving	9	O
ifosfamide	0	B-Chemical
.	9	O

Two	9	O
patients	5	O
developed	5	O
generalized	5	O
convulsions	5	B-Disease
while	9	O
one	5	O
patient	5	O
developed	5	O
continuous	5	O
non	9	B-Disease
-	7	I-Disease
convulsive	5	I-Disease
status	9	I-Disease
epilepticus	5	I-Disease
(	9	O
NCSE	5	B-Disease
)	9	O
that	5	O
required	9	O
ICU	5	O
admission	5	O
and	5	O
intubation	5	O
.	9	O

Initial	9	O
EEG	5	O
showed	9	O
epileptiform	5	O
discharges	5	O
in	5	O
three	9	O
patients	5	O
;	9	O
run	5	O
of	5	O
triphasic	5	O
waves	5	O
in	5	O
one	5	O
patient	5	O
and	5	O
moderate	9	O
degree	5	O
diffuse	5	O
generalized	5	O
slowing	5	O
.	9	O

Mixed	9	O
pattern	9	O
with	5	O
the	5	O
presence	9	O
of	5	O
both	9	O
sharps	5	O
and	5	O
triphasic	5	O
waves	5	O
were	9	O
also	9	O
noted	9	O
.	9	O

Repeat	9	O
EEGs	5	O
within	9	O
24	9	O
_	7	O
h	0	O
of	5	O
symptom	5	O
onset	5	O
showed	9	O
marked	9	O
improvement	5	O
that	5	O
was	9	O
correlated	9	O
with	5	O
clinical	5	O
improvement	5	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Severity	5	O
of	5	O
ifosfamide	0	B-Chemical
related	9	O
encephalopathy	5	B-Disease
correlates	9	O
with	5	O
EEG	5	O
changes	9	O
.	9	O

We	9	O
suggest	9	O
a	5	O
timely	5	O
EEG	5	O
evaluation	5	O
for	5	O
patients	5	O
receiving	9	O
ifosfamide	0	B-Chemical
who	5	O
develop	5	O
features	5	O
of	5	O
encephalopathy	5	B-Disease
.	9	O

Incidence	9	O
of	5	O
contrast	9	B-Chemical
-	7	O
induced	3	O
nephropathy	9	B-Disease
in	5	O
hospitalised	5	O
patients	5	O
with	5	O
cancer	3	B-Disease
.	9	O

OBJECTIVES	2	O
:	9	O
To	9	O
determine	9	O
the	5	O
frequency	5	O
of	5	O
and	5	O
possible	5	O
factors	9	O
related	9	O
to	5	O
contrast	9	B-Chemical
-	7	O
induced	3	O
nephropathy	9	B-Disease
(	9	O
CIN	9	O
)	9	O
in	5	O
hospitalised	5	O
patients	5	O
with	5	O
cancer	3	B-Disease
.	9	O

METHODS	2	O
:	9	O
Ninety	5	O
adult	9	O
patients	5	O
were	9	O
enrolled	5	O
.	9	O

Patients	5	O
with	5	O
risk	5	O
factors	9	O
for	5	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
were	9	O
excluded	9	O
.	9	O

Blood	9	O
samples	9	O
were	9	O
examined	9	O
the	5	O
day	9	O
before	9	O
contrast	9	B-Chemical
-	7	O
enhanced	3	O
computed	5	O
tomography	5	O
(	9	O
CT	9	O
)	9	O
and	5	O
serially	9	O
for	5	O
3	9	O
days	9	O
thereafter	9	O
.	9	O

CIN	9	O
was	9	O
defined	5	O
as	5	O
an	5	O
increase	9	O
in	5	O
serum	9	O
creatinine	0	B-Chemical
(	9	O
Cr	0	B-Chemical
)	9	O
of	5	O
0	7	O
.	9	O
5	9	O
mg	0	O
/	9	O
dl	7	O
or	5	O
more	5	O
,	9	O
or	5	O
elevation	9	O
of	5	O
Cr	0	B-Chemical
to	5	O
25	9	O
%	9	O
over	5	O
baseline	5	O
.	9	O

Relationships	5	O
between	5	O
CIN	9	O
and	5	O
possible	5	O
risk	5	O
factors	9	O
were	9	O
investigated	9	O
.	9	O

RESULTS	9	O
:	9	O
CIN	9	O
was	9	O
detected	9	O
in	5	O
18	7	O
/	9	O
90	9	O
(	9	O
20	9	O
%	9	O
)	9	O
patients	5	O
.	9	O

CIN	9	O
developed	5	O
in	5	O
25	9	O
.	9	O
5	9	O
%	9	O
patients	5	O
who	5	O
underwent	5	O
chemotherapy	5	O
and	5	O
in	5	O
11	7	O
%	9	O
patients	5	O
who	5	O
did	9	O
not	5	O
(	9	O
P	9	O
=	7	O
0	7	O
.	9	O
1	9	O
)	9	O
.	9	O

CIN	9	O
more	5	O
frequently	5	O
developed	5	O
in	5	O
patients	5	O
who	5	O
had	9	O
undergone	5	O
CT	9	O
within	9	O
45	9	O
days	9	O
after	9	O
the	5	O
last	5	O
chemotherapy	5	O
(	9	O
P	9	O
=	7	O
0	7	O
.	9	O
005	7	O
)	9	O
;	9	O
it	5	O
was	9	O
also	9	O
an	5	O
independent	9	O
risk	5	O
factor	9	O
(	9	O
P	9	O
=	7	O
0	7	O
.	9	O
017	7	O
)	9	O
.	9	O

CIN	9	O
was	9	O
significantly	9	O
more	5	O
after	9	O
treatment	9	O
with	5	O
bevacizumab	9	B-Chemical
/	9	O
irinotecan	0	B-Chemical
(	9	O
P	9	O
=	7	O
0	7	O
.	9	O
021	7	O
)	9	O
and	5	O
in	5	O
patients	5	O
with	5	O
hypertension	5	B-Disease
(	9	O
P	9	O
=	7	O
0	7	O
.	9	O
044	7	O
)	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
The	5	O
incidence	5	O
of	5	O
CIN	9	O
after	9	O
CT	9	O
in	5	O
hospitalised	5	O
oncological	5	O
patients	5	O
was	9	O
20	9	O
%	9	O
.	9	O

CIN	9	O
developed	5	O
4	9	O
.	9	O
5	9	O
-	7	O
times	5	O
more	5	O
frequently	5	O
in	5	O
patients	5	O
with	5	O
cancer	3	B-Disease
who	5	O
had	9	O
undergone	5	O
recent	5	O
chemotherapy	5	O
.	9	O

Hypertension	7	B-Disease
and	5	O
the	5	O
combination	9	O
of	5	O
bevacizumab	9	B-Chemical
/	9	O
irinotecan	0	B-Chemical
may	5	O
be	5	O
additional	9	O
risk	5	O
factors	9	O
for	5	O
CIN	9	O
development	9	O
.	9	O

KEY	2	O
POINTS	2	O
:	9	O
.	9	O

Contrast	5	B-Chemical
-	7	O
induced	3	O
nephropathy	9	B-Disease
(	9	O
CIN	9	O
)	9	O
is	5	O
a	5	O
concern	5	O
for	5	O
oncological	5	O
patients	5	O
undergoing	9	O
CT	9	O
.	9	O

.	9	O
CIN	9	O
occurs	9	O
more	5	O
often	5	O
when	5	O
CT	9	O
is	5	O
performed	9	O
<	0	O
45	9	O
days	9	O
after	9	O
chemotherapy	5	O
.	9	O

.	9	O
Hypertension	7	B-Disease
and	5	O
treatment	9	O
with	5	O
bevacizumab	9	B-Chemical
appear	9	O
to	5	O
be	5	O
additional	9	O
risk	5	O
factors	9	O
.	9	O

Syndrome	5	B-Disease
of	5	I-Disease
inappropriate	5	I-Disease
antidiuretic	5	I-Disease
hormone	9	I-Disease
secretion	3	O
associated	9	O
with	5	O
desvenlafaxine	5	B-Chemical
.	9	O

OBJECTIVE	2	O
:	9	O
To	9	O
report	5	O
a	5	O
case	5	O
of	5	O
syndrome	5	B-Disease
of	5	I-Disease
inappropriate	5	I-Disease
anti	3	I-Disease
-	7	I-Disease
diuretic	5	I-Disease
hormone	9	I-Disease
(	9	O
SIADH	5	B-Disease
)	9	O
secretion	3	O
associated	9	O
with	5	O
desvenlafaxine	5	B-Chemical
.	9	O

CASE	2	O
SUMMARY	9	O
:	9	O
A	9	O
57	7	O
-	7	O
year	5	O
old	5	O
female	9	O
with	5	O
hyponatraemia	5	B-Disease
.	9	O

Her	5	O
medications	5	O
included	5	O
desvenlafaxine	5	B-Chemical
,	9	O
and	5	O
symptoms	5	O
included	5	O
nausea	5	B-Disease
,	9	O
anxiety	5	B-Disease
and	5	O
confusion	5	B-Disease
.	9	O

The	5	O
serum	9	O
sodium	0	B-Chemical
at	9	O
this	5	O
time	5	O
was	9	O
120	9	O
mmol	0	O
/	9	O
L	0	O
,	9	O
serum	9	O
osmolality	0	O
was	9	O
263	7	O
mosmol	0	O
/	9	O
kg	0	O
,	9	O
urine	9	O
osmolality	0	O
410	9	O
mosmol	0	O
/	9	O
kg	0	O
and	5	O
urine	9	O
sodium	0	B-Chemical
63	7	O
mmol	0	O
/	9	O
L	0	O
,	9	O
consistent	9	O
with	5	O
a	5	O
diagnosis	5	O
of	5	O
SIADH	5	B-Disease
.	9	O

Desvenlafaxine	7	B-Chemical
was	9	O
ceased	5	O
and	5	O
fluid	5	O
restriction	9	O
implemented	5	O
.	9	O

After	9	O
4	9	O
days	9	O
the	5	O
sodium	0	B-Chemical
increased	9	O
to	5	O
128	9	O
mmol	0	O
/	9	O
L	0	O
and	5	O
fluid	5	O
restriction	9	O
was	9	O
relaxed	5	O
.	9	O

During	5	O
her	5	O
further	9	O
3	9	O
weeks	9	O
inpatient	5	O
admission	5	O
the	5	O
serum	9	O
sodium	0	B-Chemical
ranged	9	O
from	9	O
134	7	O
to	5	O
137	7	O
mmol	0	O
/	9	O
L	0	O
during	5	O
treatment	9	O
with	5	O
mirtazapine	5	B-Chemical
.	9	O

DISCUSSION	9	O
:	9	O
SIADH	5	B-Disease
has	9	O
been	9	O
widely	5	O
reported	9	O
with	5	O
a	5	O
range	9	O
of	5	O
antidepressants	5	O
.	9	O

This	5	O
case	5	O
report	5	O
suggests	9	O
that	5	O
desvenlafaxine	5	B-Chemical
might	9	O
cause	5	O
clinically	5	O
significant	9	O
hyponatremia	5	B-Disease
.	9	O

CONCLUSIONS	5	O
:	9	O
Clinicians	5	O
should	5	O
be	5	O
aware	5	O
of	5	O
the	5	O
potential	9	O
for	5	O
antidepressants	5	O
to	5	O
cause	5	O
hyponatremia	5	B-Disease
,	9	O
and	5	O
take	5	O
appropriate	5	O
corrective	5	O
action	5	O
where	5	O
necessary	5	O
.	9	O

Oxidative	9	O
stress	9	O
on	5	O
cardiotoxicity	9	B-Disease
after	9	O
treatment	9	O
with	5	O
single	9	O
and	5	O
multiple	5	O
doses	0	O
of	5	O
doxorubicin	0	B-Chemical
.	9	O

The	5	O
mechanism	9	O
of	5	O
doxorubicin	0	B-Chemical
(	9	O
DOX	0	B-Chemical
)	9	O
-	7	O
induced	3	O
cardiotoxicity	9	B-Disease
remains	9	O
controversial	9	O
.	9	O

Wistar	9	O
rats	9	O
(	9	O
n	9	O
=	7	O
66	7	O
)	9	O
received	9	O
DOX	0	B-Chemical
injections	9	O
intraperitoneally	0	O
and	5	O
were	9	O
randomly	5	O
assigned	5	O
to	5	O
2	9	O
experimental	5	O
protocols	5	O
:	9	O
(	9	O
1	9	O
)	9	O
rats	9	O
were	9	O
killed	9	O
before	9	O
(	9	O
-	7	O
24	9	O
h	0	O
,	9	O
n	9	O
=	7	O
8	9	O
)	9	O
and	5	O
24	9	O
h	0	O
after	9	O
(	9	O
+	9	O
24	9	O
h	0	O
,	9	O
n	9	O
=	7	O
8	9	O
)	9	O
a	5	O
single	9	O
dose	9	O
of	5	O
DOX	0	B-Chemical
(	9	O
4	9	O
mg	0	O
/	9	O
kg	0	O
body	5	O
weight	9	O
)	9	O
to	5	O
determine	9	O
the	5	O
DOX	0	B-Chemical
acute	9	O
effect	9	O
and	5	O
(	9	O
2	9	O
)	9	O
rats	9	O
(	9	O
n	9	O
=	7	O
58	7	O
)	9	O
received	9	O
4	9	O
injections	9	O
of	5	O
DOX	0	B-Chemical
(	9	O
4	9	O
mg	0	O
/	9	O
kg	0	O
body	5	O
weight	9	O
/	9	O
week	9	O
)	9	O
and	5	O
were	9	O
killed	9	O
before	9	O
the	5	O
first	9	O
injection	9	O
(	9	O
M0	9	O
)	9	O
and	5	O
1	9	O
week	9	O
after	9	O
each	5	O
injection	9	O
(	9	O
M1	9	O
,	9	O
M2	9	O
,	9	O
M3	9	O
,	9	O
and	5	O
M4	9	O
)	9	O
to	5	O
determine	9	O
the	5	O
chronological	5	O
effects	9	O
.	9	O

Animals	9	O
used	5	O
at	9	O
M0	9	O
(	9	O
n	9	O
=	7	O
8	9	O
)	9	O
were	9	O
also	9	O
used	5	O
at	9	O
moment	5	O
-	7	O
24	9	O
h	0	O
of	5	O
acute	9	O
study	9	O
.	9	O

Cardiac	9	O
total	9	O
antioxidant	0	O
performance	5	O
(	9	O
TAP	9	O
)	9	O
,	9	O
DNA	9	O
damage	9	O
,	9	O
and	5	O
morphology	9	O
analyses	9	O
were	9	O
carried	9	O
out	9	O
at	9	O
each	5	O
time	5	O
point	5	O
.	9	O

Single	9	O
dose	9	O
of	5	O
DOX	0	B-Chemical
was	9	O
associated	9	O
with	5	O
increased	9	O
cardiac	5	B-Disease
disarrangement	5	I-Disease
,	9	O
necrosis	9	B-Disease
,	9	O
and	5	O
DNA	9	O
damage	9	O
(	9	O
strand	1	O
breaks	5	O
(	9	O
SBs	5	O
)	9	O
and	5	O
oxidized	0	O
pyrimidines	0	O
)	9	O
and	5	O
decreased	9	O
TAP	9	O
.	9	O

The	5	O
chronological	5	O
study	9	O
showed	9	O
an	5	O
effect	9	O
of	5	O
a	5	O
cumulative	5	O
dose	9	O
on	5	O
body	5	O
weight	9	O
(	9	O
R	9	O
=	7	O
-	7	O
0	7	O
.	9	O
99	7	O
,	9	O
p	7	O
=	7	O
0	7	O
.	9	O
011	2	O
)	9	O
,	9	O
necrosis	9	B-Disease
(	9	O
R	9	O
=	7	O
1	9	O
.	9	O
00	7	O
,	9	O
p	7	O
=	7	O
0	7	O
.	9	O
004	7	O
)	9	O
,	9	O
TAP	9	O
(	9	O
R	9	O
=	7	O
0	7	O
.	9	O
95	7	O
,	9	O
p	7	O
=	7	O
0	7	O
.	9	O
049	7	O
)	9	O
,	9	O
and	5	O
DNA	9	O
SBs	5	O
(	9	O
R	9	O
=	7	O
-	7	O
0	7	O
.	9	O
95	7	O
,	9	O
p	7	O
=	7	O
0	7	O
.	9	O
049	7	O
)	9	O
.	9	O

DNA	9	O
SBs	5	O
damage	9	O
was	9	O
negatively	9	O
associated	9	O
with	5	O
TAP	9	O
(	9	O
R	9	O
=	7	O
-	7	O
0	7	O
.	9	O
98	7	O
,	9	O
p	7	O
=	7	O
0	7	O
.	9	O
018	7	O
)	9	O
,	9	O
and	5	O
necrosis	9	B-Disease
(	9	O
R	9	O
=	7	O
-	7	O
0	7	O
.	9	O
97	7	O
,	9	O
p	7	O
=	7	O
0	7	O
.	9	O
027	9	O
)	9	O
.	9	O

Our	9	O
results	9	O
suggest	9	O
that	5	O
oxidative	9	O
damage	9	O
is	5	O
associated	9	O
with	5	O
acute	9	O
cardiotoxicity	9	B-Disease
induced	3	O
by	9	O
a	5	O
single	9	O
dose	9	O
of	5	O
DOX	0	B-Chemical
only	9	O
.	9	O

Increased	9	O
resistance	9	O
to	5	O
the	5	O
oxidative	9	O
stress	9	O
is	5	O
plausible	5	O
for	5	O
the	5	O
multiple	5	O
dose	9	O
of	5	O
DOX	0	B-Chemical
.	9	O

Thus	9	O
,	9	O
different	9	O
mechanisms	9	O
may	5	O
be	5	O
involved	9	O
in	5	O
acute	9	O
toxicity	9	B-Disease
versus	9	O
chronic	5	O
toxicity	9	B-Disease
.	9	O

Tacrolimus	0	B-Chemical
-	7	O
related	9	O
seizure	5	B-Disease
after	9	O
pediatric	5	O
liver	9	O
transplantation	9	O
-	7	O
-	7	O
a	5	O
single	9	O
-	7	O
center	5	O
experience	5	O
.	9	O

To	9	O
identify	9	O
the	5	O
risk	5	O
factors	9	O
for	5	O
new	5	O
-	7	O
onset	5	O
seizures	5	B-Disease
after	9	O
pediatric	5	O
LT	9	O
and	5	O
to	5	O
assess	5	O
their	5	O
clinical	5	O
implications	5	O
and	5	O
long	5	O
-	7	O
term	5	O
prognosis	5	O
.	9	O

The	5	O
clinical	5	O
and	5	O
laboratory	9	O
data	5	O
of	5	O
27	7	O
consecutive	5	O
children	5	O
who	5	O
underwent	5	O
LT	9	O
from	9	O
January	2	O
2007	2	O
to	5	O
December	2	O
2010	2	O
in	5	O
our	5	O
center	5	O
were	9	O
analyzed	9	O
retrospectively	5	O
.	9	O

Patients	5	O
were	9	O
divided	5	O
into	9	O
seizures	5	B-Disease
group	9	O
and	5	O
a	5	O
non	9	O
-	7	O
seizures	5	B-Disease
group	9	O
.	9	O

Pre	9	O
-	7	O
operative	5	O
,	9	O
intra	5	O
-	7	O
operative	5	O
,	9	O
and	5	O
post	9	O
-	7	O
operative	5	O
data	5	O
were	9	O
collected	9	O
.	9	O

Seizures	5	B-Disease
occurred	9	O
in	5	O
four	9	O
children	5	O
,	9	O
an	5	O
incidence	5	O
of	5	O
14	7	O
.	9	O
8	9	O
%	9	O
.	9	O

All	9	O
exhibited	9	O
generalized	5	O
tonic	5	B-Disease
-	7	I-Disease
clonic	5	I-Disease
seizures	5	I-Disease
within	9	O
the	5	O
first	9	O
two	5	O
wk	9	O
after	9	O
LT	9	O
.	9	O

Univariate	5	O
analysis	9	O
showed	9	O
that	5	O
the	5	O
risk	5	O
factors	9	O
associated	9	O
with	5	O
seizures	5	B-Disease
after	9	O
pediatric	5	O
LT	9	O
included	5	O
gender	5	O
,	9	O
pediatric	5	O
end	9	B-Disease
-	7	I-Disease
stage	9	I-Disease
liver	9	I-Disease
disease	5	I-Disease
score	5	O
before	9	O
surgery	5	O
,	9	O
Child	5	O
-	7	O
Pugh	6	O
score	5	O
before	9	O
surgery	5	O
,	9	O
serum	9	O
total	9	O
bilirubin	0	B-Chemical
after	9	O
surgery	5	O
,	9	O
and	5	O
trough	9	O
TAC	9	B-Chemical
level	9	O
.	9	O

Multivariate	5	O
analysis	9	O
showed	9	O
that	5	O
trough	9	O
TAC	9	B-Chemical
level	9	O
was	9	O
the	5	O
only	9	O
independent	9	O
risk	5	O
factor	9	O
associated	9	O
with	5	O
the	5	O
seizures	5	B-Disease
.	9	O

All	9	O
children	5	O
who	5	O
experienced	5	O
seizures	5	B-Disease
survived	9	O
with	5	O
good	5	O
graft	5	O
function	9	O
and	5	O
remained	9	O
seizure	5	B-Disease
-	7	O
free	9	O
without	9	O
anti	3	O
-	7	O
epileptic	5	B-Disease
drugs	5	O
over	5	O
a	5	O
mean	5	O
follow	5	O
-	7	O
up	5	O
period	5	O
of	5	O
33	7	O
.	9	O
7	9	O
+	9	O
14	7	O
.	9	O
6	9	O
months	5	O
.	9	O

High	9	O
trough	9	O
TAC	9	B-Chemical
level	9	O
was	9	O
the	5	O
predominant	9	O
factor	9	O
that	5	O
contributed	9	O
to	5	O
seizures	5	B-Disease
in	5	O
the	5	O
early	9	O
post	9	O
-	7	O
operative	5	O
period	5	O
after	9	O
pediatric	5	O
LT	9	O
.	9	O

High	9	O
PELD	5	O
and	5	O
Child	5	O
-	7	O
Pugh	6	O
scores	5	O
before	9	O
LT	9	O
and	5	O
high	9	O
post	9	O
-	7	O
operative	5	O
serum	9	O
Tbil	7	O
may	5	O
be	5	O
contributory	5	O
risk	5	O
factors	9	O
for	5	O
TAC	9	B-Chemical
-	7	O
related	9	O
seizures	5	B-Disease
.	9	O

The	5	O
flavonoid	0	B-Chemical
apigenin	0	B-Chemical
delays	5	O
forgetting	5	O
of	5	O
passive	5	O
avoidance	5	O
conditioning	5	O
in	5	O
rats	9	O
.	9	O

The	5	O
present	9	O
experiments	9	O
were	9	O
performed	9	O
to	5	O
study	9	O
the	5	O
effect	9	O
of	5	O
the	5	O
flavonoid	0	B-Chemical
apigenin	0	B-Chemical
(	9	O
20	9	O
mg	0	O
/	9	O
kg	0	O
intraperitoneally	0	O
(	9	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
,	9	O
1	9	O
h	0	O
before	9	O
acquisition	5	O
)	9	O
,	9	O
on	5	O
24	9	O
h	0	O
retention	9	O
performance	5	O
and	5	O
forgetting	5	O
of	5	O
a	5	O
step	9	O
-	7	O
through	9	O
passive	5	O
avoidance	5	O
task	5	O
,	9	O
in	5	O
young	5	O
male	9	O
Wistar	9	O
rats	9	O
.	9	O

There	5	O
were	9	O
no	9	O
differences	9	O
between	5	O
saline	0	O
-	7	O
and	5	O
apigenin	0	B-Chemical
-	7	O
treated	3	O
groups	9	O
in	5	O
the	5	O
24	9	O
h	0	O
retention	9	O
trial	5	O
.	9	O

Furthermore	9	O
,	9	O
apigenin	0	B-Chemical
did	9	O
not	5	O
prevent	5	O
the	5	O
amnesia	5	B-Disease
induced	3	O
by	9	O
scopolamine	0	B-Chemical
(	9	O
1mg	0	O
/	9	O
kg	0	O
,	9	O
i	9	O
.	9	O
p	7	O
.	9	O
,	9	O
30	9	O
min	0	O
before	9	O
the	5	O
acquisition	5	O
)	9	O
.	9	O

The	5	O
saline	0	O
-	7	O
and	5	O
apigenin	0	B-Chemical
-	7	O
treated	3	O
rats	9	O
that	5	O
did	9	O
not	5	O
step	9	O
through	9	O
into	9	O
the	5	O
dark	9	O
compartment	9	O
during	5	O
the	5	O
cut	9	O
-	7	O
off	5	O
time	5	O
(	9	O
540	9	O
s	9	O
)	9	O
were	9	O
retested	9	O
weekly	5	O
for	5	O
up	5	O
to	5	O
eight	9	O
weeks	9	O
.	9	O

In	9	O
the	5	O
saline	0	O
treated	3	O
group	9	O
,	9	O
the	5	O
first	9	O
significant	9	O
decline	9	O
in	5	O
passive	5	O
avoidance	5	O
response	9	O
was	9	O
observed	9	O
at	9	O
four	9	O
weeks	9	O
,	9	O
and	5	O
complete	9	O
memory	5	B-Disease
loss	9	I-Disease
was	9	O
found	9	O
five	9	O
weeks	9	O
after	9	O
the	5	O
acquisition	5	O
of	5	O
the	5	O
passive	5	O
avoidance	5	O
task	5	O
.	9	O

At	9	O
the	5	O
end	9	O
of	5	O
the	5	O
experimental	5	O
period	5	O
,	9	O
60	9	O
%	9	O
of	5	O
the	5	O
animals	9	O
treated	3	O
with	5	O
apigenin	0	B-Chemical
still	5	O
did	9	O
not	5	O
step	9	O
through	9	O
.	9	O

These	5	O
data	5	O
suggest	9	O
that	5	O
1	9	O
)	9	O
apigenin	0	B-Chemical
delays	5	O
the	5	O
long	5	O
-	7	O
term	5	O
forgetting	5	O
but	9	O
did	9	O
not	5	O
modulate	9	O
the	5	O
24	9	O
h	0	O
retention	9	O
of	5	O
fear	5	O
memory	5	O
and	5	O
2	9	O
)	9	O
the	5	O
obtained	9	O
beneficial	9	O
effect	9	O
of	5	O
apigenin	0	B-Chemical
on	5	O
the	5	O
passive	5	O
avoidance	5	O
conditioning	5	O
is	5	O
mediated	3	O
by	9	O
mechanisms	9	O
that	5	O
do	5	O
not	5	O
implicate	9	O
its	9	O
action	5	O
on	5	O
the	5	O
muscarinic	3	O
cholinergic	3	O
system	5	O
.	9	O

Histamine	0	B-Chemical
antagonists	3	O
and	5	O
d	9	B-Chemical
-	7	I-Chemical
tubocurarine	0	I-Chemical
-	7	O
induced	3	O
hypotension	5	B-Disease
in	5	O
cardiac	5	O
surgical	5	O
patients	5	O
.	9	O

Hemodynamic	5	O
effects	9	O
and	5	O
histamine	0	B-Chemical
release	9	O
by	9	O
bolus	0	O
injection	9	O
of	5	O
0	7	O
.	9	O
35	9	O
mg	0	O
/	9	O
kg	0	O
of	5	O
d	9	B-Chemical
-	7	I-Chemical
tubocurarine	0	I-Chemical
were	9	O
studied	9	O
in	5	O
24	9	O
patients	5	O
.	9	O

H1	9	O
-	7	O
and	5	O
H2	9	O
-	7	O
histamine	0	B-Chemical
antagonists	3	O
or	5	O
placebo	9	O
were	9	O
given	5	O
before	9	O
dosing	9	O
with	5	O
d	9	B-Chemical
-	7	I-Chemical
tubocurarine	0	I-Chemical
in	5	O
a	5	O
randomized	5	O
double	9	O
-	7	O
blind	5	O
fashion	5	O
to	5	O
four	9	O
groups	9	O
:	9	O
group	9	O
1	9	O
-	7	O
-	7	O
placebo	9	O
;	9	O
group	9	O
2	9	O
-	7	O
-	7	O
cimetidine	0	B-Chemical
,	9	O
4	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
plus	9	O
placebo	9	O
;	9	O
group	9	O
3	9	O
-	7	O
-	7	O
chlorpheniramine	0	B-Chemical
,	9	O
0	7	O
.	9	O
1	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
plus	9	O
placebo	9	O
;	9	O
and	5	O
group	9	O
4	9	O
-	7	O
-	7	O
cimetidine	0	B-Chemical
plus	9	O
chlorpheniramine	0	B-Chemical
.	9	O

Histamine	0	B-Chemical
release	9	O
occurred	9	O
in	5	O
most	9	O
patients	5	O
,	9	O
the	5	O
highest	9	O
level	9	O
2	9	O
minutes	0	O
after	9	O
d	9	B-Chemical
-	7	I-Chemical
tubocurarine	0	I-Chemical
dosing	9	O
.	9	O

Group	9	O
1	9	O
had	9	O
a	5	O
moderate	9	O
negative	9	O
correlation	9	O
between	5	O
plasma	9	O
histamine	0	B-Chemical
change	9	O
and	5	O
systemic	9	O
vascular	5	O
resistance	9	O
(	9	O
r	9	O
=	7	O
0	7	O
.	9	O
58	7	O
;	9	O
P	9	O
less	5	O
than	5	O
0	7	O
.	9	O
05	7	O
)	9	O
not	5	O
present	9	O
in	5	O
group	9	O
4	9	O
.	9	O

Prior	9	O
dosing	9	O
with	5	O
antagonists	3	O
partially	9	O
prevented	9	O
the	5	O
fall	5	O
in	5	O
systemic	9	O
vascular	5	O
resistance	9	O
.	9	O

These	5	O
data	5	O
demonstrate	9	O
that	5	O
the	5	O
hemodynamic	5	O
changes	9	O
associated	9	O
with	5	O
d	9	B-Chemical
-	7	I-Chemical
tubocurarine	0	I-Chemical
dosing	9	O
are	5	O
only	9	O
partially	9	O
explained	5	O
by	9	O
histamine	0	B-Chemical
release	9	O
.	9	O

Thus	9	O
prior	9	O
dosing	9	O
with	5	O
H1	9	O
-	7	O
and	5	O
H2	9	O
-	7	O
antagonists	3	O
provides	5	O
only	9	O
partial	9	O
protection	9	O
.	9	O

Cholecystokinin	7	B-Chemical
-	7	I-Chemical
octapeptide	0	I-Chemical
restored	3	O
morphine	0	B-Chemical
-	7	O
induced	3	O
hippocampal	3	O
long	5	O
-	7	O
term	5	O
potentiation	3	O
impairment	5	O
in	5	O
rats	9	O
.	9	O

Cholecystokinin	7	B-Chemical
-	7	I-Chemical
octapeptide	0	I-Chemical
(	9	O
CCK	3	B-Chemical
-	7	I-Chemical
8	9	I-Chemical
)	9	O
,	9	O
which	5	O
is	5	O
a	5	O
typical	9	O
brain	5	O
-	7	O
gut	9	O
peptide	9	O
,	9	O
exerts	9	O
a	5	O
wide	5	O
range	9	O
of	5	O
biological	5	O
activities	9	O
on	5	O
the	5	O
central	5	O
nervous	5	O
system	5	O
.	9	O

We	9	O
have	5	O
previously	9	O
reported	9	O
that	5	O
CCK	3	B-Chemical
-	7	I-Chemical
8	9	I-Chemical
significantly	9	O
alleviated	9	O
morphine	0	B-Chemical
-	7	O
induced	3	O
amnesia	5	B-Disease
and	5	O
reversed	9	O
spine	5	O
density	9	O
decreases	9	O
in	5	O
the	5	O
CA1	3	O
region	9	O
of	5	O
the	5	O
hippocampus	9	O
in	5	O
morphine	0	B-Chemical
-	7	O
treated	3	O
animals	9	O
.	9	O

Here	9	O
,	9	O
we	5	O
investigated	9	O
the	5	O
effects	9	O
of	5	O
CCK	3	B-Chemical
-	7	I-Chemical
8	9	I-Chemical
on	5	O
long	5	O
-	7	O
term	5	O
potentiation	3	O
(	9	O
LTP	3	O
)	9	O
in	5	O
the	5	O
lateral	5	O
perforant	5	O
path	5	O
(	9	O
LPP	9	O
)	9	O
-	7	O
granule	3	O
cell	3	O
synapse	5	O
of	5	O
rat	3	O
dentate	3	O
gyrus	5	O
(	9	O
DG	9	O
)	9	O
in	5	O
acute	9	O
saline	0	O
or	5	O
morphine	0	B-Chemical
-	7	O
treated	3	O
rats	9	O
.	9	O

Population	5	O
spikes	5	O
(	9	O
PS	9	O
)	9	O
,	9	O
which	5	O
were	9	O
evoked	5	O
by	9	O
stimulation	3	O
of	5	O
the	5	O
LPP	9	O
,	9	O
were	9	O
recorded	5	O
in	5	O
the	5	O
DG	9	O
region	9	O
.	9	O

Acute	5	O
morphine	0	B-Chemical
(	9	O
30mg	0	O
/	9	O
kg	0	O
,	9	O
s	9	O
.	9	O
c	9	O
.	9	O
)	9	O
treatment	9	O
significantly	9	O
attenuated	3	O
hippocampal	3	O
LTP	3	O
and	5	O
CCK	3	B-Chemical
-	7	I-Chemical
8	9	I-Chemical
(	9	O
1ug	3	O
,	9	O
i	9	O
.	9	O
c	9	O
.	9	O
v	0	O
.	9	O
)	9	O
restored	3	O
the	5	O
amplitude	5	O
of	5	O
PS	9	O
that	5	O
was	9	O
attenuated	3	O
by	9	O
morphine	0	B-Chemical
injection	9	O
.	9	O

Furthermore	9	O
,	9	O
microinjection	3	O
of	5	O
CCK	3	B-Chemical
-	7	I-Chemical
8	9	I-Chemical
(	9	O
0	7	O
.	9	O
1	9	O
and	5	O
1ug	3	O
,	9	O
i	9	O
.	9	O
c	9	O
.	9	O
v	0	O
.	9	O
)	9	O
also	9	O
significantly	9	O
augmented	9	O
hippocampal	3	O
LTP	3	O
in	5	O
saline	0	O
-	7	O
treated	3	O
(	9	O
1ml	0	O
/	9	O
kg	0	O
,	9	O
s	9	O
.	9	O
c	9	O
.	9	O
)	9	O
rats	9	O
.	9	O

Pre	9	O
-	7	O
treatment	9	O
of	5	O
the	5	O
CCK2	3	O
receptor	3	O
antagonist	3	O
L	0	O
-	7	O
365	9	O
,	9	O
260	9	O
(	9	O
10ug	3	O
,	9	O
i	9	O
.	9	O
c	9	O
.	9	O
v	0	O
)	9	O
reversed	9	O
the	5	O
effects	9	O
of	5	O
CCK	3	B-Chemical
-	7	I-Chemical
8	9	I-Chemical
,	9	O
but	9	O
the	5	O
CCK1	3	O
receptor	3	O
antagonist	3	O
L	0	O
-	7	O
364	7	O
,	9	O
718	7	O
(	9	O
10ug	3	O
,	9	O
i	9	O
.	9	O
c	9	O
.	9	O
v	0	O
)	9	O
did	9	O
not	5	O
.	9	O

The	5	O
present	9	O
results	9	O
demonstrate	9	O
that	5	O
CCK	3	B-Chemical
-	7	I-Chemical
8	9	I-Chemical
attenuates	3	O
the	5	O
effect	9	O
of	5	O
morphine	0	B-Chemical
on	5	O
hippocampal	3	O
LTP	3	O
through	9	O
CCK2	3	O
receptors	3	O
and	5	O
suggest	9	O
an	5	O
ameliorative	0	O
function	9	O
of	5	O
CCK	3	B-Chemical
-	7	I-Chemical
8	9	I-Chemical
on	5	O
morphine	0	B-Chemical
-	7	O
induced	3	O
memory	5	B-Disease
impairment	5	I-Disease
.	9	O

Glial	3	O
activation	3	O
and	5	O
post	9	O
-	7	O
synaptic	5	O
neurotoxicity	9	B-Disease
:	9	O
the	5	O
key	9	O
events	5	O
in	5	O
Streptozotocin	0	B-Chemical
(	9	O
ICV	9	O
)	9	O
induced	3	O
memory	5	B-Disease
impairment	5	I-Disease
in	5	O
rats	9	O
.	9	O

In	9	O
the	5	O
present	9	O
study	9	O
the	5	O
role	9	O
of	5	O
glial	3	O
activation	3	O
and	5	O
post	9	O
synaptic	5	O
toxicity	9	B-Disease
in	5	O
ICV	9	O
Streptozotocin	0	B-Chemical
(	9	O
STZ	0	B-Chemical
)	9	O
induced	3	O
memory	5	B-Disease
impaired	9	I-Disease
rats	9	O
was	9	O
explored	9	O
.	9	O

In	9	O
experiment	9	O
set	5	O
up	5	O
1	9	O
:	9	O
Memory	5	B-Disease
deficit	5	I-Disease
was	9	O
found	9	O
in	5	O
Morris	6	O
water	0	O
maze	5	O
test	5	O
on	5	O
14	7	O
-	7	O
16	9	O
days	9	O
after	9	O
STZ	0	B-Chemical
(	9	O
ICV	9	O
;	9	O
3mg	0	O
/	9	O
Kg	0	O
)	9	O
administration	9	O
.	9	O

STZ	0	B-Chemical
causes	9	O
increased	9	O
expression	3	O
of	5	O
GFAP	3	O
,	9	O
CD11b	3	O
and	5	O
TNF	3	O
-	7	O
a	5	O
indicating	9	O
glial	3	O
activation	3	O
and	5	O
neuroinflammation	3	B-Disease
.	9	O

STZ	0	B-Chemical
also	9	O
significantly	9	O
increased	9	O
the	5	O
level	9	O
of	5	O
ROS	3	O
,	9	O
nitrite	0	B-Chemical
,	9	O
Ca	0	B-Chemical
(	9	O
2	9	O
+	9	O
)	9	O
and	5	O
reduced	9	O
the	5	O
mitochondrial	9	O
activity	9	O
in	5	O
synaptosomal	3	O
preparation	9	O
illustrating	9	O
free	9	O
radical	0	O
generation	9	O
and	5	O
excitotoxicity	3	B-Disease
.	9	O

Increased	9	O
expression	3	O
and	5	O
activity	9	O
of	5	O
Caspase	3	O
-	7	O
3	9	O
was	9	O
also	9	O
observed	9	O
in	5	O
STZ	0	B-Chemical
treated	3	O
rat	3	O
which	5	O
specify	5	O
apoptotic	3	O
cell	3	O
death	9	O
in	5	O
hippocampus	9	O
and	5	O
cortex	5	O
.	9	O

STZ	0	B-Chemical
treatment	9	O
showed	9	O
decrease	9	O
expression	3	O
of	5	O
post	9	O
synaptic	5	O
markers	3	O
CaMKIIa	3	O
and	5	O
PSD	9	O
-	7	O
95	7	O
,	9	O
while	9	O
,	9	O
expression	3	O
of	5	O
pre	9	O
synaptic	5	O
markers	3	O
(	9	O
synaptophysin	3	O
and	5	O
SNAP	9	O
-	7	O
25	9	O
)	9	O
remains	9	O
unaltered	9	O
indicating	9	O
selective	9	O
post	9	O
synaptic	5	O
neurotoxicity	9	B-Disease
.	9	O

Oral	9	O
treatment	9	O
with	5	O
Memantine	0	B-Chemical
(	9	O
10mg	0	O
/	9	O
kg	0	O
)	9	O
and	5	O
Ibuprofen	0	B-Chemical
(	9	O
50	0	O
mg	0	O
/	9	O
kg	0	O
)	9	O
daily	5	O
for	5	O
13	7	O
days	9	O
attenuated	3	O
STZ	0	B-Chemical
induced	3	O
glial	3	O
activation	3	O
,	9	O
apoptotic	3	O
cell	3	O
death	9	O
and	5	O
post	9	O
synaptic	5	O
neurotoxicity	9	B-Disease
in	5	O
rat	3	O
brain	5	O
.	9	O

Further	9	O
,	9	O
in	5	O
experiment	9	O
set	5	O
up	5	O
2	9	O
:	9	O
where	5	O
memory	5	O
function	9	O
was	9	O
not	5	O
affected	9	O
i	9	O
.	9	O
e	9	O
.	9	O
7	9	O
-	7	O
9	7	O
days	9	O
after	9	O
STZ	0	B-Chemical
treatment	9	O
.	9	O

The	5	O
level	9	O
of	5	O
GFAP	3	O
,	9	O
CD11b	3	O
,	9	O
TNF	3	O
-	7	O
a	5	O
,	9	O
ROS	3	O
and	5	O
nitrite	0	B-Chemical
levels	3	O
were	9	O
increased	9	O
.	9	O

On	5	O
the	5	O
other	5	O
hand	5	O
,	9	O
apoptotic	3	O
marker	3	O
,	9	O
synaptic	5	O
markers	3	O
,	9	O
mitochondrial	9	O
activity	9	O
and	5	O
Ca	0	B-Chemical
(	9	O
2	9	O
+	9	O
)	9	O
levels	3	O
remained	9	O
unaffected	9	O
.	9	O

Collective	5	O
data	5	O
indicates	9	O
that	5	O
neuroinflammatory	3	B-Disease
process	5	O
and	5	O
oxidative	9	O
stress	9	O
occurs	9	O
earlier	9	O
to	5	O
apoptosis	3	O
and	5	O
does	9	O
not	5	O
affect	9	O
memory	5	O
function	9	O
.	9	O

Present	7	O
study	9	O
clearly	9	O
suggests	9	O
that	5	O
glial	3	O
activation	3	O
and	5	O
post	9	O
synaptic	5	O
neurotoxicity	9	B-Disease
are	5	O
the	5	O
key	9	O
factors	9	O
in	5	O
STZ	0	B-Chemical
induced	3	O
memory	5	B-Disease
impairment	5	I-Disease
and	5	O
neuronal	3	O
cell	3	O
death	9	O
.	9	O

Comparison	9	O
of	5	O
effects	9	O
of	5	O
isotonic	0	O
sodium	0	B-Chemical
chloride	0	I-Chemical
with	5	O
diltiazem	0	B-Chemical
in	5	O
prevention	5	O
of	5	O
contrast	9	B-Chemical
-	7	O
induced	3	O
nephropathy	9	B-Disease
.	9	O

INTRODUCTION	5	O
AND	2	O
OBJECTIVE	2	O
:	9	O
Contrast	5	B-Chemical
-	7	O
induced	3	O
nephropathy	9	B-Disease
(	9	O
CIN	9	O
)	9	O
significantly	9	O
increases	9	O
the	5	O
morbidity	5	O
and	5	O
mortality	5	O
of	5	O
patients	5	O
.	9	O

The	5	O
aim	5	O
of	5	O
this	5	O
study	9	O
is	5	O
to	5	O
investigate	9	O
and	5	O
compare	9	O
the	5	O
protective	9	O
effects	9	O
of	5	O
isotonic	0	O
sodium	0	B-Chemical
chloride	0	I-Chemical
with	5	O
sodium	0	B-Chemical
bicarbonate	0	I-Chemical
infusion	0	O
and	5	O
isotonic	0	O
sodium	0	B-Chemical
chloride	0	I-Chemical
infusion	0	O
with	5	O
diltiazem	0	B-Chemical
,	9	O
a	5	O
calcium	0	B-Chemical
channel	9	O
blocker	0	O
,	9	O
in	5	O
preventing	9	O
CIN	9	O
.	9	O

MATERIALS	2	O
AND	2	O
METHODS	2	O
:	9	O
Our	9	O
study	9	O
included	5	O
patients	5	O
who	5	O
were	9	O
administered	9	O
30	9	O
-	7	O
60	9	O
mL	0	O
of	5	O
iodinated	0	O
contrast	9	B-Chemical
agent	9	O
for	5	O
percutaneous	5	O
coronary	5	O
angiography	5	O
(	9	O
PCAG	7	O
)	9	O
,	9	O
all	5	O
with	5	O
creatinine	0	B-Chemical
values	5	O
between	5	O
1	9	O
.	9	O
1	9	O
and	5	O
3	9	O
.	9	O
1	9	O
mg	0	O
/	9	O
dL	7	O
.	9	O

Patients	5	O
were	9	O
divided	5	O
into	9	O
three	9	O
groups	9	O
and	5	O
each	5	O
group	9	O
had	9	O
20	9	O
patients	5	O
.	9	O

The	5	O
first	9	O
group	9	O
of	5	O
patients	5	O
was	9	O
administered	9	O
isotonic	0	O
sodium	0	B-Chemical
chloride	0	I-Chemical
;	9	O
the	5	O
second	9	O
group	9	O
was	9	O
administered	9	O
a	5	O
solution	0	O
that	5	O
of	5	O
5	9	O
%	9	O
dextrose	0	B-Chemical
and	5	O
sodium	0	B-Chemical
bicarbonate	0	I-Chemical
,	9	O
while	9	O
the	5	O
third	9	O
group	9	O
was	9	O
administered	9	O
isotonic	0	O
sodium	0	B-Chemical
chloride	0	I-Chemical
before	9	O
and	5	O
after	9	O
the	5	O
contrast	9	B-Chemical
injection	9	O
.	9	O

The	5	O
third	9	O
group	9	O
received	9	O
an	5	O
additional	9	O
injection	9	O
of	5	O
diltiazem	0	B-Chemical
the	5	O
day	9	O
before	9	O
and	5	O
first	9	O
2	9	O
days	9	O
after	9	O
the	5	O
contrast	9	B-Chemical
injection	9	O
.	9	O

All	9	O
of	5	O
the	5	O
patients	5	O
'	9	O
plasma	9	O
blood	9	B-Chemical
urea	0	I-Chemical
nitrogen	0	I-Chemical
(	9	O
BUN	0	B-Chemical
)	9	O
and	5	O
creatinine	0	B-Chemical
levels	3	O
were	9	O
measured	9	O
on	5	O
the	5	O
second	9	O
and	5	O
seventh	9	O
day	9	O
after	9	O
the	5	O
administration	9	O
of	5	O
intravenous	0	O
contrast	9	B-Chemical
material	5	O
.	9	O

RESULTS	9	O
:	9	O
The	5	O
basal	3	O
creatinine	0	B-Chemical
levels	3	O
were	9	O
similar	9	O
for	5	O
all	5	O
three	9	O
groups	9	O
(	9	O
p	7	O
>	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

Among	9	O
a	5	O
total	9	O
of	5	O
60	9	O
patients	5	O
included	5	O
in	5	O
the	5	O
study	9	O
,	9	O
16	9	O
patients	5	O
developed	5	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
(	9	O
ARF	9	B-Disease
)	9	O
on	5	O
the	5	O
second	9	O
day	9	O
after	9	O
contrast	9	B-Chemical
material	5	O
was	9	O
injected	3	O
(	9	O
26	7	O
.	9	O
6	9	O
%	9	O
)	9	O
.	9	O

The	5	O
number	9	O
of	5	O
patients	5	O
who	5	O
developed	5	O
ARF	9	B-Disease
on	5	O
the	5	O
second	9	O
day	9	O
after	9	O
the	5	O
injection	9	O
in	5	O
the	5	O
first	9	O
group	9	O
was	9	O
five	9	O
(	9	O
25	9	O
%	9	O
)	9	O
,	9	O
in	5	O
the	5	O
second	9	O
group	9	O
was	9	O
six	9	O
(	9	O
30	9	O
%	9	O
)	9	O
and	5	O
the	5	O
third	9	O
group	9	O
was	9	O
five	9	O
(	9	O
25	9	O
%	9	O
)	9	O
(	9	O
p	7	O
>	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

CONCLUSION	5	O
:	9	O
There	5	O
was	9	O
no	9	O
significant	9	O
difference	9	O
between	5	O
isotonic	0	O
sodium	0	B-Chemical
chloride	0	I-Chemical
,	9	O
sodium	0	B-Chemical
bicarbonate	0	I-Chemical
and	5	O
isotonic	0	O
sodium	0	B-Chemical
chloride	0	I-Chemical
with	5	O
diltiazem	0	B-Chemical
application	5	O
in	5	O
prevention	5	O
of	5	O
CIN	9	O
.	9	O

Neurocognitive	5	O
and	5	O
neuroradiologic	5	O
central	5	O
nervous	5	O
system	5	O
late	9	O
effects	9	O
in	5	O
children	5	O
treated	3	O
on	5	O
Pediatric	2	O
Oncology	2	O
Group	9	O
(	9	O
POG	0	O
)	9	O
P9605	4	O
(	9	O
standard	5	O
risk	5	O
)	9	O
and	5	O
P9201	_	O
(	9	O
lesser	9	O
risk	5	O
)	9	O
acute	9	B-Disease
lymphoblastic	3	I-Disease
leukemia	3	I-Disease
protocols	5	O
(	9	O
ACCL0131	_	O
)	9	O
:	9	O
a	5	O
methotrexate	9	B-Chemical
consequence	5	O
?	5	O

A	9	O
report	5	O
from	9	O
the	5	O
Children	5	O
'	9	O
s	9	O
Oncology	2	O
Group	9	O
.	9	O

Concerns	5	O
about	5	O
long	5	O
-	7	O
term	5	O
methotrexate	9	B-Chemical
(	9	O
MTX	0	B-Chemical
)	9	O
neurotoxicity	9	B-Disease
in	5	O
the	5	O
1990s	5	O
led	9	O
to	5	O
modifications	9	O
in	5	O
intrathecal	3	O
(	9	O
IT	9	O
)	9	O
therapy	5	O
,	9	O
leucovorin	0	O
rescue	3	O
,	9	O
and	5	O
frequency	5	O
of	5	O
systemic	9	O
MTX	0	B-Chemical
administration	9	O
in	5	O
children	5	O
with	5	O
acute	9	B-Disease
lymphoblastic	3	I-Disease
leukemia	3	I-Disease
.	9	O

In	9	O
this	5	O
study	9	O
,	9	O
neurocognitive	5	O
outcomes	5	O
and	5	O
neuroradiologic	5	O
evidence	9	O
of	5	O
leukoencephalopathy	5	B-Disease
were	9	O
compared	9	O
in	5	O
children	5	O
treated	3	O
with	5	O
intense	9	O
central	5	O
nervous	5	O
system	5	O
(	9	O
CNS	9	O
)	9	O
-	7	O
directed	9	O
therapy	5	O
(	9	O
P9605	4	O
)	9	O
versus	9	O
those	5	O
receiving	9	O
fewer	5	O
CNS	9	O
-	7	O
directed	9	O
treatment	9	O
days	9	O
during	5	O
intensive	5	O
consolidation	5	O
(	9	O
P9201	_	O
)	9	O
.	9	O

A	9	O
total	9	O
of	5	O
66	7	O
children	5	O
from	9	O
16	9	O
Pediatric	2	O
Oncology	2	O
Group	9	O
institutions	5	O
with	5	O
"	5	O
standard	5	O
-	7	O
risk	5	O
"	5	O
acute	9	B-Disease
lymphoblastic	3	I-Disease
leukemia	3	I-Disease
,	9	O
1	9	O
.	9	O
00	7	O
to	5	O
9	7	O
.	9	O
99	7	O
years	5	O
at	9	O
diagnosis	5	O
,	9	O
without	9	O
evidence	9	O
of	5	O
CNS	9	O
leukemia	3	B-Disease
at	9	O
diagnosis	5	O
were	9	O
enrolled	5	O
on	5	O
ACCL0131	_	O
:	9	O
28	7	O
from	9	O
P9201	_	O
and	5	O
38	7	O
from	9	O
P9605	4	O
.	9	O

Magnetic	5	O
resonance	5	O
imaging	5	O
scans	5	O
and	5	O
standard	5	O
neuropsychological	5	O
tests	5	O
were	9	O
performed	9	O
>	0	O
2	9	O
.	9	O
6	9	O
years	5	O
after	9	O
the	5	O
end	9	O
of	5	O
treatment	9	O
.	9	O

Significantly	9	O
more	5	O
P9605	4	O
patients	5	O
developed	5	O
leukoencephalopathy	5	B-Disease
compared	9	O
with	5	O
P9201	_	O
patients	5	O
(	9	O
68	7	O
%	9	O
,	9	O
95	7	O
%	9	O
confidence	5	O
interval	5	O
49	7	O
%	9	O
-	7	O
83	7	O
%	9	O
vs	7	O
.	9	O
22	7	O
%	9	O
,	9	O
95	7	O
%	9	O
confidence	5	O
interval	5	O
5	9	O
%	9	O
-	7	O
44	7	O
%	9	O
;	9	O
P	9	O
=	7	O
0	7	O
.	9	O
001	9	O
)	9	O
identified	9	O
as	5	O
late	9	O
as	5	O
7	9	O
.	9	O
7	9	O
years	5	O
after	9	O
the	5	O
end	9	O
of	5	O
treatment	9	O
.	9	O

Overall	9	O
,	9	O
40	9	O
%	9	O
of	5	O
patients	5	O
scored	5	O
<	0	O
85	9	O
on	5	O
either	9	O
Verbal	5	O
or	5	O
Performance	5	O
IQ	5	O
.	9	O

Children	5	O
on	5	O
both	9	O
studies	9	O
had	9	O
significant	9	O
attention	5	B-Disease
problems	5	I-Disease
,	9	O
but	9	O
P9605	4	O
children	5	O
scored	5	O
below	9	O
average	5	O
on	5	O
more	5	O
neurocognitive	5	O
measures	5	O
than	5	O
those	5	O
treated	3	O
on	5	O
P9201	_	O
(	9	O
82	7	O
%	9	O
,	9	O
14	7	O
/	9	O
17	7	O
measures	5	O
vs	7	O
.	9	O
24	9	O
%	9	O
,	9	O
4	9	O
/	9	O
17	7	O
measures	5	O
)	9	O
.	9	O

This	5	O
supports	9	O
ongoing	5	O
concerns	5	O
about	5	O
intensive	5	O
MTX	0	B-Chemical
exposure	9	O
as	5	O
a	5	O
major	9	O
contributor	9	O
to	5	O
CNS	9	O
late	9	O
effects	9	O
.	9	O

Tranexamic	0	B-Chemical
acid	0	I-Chemical
overdosage	5	O
-	7	O
induced	3	O
generalized	5	O
seizure	5	B-Disease
in	5	O
renal	9	B-Disease
failure	5	I-Disease
.	9	O

We	9	O
report	5	O
a	5	O
45	9	O
-	7	O
year	5	O
-	7	O
old	5	O
lady	5	O
with	5	O
chronic	5	B-Disease
kidney	9	I-Disease
disease	5	I-Disease
stage	9	O
4	9	O
due	5	O
to	5	O
chronic	5	O
tubulointerstial	9	B-Disease
disease	5	I-Disease
.	9	O

She	5	O
was	9	O
admitted	5	O
to	5	O
our	5	O
center	5	O
for	5	O
severe	5	O
anemia	9	B-Disease
due	5	O
to	5	O
menorrhagia	5	B-Disease
and	5	O
deterioration	5	B-Disease
of	5	I-Disease
renal	9	I-Disease
function	9	I-Disease
.	9	O

She	5	O
was	9	O
infused	9	O
three	9	O
units	9	O
of	5	O
packed	0	O
cells	3	O
during	5	O
a	5	O
session	5	O
of	5	O
hemodialysis	5	O
.	9	O

Tranexamic	0	B-Chemical
acid	0	I-Chemical
(	9	O
TNA	0	B-Chemical
)	9	O
1	9	O
g	0	O
8	9	O
-	7	O
hourly	5	O
was	9	O
administered	9	O
to	5	O
her	5	O
to	5	O
control	9	O
bleeding	5	B-Disease
per	9	O
vaginum	5	O
.	9	O

Two	9	O
hours	9	O
after	9	O
the	5	O
sixth	9	O
dose	9	O
of	5	O
TNA	0	B-Chemical
,	9	O
she	5	O
had	9	O
an	5	O
episode	5	O
of	5	O
generalized	5	O
tonic	5	B-Disease
clonic	5	I-Disease
convulsions	5	I-Disease
.	9	O

TNA	0	B-Chemical
was	9	O
discontinued	5	O
.	9	O

Investigations	9	O
of	5	O
the	5	O
patient	5	O
revealed	9	O
no	9	O
biochemical	9	O
or	5	O
structural	9	O
central	5	O
nervous	5	B-Disease
system	5	I-Disease
abnormalities	9	I-Disease
that	5	O
could	9	O
have	5	O
provoked	9	O
the	5	O
convulsions	5	B-Disease
.	9	O

She	5	O
did	9	O
not	5	O
require	5	O
any	5	O
further	9	O
dialytic	5	O
support	5	O
.	9	O

She	5	O
had	9	O
no	9	O
further	9	O
episodes	5	O
of	5	O
convulsion	5	B-Disease
till	9	O
dis	5	O
-	7	O
charge	5	O
and	5	O
during	5	O
the	5	O
two	5	O
months	5	O
of	5	O
follow	5	O
-	7	O
up	5	O
.	9	O

Thus	9	O
,	9	O
the	5	O
precipitating	9	O
cause	5	O
of	5	O
convulsions	5	B-Disease
was	9	O
believed	5	O
to	5	O
be	5	O
an	5	O
overdose	0	B-Disease
of	5	O
TNA	0	B-Chemical
.	9	O

Pre	9	O
-	7	O
treatment	9	O
of	5	O
bupivacaine	0	B-Chemical
-	7	O
induced	3	O
cardiovascular	5	B-Disease
depression	5	I-Disease
using	9	O
different	9	O
lipid	0	O
formulations	0	O
of	5	O
propofol	0	B-Chemical
.	9	O

BACKGROUND	2	O
:	9	O
Pre	9	O
-	7	O
treatment	9	O
with	5	O
lipid	0	O
emulsions	0	O
has	9	O
been	9	O
shown	9	O
to	5	O
increase	9	O
lethal	9	O
doses	0	O
of	5	O
bupivacaine	0	B-Chemical
,	9	O
and	5	O
the	5	O
lipid	0	O
content	9	O
of	5	O
propofol	0	B-Chemical
may	5	O
alleviate	5	O
bupivacaine	0	B-Chemical
-	7	O
induced	3	O
cardiotoxicity	9	B-Disease
.	9	O

The	5	O
aim	5	O
of	5	O
this	5	O
study	9	O
is	5	O
to	5	O
investigate	9	O
the	5	O
effects	9	O
of	5	O
propofol	0	B-Chemical
in	5	O
intralipid	0	O
or	5	O
medialipid	_	O
emulsions	0	O
on	5	O
bupivacaine	0	B-Chemical
-	7	O
induced	3	O
cardiotoxicity	9	B-Disease
.	9	O

METHODS	2	O
:	9	O
Rats	9	O
were	9	O
anaesthetised	5	O
with	5	O
ketamine	0	B-Chemical
and	5	O
were	9	O
given	5	O
0	7	O
.	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
/	9	O
min	0	O
propofol	0	B-Chemical
in	5	O
intralipid	0	O
(	9	O
Group	9	O
P	9	O
)	9	O
,	9	O
propofol	0	B-Chemical
in	5	O
medialipid	_	O
(	9	O
Group	9	O
L	0	O
)	9	O
,	9	O
or	5	O
saline	0	O
(	9	O
Group	9	O
C	9	O
)	9	O
over	5	O
20	9	O
min	0	O
.	9	O

Thereafter	9	O
,	9	O
2	9	O
mg	0	O
/	9	O
kg	0	O
/	9	O
min	0	O
bupivacaine	0	B-Chemical
0	7	O
.	9	O
5	9	O
%	9	O
was	9	O
infused	9	O
.	9	O

We	9	O
recorded	5	O
time	5	O
to	5	O
first	9	O
dysrhythmia	5	B-Disease
occurrence	5	O
,	9	O
respective	9	O
times	5	O
to	5	O
25	9	O
%	9	O
and	5	O
50	0	O
%	9	O
reduction	9	O
of	5	O
the	5	O
heart	5	O
rate	9	O
(	9	O
HR	9	O
)	9	O
and	5	O
mean	5	O
arterial	5	O
pressure	5	O
,	9	O
and	5	O
time	5	O
to	5	O
asystole	5	B-Disease
and	5	O
total	9	O
amount	9	O
of	5	O
bupivacaine	0	B-Chemical
consumption	5	O
.	9	O

Blood	9	O
and	5	O
tissue	9	O
samples	9	O
were	9	O
collected	9	O
following	9	O
asystole	5	B-Disease
.	9	O

RESULTS	9	O
:	9	O
The	5	O
time	5	O
to	5	O
first	9	O
dysrhythmia	5	B-Disease
occurrence	5	O
,	9	O
time	5	O
to	5	O
25	9	O
%	9	O
and	5	O
50	0	O
%	9	O
reductions	9	O
in	5	O
HR	9	O
,	9	O
and	5	O
time	5	O
to	5	O
asystole	5	B-Disease
were	9	O
longer	5	O
in	5	O
Group	9	O
P	9	O
than	5	O
the	5	O
other	5	O
groups	9	O
.	9	O

The	5	O
cumulative	5	O
bupivacaine	0	B-Chemical
dose	9	O
given	5	O
at	9	O
those	5	O
time	5	O
points	5	O
was	9	O
higher	9	O
in	5	O
Group	9	O
P	9	O
.	9	O
Plasma	0	O
bupivacaine	0	B-Chemical
levels	3	O
were	9	O
significantly	9	O
lower	9	O
in	5	O
Group	9	O
P	9	O
than	5	O
in	5	O
Group	9	O
C	9	O
.	9	O
Bupivacaine	0	B-Chemical
levels	3	O
in	5	O
the	5	O
brain	5	O
and	5	O
heart	5	O
were	9	O
significantly	9	O
lower	9	O
in	5	O
Group	9	O
P	9	O
and	5	O
Group	9	O
L	0	O
than	5	O
in	5	O
Group	9	O
C	9	O
.	9	O

CONCLUSION	5	O
:	9	O
We	9	O
conclude	9	O
that	5	O
pre	9	O
-	7	O
treatment	9	O
with	5	O
propofol	0	B-Chemical
in	5	O
intralipid	0	O
,	9	O
compared	9	O
with	5	O
propofol	0	B-Chemical
in	5	O
medialipid	_	O
or	5	O
saline	0	O
,	9	O
delayed	9	O
the	5	O
onset	5	O
of	5	O
bupivacaine	0	B-Chemical
-	7	O
induced	3	O
cardiotoxic	5	B-Disease
effects	9	O
as	5	O
well	9	O
as	5	O
reduced	9	O
plasma	9	O
bupivacaine	0	B-Chemical
levels	3	O
.	9	O

Further	9	O
studies	9	O
are	5	O
needed	5	O
to	5	O
explore	5	O
tissue	9	O
bupivacaine	0	B-Chemical
levels	3	O
of	5	O
propofol	0	B-Chemical
in	5	O
medialipid	_	O
and	5	O
adapt	5	O
these	5	O
results	9	O
to	5	O
clinical	5	O
practice	5	O
.	9	O

Drug	5	B-Disease
-	7	I-Disease
Induced	9	I-Disease
Acute	5	I-Disease
Liver	9	I-Disease
Injury	5	I-Disease
Within	9	O
12	9	O
Hours	7	O
After	9	O
Fluvastatin	7	B-Chemical
Therapy	5	O
.	9	O

Although	9	O
statins	5	B-Chemical
are	5	O
generally	5	O
well	9	O
-	7	O
tolerated	9	O
drugs	5	O
,	9	O
recent	5	O
cases	5	O
of	5	O
drug	5	B-Disease
-	7	I-Disease
induced	3	I-Disease
liver	9	I-Disease
injury	9	I-Disease
associated	9	O
with	5	O
their	5	O
use	5	O
have	5	O
been	9	O
reported	9	O
.	9	O

A	9	O
52	7	O
-	7	O
year	5	O
-	7	O
old	5	O
Chinese	9	O
man	5	O
reported	9	O
with	5	O
liver	9	B-Disease
damage	9	I-Disease
,	9	O
which	5	O
appeared	9	O
12	9	O
hours	9	O
after	9	O
beginning	5	O
treatment	9	O
with	5	O
fluvastatin	0	B-Chemical
.	9	O

Patient	5	O
presented	5	O
with	5	O
complaints	5	O
of	5	O
increasing	9	O
nausea	5	B-Disease
,	9	O
anorexia	5	B-Disease
,	9	O
and	5	O
upper	9	O
abdominal	5	B-Disease
pain	5	I-Disease
.	9	O

His	9	O
laboratory	9	O
values	5	O
showed	9	O
elevated	9	O
creatine	0	B-Chemical
kinase	3	O
and	5	O
transaminases	9	O
.	9	O

Testing	5	O
for	5	O
autoantibodies	3	O
was	9	O
also	9	O
negative	9	O
.	9	O

The	5	O
liver	9	O
biochemistries	5	O
eventually	5	O
normalized	9	O
within	9	O
3	9	O
weeks	9	O
of	5	O
stopping	5	O
the	5	O
fluvastatin	0	B-Chemical
.	9	O

Therefore	9	O
,	9	O
when	5	O
prescribing	5	O
statins	5	O
,	9	O
the	5	O
possibility	9	O
of	5	O
hepatic	9	B-Disease
damage	9	I-Disease
should	5	O
be	5	O
taken	5	O
into	9	O
account	5	O
.	9	O

Fluconazole	0	B-Chemical
associated	9	O
agranulocytosis	5	B-Disease
and	5	O
thrombocytopenia	9	B-Disease
.	9	O

CASE	2	O
:	9	O
We	9	O
describe	5	O
a	5	O
second	9	O
case	5	O
of	5	O
fluconazole	9	B-Chemical
associated	9	O
agranulocytosis	5	B-Disease
with	5	O
thrombocytopenia	9	B-Disease
and	5	O
recovery	9	O
upon	9	O
discontinuation	5	O
of	5	O
therapy	5	O
.	9	O

The	5	O
patient	5	O
began	5	O
to	5	O
have	5	O
changes	9	O
in	5	O
white	9	O
blood	9	O
cells	3	O
and	5	O
platelets	3	O
within	9	O
48	9	O
h	0	O
of	5	O
administration	9	O
of	5	O
fluconazole	9	B-Chemical
and	5	O
began	5	O
to	5	O
recover	9	O
with	5	O
48	9	O
h	0	O
of	5	O
discontinuation	5	O
.	9	O

This	5	O
case	5	O
highlights	5	O
that	5	O
drug	5	O
-	7	O
induced	3	O
blood	9	B-Disease
dyscrasias	5	I-Disease
can	5	O
occur	5	O
unexpectedly	9	O
as	5	O
a	5	O
result	9	O
of	5	O
treatment	9	O
with	5	O
a	5	O
commonly	5	O
used	5	O
drug	5	O
thought	5	O
to	5	O
be	5	O
"	5	O
safe	5	O
"	5	O
.	9	O

CONCLUSION	5	O
:	9	O
According	5	O
to	5	O
Naranjo	6	O
'	9	O
s	9	O
algorithm	5	O
the	5	O
likelihood	5	O
that	5	O
our	5	O
patient	5	O
'	9	O
s	9	O
agranulocytosis	5	B-Disease
and	5	O
thrombocytopenia	9	B-Disease
occurred	9	O
as	5	O
a	5	O
result	9	O
of	5	O
therapy	5	O
with	5	O
fluconazole	9	B-Chemical
is	5	O
probable	9	O
,	9	O
with	5	O
a	5	O
total	9	O
of	5	O
six	9	O
points	5	O
.	9	O

We	9	O
feel	5	O
that	5	O
the	5	O
weight	9	O
of	5	O
the	5	O
overall	5	O
evidence	9	O
of	5	O
this	5	O
evidence	9	O
is	5	O
strong	9	O
.	9	O

In	9	O
particular	5	O
the	5	O
temporal	5	O
relationship	5	O
of	5	O
bone	5	B-Disease
marrow	3	I-Disease
suppression	9	I-Disease
to	5	O
the	5	O
initiation	9	O
of	5	O
fluconazole	9	B-Chemical
and	5	O
the	5	O
abatement	5	O
of	5	O
symptoms	5	O
that	5	O
rapidly	9	O
reversed	9	O
immediately	9	O
following	9	O
discontinuation	5	O
.	9	O

Two	9	O
-	7	O
dimensional	5	O
speckle	5	O
tracking	5	O
echocardiography	5	O
combined	9	O
with	5	O
high	9	O
-	7	O
sensitive	9	O
cardiac	5	O
troponin	9	O
T	3	O
in	5	O
early	9	O
detection	9	O
and	5	O
prediction	5	O
of	5	O
cardiotoxicity	9	B-Disease
during	5	O
epirubicine	0	B-Chemical
-	7	O
based	5	O
chemotherapy	5	O
.	9	O

AIMS	5	O
:	9	O
To	9	O
investigate	9	O
whether	9	O
alterations	9	O
of	5	O
myocardial	9	B-Disease
strain	1	I-Disease
and	5	O
high	9	O
-	7	O
sensitive	9	O
cardiac	5	O
troponin	9	O
T	3	O
(	9	O
cTnT	3	O
)	9	O
could	9	O
predict	5	O
future	5	O
cardiac	5	B-Disease
dysfunction	9	I-Disease
in	5	O
patients	5	O
after	9	O
epirubicin	0	B-Chemical
exposure	9	O
.	9	O

METHODS	2	O
:	9	O
Seventy	5	O
-	7	O
five	9	O
patients	5	O
with	5	O
non	9	B-Disease
-	7	I-Disease
Hodgkin	5	I-Disease
lymphoma	9	I-Disease
treated	3	O
with	5	O
epirubicin	0	B-Chemical
were	9	O
studied	9	O
.	9	O

Blood	9	O
collection	5	O
and	5	O
echocardiography	5	O
were	9	O
performed	9	O
at	9	O
baseline	5	O
,	9	O
1	9	O
day	9	O
after	9	O
the	5	O
third	9	O
cycle	9	O
,	9	O
and	5	O
1	9	O
day	9	O
after	9	O
completion	5	O
of	5	O
chemotherapy	5	O
.	9	O

Patients	5	O
were	9	O
studied	9	O
using	9	O
echocardiography	5	O
during	5	O
follow	5	O
-	7	O
up	5	O
.	9	O

Global	5	O
longitudinal	5	O
(	9	O
GLS	9	O
)	9	O
,	9	O
circumferential	5	O
(	9	O
GCS	9	O
)	9	O
,	9	O
and	5	O
radial	5	O
strain	1	O
(	9	O
GRS	5	O
)	9	O
were	9	O
calculated	5	O
using	9	O
speckle	5	O
tracking	5	O
echocardiography	5	O
.	9	O

Left	9	O
ventricular	5	O
ejection	5	O
fraction	9	O
was	9	O
analysed	9	O
by	9	O
real	5	O
-	7	O
time	5	O
3D	5	O
echocardiography	5	O
.	9	O

Cardiotoxicity	9	B-Disease
was	9	O
defined	5	O
as	5	O
a	5	O
reduction	9	O
of	5	O
the	5	O
LVEF	5	O
of	5	O
>	0	O
5	9	O
%	9	O
to	5	O
<	0	O
55	7	O
%	9	O
with	5	O
symptoms	5	O
of	5	O
heart	5	B-Disease
failure	5	I-Disease
or	5	O
an	5	O
asymptomatic	5	O
reduction	9	O
of	5	O
the	5	O
LVEF	5	O
of	5	O
>	0	O
10	9	O
%	9	O
to	5	O
<	0	O
55	7	O
%	9	O
.	9	O

RESULTS	9	O
:	9	O
Fourteen	9	O
patients	5	O
(	9	O
18	7	O
.	9	O
67	7	O
%	9	O
)	9	O
developed	5	O
cardiotoxicity	9	B-Disease
after	9	O
treatment	9	O
.	9	O

GLS	9	O
(	9	O
-	7	O
18	7	O
.	9	O
48	9	O
+	9	O
1	9	O
.	9	O
72	9	O
%	9	O
vs	7	O
.	9	O
-	7	O
15	9	O
.	9	O
96	9	O
+	9	O
1	9	O
.	9	O
6	9	O
%	9	O
)	9	O
,	9	O
GCS	9	O
(	9	O
-	7	O
20	9	O
.	9	O
93	7	O
+	9	O
2	9	O
.	9	O
86	7	O
%	9	O
vs	7	O
.	9	O
-	7	O
19	7	O
.	9	O
20	9	O
+	9	O
3	9	O
.	9	O
21	7	O
%	9	O
)	9	O
,	9	O
and	5	O
GRS	5	O
(	9	O
39	7	O
.	9	O
23	7	O
+	9	O
6	9	O
.	9	O
44	7	O
%	9	O
vs	7	O
.	9	O
34	7	O
.	9	O
98	7	O
+	9	O
6	9	O
.	9	O
2	9	O
%	9	O
)	9	O
were	9	O
markedly	9	O
reduced	9	O
and	5	O
cTnT	3	O
was	9	O
elevated	9	O
from	9	O
0	7	O
.	9	O
0010	7	O
+	9	O
0	7	O
.	9	O
0020	2	O
to	5	O
0	7	O
.	9	O
0073	7	O
+	9	O
0	7	O
.	9	O
0038	7	O
ng	0	O
/	9	O
mL	0	O
(	9	O
P	9	O
all	5	O
<	0	O
0	7	O
.	9	O
01	7	O
)	9	O
at	9	O
the	5	O
completion	5	O
of	5	O
chemotherapy	5	O
compared	9	O
with	5	O
baseline	5	O
values	5	O
.	9	O

A	9	O
>	0	O
15	9	O
.	9	O
9	7	O
%	9	O
decrease	9	O
in	5	O
GLS	9	O
[	9	O
sensitivity	9	O
,	9	O
86	7	O
%	9	O
;	9	O
specificity	9	O
,	9	O
75	9	O
%	9	O
;	9	O
area	5	O
under	9	O
the	5	O
curve	9	O
(	9	O
AUC	9	O
)	9	O
=	7	O
0	7	O
.	9	O
815	7	O
;	9	O
P	9	O
=	7	O
0	7	O
.	9	O
001	9	O
]	9	O
and	5	O
a	5	O
>	0	O
0	7	O
.	9	O
004	7	O
ng	0	O
/	9	O
mL	0	O
elevation	9	O
in	5	O
cTnT	3	O
(	9	O
sensitivity	9	O
,	9	O
79	7	O
%	9	O
;	9	O
specificity	9	O
,	9	O
64	7	O
%	9	O
;	9	O
AUC	9	O
=	7	O
0	7	O
.	9	O
757	7	O
;	9	O
P	9	O
=	7	O
0	7	O
.	9	O
005	7	O
)	9	O
from	9	O
baseline	5	O
to	5	O
the	5	O
third	9	O
cycle	9	O
of	5	O
chemotherapy	5	O
predicted	9	O
later	9	O
cardiotoxicity	9	B-Disease
.	9	O

The	5	O
decrease	9	O
in	5	O
GLS	9	O
remained	9	O
the	5	O
only	9	O
independent	9	O
predictor	5	O
of	5	O
cardiotoxicity	9	B-Disease
(	9	O
P	9	O
=	7	O
0	7	O
.	9	O
000	9	O
)	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
GLS	9	O
combined	9	O
with	5	O
cTnT	3	O
may	5	O
provide	5	O
a	5	O
reliable	5	O
and	5	O
non	9	O
-	7	O
invasive	5	O
method	5	O
to	5	O
predict	5	O
cardiac	5	B-Disease
dysfunction	9	I-Disease
in	5	O
patients	5	O
receiving	9	O
anthracycline	9	B-Chemical
-	7	O
based	5	O
chemotherapy	5	O
.	9	O

Prevention	2	O
of	5	O
etomidate	5	B-Chemical
-	7	O
induced	3	O
myoclonus	5	B-Disease
:	9	O
which	5	O
is	5	O
superior	5	O
:	9	O
Fentanyl	0	B-Chemical
,	9	O
midazolam	0	B-Chemical
,	9	O
or	5	O
a	5	O
combination	9	O
?	5	O

A	9	O
Retrospective	9	O
comparative	9	O
study	9	O
.	9	O

BACKGROUND	2	O
:	9	O
In	9	O
this	5	O
retrospective	5	O
comparative	9	O
study	9	O
,	9	O
we	5	O
aimed	5	O
to	5	O
compare	9	O
the	5	O
effectiveness	5	O
of	5	O
fentanyl	0	B-Chemical
,	9	O
midazolam	0	B-Chemical
,	9	O
and	5	O
a	5	O
combination	9	O
of	5	O
fentanyl	0	B-Chemical
and	5	O
midazolam	0	B-Chemical
to	5	O
prevent	5	O
etomidate	5	B-Chemical
-	7	O
induced	3	O
myoclonus	5	B-Disease
.	9	O

MATERIAL	2	O
AND	2	O
METHODS	2	O
:	9	O
This	5	O
study	9	O
was	9	O
performed	9	O
based	5	O
on	5	O
anesthesia	5	O
records	5	O
.	9	O

Depending	5	O
on	5	O
the	5	O
drugs	5	O
that	5	O
would	5	O
be	5	O
given	5	O
before	9	O
the	5	O
induction	3	O
of	5	O
anesthesia	5	O
with	5	O
etomidate	5	B-Chemical
,	9	O
the	5	O
patients	5	O
were	9	O
separated	9	O
into	9	O
4	9	O
groups	9	O
:	9	O
no	9	O
pretreatment	0	O
(	9	O
Group	9	O
NP	9	O
)	9	O
,	9	O
fentanyl	0	B-Chemical
1	9	O
ug	0	O
.	9	O
kg	0	O
-	7	O
1	9	O
(	9	O
Group	9	O
F	7	O
)	9	O
,	9	O
midazolam	0	B-Chemical
0	7	O
.	9	O
03	7	O
mg	0	O
.	9	O
kg	0	O
-	7	O
1	9	O
(	9	O
Group	9	O
M	9	O
)	9	O
,	9	O
and	5	O
midazolam	0	B-Chemical
0	7	O
.	9	O
015	7	O
mg	0	O
.	9	O
kg	0	O
-	7	O
1	9	O
+	9	O
fentanyl	0	B-Chemical
0	7	O
.	9	O
5	9	O
ug	0	O
.	9	O
kg	0	O
-	7	O
1	9	O
(	9	O
Group	9	O
FM	9	O
)	9	O
.	9	O

Patients	5	O
who	5	O
received	9	O
the	5	O
same	9	O
anesthetic	5	O
procedure	5	O
were	9	O
selected	9	O
:	9	O
2	9	O
minutes	0	O
after	9	O
intravenous	0	O
injections	9	O
of	5	O
the	5	O
pretreatment	0	O
drugs	5	O
,	9	O
anesthesia	5	O
is	5	O
induced	3	O
with	5	O
0	7	O
.	9	O
3	9	O
mg	0	O
.	9	O
kg	0	O
-	7	O
1	9	O
etomidate	5	B-Chemical
injected	3	O
intravenously	0	O
over	5	O
a	5	O
period	5	O
of	5	O
20	9	O
-	7	O
30	9	O
seconds	5	O
.	9	O

Myoclonic	7	B-Disease
movements	5	I-Disease
are	5	O
evaluated	9	O
,	9	O
which	5	O
were	9	O
observed	9	O
and	5	O
graded	5	O
according	9	O
to	5	O
clinical	5	O
severity	5	O
during	5	O
the	5	O
2	9	O
minutes	0	O
after	9	O
etomidate	5	B-Chemical
injection	9	O
.	9	O

The	5	O
severity	5	O
of	5	O
pain	5	B-Disease
due	5	O
to	5	O
etomidate	5	B-Chemical
injection	9	O
,	9	O
mean	5	O
arterial	5	O
pressure	5	O
,	9	O
heart	5	O
rate	9	O
,	9	O
and	5	O
adverse	5	O
effects	9	O
were	9	O
also	9	O
evaluated	9	O
.	9	O

RESULTS	9	O
:	9	O
Study	5	O
results	9	O
showed	9	O
that	5	O
myoclonus	5	B-Disease
incidence	5	O
was	9	O
85	9	O
%	9	O
,	9	O
40	9	O
%	9	O
,	9	O
70	9	O
%	9	O
,	9	O
and	5	O
25	9	O
%	9	O
in	5	O
Group	9	O
NP	9	O
,	9	O
Group	9	O
F	7	O
,	9	O
Group	9	O
M	9	O
,	9	O
and	5	O
Group	9	O
FM	9	O
,	9	O
respectively	9	O
,	9	O
and	5	O
were	9	O
significantly	9	O
lower	9	O
in	5	O
Group	9	O
F	7	O
and	5	O
Group	9	O
FM	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
We	9	O
conclude	9	O
that	5	O
pretreatment	0	O
with	5	O
fentanyl	0	B-Chemical
or	5	O
combination	9	O
of	5	O
fentanyl	0	B-Chemical
and	5	O
midazolam	0	B-Chemical
was	9	O
effective	5	O
in	5	O
preventing	9	O
etomidate	5	B-Chemical
-	7	O
induced	3	O
myoclonus	5	B-Disease
.	9	O

Convulsant	2	O
effect	9	O
of	5	O
lindane	0	B-Chemical
and	5	O
regional	5	O
brain	5	O
concentration	0	O
of	5	O
GABA	0	B-Chemical
and	5	O
dopamine	5	B-Chemical
.	9	O

Lindane	0	B-Chemical
(	9	O
gamma	9	B-Chemical
-	7	I-Chemical
hexachlorocyclohexane	0	I-Chemical
)	9	O
is	5	O
an	5	O
organochlorine	0	O
insecticide	5	O
with	5	O
known	9	O
neurotoxic	9	B-Disease
effects	9	O
.	9	O

Its	5	O
mechanism	9	O
of	5	O
action	5	O
is	5	O
not	5	O
well	9	O
understood	5	O
although	9	O
it	5	O
has	9	O
been	9	O
proposed	5	O
that	5	O
lindane	0	B-Chemical
acts	9	O
as	5	O
a	5	O
non	9	O
-	7	O
competitive	9	O
antagonist	3	O
at	9	O
the	5	O
gamma	9	B-Chemical
-	7	I-Chemical
aminobutyric	0	I-Chemical
acid	0	I-Chemical
(	9	O
GABA	0	B-Chemical
)	9	O
-	7	O
A	9	O
receptor	3	O
.	9	O

We	9	O
studied	9	O
the	5	O
effect	9	O
of	5	O
lindane	0	B-Chemical
(	9	O
150	0	O
mg	0	O
/	9	O
kg	0	O
)	9	O
on	5	O
the	5	O
GABAergic	3	O
and	5	O
dopaminergic	5	O
systems	5	O
by	9	O
measuring	9	O
the	5	O
concentration	0	O
of	5	O
GABA	0	B-Chemical
,	9	O
dopamine	5	B-Chemical
and	5	O
its	9	O
metabolites	0	O
in	5	O
7	9	O
brain	5	O
areas	5	O
at	9	O
the	5	O
onset	5	O
of	5	O
seizures	5	B-Disease
.	9	O

All	9	O
animals	9	O
suffered	5	O
tonic	5	O
convulsions	5	B-Disease
at	9	O
18	7	O
.	9	O
3	9	O
+	9	O
/	9	O
-	7	O
1	9	O
.	9	O
4	9	O
min	0	O
after	9	O
lindane	0	B-Chemical
administration	9	O
.	9	O

The	5	O
concentration	0	O
of	5	O
GABA	0	B-Chemical
was	9	O
only	9	O
slightly	9	O
but	9	O
significantly	9	O
decreased	9	O
in	5	O
the	5	O
colliculi	5	O
without	9	O
modifications	9	O
in	5	O
the	5	O
other	5	O
areas	5	O
.	9	O

The	5	O
concentration	0	O
of	5	O
dopamine	5	B-Chemical
was	9	O
increased	9	O
in	5	O
the	5	O
mesencephalon	3	O
and	5	O
that	5	O
of	5	O
its	9	O
metabolite	0	O
DOPAC	0	B-Chemical
was	9	O
also	9	O
increased	9	O
in	5	O
the	5	O
mesencephalon	3	O
and	5	O
the	5	O
striatum	9	O
.	9	O

Cholestatic	7	B-Disease
presentation	5	O
of	5	O
yellow	9	O
phosphorus	0	B-Chemical
poisoning	5	B-Disease
.	9	O

Yellow	9	O
phosphorus	0	B-Chemical
,	9	O
a	5	O
component	9	O
of	5	O
certain	5	O
pesticide	5	O
pastes	0	O
and	5	O
fireworks	5	O
,	9	O
is	5	O
well	9	O
known	9	O
to	5	O
cause	5	O
hepatotoxicity	9	B-Disease
.	9	O

Poisoning	2	B-Disease
with	5	O
yellow	9	O
phosphorus	0	B-Chemical
classically	5	O
manifests	5	O
with	5	O
acute	9	B-Disease
hepatitis	9	I-Disease
leading	9	O
to	5	O
acute	9	B-Disease
liver	9	I-Disease
failure	5	I-Disease
which	5	O
may	5	O
need	5	O
liver	9	O
transplantation	9	O
.	9	O

We	9	O
present	9	O
a	5	O
case	5	O
of	5	O
yellow	9	O
phosphorus	0	B-Chemical
poisoning	5	B-Disease
in	5	O
which	5	O
a	5	O
patient	5	O
presented	5	O
with	5	O
florid	5	O
clinical	5	O
features	5	O
of	5	O
cholestasis	5	B-Disease
highlighting	9	O
the	5	O
fact	9	O
that	5	O
cholestasis	5	B-Disease
can	5	O
rarely	5	O
be	5	O
a	5	O
presenting	5	O
feature	5	O
of	5	O
yellow	9	O
phosphorus	0	B-Chemical
hepatotoxicity	9	B-Disease
.	9	O

Vasovagal	5	B-Disease
syncope	5	I-Disease
and	5	O
severe	5	O
bradycardia	5	B-Disease
following	9	O
intranasal	9	O
dexmedetomidine	5	B-Chemical
for	5	O
pediatric	5	O
procedural	5	O
sedation	5	O
.	9	O

We	9	O
report	5	O
syncope	5	B-Disease
and	5	O
bradycardia	5	B-Disease
in	5	O
an	5	O
11	7	O
-	7	O
year	5	O
-	7	O
old	5	O
girl	5	O
following	9	O
administration	9	O
of	5	O
intranasal	9	O
dexmedetomidine	5	B-Chemical
for	5	O
sedation	5	O
for	5	O
a	5	O
voiding	5	O
cystourethrogram	5	O
.	9	O

Following	9	O
successful	5	O
completion	5	O
of	5	O
VCUG	5	O
and	5	O
a	5	O
60	9	O
-	7	O
min	0	O
recovery	9	O
period	5	O
,	9	O
the	5	O
patient	5	O
'	9	O
s	9	O
level	9	O
of	5	O
consciousness	5	O
and	5	O
vital	5	O
signs	5	O
returned	5	O
to	5	O
presedation	5	O
levels	3	O
.	9	O

Upon	9	O
leaving	5	O
the	5	O
sedation	5	O
area	5	O
,	9	O
the	5	O
patient	5	O
collapsed	5	O
,	9	O
with	5	O
no	9	O
apparent	9	O
inciting	5	O
event	5	O
.	9	O

The	5	O
patient	5	O
quickly	5	O
regained	5	O
consciousness	5	O
and	5	O
no	9	O
injury	9	O
occurred	9	O
.	9	O

The	5	O
primary	9	O
abnormality	9	O
found	9	O
was	9	O
persistent	5	O
bradycardia	5	B-Disease
,	9	O
and	5	O
she	5	O
was	9	O
admitted	5	O
to	5	O
the	5	O
hospital	5	O
for	5	O
telemetric	5	O
observation	9	O
.	9	O

The	5	O
bradycardia	5	B-Disease
lasted	5	O
~	9	O
2	9	O
h	0	O
,	9	O
and	5	O
further	9	O
cardiac	5	O
workup	5	O
revealed	9	O
no	9	O
underlying	5	O
abnormality	9	O
.	9	O

Unanticipated	5	O
and	5	O
previously	9	O
unreported	9	O
outcomes	5	O
may	5	O
be	5	O
witnessed	5	O
as	5	O
we	5	O
expand	5	O
the	5	O
use	5	O
of	5	O
certain	5	O
sedatives	5	O
to	5	O
alternative	5	O
routes	5	O
of	5	O
administration	9	O
.	9	O

Paradoxical	5	O
severe	5	O
agitation	5	B-Disease
induced	3	O
by	9	O
add	5	O
-	7	O
on	5	O
high	9	O
-	7	O
doses	0	O
quetiapine	5	B-Chemical
in	5	O
schizo	5	B-Disease
-	7	I-Disease
affective	5	I-Disease
disorder	5	I-Disease
.	9	O

We	9	O
report	5	O
the	5	O
case	5	O
of	5	O
a	5	O
35	9	O
-	7	O
year	5	O
-	7	O
old	5	O
patient	5	O
suffering	5	O
from	9	O
schizo	5	B-Disease
-	7	I-Disease
affective	5	I-Disease
disorder	5	I-Disease
since	9	O
the	5	O
age	5	O
of	5	O
19	7	O
years	5	O
,	9	O
treated	3	O
by	9	O
a	5	O
combination	9	O
of	5	O
first	9	O
-	7	O
generation	9	O
antipsychotics	5	O
,	9	O
zuclopenthixol	0	B-Chemical
(	9	O
100	0	O
mg	0	O
/	9	O
day	9	O
)	9	O
and	5	O
lithium	0	B-Chemical
(	9	O
1200	0	O
mg	0	O
/	9	O
day	9	O
)	9	O
(	9	O
serum	9	O
lithium	0	B-Chemical
=	7	O
0	7	O
.	9	O
85	9	O
mEq	0	O
/	9	O
l	0	O
)	9	O
.	9	O

This	5	O
patient	5	O
had	9	O
no	9	O
associated	9	O
personality	5	B-Disease
disorder	5	I-Disease
(	9	O
particularly	5	O
no	9	O
antisocial	5	B-Disease
disorder	5	I-Disease
)	9	O
and	5	O
no	9	O
substance	5	B-Disease
abuse	5	I-Disease
disorder	5	I-Disease
.	9	O

Within	9	O
the	5	O
48	9	O
h	0	O
following	9	O
the	5	O
gradual	9	O
introduction	9	O
of	5	O
quetiapine	5	B-Chemical
(	9	O
up	5	O
to	5	O
600	0	O
mg	0	O
/	9	O
day	9	O
)	9	O
,	9	O
the	5	O
patient	5	O
presented	5	O
severe	5	O
agitation	5	B-Disease
without	9	O
an	5	O
environmental	5	O
explanation	5	O
,	9	O
contrasting	9	O
with	5	O
the	5	O
absence	3	O
of	5	O
a	5	O
history	5	O
of	5	O
aggressiveness	5	B-Disease
or	5	O
personality	5	B-Disease
disorder	5	I-Disease
.	9	O

The	5	O
diagnoses	5	O
of	5	O
manic	5	B-Disease
shift	9	O
and	5	O
akathisia	5	B-Disease
were	9	O
dismissed	5	O
.	9	O

The	5	O
withdrawal	5	O
and	5	O
the	5	O
gradual	9	O
reintroduction	9	O
of	5	O
quetiapine	5	B-Chemical
2	9	O
weeks	9	O
later	9	O
,	9	O
which	5	O
led	9	O
to	5	O
another	9	O
severe	5	O
agitation	5	B-Disease
,	9	O
enabled	5	O
us	5	O
to	5	O
attribute	5	O
the	5	O
agitation	5	B-Disease
specifically	9	O
to	5	O
quetiapine	5	B-Chemical
.	9	O

Antioxidant	0	O
effects	9	O
of	5	O
bovine	9	O
lactoferrin	0	O
on	5	O
dexamethasone	0	B-Chemical
-	7	O
induced	3	O
hypertension	5	B-Disease
in	5	O
rat	3	O
.	9	O

Dexamethasone	0	B-Chemical
-	7	O
(	9	O
Dex	3	B-Chemical
-	7	O
)	9	O
induced	3	O
hypertension	5	B-Disease
is	5	O
associated	9	O
with	5	O
enhanced	3	O
oxidative	9	O
stress	9	O
.	9	O

Lactoferrin	0	O
(	9	O
LF	9	O
)	9	O
is	5	O
an	5	O
iron	0	B-Chemical
-	7	O
binding	1	O
glycoprotein	3	O
with	5	O
antihypertensive	5	O
properties	9	O
.	9	O

In	9	O
this	5	O
study	9	O
,	9	O
we	5	O
investigated	9	O
the	5	O
effect	9	O
of	5	O
chronic	5	O
administration	9	O
of	5	O
LF	9	O
on	5	O
oxidative	9	O
stress	9	O
and	5	O
hypertension	5	B-Disease
upon	9	O
Dex	3	B-Chemical
administration	9	O
.	9	O

Male	7	O
Wistar	9	O
rats	9	O
were	9	O
treated	3	O
by	9	O
Dex	3	B-Chemical
(	9	O
30	9	O
u	9	O
g	0	O
/	9	O
kg	0	O
/	9	O
day	9	O
subcutaneously	3	O
)	9	O
or	5	O
saline	0	O
for	5	O
14	7	O
days	9	O
.	9	O

Oral	9	O
bovine	9	O
LF	9	O
(	9	O
30	9	O
,	9	O
100	0	O
,	9	O
300	0	O
mg	0	O
/	9	O
kg	0	O
)	9	O
was	9	O
given	5	O
from	9	O
day	9	O
8	9	O
to	5	O
14	7	O
in	5	O
a	5	O
reversal	9	O
study	9	O
.	9	O

In	9	O
a	5	O
prevention	5	O
study	9	O
,	9	O
rats	9	O
received	9	O
4	9	O
days	9	O
of	5	O
LF	9	O
treatment	9	O
followed	9	O
by	9	O
Dex	3	B-Chemical
and	5	O
continued	9	O
during	5	O
the	5	O
test	5	O
period	5	O
.	9	O

Systolic	7	O
blood	9	O
pressure	5	O
(	9	O
SBP	9	O
)	9	O
was	9	O
measured	9	O
using	9	O
tail	9	O
-	7	O
cuff	5	O
method	5	O
.	9	O

Thymus	9	O
weight	9	O
was	9	O
used	5	O
as	5	O
a	5	O
marker	3	O
of	5	O
glucocorticoid	9	O
activity	9	O
.	9	O

Plasma	0	O
hydrogen	0	B-Chemical
peroxide	0	I-Chemical
(	9	O
H2O2	0	B-Chemical
)	9	O
concentration	0	O
and	5	O
ferric	0	O
reducing	9	O
antioxidant	0	O
power	5	O
(	9	O
FRAP	0	O
)	9	O
value	9	O
were	9	O
determined	9	O
.	9	O

Dexamethasone	0	B-Chemical
significantly	9	O
increased	9	O
SBP	9	O
and	5	O
plasma	9	O
H2O2	0	B-Chemical
level	9	O
and	5	O
decreased	9	O
thymus	3	O
and	5	O
body	5	O
weights	5	O
.	9	O

LF	9	O
lowered	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
01	7	O
)	9	O
and	5	O
dose	9	O
dependently	3	O
prevented	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
Dex	3	B-Chemical
-	7	O
induced	3	O
hypertension	5	B-Disease
.	9	O

LF	9	O
prevented	9	O
body	5	O
weight	9	B-Disease
loss	9	I-Disease
and	5	O
significantly	9	O
reduced	9	O
the	5	O
elevated	9	O
plasma	9	O
H2O2	0	B-Chemical
and	5	O
increased	9	O
FRAP	0	O
values	5	O
.	9	O

Chronic	9	O
administration	9	O
of	5	O
LF	9	O
strongly	9	O
reduced	9	O
the	5	O
blood	9	O
pressure	5	O
and	5	O
production	9	O
of	5	O
ROS	3	O
and	5	O
improved	5	O
antioxidant	0	O
capacity	9	O
in	5	O
Dex	3	B-Chemical
-	7	O
induced	3	O
hypertension	5	B-Disease
,	9	O
suggesting	9	O
the	5	O
role	9	O
of	5	O
inhibition	3	O
of	5	O
oxidative	9	O
stress	9	O
as	5	O
another	9	O
mechanism	9	O
of	5	O
antihypertensive	5	O
action	5	O
of	5	O
LF	9	O
.	9	O

The	5	O
association	9	O
between	5	O
tranexamic	0	B-Chemical
acid	0	I-Chemical
and	5	O
convulsive	5	B-Disease
seizures	5	B-Disease
after	9	O
cardiac	5	O
surgery	5	O
:	9	O
a	5	O
multivariate	5	O
analysis	9	O
in	5	O
11	7	O
529	7	O
patients	5	O
.	9	O

Because	9	O
of	5	O
a	5	O
lack	9	O
of	5	O
contemporary	5	O
data	5	O
regarding	5	O
seizures	5	B-Disease
after	9	O
cardiac	5	O
surgery	5	O
,	9	O
we	5	O
undertook	9	O
a	5	O
retrospective	5	O
analysis	9	O
of	5	O
prospectively	5	O
collected	9	O
data	5	O
from	9	O
11	7	O
529	7	O
patients	5	O
in	5	O
whom	5	O
cardiopulmonary	5	O
bypass	5	O
was	9	O
used	5	O
from	9	O
January	2	O
2004	2	O
to	5	O
December	2	O
2010	2	O
.	9	O

A	9	O
convulsive	5	B-Disease
seizure	5	B-Disease
was	9	O
defined	5	O
as	5	O
a	5	O
transient	9	O
episode	5	O
of	5	O
disturbed	5	O
brain	5	O
function	9	O
characterised	9	O
by	9	O
abnormal	9	B-Disease
involuntary	5	I-Disease
motor	5	I-Disease
movements	5	I-Disease
.	9	O

Multivariate	5	O
regression	5	O
analysis	9	O
was	9	O
performed	9	O
to	5	O
identify	9	O
independent	9	O
predictors	5	O
of	5	O
postoperative	5	O
seizures	5	B-Disease
.	9	O

A	9	O
total	9	O
of	5	O
100	0	O
(	9	O
0	7	O
.	9	O
9	7	O
%	9	O
)	9	O
patients	5	O
developed	5	O
postoperative	5	O
convulsive	5	B-Disease
seizures	5	B-Disease
.	9	O

Generalised	5	B-Disease
and	5	I-Disease
focal	5	I-Disease
seizures	5	I-Disease
were	9	O
identified	9	O
in	5	O
68	7	O
and	5	O
32	7	O
patients	5	O
,	9	O
respectively	9	O
.	9	O

The	5	O
median	9	O
(	9	O
IQR	7	O
[	9	O
range	9	O
]	9	O
)	9	O
time	5	O
after	9	O
surgery	5	O
when	5	O
the	5	O
seizure	5	B-Disease
occurred	9	O
was	9	O
7	9	O
(	9	O
6	9	O
-	7	O
12	9	O
[	9	O
1	9	O
-	7	O
216	7	O
]	9	O
)	9	O
h	0	O
and	5	O
8	9	O
(	9	O
6	9	O
-	7	O
11	7	O
[	9	O
4	9	O
-	7	O
18	7	O
]	9	O
)	9	O
h	0	O
,	9	O
respectively	9	O
.	9	O

Epileptiform	5	O
findings	9	O
on	5	O
electroencephalography	5	O
were	9	O
seen	9	O
in	5	O
19	7	O
patients	5	O
.	9	O

Independent	9	O
predictors	5	O
of	5	O
postoperative	5	O
seizures	5	B-Disease
included	5	O
age	5	O
,	9	O
female	9	O
sex	5	O
,	9	O
redo	5	O
cardiac	5	O
surgery	5	O
,	9	O
calcification	5	O
of	5	O
ascending	5	O
aorta	9	O
,	9	O
congestive	5	B-Disease
heart	5	I-Disease
failure	5	I-Disease
,	9	O
deep	5	O
hypothermic	5	B-Disease
circulatory	5	O
arrest	3	O
,	9	O
duration	5	O
of	5	O
aortic	9	O
cross	5	O
-	7	O
clamp	5	O
and	5	O
tranexamic	0	B-Chemical
acid	0	I-Chemical
.	9	O

When	9	O
tested	9	O
in	5	O
a	5	O
multivariate	5	O
regression	5	O
analysis	9	O
,	9	O
tranexamic	0	B-Chemical
acid	0	I-Chemical
was	9	O
a	5	O
strong	9	O
independent	9	O
predictor	5	O
of	5	O
seizures	5	B-Disease
(	9	O
OR	9	O
14	7	O
.	9	O
3	9	O
,	9	O
95	7	O
%	9	O
CI	7	O
5	9	O
.	9	O
5	9	O
-	7	O
36	9	O
.	9	O
7	9	O
;	9	O
p	7	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
.	9	O

Patients	5	O
with	5	O
convulsive	5	B-Disease
seizures	5	B-Disease
had	9	O
2	9	O
.	9	O
5	9	O
times	5	O
higher	9	O
in	5	O
-	7	O
hospital	5	O
mortality	5	O
rates	5	O
and	5	O
twice	9	O
the	5	O
length	9	O
of	5	O
hospital	5	O
stay	5	O
compared	9	O
with	5	O
patients	5	O
without	9	O
convulsive	5	B-Disease
seizures	5	B-Disease
.	9	O

Mean	9	O
(	9	O
IQR	7	O
[	9	O
range	9	O
]	9	O
)	9	O
length	9	O
of	5	O
stay	5	O
in	5	O
the	5	O
intensive	5	O
care	5	O
unit	5	O
was	9	O
115	7	O
(	9	O
49	7	O
-	7	O
228	7	O
[	9	O
32	7	O
-	7	O
481	7	O
]	9	O
)	9	O
h	0	O
in	5	O
patients	5	O
with	5	O
convulsive	5	B-Disease
seizures	5	B-Disease
compared	9	O
with	5	O
26	7	O
(	9	O
22	7	O
-	7	O
69	7	O
[	9	O
14	7	O
-	7	O
1080	7	O
]	9	O
)	9	O
h	0	O
in	5	O
patients	5	O
without	9	O
seizures	5	B-Disease
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
.	9	O

Convulsive	2	B-Disease
seizures	5	B-Disease
are	5	O
a	5	O
serious	5	O
postoperative	5	B-Disease
complication	5	I-Disease
after	9	O
cardiac	5	O
surgery	5	O
.	9	O

As	9	O
tranexamic	0	B-Chemical
acid	0	I-Chemical
is	5	O
the	5	O
only	9	O
modifiable	5	O
factor	9	O
,	9	O
its	9	O
administration	9	O
,	9	O
particularly	5	O
in	5	O
doses	0	O
exceeding	9	O
80	9	O
mg	0	O
.	9	O
kg	0	O
(	9	O
-	7	O
1	9	O
)	9	O
,	9	O
should	5	O
be	5	O
weighed	9	O
against	9	O
the	5	O
risk	5	O
of	5	O
postoperative	5	O
seizures	5	B-Disease
.	9	O

Dysfunctional	5	B-Disease
overnight	0	I-Disease
memory	5	I-Disease
consolidation	5	O
in	5	O
ecstasy	5	B-Chemical
users	5	O
.	9	O

Sleep	5	O
plays	9	O
an	5	O
important	9	O
role	9	O
in	5	O
the	5	O
consolidation	5	O
and	5	O
integration	5	O
of	5	O
memory	5	O
in	5	O
a	5	O
process	5	O
called	5	O
overnight	0	O
memory	5	O
consolidation	5	O
.	9	O

Previous	9	O
studies	9	O
indicate	9	O
that	5	O
ecstasy	5	B-Chemical
users	5	O
have	5	O
marked	9	O
and	5	O
persistent	5	O
neurocognitive	5	O
and	5	O
sleep	5	B-Disease
-	7	I-Disease
related	9	I-Disease
impairments	5	I-Disease
.	9	O

We	9	O
extend	9	O
past	5	O
research	5	O
by	9	O
examining	5	O
overnight	0	O
memory	5	O
consolidation	5	O
among	5	O
regular	5	O
ecstasy	5	B-Chemical
users	5	O
(	9	O
n	9	O
=	7	O
12	9	O
)	9	O
and	5	O
drug	5	O
naive	3	O
healthy	5	O
controls	9	O
(	9	O
n	9	O
=	7	O
26	7	O
)	9	O
.	9	O

Memory	5	O
recall	5	O
of	5	O
word	5	O
pairs	9	O
was	9	O
evaluated	9	O
before	9	O
and	5	O
after	9	O
a	5	O
period	5	O
of	5	O
sleep	5	O
,	9	O
with	5	O
and	5	O
without	9	O
interference	9	O
prior	9	O
to	5	O
testing	5	O
.	9	O

In	9	O
addition	9	O
,	9	O
we	5	O
assessed	9	O
neurocognitive	5	O
performances	5	O
across	5	O
tasks	5	O
of	5	O
learning	5	O
,	9	O
memory	5	O
and	5	O
executive	5	O
functioning	5	O
.	9	O

Ecstasy	7	B-Chemical
users	5	O
demonstrated	9	O
impaired	9	B-Disease
overnight	0	I-Disease
memory	5	I-Disease
consolidation	5	O
,	9	O
a	5	O
finding	9	O
that	5	O
was	9	O
more	5	O
pronounced	9	O
following	9	O
associative	5	O
interference	9	O
.	9	O

Additionally	9	O
,	9	O
ecstasy	5	B-Chemical
users	5	O
demonstrated	9	O
impairments	5	O
on	5	O
tasks	5	O
recruiting	9	O
frontostriatal	5	O
and	5	O
hippocampal	3	O
neural	5	O
circuitry	5	O
,	9	O
in	5	O
the	5	O
domains	1	O
of	5	O
proactive	5	O
interference	9	O
memory	5	O
,	9	O
long	5	O
-	7	O
term	5	O
memory	5	O
,	9	O
encoding	1	O
,	9	O
working	5	O
memory	5	O
and	5	O
complex	9	O
planning	5	O
.	9	O

We	9	O
suggest	9	O
that	5	O
ecstasy	5	B-Chemical
-	7	O
associated	9	O
dysfunction	9	O
in	5	O
fronto	5	O
-	7	O
temporal	5	O
circuitry	5	O
may	5	O
underlie	5	O
overnight	0	O
consolidation	5	O
memory	5	B-Disease
impairments	5	I-Disease
in	5	O
regular	5	O
ecstasy	5	B-Chemical
users	5	O
.	9	O

Normoammonemic	_	O
encephalopathy	5	B-Disease
:	9	O
solely	9	O
valproate	0	B-Chemical
induced	3	O
or	5	O
multiple	5	O
mechanisms	9	O
?	5	O

A	9	O
77	7	O
-	7	O
year	5	O
-	7	O
old	5	O
woman	5	O
presented	5	O
with	5	O
subacute	5	O
onset	5	O
progressive	5	O
confusion	5	B-Disease
,	9	O
aggression	5	B-Disease
,	9	O
auditory	5	B-Disease
hallucinations	5	I-Disease
and	5	O
delusions	5	B-Disease
.	9	O

In	9	O
the	5	O
preceding	5	O
months	5	O
,	9	O
the	5	O
patient	5	O
had	9	O
a	5	O
number	9	O
of	5	O
admissions	5	O
with	5	O
transient	9	O
unilateral	5	O
hemiparesis	5	B-Disease
with	5	O
facial	5	O
droop	5	O
,	9	O
and	5	O
had	9	O
been	9	O
started	5	O
on	5	O
valproate	0	B-Chemical
for	5	O
presumed	9	O
hemiplegic	5	B-Disease
migraine	5	I-Disease
.	9	O

Valproate	0	B-Chemical
was	9	O
withdrawn	9	O
soon	5	O
after	9	O
admission	5	O
and	5	O
her	5	O
cognitive	5	O
abilities	5	O
have	5	O
gradually	9	O
improved	5	O
over	5	O
3	9	O
months	5	O
of	5	O
follow	5	O
-	7	O
up	5	O
.	9	O

Valproate	0	B-Chemical
levels	3	O
taken	5	O
prior	9	O
to	5	O
withdrawal	5	O
were	9	O
subtherapeutic	5	O
and	5	O
the	5	O
patient	5	O
was	9	O
normoammonaemic	_	O
.	9	O

EEG	5	O
undertaken	5	O
during	5	O
inpatient	5	O
stay	5	O
showed	9	O
changes	9	O
consistent	9	O
with	5	O
encephalopathy	5	B-Disease
,	9	O
and	5	O
low	9	O
titre	9	O
N	9	B-Chemical
-	7	I-Chemical
methyl	0	I-Chemical
-	7	I-Chemical
D	9	I-Chemical
-	7	I-Chemical
aspartate	1	I-Chemical
(	9	O
NMDA	3	B-Chemical
)	9	O
receptor	3	O
antibodies	3	O
were	9	O
present	9	O
in	5	O
this	5	O
patient	5	O
.	9	O

The	5	O
possible	5	O
aetiologies	5	O
of	5	O
valproate	0	B-Chemical
-	7	O
induced	3	O
encephalopathy	5	B-Disease
and	5	O
NMDA	3	B-Chemical
receptor	3	O
-	7	O
associated	9	O
encephalitis	5	B-Disease
present	9	O
a	5	O
diagnostic	5	O
dilemma	5	O
.	9	O

We	9	O
present	9	O
a	5	O
putative	1	O
combinatorial	5	O
hypothesis	9	O
to	5	O
explain	9	O
this	5	O
patient	5	O
'	9	O
s	9	O
symptoms	5	O
.	9	O

Cerebellar	9	B-Disease
and	5	I-Disease
oculomotor	5	I-Disease
dysfunction	9	I-Disease
induced	3	O
by	9	O
rapid	5	O
infusion	0	O
of	5	O
pethidine	5	B-Chemical
.	9	O

Pethidine	0	B-Chemical
is	5	O
an	5	O
opioid	5	O
that	5	O
gains	5	O
its	9	O
popularity	5	O
for	5	O
the	5	O
effective	5	O
pain	5	B-Disease
control	9	O
through	9	O
acting	9	O
on	5	O
the	5	O
opioid	5	O
-	7	O
receptors	3	O
.	9	O

However	9	O
,	9	O
rapid	5	O
pain	5	B-Disease
relief	5	O
sometimes	5	O
brings	5	O
about	5	O
unfavourable	5	O
side	5	O
effects	9	O
that	5	O
largely	9	O
limit	5	O
its	9	O
clinical	5	O
utility	5	O
.	9	O

Common	9	O
side	5	O
effects	9	O
include	5	O
nausea	5	B-Disease
,	9	O
vomiting	5	B-Disease
and	5	O
hypotension	5	B-Disease
.	9	O

In	9	O
patients	5	O
with	5	O
impaired	9	B-Disease
renal	9	I-Disease
and	5	I-Disease
liver	9	I-Disease
function	9	I-Disease
,	9	O
and	5	O
those	5	O
who	5	O
need	5	O
long	5	O
-	7	O
term	5	O
pain	5	B-Disease
control	9	O
,	9	O
pethidine	5	B-Chemical
may	5	O
cause	5	O
excitatory	5	O
central	5	O
nervous	5	O
system	5	O
(	9	O
CNS	9	O
)	9	O
effects	9	O
through	9	O
its	9	O
neurotoxic	9	B-Disease
metabolite	0	O
,	9	O
norpethidine	0	B-Chemical
,	9	O
resulting	9	O
in	5	O
irritability	5	B-Disease
and	5	O
seizure	5	B-Disease
attack	5	O
.	9	O

On	5	O
the	5	O
contrary	9	O
,	9	O
though	9	O
not	5	O
clinically	5	O
apparent	9	O
,	9	O
pethidine	5	B-Chemical
potentially	5	O
causes	9	O
inhibitory	3	O
impacts	5	O
on	5	O
the	5	O
CNS	9	O
and	5	O
impairs	9	O
normal	9	O
cerebellar	5	O
and	5	O
oculomotor	5	O
function	9	O
in	5	O
the	5	O
short	5	O
term	5	O
.	9	O

In	9	O
this	5	O
case	5	O
report	5	O
,	9	O
we	5	O
highlight	5	O
opioid	5	O
'	9	O
s	9	O
inhibitory	3	O
side	5	O
effects	9	O
on	5	O
the	5	O
cerebellar	5	O
structure	9	O
that	5	O
causes	9	O
dysmetria	5	B-Disease
,	9	O
dysarthria	5	B-Disease
,	9	O
reduced	9	O
smooth	5	O
pursuit	5	O
gain	5	O
and	5	O
decreased	9	O
saccadic	5	O
velocity	5	O
.	9	O

Baboon	9	B-Disease
syndrome	5	I-Disease
induced	3	O
by	9	O
ketoconazole	0	B-Chemical
.	9	O

A	9	O
27	7	O
-	7	O
year	5	O
-	7	O
old	5	O
male	9	O
patient	5	O
presented	5	O
with	5	O
a	5	O
maculopapular	5	B-Disease
eruption	5	I-Disease
on	5	O
the	5	O
flexural	5	O
areas	5	O
and	5	O
buttocks	5	O
after	9	O
using	9	O
oral	9	O
ketoconazole	0	B-Chemical
.	9	O

The	5	O
patient	5	O
was	9	O
diagnosed	5	O
with	5	O
drug	5	O
-	7	O
induced	3	O
baboon	9	B-Disease
syndrome	5	I-Disease
based	5	O
on	5	O
his	5	O
history	5	O
,	9	O
which	5	O
included	5	O
prior	9	O
sensitivity	9	O
to	5	O
topical	0	O
ketoconazole	0	B-Chemical
,	9	O
a	5	O
physical	5	O
examination	5	O
,	9	O
and	5	O
histopathological	9	O
findings	9	O
.	9	O

Baboon	9	B-Disease
syndrome	5	I-Disease
is	5	O
a	5	O
drug	5	O
-	7	O
or	5	O
contact	5	O
allergen	9	O
-	7	O
related	9	O
maculopapular	5	B-Disease
eruption	5	I-Disease
that	5	O
typically	5	O
involves	5	O
the	5	O
flexural	5	O
and	5	O
gluteal	5	O
areas	5	O
.	9	O

To	9	O
the	5	O
best	5	O
of	5	O
our	5	O
knowledge	5	O
,	9	O
this	5	O
is	5	O
the	5	O
first	9	O
reported	9	O
case	5	O
of	5	O
ketoconazole	0	B-Chemical
-	7	O
induced	3	O
baboon	9	B-Disease
syndrome	5	I-Disease
in	5	O
the	5	O
English	5	O
literature	5	O
.	9	O

A	9	O
Case	5	O
of	5	O
Sudden	5	B-Disease
Cardiac	9	I-Disease
Death	9	I-Disease
due	5	O
to	5	O
Pilsicainide	9	B-Chemical
-	7	O
Induced	9	O
Torsades	2	B-Disease
de	2	I-Disease
Pointes	2	I-Disease
.	9	O

An	5	O
84	7	O
-	7	O
year	5	O
-	7	O
old	5	O
male	9	O
received	9	O
oral	9	O
pilsicainide	5	B-Chemical
,	9	O
a	5	O
pure	9	O
sodium	0	B-Chemical
channel	9	O
blocker	0	O
with	5	O
slow	5	O
recovery	9	O
kinetics	9	O
,	9	O
to	5	O
convert	9	O
his	5	O
paroxysmal	5	O
atrial	5	B-Disease
fibrillation	5	I-Disease
to	5	O
a	5	O
sinus	5	O
rhythm	5	O
;	9	O
the	5	O
patient	5	O
developed	5	O
sudden	5	B-Disease
cardiac	5	I-Disease
death	9	I-Disease
two	5	O
days	9	O
later	9	O
.	9	O

The	5	O
Holter	5	O
electrocardiogram	5	O
,	9	O
which	5	O
was	9	O
worn	5	O
by	9	O
chance	5	O
,	9	O
revealed	9	O
torsade	5	B-Disease
de	2	I-Disease
pointes	5	I-Disease
with	5	O
gradually	9	O
prolonged	9	O
QT	5	O
intervals	5	O
.	9	O

This	5	O
drug	5	O
is	5	O
rapidly	9	O
absorbed	0	O
from	9	O
the	5	O
gastrointestinal	9	O
tract	9	O
,	9	O
and	5	O
most	9	O
of	5	O
it	5	O
is	5	O
excreted	0	O
from	9	O
the	5	O
kidney	9	O
.	9	O

Although	9	O
the	5	O
patient	5	O
'	9	O
s	9	O
renal	9	O
function	9	O
was	9	O
not	5	O
highly	9	O
impaired	9	O
and	5	O
the	5	O
dose	9	O
of	5	O
pilsicainide	5	B-Chemical
was	9	O
low	9	O
,	9	O
the	5	O
plasma	9	O
concentration	0	O
of	5	O
pilsicainide	5	B-Chemical
may	5	O
have	5	O
been	9	O
high	9	O
,	9	O
which	5	O
can	5	O
produce	9	O
torsades	5	B-Disease
de	2	I-Disease
pointes	5	I-Disease
in	5	O
the	5	O
octogenarian	5	O
.	9	O

Although	9	O
the	5	O
oral	9	O
administration	9	O
of	5	O
class	9	O
IC	9	O
drugs	5	O
,	9	O
including	9	O
pilsicainide	5	B-Chemical
,	9	O
is	5	O
effective	5	O
to	5	O
terminate	9	O
atrial	5	B-Disease
fibrillation	5	I-Disease
,	9	O
careful	5	O
consideration	5	O
must	5	O
be	5	O
taken	5	O
before	9	O
giving	5	O
these	5	O
drugs	5	O
to	5	O
octogenarians	5	O
.	9	O

All	9	B-Chemical
-	7	I-Chemical
trans	9	I-Chemical
retinoic	3	I-Chemical
acid	0	I-Chemical
-	7	O
induced	3	O
inflammatory	3	O
myositis	9	B-Disease
in	5	O
a	5	O
patient	5	O
with	5	O
acute	9	B-Disease
promyelocytic	3	I-Disease
leukemia	3	I-Disease
.	9	O

All	9	B-Chemical
-	7	I-Chemical
trans	9	I-Chemical
retinoic	3	I-Chemical
acid	0	I-Chemical
(	9	O
ATRA	3	B-Chemical
)	9	O
,	9	O
a	5	O
component	9	O
of	5	O
standard	5	O
therapy	5	O
for	5	O
acute	9	B-Disease
promyelocytic	3	I-Disease
leukemia	3	I-Disease
(	9	O
APL	3	B-Disease
)	9	O
,	9	O
is	5	O
associated	9	O
with	5	O
potentially	5	O
serious	5	O
but	9	O
treatable	5	O
adverse	5	O
effects	9	O
involving	5	O
numerous	9	O
organ	5	O
systems	5	O
,	9	O
including	9	O
rare	5	O
skeletal	9	O
muscle	9	O
involvement	9	O
.	9	O

Only	9	O
a	5	O
handful	5	O
of	5	O
cases	5	O
of	5	O
ATRA	3	B-Chemical
-	7	O
induced	3	O
myositis	9	B-Disease
in	5	O
children	5	O
have	5	O
been	9	O
reported	9	O
,	9	O
and	5	O
none	9	O
in	5	O
the	5	O
radiology	5	O
literature	5	O
.	9	O

We	9	O
present	9	O
such	5	O
a	5	O
case	5	O
in	5	O
a	5	O
15	9	O
-	7	O
year	5	O
-	7	O
old	5	O
boy	5	O
with	5	O
APL	3	B-Disease
,	9	O
where	5	O
recognition	5	O
of	5	O
imaging	5	O
findings	9	O
played	9	O
a	5	O
crucial	9	O
role	9	O
in	5	O
making	5	O
the	5	O
diagnosis	5	O
and	5	O
facilitated	5	O
prompt	5	O
,	9	O
effective	5	O
treatment	9	O
.	9	O

Tolerability	5	O
of	5	O
lomustine	0	B-Chemical
in	5	O
combination	9	O
with	5	O
cyclophosphamide	0	B-Chemical
in	5	O
dogs	5	O
with	5	O
lymphoma	9	B-Disease
.	9	O

This	5	O
retrospective	5	O
study	9	O
describes	5	O
toxicity	9	B-Disease
associated	9	O
with	5	O
a	5	O
protocol	9	O
of	5	O
lomustine	0	B-Chemical
(	9	O
CCNU	0	B-Chemical
)	9	O
and	5	O
cyclophosphamide	0	B-Chemical
(	9	O
CTX	9	B-Chemical
)	9	O
in	5	O
dogs	5	O
with	5	O
lymphoma	9	B-Disease
.	9	O

CCNU	0	B-Chemical
was	9	O
administered	9	O
per	9	O
os	9	O
(	9	O
PO	9	O
)	9	O
at	9	O
a	5	O
targeted	9	O
dosage	9	O
of	5	O
60	9	O
mg	0	O
/	9	O
m	9	O
(	9	O
2	9	O
)	9	O
body	5	O
surface	9	O
area	5	O
on	5	O
day	9	O
0	7	O
,	9	O
CTX	9	B-Chemical
was	9	O
administered	9	O
PO	9	O
at	9	O
a	5	O
targeted	9	O
dosage	9	O
of	5	O
250	0	O
mg	0	O
/	9	O
m	9	O
(	9	O
2	9	O
)	9	O
divided	5	O
over	5	O
days	9	O
0	7	O
through	9	O
4	9	O
,	9	O
and	5	O
all	5	O
dogs	5	O
received	9	O
prophylactic	5	O
antibiotics	5	O
.	9	O

Ninety	5	O
treatments	9	O
were	9	O
given	5	O
to	5	O
the	5	O
57	7	O
dogs	5	O
included	5	O
in	5	O
the	5	O
study	9	O
.	9	O

Neutropenia	7	B-Disease
was	9	O
the	5	O
principal	5	O
toxic	0	O
effect	9	O
,	9	O
and	5	O
the	5	O
overall	5	O
frequency	5	O
of	5	O
grade	9	O
4	9	O
neutropenia	5	B-Disease
after	9	O
the	5	O
first	9	O
treatment	9	O
of	5	O
CCNU	0	B-Chemical
/	9	O
CTX	9	B-Chemical
was	9	O
30	9	O
%	9	O
(	9	O
95	7	O
%	9	O
confidence	5	O
interval	5	O
,	9	O
19	7	O
-	7	O
43	7	O
%	9	O
)	9	O
.	9	O

The	5	O
mean	5	O
body	5	O
weight	9	O
of	5	O
dogs	5	O
with	5	O
grade	9	O
4	9	O
neutropenia	5	B-Disease
(	9	O
19	7	O
.	9	O
7	9	O
kg	0	O
+	9	O
13	7	O
.	9	O
4	9	O
kg	0	O
)	9	O
was	9	O
significantly	9	O
less	5	O
than	5	O
the	5	O
mean	5	O
body	5	O
weight	9	O
of	5	O
dogs	5	O
that	5	O
did	9	O
not	5	O
develop	5	O
grade	9	O
4	9	O
neutropenia	5	B-Disease
(	9	O
31	7	O
.	9	O
7	9	O
kg	0	O
+	9	O
12	9	O
.	9	O
4	9	O
kg	0	O
;	9	O
P	9	O
=	7	O
.	9	O
005	7	O
)	9	O
.	9	O

One	5	O
dog	5	O
(	9	O
3	9	O
%	9	O
)	9	O
developed	5	O
hematologic	5	O
changes	9	O
suggestive	9	O
of	5	O
hepatotoxicity	9	B-Disease
.	9	O

No	9	O
dogs	5	O
had	9	O
evidence	9	O
of	5	O
either	9	O
renal	9	B-Disease
toxicity	9	I-Disease
or	5	O
hemorrhagic	5	B-Disease
cystitis	9	I-Disease
.	9	O

Adverse	5	O
gastrointestinal	9	O
effects	9	O
were	9	O
uncommon	5	O
.	9	O

On	5	O
the	5	O
basis	5	O
of	5	O
the	5	O
findings	9	O
reported	9	O
herein	9	O
,	9	O
a	5	O
dose	9	O
of	5	O
60	9	O
mg	0	O
/	9	O
m	9	O
(	9	O
2	9	O
)	9	O
of	5	O
CCNU	0	B-Chemical
combined	9	O
with	5	O
250	0	O
mg	0	O
/	9	O
m	9	O
(	9	O
2	9	O
)	9	O
of	5	O
CTX	9	B-Chemical
(	9	O
divided	5	O
over	5	O
5	9	O
days	9	O
)	9	O
q	9	O
4	9	O
wk	9	O
is	5	O
tolerable	5	O
in	5	O
tumor	3	B-Disease
-	7	O
bearing	3	O
dogs	5	O
.	9	O

Nelarabine	0	B-Chemical
neurotoxicity	9	B-Disease
with	5	O
concurrent	5	O
intrathecal	3	O
chemotherapy	5	O
:	9	O
Case	5	O
report	5	O
and	5	O
review	5	O
of	5	O
literature	5	O
.	9	O

Severe	9	O
nelarabine	5	B-Chemical
neurotoxicity	9	B-Disease
in	5	O
a	5	O
patient	5	O
who	5	O
received	9	O
concurrent	5	O
intrathecal	3	O
(	9	O
IT	9	O
)	9	O
chemotherapy	5	O
is	5	O
reported	9	O
.	9	O

A	9	O
37	9	O
-	7	O
year	5	O
-	7	O
old	5	O
Caucasian	9	O
woman	5	O
with	5	O
a	5	O
history	5	O
of	5	O
T	3	B-Disease
-	7	I-Disease
cell	3	I-Disease
lymphoblastic	3	I-Disease
lymphoma	9	I-Disease
was	9	O
admitted	5	O
for	5	O
relapsed	5	O
disease	5	O
.	9	O

She	5	O
was	9	O
originally	9	O
treated	3	O
with	5	O
induction	3	O
chemotherapy	5	O
followed	9	O
by	9	O
an	5	O
autologous	3	O
transplant	9	O
.	9	O

She	5	O
developed	5	O
relapsed	5	O
disease	5	O
10	9	O
months	5	O
later	9	O
with	5	O
leukemic	3	B-Disease
involvement	9	O
.	9	O

She	5	O
was	9	O
re	5	O
-	7	O
induced	3	O
with	5	O
nelarabine	5	B-Chemical
1500	9	O
mg	0	O
/	9	O
m	9	O
(	9	O
2	9	O
)	9	O
on	5	O
days	9	O
1	9	O
,	9	O
3	9	O
,	9	O
and	5	O
5	9	O
with	5	O
1	9	O
dose	9	O
of	5	O
IT	9	O
cytarabine	0	B-Chemical
100	0	O
mg	0	O
on	5	O
day	9	O
2	9	O
as	5	O
central	5	O
nervous	5	O
system	5	O
(	9	O
CNS	9	O
)	9	O
prophylaxis	5	O
.	9	O

At	9	O
the	5	O
time	5	O
of	5	O
treatment	9	O
,	9	O
she	5	O
was	9	O
on	5	O
continuous	5	O
renal	9	O
replacement	9	O
therapy	5	O
due	5	O
to	5	O
sequelae	5	O
of	5	O
tumor	3	B-Disease
lysis	3	I-Disease
syndrome	5	I-Disease
(	9	O
TLS	9	B-Disease
)	9	O
.	9	O

She	5	O
tolerated	9	O
therapy	5	O
well	9	O
,	9	O
entered	5	O
a	5	O
complete	9	O
remission	5	O
,	9	O
and	5	O
recovered	9	O
her	5	O
renal	9	O
function	9	O
.	9	O

She	5	O
received	9	O
a	5	O
second	9	O
cycle	9	O
of	5	O
nelarabine	5	B-Chemical
without	9	O
additional	9	O
IT	9	O
prophylaxis	5	O
one	5	O
month	5	O
later	9	O
.	9	O

A	9	O
week	9	O
after	9	O
this	5	O
second	9	O
cycle	9	O
,	9	O
she	5	O
noted	9	O
numbness	5	O
in	5	O
her	5	O
lower	9	O
extremities	5	O
.	9	O

Predominantly	9	O
sensory	5	O
,	9	O
though	9	O
also	9	O
motor	5	O
and	5	O
autonomic	5	O
,	9	O
peripheral	9	B-Disease
neuropathy	5	I-Disease
started	5	O
in	5	O
her	5	O
feet	5	O
,	9	O
ascended	5	O
proximally	5	O
to	5	O
the	5	O
mid	9	O
-	7	O
thoracic	5	O
region	9	O
,	9	O
and	5	O
eventually	5	O
included	5	O
her	5	O
distal	9	O
upper	9	O
extremities	5	O
.	9	O

A	9	O
magnetic	0	O
resonance	5	O
imaging	5	O
(	9	O
MRI	5	O
)	9	O
of	5	O
her	5	O
spine	5	O
demonstrated	9	O
changes	9	O
from	9	O
C2	9	O
to	5	O
C6	9	O
consistent	9	O
with	5	O
subacute	5	O
combined	9	O
degeneration	9	O
.	9	O

Nelarabine	0	B-Chemical
was	9	O
felt	5	O
to	5	O
be	5	O
the	5	O
cause	5	O
of	5	O
her	5	O
symptoms	5	O
.	9	O

Her	5	O
neuropathy	5	B-Disease
stabilized	9	O
and	5	O
showed	9	O
slight	9	O
improvement	5	O
and	5	O
ultimately	5	O
received	9	O
an	5	O
unrelated	9	O
,	9	O
reduced	9	O
-	7	O
intensity	5	O
allogeneic	3	O
transplant	9	O
while	9	O
in	5	O
complete	9	O
remission	5	O
,	9	O
but	9	O
relapsed	5	O
disease	5	O
10	9	O
weeks	9	O
later	9	O
.	9	O

She	5	O
is	5	O
currently	5	O
being	5	O
treated	3	O
with	5	O
best	5	O
supportive	5	O
care	5	O
.	9	O

To	9	O
our	5	O
knowledge	5	O
,	9	O
this	5	O
is	5	O
the	5	O
first	9	O
published	9	O
case	5	O
report	5	O
of	5	O
severe	5	O
neurotoxicity	9	B-Disease
caused	9	O
by	9	O
nelarabine	5	B-Chemical
in	5	O
a	5	O
patient	5	O
who	5	O
received	9	O
concurrent	5	O
IT	9	O
chemotherapy	5	O
.	9	O

Valproate	0	B-Chemical
-	7	O
induced	3	O
hyperammonemic	5	B-Disease
encephalopathy	5	B-Disease
in	5	O
a	5	O
renal	9	O
transplanted	3	O
patient	5	O
.	9	O

Neurological	5	B-Disease
complications	5	I-Disease
after	9	O
renal	9	O
transplantation	9	O
constitute	9	O
an	5	O
important	9	O
cause	5	O
of	5	O
morbidity	5	O
and	5	O
mortality	5	O
.	9	O

Their	5	O
differential	9	O
diagnosis	5	O
is	5	O
difficult	5	O
and	5	O
essential	9	O
for	5	O
subsequent	9	O
patient	5	O
'	9	O
s	9	O
management	5	O
.	9	O

Valproate	0	B-Chemical
-	7	O
induced	3	O
hyperammonemic	5	B-Disease
encephalopathy	5	B-Disease
is	5	O
an	5	O
uncommon	5	O
but	9	O
serious	5	O
effect	9	O
of	5	O
valproate	0	B-Chemical
treatment	9	O
.	9	O

Here	9	O
,	9	O
we	5	O
describe	5	O
the	5	O
case	5	O
of	5	O
a	5	O
15	9	O
-	7	O
year	5	O
-	7	O
old	5	O
girl	5	O
who	5	O
was	9	O
on	5	O
a	5	O
long	5	O
-	7	O
term	5	O
therapy	5	O
with	5	O
valproate	0	B-Chemical
due	5	O
to	5	O
epilepsy	5	B-Disease
and	5	O
revealed	9	O
impaired	9	B-Disease
consciousness	5	I-Disease
with	5	O
hyperammonemia	5	B-Disease
12	9	O
days	9	O
after	9	O
renal	9	O
transplantation	9	O
.	9	O

After	9	O
withdraw	5	O
of	5	O
valproate	0	B-Chemical
,	9	O
patients	5	O
'	9	O
symptoms	5	O
resolved	9	O
within	9	O
24	9	O
h	0	O
.	9	O

Clinicians	5	O
should	5	O
increase	9	O
their	5	O
awareness	5	O
for	5	O
potential	9	O
complication	5	O
of	5	O
valproate	0	B-Chemical
,	9	O
especially	5	O
in	5	O
transplanted	3	O
patients	5	O
.	9	O

Necrotising	5	B-Disease
fasciitis	5	I-Disease
after	9	O
bortezomib	3	B-Chemical
and	5	O
dexamethasone	0	B-Chemical
-	7	O
containing	0	O
regimen	5	O
in	5	O
an	5	O
elderly	5	O
patient	5	O
of	5	O
Waldenstrom	2	B-Disease
macroglobulinaemia	2	I-Disease
.	9	O

Bortezomib	3	B-Chemical
and	5	O
high	9	O
-	7	O
dose	9	O
dexamethasone	0	B-Chemical
-	7	O
containing	0	O
regimens	5	O
are	5	O
considered	5	O
to	5	O
be	5	O
generally	5	O
tolerable	5	O
with	5	O
few	5	O
severe	5	O
bacterial	9	B-Disease
infections	5	I-Disease
in	5	O
patients	5	O
with	5	O
B	9	O
-	7	O
cell	3	O
malignancies	5	B-Disease
.	9	O

However	9	O
,	9	O
information	5	O
is	5	O
limited	5	O
concerning	5	O
the	5	O
safety	5	O
of	5	O
the	5	O
regimen	5	O
in	5	O
elderly	5	O
patients	5	O
.	9	O

We	9	O
report	5	O
a	5	O
case	5	O
of	5	O
a	5	O
76	7	O
-	7	O
year	5	O
-	7	O
old	5	O
man	5	O
with	5	O
Waldenstrom	2	B-Disease
macroglobulinaemia	2	I-Disease
who	5	O
suffered	5	O
necrotising	5	B-Disease
fasciitis	5	I-Disease
without	9	O
neutropenia	5	B-Disease
after	9	O
the	5	O
combination	9	O
treatment	9	O
with	5	O
bortezomib	3	B-Chemical
,	9	O
high	9	O
-	7	O
dose	9	O
dexamethasone	0	B-Chemical
and	5	O
rituximab	9	O
.	9	O

Despite	5	O
immediate	5	O
intravenous	0	O
antimicrobial	9	O
therapy	5	O
,	9	O
he	5	O
succumbed	3	O
23	7	O
h	0	O
after	9	O
the	5	O
onset	5	O
.	9	O

Physicians	5	O
should	5	O
recognise	5	O
the	5	O
possibility	9	O
of	5	O
fatal	5	O
bacterial	9	B-Disease
infections	5	I-Disease
related	9	O
to	5	O
bortezomib	3	B-Chemical
plus	9	O
high	9	O
-	7	O
dose	9	O
dexamethasone	0	B-Chemical
in	5	O
elderly	5	O
patients	5	O
,	9	O
and	5	O
we	5	O
believe	5	O
this	5	O
case	5	O
warrants	9	O
further	9	O
investigation	9	O
.	9	O

An	5	O
integrated	5	O
characterization	9	O
of	5	O
serological	9	O
,	9	O
pathological	5	O
,	9	O
and	5	O
functional	9	O
events	5	O
in	5	O
doxorubicin	0	B-Chemical
-	7	O
induced	3	O
cardiotoxicity	9	B-Disease
.	9	O

Many	5	O
efficacious	5	O
cancer	3	B-Disease
treatments	9	O
cause	5	O
significant	9	O
cardiac	5	O
morbidity	5	O
,	9	O
yet	9	O
biomarkers	9	O
or	5	O
functional	9	O
indices	5	O
of	5	O
early	9	O
damage	9	O
,	9	O
which	5	O
would	5	O
allow	5	O
monitoring	5	O
and	5	O
intervention	5	O
,	9	O
are	5	O
lacking	1	O
.	9	O

In	9	O
this	5	O
study	9	O
,	9	O
we	5	O
have	5	O
utilized	9	O
a	5	O
rat	3	O
model	5	O
of	5	O
progressive	5	O
doxorubicin	0	B-Chemical
(	9	O
DOX	0	B-Chemical
)	9	O
-	7	O
induced	3	O
cardiomyopathy	5	B-Disease
,	9	O
applying	5	O
multiple	5	O
approaches	5	O
,	9	O
including	9	O
cardiac	5	O
magnetic	0	O
resonance	5	O
imaging	5	O
(	9	O
MRI	5	O
)	9	O
,	9	O
to	5	O
provide	5	O
the	5	O
most	9	O
comprehensive	5	O
characterization	9	O
to	5	O
date	5	O
of	5	O
the	5	O
timecourse	5	O
of	5	O
serological	9	O
,	9	O
pathological	5	O
,	9	O
and	5	O
functional	9	O
events	5	O
underlying	5	O
this	5	O
toxicity	9	B-Disease
.	9	O

Hannover	2	O
Wistar	9	O
rats	9	O
were	9	O
dosed	0	O
with	5	O
1	9	O
.	9	O
25	9	O
mg	0	O
/	9	O
kg	0	O
DOX	0	B-Chemical
weekly	5	O
for	5	O
8	9	O
weeks	9	O
followed	9	O
by	9	O
a	5	O
4	9	O
week	9	O
off	5	O
-	7	O
dosing	9	O
"	5	O
recovery	9	O
"	5	O
period	5	O
.	9	O

Electron	0	O
microscopy	9	O
of	5	O
the	5	O
myocardium	9	O
revealed	9	O
subcellular	3	B-Disease
degeneration	9	I-Disease
and	5	O
marked	9	O
mitochondrial	9	O
changes	9	O
after	9	O
a	5	O
single	9	O
dose	9	O
.	9	O

Histopathological	9	O
analysis	9	O
revealed	9	O
progressive	5	O
cardiomyocyte	3	B-Disease
degeneration	9	I-Disease
,	9	O
hypertrophy	9	B-Disease
/	9	O
cytomegaly	3	O
,	9	O
and	5	O
extensive	5	O
vacuolation	3	O
after	9	O
two	5	O
doses	0	O
.	9	O

Extensive	9	O
replacement	9	O
fibrosis	9	B-Disease
(	9	O
quantified	9	O
by	9	O
Sirius	0	O
red	9	O
staining	3	O
)	9	O
developed	5	O
during	5	O
the	5	O
off	5	O
-	7	O
dosing	9	O
period	5	O
.	9	O

Functional	9	O
indices	5	O
assessed	9	O
by	9	O
cardiac	5	O
MRI	5	O
(	9	O
including	9	O
left	5	O
ventricular	5	O
ejection	5	O
fraction	9	O
(	9	O
LVEF	5	O
)	9	O
,	9	O
cardiac	5	O
output	5	O
,	9	O
and	5	O
E	9	O
/	9	O
A	9	O
ratio	9	O
)	9	O
declined	9	O
progressively	9	O
,	9	O
reaching	5	O
statistical	5	O
significance	9	O
after	9	O
two	5	O
doses	0	O
and	5	O
culminating	9	O
in	5	O
"	5	O
clinical	5	O
"	5	O
LV	9	B-Disease
dysfunction	9	I-Disease
by	9	O
12	9	O
weeks	9	O
.	9	O

Significant	9	O
increases	9	O
in	5	O
peak	9	O
myocardial	9	O
contrast	9	O
enhancement	9	O
and	5	O
serological	9	O
cardiac	5	O
troponin	9	O
I	9	O
(	9	O
cTnI	9	O
)	9	O
emerged	9	O
after	9	O
eight	9	O
doses	0	O
,	9	O
importantly	9	O
preceding	5	O
the	5	O
LVEF	5	O
decline	9	O
to	5	O
<	0	O
50	0	O
%	9	O
.	9	O

Troponin	7	O
I	9	O
levels	3	O
positively	9	O
correlated	9	O
with	5	O
delayed	9	O
and	5	O
peak	9	O
gadolinium	0	B-Chemical
contrast	9	O
enhancement	9	O
,	9	O
histopathological	9	O
grading	5	O
,	9	O
and	5	O
diastolic	5	B-Disease
dysfunction	9	I-Disease
.	9	O

In	9	O
summary	9	O
,	9	O
subcellular	3	O
cardiomyocyte	3	B-Disease
degeneration	9	I-Disease
was	9	O
the	5	O
earliest	9	O
marker	3	O
,	9	O
followed	9	O
by	9	O
progressive	5	O
functional	9	O
decline	9	O
and	5	O
histopathological	9	O
manifestations	5	O
.	9	O

Myocardial	9	O
contrast	9	O
enhancement	9	O
and	5	O
elevations	9	O
in	5	O
cTnI	9	O
occurred	9	O
later	9	O
.	9	O

However	9	O
,	9	O
all	5	O
indices	5	O
predated	4	O
"	5	O
clinical	5	O
"	5	O
LV	9	B-Disease
dysfunction	9	I-Disease
and	5	O
thus	9	O
warrant	9	O
further	9	O
evaluation	5	O
as	5	O
predictive	5	O
biomarkers	9	O
.	9	O

Intradermal	3	O
glutamate	0	B-Chemical
and	5	O
capsaicin	0	B-Chemical
injections	9	O
:	9	O
intra	5	O
-	7	O
and	5	O
interindividual	5	O
variability	5	O
of	5	O
provoked	9	O
hyperalgesia	3	B-Disease
and	5	O
allodynia	5	B-Disease
.	9	O

Intradermal	3	O
injections	9	O
of	5	O
glutamate	0	B-Chemical
and	5	O
capsaicin	0	B-Chemical
are	5	O
attractive	5	O
to	5	O
use	5	O
in	5	O
human	3	O
experimental	5	O
pain	5	B-Disease
models	5	O
because	5	O
hyperalgesia	3	B-Disease
and	5	O
allodynia	5	B-Disease
mimic	9	O
isolated	9	O
aspects	5	O
of	5	O
clinical	5	O
pain	5	B-Disease
disorders	5	I-Disease
.	9	O

The	5	O
aim	5	O
of	5	O
the	5	O
present	9	O
study	9	O
was	9	O
to	5	O
investigate	9	O
the	5	O
reproducibility	5	O
of	5	O
these	5	O
models	5	O
.	9	O

Twenty	9	O
healthy	5	O
male	9	O
volunteers	5	O
(	9	O
mean	5	O
age	5	O
24	9	O
years	5	O
;	9	O
range	9	O
18	7	O
-	7	O
38	7	O
years	5	O
)	9	O
received	9	O
intradermal	9	O
injections	9	O
of	5	O
glutamate	0	B-Chemical
and	5	O
capsaicin	0	B-Chemical
in	5	O
the	5	O
volar	5	O
forearm	5	O
.	9	O

Magnitudes	5	O
of	5	O
secondary	9	O
pinprick	5	O
hyperalgesia	3	B-Disease
and	5	O
brush	9	O
-	7	O
evoked	5	O
allodynia	5	B-Disease
were	9	O
investigated	9	O
using	9	O
von	6	O
Frey	6	O
filaments	9	O
(	9	O
gauges	5	O
10	9	O
,	9	O
15	9	O
,	9	O
60	9	O
and	5	O
100	0	O
g	0	O
)	9	O
and	5	O
brush	9	O
strokes	5	O
.	9	O

Areas	5	O
of	5	O
secondary	9	B-Disease
hyperalgesia	3	I-Disease
and	5	O
allodynia	5	B-Disease
were	9	O
quantified	9	O
immediately	9	O
after	9	O
injection	9	O
and	5	O
after	9	O
15	9	O
,	9	O
30	9	O
and	5	O
60	9	O
min	0	O
.	9	O

Two	9	O
identical	9	O
experiments	9	O
separated	9	O
by	9	O
at	9	O
least	9	O
7	9	O
days	9	O
were	9	O
performed	9	O
.	9	O

Reproducibility	5	O
across	5	O
and	5	O
within	9	O
volunteers	5	O
(	9	O
inter	5	O
-	7	O
and	5	O
intra	5	O
-	7	O
individual	5	O
variation	5	O
,	9	O
respectively	9	O
)	9	O
was	9	O
assessed	9	O
using	9	O
intraclass	5	O
correlation	9	O
coefficient	5	O
(	9	O
ICC	5	O
)	9	O
and	5	O
coefficient	5	O
of	5	O
variation	5	O
(	9	O
CV	9	O
)	9	O
.	9	O

Secondary	9	O
pinprick	5	O
hyperalgesia	3	B-Disease
was	9	O
observed	9	O
as	5	O
a	5	O
marked	9	O
increase	9	O
in	5	O
the	5	O
visual	5	O
analogue	0	O
scale	5	O
(	9	O
VAS	5	O
)	9	O
response	9	O
to	5	O
von	6	O
Frey	6	O
gauges	5	O
60	9	O
and	5	O
100	0	O
g	0	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
after	9	O
glutamate	0	B-Chemical
injection	9	O
.	9	O

For	9	O
capsaicin	0	B-Chemical
,	9	O
secondary	9	O
pinprick	5	O
hyperalgesia	3	B-Disease
was	9	O
detected	9	O
with	5	O
all	5	O
von	6	O
Frey	6	O
gauges	5	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
.	9	O

Glutamate	0	B-Chemical
evoked	5	O
reproducible	5	O
VAS	5	O
response	9	O
to	5	O
all	5	O
von	6	O
Frey	6	O
gauges	5	O
(	9	O
ICC	5	O
>	0	O
0	7	O
.	9	O
60	9	O
)	9	O
and	5	O
brush	9	O
strokes	5	O
(	9	O
ICC	5	O
>	0	O
0	7	O
.	9	O
83	7	O
)	9	O
.	9	O

Capsaicin	0	B-Chemical
injection	9	O
was	9	O
reproducible	5	O
for	5	O
secondary	9	B-Disease
hyperalgesia	3	I-Disease
(	9	O
ICC	5	O
>	0	O
0	7	O
.	9	O
70	9	O
)	9	O
and	5	O
allodynia	5	B-Disease
(	9	O
ICC	5	O
>	0	O
0	7	O
.	9	O
71	7	O
)	9	O
.	9	O

Intra	5	O
-	7	O
individual	5	O
variability	5	O
was	9	O
generally	5	O
lower	9	O
for	5	O
the	5	O
VAS	5	O
response	9	O
to	5	O
von	6	O
Frey	6	O
and	5	O
brush	9	O
compared	9	O
with	5	O
areas	5	O
of	5	O
secondary	9	B-Disease
hyperalgesia	3	I-Disease
and	5	O
allodynia	5	B-Disease
.	9	O

In	9	O
conclusion	9	O
,	9	O
glutamate	0	B-Chemical
and	5	O
capsaicin	0	B-Chemical
yield	9	O
reproducible	5	O
hyperalgesic	3	B-Disease
and	5	O
allodynic	5	B-Disease
responses	5	O
,	9	O
and	5	O
the	5	O
present	9	O
model	5	O
is	5	O
well	9	O
suited	5	O
for	5	O
basic	5	O
research	5	O
,	9	O
as	5	O
well	9	O
as	5	O
for	5	O
assessing	5	O
the	5	O
modulation	9	O
of	5	O
central	5	O
phenomena	5	O
.	9	O

Ocular	5	O
-	7	O
specific	9	O
ER	3	O
stress	9	O
reduction	9	O
rescues	3	O
glaucoma	5	B-Disease
in	5	O
murine	3	O
glucocorticoid	9	O
-	7	O
induced	3	O
glaucoma	5	B-Disease
.	9	O

Administration	2	O
of	5	O
glucocorticoids	9	O
induces	3	O
ocular	5	B-Disease
hypertension	5	I-Disease
in	5	O
some	5	O
patients	5	O
.	9	O

If	5	O
untreated	3	O
,	9	O
these	5	O
patients	5	O
can	5	O
develop	5	O
a	5	O
secondary	9	O
glaucoma	5	B-Disease
that	5	O
resembles	9	O
primary	9	B-Disease
open	5	I-Disease
-	7	I-Disease
angle	5	I-Disease
glaucoma	5	I-Disease
(	9	O
POAG	5	B-Disease
)	9	O
.	9	O

The	5	O
underlying	5	O
pathology	5	O
of	5	O
glucocorticoid	9	O
-	7	O
induced	3	O
glaucoma	5	B-Disease
is	5	O
not	5	O
fully	9	O
understood	5	O
,	9	O
due	5	O
in	5	O
part	9	O
to	5	O
lack	9	O
of	5	O
an	5	O
appropriate	5	O
animal	5	O
model	5	O
.	9	O

Here	9	O
,	9	O
we	5	O
developed	5	O
a	5	O
murine	3	O
model	5	O
of	5	O
glucocorticoid	9	O
-	7	O
induced	3	O
glaucoma	5	B-Disease
that	5	O
exhibits	9	O
glaucoma	5	B-Disease
features	5	O
that	5	O
are	5	O
observed	9	O
in	5	O
patients	5	O
.	9	O

Treatment	9	O
of	5	O
WT	3	O
mice	3	O
with	5	O
topical	0	O
ocular	5	O
0	7	O
.	9	O
1	9	O
%	9	O
dexamethasone	0	B-Chemical
led	9	O
to	5	O
elevation	9	O
of	5	O
intraocular	5	O
pressure	5	O
(	9	O
IOP	5	O
)	9	O
,	9	O
functional	9	O
and	5	O
structural	9	O
loss	9	O
of	5	O
retinal	5	B-Disease
ganglion	5	I-Disease
cells	3	O
,	9	O
and	5	O
axonal	3	B-Disease
degeneration	9	I-Disease
,	9	O
resembling	9	O
glucocorticoid	9	O
-	7	O
induced	3	O
glaucoma	5	B-Disease
in	5	O
human	3	O
patients	5	O
.	9	O

Furthermore	9	O
,	9	O
dexamethasone	0	B-Chemical
-	7	O
induced	3	O
ocular	5	B-Disease
hypertension	5	I-Disease
was	9	O
associated	9	O
with	5	O
chronic	5	O
ER	3	O
stress	9	O
of	5	O
the	5	O
trabecular	5	O
meshwork	5	O
(	9	O
TM	9	O
)	9	O
.	9	O

Similar	9	O
to	5	O
patients	5	O
,	9	O
withdrawal	5	O
of	5	O
dexamethasone	0	B-Chemical
treatment	9	O
reduced	9	O
elevated	9	O
IOP	5	O
and	5	O
ER	3	O
stress	9	O
in	5	O
this	5	O
animal	5	O
model	5	O
.	9	O

Dexamethasone	0	B-Chemical
induced	3	O
the	5	O
transcriptional	1	O
factor	9	O
CHOP	3	O
,	9	O
a	5	O
marker	3	O
for	5	O
chronic	5	O
ER	3	O
stress	9	O
,	9	O
in	5	O
the	5	O
anterior	5	O
segment	9	O
tissues	9	O
,	9	O
and	5	O
Chop	3	O
deletion	1	O
reduced	9	O
ER	3	O
stress	9	O
in	5	O
these	5	O
tissues	9	O
and	5	O
prevented	9	O
dexamethasone	0	B-Chemical
-	7	O
induced	3	O
ocular	5	B-Disease
hypertension	5	I-Disease
.	9	O

Furthermore	9	O
,	9	O
reduction	9	O
of	5	O
ER	3	O
stress	9	O
in	5	O
the	5	O
TM	9	O
with	5	O
sodium	0	B-Chemical
4	9	I-Chemical
-	7	I-Chemical
phenylbutyrate	0	I-Chemical
prevented	9	O
dexamethasone	0	B-Chemical
-	7	O
induced	3	O
ocular	5	B-Disease
hypertension	5	I-Disease
in	5	O
WT	3	O
mice	3	O
.	9	O

Our	9	O
data	5	O
indicate	9	O
that	5	O
ER	3	O
stress	9	O
contributes	9	O
to	5	O
glucocorticoid	9	O
-	7	O
induced	3	O
ocular	5	B-Disease
hypertension	5	I-Disease
and	5	O
suggest	9	O
that	5	O
reducing	9	O
ER	3	O
stress	9	O
has	9	O
potential	9	O
as	5	O
a	5	O
therapeutic	5	O
strategy	5	O
for	5	O
treating	5	O
glucocorticoid	9	O
-	7	O
induced	3	O
glaucoma	5	B-Disease
.	9	O

Effects	9	O
of	5	O
ginsenosides	0	B-Chemical
on	5	O
opioid	5	O
-	7	O
induced	3	O
hyperalgesia	3	B-Disease
in	5	O
mice	3	O
.	9	O

Opioid	5	O
-	7	O
induced	3	O
hyperalgesia	3	B-Disease
(	9	O
OIH	5	B-Disease
)	9	O
is	5	O
characterized	9	O
by	9	O
nociceptive	5	O
sensitization	9	O
caused	9	O
by	9	O
the	5	O
cessation	5	O
of	5	O
chronic	5	O
opioid	5	O
use	5	O
.	9	O

OIH	5	B-Disease
can	5	O
limit	5	O
the	5	O
clinical	5	O
use	5	O
of	5	O
opioid	5	O
analgesics	5	O
and	5	O
complicate	5	O
withdrawal	5	O
from	9	O
opioid	5	B-Disease
addiction	5	I-Disease
.	9	O

In	9	O
this	5	O
study	9	O
,	9	O
we	5	O
investigated	9	O
the	5	O
effects	9	O
of	5	O
Re	9	B-Chemical
,	9	I-Chemical
Rg1	0	I-Chemical
,	9	I-Chemical
and	5	I-Chemical
Rb1	3	I-Chemical
ginsenosides	0	I-Chemical
,	9	O
the	5	O
bioactive	0	O
components	5	O
of	5	O
ginseng	4	O
,	9	O
on	5	O
OIH	5	B-Disease
.	9	O

OIH	5	B-Disease
was	9	O
achieved	5	O
in	5	O
mice	3	O
after	9	O
subcutaneous	9	O
administration	9	O
of	5	O
morphine	0	B-Chemical
for	5	O
7	9	O
consecutive	5	O
days	9	O
three	9	O
times	5	O
per	9	O
day	9	O
.	9	O

During	5	O
withdrawal	5	O
(	9	O
days	9	O
8	9	O
and	5	O
9	7	O
)	9	O
,	9	O
these	5	O
mice	3	O
were	9	O
administered	9	O
Re	9	B-Chemical
,	9	O
Rg1	0	B-Chemical
,	9	O
or	5	O
Rb1	3	B-Chemical
intragastrically	0	O
two	5	O
times	5	O
per	9	O
day	9	O
.	9	O

On	5	O
the	5	O
test	5	O
day	9	O
(	9	O
day	9	O
10	9	O
)	9	O
,	9	O
mice	3	O
were	9	O
subjected	9	O
to	5	O
the	5	O
thermal	9	O
sensitivity	9	O
test	5	O
and	5	O
the	5	O
acetic	0	B-Chemical
acid	0	I-Chemical
-	7	O
induced	3	O
writhing	0	O
test	5	O
.	9	O

Re	9	B-Chemical
(	9	O
300	0	O
mg	0	O
/	9	O
kg	0	O
)	9	O
inhibited	3	O
OIH	5	B-Disease
in	5	O
both	9	O
the	5	O
thermal	9	O
sensitivity	9	O
test	5	O
and	5	O
the	5	O
acetic	0	B-Chemical
acid	0	I-Chemical
-	7	O
induced	3	O
writhing	0	O
test	5	O
.	9	O

However	9	O
,	9	O
the	5	O
Rg1	0	B-Chemical
and	5	I-Chemical
Rb1	3	I-Chemical
ginsenosides	0	I-Chemical
failed	9	O
to	5	O
prevent	5	O
OIH	5	B-Disease
in	5	O
either	9	O
test	5	O
.	9	O

Furthermore	9	O
,	9	O
Rg1	0	B-Chemical
showed	9	O
a	5	O
tendency	5	O
to	5	O
aggravate	9	O
OIH	5	B-Disease
in	5	O
the	5	O
acetic	0	B-Chemical
acid	0	I-Chemical
-	7	O
induced	3	O
writhing	0	O
test	5	O
.	9	O

Our	9	O
data	5	O
suggested	9	O
that	5	O
the	5	O
ginsenoside	0	B-Chemical
Re	9	I-Chemical
,	9	O
but	9	O
not	5	O
Rg1	0	B-Chemical
or	5	O
Rb1	3	B-Chemical
,	9	O
may	5	O
contribute	9	O
toward	5	O
reversal	9	O
of	5	O
OIH	5	B-Disease
.	9	O

A	9	O
comparison	9	O
of	5	O
severe	5	O
hemodynamic	5	O
disturbances	5	O
between	5	O
dexmedetomidine	5	B-Chemical
and	5	O
propofol	0	B-Chemical
for	5	O
sedation	5	O
in	5	O
neurocritical	5	O
care	5	O
patients	5	O
.	9	O

OBJECTIVE	2	O
:	9	O
Dexmedetomidine	0	B-Chemical
and	5	O
propofol	0	B-Chemical
are	5	O
commonly	5	O
used	5	O
sedatives	5	O
in	5	O
neurocritical	5	O
care	5	O
as	5	O
they	5	O
allow	5	O
for	5	O
frequent	5	O
neurologic	5	O
examinations	5	O
.	9	O

However	9	O
,	9	O
both	9	O
agents	5	O
are	5	O
associated	9	O
with	5	O
significant	9	O
hemodynamic	5	O
side	5	O
effects	9	O
.	9	O

The	5	O
primary	9	O
objective	5	O
of	5	O
this	5	O
study	9	O
is	5	O
to	5	O
compare	9	O
the	5	O
prevalence	5	O
of	5	O
severe	5	O
hemodynamic	5	O
effects	9	O
in	5	O
neurocritical	5	O
care	5	O
patients	5	O
receiving	9	O
dexmedetomidine	5	B-Chemical
and	5	O
propofol	0	B-Chemical
.	9	O

DESIGN	2	O
:	9	O
Multicenter	2	O
,	9	O
retrospective	5	O
,	9	O
propensity	5	O
-	7	O
matched	9	O
cohort	9	O
study	9	O
.	9	O

SETTING	2	O
:	9	O
Neurocritical	2	O
care	5	O
units	9	O
at	9	O
two	5	O
academic	5	O
medical	5	O
centers	5	O
with	5	O
dedicated	5	O
neurocritical	5	O
care	5	O
teams	5	O
and	5	O
board	5	O
-	7	O
certified	5	O
neurointensivists	5	O
.	9	O

PATIENTS	2	O
:	9	O
Neurocritical	2	O
care	5	O
patients	5	O
admitted	5	O
between	5	O
July	2	O
2009	2	O
and	5	O
September	2	O
2012	2	O
were	9	O
evaluated	9	O
and	5	O
then	9	O
matched	9	O
1	9	O
:	9	O
1	9	O
based	5	O
on	5	O
propensity	5	O
scoring	5	O
of	5	O
baseline	5	O
characteristics	5	O
.	9	O

INTERVENTIONS	2	O
:	9	O
Continuous	5	O
sedation	5	O
with	5	O
dexmedetomidine	5	B-Chemical
or	5	O
propofol	0	B-Chemical
.	9	O

MEASUREMENTS	2	O
AND	2	O
MAIN	2	O
RESULTS	9	O
:	9	O
A	9	O
total	9	O
of	5	O
342	7	O
patients	5	O
(	9	O
105	9	O
dexmedetomidine	5	B-Chemical
and	5	O
237	7	O
propofol	0	B-Chemical
)	9	O
were	9	O
included	5	O
in	5	O
the	5	O
analysis	9	O
,	9	O
with	5	O
190	9	O
matched	9	O
(	9	O
95	7	O
in	5	O
each	5	O
group	9	O
)	9	O
by	9	O
propensity	5	O
score	5	O
.	9	O

The	5	O
primary	9	O
outcome	5	O
of	5	O
this	5	O
study	9	O
was	9	O
a	5	O
composite	5	O
of	5	O
severe	5	O
hypotension	5	B-Disease
(	9	O
mean	5	O
arterial	5	O
pressure	5	O
<	0	O
60	9	O
mm	9	O
Hg	0	O
)	9	O
and	5	O
bradycardia	5	B-Disease
(	9	O
heart	5	O
rate	9	O
<	0	O
50	0	O
beats	5	O
/	9	O
min	0	O
)	9	O
during	5	O
sedative	5	O
infusion	0	O
.	9	O

No	9	O
difference	9	O
in	5	O
the	5	O
primary	9	O
composite	5	O
outcome	5	O
in	5	O
both	9	O
the	5	O
unmatched	5	O
(	9	O
30	9	O
%	9	O
vs	7	O
30	9	O
%	9	O
,	9	O
p	7	O
=	7	O
0	7	O
.	9	O
94	7	O
)	9	O
or	5	O
matched	9	O
cohorts	9	O
(	9	O
28	7	O
%	9	O
vs	7	O
34	7	O
%	9	O
,	9	O
p	7	O
=	7	O
0	7	O
.	9	O
35	9	O
)	9	O
could	9	O
be	5	O
found	9	O
.	9	O

When	9	O
analyzed	9	O
separately	9	O
,	9	O
no	9	O
differences	9	O
could	9	O
be	5	O
found	9	O
in	5	O
the	5	O
prevalence	5	O
of	5	O
severe	5	O
hypotension	5	B-Disease
or	5	O
bradycardia	5	B-Disease
in	5	O
either	9	O
the	5	O
unmatched	5	O
or	5	O
matched	9	O
cohorts	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Severe	9	O
hypotension	5	B-Disease
and	5	O
bradycardia	5	B-Disease
occur	5	O
at	9	O
similar	9	O
prevalence	5	O
in	5	O
neurocritical	5	O
care	5	O
patients	5	O
who	5	O
receive	5	O
dexmedetomidine	5	B-Chemical
or	5	O
propofol	0	B-Chemical
.	9	O

Providers	5	O
should	5	O
similarly	9	O
consider	5	O
the	5	O
likelihood	5	O
of	5	O
hypotension	5	B-Disease
or	5	O
bradycardia	5	B-Disease
before	9	O
starting	9	O
either	9	O
sedative	5	O
.	9	O

Hydroxytyrosol	0	B-Chemical
ameliorates	3	O
oxidative	9	O
stress	9	O
and	5	O
mitochondrial	9	B-Disease
dysfunction	9	I-Disease
in	5	O
doxorubicin	0	B-Chemical
-	7	O
induced	3	O
cardiotoxicity	9	B-Disease
in	5	O
rats	9	O
with	5	O
breast	3	B-Disease
cancer	3	I-Disease
.	9	O

Oxidative	9	O
stress	9	O
is	5	O
involved	9	O
in	5	O
several	9	O
processes	5	O
including	9	O
cancer	3	B-Disease
,	9	O
aging	5	O
and	5	O
cardiovascular	5	B-Disease
disease	5	I-Disease
,	9	O
and	5	O
has	9	O
been	9	O
shown	9	O
to	5	O
potentiate	3	O
the	5	O
therapeutic	5	O
effect	9	O
of	5	O
drugs	5	O
such	5	O
as	5	O
doxorubicin	0	B-Chemical
.	9	O

Doxorubicin	0	B-Chemical
causes	9	O
significant	9	O
cardiotoxicity	9	B-Disease
characterized	9	O
by	9	O
marked	9	O
increases	9	O
in	5	O
oxidative	9	O
stress	9	O
and	5	O
mitochondrial	9	B-Disease
dysfunction	9	I-Disease
.	9	O

Herein	9	O
,	9	O
we	5	O
investigate	9	O
whether	9	O
doxorubicin	0	B-Chemical
-	7	O
associated	9	O
chronic	5	O
cardiac	5	B-Disease
toxicity	9	I-Disease
can	5	O
be	5	O
ameliorated	9	O
with	5	O
the	5	O
antioxidant	0	O
hydroxytyrosol	0	B-Chemical
in	5	O
rats	9	O
with	5	O
breast	3	B-Disease
cancer	3	I-Disease
.	9	O

Thirty	9	O
-	7	O
six	9	O
rats	9	O
bearing	3	O
breast	3	B-Disease
tumors	3	I-Disease
induced	3	O
chemically	0	O
were	9	O
divided	5	O
into	9	O
4	9	O
groups	9	O
:	9	O
control	9	O
,	9	O
hydroxytyrosol	0	B-Chemical
(	9	O
0	7	O
.	9	O
5mg	0	O
/	9	O
kg	0	O
,	9	O
5days	0	O
/	9	O
week	9	O
)	9	O
,	9	O
doxorubicin	0	B-Chemical
(	9	O
1mg	0	O
/	9	O
kg	0	O
/	9	O
week	9	O
)	9	O
,	9	O
and	5	O
doxorubicin	0	B-Chemical
plus	9	O
hydroxytyrosol	0	B-Chemical
.	9	O

Cardiac	9	B-Disease
disturbances	5	I-Disease
at	9	O
the	5	O
cellular	3	O
and	5	O
mitochondrial	9	O
level	9	O
,	9	O
mitochondrial	9	O
electron	0	O
transport	9	O
chain	9	O
complexes	9	O
I	9	O
-	7	O
IV	9	O
and	5	O
apoptosis	3	O
-	7	O
inducing	3	O
factor	9	O
,	9	O
and	5	O
oxidative	9	O
stress	9	O
markers	3	O
have	5	O
been	9	O
analyzed	9	O
.	9	O

Hydroxytyrosol	0	B-Chemical
improved	5	O
the	5	O
cardiac	5	B-Disease
disturbances	5	I-Disease
enhanced	3	O
by	9	O
doxorubicin	0	B-Chemical
by	9	O
significantly	9	O
reducing	9	O
the	5	O
percentage	9	O
of	5	O
altered	9	O
mitochondria	3	O
and	5	O
oxidative	9	O
damage	9	O
.	9	O

These	5	O
results	9	O
suggest	9	O
that	5	O
hydroxytyrosol	0	B-Chemical
improve	5	O
the	5	O
mitochondrial	9	O
electron	0	O
transport	9	O
chain	9	O
.	9	O

This	5	O
study	9	O
demonstrates	9	O
that	5	O
hydroxytyrosol	0	B-Chemical
protect	9	O
rat	3	O
heart	5	B-Disease
damage	9	I-Disease
provoked	9	O
by	9	O
doxorubicin	0	B-Chemical
decreasing	9	O
oxidative	9	O
damage	9	O
and	5	O
mitochondrial	9	O
alterations	9	O
.	9	O

Amiodarone	7	B-Chemical
-	7	O
induced	3	O
myxoedema	5	B-Disease
coma	5	I-Disease
.	9	O

A	9	O
62	7	O
-	7	O
year	5	O
-	7	O
old	5	O
man	5	O
was	9	O
found	9	O
to	5	O
have	5	O
bradycardia	5	B-Disease
,	9	O
hypothermia	5	B-Disease
and	5	O
respiratory	5	B-Disease
failure	5	I-Disease
3	9	O
weeks	9	O
after	9	O
initiation	9	O
of	5	O
amiodarone	0	B-Chemical
therapy	5	O
for	5	O
atrial	5	B-Disease
fibrillation	5	I-Disease
.	9	O

Thyroid	9	O
-	7	O
stimulating	9	O
hormone	9	O
was	9	O
found	9	O
to	5	O
be	5	O
168	7	O
uIU	7	O
/	9	O
mL	0	O
(	9	O
nl	0	O
.	9	O
0	7	O
.	9	O
3	9	O
-	7	O
5	9	O
uIU	7	O
/	9	O
mL	0	O
)	9	O
and	5	O
free	9	O
thyroxine	0	B-Chemical
(	9	O
FT4	5	O
)	9	O
was	9	O
<	0	O
0	7	O
.	9	O
2	9	O
ng	0	O
/	9	O
dL	7	O
(	9	O
nl	0	O
.	9	O
0	7	O
.	9	O
8	9	O
-	7	O
1	9	O
.	9	O
8	9	O
ng	0	O
/	9	O
dL	7	O
)	9	O
.	9	O

He	5	O
received	9	O
intravenous	0	O
fluids	5	O
,	9	O
vasopressor	5	O
therapy	5	O
and	5	O
stress	9	O
dose	9	O
steroids	9	B-Chemical
;	9	O
he	5	O
was	9	O
intubated	5	O
and	5	O
admitted	5	O
to	5	O
the	5	O
intensive	5	O
care	5	O
unit	5	O
.	9	O

He	5	O
received	9	O
500	0	O
ug	0	O
of	5	O
intravenous	0	O
levothyroxine	5	B-Chemical
in	5	O
the	5	O
first	9	O
18	7	O
h	0	O
of	5	O
therapy	5	O
,	9	O
and	5	O
150	0	O
ug	0	O
intravenous	0	O
daily	5	O
thereafter	9	O
.	9	O

Haemodynamic	5	O
improvement	5	O
,	9	O
along	9	O
with	5	O
complete	9	O
recovery	9	O
of	5	O
mental	5	O
status	9	O
,	9	O
occurred	9	O
after	9	O
48	9	O
h	0	O
.	9	O

Twelve	9	O
hours	9	O
after	9	O
the	5	O
initiation	9	O
of	5	O
therapy	5	O
,	9	O
FT4	5	O
was	9	O
0	7	O
.	9	O
96	9	O
ng	0	O
/	9	O
dL	7	O
.	9	O

The	5	O
patient	5	O
was	9	O
maintained	9	O
on	5	O
levothyroxine	5	B-Chemical
175	7	O
(	9	O
g	0	O
POorally	_	O
daily	5	O
.	9	O

A	9	O
thyroid	9	O
ultrasound	5	O
showed	9	O
diffuse	5	O
heterogeneity	9	O
.	9	O

The	5	O
24	9	O
hour	0	O
excretion	0	O
of	5	O
iodine	0	B-Chemical
was	9	O
3657	7	O
(	9	O
mcg	0	O
(	9	O
25	9	O
-	7	O
756	7	O
(	9	O
mcg	0	O
)	9	O
.	9	O

The	5	O
only	9	O
two	5	O
cases	5	O
of	5	O
amiodarone	0	B-Chemical
-	7	O
induced	3	O
myxoedema	5	B-Disease
coma	5	I-Disease
in	5	O
the	5	O
literature	5	O
report	5	O
patient	5	O
death	9	O
despite	9	O
supportive	5	O
therapy	5	O
and	5	O
thyroid	9	O
hormone	9	O
replacement	9	O
.	9	O

This	5	O
case	5	O
represents	9	O
the	5	O
most	9	O
thoroughly	9	O
investigated	9	O
case	5	O
of	5	O
amiodarone	0	B-Chemical
-	7	O
induced	3	O
myxoedema	5	B-Disease
coma	5	I-Disease
with	5	O
a	5	O
history	5	O
significant	9	O
for	5	O
subclinical	5	O
thyroid	9	B-Disease
disease	5	I-Disease
.	9	O

Use	5	O
of	5	O
argatroban	5	B-Chemical
and	5	O
catheter	5	O
-	7	O
directed	9	O
thrombolysis	5	B-Disease
with	5	O
alteplase	5	O
in	5	O
an	5	O
oncology	5	O
patient	5	O
with	5	O
heparin	0	B-Chemical
-	7	O
induced	3	O
thrombocytopenia	9	B-Disease
with	5	O
thrombosis	5	B-Disease
.	9	O

PURPOSE	2	O
:	9	O
The	5	O
case	5	O
of	5	O
an	5	O
oncology	5	O
patient	5	O
who	5	O
developed	5	O
heparin	0	B-Chemical
-	7	O
induced	3	O
thrombocytopenia	9	B-Disease
with	5	O
thrombosis	5	B-Disease
(	9	O
HITT	5	B-Disease
)	9	O
and	5	O
was	9	O
treated	3	O
with	5	O
argatroban	5	B-Chemical
plus	9	O
catheter	5	O
-	7	O
directed	9	O
thrombolysis	5	B-Disease
(	9	O
CDT	5	O
)	9	O
with	5	O
alteplase	5	O
is	5	O
presented	5	O
.	9	O

SUMMARY	9	O
:	9	O
A	9	O
63	7	O
-	7	O
year	5	O
-	7	O
old	5	O
Caucasian	9	O
man	5	O
with	5	O
renal	9	O
amyloidosis	5	B-Disease
undergoing	9	O
peripheral	9	O
blood	9	O
stem	3	O
cell	3	O
collection	5	O
for	5	O
an	5	O
autologous	3	O
stem	3	O
cell	3	O
transplant	9	O
developed	5	O
extensive	5	O
bilateral	5	O
upper	9	B-Disease
-	7	I-Disease
extremity	5	I-Disease
deep	5	I-Disease
venous	5	I-Disease
thrombosis	5	I-Disease
(	9	O
DVT	5	B-Disease
)	9	O
and	5	O
pulmonary	5	B-Disease
embolism	5	I-Disease
secondary	9	O
to	5	O
heparin	0	B-Chemical
-	7	O
induced	3	O
thrombocytopenia	9	B-Disease
.	9	O

A	9	O
continuous	5	O
i	9	O
.	9	O
v	0	O
.	9	O
infusion	0	O
of	5	O
argatroban	5	B-Chemical
was	9	O
initiated	9	O
,	9	O
and	5	O
the	5	O
patient	5	O
was	9	O
managed	5	O
on	5	O
the	5	O
general	5	O
medical	5	O
floor	5	O
.	9	O

After	9	O
one	5	O
week	9	O
of	5	O
therapy	5	O
,	9	O
he	5	O
was	9	O
transferred	9	O
to	5	O
the	5	O
intensive	5	O
care	5	O
unit	5	O
with	5	O
cardiopulmonary	5	O
compromise	5	O
related	9	O
to	5	O
superior	5	B-Disease
vena	5	I-Disease
cava	5	I-Disease
(	9	I-Disease
SVC	5	I-Disease
)	9	I-Disease
syndrome	5	I-Disease
.	9	O

A	9	O
percutaneous	5	O
mechanical	5	O
thrombectomy	5	O
and	5	O
CDT	5	O
with	5	O
alteplase	5	O
were	9	O
attempted	5	O
,	9	O
but	9	O
the	5	O
procedure	5	O
was	9	O
aborted	5	O
due	5	O
to	5	O
epistaxis	5	B-Disease
.	9	O

The	5	O
epistaxis	5	B-Disease
resolved	9	O
the	5	O
next	9	O
day	9	O
,	9	O
and	5	O
the	5	O
patient	5	O
was	9	O
restarted	5	O
on	5	O
argatroban	5	B-Chemical
.	9	O

A	9	O
second	9	O
percutaneous	5	O
mechanical	5	O
thrombectomy	5	O
was	9	O
performed	9	O
six	9	O
days	9	O
later	9	O
and	5	O
resulted	9	O
in	5	O
partial	9	O
revascularization	5	O
of	5	O
the	5	O
SVC	5	O
and	5	O
central	5	O
veins	5	O
.	9	O

Postthrombectomy	_	O
continuous	5	O
CDT	5	O
with	5	O
alteplase	5	O
was	9	O
commenced	5	O
while	9	O
argatroban	5	B-Chemical
was	9	O
withheld	5	O
,	9	O
and	5	O
complete	9	O
patency	5	O
of	5	O
the	5	O
SVC	5	O
and	5	O
central	5	O
veins	5	O
was	9	O
achieved	5	O
after	9	O
three	9	O
days	9	O
of	5	O
therapy	5	O
.	9	O

Alteplase	5	O
was	9	O
discontinued	5	O
,	9	O
and	5	O
the	5	O
patient	5	O
was	9	O
reinitiated	5	O
on	5	O
argatroban	5	B-Chemical
;	9	O
ultimately	5	O
,	9	O
he	5	O
was	9	O
transitioned	5	O
to	5	O
warfarin	5	B-Chemical
for	5	O
long	5	O
-	7	O
term	5	O
anticoagulation	5	O
.	9	O

Although	9	O
the	5	O
patient	5	O
recovered	9	O
,	9	O
he	5	O
experienced	5	O
permanent	5	O
vision	5	B-Disease
and	5	I-Disease
hearing	5	I-Disease
loss	9	I-Disease
,	9	O
as	5	O
well	9	O
as	5	O
end	9	B-Disease
-	7	I-Disease
stage	9	I-Disease
renal	9	I-Disease
disease	5	I-Disease
.	9	O

CONCLUSION	5	O
:	9	O
A	9	O
63	7	O
-	7	O
year	5	O
-	7	O
old	5	O
man	5	O
with	5	O
renal	9	O
amyloidosis	5	B-Disease
and	5	O
SVC	5	B-Disease
syndrome	5	I-Disease
secondary	9	O
to	5	O
HITT	5	B-Disease
was	9	O
successfully	5	O
treated	3	O
with	5	O
argatroban	5	B-Chemical
and	5	O
CDT	5	O
with	5	O
alteplase	5	O
.	9	O

Effects	9	O
of	5	O
dehydroepiandrosterone	0	B-Chemical
in	5	O
amphetamine	5	B-Chemical
-	7	O
induced	3	O
schizophrenia	5	B-Disease
models	5	O
in	5	O
mice	3	O
.	9	O

OBJECTIVE	2	O
:	9	O
To	9	O
examine	9	O
the	5	O
effects	9	O
of	5	O
dehydroepiandrosterone	0	B-Chemical
(	9	O
DHEA	0	B-Chemical
)	9	O
on	5	O
animal	5	O
models	5	O
of	5	O
schizophrenia	5	B-Disease
.	9	O

METHODS	2	O
:	9	O
Seventy	5	O
Swiss	2	O
albino	3	O
female	9	O
mice	3	O
(	9	O
25	9	O
-	7	O
35	9	O
g	0	O
)	9	O
were	9	O
divided	5	O
into	9	O
4	9	O
groups	9	O
:	9	O
amphetamine	5	B-Chemical
-	7	O
free	9	O
(	9	O
control	9	O
)	9	O
,	9	O
amphetamine	5	B-Chemical
,	9	O
50	0	O
,	9	O
and	5	O
100	0	O
mg	0	O
/	9	O
kg	0	O
DHEA	0	B-Chemical
.	9	O

The	5	O
DHEA	0	B-Chemical
was	9	O
administered	9	O
intraperitoneally	0	O
(	9	O
ip	0	O
)	9	O
for	5	O
5	9	O
days	9	O
.	9	O

Amphetamine	7	B-Chemical
(	9	O
3	9	O
mg	0	O
/	9	O
kg	0	O
ip	0	O
)	9	O
induced	3	O
hyper	5	B-Disease
locomotion	5	O
,	9	O
apomorphine	0	B-Chemical
(	9	O
1	9	O
.	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
subcutaneously	3	O
[	9	O
sc	9	O
]	9	O
)	9	O
induced	3	O
climbing	5	O
,	9	O
and	5	O
haloperidol	5	B-Chemical
(	9	O
1	9	O
.	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
sc	9	O
)	9	O
induced	3	O
catalepsy	5	B-Disease
tests	5	O
were	9	O
used	5	O
as	5	O
animal	5	O
models	5	O
of	5	O
schizophrenia	5	B-Disease
.	9	O

The	5	O
study	9	O
was	9	O
conducted	9	O
at	9	O
the	5	O
Animal	2	O
Experiment	5	O
Laboratories	0	O
,	9	O
Department	2	O
of	5	O
Pharmacology	2	O
,	9	O
Medical	2	O
School	2	O
,	9	O
Eskisehir	2	O
Osmangazi	2	O
University	2	O
,	9	O
Eskisehir	2	O
,	9	O
Turkey	4	O
between	5	O
March	2	O
and	5	O
May	2	O
2012	2	O
.	9	O

Statistical	5	O
analysis	9	O
was	9	O
carried	9	O
out	9	O
using	9	O
Kruskal	5	O
-	7	O
Wallis	9	O
test	5	O
for	5	O
hyper	5	B-Disease
locomotion	5	O
,	9	O
and	5	O
one	5	O
-	7	O
way	5	O
ANOVA	5	O
for	5	O
climbing	5	O
and	5	O
catalepsy	5	B-Disease
tests	5	O
.	9	O

RESULTS	9	O
:	9	O
In	9	O
the	5	O
amphetamine	5	B-Chemical
-	7	O
induced	3	O
locomotion	5	O
test	5	O
,	9	O
there	5	O
were	9	O
significant	9	O
increases	9	O
in	5	O
all	5	O
movements	5	O
compared	9	O
with	5	O
the	5	O
amphetamine	5	B-Chemical
-	7	O
free	9	O
group	9	O
.	9	O

Both	9	O
DHEA	0	B-Chemical
50	0	O
mg	0	O
/	9	O
kg	0	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
,	9	O
and	5	O
100	0	O
mg	0	O
/	9	O
kg	0	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
01	7	O
)	9	O
significantly	9	O
decreased	9	O
all	5	O
movements	5	O
compared	9	O
with	5	O
the	5	O
amphetamine	5	B-Chemical
-	7	O
induced	3	O
locomotion	5	O
group	9	O
.	9	O

There	5	O
was	9	O
a	5	O
significant	9	O
difference	9	O
between	5	O
groups	9	O
in	5	O
the	5	O
haloperidol	5	B-Chemical
-	7	O
induced	3	O
catalepsy	5	B-Disease
test	5	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

There	5	O
was	9	O
no	9	O
significant	9	O
difference	9	O
between	5	O
groups	9	O
in	5	O
terms	5	O
of	5	O
total	9	O
climbing	5	O
time	5	O
in	5	O
the	5	O
apomorphine	0	B-Chemical
-	7	O
induced	3	O
climbing	5	O
test	5	O
(	9	O
p	7	O
>	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

CONCLUSION	5	O
:	9	O
We	9	O
observed	9	O
that	5	O
DHEA	0	B-Chemical
reduced	9	O
locomotor	5	O
activity	9	O
and	5	O
increased	9	O
catalepsy	5	B-Disease
at	9	O
both	9	O
doses	0	O
,	9	O
while	9	O
it	5	O
had	9	O
no	9	O
effect	9	O
on	5	O
climbing	5	O
behavior	5	O
.	9	O

We	9	O
suggest	9	O
that	5	O
DHEA	0	B-Chemical
displays	9	O
typical	9	O
neuroleptic	5	O
-	7	O
like	9	O
effects	9	O
,	9	O
and	5	O
may	5	O
be	5	O
used	5	O
in	5	O
the	5	O
treatment	9	O
of	5	O
schizophrenia	5	B-Disease
.	9	O

Availability	5	O
of	5	O
human	3	O
induced	3	O
pluripotent	3	O
stem	3	O
cell	3	O
-	7	O
derived	9	O
cardiomyocytes	3	O
in	5	O
assessment	5	O
of	5	O
drug	5	O
potential	9	O
for	5	O
QT	5	B-Disease
prolongation	9	I-Disease
.	9	O

Field	9	O
potential	9	O
duration	5	O
(	9	O
FPD	5	O
)	9	O
in	5	O
human	3	O
-	7	O
induced	3	O
pluripotent	3	O
stem	3	O
cell	3	O
-	7	O
derived	9	O
cardiomyocytes	3	O
(	9	O
hiPS	3	O
-	7	O
CMs	5	O
)	9	O
,	9	O
which	5	O
can	5	O
express	3	O
QT	5	O
interval	5	O
in	5	O
an	5	O
electrocardiogram	5	O
,	9	O
is	5	O
reported	9	O
to	5	O
be	5	O
a	5	O
useful	5	O
tool	5	O
to	5	O
predict	5	O
K	9	B-Chemical
(	9	O
+	9	O
)	9	O
channel	9	O
and	5	O
Ca	0	B-Chemical
(	9	O
2	9	O
+	9	O
)	9	O
channel	9	O
blocker	0	O
effects	9	O
on	5	O
QT	5	O
interval	5	O
.	9	O

However	9	O
,	9	O
there	5	O
is	5	O
no	9	O
report	5	O
showing	9	O
that	5	O
this	5	O
technique	5	O
can	5	O
be	5	O
used	5	O
to	5	O
predict	5	O
multichannel	5	O
blocker	0	O
potential	9	O
for	5	O
QT	5	B-Disease
prolongation	9	I-Disease
.	9	O

The	5	O
aim	5	O
of	5	O
this	5	O
study	9	O
is	5	O
to	5	O
show	9	O
that	5	O
FPD	5	O
from	9	O
MEA	0	O
(	9	O
Multielectrode	5	O
array	5	O
)	9	O
of	5	O
hiPS	3	O
-	7	O
CMs	5	O
can	5	O
detect	9	O
QT	5	B-Disease
prolongation	9	I-Disease
induced	3	O
by	9	O
multichannel	5	O
blockers	9	O
.	9	O

hiPS	3	O
-	7	O
CMs	5	O
were	9	O
seeded	3	O
onto	0	O
MEA	0	O
and	5	O
FPD	5	O
was	9	O
measured	9	O
for	5	O
2min	0	O
every	5	O
10min	0	O
for	5	O
30min	0	O
after	9	O
drug	5	O
exposure	9	O
for	5	O
the	5	O
vehicle	3	O
and	5	O
each	5	O
drug	5	O
concentration	0	O
.	9	O

IKr	5	O
and	5	O
IKs	0	O
blockers	9	O
concentration	0	O
-	7	O
dependently	3	O
prolonged	9	O
corrected	5	O
FPD	5	O
(	9	O
FPDc	_	O
)	9	O
,	9	O
whereas	9	O
Ca	0	B-Chemical
(	9	O
2	9	O
+	9	O
)	9	O
channel	9	O
blockers	9	O
concentration	0	O
-	7	O
dependently	3	O
shortened	9	O
FPDc	_	O
.	9	O

Also	9	O
,	9	O
the	5	O
multichannel	5	O
blockers	9	O
Amiodarone	7	B-Chemical
,	9	O
Paroxetine	7	B-Chemical
,	9	O
Terfenadine	0	B-Chemical
and	5	O
Citalopram	7	B-Chemical
prolonged	9	O
FPDc	_	O
in	5	O
a	5	O
concentration	0	O
dependent	9	O
manner	9	O
.	9	O

Finally	9	O
,	9	O
the	5	O
IKr	5	O
blockers	9	O
,	9	O
Terfenadine	0	B-Chemical
and	5	O
Citalopram	7	B-Chemical
,	9	O
which	5	O
are	5	O
reported	9	O
to	5	O
cause	5	O
Torsade	2	B-Disease
de	2	I-Disease
Pointes	2	I-Disease
(	9	O
TdP	5	B-Disease
)	9	O
in	5	O
clinical	5	O
practice	5	O
,	9	O
produced	9	O
early	9	O
afterdepolarization	5	O
(	9	O
EAD	5	O
)	9	O
.	9	O

hiPS	3	O
-	7	O
CMs	5	O
using	9	O
MEA	0	O
system	5	O
and	5	O
FPDc	_	O
can	5	O
predict	5	O
the	5	O
effects	9	O
of	5	O
drug	5	O
candidates	9	O
on	5	O
QT	5	O
interval	5	O
.	9	O

This	5	O
study	9	O
also	9	O
shows	9	O
that	5	O
this	5	O
assay	3	O
can	5	O
help	5	O
detect	9	O
EAD	5	O
for	5	O
drugs	5	O
with	5	O
TdP	5	B-Disease
potential	9	O
.	9	O

Dermal	3	O
developmental	9	O
toxicity	9	B-Disease
of	5	O
N	9	O
-	7	O
phenylimide	_	O
herbicides	0	O
in	5	O
rats	9	O
.	9	O

BACKGROUND	2	O
:	9	O
S	9	B-Chemical
-	7	I-Chemical
53482	_	I-Chemical
and	5	O
S	9	B-Chemical
-	7	I-Chemical
23121	7	I-Chemical
are	5	O
N	9	O
-	7	O
phenylimide	_	O
herbicides	0	O
and	5	O
produced	9	O
embryolethality	3	B-Disease
,	9	O
teratogenicity	5	B-Disease
(	9	O
mainly	9	O
ventricular	5	B-Disease
septal	5	I-Disease
defects	9	I-Disease
and	5	O
wavy	5	O
ribs	5	O
)	9	O
,	9	O
and	5	O
growth	3	B-Disease
retardation	9	I-Disease
in	5	O
rats	9	O
in	5	O
conventional	5	O
oral	9	O
developmental	9	O
toxicity	9	B-Disease
studies	9	O
.	9	O

Our	9	O
objective	5	O
in	5	O
this	5	O
study	9	O
was	9	O
to	5	O
investigate	9	O
whether	9	O
the	5	O
compounds	0	O
induce	3	O
developmental	9	O
toxicity	9	B-Disease
via	9	O
the	5	O
dermal	3	O
route	5	O
,	9	O
which	5	O
is	5	O
more	5	O
relevant	5	O
to	5	O
occupational	5	O
exposure	9	O
,	9	O
hence	5	O
better	5	O
addressing	5	O
human	3	O
health	5	O
risks	5	O
.	9	O

METHODS	2	O
:	9	O
S	9	B-Chemical
-	7	I-Chemical
53482	_	I-Chemical
was	9	O
administered	9	O
dermally	0	O
to	5	O
rats	9	O
at	9	O
30	9	O
,	9	O
100	0	O
,	9	O
and	5	O
300	0	O
mg	0	O
/	9	O
kg	0	O
during	5	O
organogenesis	9	O
,	9	O
and	5	O
S	9	B-Chemical
-	7	I-Chemical
23121	7	I-Chemical
was	9	O
administered	9	O
at	9	O
200	0	O
,	9	O
400	0	O
,	9	O
and	5	O
800	0	O
mg	0	O
/	9	O
kg	0	O
(	9	O
the	5	O
maximum	5	O
applicable	5	O
dose	9	O
level	9	O
)	9	O
.	9	O

Fetuses	5	O
were	9	O
obtained	9	O
by	9	O
a	5	O
Cesarean	5	O
section	5	O
and	5	O
examined	9	O
for	5	O
external	5	O
,	9	O
visceral	9	O
,	9	O
and	5	O
skeletal	9	O
alterations	9	O
.	9	O

RESULTS	9	O
:	9	O
Dermal	3	O
exposure	9	O
of	5	O
rats	9	O
to	5	O
S	9	B-Chemical
-	7	I-Chemical
53482	_	I-Chemical
at	9	O
300	0	O
mg	0	O
/	9	O
kg	0	O
produced	9	O
patterns	5	O
of	5	O
developmental	9	O
toxicity	9	B-Disease
similar	9	O
to	5	O
those	5	O
resulting	9	O
from	9	O
oral	9	O
exposure	9	O
.	9	O

Toxicity	9	B-Disease
included	5	O
embryolethality	3	B-Disease
,	9	O
teratogenicity	5	B-Disease
,	9	O
and	5	O
growth	3	B-Disease
retardation	9	I-Disease
.	9	O

Dermal	3	O
administration	9	O
of	5	O
S	9	B-Chemical
-	7	I-Chemical
23121	7	I-Chemical
at	9	O
800	0	O
mg	0	O
/	9	O
kg	0	O
resulted	9	O
in	5	O
an	5	O
increased	9	O
incidence	5	O
of	5	O
embryonic	3	B-Disease
death	9	I-Disease
and	5	O
ventricular	5	B-Disease
septal	5	I-Disease
defect	9	I-Disease
,	9	O
but	9	O
retarded	9	O
fetal	9	O
growth	3	O
was	9	O
not	5	O
observed	9	O
as	5	O
it	5	O
was	9	O
following	9	O
oral	9	O
exposure	9	O
to	5	O
S	9	B-Chemical
-	7	I-Chemical
23121	7	I-Chemical
.	9	O

CONCLUSIONS	5	O
:	9	O
Based	9	O
on	5	O
the	5	O
results	9	O
,	9	O
S	9	B-Chemical
-	7	I-Chemical
53482	_	I-Chemical
and	5	O
S	9	B-Chemical
-	7	I-Chemical
23121	7	I-Chemical
were	9	O
teratogenic	5	B-Disease
when	5	O
administered	9	O
dermally	0	O
to	5	O
pregnant	5	O
rats	9	O
as	5	O
were	9	O
the	5	O
compounds	0	O
administered	9	O
orally	0	O
.	9	O

Thus	9	O
,	9	O
investigation	9	O
of	5	O
the	5	O
mechanism	9	O
and	5	O
its	9	O
human	3	O
relevancy	5	O
become	5	O
more	5	O
important	9	O
.	9	O

Rates	5	O
of	5	O
Renal	9	B-Disease
Toxicity	9	I-Disease
in	5	O
Cancer	2	B-Disease
Patients	5	O
Receiving	5	O
Cisplatin	0	B-Chemical
With	5	O
and	5	O
Without	9	O
Mannitol	0	B-Chemical
.	9	O

BACKGROUND	2	O
:	9	O
Cisplatin	0	B-Chemical
is	5	O
a	5	O
widely	5	O
used	5	O
antineoplastic	9	O
.	9	O

One	5	O
of	5	O
the	5	O
major	9	O
complications	5	O
of	5	O
cisplatin	3	B-Chemical
use	5	O
is	5	O
dose	9	O
-	7	O
limiting	9	O
nephrotoxicity	9	B-Disease
.	9	O

There	5	O
are	5	O
many	5	O
strategies	5	O
to	5	O
prevent	5	O
this	5	O
toxicity	9	B-Disease
,	9	O
including	9	O
the	5	O
use	5	O
of	5	O
mannitol	0	B-Chemical
as	5	O
a	5	O
nephroprotectant	0	O
in	5	O
combination	9	O
with	5	O
hydration	0	O
.	9	O

OBJECTIVE	2	O
:	9	O
We	9	O
aimed	5	O
to	5	O
evaluate	9	O
the	5	O
rates	5	O
of	5	O
cisplatin	3	B-Chemical
-	7	O
induced	3	O
nephrotoxicity	9	B-Disease
in	5	O
cancer	3	B-Disease
patients	5	O
receiving	9	O
single	9	O
-	7	O
agent	9	O
cisplatin	3	B-Chemical
with	5	O
and	5	O
without	9	O
mannitol	0	B-Chemical
.	9	O

METHODS	2	O
:	9	O
This	5	O
single	9	O
-	7	O
center	5	O
retrospective	5	O
analysis	9	O
was	9	O
a	5	O
quasi	5	O
experiment	9	O
created	5	O
by	9	O
the	5	O
national	5	O
mannitol	0	B-Chemical
shortage	5	O
.	9	O

Data	5	O
were	9	O
collected	9	O
on	5	O
adult	9	O
cancer	3	B-Disease
patients	5	O
receiving	9	O
single	9	O
-	7	O
agent	9	O
cisplatin	3	B-Chemical
as	5	O
an	5	O
outpatient	5	O
from	9	O
January	2	O
2011	2	O
to	5	O
September	2	O
2012	2	O
.	9	O

The	5	O
primary	9	O
outcome	5	O
was	9	O
acute	9	B-Disease
kidney	9	I-Disease
injury	9	I-Disease
(	9	O
AKI	5	B-Disease
)	9	O
.	9	O

RESULTS	9	O
:	9	O
We	9	O
evaluated	9	O
143	7	O
patients	5	O
who	5	O
received	9	O
single	9	O
-	7	O
agent	9	O
cisplatin	3	B-Chemical
;	9	O
97	7	O
.	9	O
2	9	O
%	9	O
of	5	O
patients	5	O
had	9	O
head	5	B-Disease
and	5	I-Disease
neck	5	I-Disease
cancer	3	I-Disease
as	5	O
their	5	O
primary	9	O
malignancy	5	B-Disease
.	9	O

Patients	5	O
who	5	O
did	9	O
not	5	O
receive	5	O
mannitol	0	B-Chemical
were	9	O
more	5	O
likely	5	O
to	5	O
develop	5	O
nephrotoxicity	9	B-Disease
:	9	O
odds	5	O
ratio	9	O
[	9	O
OR	9	O
]	9	O
=	7	O
2	9	O
.	9	O
646	7	O
(	9	O
95	7	O
%	9	O
CI	7	O
=	7	O
1	9	O
.	9	O
008	7	O
,	9	O
6	9	O
.	9	O
944	7	O
;	9	O
P	9	O
=	7	O
0	7	O
.	9	O
048	7	O
)	9	O
.	9	O

Patients	5	O
who	5	O
received	9	O
the	5	O
100	0	O
mg	0	O
/	9	O
m	9	O
(	9	O
2	9	O
)	9	O
dosing	9	O
and	5	O
patients	5	O
who	5	O
had	9	O
a	5	O
history	5	O
of	5	O
hypertension	5	B-Disease
also	9	O
had	9	O
a	5	O
higher	9	O
likelihood	5	O
of	5	O
developing	5	O
nephrotoxicity	9	B-Disease
:	9	O
OR	9	O
=	7	O
11	7	O
.	9	O
494	7	O
(	9	O
95	7	O
%	9	O
CI	7	O
=	7	O
4	9	O
.	9	O
149	7	O
,	9	O
32	7	O
.	9	O
258	7	O
;	9	O
P	9	O
<	0	O
0	7	O
.	9	O
0001	7	O
)	9	O
and	5	O
OR	9	O
=	7	O
3	9	O
.	9	O
219	7	O
(	9	O
95	7	O
%	9	O
CI	7	O
=	7	O
1	9	O
.	9	O
228	7	O
,	9	O
8	9	O
.	9	O
439	7	O
;	9	O
P	9	O
=	7	O
0	7	O
.	9	O
017	7	O
)	9	O
,	9	O
respectively	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
When	9	O
limited	5	O
quantities	9	O
of	5	O
mannitol	0	B-Chemical
are	5	O
available	5	O
,	9	O
it	5	O
should	5	O
preferentially	9	O
be	5	O
given	5	O
to	5	O
patients	5	O
at	9	O
particularly	5	O
high	9	O
risk	5	O
of	5	O
nephrotoxicity	9	B-Disease
.	9	O

Our	9	O
analysis	9	O
suggests	9	O
that	5	O
those	5	O
patients	5	O
receiving	9	O
the	5	O
dosing	9	O
schedule	5	O
of	5	O
100	0	O
mg	0	O
/	9	O
m	9	O
(	9	O
2	9	O
)	9	O
cisplatin	3	B-Chemical
every	5	O
3	9	O
weeks	9	O
and	5	O
those	5	O
with	5	O
hypertension	5	B-Disease
are	5	O
at	9	O
the	5	O
greatest	9	O
risk	5	O
of	5	O
nephrotoxicity	9	B-Disease
and	5	O
would	5	O
benefit	5	O
from	9	O
the	5	O
addition	9	O
of	5	O
mannitol	0	B-Chemical
.	9	O

Metformin	0	B-Chemical
protects	3	O
against	9	O
seizures	5	B-Disease
,	9	O
learning	5	B-Disease
and	5	I-Disease
memory	5	I-Disease
impairments	5	I-Disease
and	5	O
oxidative	9	O
damage	9	O
induced	3	O
by	9	O
pentylenetetrazole	0	B-Chemical
-	7	O
induced	3	O
kindling	5	O
in	5	O
mice	3	O
.	9	O

Cognitive	5	B-Disease
impairment	5	I-Disease
,	9	O
the	5	O
most	9	O
common	5	O
and	5	O
severe	5	O
comorbidity	5	O
of	5	O
epilepsy	5	B-Disease
,	9	O
greatly	9	O
diminishes	9	O
the	5	O
quality	5	O
of	5	O
life	5	O
.	9	O

However	9	O
,	9	O
current	5	O
therapeutic	5	O
interventions	5	O
for	5	O
epilepsy	5	B-Disease
can	5	O
also	9	O
cause	5	O
untoward	5	O
cognitive	5	O
effects	9	O
.	9	O

Thus	9	O
,	9	O
there	5	O
is	5	O
an	5	O
urgent	5	O
need	5	O
for	5	O
new	5	O
kinds	5	O
of	5	O
agents	5	O
targeting	3	O
both	9	O
seizures	5	B-Disease
and	5	O
cognition	5	B-Disease
deficits	5	I-Disease
.	9	O

Oxidative	9	O
stress	9	O
is	5	O
considered	5	O
to	5	O
play	9	O
an	5	O
important	9	O
role	9	O
in	5	O
epileptogenesis	5	O
and	5	O
cognitive	5	B-Disease
deficits	5	I-Disease
,	9	O
and	5	O
antioxidants	0	O
have	5	O
a	5	O
putative	1	O
antiepileptic	5	O
potential	9	O
.	9	O

Metformin	0	B-Chemical
,	9	O
the	5	O
most	9	O
commonly	5	O
prescribed	5	O
antidiabetic	0	O
oral	9	O
drug	5	O
,	9	O
has	9	O
antioxidant	0	O
properties	9	O
.	9	O

This	5	O
study	9	O
was	9	O
designed	9	O
to	5	O
evaluate	9	O
the	5	O
ameliorative	0	O
effects	9	O
of	5	O
metformin	3	B-Chemical
on	5	O
seizures	5	B-Disease
,	9	O
cognitive	5	B-Disease
impairment	5	I-Disease
and	5	O
brain	5	O
oxidative	9	O
stress	9	O
markers	3	O
observed	9	O
in	5	O
pentylenetetrazole	0	B-Chemical
-	7	O
induced	3	O
kindling	5	O
animals	9	O
.	9	O

Male	7	O
C57BL	3	O
/	9	O
6	9	O
mice	3	O
were	9	O
administered	9	O
with	5	O
subconvulsive	5	O
dose	9	O
of	5	O
pentylenetetrazole	0	B-Chemical
(	9	O
37	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
every	5	O
other	5	O
day	9	O
for	5	O
14	7	O
injections	9	O
.	9	O

Metformin	0	B-Chemical
was	9	O
injected	3	O
intraperitoneally	0	O
in	5	O
dose	9	O
of	5	O
200mg	0	O
/	9	O
kg	0	O
along	9	O
with	5	O
alternate	9	O
-	7	O
day	9	O
PTZ	0	B-Chemical
.	9	O

We	9	O
found	9	O
that	5	O
metformin	3	B-Chemical
suppressed	3	O
the	5	O
progression	9	O
of	5	O
kindling	5	O
,	9	O
ameliorated	9	O
the	5	O
cognitive	5	B-Disease
impairment	5	I-Disease
and	5	O
decreased	9	O
brain	5	O
oxidative	9	O
stress	9	O
.	9	O

Thus	9	O
the	5	O
present	9	O
study	9	O
concluded	9	O
that	5	O
metformin	3	B-Chemical
may	5	O
be	5	O
a	5	O
potential	9	O
agent	9	O
for	5	O
the	5	O
treatment	9	O
of	5	O
epilepsy	5	B-Disease
as	5	O
well	9	O
as	5	O
a	5	O
protective	9	O
medicine	5	O
against	9	O
cognitive	5	B-Disease
impairment	5	I-Disease
induced	3	O
by	9	O
seizures	5	B-Disease
.	9	O

P53	3	O
inhibition	3	O
exacerbates	9	O
late	9	O
-	7	O
stage	9	O
anthracycline	9	B-Chemical
cardiotoxicity	9	B-Disease
.	9	O

AIMS	5	O
:	9	O
Doxorubicin	0	B-Chemical
(	9	O
DOX	0	B-Chemical
)	9	O
is	5	O
an	5	O
effective	5	O
anti	3	O
-	7	O
cancer	3	B-Disease
therapeutic	5	O
,	9	O
but	9	O
is	5	O
associated	9	O
with	5	O
both	9	O
acute	9	O
and	5	O
late	9	O
-	7	O
stage	9	O
cardiotoxicity	9	B-Disease
.	9	O

Children	5	O
are	5	O
particularly	5	O
sensitive	9	O
to	5	O
DOX	0	B-Chemical
-	7	O
induced	3	O
heart	5	B-Disease
failure	5	I-Disease
.	9	O

Here	9	O
,	9	O
the	5	O
impact	5	O
of	5	O
p53	3	O
inhibition	3	O
on	5	O
acute	9	O
vs	7	O
.	9	O
late	9	O
-	7	O
stage	9	O
DOX	0	B-Chemical
cardiotoxicity	9	B-Disease
was	9	O
examined	9	O
in	5	O
a	5	O
juvenile	4	O
model	5	O
.	9	O

METHODS	2	O
AND	2	O
RESULTS	9	O
:	9	O
Two	9	O
-	7	O
week	9	O
-	7	O
old	5	O
MHC	3	O
-	7	O
CB7	0	O
mice	3	O
(	9	O
which	5	O
express	3	O
dominant	9	O
-	7	O
interfering	3	O
p53	3	O
in	5	O
cardiomyocytes	3	O
)	9	O
and	5	O
their	5	O
non	9	O
-	7	O
transgenic	3	O
(	9	O
NON	2	O
-	7	O
TXG	1	O
)	9	O
littermates	3	O
received	9	O
weekly	5	O
DOX	0	B-Chemical
injections	9	O
for	5	O
5	9	O
weeks	9	O
(	9	O
25	9	O
mg	0	O
/	9	O
kg	0	O
cumulative	5	O
dose	9	O
)	9	O
.	9	O

One	5	O
week	9	O
after	9	O
the	5	O
last	5	O
DOX	0	B-Chemical
treatment	9	O
(	9	O
acute	9	O
stage	9	O
)	9	O
,	9	O
MHC	3	O
-	7	O
CB7	0	O
mice	3	O
exhibited	9	O
improved	5	O
cardiac	5	O
function	9	O
and	5	O
lower	9	O
levels	3	O
of	5	O
cardiomyocyte	3	O
apoptosis	3	O
when	5	O
compared	9	O
with	5	O
the	5	O
NON	2	O
-	7	O
TXG	1	O
mice	3	O
.	9	O

Surprisingly	9	O
,	9	O
by	9	O
13	7	O
weeks	9	O
following	9	O
the	5	O
last	5	O
DOX	0	B-Chemical
treatment	9	O
(	9	O
late	9	O
stage	9	O
)	9	O
,	9	O
MHC	3	O
-	7	O
CB7	0	O
exhibited	9	O
a	5	O
progressive	5	O
decrease	9	O
in	5	O
cardiac	5	O
function	9	O
and	5	O
higher	9	O
rates	5	O
of	5	O
cardiomyocyte	3	O
apoptosis	3	O
when	5	O
compared	9	O
with	5	O
NON	2	O
-	7	O
TXG	1	O
mice	3	O
.	9	O

p53	3	O
inhibition	3	O
blocked	3	O
transient	9	O
DOX	0	B-Chemical
-	7	O
induced	3	O
STAT3	3	O
activation	3	O
in	5	O
MHC	3	O
-	7	O
CB7	0	O
mice	3	O
,	9	O
which	5	O
was	9	O
associated	9	O
with	5	O
enhanced	3	O
induction	3	O
of	5	O
the	5	O
DNA	9	O
repair	9	O
proteins	1	O
Ku70	1	O
and	5	O
Ku80	3	O
.	9	O

Mice	3	O
with	5	O
cardiomyocyte	3	O
-	7	O
restricted	9	O
deletion	1	O
of	5	O
STAT3	3	O
exhibited	9	O
worse	5	O
cardiac	5	O
function	9	O
,	9	O
higher	9	O
levels	3	O
of	5	O
cardiomyocyte	3	O
apoptosis	3	O
,	9	O
and	5	O
a	5	O
greater	5	O
induction	3	O
of	5	O
Ku70	1	O
and	5	O
Ku80	3	O
in	5	O
response	9	O
to	5	O
DOX	0	B-Chemical
treatment	9	O
during	5	O
the	5	O
acute	9	O
stage	9	O
when	5	O
compared	9	O
with	5	O
control	9	O
animals	9	O
.	9	O

CONCLUSION	5	O
:	9	O
These	5	O
data	5	O
support	5	O
a	5	O
model	5	O
wherein	9	O
a	5	O
p53	3	O
-	7	O
dependent	9	O
cardioprotective	9	O
pathway	3	O
,	9	O
mediated	3	O
via	9	O
STAT3	3	O
activation	3	O
,	9	O
mitigates	9	O
DOX	0	B-Chemical
-	7	O
induced	3	O
myocardial	9	O
stress	9	O
during	5	O
drug	5	O
delivery	5	O
.	9	O

Furthermore	9	O
,	9	O
these	5	O
data	5	O
suggest	9	O
an	5	O
explanation	5	O
as	5	O
to	5	O
how	5	O
p53	3	O
inhibition	3	O
can	5	O
result	9	O
in	5	O
cardioprotection	3	O
during	5	O
drug	5	O
treatment	9	O
and	5	O
,	9	O
paradoxically	9	O
,	9	O
enhanced	3	O
cardiotoxicity	9	B-Disease
long	5	O
after	9	O
the	5	O
cessation	5	O
of	5	O
drug	5	O
treatment	9	O
.	9	O

Metronidazole	0	B-Chemical
-	7	O
induced	3	O
encephalopathy	5	B-Disease
:	9	O
an	5	O
uncommon	5	O
scenario	5	O
.	9	O

Metronidazole	0	B-Chemical
can	5	O
produce	9	O
neurological	5	O
complications	5	O
although	9	O
it	5	O
is	5	O
not	5	O
a	5	O
common	5	O
scenario	5	O
.	9	O

We	9	O
present	9	O
a	5	O
case	5	O
where	5	O
a	5	O
patient	5	O
developed	5	O
features	5	O
of	5	O
encephalopathy	5	B-Disease
following	9	O
prolonged	9	O
metronidazole	0	B-Chemical
intake	5	O
.	9	O

Magnetic	5	O
resonance	5	O
imaging	5	O
(	9	O
MRI	5	O
)	9	O
brain	5	O
showed	9	O
abnormal	9	O
signal	9	O
intensity	5	O
involving	5	O
both	9	O
dentate	3	O
nuclei	3	O
of	5	O
cerebellum	9	O
and	5	O
splenium	5	O
of	5	O
corpus	5	O
callosum	5	O
.	9	O

The	5	O
diagnosis	5	O
of	5	O
metronidazole	0	B-Chemical
toxicity	9	B-Disease
was	9	O
made	5	O
by	9	O
the	5	O
MRI	5	O
findings	9	O
and	5	O
supported	9	O
clinically	5	O
.	9	O

Aconitine	0	B-Chemical
-	7	O
induced	3	O
Ca2	0	B-Chemical
+	9	O
overload	9	O
causes	9	O
arrhythmia	5	B-Disease
and	5	O
triggers	9	O
apoptosis	3	O
through	9	O
p38	3	O
MAPK	3	O
signaling	3	O
pathway	3	O
in	5	O
rats	9	O
.	9	O

Aconitine	0	B-Chemical
is	5	O
a	5	O
major	9	O
bioactive	0	O
diterpenoid	0	O
alkaloid	0	O
with	5	O
high	9	O
content	9	O
derived	9	O
from	9	O
herbal	5	O
aconitum	0	O
plants	4	O
.	9	O

Emerging	2	O
evidence	9	O
indicates	9	O
that	5	O
voltage	5	O
-	7	O
dependent	9	O
Na	0	B-Chemical
(	9	O
+	9	O
)	9	O
channels	9	O
have	5	O
pivotal	9	O
roles	9	O
in	5	O
the	5	O
cardiotoxicity	9	B-Disease
of	5	O
aconitine	0	B-Chemical
.	9	O

However	9	O
,	9	O
no	9	O
reports	9	O
are	5	O
available	5	O
on	5	O
the	5	O
role	9	O
of	5	O
Ca	0	B-Chemical
(	9	O
2	9	O
+	9	O
)	9	O
in	5	O
aconitine	0	B-Chemical
poisoning	5	B-Disease
.	9	O

In	9	O
this	5	O
study	9	O
,	9	O
we	5	O
explored	9	O
the	5	O
importance	5	O
of	5	O
pathological	5	O
Ca	0	B-Chemical
(	9	O
2	9	O
+	9	O
)	9	O
signaling	3	O
in	5	O
aconitine	0	B-Chemical
poisoning	5	B-Disease
in	5	O
vitro	3	O
and	5	O
in	5	O
vivo	3	O
.	9	O

We	9	O
found	9	O
that	5	O
Ca	0	B-Chemical
(	9	O
2	9	O
+	9	O
)	9	O
overload	9	O
lead	5	O
to	5	O
accelerated	9	O
beating	5	O
rhythm	5	O
in	5	O
adult	9	O
rat	3	O
ventricular	5	O
myocytes	3	O
and	5	O
caused	9	O
arrhythmia	5	B-Disease
in	5	O
conscious	5	O
freely	5	O
moving	5	O
rats	9	O
.	9	O

To	9	O
investigate	9	O
effects	9	O
of	5	O
aconitine	0	B-Chemical
on	5	O
myocardial	9	B-Disease
injury	9	I-Disease
,	9	O
we	5	O
performed	9	O
cytotoxicity	3	B-Disease
assay	3	O
in	5	O
neonatal	9	O
rat	3	O
ventricular	5	O
myocytes	3	O
(	9	O
NRVMs	3	O
)	9	O
,	9	O
as	5	O
well	9	O
as	5	O
measured	9	O
lactate	0	B-Chemical
dehydrogenase	1	O
level	9	O
in	5	O
the	5	O
culture	9	O
medium	0	O
of	5	O
NRVMs	3	O
and	5	O
activities	9	O
of	5	O
serum	9	O
cardiac	5	O
enzymes	1	O
in	5	O
rats	9	O
.	9	O

The	5	O
results	9	O
showed	9	O
that	5	O
aconitine	0	B-Chemical
resulted	9	O
in	5	O
myocardial	9	B-Disease
injury	9	I-Disease
and	5	O
reduced	9	O
NRVMs	3	O
viability	3	O
dose	9	O
-	7	O
dependently	3	O
.	9	O

To	9	O
confirm	9	O
the	5	O
pro	9	O
-	7	O
apoptotic	3	O
effects	9	O
,	9	O
we	5	O
performed	9	O
flow	5	O
cytometric	3	O
detection	9	O
,	9	O
cardiac	5	O
histology	9	O
,	9	O
transmission	5	O
electron	0	O
microscopy	9	O
and	5	O
terminal	9	O
deoxynucleotidyl	3	O
transferase	1	O
-	7	O
mediated	3	O
dUTP	0	B-Chemical
-	7	O
biotin	0	B-Chemical
nick	0	O
end	9	O
labeling	3	O
assay	3	O
.	9	O

The	5	O
results	9	O
showed	9	O
that	5	O
aconitine	0	B-Chemical
stimulated	3	O
apoptosis	3	O
time	5	O
-	7	O
dependently	3	O
.	9	O

The	5	O
expression	3	O
analysis	9	O
of	5	O
Ca	0	B-Chemical
(	9	O
2	9	O
+	9	O
)	9	O
handling	5	O
proteins	1	O
demonstrated	9	O
that	5	O
aconitine	0	B-Chemical
promoted	3	O
Ca	0	B-Chemical
(	9	O
2	9	O
+	9	O
)	9	O
overload	9	O
through	9	O
the	5	O
expression	3	O
regulation	9	O
of	5	O
Ca	0	B-Chemical
(	9	O
2	9	O
+	9	O
)	9	O
handling	5	O
proteins	1	O
.	9	O

The	5	O
expression	3	O
analysis	9	O
of	5	O
apoptosis	3	O
-	7	O
related	9	O
proteins	1	O
revealed	9	O
that	5	O
pro	9	O
-	7	O
apoptotic	3	O
protein	1	O
expression	3	O
was	9	O
upregulated	3	O
,	9	O
and	5	O
anti	3	O
-	7	O
apoptotic	3	O
protein	1	O
BCL	9	O
-	7	O
2	9	O
expression	3	O
was	9	O
downregulated	3	O
.	9	O

Furthermore	9	O
,	9	O
increased	9	O
phosphorylation	3	O
of	5	O
MAPK	3	O
family	9	O
members	9	O
,	9	O
especially	5	O
the	5	O
P	9	O
-	7	O
P38	3	O
/	9	O
P38	3	O
ratio	9	O
was	9	O
found	9	O
in	5	O
cardiac	5	O
tissues	9	O
.	9	O

Hence	9	O
,	9	O
our	5	O
results	9	O
suggest	9	O
that	5	O
aconitine	0	B-Chemical
significantly	9	O
aggravates	9	O
Ca	0	B-Chemical
(	9	O
2	9	O
+	9	O
)	9	O
overload	9	O
and	5	O
causes	9	O
arrhythmia	5	B-Disease
and	5	O
finally	9	O
promotes	3	O
apoptotic	3	O
development	9	O
via	9	O
phosphorylation	3	O
of	5	O
P38	3	O
mitogen	3	O
-	7	O
activated	3	O
protein	1	O
kinase	3	O
.	9	O

Chronic	9	O
treatment	9	O
with	5	O
metformin	3	B-Chemical
suppresses	3	O
toll	5	O
-	7	O
like	9	O
receptor	3	O
4	9	O
signaling	3	O
and	5	O
attenuates	3	O
left	5	B-Disease
ventricular	5	I-Disease
dysfunction	9	I-Disease
following	9	O
myocardial	9	B-Disease
infarction	5	I-Disease
.	9	O

Acute	5	O
treatment	9	O
with	5	O
metformin	3	B-Chemical
has	9	O
a	5	O
protective	9	O
effect	9	O
in	5	O
myocardial	9	B-Disease
infarction	5	I-Disease
by	9	O
suppression	9	O
of	5	O
inflammatory	3	O
responses	5	O
due	5	O
to	5	O
activation	3	O
of	5	O
AMP	0	B-Chemical
-	7	O
activated	3	O
protein	1	O
kinase	3	O
(	9	O
AMPK	3	O
)	9	O
.	9	O

In	9	O
the	5	O
present	9	O
study	9	O
,	9	O
the	5	O
effect	9	O
of	5	O
chronic	5	O
pre	9	O
-	7	O
treatment	9	O
with	5	O
metformin	3	B-Chemical
on	5	O
cardiac	5	B-Disease
dysfunction	9	I-Disease
and	5	O
toll	5	O
-	7	O
like	9	O
receptor	3	O
4	9	O
(	9	O
TLR4	3	O
)	9	O
activities	9	O
following	9	O
myocardial	9	B-Disease
infarction	5	I-Disease
and	5	O
their	5	O
relation	5	O
with	5	O
AMPK	3	O
were	9	O
assessed	9	O
.	9	O

Male	7	O
Wistar	9	O
rats	9	O
were	9	O
randomly	5	O
assigned	5	O
to	5	O
one	5	O
of	5	O
5	9	O
groups	9	O
(	9	O
n	9	O
=	7	O
6	9	O
)	9	O
:	9	O
normal	9	O
control	9	O
and	5	O
groups	9	O
were	9	O
injected	3	O
isoproterenol	0	B-Chemical
after	9	O
chronic	5	O
pre	9	O
-	7	O
treatment	9	O
with	5	O
0	7	O
,	9	O
25	9	O
,	9	O
50	0	O
,	9	O
or	5	O
100mg	0	O
/	9	O
kg	0	O
of	5	O
metformin	3	B-Chemical
twice	9	O
daily	5	O
for	5	O
14	7	O
days	9	O
.	9	O

Isoproterenol	0	B-Chemical
(	9	O
100mg	0	O
/	9	O
kg	0	O
)	9	O
was	9	O
injected	3	O
subcutaneously	3	O
on	5	O
the	5	O
13th	9	O
and	5	O
14th	9	O
days	9	O
to	5	O
induce	3	O
acute	9	B-Disease
myocardial	9	I-Disease
infarction	5	I-Disease
.	9	O

Isoproterenol	0	B-Chemical
alone	9	O
decreased	9	O
left	5	O
ventricular	5	O
systolic	5	O
pressure	5	O
and	5	O
myocardial	9	O
contractility	9	O
indexed	5	O
as	5	O
LVdp	7	O
/	9	O
dtmax	0	O
and	5	O
LVdp	7	O
/	9	O
dtmin	0	O
.	9	O

The	5	O
left	5	B-Disease
ventricular	5	I-Disease
dysfunction	9	I-Disease
was	9	O
significantly	9	O
lower	9	O
in	5	O
the	5	O
groups	9	O
treated	3	O
with	5	O
25	9	O
and	5	O
50mg	0	O
/	9	O
kg	0	O
of	5	O
metformin	3	B-Chemical
.	9	O

Metfromin	_	O
markedly	9	O
lowered	9	O
isoproterenol	0	B-Chemical
-	7	O
induced	3	O
elevation	9	O
in	5	O
the	5	O
levels	3	O
of	5	O
TLR4	3	O
mRNA	3	O
,	9	O
myeloid	3	O
differentiation	3	O
protein	1	O
88	7	O
(	9	O
MyD88	3	O
)	9	O
,	9	O
tumor	3	B-Disease
necrosis	9	B-Disease
factor	9	O
-	7	O
alpha	9	O
(	9	O
TNF	3	O
-	7	O
a	5	O
)	9	O
,	9	O
and	5	O
interleukin	3	O
6	9	O
(	9	O
IL	0	O
-	7	O
6	9	O
)	9	O
in	5	O
the	5	O
heart	5	O
tissues	9	O
.	9	O

Similar	9	O
changes	9	O
were	9	O
also	9	O
seen	9	O
in	5	O
the	5	O
serum	9	O
levels	3	O
of	5	O
TNF	3	O
-	7	O
a	5	O
and	5	O
IL	0	O
-	7	O
6	9	O
.	9	O

However	9	O
,	9	O
the	5	O
lower	9	O
doses	0	O
of	5	O
25	9	O
and	5	O
50mg	0	O
/	9	O
kg	0	O
were	9	O
more	5	O
effective	5	O
than	5	O
100mg	0	O
/	9	O
kg	0	O
.	9	O

Phosphorylated	3	O
AMPKa	3	O
(	9	O
p	7	O
-	7	O
AMPK	3	O
)	9	O
in	5	O
the	5	O
myocardium	9	O
was	9	O
significantly	9	O
elevated	9	O
by	9	O
25mg	0	O
/	9	O
kg	0	O
of	5	O
metformin	3	B-Chemical
,	9	O
slightly	9	O
by	9	O
50mg	0	O
/	9	O
kg	0	O
,	9	O
but	9	O
not	5	O
by	9	O
100mg	0	O
/	9	O
kg	0	O
.	9	O

Chronic	9	O
pre	9	O
-	7	O
treatment	9	O
with	5	O
metformin	3	B-Chemical
reduces	9	O
post	9	O
-	7	O
myocardial	9	B-Disease
infarction	5	I-Disease
cardiac	5	O
dysfunction	9	O
and	5	O
suppresses	3	O
inflammatory	3	O
responses	5	O
,	9	O
possibly	9	O
through	9	O
inhibition	3	O
of	5	O
TLR4	3	O
activities	9	O
.	9	O

This	5	O
mechanism	9	O
can	5	O
be	5	O
considered	5	O
as	5	O
a	5	O
target	9	O
to	5	O
protect	9	O
infarcted	3	O
myocardium	9	O
.	9	O

Unusual	9	O
complications	5	O
of	5	O
antithyroid	0	O
drug	5	O
therapy	5	O
:	9	O
four	9	O
case	5	O
reports	9	O
and	5	O
review	5	O
of	5	O
literature	5	O
.	9	O

Two	9	O
cases	5	O
of	5	O
propylthiouracil	0	B-Chemical
-	7	O
associated	9	O
acute	9	O
hepatitis	9	B-Disease
,	9	O
one	5	O
case	5	O
of	5	O
fatal	5	O
methimazole	0	B-Chemical
-	7	O
associated	9	O
hepatocellular	9	B-Disease
necrosis	9	I-Disease
and	5	O
one	5	O
case	5	O
of	5	O
propylthiouracil	0	B-Chemical
-	7	O
associated	9	O
lupus	9	B-Disease
-	7	I-Disease
like	9	I-Disease
syndrome	5	I-Disease
are	5	O
described	9	O
.	9	O

The	5	O
literature	5	O
related	9	O
to	5	O
antithyroid	0	O
drug	5	O
side	5	O
effects	9	O
and	5	O
the	5	O
mechanisms	9	O
for	5	O
their	5	O
occurrence	5	O
are	5	O
reviewed	9	O
and	5	O
the	5	O
efficacy	9	O
and	5	O
complications	5	O
of	5	O
thyroidectomy	5	O
and	5	O
radioiodine	5	O
compared	9	O
to	5	O
those	5	O
of	5	O
antithyroid	0	O
drugs	5	O
.	9	O

It	5	O
is	5	O
concluded	9	O
that	5	O
in	5	O
most	9	O
circumstances	5	O
131I	0	O
is	5	O
the	5	O
therapy	5	O
of	5	O
choice	5	O
for	5	O
hyperthyroidism	5	B-Disease
.	9	O

Neuroleptic	2	B-Disease
malignant	3	I-Disease
syndrome	5	I-Disease
induced	3	O
by	9	O
combination	9	O
therapy	5	O
with	5	O
tetrabenazine	5	B-Chemical
and	5	O
tiapride	0	B-Chemical
in	5	O
a	5	O
Japanese	9	O
patient	5	O
with	5	O
Huntington	9	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
at	9	O
the	5	O
terminal	9	O
stage	9	O
of	5	O
recurrent	5	O
breast	3	B-Disease
cancer	3	I-Disease
.	9	O

We	9	O
herein	9	O
describe	5	O
the	5	O
case	5	O
of	5	O
an	5	O
81	7	O
-	7	O
year	5	O
-	7	O
old	5	O
Japanese	9	O
woman	5	O
with	5	O
neuroleptic	5	B-Disease
malignant	3	I-Disease
syndrome	5	I-Disease
that	5	O
occurred	9	O
36	9	O
days	9	O
after	9	O
the	5	O
initiation	9	O
of	5	O
combination	9	O
therapy	5	O
with	5	O
tiapride	0	B-Chemical
(	9	O
75	9	O
mg	0	O
/	9	O
day	9	O
)	9	O
and	5	O
tetrabenazine	5	B-Chemical
(	9	O
12	9	O
.	9	O
5	9	O
mg	0	O
/	9	O
day	9	O
)	9	O
for	5	O
Huntington	9	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
.	9	O

The	5	O
patient	5	O
had	9	O
been	9	O
treated	3	O
with	5	O
tiapride	0	B-Chemical
or	5	O
tetrabenazine	5	B-Chemical
alone	9	O
without	9	O
any	5	O
adverse	5	O
effects	9	O
before	9	O
the	5	O
administration	9	O
of	5	O
the	5	O
combination	9	O
therapy	5	O
.	9	O

She	5	O
also	9	O
had	9	O
advanced	5	O
breast	3	B-Disease
cancer	3	I-Disease
when	5	O
the	5	O
combination	9	O
therapy	5	O
was	9	O
initiated	9	O
.	9	O

To	9	O
the	5	O
best	5	O
of	5	O
our	5	O
knowledge	5	O
,	9	O
the	5	O
occurrence	5	O
of	5	O
neuroleptic	5	B-Disease
malignant	3	I-Disease
syndrome	5	I-Disease
due	5	O
to	5	O
combination	9	O
therapy	5	O
with	5	O
tetrabenazine	5	B-Chemical
and	5	O
tiapride	0	B-Chemical
has	9	O
not	5	O
been	9	O
previously	9	O
reported	9	O
.	9	O

Tetrabenazine	0	B-Chemical
should	5	O
be	5	O
administered	9	O
very	5	O
carefully	5	O
in	5	O
combination	9	O
with	5	O
other	5	O
neuroleptic	5	B-Chemical
drugs	5	I-Chemical
,	9	O
particularly	5	O
in	5	O
patients	5	O
with	5	O
a	5	O
worsening	5	O
general	5	O
condition	5	O
.	9	O

A	9	O
metoprolol	0	B-Chemical
-	7	O
terbinafine	0	B-Chemical
combination	9	O
induced	3	O
bradycardia	5	B-Disease
.	9	O

To	9	O
report	5	O
a	5	O
sinus	5	B-Disease
bradycardia	5	I-Disease
induced	3	O
by	9	O
metoprolol	0	B-Chemical
and	5	O
terbinafine	0	B-Chemical
drug	5	O
-	7	O
drug	5	O
interaction	9	O
and	5	O
its	9	O
management	5	O
.	9	O

A	9	O
63	7	O
year	5	O
-	7	O
old	5	O
Caucasian	9	O
man	5	O
on	5	O
metoprolol	0	B-Chemical
200	0	O
mg	0	O
/	9	O
day	9	O
for	5	O
stable	9	O
coronary	5	B-Disease
artery	5	I-Disease
disease	5	I-Disease
was	9	O
prescribed	5	O
a	5	O
90	9	O
-	7	O
day	9	O
course	5	O
of	5	O
oral	9	O
terbinafine	0	B-Chemical
250	0	O
mg	0	O
/	9	O
day	9	O
for	5	O
onychomycosis	5	B-Disease
.	9	O

On	5	O
the	5	O
49th	2	O
day	9	O
of	5	O
terbinafine	0	B-Chemical
therapy	5	O
,	9	O
he	5	O
was	9	O
brought	5	O
to	5	O
the	5	O
emergency	5	O
room	9	O
for	5	O
a	5	O
decrease	9	O
of	5	O
his	5	O
global	5	O
health	5	O
status	9	O
,	9	O
confusion	5	B-Disease
and	5	O
falls	5	O
.	9	O

The	5	O
electrocardiogram	5	O
revealed	9	O
a	5	O
37	9	O
beats	5	O
/	9	O
min	0	O
sinus	5	B-Disease
bradycardia	5	I-Disease
.	9	O

A	9	O
score	5	O
of	5	O
7	9	O
on	5	O
the	5	O
Naranjo	6	O
adverse	5	B-Disease
drug	5	I-Disease
reaction	9	I-Disease
probability	5	O
scale	5	O
indicates	9	O
a	5	O
probable	9	O
relationship	5	O
between	5	O
the	5	O
patient	5	O
'	9	O
s	9	O
sinus	5	B-Disease
bradycardia	5	I-Disease
and	5	O
the	5	O
drug	5	O
interaction	9	O
between	5	O
metoprolol	0	B-Chemical
and	5	O
terbinafine	0	B-Chemical
.	9	O

The	5	O
heart	5	O
rate	9	O
ameliorated	9	O
first	9	O
with	5	O
a	5	O
decrease	9	O
in	5	O
the	5	O
dose	9	O
of	5	O
metoprolol	0	B-Chemical
.	9	O

It	5	O
was	9	O
subsequently	9	O
changed	9	O
to	5	O
bisoprolol	0	B-Chemical
and	5	O
the	5	O
heart	5	O
rate	9	O
remained	9	O
normal	9	O
.	9	O

By	5	O
inhibiting	3	O
the	5	O
cytochrome	0	O
P450	1	O
2D6	0	O
,	9	O
terbinafine	0	B-Chemical
had	9	O
decreased	9	O
metoprolol	0	B-Chemical
'	9	O
s	9	O
clearance	9	O
,	9	O
leading	9	O
in	5	O
metoprolol	0	B-Chemical
accumulation	9	O
which	5	O
has	9	O
resulted	9	O
in	5	O
clinically	5	O
significant	9	O
sinus	5	B-Disease
bradycardia	5	I-Disease
.	9	O

Optochiasmatic	_	O
and	5	O
peripheral	9	B-Disease
neuropathy	5	I-Disease
due	5	O
to	5	O
ethambutol	0	B-Chemical
overtreatment	5	O
.	9	O

Ethambutol	0	B-Chemical
is	5	O
known	9	O
to	5	O
cause	5	O
optic	5	B-Disease
neuropathy	5	I-Disease
and	5	O
,	9	O
more	5	O
rarely	5	O
,	9	O
axonal	3	O
polyneuropathy	5	B-Disease
.	9	O

We	9	O
characterize	9	O
the	5	O
clinical	5	O
,	9	O
neurophysiological	5	O
,	9	O
and	5	O
neuroimaging	5	O
findings	9	O
in	5	O
a	5	O
72	9	O
-	7	O
year	5	O
-	7	O
old	5	O
man	5	O
who	5	O
developed	5	O
visual	5	B-Disease
loss	9	I-Disease
and	5	O
paresthesias	5	B-Disease
after	9	O
11	7	O
weeks	9	O
of	5	O
exposure	9	O
to	5	O
a	5	O
supratherapeutic	5	O
dose	9	O
of	5	O
ethambutol	0	B-Chemical
.	9	O

This	5	O
case	5	O
demonstrates	9	O
the	5	O
selective	9	O
vulnerability	5	O
of	5	O
the	5	O
anterior	5	O
visual	5	O
pathways	9	O
and	5	O
peripheral	9	O
nerves	5	O
to	5	O
ethambutol	0	B-Chemical
toxicity	9	B-Disease
.	9	O

Testosterone	0	B-Chemical
ameliorates	3	O
streptozotocin	0	B-Chemical
-	7	O
induced	3	O
memory	5	B-Disease
impairment	5	I-Disease
in	5	O
male	9	O
rats	9	O
.	9	O

AIM	9	O
:	9	O
To	9	O
study	9	O
the	5	O
effects	9	O
of	5	O
testosterone	9	B-Chemical
on	5	O
streptozotocin	0	B-Chemical
(	9	O
STZ	0	B-Chemical
)	9	O
-	7	O
induced	3	O
memory	5	B-Disease
impairment	5	I-Disease
in	5	O
male	9	O
rats	9	O
.	9	O

METHODS	2	O
:	9	O
Adult	9	O
male	9	O
Wistar	9	O
rats	9	O
were	9	O
intracerebroventricularly	3	O
(	9	O
icv	0	O
)	9	O
infused	9	O
with	5	O
STZ	0	B-Chemical
(	9	O
750	0	O
ug	0	O
)	9	O
on	5	O
d	9	O
1	9	O
and	5	O
d	9	O
3	9	O
,	9	O
and	5	O
a	5	O
passive	5	O
avoidance	5	O
task	5	O
was	9	O
assessed	9	O
2	9	O
weeks	9	O
after	9	O
the	5	O
first	9	O
injection	9	O
of	5	O
STZ	0	B-Chemical
.	9	O

Castration	3	O
surgery	5	O
was	9	O
performed	9	O
in	5	O
another	9	O
group	9	O
of	5	O
rats	9	O
,	9	O
and	5	O
the	5	O
passive	5	O
avoidance	5	O
task	5	O
was	9	O
assessed	9	O
4	9	O
weeks	9	O
after	9	O
the	5	O
operation	5	O
.	9	O

Testosterone	0	B-Chemical
(	9	O
1	9	O
mg	0	O
.	9	O
kg	0	O
(	9	O
-	7	O
1	9	O
)	9	O
.	9	O
d	9	O
(	9	O
-	7	O
1	9	O
)	9	O
,	9	O
sc	9	O
)	9	O
,	9	O
the	5	O
androgen	3	B-Chemical
receptor	3	O
antagonist	3	O
flutamide	0	B-Chemical
(	9	O
10	9	O
mg	0	O
.	9	O
kg	0	O
(	9	O
-	7	O
1	9	O
)	9	O
.	9	O
d	9	O
(	9	O
-	7	O
1	9	O
)	9	O
,	9	O
ip	0	O
)	9	O
,	9	O
the	5	O
estrogen	3	B-Chemical
receptor	3	O
antagonist	3	O
tamoxifen	9	B-Chemical
(	9	O
1	9	O
mg	0	O
.	9	O
kg	0	O
(	9	O
-	7	O
1	9	O
)	9	O
.	9	O
d	9	O
(	9	O
-	7	O
1	9	O
)	9	O
,	9	O
ip	0	O
)	9	O
or	5	O
the	5	O
aromatase	3	O
inhibitor	3	O
letrozole	0	B-Chemical
(	9	O
4	9	O
mg	0	O
.	9	O
kg	0	O
(	9	O
-	7	O
1	9	O
)	9	O
.	9	O
d	9	O
(	9	O
-	7	O
1	9	O
)	9	O
,	9	O
ip	0	O
)	9	O
were	9	O
administered	9	O
for	5	O
6	9	O
d	9	O
after	9	O
the	5	O
first	9	O
injection	9	O
of	5	O
STZ	0	B-Chemical
.	9	O

RESULTS	9	O
:	9	O
STZ	0	B-Chemical
administration	9	O
and	5	O
castration	3	O
markedly	9	O
decreased	9	O
both	9	O
STL1	1	O
(	9	O
the	5	O
short	5	O
memory	5	O
)	9	O
and	5	O
STL2	1	O
(	9	O
the	5	O
long	5	O
memory	5	O
)	9	O
in	5	O
passive	5	O
avoidance	5	O
tests	5	O
.	9	O

Testosterone	0	B-Chemical
replacement	9	O
almost	9	O
restored	3	O
the	5	O
STL1	1	O
and	5	O
STL2	1	O
in	5	O
castrated	3	O
rats	9	O
,	9	O
and	5	O
significantly	9	O
prolonged	9	O
the	5	O
STL1	1	O
and	5	O
STL2	1	O
in	5	O
STZ	0	B-Chemical
-	7	O
treated	3	O
rats	9	O
.	9	O

Administration	2	O
of	5	O
flutamide	0	B-Chemical
,	9	O
letrozole	0	B-Chemical
or	5	O
tamoxifen	9	B-Chemical
significantly	9	O
impaired	9	B-Disease
the	5	I-Disease
memory	5	I-Disease
in	5	O
intact	9	O
rats	9	O
,	9	O
and	5	O
significantly	9	O
attenuated	3	O
the	5	O
testosterone	9	B-Chemical
replacement	9	O
in	5	O
improving	5	O
STZ	0	B-Chemical
-	7	O
and	5	O
castration	3	O
-	7	O
induced	3	O
memory	5	B-Disease
impairment	5	I-Disease
.	9	O

CONCLUSION	5	O
:	9	O
Testosterone	0	B-Chemical
administration	9	O
ameliorates	3	O
STZ	0	B-Chemical
-	7	O
and	5	O
castration	3	O
-	7	O
induced	3	O
memory	5	B-Disease
impairment	5	I-Disease
in	5	O
male	9	O
Wistar	9	O
rats	9	O
.	9	O

Behavioral	5	O
and	5	O
neurochemical	5	O
studies	9	O
in	5	O
mice	3	O
pretreated	3	O
with	5	O
garcinielliptone	_	B-Chemical
FC	9	I-Chemical
in	5	O
pilocarpine	0	B-Chemical
-	7	O
induced	3	O
seizures	5	B-Disease
.	9	O

Garcinielliptone	_	B-Chemical
FC	9	I-Chemical
(	9	O
GFC	5	B-Chemical
)	9	O
isolated	9	O
from	9	O
hexanic	0	O
fraction	9	O
seed	4	O
extract	0	O
of	5	O
species	4	O
Platonia	9	O
insignis	4	O
Mart	4	O
.	9	O

It	5	O
is	5	O
widely	5	O
used	5	O
in	5	O
folk	5	O
medicine	5	O
to	5	O
treat	5	O
skin	5	B-Disease
diseases	5	I-Disease
in	5	O
both	9	O
humans	9	O
and	5	O
animals	9	O
as	5	O
well	9	O
as	5	O
the	5	O
seed	4	O
decoction	0	O
has	9	O
been	9	O
used	5	O
to	5	O
treat	5	O
diarrheas	5	B-Disease
and	5	O
inflammatory	3	B-Disease
diseases	5	I-Disease
.	9	O

However	9	O
,	9	O
there	5	O
is	5	O
no	9	O
research	5	O
on	5	O
GFC	5	B-Chemical
effects	9	O
in	5	O
the	5	O
central	5	O
nervous	5	O
system	5	O
of	5	O
rodents	9	O
.	9	O

The	5	O
present	9	O
study	9	O
aimed	5	O
to	5	O
evaluate	9	O
the	5	O
GFC	5	B-Chemical
effects	9	O
at	9	O
doses	0	O
of	5	O
25	9	O
,	9	O
50	0	O
or	5	O
75	9	O
mg	0	O
/	9	O
kg	0	O
on	5	O
seizure	5	B-Disease
parameters	5	O
to	5	O
determine	9	O
their	5	O
anticonvulsant	5	O
activity	9	O
and	5	O
its	9	O
effects	9	O
on	5	O
amino	1	B-Chemical
acid	0	I-Chemical
(	9	O
r	9	B-Chemical
-	7	I-Chemical
aminobutyric	0	I-Chemical
acid	0	I-Chemical
(	9	O
GABA	0	B-Chemical
)	9	O
,	9	O
glutamine	0	B-Chemical
,	9	O
aspartate	1	B-Chemical
and	5	O
glutathione	0	B-Chemical
)	9	O
levels	3	O
as	5	O
well	9	O
as	5	O
on	5	O
acetylcholinesterase	0	O
(	9	O
AChE	0	O
)	9	O
activity	9	O
in	5	O
mice	3	O
hippocampus	9	O
after	9	O
seizures	5	B-Disease
.	9	O

GFC	5	B-Chemical
produced	9	O
an	5	O
increased	9	O
latency	5	O
to	5	O
first	9	O
seizure	5	B-Disease
,	9	O
at	9	O
doses	0	O
25mg	0	O
/	9	O
kg	0	O
(	9	O
20	9	O
.	9	O
12	9	O
+	9	O
2	9	O
.	9	O
20	9	O
min	0	O
)	9	O
,	9	O
50mg	0	O
/	9	O
kg	0	O
(	9	O
20	9	O
.	9	O
95	7	O
+	9	O
2	9	O
.	9	O
21	7	O
min	0	O
)	9	O
or	5	O
75	9	O
mg	0	O
/	9	O
kg	0	O
(	9	O
23	7	O
.	9	O
43	7	O
+	9	O
1	9	O
.	9	O
99	7	O
min	0	O
)	9	O
when	5	O
compared	9	O
with	5	O
seized	5	O
mice	3	O
.	9	O

In	9	O
addition	9	O
,	9	O
GABA	0	B-Chemical
content	9	O
of	5	O
mice	3	O
hippocampus	9	O
treated	3	O
with	5	O
GFC75	_	O
plus	9	O
P400	5	O
showed	9	O
an	5	O
increase	9	O
of	5	O
46	7	O
.	9	O
90	9	O
%	9	O
when	5	O
compared	9	O
with	5	O
seized	5	O
mice	3	O
.	9	O

In	9	O
aspartate	1	B-Chemical
,	9	O
glutamine	0	B-Chemical
and	5	O
glutamate	0	B-Chemical
levels	3	O
detected	9	O
a	5	O
decrease	9	O
of	5	O
5	9	O
.	9	O
21	7	O
%	9	O
,	9	O
13	7	O
.	9	O
55	7	O
%	9	O
and	5	O
21	7	O
.	9	O
80	9	O
%	9	O
,	9	O
respectively	9	O
in	5	O
mice	3	O
hippocampus	9	O
treated	3	O
with	5	O
GFC75	_	O
plus	9	O
P400	5	O
when	5	O
compared	9	O
with	5	O
seized	5	O
mice	3	O
.	9	O

Hippocampus	7	O
mice	3	O
treated	3	O
with	5	O
GFC75	_	O
plus	9	O
P400	5	O
showed	9	O
an	5	O
increase	9	O
in	5	O
AChE	0	O
activity	9	O
(	9	O
63	7	O
.	9	O
30	9	O
%	9	O
)	9	O
when	5	O
compared	9	O
with	5	O
seized	5	O
mice	3	O
.	9	O

The	5	O
results	9	O
indicate	9	O
that	5	O
GFC	5	B-Chemical
can	5	O
exert	9	O
anticonvulsant	5	O
activity	9	O
and	5	O
reduce	5	O
the	5	O
frequency	5	O
of	5	O
installation	5	O
of	5	O
pilocarpine	0	B-Chemical
-	7	O
induced	3	O
status	9	B-Disease
epilepticus	5	I-Disease
,	9	O
as	5	O
demonstrated	9	O
by	9	O
increase	9	O
in	5	O
latency	5	O
to	5	O
first	9	O
seizure	5	B-Disease
and	5	O
decrease	9	O
in	5	O
mortality	5	O
rate	9	O
of	5	O
animals	9	O
.	9	O

In	9	O
conclusion	9	O
,	9	O
our	5	O
data	5	O
suggest	9	O
that	5	O
GFC	5	B-Chemical
may	5	O
influence	5	O
in	5	O
epileptogenesis	5	O
and	5	O
promote	3	O
anticonvulsant	5	O
actions	5	O
in	5	O
pilocarpine	0	B-Chemical
model	5	O
by	9	O
modulating	9	O
the	5	O
GABA	0	B-Chemical
and	5	O
glutamate	0	B-Chemical
contents	9	O
and	5	O
of	5	O
AChE	0	O
activity	9	O
in	5	O
seized	5	O
mice	3	O
hippocampus	9	O
.	9	O

This	5	O
compound	0	O
may	5	O
be	5	O
useful	5	O
to	5	O
produce	9	O
neuronal	3	O
protection	9	O
and	5	O
it	5	O
can	5	O
be	5	O
considered	5	O
as	5	O
an	5	O
anticonvulsant	5	O
agent	9	O
.	9	O

Standard	9	O
operating	5	O
procedures	5	O
for	5	O
antibiotic	5	O
therapy	5	O
and	5	O
the	5	O
occurrence	5	O
of	5	O
acute	9	B-Disease
kidney	9	I-Disease
injury	9	I-Disease
:	9	O
a	5	O
prospective	5	O
,	9	O
clinical	5	O
,	9	O
non	9	O
-	7	O
interventional	5	O
,	9	O
observational	5	O
study	9	O
.	9	O

INTRODUCTION	5	O
:	9	O
Acute	5	B-Disease
kidney	9	I-Disease
injury	9	I-Disease
(	9	O
AKI	5	B-Disease
)	9	O
occurs	9	O
in	5	O
7	9	O
%	9	O
of	5	O
hospitalized	5	O
and	5	O
66	7	O
%	9	O
of	5	O
Intensive	2	O
Care	2	O
Unit	2	O
(	9	O
ICU	5	O
)	9	O
patients	5	O
.	9	O

It	5	O
increases	9	O
mortality	5	O
,	9	O
hospital	5	O
length	9	O
of	5	O
stay	5	O
,	9	O
and	5	O
costs	5	O
.	9	O

The	5	O
aim	5	O
of	5	O
this	5	O
study	9	O
was	9	O
to	5	O
investigate	9	O
,	9	O
whether	9	O
there	5	O
is	5	O
an	5	O
association	9	O
between	5	O
adherence	5	O
to	5	O
guidelines	5	O
(	9	O
standard	5	O
operating	5	O
procedures	5	O
(	9	O
SOP	5	O
)	9	O
)	9	O
for	5	O
potentially	5	O
nephrotoxic	5	B-Disease
antibiotics	5	O
and	5	O
the	5	O
occurrence	5	O
of	5	O
AKI	5	B-Disease
.	9	O

METHODS	2	O
:	9	O
This	5	O
study	9	O
was	9	O
carried	9	O
out	9	O
as	5	O
a	5	O
prospective	5	O
,	9	O
clinical	5	O
,	9	O
non	9	O
-	7	O
interventional	5	O
,	9	O
observational	5	O
study	9	O
.	9	O

Data	5	O
collection	5	O
was	9	O
performed	9	O
over	5	O
a	5	O
total	9	O
of	5	O
170	9	O
days	9	O
in	5	O
three	9	O
ICUs	5	O
at	9	O
Charite	2	O
-	7	O
Universitaetsmedizin	2	O
Berlin	2	O
.	9	O

A	9	O
total	9	O
of	5	O
675	7	O
patients	5	O
were	9	O
included	5	O
;	9	O
163	7	O
of	5	O
these	5	O
had	9	O
therapy	5	O
with	5	O
vancomycin	9	B-Chemical
,	9	O
gentamicin	0	B-Chemical
,	9	O
or	5	O
tobramycin	0	B-Chemical
;	9	O
were	9	O
>	0	O
18	7	O
years	5	O
;	9	O
and	5	O
treated	3	O
in	5	O
the	5	O
ICU	5	O
for	5	O
>	0	O
24	9	O
hours	9	O
.	9	O

Patients	5	O
with	5	O
an	5	O
adherence	5	O
to	5	O
SOP	5	O
>	0	O
70	9	O
%	9	O
were	9	O
classified	5	O
into	9	O
the	5	O
high	9	O
adherence	5	O
group	9	O
(	9	O
HAG	3	O
)	9	O
and	5	O
patients	5	O
with	5	O
an	5	O
adherence	5	O
of	5	O
<	0	O
70	9	O
%	9	O
into	9	O
the	5	O
low	9	O
adherence	5	O
group	9	O
(	9	O
LAG	9	O
)	9	O
.	9	O

AKI	5	B-Disease
was	9	O
defined	5	O
according	9	O
to	5	O
RIFLE	5	O
criteria	5	O
.	9	O

Adherence	5	O
to	5	O
SOPs	5	O
was	9	O
evaluated	9	O
by	9	O
retrospective	5	O
expert	5	O
audit	5	O
.	9	O

Development	2	O
of	5	O
AKI	5	B-Disease
was	9	O
compared	9	O
between	5	O
groups	9	O
with	5	O
exact	5	O
Chi2	9	O
-	7	O
test	5	O
and	5	O
multivariate	5	O
logistic	5	O
regression	5	O
analysis	9	O
(	9	O
two	5	O
-	7	O
sided	5	O
P	9	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

RESULTS	9	O
:	9	O
LAG	9	O
consisted	5	O
of	5	O
75	9	O
patients	5	O
(	9	O
46	7	O
%	9	O
)	9	O
versus	9	O
88	7	O
HAG	3	O
patients	5	O
(	9	O
54	7	O
%	9	O
)	9	O
.	9	O

AKI	5	B-Disease
occurred	9	O
significantly	9	O
more	5	O
often	5	O
in	5	O
LAG	9	O
with	5	O
36	9	O
%	9	O
versus	9	O
21	7	O
%	9	O
in	5	O
HAG	3	O
(	9	O
P	9	O
=	7	O
0	7	O
.	9	O
035	7	O
)	9	O
.	9	O

Basic	9	O
characteristics	5	O
were	9	O
comparable	9	O
,	9	O
except	9	O
an	5	O
increased	9	O
rate	9	O
of	5	O
soft	5	O
tissue	9	O
infections	5	B-Disease
in	5	O
LAG	9	O
.	9	O

Multivariate	5	O
analysis	9	O
revealed	9	O
an	5	O
odds	5	O
ratio	9	O
of	5	O
2	9	O
.	9	O
5	9	O
-	7	O
fold	9	O
for	5	O
LAG	9	O
to	5	O
develop	5	O
AKI	5	B-Disease
compared	9	O
with	5	O
HAG	3	O
(	9	O
95	7	O
%	9	O
confidence	5	O
interval	5	O
1	9	O
.	9	O
195	7	O
to	5	O
5	9	O
.	9	O
124	7	O
,	9	O
P	9	O
=	7	O
0	7	O
.	9	O
039	7	O
)	9	O
.	9	O

CONCLUSION	5	O
:	9	O
Low	9	O
adherence	5	O
to	5	O
SOPs	5	O
for	5	O
potentially	5	O
nephrotoxic	5	B-Disease
antibiotics	5	O
was	9	O
associated	9	O
with	5	O
a	5	O
higher	9	O
occurrence	5	O
of	5	O
AKI	5	B-Disease
.	9	O

TRIAL	2	O
REGISTRATION	2	O
:	9	O
Current	9	O
Controlled	5	O
Trials	5	O
ISRCTN54598675	_	O
.	9	O

Registered	5	O
17	7	O
August	2	O
2007	2	O
.	9	O

Rhabdomyolysis	5	B-Disease
in	5	O
a	5	O
hepatitis	9	B-Disease
C	9	I-Disease
virus	9	I-Disease
infected	3	I-Disease
patient	5	O
treated	3	O
with	5	O
telaprevir	5	B-Chemical
and	5	O
simvastatin	0	B-Chemical
.	9	O

A	9	O
46	7	O
-	7	O
year	5	O
old	5	O
man	5	O
with	5	O
a	5	O
chronic	5	O
hepatitis	9	B-Disease
C	9	I-Disease
virus	9	I-Disease
infection	9	I-Disease
received	9	O
triple	9	O
therapy	5	O
with	5	O
ribavirin	9	B-Chemical
,	9	O
pegylated	0	B-Chemical
interferon	3	I-Chemical
and	5	O
telaprevir	5	B-Chemical
.	9	O

The	5	O
patient	5	O
also	9	O
received	9	O
simvastatin	0	B-Chemical
.	9	O

One	5	O
month	5	O
after	9	O
starting	9	O
the	5	O
antiviral	9	O
therapy	5	O
,	9	O
the	5	O
patient	5	O
was	9	O
admitted	5	O
to	5	O
the	5	O
hospital	5	O
because	5	O
he	5	O
developed	5	O
rhabdomyolysis	5	B-Disease
.	9	O

At	9	O
admission	5	O
simvastatin	0	B-Chemical
and	5	O
all	5	O
antiviral	9	O
drugs	5	O
were	9	O
discontinued	5	O
because	5	O
toxicity	9	B-Disease
due	5	O
to	5	O
a	5	O
drug	5	O
-	7	O
drug	5	O
interaction	9	O
was	9	O
suspected	5	O
.	9	O

The	5	O
creatine	0	B-Chemical
kinase	3	O
peaked	9	O
at	9	O
62	7	O
,	9	O
246	7	O
IU	0	O
/	9	O
L	0	O
and	5	O
the	5	O
patient	5	O
was	9	O
treated	3	O
with	5	O
intravenous	0	O
normal	9	O
saline	0	O
.	9	O

The	5	O
patient	5	O
'	9	O
s	9	O
renal	9	O
function	9	O
remained	9	O
unaffected	9	O
.	9	O

Fourteen	9	O
days	9	O
after	9	O
hospitalization	5	O
,	9	O
creatine	0	B-Chemical
kinase	3	O
level	9	O
had	9	O
returned	5	O
to	5	O
230	9	O
IU	0	O
/	9	O
L	0	O
and	5	O
the	5	O
patient	5	O
was	9	O
discharged	5	O
.	9	O

Telaprevir	0	B-Chemical
was	9	O
considered	5	O
the	5	O
probable	9	O
causative	9	O
agent	9	O
of	5	O
an	5	O
interaction	9	O
with	5	O
simvastatin	0	B-Chemical
according	9	O
to	5	O
the	5	O
Drug	5	O
Interaction	9	O
Probability	5	O
Scale	5	O
.	9	O

The	5	O
interaction	9	O
is	5	O
due	5	O
to	5	O
inhibition	3	O
of	5	O
CYP3A4	3	O
-	7	O
mediated	3	O
simvastatin	0	B-Chemical
clearance	9	O
.	9	O

Simvastatin	0	B-Chemical
plasma	9	O
concentration	0	O
increased	9	O
30	9	O
times	5	O
in	5	O
this	5	O
patient	5	O
and	5	O
statin	5	B-Chemical
induced	3	O
muscle	9	B-Disease
toxicity	9	I-Disease
is	5	O
related	9	O
to	5	O
the	5	O
concentration	0	O
of	5	O
the	5	O
statin	5	B-Chemical
in	5	O
blood	9	O
.	9	O

In	9	O
conclusion	9	O
,	9	O
with	5	O
this	5	O
case	5	O
we	5	O
illustrate	5	O
that	5	O
telaprevir	5	B-Chemical
as	5	O
well	9	O
as	5	O
statins	5	B-Chemical
are	5	O
susceptible	9	O
to	5	O
clinical	5	O
relevant	5	O
drug	5	O
-	7	O
drug	5	O
interactions	9	O
.	9	O

Combination	9	O
of	5	O
bortezomib	3	B-Chemical
,	9	O
thalidomide	0	B-Chemical
,	9	O
and	5	O
dexamethasone	0	B-Chemical
(	9	O
VTD	0	O
)	9	O
as	5	O
a	5	O
consolidation	5	O
therapy	5	O
after	9	O
autologous	3	O
stem	3	O
cell	3	O
transplantation	9	O
for	5	O
symptomatic	5	O
multiple	5	B-Disease
myeloma	3	I-Disease
in	5	O
Japanese	9	O
patients	5	O
.	9	O

Consolidation	5	O
therapy	5	O
for	5	O
patients	5	O
with	5	O
multiple	5	B-Disease
myeloma	3	I-Disease
(	9	O
MM	9	B-Disease
)	9	O
has	9	O
been	9	O
widely	5	O
adopted	5	O
to	5	O
improve	5	O
treatment	9	O
response	9	O
following	9	O
autologous	3	O
stem	3	O
cell	3	O
transplantation	9	O
.	9	O

In	9	O
this	5	O
study	9	O
,	9	O
we	5	O
retrospectively	5	O
analyzed	9	O
the	5	O
safety	5	O
and	5	O
efficacy	9	O
of	5	O
combination	9	O
regimen	5	O
of	5	O
bortezomib	3	B-Chemical
,	9	O
thalidomide	0	B-Chemical
,	9	O
and	5	O
dexamethasone	0	B-Chemical
(	9	O
VTD	0	O
)	9	O
as	5	O
consolidation	5	O
therapy	5	O
in	5	O
24	9	O
Japanese	9	O
patients	5	O
with	5	O
newly	9	O
diagnosed	5	O
MM	9	B-Disease
.	9	O

VTD	0	O
consisted	5	O
of	5	O
bortezomib	3	B-Chemical
at	9	O
a	5	O
dose	9	O
of	5	O
1	9	O
.	9	O
3	9	O
mg	0	O
/	9	O
m	9	O
(	9	O
2	9	O
)	9	O
and	5	O
dexamethasone	0	B-Chemical
at	9	O
a	5	O
dose	9	O
of	5	O
40	9	O
mg	0	O
/	9	O
day	9	O
on	5	O
days	9	O
1	9	O
,	9	O
8	9	O
,	9	O
15	9	O
,	9	O
and	5	O
22	7	O
of	5	O
a	5	O
35	9	O
-	7	O
day	9	O
cycle	9	O
,	9	O
with	5	O
daily	5	O
oral	9	O
thalidomide	0	B-Chemical
at	9	O
a	5	O
dose	9	O
of	5	O
100	0	O
mg	0	O
/	9	O
day	9	O
.	9	O

Grade	9	O
3	9	O
-	7	O
4	9	O
neutropenia	5	B-Disease
and	5	O
thrombocytopenia	9	B-Disease
were	9	O
documented	9	O
in	5	O
four	9	O
and	5	O
three	9	O
patients	5	O
(	9	O
17	7	O
and	5	O
13	7	O
%	9	O
)	9	O
,	9	O
respectively	9	O
,	9	O
but	9	O
drug	5	O
dose	9	O
reduction	9	O
due	5	O
to	5	O
cytopenia	5	B-Disease
was	9	O
not	5	O
required	9	O
in	5	O
any	5	O
case	5	O
.	9	O

Peripheral	9	B-Disease
neuropathy	5	I-Disease
was	9	O
common	5	O
(	9	O
63	7	O
%	9	O
)	9	O
,	9	O
but	9	O
severe	5	O
grade	9	O
3	9	O
-	7	O
4	9	O
peripheral	9	B-Disease
neuropathy	5	I-Disease
was	9	O
not	5	O
observed	9	O
.	9	O

Very	5	O
good	5	O
partial	9	O
response	9	O
or	5	O
better	5	O
response	9	O
(	9	O
>	0	O
VGPR	7	O
)	9	O
rates	5	O
before	9	O
and	5	O
after	9	O
consolidation	5	O
therapy	5	O
were	9	O
54	7	O
and	5	O
79	7	O
%	9	O
,	9	O
respectively	9	O
.	9	O

Patients	5	O
had	9	O
a	5	O
significant	9	O
probability	5	O
of	5	O
improving	5	O
from	9	O
<	0	O
VGPR	7	O
before	9	O
consolidation	5	O
therapy	5	O
to	5	O
>	0	O
VGPR	7	O
after	9	O
consolidation	5	O
therapy	5	O
(	9	O
p	7	O
=	7	O
0	7	O
.	9	O
041	7	O
)	9	O
.	9	O

The	5	O
VTD	0	O
regimen	5	O
may	5	O
be	5	O
safe	5	O
and	5	O
effective	5	O
as	5	O
a	5	O
consolidation	5	O
therapy	5	O
in	5	O
the	5	O
treatment	9	O
of	5	O
MM	9	O
in	5	O
Japanese	9	O
population	5	O
.	9	O

Conversion	9	O
to	5	O
sirolimus	0	B-Chemical
ameliorates	3	O
cyclosporine	0	B-Chemical
-	7	O
induced	3	O
nephropathy	9	B-Disease
in	5	O
the	5	O
rat	3	O
:	9	O
focus	5	O
on	5	O
serum	9	O
,	9	O
urine	9	O
,	9	O
gene	1	O
,	9	O
and	5	O
protein	1	O
renal	9	O
expression	3	O
biomarkers	9	O
.	9	O

Protocols	5	O
of	5	O
conversion	9	O
from	9	O
cyclosporin	0	B-Chemical
A	9	I-Chemical
(	9	O
CsA	0	B-Chemical
)	9	O
to	5	O
sirolimus	0	B-Chemical
(	9	O
SRL	0	B-Chemical
)	9	O
have	5	O
been	9	O
widely	5	O
used	5	O
in	5	O
immunotherapy	5	O
after	9	O
transplantation	9	O
to	5	O
prevent	5	O
CsA	0	B-Chemical
-	7	O
induced	3	O
nephropathy	9	B-Disease
,	9	O
but	9	O
the	5	O
molecular	9	O
mechanisms	9	O
underlying	5	O
these	5	O
protocols	5	O
remain	9	O
nuclear	3	O
.	9	O

This	5	O
study	9	O
aimed	5	O
to	5	O
identify	9	O
the	5	O
molecular	9	O
pathways	9	O
and	5	O
putative	1	O
biomarkers	9	O
of	5	O
CsA	0	B-Chemical
-	7	O
to	5	O
-	7	O
SRL	0	B-Chemical
conversion	9	O
in	5	O
a	5	O
rat	3	O
model	5	O
.	9	O

Four	9	O
animal	5	O
groups	9	O
(	9	O
n	9	O
=	7	O
6	9	O
)	9	O
were	9	O
tested	9	O
during	5	O
9	7	O
weeks	9	O
:	9	O
control	9	O
,	9	O
CsA	0	B-Chemical
,	9	O
SRL	0	B-Chemical
,	9	O
and	5	O
conversion	9	O
(	9	O
CsA	0	B-Chemical
for	5	O
3	9	O
weeks	9	O
followed	9	O
by	9	O
SRL	0	B-Chemical
for	5	O
6	9	O
weeks	9	O
)	9	O
.	9	O

Classical	9	O
and	5	O
emergent	5	O
serum	9	O
,	9	O
urinary	9	O
,	9	O
and	5	O
kidney	9	O
tissue	9	O
(	9	O
gene	1	O
and	5	O
protein	1	O
expression	3	O
)	9	O
markers	3	O
were	9	O
assessed	9	O
.	9	O

Renal	9	B-Disease
lesions	5	I-Disease
were	9	O
analyzed	9	O
in	5	O
hematoxylin	3	B-Chemical
and	5	O
eosin	3	B-Chemical
,	9	O
periodic	5	O
acid	0	O
-	7	O
Schiff	0	O
,	9	O
and	5	O
Masson	9	O
'	9	O
s	9	O
trichrome	3	O
stains	9	O
.	9	O

SRL	0	B-Chemical
-	7	O
treated	3	O
rats	9	O
presented	5	O
proteinuria	9	B-Disease
and	5	O
NGAL	9	O
(	9	O
serum	9	O
and	5	O
urinary	9	O
)	9	O
as	5	O
the	5	O
best	5	O
markers	3	O
of	5	O
renal	9	B-Disease
impairment	5	I-Disease
.	9	O

Short	5	O
CsA	0	B-Chemical
treatment	9	O
presented	5	O
slight	9	O
or	5	O
even	5	O
absent	9	O
kidney	9	B-Disease
lesions	5	I-Disease
and	5	O
TGF	3	O
-	7	O
b	9	O
,	9	O
NF	9	O
-	7	O
kb	1	O
,	9	O
mTOR	3	O
,	9	O
PCNA	3	O
,	9	O
TP53	1	O
,	9	O
KIM	2	O
-	7	O
1	9	O
,	9	O
and	5	O
CTGF	3	O
as	5	O
relevant	5	O
gene	1	O
and	5	O
protein	1	O
changes	9	O
.	9	O

Prolonged	9	O
CsA	0	B-Chemical
exposure	9	O
aggravated	9	O
renal	9	B-Disease
damage	9	I-Disease
,	9	O
without	9	O
clear	9	O
changes	9	O
on	5	O
the	5	O
traditional	5	O
markers	3	O
,	9	O
but	9	O
with	5	O
changes	9	O
in	5	O
serums	9	O
TGF	3	O
-	7	O
b	9	O
and	5	O
IL	0	O
-	7	O
7	9	O
,	9	O
TBARs	0	O
clearance	9	O
,	9	O
and	5	O
kidney	9	O
TGF	3	O
-	7	O
b	9	O
and	5	O
mTOR	3	O
.	9	O

Conversion	9	O
to	5	O
SRL	0	B-Chemical
prevented	9	O
CsA	0	B-Chemical
-	7	O
induced	3	O
renal	9	B-Disease
damage	9	I-Disease
evolution	5	O
(	9	O
absent	9	O
/	9	O
mild	9	O
grade	9	O
lesions	5	O
)	9	O
,	9	O
while	9	O
NGAL	9	O
(	9	O
serum	9	O
versus	9	O
urine	9	O
)	9	O
seems	5	O
to	5	O
be	5	O
a	5	O
feasible	5	O
biomarker	9	O
of	5	O
CsA	0	B-Chemical
replacement	9	O
to	5	O
SRL	0	B-Chemical
.	9	O

Kinin	3	O
B2	9	O
receptor	3	O
deletion	1	O
and	5	O
blockage	9	O
ameliorates	3	O
cisplatin	3	B-Chemical
-	7	O
induced	3	O
acute	9	B-Disease
renal	9	I-Disease
injury	9	I-Disease
.	9	O

Cisplatin	0	B-Chemical
treatment	9	O
has	9	O
been	9	O
adopted	5	O
in	5	O
some	5	O
chemotherapies	5	O
;	9	O
however	9	O
,	9	O
this	5	O
drug	5	O
can	5	O
induce	3	O
acute	9	B-Disease
kidney	9	I-Disease
injury	9	I-Disease
due	5	O
its	9	O
ability	9	O
to	5	O
negatively	9	O
affect	9	O
renal	9	O
function	9	O
,	9	O
augment	9	O
serum	9	O
levels	3	O
of	5	O
creatinine	0	B-Chemical
and	5	O
urea	0	B-Chemical
,	9	O
increase	9	O
the	5	O
acute	9	B-Disease
tubular	9	I-Disease
necrosis	9	I-Disease
score	5	O
and	5	O
up	5	O
-	7	O
regulate	3	O
cytokines	3	O
(	9	O
e	9	O
.	9	O
g	0	O
.	9	O
,	9	O
IL	0	O
-	7	O
1b	9	O
and	5	O
TNF	3	O
-	7	O
a	5	O
)	9	O
.	9	O

The	5	O
kinin	0	O
B2	9	O
receptor	3	O
has	9	O
been	9	O
associated	9	O
with	5	O
the	5	O
inflammation	9	B-Disease
process	5	O
,	9	O
as	5	O
well	9	O
as	5	O
the	5	O
regulation	9	O
of	5	O
cytokine	3	O
expression	3	O
,	9	O
and	5	O
its	9	O
deletion	1	O
resulted	9	O
in	5	O
an	5	O
improvement	5	O
in	5	O
the	5	O
diabetic	9	B-Disease
nephropathy	9	I-Disease
status	9	O
.	9	O

To	9	O
examine	9	O
the	5	O
role	9	O
of	5	O
the	5	O
kinin	0	O
B2	9	O
receptor	3	O
in	5	O
cisplatin	3	B-Chemical
-	7	O
induced	3	O
acute	9	B-Disease
kidney	9	I-Disease
injury	9	I-Disease
,	9	O
kinin	0	O
B2	9	O
receptor	3	O
knockout	3	O
mice	3	O
were	9	O
challenged	3	O
with	5	O
cisplatin	3	B-Chemical
.	9	O

Additionally	9	O
,	9	O
WT	3	O
mice	3	O
were	9	O
treated	3	O
with	5	O
a	5	O
B2	9	O
receptor	3	O
antagonist	3	O
after	9	O
cisplatin	3	B-Chemical
administration	9	O
.	9	O

B2	9	O
receptor	3	O
-	7	O
deficient	3	O
mice	3	O
were	9	O
less	5	O
sensitive	9	O
to	5	O
this	5	O
drug	5	O
than	5	O
the	5	O
WT	3	O
mice	3	O
,	9	O
as	5	O
shown	9	O
by	9	O
reduced	9	O
weight	9	B-Disease
loss	9	I-Disease
,	9	O
better	5	O
preservation	9	O
of	5	O
kidney	9	O
function	9	O
,	9	O
down	9	O
regulation	9	O
of	5	O
inflammatory	3	O
cytokines	3	O
and	5	O
less	5	O
acute	9	B-Disease
tubular	9	I-Disease
necrosis	9	I-Disease
.	9	O

Moreover	9	O
,	9	O
treatment	9	O
with	5	O
the	5	O
kinin	0	O
B2	9	O
receptor	3	O
antagonist	3	O
effectively	5	O
reduced	9	O
the	5	O
levels	3	O
of	5	O
serum	9	O
creatinine	0	B-Chemical
and	5	O
blood	9	O
urea	0	B-Chemical
after	9	O
cisplatin	3	B-Chemical
administration	9	O
.	9	O

Thus	9	O
,	9	O
our	5	O
data	5	O
suggest	9	O
that	5	O
the	5	O
kinin	0	O
B2	9	O
receptor	3	O
is	5	O
involved	9	O
in	5	O
cisplatin	3	B-Chemical
-	7	O
induced	3	O
acute	9	B-Disease
kidney	9	I-Disease
injury	9	I-Disease
by	9	O
mediating	9	O
the	5	O
necrotic	3	B-Disease
process	5	O
and	5	O
the	5	O
expression	3	O
of	5	O
inflammatory	3	O
cytokines	3	O
,	9	O
thus	9	O
resulting	9	O
in	5	O
declined	9	O
renal	9	O
function	9	O
.	9	O

These	5	O
results	9	O
highlight	5	O
the	5	O
kinin	0	O
B2	9	O
receptor	3	O
antagonist	3	O
treatment	9	O
in	5	O
amelioration	9	O
of	5	O
nephrotoxicity	9	B-Disease
induced	3	O
by	9	O
cisplatin	3	B-Chemical
therapy	5	O
.	9	O

Safety	5	O
and	5	O
efficacy	9	O
of	5	O
fluocinolone	0	B-Chemical
acetonide	0	I-Chemical
intravitreal	0	O
implant	5	O
(	9	O
0	7	O
.	9	O
59	7	O
mg	0	O
)	9	O
in	5	O
birdshot	5	B-Disease
retinochoroidopathy	5	I-Disease
.	9	O

PURPOSE	2	O
:	9	O
To	9	O
report	5	O
the	5	O
treatment	9	O
outcomes	5	O
of	5	O
the	5	O
fluocinolone	0	B-Chemical
acetonide	0	I-Chemical
intravitreal	0	O
implant	5	O
(	9	O
0	7	O
.	9	O
59	7	O
mg	0	O
)	9	O
in	5	O
patients	5	O
with	5	O
birdshot	5	B-Disease
retinochoroidopathy	5	I-Disease
whose	9	O
disease	5	O
is	5	O
refractory	9	O
or	5	O
intolerant	9	O
to	5	O
conventional	5	O
immunomodulatory	9	O
therapy	5	O
.	9	O

METHODS	2	O
:	9	O
A	9	O
retrospective	5	O
case	5	O
series	5	O
involving	5	O
11	7	O
birdshot	5	B-Disease
retinochoroidopathy	5	I-Disease
patients	5	O
(	9	O
11	7	O
eyes	5	O
)	9	O
.	9	O

Eleven	9	O
patients	5	O
(	9	O
11	7	O
eyes	5	O
)	9	O
underwent	5	O
surgery	5	O
for	5	O
fluocinolone	0	B-Chemical
acetonide	0	I-Chemical
implant	5	O
(	9	O
0	7	O
.	9	O
59	7	O
mg	0	O
)	9	O
.	9	O

Treatment	9	O
outcomes	5	O
of	5	O
interest	5	O
were	9	O
noted	9	O
at	9	O
baseline	5	O
,	9	O
before	9	O
fluocinolone	0	B-Chemical
acetonide	0	I-Chemical
implant	5	O
,	9	O
and	5	O
then	9	O
at	9	O
6	9	O
months	5	O
,	9	O
1	9	O
year	5	O
,	9	O
2	9	O
years	5	O
,	9	O
3	9	O
years	5	O
,	9	O
and	5	O
beyond	5	O
3	9	O
years	5	O
.	9	O

Disease	2	O
activity	9	O
markers	3	O
,	9	O
including	9	O
signs	5	O
of	5	O
ocular	5	O
inflammation	9	B-Disease
,	9	O
evidence	9	O
of	5	O
retinal	5	B-Disease
vasculitis	5	I-Disease
,	9	O
Swedish	5	O
interactive	5	O
threshold	5	O
algorithm	5	O
-	7	O
short	5	O
wavelength	0	O
automated	5	O
perimetry	5	O
Humphrey	6	O
visual	5	O
field	5	O
analysis	9	O
,	9	O
electroretinographic	5	O
parameters	5	O
,	9	O
and	5	O
optical	5	O
coherence	5	O
tomography	5	O
were	9	O
recorded	5	O
.	9	O

Data	5	O
on	5	O
occurrence	5	O
of	5	O
cataract	5	B-Disease
and	5	O
raised	9	B-Disease
intraocular	5	I-Disease
pressure	5	I-Disease
were	9	O
collected	9	O
in	5	O
all	5	O
eyes	5	O
.	9	O

RESULTS	9	O
:	9	O
Intraocular	5	O
inflammation	9	B-Disease
was	9	O
present	9	O
in	5	O
54	7	O
.	9	O
5	9	O
,	9	O
9	7	O
.	9	O
9	7	O
,	9	O
11	7	O
.	9	O
1	9	O
,	9	O
and	5	O
0	7	O
%	9	O
of	5	O
patients	5	O
at	9	O
baseline	5	O
,	9	O
6	9	O
months	5	O
,	9	O
1	9	O
year	5	O
,	9	O
2	9	O
years	5	O
,	9	O
3	9	O
years	5	O
,	9	O
and	5	O
beyond	5	O
3	9	O
years	5	O
after	9	O
receiving	9	O
the	5	O
implant	5	O
,	9	O
respectively	9	O
.	9	O

Active	9	O
vasculitis	5	B-Disease
was	9	O
noted	9	O
in	5	O
36	9	O
.	9	O
3	9	O
%	9	O
patients	5	O
at	9	O
baseline	5	O
and	5	O
0	7	O
%	9	O
at	9	O
3	9	O
years	5	O
of	5	O
follow	5	O
-	7	O
up	5	O
.	9	O

More	5	O
than	5	O
20	9	O
%	9	O
(	9	O
47	7	O
.	9	O
61	7	O
-	7	O
67	7	O
.	9	O
2	9	O
%	9	O
)	9	O
reduction	9	O
in	5	O
central	5	O
retinal	5	O
thickness	5	O
was	9	O
noted	9	O
in	5	O
all	5	O
patients	5	O
with	5	O
cystoid	5	B-Disease
macular	5	I-Disease
edema	5	I-Disease
at	9	O
6	9	O
months	5	O
,	9	O
1	9	O
year	5	O
,	9	O
2	9	O
years	5	O
,	9	O
and	5	O
3	9	O
years	5	O
postimplant	5	O
.	9	O

At	9	O
baseline	5	O
,	9	O
54	7	O
.	9	O
5	9	O
%	9	O
patients	5	O
were	9	O
on	5	O
immunomodulatory	9	O
agents	5	O
.	9	O

This	5	O
percentage	9	O
decreased	9	O
to	5	O
45	9	O
.	9	O
45	9	O
,	9	O
44	7	O
.	9	O
4	9	O
,	9	O
and	5	O
14	7	O
.	9	O
28	7	O
%	9	O
at	9	O
1	9	O
year	5	O
,	9	O
2	9	O
years	5	O
,	9	O
and	5	O
3	9	O
years	5	O
postimplant	5	O
,	9	O
respectively	9	O
.	9	O

Adverse	5	O
events	5	O
included	5	O
increased	9	B-Disease
intraocular	5	I-Disease
pressure	5	I-Disease
(	9	O
54	7	O
.	9	O
5	9	O
%	9	O
)	9	O
and	5	O
cataract	5	B-Disease
formation	9	O
(	9	O
100	0	O
%	9	O
)	9	O
.	9	O

CONCLUSION	5	O
:	9	O
The	5	O
data	5	O
suggest	9	O
that	5	O
fluocinolone	0	B-Chemical
acetonide	0	I-Chemical
implant	5	O
(	9	O
0	7	O
.	9	O
59	7	O
mg	0	O
)	9	O
helps	5	O
to	5	O
control	9	O
inflammation	9	B-Disease
in	5	O
otherwise	9	O
treatment	9	O
-	7	O
refractory	9	O
cases	5	O
of	5	O
birdshot	5	B-Disease
retinochoroidopathy	5	I-Disease
.	9	O

It	5	O
is	5	O
associated	9	O
with	5	O
significant	9	O
side	5	O
effects	9	O
of	5	O
cataract	5	B-Disease
and	5	O
ocular	5	B-Disease
hypertension	5	I-Disease
requiring	5	O
treatment	9	O
.	9	O

Optimal	5	O
precurarizing	9	O
dose	9	O
of	5	O
rocuronium	0	B-Chemical
to	5	O
decrease	9	O
fasciculation	5	B-Disease
and	5	O
myalgia	5	B-Disease
following	9	O
succinylcholine	5	B-Chemical
administration	9	O
.	9	O

BACKGROUND	2	O
:	9	O
Succinylcholine	0	B-Chemical
commonly	5	O
produces	9	O
frequent	5	O
adverse	5	O
effects	9	O
,	9	O
including	9	O
muscle	9	B-Disease
fasciculation	5	I-Disease
and	5	O
myalgia	5	B-Disease
.	9	O

The	5	O
current	5	O
study	9	O
identified	9	O
the	5	O
optimal	5	O
dose	9	O
of	5	O
rocuronium	0	B-Chemical
to	5	O
prevent	5	O
succinylcholine	5	B-Chemical
-	7	O
induced	3	O
fasciculation	5	B-Disease
and	5	O
myalgia	5	B-Disease
and	5	O
evaluated	9	O
the	5	O
influence	5	O
of	5	O
rocuronium	0	B-Chemical
on	5	O
the	5	O
speed	5	O
of	5	O
onset	5	O
produced	9	O
by	9	O
succinylcholine	5	B-Chemical
.	9	O

METHODS	2	O
:	9	O
This	5	O
randomized	5	O
,	9	O
double	9	O
-	7	O
blinded	5	O
study	9	O
was	9	O
conducted	9	O
in	5	O
100	0	O
patients	5	O
randomly	5	O
allocated	5	O
into	9	O
five	9	O
groups	9	O
of	5	O
20	9	O
patients	5	O
each	5	O
.	9	O

Patients	5	O
were	9	O
randomized	5	O
to	5	O
receive	5	O
0	7	O
.	9	O
02	7	O
,	9	O
0	7	O
.	9	O
03	7	O
,	9	O
0	7	O
.	9	O
04	7	O
,	9	O
0	7	O
.	9	O
05	7	O
and	5	O
0	7	O
.	9	O
06	7	O
mg	0	O
/	9	O
kg	0	O
rocuronium	0	B-Chemical
as	5	O
a	5	O
precurarizing	9	O
dose	9	O
.	9	O

Neuromuscular	2	O
monitoring	5	O
after	9	O
each	5	O
precurarizing	9	O
dose	9	O
was	9	O
recorded	5	O
from	9	O
the	5	O
adductor	5	O
pollicis	5	O
muscle	9	O
using	9	O
acceleromyography	5	O
with	5	O
train	5	O
-	7	O
of	5	O
-	7	O
four	9	O
stimulation	3	O
of	5	O
the	5	O
ulnar	5	O
nerve	5	O
.	9	O

All	9	O
patients	5	O
received	9	O
succinylcholine	5	B-Chemical
1	9	O
.	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
at	9	O
2	9	O
minutes	0	O
after	9	O
the	5	O
precurarization	0	O
,	9	O
and	5	O
were	9	O
assessed	9	O
the	5	O
incidence	5	O
and	5	O
severity	5	O
of	5	O
fasciculations	5	B-Disease
,	9	O
while	9	O
myalgia	5	B-Disease
was	9	O
assessed	9	O
at	9	O
24	9	O
hours	9	O
after	9	O
surgery	5	O
.	9	O

RESULTS	9	O
:	9	O
The	5	O
incidence	5	O
and	5	O
severity	5	O
of	5	O
visible	9	O
muscle	9	B-Disease
fasciculation	5	I-Disease
was	9	O
significantly	9	O
less	5	O
with	5	O
increasing	9	O
the	5	O
amount	9	O
of	5	O
precurarizing	9	O
dose	9	O
of	5	O
rocuronium	0	B-Chemical
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
.	9	O

Those	5	O
of	5	O
myalgia	5	B-Disease
tend	5	O
to	5	O
decrease	9	O
according	9	O
to	5	O
increasing	9	O
the	5	O
amount	9	O
of	5	O
precurarizing	9	O
dose	9	O
of	5	O
rocuronium	0	B-Chemical
,	9	O
but	9	O
there	5	O
was	9	O
no	9	O
significance	9	O
(	9	O
P	9	O
=	7	O
0	7	O
.	9	O
072	7	O
)	9	O
.	9	O

The	5	O
onset	5	O
time	5	O
of	5	O
succinylcholine	5	B-Chemical
was	9	O
significantly	9	O
longer	5	O
with	5	O
increasing	9	O
the	5	O
amount	9	O
of	5	O
precurarizing	9	O
dose	9	O
of	5	O
rocuronium	0	B-Chemical
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Precurarization	_	O
with	5	O
0	7	O
.	9	O
04	7	O
mg	0	O
/	9	O
kg	0	O
rocuronium	0	B-Chemical
was	9	O
the	5	O
optimal	5	O
dose	9	O
considering	5	O
the	5	O
reduction	9	O
in	5	O
the	5	O
incidence	5	O
and	5	O
severity	5	O
of	5	O
fasciculation	5	B-Disease
and	5	O
myalgia	5	B-Disease
with	5	O
acceptable	5	O
onset	5	O
time	5	O
,	9	O
and	5	O
the	5	O
safe	5	O
and	5	O
effective	5	O
precurarization	0	O
.	9	O

Absence	9	O
of	5	O
PKC	3	O
-	7	O
alpha	9	O
attenuates	3	O
lithium	0	B-Chemical
-	7	O
induced	3	O
nephrogenic	5	B-Disease
diabetes	5	I-Disease
insipidus	5	I-Disease
.	9	O

Lithium	0	B-Chemical
,	9	O
an	5	O
effective	5	O
antipsychotic	5	O
,	9	O
induces	3	O
nephrogenic	5	B-Disease
diabetes	5	I-Disease
insipidus	5	I-Disease
(	9	O
NDI	5	B-Disease
)	9	O
in	5	O
40	9	O
%	9	O
of	5	O
patients	5	O
.	9	O

The	5	O
decreased	9	O
capacity	9	O
to	5	O
concentrate	9	O
urine	9	O
is	5	O
likely	5	O
due	5	O
to	5	O
lithium	0	B-Chemical
acutely	9	O
disrupting	9	O
the	5	O
cAMP	3	B-Chemical
pathway	3	O
and	5	O
chronically	9	O
reducing	9	O
urea	0	B-Chemical
transporter	1	O
(	9	O
UT	9	O
-	7	O
A1	9	O
)	9	O
and	5	O
water	0	O
channel	9	O
(	9	O
AQP2	3	O
)	9	O
expression	3	O
in	5	O
the	5	O
inner	9	O
medulla	9	O
.	9	O

Targeting	9	O
an	5	O
alternative	5	O
signaling	3	O
pathway	3	O
,	9	O
such	5	O
as	5	O
PKC	3	O
-	7	O
mediated	3	O
signaling	3	O
,	9	O
may	5	O
be	5	O
an	5	O
effective	5	O
method	5	O
of	5	O
treating	5	O
lithium	0	B-Chemical
-	7	O
induced	3	O
polyuria	5	B-Disease
.	9	O

PKC	3	O
-	7	O
alpha	9	O
null	1	O
mice	3	O
(	9	O
PKCa	3	O
KO	3	O
)	9	O
and	5	O
strain	1	O
-	7	O
matched	9	O
wild	1	O
type	9	O
(	9	O
WT	3	O
)	9	O
controls	9	O
were	9	O
treated	3	O
with	5	O
lithium	0	B-Chemical
for	5	O
0	7	O
,	9	O
3	9	O
or	5	O
5	9	O
days	9	O
.	9	O

WT	3	O
mice	3	O
had	9	O
increased	9	O
urine	9	O
output	5	O
and	5	O
lowered	9	O
urine	9	O
osmolality	0	O
after	9	O
3	9	O
and	5	O
5	9	O
days	9	O
of	5	O
treatment	9	O
whereas	9	O
PKCa	3	O
KO	3	O
mice	3	O
had	9	O
no	9	O
change	9	O
in	5	O
urine	9	O
output	5	O
or	5	O
concentration	0	O
.	9	O

Western	3	O
blot	3	O
analysis	9	O
revealed	9	O
that	5	O
AQP2	3	O
expression	3	O
in	5	O
medullary	5	O
tissues	9	O
was	9	O
lowered	9	O
after	9	O
3	9	O
and	5	O
5	9	O
days	9	O
in	5	O
WT	3	O
mice	3	O
;	9	O
however	9	O
,	9	O
AQP2	3	O
was	9	O
unchanged	9	O
in	5	O
PKCa	3	O
KO	3	O
.	9	O

Similar	9	O
results	9	O
were	9	O
observed	9	O
with	5	O
UT	9	O
-	7	O
A1	9	O
expression	3	O
.	9	O

Animals	9	O
were	9	O
also	9	O
treated	3	O
with	5	O
lithium	0	B-Chemical
for	5	O
6	9	O
weeks	9	O
.	9	O

Lithium	0	B-Chemical
-	7	O
treated	3	O
WT	3	O
mice	3	O
had	9	O
19	7	O
-	7	O
fold	9	O
increased	9	O
urine	9	O
output	5	O
whereas	9	O
treated	3	O
PKCa	3	O
KO	3	O
animals	9	O
had	9	O
a	5	O
4	9	O
-	7	O
fold	9	O
increase	9	O
in	5	O
output	5	O
.	9	O

AQP2	3	O
and	5	O
UT	9	O
-	7	O
A1	9	O
expression	3	O
was	9	O
lowered	9	O
in	5	O
6	9	O
week	9	O
lithium	0	B-Chemical
-	7	O
treated	3	O
WT	3	O
animals	9	O
whereas	9	O
in	5	O
treated	3	O
PKCa	3	O
KO	3	O
mice	3	O
,	9	O
AQP2	3	O
was	9	O
only	9	O
reduced	9	O
by	9	O
2	9	O
-	7	O
fold	9	O
and	5	O
UT	9	O
-	7	O
A1	9	O
expression	3	O
was	9	O
unaffected	9	O
.	9	O

Urinary	9	O
sodium	0	B-Chemical
,	9	O
potassium	0	B-Chemical
and	5	O
calcium	0	B-Chemical
were	9	O
elevated	9	O
in	5	O
lithium	0	B-Chemical
-	7	O
fed	9	O
WT	3	O
but	9	O
not	5	O
in	5	O
lithium	0	B-Chemical
-	7	O
fed	9	O
PKCa	3	O
KO	3	O
mice	3	O
.	9	O

Our	9	O
data	5	O
show	9	O
that	5	O
ablation	9	O
of	5	O
PKCa	3	O
preserves	9	O
AQP2	3	O
and	5	O
UT	9	O
-	7	O
A1	9	O
protein	1	O
expression	3	O
and	5	O
localization	3	O
in	5	O
lithium	0	B-Chemical
-	7	O
induced	3	O
NDI	5	B-Disease
,	9	O
and	5	O
prevents	9	O
the	5	O
development	9	O
of	5	O
the	5	O
severe	5	O
polyuria	5	B-Disease
associated	9	O
with	5	O
lithium	0	B-Chemical
therapy	5	O
.	9	O

Is	9	O
Dysguesia	9	B-Disease
Going	5	O
to	5	O
be	5	O
a	5	O
Rare	9	O
or	5	O
a	5	O
Common	9	O
Side	5	O
-	7	O
effect	9	O
of	5	O
Amlodipine	0	B-Chemical
?	5	O

A	9	O
very	5	O
rare	5	O
side	5	O
-	7	O
effect	9	O
of	5	O
amlodipine	0	B-Chemical
is	5	O
dysguesia	5	B-Disease
.	9	O

A	9	O
review	5	O
of	5	O
the	5	O
literature	5	O
produced	9	O
only	9	O
one	5	O
case	5	O
.	9	O

We	9	O
report	5	O
a	5	O
case	5	O
about	5	O
a	5	O
female	9	O
with	5	O
essential	9	O
hypertension	5	B-Disease
on	5	O
drug	5	O
treatment	9	O
with	5	O
amlodipine	0	B-Chemical
developed	5	O
loss	9	B-Disease
of	5	I-Disease
taste	5	I-Disease
sensation	5	I-Disease
.	9	O

Condition	5	O
moderately	9	O
improved	5	O
on	5	O
stoppage	5	O
of	5	O
the	5	O
drug	5	O
for	5	O
25	9	O
days	9	O
.	9	O

We	9	O
conclude	9	O
that	5	O
amlodipine	0	B-Chemical
can	5	O
cause	5	O
dysguesia	5	B-Disease
.	9	O

Here	9	O
,	9	O
we	5	O
describe	5	O
the	5	O
clinical	5	O
presentation	5	O
and	5	O
review	5	O
the	5	O
relevant	5	O
literature	5	O
on	5	O
amlodipine	0	B-Chemical
and	5	O
dysguesia	5	B-Disease
.	9	O

Rhabdomyolysis	5	B-Disease
in	5	O
association	9	O
with	5	O
simvastatin	0	B-Chemical
and	5	O
dosage	9	O
increment	9	O
in	5	O
clarithromycin	0	B-Chemical
.	9	O

Clarithromycin	7	B-Chemical
is	5	O
the	5	O
most	9	O
documented	9	O
cytochrome	0	O
P450	1	O
3A4	0	O
(	9	O
CYP3A4	3	O
)	9	O
inhibitor	3	O
to	5	O
cause	5	O
an	5	O
adverse	5	O
interaction	9	O
with	5	O
simvastatin	0	B-Chemical
.	9	O

This	5	O
particular	5	O
case	5	O
is	5	O
of	5	O
interest	5	O
as	5	O
rhabdomyolysis	5	B-Disease
only	9	O
occurred	9	O
after	9	O
an	5	O
increase	9	O
in	5	O
the	5	O
dose	9	O
of	5	O
clarithromycin	0	B-Chemical
.	9	O

The	5	O
patient	5	O
developed	5	O
raised	9	O
cardiac	5	O
biomarkers	9	O
without	9	O
any	5	O
obvious	9	O
cardiac	5	O
issues	5	O
,	9	O
a	5	O
phenomenon	5	O
that	5	O
has	9	O
been	9	O
linked	9	O
to	5	O
rhabdomyolysis	5	B-Disease
previously	9	O
.	9	O

To	9	O
date	5	O
,	9	O
there	5	O
has	9	O
been	9	O
no	9	O
reported	9	O
effect	9	O
of	5	O
rhabdomyolysis	5	B-Disease
on	5	O
the	5	O
structure	9	O
and	5	O
function	9	O
of	5	O
cardiac	5	O
muscle	9	O
.	9	O

Clinicians	5	O
need	5	O
to	5	O
be	5	O
aware	5	O
of	5	O
prescribing	5	O
concomitant	9	O
medications	5	O
that	5	O
increase	9	O
the	5	O
risk	5	O
of	5	O
myopathy	9	B-Disease
or	5	O
inhibit	3	O
the	5	O
CYP3A4	3	O
enzyme	0	O
.	9	O

Our	9	O
case	5	O
suggests	9	O
that	5	O
troponin	9	O
elevation	9	O
could	9	O
be	5	O
associated	9	O
with	5	O
statin	5	B-Chemical
induced	3	O
rhabdomyolysis	5	B-Disease
,	9	O
which	5	O
may	5	O
warrant	9	O
further	9	O
studies	9	O
.	9	O

Characterization	9	O
of	5	O
a	5	O
novel	9	O
BCHE	7	O
"	5	O
silent	9	O
"	5	O
allele	1	O
:	9	O
point	5	O
mutation	1	O
(	9	O
p	7	O
.	9	O
Val204Asp	_	O
)	9	O
causes	9	O
loss	9	O
of	5	O
activity	9	O
and	5	O
prolonged	9	O
apnea	5	B-Disease
with	5	O
suxamethonium	5	B-Chemical
.	9	O

Butyrylcholinesterase	7	B-Disease
deficiency	9	I-Disease
is	5	O
characterized	9	O
by	9	O
prolonged	9	O
apnea	5	B-Disease
after	9	O
the	5	O
use	5	O
of	5	O
muscle	9	O
relaxants	5	O
(	9	O
suxamethonium	5	B-Chemical
or	5	O
mivacurium	0	B-Chemical
)	9	O
in	5	O
patients	5	O
who	5	O
have	5	O
mutations	1	O
in	5	O
the	5	O
BCHE	7	O
gene	1	O
.	9	O

Here	9	O
,	9	O
we	5	O
report	5	O
a	5	O
case	5	O
of	5	O
prolonged	9	O
neuromuscular	5	O
block	9	O
after	9	O
administration	9	O
of	5	O
suxamethonium	5	B-Chemical
leading	9	O
to	5	O
the	5	O
discovery	9	O
of	5	O
a	5	O
novel	9	O
BCHE	7	O
variant	1	O
(	9	O
c	9	O
.	9	O
695T	_	O
>	0	O
A	9	O
,	9	O
p	7	O
.	9	O
Val204Asp	_	O
)	9	O
.	9	O

Inhibition	3	O
studies	9	O
,	9	O
kinetic	9	O
analysis	9	O
and	5	O
molecular	9	O
dynamics	5	O
were	9	O
undertaken	5	O
to	5	O
understand	5	O
how	5	O
this	5	O
mutation	1	O
disrupts	9	O
the	5	O
catalytic	1	O
triad	9	O
and	5	O
determines	5	O
a	5	O
"	5	O
silent	9	O
"	5	O
phenotype	3	O
.	9	O

Low	9	O
activity	9	O
of	5	O
patient	5	O
plasma	9	O
butyrylcholinesterase	0	O
with	5	O
butyrylthiocholine	0	B-Chemical
(	9	O
BTC	9	B-Chemical
)	9	O
and	5	O
benzoylcholine	0	B-Chemical
,	9	O
and	5	O
values	5	O
of	5	O
dibucaine	0	B-Chemical
and	5	O
fluoride	0	B-Chemical
numbers	9	O
fit	5	O
with	5	O
heterozygous	1	O
atypical	5	O
silent	9	O
genotype	9	O
.	9	O

Electrophoretic	0	O
analysis	9	O
of	5	O
plasma	9	O
BChE	0	O
of	5	O
the	5	O
proband	9	O
and	5	O
his	5	O
mother	5	O
showed	9	O
that	5	O
patient	5	O
has	9	O
a	5	O
reduced	9	O
amount	9	O
of	5	O
tetrameric	1	O
enzyme	0	O
in	5	O
plasma	9	O
and	5	O
that	5	O
minor	9	O
fast	5	O
-	7	O
moving	5	O
BChE	0	O
components	5	O
:	9	O
monomer	0	O
,	9	O
dimer	1	O
,	9	O
and	5	O
monomer	0	O
-	7	O
albumin	0	O
conjugate	0	O
are	5	O
missing	5	O
.	9	O

Kinetic	0	O
analysis	9	O
showed	9	O
that	5	O
the	5	O
p	7	O
.	9	O
Val204Asp	_	O
/	9	O
p	7	O
.	9	O
Asp70Gly	9	O
-	7	O
p	7	O
.	9	O
Ala539Thr	9	O
BChE	0	O
displays	9	O
a	5	O
pure	9	O
Michaelian	5	O
behavior	5	O
with	5	O
BTC	9	B-Chemical
as	5	O
the	5	O
substrate	0	O
.	9	O

Both	9	O
catalytic	1	O
parameters	5	O
Km	0	O
=	7	O
265	7	O
uM	0	O
for	5	O
BTC	9	B-Chemical
,	9	O
two	5	O
times	5	O
higher	9	O
than	5	O
that	5	O
of	5	O
the	5	O
atypical	5	O
enzyme	0	O
,	9	O
and	5	O
a	5	O
low	9	O
Vmax	0	O
are	5	O
consistent	9	O
with	5	O
the	5	O
absence	3	O
of	5	O
activity	9	O
against	9	O
suxamethonium	5	B-Chemical
.	9	O

Molecular	9	O
dynamic	5	O
(	9	O
MD	9	O
)	9	O
simulations	5	O
showed	9	O
that	5	O
the	5	O
overall	5	O
effect	9	O
of	5	O
the	5	O
mutation	1	O
p	7	O
.	9	O
Val204Asp	_	O
is	5	O
disruption	9	O
of	5	O
hydrogen	0	B-Chemical
bonding	5	O
between	5	O
Gln223	1	O
and	5	O
Glu441	1	O
,	9	O
leading	9	O
Ser198	1	O
and	5	O
His438	1	O
to	5	O
move	5	O
away	5	O
from	9	O
each	5	O
other	5	O
with	5	O
subsequent	9	O
disruption	9	O
of	5	O
the	5	O
catalytic	1	O
triad	9	O
functionality	9	O
regardless	9	O
of	5	O
the	5	O
type	9	O
of	5	O
substrate	0	O
.	9	O

MD	9	O
also	9	O
showed	9	O
that	5	O
the	5	O
enzyme	0	O
volume	9	O
is	5	O
increased	9	O
,	9	O
suggesting	9	O
a	5	O
pre	9	O
-	7	O
denaturation	0	O
state	5	O
.	9	O

This	5	O
fits	5	O
with	5	O
the	5	O
reduced	9	O
concentration	0	O
of	5	O
p	7	O
.	9	O
Ala204Asp	_	O
/	9	O
p	7	O
.	9	O
Asp70Gly	9	O
-	7	O
p	7	O
.	9	O
Ala539Thr	9	O
tetrameric	1	O
enzyme	0	O
in	5	O
the	5	O
plasma	9	O
and	5	O
non	9	O
-	7	O
detectable	9	O
fast	5	O
moving	5	O
-	7	O
bands	9	O
on	5	O
electrophoresis	0	O
gels	0	O
.	9	O

Delayed	5	O
anemia	9	B-Disease
after	9	O
treatment	9	O
with	5	O
injectable	5	O
artesunate	0	B-Chemical
in	5	O
the	5	O
Democratic	4	O
Republic	2	O
of	5	O
the	5	O
Congo	4	O
:	9	O
a	5	O
manageable	5	O
issue	5	O
.	9	O

Cases	9	O
of	5	O
delayed	9	O
hemolytic	0	B-Disease
anemia	9	I-Disease
have	5	O
been	9	O
described	9	O
after	9	O
treatment	9	O
with	5	O
injectable	5	O
artesunate	0	B-Chemical
,	9	O
the	5	O
current	5	O
World	5	O
Health	2	O
Organization	2	O
(	9	O
WHO	5	O
)	9	O
-	7	O
recommended	5	O
first	9	O
-	7	O
line	9	O
drug	5	O
for	5	O
the	5	O
treatment	9	O
of	5	O
severe	5	O
malaria	5	B-Disease
.	9	O

A	9	O
total	9	O
of	5	O
350	9	O
patients	5	O
(	9	O
215	7	O
[	9	O
61	7	O
.	9	O
4	9	O
%	9	O
]	9	O
<	0	O
5	9	O
years	5	O
of	5	O
age	5	O
and	5	O
135	7	O
[	9	O
38	7	O
.	9	O
6	9	O
%	9	O
]	9	O
>	0	O
5	9	O
years	5	O
of	5	O
age	5	O
)	9	O
were	9	O
followed	9	O
-	7	O
up	5	O
after	9	O
treatment	9	O
with	5	O
injectable	5	O
artesunate	0	B-Chemical
for	5	O
severe	5	O
malaria	5	B-Disease
in	5	O
hospitals	5	O
and	5	O
health	5	O
centers	5	O
of	5	O
the	5	O
Democratic	4	O
Republic	2	O
of	5	O
the	5	O
Congo	4	O
.	9	O

Complete	9	O
series	5	O
of	5	O
hemoglobin	0	O
(	9	O
Hb	9	O
)	9	O
measurements	5	O
were	9	O
available	5	O
for	5	O
201	7	O
patients	5	O
.	9	O

A	9	O
decrease	9	O
in	5	O
Hb	9	O
levels	3	O
between	5	O
2	9	O
and	5	O
5	9	O
g	0	O
/	9	O
dL	7	O
was	9	O
detected	9	O
in	5	O
23	7	O
(	9	O
11	7	O
.	9	O
4	9	O
%	9	O
)	9	O
patients	5	O
during	5	O
the	5	O
follow	5	O
-	7	O
up	5	O
period	5	O
.	9	O

For	9	O
five	9	O
patients	5	O
,	9	O
Hb	9	O
levels	3	O
decreased	9	O
below	9	O
5	9	O
g	0	O
/	9	O
dL	7	O
during	5	O
at	9	O
least	9	O
one	5	O
follow	5	O
-	7	O
up	5	O
visit	5	O
.	9	O

All	9	O
cases	5	O
of	5	O
delayed	9	O
anemia	9	B-Disease
were	9	O
clinically	5	O
manageable	5	O
and	5	O
resolved	9	O
within	9	O
one	5	O
month	5	O
.	9	O

Regulation	9	O
of	5	O
signal	9	O
transducer	5	O
and	5	O
activator	3	O
of	5	O
transcription	1	O
3	9	O
and	5	O
apoptotic	3	O
pathways	9	O
by	9	O
betaine	0	B-Chemical
attenuates	3	O
isoproterenol	0	B-Chemical
-	7	O
induced	3	O
acute	9	O
myocardial	9	B-Disease
injury	9	I-Disease
in	5	O
rats	9	O
.	9	O

The	5	O
present	9	O
study	9	O
was	9	O
designed	9	O
to	5	O
investigate	9	O
the	5	O
cardioprotective	9	O
effects	9	O
of	5	O
betaine	0	B-Chemical
on	5	O
acute	9	O
myocardial	9	B-Disease
ischemia	9	I-Disease
induced	3	O
experimentally	9	O
in	5	O
rats	9	O
focusing	5	O
on	5	O
regulation	9	O
of	5	O
signal	9	O
transducer	5	O
and	5	O
activator	3	O
of	5	O
transcription	1	O
3	9	O
(	9	O
STAT3	3	O
)	9	O
and	5	O
apoptotic	3	O
pathways	9	O
as	5	O
the	5	O
potential	9	O
mechanism	9	O
underlying	5	O
the	5	O
drug	5	O
effect	9	O
.	9	O

Male	7	O
Sprague	9	O
Dawley	0	O
rats	9	O
were	9	O
treated	3	O
with	5	O
betaine	0	B-Chemical
(	9	O
100	0	O
,	9	O
200	0	O
,	9	O
and	5	O
400	0	O
mg	0	O
/	9	O
kg	0	O
)	9	O
orally	0	O
for	5	O
40	9	O
days	9	O
.	9	O

Acute	5	O
myocardial	9	B-Disease
ischemic	9	I-Disease
injury	9	I-Disease
was	9	O
induced	3	O
in	5	O
rats	9	O
by	9	O
subcutaneous	9	O
injection	9	O
of	5	O
isoproterenol	0	B-Chemical
(	9	O
85	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
,	9	O
for	5	O
two	5	O
consecutive	5	O
days	9	O
.	9	O

Serum	9	O
cardiac	5	O
marker	3	O
enzyme	0	O
,	9	O
histopathological	9	O
variables	5	O
and	5	O
expression	3	O
of	5	O
protein	1	O
levels	3	O
were	9	O
analyzed	9	O
.	9	O

Oral	9	O
administration	9	O
of	5	O
betaine	0	B-Chemical
(	9	O
200	0	O
and	5	O
400	0	O
mg	0	O
/	9	O
kg	0	O
)	9	O
significantly	9	O
reduced	9	O
the	5	O
level	9	O
of	5	O
cardiac	5	O
marker	3	O
enzyme	0	O
in	5	O
the	5	O
serum	9	O
and	5	O
prevented	9	O
left	5	O
ventricular	5	B-Disease
remodeling	9	I-Disease
.	9	O

Western	3	O
blot	3	O
analysis	9	O
showed	9	O
that	5	O
isoproterenol	0	B-Chemical
-	7	O
induced	3	O
phosphorylation	3	O
of	5	O
STAT3	3	O
was	9	O
maintained	9	O
or	5	O
further	9	O
enhanced	3	O
by	9	O
betaine	0	B-Chemical
treatment	9	O
in	5	O
myocardium	9	O
.	9	O

Furthermore	9	O
,	9	O
betaine	0	B-Chemical
(	9	O
200	0	O
and	5	O
400	0	O
mg	0	O
/	9	O
kg	0	O
)	9	O
treatment	9	O
increased	9	O
the	5	O
ventricular	5	O
expression	3	O
of	5	O
Bcl	3	O
-	7	O
2	9	O
and	5	O
reduced	9	O
the	5	O
level	9	O
of	5	O
Bax	3	O
,	9	O
therefore	5	O
causing	9	O
a	5	O
significant	9	O
increase	9	O
in	5	O
the	5	O
ratio	9	O
of	5	O
Bcl	3	O
-	7	O
2	9	O
/	9	O
Bax	3	O
.	9	O

The	5	O
protective	9	O
role	9	O
of	5	O
betaine	0	B-Chemical
on	5	O
myocardial	9	B-Disease
damage	9	I-Disease
was	9	O
further	9	O
confirmed	9	O
by	9	O
histopathological	9	O
examination	5	O
.	9	O

In	9	O
summary	9	O
,	9	O
our	5	O
results	9	O
showed	9	O
that	5	O
betaine	0	B-Chemical
pretreatment	0	O
attenuated	3	O
isoproterenol	0	B-Chemical
-	7	O
induced	3	O
acute	9	O
myocardial	9	B-Disease
ischemia	9	I-Disease
via	9	O
the	5	O
regulation	9	O
of	5	O
STAT3	3	O
and	5	O
apoptotic	3	O
pathways	9	O
.	9	O

Quetiapine	7	B-Chemical
-	7	O
induced	3	O
neutropenia	5	B-Disease
in	5	O
a	5	O
bipolar	5	B-Disease
patient	5	O
with	5	O
hepatocellular	9	B-Disease
carcinoma	3	I-Disease
.	9	O

OBJECTIVE	2	O
:	9	O
Quetiapine	7	B-Chemical
is	5	O
a	5	O
dibenzothiazepine	5	O
derivative	0	O
,	9	O
similar	9	O
to	5	O
clozapine	5	B-Chemical
,	9	O
which	5	O
has	9	O
the	5	O
highest	9	O
risk	5	O
of	5	O
causing	9	O
blood	9	B-Disease
dyscrasias	5	I-Disease
,	9	O
especially	5	O
neutropenia	5	B-Disease
.	9	O

There	5	O
are	5	O
some	5	O
case	5	O
reports	9	O
about	5	O
this	5	O
side	5	O
effect	9	O
of	5	O
quetiapine	5	B-Chemical
,	9	O
but	9	O
possible	5	O
risk	5	O
factors	9	O
are	5	O
seldom	5	O
discussed	5	O
and	5	O
identified	9	O
.	9	O

A	9	O
case	5	O
of	5	O
a	5	O
patient	5	O
with	5	O
hepatocellular	9	B-Disease
carcinoma	3	I-Disease
that	5	O
developed	5	O
neutropenia	5	B-Disease
after	9	O
treatment	9	O
with	5	O
quetiapine	5	B-Chemical
is	5	O
described	9	O
here	5	O
.	9	O

CASE	2	O
REPORT	5	O
:	9	O
A	9	O
62	7	O
-	7	O
year	5	O
-	7	O
old	5	O
Taiwanese	9	O
widow	5	O
with	5	O
bipolar	5	B-Disease
disorder	5	I-Disease
was	9	O
diagnosed	5	O
with	5	O
hepatocellular	9	B-Disease
carcinoma	3	I-Disease
at	9	O
age	5	O
60	9	O
.	9	O

She	5	O
developed	5	O
leucopenia	5	B-Disease
after	9	O
being	5	O
treated	3	O
with	5	O
quetiapine	5	B-Chemical
.	9	O

After	9	O
quetiapine	5	B-Chemical
was	9	O
discontinued	5	O
,	9	O
her	5	O
white	9	O
blood	9	O
cell	3	O
count	9	O
returned	5	O
to	5	O
normal	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Although	9	O
neutropenia	5	B-Disease
is	5	O
not	5	O
a	5	O
common	5	O
side	5	O
effect	9	O
of	5	O
quetiapine	5	B-Chemical
,	9	O
physicians	5	O
should	5	O
be	5	O
cautious	5	O
about	5	O
its	9	O
presentation	5	O
and	5	O
associated	9	O
risk	5	O
factors	9	O
.	9	O

Hepatic	9	B-Disease
dysfunction	9	I-Disease
may	5	O
be	5	O
one	5	O
of	5	O
the	5	O
possible	5	O
risk	5	O
factors	9	O
,	9	O
and	5	O
concomitant	9	O
fever	5	B-Disease
may	5	O
be	5	O
a	5	O
diagnostic	5	O
marker	3	O
for	5	O
adverse	5	O
reaction	9	O
to	5	O
quetiapine	5	B-Chemical
.	9	O

Lateral	9	O
antebrachial	5	O
cutaneous	5	O
neuropathy	5	B-Disease
after	9	O
steroid	9	B-Chemical
injection	9	O
at	9	O
lateral	5	O
epicondyle	5	O
.	9	O

BACKGROUND	2	O
AND	2	O
OBJECTIVES	2	O
:	9	O
This	5	O
report	5	O
aimed	5	O
to	5	O
present	9	O
a	5	O
case	5	O
of	5	O
lateral	5	O
antebrachial	5	O
cutaneous	5	O
neuropathy	5	B-Disease
(	9	O
LACNP	_	O
)	9	O
that	5	O
occurred	9	O
after	9	O
a	5	O
steroid	9	B-Chemical
injection	9	O
in	5	O
the	5	O
lateral	5	O
epicondyle	5	O
to	5	O
treat	5	O
lateral	5	B-Disease
epicondylitis	5	I-Disease
in	5	O
a	5	O
40	9	O
-	7	O
year	5	O
-	7	O
old	5	O
woman	5	O
.	9	O

MATERIAL	2	O
AND	2	O
METHOD	2	O
:	9	O
A	9	O
40	9	O
-	7	O
year	5	O
-	7	O
old	5	O
woman	5	O
presented	5	O
with	5	O
decreased	9	O
sensation	5	O
and	5	O
paresthesia	5	B-Disease
over	5	O
her	5	O
right	5	O
lateral	5	O
forearm	5	O
;	9	O
the	5	O
paresthesia	5	B-Disease
had	9	O
occurred	9	O
after	9	O
a	5	O
steroid	9	B-Chemical
injection	9	O
in	5	O
the	5	O
right	5	O
lateral	5	O
epicondyle	5	O
3	9	O
months	5	O
before	9	O
.	9	O

Her	5	O
sensation	5	O
of	5	O
light	9	O
touch	5	O
and	5	O
pain	5	B-Disease
was	9	O
diminished	9	O
over	5	O
the	5	O
lateral	5	O
side	5	O
of	5	O
the	5	O
right	5	O
forearm	5	O
and	5	O
wrist	5	O
area	5	O
.	9	O

RESULTS	9	O
:	9	O
The	5	O
sensory	5	O
action	5	O
potential	9	O
amplitude	5	O
of	5	O
the	5	O
right	5	O
lateral	5	O
antebrachial	5	O
cutaneous	5	O
nerve	5	O
(	9	O
LACN	5	O
)	9	O
(	9	O
6	9	O
.	9	O
2	9	O
uV	7	O
)	9	O
was	9	O
lower	9	O
than	5	O
that	5	O
of	5	O
the	5	O
left	5	O
(	9	O
13	7	O
.	9	O
1	9	O
uV	7	O
)	9	O
.	9	O

The	5	O
difference	9	O
of	5	O
amplitude	5	O
between	5	O
both	9	O
sides	5	O
was	9	O
significant	9	O
because	5	O
there	5	O
was	9	O
more	5	O
than	5	O
a	5	O
50	0	O
%	9	O
reduction	9	O
.	9	O

She	5	O
was	9	O
diagnosed	5	O
with	5	O
right	5	O
LACNP	_	O
(	9	O
mainly	9	O
axonal	3	O
involvement	9	O
)	9	O
on	5	O
the	5	O
basis	5	O
of	5	O
the	5	O
clinical	5	O
manifestation	5	O
and	5	O
the	5	O
electrodiagnostic	5	O
findings	9	O
.	9	O

Her	5	O
symptoms	5	O
improved	5	O
through	9	O
physical	5	O
therapy	5	O
but	9	O
persisted	9	O
to	5	O
some	5	O
degree	5	O
.	9	O

CONCLUSION	5	O
:	9	O
This	5	O
report	5	O
describes	5	O
the	5	O
case	5	O
of	5	O
a	5	O
woman	5	O
with	5	O
LACNP	_	O
that	5	O
developed	5	O
after	9	O
a	5	O
steroid	9	B-Chemical
injection	9	O
for	5	O
the	5	O
treatment	9	O
of	5	O
lateral	5	B-Disease
epicondylitis	5	I-Disease
.	9	O

An	5	O
electrodiagnostic	5	O
study	9	O
,	9	O
including	9	O
a	5	O
nerve	5	O
conduction	5	O
study	9	O
of	5	O
the	5	O
LACN	5	O
,	9	O
was	9	O
helpful	6	O
to	5	O
diagnose	5	O
right	5	O
LACNP	_	O
and	5	O
to	5	O
find	5	O
the	5	O
passage	9	O
of	5	O
the	5	O
LACN	5	O
on	5	O
the	5	O
lateral	5	O
epicondyle	5	O
.	9	O

Curcumin	0	B-Chemical
prevents	9	O
maleate	0	B-Chemical
-	7	O
induced	3	O
nephrotoxicity	9	B-Disease
:	9	O
relation	5	O
to	5	O
hemodynamic	5	O
alterations	9	O
,	9	O
oxidative	9	O
stress	9	O
,	9	O
mitochondrial	9	O
oxygen	0	B-Chemical
consumption	5	O
and	5	O
activity	9	O
of	5	O
respiratory	5	O
complex	9	O
I	9	O
.	9	O

The	5	O
potential	9	O
protective	9	O
effect	9	O
of	5	O
the	5	O
dietary	5	O
antioxidant	0	O
curcumin	0	B-Chemical
(	9	O
120	9	O
mg	0	O
/	9	O
Kg	0	O
/	9	O
day	9	O
for	5	O
6	9	O
days	9	O
)	9	O
against	9	O
the	5	O
renal	9	B-Disease
injury	9	I-Disease
induced	3	O
by	9	O
maleate	0	B-Chemical
was	9	O
evaluated	9	O
.	9	O

Tubular	9	O
proteinuria	9	B-Disease
and	5	O
oxidative	9	O
stress	9	O
were	9	O
induced	3	O
by	9	O
a	5	O
single	9	O
injection	9	O
of	5	O
maleate	0	B-Chemical
(	9	O
400	0	O
mg	0	O
/	9	O
kg	0	O
)	9	O
in	5	O
rats	9	O
.	9	O

Maleate	0	B-Chemical
-	7	O
induced	3	O
renal	9	B-Disease
injury	9	I-Disease
included	5	O
increase	9	O
in	5	O
renal	9	O
vascular	5	O
resistance	9	O
and	5	O
in	5	O
the	5	O
urinary	9	O
excretion	0	O
of	5	O
total	9	O
protein	1	O
,	9	O
glucose	0	B-Chemical
,	9	O
sodium	0	B-Chemical
,	9	O
neutrophil	3	O
gelatinase	3	O
-	7	O
associated	9	O
lipocalin	9	O
(	9	O
NGAL	9	O
)	9	O
and	5	O
N	9	O
-	7	O
acetyl	0	O
b	9	O
-	7	O
D	9	O
-	7	O
glucosaminidase	0	O
(	9	O
NAG	0	O
)	9	O
,	9	O
upregulation	3	O
of	5	O
kidney	9	B-Disease
injury	9	I-Disease
molecule	3	O
(	9	O
KIM	2	O
)	9	O
-	7	O
1	9	O
,	9	O
decrease	9	O
in	5	O
renal	9	O
blood	9	O
flow	5	O
and	5	O
claudin	3	O
-	7	O
2	9	O
expression	3	O
besides	9	O
of	5	O
necrosis	9	B-Disease
and	5	O
apoptosis	3	O
of	5	O
tubular	9	O
cells	3	O
on	5	O
24	9	O
h	0	O
.	9	O

Oxidative	9	O
stress	9	O
was	9	O
determined	9	O
by	9	O
measuring	9	O
the	5	O
oxidation	0	O
of	5	O
lipids	0	O
and	5	O
proteins	1	O
and	5	O
diminution	9	O
in	5	O
renal	9	O
Nrf2	3	O
levels	3	O
.	9	O

Studies	9	O
were	9	O
also	9	O
conducted	9	O
in	5	O
renal	9	O
epithelial	3	O
LLC	2	O
-	7	O
PK1	1	O
cells	3	O
and	5	O
in	5	O
mitochondria	3	O
isolated	9	O
from	9	O
kidneys	9	O
of	5	O
all	5	O
the	5	O
experimental	5	O
groups	9	O
.	9	O

Maleate	0	B-Chemical
induced	3	O
cell	3	O
damage	9	O
and	5	O
reactive	9	O
oxygen	0	B-Chemical
species	4	O
(	9	O
ROS	3	O
)	9	O
production	9	O
in	5	O
LLC	2	O
-	7	O
PK1	1	O
cells	3	O
in	5	O
culture	9	O
.	9	O

In	9	O
addition	9	O
,	9	O
maleate	0	B-Chemical
treatment	9	O
reduced	9	O
oxygen	0	B-Chemical
consumption	5	O
in	5	O
ADP	0	B-Chemical
-	7	O
stimulated	3	O
mitochondria	3	O
and	5	O
diminished	9	O
respiratory	5	O
control	9	O
index	5	O
when	5	O
using	9	O
malate	0	B-Chemical
/	9	O
glutamate	0	B-Chemical
as	5	O
substrate	0	O
.	9	O

The	5	O
activities	9	O
of	5	O
both	9	O
complex	9	O
I	9	O
and	5	O
aconitase	1	O
were	9	O
also	9	O
diminished	9	O
.	9	O

All	9	O
the	5	O
above	9	O
-	7	O
described	9	O
alterations	9	O
were	9	O
prevented	9	O
by	9	O
curcumin	0	B-Chemical
.	9	O

It	5	O
is	5	O
concluded	9	O
that	5	O
curcumin	0	B-Chemical
is	5	O
able	9	O
to	5	O
attenuate	9	O
in	5	O
vivo	3	O
maleate	0	B-Chemical
-	7	O
induced	3	O
nephropathy	9	B-Disease
and	5	O
in	5	O
vitro	3	O
cell	3	O
damage	9	O
.	9	O

The	5	O
in	5	O
vivo	3	O
protection	9	O
was	9	O
associated	9	O
to	5	O
the	5	O
prevention	5	O
of	5	O
oxidative	9	O
stress	9	O
and	5	O
preservation	9	O
of	5	O
mitochondrial	9	O
oxygen	0	B-Chemical
consumption	5	O
and	5	O
activity	9	O
of	5	O
respiratory	5	O
complex	9	O
I	9	O
,	9	O
and	5	O
the	5	O
in	5	O
vitro	3	O
protection	9	O
was	9	O
associated	9	O
to	5	O
the	5	O
prevention	5	O
of	5	O
ROS	3	O
production	9	O
.	9	O

Anticonvulsant	0	O
actions	5	O
of	5	O
MK	9	B-Chemical
-	7	I-Chemical
801	7	I-Chemical
on	5	O
the	5	O
lithium	0	B-Chemical
-	7	O
pilocarpine	0	B-Chemical
model	5	O
of	5	O
status	9	B-Disease
epilepticus	5	I-Disease
in	5	O
rats	9	O
.	9	O

MK	9	B-Chemical
-	7	I-Chemical
801	7	I-Chemical
,	9	O
a	5	O
noncompetitive	0	O
N	9	B-Chemical
-	7	I-Chemical
methyl	0	I-Chemical
-	7	I-Chemical
D	9	I-Chemical
-	7	I-Chemical
aspartate	1	I-Chemical
(	9	O
NMDA	3	B-Chemical
)	9	O
receptor	3	O
antagonist	3	O
,	9	O
was	9	O
tested	9	O
for	5	O
anticonvulsant	5	O
effects	9	O
in	5	O
rats	9	O
using	9	O
two	5	O
seizure	5	B-Disease
models	5	O
,	9	O
coadministration	0	O
of	5	O
lithium	0	B-Chemical
and	5	O
pilocarpine	0	B-Chemical
and	5	O
administration	9	O
of	5	O
a	5	O
high	9	O
dose	9	O
of	5	O
pilocarpine	0	B-Chemical
alone	9	O
.	9	O

Three	9	O
major	9	O
results	9	O
are	5	O
reported	9	O
.	9	O

First	9	O
,	9	O
pretreatment	0	O
with	5	O
MK	9	B-Chemical
-	7	I-Chemical
801	7	I-Chemical
produced	9	O
an	5	O
effective	5	O
and	5	O
dose	9	O
-	7	O
dependent	9	O
anticonvulsant	5	O
action	5	O
with	5	O
the	5	O
lithium	0	B-Chemical
-	7	O
pilocarpine	0	B-Chemical
model	5	O
but	9	O
not	5	O
with	5	O
rats	9	O
treated	3	O
with	5	O
pilocarpine	0	B-Chemical
alone	9	O
,	9	O
suggesting	9	O
that	5	O
different	9	O
biochemical	9	O
mechanisms	9	O
control	9	O
seizures	5	B-Disease
in	5	O
these	5	O
two	5	O
models	5	O
.	9	O

Second	9	O
,	9	O
the	5	O
anticonvulsant	5	O
effect	9	O
of	5	O
MK	9	B-Chemical
-	7	I-Chemical
801	7	I-Chemical
in	5	O
the	5	O
lithium	0	B-Chemical
-	7	O
pilocarpine	0	B-Chemical
model	5	O
only	9	O
occurred	9	O
after	9	O
initial	9	O
periods	5	O
of	5	O
seizure	5	B-Disease
activity	9	O
.	9	O

This	5	O
observation	9	O
is	5	O
suggested	9	O
to	5	O
be	5	O
an	5	O
in	5	O
vivo	3	O
demonstration	9	O
of	5	O
the	5	O
conclusion	9	O
derived	9	O
from	9	O
in	5	O
vitro	3	O
experiments	9	O
that	5	O
MK	9	B-Chemical
-	7	I-Chemical
801	7	I-Chemical
binding	1	O
requires	5	O
agonist	3	O
-	7	O
induced	3	O
opening	5	O
of	5	O
the	5	O
channel	9	O
sites	9	O
of	5	O
the	5	O
NMDA	3	B-Chemical
receptor	3	O
.	9	O

Third	9	O
,	9	O
although	9	O
it	5	O
is	5	O
relatively	5	O
easy	5	O
to	5	O
block	9	O
seizures	5	B-Disease
induced	3	O
by	9	O
lithium	0	B-Chemical
and	5	O
pilocarpine	0	B-Chemical
by	9	O
administration	9	O
of	5	O
anticonvulsants	5	O
prior	9	O
to	5	O
pilocarpine	0	B-Chemical
,	9	O
it	5	O
is	5	O
more	5	O
difficult	5	O
to	5	O
terminate	9	O
ongoing	5	O
status	9	B-Disease
epilepticus	5	I-Disease
and	5	O
block	9	O
the	5	O
lethality	3	O
of	5	O
the	5	O
seizures	5	B-Disease
.	9	O

Administration	2	O
of	5	O
MK	9	B-Chemical
-	7	I-Chemical
801	7	I-Chemical
30	9	O
or	5	O
60	9	O
min	0	O
after	9	O
pilocarpine	0	B-Chemical
,	9	O
i	9	O
.	9	O
e	9	O
.	9	O
,	9	O
during	5	O
status	9	B-Disease
epilepticus	5	I-Disease
,	9	O
gradually	9	O
reduced	9	O
electrical	5	O
and	5	O
behavioral	5	O
seizure	5	B-Disease
activity	9	O
and	5	O
greatly	9	O
enhanced	3	O
the	5	O
survival	9	O
rate	9	O
.	9	O

These	5	O
results	9	O
suggest	9	O
that	5	O
activation	3	O
of	5	O
NMDA	3	B-Chemical
receptors	3	O
plays	9	O
an	5	O
important	9	O
role	9	O
in	5	O
status	9	B-Disease
epilepticus	5	I-Disease
and	5	O
brain	5	B-Disease
damage	9	I-Disease
in	5	O
the	5	O
lithium	0	B-Chemical
-	7	O
pilocarpine	0	B-Chemical
model	5	O
.	9	O

This	5	O
was	9	O
further	9	O
supported	9	O
by	9	O
results	9	O
showing	9	O
that	5	O
nonconvulsive	5	O
doses	0	O
of	5	O
NMDA	3	B-Chemical
and	5	O
pilocarpine	0	B-Chemical
were	9	O
synergistic	9	O
,	9	O
resulting	9	O
in	5	O
status	9	B-Disease
epilepticus	5	I-Disease
and	5	O
subsequent	9	O
mortality	5	O
.	9	O

Continuous	5	O
infusion	0	O
tobramycin	0	B-Chemical
combined	9	O
with	5	O
carbenicillin	0	B-Chemical
for	5	O
infections	5	B-Disease
in	5	O
cancer	3	B-Disease
patients	5	O
.	9	O

The	5	O
cure	5	O
rate	9	O
of	5	O
infections	5	B-Disease
in	5	O
cancer	3	B-Disease
patients	5	O
is	5	O
adversely	5	O
affected	9	O
by	9	O
neutropenia	5	B-Disease
(	9	O
less	5	O
than	5	O
1	9	O
,	9	O
000	9	O
/	9	O
mm3	9	O
)	9	O
.	9	O

In	9	O
particular	5	O
,	9	O
patients	5	O
with	5	O
severe	5	O
neutropenia	5	B-Disease
(	9	O
less	5	O
than	5	O
100	0	O
/	9	O
mm3	9	O
)	9	O
have	5	O
shown	9	O
a	5	O
poor	5	O
response	9	O
to	5	O
antibiotics	5	O
.	9	O

To	9	O
overcome	5	O
the	5	O
adverse	5	O
effects	9	O
of	5	O
neutropenia	5	B-Disease
,	9	O
tobramycin	0	B-Chemical
was	9	O
given	5	O
by	9	O
continuous	5	O
infusion	0	O
and	5	O
combined	9	O
with	5	O
intermittent	5	O
carbenicillin	0	B-Chemical
.	9	O

Tobramycin	0	B-Chemical
was	9	O
given	5	O
to	5	O
a	5	O
total	9	O
daily	5	O
dose	9	O
of	5	O
300	0	O
mg	0	O
/	9	O
m2	7	O
and	5	O
carbenicillin	0	B-Chemical
was	9	O
given	5	O
at	9	O
a	5	O
dose	9	O
of	5	O
5	9	O
gm	0	O
every	5	O
four	9	O
hours	9	O
.	9	O

There	5	O
were	9	O
125	9	O
infectious	5	O
episodes	5	O
in	5	O
116	7	O
cancer	3	B-Disease
patients	5	O
receiving	9	O
myelosuppressive	5	O
chemotherapy	5	O
.	9	O

The	5	O
overall	5	O
cure	5	O
rate	9	O
was	9	O
70	9	O
%	9	O
.	9	O

Pneumonia	7	B-Disease
was	9	O
the	5	O
most	9	O
common	5	O
infection	9	B-Disease
and	5	O
61	7	O
%	9	O
of	5	O
59	7	O
episodes	5	O
were	9	O
cured	5	O
.	9	O

Gram	9	O
-	7	O
negative	9	O
bacilli	9	O
were	9	O
the	5	O
most	9	O
common	5	O
causative	9	O
organisms	9	O
and	5	O
69	7	O
%	9	O
of	5	O
these	5	O
infections	5	B-Disease
were	9	O
cured	5	O
.	9	O

The	5	O
most	9	O
common	5	O
pathogen	9	O
was	9	O
Klebsiella	4	O
pneumoniae	4	B-Disease
and	5	O
this	5	O
,	9	O
together	9	O
with	5	O
Escherichia	1	O
coli	1	O
and	5	O
Pseudomonas	4	O
aeruginosa	4	O
,	9	O
accounted	5	O
for	5	O
74	7	O
%	9	O
of	5	O
all	5	O
gram	9	B-Disease
-	7	I-Disease
negative	9	I-Disease
bacillary	5	I-Disease
infections	5	I-Disease
.	9	O

Response	5	O
was	9	O
not	5	O
influenced	5	O
by	9	O
the	5	O
initial	9	O
neutrophil	3	O
count	9	O
,	9	O
with	5	O
a	5	O
62	7	O
%	9	O
cure	5	O
rate	9	O
for	5	O
39	7	O
episodes	5	O
associated	9	O
with	5	O
severe	5	O
neutropenia	5	B-Disease
.	9	O

However	9	O
,	9	O
failure	5	O
of	5	O
the	5	O
neutrophil	3	O
count	9	O
to	5	O
increase	9	O
during	5	O
therapy	5	O
adversely	5	O
affected	9	O
response	9	O
.	9	O

Azotemia	7	B-Disease
was	9	O
the	5	O
major	9	O
side	5	O
effect	9	O
recognized	9	O
,	9	O
and	5	O
it	5	O
occurred	9	O
in	5	O
11	7	O
%	9	O
of	5	O
episodes	5	O
.	9	O

Major	9	O
azotemia	5	B-Disease
(	9	O
serum	9	O
creatinine	0	B-Chemical
greater	5	O
than	5	O
2	9	O
.	9	O
5	9	O
mg	0	O
/	9	O
dl	7	O
or	5	O
BUN	0	O
greater	5	O
than	5	O
50	0	O
mg	0	O
/	9	O
dl	7	O
)	9	O
occurred	9	O
in	5	O
only	9	O
2	9	O
%	9	O
.	9	O

Azotemia	7	B-Disease
was	9	O
not	5	O
related	9	O
to	5	O
duration	5	O
of	5	O
therapy	5	O
or	5	O
serum	9	O
tobramycin	0	B-Chemical
concentration	0	O
.	9	O

This	5	O
antibiotic	5	O
regimen	5	O
showed	9	O
both	9	O
therapeutic	5	O
efficacy	9	O
and	5	O
acceptable	5	O
renal	9	B-Disease
toxicity	9	I-Disease
for	5	O
these	5	O
patients	5	O
.	9	O

Incidence	9	O
of	5	O
solid	9	O
tumours	3	B-Disease
among	5	O
pesticide	5	O
applicators	5	O
exposed	9	O
to	5	O
the	5	O
organophosphate	0	B-Chemical
insecticide	5	O
diazinon	0	B-Chemical
in	5	O
the	5	O
Agricultural	2	O
Health	2	O
Study	5	O
:	9	O
an	5	O
updated	5	O
analysis	9	O
.	9	O

OBJECTIVE	2	O
:	9	O
Diazinon	7	B-Chemical
,	9	O
a	5	O
common	5	O
organophosphate	0	B-Chemical
insecticide	5	O
with	5	O
genotoxic	9	O
properties	9	O
,	9	O
was	9	O
previously	9	O
associated	9	O
with	5	O
lung	9	B-Disease
cancer	3	I-Disease
in	5	O
the	5	O
Agricultural	2	O
Health	2	O
Study	5	O
(	9	O
AHS	5	O
)	9	O
cohort	9	O
,	9	O
but	9	O
few	5	O
other	5	O
epidemiological	5	O
studies	9	O
have	5	O
examined	9	O
diazinon	0	B-Chemical
-	7	O
associated	9	O
cancer	3	B-Disease
risk	5	O
.	9	O

We	9	O
used	5	O
updated	5	O
diazinon	0	B-Chemical
exposure	9	O
and	5	O
cancer	3	B-Disease
incidence	5	O
information	5	O
to	5	O
evaluate	9	O
solid	9	O
tumour	3	B-Disease
risk	5	O
in	5	O
the	5	O
AHS	5	O
.	9	O

METHODS	2	O
:	9	O
Male	7	O
pesticide	5	O
applicators	5	O
in	5	O
Iowa	2	O
and	5	O
North	4	O
Carolina	2	O
reported	9	O
lifetime	5	O
diazinon	0	B-Chemical
use	5	O
at	9	O
enrolment	5	O
(	9	O
1993	2	O
-	7	O
1997	2	O
)	9	O
and	5	O
follow	5	O
-	7	O
up	5	O
(	9	O
1998	2	O
-	7	O
2005	2	O
)	9	O
;	9	O
cancer	3	B-Disease
incidence	5	O
was	9	O
assessed	9	O
through	9	O
2010	2	O
(	9	O
North	4	O
Carolina	2	O
)	9	O
/	9	O
2011	2	O
(	9	O
Iowa	2	O
)	9	O
.	9	O

Among	9	O
applicators	5	O
with	5	O
usage	9	O
information	5	O
sufficient	9	O
to	5	O
evaluate	9	O
exposure	9	O
-	7	O
response	9	O
patterns	5	O
,	9	O
we	5	O
used	5	O
Poisson	5	O
regression	5	O
to	5	O
estimate	5	O
adjusted	9	O
rate	9	O
ratios	9	O
(	9	O
RRs	5	O
)	9	O
and	5	O
95	7	O
%	9	O
CI	7	O
for	5	O
cancer	3	B-Disease
sites	9	O
with	5	O
>	0	O
10	9	O
exposed	9	O
cases	5	O
for	5	O
both	9	O
lifetime	5	O
(	9	O
LT	9	O
)	9	O
exposure	9	O
days	9	O
and	5	O
intensity	5	O
-	7	O
weighted	5	O
(	9	O
IW	9	O
)	9	O
lifetime	5	O
exposure	9	O
days	9	O
(	9	O
accounting	5	O
for	5	O
factors	9	O
impacting	5	O
exposure	9	O
)	9	O
.	9	O

RESULTS	9	O
:	9	O
We	9	O
observed	9	O
elevated	9	O
lung	9	B-Disease
cancer	3	I-Disease
risks	5	O
(	9	O
N	9	O
=	7	O
283	7	O
)	9	O
among	5	O
applicators	5	O
with	5	O
the	5	O
greatest	9	O
number	9	O
of	5	O
LT	9	O
(	9	O
RR	9	O
=	7	O
1	9	O
.	9	O
60	9	O
;	9	O
95	7	O
%	9	O
CI	7	O
1	9	O
.	9	O
11	7	O
to	5	O
2	9	O
.	9	O
31	7	O
;	9	O
Ptrend	7	O
=	7	O
0	7	O
.	9	O
02	7	O
)	9	O
and	5	O
IW	9	O
days	9	O
of	5	O
diazinon	0	B-Chemical
use	5	O
(	9	O
RR	9	O
=	7	O
1	9	O
.	9	O
41	7	O
;	9	O
95	7	O
%	9	O
CI	7	O
0	7	O
.	9	O
98	7	O
to	5	O
2	9	O
.	9	O
04	7	O
;	9	O
Ptrend	7	O
=	7	O
0	7	O
.	9	O
08	7	O
)	9	O
.	9	O

Kidney	9	B-Disease
cancer	3	I-Disease
(	9	O
N	9	O
=	7	O
94	7	O
)	9	O
risks	5	O
were	9	O
non	9	O
-	7	O
significantly	9	O
elevated	9	O
(	9	O
RRLT	_	O
days	9	O
=	7	O
1	9	O
.	9	O
77	7	O
;	9	O
95	7	O
%	9	O
CI	7	O
0	7	O
.	9	O
90	9	O
to	5	O
3	9	O
.	9	O
51	7	O
;	9	O
Ptrend	7	O
=	7	O
0	7	O
.	9	O
09	7	O
;	9	O
RRIW	_	O
days	9	O
1	9	O
.	9	O
37	9	O
;	9	O
95	7	O
%	9	O
CI	7	O
0	7	O
.	9	O
64	7	O
to	5	O
2	9	O
.	9	O
92	7	O
;	9	O
Ptrend	7	O
=	7	O
0	7	O
.	9	O
50	0	O
)	9	O
,	9	O
as	5	O
were	9	O
risks	5	O
for	5	O
aggressive	5	O
prostate	3	B-Disease
cancer	3	I-Disease
(	9	O
N	9	O
=	7	O
656	7	O
)	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Our	9	O
updated	5	O
evaluation	5	O
of	5	O
diazinon	0	B-Chemical
provides	5	O
additional	9	O
evidence	9	O
of	5	O
an	5	O
association	9	O
with	5	O
lung	9	B-Disease
cancer	3	I-Disease
risk	5	O
.	9	O

Newly	9	O
identified	9	O
links	5	O
to	5	O
kidney	9	B-Disease
cancer	3	I-Disease
and	5	O
associations	5	O
with	5	O
aggressive	5	O
prostate	3	B-Disease
cancer	3	I-Disease
require	5	O
further	9	O
evaluation	5	O
.	9	O

Associations	5	O
of	5	O
Ozone	0	B-Chemical
and	5	O
PM2	1	O
.	9	O
5	9	O
Concentrations	0	O
With	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
Disease	2	I-Disease
Among	9	O
Participants	5	O
in	5	O
the	5	O
Agricultural	2	O
Health	2	O
Study	5	O
.	9	O

OBJECTIVE	2	O
:	9	O
This	5	O
study	9	O
describes	5	O
associations	5	O
of	5	O
ozone	0	B-Chemical
and	5	O
fine	5	O
particulate	0	B-Chemical
matter	5	I-Chemical
with	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
observed	9	O
among	5	O
farmers	5	O
in	5	O
North	4	O
Carolina	2	O
and	5	O
Iowa	2	O
.	9	O

METHODS	2	O
:	9	O
We	9	O
used	5	O
logistic	5	O
regression	5	O
to	5	O
determine	9	O
the	5	O
associations	5	O
of	5	O
these	5	O
pollutants	5	O
with	5	O
self	5	O
-	7	O
reported	9	O
,	9	O
doctor	5	O
-	7	O
diagnosed	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
.	9	O

Daily	5	O
predicted	9	O
pollutant	5	O
concentrations	0	O
were	9	O
used	5	O
to	5	O
derive	5	O
surrogates	5	O
of	5	O
long	5	O
-	7	O
term	5	O
exposure	9	O
and	5	O
link	5	O
them	5	O
to	5	O
study	9	O
participants	5	O
'	9	O
geocoded	5	O
addresses	5	O
.	9	O

RESULTS	9	O
:	9	O
We	9	O
observed	9	O
positive	9	O
associations	5	O
of	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
with	5	O
ozone	0	B-Chemical
(	9	O
odds	5	O
ratio	9	O
=	7	O
1	9	O
.	9	O
39	7	O
;	9	O
95	7	O
%	9	O
CI	7	O
:	9	O
0	7	O
.	9	O
98	7	O
to	5	O
1	9	O
.	9	O
98	7	O
)	9	O
and	5	O
fine	5	O
particulate	0	B-Chemical
matter	5	I-Chemical
(	9	O
odds	5	O
ratio	9	O
=	7	O
1	9	O
.	9	O
34	7	O
;	9	O
95	7	O
%	9	O
CI	7	O
:	9	O
0	7	O
.	9	O
93	7	O
to	5	O
1	9	O
.	9	O
93	7	O
)	9	O
in	5	O
North	4	O
Carolina	2	O
but	9	O
not	5	O
in	5	O
Iowa	2	O
.	9	O

CONCLUSIONS	5	O
:	9	O
The	5	O
plausibility	5	O
of	5	O
an	5	O
effect	9	O
of	5	O
ambient	5	O
concentrations	0	O
of	5	O
these	5	O
pollutants	5	O
on	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
risk	5	O
is	5	O
supported	9	O
by	9	O
experimental	5	O
data	5	O
demonstrating	9	O
damage	9	O
to	5	O
dopaminergic	5	O
neurons	3	O
at	9	O
relevant	5	O
concentrations	0	O
.	9	O

Additional	9	O
studies	9	O
are	5	O
needed	5	O
to	5	O
address	5	O
uncertainties	5	O
related	9	O
to	5	O
confounding	5	O
and	5	O
to	5	O
examine	9	O
temporal	5	O
aspects	5	O
of	5	O
the	5	O
associations	5	O
we	5	O
observed	9	O
.	9	O

Low	9	O
functional	9	O
programming	5	O
of	5	O
renal	9	O
AT2R	3	O
mediates	3	O
the	5	O
developmental	9	O
origin	9	O
of	5	O
glomerulosclerosis	3	B-Disease
in	5	O
adult	9	O
offspring	9	O
induced	3	O
by	9	O
prenatal	5	O
caffeine	0	B-Chemical
exposure	9	O
.	9	O

UNASSIGNED	_	O
:	9	O
Our	9	O
previous	9	O
study	9	O
has	9	O
indicated	9	O
that	5	O
prenatal	5	O
caffeine	0	B-Chemical
exposure	9	O
(	9	O
PCE	9	O
)	9	O
could	9	O
induce	3	O
intrauterine	5	B-Disease
growth	3	I-Disease
retardation	9	I-Disease
(	9	O
IUGR	9	B-Disease
)	9	O
of	5	O
offspring	9	O
.	9	O

Recent	9	O
research	5	O
suggested	9	O
that	5	O
IUGR	9	B-Disease
is	5	O
a	5	O
risk	5	O
factor	9	O
for	5	O
glomerulosclerosis	3	B-Disease
.	9	O

However	9	O
,	9	O
whether	9	O
PCE	9	O
could	9	O
induce	3	O
glomerulosclerosis	3	B-Disease
and	5	O
its	9	O
underlying	5	O
mechanisms	9	O
remain	9	O
unknown	9	O
.	9	O

This	5	O
study	9	O
aimed	5	O
to	5	O
demonstrate	9	O
the	5	O
induction	3	O
to	5	O
glomerulosclerosis	3	B-Disease
in	5	O
adult	9	O
offspring	9	O
by	9	O
PCE	9	O
and	5	O
its	9	O
intrauterine	5	O
programming	5	O
mechanisms	9	O
.	9	O

A	9	O
rat	3	O
model	5	O
of	5	O
IUGR	9	B-Disease
was	9	O
established	9	O
by	9	O
PCE	9	O
,	9	O
male	9	O
fetuses	9	O
and	5	O
adult	9	O
offspring	9	O
at	9	O
the	5	O
age	5	O
of	5	O
postnatal	9	O
week	9	O
24	9	O
were	9	O
euthanized	9	O
.	9	O

The	5	O
results	9	O
revealed	9	O
that	5	O
the	5	O
adult	9	O
offspring	9	O
kidneys	9	O
in	5	O
the	5	O
PCE	9	O
group	9	O
exhibited	9	O
glomerulosclerosis	3	B-Disease
as	5	O
well	9	O
as	5	O
interstitial	9	B-Disease
fibrosis	9	I-Disease
,	9	O
accompanied	9	O
by	9	O
elevated	9	O
levels	3	O
of	5	O
serum	9	O
creatinine	0	B-Chemical
and	5	O
urine	9	O
protein	1	O
.	9	O

Renal	9	O
angiotensin	9	B-Chemical
II	9	I-Chemical
receptor	3	O
type	9	O
2	9	O
(	9	O
AT2R	3	O
)	9	O
gene	1	O
expression	3	O
in	5	O
adult	9	O
offspring	9	O
was	9	O
reduced	9	O
by	9	O
PCE	9	O
,	9	O
whereas	9	O
the	5	O
renal	9	O
angiotensin	9	B-Chemical
II	9	I-Chemical
receptor	3	O
type	9	O
1a	9	O
(	9	O
AT1aR	3	O
)	9	O
/	9	O
AT2R	3	O
expression	3	O
ratio	9	O
was	9	O
increased	9	O
.	9	O

The	5	O
fetal	9	O
kidneys	9	O
in	5	O
the	5	O
PCE	9	O
group	9	O
displayed	9	O
an	5	O
enlarged	9	O
Bowman	6	O
'	9	O
s	9	O
space	5	O
and	5	O
a	5	O
shrunken	5	O
glomerular	5	O
tuft	4	O
,	9	O
accompanied	9	O
by	9	O
a	5	O
reduced	9	O
cortex	5	O
width	5	O
and	5	O
an	5	O
increase	9	O
in	5	O
the	5	O
nephrogenic	5	O
zone	9	O
/	9	O
cortical	5	O
zone	9	O
ratio	9	O
.	9	O

Observation	5	O
by	9	O
electronic	5	O
microscope	0	O
revealed	9	O
structural	9	O
damage	9	O
of	5	O
podocytes	3	O
;	9	O
the	5	O
reduced	9	O
expression	3	O
level	9	O
of	5	O
podocyte	3	O
marker	3	O
genes	1	O
,	9	O
nephrin	3	O
and	5	O
podocin	3	O
,	9	O
was	9	O
also	9	O
detected	9	O
by	9	O
q	9	O
-	7	O
PCR	9	O
.	9	O

Moreover	9	O
,	9	O
AT2R	3	O
gene	1	O
and	5	O
protein	1	O
expressions	9	O
in	5	O
fetal	9	O
kidneys	9	O
were	9	O
inhibited	3	O
by	9	O
PCE	9	O
,	9	O
associated	9	O
with	5	O
the	5	O
repression	1	O
of	5	O
the	5	O
gene	1	O
expression	3	O
of	5	O
glial	3	O
-	7	O
cell	3	O
-	7	O
line	9	O
-	7	O
derived	9	O
neurotrophic	3	O
factor	9	O
(	9	O
GDNF	3	O
)	9	O
/	9	O
tyrosine	3	B-Chemical
kinase	3	O
receptor	3	O
(	9	O
c	9	O
-	7	O
Ret	3	O
)	9	O
signaling	3	O
pathway	3	O
.	9	O

These	5	O
results	9	O
demonstrated	9	O
that	5	O
PCE	9	O
could	9	O
induce	3	O
dysplasia	5	B-Disease
of	5	I-Disease
fetal	9	I-Disease
kidneys	9	I-Disease
as	5	O
well	9	O
as	5	O
glomerulosclerosis	3	B-Disease
of	5	O
adult	9	O
offspring	9	O
,	9	O
and	5	O
the	5	O
low	9	O
functional	9	O
programming	5	O
of	5	O
renal	9	O
AT2R	3	O
might	9	O
mediate	3	O
the	5	O
developmental	9	O
origin	9	O
of	5	O
adult	9	O
glomerulosclerosis	3	B-Disease
.	9	O

1	9	B-Chemical
,	9	I-Chemical
3	9	I-Chemical
-	7	I-Chemical
Butadiene	0	I-Chemical
,	9	O
CML	3	B-Disease
and	5	O
the	5	O
t	5	O
(	9	O
9	7	O
:	9	O
22	7	O
)	9	O
translocation	3	O
:	9	O
A	9	O
reality	5	O
check	5	O
.	9	O

UNASSIGNED	_	O
:	9	O
Epidemiological	5	O
studies	9	O
of	5	O
1	9	B-Chemical
,	9	I-Chemical
3	9	I-Chemical
-	7	I-Chemical
butadiene	0	I-Chemical
have	5	O
suggest	9	O
that	5	O
exposures	5	O
to	5	O
humans	9	O
are	5	O
associated	9	O
with	5	O
chronic	5	B-Disease
myeloid	3	I-Disease
leukemia	3	I-Disease
(	9	O
CML	3	B-Disease
)	9	O
.	9	O

CML	3	B-Disease
has	9	O
a	5	O
well	9	O
-	7	O
documented	9	O
association	9	O
with	5	O
ionizing	3	O
radiation	9	O
,	9	O
but	9	O
reports	9	O
of	5	O
associations	5	O
with	5	O
chemical	0	O
exposures	5	O
have	5	O
been	9	O
questioned	5	O
.	9	O

Ionizing	3	O
radiation	9	O
is	5	O
capable	9	O
of	5	O
inducing	3	O
the	5	O
requisite	5	O
CML	3	B-Disease
-	7	O
associated	9	O
t	5	O
(	9	O
9	7	O
:	9	O
22	7	O
)	9	O
translocation	3	O
(	9	O
Philadelphia	2	B-Disease
chromosome	1	I-Disease
)	9	O
in	5	O
appropriate	5	O
cells	3	O
in	5	O
vitro	3	O
but	9	O
,	9	O
thus	9	O
far	5	O
,	9	O
chemicals	0	O
have	5	O
not	5	O
shown	9	O
this	5	O
capacity	9	O
.	9	O

We	9	O
have	5	O
proposed	5	O
that	5	O
1	9	B-Chemical
,	9	I-Chemical
3	9	I-Chemical
-	7	I-Chemical
butadiene	0	I-Chemical
metabolites	0	O
be	5	O
so	5	O
tested	9	O
as	5	O
a	5	O
reality	5	O
check	5	O
on	5	O
the	5	O
epidemiological	5	O
reports	9	O
.	9	O

In	9	O
order	5	O
to	5	O
conduct	5	O
reliable	5	O
testing	5	O
in	5	O
this	5	O
regard	5	O
,	9	O
it	5	O
is	5	O
essential	9	O
that	5	O
a	5	O
positive	9	O
control	9	O
for	5	O
induction	3	O
be	5	O
available	5	O
.	9	O

We	9	O
have	5	O
used	5	O
ionizing	3	O
radiation	9	O
to	5	O
develop	5	O
such	5	O
a	5	O
control	9	O
.	9	O

Results	9	O
described	9	O
here	5	O
demonstrate	9	O
that	5	O
this	5	O
agent	9	O
does	9	O
in	5	O
fact	9	O
induce	3	O
pathogenic	9	O
t	5	O
(	9	O
9	7	O
:	9	O
22	7	O
)	9	O
translocations	9	O
in	5	O
a	5	O
human	3	O
myeloid	3	O
cell	3	O
line	9	O
in	5	O
vitro	3	O
,	9	O
but	9	O
does	9	O
so	5	O
at	9	O
low	9	O
frequencies	9	O
.	9	O

Conditions	9	O
that	5	O
will	5	O
be	5	O
required	9	O
for	5	O
studies	9	O
of	5	O
1	9	B-Chemical
,	9	I-Chemical
3	9	I-Chemical
-	7	I-Chemical
butadiene	0	I-Chemical
are	5	O
discussed	5	O
.	9	O

Cancer	2	B-Disease
incidence	5	O
and	5	O
metolachlor	0	B-Chemical
use	5	O
in	5	O
the	5	O
Agricultural	2	O
Health	2	O
Study	5	O
:	9	O
An	5	O
update	5	O
.	9	O

UNASSIGNED	_	O
:	9	O
Metolachlor	7	B-Chemical
,	9	O
a	5	O
widely	5	O
used	5	O
herbicide	0	O
,	9	O
is	5	O
classified	5	O
as	5	O
a	5	O
Group	9	O
C	9	O
carcinogen	0	O
by	9	O
the	5	O
U	9	O
.	9	O
S	9	O
.	9	O

Environmental	2	O
Protection	2	O
Agency	2	O
based	5	O
on	5	O
increased	9	O
liver	9	B-Disease
neoplasms	5	I-Disease
in	5	O
female	9	O
rats	9	O
.	9	O

Epidemiologic	5	O
studies	9	O
of	5	O
the	5	O
health	5	O
effects	9	O
of	5	O
metolachlor	0	B-Chemical
have	5	O
been	9	O
limited	5	O
.	9	O

The	5	O
Agricultural	2	O
Health	2	O
Study	5	O
(	9	O
AHS	5	O
)	9	O
is	5	O
a	5	O
prospective	5	O
cohort	9	O
study	9	O
including	9	O
licensed	5	O
private	5	O
and	5	O
commercial	5	O
pesticide	5	O
applicators	5	O
in	5	O
Iowa	2	O
and	5	O
North	4	O
Carolina	2	O
enrolled	5	O
1993	2	O
-	7	O
1997	2	O
.	9	O

We	9	O
evaluated	9	O
cancer	3	B-Disease
incidence	5	O
through	9	O
2010	2	O
/	9	O
2011	2	O
(	9	O
NC	9	O
/	9	O
IA	9	O
)	9	O
for	5	O
49	7	O
,	9	O
616	7	O
applicators	5	O
,	9	O
53	7	O
%	9	O
of	5	O
whom	5	O
reported	9	O
ever	5	O
using	9	O
metolachlor	0	B-Chemical
.	9	O

We	9	O
used	5	O
Poisson	5	O
regression	5	O
to	5	O
evaluate	9	O
relations	5	O
between	5	O
two	5	O
metrics	5	O
of	5	O
metolachlor	0	B-Chemical
use	5	O
(	9	O
lifetime	5	O
days	9	O
,	9	O
intensity	5	O
-	7	O
weighted	5	O
lifetime	5	O
days	9	O
)	9	O
and	5	O
cancer	3	B-Disease
incidence	5	O
.	9	O

We	9	O
saw	5	O
no	9	O
association	9	O
between	5	O
metolachlor	0	B-Chemical
use	5	O
and	5	O
incidence	5	O
of	5	O
all	5	O
cancers	9	B-Disease
combined	9	O
(	9	O
n	9	O
=	7	O
5	9	O
,	9	O
701	7	O
with	5	O
a	5	O
5	9	O
-	7	O
year	5	O
lag	5	O
)	9	O
or	5	O
most	9	O
site	9	O
-	7	O
specific	9	O
cancers	9	B-Disease
.	9	O

For	9	O
liver	9	B-Disease
cancer	3	I-Disease
,	9	O
in	5	O
analyses	9	O
restricted	9	O
to	5	O
exposed	9	O
workers	5	O
,	9	O
elevations	9	O
observed	9	O
at	9	O
higher	9	O
categories	5	O
of	5	O
use	5	O
were	9	O
not	5	O
statistically	9	O
significant	9	O
.	9	O

However	9	O
,	9	O
trends	5	O
for	5	O
both	9	O
lifetime	5	O
and	5	O
intensity	5	O
-	7	O
weighted	5	O
lifetime	5	O
days	9	O
of	5	O
metolachor	_	B-Chemical
use	5	O
were	9	O
positive	9	O
and	5	O
statistically	9	O
significant	9	O
with	5	O
an	5	O
unexposed	9	O
reference	9	O
group	9	O
.	9	O

A	9	O
similar	9	O
pattern	9	O
was	9	O
observed	9	O
for	5	O
follicular	9	B-Disease
cell	3	I-Disease
lymphoma	9	I-Disease
,	9	O
but	9	O
no	9	O
other	5	O
lymphoma	9	B-Disease
subtypes	9	O
.	9	O

An	5	O
earlier	9	O
suggestion	9	O
of	5	O
increased	9	O
lung	9	B-Disease
cancer	3	I-Disease
risk	5	O
at	9	O
high	9	O
levels	3	O
of	5	O
metolachlor	0	B-Chemical
use	5	O
in	5	O
this	5	O
cohort	9	O
was	9	O
not	5	O
confirmed	9	O
in	5	O
this	5	O
update	5	O
.	9	O

This	5	O
suggestion	9	O
of	5	O
an	5	O
association	9	O
between	5	O
metolachlor	0	B-Chemical
and	5	O
liver	9	B-Disease
cancer	3	I-Disease
among	5	O
pesticide	5	O
applicators	5	O
is	5	O
a	5	O
novel	9	O
finding	9	O
and	5	O
echoes	5	O
observation	9	O
of	5	O
increased	9	O
liver	9	B-Disease
neoplasms	5	I-Disease
in	5	O
some	5	O
animal	5	O
studies	9	O
.	9	O

However	9	O
,	9	O
our	5	O
findings	9	O
for	5	O
both	9	O
liver	9	B-Disease
cancer	3	I-Disease
and	5	O
follicular	9	O
cell	3	O
lymphoma	9	B-Disease
warrant	9	O
follow	5	O
-	7	O
up	5	O
to	5	O
better	5	O
differentiate	9	O
effects	9	O
of	5	O
metolachlor	0	B-Chemical
use	5	O
from	9	O
other	5	O
factors	9	O
.	9	O

Mechanisms	9	O
Underlying	5	O
Latent	5	O
Disease	2	O
Risk	5	O
Associated	9	O
with	5	O
Early	9	O
-	7	O
Life	2	O
Arsenic	0	B-Chemical
Exposure	9	O
:	9	O
Current	9	O
Research	2	O
Trends	5	O
and	5	O
Scientific	0	O
Gaps	5	O
.	9	O

BACKGROUND	2	O
:	9	O
Millions	5	O
of	5	O
individuals	5	O
worldwide	5	O
,	9	O
particularly	5	O
those	5	O
living	5	O
in	5	O
rural	5	O
and	5	O
developing	5	O
areas	5	O
,	9	O
are	5	O
exposed	9	O
to	5	O
harmful	5	O
levels	3	O
of	5	O
inorganic	0	B-Chemical
arsenic	0	I-Chemical
(	9	O
iAs	5	B-Chemical
)	9	O
in	5	O
their	5	O
drinking	5	O
water	0	O
.	9	O

Inorganic	0	B-Chemical
As	9	I-Chemical
exposure	9	O
during	5	O
key	9	O
developmental	9	O
periods	5	O
is	5	O
associated	9	O
with	5	O
a	5	O
variety	5	O
of	5	O
adverse	5	O
health	5	O
effects	9	O
including	9	O
those	5	O
that	5	O
are	5	O
evident	9	O
in	5	O
adulthood	5	O
.	9	O

There	5	O
is	5	O
considerable	5	O
interest	5	O
in	5	O
identifying	5	O
the	5	O
molecular	9	O
mechanisms	9	O
that	5	O
relate	5	O
early	9	O
-	7	O
life	5	O
iAs	5	B-Chemical
exposure	9	O
to	5	O
the	5	O
development	9	O
of	5	O
these	5	O
latent	5	O
diseases	5	O
,	9	O
particularly	5	O
in	5	O
relationship	5	O
to	5	O
cancer	3	B-Disease
.	9	O

OBJECTIVES	2	O
:	9	O
This	5	O
work	5	O
summarizes	5	O
research	5	O
on	5	O
the	5	O
molecular	9	O
mechanisms	9	O
that	5	O
underlie	5	O
the	5	O
increased	9	O
risk	5	O
of	5	O
cancer	3	B-Disease
development	9	O
in	5	O
adulthood	5	O
that	5	O
is	5	O
associated	9	O
with	5	O
early	9	O
-	7	O
life	5	O
iAs	5	B-Chemical
exposure	9	O
.	9	O

DISCUSSION	9	O
:	9	O
Epigenetic	5	O
reprogramming	3	O
that	5	O
imparts	9	O
functional	9	O
changes	9	O
in	5	O
gene	1	O
expression	3	O
,	9	O
the	5	O
development	9	O
of	5	O
cancer	3	B-Disease
stem	3	O
cells	3	O
,	9	O
and	5	O
immunomodulation	3	O
are	5	O
plausible	5	O
underlying	5	O
mechanisms	9	O
by	9	O
which	5	O
early	9	O
-	7	O
life	5	O
iAs	5	B-Chemical
exposure	9	O
elicits	9	O
latent	5	O
carcinogenic	0	O
effects	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Evidence	9	O
is	5	O
mounting	9	O
that	5	O
relates	5	O
early	9	O
-	7	O
life	5	O
iAs	5	B-Chemical
exposure	9	O
and	5	O
cancer	3	B-Disease
development	9	O
later	9	O
in	5	O
life	5	O
.	9	O

Future	5	O
research	5	O
should	5	O
include	5	O
animal	5	O
studies	9	O
that	5	O
address	5	O
mechanistic	9	O
hypotheses	5	O
and	5	O
studies	9	O
of	5	O
human	3	O
populations	9	O
that	5	O
integrate	5	O
early	9	O
-	7	O
life	5	O
exposure	9	O
,	9	O
molecular	9	O
alterations	9	O
,	9	O
and	5	O
latent	5	O
disease	5	O
outcomes	5	O
.	9	O

Nifedipine	0	B-Chemical
induced	3	O
bradycardia	5	B-Disease
in	5	O
a	5	O
patient	5	O
with	5	O
autonomic	5	B-Disease
neuropathy	5	I-Disease
.	9	O

An	5	O
80	9	O
year	5	O
old	5	O
diabetic	9	B-Disease
male	9	O
with	5	O
evidence	9	O
of	5	O
peripheral	9	B-Disease
and	5	I-Disease
autonomic	5	I-Disease
neuropathy	5	I-Disease
was	9	O
admitted	5	O
with	5	O
chest	5	B-Disease
pain	5	I-Disease
.	9	O

He	5	O
was	9	O
found	9	O
to	5	O
have	5	O
atrial	5	B-Disease
flutter	5	I-Disease
at	9	O
a	5	O
ventricular	5	O
rate	9	O
of	5	O
70	9	O
/	9	O
min	0	O
which	5	O
slowed	9	O
down	9	O
to	5	O
30	9	O
-	7	O
40	9	O
/	9	O
min	0	O
when	5	O
nifedipine	0	B-Chemical
(	9	O
60	9	O
mg	0	O
)	9	O
in	5	O
3	9	O
divided	5	O
doses	0	O
,	9	O
during	5	O
which	5	O
he	5	O
was	9	O
paced	5	O
at	9	O
a	5	O
rate	9	O
of	5	O
70	9	O
/	9	O
min	0	O
.	9	O

This	5	O
is	5	O
inconsistent	5	O
with	5	O
the	5	O
well	9	O
-	7	O
established	9	O
finding	9	O
that	5	O
nifedipine	0	B-Chemical
induces	3	O
tachycardia	5	B-Disease
in	5	O
normally	9	O
innervated	5	O
hearts	3	O
.	9	O

However	9	O
,	9	O
in	5	O
hearts	3	O
deprived	9	O
of	5	O
compensatory	5	O
sympathetic	5	O
drive	5	O
,	9	O
it	5	O
may	5	O
lead	5	O
to	5	O
bradycardia	5	B-Disease
.	9	O

The	5	O
effect	9	O
of	5	O
haloperidol	5	B-Chemical
in	5	O
cocaine	5	B-Chemical
and	5	O
amphetamine	5	B-Chemical
intoxication	9	O
.	9	O

The	5	O
effectiveness	5	O
of	5	O
haloperidol	5	B-Chemical
pretreatment	0	O
in	5	O
preventing	9	O
the	5	O
toxic	0	O
effects	9	O
of	5	O
high	9	O
doses	0	O
of	5	O
amphetamine	5	B-Chemical
and	5	O
cocaine	5	B-Chemical
was	9	O
studied	9	O
in	5	O
rats	9	O
.	9	O

In	9	O
this	5	O
model	5	O
,	9	O
toxic	0	O
effects	9	O
were	9	O
induced	3	O
by	9	O
intraperitoneal	0	O
(	9	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
injection	9	O
of	5	O
amphetamine	5	B-Chemical
75	9	O
mg	0	O
/	9	O
kg	0	O
(	9	O
100	0	O
%	9	O
death	9	O
rate	9	O
)	9	O
or	5	O
cocaine	5	B-Chemical
70	9	O
mg	0	O
/	9	O
kg	0	O
(	9	O
82	7	O
%	9	O
death	9	O
rate	9	O
)	9	O
.	9	O

Haloperidol	7	B-Chemical
failed	9	O
to	5	O
prevent	5	O
amphetamine	5	B-Chemical
-	7	O
induced	3	O
seizures	5	B-Disease
,	9	O
but	9	O
did	9	O
lower	9	O
the	5	O
mortality	5	O
rate	9	O
at	9	O
most	9	O
doses	0	O
tested	9	O
.	9	O

Haloperidol	7	B-Chemical
decreased	9	O
the	5	O
incidence	5	O
of	5	O
cocaine	5	B-Chemical
-	7	O
induced	3	O
seizures	5	B-Disease
at	9	O
the	5	O
two	5	O
highest	9	O
doses	0	O
,	9	O
but	9	O
the	5	O
lowering	9	O
of	5	O
the	5	O
mortality	5	O
rate	9	O
did	9	O
not	5	O
reach	5	O
statistical	5	O
significance	9	O
at	9	O
any	5	O
dose	9	O
.	9	O

These	5	O
data	5	O
suggest	9	O
a	5	O
protective	9	O
role	9	O
for	5	O
the	5	O
central	5	O
dopamine	5	B-Chemical
blocker	0	O
haloperidol	5	B-Chemical
against	9	O
death	9	O
from	9	O
high	9	O
-	7	O
dose	9	O
amphetamine	5	B-Chemical
exposure	9	O
without	9	O
reducing	9	O
the	5	O
incidence	5	O
of	5	O
seizures	5	B-Disease
.	9	O

In	9	O
contrast	9	O
,	9	O
haloperidol	5	B-Chemical
demonstrated	9	O
an	5	O
ability	9	O
to	5	O
reduce	5	O
cocaine	5	B-Chemical
-	7	O
induced	3	O
seizures	5	B-Disease
without	9	O
significantly	9	O
reducing	9	O
mortality	5	O
.	9	O

Autoradiographic	0	O
evidence	9	O
of	5	O
estrogen	3	B-Chemical
binding	1	O
sites	9	O
in	5	O
nuclei	3	O
of	5	O
diethylstilbesterol	0	B-Chemical
induced	3	O
hamster	3	O
renal	9	B-Disease
carcinomas	3	I-Disease
.	9	O

Estrogen	9	B-Chemical
binding	1	O
sites	9	O
were	9	O
demonstrated	9	O
by	9	O
autoradiography	0	O
in	5	O
one	5	O
transplantable	3	O
and	5	O
five	9	O
primary	9	O
diethylstilbesterol	0	B-Chemical
induced	3	O
renal	9	B-Disease
carcinomas	3	I-Disease
in	5	O
three	9	O
hamsters	9	O
.	9	O

Radiolabelling	0	O
,	9	O
following	9	O
the	5	O
in	5	O
vivo	3	O
injection	9	O
of	5	O
3H	0	O
-	7	O
17	7	O
beta	9	O
estradiol	0	B-Chemical
,	9	O
was	9	O
increased	9	O
only	9	O
over	5	O
the	5	O
nuclei	3	O
of	5	O
tumor	3	B-Disease
cells	3	O
;	9	O
stereologic	5	O
analysis	9	O
revealed	9	O
a	5	O
4	9	O
.	9	O
5	9	O
-	7	O
to	5	O
6	9	O
.	9	O
7	9	O
-	7	O
times	5	O
higher	9	O
concentration	0	O
of	5	O
reduced	9	O
silver	0	B-Chemical
grains	0	O
over	5	O
nuclei	3	O
than	5	O
cytoplasm	3	O
of	5	O
these	5	O
cells	3	O
.	9	O

Despite	5	O
rapid	5	O
tubular	9	O
excretion	0	O
of	5	O
estradiol	0	B-Chemical
which	5	O
peaked	9	O
in	5	O
less	5	O
than	5	O
1	9	O
h	0	O
,	9	O
the	5	O
normal	9	O
cells	3	O
did	9	O
not	5	O
appear	9	O
to	5	O
bind	1	O
the	5	O
ligand	3	O
.	9	O

This	5	O
is	5	O
the	5	O
first	9	O
published	9	O
report	5	O
documenting	5	O
the	5	O
preferential	9	O
in	5	O
vivo	3	O
binding	1	O
of	5	O
estrogen	3	B-Chemical
to	5	O
nuclei	3	O
of	5	O
cells	3	O
in	5	O
estrogen	3	B-Chemical
induced	3	O
hamster	3	O
renal	9	B-Disease
carcinomas	3	I-Disease
.	9	O

Bradycardia	7	B-Disease
due	5	O
to	5	O
biperiden	5	B-Chemical
.	9	O

In	9	O
a	5	O
38	7	O
-	7	O
year	5	O
-	7	O
old	5	O
male	9	O
patient	5	O
suffering	5	O
from	9	O
a	5	O
severe	5	O
postzosteric	_	B-Disease
trigeminal	5	B-Disease
neuralgia	5	I-Disease
,	9	O
intravenous	0	O
application	5	O
of	5	O
10	9	O
mg	0	O
biperiden	5	B-Chemical
lactate	0	I-Chemical
led	9	O
to	5	O
a	5	O
long	5	O
-	7	O
lasting	5	O
paradoxical	5	O
reaction	9	O
characterized	9	O
by	9	O
considerable	5	O
bradycardia	5	B-Disease
,	9	O
dysarthria	5	B-Disease
,	9	O
and	5	O
dysphagia	5	B-Disease
.	9	O

The	5	O
heart	5	O
rate	9	O
was	9	O
back	5	O
to	5	O
normal	9	O
within	9	O
12	9	O
hours	9	O
upon	9	O
administration	9	O
of	5	O
orciprenaline	0	B-Chemical
under	9	O
cardiac	5	O
monitoring	5	O
in	5	O
an	5	O
intensive	5	O
care	5	O
unit	5	O
.	9	O

Bradycardia	7	B-Disease
induced	3	O
by	9	O
biperiden	5	B-Chemical
is	5	O
attributed	9	O
to	5	O
the	5	O
speed	5	O
of	5	O
injection	9	O
and	5	O
to	5	O
a	5	O
dose	9	O
-	7	O
related	9	O
dual	9	O
effect	9	O
of	5	O
atropine	0	B-Chemical
-	7	O
like	9	O
drugs	5	O
on	5	O
muscarine	0	B-Chemical
receptors	3	O
.	9	O

Deliberate	5	O
hypotension	5	B-Disease
induced	3	O
by	9	O
labetalol	0	B-Chemical
with	5	O
halothane	0	B-Chemical
,	9	O
enflurane	0	B-Chemical
or	5	O
isoflurane	0	B-Chemical
for	5	O
middle	9	O
-	7	O
ear	5	O
surgery	5	O
.	9	O

The	5	O
feasibility	5	O
of	5	O
using	9	O
labetalol	0	B-Chemical
,	9	O
an	5	O
alpha	9	O
-	7	O
and	5	O
beta	9	O
-	7	O
adrenergic	9	O
blocking	3	O
agent	9	O
,	9	O
as	5	O
a	5	O
hypotensive	5	B-Disease
agent	9	O
in	5	O
combination	9	O
with	5	O
inhalation	5	O
anaesthetics	5	O
(	9	O
halothane	0	B-Chemical
,	9	O
enflurane	0	B-Chemical
or	5	O
isoflurane	0	B-Chemical
)	9	O
was	9	O
studied	9	O
in	5	O
23	7	O
adult	9	O
patients	5	O
undergoing	9	O
middle	9	O
-	7	O
ear	5	O
surgery	5	O
.	9	O

The	5	O
mean	5	O
arterial	5	O
pressure	5	O
was	9	O
decreased	9	O
from	9	O
86	7	O
+	9	O
/	9	O
-	7	O
5	9	O
(	9	O
s	9	O
.	9	O
e	9	O
.	9	O
mean	5	O
)	9	O
mmHg	7	O
to	5	O
52	7	O
+	9	O
/	9	O
-	7	O
1	9	O
mmHg	7	O
(	9	O
11	7	O
.	9	O
5	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
7	9	O
to	5	O
6	9	O
.	9	O
9	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
1	9	O
kPa	0	O
)	9	O
for	5	O
98	7	O
+	9	O
/	9	O
-	7	O
10	9	O
min	0	O
in	5	O
the	5	O
halothane	0	B-Chemical
(	9	O
H	9	B-Chemical
)	9	O
group	9	O
,	9	O
from	9	O
79	7	O
+	9	O
/	9	O
-	7	O
5	9	O
to	5	O
53	7	O
+	9	O
/	9	O
-	7	O
1	9	O
mmHg	7	O
(	9	O
10	9	O
.	9	O
5	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
7	9	O
to	5	O
7	9	O
.	9	O
1	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
1	9	O
kPa	0	O
)	9	O
for	5	O
129	9	O
+	9	O
/	9	O
-	7	O
11	7	O
min	0	O
in	5	O
the	5	O
enflurane	0	B-Chemical
(	9	O
E	9	B-Chemical
)	9	O
group	9	O
,	9	O
and	5	O
from	9	O
80	9	O
+	9	O
/	9	O
-	7	O
4	9	O
to	5	O
49	7	O
+	9	O
/	9	O
-	7	O
1	9	O
mmHg	7	O
(	9	O
10	9	O
.	9	O
7	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
5	9	O
to	5	O
6	9	O
.	9	O
5	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
1	9	O
kPa	0	O
)	9	O
for	5	O
135	7	O
+	9	O
/	9	O
-	7	O
15	9	O
min	0	O
in	5	O
the	5	O
isoflurane	0	B-Chemical
(	9	O
I	9	B-Chemical
)	9	O
group	9	O
.	9	O

The	5	O
mean	5	O
H	9	B-Chemical
concentration	0	O
during	5	O
hypotension	5	B-Disease
in	5	O
the	5	O
inspiratory	5	O
gas	0	O
was	9	O
0	7	O
.	9	O
7	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
1	9	O
vol	0	O
%	9	O
,	9	O
the	5	O
mean	5	O
E	9	B-Chemical
concentration	0	O
1	9	O
.	9	O
6	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
2	9	O
vol	0	O
%	9	O
,	9	O
and	5	O
the	5	O
mean	5	O
I	9	B-Chemical
concentration	0	O
1	9	O
.	9	O
0	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
1	9	O
vol	0	O
%	9	O
.	9	O

In	9	O
addition	9	O
,	9	O
the	5	O
patients	5	O
received	9	O
fentanyl	0	B-Chemical
and	5	O
d	9	B-Chemical
-	7	I-Chemical
tubocurarine	0	I-Chemical
.	9	O

The	5	O
initial	9	O
dose	9	O
of	5	O
labetalol	0	B-Chemical
for	5	O
lowering	9	O
blood	9	O
pressure	5	O
was	9	O
similar	9	O
,	9	O
0	7	O
.	9	O
52	7	O
-	7	O
0	7	O
.	9	O
59	7	O
mg	0	O
/	9	O
kg	0	O
,	9	O
in	5	O
all	5	O
the	5	O
groups	9	O
.	9	O

During	5	O
hypotension	5	B-Disease
,	9	O
the	5	O
heart	5	O
rate	9	O
was	9	O
stable	9	O
without	9	O
tachy	5	B-Disease
-	7	I-Disease
or	5	I-Disease
bradycardia	5	I-Disease
.	9	O

The	5	O
operating	5	O
conditions	9	O
regarding	5	O
bleeding	5	B-Disease
were	9	O
estimated	5	O
in	5	O
a	5	O
double	9	O
-	7	O
blind	5	O
manner	9	O
,	9	O
and	5	O
did	9	O
not	5	O
differ	9	O
significantly	9	O
between	5	O
the	5	O
groups	9	O
.	9	O

During	5	O
hypotension	5	B-Disease
,	9	O
the	5	O
serum	9	O
creatinine	0	B-Chemical
concentration	0	O
rose	9	O
significantly	9	O
in	5	O
all	5	O
groups	9	O
from	9	O
the	5	O
values	5	O
before	9	O
hypotension	5	B-Disease
and	5	O
returned	5	O
postoperatively	5	O
to	5	O
the	5	O
initial	9	O
level	9	O
in	5	O
the	5	O
other	5	O
groups	9	O
,	9	O
except	9	O
the	5	O
isoflurane	0	B-Chemical
group	9	O
.	9	O

After	9	O
hypotension	5	B-Disease
there	5	O
was	9	O
no	9	O
rebound	5	O
phenomenon	5	O
in	5	O
either	9	O
blood	9	O
pressure	5	O
or	5	O
heart	5	O
rate	9	O
.	9	O

These	5	O
results	9	O
indicate	9	O
that	5	O
labetalol	0	B-Chemical
induces	3	O
easily	5	O
adjustable	5	O
hypotension	5	B-Disease
without	9	O
compensatory	5	O
tachycardia	5	B-Disease
and	5	O
rebound	5	O
hypertension	5	B-Disease
.	9	O

Convulsion	7	B-Disease
following	9	O
intravenous	0	O
fluorescein	0	B-Chemical
angiography	5	O
.	9	O

Tonic	5	B-Disease
-	7	I-Disease
clonic	5	I-Disease
seizures	5	I-Disease
followed	9	O
intravenous	0	O
fluorescein	0	B-Chemical
injection	9	O
for	5	O
fundus	5	O
angiography	5	O
in	5	O
a	5	O
47	7	O
-	7	O
year	5	O
-	7	O
old	5	O
male	9	O
.	9	O

Despite	5	O
precautions	5	O
this	5	O
adverse	5	O
reaction	9	O
recurred	5	O
on	5	O
re	5	O
-	7	O
exposure	9	O
to	5	O
intravenous	0	O
fluorescein	0	B-Chemical
.	9	O

Pharmacology	2	O
of	5	O
ACC	9	B-Chemical
-	7	I-Chemical
9653	7	I-Chemical
(	9	O
phenytoin	0	B-Chemical
prodrug	0	O
)	9	O
.	9	O

ACC	9	B-Chemical
-	7	I-Chemical
9653	7	I-Chemical
,	9	O
the	5	O
disodium	0	B-Chemical
phosphate	0	I-Chemical
ester	0	I-Chemical
of	5	O
3	9	B-Chemical
-	7	I-Chemical
hydroxymethyl	0	I-Chemical
-	7	I-Chemical
5	9	I-Chemical
,	9	I-Chemical
5	9	I-Chemical
-	7	I-Chemical
diphenylhydantoin	0	I-Chemical
,	9	O
is	5	O
a	5	O
prodrug	0	O
of	5	O
phenytoin	0	B-Chemical
with	5	O
advantageous	5	O
physicochemical	0	O
properties	9	O
.	9	O

ACC	9	B-Chemical
-	7	I-Chemical
9653	7	I-Chemical
is	5	O
rapidly	9	O
converted	9	O
enzymatically	0	O
to	5	O
phenytoin	0	B-Chemical
in	5	O
vivo	3	O
.	9	O

ACC	9	B-Chemical
-	7	I-Chemical
9653	7	I-Chemical
and	5	O
phenytoin	0	B-Chemical
sodium	0	I-Chemical
have	5	O
equivalent	9	O
anticonvulsant	5	O
activity	9	O
against	9	O
seizures	5	B-Disease
induced	3	O
by	9	O
maximal	9	O
electroshock	5	O
(	9	O
MES	0	O
)	9	O
in	5	O
mice	3	O
following	9	O
i	9	O
.	9	O
p	7	O
.	9	O
,	9	O
oral	9	O
,	9	O
or	5	O
i	9	O
.	9	O
v	0	O
.	9	O
administration	9	O
.	9	O

The	5	O
ED50	0	O
doses	0	O
were	9	O
16	9	O
mg	0	O
/	9	O
kg	0	O
for	5	O
i	9	O
.	9	O
v	0	O
.	9	O
ACC	9	B-Chemical
-	7	I-Chemical
9653	7	I-Chemical
and	5	O
8	9	O
mg	0	O
/	9	O
kg	0	O
for	5	O
i	9	O
.	9	O
v	0	O
.	9	O
phenytoin	0	B-Chemical
sodium	0	I-Chemical
.	9	O

ACC	9	B-Chemical
-	7	I-Chemical
9653	7	I-Chemical
and	5	O
phenytoin	0	B-Chemical
sodium	0	I-Chemical
have	5	O
similar	9	O
antiarrhythmic	5	O
activity	9	O
against	9	O
ouabain	0	B-Chemical
-	7	O
induced	3	O
ventricular	5	B-Disease
tachycardia	5	I-Disease
in	5	O
anesthetized	0	O
dogs	5	O
.	9	O

The	5	O
total	9	O
doses	0	O
of	5	O
ACC	9	B-Chemical
-	7	I-Chemical
9653	7	I-Chemical
or	5	O
phenytoin	0	B-Chemical
sodium	0	I-Chemical
necessary	5	O
to	5	O
convert	9	O
the	5	O
arrhythmia	5	B-Disease
to	5	O
a	5	O
normal	9	O
sinus	5	O
rhythm	5	O
were	9	O
24	9	O
+	9	O
/	9	O
-	7	O
6	9	O
and	5	O
14	7	O
+	9	O
/	9	O
-	7	O
3	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
respectively	9	O
.	9	O

Only	9	O
phenytoin	0	B-Chemical
sodium	0	I-Chemical
displayed	9	O
in	5	O
vitro	3	O
antiarrhythmic	5	O
activity	9	O
against	9	O
strophanthidin	0	B-Chemical
-	7	O
induced	3	O
arrhythmias	5	B-Disease
in	5	O
guinea	9	O
pig	9	O
right	5	O
atria	9	O
.	9	O

In	9	O
anesthetized	0	O
dogs	5	O
,	9	O
a	5	O
high	9	O
dose	9	O
of	5	O
ACC	9	B-Chemical
-	7	I-Chemical
9653	7	I-Chemical
(	9	O
31	7	O
mg	0	O
/	9	O
kg	0	O
)	9	O
was	9	O
infused	9	O
over	5	O
15	9	O
,	9	O
20	9	O
,	9	O
and	5	O
30	9	O
min	0	O
and	5	O
the	5	O
responses	5	O
were	9	O
compared	9	O
to	5	O
an	5	O
equimolar	0	O
dose	9	O
of	5	O
phenytoin	0	B-Chemical
sodium	0	I-Chemical
(	9	O
21	7	O
mg	0	O
/	9	O
kg	0	O
)	9	O
.	9	O

The	5	O
ACC	9	B-Chemical
-	7	I-Chemical
9653	7	I-Chemical
and	5	O
phenytoin	0	B-Chemical
sodium	0	I-Chemical
treatments	9	O
produced	9	O
similar	9	O
marked	9	O
reductions	9	O
in	5	O
diastolic	5	O
blood	9	O
pressure	5	O
and	5	O
contractile	9	O
force	5	O
(	9	O
LVdP	7	O
/	9	O
dt	9	O
)	9	O
.	9	O

The	5	O
maximum	5	O
effects	9	O
of	5	O
each	5	O
treatment	9	O
occurred	9	O
at	9	O
the	5	O
time	5	O
of	5	O
maximum	5	O
phenytoin	0	B-Chemical
sodium	0	I-Chemical
levels	3	O
.	9	O

Acute	5	O
toxicity	9	B-Disease
studies	9	O
of	5	O
ACC	9	B-Chemical
-	7	I-Chemical
9653	7	I-Chemical
and	5	O
phenytoin	0	B-Chemical
sodium	0	I-Chemical
were	9	O
carried	9	O
out	9	O
in	5	O
mice	3	O
,	9	O
rats	9	O
,	9	O
rabbits	9	O
,	9	O
and	5	O
dogs	5	O
by	9	O
i	9	O
.	9	O
v	0	O
.	9	O
,	9	O
i	9	O
.	9	O
m	9	O
.	9	O
,	9	O
and	5	O
i	9	O
.	9	O
p	7	O
.	9	O
routes	5	O
of	5	O
administration	9	O
.	9	O

The	5	O
systemic	9	O
toxic	0	O
signs	5	O
of	5	O
both	9	O
agents	5	O
were	9	O
similar	9	O
and	5	O
occurred	9	O
at	9	O
approximately	9	O
equivalent	9	O
doses	0	O
.	9	O

Importantly	9	O
,	9	O
the	5	O
local	5	O
irritation	5	O
of	5	O
ACC	9	B-Chemical
-	7	I-Chemical
9653	7	I-Chemical
was	9	O
markedly	9	O
less	5	O
than	5	O
phenytoin	0	B-Chemical
sodium	0	I-Chemical
following	9	O
i	9	O
.	9	O
m	9	O
.	9	O
administration	9	O
.	9	O
(	9	O
ABSTRACT	2	O
TRUNCATED	2	O
AT	9	O
250	0	O
WORDS	3	O
)	9	O

Tachyphylaxis	5	O
to	5	O
systemic	9	O
but	9	O
not	5	O
to	5	O
airway	5	O
responses	5	O
during	5	O
prolonged	9	O
therapy	5	O
with	5	O
high	9	O
dose	9	O
inhaled	5	O
salbutamol	0	B-Chemical
in	5	O
asthmatics	9	B-Disease
.	9	O

High	9	O
doses	0	O
of	5	O
inhaled	5	O
salbutamol	0	B-Chemical
produce	9	O
substantial	9	O
improvements	5	O
in	5	O
airway	5	O
response	9	O
in	5	O
patients	5	O
with	5	O
asthma	5	B-Disease
,	9	O
and	5	O
are	5	O
associated	9	O
with	5	O
dose	9	O
-	7	O
dependent	9	O
systemic	9	O
beta	9	O
-	7	O
adrenoceptor	5	O
responses	5	O
.	9	O

The	5	O
purpose	5	O
of	5	O
the	5	O
present	9	O
study	9	O
was	9	O
to	5	O
investigate	9	O
whether	9	O
tachyphylaxis	5	O
occurs	9	O
during	5	O
prolonged	9	O
treatment	9	O
with	5	O
high	9	O
dose	9	O
inhaled	5	O
salbutamol	0	B-Chemical
.	9	O

Twelve	9	O
asthmatic	9	B-Disease
patients	5	O
(	9	O
FEV1	5	O
,	9	O
81	7	O
+	9	O
/	9	O
-	7	O
4	9	O
%	9	O
predicted	9	O
)	9	O
,	9	O
requiring	5	O
only	9	O
occasional	5	O
inhaled	5	O
beta	9	O
-	7	O
agonists	3	O
as	5	O
their	5	O
sole	9	O
therapy	5	O
,	9	O
were	9	O
given	5	O
a	5	O
14	7	O
-	7	O
day	9	O
treatment	9	O
with	5	O
high	9	O
dose	9	O
inhaled	5	O
salbutamol	0	B-Chemical
(	9	O
HDS	5	O
)	9	O
,	9	O
4	9	O
,	9	O
000	9	O
micrograms	0	O
daily	5	O
,	9	O
low	9	O
dose	9	O
inhaled	5	O
salbutamol	0	B-Chemical
(	9	O
LDS	9	O
)	9	O
,	9	O
800	0	O
micrograms	0	O
daily	5	O
,	9	O
or	5	O
placebo	9	O
(	9	O
PI	9	O
)	9	O
by	9	O
metered	5	O
-	7	O
dose	9	O
inhaler	5	O
in	5	O
a	5	O
double	9	O
-	7	O
blind	5	O
,	9	O
randomized	5	O
crossover	5	O
design	5	O
.	9	O

During	5	O
the	5	O
14	7	O
-	7	O
day	9	O
run	5	O
-	7	O
in	5	O
and	5	O
during	5	O
washout	0	O
periods	5	O
,	9	O
inhaled	5	O
beta	9	O
-	7	O
agonists	3	O
were	9	O
withheld	5	O
and	5	O
ipratropium	5	B-Chemical
bromide	0	I-Chemical
was	9	O
substituted	0	O
for	5	O
rescue	3	O
purposes	5	O
.	9	O

At	9	O
the	5	O
end	9	O
of	5	O
each	5	O
14	7	O
-	7	O
day	9	O
treatment	9	O
,	9	O
a	5	O
dose	9	O
-	7	O
response	9	O
curve	9	O
(	9	O
DRC	2	O
)	9	O
was	9	O
performed	9	O
,	9	O
and	5	O
airway	5	O
(	9	O
FEV1	5	O
,	9	O
FEF25	7	O
-	7	O
75	9	O
)	9	O
chronotropic	5	O
(	9	O
HR	9	O
)	9	O
,	9	O
tremor	5	B-Disease
,	9	O
and	5	O
metabolic	9	O
(	9	O
K	9	B-Chemical
,	9	O
Glu	0	B-Chemical
)	9	O
responses	5	O
were	9	O
measured	9	O
at	9	O
each	5	O
step	9	O
(	9	O
from	9	O
100	0	O
to	5	O
4	9	O
,	9	O
000	9	O
micrograms	0	O
)	9	O
.	9	O

Treatment	9	O
had	9	O
no	9	O
significant	9	O
effect	9	O
on	5	O
baseline	5	O
values	5	O
.	9	O

There	5	O
were	9	O
dose	9	O
-	7	O
dependent	9	O
increases	9	O
in	5	O
FEV1	5	O
and	5	O
FEF25	7	O
-	7	O
75	9	O
(	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
001	9	O
)	9	O
,	9	O
and	5	O
pretreatment	0	O
with	5	O
HDS	5	O
did	9	O
not	5	O
displace	9	O
the	5	O
DRC	2	O
to	5	O
the	5	O
right	5	O
.	9	O

DRC	2	O
for	5	O
HR	9	O
(	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
001	9	O
)	9	O
,	9	O
K	9	B-Chemical
(	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
001	9	O
)	9	O
,	9	O
and	5	O
Glu	0	B-Chemical
(	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
005	7	O
)	9	O
were	9	O
attenuated	3	O
after	9	O
treatment	9	O
with	5	O
HDS	5	O
compared	9	O
with	5	O
PI	9	O
.	9	O

There	5	O
were	9	O
also	9	O
differences	9	O
between	5	O
HDS	5	O
and	5	O
LDS	9	O
for	5	O
HR	9	O
(	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
001	9	O
)	9	O
and	5	O
Glu	0	B-Chemical
(	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
05	7	O
)	9	O
responses	5	O
.	9	O

Frequency	5	O
and	5	O
severity	5	O
of	5	O
subjective	5	O
adverse	5	O
effects	9	O
were	9	O
also	9	O
reduced	9	O
after	9	O
HDS	5	O
:	9	O
tremor	5	B-Disease
(	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
001	9	O
)	9	O
,	9	O
palpitations	5	B-Disease
(	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
001	9	O
)	9	O
.	9	O
(	9	O
ABSTRACT	2	O
TRUNCATED	2	O
AT	9	O
250	0	O
WORDS	3	O
)	9	O

Phenytoin	0	B-Chemical
induced	3	O
fatal	5	O
hepatic	9	B-Disease
injury	9	I-Disease
.	9	O

A	9	O
61	7	O
year	5	O
old	5	O
female	9	O
developed	5	O
fatal	5	O
hepatic	9	B-Disease
failure	5	I-Disease
after	9	O
phenytoin	0	B-Chemical
administration	9	O
.	9	O

A	9	O
typical	9	O
multisystem	5	O
clinical	5	O
pattern	9	O
precedes	9	O
the	5	O
manifestations	5	O
of	5	O
hepatic	9	B-Disease
injury	9	I-Disease
.	9	O

The	5	O
hematologic	5	O
,	9	O
biochemical	9	O
and	5	O
pathologic	5	O
features	5	O
indicate	9	O
a	5	O
mixed	9	O
hepatocellular	9	B-Disease
damage	9	I-Disease
due	5	O
to	5	O
drug	5	B-Disease
hypersensitivity	9	I-Disease
.	9	O

In	9	O
a	5	O
patient	5	O
receiving	9	O
phenytoin	0	B-Chemical
who	5	O
presents	5	O
a	5	O
viral	9	O
-	7	O
like	9	O
illness	5	O
,	9	O
early	9	O
recognition	5	O
and	5	O
discontinuation	5	O
of	5	O
the	5	O
drug	5	O
are	5	O
mandatory	5	O
.	9	O

Treatment	9	O
of	5	O
lethal	9	O
pertussis	9	B-Chemical
vaccine	5	I-Chemical
reaction	9	O
with	5	O
histamine	0	B-Chemical
H1	9	O
antagonists	3	O
.	9	O

We	9	O
studied	9	O
mortality	5	O
after	9	O
pertussis	9	B-Disease
immunization	9	O
in	5	O
the	5	O
mouse	3	O
.	9	O

Without	9	O
treatment	9	O
,	9	O
73	7	O
of	5	O
92	7	O
animals	9	O
(	9	O
80	9	O
%	9	O
)	9	O
died	9	O
after	9	O
injection	9	O
of	5	O
bovine	9	O
serum	9	O
albumin	0	O
(	9	O
BSA	0	O
)	9	O
on	5	O
day	9	O
+	9	O
7	9	O
of	5	O
pertussis	9	B-Disease
immunization	9	O
.	9	O

After	9	O
pretreatment	0	O
with	5	O
3	9	O
mg	0	O
of	5	O
cyproheptadine	0	B-Chemical
,	9	O
2	9	O
mg	0	O
mianserin	0	B-Chemical
,	9	O
or	5	O
2	9	O
mg	0	O
chlorpheniramine	0	B-Chemical
,	9	O
only	9	O
5	9	O
of	5	O
105	9	O
animals	9	O
(	9	O
5	9	O
%	9	O
)	9	O
died	9	O
after	9	O
receiving	9	O
BSA	0	O
on	5	O
day	9	O
+	9	O
7	9	O
(	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
001	9	O
)	9	O
.	9	O

Blockade	3	O
of	5	O
histamine	0	B-Chemical
H1	9	O
receptors	3	O
may	5	O
reduce	5	O
mortality	5	O
in	5	O
pertussis	9	B-Disease
immunization	9	O
-	7	O
induced	3	O
encephalopathy	5	B-Disease
in	5	O
mice	3	O
.	9	O

Support	5	O
for	5	O
adrenaline	0	B-Chemical
-	7	O
hypertension	5	B-Disease
hypothesis	9	O
:	9	O
18	7	O
hour	0	O
pressor	5	O
effect	9	O
after	9	O
6	9	O
hours	9	O
adrenaline	0	B-Chemical
infusion	0	O
.	9	O

In	9	O
a	5	O
double	9	O
blind	5	O
,	9	O
crossover	5	O
study	9	O
6	9	O
h	0	O
infusions	9	O
of	5	O
adrenaline	0	B-Chemical
(	9	O
15	9	O
ng	0	O
/	9	O
kg	0	O
/	9	O
min	0	O
;	9	O
1	9	O
ng	0	O
=	7	O
5	9	O
.	9	O
458	7	O
pmol	0	O
)	9	O
,	9	O
noradrenaline	0	B-Chemical
(	9	O
30	9	O
ng	0	O
/	9	O
kg	0	O
/	9	O
min	0	O
;	9	O
1	9	O
ng	0	O
=	7	O
5	9	O
.	9	O
911	7	O
pmol	0	O
)	9	O
,	9	O
and	5	O
a	5	O
5	9	O
%	9	O
dextrose	0	B-Chemical
solution	0	O
(	9	O
5	9	O
.	9	O
4	9	O
ml	0	O
/	9	O
h	0	O
)	9	O
,	9	O
were	9	O
given	5	O
to	5	O
ten	9	O
healthy	5	O
volunteers	5	O
in	5	O
random	5	O
order	5	O
2	9	O
weeks	9	O
apart	9	O
.	9	O

By	5	O
means	5	O
of	5	O
intra	5	O
-	7	O
arterial	5	O
ambulatory	5	O
monitoring	5	O
the	5	O
haemodynamic	5	O
effects	9	O
were	9	O
followed	9	O
for	5	O
18	7	O
h	0	O
after	9	O
the	5	O
infusions	9	O
were	9	O
stopped	9	O
.	9	O

Adrenaline	0	B-Chemical
,	9	O
but	9	O
not	5	O
noradrenaline	0	B-Chemical
,	9	O
caused	9	O
a	5	O
delayed	9	O
and	5	O
protracted	5	O
pressor	5	O
effect	9	O
.	9	O

Over	5	O
the	5	O
total	9	O
postinfusion	0	O
period	5	O
systolic	5	O
and	5	O
diastolic	5	O
arterial	5	O
pressure	5	O
were	9	O
6	9	O
(	9	O
SEM	9	O
2	9	O
)	9	O
%	9	O
and	5	O
7	9	O
(	9	O
2	9	O
)	9	O
%	9	O
,	9	O
respectively	9	O
,	9	O
higher	9	O
than	5	O
after	9	O
dextrose	0	B-Chemical
infusion	0	O
(	9	O
ANOVA	5	O
,	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
001	9	O
)	9	O
.	9	O

Thus	9	O
,	9	O
"	5	O
stress	9	O
"	5	O
levels	3	O
of	5	O
adrenaline	0	B-Chemical
(	9	O
230	9	O
pg	7	O
/	9	O
ml	0	O
)	9	O
for	5	O
6	9	O
h	0	O
cause	5	O
a	5	O
delayed	9	O
and	5	O
protracted	5	O
pressor	5	O
effect	9	O
.	9	O

These	5	O
findings	9	O
are	5	O
strong	9	O
support	5	O
for	5	O
the	5	O
adrenaline	0	B-Chemical
-	7	O
hypertension	5	B-Disease
hypothesis	9	O
in	5	O
man	5	O
.	9	O

Effect	0	O
of	5	O
alkylxanthines	9	B-Chemical
on	5	O
gentamicin	0	B-Chemical
-	7	O
induced	3	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
in	5	O
the	5	O
rat	3	O
.	9	O

Adenosine	0	B-Chemical
antagonists	3	O
have	5	O
been	9	O
previously	9	O
shown	9	O
to	5	O
be	5	O
of	5	O
benefit	5	O
in	5	O
some	5	O
ischaemic	5	B-Disease
and	5	O
nephrotoxic	5	B-Disease
models	5	O
of	5	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
(	9	O
ARF	9	B-Disease
)	9	O
.	9	O

In	9	O
the	5	O
present	9	O
study	9	O
,	9	O
the	5	O
effects	9	O
of	5	O
three	9	O
alkylxanthines	9	B-Chemical
with	5	O
different	9	O
potencies	0	O
as	5	O
adenosine	0	B-Chemical
antagonists	3	O
8	9	B-Chemical
-	7	I-Chemical
phenyltheophylline	_	I-Chemical
,	9	O
theophylline	0	B-Chemical
and	5	O
enprofylline	0	B-Chemical
,	9	O
were	9	O
examined	9	O
in	5	O
rats	9	O
developing	5	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
after	9	O
4	9	O
daily	5	O
injections	9	O
of	5	O
gentamicin	0	B-Chemical
(	9	O
200	0	O
mg	0	O
kg	0	O
-	7	O
1	9	O
)	9	O
.	9	O

Renal	9	O
function	9	O
was	9	O
assessed	9	O
by	9	O
biochemical	9	O
(	9	O
plasma	9	O
urea	0	B-Chemical
and	5	O
creatinine	0	B-Chemical
)	9	O
,	9	O
functional	9	O
(	9	O
urine	9	O
analysis	9	O
and	5	O
[	9	O
3H	0	O
]	9	O
inulin	0	O
and	5	O
[	9	O
14C	0	O
]	9	O
p	7	B-Chemical
-	7	I-Chemical
aminohippuric	9	I-Chemical
acid	0	I-Chemical
clearances	5	O
)	9	O
and	5	O
morphological	9	O
(	9	O
degree	5	O
of	5	O
necrosis	9	B-Disease
)	9	O
indices	5	O
.	9	O

The	5	O
various	9	O
drug	5	O
treatments	9	O
produced	9	O
improvements	5	O
in	5	O
some	5	O
,	9	O
but	9	O
not	5	O
all	5	O
,	9	O
measurements	5	O
of	5	O
renal	9	O
function	9	O
.	9	O

However	9	O
,	9	O
any	5	O
improvement	5	O
produced	9	O
by	9	O
drug	5	O
treatment	9	O
was	9	O
largely	9	O
a	5	O
result	9	O
of	5	O
a	5	O
beneficial	9	O
effect	9	O
exerted	9	O
by	9	O
its	9	O
vehicle	3	O
(	9	O
polyethylene	0	B-Chemical
glycol	0	I-Chemical
and	5	O
NaOH	0	B-Chemical
)	9	O
.	9	O

The	5	O
lack	9	O
of	5	O
any	5	O
consistent	9	O
protective	9	O
effect	9	O
noted	9	O
with	5	O
the	5	O
alkylxanthines	9	B-Chemical
tested	9	O
in	5	O
the	5	O
present	9	O
study	9	O
indicates	9	O
that	5	O
adenosine	0	B-Chemical
plays	9	O
little	9	O
,	9	O
if	5	O
any	5	O
,	9	O
pathophysiological	5	O
role	9	O
in	5	O
gentamicin	0	B-Chemical
-	7	O
induced	3	O
ARF	9	B-Disease
.	9	O

Adverse	5	O
ocular	5	O
reactions	9	O
possibly	9	O
associated	9	O
with	5	O
isotretinoin	5	B-Chemical
.	9	O

A	9	O
total	9	O
of	5	O
261	7	O
adverse	5	O
ocular	5	O
reactions	9	O
occurred	9	O
in	5	O
237	7	O
patients	5	O
who	5	O
received	9	O
isotretinoin	5	B-Chemical
,	9	O
a	5	O
commonly	5	O
used	5	O
drug	5	O
in	5	O
the	5	O
treatment	9	O
of	5	O
severe	5	O
cystic	5	O
acne	5	B-Disease
.	9	O

Blepharoconjunctivitis	9	B-Disease
,	9	O
subjective	5	O
complaints	5	O
of	5	O
dry	0	B-Disease
eyes	5	I-Disease
,	9	O
blurred	5	B-Disease
vision	5	I-Disease
,	9	O
contact	5	O
lens	5	O
intolerance	5	O
,	9	O
and	5	O
photodermatitis	5	B-Disease
are	5	O
reversible	9	O
side	5	O
effects	9	O
.	9	O

More	5	O
serious	5	O
ocular	5	O
adverse	5	O
reactions	9	O
include	5	O
papilledema	5	B-Disease
,	9	O
pseudotumor	5	B-Disease
cerebri	5	I-Disease
,	9	O
and	5	O
white	9	O
or	5	O
gray	9	O
subepithelial	5	O
corneal	5	B-Disease
opacities	5	I-Disease
;	9	O
all	5	O
of	5	O
these	5	O
are	5	O
reversible	9	O
if	5	O
the	5	O
drug	5	O
is	5	O
discontinued	5	O
.	9	O

Reported	5	O
cases	5	O
of	5	O
decreased	9	O
dark	9	O
adaptation	5	O
are	5	O
under	9	O
investigation	9	O
.	9	O

Isotretinoin	0	B-Chemical
is	5	O
contraindicated	5	O
in	5	O
pregnancy	5	O
because	5	O
of	5	O
the	5	O
many	5	O
reported	9	O
congenital	5	B-Disease
abnormalities	9	I-Disease
after	9	O
maternal	9	O
use	5	O
(	9	O
including	9	O
microphthalmos	5	B-Disease
,	9	O
orbital	5	O
hypertelorism	5	B-Disease
,	9	O
and	5	O
optic	5	B-Disease
nerve	5	I-Disease
hypoplasia	5	I-Disease
)	9	O
.	9	O

Procaterol	7	B-Chemical
and	5	O
terbutaline	0	B-Chemical
in	5	O
bronchial	9	B-Disease
asthma	5	I-Disease
.	9	O

A	9	O
double	9	O
-	7	O
blind	5	O
,	9	O
placebo	9	O
-	7	O
controlled	5	O
,	9	O
cross	5	O
-	7	O
over	5	O
study	9	O
.	9	O

Procaterol	7	B-Chemical
,	9	O
a	5	O
new	5	O
beta	9	O
-	7	O
2	9	O
adrenoceptor	5	O
stimulant	5	O
,	9	O
was	9	O
studied	9	O
in	5	O
a	5	O
double	9	O
-	7	O
blind	5	O
,	9	O
placebo	9	O
-	7	O
controlled	5	O
,	9	O
cross	5	O
-	7	O
over	5	O
trial	5	O
in	5	O
patients	5	O
with	5	O
bronchial	9	B-Disease
asthma	5	I-Disease
.	9	O

Oral	9	O
procaterol	0	B-Chemical
50	0	O
micrograms	0	O
b	9	O
.	9	O
d	9	O
.	9	O
,	9	O
procaterol	0	B-Chemical
100	0	O
micrograms	0	O
b	9	O
.	9	O
d	9	O
.	9	O
,	9	O
and	5	O
terbutaline	0	B-Chemical
5	9	O
mg	0	O
t	5	O
.	9	O
i	9	O
.	9	O
d	9	O
.	9	O
,	9	O
were	9	O
compared	9	O
when	5	O
given	5	O
randomly	5	O
in	5	O
1	9	O
-	7	O
week	9	O
treatment	9	O
periods	5	O
.	9	O

The	5	O
best	5	O
clinical	5	O
effect	9	O
was	9	O
found	9	O
with	5	O
terbutaline	0	B-Chemical
.	9	O

Both	9	O
anti	3	O
-	7	O
asthmatic	9	B-Disease
and	5	O
tremorgenic	0	B-Disease
effects	9	O
of	5	O
procaterol	0	B-Chemical
were	9	O
dose	9	O
-	7	O
related	9	O
.	9	O

Procaterol	7	B-Chemical
appeared	9	O
effective	5	O
in	5	O
the	5	O
doses	0	O
tested	9	O
,	9	O
and	5	O
a	5	O
twice	9	O
daily	5	O
regimen	5	O
would	5	O
appear	9	O
to	5	O
be	5	O
suitable	5	O
with	5	O
this	5	O
drug	5	O
.	9	O

Subacute	5	O
effects	9	O
of	5	O
propranolol	0	B-Chemical
and	5	O
B	9	O
24	9	O
/	9	O
76	7	O
on	5	O
isoproterenol	0	B-Chemical
-	7	O
induced	3	O
rat	3	O
heart	5	B-Disease
hypertrophy	9	I-Disease
in	5	O
correlation	9	O
with	5	O
blood	9	O
pressure	5	O
.	9	O

We	9	O
compared	9	O
the	5	O
potential	9	O
beta	9	O
-	7	O
receptor	3	O
blocker	0	O
,	9	O
B	9	O
24	9	O
/	9	O
76	7	O
i	9	O
.	9	O
e	9	O
.	9	O
1	9	O
-	7	O
(	9	O
2	9	O
,	9	O
4	9	O
-	7	O
dichlorophenoxy	0	O
)	9	O
-	7	O
3	9	O
[	9	O
2	9	O
-	7	O
3	9	O
,	9	O
4	9	O
-	7	O
dimethoxyphenyl	0	O
)	9	O
ethanolamino	_	O
]	9	O
-	7	O
prop	5	O
an	5	O
-	7	O
2	9	O
-	7	O
ol	3	O
,	9	O
which	5	O
is	5	O
characterized	9	O
by	9	O
beta	9	O
1	9	O
-	7	O
adrenoceptor	5	O
blocking	3	O
and	5	O
beta	9	O
2	9	O
-	7	O
adrenoceptor	5	O
stimulating	9	O
properties	9	O
with	5	O
propranolol	0	B-Chemical
.	9	O

The	5	O
studies	9	O
were	9	O
performed	9	O
using	9	O
an	5	O
experimental	5	O
model	5	O
of	5	O
isoproterenol	0	B-Chemical
-	7	O
induced	3	O
heart	5	B-Disease
hypertrophy	9	I-Disease
in	5	O
rats	9	O
.	9	O

A	9	O
correlation	9	O
of	5	O
the	5	O
blood	9	O
pressure	5	O
was	9	O
neither	9	O
found	9	O
in	5	O
the	5	O
development	9	O
nor	9	O
in	5	O
the	5	O
attempt	5	O
to	5	O
suppress	3	O
the	5	O
development	9	O
of	5	O
heart	5	B-Disease
hypertrophy	9	I-Disease
with	5	O
the	5	O
two	5	O
beta	9	O
-	7	O
receptor	3	O
blockers	9	O
.	9	O

Both	9	O
beta	9	O
-	7	O
blockers	9	O
influenced	5	O
the	5	O
development	9	O
of	5	O
hypertrophy	9	B-Disease
to	5	O
a	5	O
different	9	O
,	9	O
but	9	O
not	5	O
reproducible	5	O
extent	9	O
.	9	O

It	5	O
was	9	O
possible	5	O
to	5	O
suppress	3	O
the	5	O
increased	9	O
ornithine	0	B-Chemical
decarboxylase	1	O
activity	9	O
with	5	O
both	9	O
beta	9	O
-	7	O
blockers	9	O
in	5	O
hypertrophied	9	B-Disease
hearts	3	I-Disease
,	9	O
but	9	O
there	5	O
was	9	O
no	9	O
effect	9	O
on	5	O
the	5	O
heart	5	O
mass	9	O
.	9	O

Neither	9	O
propranolol	0	B-Chemical
nor	9	O
B	9	O
24	9	O
/	9	O
76	7	O
could	9	O
stop	9	O
the	5	O
changes	9	O
in	5	O
the	5	O
characteristic	9	O
myosin	3	O
isoenzyme	9	O
pattern	9	O
of	5	O
the	5	O
hypertrophied	9	B-Disease
rat	3	O
heart	5	O
.	9	O

Thus	9	O
,	9	O
the	5	O
investigations	9	O
did	9	O
not	5	O
provide	5	O
any	5	O
evidence	9	O
that	5	O
the	5	O
beta	9	O
-	7	O
receptor	3	O
blockers	9	O
propranolol	0	B-Chemical
and	5	O
B	9	O
24	9	O
/	9	O
76	7	O
have	5	O
the	5	O
potency	9	O
to	5	O
prevent	5	O
isoproterenol	0	B-Chemical
from	9	O
producing	9	O
heart	5	B-Disease
hypertrophy	9	I-Disease
.	9	O

Increased	9	O
anxiogenic	5	O
effects	9	O
of	5	O
caffeine	0	B-Chemical
in	5	O
panic	5	B-Disease
disorders	5	I-Disease
.	9	O

The	5	O
effects	9	O
of	5	O
oral	9	O
administration	9	O
of	5	O
caffeine	0	B-Chemical
(	9	O
10	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
on	5	O
behavioral	5	O
ratings	5	O
,	9	O
somatic	9	O
symptoms	5	O
,	9	O
blood	9	O
pressure	5	O
and	5	O
plasma	9	O
levels	3	O
of	5	O
3	9	B-Chemical
-	7	I-Chemical
methoxy	0	I-Chemical
-	7	I-Chemical
4	9	I-Chemical
-	7	I-Chemical
hydroxyphenethyleneglycol	_	I-Chemical
(	9	O
MHPG	0	B-Chemical
)	9	O
and	5	O
cortisol	5	B-Chemical
were	9	O
determined	9	O
in	5	O
17	7	O
healthy	5	O
subjects	5	O
and	5	O
21	7	O
patients	5	O
meeting	5	O
DSM	4	O
-	7	O
III	9	O
criteria	5	O
for	5	O
agoraphobia	5	B-Disease
with	5	O
panic	5	B-Disease
attacks	5	I-Disease
or	5	O
panic	5	B-Disease
disorder	5	I-Disease
.	9	O

Caffeine	0	B-Chemical
produced	9	O
significantly	9	O
greater	5	O
increases	9	O
in	5	O
subject	5	O
-	7	O
rated	5	O
anxiety	5	B-Disease
,	9	O
nervousness	5	O
,	9	O
fear	5	O
,	9	O
nausea	5	B-Disease
,	9	O
palpitations	5	B-Disease
,	9	O
restlessness	5	B-Disease
,	9	O
and	5	O
tremors	5	B-Disease
in	5	O
the	5	O
patients	5	O
compared	9	O
with	5	O
healthy	5	O
subjects	5	O
.	9	O

In	9	O
the	5	O
patients	5	O
,	9	O
but	9	O
not	5	O
the	5	O
healthy	5	O
subjects	5	O
,	9	O
these	5	O
symptoms	5	O
were	9	O
significantly	9	O
correlated	9	O
with	5	O
plasma	9	O
caffeine	0	B-Chemical
levels	3	O
.	9	O

Seventy	5	O
-	7	O
one	5	O
percent	5	O
of	5	O
the	5	O
patients	5	O
reported	9	O
that	5	O
the	5	O
behavioral	5	O
effects	9	O
of	5	O
caffeine	0	B-Chemical
were	9	O
similar	9	O
to	5	O
those	5	O
experienced	5	O
during	5	O
panic	5	B-Disease
attacks	5	I-Disease
.	9	O

Caffeine	0	B-Chemical
did	9	O
not	5	O
alter	9	O
plasma	9	O
MHPG	0	B-Chemical
levels	3	O
in	5	O
either	9	O
the	5	O
healthy	5	O
subjects	5	O
or	5	O
patients	5	O
.	9	O

Caffeine	0	B-Chemical
increased	9	O
plasma	9	O
cortisol	5	B-Chemical
levels	3	O
equally	9	O
in	5	O
the	5	O
patient	5	O
and	5	O
healthy	5	O
groups	9	O
.	9	O

Because	9	O
caffeine	0	B-Chemical
is	5	O
an	5	O
adenosine	0	B-Chemical
receptor	3	O
antagonist	3	O
,	9	O
these	5	O
results	9	O
suggest	9	O
that	5	O
some	5	O
panic	5	B-Disease
disorder	5	I-Disease
patients	5	O
may	5	O
have	5	O
abnormalities	9	B-Disease
in	5	I-Disease
neuronal	3	I-Disease
systems	5	I-Disease
involving	5	O
adenosine	0	B-Chemical
.	9	O

Patients	5	O
with	5	O
anxiety	5	B-Disease
disorders	5	I-Disease
may	5	O
benefit	5	O
by	9	O
avoiding	5	O
caffeine	0	B-Chemical
-	7	O
containing	0	O
foods	5	O
and	5	O
beverages	5	O
.	9	O

Comparison	9	O
of	5	O
the	5	O
effect	9	O
of	5	O
oxitropium	0	B-Chemical
bromide	0	I-Chemical
and	5	O
of	5	O
slow	5	O
-	7	O
release	9	O
theophylline	0	B-Chemical
on	5	O
nocturnal	5	O
asthma	5	B-Disease
.	9	O

The	5	O
effects	9	O
of	5	O
a	5	O
new	5	O
inhaled	5	O
antimuscarinic	5	O
drug	5	O
,	9	O
oxitropium	0	B-Chemical
bromide	0	I-Chemical
,	9	O
and	5	O
of	5	O
a	5	O
slow	5	O
-	7	O
release	9	O
theophylline	0	B-Chemical
preparation	9	O
upon	9	O
nocturnal	5	O
asthma	5	B-Disease
were	9	O
compared	9	O
in	5	O
a	5	O
placebo	9	O
-	7	O
controlled	5	O
double	9	O
-	7	O
blind	5	O
study	9	O
.	9	O

Two	9	O
samples	9	O
were	9	O
studied	9	O
:	9	O
12	9	O
patients	5	O
received	9	O
oxitropium	0	B-Chemical
at	9	O
600	0	O
micrograms	0	O
(	9	O
6	9	O
subjects	5	O
)	9	O
or	5	O
at	9	O
400	0	O
micrograms	0	O
t	5	O
.	9	O
i	9	O
.	9	O
d	9	O
.	9	O

(	9	O
6	9	O
subjects	5	O
)	9	O
whereas	9	O
11	7	O
received	9	O
theophylline	0	B-Chemical
at	9	O
300	0	O
mg	0	O
b	9	O
.	9	O
i	9	O
.	9	O
d	9	O
.	9	O

Morning	5	O
dipping	5	O
,	9	O
assessed	9	O
by	9	O
the	5	O
fall	5	O
in	5	O
peak	9	O
flow	5	O
overnight	0	O
,	9	O
was	9	O
significantly	9	O
reduced	9	O
in	5	O
the	5	O
periods	5	O
when	5	O
either	9	O
active	9	O
drug	5	O
was	9	O
taken	5	O
,	9	O
whereas	9	O
no	9	O
difference	9	O
was	9	O
noticed	9	O
during	5	O
the	5	O
placebo	9	O
administration	9	O
.	9	O

No	9	O
significant	9	O
difference	9	O
was	9	O
noticed	9	O
between	5	O
results	9	O
obtained	9	O
with	5	O
either	9	O
active	9	O
drug	5	O
,	9	O
as	5	O
well	9	O
as	5	O
with	5	O
either	9	O
dosage	9	O
of	5	O
oxitropium	0	B-Chemical
.	9	O

No	9	O
subject	5	O
reported	9	O
side	5	O
effects	9	O
of	5	O
oxitropium	0	B-Chemical
,	9	O
as	5	O
compared	9	O
to	5	O
three	9	O
subjects	5	O
reporting	5	O
nausea	5	B-Disease
,	9	O
vomiting	5	B-Disease
and	5	O
tremors	5	B-Disease
after	9	O
theophylline	0	B-Chemical
.	9	O

Oxitropium	0	B-Chemical
proves	5	O
to	5	O
be	5	O
a	5	O
valuable	5	O
alternative	5	O
to	5	O
theophylline	0	B-Chemical
in	5	O
nocturnal	5	O
asthma	5	B-Disease
,	9	O
since	9	O
it	5	O
is	5	O
equally	9	O
potent	3	O
,	9	O
safer	5	O
and	5	O
does	9	O
not	5	O
require	5	O
the	5	O
titration	0	O
of	5	O
dosage	9	O
.	9	O

Penicillin	0	B-Chemical
anaphylaxis	9	B-Disease
.	9	O

A	9	O
case	5	O
of	5	O
oral	9	O
penicillin	0	B-Chemical
anaphylaxis	9	B-Disease
is	5	O
described	9	O
,	9	O
and	5	O
the	5	O
terminology	5	O
,	9	O
occurrence	5	O
,	9	O
clinical	5	O
manifestations	5	O
,	9	O
pathogenesis	9	O
,	9	O
prevention	5	O
,	9	O
and	5	O
treatment	9	O
of	5	O
anaphylaxis	9	B-Disease
are	5	O
reviewed	9	O
.	9	O

Emergency	2	O
physicians	5	O
should	5	O
be	5	O
aware	5	O
of	5	O
oral	9	O
penicillin	0	B-Chemical
anaphylaxis	9	B-Disease
in	5	O
order	5	O
to	5	O
prevent	5	O
its	9	O
occurrence	5	O
by	9	O
prescribing	5	O
the	5	O
antibiotic	5	O
judiciously	5	O
and	5	O
knowledgeably	5	O
and	5	O
to	5	O
offer	5	O
optimal	5	O
medical	5	O
therapy	5	O
once	5	O
this	5	O
life	5	O
-	7	O
threatening	5	O
reaction	9	O
has	9	O
begun	5	O
.	9	O

Reversible	0	O
valproic	0	B-Chemical
acid	0	I-Chemical
-	7	O
induced	3	O
dementia	5	B-Disease
:	9	O
a	5	O
case	5	O
report	5	O
.	9	O

Reversible	0	O
valproic	0	B-Chemical
acid	0	I-Chemical
-	7	O
induced	3	O
dementia	5	B-Disease
was	9	O
documented	9	O
in	5	O
a	5	O
21	7	O
-	7	O
year	5	O
-	7	O
old	5	O
man	5	O
with	5	O
epilepsy	5	B-Disease
who	5	O
had	9	O
a	5	O
3	9	O
-	7	O
year	5	O
history	5	O
of	5	O
insidious	5	O
progressive	5	O
decline	9	O
in	5	O
global	5	O
cognitive	5	O
abilities	5	O
documented	9	O
by	9	O
serial	9	O
neuropsychological	5	O
studies	9	O
.	9	O

Repeat	9	O
neuropsychological	5	O
testing	5	O
7	9	O
weeks	9	O
after	9	O
discontinuation	5	O
of	5	O
the	5	O
drug	5	O
revealed	9	O
dramatic	9	O
improvement	5	O
in	5	O
IQ	5	O
,	9	O
memory	5	O
,	9	O
naming	5	O
,	9	O
and	5	O
other	5	O
tasks	5	O
commensurate	5	O
with	5	O
clinical	5	O
recovery	9	O
in	5	O
his	5	O
intellectual	5	O
capacity	9	O
.	9	O

Possible	9	O
pathophysiological	5	O
mechanisms	9	O
which	5	O
may	5	O
have	5	O
been	9	O
operative	5	O
in	5	O
this	5	O
case	5	O
include	5	O
:	9	O
a	5	O
direct	9	O
central	5	O
nervous	5	O
system	5	O
(	9	O
CNS	9	O
)	9	O
toxic	0	O
effect	9	O
of	5	O
valproic	0	B-Chemical
acid	0	I-Chemical
;	9	O
a	5	O
paradoxical	5	O
epileptogenic	5	O
effect	9	O
secondary	9	O
to	5	O
the	5	O
drug	5	O
;	9	O
and	5	O
an	5	O
indirect	5	O
CNS	9	O
toxic	0	O
effect	9	O
mediated	3	O
through	9	O
valproic	0	B-Chemical
acid	0	I-Chemical
-	7	O
induced	3	O
hyperammonemia	5	B-Disease
.	9	O

Reversal	9	O
of	5	O
scopolamine	0	B-Chemical
-	7	O
induced	3	O
amnesia	5	B-Disease
of	5	O
passive	5	O
avoidance	5	O
by	9	O
pre	9	O
-	7	O
and	5	O
post	9	O
-	7	O
training	5	O
naloxone	0	B-Chemical
.	9	O

In	9	O
a	5	O
series	5	O
of	5	O
five	9	O
experiments	9	O
,	9	O
the	5	O
modulating	9	O
role	9	O
of	5	O
naloxone	0	B-Chemical
on	5	O
a	5	O
scopolamine	0	B-Chemical
-	7	O
induced	3	O
retention	9	B-Disease
deficit	5	I-Disease
in	5	O
a	5	O
passive	5	O
avoidance	5	O
paradigm	5	O
was	9	O
investigated	9	O
in	5	O
mice	3	O
.	9	O

Scopolamine	0	B-Chemical
,	9	O
but	9	O
not	5	O
methyl	0	B-Chemical
scopolamine	0	I-Chemical
(	9	O
1	9	O
and	5	O
3	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
,	9	O
induced	3	O
an	5	O
amnesia	5	B-Disease
as	5	O
measured	9	O
by	9	O
latency	5	O
and	5	O
duration	5	O
parameters	5	O
.	9	O

Naloxone	0	B-Chemical
(	9	O
0	7	O
.	9	O
3	9	O
,	9	O
1	9	O
,	9	O
3	9	O
,	9	O
and	5	O
10	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
injected	3	O
prior	9	O
to	5	O
training	5	O
attenuated	3	O
the	5	O
retention	9	B-Disease
deficit	5	I-Disease
with	5	O
a	5	O
peak	9	O
of	5	O
activity	9	O
at	9	O
3	9	O
mg	0	O
/	9	O
kg	0	O
.	9	O

The	5	O
effect	9	O
of	5	O
naloxone	0	B-Chemical
could	9	O
be	5	O
antagonized	3	O
with	5	O
morphine	0	B-Chemical
(	9	O
1	9	O
,	9	O
3	9	O
,	9	O
and	5	O
10	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
,	9	O
demonstrating	9	O
the	5	O
opioid	5	O
specificity	9	O
of	5	O
the	5	O
naloxone	0	B-Chemical
effect	9	O
.	9	O

Post	9	O
-	7	O
training	5	O
administration	9	O
of	5	O
naloxone	0	B-Chemical
(	9	O
3	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
as	5	O
a	5	O
single	9	O
or	5	O
as	5	O
a	5	O
split	5	O
dose	9	O
also	9	O
attenuated	3	O
the	5	O
scopolamine	0	B-Chemical
-	7	O
induced	3	O
amnesia	5	B-Disease
.	9	O

Control	9	O
experiments	9	O
indicated	9	O
that	5	O
neither	9	O
an	5	O
increase	9	O
in	5	O
pain	5	B-Disease
sensitivity	9	O
(	9	O
pre	9	O
-	7	O
training	5	O
naloxone	0	B-Chemical
)	9	O
nor	9	O
an	5	O
induced	3	O
aversive	5	O
state	5	O
(	9	O
post	9	O
-	7	O
training	5	O
naloxone	0	B-Chemical
)	9	O
appear	9	O
to	5	O
be	5	O
responsible	9	O
for	5	O
the	5	O
influence	5	O
of	5	O
naloxone	0	B-Chemical
on	5	O
the	5	O
scopolamine	0	B-Chemical
-	7	O
induced	3	O
retention	9	B-Disease
deficit	5	I-Disease
.	9	O

These	5	O
results	9	O
extend	9	O
previous	9	O
findings	9	O
implicating	9	O
a	5	O
cholinergic	3	O
-	7	O
opioid	5	O
interaction	9	O
in	5	O
memory	5	O
processes	5	O
.	9	O

A	9	O
possible	5	O
mechanism	9	O
for	5	O
this	5	O
interaction	9	O
involving	5	O
the	5	O
septo	2	O
-	7	O
hippocampal	3	O
cholinergic	3	O
pathway	3	O
is	5	O
discussed	5	O
.	9	O

Electron	0	O
microscopic	9	O
investigations	9	O
of	5	O
the	5	O
cyclophosphamide	0	B-Chemical
-	7	O
induced	3	O
lesions	5	B-Disease
of	5	I-Disease
the	5	I-Disease
urinary	9	I-Disease
bladder	9	I-Disease
of	5	O
the	5	O
rat	3	O
and	5	O
their	5	O
prevention	5	O
by	9	O
mesna	0	B-Chemical
.	9	O

Fully	9	O
developed	5	O
cyclophosphamide	0	B-Chemical
-	7	O
induced	3	O
cystitis	9	B-Disease
is	5	O
characterized	9	O
by	9	O
nearly	9	O
complete	9	O
detachment	9	O
of	5	O
the	5	O
urothelium	3	O
,	9	O
severe	5	O
submucosal	5	O
edema	5	B-Disease
owing	5	O
to	5	O
damage	9	O
to	5	O
the	5	O
microvascular	5	O
bed	5	O
and	5	O
focal	5	O
muscle	9	O
necroses	5	B-Disease
.	9	O

The	5	O
initial	9	O
response	9	O
to	5	O
the	5	O
primary	9	O
attack	5	O
by	9	O
the	5	O
cyclophosphamide	0	B-Chemical
metabolites	0	O
seems	5	O
to	5	O
be	5	O
fragmentation	9	O
of	5	O
the	5	O
luminal	3	B-Chemical
membrane	9	O
.	9	O

This	5	O
damages	9	O
the	5	O
cellular	3	O
barrier	5	O
against	9	O
the	5	O
hypertonic	0	O
urine	9	O
.	9	O

Subsequent	9	O
breaks	5	O
in	5	O
the	5	O
lateral	5	O
cell	3	O
membranes	0	O
of	5	O
the	5	O
superficial	5	O
cells	3	O
and	5	O
in	5	O
all	5	O
the	5	O
plasma	9	O
membranes	0	O
of	5	O
the	5	O
intermediate	9	O
and	5	O
basal	3	O
cells	3	O
,	9	O
intercellular	3	O
and	5	O
intracellular	3	O
edema	5	B-Disease
and	5	O
disintegration	9	O
of	5	O
the	5	O
desmosomes	3	O
and	5	O
hemidesmosomes	3	O
lead	5	O
to	5	O
progressive	5	O
degeneration	9	O
and	5	O
detachment	9	O
of	5	O
the	5	O
epithelial	3	O
cells	3	O
with	5	O
exposure	9	O
and	5	O
splitting	5	O
of	5	O
the	5	O
basal	3	O
membrane	9	O
.	9	O

The	5	O
morphological	9	O
changes	9	O
of	5	O
the	5	O
endothelial	3	O
cells	3	O
,	9	O
which	5	O
become	5	O
more	5	O
pronounced	9	O
in	5	O
the	5	O
later	9	O
stages	9	O
of	5	O
the	5	O
experiment	9	O
,	9	O
the	5	O
involvement	9	O
of	5	O
blood	9	O
vessels	5	O
regardless	9	O
of	5	O
their	5	O
diameter	9	O
and	5	O
the	5	O
location	5	O
-	7	O
dependent	9	O
extent	9	O
of	5	O
the	5	O
damage	9	O
indicate	9	O
a	5	O
direct	9	O
type	9	O
of	5	O
damage	9	O
which	5	O
is	5	O
preceded	9	O
by	9	O
a	5	O
mediator	9	O
-	7	O
induced	3	O
increase	9	O
in	5	O
permeability	0	O
,	9	O
the	5	O
morphological	9	O
correlate	9	O
of	5	O
which	5	O
is	5	O
the	5	O
formation	9	O
of	5	O
gaps	5	O
in	5	O
the	5	O
interendothelial	3	O
cell	3	O
connections	5	O
on	5	O
the	5	O
venules	3	O
.	9	O

These	5	O
changes	9	O
can	5	O
be	5	O
effectively	5	O
prevented	9	O
by	9	O
mesna	0	B-Chemical
.	9	O

The	5	O
only	9	O
sign	5	O
of	5	O
a	5	O
possible	5	O
involvement	9	O
is	5	O
the	5	O
increase	9	O
in	5	O
the	5	O
number	9	O
of	5	O
specific	9	O
granules	9	O
with	5	O
a	5	O
presumed	9	O
lysosomal	3	O
function	9	O
in	5	O
the	5	O
superficial	5	O
cells	3	O
.	9	O

Increase	9	O
in	5	O
intragastric	0	O
pressure	5	O
during	5	O
suxamethonium	5	B-Chemical
-	7	O
induced	3	O
muscle	9	B-Disease
fasciculations	5	I-Disease
in	5	O
children	5	O
:	9	O
inhibition	3	O
by	9	O
alfentanil	0	B-Chemical
.	9	O

Changes	9	O
in	5	O
intragastric	0	O
pressure	5	O
after	9	O
the	5	O
administration	9	O
of	5	O
suxamethonium	5	B-Chemical
1	9	O
.	9	O
5	9	O
mg	0	O
kg	0	O
-	7	O
1	9	O
i	9	O
.	9	O
v	0	O
.	9	O
were	9	O
studied	9	O
in	5	O
32	7	O
children	5	O
(	9	O
mean	5	O
age	5	O
6	9	O
.	9	O
9	7	O
yr	7	O
)	9	O
pretreated	3	O
with	5	O
either	9	O
physiological	9	O
saline	0	O
or	5	O
alfentanil	0	B-Chemical
50	0	O
micrograms	0	O
kg	0	O
-	7	O
1	9	O
.	9	O

Anaesthesia	2	O
was	9	O
induced	3	O
with	5	O
thiopentone	0	B-Chemical
5	9	O
mg	0	O
kg	0	O
-	7	O
1	9	O
.	9	O

The	5	O
incidence	5	O
and	5	O
intensity	5	O
of	5	O
muscle	9	B-Disease
fasciculations	5	I-Disease
caused	9	O
by	9	O
suxamethonium	5	B-Chemical
were	9	O
significantly	9	O
greater	5	O
in	5	O
the	5	O
control	9	O
than	5	O
in	5	O
the	5	O
alfentanil	0	B-Chemical
group	9	O
.	9	O

The	5	O
intragastric	0	O
pressure	5	O
during	5	O
muscle	9	B-Disease
fasciculations	5	I-Disease
was	9	O
significantly	9	O
higher	9	O
in	5	O
the	5	O
control	9	O
group	9	O
(	9	O
16	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
7	9	O
(	9	O
SEM	9	O
)	9	O
cm	9	O
H2O	0	B-Chemical
)	9	O
than	5	O
in	5	O
the	5	O
alfentanil	0	B-Chemical
group	9	O
(	9	O
7	9	O
.	9	O
7	9	O
+	9	O
/	9	O
-	7	O
1	9	O
.	9	O
5	9	O
(	9	O
SEM	9	O
)	9	O
cm	9	O
H2O	0	B-Chemical
)	9	O
.	9	O

The	5	O
increase	9	O
in	5	O
intragastric	0	O
pressure	5	O
was	9	O
directly	9	O
related	9	O
to	5	O
the	5	O
intensity	5	O
of	5	O
muscle	9	B-Disease
fasciculations	5	I-Disease
(	9	O
regression	5	O
line	9	O
:	9	O
y	9	O
=	7	O
0	7	O
.	9	O
5	9	O
+	9	O
4	9	O
.	9	O
78x	9	O
with	5	O
r	9	O
of	5	O
0	7	O
.	9	O
78	7	O
)	9	O
.	9	O

It	5	O
is	5	O
concluded	9	O
that	5	O
intragastric	0	O
pressure	5	O
increases	9	O
significantly	9	O
during	5	O
muscle	9	B-Disease
fasciculations	5	I-Disease
caused	9	O
by	9	O
suxamethonium	5	B-Chemical
in	5	O
healthy	5	O
children	5	O
.	9	O

Alfentanil	0	B-Chemical
50	0	O
micrograms	0	O
kg	0	O
-	7	O
1	9	O
effectively	5	O
inhibits	3	O
the	5	O
incidence	5	O
and	5	O
intensity	5	O
of	5	O
suxamethonium	5	B-Chemical
-	7	O
induced	3	O
muscle	9	B-Disease
fasciculations	5	I-Disease
;	9	O
moreover	9	O
,	9	O
intragastric	0	O
pressure	5	O
remains	9	O
at	9	O
its	9	O
control	9	O
value	9	O
.	9	O

Acute	5	O
insulin	3	O
treatment	9	O
normalizes	9	O
the	5	O
resistance	9	O
to	5	O
the	5	O
cardiotoxic	5	B-Disease
effect	9	O
of	5	O
isoproterenol	0	B-Chemical
in	5	O
streptozotocin	0	B-Chemical
diabetic	9	B-Disease
rats	9	O
.	9	O

A	9	O
morphometric	5	O
study	9	O
of	5	O
isoproterenol	0	B-Chemical
induced	3	O
myocardial	9	O
fibrosis	9	B-Disease
.	9	O

The	5	O
acute	9	O
effect	9	O
of	5	O
insulin	3	O
treatment	9	O
on	5	O
the	5	O
earlier	9	O
reported	9	O
protective	9	O
effect	9	O
of	5	O
streptozotocin	0	B-Chemical
diabetes	5	B-Disease
against	9	O
the	5	O
cardiotoxic	5	B-Disease
effect	9	O
of	5	O
high	9	O
doses	0	O
of	5	O
isoproterenol	0	B-Chemical
(	9	O
ISO	0	B-Chemical
)	9	O
was	9	O
investigated	9	O
in	5	O
rats	9	O
.	9	O

Thirty	9	O
to	5	O
135	7	O
min	0	O
after	9	O
the	5	O
injection	9	O
of	5	O
crystalline	0	O
insulin	3	O
,	9	O
ISO	0	B-Chemical
was	9	O
given	5	O
subcutaneously	3	O
and	5	O
when	5	O
ISO	0	B-Chemical
induced	3	O
fibrosis	9	B-Disease
in	5	O
the	5	O
myocardium	9	O
was	9	O
morphometrically	5	O
analyzed	9	O
7	9	O
days	9	O
later	9	O
,	9	O
a	5	O
highly	9	O
significant	9	O
correlation	9	O
(	9	O
r	9	O
=	7	O
0	7	O
.	9	O
83	7	O
,	9	O
2	9	O
p	7	O
=	7	O
0	7	O
.	9	O
006	7	O
)	9	O
to	5	O
the	5	O
slope	5	O
of	5	O
the	5	O
fall	5	O
in	5	O
blood	9	O
glucose	0	B-Chemical
after	9	O
insulin	3	O
treatment	9	O
appeared	9	O
.	9	O

The	5	O
myocardial	9	O
content	9	O
of	5	O
catecholamines	9	B-Chemical
was	9	O
estimated	5	O
in	5	O
these	5	O
8	9	O
day	9	O
diabetic	9	B-Disease
rats	9	O
.	9	O

The	5	O
norepinephrine	9	B-Chemical
content	9	O
was	9	O
significantly	9	O
increased	9	O
while	9	O
epinephrine	0	B-Chemical
remained	9	O
unchanged	9	O
.	9	O

An	5	O
enhanced	3	O
sympathetic	5	O
nervous	5	O
system	5	O
activity	9	O
with	5	O
a	5	O
consequent	9	O
down	9	O
regulation	9	O
of	5	O
the	5	O
myocardial	9	O
beta	9	O
-	7	O
adrenergic	9	O
receptors	3	O
could	9	O
,	9	O
therefore	5	O
,	9	O
explain	9	O
this	5	O
catecholamine	9	B-Chemical
resistance	9	O
.	9	O

The	5	O
rapid	5	O
reversion	9	O
after	9	O
insulin	3	O
treatment	9	O
excludes	9	O
the	5	O
possibility	9	O
that	5	O
streptozotocin	0	B-Chemical
in	5	O
itself	9	O
causes	9	O
the	5	O
ISO	0	B-Chemical
resistance	9	O
and	5	O
points	5	O
towards	5	O
a	5	O
direct	9	O
insulin	3	O
effect	9	O
on	5	O
myocardial	9	O
catecholamine	9	B-Chemical
sensitivity	9	O
in	5	O
diabetic	9	B-Disease
rats	9	O
.	9	O

The	5	O
phenomenon	5	O
described	9	O
might	9	O
elucidate	9	O
pathogenetic	5	O
mechanisms	9	O
behind	5	O
toxic	0	O
myocardial	9	O
cell	3	O
degeneration	9	O
and	5	O
may	5	O
possibly	9	O
have	5	O
relevance	9	O
for	5	O
acute	9	O
cardiovascular	5	O
complications	5	O
in	5	O
diabetic	9	B-Disease
patients	5	O
.	9	O

Differential	9	O
effects	9	O
of	5	O
non	9	O
-	7	O
steroidal	0	O
anti	3	O
-	7	O
inflammatory	3	O
drugs	5	O
on	5	O
seizures	5	B-Disease
produced	9	O
by	9	O
pilocarpine	0	B-Chemical
in	5	O
rats	9	O
.	9	O

The	5	O
muscarinic	3	O
cholinergic	3	O
agonist	3	O
pilocarpine	0	B-Chemical
induces	3	O
in	5	O
rats	9	O
seizures	5	B-Disease
and	5	O
status	9	B-Disease
epilepticus	5	I-Disease
followed	9	O
by	9	O
widespread	5	O
damage	9	O
to	5	O
the	5	O
forebrain	3	O
.	9	O

The	5	O
present	9	O
study	9	O
was	9	O
designed	9	O
to	5	O
investigate	9	O
the	5	O
effect	9	O
of	5	O
5	9	O
non	9	O
-	7	O
steroidal	0	O
anti	3	O
-	7	O
inflammatory	3	O
drugs	5	O
,	9	O
sodium	0	B-Chemical
salicylate	0	I-Chemical
,	9	O
phenylbutazone	0	B-Chemical
,	9	O
indomethacin	0	B-Chemical
,	9	O
ibuprofen	0	B-Chemical
and	5	O
mefenamic	0	B-Chemical
acid	0	I-Chemical
,	9	O
on	5	O
seizures	5	B-Disease
produced	9	O
by	9	O
pilocarpine	0	B-Chemical
.	9	O

Pretreatment	3	O
of	5	O
rats	9	O
with	5	O
sodium	0	B-Chemical
salicylate	0	I-Chemical
,	9	O
ED50	0	O
103	7	O
mg	0	O
/	9	O
kg	0	O
(	9	O
60	9	O
-	7	O
174	7	O
)	9	O
,	9	O
and	5	O
phenylbutazone	0	B-Chemical
,	9	O
59	7	O
mg	0	O
/	9	O
kg	0	O
(	9	O
50	0	O
-	7	O
70	9	O
)	9	O
converted	9	O
the	5	O
non	9	O
-	7	O
convulsant	0	O
dose	9	O
of	5	O
pilocarpine	0	B-Chemical
,	9	O
200	0	O
mg	0	O
/	9	O
kg	0	O
,	9	O
to	5	O
a	5	O
convulsant	0	O
one	5	O
.	9	O

Indomethacin	0	B-Chemical
,	9	O
1	9	O
-	7	O
10	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
and	5	O
ibuprofen	0	B-Chemical
,	9	O
10	9	O
-	7	O
100	0	O
mg	0	O
/	9	O
kg	0	O
,	9	O
failed	9	O
to	5	O
modulate	9	O
seizures	5	B-Disease
produced	9	O
by	9	O
pilocarpine	0	B-Chemical
.	9	O

Mefenamic	0	B-Chemical
acid	0	I-Chemical
,	9	O
26	7	O
(	9	O
22	7	O
-	7	O
30	9	O
)	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
prevented	9	O
seizures	5	B-Disease
and	5	O
protected	9	O
rats	9	O
from	9	O
seizure	5	B-Disease
-	7	O
related	9	O
brain	5	B-Disease
damage	9	I-Disease
induced	3	O
by	9	O
pilocarpine	0	B-Chemical
,	9	O
380	9	O
mg	0	O
/	9	O
kg	0	O
.	9	O

These	5	O
results	9	O
indicate	9	O
that	5	O
non	9	O
-	7	O
steroidal	0	O
anti	3	O
-	7	O
inflammatory	3	O
drugs	5	O
differentially	9	O
modulate	9	O
the	5	O
threshold	5	O
for	5	O
pilocarpine	0	B-Chemical
-	7	O
induced	3	O
seizures	5	B-Disease
.	9	O

Acute	5	B-Disease
neurologic	5	I-Disease
dysfunction	9	I-Disease
after	9	O
high	9	O
-	7	O
dose	9	O
etoposide	3	B-Chemical
therapy	5	O
for	5	O
malignant	3	B-Disease
glioma	3	I-Disease
.	9	O

Etoposide	3	B-Chemical
(	9	O
VP	9	B-Chemical
-	7	I-Chemical
16	9	I-Chemical
-	7	I-Chemical
213	7	I-Chemical
)	9	O
has	9	O
been	9	O
used	5	O
in	5	O
the	5	O
treatment	9	O
of	5	O
many	5	O
solid	9	O
tumors	3	B-Disease
and	5	O
hematologic	5	B-Disease
malignancies	5	I-Disease
.	9	O

When	9	O
used	5	O
in	5	O
high	9	O
doses	0	O
and	5	O
in	5	O
conjunction	9	O
with	5	O
autologous	3	O
bone	5	O
marrow	3	O
transplantation	9	O
,	9	O
this	5	O
agent	9	O
has	9	O
activity	9	O
against	9	O
several	9	O
treatment	9	O
-	7	O
resistant	9	O
cancers	9	B-Disease
including	9	O
malignant	3	B-Disease
glioma	3	I-Disease
.	9	O

In	9	O
six	9	O
of	5	O
eight	9	O
patients	5	O
(	9	O
75	9	O
%	9	O
)	9	O
who	5	O
we	5	O
treated	3	O
for	5	O
recurrent	5	O
or	5	O
resistant	9	O
glioma	3	B-Disease
,	9	O
sudden	5	O
severe	5	O
neurologic	5	B-Disease
deterioration	5	I-Disease
occurred	9	O
.	9	O

This	5	O
developed	5	O
a	5	O
median	9	O
of	5	O
9	7	O
days	9	O
after	9	O
initiation	9	O
of	5	O
high	9	O
-	7	O
dose	9	O
etoposide	3	B-Chemical
therapy	5	O
.	9	O

Significant	9	O
clinical	5	O
manifestations	5	O
have	5	O
included	5	O
confusion	5	B-Disease
,	9	O
papilledema	5	B-Disease
,	9	O
somnolence	5	B-Disease
,	9	O
exacerbation	5	O
of	5	O
motor	5	B-Disease
deficits	5	I-Disease
,	9	O
and	5	O
sharp	5	O
increase	9	O
in	5	O
seizure	5	B-Disease
activity	9	O
.	9	O

These	5	O
abnormalities	9	O
resolved	9	O
rapidly	9	O
after	9	O
initiation	9	O
of	5	O
high	9	O
-	7	O
dose	9	O
intravenous	0	O
dexamethasone	0	B-Chemical
therapy	5	O
.	9	O

In	9	O
all	5	O
patients	5	O
,	9	O
computerized	5	O
tomographic	5	O
(	9	O
CT	9	O
)	9	O
brain	5	O
scans	5	O
demonstrated	9	O
stability	9	O
in	5	O
tumor	3	B-Disease
size	9	O
and	5	O
peritumor	3	O
edema	5	B-Disease
when	5	O
compared	9	O
with	5	O
pretransplant	5	O
scans	5	O
.	9	O

This	5	O
complication	5	O
appears	9	O
to	5	O
represent	9	O
a	5	O
significant	9	O
new	5	O
toxicity	9	B-Disease
of	5	O
high	9	O
-	7	O
dose	9	O
etoposide	3	B-Chemical
therapy	5	O
for	5	O
malignant	3	B-Disease
glioma	3	I-Disease
.	9	O

Progressive	5	O
bile	0	B-Disease
duct	5	I-Disease
injury	9	I-Disease
after	9	O
thiabendazole	0	B-Chemical
administration	9	O
.	9	O

A	9	O
27	7	O
-	7	O
yr	7	O
-	7	O
old	5	O
man	5	O
developed	5	O
jaundice	5	B-Disease
2	9	O
wk	9	O
after	9	O
exposure	9	O
to	5	O
thiabendazole	0	B-Chemical
.	9	O

Cholestasis	7	B-Disease
persisted	9	O
for	5	O
3	9	O
yr	7	O
,	9	O
at	9	O
which	5	O
time	5	O
a	5	O
liver	9	O
transplant	9	O
was	9	O
performed	9	O
.	9	O

Two	9	O
liver	9	O
biopsy	5	O
specimens	9	O
and	5	O
the	5	O
hepatectomy	5	O
specimen	9	O
were	9	O
remarkable	9	O
for	5	O
almost	9	O
complete	9	O
disappearance	9	O
of	5	O
interlobular	5	O
bile	0	O
ducts	5	O
.	9	O

Prominent	5	O
fibrosis	9	B-Disease
and	5	O
hepatocellular	9	O
regeneration	9	O
were	9	O
also	9	O
present	9	O
;	9	O
however	9	O
,	9	O
the	5	O
lobular	5	O
architecture	5	O
was	9	O
preserved	9	O
.	9	O

This	5	O
case	5	O
represents	9	O
an	5	O
example	5	O
of	5	O
"	5	O
idiosyncratic	5	O
"	5	O
drug	5	B-Disease
-	7	I-Disease
induced	3	I-Disease
liver	9	I-Disease
damage	9	I-Disease
in	5	O
which	5	O
the	5	O
primary	9	O
target	9	O
of	5	O
injury	9	O
is	5	O
the	5	O
bile	0	O
duct	5	O
.	9	O

An	5	O
autoimmune	3	O
pathogenesis	9	O
of	5	O
the	5	O
bile	0	B-Disease
duct	5	I-Disease
destruction	9	I-Disease
is	5	O
suggested	9	O
.	9	O

Differential	9	O
effects	9	O
of	5	O
1	9	B-Chemical
,	9	I-Chemical
4	9	I-Chemical
-	7	I-Chemical
dihydropyridine	0	I-Chemical
calcium	0	B-Chemical
channel	9	I-Chemical
blockers	9	I-Chemical
:	9	O
therapeutic	5	O
implications	5	O
.	9	O

Increasing	9	O
recognition	5	O
of	5	O
the	5	O
importance	5	O
of	5	O
calcium	0	B-Chemical
in	5	O
the	5	O
pathogenesis	9	O
of	5	O
cardiovascular	5	B-Disease
disease	5	I-Disease
has	9	O
stimulated	3	O
research	5	O
into	9	O
the	5	O
use	5	O
of	5	O
calcium	0	B-Chemical
channel	9	I-Chemical
blocking	3	I-Chemical
agents	5	I-Chemical
for	5	O
treatment	9	O
of	5	O
a	5	O
variety	5	O
of	5	O
cardiovascular	5	B-Disease
diseases	5	I-Disease
.	9	O

The	5	O
favorable	5	O
efficacy	9	O
and	5	O
tolerability	5	O
profiles	9	O
of	5	O
these	5	O
agents	5	O
make	5	O
them	5	O
attractive	5	O
therapeutic	5	O
modalities	5	O
.	9	O

Clinical	5	O
applications	5	O
of	5	O
calcium	0	B-Chemical
channel	9	I-Chemical
blockers	9	I-Chemical
parallel	5	O
their	5	O
tissue	9	O
selectivity	9	O
.	9	O

In	9	O
contrast	9	O
to	5	O
verapamil	0	B-Chemical
and	5	O
diltiazem	0	B-Chemical
,	9	O
which	5	O
are	5	O
roughly	5	O
equipotent	0	O
in	5	O
their	5	O
actions	5	O
on	5	O
the	5	O
heart	5	O
and	5	O
vascular	5	O
smooth	5	O
muscle	9	O
,	9	O
the	5	O
dihydropyridine	0	B-Chemical
calcium	0	B-Chemical
channel	9	I-Chemical
blockers	9	I-Chemical
are	5	O
a	5	O
group	9	O
of	5	O
potent	3	O
peripheral	9	O
vasodilator	0	O
agents	5	O
that	5	O
exert	9	O
minimal	9	O
electrophysiologic	5	O
effects	9	O
on	5	O
cardiac	5	O
nodal	5	O
or	5	O
conduction	5	O
tissue	9	O
.	9	O

As	9	O
the	5	O
first	9	O
dihydropyridine	0	B-Chemical
available	5	O
for	5	O
use	5	O
in	5	O
the	5	O
United	9	O
States	9	O
,	9	O
nifedipine	0	B-Chemical
controls	9	O
angina	5	B-Disease
and	5	O
hypertension	5	B-Disease
with	5	O
minimal	9	O
depression	5	O
of	5	O
cardiac	5	O
function	9	O
.	9	O

Additional	9	O
members	9	O
of	5	O
this	5	O
group	9	O
of	5	O
calcium	0	B-Chemical
channel	9	I-Chemical
blockers	9	I-Chemical
have	5	O
been	9	O
studied	9	O
for	5	O
a	5	O
variety	5	O
of	5	O
indications	5	O
for	5	O
which	5	O
they	5	O
may	5	O
offer	5	O
advantages	5	O
over	5	O
current	5	O
therapy	5	O
.	9	O

Once	5	O
or	5	O
twice	9	O
daily	5	O
dosage	9	O
possible	5	O
with	5	O
nitrendipine	0	B-Chemical
and	5	O
nisoldipine	0	B-Chemical
offers	5	O
a	5	O
convenient	5	O
administration	9	O
schedule	5	O
,	9	O
which	5	O
encourages	5	O
patient	5	O
compliance	5	O
in	5	O
long	5	O
-	7	O
term	5	O
therapy	5	O
of	5	O
hypertension	5	B-Disease
.	9	O

The	5	O
coronary	5	O
vasodilating	5	O
properties	9	O
of	5	O
nisoldipine	0	B-Chemical
have	5	O
led	9	O
to	5	O
the	5	O
investigation	9	O
of	5	O
this	5	O
agent	9	O
for	5	O
use	5	O
in	5	O
angina	5	B-Disease
.	9	O

Selectivity	0	O
for	5	O
the	5	O
cerebrovascular	5	O
bed	5	O
makes	5	O
nimodipine	0	B-Chemical
potentially	5	O
useful	5	O
in	5	O
the	5	O
treatment	9	O
of	5	O
subarachnoid	5	B-Disease
hemorrhage	5	I-Disease
,	9	O
migraine	5	B-Disease
headache	5	I-Disease
,	9	O
dementia	5	B-Disease
,	9	O
and	5	O
stroke	5	B-Disease
.	9	O

In	9	O
general	5	O
,	9	O
the	5	O
dihydropyridine	0	B-Chemical
calcium	0	B-Chemical
channel	9	I-Chemical
blockers	9	I-Chemical
are	5	O
usually	5	O
well	9	O
tolerated	9	O
,	9	O
with	5	O
headache	5	B-Disease
,	9	O
facial	5	O
flushing	5	B-Disease
,	9	O
palpitations	5	B-Disease
,	9	O
edema	5	B-Disease
,	9	O
nausea	5	B-Disease
,	9	O
anorexia	5	B-Disease
,	9	O
and	5	O
dizziness	5	B-Disease
being	5	O
the	5	O
more	5	O
common	5	O
adverse	5	O
effects	9	O
.	9	O

The	5	O
enhancement	9	O
of	5	O
aminonucleoside	0	B-Chemical
nephrosis	0	B-Disease
by	9	O
the	5	O
co	9	O
-	7	O
administration	9	O
of	5	O
protamine	0	O
.	9	O

An	5	O
experimental	5	O
model	5	O
of	5	O
focal	5	B-Disease
segmental	5	I-Disease
glomerular	5	I-Disease
sclerosis	5	I-Disease
(	9	O
FSGS	9	B-Disease
)	9	O
was	9	O
developed	5	O
in	5	O
rats	9	O
by	9	O
the	5	O
combined	9	O
administration	9	O
of	5	O
puromycin	3	B-Chemical
-	7	I-Chemical
aminonucleoside	0	I-Chemical
(	9	O
AMNS	9	B-Chemical
)	9	O
and	5	O
protamine	0	B-Chemical
sulfate	0	I-Chemical
(	9	O
PS	9	B-Chemical
)	9	O
.	9	O

Male	7	O
Sprague	9	O
-	7	O
Dawley	0	O
rats	9	O
,	9	O
uninephrectomized	3	O
three	9	O
weeks	9	O
before	9	O
,	9	O
received	9	O
daily	5	O
injections	9	O
of	5	O
subcutaneous	9	O
AMNS	9	B-Chemical
(	9	O
1	9	O
mg	0	O
/	9	O
100	0	O
g	0	O
body	5	O
wt	3	O
)	9	O
and	5	O
intravenous	0	O
PS	9	B-Chemical
(	9	O
2	9	O
separated	9	O
doses	0	O
of	5	O
2	9	O
.	9	O
5	9	O
mg	0	O
/	9	O
100	0	O
g	0	O
body	5	O
wt	3	O
)	9	O
for	5	O
four	9	O
days	9	O
.	9	O

The	5	O
series	5	O
of	5	O
injections	9	O
were	9	O
repeated	5	O
another	9	O
three	9	O
times	5	O
at	9	O
10	9	O
day	9	O
intervals	5	O
.	9	O

The	5	O
animals	9	O
were	9	O
sacrificed	3	O
on	5	O
days	9	O
24	9	O
,	9	O
52	7	O
,	9	O
and	5	O
80	9	O
.	9	O

They	5	O
developed	5	O
nephrotic	5	B-Disease
syndrome	5	I-Disease
and	5	O
finally	9	O
renal	9	B-Disease
failure	5	I-Disease
.	9	O

The	5	O
time	5	O
-	7	O
course	5	O
curve	9	O
of	5	O
creatinine	0	B-Chemical
clearance	9	O
dropped	9	O
and	5	O
showed	9	O
significant	9	O
difference	9	O
(	9	O
P	9	O
less	5	O
than	5	O
0	7	O
.	9	O
01	7	O
)	9	O
from	9	O
that	5	O
of	5	O
each	5	O
control	9	O
group	9	O
,	9	O
such	5	O
as	5	O
,	9	O
AMNS	9	B-Chemical
alone	9	O
,	9	O
PS	9	B-Chemical
alone	9	O
or	5	O
saline	0	O
injected	3	O
.	9	O

Their	5	O
glomeruli	9	O
showed	9	O
changes	9	O
of	5	O
progressive	5	O
FSGS	9	B-Disease
.	9	O

The	5	O
ultrastructural	9	O
studies	9	O
in	5	O
the	5	O
initial	9	O
stage	9	O
revealed	9	O
significant	9	O
lack	9	O
of	5	O
particles	0	O
of	5	O
perfused	0	O
ruthenium	0	B-Chemical
red	9	O
on	5	O
the	5	O
lamina	9	O
rara	2	O
externa	4	O
and	5	O
marked	9	O
changes	9	O
in	5	O
epithelial	3	O
cell	3	O
cytoplasm	3	O
.	9	O

Therefore	9	O
,	9	O
it	5	O
is	5	O
suggested	9	O
that	5	O
the	5	O
administration	9	O
of	5	O
PS	9	B-Chemical
enhances	3	O
the	5	O
toxicity	9	B-Disease
of	5	O
AMNS	9	B-Chemical
on	5	O
the	5	O
glomerulus	9	O
and	5	O
readily	9	O
produces	9	O
progressive	5	O
FSGS	9	B-Disease
in	5	O
rats	9	O
resulting	9	O
in	5	O
the	5	O
end	9	B-Disease
-	7	I-Disease
stage	9	I-Disease
renal	9	I-Disease
disease	5	I-Disease
.	9	O

Theophylline	0	B-Chemical
neurotoxicity	9	B-Disease
in	5	O
pregnant	5	O
rats	9	O
.	9	O

The	5	O
purpose	5	O
of	5	O
this	5	O
investigation	9	O
was	9	O
to	5	O
determine	9	O
whether	9	O
the	5	O
neurotoxicity	9	B-Disease
of	5	O
theophylline	0	B-Chemical
is	5	O
altered	9	O
in	5	O
advanced	5	O
pregnancy	5	O
.	9	O

Sprague	9	O
-	7	O
Dawley	0	O
rats	9	O
that	5	O
were	9	O
20	9	O
days	9	O
pregnant	5	O
and	5	O
nonpregnant	5	O
rats	9	O
of	5	O
the	5	O
same	9	O
age	5	O
and	5	O
strain	1	O
received	9	O
infusions	9	O
of	5	O
aminophylline	0	B-Chemical
until	5	O
onset	5	O
of	5	O
maximal	9	O
seizures	5	B-Disease
which	5	O
occurred	9	O
after	9	O
28	7	O
and	5	O
30	9	O
minutes	0	O
respectively	9	O
.	9	O

Theophylline	0	B-Chemical
concentrations	0	O
at	9	O
this	5	O
endpoint	5	O
in	5	O
serum	9	O
(	9	O
total	9	O
)	9	O
and	5	O
CSF	9	O
were	9	O
similar	9	O
but	9	O
serum	9	O
(	9	O
free	9	O
)	9	O
and	5	O
brain	5	O
concentrations	0	O
were	9	O
slightly	9	O
different	9	O
in	5	O
pregnant	5	O
rats	9	O
.	9	O

Theophylline	0	B-Chemical
serum	9	O
protein	1	O
binding	1	O
determined	9	O
by	9	O
equilibrium	9	O
dialysis	5	O
was	9	O
lower	9	O
in	5	O
pregnant	5	O
rats	9	O
.	9	O

Fetal	9	O
serum	9	O
concentrations	0	O
at	9	O
onset	5	O
of	5	O
seizures	5	B-Disease
in	5	O
the	5	O
mother	5	O
were	9	O
similar	9	O
to	5	O
maternal	9	O
brain	5	O
and	5	O
CSF	9	O
concentrations	0	O
and	5	O
correlated	9	O
significantly	9	O
with	5	O
the	5	O
former	5	O
.	9	O

It	5	O
is	5	O
concluded	9	O
that	5	O
advanced	5	O
pregnancy	5	O
has	9	O
a	5	O
negligible	9	O
effect	9	O
on	5	O
the	5	O
neurotoxic	9	B-Disease
response	9	O
to	5	O
theophylline	0	B-Chemical
in	5	O
rats	9	O
.	9	O

Hyperkalemia	7	B-Disease
induced	3	O
by	9	O
indomethacin	0	B-Chemical
and	5	O
naproxen	0	B-Chemical
and	5	O
reversed	9	O
by	9	O
fludrocortisone	0	B-Chemical
.	9	O

We	9	O
have	5	O
described	9	O
a	5	O
patient	5	O
with	5	O
severe	5	O
rheumatoid	9	B-Disease
arthritis	9	I-Disease
and	5	O
a	5	O
history	5	O
of	5	O
mefenamic	0	B-Chemical
acid	0	I-Chemical
nephropathy	9	B-Disease
in	5	O
whom	5	O
hyperkalemia	5	B-Disease
and	5	O
inappropriate	5	O
hypoaldosteronism	5	B-Disease
were	9	O
caused	9	O
by	9	O
both	9	O
indomethacin	0	B-Chemical
and	5	O
naproxen	0	B-Chemical
,	9	O
without	9	O
major	9	O
decline	9	O
in	5	O
renal	9	O
function	9	O
.	9	O

It	5	O
is	5	O
likely	5	O
that	5	O
preexisting	9	O
renal	9	B-Disease
disease	5	I-Disease
predisposed	5	O
this	5	O
patient	5	O
to	5	O
type	9	B-Disease
IV	9	I-Disease
renal	9	I-Disease
tubular	9	I-Disease
acidosis	5	I-Disease
with	5	O
prostaglandin	0	B-Chemical
synthetase	1	O
inhibitors	3	O
.	9	O

Because	9	O
he	5	O
was	9	O
unable	9	O
to	5	O
discontinue	5	O
nonsteroidal	5	O
anti	3	O
-	7	O
inflammatory	3	O
drug	5	O
therapy	5	O
,	9	O
fludrocortisone	0	B-Chemical
was	9	O
added	0	O
,	9	O
correcting	5	O
the	5	O
hyperkalemia	5	B-Disease
and	5	O
allowing	5	O
indomethacin	0	B-Chemical
therapy	5	O
to	5	O
be	5	O
continued	9	O
safely	5	O
.	9	O

Hypotension	7	B-Disease
as	5	O
a	5	O
manifestation	5	O
of	5	O
cardiotoxicity	9	B-Disease
in	5	O
three	9	O
patients	5	O
receiving	9	O
cisplatin	3	B-Chemical
and	5	O
5	9	B-Chemical
-	7	I-Chemical
fluorouracil	0	I-Chemical
.	9	O

Cardiac	9	O
symptoms	5	O
,	9	O
including	9	O
hypotension	5	B-Disease
,	9	O
developed	5	O
in	5	O
three	9	O
patients	5	O
with	5	O
advanced	5	O
colorectal	9	B-Disease
carcinoma	3	I-Disease
while	9	O
being	5	O
treated	3	O
with	5	O
cisplatin	3	B-Chemical
(	9	O
CDDP	3	B-Chemical
)	9	O
and	5	O
5	9	B-Chemical
-	7	I-Chemical
fluorouracil	0	I-Chemical
(	9	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
)	9	O
.	9	O

In	9	O
two	5	O
patients	5	O
,	9	O
hypotension	5	B-Disease
was	9	O
associated	9	O
with	5	O
severe	5	O
left	5	B-Disease
ventricular	5	I-Disease
dysfunction	9	I-Disease
.	9	O

All	9	O
three	9	O
patients	5	O
required	9	O
therapy	5	O
discontinuation	5	O
.	9	O

Cardiac	9	O
enzymes	1	O
remained	9	O
normal	9	O
despite	9	O
transient	9	O
electrocardiographic	5	O
(	9	O
EKG	5	O
)	9	O
changes	9	O
.	9	O

The	5	O
presentation	5	O
and	5	O
cardiac	5	O
evaluation	5	O
(	9	O
hemodynamic	5	O
,	9	O
echocardiographic	5	O
,	9	O
and	5	O
scintigraphic	5	O
)	9	O
of	5	O
these	5	O
patients	5	O
suggest	9	O
new	5	O
manifestations	5	O
of	5	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
cardiotoxicity	9	B-Disease
that	5	O
may	5	O
be	5	O
influenced	5	O
by	9	O
CDDP	3	B-Chemical
.	9	O

The	5	O
possible	5	O
pathophysiologic	5	O
mechanisms	9	O
are	5	O
discussed	5	O
.	9	O

Fatal	5	O
aplastic	5	B-Disease
anemia	9	I-Disease
in	5	O
a	5	O
patient	5	O
treated	3	O
with	5	O
carbamazepine	0	B-Chemical
.	9	O

A	9	O
case	5	O
of	5	O
fatal	5	O
aplastic	5	B-Disease
anemia	9	I-Disease
due	5	O
to	5	O
carbamazepine	0	B-Chemical
treatment	9	O
in	5	O
an	5	O
epileptic	5	B-Disease
woman	5	O
is	5	O
reported	9	O
.	9	O

Despite	5	O
concerns	5	O
of	5	O
fatal	5	O
bone	5	B-Disease
marrow	3	I-Disease
toxicity	9	I-Disease
due	5	O
to	5	O
carbamazepine	0	B-Chemical
,	9	O
this	5	O
is	5	O
only	9	O
the	5	O
fourth	9	O
documented	9	O
and	5	O
published	9	O
report	5	O
.	9	O

Carbamazepine	0	B-Chemical
is	5	O
a	5	O
safe	5	O
drug	5	O
,	9	O
but	9	O
physicians	5	O
and	5	O
patients	5	O
should	5	O
be	5	O
aware	5	O
of	5	O
the	5	O
exceedingly	5	O
rare	5	O
but	9	O
potentially	5	O
fatal	5	O
side	5	O
effects	9	O
,	9	O
better	5	O
prevented	9	O
by	9	O
clinical	5	O
than	5	O
by	9	O
laboratory	9	O
monitoring	5	O
.	9	O

Participation	5	O
of	5	O
a	5	O
bulbospinal	5	O
serotonergic	5	O
pathway	3	O
in	5	O
the	5	O
rat	3	O
brain	5	O
in	5	O
clonidine	0	B-Chemical
-	7	O
induced	3	O
hypotension	5	B-Disease
and	5	O
bradycardia	5	B-Disease
.	9	O

The	5	O
effects	9	O
of	5	O
microinjection	3	O
of	5	O
clonidine	0	B-Chemical
(	9	O
1	9	O
-	7	O
10	9	O
micrograms	0	O
in	5	O
1	9	O
microliter	0	O
)	9	O
into	9	O
a	5	O
region	9	O
adjacent	9	O
to	5	O
the	5	O
ventrolateral	5	O
surface	9	O
of	5	O
the	5	O
medulla	9	O
oblongata	5	O
on	5	O
cardiovascular	5	O
function	9	O
were	9	O
assessed	9	O
in	5	O
urethane	0	B-Chemical
-	7	O
anesthetized	0	O
rats	9	O
.	9	O

Intramedullary	5	O
administration	9	O
of	5	O
clonidine	0	B-Chemical
,	9	O
but	9	O
not	5	O
saline	0	O
vehicle	3	O
,	9	O
caused	9	O
a	5	O
dose	9	O
-	7	O
dependent	9	O
decrease	9	O
in	5	O
both	9	O
the	5	O
mean	5	O
arterial	5	O
pressure	5	O
and	5	O
the	5	O
heart	5	O
rate	9	O
.	9	O

The	5	O
clonidine	0	B-Chemical
-	7	O
induced	3	O
hypotension	5	B-Disease
was	9	O
antagonized	3	O
by	9	O
prior	9	O
spinal	5	O
transection	5	O
,	9	O
but	9	O
not	5	O
bilateral	5	O
vagotomy	5	O
.	9	O

On	5	O
the	5	O
other	5	O
hand	5	O
,	9	O
the	5	O
clonidine	0	B-Chemical
-	7	O
induced	3	O
bradycardia	5	B-Disease
was	9	O
antagonized	3	O
by	9	O
prior	9	O
bilateral	5	O
vagotomy	5	O
,	9	O
but	9	O
not	5	O
spinal	5	O
transection	5	O
.	9	O

Furthermore	9	O
,	9	O
selective	9	O
destruction	9	O
of	5	O
the	5	O
spinal	5	O
5	9	B-Chemical
-	7	I-Chemical
HT	9	I-Chemical
nerves	5	O
,	9	O
produced	9	O
by	9	O
bilateral	5	O
spinal	5	O
injection	9	O
of	5	O
5	9	B-Chemical
,	9	I-Chemical
7	9	I-Chemical
-	7	I-Chemical
dihydroxytryptamine	9	I-Chemical
,	9	O
reduced	9	O
the	5	O
magnitude	5	O
of	5	O
the	5	O
vasodepressor	5	O
or	5	O
the	5	O
bradycardiac	5	B-Disease
responses	5	O
to	5	O
clonidine	0	B-Chemical
microinjected	3	O
into	9	O
the	5	O
area	5	O
near	9	O
the	5	O
ventrolateral	5	O
surface	9	O
of	5	O
the	5	O
medulla	9	O
oblongata	5	O
in	5	O
rats	9	O
.	9	O

The	5	O
data	5	O
indicate	9	O
that	5	O
a	5	O
bulbospinal	5	O
serotonergic	5	O
pathway	3	O
is	5	O
involved	9	O
in	5	O
development	9	O
of	5	O
clonidine	0	B-Chemical
-	7	O
induced	3	O
hypotension	5	B-Disease
and	5	O
bradycardia	5	B-Disease
.	9	O

The	5	O
induced	3	O
hypotension	5	B-Disease
is	5	O
brought	5	O
about	5	O
by	9	O
a	5	O
decrease	9	O
in	5	O
sympathetic	5	O
efferent	5	O
activity	9	O
,	9	O
whereas	9	O
the	5	O
induced	3	O
bradycardia	5	B-Disease
was	9	O
due	5	O
to	5	O
an	5	O
increase	9	O
in	5	O
vagal	5	O
efferent	5	O
activity	9	O
.	9	O

Hypertension	7	B-Disease
in	5	O
neuroblastoma	3	B-Disease
induced	3	O
by	9	O
imipramine	0	B-Chemical
.	9	O

Hypertension	7	B-Disease
is	5	O
a	5	O
well	9	O
-	7	O
known	9	O
finding	9	O
in	5	O
some	5	O
patients	5	O
with	5	O
neuroblastoma	3	B-Disease
.	9	O

However	9	O
,	9	O
it	5	O
has	9	O
not	5	O
previously	9	O
been	9	O
described	9	O
in	5	O
association	9	O
with	5	O
the	5	O
use	5	O
of	5	O
Imipramine	0	B-Chemical
.	9	O

We	9	O
report	5	O
the	5	O
occurrence	5	O
of	5	O
severe	5	O
hypertension	5	B-Disease
(	9	O
blood	9	O
pressure	5	O
190	9	O
/	9	O
160	9	O
)	9	O
in	5	O
a	5	O
4	9	O
-	7	O
year	5	O
-	7	O
old	5	O
girl	5	O
with	5	O
neuroblastoma	3	B-Disease
who	5	O
was	9	O
given	5	O
Imipramine	0	B-Chemical
to	5	O
control	9	O
a	5	O
behavior	5	B-Disease
disorder	5	I-Disease
.	9	O

It	5	O
was	9	O
determined	9	O
later	9	O
that	5	O
this	5	O
patient	5	O
'	9	O
s	9	O
tumor	3	B-Disease
was	9	O
recurring	5	O
at	9	O
the	5	O
time	5	O
of	5	O
her	5	O
hypertensive	5	B-Disease
episode	5	O
.	9	O

Since	9	O
she	5	O
had	9	O
no	9	O
blood	9	O
pressure	5	O
elevation	9	O
at	9	O
initial	9	O
diagnosis	5	O
and	5	O
none	9	O
following	9	O
discontinuation	5	O
of	5	O
the	5	O
Imipramine	0	B-Chemical
(	9	O
when	5	O
she	5	O
was	9	O
in	5	O
florid	5	O
relapse	5	O
)	9	O
,	9	O
we	5	O
believe	5	O
that	5	O
this	5	O
drug	5	O
rather	5	O
than	5	O
her	5	O
underlying	5	O
disease	5	O
alone	9	O
caused	9	O
her	5	O
hypertension	5	B-Disease
.	9	O

The	5	O
mechanism	9	O
for	5	O
this	5	O
reaction	9	O
is	5	O
believed	5	O
to	5	O
be	5	O
increased	9	O
levels	3	O
of	5	O
vasoactive	5	O
catecholamines	9	B-Chemical
due	5	O
to	5	O
interference	9	O
of	5	O
their	5	O
physiologic	9	O
inactivation	9	O
by	9	O
Imipramine	0	B-Chemical
.	9	O

From	5	O
this	5	O
experience	5	O
,	9	O
we	5	O
urge	5	O
extreme	5	O
caution	5	O
in	5	O
the	5	O
use	5	O
of	5	O
tricyclic	0	O
antidepressants	5	O
in	5	O
children	5	O
with	5	O
active	9	O
neuroblastoma	3	B-Disease
.	9	O

Rechallenge	3	O
of	5	O
patients	5	O
who	5	O
developed	5	O
oral	9	B-Disease
candidiasis	5	I-Disease
or	5	O
hoarseness	5	B-Disease
with	5	O
beclomethasone	0	B-Chemical
dipropionate	0	I-Chemical
.	9	O

Of	9	O
158	7	O
asthmatic	9	B-Disease
patients	5	O
who	5	O
were	9	O
placed	5	O
on	5	O
inhaled	5	O
beclomethasone	0	B-Chemical
,	9	O
15	9	O
(	9	O
9	7	O
.	9	O
5	9	O
%	9	O
)	9	O
developed	5	O
either	9	O
hoarseness	5	B-Disease
(	9	O
8	9	O
)	9	O
,	9	O
oral	9	O
thrush	4	B-Disease
(	9	O
6	9	O
)	9	O
,	9	O
or	5	O
both	9	O
(	9	O
1	9	O
)	9	O
.	9	O

When	9	O
their	5	O
adverse	5	O
reactions	9	O
subsided	5	O
,	9	O
seven	9	O
of	5	O
these	5	O
15	9	O
patients	5	O
were	9	O
rechallenged	3	O
with	5	O
inhaled	5	O
beclomethasone	0	B-Chemical
.	9	O

These	5	O
included	5	O
five	9	O
cases	5	O
who	5	O
developed	5	O
hoarseness	5	B-Disease
and	5	O
three	9	O
who	5	O
developed	5	O
Candidiasis	7	B-Disease
.	9	O

One	5	O
patient	5	O
had	9	O
both	9	O
.	9	O

Oral	9	O
thrush	4	B-Disease
did	9	O
not	5	O
recur	5	O
,	9	O
but	9	O
60	9	O
%	9	O
(	9	O
3	9	O
/	9	O
5	9	O
)	9	O
of	5	O
patients	5	O
with	5	O
hoarseness	5	B-Disease
had	9	O
recurrence	5	O
.	9	O

We	9	O
conclude	9	O
that	5	O
patients	5	O
may	5	O
be	5	O
restarted	5	O
on	5	O
inhaled	5	O
beclomethasone	0	B-Chemical
when	5	O
clinically	5	O
indicated	9	O
;	9	O
however	9	O
,	9	O
because	5	O
of	5	O
the	5	O
high	9	O
recurrence	5	O
rate	9	O
,	9	O
patients	5	O
who	5	O
develop	5	O
hoarseness	5	B-Disease
should	5	O
not	5	O
be	5	O
re	5	O
-	7	O
challenged	3	O
.	9	O

Concomitant	9	O
use	5	O
of	5	O
oral	9	O
prednisone	0	B-Chemical
and	5	O
topical	0	O
beclomethasone	0	B-Chemical
may	5	O
increase	9	O
the	5	O
risk	5	O
of	5	O
developing	5	O
hoarseness	5	B-Disease
or	5	O
candidiasis	5	B-Disease
.	9	O

Cyclophosphamide	0	B-Chemical
cardiotoxicity	9	B-Disease
:	9	O
an	5	O
analysis	9	O
of	5	O
dosing	9	O
as	5	O
a	5	O
risk	5	O
factor	9	O
.	9	O

Patients	5	O
who	5	O
undergo	9	O
bone	5	O
marrow	3	O
transplantation	9	O
are	5	O
generally	5	O
immunosuppressed	5	O
with	5	O
a	5	O
dose	9	O
of	5	O
cyclophosphamide	0	B-Chemical
(	9	O
CYA	4	B-Chemical
)	9	O
which	5	O
is	5	O
usually	5	O
calculated	5	O
based	5	O
on	5	O
the	5	O
patient	5	O
'	9	O
s	9	O
weight	9	O
.	9	O

At	9	O
these	5	O
high	9	O
doses	0	O
of	5	O
CYA	4	B-Chemical
,	9	O
serious	5	O
cardiotoxicity	9	B-Disease
may	5	O
occur	5	O
,	9	O
but	9	O
definitive	5	O
risk	5	O
factors	9	O
for	5	O
the	5	O
development	9	O
of	5	O
such	5	O
cardiotoxicity	9	B-Disease
have	5	O
not	5	O
been	9	O
described	9	O
.	9	O

Since	9	O
chemotherapeutic	3	O
agent	9	O
toxicity	9	B-Disease
generally	5	O
correlates	9	O
with	5	O
dose	9	O
per	9	O
body	5	O
surface	9	O
area	5	O
,	9	O
we	5	O
retrospectively	5	O
calculated	5	O
the	5	O
dose	9	O
of	5	O
CYA	4	B-Chemical
in	5	O
patients	5	O
transplanted	3	O
at	9	O
our	5	O
institution	5	O
to	5	O
determine	9	O
whether	9	O
the	5	O
incidence	5	O
of	5	O
CYA	4	B-Chemical
cardiotoxicity	9	B-Disease
correlated	9	O
with	5	O
the	5	O
dose	9	O
per	9	O
body	5	O
surface	9	O
area	5	O
.	9	O

Eighty	5	O
patients	5	O
who	5	O
were	9	O
to	5	O
receive	5	O
CYA	4	B-Chemical
50	0	O
mg	0	O
/	9	O
kg	0	O
/	9	O
d	9	O
for	5	O
four	9	O
days	9	O
as	5	O
preparation	9	O
for	5	O
marrow	3	O
grafting	5	O
underwent	5	O
a	5	O
total	9	O
of	5	O
84	7	O
transplants	9	O
for	5	O
aplastic	5	B-Disease
anemia	9	I-Disease
,	9	O
Wiskott	1	B-Disease
-	7	I-Disease
Aldrich	0	I-Disease
syndrome	5	I-Disease
,	9	O
or	5	O
severe	5	B-Disease
combined	9	I-Disease
immunodeficiency	9	I-Disease
syndrome	5	I-Disease
.	9	O

Fourteen	9	O
of	5	O
84	7	O
(	9	O
17	7	O
%	9	O
)	9	O
patients	5	O
had	9	O
symptoms	5	O
and	5	O
signs	5	O
consistent	9	O
with	5	O
CYA	4	B-Chemical
cardiotoxicity	9	B-Disease
within	9	O
ten	9	O
days	9	O
of	5	O
receiving	9	O
1	9	O
to	5	O
4	9	O
doses	0	O
of	5	O
CYA	4	B-Chemical
.	9	O

Six	9	O
of	5	O
the	5	O
14	7	O
patients	5	O
died	9	O
with	5	O
congestive	5	B-Disease
heart	5	I-Disease
failure	5	I-Disease
.	9	O

The	5	O
dose	9	O
of	5	O
CYA	4	B-Chemical
per	9	O
body	5	O
surface	9	O
area	5	O
was	9	O
calculated	5	O
for	5	O
all	5	O
patients	5	O
and	5	O
the	5	O
patients	5	O
were	9	O
divided	5	O
into	9	O
two	5	O
groups	9	O
based	5	O
on	5	O
daily	5	O
CYA	4	B-Chemical
dose	9	O
:	9	O
Group	9	O
1	9	O
,	9	O
CYA	4	B-Chemical
less	5	O
than	5	O
or	5	O
equal	9	O
to	5	O
1	9	O
.	9	O
55	7	O
g	0	O
/	9	O
m2	7	O
/	9	O
d	9	O
;	9	O
Group	9	O
2	9	O
,	9	O
CYA	4	B-Chemical
greater	5	O
than	5	O
1	9	O
.	9	O
55	7	O
g	0	O
/	9	O
m2	7	O
/	9	O
d	9	O
.	9	O

Cardiotoxicity	9	B-Disease
that	5	O
was	9	O
thought	5	O
to	5	O
be	5	O
related	9	O
to	5	O
CYA	4	B-Chemical
occurred	9	O
in	5	O
1	9	O
/	9	O
32	7	O
(	9	O
3	9	O
%	9	O
)	9	O
of	5	O
patients	5	O
in	5	O
Group	9	O
1	9	O
and	5	O
in	5	O
13	7	O
/	9	O
52	7	O
(	9	O
25	9	O
%	9	O
)	9	O
patients	5	O
in	5	O
Group	9	O
2	9	O
(	9	O
P	9	O
less	5	O
than	5	O
0	7	O
.	9	O
025	7	O
)	9	O
.	9	O

Congestive	7	B-Disease
heart	5	I-Disease
failure	5	I-Disease
caused	9	O
or	5	O
contributed	9	O
to	5	O
death	9	O
in	5	O
0	7	O
/	9	O
32	7	O
patients	5	O
in	5	O
Group	9	O
1	9	O
v	0	O
6	9	O
/	9	O
52	7	O
(	9	O
12	9	O
%	9	O
)	9	O
of	5	O
patients	5	O
in	5	O
Group	9	O
2	9	O
(	9	O
P	9	O
less	5	O
than	5	O
0	7	O
.	9	O
25	9	O
)	9	O
.	9	O

There	5	O
was	9	O
no	9	O
difference	9	O
in	5	O
the	5	O
rate	9	O
of	5	O
engraftment	3	O
of	5	O
evaluable	9	O
patients	5	O
in	5	O
the	5	O
two	5	O
groups	9	O
(	9	O
P	9	O
greater	5	O
than	5	O
0	7	O
.	9	O
5	9	O
)	9	O
.	9	O

We	9	O
conclude	9	O
that	5	O
the	5	O
CYA	4	B-Chemical
cardiotoxicity	9	B-Disease
correlates	9	O
with	5	O
CYA	4	B-Chemical
dosage	9	O
as	5	O
calculated	5	O
by	9	O
body	5	O
surface	9	O
area	5	O
,	9	O
and	5	O
that	5	O
patients	5	O
with	5	O
aplastic	5	B-Disease
anemia	9	I-Disease
and	5	O
immunodeficiencies	5	B-Disease
can	5	O
be	5	O
effectively	5	O
prepared	0	O
for	5	O
bone	5	O
marrow	3	O
grafting	5	O
at	9	O
a	5	O
CYA	4	B-Chemical
dose	9	O
of	5	O
1	9	O
.	9	O
55	7	O
g	0	O
/	9	O
m2	7	O
/	9	O
d	9	O
for	5	O
four	9	O
days	9	O
with	5	O
a	5	O
lower	9	O
incidence	5	O
of	5	O
cardiotoxicity	9	B-Disease
than	5	O
patients	5	O
whose	9	O
CYA	4	B-Chemical
dosage	9	O
is	5	O
calculated	5	O
based	5	O
on	5	O
weight	9	O
.	9	O

This	5	O
study	9	O
reaffirms	5	O
the	5	O
principle	5	O
that	5	O
drug	5	O
toxicity	9	B-Disease
correlates	9	O
with	5	O
dose	9	O
per	9	O
body	5	O
surface	9	O
area	5	O
.	9	O

Studies	9	O
of	5	O
risk	5	O
factors	9	O
for	5	O
aminoglycoside	9	B-Chemical
nephrotoxicity	9	B-Disease
.	9	O

The	5	O
epidemiology	5	O
of	5	O
aminoglycoside	9	B-Chemical
-	7	O
induced	3	O
nephrotoxicity	9	B-Disease
is	5	O
not	5	O
fully	9	O
understood	5	O
.	9	O

Experimental	9	O
studies	9	O
in	5	O
healthy	5	O
human	3	O
volunteers	5	O
indicate	9	O
aminoglycosides	9	B-Chemical
cause	5	O
proximal	9	O
tubular	9	O
damage	9	O
in	5	O
most	9	O
patients	5	O
,	9	O
but	9	O
rarely	5	O
,	9	O
if	5	O
ever	5	O
,	9	O
cause	5	O
glomerular	5	B-Disease
or	5	I-Disease
tubular	9	I-Disease
dysfunction	9	I-Disease
.	9	O

Clinical	5	O
trials	5	O
of	5	O
aminoglycosides	9	B-Chemical
in	5	O
seriously	5	O
ill	5	O
patients	5	O
indicate	9	O
that	5	O
the	5	O
relative	9	O
risk	5	O
for	5	O
developing	5	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
during	5	O
therapy	5	O
ranges	5	O
from	9	O
8	9	O
to	5	O
10	9	O
and	5	O
that	5	O
the	5	O
attributable	9	O
risk	5	O
is	5	O
70	9	O
%	9	O
to	5	O
80	9	O
%	9	O
.	9	O

Further	9	O
analysis	9	O
of	5	O
these	5	O
data	5	O
suggests	9	O
that	5	O
the	5	O
duration	5	O
of	5	O
therapy	5	O
,	9	O
plasma	9	O
aminoglycoside	9	B-Chemical
levels	3	O
,	9	O
liver	9	B-Disease
disease	5	I-Disease
,	9	O
advanced	5	O
age	5	O
,	9	O
high	9	O
initial	9	O
estimated	5	O
creatinine	0	B-Chemical
clearance	9	O
and	5	O
,	9	O
possibly	9	O
,	9	O
female	9	O
gender	5	O
all	5	O
increase	9	O
the	5	O
risk	5	O
for	5	O
nephrotoxicity	9	B-Disease
.	9	O

Other	9	O
causes	9	O
of	5	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
,	9	O
such	5	O
as	5	O
shock	9	B-Disease
,	9	O
appear	9	O
to	5	O
have	5	O
an	5	O
additive	9	O
effect	9	O
.	9	O

Predictive	5	O
models	5	O
have	5	O
been	9	O
developed	5	O
from	9	O
these	5	O
analyses	9	O
that	5	O
should	5	O
be	5	O
useful	5	O
for	5	O
identifying	5	O
patients	5	O
at	9	O
high	9	O
risk	5	O
.	9	O

These	5	O
models	5	O
may	5	O
also	9	O
be	5	O
useful	5	O
in	5	O
developing	5	O
insights	5	O
into	9	O
the	5	O
pathophysiology	9	O
of	5	O
aminoglycoside	9	B-Chemical
-	7	O
induced	3	O
nephrotoxicity	9	B-Disease
.	9	O

Central	4	O
action	5	O
of	5	O
narcotic	5	O
analgesics	5	O
.	9	O

Part	9	O
IV	9	O
.	9	O

Noradrenergic	5	O
influences	5	O
on	5	O
the	5	O
activity	9	O
of	5	O
analgesics	5	O
in	5	O
rats	9	O
.	9	O

The	5	O
effect	9	O
of	5	O
clonidine	0	B-Chemical
,	9	O
naphazoline	0	B-Chemical
and	5	O
xylometazoline	0	B-Chemical
on	5	O
analgesia	5	O
induced	3	O
by	9	O
morphine	0	B-Chemical
,	9	O
codeine	0	B-Chemical
,	9	O
fentanyl	0	B-Chemical
and	5	O
pentazocine	0	B-Chemical
,	9	O
and	5	O
on	5	O
cataleptic	5	B-Disease
effect	9	O
of	5	O
morphine	0	B-Chemical
,	9	O
codine	_	B-Chemical
and	5	O
fentanyl	0	B-Chemical
was	9	O
studied	9	O
in	5	O
rats	9	O
.	9	O

The	5	O
biochemical	9	O
assays	3	O
on	5	O
the	5	O
influence	5	O
of	5	O
four	9	O
analgesics	5	O
on	5	O
the	5	O
brain	5	O
concentration	0	O
and	5	O
turnover	9	O
of	5	O
noradrenaline	0	B-Chemical
(	9	O
NA	7	B-Chemical
)	9	O
were	9	O
also	9	O
performed	9	O
.	9	O

It	5	O
was	9	O
found	9	O
that	5	O
three	9	O
drugs	5	O
stimulating	9	O
central	5	O
NA	7	B-Chemical
receptors	3	O
failed	9	O
to	5	O
affect	9	O
the	5	O
analgesic	5	O
ED50	0	O
of	5	O
all	5	O
antinociceptive	0	O
agents	5	O
and	5	O
they	5	O
enhanced	3	O
catalepsy	5	B-Disease
induced	3	O
by	9	O
morphine	0	B-Chemical
and	5	O
fentanyl	0	B-Chemical
.	9	O

Codeine	0	B-Chemical
catalepsy	5	B-Disease
was	9	O
increased	9	O
by	9	O
clonidine	0	B-Chemical
and	5	O
decreased	9	O
by	9	O
naphazoline	0	B-Chemical
and	5	O
xylometazoline	0	B-Chemical
.	9	O

The	5	O
brain	5	O
concentration	0	O
of	5	O
NA	7	B-Chemical
was	9	O
not	5	O
changed	9	O
by	9	O
morphine	0	B-Chemical
and	5	O
fentanyl	0	B-Chemical
,	9	O
but	9	O
one	5	O
of	5	O
the	5	O
doses	0	O
of	5	O
codeine	0	B-Chemical
(	9	O
45	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
slightly	9	O
enhanced	3	O
it	5	O
.	9	O

Pentazocine	7	B-Chemical
dose	9	O
-	7	O
dependently	3	O
decreased	9	O
the	5	O
brain	5	O
level	9	O
of	5	O
NA	7	B-Chemical
.	9	O

The	5	O
rate	9	O
of	5	O
NA	7	B-Chemical
turnover	9	O
was	9	O
not	5	O
altered	9	O
by	9	O
analgesics	5	O
except	9	O
for	5	O
the	5	O
higher	9	O
dose	9	O
of	5	O
fentanyl	0	B-Chemical
(	9	O
0	7	O
.	9	O
2	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
following	9	O
which	5	O
the	5	O
disappearance	9	O
of	5	O
NA	7	B-Chemical
from	9	O
the	5	O
brain	5	O
was	9	O
diminished	9	O
.	9	O

The	5	O
results	9	O
are	5	O
discussed	5	O
in	5	O
the	5	O
light	9	O
of	5	O
various	9	O
and	5	O
non	9	O
-	7	O
uniform	5	O
data	5	O
from	9	O
the	5	O
literature	5	O
.	9	O

It	5	O
is	5	O
suggested	9	O
that	5	O
in	5	O
rats	9	O
the	5	O
brain	5	O
NA	7	B-Chemical
plays	9	O
a	5	O
less	5	O
important	9	O
function	9	O
than	5	O
the	5	O
other	5	O
monoamines	0	B-Chemical
in	5	O
the	5	O
behavioural	5	O
activity	9	O
of	5	O
potent	3	O
analgesics	5	O
.	9	O

Flurothyl	9	B-Chemical
seizure	5	B-Disease
thresholds	5	O
in	5	O
mice	3	O
treated	3	O
neonatally	3	O
with	5	O
a	5	O
single	9	O
injection	9	O
of	5	O
monosodium	0	B-Chemical
glutamate	0	I-Chemical
(	9	O
MSG	9	B-Chemical
)	9	O
:	9	O
evaluation	5	O
of	5	O
experimental	5	O
parameters	5	O
in	5	O
flurothyl	0	B-Chemical
seizure	5	B-Disease
testing	5	O
.	9	O

Monosodium	0	B-Chemical
glutamate	0	I-Chemical
(	9	O
MSG	9	B-Chemical
)	9	O
administration	9	O
to	5	O
neonatal	9	O
rodents	9	O
produces	9	O
convulsions	5	B-Disease
and	5	O
results	9	O
in	5	O
numerous	9	O
biochemical	9	O
and	5	O
behavioral	5	O
deficits	5	O
.	9	O

These	5	O
studies	9	O
were	9	O
undertaken	5	O
to	5	O
determine	9	O
if	5	O
neonatal	9	O
administration	9	O
of	5	O
MSG	9	B-Chemical
produced	9	O
permanent	5	O
alterations	9	O
in	5	O
seizure	5	B-Disease
susceptibility	9	O
,	9	O
since	9	O
previous	9	O
investigations	9	O
were	9	O
inconclusive	9	O
.	9	O

A	9	O
flurothyl	0	B-Chemical
ether	0	B-Chemical
seizure	5	B-Disease
screening	5	O
technique	5	O
was	9	O
used	5	O
to	5	O
evaluate	9	O
seizure	5	B-Disease
susceptibility	9	O
in	5	O
adult	9	O
mice	3	O
that	5	O
received	9	O
neonatal	9	O
injections	9	O
of	5	O
MSG	9	B-Chemical
(	9	O
4	9	O
mg	0	O
/	9	O
g	0	O
and	5	O
1	9	O
mg	0	O
/	9	O
g	0	O
)	9	O
.	9	O

MSG	9	B-Chemical
treatment	9	O
resulted	9	O
in	5	O
significant	9	O
reductions	9	O
in	5	O
whole	9	O
brain	5	O
weight	9	O
but	9	O
did	9	O
not	5	O
alter	9	O
seizure	5	B-Disease
threshold	5	O
.	9	O

A	9	O
naloxone	0	B-Chemical
(	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
challenge	9	O
was	9	O
also	9	O
ineffective	9	O
in	5	O
altering	9	O
the	5	O
seizure	5	B-Disease
thresholds	5	O
of	5	O
either	9	O
control	9	O
of	5	O
MSG	9	B-Chemical
-	7	O
treated	3	O
mice	3	O
.	9	O

Flurothyl	9	B-Chemical
ether	0	B-Chemical
produced	9	O
hypothermia	5	B-Disease
which	5	O
was	9	O
correlated	9	O
with	5	O
the	5	O
duration	5	O
of	5	O
flurothyl	0	B-Chemical
exposure	9	O
;	9	O
however	9	O
,	9	O
the	5	O
relationship	5	O
of	5	O
hypothermia	5	B-Disease
to	5	O
seizure	5	B-Disease
induction	3	O
was	9	O
unclear	9	O
.	9	O

Flurothyl	9	B-Chemical
seizure	5	B-Disease
testing	5	O
proved	9	O
to	5	O
be	5	O
a	5	O
rapid	5	O
and	5	O
reliable	5	O
technique	5	O
with	5	O
which	5	O
to	5	O
evaluate	9	O
seizure	5	B-Disease
susceptibility	9	O
.	9	O

Susceptibility	9	O
to	5	O
seizures	5	B-Disease
produced	9	O
by	9	O
pilocarpine	0	B-Chemical
in	5	O
rats	9	O
after	9	O
microinjection	3	O
of	5	O
isoniazid	0	B-Chemical
or	5	O
gamma	9	B-Chemical
-	7	I-Chemical
vinyl	0	I-Chemical
-	7	I-Chemical
GABA	0	I-Chemical
into	9	O
the	5	O
substantia	9	O
nigra	4	O
.	9	O

Pilocarpine	0	B-Chemical
,	9	O
given	5	O
intraperitoneally	0	O
to	5	O
rats	9	O
,	9	O
reproduces	5	O
the	5	O
neuropathological	5	O
sequelae	5	O
of	5	O
temporal	5	B-Disease
lobe	5	I-Disease
epilepsy	5	I-Disease
and	5	O
provides	5	O
a	5	O
relevant	5	O
animal	5	O
model	5	O
for	5	O
studying	5	O
mechanisms	9	O
of	5	O
buildup	5	O
of	5	O
convulsive	5	B-Disease
activity	9	O
and	5	O
pathways	9	O
operative	5	O
in	5	O
the	5	O
generalization	5	O
and	5	O
propagation	5	O
of	5	O
seizures	5	B-Disease
within	9	O
the	5	O
forebrain	3	O
.	9	O

In	9	O
the	5	O
present	9	O
study	9	O
,	9	O
the	5	O
effects	9	O
of	5	O
manipulating	5	O
the	5	O
activity	9	O
of	5	O
the	5	O
gamma	9	B-Chemical
-	7	I-Chemical
aminobutyric	0	I-Chemical
acid	0	I-Chemical
(	9	O
GABA	0	B-Chemical
)	9	O
-	7	O
mediated	3	O
synaptic	5	O
inhibition	3	O
within	9	O
the	5	O
substantia	9	O
nigra	4	O
on	5	O
seizures	5	B-Disease
produced	9	O
by	9	O
pilocarpine	0	B-Chemical
in	5	O
rats	9	O
,	9	O
were	9	O
investigated	9	O
.	9	O

In	9	O
animals	9	O
pretreated	3	O
with	5	O
microinjections	9	O
of	5	O
isoniazid	0	B-Chemical
,	9	O
150	0	O
micrograms	0	O
,	9	O
an	5	O
inhibitor	3	O
of	5	O
activity	9	O
of	5	O
the	5	O
GABA	0	B-Chemical
-	7	O
synthesizing	9	O
enzyme	0	O
,	9	O
L	0	B-Chemical
-	7	I-Chemical
glutamic	0	I-Chemical
acid	0	I-Chemical
decarboxylase	1	O
,	9	O
into	9	O
the	5	O
substantia	9	O
nigra	4	O
pars	4	O
reticulata	4	O
(	9	O
SNR	5	O
)	9	O
,	9	O
bilaterally	5	O
,	9	O
non	9	O
-	7	O
convulsant	0	O
doses	0	O
of	5	O
pilocarpine	0	B-Chemical
,	9	O
100	0	O
and	5	O
200	0	O
mg	0	O
/	9	O
kg	0	O
,	9	O
resulted	9	O
in	5	O
severe	5	O
motor	5	O
limbic	5	O
seizures	5	B-Disease
and	5	O
status	9	B-Disease
epilepticus	5	I-Disease
.	9	O

Electroencephalographic	5	O
and	5	O
behavioral	5	O
monitoring	5	O
revealed	9	O
a	5	O
profound	9	O
reduction	9	O
of	5	O
the	5	O
threshold	5	O
for	5	O
pilocarpine	0	B-Chemical
-	7	O
induced	3	O
convulsions	5	B-Disease
.	9	O

Morphological	9	O
analysis	9	O
of	5	O
frontal	5	O
forebrain	3	O
sections	9	O
with	5	O
light	9	O
microscopy	9	O
revealed	9	O
seizure	5	B-Disease
-	7	O
related	9	O
damage	9	O
to	5	O
the	5	O
hippocampal	3	O
formation	9	O
,	9	O
thalamus	5	O
,	9	O
amygdala	5	O
,	9	O
olfactory	5	O
cortex	5	O
,	9	O
substantia	9	O
nigra	4	O
and	5	O
neocortex	5	O
,	9	O
which	5	O
is	5	O
typically	5	O
observed	9	O
with	5	O
pilocarpine	0	B-Chemical
in	5	O
doses	0	O
exceeding	9	O
350	9	O
mg	0	O
/	9	O
kg	0	O
.	9	O

Bilateral	5	O
intrastriatal	3	O
injections	9	O
of	5	O
isoniazid	0	B-Chemical
did	9	O
not	5	O
augment	9	O
seizures	5	B-Disease
produced	9	O
by	9	O
pilocarpine	0	B-Chemical
,	9	O
200	0	O
mg	0	O
/	9	O
kg	0	O
.	9	O

Application	9	O
of	5	O
an	5	O
irreversible	9	O
inhibitor	3	O
of	5	O
GABA	0	B-Chemical
transaminase	0	O
,	9	O
gamma	9	B-Chemical
-	7	I-Chemical
vinyl	0	I-Chemical
-	7	I-Chemical
GABA	0	I-Chemical
(	9	O
D	9	B-Chemical
,	9	I-Chemical
L	0	I-Chemical
-	7	I-Chemical
4	9	I-Chemical
-	7	I-Chemical
amino	1	I-Chemical
-	7	I-Chemical
hex	0	I-Chemical
-	7	I-Chemical
5	9	I-Chemical
-	7	I-Chemical
enoic	0	I-Chemical
acid	0	I-Chemical
)	9	O
,	9	O
5	9	O
micrograms	0	O
,	9	O
into	9	O
the	5	O
SNR	5	O
,	9	O
bilaterally	5	O
,	9	O
suppressed	3	O
the	5	O
appearance	9	O
of	5	O
electrographic	5	O
and	5	O
behavioral	5	O
seizures	5	B-Disease
produced	9	O
by	9	O
pilocarpine	0	B-Chemical
,	9	O
380	9	O
mg	0	O
/	9	O
kg	0	O
.	9	O

This	5	O
treatment	9	O
was	9	O
also	9	O
sufficient	9	O
to	5	O
protect	9	O
animals	9	O
from	9	O
the	5	O
occurrence	5	O
of	5	O
brain	5	B-Disease
damage	9	I-Disease
.	9	O

Microinjections	3	O
of	5	O
gamma	9	B-Chemical
-	7	I-Chemical
vinyl	0	I-Chemical
-	7	I-Chemical
GABA	0	I-Chemical
,	9	O
5	9	O
micrograms	0	O
,	9	O
into	9	O
the	5	O
dorsal	5	O
striatum	9	O
,	9	O
bilaterally	5	O
,	9	O
failed	9	O
to	5	O
prevent	5	O
the	5	O
development	9	O
of	5	O
convulsions	5	B-Disease
produced	9	O
by	9	O
pilocarpine	0	B-Chemical
,	9	O
380	9	O
mg	0	O
/	9	O
kg	0	O
.	9	O

The	5	O
results	9	O
demonstrate	9	O
that	5	O
the	5	O
threshold	5	O
for	5	O
pilocarpine	0	B-Chemical
-	7	O
induced	3	O
seizures	5	B-Disease
in	5	O
rats	9	O
is	5	O
subjected	9	O
to	5	O
the	5	O
regulation	9	O
of	5	O
the	5	O
GABA	0	B-Chemical
-	7	O
mediated	3	O
synaptic	5	O
inhibition	3	O
within	9	O
the	5	O
substantia	9	O
nigra	4	O
.	9	O

Human	9	O
and	5	O
canine	9	O
ventricular	5	O
vasoactive	5	O
intestinal	9	O
polypeptide	1	O
:	9	O
decrease	9	O
with	5	O
heart	5	B-Disease
failure	5	I-Disease
.	9	O

Vasoactive	7	O
intestinal	9	O
polypeptide	1	O
(	9	O
VIP	9	O
)	9	O
is	5	O
a	5	O
systemic	9	O
and	5	O
coronary	5	O
vasodilator	0	O
that	5	O
may	5	O
have	5	O
positive	9	O
inotropic	5	O
properties	9	O
.	9	O

Myocardial	9	O
levels	3	O
of	5	O
VIP	9	O
were	9	O
assayed	3	O
before	9	O
and	5	O
after	9	O
the	5	O
development	9	O
of	5	O
heart	5	B-Disease
failure	5	I-Disease
in	5	O
two	5	O
canine	9	O
models	5	O
.	9	O

In	9	O
the	5	O
first	9	O
,	9	O
cobalt	0	B-Chemical
cardiomyopathy	5	B-Disease
was	9	O
induced	3	O
in	5	O
eight	9	O
dogs	5	O
;	9	O
VIP	9	O
(	9	O
by	9	O
radioimmunoassay	0	O
)	9	O
decreased	9	O
from	9	O
35	9	O
+	9	O
/	9	O
-	7	O
11	7	O
pg	7	O
/	9	O
mg	0	O
protein	1	O
(	9	O
mean	5	O
+	9	O
/	9	O
-	7	O
SD	7	O
)	9	O
to	5	O
5	9	O
+	9	O
/	9	O
-	7	O
4	9	O
pg	7	O
/	9	O
mg	0	O
protein	1	O
(	9	O
P	9	O
less	5	O
than	5	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

In	9	O
six	9	O
dogs	5	O
with	5	O
doxorubicin	0	B-Chemical
-	7	O
induced	3	O
heart	5	B-Disease
failure	5	I-Disease
,	9	O
VIP	9	O
decreased	9	O
from	9	O
31	7	O
+	9	O
/	9	O
-	7	O
7	9	O
to	5	O
11	7	O
+	9	O
/	9	O
-	7	O
4	9	O
pg	7	O
/	9	O
mg	0	O
protein	1	O
(	9	O
P	9	O
less	5	O
than	5	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

In	9	O
addition	9	O
,	9	O
VIP	9	O
content	9	O
of	5	O
left	5	O
ventricular	5	O
muscle	9	O
of	5	O
resected	5	O
failing	5	O
hearts	3	O
in	5	O
10	9	O
patients	5	O
receiving	9	O
a	5	O
heart	5	O
transplant	9	O
was	9	O
compared	9	O
with	5	O
the	5	O
papillary	5	O
muscles	5	O
in	5	O
14	7	O
patients	5	O
(	9	O
five	9	O
with	5	O
rheumatic	5	B-Disease
disease	5	I-Disease
,	9	O
nine	9	O
with	5	O
myxomatous	5	B-Disease
degeneration	9	I-Disease
)	9	O
receiving	9	O
mitral	5	O
valve	5	O
prostheses	5	O
.	9	O

The	5	O
lowest	9	O
myocardial	9	O
VIP	9	O
concentration	0	O
was	9	O
found	9	O
in	5	O
the	5	O
hearts	3	O
of	5	O
patients	5	O
with	5	O
coronary	5	B-Disease
disease	5	I-Disease
(	9	O
one	5	O
patient	5	O
receiving	9	O
a	5	O
transplant	9	O
and	5	O
three	9	O
receiving	9	O
mitral	5	O
prostheses	5	O
)	9	O
(	9	O
6	9	O
.	9	O
3	9	O
+	9	O
/	9	O
-	7	O
1	9	O
.	9	O
9	7	O
pg	7	O
/	9	O
mg	0	O
protein	1	O
)	9	O
.	9	O

The	5	O
other	5	O
patients	5	O
undergoing	9	O
transplantation	9	O
had	9	O
an	5	O
average	5	O
ejection	5	O
fraction	9	O
of	5	O
17	7	O
%	9	O
+	9	O
/	9	O
-	7	O
6	9	O
%	9	O
and	5	O
a	5	O
VIP	9	O
level	9	O
of	5	O
8	9	O
.	9	O
8	9	O
+	9	O
/	9	O
-	7	O
3	9	O
.	9	O
9	7	O
pg	7	O
/	9	O
mg	0	O
protein	1	O
.	9	O

The	5	O
hearts	3	O
without	9	O
coronary	5	B-Disease
artery	5	I-Disease
disease	5	I-Disease
(	9	O
average	5	O
ejection	5	O
fraction	9	O
of	5	O
this	5	O
group	9	O
62	7	O
%	9	O
+	9	O
/	9	O
-	7	O
10	9	O
%	9	O
)	9	O
had	9	O
a	5	O
VIP	9	O
concentration	0	O
of	5	O
14	7	O
.	9	O
1	9	O
+	9	O
/	9	O
-	7	O
7	9	O
.	9	O
9	7	O
pg	7	O
/	9	O
mg	0	O
protein	1	O
,	9	O
and	5	O
this	5	O
was	9	O
greater	5	O
than	5	O
in	5	O
hearts	3	O
of	5	O
the	5	O
patients	5	O
with	5	O
coronary	5	B-Disease
disease	5	I-Disease
and	5	O
the	5	O
hearts	3	O
of	5	O
patients	5	O
receiving	9	O
a	5	O
transplant	9	O
(	9	O
P	9	O
less	5	O
than	5	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

Myocardial	9	O
catecholamines	9	B-Chemical
were	9	O
also	9	O
determined	9	O
in	5	O
14	7	O
subjects	5	O
;	9	O
a	5	O
weak	9	O
correlation	9	O
(	9	O
r	9	O
=	7	O
0	7	O
.	9	O
57	7	O
,	9	O
P	9	O
less	5	O
than	5	O
0	7	O
.	9	O
05	7	O
)	9	O
between	5	O
the	5	O
tissue	9	O
concentrations	0	O
of	5	O
VIP	9	O
and	5	O
norepinephrine	9	B-Chemical
was	9	O
noted	9	O
.	9	O
(	9	O
ABSTRACT	2	O
TRUNCATED	2	O
AT	9	O
250	0	O
WORDS	3	O
)	9	O

Non	9	O
-	7	O
invasive	5	O
detection	9	O
of	5	O
coronary	5	B-Disease
artery	5	I-Disease
disease	5	I-Disease
by	9	O
body	5	O
surface	9	O
electrocardiographic	5	O
mapping	5	O
after	9	O
dipyridamole	0	B-Chemical
infusion	0	O
.	9	O

Electrocardiographic	5	O
changes	9	O
after	9	O
dipyridamole	0	B-Chemical
infusion	0	O
(	9	O
0	7	O
.	9	O
568	7	O
mg	0	O
/	9	O
kg	0	O
/	9	O
4	9	O
min	0	O
)	9	O
were	9	O
studied	9	O
in	5	O
41	7	O
patients	5	O
with	5	O
coronary	5	B-Disease
artery	5	I-Disease
disease	5	I-Disease
and	5	O
compared	9	O
with	5	O
those	5	O
after	9	O
submaximal	5	O
treadmill	5	O
exercise	5	O
by	9	O
use	5	O
of	5	O
the	5	O
body	5	O
surface	9	O
mapping	5	O
technique	5	O
.	9	O

Patients	5	O
were	9	O
divided	5	O
into	9	O
three	9	O
groups	9	O
;	9	O
19	7	O
patients	5	O
without	9	O
myocardial	9	B-Disease
infarction	5	I-Disease
(	9	O
non	9	O
-	7	O
MI	9	B-Disease
group	9	O
)	9	O
,	9	O
14	7	O
with	5	O
anterior	5	B-Disease
infarction	5	I-Disease
(	9	O
ANT	9	B-Disease
-	7	I-Disease
MI	9	I-Disease
)	9	O
and	5	O
eight	9	O
with	5	O
inferior	5	B-Disease
infarction	5	I-Disease
(	9	O
INF	9	B-Disease
-	7	I-Disease
MI	9	I-Disease
)	9	O
.	9	O

Eighty	5	O
-	7	O
seven	9	O
unipolar	5	O
electrocardiograms	5	O
(	9	O
ECGs	5	O
)	9	O
distributed	5	O
over	5	O
the	5	O
entire	9	O
thoracic	5	O
surface	9	O
were	9	O
simultaneously	5	O
recorded	5	O
.	9	O

After	9	O
dipyridamole	0	B-Chemical
,	9	O
ischemic	9	B-Disease
ST	9	O
-	7	O
segment	9	O
depression	5	B-Disease
(	9	O
0	7	O
.	9	O
05	7	O
mV	0	O
or	5	O
more	5	O
)	9	O
was	9	O
observed	9	O
in	5	O
84	7	O
%	9	O
of	5	O
the	5	O
non	9	O
-	7	O
MI	9	B-Disease
group	9	O
,	9	O
29	7	O
%	9	O
of	5	O
the	5	O
ANT	9	B-Disease
-	7	I-Disease
MI	9	I-Disease
group	9	O
,	9	O
63	7	O
%	9	O
of	5	O
the	5	O
INF	9	B-Disease
-	7	I-Disease
MI	9	I-Disease
group	9	O
and	5	O
61	7	O
%	9	O
of	5	O
the	5	O
total	9	O
population	5	O
.	9	O

Exercise	5	O
-	7	O
induced	3	O
ST	9	O
depression	5	B-Disease
was	9	O
observed	9	O
in	5	O
84	7	O
%	9	O
of	5	O
the	5	O
non	9	O
-	7	O
MI	9	B-Disease
group	9	O
,	9	O
43	7	O
%	9	O
of	5	O
the	5	O
ANT	9	B-Disease
-	7	I-Disease
MI	9	I-Disease
group	9	O
,	9	O
38	7	O
%	9	O
of	5	O
the	5	O
INF	9	B-Disease
-	7	I-Disease
MI	9	I-Disease
group	9	O
and	5	O
61	7	O
%	9	O
of	5	O
the	5	O
total	9	O
.	9	O

For	9	O
individual	5	O
patients	5	O
,	9	O
there	5	O
were	9	O
no	9	O
obvious	9	O
differences	9	O
between	5	O
the	5	O
body	5	O
surface	9	O
distribution	9	O
of	5	O
ST	9	O
depression	5	B-Disease
in	5	O
both	9	O
tests	5	O
.	9	O

The	5	O
increase	9	O
in	5	O
pressure	5	O
rate	9	O
product	9	O
after	9	O
dipyridamole	0	B-Chemical
was	9	O
significantly	9	O
less	5	O
than	5	O
that	5	O
during	5	O
the	5	O
treadmill	5	O
exercise	5	O
.	9	O

The	5	O
data	5	O
suggest	9	O
that	5	O
the	5	O
dipyridamole	0	B-Chemical
-	7	O
induced	3	O
myocardial	9	B-Disease
ischemia	9	I-Disease
is	5	O
caused	9	O
by	9	O
the	5	O
inhomogenous	5	O
distribution	9	O
of	5	O
myocardial	9	O
blood	9	O
flow	5	O
.	9	O

We	9	O
conclude	9	O
that	5	O
the	5	O
dipyridamole	0	B-Chemical
ECG	5	O
test	5	O
is	5	O
as	5	O
useful	5	O
as	5	O
the	5	O
exercise	5	O
ECG	5	O
test	5	O
for	5	O
the	5	O
assessment	5	O
of	5	O
coronary	5	B-Disease
artery	5	I-Disease
disease	5	I-Disease
.	9	O

Bradycardia	7	B-Disease
after	9	O
high	9	O
-	7	O
dose	9	O
intravenous	0	O
methylprednisolone	0	B-Chemical
therapy	5	O
.	9	O

In	9	O
5	9	O
consecutive	5	O
patients	5	O
with	5	O
rheumatoid	9	B-Disease
arthritis	9	I-Disease
who	5	O
received	9	O
intravenous	0	O
high	9	O
-	7	O
dose	9	O
methylprednisolone	0	B-Chemical
(	9	O
MP	9	B-Chemical
)	9	O
therapy	5	O
(	9	O
1	9	O
g	0	O
daily	5	O
for	5	O
2	9	O
or	5	O
3	9	O
consecutive	5	O
days	9	O
)	9	O
,	9	O
a	5	O
decline	9	O
in	5	O
pulse	5	O
rate	9	O
was	9	O
observed	9	O
,	9	O
most	9	O
pronounced	9	O
on	5	O
day	9	O
4	9	O
.	9	O

In	9	O
one	5	O
of	5	O
the	5	O
5	9	O
patients	5	O
the	5	O
bradycardia	5	B-Disease
was	9	O
associated	9	O
with	5	O
complaints	5	O
of	5	O
substernal	5	O
pressure	5	O
.	9	O

Reversal	9	O
to	5	O
normal	9	O
heart	5	O
rate	9	O
was	9	O
found	9	O
on	5	O
day	9	O
7	9	O
.	9	O

Electrocardiographic	5	O
registrations	5	O
showed	9	O
sinus	5	B-Disease
bradycardia	5	I-Disease
in	5	O
all	5	O
cases	5	O
.	9	O

No	9	O
significant	9	O
changes	9	O
in	5	O
plasma	9	O
concentrations	0	O
of	5	O
electrolytes	0	O
were	9	O
found	9	O
.	9	O

Careful	5	O
observation	9	O
of	5	O
patients	5	O
receiving	9	O
high	9	O
-	7	O
dose	9	O
MP	9	B-Chemical
is	5	O
recommended	5	O
.	9	O

High	9	O
-	7	O
dose	9	O
MP	9	B-Chemical
may	5	O
be	5	O
contraindicated	5	O
in	5	O
patients	5	O
with	5	O
known	9	O
heart	5	B-Disease
disease	5	I-Disease
.	9	O

Two	9	O
cases	5	O
of	5	O
downbeat	5	B-Disease
nystagmus	5	I-Disease
and	5	O
oscillopsia	5	B-Disease
associated	9	O
with	5	O
carbamazepine	0	B-Chemical
.	9	O

Downbeat	5	B-Disease
nystagmus	5	I-Disease
is	5	O
often	5	O
associated	9	O
with	5	O
structural	9	O
lesions	5	O
at	9	O
the	5	O
craniocervical	5	O
junction	9	O
,	9	O
but	9	O
has	9	O
occasionally	5	O
been	9	O
reported	9	O
as	5	O
a	5	O
manifestation	5	O
of	5	O
metabolic	9	O
imbalance	9	O
or	5	O
drug	5	O
intoxication	9	O
.	9	O

We	9	O
recorded	5	O
the	5	O
eye	5	O
movements	5	O
of	5	O
two	5	O
patients	5	O
with	5	O
reversible	9	O
downbeat	5	B-Disease
nystagmus	5	I-Disease
related	9	O
to	5	O
carbamazepine	0	B-Chemical
therapy	5	O
.	9	O

The	5	O
nystagmus	5	B-Disease
of	5	O
both	9	O
patients	5	O
resolved	9	O
after	9	O
reduction	9	O
of	5	O
the	5	O
serum	9	O
carbamazepine	0	B-Chemical
levels	3	O
.	9	O

Neuroradiologic	9	O
investigations	9	O
including	9	O
magnetic	0	O
resonance	5	O
imaging	5	O
scans	5	O
in	5	O
both	9	O
patients	5	O
showed	9	O
no	9	O
evidence	9	O
of	5	O
intracranial	5	O
abnormality	9	O
.	9	O

In	9	O
patients	5	O
with	5	O
downbeat	5	B-Disease
nystagmus	5	I-Disease
who	5	O
are	5	O
taking	5	O
anticonvulsant	5	O
medications	5	O
,	9	O
consideration	5	O
should	5	O
be	5	O
given	5	O
to	5	O
reduction	9	O
in	5	O
dose	9	O
before	9	O
further	9	O
investigation	9	O
is	5	O
undertaken	5	O
.	9	O

Improvement	5	O
by	9	O
denopamine	9	B-Chemical
(	9	O
TA	9	B-Chemical
-	7	I-Chemical
064	7	I-Chemical
)	9	O
of	5	O
pentobarbital	0	B-Chemical
-	7	O
induced	3	O
cardiac	5	B-Disease
failure	5	I-Disease
in	5	O
the	5	O
dog	5	O
heart	5	O
-	7	O
lung	9	O
preparation	9	O
.	9	O

The	5	O
efficacy	9	O
of	5	O
denopamine	9	B-Chemical
,	9	O
an	5	O
orally	0	O
active	9	O
beta	9	O
1	9	O
-	7	O
adrenoceptor	5	O
agonist	3	O
,	9	O
in	5	O
improving	5	O
cardiac	5	B-Disease
failure	5	I-Disease
was	9	O
assessed	9	O
in	5	O
dog	5	O
heart	5	O
-	7	O
lung	9	O
preparations	9	O
.	9	O

Cardiac	9	O
functions	9	O
depressed	5	O
by	9	O
pentobarbital	0	B-Chemical
(	9	O
118	7	O
+	9	O
/	9	O
-	7	O
28	7	O
mg	0	O
;	9	O
mean	5	O
value	9	O
+	9	O
/	9	O
-	7	O
SD	7	O
)	9	O
such	5	O
that	5	O
cardiac	5	O
output	5	O
and	5	O
maximum	5	O
rate	9	O
of	5	O
rise	9	O
of	5	O
left	5	O
ventricular	5	O
pressure	5	O
(	9	O
LV	9	O
dP	5	O
/	9	O
dt	9	O
max	9	O
)	9	O
had	9	O
been	9	O
reduced	9	O
by	9	O
about	5	O
35	9	O
%	9	O
and	5	O
26	7	O
%	9	O
of	5	O
the	5	O
respective	9	O
controls	9	O
were	9	O
improved	5	O
by	9	O
denopamine	9	B-Chemical
(	9	O
10	9	O
-	7	O
300	0	O
micrograms	0	O
)	9	O
in	5	O
a	5	O
dose	9	O
-	7	O
dependent	9	O
manner	9	O
.	9	O

With	5	O
100	0	O
micrograms	0	O
denopamine	9	B-Chemical
,	9	O
almost	9	O
complete	9	O
restoration	5	O
of	5	O
cardiac	5	O
performance	5	O
was	9	O
attained	9	O
,	9	O
associated	9	O
with	5	O
a	5	O
slight	9	O
increase	9	O
in	5	O
heart	5	O
rate	9	O
.	9	O

No	9	O
arrhythmias	5	B-Disease
were	9	O
induced	3	O
by	9	O
these	5	O
doses	0	O
of	5	O
denopamine	9	B-Chemical
.	9	O

The	5	O
results	9	O
warrant	9	O
clinical	5	O
trials	5	O
of	5	O
denopamine	9	B-Chemical
in	5	O
the	5	O
treatment	9	O
of	5	O
cardiac	5	B-Disease
failure	5	I-Disease
.	9	O

Clonazepam	0	B-Chemical
monotherapy	5	O
for	5	O
epilepsy	5	B-Disease
in	5	O
childhood	5	O
.	9	O

Sixty	5	O
patients	5	O
(	9	O
age	5	O
-	7	O
range	9	O
one	5	O
month	5	O
to	5	O
14	7	O
years	5	O
)	9	O
with	5	O
other	5	O
types	9	O
of	5	O
epilepsy	5	B-Disease
than	5	O
infantile	5	B-Disease
spasms	5	I-Disease
were	9	O
treated	3	O
with	5	O
clonazepam	0	B-Chemical
.	9	O

Disappearance	9	O
of	5	O
seizures	5	B-Disease
and	5	O
normalization	5	O
of	5	O
abnormal	9	O
EEG	5	O
with	5	O
disappearance	9	O
of	5	O
seizures	5	B-Disease
were	9	O
recognized	9	O
in	5	O
77	7	O
%	9	O
and	5	O
50	0	O
%	9	O
,	9	O
respectively	9	O
.	9	O

Seizures	5	B-Disease
disappeared	9	O
in	5	O
71	7	O
%	9	O
of	5	O
the	5	O
patients	5	O
with	5	O
generalized	5	O
seizures	5	B-Disease
and	5	O
89	7	O
%	9	O
of	5	O
partial	9	O
seizures	5	B-Disease
.	9	O

Improvement	5	O
of	5	O
abnormal	9	O
EEG	5	O
was	9	O
noticed	9	O
in	5	O
76	7	O
%	9	O
of	5	O
diffuse	5	O
paroxysms	5	O
and	5	O
in	5	O
67	7	O
%	9	O
of	5	O
focal	5	O
paroxysms	5	O
.	9	O

In	9	O
excellent	5	O
cases	5	O
,	9	O
mean	5	O
effective	5	O
dosages	9	O
were	9	O
0	7	O
.	9	O
086	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
021	7	O
mg	0	O
/	9	O
kg	0	O
/	9	O
day	9	O
in	5	O
infants	5	O
and	5	O
0	7	O
.	9	O
057	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
022	7	O
mg	0	O
/	9	O
kg	0	O
/	9	O
day	9	O
in	5	O
schoolchildren	5	O
,	9	O
this	5	O
difference	9	O
was	9	O
statistically	9	O
significant	9	O
(	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
005	7	O
)	9	O
.	9	O

The	5	O
incidence	5	O
of	5	O
side	5	O
effects	9	O
such	5	O
as	5	O
drowsiness	5	B-Disease
and	5	O
ataxia	5	B-Disease
was	9	O
only	9	O
5	9	O
%	9	O
.	9	O

Postmarketing	5	O
study	9	O
of	5	O
timolol	0	B-Chemical
-	7	O
hydrochlorothiazide	0	B-Chemical
antihypertensive	5	O
therapy	5	O
.	9	O

A	9	O
postmarketing	5	O
surveillance	5	O
study	9	O
was	9	O
conducted	9	O
to	5	O
determine	9	O
the	5	O
safety	5	O
and	5	O
efficacy	9	O
of	5	O
a	5	O
fixed	9	O
-	7	O
ratio	9	O
combination	9	O
containing	0	O
10	9	O
mg	0	O
of	5	O
timolol	0	B-Chemical
maleate	0	I-Chemical
and	5	O
25	9	O
mg	0	O
of	5	O
hydrochlorothiazide	0	B-Chemical
,	9	O
administered	9	O
twice	9	O
daily	5	O
for	5	O
one	5	O
month	5	O
to	5	O
hypertensive	5	B-Disease
patients	5	O
.	9	O

Data	5	O
on	5	O
9	7	O
,	9	O
037	7	O
patients	5	O
were	9	O
collected	9	O
by	9	O
1	9	O
,	9	O
455	7	O
participating	5	O
physicians	5	O
.	9	O

Mean	9	O
systolic	5	O
blood	9	O
pressure	5	O
decreased	9	O
25	9	O
mmHg	7	O
and	5	O
mean	5	O
diastolic	5	O
blood	9	O
pressure	5	O
declined	9	O
15	9	O
mmHg	7	O
after	9	O
one	5	O
month	5	O
of	5	O
timolol	0	B-Chemical
-	7	O
hydrochlorothiazide	0	B-Chemical
therapy	5	O
(	9	O
P	9	O
less	5	O
than	5	O
0	7	O
.	9	O
01	7	O
,	9	O
both	9	O
comparisons	5	O
)	9	O
.	9	O

Age	7	O
,	9	O
race	5	O
,	9	O
and	5	O
sex	5	O
appeared	9	O
to	5	O
have	5	O
no	9	O
influence	5	O
on	5	O
the	5	O
decrease	9	O
in	5	O
blood	9	O
pressure	5	O
.	9	O

The	5	O
antihypertensive	5	O
effect	9	O
of	5	O
the	5	O
drug	5	O
was	9	O
greater	5	O
in	5	O
patients	5	O
with	5	O
more	5	O
severe	5	O
hypertension	5	B-Disease
.	9	O

Overall	9	O
,	9	O
1	9	O
,	9	O
453	7	O
patients	5	O
experienced	5	O
a	5	O
total	9	O
of	5	O
2	9	O
,	9	O
658	7	O
adverse	5	O
events	5	O
,	9	O
the	5	O
most	9	O
common	5	O
being	5	O
fatigue	5	B-Disease
,	9	O
dizziness	5	B-Disease
,	9	O
and	5	O
weakness	5	B-Disease
.	9	O

Treatment	9	O
in	5	O
590	9	O
patients	5	O
was	9	O
discontinued	5	O
because	5	O
of	5	O
adverse	5	O
events	5	O
.	9	O

Salicylate	0	B-Chemical
nephropathy	9	B-Disease
in	5	O
the	5	O
Gunn	6	O
rat	3	O
:	9	O
potential	9	O
role	9	O
of	5	O
prostaglandins	0	B-Chemical
.	9	O

We	9	O
examined	9	O
the	5	O
potential	9	O
role	9	O
of	5	O
prostaglandins	0	B-Chemical
in	5	O
the	5	O
development	9	O
of	5	O
analgesic	5	O
nephropathy	9	B-Disease
in	5	O
the	5	O
Gunn	6	O
strain	1	O
of	5	O
rat	3	O
.	9	O

The	5	O
homozygous	1	O
Gunn	6	O
rats	9	O
have	5	O
unconjugated	3	O
hyperbilirubinemia	5	B-Disease
due	5	O
to	5	O
the	5	O
absence	3	O
of	5	O
glucuronyl	1	B-Chemical
transferase	1	O
,	9	O
leading	9	O
to	5	O
marked	9	O
bilirubin	0	B-Chemical
deposition	9	O
in	5	O
renal	9	O
medulla	9	O
and	5	O
papilla	5	O
.	9	O

These	5	O
rats	9	O
are	5	O
also	9	O
highly	9	O
susceptible	9	O
to	5	O
develop	5	O
papillary	5	B-Disease
necrosis	9	I-Disease
with	5	O
analgesic	5	O
administration	9	O
.	9	O

We	9	O
used	5	O
homozygous	1	O
(	9	O
jj	3	O
)	9	O
and	5	O
phenotypically	9	O
normal	9	O
heterozygous	1	O
(	9	O
jJ	7	O
)	9	O
animals	9	O
.	9	O

Four	9	O
groups	9	O
of	5	O
rats	9	O
(	9	O
n	9	O
=	7	O
7	9	O
)	9	O
were	9	O
studied	9	O
:	9	O
jj	3	O
and	5	O
jJ	7	O
rats	9	O
treated	3	O
either	9	O
with	5	O
aspirin	9	B-Chemical
300	0	O
mg	0	O
/	9	O
kg	0	O
every	5	O
other	5	O
day	9	O
or	5	O
sham	9	O
-	7	O
treated	3	O
.	9	O

After	9	O
one	5	O
week	9	O
,	9	O
slices	9	O
of	5	O
cortex	5	O
,	9	O
outer	9	O
and	5	O
inner	9	O
medulla	9	O
from	9	O
one	5	O
kidney	9	O
were	9	O
incubated	0	O
in	5	O
buffer	0	O
and	5	O
prostaglandin	0	B-Chemical
synthesis	9	O
was	9	O
determined	9	O
by	9	O
radioimmunoassay	0	O
.	9	O

The	5	O
other	5	O
kidney	9	O
was	9	O
examined	9	O
histologically	9	O
.	9	O

A	9	O
marked	9	O
corticomedullary	3	O
gradient	9	O
of	5	O
prostaglandin	0	B-Chemical
synthesis	9	O
was	9	O
observed	9	O
in	5	O
all	5	O
groups	9	O
.	9	O

PGE2	3	B-Chemical
synthesis	9	O
was	9	O
significantly	9	O
higher	9	O
in	5	O
outer	9	O
medulla	9	O
,	9	O
but	9	O
not	5	O
cortex	5	O
or	5	O
inner	9	O
medulla	9	O
,	9	O
of	5	O
jj	3	O
(	9	O
38	7	O
+	9	O
/	9	O
-	7	O
6	9	O
ng	0	O
/	9	O
mg	0	O
prot	7	O
)	9	O
than	5	O
jJ	7	O
rats	9	O
(	9	O
15	9	O
+	9	O
/	9	O
-	7	O
3	9	O
)	9	O
(	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
01	7	O
)	9	O
.	9	O

Aspirin	0	B-Chemical
treatment	9	O
reduced	9	O
PGE2	3	B-Chemical
synthesis	9	O
in	5	O
all	5	O
regions	9	O
,	9	O
but	9	O
outer	9	O
medullary	5	O
PGE2	3	B-Chemical
remained	9	O
higher	9	O
in	5	O
jj	3	O
(	9	O
18	7	O
+	9	O
/	9	O
-	7	O
3	9	O
)	9	O
than	5	O
jJ	7	O
rats	9	O
(	9	O
9	7	O
+	9	O
/	9	O
-	7	O
2	9	O
)	9	O
(	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

PGF2	0	B-Chemical
alpha	9	I-Chemical
was	9	O
also	9	O
significantly	9	O
higher	9	O
in	5	O
the	5	O
outer	9	O
medulla	9	O
of	5	O
jj	3	O
rats	9	O
with	5	O
and	5	O
without	9	O
aspirin	9	B-Chemical
administration	9	O
(	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

The	5	O
changes	9	O
in	5	O
renal	9	O
prostaglandin	0	B-Chemical
synthesis	9	O
were	9	O
accompanied	9	O
by	9	O
evidence	9	O
of	5	O
renal	9	B-Disease
damage	9	I-Disease
in	5	O
aspirin	9	B-Chemical
-	7	O
treated	3	O
jj	3	O
but	9	O
not	5	O
jJ	7	O
rats	9	O
as	5	O
evidenced	9	O
by	9	O
:	9	O
increased	9	O
incidence	5	O
and	5	O
severity	5	O
of	5	O
hematuria	5	B-Disease
(	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
01	7	O
)	9	O
;	9	O
increased	9	O
serum	9	O
creatinine	0	B-Chemical
(	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
05	7	O
)	9	O
;	9	O
and	5	O
increase	9	O
in	5	O
outer	9	O
medullary	5	O
histopathologic	9	O
lesions	5	O
(	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
005	7	O
compared	9	O
to	5	O
either	9	O
sham	9	O
-	7	O
treated	3	O
jj	3	O
or	5	O
aspirin	9	B-Chemical
-	7	O
treated	3	O
jJ	7	O
)	9	O
.	9	O

These	5	O
results	9	O
suggest	9	O
that	5	O
enhanced	3	O
prostaglandin	0	B-Chemical
synthesis	9	O
contributes	9	O
to	5	O
maintenance	9	O
of	5	O
renal	9	O
function	9	O
and	5	O
morphological	9	O
integrity	9	O
,	9	O
and	5	O
that	5	O
inhibition	3	O
of	5	O
prostaglandin	0	B-Chemical
synthesis	9	O
may	5	O
lead	5	O
to	5	O
pathological	5	B-Disease
renal	9	I-Disease
medullary	5	I-Disease
lesions	5	I-Disease
and	5	O
deterioration	5	B-Disease
of	5	I-Disease
renal	9	I-Disease
function	9	I-Disease
.	9	O

Prophylactic	5	O
lidocaine	0	B-Chemical
in	5	O
the	5	O
early	9	O
phase	5	O
of	5	O
suspected	5	O
myocardial	9	B-Disease
infarction	5	I-Disease
.	9	O

Four	9	O
hundred	5	O
two	5	O
patients	5	O
with	5	O
suspected	5	O
myocardial	9	B-Disease
infarction	5	I-Disease
seen	9	O
within	9	O
6	9	O
hours	9	O
of	5	O
the	5	O
onset	5	O
of	5	O
symptoms	5	O
entered	5	O
a	5	O
double	9	O
-	7	O
blind	5	O
randomized	5	O
trial	5	O
of	5	O
lidocaine	0	B-Chemical
vs	7	O
placebo	9	O
.	9	O

During	5	O
the	5	O
1	9	O
hour	0	O
after	9	O
administration	9	O
of	5	O
the	5	O
drug	5	O
the	5	O
incidence	5	O
of	5	O
ventricular	5	B-Disease
fibrillation	5	I-Disease
or	5	O
sustained	5	O
ventricular	5	B-Disease
tachycardia	5	I-Disease
among	5	O
the	5	O
204	7	O
patients	5	O
with	5	O
acute	9	O
myocardial	9	B-Disease
infarction	5	I-Disease
was	9	O
low	9	O
,	9	O
1	9	O
.	9	O
5	9	O
%	9	O
.	9	O

Lidocaine	0	B-Chemical
,	9	O
given	5	O
in	5	O
a	5	O
300	0	O
mg	0	O
dose	9	O
intramuscularly	0	O
followed	9	O
by	9	O
100	0	O
mg	0	O
intravenously	0	O
,	9	O
did	9	O
not	5	O
prevent	5	O
sustained	5	O
ventricular	5	B-Disease
tachycardia	5	I-Disease
,	9	O
although	9	O
there	5	O
was	9	O
a	5	O
significant	9	O
reduction	9	O
in	5	O
the	5	O
number	9	O
of	5	O
patients	5	O
with	5	O
warning	5	O
arrhythmias	5	B-Disease
between	5	O
15	9	O
and	5	O
45	9	O
minutes	0	O
after	9	O
the	5	O
administration	9	O
of	5	O
lidocaine	0	B-Chemical
(	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

The	5	O
average	5	O
plasma	9	O
lidocaine	0	B-Chemical
level	9	O
10	9	O
minutes	0	O
after	9	O
administration	9	O
for	5	O
patients	5	O
without	9	O
a	5	O
myocardial	9	B-Disease
infarction	5	I-Disease
was	9	O
significantly	9	O
higher	9	O
than	5	O
that	5	O
for	5	O
patients	5	O
with	5	O
an	5	O
acute	9	O
infarction	5	B-Disease
.	9	O

The	5	O
mean	5	O
plasma	9	O
lidocaine	0	B-Chemical
level	9	O
of	5	O
patients	5	O
on	5	O
beta	9	O
-	7	O
blocking	3	O
agents	5	O
was	9	O
no	9	O
different	9	O
from	9	O
that	5	O
in	5	O
patients	5	O
not	5	O
on	5	O
beta	9	O
blocking	3	O
agents	5	O
.	9	O

During	5	O
the	5	O
1	9	O
-	7	O
hour	0	O
study	9	O
period	5	O
,	9	O
the	5	O
incidence	5	O
of	5	O
central	5	O
nervous	5	O
system	5	O
side	5	O
effects	9	O
was	9	O
significantly	9	O
greater	5	O
in	5	O
the	5	O
lidocaine	0	B-Chemical
group	9	O
,	9	O
hypotension	5	B-Disease
occurred	9	O
in	5	O
11	7	O
patients	5	O
,	9	O
nine	9	O
of	5	O
whom	5	O
had	9	O
received	9	O
lidocaine	0	B-Chemical
,	9	O
and	5	O
four	9	O
patients	5	O
died	9	O
from	9	O
asystole	5	B-Disease
,	9	O
three	9	O
of	5	O
whom	5	O
had	9	O
had	9	O
lidocaine	0	B-Chemical
.	9	O

We	9	O
cannot	5	O
advocate	5	O
the	5	O
administration	9	O
of	5	O
lidocaine	0	B-Chemical
prophylactically	5	O
in	5	O
the	5	O
early	9	O
hours	9	O
of	5	O
suspected	5	O
myocardial	9	B-Disease
infarction	5	I-Disease
.	9	O

Evidence	9	O
for	5	O
a	5	O
cholinergic	3	O
role	9	O
in	5	O
haloperidol	5	B-Chemical
-	7	O
induced	3	O
catalepsy	5	B-Disease
.	9	O

Experiments	9	O
in	5	O
mice	3	O
tested	9	O
previous	9	O
evidence	9	O
that	5	O
activation	3	O
of	5	O
cholinergic	3	O
systems	5	O
promotes	3	O
catalepsy	5	B-Disease
and	5	O
that	5	O
cholinergic	3	O
mechanisms	9	O
need	5	O
to	5	O
be	5	O
intact	9	O
for	5	O
full	5	O
expression	3	O
of	5	O
neuroleptic	5	B-Chemical
-	7	O
induced	3	O
catalepsy	5	B-Disease
.	9	O

Large	9	O
doses	0	O
of	5	O
the	5	O
cholinomimetic	0	O
,	9	O
pilocarpine	0	B-Chemical
,	9	O
could	9	O
induce	3	O
catalepsy	5	B-Disease
when	5	O
peripheral	9	O
cholinergic	3	O
receptors	3	O
were	9	O
blocked	3	O
.	9	O

Low	9	O
doses	0	O
of	5	O
pilocarpine	0	B-Chemical
caused	9	O
a	5	O
pronounced	9	O
enhancement	9	O
of	5	O
the	5	O
catalepsy	5	B-Disease
that	5	O
was	9	O
induced	3	O
by	9	O
the	5	O
dopaminergic	5	O
blocker	0	O
,	9	O
haloperidol	5	B-Chemical
.	9	O

A	9	O
muscarinic	3	O
receptor	3	O
blocker	0	O
,	9	O
atropine	0	B-Chemical
,	9	O
disrupted	9	O
haloperidol	5	B-Chemical
-	7	O
induced	3	O
catalepsy	5	B-Disease
.	9	O

Intracranial	5	O
injection	9	O
of	5	O
an	5	O
acetylcholine	0	B-Chemical
-	7	O
synthesis	9	O
inhibitor	3	O
,	9	O
hemicholinium	0	B-Chemical
,	9	O
prevented	9	O
the	5	O
catalepsy	5	B-Disease
that	5	O
is	5	O
usually	5	O
induced	3	O
by	9	O
haloperidol	5	B-Chemical
.	9	O

These	5	O
findings	9	O
suggest	9	O
the	5	O
hypothesis	9	O
that	5	O
the	5	O
catalepsy	5	B-Disease
that	5	O
is	5	O
produced	9	O
by	9	O
neuroleptics	5	B-Chemical
such	5	O
as	5	O
haloperidol	5	B-Chemical
is	5	O
actually	5	O
mediated	3	O
by	9	O
intrinsic	9	O
central	5	O
cholinergic	3	O
systems	5	O
.	9	O

Alternatively	9	O
,	9	O
activation	3	O
of	5	O
central	5	O
cholinergic	3	O
systems	5	O
could	9	O
promote	3	O
catalepsy	5	B-Disease
by	9	O
suppression	9	O
of	5	O
dopaminergic	5	O
systems	5	O
.	9	O

Cardiovascular	2	B-Disease
dysfunction	9	I-Disease
and	5	O
hypersensitivity	9	B-Disease
to	5	O
sodium	0	B-Chemical
pentobarbital	0	I-Chemical
induced	3	O
by	9	O
chronic	5	O
barium	0	B-Chemical
chloride	0	I-Chemical
ingestion	9	O
.	9	O

Barium	0	B-Chemical
-	7	O
supplemented	0	O
Long	9	O
-	7	O
Evans	6	O
hooded	4	O
rats	9	O
were	9	O
characterized	9	O
by	9	O
a	5	O
persistent	5	O
hypertension	5	B-Disease
that	5	O
was	9	O
evident	9	O
after	9	O
1	9	O
month	5	O
of	5	O
barium	0	B-Chemical
(	9	O
100	0	O
micrograms	0	O
/	9	O
ml	0	O
mineral	0	O
fortified	5	O
water	0	O
)	9	O
treatment	9	O
.	9	O

Analysis	9	O
of	5	O
in	5	O
vivo	3	O
myocardial	9	O
excitability	5	O
,	9	O
contractility	9	O
,	9	O
and	5	O
metabolic	9	O
characteristics	5	O
at	9	O
16	9	O
months	5	O
revealed	9	O
other	5	O
significant	9	O
barium	0	B-Chemical
-	7	O
induced	3	O
disturbances	5	B-Disease
within	9	I-Disease
the	5	I-Disease
cardiovascular	5	I-Disease
system	5	I-Disease
.	9	O

The	5	O
most	9	O
distinctive	9	O
aspect	5	O
of	5	O
the	5	O
barium	0	B-Chemical
effect	9	O
was	9	O
a	5	O
demonstrated	9	O
hypersensitivity	9	B-Disease
of	5	O
the	5	O
cardiovascular	5	O
system	5	O
to	5	O
sodium	0	B-Chemical
pentobarbital	0	I-Chemical
.	9	O

Under	9	O
barbiturate	0	B-Chemical
anesthesia	5	O
,	9	O
virtually	9	O
all	5	O
of	5	O
the	5	O
myocardial	9	O
contractile	9	O
indices	5	O
were	9	O
depressed	5	O
significantly	9	O
in	5	O
barium	0	B-Chemical
-	7	O
exposed	9	O
rats	9	O
relative	9	O
to	5	O
the	5	O
corresponding	9	O
control	9	O
-	7	O
fed	9	O
rats	9	O
.	9	O

The	5	O
lack	9	O
of	5	O
a	5	O
similar	9	O
response	9	O
to	5	O
ketamine	0	B-Chemical
and	5	O
xylazine	0	B-Chemical
anesthesia	5	O
revealed	9	O
that	5	O
the	5	O
cardiovascular	5	O
actions	5	O
of	5	O
sodium	0	B-Chemical
pentobarbital	0	I-Chemical
in	5	O
barium	0	B-Chemical
-	7	O
treated	3	O
rats	9	O
were	9	O
linked	9	O
specifically	9	O
to	5	O
this	5	O
anesthetic	5	O
,	9	O
and	5	O
were	9	O
not	5	O
representative	9	O
of	5	O
a	5	O
generalized	5	O
anesthetic	5	O
response	9	O
.	9	O

Other	9	O
myocardial	9	O
pathophysiologic	5	O
and	5	O
metabolic	9	O
changes	9	O
induced	3	O
by	9	O
barium	0	B-Chemical
were	9	O
manifest	5	O
,	9	O
irrespective	9	O
of	5	O
the	5	O
anesthetic	5	O
employed	5	O
.	9	O

The	5	O
contractile	9	O
element	9	O
shortening	9	O
velocity	5	O
of	5	O
the	5	O
cardiac	5	O
muscle	9	O
fibers	9	O
was	9	O
significantly	9	O
slower	9	O
in	5	O
both	9	O
groups	9	O
of	5	O
barium	0	B-Chemical
-	7	O
treated	3	O
rats	9	O
relative	9	O
to	5	O
the	5	O
control	9	O
groups	9	O
,	9	O
irrespective	9	O
of	5	O
the	5	O
anesthetic	5	O
regimen	5	O
.	9	O

Similarly	9	O
,	9	O
significant	9	O
disturbances	5	O
in	5	O
myocardial	9	O
energy	5	O
metabolism	9	O
were	9	O
detected	9	O
in	5	O
the	5	O
barium	0	B-Chemical
-	7	O
exposed	9	O
rats	9	O
which	5	O
were	9	O
consistent	9	O
with	5	O
the	5	O
reduced	9	O
contractile	9	O
element	9	O
shortening	9	O
velocity	5	O
.	9	O

In	9	O
addition	9	O
,	9	O
the	5	O
excitability	5	O
of	5	O
the	5	O
cardiac	5	O
conduction	5	O
system	5	O
was	9	O
depressed	5	O
preferentially	9	O
in	5	O
the	5	O
atrioventricular	5	O
nodal	5	O
region	9	O
of	5	O
hearts	3	O
from	9	O
barium	0	B-Chemical
-	7	O
exposed	9	O
rats	9	O
.	9	O

Overall	9	O
,	9	O
the	5	O
altered	9	O
cardiac	5	O
contractility	9	O
and	5	O
excitability	5	O
characteristics	5	O
,	9	O
the	5	O
myocardial	9	O
metabolic	9	B-Disease
disturbances	5	I-Disease
,	9	O
and	5	O
the	5	O
hypersensitivity	9	B-Disease
of	5	O
the	5	O
cardiovascular	5	O
system	5	O
to	5	O
sodium	0	B-Chemical
pentobarbital	0	I-Chemical
suggest	9	O
the	5	O
existence	9	O
of	5	O
a	5	O
heretofore	5	O
undescribed	4	O
cardiomyopathic	3	B-Disease
disorder	5	I-Disease
induced	3	O
by	9	O
chronic	5	O
barium	0	B-Chemical
exposure	9	O
.	9	O

These	5	O
experimental	5	O
findings	9	O
represent	9	O
the	5	O
first	9	O
indication	5	O
that	5	O
life	5	O
-	7	O
long	5	O
barium	0	B-Chemical
ingestion	9	O
may	5	O
have	5	O
significant	9	O
adverse	5	O
effects	9	O
on	5	O
the	5	O
mammalian	9	O
cardiovascular	5	O
system	5	O
.	9	O

Propranolol	0	B-Chemical
antagonism	9	O
of	5	O
phenylpropanolamine	0	B-Chemical
-	7	O
induced	3	O
hypertension	5	B-Disease
.	9	O

Phenylpropanolamine	7	B-Chemical
(	9	O
PPA	9	B-Chemical
)	9	O
overdose	0	B-Disease
can	5	O
cause	5	O
severe	5	O
hypertension	5	B-Disease
,	9	O
intracerebral	5	B-Disease
hemorrhage	5	I-Disease
,	9	O
and	5	O
death	9	O
.	9	O

We	9	O
studied	9	O
the	5	O
efficacy	9	O
and	5	O
safety	5	O
of	5	O
propranolol	0	B-Chemical
in	5	O
the	5	O
treatment	9	O
of	5	O
PPA	9	B-Chemical
-	7	O
induced	3	O
hypertension	5	B-Disease
.	9	O

Subjects	5	O
received	9	O
propranolol	0	B-Chemical
either	9	O
by	9	O
mouth	5	O
for	5	O
48	9	O
hours	9	O
before	9	O
PPA	9	B-Chemical
or	5	O
as	5	O
a	5	O
rapid	5	O
intravenous	0	O
infusion	0	O
after	9	O
PPA	9	B-Chemical
.	9	O

PPA	9	B-Chemical
,	9	O
75	9	O
mg	0	O
alone	9	O
,	9	O
increased	9	O
blood	9	O
pressure	5	O
(	9	O
31	7	O
+	9	O
/	9	O
-	7	O
14	7	O
mm	9	O
Hg	0	O
systolic	5	O
,	9	O
20	9	O
+	9	O
/	9	O
-	7	O
5	9	O
mm	9	O
Hg	0	O
diastolic	5	O
)	9	O
,	9	O
and	5	O
propranolol	0	B-Chemical
pretreatment	0	O
antagonized	3	O
this	5	O
increase	9	O
(	9	O
12	9	O
+	9	O
/	9	O
-	7	O
10	9	O
mm	9	O
Hg	0	O
systolic	5	O
,	9	O
10	9	O
+	9	O
/	9	O
-	7	O
7	9	O
mm	9	O
Hg	0	O
diastolic	5	O
)	9	O
.	9	O

Intravenous	0	O
propranolol	0	B-Chemical
after	9	O
PPA	9	B-Chemical
also	9	O
decreased	9	O
blood	9	O
pressure	5	O
.	9	O

Left	9	O
ventricular	5	O
function	9	O
(	9	O
assessed	9	O
by	9	O
echocardiography	5	O
)	9	O
showed	9	O
that	5	O
PPA	9	B-Chemical
increased	9	O
the	5	O
stroke	5	B-Disease
volume	9	O
30	9	O
%	9	O
(	9	O
from	9	O
62	7	O
.	9	O
5	9	O
+	9	O
/	9	O
-	7	O
20	9	O
.	9	O
9	7	O
to	5	O
80	9	O
.	9	O
8	9	O
+	9	O
/	9	O
-	7	O
22	7	O
.	9	O
4	9	O
ml	0	O
)	9	O
,	9	O
the	5	O
ejection	5	O
fraction	9	O
9	7	O
%	9	O
(	9	O
from	9	O
64	7	O
%	9	O
+	9	O
/	9	O
-	7	O
10	9	O
%	9	O
to	5	O
70	9	O
%	9	O
+	9	O
/	9	O
-	7	O
7	9	O
%	9	O
)	9	O
,	9	O
and	5	O
cardiac	5	O
output	5	O
14	7	O
%	9	O
(	9	O
from	9	O
3	9	O
.	9	O
6	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
6	9	O
to	5	O
4	9	O
.	9	O
1	9	O
+	9	O
/	9	O
-	7	O
1	9	O
.	9	O
0	7	O
L	0	O
/	9	O
min	0	O
)	9	O
.	9	O

Intravenous	0	O
propranolol	0	B-Chemical
reversed	9	O
these	5	O
effects	9	O
.	9	O

Systemic	9	O
vascular	5	O
resistance	9	O
was	9	O
increased	9	O
by	9	O
PPA	9	B-Chemical
28	7	O
%	9	O
(	9	O
from	9	O
1710	7	O
+	9	O
/	9	O
-	7	O
200	0	O
to	5	O
2190	7	O
+	9	O
/	9	O
-	7	O
700	9	O
dyne	0	O
X	9	O
sec	9	O
/	9	O
cm5	7	O
)	9	O
and	5	O
was	9	O
further	9	O
increased	9	O
by	9	O
propranolol	0	B-Chemical
22	7	O
%	9	O
(	9	O
to	5	O
2660	7	O
+	9	O
/	9	O
-	7	O
1200	0	O
dyne	0	O
X	9	O
sec	9	O
/	9	O
cm5	7	O
)	9	O
.	9	O

We	9	O
conclude	9	O
that	5	O
PPA	9	B-Chemical
increases	9	O
blood	9	O
pressure	5	O
by	9	O
increasing	9	O
systemic	9	O
vascular	5	O
resistance	9	O
and	5	O
cardiac	5	O
output	5	O
,	9	O
and	5	O
that	5	O
propranolol	0	B-Chemical
antagonizes	3	O
this	5	O
increase	9	O
by	9	O
reversing	5	O
the	5	O
effect	9	O
of	5	O
PPA	9	B-Chemical
on	5	O
cardiac	5	O
output	5	O
.	9	O

That	5	O
propranolol	0	B-Chemical
antagonizes	3	O
the	5	O
pressor	5	O
effect	9	O
of	5	O
PPA	9	B-Chemical
is	5	O
in	5	O
contrast	9	O
to	5	O
the	5	O
interaction	9	O
in	5	O
which	5	O
propranolol	0	B-Chemical
enhances	3	O
the	5	O
pressor	5	O
effect	9	O
of	5	O
norepinephrine	9	B-Chemical
.	9	O

This	5	O
is	5	O
probably	9	O
because	5	O
PPA	9	B-Chemical
has	9	O
less	5	O
beta	9	O
2	9	O
activity	9	O
than	5	O
does	9	O
norepinephrine	9	B-Chemical
.	9	O

Mesangial	3	O
function	9	O
and	5	O
glomerular	5	B-Disease
sclerosis	5	I-Disease
in	5	O
rats	9	O
with	5	O
aminonucleoside	0	B-Chemical
nephrosis	0	B-Disease
.	9	O

The	5	O
possible	5	O
relationship	5	O
between	5	O
mesangial	3	B-Disease
dysfunction	9	I-Disease
and	5	O
development	9	O
of	5	O
glomerular	5	B-Disease
sclerosis	5	I-Disease
was	9	O
studied	9	O
in	5	O
the	5	O
puromycin	3	B-Chemical
aminonucleoside	0	I-Chemical
(	9	O
PAN	0	B-Chemical
)	9	O
model	5	O
.	9	O

Five	9	O
male	9	O
Wistar	9	O
rats	9	O
received	9	O
repeated	5	O
subcutaneous	9	O
PAN	0	B-Chemical
injections	9	O
;	9	O
five	9	O
controls	9	O
received	9	O
saline	0	O
only	9	O
.	9	O

After	9	O
4	9	O
weeks	9	O
the	5	O
PAN	0	B-Chemical
rats	9	O
were	9	O
severely	9	O
proteinuric	9	B-Disease
(	9	O
190	9	O
+	9	O
/	9	O
-	7	O
80	9	O
mg	0	O
/	9	O
24	9	O
hr	0	O
)	9	O
,	9	O
and	5	O
all	5	O
rats	9	O
were	9	O
given	5	O
colloidal	0	O
carbon	0	B-Chemical
(	9	O
CC	9	O
)	9	O
intravenously	0	O
.	9	O

At	9	O
5	9	O
months	5	O
glomerular	5	B-Disease
sclerosis	5	I-Disease
was	9	O
found	9	O
in	5	O
7	9	O
.	9	O
6	9	O
+	9	O
/	9	O
-	7	O
3	9	O
.	9	O
4	9	O
%	9	O
of	5	O
the	5	O
glomeruli	9	O
of	5	O
PAN	0	B-Chemical
rats	9	O
;	9	O
glomeruli	9	O
of	5	O
the	5	O
controls	9	O
were	9	O
normal	9	O
.	9	O

Glomeruli	3	O
of	5	O
PAN	0	B-Chemical
rats	9	O
contained	9	O
significantly	9	O
more	5	O
CC	9	O
than	5	O
glomeruli	9	O
of	5	O
controls	9	O
.	9	O

Glomeruli	3	O
with	5	O
sclerosis	5	B-Disease
contained	9	O
significantly	9	O
more	5	O
CC	9	O
than	5	O
non	9	O
-	7	O
sclerotic	5	O
glomeruli	9	O
in	5	O
the	5	O
same	9	O
kidneys	9	O
.	9	O

CC	9	O
was	9	O
preferentially	9	O
localized	9	O
within	9	O
the	5	O
sclerotic	5	O
areas	5	O
of	5	O
the	5	O
affected	9	O
glomeruli	9	O
.	9	O

Since	9	O
mesangial	3	O
CC	9	O
clearance	9	O
from	9	O
the	5	O
mesangium	3	O
did	9	O
not	5	O
change	9	O
during	5	O
chronic	5	O
PAN	0	B-Chemical
treatment	9	O
,	9	O
we	5	O
conclude	9	O
that	5	O
this	5	O
preferential	9	O
CC	9	O
localization	3	O
within	9	O
the	5	O
lesions	5	O
is	5	O
caused	9	O
by	9	O
an	5	O
increased	9	O
CC	9	O
uptake	0	O
shortly	9	O
after	9	O
injection	9	O
in	5	O
apparent	9	O
vulnerable	5	O
areas	5	O
where	5	O
sclerosis	5	B-Disease
will	5	O
develop	5	O
subsequently	9	O
.	9	O

Cluster	9	O
analysis	9	O
showed	9	O
a	5	O
random	5	O
distribution	9	O
of	5	O
lesions	5	O
in	5	O
the	5	O
PAN	0	B-Chemical
glomeruli	9	O
in	5	O
concordance	9	O
with	5	O
the	5	O
random	5	O
localization	3	O
of	5	O
mesangial	3	O
areas	5	O
with	5	O
dysfunction	9	O
in	5	O
this	5	O
model	5	O
.	9	O

Similar	9	O
to	5	O
the	5	O
remnant	9	O
kidney	9	O
model	5	O
in	5	O
PAN	0	B-Chemical
nephrosis	0	B-Disease
the	5	O
development	9	O
of	5	O
glomerular	5	B-Disease
sclerosis	5	I-Disease
may	5	O
be	5	O
related	9	O
to	5	O
"	5	O
mesangial	3	O
overloading	5	O
.	9	O
"	5	O

Relationship	9	O
between	5	O
nicotine	0	B-Chemical
-	7	O
induced	3	O
seizures	5	B-Disease
and	5	O
hippocampal	3	O
nicotinic	0	O
receptors	3	O
.	9	O

A	9	O
controversy	5	O
has	9	O
existed	9	O
for	5	O
several	9	O
years	5	O
concerning	5	O
the	5	O
physiological	9	O
relevance	9	O
of	5	O
the	5	O
nicotinic	0	O
receptor	3	O
measured	9	O
by	9	O
alpha	9	O
-	7	O
bungarotoxin	0	O
binding	1	O
.	9	O

Using	9	O
mice	3	O
derived	9	O
from	9	O
a	5	O
classical	9	O
F2	9	O
and	5	O
backcross	9	O
genetic	5	O
design	5	O
,	9	O
a	5	O
relationship	5	O
between	5	O
nicotine	0	B-Chemical
-	7	O
induced	3	O
seizures	5	B-Disease
and	5	O
alpha	9	O
-	7	O
bungarotoxin	0	O
nicotinic	0	O
receptor	3	O
concentration	0	O
was	9	O
found	9	O
.	9	O

Mice	3	O
sensitive	9	O
to	5	O
the	5	O
convulsant	0	O
effects	9	O
of	5	O
nicotine	0	B-Chemical
had	9	O
greater	5	O
alpha	9	O
-	7	O
bungarotoxin	0	O
binding	1	O
in	5	O
the	5	O
hippocampus	9	O
than	5	O
seizure	5	B-Disease
insensitive	9	O
mice	3	O
.	9	O

The	5	O
binding	1	O
sites	9	O
from	9	O
seizure	5	B-Disease
sensitive	9	O
and	5	O
resistant	9	O
mice	3	O
were	9	O
equally	9	O
affected	9	O
by	9	O
treatment	9	O
with	5	O
dithiothreitol	0	B-Chemical
,	9	O
trypsin	0	O
or	5	O
heat	9	O
.	9	O

Thus	9	O
it	5	O
appears	9	O
that	5	O
the	5	O
difference	9	O
between	5	O
seizure	5	B-Disease
sensitive	9	O
and	5	O
insensitive	9	O
animals	9	O
may	5	O
be	5	O
due	5	O
to	5	O
a	5	O
difference	9	O
in	5	O
hippocampal	3	O
nicotinic	0	O
receptor	3	O
concentration	0	O
as	5	O
measured	9	O
with	5	O
alpha	9	O
-	7	O
bungarotoxin	0	O
binding	1	O
.	9	O

The	5	O
role	9	O
of	5	O
p	7	B-Chemical
-	7	I-Chemical
aminophenol	0	I-Chemical
in	5	O
acetaminophen	0	B-Chemical
-	7	O
induced	3	O
nephrotoxicity	9	B-Disease
:	9	O
effect	9	O
of	5	O
bis	0	B-Chemical
(	9	I-Chemical
p	7	I-Chemical
-	7	I-Chemical
nitrophenyl	0	I-Chemical
)	9	I-Chemical
phosphate	0	I-Chemical
on	5	O
acetaminophen	0	B-Chemical
and	5	O
p	7	B-Chemical
-	7	I-Chemical
aminophenol	0	I-Chemical
nephrotoxicity	9	B-Disease
and	5	O
metabolism	9	O
in	5	O
Fischer	6	O
344	7	O
rats	9	O
.	9	O

Acetaminophen	0	B-Chemical
(	9	O
APAP	0	B-Chemical
)	9	O
produces	9	O
proximal	9	O
tubular	9	B-Disease
necrosis	9	I-Disease
in	5	O
Fischer	6	O
344	7	O
(	9	O
F344	3	O
)	9	O
rats	9	O
.	9	O

Recently	9	O
,	9	O
p	7	B-Chemical
-	7	I-Chemical
aminophenol	0	I-Chemical
(	9	O
PAP	9	B-Chemical
)	9	O
,	9	O
a	5	O
known	9	O
potent	3	O
nephrotoxicant	0	O
,	9	O
was	9	O
identified	9	O
as	5	O
a	5	O
metabolite	0	O
of	5	O
APAP	0	B-Chemical
in	5	O
F344	3	O
rats	9	O
.	9	O

The	5	O
purpose	5	O
of	5	O
this	5	O
study	9	O
was	9	O
to	5	O
determine	9	O
if	5	O
PAP	9	B-Chemical
formation	9	O
is	5	O
a	5	O
requisite	5	O
step	9	O
in	5	O
APAP	0	B-Chemical
-	7	O
induced	3	O
nephrotoxicity	9	B-Disease
.	9	O

Therefore	9	O
,	9	O
the	5	O
effect	9	O
of	5	O
bis	0	B-Chemical
(	9	I-Chemical
p	7	I-Chemical
-	7	I-Chemical
nitrophenyl	0	I-Chemical
)	9	I-Chemical
phosphate	0	I-Chemical
(	9	O
BNPP	0	B-Chemical
)	9	O
,	9	O
an	5	O
acylamidase	0	O
inhibitor	3	O
,	9	O
on	5	O
APAP	0	B-Chemical
and	5	O
PAP	9	B-Chemical
nephrotoxicity	9	B-Disease
and	5	O
metabolism	9	O
was	9	O
determined	9	O
.	9	O

BNPP	0	B-Chemical
(	9	O
1	9	O
to	5	O
8	9	O
mM	0	O
)	9	O
reduced	9	O
APAP	0	B-Chemical
deacetylation	3	O
and	5	O
covalent	0	O
binding	1	O
in	5	O
F344	3	O
renal	9	O
cortical	5	O
homogenates	9	O
in	5	O
a	5	O
concentration	0	O
-	7	O
dependent	9	O
manner	9	O
.	9	O

Pretreatment	3	O
of	5	O
animals	9	O
with	5	O
BNPP	0	B-Chemical
prior	9	O
to	5	O
APAP	0	B-Chemical
or	5	O
PAP	9	B-Chemical
administration	9	O
resulted	9	O
in	5	O
marked	9	O
reduction	9	O
of	5	O
APAP	0	B-Chemical
(	9	O
900	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
nephrotoxicity	9	B-Disease
but	9	O
not	5	O
PAP	9	B-Chemical
nephrotoxicity	9	B-Disease
.	9	O

This	5	O
result	9	O
was	9	O
not	5	O
due	5	O
to	5	O
altered	9	O
disposition	5	O
of	5	O
either	9	O
APAP	0	B-Chemical
or	5	O
acetylated	0	O
metabolites	0	O
in	5	O
plasma	9	O
or	5	O
renal	9	O
cortical	5	O
and	5	O
hepatic	9	O
tissue	9	O
.	9	O

Rather	5	O
,	9	O
BNPP	0	B-Chemical
pretreatment	0	O
reduced	9	O
the	5	O
fraction	9	O
of	5	O
APAP	0	B-Chemical
excreted	0	O
as	5	O
PAP	9	B-Chemical
by	9	O
64	7	O
and	5	O
75	9	O
%	9	O
after	9	O
APAP	0	B-Chemical
doses	0	O
of	5	O
750	0	O
and	5	O
900	9	O
mg	0	O
/	9	O
kg	0	O
.	9	O

BNPP	0	B-Chemical
did	9	O
not	5	O
alter	9	O
the	5	O
excretion	0	O
of	5	O
APAP	0	B-Chemical
or	5	O
any	5	O
of	5	O
its	9	O
non	9	O
-	7	O
deacetylated	0	O
metabolites	0	O
nor	9	O
did	9	O
BNPP	0	B-Chemical
alter	9	O
excretion	0	O
of	5	O
PAP	9	B-Chemical
or	5	O
its	9	O
metabolites	0	O
after	9	O
PAP	9	B-Chemical
doses	0	O
of	5	O
150	0	O
and	5	O
300	0	O
mg	0	O
/	9	O
kg	0	O
.	9	O

Therefore	9	O
,	9	O
the	5	O
BNPP	0	B-Chemical
-	7	O
induced	3	O
reduction	9	O
in	5	O
APAP	0	B-Chemical
-	7	O
induced	3	O
nephrotoxicity	9	B-Disease
appears	9	O
to	5	O
be	5	O
due	5	O
to	5	O
inhibition	3	O
of	5	O
APAP	0	B-Chemical
deacetylation	3	O
.	9	O

It	5	O
is	5	O
concluded	9	O
that	5	O
PAP	9	B-Chemical
formation	9	O
,	9	O
in	5	O
vivo	3	O
,	9	O
accounts	5	O
,	9	O
at	9	O
least	9	O
in	5	O
part	9	O
,	9	O
for	5	O
APAP	0	B-Chemical
-	7	O
induced	3	O
renal	9	B-Disease
tubular	9	I-Disease
necrosis	9	I-Disease
.	9	O

Morphine	0	B-Chemical
-	7	O
induced	3	O
seizures	5	B-Disease
in	5	O
newborn	9	O
infants	5	O
.	9	O

Two	9	O
neonates	9	O
suffered	5	O
from	9	O
generalized	5	O
seizures	5	B-Disease
during	5	O
the	5	O
course	5	O
of	5	O
intravenous	0	O
morphine	0	B-Chemical
sulfate	0	I-Chemical
for	5	O
post	9	O
-	7	O
operative	5	O
analgesia	5	O
.	9	O

They	5	O
received	9	O
morphine	0	B-Chemical
in	5	O
doses	0	O
of	5	O
32	7	O
micrograms	0	O
/	9	O
kg	0	O
/	9	O
hr	0	O
and	5	O
40	9	O
micrograms	0	O
/	9	O
kg	0	O
/	9	O
hr	0	O
larger	5	O
than	5	O
a	5	O
group	9	O
of	5	O
10	9	O
neonates	9	O
who	5	O
received	9	O
6	9	O
-	7	O
24	9	O
micrograms	0	O
/	9	O
kg	0	O
/	9	O
hr	0	O
and	5	O
had	9	O
no	9	O
seizures	5	B-Disease
.	9	O

Plasma	0	O
concentrations	0	O
of	5	O
morphine	0	B-Chemical
in	5	O
these	5	O
neonates	9	O
was	9	O
excessive	5	O
(	9	O
60	9	O
and	5	O
90	9	O
mg	0	O
/	9	O
ml	0	O
)	9	O
.	9	O

Other	9	O
known	9	O
reasons	5	O
for	5	O
seizures	5	B-Disease
were	9	O
ruled	9	O
out	9	O
and	5	O
the	5	O
convulsions	5	B-Disease
stopped	9	O
a	5	O
few	5	O
hours	9	O
after	9	O
cessation	5	O
of	5	O
morphine	0	B-Chemical
and	5	O
did	9	O
not	5	O
reoccur	5	O
in	5	O
the	5	O
subsequent	9	O
8	9	O
months	5	O
.	9	O

It	5	O
is	5	O
suggested	9	O
that	5	O
post	9	O
-	7	O
operative	5	O
intravenous	0	O
morphine	0	B-Chemical
should	5	O
not	5	O
exceed	5	O
20	9	O
micrograms	0	O
/	9	O
kg	0	O
/	9	O
ml	0	O
in	5	O
neonates	9	O
.	9	O

Indomethacin	0	B-Chemical
induced	3	O
hypotension	5	B-Disease
in	5	O
sodium	0	B-Chemical
and	5	O
volume	9	O
depleted	3	O
rats	9	O
.	9	O

After	9	O
a	5	O
single	9	O
oral	9	O
dose	9	O
of	5	O
4	9	O
mg	0	O
/	9	O
kg	0	O
indomethacin	0	B-Chemical
(	9	O
IDM	1	B-Chemical
)	9	O
to	5	O
sodium	0	B-Chemical
and	5	O
volume	9	O
depleted	3	O
rats	9	O
plasma	9	O
renin	9	O
activity	9	O
(	9	O
PRA	9	O
)	9	O
and	5	O
systolic	5	O
blood	9	O
pressure	5	O
fell	5	O
significantly	9	O
within	9	O
four	9	O
hours	9	O
.	9	O

In	9	O
sodium	0	B-Chemical
repleted	3	O
animals	9	O
indomethacin	0	B-Chemical
did	9	O
not	5	O
change	9	O
systolic	5	O
blood	9	O
pressure	5	O
(	9	O
BP	9	O
)	9	O
although	9	O
plasma	9	O
renin	9	O
activity	9	O
was	9	O
decreased	9	O
.	9	O

Thus	9	O
,	9	O
indomethacin	0	B-Chemical
by	9	O
inhibition	3	O
of	5	O
prostaglandin	0	B-Chemical
synthesis	9	O
may	5	O
diminish	9	O
the	5	O
blood	9	O
pressure	5	O
maintaining	9	O
effect	9	O
of	5	O
the	5	O
stimulated	3	O
renin	9	O
-	7	O
angiotensin	9	B-Chemical
system	5	O
in	5	O
sodium	0	B-Chemical
and	5	O
volume	9	O
depletion	3	O
.	9	O

On	5	O
the	5	O
antiarrhythmic	5	O
activity	9	O
of	5	O
one	5	O
N	9	O
-	7	O
substituted	0	O
piperazine	0	B-Chemical
derivative	0	O
of	5	O
trans	9	B-Chemical
-	7	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
amino	1	I-Chemical
-	7	I-Chemical
3	9	I-Chemical
-	7	I-Chemical
hydroxy	0	I-Chemical
-	7	I-Chemical
1	9	I-Chemical
,	9	I-Chemical
2	9	I-Chemical
,	9	I-Chemical
3	9	I-Chemical
,	9	I-Chemical
4	9	I-Chemical
-	7	I-Chemical
tetrahydroanaphthalene	_	I-Chemical
.	9	O

The	5	O
antiarrhythmic	5	O
activity	9	O
of	5	O
the	5	O
compound	0	O
N	9	B-Chemical
-	7	I-Chemical
(	9	I-Chemical
trans	9	I-Chemical
-	7	I-Chemical
3	9	I-Chemical
-	7	I-Chemical
hydroxy	0	I-Chemical
-	7	I-Chemical
1	9	I-Chemical
,	9	I-Chemical
2	9	I-Chemical
,	9	I-Chemical
3	9	I-Chemical
,	9	I-Chemical
4	9	I-Chemical
-	7	I-Chemical
tetrahydro	0	I-Chemical
-	7	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
naphthyl	0	I-Chemical
)	9	I-Chemical
-	7	I-Chemical
N	9	I-Chemical
-	7	I-Chemical
(	9	I-Chemical
3	9	I-Chemical
-	7	I-Chemical
oxo	0	I-Chemical
-	7	I-Chemical
3	9	I-Chemical
-	7	I-Chemical
phenyl	0	I-Chemical
-	7	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
methylpropyl	9	I-Chemical
)	9	I-Chemical
-	7	I-Chemical
piperazine	0	I-Chemical
hydrochloride	0	I-Chemical
,	9	O
referred	5	O
to	5	O
as	5	O
P11	9	B-Chemical
,	9	O
is	5	O
studied	9	O
on	5	O
anaesthesized	0	O
cats	9	O
and	5	O
Wistar	9	O
albino	3	O
rats	9	O
,	9	O
as	5	O
well	9	O
as	5	O
on	5	O
non	9	O
-	7	O
anaesthesized	0	O
rabbits	9	O
.	9	O

Four	9	O
types	9	O
of	5	O
experimental	5	O
arrhythmia	5	B-Disease
are	5	O
used	5	O
-	7	O
-	7	O
with	5	O
BaCl2	0	B-Chemical
,	9	O
with	5	O
chloroform	0	B-Chemical
-	7	O
adrenaline	0	B-Chemical
,	9	O
with	5	O
strophantine	_	B-Chemical
G	9	I-Chemical
and	5	O
with	5	O
aconitine	0	B-Chemical
.	9	O

The	5	O
compound	0	O
P11	9	B-Chemical
is	5	O
introduced	9	O
in	5	O
doses	0	O
of	5	O
0	7	O
.	9	O
25	9	O
and	5	O
0	7	O
.	9	O
50	0	O
mg	0	O
/	9	O
kg	0	O
intravenously	0	O
and	5	O
10	9	O
mg	0	O
/	9	O
kg	0	O
orally	0	O
.	9	O

The	5	O
compound	0	O
manifests	5	O
antiarrhythmic	5	O
activity	9	O
in	5	O
all	5	O
models	5	O
of	5	O
experimental	5	O
arrhythmia	5	B-Disease
used	5	O
,	9	O
causing	9	O
greatest	9	O
inhibition	3	O
on	5	O
the	5	O
arrhythmia	5	B-Disease
induced	3	O
by	9	O
chloroform	0	B-Chemical
-	7	O
adrenaline	0	B-Chemical
(	9	O
in	5	O
90	9	O
per	9	O
cent	5	O
)	9	O
and	5	O
with	5	O
BaCl2	0	B-Chemical
(	9	O
in	5	O
84	7	O
per	9	O
cent	5	O
)	9	O
.	9	O

The	5	O
results	9	O
obtained	9	O
are	5	O
associated	9	O
with	5	O
the	5	O
beta	9	O
-	7	O
adrenoblocking	_	O
and	5	O
with	5	O
the	5	O
membrane	9	O
-	7	O
stabilizing	9	O
action	5	O
of	5	O
the	5	O
compound	0	O
.	9	O

Recurrent	5	O
subarachnoid	5	B-Disease
hemorrhage	5	I-Disease
associated	9	O
with	5	O
aminocaproic	0	B-Chemical
acid	0	I-Chemical
therapy	5	O
and	5	O
acute	9	B-Disease
renal	9	I-Disease
artery	5	I-Disease
thrombosis	5	I-Disease
.	9	O

Case	5	O
report	5	O
.	9	O

Epsilon	9	B-Chemical
aminocaproic	0	I-Chemical
acid	0	I-Chemical
(	9	O
EACA	0	B-Chemical
)	9	O
has	9	O
been	9	O
used	5	O
to	5	O
prevent	5	O
rebleeding	5	O
in	5	O
patients	5	O
with	5	O
subarachnoid	5	B-Disease
hemorrhage	5	I-Disease
(	9	O
SAH	9	B-Disease
)	9	O
.	9	O

Although	9	O
this	5	O
agent	9	O
does	9	O
decrease	9	O
the	5	O
frequency	5	O
of	5	O
rebleeding	5	O
,	9	O
several	9	O
reports	9	O
have	5	O
described	9	O
thrombotic	5	B-Disease
complications	5	O
of	5	O
EACA	0	B-Chemical
therapy	5	O
.	9	O

These	5	O
complications	5	O
have	5	O
included	5	O
clinical	5	O
deterioration	5	O
and	5	O
intracranial	5	B-Disease
vascular	5	I-Disease
thrombosis	5	I-Disease
in	5	O
patients	5	O
with	5	O
SAH	9	B-Disease
,	9	O
arteriolar	5	O
and	5	O
capillary	0	O
fibrin	0	O
thrombi	5	B-Disease
in	5	O
patients	5	O
with	5	O
fibrinolytic	5	O
syndromes	5	O
treated	3	O
with	5	O
EACA	0	B-Chemical
,	9	O
or	5	O
other	5	O
thromboembolic	5	B-Disease
phenomena	5	I-Disease
.	9	O

Since	9	O
intravascular	5	O
fibrin	0	O
thrombi	5	B-Disease
are	5	O
often	5	O
observed	9	O
in	5	O
patients	5	O
with	5	O
fibrinolytic	5	O
disorders	5	O
,	9	O
EACA	0	B-Chemical
should	5	O
not	5	O
be	5	O
implicated	9	O
in	5	O
the	5	O
pathogenesis	9	O
of	5	O
fibrin	0	O
thrombi	5	B-Disease
in	5	O
patients	5	O
with	5	O
disseminated	5	B-Disease
intravascular	5	I-Disease
coagulation	5	I-Disease
or	5	O
other	5	O
"	5	O
consumption	5	B-Disease
coagulopathies	5	I-Disease
.	9	O
"	5	O
This	5	O
report	5	O
describes	5	O
subtotal	5	O
infarction	5	B-Disease
of	5	O
the	5	O
kidney	9	O
due	5	O
to	5	O
thrombosis	5	B-Disease
of	5	I-Disease
a	5	I-Disease
normal	9	I-Disease
renal	9	I-Disease
artery	5	I-Disease
.	9	O

This	5	O
occlusion	5	O
occurred	9	O
after	9	O
EACA	0	B-Chemical
therapy	5	O
in	5	O
a	5	O
patient	5	O
with	5	O
SAH	9	B-Disease
and	5	O
histopathological	9	O
documentation	5	O
of	5	O
recurrent	5	O
SAH	9	B-Disease
.	9	O

The	5	O
corresponding	9	O
clinical	5	O
event	5	O
was	9	O
characterized	9	O
by	9	O
marked	9	O
hypertension	5	B-Disease
and	5	O
abrupt	5	O
neurological	5	O
deterioration	5	O
.	9	O

Effect	0	O
of	5	O
vincristine	0	B-Chemical
sulfate	0	I-Chemical
on	5	O
Pseudomonas	4	B-Disease
infections	5	I-Disease
in	5	O
monkeys	5	O
.	9	O

In	9	O
rhesus	9	O
monkeys	5	O
,	9	O
intravenous	0	O
challenge	9	O
with	5	O
0	7	O
.	9	O
6	9	O
x	9	O
10	9	O
(	9	O
10	9	O
)	9	O
to	5	O
2	9	O
.	9	O
2	9	O
x	9	O
10	9	O
(	9	O
10	9	O
)	9	O
Pseudomonas	4	O
aeruginosa	4	O
organisms	9	O
caused	9	O
acute	9	O
illness	5	O
of	5	O
4	9	O
to	5	O
5	9	O
days	9	O
'	9	O
duration	5	O
with	5	O
spontaneous	5	O
recovery	9	O
in	5	O
13	7	O
of	5	O
15	9	O
monkeys	5	O
;	9	O
blood	9	O
cultures	3	O
became	9	O
negative	9	O
3	9	O
to	5	O
17	7	O
days	9	O
after	9	O
challenge	9	O
.	9	O

Leukocytosis	7	B-Disease
was	9	O
observed	9	O
in	5	O
all	5	O
monkeys	5	O
.	9	O

Intravenous	0	O
or	5	O
intratracheal	3	O
inoculation	9	O
of	5	O
2	9	O
.	9	O
0	7	O
to	5	O
2	9	O
.	9	O
5	9	O
mg	0	O
of	5	O
vincristine	0	B-Chemical
sulfate	0	I-Chemical
was	9	O
followed	9	O
by	9	O
leukopenia	9	B-Disease
in	5	O
4	9	O
to	5	O
5	9	O
days	9	O
.	9	O

Intravenous	0	O
inoculation	9	O
of	5	O
4	9	O
.	9	O
2	9	O
x	9	O
10	9	O
(	9	O
10	9	O
)	9	O
to	5	O
7	9	O
.	9	O
8	9	O
x	9	O
10	9	O
(	9	O
10	9	O
)	9	O
pyocin	1	O
type	9	O
6	9	O
Pseudomonas	4	O
organisms	9	O
in	5	O
monkeys	5	O
given	5	O
vincristine	0	B-Chemical
sulfate	0	I-Chemical
4	9	O
days	9	O
previously	9	O
resulted	9	O
in	5	O
fatal	5	O
infection	9	B-Disease
in	5	O
11	7	O
of	5	O
14	7	O
monkeys	5	O
,	9	O
whereas	9	O
none	9	O
of	5	O
four	9	O
receiving	9	O
Pseudomonas	4	O
alone	9	O
died	9	O
.	9	O

These	5	O
studies	9	O
suggest	9	O
that	5	O
an	5	O
antimetabolite	0	O
-	7	O
induced	3	O
leukopenia	9	B-Disease
predisposes	9	O
to	5	O
severe	5	O
Pseudomonas	4	O
sepsis	9	B-Disease
and	5	O
that	5	O
such	5	O
monkeys	5	O
may	5	O
serve	5	O
as	5	O
a	5	O
biological	5	O
model	5	O
for	5	O
study	9	O
of	5	O
comparative	9	O
efficacy	9	O
of	5	O
antimicrobial	9	O
agents	5	O
.	9	O

Modification	9	O
by	9	O
propranolol	0	B-Chemical
of	5	O
cardiovascular	5	O
effects	9	O
of	5	O
induced	3	O
hypoglycaemia	5	B-Disease
.	9	O

The	5	O
cardiovascular	5	O
effects	9	O
of	5	O
hypoglycaemia	5	B-Disease
,	9	O
with	5	O
and	5	O
without	9	O
beta	9	O
-	7	O
blockade	3	O
,	9	O
were	9	O
compared	9	O
in	5	O
fourteen	9	O
healthy	5	O
men	5	O
.	9	O

Eight	9	O
received	9	O
insulin	3	O
alone	9	O
,	9	O
and	5	O
eight	9	O
,	9	O
including	9	O
two	5	O
of	5	O
the	5	O
original	5	O
insulin	3	O
-	7	O
only	9	O
group	9	O
,	9	O
were	9	O
given	5	O
propranolol	0	B-Chemical
and	5	O
insulin	3	O
.	9	O

In	9	O
the	5	O
insulin	3	O
-	7	O
group	9	O
the	5	O
period	5	O
of	5	O
hypoglycaemia	5	B-Disease
was	9	O
associated	9	O
with	5	O
an	5	O
increase	9	O
in	5	O
heart	5	O
-	7	O
rate	9	O
and	5	O
a	5	O
fall	5	O
in	5	O
diastolic	5	O
blood	9	O
-	7	O
pressure	5	O
.	9	O

In	9	O
the	5	O
propranolol	0	B-Chemical
-	7	O
insulin	3	O
group	9	O
there	5	O
was	9	O
a	5	O
significant	9	O
fall	5	O
in	5	O
heart	5	O
-	7	O
rate	9	O
in	5	O
most	9	O
subjects	5	O
and	5	O
an	5	O
increase	9	O
in	5	O
diastolic	5	O
pressure	5	O
.	9	O

Typical	9	O
S	9	O
-	7	O
T	3	O
/	9	O
T	3	O
changes	9	O
occurred	9	O
in	5	O
the	5	O
insulin	3	O
-	7	O
group	9	O
but	9	O
in	5	O
none	9	O
of	5	O
the	5	O
propranolol	0	B-Chemical
-	7	O
insulin	3	O
group	9	O
.	9	O

Hypertension	7	B-Disease
in	5	O
diabetics	5	B-Disease
prone	5	O
to	5	O
hypoglycaemia	5	B-Disease
attacks	5	O
should	5	O
not	5	O
be	5	O
treated	3	O
with	5	O
beta	9	O
-	7	O
blockers	9	O
because	5	O
these	5	O
drugs	5	O
may	5	O
cause	5	O
a	5	O
sharp	5	O
rise	9	O
in	5	O
blood	9	O
-	7	O
pressure	5	O
in	5	O
such	5	O
patients	5	O
.	9	O

Long	9	O
-	7	O
term	5	O
propranolol	0	B-Chemical
therapy	5	O
in	5	O
pregnancy	5	O
:	9	O
maternal	9	O
and	5	O
fetal	9	O
outcome	5	O
.	9	O

Propranolol	0	B-Chemical
,	9	O
a	5	O
beta	9	O
-	7	O
adrenergic	9	O
blocking	3	O
agent	9	O
,	9	O
has	9	O
found	9	O
an	5	O
important	9	O
position	9	O
in	5	O
the	5	O
practice	5	O
of	5	O
medicine	5	O
.	9	O

Its	5	O
use	5	O
in	5	O
pregnancy	5	O
,	9	O
however	9	O
,	9	O
is	5	O
an	5	O
open	5	O
question	5	O
as	5	O
a	5	O
number	9	O
of	5	O
detrimental	9	O
side	5	O
effects	9	O
have	5	O
been	9	O
reported	9	O
in	5	O
the	5	O
fetus	5	O
and	5	O
neonate	9	O
.	9	O

Ten	9	O
patients	5	O
and	5	O
12	9	O
pregnancies	5	O
are	5	O
reported	9	O
where	5	O
chronic	5	O
propranolol	0	B-Chemical
has	9	O
been	9	O
administered	9	O
.	9	O

Five	9	O
patients	5	O
with	5	O
serial	9	O
pregnancies	5	O
with	5	O
and	5	O
without	9	O
propranolol	0	B-Chemical
therapy	5	O
are	5	O
also	9	O
examined	9	O
.	9	O

Maternal	9	O
,	9	O
fetal	9	O
,	9	O
and	5	O
neonatal	9	O
complications	5	O
are	5	O
examined	9	O
.	9	O

An	5	O
attempt	5	O
is	5	O
made	5	O
to	5	O
differentiate	9	O
drug	5	O
-	7	O
related	9	O
complications	5	O
from	9	O
maternal	9	O
disease	5	O
-	7	O
-	7	O
related	9	O
complications	5	O
.	9	O

We	9	O
conclude	9	O
that	5	O
previously	9	O
reported	9	O
hypoglycemia	5	B-Disease
,	9	O
hyperbilirubinemia	5	B-Disease
,	9	O
polycythemia	9	B-Disease
,	9	O
neonatal	9	B-Disease
apnea	5	I-Disease
,	9	O
and	5	O
bradycardia	5	B-Disease
are	5	O
not	5	O
invariable	9	O
and	5	O
cannot	5	O
be	5	O
statistically	9	O
correlated	9	O
with	5	O
chronic	5	O
propranolol	0	B-Chemical
therapy	5	O
.	9	O

Growth	9	B-Disease
retardation	9	I-Disease
,	9	O
however	9	O
,	9	O
appears	9	O
to	5	O
be	5	O
significant	9	O
in	5	O
both	9	O
of	5	O
our	5	O
series	5	O
.	9	O

Central	4	O
excitatory	5	O
actions	5	O
of	5	O
flurazepam	0	B-Chemical
.	9	O

Toxic	0	O
actions	5	O
of	5	O
flurazepam	0	B-Chemical
(	9	O
FZP	5	B-Chemical
)	9	O
were	9	O
studied	9	O
in	5	O
cats	9	O
,	9	O
mice	3	O
and	5	O
rats	9	O
.	9	O

High	9	O
doses	0	O
caused	9	O
an	5	O
apparent	9	O
central	5	O
excitation	0	O
,	9	O
most	9	O
clearly	9	O
seen	9	O
as	5	O
clonic	5	O
convulsions	5	B-Disease
,	9	O
superimposed	5	O
on	5	O
general	5	O
depression	5	B-Disease
.	9	O

Following	9	O
a	5	O
lethal	9	O
dose	9	O
,	9	O
death	9	O
was	9	O
always	5	O
associated	9	O
with	5	O
convulsions	5	B-Disease
.	9	O

Comparing	9	O
the	5	O
relative	9	O
sensitivity	9	O
to	5	O
central	5	O
depression	5	B-Disease
and	5	O
excitation	0	O
revealed	9	O
that	5	O
rats	9	O
were	9	O
least	9	O
likely	5	O
to	5	O
have	5	O
convulsions	5	B-Disease
at	9	O
doses	0	O
that	5	O
did	9	O
not	5	O
first	9	O
cause	5	O
loss	9	B-Disease
of	5	I-Disease
consciousness	5	I-Disease
,	9	O
while	9	O
cats	9	O
most	9	O
clearly	9	O
showed	9	O
marked	9	O
central	5	O
excitatory	5	O
actions	5	O
.	9	O

Signs	5	O
of	5	O
FZP	5	B-Chemical
toxocity	9	B-Disease
in	5	O
cats	9	O
included	5	O
excessive	5	O
salivation	5	B-Disease
,	9	O
extreme	5	O
apprehensive	5	O
behavior	5	O
,	9	O
retching	5	O
,	9	O
muscle	9	B-Disease
tremors	5	I-Disease
and	5	O
convulsions	5	B-Disease
.	9	O

An	5	O
interaction	9	O
between	5	O
FZP	5	B-Chemical
and	5	O
pentylenetetrazol	0	B-Chemical
(	9	O
PTZ	0	B-Chemical
)	9	O
was	9	O
shown	9	O
by	9	O
pretreating	3	O
mice	3	O
with	5	O
FZP	5	B-Chemical
before	9	O
PTZ	0	B-Chemical
challenge	9	O
.	9	O

As	9	O
a	5	O
function	9	O
of	5	O
dose	9	O
,	9	O
FZP	5	B-Chemical
first	9	O
protected	9	O
against	9	O
convulsions	5	B-Disease
and	5	O
death	9	O
.	9	O

At	9	O
higher	9	O
doses	0	O
,	9	O
however	9	O
,	9	O
convulsions	5	B-Disease
again	9	O
emerged	9	O
.	9	O

These	5	O
doses	0	O
of	5	O
FZP	5	B-Chemical
were	9	O
lower	9	O
than	5	O
those	5	O
that	5	O
would	5	O
alone	9	O
cause	5	O
convulsions	5	B-Disease
.	9	O

These	5	O
results	9	O
may	5	O
be	5	O
relevant	5	O
to	5	O
the	5	O
use	5	O
of	5	O
FZP	5	B-Chemical
in	5	O
clinical	5	O
situations	5	O
in	5	O
which	5	O
there	5	O
is	5	O
increased	9	O
neural	5	O
excitability	5	O
,	9	O
such	5	O
as	5	O
epilepsy	5	B-Disease
or	5	O
sedative	5	O
-	7	O
hypnotic	5	O
drug	5	O
withdrawal	5	O
.	9	O

Use	5	O
of	5	O
propranolol	0	B-Chemical
in	5	O
the	5	O
treatment	9	O
of	5	O
idiopathic	5	B-Disease
orthostatic	5	I-Disease
hypotension	5	I-Disease
.	9	O

Five	9	O
patients	5	O
with	5	O
idiopathic	5	B-Disease
orthostatic	5	I-Disease
hypotension	5	I-Disease
who	5	O
had	9	O
physiologic	9	O
and	5	O
biochemical	9	O
evidence	9	O
of	5	O
severe	5	O
autonomic	5	O
dysfunction	9	O
were	9	O
included	5	O
in	5	O
the	5	O
study	9	O
.	9	O

They	5	O
all	5	O
exhibited	9	O
markedly	9	O
reduced	9	O
plasma	9	O
catecholamines	9	B-Chemical
and	5	O
plasma	9	O
renin	9	O
activity	9	O
in	5	O
both	9	O
recumbent	5	O
and	5	O
upright	5	O
positions	9	O
and	5	O
had	9	O
marked	9	O
hypersensitivity	9	B-Disease
to	5	O
the	5	O
pressor	5	O
effects	9	O
of	5	O
infused	9	O
norepinephrine	9	B-Chemical
.	9	O

Treatment	9	O
with	5	O
propanolol	0	B-Chemical
administered	9	O
intravenously	0	O
(	9	O
1	9	O
-	7	O
5	9	O
mg	0	O
)	9	O
produced	9	O
increases	9	O
in	5	O
supine	5	O
and	5	O
upright	5	O
blood	9	O
pressure	5	O
in	5	O
4	9	O
of	5	O
the	5	O
5	9	O
individuals	5	O
with	5	O
rises	9	O
ranging	9	O
from	9	O
11	7	O
/	9	O
6	9	O
to	5	O
22	7	O
/	9	O
11	7	O
mmHg	7	O
.	9	O

Chronic	9	O
oral	9	O
administration	9	O
of	5	O
propranolol	0	B-Chemical
(	9	O
40	9	O
-	7	O
160	9	O
mg	0	O
/	9	O
day	9	O
)	9	O
also	9	O
elevated	9	O
the	5	O
blood	9	O
pressures	5	O
of	5	O
these	5	O
individuals	5	O
with	5	O
increases	9	O
in	5	O
the	5	O
order	5	O
of	5	O
20	9	O
-	7	O
35	9	O
/	9	O
15	9	O
-	7	O
25	9	O
mmg	7	O
being	5	O
observed	9	O
.	9	O

In	9	O
1	9	O
patient	5	O
,	9	O
marked	9	O
hypertension	5	B-Disease
was	9	O
induced	3	O
by	9	O
propranolol	0	B-Chemical
and	5	O
the	5	O
drug	5	O
had	9	O
to	5	O
be	5	O
withdrawn	9	O
.	9	O

It	5	O
otherwise	9	O
was	9	O
well	9	O
tolerated	9	O
and	5	O
no	9	O
important	9	O
side	5	O
effects	9	O
were	9	O
observed	9	O
.	9	O

Treatment	9	O
has	9	O
been	9	O
continued	9	O
in	5	O
3	9	O
individuals	5	O
for	5	O
6	9	O
-	7	O
13	7	O
months	5	O
with	5	O
persistence	9	O
of	5	O
the	5	O
pressor	5	O
effect	9	O
,	9	O
although	9	O
there	5	O
appears	9	O
to	5	O
have	5	O
been	9	O
some	5	O
decrease	9	O
in	5	O
the	5	O
degree	5	O
of	5	O
response	9	O
with	5	O
time	5	O
.	9	O

Hemodynamic	5	O
measurements	5	O
in	5	O
1	9	O
of	5	O
the	5	O
patients	5	O
demonstrated	9	O
an	5	O
increase	9	O
in	5	O
total	9	O
peripheral	9	O
resistance	9	O
and	5	O
essentially	9	O
no	9	O
change	9	O
in	5	O
cardiac	5	O
output	5	O
following	9	O
propranolol	0	B-Chemical
therapy	5	O
.	9	O

The	5	O
studies	9	O
suggest	9	O
that	5	O
propranolol	0	B-Chemical
is	5	O
a	5	O
useful	5	O
drug	5	O
in	5	O
selected	9	O
patients	5	O
with	5	O
severe	5	O
idiopathic	5	B-Disease
orthostatic	5	I-Disease
hypotension	5	I-Disease
.	9	O

Total	7	O
intravenous	0	O
anesthesia	5	O
with	5	O
etomidate	5	B-Chemical
.	9	O

III	9	O
.	9	O

Some	5	O
observations	9	O
in	5	O
adults	5	O
.	9	O

An	5	O
investigation	9	O
was	9	O
undertaken	5	O
to	5	O
determine	9	O
the	5	O
dosage	9	O
of	5	O
etomidate	5	B-Chemical
required	9	O
to	5	O
maintain	5	O
sleep	5	O
in	5	O
adults	5	O
undergoing	9	O
surgery	5	O
under	9	O
regional	5	O
local	5	O
anesthesia	5	O
.	9	O

Premedication	5	O
of	5	O
diazepam	0	B-Chemical
10	9	O
mg	0	O
and	5	O
atropine	0	B-Chemical
0	7	O
.	9	O
5	9	O
mg	0	O
was	9	O
given	5	O
,	9	O
and	5	O
sleep	5	O
was	9	O
induced	3	O
and	5	O
maintained	9	O
by	9	O
intermittent	5	O
intravenous	0	O
injections	9	O
of	5	O
etomidate	5	B-Chemical
0	7	O
.	9	O
1	9	O
/	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
given	5	O
whenever	5	O
the	5	O
patient	5	O
would	5	O
open	5	O
his	5	O
eyes	5	O
on	5	O
request	5	O
.	9	O

A	9	O
mean	5	O
overall	5	O
dose	9	O
of	5	O
etomidate	5	B-Chemical
17	7	O
.	9	O
4	9	O
microgram	0	O
/	9	O
kg	0	O
/	9	O
min	0	O
.	9	O
was	9	O
required	9	O
to	5	O
maintain	5	O
sleep	5	O
,	9	O
but	9	O
great	5	O
individual	5	O
variation	5	O
occurred	9	O
,	9	O
with	5	O
older	5	O
patients	5	O
requiring	5	O
less	5	O
drug	5	O
.	9	O

The	5	O
investigation	9	O
was	9	O
discontinued	5	O
after	9	O
18	7	O
patients	5	O
because	5	O
of	5	O
the	5	O
frequency	5	O
and	5	O
intensity	5	O
of	5	O
side	5	O
-	7	O
effects	9	O
,	9	O
particularly	5	O
pain	5	B-Disease
and	5	O
myoclonia	5	B-Disease
,	9	O
which	5	O
caused	9	O
the	5	O
technique	5	O
to	5	O
be	5	O
abandoned	5	O
in	5	O
two	5	O
cases	5	O
.	9	O

It	5	O
is	5	O
considered	5	O
unlikely	9	O
that	5	O
etomidate	5	B-Chemical
will	5	O
prove	5	O
to	5	O
be	5	O
the	5	O
hypnotic	5	O
of	5	O
choice	5	O
for	5	O
a	5	O
totally	9	O
intravenous	0	O
anesthetic	5	O
technique	5	O
in	5	O
adults	5	O
because	5	O
of	5	O
the	5	O
high	9	O
incidence	5	O
of	5	O
myoclonia	5	B-Disease
after	9	O
prolonged	9	O
administration	9	O
.	9	O

In	9	O
several	9	O
patients	5	O
uncontrollable	5	O
muscle	9	O
movements	5	O
persisted	9	O
for	5	O
many	5	O
minutes	0	O
after	9	O
complete	9	O
recovery	9	O
of	5	O
consciousness	5	O
.	9	O

Evidence	9	O
for	5	O
cardiac	5	O
beta	9	O
2	9	O
-	7	O
adrenoceptors	3	O
in	5	O
man	5	O
.	9	O

We	9	O
compared	9	O
the	5	O
effects	9	O
of	5	O
single	9	O
doses	0	O
of	5	O
50	0	O
mg	0	O
atenolol	0	B-Chemical
(	9	O
cardioselective	5	O
)	9	O
,	9	O
40	9	O
mg	0	O
propranolol	0	B-Chemical
(	9	O
nonselective	0	O
)	9	O
,	9	O
and	5	O
placebo	9	O
on	5	O
both	9	O
exercise	5	O
-	7	O
and	5	O
isoproterenol	0	B-Chemical
-	7	O
induced	3	O
tachycardia	5	B-Disease
in	5	O
two	5	O
experiments	9	O
involving	5	O
nine	9	O
normal	9	O
subjects	5	O
.	9	O

Maximal	9	O
exercise	5	O
heart	5	O
rate	9	O
was	9	O
reduced	9	O
from	9	O
187	7	O
+	9	O
/	9	O
-	7	O
4	9	O
(	9	O
SEM	9	O
)	9	O
after	9	O
placebo	9	O
to	5	O
146	7	O
+	9	O
/	9	O
-	7	O
7	9	O
bpm	5	O
after	9	O
atenolol	0	B-Chemical
and	5	O
138	7	O
+	9	O
/	9	O
-	7	O
6	9	O
bpm	5	O
after	9	O
propranolol	0	B-Chemical
,	9	O
but	9	O
there	5	O
were	9	O
no	9	O
differences	9	O
between	5	O
the	5	O
drugs	5	O
.	9	O

The	5	O
effects	9	O
on	5	O
isoproterenol	0	B-Chemical
tachycardia	5	B-Disease
were	9	O
determined	9	O
before	9	O
and	5	O
after	9	O
atropine	0	B-Chemical
(	9	O
0	7	O
.	9	O
04	7	O
mg	0	O
/	9	O
kg	0	O
IV	9	O
)	9	O
.	9	O

Isoproterenol	0	B-Chemical
sensitivity	9	O
was	9	O
determined	9	O
as	5	O
the	5	O
intravenous	0	O
dose	9	O
that	5	O
increased	9	O
heart	5	O
rate	9	O
by	9	O
25	9	O
bpm	5	O
(	9	O
CD25	3	O
)	9	O
and	5	O
this	5	O
was	9	O
increased	9	O
from	9	O
1	9	O
.	9	O
8	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
3	9	O
micrograms	0	O
after	9	O
placebo	9	O
to	5	O
38	7	O
.	9	O
9	7	O
+	9	O
/	9	O
-	7	O
8	9	O
.	9	O
3	9	O
micrograms	0	O
after	9	O
propranolol	0	B-Chemical
and	5	O
8	9	O
.	9	O
3	9	O
+	9	O
/	9	O
-	7	O
1	9	O
.	9	O
7	9	O
micrograms	0	O
after	9	O
atenolol	0	B-Chemical
.	9	O

The	5	O
difference	9	O
in	5	O
the	5	O
effects	9	O
of	5	O
the	5	O
two	5	O
was	9	O
significant	9	O
.	9	O

After	9	O
atropine	0	B-Chemical
the	5	O
CD25	3	O
was	9	O
unchanged	9	O
after	9	O
placebo	9	O
(	9	O
2	9	O
.	9	O
3	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
3	9	O
micrograms	0	O
)	9	O
and	5	O
atenolol	0	B-Chemical
(	9	O
7	9	O
.	9	O
7	9	O
+	9	O
/	9	O
-	7	O
1	9	O
.	9	O
3	9	O
micrograms	0	O
)	9	O
;	9	O
it	5	O
was	9	O
reduced	9	O
after	9	O
propranolol	0	B-Chemical
(	9	O
24	9	O
.	9	O
8	9	O
+	9	O
/	9	O
-	7	O
5	9	O
.	9	O
0	7	O
micrograms	0	O
)	9	O
,	9	O
but	9	O
remained	9	O
different	9	O
from	9	O
atenolol	0	B-Chemical
.	9	O

This	5	O
change	9	O
with	5	O
propranolol	0	B-Chemical
sensitivity	9	O
was	9	O
calculated	5	O
as	5	O
the	5	O
apparent	9	O
Ka	9	O
,	9	O
this	5	O
was	9	O
unchanged	9	O
by	9	O
atropine	0	B-Chemical
(	9	O
11	7	O
.	9	O
7	9	O
+	9	O
/	9	O
-	7	O
2	9	O
.	9	O
1	9	O
and	5	O
10	9	O
.	9	O
1	9	O
+	9	O
/	9	O
-	7	O
2	9	O
.	9	O
5	9	O
ml	0	O
/	9	O
ng	0	O
)	9	O
.	9	O

These	5	O
data	5	O
are	5	O
consistent	9	O
with	5	O
the	5	O
hypothesis	9	O
that	5	O
exercise	5	O
-	7	O
induced	3	O
tachycardia	5	B-Disease
results	9	O
largely	9	O
from	9	O
beta	9	O
1	9	O
-	7	O
receptor	3	O
activation	3	O
that	5	O
is	5	O
blocked	3	O
by	9	O
both	9	O
cardioselective	5	O
and	5	O
nonselective	0	O
drugs	5	O
,	9	O
whereas	9	O
isoproterenol	0	B-Chemical
activates	3	O
both	9	O
beta	9	O
1	9	O
-	7	O
and	5	O
beta	9	O
2	9	O
-	7	O
receptors	3	O
so	5	O
that	5	O
after	9	O
cardioselective	5	O
blockade	3	O
there	5	O
remains	9	O
a	5	O
beta	9	O
2	9	O
-	7	O
component	9	O
that	5	O
can	5	O
be	5	O
blocked	3	O
with	5	O
a	5	O
nonselective	0	O
drug	5	O
.	9	O

While	9	O
there	5	O
appear	9	O
to	5	O
be	5	O
beta	9	O
2	9	O
-	7	O
receptors	3	O
in	5	O
the	5	O
human	3	O
heart	5	O
,	9	O
their	5	O
physiologic	9	O
or	5	O
pathologic	5	O
roles	9	O
remain	9	O
to	5	O
be	5	O
defined	5	O
.	9	O

Hormones	2	O
and	5	O
risk	5	O
of	5	O
breast	3	B-Disease
cancer	3	I-Disease
.	9	O

This	5	O
paper	5	O
reports	9	O
the	5	O
results	9	O
of	5	O
a	5	O
study	9	O
of	5	O
50	0	O
menopausal	5	O
women	5	O
receiving	9	O
hormonal	9	O
replacement	9	O
therapy	5	O
.	9	O

The	5	O
majority	9	O
(	9	O
29	7	O
)	9	O
had	9	O
surgical	5	O
menopause	5	O
;	9	O
their	5	O
mean	5	O
age	5	O
was	9	O
45	9	O
.	9	O
7	9	O
years	5	O
.	9	O

It	5	O
was	9	O
hypothesized	9	O
that	5	O
progestins	5	B-Chemical
could	9	O
equilibrate	0	O
the	5	O
effects	9	O
of	5	O
the	5	O
estrogenic	0	O
stimulation	3	O
on	5	O
the	5	O
mammary	3	O
and	5	O
endometrial	9	O
target	9	O
tissues	9	O
of	5	O
women	5	O
on	5	O
hormonal	9	O
replacement	9	O
therapy	5	O
.	9	O

The	5	O
treatment	9	O
schedule	5	O
consisted	5	O
of	5	O
conjugated	0	B-Chemical
estrogens	9	I-Chemical
(	9	O
Premarin	0	B-Chemical
)	9	O
1	9	O
.	9	O
25	9	O
mg	0	O
/	9	O
day	9	O
for	5	O
21	7	O
days	9	O
and	5	O
Medroxyprogesterone	0	B-Chemical
acetate	0	I-Chemical
10	9	O
mg	0	O
/	9	O
day	9	O
for	5	O
10	9	O
days	9	O
in	5	O
each	5	O
month	5	O
.	9	O

The	5	O
mean	5	O
treatment	9	O
period	5	O
was	9	O
18	7	O
months	5	O
.	9	O

During	5	O
the	5	O
follow	5	O
-	7	O
up	5	O
period	5	O
,	9	O
attention	5	O
was	9	O
paid	5	O
to	5	O
breast	3	O
modifications	9	O
as	5	O
evidenced	9	O
by	9	O
symptomatology	5	O
,	9	O
physical	5	O
examination	5	O
,	9	O
and	5	O
plate	0	O
thermography	5	O
.	9	O

Mastodynia	9	B-Disease
was	9	O
reported	9	O
by	9	O
21	7	O
patients	5	O
,	9	O
and	5	O
physical	5	O
examination	5	O
revealed	9	O
a	5	O
light	9	O
increase	9	O
in	5	O
breast	3	O
firmness	5	O
in	5	O
12	9	O
women	5	O
and	5	O
a	5	O
moderate	9	O
increase	9	O
in	5	O
breast	3	O
nodularity	5	O
in	5	O
2	9	O
women	5	O
.	9	O

Themography	_	O
confirmed	9	O
the	5	O
existence	9	O
of	5	O
an	5	O
excessive	5	O
breast	3	O
stimulation	3	O
in	5	O
1	9	O
women	5	O
who	5	O
complained	5	O
of	5	O
moderate	9	O
mastodynia	5	B-Disease
and	5	O
in	5	O
5	9	O
of	5	O
the	5	O
7	9	O
women	5	O
who	5	O
complained	5	O
of	5	O
severe	5	O
mastodynia	5	B-Disease
.	9	O

Normalization	5	O
was	9	O
obtained	9	O
by	9	O
halving	5	O
the	5	O
estrogen	3	B-Chemical
dose	9	O
.	9	O

These	5	O
results	9	O
suggest	9	O
that	5	O
hormonal	9	O
replacement	9	O
therapy	5	O
can	5	O
be	5	O
safely	5	O
prescribed	5	O
if	5	O
the	5	O
following	9	O
criteria	5	O
are	5	O
satisfied	5	O
:	9	O
1	9	O
)	9	O
preliminary	9	O
evaluation	5	O
of	5	O
patients	5	O
from	9	O
a	5	O
clinical	5	O
,	9	O
metabolic	9	O
,	9	O
cytologic	5	O
,	9	O
and	5	O
mammographic	5	O
perspective	5	O
;	9	O
2	9	O
)	9	O
cyclic	0	O
treatment	9	O
schedule	5	O
,	9	O
with	5	O
a	5	O
progestative	9	O
phase	5	O
of	5	O
10	9	O
days	9	O
;	9	O
and	5	O
3	9	O
)	9	O
periodic	5	O
complete	9	O
follow	5	O
-	7	O
up	5	O
,	9	O
with	5	O
accurate	5	O
thermographic	5	O
evaluation	5	O
of	5	O
the	5	O
breast	3	O
target	9	O
tissues	9	O
.	9	O

Early	9	O
infections	5	B-Disease
in	5	O
kidney	9	O
,	9	O
heart	5	O
,	9	O
and	5	O
liver	9	O
transplant	9	O
recipients	9	O
on	5	O
cyclosporine	0	B-Chemical
.	9	O

Eighty	5	O
-	7	O
one	5	O
renal	9	O
,	9	O
seventeen	9	O
heart	5	O
,	9	O
and	5	O
twenty	5	O
-	7	O
four	9	O
liver	9	O
transplant	9	O
patients	5	O
were	9	O
followed	9	O
for	5	O
infection	9	B-Disease
.	9	O

Seventeen	9	O
renal	9	O
patients	5	O
received	9	O
azathioprine	5	B-Chemical
(	9	O
Aza	3	B-Chemical
)	9	O
and	5	O
prednisone	0	B-Chemical
as	5	O
part	9	O
of	5	O
a	5	O
randomized	5	O
trial	5	O
of	5	O
immunosuppression	5	O
with	5	O
21	7	O
cyclosporine	0	B-Chemical
-	7	O
and	5	O
-	7	O
prednisone	0	B-Chemical
-	7	O
treated	3	O
renal	9	O
transplant	9	O
patients	5	O
.	9	O

All	9	O
others	5	O
received	9	O
cyclosporine	0	B-Chemical
and	5	O
prednisone	0	B-Chemical
.	9	O

The	5	O
randomized	5	O
Aza	3	B-Chemical
patients	5	O
had	9	O
more	5	O
overall	5	O
infections	5	B-Disease
(	9	O
P	9	O
less	5	O
than	5	O
0	7	O
.	9	O
05	7	O
)	9	O
and	5	O
more	5	O
nonviral	9	O
infections	5	B-Disease
(	9	O
P	9	O
less	5	O
than	5	O
0	7	O
.	9	O
02	7	O
)	9	O
than	5	O
the	5	O
randomized	5	O
cyclosporine	0	B-Chemical
patients	5	O
.	9	O

Heart	2	O
and	5	O
liver	9	O
patients	5	O
had	9	O
more	5	O
infections	5	B-Disease
than	5	O
cyclosporine	0	B-Chemical
renal	9	O
patients	5	O
but	9	O
fewer	5	O
infections	5	B-Disease
than	5	O
the	5	O
Aza	3	B-Chemical
renal	9	O
patients	5	O
.	9	O

There	5	O
were	9	O
no	9	O
infectious	5	O
deaths	5	O
in	5	O
renal	9	O
transplant	9	O
patients	5	O
on	5	O
cyclosporine	0	B-Chemical
or	5	O
Aza	3	B-Chemical
,	9	O
but	9	O
infection	9	B-Disease
played	9	O
a	5	O
major	9	O
role	9	O
in	5	O
3	9	O
out	9	O
of	5	O
6	9	O
cardiac	5	O
transplant	9	O
deaths	5	O
and	5	O
in	5	O
8	9	O
out	9	O
of	5	O
9	7	O
liver	9	O
transplant	9	O
deaths	5	O
.	9	O

Renal	9	O
patients	5	O
on	5	O
cyclosporine	0	B-Chemical
had	9	O
the	5	O
fewest	5	O
bacteremias	5	B-Disease
.	9	O

Analysis	9	O
of	5	O
site	9	O
of	5	O
infection	9	B-Disease
showed	9	O
a	5	O
preponderance	9	O
of	5	O
abdominal	5	B-Disease
infections	5	I-Disease
in	5	O
liver	9	O
patients	5	O
,	9	O
intrathoracic	5	O
infections	5	B-Disease
in	5	O
heart	5	O
patients	5	O
,	9	O
and	5	O
urinary	9	B-Disease
tract	9	I-Disease
infections	5	I-Disease
in	5	O
renal	9	O
patients	5	O
.	9	O

Pulmonary	9	O
infections	5	B-Disease
were	9	O
less	5	O
common	5	O
in	5	O
cyclosporine	0	B-Chemical
-	7	O
treated	3	O
renal	9	O
patients	5	O
than	5	O
in	5	O
Aza	3	B-Chemical
-	7	O
treated	3	O
patients	5	O
(	9	O
P	9	O
less	5	O
than	5	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

Aza	3	B-Chemical
patients	5	O
had	9	O
significantly	9	O
more	5	O
staphylococcal	9	B-Disease
infections	5	I-Disease
than	5	O
all	5	O
other	5	O
transplant	9	O
groups	9	O
(	9	O
P	9	O
less	5	O
than	5	O
0	7	O
.	9	O
005	7	O
)	9	O
,	9	O
and	5	O
systemic	9	O
fungal	4	B-Disease
infections	5	I-Disease
occurred	9	O
only	9	O
in	5	O
the	5	O
liver	9	O
transplant	9	O
group	9	O
.	9	O

Cytomegalovirus	2	O
(	9	O
CMV	9	O
)	9	O
shedding	9	O
or	5	O
serological	9	O
rises	9	O
in	5	O
antibody	3	O
titer	9	O
,	9	O
or	5	O
both	9	O
occurred	9	O
in	5	O
78	7	O
%	9	O
of	5	O
cyclosporine	0	B-Chemical
patients	5	O
and	5	O
76	7	O
%	9	O
of	5	O
Aza	3	B-Chemical
patients	5	O
.	9	O

Of	9	O
the	5	O
cyclosporine	0	B-Chemical
patients	5	O
,	9	O
15	9	O
%	9	O
had	9	O
symptoms	5	O
related	9	O
to	5	O
CMV	9	B-Disease
infection	9	I-Disease
.	9	O

Serological	9	O
evidence	9	O
for	5	O
Epstein	6	B-Disease
Barr	6	I-Disease
Virus	9	I-Disease
infection	9	I-Disease
was	9	O
found	9	O
in	5	O
20	9	O
%	9	O
of	5	O
65	7	O
cyclosporine	0	B-Chemical
patients	5	O
studied	9	O
.	9	O

Three	9	O
had	9	O
associated	9	O
symptoms	5	O
,	9	O
and	5	O
one	5	O
developed	5	O
a	5	O
lymphoma	9	B-Disease
.	9	O

Structure	9	O
-	7	O
activity	9	O
and	5	O
dose	9	O
-	7	O
effect	9	O
relationships	5	O
of	5	O
the	5	O
antagonism	9	O
of	5	O
picrotoxin	0	B-Chemical
-	7	O
induced	3	O
seizures	5	B-Disease
by	9	O
cholecystokinin	3	B-Chemical
,	9	O
fragments	9	O
and	5	O
analogues	0	O
of	5	O
cholecystokinin	3	B-Chemical
in	5	O
mice	3	O
.	9	O

Intraperitoneal	0	O
administration	9	O
of	5	O
cholecystokinin	3	B-Chemical
octapeptide	0	I-Chemical
sulphate	0	O
ester	0	O
(	9	O
CCK	3	B-Chemical
-	7	I-Chemical
8	9	I-Chemical
-	7	O
SE	9	O
)	9	O
and	5	O
nonsulphated	9	O
cholecystokinin	3	B-Chemical
octapeptide	0	I-Chemical
(	9	O
CCK	3	B-Chemical
-	7	I-Chemical
8	9	I-Chemical
-	7	O
NS	7	O
)	9	O
enhanced	3	O
the	5	O
latency	5	O
of	5	O
seizures	5	B-Disease
induced	3	O
by	9	O
picrotoxin	0	B-Chemical
in	5	O
mice	3	O
.	9	O

Experiments	9	O
with	5	O
N	9	O
-	7	O
and	5	O
C	9	O
-	7	O
terminal	9	O
fragments	9	O
revealed	9	O
that	5	O
the	5	O
C	9	O
-	7	O
terminal	9	O
tetrapeptide	0	O
(	9	O
CCK	3	O
-	7	O
5	9	O
-	7	O
8	9	O
)	9	O
was	9	O
the	5	O
active	9	O
centre	5	O
of	5	O
the	5	O
CCK	3	O
octapeptide	0	O
molecule	3	O
.	9	O

The	5	O
analogues	0	O
CCK	3	B-Chemical
-	7	I-Chemical
8	9	I-Chemical
-	7	O
SE	9	O
and	5	O
CCK	3	B-Chemical
-	7	I-Chemical
8	9	I-Chemical
-	7	O
NS	7	O
(	9	O
dose	9	O
range	9	O
0	7	O
.	9	O
2	9	O
-	7	O
6	9	O
.	9	O
4	9	O
mumol	7	O
/	9	O
kg	0	O
)	9	O
and	5	O
caerulein	0	B-Chemical
dose	9	O
range	9	O
0	7	O
.	9	O
1	9	O
-	7	O
0	7	O
.	9	O
8	9	O
mumol	7	O
/	9	O
kg	0	O
)	9	O
showed	9	O
bell	5	O
-	7	O
shaped	5	O
dose	9	O
-	7	O
effect	9	O
curves	5	O
,	9	O
with	5	O
the	5	O
greatest	9	O
maximum	5	O
inhibition	3	O
for	5	O
CCK	3	B-Chemical
-	7	I-Chemical
8	9	I-Chemical
-	7	O
NS	7	O
.	9	O

The	5	O
peptide	9	O
CCK	3	O
-	7	O
5	9	O
-	7	O
8	9	O
had	9	O
weak	9	O
anticonvulsant	5	O
activity	9	O
in	5	O
comparison	9	O
to	5	O
the	5	O
octapeptides	1	O
,	9	O
3	9	O
.	9	O
2	9	O
mumol	7	O
/	9	O
kg	0	O
and	5	O
larger	5	O
doses	0	O
of	5	O
the	5	O
reference	9	O
drug	5	O
,	9	O
diazepam	0	B-Chemical
,	9	O
totally	9	O
prevented	9	O
picrotoxin	0	B-Chemical
-	7	O
induced	3	O
seizures	5	B-Disease
and	5	O
mortality	5	O
.	9	O

The	5	O
maximum	5	O
effect	9	O
of	5	O
the	5	O
peptides	9	O
tested	9	O
was	9	O
less	5	O
than	5	O
that	5	O
of	5	O
diazepam	0	B-Chemical
.	9	O

Experiments	9	O
with	5	O
analogues	0	O
and	5	O
derivatives	0	O
of	5	O
CCK	3	O
-	7	O
5	9	O
-	7	O
8	9	O
demonstrated	9	O
that	5	O
the	5	O
effectiveness	5	O
of	5	O
the	5	O
beta	9	O
-	7	O
alanyl	1	O
derivatives	0	O
of	5	O
CCK	3	O
-	7	O
5	9	O
-	7	O
8	9	O
were	9	O
enhanced	3	O
and	5	O
that	5	O
they	5	O
were	9	O
equipotent	0	O
with	5	O
CCK	3	B-Chemical
-	7	I-Chemical
8	9	I-Chemical
-	7	O
SE	9	O
.	9	O

Of	9	O
the	5	O
CCK	3	O
-	7	O
2	9	O
-	7	O
8	9	O
analogues	0	O
,	9	O
Ser	1	O
(	9	O
SO3H	0	O
)	9	O
7	9	O
-	7	O
Ac	9	O
-	7	O
CCK	3	O
-	7	O
2	9	O
-	7	O
8	9	O
-	7	O
SE	9	O
and	5	O
Thr	1	O
(	9	O
SO3H	0	O
)	9	O
7	9	O
-	7	O
Ac	9	O
-	7	O
CCK	3	O
-	7	O
2	9	O
-	7	O
8	9	O
-	7	O
SE	9	O
and	5	O
Hyp	9	O
(	9	O
SO3H	0	O
)	9	O
-	7	O
Ac	9	O
-	7	O
CCK	3	O
-	7	O
2	9	O
-	7	O
8	9	O
-	7	O
SE	9	O
were	9	O
slightly	9	O
more	5	O
active	9	O
than	5	O
CCK	3	B-Chemical
-	7	I-Chemical
8	9	I-Chemical
-	7	O
SE	9	O
.	9	O

Vasopressin	0	B-Chemical
as	5	O
a	5	O
possible	5	O
contributor	9	O
to	5	O
hypertension	5	B-Disease
.	9	O

The	5	O
role	9	O
of	5	O
vasopressin	9	B-Chemical
as	5	O
a	5	O
pressor	5	O
agent	9	O
to	5	O
the	5	O
hypertensive	5	B-Disease
process	5	O
was	9	O
examined	9	O
.	9	O

Vasopressin	0	B-Chemical
plays	9	O
a	5	O
major	9	O
role	9	O
in	5	O
the	5	O
pathogenesis	9	O
of	5	O
DOCA	0	B-Chemical
-	7	O
salt	0	O
hypertension	5	B-Disease
,	9	O
since	9	O
the	5	O
elevation	9	O
of	5	O
blood	9	O
pressure	5	O
was	9	O
not	5	O
substantial	9	O
in	5	O
the	5	O
rats	9	O
with	5	O
lithium	0	B-Chemical
-	7	O
treated	3	O
diabetes	5	B-Disease
insipidus	5	I-Disease
after	9	O
DOCA	0	B-Chemical
-	7	O
salt	0	O
treatment	9	O
.	9	O

Administration	2	O
of	5	O
DDAVP	0	B-Chemical
which	5	O
has	9	O
antidiuretic	5	O
action	5	O
but	9	O
minimal	9	O
vasopressor	5	O
effect	9	O
failed	9	O
to	5	O
increase	9	O
blood	9	O
pressure	5	O
to	5	O
the	5	O
levels	3	O
observed	9	O
after	9	O
administration	9	O
of	5	O
AVP	9	O
.	9	O

Furthermore	9	O
,	9	O
the	5	O
pressor	5	O
action	5	O
of	5	O
vasopressin	9	B-Chemical
appears	9	O
to	5	O
be	5	O
important	9	O
in	5	O
the	5	O
development	9	O
of	5	O
this	5	O
model	5	O
of	5	O
hypertension	5	B-Disease
,	9	O
since	9	O
the	5	O
enhanced	3	O
pressor	5	O
responsiveness	9	O
to	5	O
the	5	O
hormone	9	O
was	9	O
observed	9	O
in	5	O
the	5	O
initial	9	O
stage	9	O
of	5	O
hypertension	5	B-Disease
.	9	O

Increased	9	O
secretion	3	O
of	5	O
vasopressin	9	B-Chemical
from	9	O
neurohypophysis	9	O
also	9	O
promotes	3	O
the	5	O
function	9	O
of	5	O
the	5	O
hormone	9	O
as	5	O
a	5	O
pathogenetic	5	O
factor	9	O
in	5	O
hypertension	5	B-Disease
.	9	O

An	5	O
unproportional	5	O
release	9	O
of	5	O
vasopressin	9	B-Chemical
compared	9	O
to	5	O
plasma	9	O
osmolality	0	O
may	5	O
be	5	O
induced	3	O
by	9	O
the	5	O
absence	3	O
of	5	O
an	5	O
adjusting	5	O
control	9	O
of	5	O
angiotensin	9	B-Chemical
II	9	O
forming	9	O
and	5	O
receptor	3	O
binding	1	O
capacity	9	O
for	5	O
sodium	0	B-Chemical
balance	5	O
in	5	O
the	5	O
brain	5	O
.	9	O

However	9	O
,	9	O
the	5	O
role	9	O
of	5	O
vasopressin	9	B-Chemical
remains	9	O
to	5	O
be	5	O
determined	9	O
in	5	O
human	3	O
essential	9	O
hypertension	5	B-Disease
.	9	O

Toxic	0	B-Disease
hepatitis	9	I-Disease
induced	3	O
by	9	O
disulfiram	0	B-Chemical
in	5	O
a	5	O
non	9	O
-	7	O
alcoholic	5	O
.	9	O

A	9	O
reversible	9	O
toxic	0	B-Disease
liver	9	I-Disease
damage	9	I-Disease
was	9	O
observed	9	O
in	5	O
a	5	O
non	9	O
-	7	O
alcoholic	5	O
woman	5	O
treated	3	O
with	5	O
disulfiram	0	B-Chemical
.	9	O

The	5	O
causative	9	O
relationship	5	O
was	9	O
proven	5	O
by	9	O
challenge	9	O
.	9	O

Atrial	7	B-Disease
thrombosis	5	I-Disease
involving	5	O
the	5	O
heart	5	O
of	5	O
F	7	O
-	7	O
344	7	O
rats	9	O
ingesting	5	O
quinacrine	0	B-Chemical
hydrochloride	0	I-Chemical
.	9	O

Quinacrine	0	B-Chemical
hydrochloride	0	I-Chemical
is	5	O
toxic	0	O
for	5	O
the	5	O
heart	5	O
of	5	O
F	7	O
-	7	O
344	7	O
rats	9	O
.	9	O

Rats	9	O
treated	3	O
with	5	O
500	0	O
ppm	0	O
quinacrine	0	B-Chemical
hydrochloride	0	I-Chemical
in	5	O
the	5	O
diet	9	O
all	5	O
developed	5	O
a	5	O
high	9	O
incidence	5	O
of	5	O
left	5	O
atrial	5	B-Disease
thrombosis	5	I-Disease
.	9	O

The	5	O
lesion	5	O
was	9	O
associated	9	O
with	5	O
cardiac	5	B-Disease
hypertrophy	9	I-Disease
and	5	O
dilatation	5	O
and	5	O
focal	5	O
myocardial	9	B-Disease
degeneration	9	I-Disease
.	9	O

Rats	9	O
died	9	O
from	9	O
cardiac	5	B-Disease
hypertrophy	9	I-Disease
with	5	O
severe	5	O
acute	9	O
and	5	O
chronic	5	O
congestion	5	O
of	5	O
the	5	O
lungs	3	O
,	9	O
liver	9	O
,	9	O
and	5	O
other	5	O
organs	9	O
.	9	O

Seventy	5	O
percent	5	O
of	5	O
rats	9	O
given	5	O
250	0	O
ppm	0	O
quinacrine	0	B-Chemical
hydrochloride	0	I-Chemical
and	5	O
1	9	O
,	9	O
000	9	O
ppm	0	O
sodium	0	B-Chemical
nitrite	0	I-Chemical
simultaneously	5	O
in	5	O
the	5	O
diet	9	O
had	9	O
thrombosis	5	B-Disease
of	5	O
the	5	O
atria	9	O
of	5	O
the	5	O
heart	5	O
,	9	O
while	9	O
untreated	3	O
control	9	O
rats	9	O
in	5	O
this	5	O
laboratory	9	O
did	9	O
not	5	O
have	5	O
atrial	5	B-Disease
thrombosis	5	I-Disease
.	9	O

Sodium	0	B-Chemical
nitrite	0	I-Chemical
in	5	O
combination	9	O
with	5	O
quinacrine	0	B-Chemical
hydrochloride	0	I-Chemical
appeared	9	O
to	5	O
have	5	O
no	9	O
additional	9	O
effect	9	O
.	9	O

Alternating	5	B-Disease
sinus	5	I-Disease
rhythm	5	I-Disease
and	5	O
intermittent	5	O
sinoatrial	5	B-Disease
block	9	I-Disease
induced	3	O
by	9	O
propranolol	0	B-Chemical
.	9	O

Alternating	5	B-Disease
sinus	5	I-Disease
rhythm	5	I-Disease
and	5	O
intermittent	5	O
sinoatrial	5	B-Disease
(	9	I-Disease
S	9	I-Disease
-	7	I-Disease
A	9	I-Disease
)	9	I-Disease
block	9	I-Disease
was	9	O
observed	9	O
in	5	O
a	5	O
57	7	O
-	7	O
year	5	O
-	7	O
old	5	O
woman	5	O
,	9	O
under	9	O
treatment	9	O
for	5	O
angina	5	B-Disease
with	5	O
80	9	O
mg	0	O
propranolol	0	B-Chemical
daily	5	O
.	9	O

The	5	O
electrocardiogram	5	O
showed	9	O
alternation	5	O
of	5	O
long	5	O
and	5	O
short	5	O
P	9	O
-	7	O
P	9	O
intervals	5	O
and	5	O
occasional	5	O
pauses	5	O
.	9	O

These	5	O
pauses	5	O
were	9	O
always	5	O
preceded	9	O
by	9	O
the	5	O
short	5	O
P	9	O
-	7	O
P	9	O
intervals	5	O
and	5	O
were	9	O
usually	5	O
followed	9	O
by	9	O
one	5	O
or	5	O
two	5	O
P	9	O
-	7	O
P	9	O
intervals	5	O
of	5	O
0	7	O
.	9	O
92	7	O
-	7	O
0	7	O
.	9	O
95	7	O
s	9	O
representing	9	O
the	5	O
basic	5	O
sinus	5	O
cycle	9	O
.	9	O

Following	9	O
these	5	O
basic	5	O
sinus	5	O
cycles	9	O
,	9	O
alternating	5	B-Disease
rhythm	5	I-Disease
started	5	O
with	5	O
the	5	O
longer	5	O
P	9	O
-	7	O
P	9	O
interval	5	O
.	9	O

The	5	O
long	5	O
P	9	O
-	7	O
P	9	O
intervals	5	O
ranged	9	O
between	5	O
1	9	O
.	9	O
04	7	O
-	7	O
1	9	O
.	9	O
12	9	O
s	9	O
and	5	O
the	5	O
short	5	O
P	9	O
-	7	O
P	9	O
intervals	5	O
between	5	O
0	7	O
.	9	O
80	9	O
-	7	O
0	7	O
.	9	O
84	7	O
s	9	O
,	9	O
respectively	9	O
.	9	O

The	5	O
duration	5	O
of	5	O
the	5	O
pauses	5	O
were	9	O
equal	9	O
or	5	O
almost	9	O
equal	9	O
to	5	O
one	5	O
short	5	O
plus	9	O
one	5	O
long	5	O
P	9	O
-	7	O
P	9	O
interval	5	O
or	5	O
to	5	O
twice	9	O
the	5	O
basic	5	O
sinus	5	O
cycle	9	O
.	9	O

In	9	O
one	5	O
recording	5	O
a	5	O
short	5	O
period	5	O
of	5	O
regular	5	O
sinus	5	O
rhythm	5	O
with	5	O
intermittent	5	O
2	9	O
/	9	O
1	9	O
S	9	B-Disease
-	7	I-Disease
A	9	I-Disease
block	9	I-Disease
was	9	O
observed	9	O
.	9	O

This	5	O
short	5	O
period	5	O
of	5	O
sinus	5	O
rhythm	5	O
was	9	O
interrupted	5	O
by	9	O
sudden	5	O
prolongation	9	O
of	5	O
the	5	O
P	9	O
-	7	O
P	9	O
interval	5	O
starting	9	O
the	5	O
alternative	5	O
rhythm	5	O
.	9	O

There	5	O
were	9	O
small	9	O
changes	9	O
in	5	O
the	5	O
shape	5	O
of	5	O
the	5	O
P	9	O
waves	5	O
and	5	O
P	9	O
-	7	O
R	9	O
intervals	5	O
.	9	O

S	9	O
-	7	O
A	9	O
conduction	5	O
through	9	O
two	5	O
pathways	9	O
,	9	O
the	5	O
first	9	O
with	5	O
2	9	O
/	9	O
1	9	O
block	9	O
the	5	O
second	9	O
having	5	O
0	7	O
.	9	O
12	9	O
-	7	O
0	7	O
.	9	O
14	7	O
s	9	O
longer	5	O
conduction	5	O
time	5	O
and	5	O
with	5	O
occasional	5	O
2	9	O
/	9	O
1	9	O
block	9	O
was	9	O
proposed	5	O
for	5	O
the	5	O
explanation	5	O
of	5	O
the	5	O
alternating	5	O
P	9	O
-	7	O
P	9	O
interval	5	O
and	5	O
other	5	O
electrocardiographic	5	O
features	5	O
seen	9	O
.	9	O

Atropine	0	B-Chemical
1	9	O
mg	0	O
given	5	O
intravenously	0	O
resulted	9	O
in	5	O
shortening	9	O
of	5	O
all	5	O
P	9	O
-	7	O
P	9	O
intervals	5	O
without	9	O
changing	5	O
the	5	O
rhythm	5	O
.	9	O

The	5	O
abnormal	9	O
rhythm	5	O
disappeared	9	O
with	5	O
the	5	O
withdrawal	5	O
of	5	O
propranolol	0	B-Chemical
and	5	O
when	5	O
the	5	O
drug	5	O
was	9	O
restarted	5	O
a	5	O
2	9	O
/	9	O
1	9	O
S	9	B-Disease
-	7	I-Disease
A	9	I-Disease
block	9	I-Disease
was	9	O
seen	9	O
.	9	O

This	5	O
was	9	O
accepted	5	O
as	5	O
evidence	9	O
for	5	O
propranolol	0	B-Chemical
being	5	O
the	5	O
cause	5	O
of	5	O
this	5	O
conduction	5	B-Disease
disorder	5	I-Disease
.	9	O

Antitumor	0	O
effect	9	O
,	9	O
cardiotoxicity	9	B-Disease
,	9	O
and	5	O
nephrotoxicity	9	B-Disease
of	5	O
doxorubicin	0	B-Chemical
in	5	O
the	5	O
IgM	3	O
solid	9	O
immunocytoma	3	B-Disease
-	7	O
bearing	3	O
LOU	2	O
/	9	O
M	9	O
/	9	O
WSL	0	O
rat	3	O
.	9	O

Antitumor	0	O
activity	9	O
,	9	O
cardiotoxicity	9	B-Disease
,	9	O
and	5	O
nephrotoxicity	9	B-Disease
induced	3	O
by	9	O
doxorubicin	0	B-Chemical
were	9	O
studied	9	O
in	5	O
LOU	2	O
/	9	O
M	9	O
/	9	O
WSL	0	O
inbred	9	O
rats	9	O
each	5	O
bearing	3	O
a	5	O
transplantable	3	O
solid	9	O
IgM	3	O
immunocytoma	3	B-Disease
.	9	O

Animals	9	O
with	5	O
a	5	O
tumor	3	B-Disease
(	9	O
diameter	9	O
,	9	O
15	9	O
.	9	O
8	9	O
+	9	O
/	9	O
-	7	O
3	9	O
.	9	O
3	9	O
mm	9	O
)	9	O
were	9	O
treated	3	O
with	5	O
iv	9	O
injections	9	O
of	5	O
doxorubicin	0	B-Chemical
on	5	O
5	9	O
consecutive	5	O
days	9	O
,	9	O
followed	9	O
by	9	O
1	9	O
weekly	5	O
injection	9	O
for	5	O
7	9	O
weeks	9	O
(	9	O
dose	9	O
range	9	O
,	9	O
0	7	O
.	9	O
015	7	O
-	7	O
4	9	O
.	9	O
0	7	O
mg	0	O
/	9	O
kg	0	O
body	5	O
wt	3	O
)	9	O
.	9	O

Tumor	9	B-Disease
regression	5	O
was	9	O
observed	9	O
with	5	O
0	7	O
.	9	O
5	9	O
mg	0	O
doxorubicin	0	B-Chemical
/	9	O
kg	0	O
.	9	O

Complete	9	O
disappearance	9	O
of	5	O
the	5	O
tumor	3	B-Disease
was	9	O
induced	3	O
with	5	O
1	9	O
.	9	O
0	7	O
mg	0	O
doxorubicin	0	B-Chemical
/	9	O
kg	0	O
.	9	O

Histologic	9	O
evidence	9	O
of	5	O
cardiotoxicity	9	B-Disease
scored	5	O
as	5	O
grade	9	O
III	9	O
was	9	O
only	9	O
observed	9	O
at	9	O
a	5	O
dose	9	O
of	5	O
1	9	O
.	9	O
0	7	O
mg	0	O
doxorubicin	0	B-Chemical
/	9	O
kg	0	O
.	9	O

Light	9	O
microscopic	9	O
evidence	9	O
of	5	O
renal	9	B-Disease
damage	9	I-Disease
was	9	O
seen	9	O
above	9	O
a	5	O
dose	9	O
of	5	O
0	7	O
.	9	O
5	9	O
mg	0	O
doxorubicin	0	B-Chemical
/	9	O
kg	0	O
,	9	O
which	5	O
resulted	9	O
in	5	O
albuminuria	9	B-Disease
and	5	O
very	5	O
low	9	O
serum	9	O
albumin	0	O
levels	3	O
.	9	O

In	9	O
the	5	O
group	9	O
that	5	O
received	9	O
1	9	O
.	9	O
0	7	O
mg	0	O
doxorubicin	0	B-Chemical
/	9	O
kg	0	O
,	9	O
the	5	O
serum	9	O
albumin	0	O
level	9	O
decreased	9	O
from	9	O
33	7	O
.	9	O
6	9	O
+	9	O
/	9	O
-	7	O
4	9	O
.	9	O
1	9	O
to	5	O
1	9	O
.	9	O
5	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
5	9	O
g	0	O
/	9	O
liter	0	O
.	9	O

Ascites	9	B-Disease
and	5	O
hydrothorax	5	B-Disease
were	9	O
observed	9	O
simultaneously	5	O
.	9	O

The	5	O
same	9	O
experiments	9	O
were	9	O
performed	9	O
with	5	O
non	9	O
-	7	O
tumor	3	B-Disease
-	7	O
bearing	3	O
rats	9	O
,	9	O
in	5	O
which	5	O
no	9	O
major	9	O
differences	9	O
were	9	O
observed	9	O
.	9	O

In	9	O
conclusion	9	O
,	9	O
antitumor	3	O
activity	9	O
,	9	O
cardiotoxicity	9	B-Disease
,	9	O
and	5	O
nephrotoxicity	9	B-Disease
were	9	O
studied	9	O
simultaneously	5	O
in	5	O
the	5	O
same	9	O
LOU	2	O
/	9	O
M	9	O
/	9	O
WSL	0	O
rat	3	O
.	9	O

Albuminuria	7	B-Disease
due	5	O
to	5	O
renal	9	B-Disease
damage	9	I-Disease
led	9	O
to	5	O
extremely	5	O
low	9	O
serum	9	O
albumin	0	O
levels	3	O
,	9	O
so	5	O
ascites	3	B-Disease
and	5	O
hydrothorax	5	B-Disease
were	9	O
not	5	O
necessarily	5	O
a	5	O
consequence	5	O
of	5	O
the	5	O
observed	9	O
cardiomyopathy	5	B-Disease
.	9	O

Intraoperative	5	O
bradycardia	5	B-Disease
and	5	O
hypotension	5	B-Disease
associated	9	O
with	5	O
timolol	0	B-Chemical
and	5	O
pilocarpine	0	B-Chemical
eye	5	O
drops	0	O
.	9	O

A	9	O
69	7	O
-	7	O
yr	7	O
-	7	O
old	5	O
man	5	O
,	9	O
who	5	O
was	9	O
concurrently	9	O
being	5	O
treated	3	O
with	5	O
pilocarpine	0	B-Chemical
nitrate	0	I-Chemical
and	5	O
timolol	0	B-Chemical
maleate	0	I-Chemical
eye	5	O
drops	0	O
,	9	O
developed	5	O
a	5	O
bradycardia	5	B-Disease
and	5	O
became	9	O
hypotensive	5	B-Disease
during	5	O
halothane	0	B-Chemical
anaesthesia	5	O
.	9	O

Both	9	O
timolol	0	B-Chemical
and	5	O
pilocarpine	0	B-Chemical
were	9	O
subsequently	9	O
identified	9	O
in	5	O
a	5	O
24	9	O
-	7	O
h	0	O
collection	5	O
of	5	O
urine	9	O
.	9	O

Timolol	7	B-Chemical
(	9	O
but	9	O
not	5	O
pilocarpine	0	B-Chemical
)	9	O
was	9	O
detected	9	O
in	5	O
a	5	O
sample	9	O
of	5	O
plasma	9	O
removed	9	O
during	5	O
surgery	5	O
;	9	O
the	5	O
plasma	9	O
concentration	0	O
of	5	O
timolol	0	B-Chemical
(	9	O
2	9	O
.	9	O
6	9	O
ng	0	O
ml	0	O
-	7	O
1	9	O
)	9	O
was	9	O
consistent	9	O
with	5	O
partial	9	O
beta	9	O
-	7	O
adrenoceptor	5	O
blockade	3	O
.	9	O

It	5	O
is	5	O
postulated	9	O
that	5	O
this	5	O
action	5	O
may	5	O
have	5	O
been	9	O
enhanced	3	O
during	5	O
halothane	0	B-Chemical
anaesthesia	5	O
with	5	O
resultant	9	O
bradycardia	5	B-Disease
and	5	O
hypotension	5	B-Disease
.	9	O

Pilocarpine	0	B-Chemical
may	5	O
have	5	O
had	9	O
a	5	O
contributory	5	O
effect	9	O
.	9	O

Succinylcholine	0	B-Chemical
apnoea	5	B-Disease
:	9	O
attempted	5	O
reversal	9	O
with	5	O
anticholinesterases	0	O
.	9	O

Anticholinesterases	9	O
were	9	O
administered	9	O
in	5	O
an	5	O
attempt	5	O
to	5	O
antagonize	3	O
prolonged	9	O
neuromuscular	5	B-Disease
blockade	3	I-Disease
following	9	O
the	5	O
administration	9	O
of	5	O
succinylcholine	5	B-Chemical
in	5	O
a	5	O
patient	5	O
later	9	O
found	9	O
to	5	O
be	5	O
homozygous	1	O
for	5	O
atypical	5	O
plasma	9	O
cholinesterase	0	O
.	9	O

Edrophonium	5	B-Chemical
10	9	O
mg	0	O
,	9	O
given	5	O
74	7	O
min	0	O
after	9	O
succinylcholine	5	B-Chemical
,	9	O
when	5	O
train	5	O
-	7	O
of	5	O
-	7	O
four	9	O
stimulation	3	O
was	9	O
characteristic	9	O
of	5	O
phase	5	O
II	9	O
block	9	O
,	9	O
produced	9	O
partial	9	O
antagonism	9	O
which	5	O
was	9	O
not	5	O
sustained	5	O
.	9	O

Repeated	5	O
doses	0	O
of	5	O
edrophonium	0	B-Chemical
to	5	O
70	9	O
mg	0	O
and	5	O
neostigmine	0	B-Chemical
to	5	O
2	9	O
.	9	O
5	9	O
mg	0	O
did	9	O
not	5	O
antagonize	3	O
or	5	O
augment	9	O
the	5	O
block	9	O
.	9	O

Spontaneous	9	O
respiration	9	O
recommenced	5	O
200	0	O
min	0	O
after	9	O
succinylcholine	5	B-Chemical
administration	9	O
.	9	O

It	5	O
is	5	O
concluded	9	O
that	5	O
anticholinesterases	0	O
are	5	O
only	9	O
partially	9	O
effective	5	O
in	5	O
restoring	9	O
neuromuscular	5	O
function	9	O
in	5	O
succinylcholine	5	B-Chemical
apnoea	5	B-Disease
despite	9	O
muscle	9	O
twitch	5	O
activity	9	O
typical	9	O
of	5	O
phase	5	O
II	9	O
block	9	O
.	9	O

Effect	0	O
of	5	O
doxorubicin	0	B-Chemical
on	5	O
[	9	B-Chemical
omega	9	I-Chemical
-	7	I-Chemical
I	9	I-Chemical
-	7	I-Chemical
131	7	I-Chemical
]	9	I-Chemical
heptadecanoic	0	I-Chemical
acid	0	I-Chemical
myocardial	9	O
scintigraphy	5	O
and	5	O
echocardiography	5	O
in	5	O
dogs	5	O
.	9	O

The	5	O
effects	9	O
of	5	O
serial	9	O
treatment	9	O
with	5	O
doxorubicin	0	B-Chemical
on	5	O
dynamic	5	O
myocardial	9	O
scintigraphy	5	O
with	5	O
[	9	B-Chemical
omega	9	I-Chemical
-	7	I-Chemical
I	9	I-Chemical
-	7	I-Chemical
131	7	I-Chemical
]	9	I-Chemical
heptadecanoic	0	I-Chemical
acid	0	I-Chemical
(	9	O
I	9	B-Chemical
-	7	I-Chemical
131	7	I-Chemical
HA	9	I-Chemical
)	9	O
,	9	O
and	5	O
on	5	O
global	5	O
left	5	O
-	7	O
ventricular	5	O
function	9	O
determined	9	O
echocardiographically	5	O
,	9	O
were	9	O
studied	9	O
in	5	O
a	5	O
group	9	O
of	5	O
nine	9	O
mongrel	5	O
dogs	5	O
.	9	O

Total	7	O
extractable	0	O
myocardial	9	O
lipid	0	O
was	9	O
compared	9	O
postmortem	9	O
between	5	O
a	5	O
group	9	O
of	5	O
control	9	O
dogs	5	O
and	5	O
doxorubicin	0	B-Chemical
-	7	O
treated	3	O
dogs	5	O
.	9	O

A	9	O
significant	9	O
and	5	O
then	9	O
progressive	5	O
fall	5	O
in	5	O
global	5	O
LV	9	O
function	9	O
was	9	O
observed	9	O
at	9	O
a	5	O
cumulative	5	O
doxorubicin	0	B-Chemical
dose	9	O
of	5	O
4	9	O
mg	0	O
/	9	O
kg	0	O
.	9	O

A	9	O
significant	9	O
increase	9	O
in	5	O
the	5	O
myocardial	9	O
t1	9	O
/	9	O
2	9	O
of	5	O
the	5	O
I	9	B-Chemical
-	7	I-Chemical
131	7	I-Chemical
HA	9	I-Chemical
was	9	O
observed	9	O
only	9	O
at	9	O
a	5	O
higher	9	O
cumulative	5	O
dose	9	O
,	9	O
10	9	O
mg	0	O
/	9	O
kg	0	O
.	9	O

No	9	O
significant	9	O
alteration	9	O
in	5	O
total	9	O
extractable	0	O
myocardial	9	O
lipids	0	O
was	9	O
observed	9	O
between	5	O
control	9	O
dogs	5	O
and	5	O
those	5	O
treated	3	O
with	5	O
doxorubicin	0	B-Chemical
.	9	O

Our	9	O
findings	9	O
suggest	9	O
that	5	O
the	5	O
changes	9	O
leading	9	O
to	5	O
an	5	O
alteration	9	O
of	5	O
myocardial	9	O
dynamic	5	O
imaging	5	O
with	5	O
I	9	B-Chemical
-	7	I-Chemical
131	7	I-Chemical
HA	9	I-Chemical
are	5	O
not	5	O
the	5	O
initiating	9	O
factor	9	O
in	5	O
doxorubicin	0	B-Chemical
cardiotoxicity	9	B-Disease
.	9	O

Hemodynamics	5	O
and	5	O
myocardial	9	O
metabolism	9	O
under	9	O
deliberate	5	O
hypotension	5	B-Disease
.	9	O

An	5	O
experimental	5	O
study	9	O
in	5	O
dogs	5	O
.	9	O

Coronary	5	O
blood	9	O
flow	5	O
,	9	O
cardiac	5	O
work	5	O
and	5	O
metabolism	9	O
were	9	O
studied	9	O
in	5	O
dogs	5	O
under	9	O
sodium	0	B-Chemical
nitroprusside	0	I-Chemical
(	9	O
SNP	9	B-Chemical
)	9	O
and	5	O
trimetaphan	9	B-Chemical
(	9	O
TMP	0	B-Chemical
)	9	O
deliberate	5	O
hypotension	5	B-Disease
(	9	O
20	9	O
%	9	O
and	5	O
40	9	O
%	9	O
mean	5	O
pressure	5	O
decrease	9	O
from	9	O
baseline	5	O
)	9	O
.	9	O

Regarding	9	O
the	5	O
effects	9	O
of	5	O
drug	5	O
-	7	O
induced	3	O
hypotension	5	B-Disease
on	5	O
coronary	5	O
blood	9	O
flow	5	O
,	9	O
aortic	9	O
and	5	O
coronary	5	O
sinus	5	O
metabolic	9	O
data	5	O
(	9	O
pH	0	O
,	9	O
pO2	5	O
,	9	O
pCO2	0	O
)	9	O
we	5	O
could	9	O
confirm	9	O
that	5	O
nitroprusside	0	B-Chemical
hypotension	5	B-Disease
could	9	O
be	5	O
safely	5	O
used	5	O
to	5	O
30	9	O
%	9	O
mean	5	O
blood	9	O
pressure	5	O
decrease	9	O
from	9	O
control	9	O
,	9	O
trimetaphan	9	B-Chemical
hypotension	5	B-Disease
to	5	O
20	9	O
%	9	O
mean	5	O
blood	9	O
pressure	5	O
decrease	9	O
.	9	O

Cardiac	9	O
work	5	O
was	9	O
significantly	9	O
reduced	9	O
during	5	O
SNP	9	B-Chemical
hypotension	5	B-Disease
.	9	O

Myocardial	9	O
O2	0	B-Chemical
consumption	5	O
and	5	O
O2	0	B-Chemical
availability	5	O
were	9	O
directly	9	O
dependent	9	O
on	5	O
the	5	O
coronary	5	O
perfusion	5	O
.	9	O

Careful	5	O
invasive	5	O
monitoring	5	O
of	5	O
the	5	O
blood	9	O
pressure	5	O
,	9	O
blood	9	O
gases	0	O
and	5	O
of	5	O
the	5	O
ECG	5	O
ST	9	O
-	7	O
T	3	O
segment	9	O
is	5	O
mandatory	5	O
.	9	O

Evidence	9	O
for	5	O
a	5	O
selective	9	O
brain	5	O
noradrenergic	5	O
involvement	9	O
in	5	O
the	5	O
locomotor	5	O
stimulant	5	O
effects	9	O
of	5	O
amphetamine	5	B-Chemical
in	5	O
the	5	O
rat	3	O
.	9	O

Male	7	O
rats	9	O
received	9	O
the	5	O
noradrenaline	0	B-Chemical
neurotoxin	0	O
DSP4	0	B-Chemical
(	9	O
50	0	O
mg	0	O
/	9	O
kg	0	O
)	9	O
7	9	O
days	9	O
prior	9	O
to	5	O
injection	9	O
of	5	O
D	9	B-Chemical
-	7	I-Chemical
amphetamine	5	I-Chemical
(	9	O
10	9	O
or	5	O
40	9	O
mumol	7	O
/	9	O
kg	0	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
.	9	O

The	5	O
hyperactivity	5	B-Disease
induced	3	O
by	9	O
D	9	B-Chemical
-	7	I-Chemical
amphetamine	5	I-Chemical
(	9	O
10	9	O
mumol	7	O
/	9	O
kg	0	O
)	9	O
was	9	O
significantly	9	O
reduced	9	O
by	9	O
DSP4	0	B-Chemical
pretreatment	0	O
.	9	O

However	9	O
,	9	O
the	5	O
increased	9	O
rearings	5	O
and	5	O
the	5	O
amphetamine	5	B-Chemical
-	7	O
induced	3	O
stereotypies	5	B-Disease
were	9	O
not	5	O
blocked	3	O
by	9	O
pretreatment	0	O
with	5	O
DSP4	0	B-Chemical
.	9	O

The	5	O
reduction	9	O
of	5	O
amphetamine	5	B-Chemical
hyperactivity	5	B-Disease
induced	3	O
by	9	O
DSP4	0	B-Chemical
was	9	O
blocked	3	O
by	9	O
pretreatment	0	O
with	5	O
the	5	O
noradrenaline	0	B-Chemical
-	7	O
uptake	0	O
blocking	3	O
agent	9	O
,	9	O
desipramine	0	B-Chemical
,	9	O
which	5	O
prevents	9	O
the	5	O
neurotoxic	9	B-Disease
action	5	O
of	5	O
DSP4	0	B-Chemical
.	9	O

The	5	O
present	9	O
results	9	O
suggest	9	O
a	5	O
selective	9	O
involvement	9	O
of	5	O
central	5	O
noradrenergic	5	O
neurones	3	O
in	5	O
the	5	O
locomotor	5	O
stimulant	5	O
effect	9	O
of	5	O
amphetamine	5	B-Chemical
in	5	O
the	5	O
rat	3	O
.	9	O

Accelerated	9	B-Disease
junctional	9	I-Disease
rhythms	5	I-Disease
during	5	O
oral	9	O
verapamil	0	B-Chemical
therapy	5	O
.	9	O

This	5	O
study	9	O
examined	9	O
the	5	O
frequency	5	O
of	5	O
atrioventricular	5	O
(	9	O
AV	9	O
)	9	O
dissociation	9	O
and	5	O
accelerated	9	B-Disease
junctional	9	I-Disease
rhythms	5	I-Disease
in	5	O
59	7	O
patients	5	O
receiving	9	O
oral	9	O
verapamil	0	B-Chemical
.	9	O

Accelerated	9	B-Disease
junctional	9	I-Disease
rhythms	5	I-Disease
and	5	O
AV	9	O
dissociation	9	O
were	9	O
frequent	5	O
in	5	O
patients	5	O
with	5	O
supraventricular	5	B-Disease
tachyarrhythmias	5	I-Disease
,	9	O
particularly	5	O
AV	9	O
nodal	5	O
reentry	5	O
.	9	O

Verapamil	0	B-Chemical
administration	9	O
to	5	O
these	5	O
patients	5	O
led	9	O
to	5	O
an	5	O
asymptomatic	5	O
increase	9	O
in	5	O
activity	9	O
of	5	O
these	5	O
junctional	9	O
pacemakers	5	O
.	9	O

In	9	O
patients	5	O
with	5	O
various	9	O
chest	5	B-Disease
pain	5	I-Disease
syndromes	5	O
,	9	O
verapamil	0	B-Chemical
neither	9	O
increased	9	O
the	5	O
frequency	5	O
of	5	O
junctional	9	O
rhythms	5	O
nor	9	O
suppressed	3	O
their	5	O
role	9	O
as	5	O
escape	5	O
rhythms	5	O
under	9	O
physiologically	9	O
appropriate	5	O
circumstances	5	O
.	9	O

Interstrain	9	O
variation	5	O
in	5	O
acute	9	O
toxic	0	O
response	9	O
to	5	O
caffeine	0	B-Chemical
among	5	O
inbred	9	O
mice	3	O
.	9	O

Acute	5	O
toxic	0	O
dosage	9	O
-	7	O
dependent	9	O
behavioral	5	O
effects	9	O
of	5	O
caffeine	0	B-Chemical
were	9	O
compared	9	O
in	5	O
adult	9	O
males	9	O
from	9	O
seven	9	O
inbred	9	O
mouse	3	O
strains	1	O
(	9	O
A	9	O
/	9	O
J	9	O
,	9	O
BALB	3	O
/	9	O
cJ	3	O
,	9	O
CBA	3	O
/	9	O
J	9	O
,	9	O
C3H	3	O
/	9	O
HeJ	3	O
,	9	O
C57BL	3	O
/	9	O
6J	3	O
,	9	O
DBA	3	O
/	9	O
2J	3	O
,	9	O
SWR	3	O
/	9	O
J	9	O
)	9	O
.	9	O

C57BL	3	O
/	9	O
6J	3	O
,	9	O
chosen	5	O
as	5	O
a	5	O
"	5	O
prototypic	9	O
"	5	O
mouse	3	O
strain	1	O
,	9	O
was	9	O
used	5	O
to	5	O
determine	9	O
behavioral	5	O
responses	5	O
to	5	O
a	5	O
broad	5	O
range	9	O
(	9	O
5	9	O
-	7	O
500	0	O
mg	0	O
/	9	O
kg	0	O
)	9	O
of	5	O
caffeine	0	B-Chemical
doses	0	O
.	9	O

Five	9	O
phenotypic	9	O
characteristics	5	O
-	7	O
-	7	O
locomotor	5	O
activity	9	O
,	9	O
righting	5	O
ability	9	O
,	9	O
clonic	5	B-Disease
seizure	5	I-Disease
induction	3	O
,	9	O
stress	9	O
-	7	O
induced	3	O
lethality	3	O
,	9	O
death	9	O
without	9	O
external	5	O
stress	9	O
-	7	O
-	7	O
were	9	O
scored	5	O
at	9	O
various	9	O
caffeine	0	B-Chemical
doses	0	O
in	5	O
drug	5	O
-	7	O
naive	3	O
animals	9	O
under	9	O
empirically	5	O
optimized	9	O
,	9	O
rigidly	5	O
constant	9	O
experimental	5	O
conditions	9	O
.	9	O

Mice	3	O
(	9	O
n	9	O
=	7	O
12	9	O
for	5	O
each	5	O
point	5	O
)	9	O
received	9	O
single	9	O
IP	9	O
injections	9	O
of	5	O
a	5	O
fixed	9	O
volume	9	O
/	9	O
g	0	O
body	5	O
weight	9	O
of	5	O
physiological	9	O
saline	0	O
carrier	9	O
with	5	O
or	5	O
without	9	O
caffeine	0	B-Chemical
in	5	O
doses	0	O
ranging	9	O
from	9	O
125	9	O
-	7	O
500	0	O
mg	0	O
/	9	O
kg	0	O
.	9	O

Loss	9	O
of	5	O
righting	5	O
ability	9	O
was	9	O
scored	5	O
at	9	O
1	9	O
,	9	O
3	9	O
,	9	O
5	9	O
min	0	O
post	9	O
dosing	9	O
and	5	O
at	9	O
5	9	O
min	0	O
intervals	5	O
thereafter	9	O
for	5	O
20	9	O
min	0	O
.	9	O

In	9	O
the	5	O
same	9	O
animals	9	O
the	5	O
occurrence	5	O
of	5	O
clonic	5	B-Disease
seizures	5	I-Disease
was	9	O
scored	5	O
as	5	O
to	5	O
time	5	O
of	5	O
onset	5	O
and	5	O
severity	5	O
for	5	O
20	9	O
min	0	O
after	9	O
drug	5	O
administration	9	O
.	9	O

When	9	O
these	5	O
proceeded	9	O
to	5	O
tonic	5	B-Disease
seizures	5	I-Disease
,	9	O
death	9	O
occurred	9	O
in	5	O
less	5	O
than	5	O
20	9	O
min	0	O
.	9	O

Animals	9	O
surviving	9	O
for	5	O
20	9	O
min	0	O
were	9	O
immediately	9	O
stressed	9	O
by	9	O
a	5	O
swim	5	O
test	5	O
in	5	O
25	9	O
degrees	5	O
C	9	O
water	0	O
,	9	O
and	5	O
death	9	O
-	7	O
producing	9	O
tonic	5	B-Disease
seizures	5	I-Disease
were	9	O
scored	5	O
for	5	O
2	9	O
min	0	O
.	9	O

In	9	O
other	5	O
animals	9	O
locomotor	5	O
activity	9	O
was	9	O
measured	9	O
15	9	O
or	5	O
60	9	O
min	0	O
after	9	O
caffeine	0	B-Chemical
administration	9	O
.	9	O

By	5	O
any	5	O
single	9	O
behavioral	5	O
criterion	5	O
or	5	O
a	5	O
combination	9	O
of	5	O
these	5	O
criteria	5	O
,	9	O
marked	9	O
differences	9	O
in	5	O
response	9	O
to	5	O
toxic	0	O
caffeine	0	B-Chemical
doses	0	O
were	9	O
observed	9	O
between	5	O
strains	1	O
.	9	O

These	5	O
results	9	O
indicate	9	O
that	5	O
behavioral	5	O
toxicity	9	B-Disease
testing	5	O
of	5	O
alkylxanthines	9	B-Chemical
in	5	O
a	5	O
single	9	O
mouse	3	O
strain	1	O
may	5	O
be	5	O
misleading	5	O
and	5	O
suggest	9	O
that	5	O
toxic	0	O
responses	5	O
of	5	O
the	5	O
central	5	O
nervous	5	O
system	5	O
to	5	O
this	5	O
class	9	O
of	5	O
compounds	0	O
are	5	O
genetically	9	O
influenced	5	O
in	5	O
mammals	4	O
.	9	O

Treatment	9	O
of	5	O
ovarian	9	B-Disease
cancer	3	I-Disease
with	5	O
a	5	O
combination	9	O
of	5	O
cis	9	B-Chemical
-	7	I-Chemical
platinum	0	I-Chemical
,	9	O
adriamycin	3	B-Chemical
,	9	O
cyclophosphamide	0	B-Chemical
and	5	O
hexamethylmelamine	0	B-Chemical
.	9	O

During	5	O
the	5	O
last	5	O
2	9	O
1	9	O
/	9	O
2	9	O
years	5	O
,	9	O
38	7	O
patients	5	O
with	5	O
ovarian	9	B-Disease
cancer	3	I-Disease
were	9	O
treated	3	O
with	5	O
a	5	O
combination	9	O
of	5	O
cisplatinum	0	B-Chemical
(	9	O
CPDD	5	B-Chemical
)	9	O
,	9	O
50	0	O
mg	0	O
/	9	O
m2	7	O
,	9	O
adriamycin	3	B-Chemical
,	9	O
30	9	O
mg	0	O
/	9	O
m2	7	O
,	9	O
cyclophosphamide	0	B-Chemical
,	9	O
300	0	O
mg	0	O
/	9	O
m2	7	O
,	9	O
on	5	O
day	9	O
1	9	O
;	9	O
and	5	O
hexamethylmelamine	0	B-Chemical
(	9	O
HMM	5	B-Chemical
)	9	O
,	9	O
6	9	O
mg	0	O
/	9	O
kg	0	O
daily	5	O
,	9	O
for	5	O
14	7	O
days	9	O
.	9	O

Each	5	O
course	5	O
was	9	O
repeated	5	O
monthly	5	O
.	9	O

2	9	O
patients	5	O
had	9	O
stage	9	O
II	9	O
,	9	O
14	7	O
stage	9	O
III	9	O
and	5	O
22	7	O
stage	9	O
IV	9	O
disease	5	O
.	9	O

14	7	O
of	5	O
the	5	O
38	7	O
patients	5	O
were	9	O
previously	9	O
treated	3	O
with	5	O
chemotherapy	5	O
,	9	O
1	9	O
with	5	O
radiation	9	O
,	9	O
6	9	O
with	5	O
both	9	O
chemotherapy	5	O
and	5	O
radiation	9	O
,	9	O
and	5	O
17	7	O
did	9	O
not	5	O
have	5	O
any	5	O
treatment	9	O
before	9	O
CPDD	5	B-Chemical
combination	9	O
.	9	O

31	7	O
of	5	O
the	5	O
38	7	O
cases	5	O
(	9	O
81	7	O
.	9	O
5	9	O
%	9	O
)	9	O
demonstrated	9	O
objective	5	O
responses	5	O
lasting	5	O
for	5	O
2	9	O
months	5	O
or	5	O
more	5	O
.	9	O

These	5	O
responses	5	O
were	9	O
partial	9	O
in	5	O
19	7	O
and	5	O
complete	9	O
in	5	O
12	9	O
cases	5	O
.	9	O

Hematologic	7	B-Disease
toxicity	9	I-Disease
was	9	O
moderate	9	O
and	5	O
with	5	O
reversible	9	O
anemia	9	B-Disease
developing	5	O
in	5	O
71	7	O
%	9	O
of	5	O
patients	5	O
.	9	O

Gastrointestinal	9	O
side	5	O
effects	9	O
from	9	O
CPDD	5	B-Chemical
were	9	O
universal	5	O
.	9	O

HMM	5	B-Chemical
gastrointestinal	9	B-Disease
toxicity	9	I-Disease
necessitated	5	O
discontinuation	5	O
of	5	O
the	5	O
drug	5	O
in	5	O
5	9	O
patients	5	O
.	9	O

Severe	9	O
nephrotoxicity	9	B-Disease
was	9	O
observed	9	O
in	5	O
2	9	O
patients	5	O
but	9	O
was	9	O
reversible	9	O
.	9	O

There	5	O
were	9	O
no	9	O
drug	5	O
-	7	O
related	9	O
deaths	5	O
.	9	O

Nontraumatic	5	O
dissecting	5	B-Disease
aneurysm	5	I-Disease
of	5	O
the	5	O
basilar	5	O
artery	5	O
.	9	O

A	9	O
case	5	O
of	5	O
nontraumatic	5	O
dissecting	5	B-Disease
aneurysm	5	I-Disease
of	5	O
the	5	O
basilar	5	O
artery	5	O
in	5	O
association	9	O
with	5	O
hypertension	5	B-Disease
,	9	O
smoke	5	O
,	9	O
and	5	O
oral	9	B-Chemical
contraceptives	5	I-Chemical
is	5	O
reported	9	O
in	5	O
a	5	O
young	5	O
female	9	O
patient	5	O
with	5	O
a	5	O
locked	5	B-Disease
-	7	I-Disease
in	5	I-Disease
syndrome	5	I-Disease
.	9	O

A	9	O
method	5	O
for	5	O
the	5	O
measurement	5	O
of	5	O
tremor	5	B-Disease
,	9	O
and	5	O
a	5	O
comparison	9	O
of	5	O
the	5	O
effects	9	O
of	5	O
tocolytic	5	O
beta	9	O
-	7	O
mimetics	3	O
.	9	O

A	9	O
method	5	O
permitting	5	O
measurement	5	O
of	5	O
finger	5	O
tremor	5	B-Disease
as	5	O
a	5	O
displacement	5	O
-	7	O
time	5	O
curve	9	O
is	5	O
described	9	O
,	9	O
using	9	O
a	5	O
test	5	O
system	5	O
with	5	O
simple	5	O
amplitude	5	O
calibration	5	O
.	9	O

The	5	O
coordinates	5	O
of	5	O
the	5	O
inversion	5	O
points	5	O
of	5	O
the	5	O
displacement	5	O
-	7	O
time	5	O
curves	5	O
were	9	O
transferred	9	O
through	9	O
graphical	5	O
input	5	O
equipment	5	O
to	5	O
punched	5	O
tape	5	O
.	9	O

By	5	O
means	5	O
of	5	O
a	5	O
computer	5	O
program	5	O
,	9	O
periods	5	O
and	5	O
amplitudes	5	O
of	5	O
tremor	5	B-Disease
oscillations	5	O
were	9	O
calculated	5	O
and	5	O
classified	5	O
.	9	O

The	5	O
event	5	O
frequency	5	O
for	5	O
each	5	O
class	9	O
of	5	O
periods	5	O
and	5	O
amplitudes	5	O
was	9	O
determined	9	O
.	9	O

The	5	O
actions	5	O
of	5	O
fenoterol	0	B-Chemical
-	7	I-Chemical
hydrobromide	0	I-Chemical
,	9	O
ritodrin	_	B-Chemical
-	7	I-Chemical
HCl	0	I-Chemical
and	5	O
placebo	9	O
given	5	O
to	5	O
10	9	O
healthy	5	O
subjects	5	O
by	9	O
intravenous	0	O
infusion	0	O
in	5	O
a	5	O
double	9	O
-	7	O
blind	5	O
crossover	5	O
study	9	O
were	9	O
tested	9	O
by	9	O
this	5	O
method	5	O
.	9	O

At	9	O
therapeutic	5	O
doses	0	O
both	9	O
substances	0	O
raised	9	O
the	5	O
mean	5	O
tremor	5	B-Disease
amplitude	5	O
to	5	O
about	5	O
three	9	O
times	5	O
the	5	O
control	9	O
level	9	O
.	9	O

At	9	O
the	5	O
same	9	O
time	5	O
,	9	O
the	5	O
mean	5	O
period	5	O
within	9	O
each	5	O
class	9	O
of	5	O
amplitudes	5	O
shortened	9	O
by	9	O
10	9	O
-	7	O
-	7	O
20	9	O
ms	5	O
,	9	O
whereas	9	O
the	5	O
mean	5	O
periods	5	O
calculated	5	O
from	9	O
all	5	O
oscillations	5	O
together	9	O
did	9	O
not	5	O
change	9	O
significantly	9	O
.	9	O

After	9	O
the	5	O
end	9	O
of	5	O
fenoterol	0	B-Chemical
-	7	I-Chemical
hydrobromide	0	I-Chemical
infusion	0	O
,	9	O
tremor	5	B-Disease
amplitudes	5	O
decreased	9	O
significantly	9	O
faster	5	O
than	5	O
those	5	O
following	9	O
ritodrin	_	B-Chemical
-	7	I-Chemical
HCl	0	I-Chemical
infusion	0	O
.	9	O

Propylthiouracil	0	B-Chemical
-	7	O
induced	3	O
hepatic	9	B-Disease
damage	9	I-Disease
.	9	O

Two	9	O
cases	5	O
of	5	O
propylthiouracil	0	B-Chemical
-	7	O
induced	3	O
liver	9	B-Disease
damage	9	I-Disease
have	5	O
been	9	O
observed	9	O
.	9	O

The	5	O
first	9	O
case	5	O
is	5	O
of	5	O
an	5	O
acute	9	O
type	9	O
of	5	O
damage	9	O
,	9	O
proven	5	O
by	9	O
rechallenge	3	O
;	9	O
the	5	O
second	9	O
presents	5	O
a	5	O
clinical	5	O
and	5	O
histologic	9	O
picture	5	O
resembling	9	O
chronic	5	B-Disease
active	9	I-Disease
hepatitis	9	I-Disease
,	9	O
with	5	O
spontaneous	5	O
remission	5	O
.	9	O

Studies	9	O
on	5	O
the	5	O
bradycardia	5	B-Disease
induced	3	O
by	9	O
bepridil	0	B-Chemical
.	9	O

Bepridil	0	B-Chemical
,	9	O
a	5	O
novel	9	O
active	9	O
compound	0	O
for	5	O
prophylactic	5	O
treatment	9	O
of	5	O
anginal	5	B-Disease
attacks	5	I-Disease
,	9	O
induced	3	O
persistent	5	O
bradycardia	5	B-Disease
and	5	O
a	5	O
non	9	O
-	7	O
specific	9	O
anti	3	O
-	7	O
tachycardial	9	B-Disease
effect	9	O
,	9	O
the	5	O
mechanisms	9	O
of	5	O
which	5	O
were	9	O
investigated	9	O
in	5	O
vitro	3	O
and	5	O
in	5	O
vivo	3	O
.	9	O

In	9	O
vitro	3	O
perfusion	5	O
of	5	O
bepridil	0	B-Chemical
in	5	O
the	5	O
life	5	O
-	7	O
support	5	O
medium	0	O
for	5	O
isolated	9	O
sino	2	O
-	7	O
atrial	5	O
tissue	9	O
from	9	O
rabbit	3	O
heart	5	O
,	9	O
caused	9	O
a	5	O
reduction	9	O
in	5	O
action	5	O
potential	9	O
(	9	O
AP	9	O
)	9	O
spike	5	O
frequency	5	O
(	9	O
recorded	5	O
by	9	O
KCl	0	B-Chemical
microelectrodes	5	O
)	9	O
starting	9	O
at	9	O
doses	0	O
of	5	O
5	9	O
X	9	O
10	9	O
(	9	O
-	7	O
6	9	O
)	9	O
M	9	O
.	9	O

This	5	O
effect	9	O
was	9	O
dose	9	O
-	7	O
dependent	9	O
up	5	O
to	5	O
concentrations	0	O
of	5	O
5	9	O
X	9	O
10	9	O
(	9	O
-	7	O
5	9	O
)	9	O
M	9	O
,	9	O
whereupon	9	O
blockade	3	O
of	5	O
sinus	5	O
activity	9	O
set	5	O
in	5	O
.	9	O

Bepridil	0	B-Chemical
at	9	O
a	5	O
dose	9	O
of	5	O
5	9	O
X	9	O
10	9	O
(	9	O
-	7	O
6	9	O
)	9	O
M	9	O
,	9	O
induced	3	O
a	5	O
concomitant	9	O
reduction	9	O
in	5	O
AP	9	O
amplitude	5	O
(	9	O
falling	5	O
from	9	O
71	7	O
+	9	O
/	9	O
-	7	O
8	9	O
mV	0	O
to	5	O
47	7	O
+	9	O
/	9	O
-	7	O
6	9	O
mV	0	O
)	9	O
,	9	O
maximum	5	O
systolic	5	O
depolarization	9	O
velocity	5	O
(	9	O
phase	5	O
0	7	O
)	9	O
which	5	O
fell	5	O
from	9	O
1	9	O
.	9	O
85	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
35	9	O
V	9	O
/	9	O
s	9	O
to	5	O
0	7	O
.	9	O
84	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
28	7	O
V	9	O
/	9	O
s	9	O
,	9	O
together	9	O
with	5	O
maximum	5	O
diastolic	5	O
depolarization	9	O
velocity	5	O
(	9	O
phase	5	O
4	9	O
)	9	O
which	5	O
fell	5	O
from	9	O
38	7	O
+	9	O
/	9	O
-	7	O
3	9	O
mV	0	O
/	9	O
s	9	O
to	5	O
24	9	O
+	9	O
/	9	O
-	7	O
5	9	O
mV	0	O
/	9	O
s	9	O
.	9	O

In	9	O
vivo	3	O
injection	9	O
of	5	O
bepridil	0	B-Chemical
at	9	O
a	5	O
dose	9	O
of	5	O
5	9	O
mg	0	O
/	9	O
kg	0	O
(	9	O
i	9	O
.	9	O
v	0	O
.	9	O
)	9	O
into	9	O
6	9	O
anaesthetized	0	O
dogs	5	O
which	5	O
had	9	O
undergone	5	O
ablation	9	O
of	5	O
all	5	O
the	5	O
extrinsic	5	O
cardiac	5	O
afferent	5	O
nerve	5	O
supply	5	O
,	9	O
together	9	O
with	5	O
a	5	O
bilateral	5	O
medullo	9	O
-	7	O
adrenalectomy	5	O
,	9	O
caused	9	O
a	5	O
marked	9	O
reduction	9	O
in	5	O
heart	5	O
rate	9	O
which	5	O
fell	5	O
from	9	O
98	7	O
.	9	O
7	9	O
+	9	O
/	9	O
-	7	O
4	9	O
.	9	O
2	9	O
beats	5	O
/	9	O
min	0	O
to	5	O
76	7	O
+	9	O
/	9	O
-	7	O
5	9	O
.	9	O
3	9	O
beats	5	O
/	9	O
min	0	O
sustained	5	O
for	5	O
more	5	O
than	5	O
45	9	O
min	0	O
.	9	O

It	5	O
is	5	O
concluded	9	O
that	5	O
bepridil	0	B-Chemical
reduces	9	O
heart	5	O
rate	9	O
by	9	O
acting	9	O
directly	9	O
on	5	O
the	5	O
sinus	5	O
node	5	O
.	9	O

This	5	O
effect	9	O
,	9	O
which	5	O
results	9	O
in	5	O
a	5	O
flattening	5	O
of	5	O
the	5	O
phase	5	O
0	7	O
and	5	O
phase	5	O
4	9	O
slope	5	O
,	9	O
together	9	O
with	5	O
a	5	O
longer	5	O
AP	9	O
duration	5	O
,	9	O
may	5	O
be	5	O
due	5	O
to	5	O
an	5	O
increase	9	O
in	5	O
the	5	O
time	5	O
constants	0	O
of	5	O
slow	5	O
inward	5	O
ionic	0	O
currents	0	O
(	9	O
already	5	O
demonstrated	9	O
elsewhere	9	O
)	9	O
,	9	O
but	9	O
also	9	O
to	5	O
an	5	O
increased	9	O
time	5	O
constant	9	O
for	5	O
deactivation	9	O
of	5	O
the	5	O
outward	5	O
potassium	0	B-Chemical
current	5	O
(	9	O
Ip	6	O
)	9	O
.	9	O

Hepatitis	9	B-Disease
and	5	O
renal	9	B-Disease
tubular	9	I-Disease
acidosis	5	I-Disease
after	9	O
anesthesia	5	O
with	5	O
methoxyflurane	0	B-Chemical
.	9	O

A	9	O
69	7	O
-	7	O
year	5	O
-	7	O
old	5	O
man	5	O
operated	5	O
for	5	O
acute	9	B-Disease
cholecystitis	5	I-Disease
under	9	O
methoxyflurane	0	B-Chemical
anesthesia	5	O
developed	5	O
postoperatively	5	O
a	5	O
hepatic	9	B-Disease
insufficiency	9	I-Disease
syndrome	5	I-Disease
and	5	O
renal	9	B-Disease
tubular	9	I-Disease
acidosis	5	I-Disease
.	9	O

Massive	5	O
bleeding	5	B-Disease
appeared	9	O
during	5	O
surgery	5	O
which	5	O
lasted	5	O
for	5	O
six	9	O
hours	9	O
.	9	O

Postoperative	5	O
evolution	5	O
under	9	O
supportive	5	O
therapy	5	O
was	9	O
favourable	5	O
.	9	O

Complete	9	O
recovery	9	O
was	9	O
confirmed	9	O
by	9	O
repeated	5	O
controls	9	O
performed	9	O
over	5	O
a	5	O
period	5	O
of	5	O
one	5	O
year	5	O
after	9	O
surgery	5	O
.	9	O

Pituitary	2	O
response	9	O
to	5	O
luteinizing	0	O
hormone	9	O
-	7	O
releasing	9	O
hormone	9	O
during	5	O
haloperidol	5	B-Chemical
-	7	O
induced	3	O
hyperprolactinemia	5	B-Disease
.	9	O

The	5	O
effects	9	O
of	5	O
a	5	O
6	9	O
-	7	O
hour	0	O
infusion	0	O
with	5	O
haloperidol	5	B-Chemical
on	5	O
serum	9	O
prolactin	3	O
and	5	O
luteinizing	0	O
hormone	9	O
(	9	O
LH	9	O
)	9	O
levels	3	O
was	9	O
studied	9	O
in	5	O
a	5	O
group	9	O
of	5	O
male	9	O
subjects	5	O
.	9	O

Five	9	O
hours	9	O
after	9	O
starting	9	O
the	5	O
infusions	9	O
,	9	O
a	5	O
study	9	O
of	5	O
the	5	O
pituitary	3	O
responses	5	O
to	5	O
LH	9	O
-	7	O
releasing	9	O
hormone	9	O
(	9	O
LH	9	O
-	7	O
RH	9	O
)	9	O
was	9	O
carried	9	O
out	9	O
.	9	O

Control	9	O
patients	5	O
received	9	O
infusions	9	O
of	5	O
0	7	O
.	9	O
9	7	O
%	9	O
NaCl	0	B-Chemical
solution	0	O
.	9	O

During	5	O
the	5	O
course	5	O
of	5	O
haloperidol	5	B-Chemical
infusions	9	O
,	9	O
significant	9	O
hyperprolactinemia	5	B-Disease
was	9	O
found	9	O
,	9	O
together	9	O
with	5	O
an	5	O
abolished	3	O
pituitary	3	O
response	9	O
to	5	O
LH	9	O
-	7	O
RH	9	O
,	9	O
as	5	O
compared	9	O
with	5	O
responses	5	O
of	5	O
control	9	O
subjects	5	O
.	9	O

Antirifampicin	_	O
antibodies	3	O
in	5	O
acute	9	O
rifampicin	0	B-Chemical
-	7	O
associated	9	O
renal	9	B-Disease
failure	5	I-Disease
.	9	O

5	9	O
patients	5	O
with	5	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
(	9	O
3	9	O
with	5	O
thrombopenia	5	B-Disease
and	5	O
hemolysis	9	B-Disease
)	9	O
induced	3	O
by	9	O
the	5	O
reintroduction	9	O
of	5	O
rifampicin	0	B-Chemical
are	5	O
described	9	O
.	9	O

No	9	O
correlation	9	O
was	9	O
found	9	O
between	5	O
the	5	O
severity	5	O
of	5	O
clinical	5	O
manifestations	5	O
and	5	O
the	5	O
total	9	O
dose	9	O
taken	5	O
by	9	O
the	5	O
patients	5	O
.	9	O

In	9	O
all	5	O
but	9	O
1	9	O
patient	5	O
,	9	O
antirifampicin	_	O
antibodies	3	O
were	9	O
detected	9	O
.	9	O

Antibodies	3	O
suggested	9	O
to	5	O
be	5	O
of	5	O
the	5	O
IgM	3	O
class	9	O
were	9	O
detected	9	O
in	5	O
all	5	O
3	9	O
patients	5	O
with	5	O
hematological	9	B-Disease
disorders	5	I-Disease
.	9	O

The	5	O
pattern	9	O
of	5	O
non	9	O
-	7	O
specific	9	O
acute	9	B-Disease
tubular	9	I-Disease
necrosis	9	I-Disease
found	9	O
in	5	O
the	5	O
2	9	O
biopsied	9	O
patients	5	O
,	9	O
indistinguishable	9	O
from	9	O
that	5	O
of	5	O
ischemic	9	O
origin	9	O
,	9	O
raised	9	O
the	5	O
possibility	9	O
of	5	O
a	5	O
vascular	5	O
-	7	O
mediated	3	O
damage	9	O
.	9	O

In	9	O
3	9	O
patients	5	O
,	9	O
the	5	O
possibility	9	O
of	5	O
a	5	O
triggering	9	O
immunoallergic	5	O
mechanism	9	O
is	5	O
discussed	5	O
.	9	O

Cardiovascular	2	O
effects	9	O
of	5	O
hypotension	5	B-Disease
induced	3	O
by	9	O
adenosine	0	B-Chemical
triphosphate	0	I-Chemical
and	5	O
sodium	0	B-Chemical
nitroprusside	0	I-Chemical
on	5	O
dogs	5	O
with	5	O
denervated	3	O
hearts	3	O
.	9	O

Adenosine	0	B-Chemical
triphosphate	0	I-Chemical
(	9	O
ATP	0	B-Chemical
)	9	O
and	5	O
sodium	0	B-Chemical
nitroprusside	0	I-Chemical
(	9	O
SNP	9	B-Chemical
)	9	O
are	5	O
administered	9	O
to	5	O
patients	5	O
to	5	O
induce	3	O
and	5	O
control	9	O
hypotension	5	B-Disease
during	5	O
anesthesia	5	O
.	9	O

SNP	9	B-Chemical
is	5	O
authorized	5	O
for	5	O
clinical	5	O
use	5	O
in	5	O
USA	0	O
and	5	O
UK	2	O
,	9	O
and	5	O
ATP	0	B-Chemical
is	5	O
clinically	5	O
used	5	O
in	5	O
other	5	O
countries	5	O
such	5	O
as	5	O
Japan	2	O
.	9	O

We	9	O
investigated	9	O
how	5	O
these	5	O
two	5	O
drugs	5	O
act	9	O
on	5	O
the	5	O
cardiovascular	5	O
systems	5	O
of	5	O
20	9	O
dogs	5	O
whose	9	O
hearts	3	O
had	9	O
been	9	O
denervated	3	O
by	9	O
a	5	O
procedure	5	O
we	5	O
had	9	O
devised	5	O
.	9	O

ATP	0	B-Chemical
(	9	O
10	9	O
dogs	5	O
)	9	O
or	5	O
SNP	9	B-Chemical
(	9	O
10	9	O
dogs	5	O
)	9	O
was	9	O
administered	9	O
to	5	O
reduce	5	O
mean	5	O
arterial	5	O
pressure	5	O
by	9	O
30	9	O
%	9	O
to	5	O
70	9	O
%	9	O
of	5	O
control	9	O
.	9	O

Before	9	O
,	9	O
during	5	O
and	5	O
after	9	O
induced	3	O
hypotension	5	B-Disease
,	9	O
we	5	O
measured	9	O
major	9	O
cardiovascular	5	O
parameters	5	O
.	9	O

Hypotension	7	B-Disease
induced	3	O
by	9	O
ATP	0	B-Chemical
was	9	O
accompanied	9	O
by	9	O
significant	9	O
decreases	9	O
in	5	O
mean	5	O
pulmonary	5	O
arterial	5	O
pressure	5	O
(	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
001	9	O
)	9	O
,	9	O
central	5	O
venous	5	O
pressure	5	O
(	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
001	9	O
)	9	O
,	9	O
left	5	O
ventricular	5	O
end	9	O
-	7	O
diastolic	5	O
pressure	5	O
(	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
001	9	O
)	9	O
,	9	O
total	9	O
peripheral	9	O
resistance	9	O
(	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
001	9	O
)	9	O
,	9	O
rate	9	O
pressure	5	O
product	9	O
(	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
001	9	O
)	9	O
,	9	O
total	9	O
body	5	O
oxygen	0	B-Chemical
consumption	5	O
(	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
05	7	O
)	9	O
,	9	O
and	5	O
heart	5	O
rate	9	O
(	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
001	9	O
)	9	O
;	9	O
all	5	O
these	5	O
variables	5	O
returned	5	O
normal	9	O
within	9	O
30	9	O
min	0	O
after	9	O
ATP	0	B-Chemical
was	9	O
stopped	9	O
.	9	O

Cardiac	9	O
output	5	O
did	9	O
not	5	O
change	9	O
.	9	O

During	5	O
hypotension	5	B-Disease
produced	9	O
by	9	O
SNP	9	B-Chemical
similar	9	O
decreases	9	O
were	9	O
observed	9	O
in	5	O
mean	5	O
pulmonary	5	O
arterial	5	O
pressure	5	O
(	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
01	7	O
)	9	O
,	9	O
central	5	O
venous	5	O
pressure	5	O
(	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
001	9	O
)	9	O
,	9	O
left	5	O
ventricular	5	O
end	9	O
-	7	O
diastolic	5	O
pressure	5	O
(	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
01	7	O
)	9	O
,	9	O
total	9	O
peripheral	9	O
resistance	9	O
(	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
001	9	O
)	9	O
,	9	O
rate	9	O
pressure	5	O
product	9	O
(	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
001	9	O
)	9	O
,	9	O
and	5	O
oxygen	0	B-Chemical
content	9	O
difference	9	O
between	5	O
arterial	5	O
and	5	O
mixed	9	O
venous	5	O
blood	9	O
(	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
05	7	O
)	9	O
,	9	O
while	9	O
heart	5	O
rate	9	O
(	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
001	9	O
)	9	O
and	5	O
cardiac	5	O
output	5	O
(	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
05	7	O
)	9	O
were	9	O
increased	9	O
.	9	O

Recoveries	0	O
of	5	O
heart	5	O
rate	9	O
and	5	O
left	5	O
ventricular	5	O
end	9	O
-	7	O
diastolic	5	O
pressure	5	O
were	9	O
not	5	O
shown	9	O
within	9	O
60	9	O
min	0	O
after	9	O
SNP	9	B-Chemical
had	9	O
been	9	O
stopped	9	O
.	9	O

Both	9	O
ATP	0	B-Chemical
and	5	O
SNP	9	B-Chemical
should	5	O
act	9	O
on	5	O
the	5	O
pacemaker	5	O
tissue	9	O
of	5	O
the	5	O
heart	5	O
.	9	O

Comparative	9	O
study	9	O
:	9	O
Endografine	_	B-Chemical
(	9	O
diatrizoate	0	B-Chemical
)	9	O
,	9	O
Vasurix	_	B-Chemical
polyvidone	0	I-Chemical
(	9	O
acetrizoate	9	B-Chemical
)	9	O
,	9	O
Dimer	0	B-Chemical
-	7	I-Chemical
X	9	I-Chemical
(	9	O
iocarmate	_	B-Chemical
)	9	O
and	5	O
Hexabrix	0	B-Chemical
(	9	O
ioxaglate	0	B-Chemical
)	9	O
in	5	O
hysterosalpingography	5	O
.	9	O

Side	5	O
effects	9	O
of	5	O
hysterosalpingography	5	O
with	5	O
Dimer	0	B-Chemical
-	7	I-Chemical
X	9	I-Chemical
,	9	O
Hexabrix	0	B-Chemical
,	9	O
Vasurix	_	B-Chemical
polyvidone	0	I-Chemical
and	5	O
Endografine	_	B-Chemical
in	5	O
142	7	O
consecutive	5	O
patients	5	O
,	9	O
receiving	9	O
one	5	O
of	5	O
the	5	O
four	9	O
tested	9	O
media	9	O
were	9	O
evaluated	9	O
from	9	O
replies	5	O
to	5	O
postal	5	O
questionnaires	5	O
.	9	O

The	5	O
Dimer	0	B-Chemical
-	7	I-Chemical
X	9	I-Chemical
group	9	O
had	9	O
a	5	O
higher	9	O
incidence	5	O
of	5	O
nausea	5	B-Disease
and	5	O
dizziness	5	B-Disease
.	9	O

The	5	O
Endografine	_	B-Chemical
group	9	O
had	9	O
a	5	O
higher	9	O
incidence	5	O
of	5	O
abdominal	5	B-Disease
pain	5	I-Disease
.	9	O

These	5	O
differences	9	O
occur	5	O
especially	5	O
in	5	O
the	5	O
age	5	O
groups	9	O
under	9	O
30	9	O
years	5	O
.	9	O

Hexabrix	0	B-Chemical
and	5	O
Vasurix	_	B-Chemical
polyvidone	0	I-Chemical
are	5	O
considered	5	O
the	5	O
best	5	O
contrast	9	B-Chemical
media	9	I-Chemical
for	5	O
hysterosalpingography	5	O
and	5	O
perhaps	5	O
because	5	O
of	5	O
its	9	O
low	9	O
toxicity	9	B-Disease
Hexabrix	0	B-Chemical
should	5	O
be	5	O
preferred	5	O
.	9	O

Post	9	O
-	7	O
suxamethonium	5	B-Chemical
pains	5	B-Disease
in	5	O
Nigerian	5	O
surgical	5	O
patients	5	O
.	9	O

Contrary	9	O
to	5	O
an	5	O
earlier	9	O
report	5	O
by	9	O
Coxon	6	O
,	9	O
scoline	0	B-Chemical
pain	5	B-Disease
occurs	9	O
in	5	O
African	5	O
negroes	5	O
.	9	O

Its	5	O
incidence	5	O
was	9	O
determined	9	O
in	5	O
a	5	O
prospective	5	O
study	9	O
involving	5	O
a	5	O
total	9	O
of	5	O
100	0	O
Nigerian	5	O
patients	5	O
(	9	O
50	0	O
out	9	O
-	7	O
patients	5	O
and	5	O
50	0	O
in	5	O
-	7	O
patients	5	O
)	9	O
.	9	O

About	9	O
62	7	O
%	9	O
of	5	O
the	5	O
out	9	O
-	7	O
patients	5	O
developed	5	O
scoline	0	B-Chemical
pain	5	B-Disease
as	5	O
compared	9	O
with	5	O
about	5	O
26	7	O
%	9	O
among	5	O
the	5	O
in	5	O
-	7	O
patients	5	O
.	9	O

The	5	O
abolition	5	O
of	5	O
muscle	9	O
fasciculations	5	B-Disease
(	9	O
by	9	O
0	7	O
.	9	O
075mg	_	O
/	9	O
kg	0	O
dose	9	O
of	5	O
Fazadinium	_	B-Chemical
)	9	O
did	9	O
not	5	O
influence	5	O
the	5	O
occurrence	5	O
of	5	O
scoline	0	B-Chemical
pain	5	B-Disease
.	9	O

Neither	9	O
the	5	O
type	9	O
of	5	O
induction	3	O
agent	9	O
(	9	O
Althesin	5	B-Chemical
or	5	O
Thiopentone	0	B-Chemical
)	9	O
nor	9	O
the	5	O
salt	0	O
preparation	9	O
of	5	O
suxamethonium	5	B-Chemical
used	5	O
(	9	O
chloride	0	B-Chemical
or	5	O
bromide	0	B-Chemical
)	9	O
,	9	O
affected	9	O
the	5	O
incidence	5	O
of	5	O
scoline	0	B-Chemical
pain	5	B-Disease
.	9	O

Invasive	9	O
carcinoma	3	B-Disease
of	5	I-Disease
the	5	I-Disease
renal	9	I-Disease
pelvis	5	I-Disease
following	9	O
cyclophosphamide	0	B-Chemical
therapy	5	O
for	5	O
nonmalignant	3	O
disease	5	O
.	9	O

A	9	O
47	7	O
-	7	O
year	5	O
-	7	O
old	5	O
woman	5	O
with	5	O
right	5	O
hydroureteronephrosis	5	B-Disease
due	5	O
to	5	O
ureterovesical	5	O
junction	9	O
obstruction	5	O
had	9	O
gross	5	O
hematuria	5	B-Disease
after	9	O
being	5	O
treated	3	O
for	5	O
five	9	O
years	5	O
wtih	3	O
cyclophosphamide	0	B-Chemical
for	5	O
cerebral	5	B-Disease
vasculitis	5	I-Disease
.	9	O

A	9	O
right	5	O
nephroureterectomy	5	O
was	9	O
required	9	O
for	5	O
control	9	O
of	5	O
bleeding	5	B-Disease
.	9	O

The	5	O
pathology	5	O
specimen	9	O
contained	9	O
clinically	5	O
occult	5	O
invasive	5	O
carcinoma	3	B-Disease
of	5	I-Disease
the	5	I-Disease
renal	9	I-Disease
pelvis	5	I-Disease
.	9	O

Although	9	O
the	5	O
ability	9	O
of	5	O
cyclophosphamide	0	B-Chemical
to	5	O
cause	5	O
hemorrhagic	5	B-Disease
cystitis	9	I-Disease
and	5	O
urine	9	O
cytologic	5	O
abnormalities	9	O
indistinguishable	9	O
from	9	O
high	9	O
grade	9	O
carcinoma	3	B-Disease
is	5	O
well	9	O
known	9	O
,	9	O
it	5	O
is	5	O
less	5	O
widely	5	O
appreciated	5	O
that	5	O
it	5	O
is	5	O
also	9	O
associated	9	O
with	5	O
carcinoma	3	B-Disease
of	5	I-Disease
the	5	I-Disease
urinary	9	I-Disease
tract	9	I-Disease
.	9	O

Twenty	9	O
carcinomas	3	B-Disease
of	5	I-Disease
the	5	I-Disease
urinary	9	I-Disease
bladder	9	I-Disease
and	5	O
one	5	O
carcinoma	3	B-Disease
of	5	I-Disease
the	5	I-Disease
prostate	3	I-Disease
have	5	O
been	9	O
reported	9	O
in	5	O
association	9	O
with	5	O
its	9	O
use	5	O
.	9	O

The	5	O
present	9	O
case	5	O
is	5	O
the	5	O
first	9	O
carcinoma	3	B-Disease
of	5	I-Disease
the	5	I-Disease
renal	9	I-Disease
pelvis	5	I-Disease
reported	9	O
in	5	O
association	9	O
with	5	O
cyclophosphamide	0	B-Chemical
treatment	9	O
.	9	O

It	5	O
is	5	O
the	5	O
third	9	O
urinary	9	B-Disease
tract	9	I-Disease
cancer	3	I-Disease
reported	9	O
in	5	O
association	9	O
with	5	O
cyclophosphamide	0	B-Chemical
treatment	9	O
for	5	O
nonmalignant	3	O
disease	5	O
.	9	O

The	5	O
association	9	O
of	5	O
the	5	O
tumor	3	B-Disease
with	5	O
preexisting	9	O
hydroureteronephrosis	5	B-Disease
suggests	9	O
that	5	O
stasis	5	O
prolonged	9	O
and	5	O
intensified	5	O
exposure	9	O
of	5	O
upper	9	O
urinary	9	O
tract	9	O
epithelium	3	O
to	5	O
cyclophosphamide	0	B-Chemical
.	9	O

Patients	5	O
who	5	O
are	5	O
candidates	9	O
for	5	O
long	5	O
-	7	O
term	5	O
cyclophosphamide	0	B-Chemical
treatment	9	O
should	5	O
be	5	O
routinely	9	O
evaluated	9	O
for	5	O
obstructive	5	B-Disease
uropathy	5	I-Disease
.	9	O

Medial	5	O
changes	9	O
in	5	O
arterial	5	O
spasm	5	B-Disease
induced	3	O
by	9	O
L	0	B-Chemical
-	7	I-Chemical
norepinephrine	9	I-Chemical
.	9	O

In	9	O
normal	9	O
rats	9	O
,	9	O
the	5	O
media	9	O
of	5	O
small	9	O
arteries	5	O
(	9	O
0	7	O
.	9	O
4	9	O
-	7	O
-	7	O
0	7	O
.	9	O
2	9	O
mm	9	O
in	5	O
diameter	9	O
)	9	O
previously	9	O
was	9	O
shown	9	O
to	5	O
contain	9	O
intracellular	3	O
vacuoles	9	O
,	9	O
identified	9	O
ultrastructurally	3	O
as	5	O
herniations	5	O
of	5	O
one	5	O
smooth	5	O
muscle	9	O
cell	3	O
into	9	O
another	9	O
.	9	O

The	5	O
hypothesis	9	O
that	5	O
intense	9	O
vasoconstriction	9	O
would	5	O
increase	9	O
the	5	O
number	9	O
of	5	O
such	5	O
vacuoles	9	O
has	9	O
been	9	O
tested	9	O
.	9	O

In	9	O
the	5	O
media	9	O
of	5	O
the	5	O
saphenous	5	O
artery	5	O
and	5	O
its	9	O
distal	9	O
branch	5	O
,	9	O
vasoconstriction	9	O
induced	3	O
by	9	O
L	0	B-Chemical
-	7	I-Chemical
norepinephrine	9	I-Chemical
produced	9	O
many	5	O
cell	3	O
-	7	O
to	5	O
-	7	O
cell	3	O
hernias	5	B-Disease
within	9	O
15	9	O
minutes	0	O
.	9	O

At	9	O
1	9	O
day	9	O
their	5	O
number	9	O
was	9	O
reduced	9	O
to	5	O
about	5	O
1	9	O
/	9	O
10	9	O
of	5	O
the	5	O
original	5	O
number	9	O
.	9	O

By	5	O
7	9	O
days	9	O
the	5	O
vessel	5	O
was	9	O
almost	9	O
restored	3	O
to	5	O
normal	9	O
.	9	O

Triple	9	O
stimulation	3	O
over	5	O
1	9	O
day	9	O
induced	3	O
more	5	O
severe	5	O
changes	9	O
in	5	O
the	5	O
media	9	O
.	9	O

These	5	O
findings	9	O
suggest	9	O
that	5	O
smooth	5	O
muscle	9	O
cells	3	O
are	5	O
susceptible	9	O
to	5	O
damage	9	O
in	5	O
the	5	O
course	5	O
of	5	O
their	5	O
specific	9	O
function	9	O
.	9	O

The	5	O
experimental	5	O
data	5	O
are	5	O
discussed	5	O
in	5	O
relation	5	O
to	5	O
medial	5	O
changes	9	O
observed	9	O
in	5	O
other	5	O
instances	5	O
of	5	O
arterial	5	O
spasm	5	B-Disease
.	9	O

Endothelial	3	O
changes	9	O
that	5	O
developed	5	O
in	5	O
the	5	O
same	9	O
experimental	5	O
model	5	O
were	9	O
described	9	O
in	5	O
a	5	O
previous	9	O
paper	5	O
.	9	O

Bilateral	5	O
retinal	5	B-Disease
artery	5	I-Disease
and	5	I-Disease
choriocapillaris	5	I-Disease
occlusion	5	I-Disease
following	9	O
the	5	O
injection	9	O
of	5	O
long	5	O
-	7	O
acting	9	O
corticosteroid	5	B-Chemical
suspensions	0	O
in	5	O
combination	9	O
with	5	O
other	5	O
drugs	5	O
:	9	O
I	9	O
.	9	O

Clinical	5	O
studies	9	O
.	9	O

Two	9	O
well	9	O
-	7	O
documented	9	O
cases	5	O
of	5	O
bilateral	5	O
retinal	5	B-Disease
artery	5	I-Disease
and	5	I-Disease
choriocapillaris	5	I-Disease
occlusions	5	I-Disease
with	5	O
blindness	5	B-Disease
following	9	O
head	5	O
and	5	O
neck	5	O
soft	5	O
-	7	O
tissue	9	O
injection	9	O
with	5	O
methylprednisolone	0	B-Chemical
acetate	0	I-Chemical
in	5	O
combination	9	O
with	5	O
lidocaine	0	B-Chemical
,	9	O
epinephrine	0	B-Chemical
,	9	O
or	5	O
penicillin	0	B-Chemical
are	5	O
reported	9	O
.	9	O

One	5	O
case	5	O
had	9	O
only	9	O
a	5	O
unilateral	5	O
injection	9	O
.	9	O

The	5	O
acute	9	O
observations	9	O
included	5	O
hazy	5	O
sensorium	5	O
,	9	O
superior	5	O
gaze	5	O
palsy	5	B-Disease
,	9	O
pupillary	5	B-Disease
abnormalities	9	I-Disease
,	9	O
and	5	O
conjunctival	5	O
hemorrhages	5	B-Disease
with	5	O
edema	5	B-Disease
.	9	O

Follow	5	O
-	7	O
up	5	O
changes	9	O
showed	9	O
marked	9	O
visual	5	B-Disease
loss	9	I-Disease
,	9	O
constricted	5	O
visual	5	O
fields	5	O
,	9	O
optic	5	O
nerve	5	O
pallor	5	O
,	9	O
vascular	5	O
attenuation	9	O
,	9	O
and	5	O
chorioretinal	5	B-Disease
atrophy	5	I-Disease
.	9	O

The	5	O
literature	5	O
is	5	O
reviewed	9	O
,	9	O
and	5	O
possible	5	O
causes	9	O
are	5	O
discussed	5	O
.	9	O

Abnormalities	9	O
of	5	O
the	5	O
pupil	5	O
and	5	O
visual	5	O
-	7	O
evoked	5	O
potential	9	O
in	5	O
quinine	0	B-Chemical
amblyopia	5	B-Disease
.	9	O

Total	7	O
blindness	5	B-Disease
with	5	O
a	5	O
transient	9	O
tonic	5	B-Disease
pupillary	5	I-Disease
response	9	O
,	9	O
denervation	5	O
supersensitivity	5	O
,	9	O
and	5	O
abnormal	9	O
visual	5	O
-	7	O
evoked	5	O
potentials	5	O
developed	5	O
in	5	O
a	5	O
54	7	O
-	7	O
year	5	O
-	7	O
old	5	O
man	5	O
after	9	O
the	5	O
use	5	O
of	5	O
quinine	0	B-Chemical
sulfate	0	I-Chemical
for	5	O
leg	5	B-Disease
cramps	5	I-Disease
.	9	O

He	5	O
later	9	O
recovered	9	O
normal	9	O
visual	5	O
acuity	5	O
.	9	O

A	9	O
transient	9	O
tonic	5	B-Disease
pupillary	5	I-Disease
response	9	O
,	9	O
denervation	5	O
supersensitivity	5	O
,	9	O
and	5	O
abnormal	9	O
visual	5	O
-	7	O
evoked	5	O
potentials	5	O
in	5	O
quinine	0	B-Chemical
toxicity	9	B-Disease
,	9	O
to	5	O
our	5	O
knowledge	5	O
,	9	O
have	5	O
not	5	O
been	9	O
previously	9	O
reported	9	O
.	9	O

Suxamethonium	0	B-Chemical
-	7	O
induced	3	O
jaw	5	B-Disease
stiffness	5	I-Disease
and	5	O
myalgia	5	B-Disease
associated	9	O
with	5	O
atypical	5	O
cholinesterase	0	O
:	9	O
case	5	O
report	5	O
.	9	O

An	5	O
11	7	O
-	7	O
year	5	O
-	7	O
old	5	O
boy	5	O
was	9	O
given	5	O
halothane	0	B-Chemical
,	9	O
nitrous	0	B-Chemical
oxide	0	I-Chemical
and	5	O
oxygen	0	B-Chemical
,	9	O
pancuronium	0	B-Chemical
0	7	O
.	9	O
4	9	O
mg	0	O
and	5	O
suxamethonium	5	B-Chemical
100	0	O
mg	0	O
for	5	O
induction	3	O
of	5	O
anaesthesia	5	O
.	9	O

In	9	O
response	9	O
to	5	O
this	5	O
a	5	O
marked	9	O
jaw	5	B-Disease
stiffness	5	I-Disease
occurred	9	O
which	5	O
lasted	5	O
for	5	O
two	5	O
minutes	0	O
and	5	O
the	5	O
anaesthesia	5	O
were	9	O
terminated	9	O
.	9	O

Four	9	O
hours	9	O
of	5	O
apnoea	5	B-Disease
ensued	5	O
and	5	O
he	5	O
suffered	5	O
generalized	5	O
severe	5	O
myalgia	5	B-Disease
lasting	5	O
for	5	O
one	5	O
week	9	O
.	9	O

He	5	O
was	9	O
found	9	O
to	5	O
have	5	O
atypical	5	O
plasma	9	O
cholinesterase	0	O
with	5	O
a	5	O
dibucaine	0	B-Chemical
number	9	O
of	5	O
12	9	O
,	9	O
indicating	9	O
homozygocity	1	O
.	9	O

This	5	O
was	9	O
verified	9	O
by	9	O
study	9	O
of	5	O
the	5	O
family	9	O
.	9	O

The	5	O
case	5	O
shows	9	O
that	5	O
prolonged	9	B-Disease
jaw	5	I-Disease
rigidity	5	I-Disease
and	5	O
myalgia	5	B-Disease
may	5	O
occur	5	O
after	9	O
suxamethonium	5	B-Chemical
in	5	O
patients	5	O
with	5	O
atypical	5	O
cholinesterase	0	O
despite	9	O
pretreatment	0	O
with	5	O
pancuronium	0	B-Chemical
.	9	O

Indomethacin	0	B-Chemical
-	7	O
induced	3	O
hyperkalemia	5	B-Disease
in	5	O
three	9	O
patients	5	O
with	5	O
gouty	5	B-Disease
arthritis	9	I-Disease
.	9	O

We	9	O
describe	5	O
three	9	O
patients	5	O
in	5	O
whom	5	O
severe	5	O
,	9	O
life	5	O
-	7	O
threatening	5	O
hyperkalemia	5	B-Disease
and	5	O
renal	9	B-Disease
insufficiency	9	I-Disease
developed	5	O
after	9	O
treatment	9	O
of	5	O
acute	9	O
gouty	5	B-Disease
arthritis	9	I-Disease
with	5	O
indomethacin	0	B-Chemical
.	9	O

This	5	O
complication	5	O
may	5	O
result	9	O
from	9	O
an	5	O
inhibition	3	O
of	5	O
prostaglandin	0	B-Chemical
synthesis	9	O
and	5	O
consequent	9	O
hyporeninemic	9	B-Disease
hypoaidosteronism	_	I-Disease
.	9	O

Careful	5	O
attention	5	O
to	5	O
renal	9	O
function	9	O
and	5	O
potassium	0	B-Chemical
balance	5	O
in	5	O
patients	5	O
receiving	9	O
indomethacin	0	B-Chemical
or	5	O
other	5	O
nonsteroidal	5	O
anti	3	O
-	7	O
inflammatory	3	O
agents	5	O
,	9	O
particularly	5	O
in	5	O
those	5	O
patients	5	O
with	5	O
diabetes	5	B-Disease
mellitus	9	I-Disease
or	5	O
preexisting	9	O
renal	9	B-Disease
disease	5	I-Disease
,	9	O
will	5	O
help	5	O
prevent	5	O
this	5	O
potentially	5	O
serious	5	O
complication	5	O
.	9	O

Etomidate	0	B-Chemical
:	9	O
a	5	O
foreshortened	5	O
clinical	5	O
trial	5	O
.	9	O

A	9	O
clinical	5	O
evaluation	5	O
of	5	O
etomidate	5	B-Chemical
for	5	O
outpatient	5	O
cystoscopy	5	O
was	9	O
embarked	5	O
upon	9	O
.	9	O

Unpremedicated	_	O
patients	5	O
were	9	O
given	5	O
fentanyl	0	B-Chemical
1	9	O
microgram	0	O
/	9	O
kg	0	O
followed	9	O
by	9	O
etomidate	5	B-Chemical
0	7	O
.	9	O
3	9	O
mg	0	O
/	9	O
kg	0	O
.	9	O

Anaesthesia	2	O
was	9	O
maintained	9	O
with	5	O
intermittent	5	O
etomidate	5	B-Chemical
in	5	O
2	9	O
-	7	O
4	9	O
mg	0	O
doses	0	O
.	9	O

Patients	5	O
were	9	O
interviewed	5	O
personally	5	O
later	9	O
the	5	O
same	9	O
day	9	O
,	9	O
and	5	O
by	9	O
questionnaire	5	O
three	9	O
to	5	O
four	9	O
weeks	9	O
later	9	O
.	9	O

The	5	O
trial	5	O
was	9	O
discontinued	5	O
after	9	O
20	9	O
cases	5	O
because	5	O
of	5	O
an	5	O
unacceptable	5	O
incidence	5	O
of	5	O
side	5	O
effects	9	O
.	9	O

Venous	5	O
pain	5	B-Disease
occurred	9	O
in	5	O
68	7	O
%	9	O
of	5	O
patients	5	O
and	5	O
50	0	O
%	9	O
had	9	O
redness	5	O
,	9	O
pain	5	B-Disease
or	5	O
swelling	5	B-Disease
related	9	O
to	5	O
the	5	O
injection	9	O
site	9	O
,	9	O
in	5	O
some	5	O
cases	5	O
lasting	5	O
up	5	O
to	5	O
three	9	O
weeks	9	O
after	9	O
anaesthesia	5	O
.	9	O

Skeletal	9	O
movements	5	O
occurred	9	O
in	5	O
50	0	O
%	9	O
of	5	O
patients	5	O
;	9	O
30	9	O
%	9	O
experienced	5	O
respiratory	5	B-Disease
upset	5	I-Disease
,	9	O
one	5	O
sufficiently	5	O
severe	5	O
to	5	O
necessitate	5	O
abandoning	5	O
the	5	O
technique	5	O
.	9	O

Nausea	7	B-Disease
and	5	O
vomiting	5	B-Disease
occurred	9	O
in	5	O
40	9	O
%	9	O
and	5	O
25	9	O
%	9	O
had	9	O
disturbing	5	O
emergence	9	O
psychoses	5	B-Disease
.	9	O

Levodopa	0	B-Chemical
-	7	O
induced	3	O
dyskinesias	5	B-Disease
are	5	O
improved	5	O
by	9	O
fluoxetine	0	B-Chemical
.	9	O

We	9	O
evaluated	9	O
the	5	O
severity	5	O
of	5	O
motor	5	B-Disease
disability	5	I-Disease
and	5	O
dyskinesias	5	B-Disease
in	5	O
seven	9	O
levodopa	5	B-Chemical
-	7	O
responsive	9	O
patients	5	O
with	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
after	9	O
an	5	O
acute	9	O
challenge	9	O
with	5	O
the	5	O
mixed	9	O
dopamine	5	B-Chemical
agonist	3	O
,	9	O
apomorphine	0	B-Chemical
,	9	O
before	9	O
and	5	O
after	9	O
the	5	O
administration	9	O
of	5	O
fluoxetine	0	B-Chemical
(	9	O
20	9	O
mg	0	O
twice	9	O
per	9	O
day	9	O
)	9	O
for	5	O
11	7	O
+	9	O
/	9	O
-	7	O
1	9	O
days	9	O
.	9	O

After	9	O
fluoxetine	0	B-Chemical
treatment	9	O
,	9	O
there	5	O
was	9	O
a	5	O
significant	9	O
47	7	O
%	9	O
improvement	5	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
of	5	O
apomorphine	0	B-Chemical
-	7	O
induced	3	O
dyskinesias	5	B-Disease
without	9	O
modification	9	O
of	5	O
parkinsonian	5	B-Disease
motor	5	B-Disease
disability	5	I-Disease
.	9	O

The	5	O
dyskinesias	5	B-Disease
were	9	O
reduced	9	O
predominantly	9	O
in	5	O
the	5	O
lower	9	O
limbs	5	O
during	5	O
the	5	O
onset	5	O
and	5	O
disappearance	9	O
of	5	O
dystonic	5	B-Disease
dyskinesias	5	I-Disease
(	9	O
onset	5	O
-	7	O
and	5	O
end	9	O
-	7	O
of	5	O
-	7	O
dose	9	O
dyskinesias	5	B-Disease
)	9	O
and	5	O
in	5	O
the	5	O
upper	9	O
limbs	5	O
during	5	O
choreic	5	B-Disease
mid	9	I-Disease
-	7	I-Disease
dose	9	I-Disease
dyskinesias	5	I-Disease
.	9	O

The	5	O
results	9	O
suggest	9	O
that	5	O
increased	9	O
brain	5	O
serotoninergic	5	O
transmission	5	O
with	5	O
fluoxetine	0	B-Chemical
may	5	O
reduce	5	O
levodopa	5	B-Chemical
-	7	O
or	5	O
dopamine	5	B-Chemical
agonist	3	O
-	7	O
induced	3	O
dyskinesias	5	B-Disease
without	9	O
aggravating	5	O
parkinsonian	5	B-Disease
motor	5	B-Disease
disability	5	I-Disease
.	9	O

A	9	O
large	5	O
population	5	O
-	7	O
based	5	O
follow	5	O
-	7	O
up	5	O
study	9	O
of	5	O
trimethoprim	0	B-Chemical
-	7	I-Chemical
sulfamethoxazole	0	I-Chemical
,	9	O
trimethoprim	0	B-Chemical
,	9	O
and	5	O
cephalexin	0	B-Chemical
for	5	O
uncommon	5	O
serious	5	O
drug	5	B-Disease
toxicity	9	I-Disease
.	9	O

We	9	O
conducted	9	O
a	5	O
population	5	O
-	7	O
based	5	O
45	9	O
-	7	O
day	9	O
follow	5	O
-	7	O
up	5	O
study	9	O
of	5	O
232	7	O
,	9	O
390	9	O
people	5	O
who	5	O
were	9	O
prescribed	5	O
trimethoprim	0	B-Chemical
-	7	I-Chemical
sulfamethoxazole	0	I-Chemical
(	9	O
TMP	0	B-Chemical
-	7	I-Chemical
SMZ	0	I-Chemical
)	9	O
,	9	O
266	7	O
,	9	O
951	7	O
prescribed	5	O
trimethoprim	0	B-Chemical
alone	9	O
,	9	O
and	5	O
196	7	O
,	9	O
397	7	O
prescribed	5	O
cephalexin	0	B-Chemical
,	9	O
to	5	O
estimate	5	O
the	5	O
risk	5	O
of	5	O
serious	5	O
liver	9	B-Disease
,	9	I-Disease
blood	9	I-Disease
,	9	I-Disease
skin	5	I-Disease
,	9	I-Disease
and	5	I-Disease
renal	9	I-Disease
disorders	5	I-Disease
resulting	9	O
in	5	O
referral	5	O
or	5	O
hospitalization	5	O
associated	9	O
with	5	O
these	5	O
drugs	5	O
.	9	O

The	5	O
results	9	O
were	9	O
based	5	O
on	5	O
information	5	O
recorded	5	O
on	5	O
office	5	O
computers	5	O
by	9	O
selected	9	O
general	5	O
practitioners	5	O
in	5	O
the	5	O
United	9	O
Kingdom	2	O
,	9	O
together	9	O
with	5	O
a	5	O
review	5	O
of	5	O
clinical	5	O
records	5	O
.	9	O

The	5	O
risk	5	O
of	5	O
clinically	5	O
important	9	O
idiopathic	5	O
liver	9	B-Disease
disease	5	I-Disease
was	9	O
similar	9	O
for	5	O
persons	5	O
prescribed	5	O
TMP	0	B-Chemical
-	7	I-Chemical
SMZ	0	I-Chemical
(	9	O
5	9	O
.	9	O
2	9	O
/	9	O
100	0	O
,	9	O
000	9	O
)	9	O
and	5	O
those	5	O
prescribed	5	O
trimethoprim	0	B-Chemical
alone	9	O
(	9	O
3	9	O
.	9	O
8	9	O
/	9	O
100	0	O
,	9	O
000	9	O
)	9	O
.	9	O

The	5	O
risk	5	O
for	5	O
those	5	O
prescribed	5	O
cephalexin	0	B-Chemical
was	9	O
somewhat	5	O
lower	9	O
(	9	O
2	9	O
.	9	O
0	7	O
/	9	O
100	0	O
,	9	O
000	9	O
)	9	O
.	9	O

Only	9	O
five	9	O
patients	5	O
experienced	5	O
blood	9	O
disorders	5	O
,	9	O
one	5	O
of	5	O
whom	5	O
was	9	O
exposed	9	O
to	5	O
TMP	0	B-Chemical
-	7	I-Chemical
SMZ	0	I-Chemical
;	9	O
of	5	O
seven	9	O
with	5	O
erythema	5	B-Disease
multiforme	9	I-Disease
and	5	O
Stevens	6	B-Disease
-	7	I-Disease
Johnson	6	I-Disease
syndrome	5	I-Disease
,	9	O
four	9	O
were	9	O
exposed	9	O
to	5	O
TMP	0	B-Chemical
-	7	I-Chemical
SMZ	0	I-Chemical
.	9	O

The	5	O
one	5	O
case	5	O
of	5	O
toxic	0	B-Disease
epidermal	3	I-Disease
necrolysis	5	I-Disease
occurred	9	O
in	5	O
a	5	O
patient	5	O
who	5	O
took	5	O
cephalexin	0	B-Chemical
.	9	O

Finally	9	O
,	9	O
only	9	O
five	9	O
cases	5	O
of	5	O
acute	9	O
parenchymal	5	O
renal	9	B-Disease
disease	5	I-Disease
occurred	9	O
,	9	O
none	9	O
likely	5	O
to	5	O
be	5	O
caused	9	O
by	9	O
a	5	O
study	9	O
drug	5	O
.	9	O

We	9	O
conclude	9	O
that	5	O
the	5	O
risk	5	O
of	5	O
the	5	O
serious	5	O
diseases	5	O
studied	9	O
is	5	O
small	9	O
for	5	O
the	5	O
three	9	O
agents	5	O
,	9	O
and	5	O
compares	5	O
reasonably	5	O
with	5	O
the	5	O
risk	5	O
for	5	O
many	5	O
other	5	O
antibiotics	5	O
.	9	O

Clinical	5	O
safety	5	O
of	5	O
lidocaine	0	B-Chemical
in	5	O
patients	5	O
with	5	O
cocaine	5	B-Chemical
-	7	O
associated	9	O
myocardial	9	B-Disease
infarction	5	I-Disease
.	9	O

STUDY	2	O
OBJECTIVE	2	O
:	9	O
To	9	O
evaluate	9	O
the	5	O
safety	5	O
of	5	O
lidocaine	0	B-Chemical
in	5	O
the	5	O
setting	5	O
of	5	O
cocaine	5	B-Chemical
-	7	O
induced	3	O
myocardial	9	B-Disease
infarction	5	I-Disease
(	9	O
MI	9	B-Disease
)	9	O
.	9	O

DESIGN	2	O
:	9	O
A	9	O
retrospective	5	O
,	9	O
multicenter	5	O
study	9	O
.	9	O

SETTING	2	O
:	9	O
Twenty	9	O
-	7	O
nine	9	O
university	5	O
,	9	O
university	5	O
-	7	O
affiliated	2	O
,	9	O
or	5	O
community	5	O
hospitals	5	O
during	5	O
a	5	O
6	9	O
-	7	O
year	5	O
period	5	O
(	9	O
total	9	O
of	5	O
117	7	O
cumulative	5	O
hospital	5	O
-	7	O
years	5	O
)	9	O
.	9	O

PARTICIPANTS	2	O
:	9	O
Patients	5	O
with	5	O
cocaine	5	B-Chemical
-	7	O
associated	9	O
MI	9	B-Disease
who	5	O
received	9	O
lidocaine	0	B-Chemical
in	5	O
the	5	O
emergency	5	O
department	5	O
.	9	O

RESULTS	9	O
:	9	O
Of	9	O
29	7	O
patients	5	O
who	5	O
received	9	O
lidocaine	0	B-Chemical
in	5	O
the	5	O
setting	5	O
of	5	O
cocaine	5	B-Chemical
-	7	O
associated	9	O
MI	9	B-Disease
,	9	O
no	9	O
patient	5	O
died	9	O
;	9	O
exhibited	9	O
bradydysrhythmias	_	B-Disease
,	9	O
ventricular	5	B-Disease
tachycardia	5	I-Disease
,	9	O
or	5	O
ventricular	5	B-Disease
fibrillation	5	I-Disease
;	9	O
or	5	O
experienced	5	O
seizures	5	B-Disease
after	9	O
administration	9	O
of	5	O
lidocaine	0	B-Chemical
(	9	O
95	7	O
%	9	O
confidence	5	O
interval	5	O
,	9	O
0	7	O
%	9	O
to	5	O
11	7	O
%	9	O
)	9	O
.	9	O

CONCLUSION	5	O
:	9	O
Despite	5	O
theoretical	5	O
concerns	5	O
that	5	O
lidocaine	0	B-Chemical
may	5	O
enhance	9	O
cocaine	5	B-Chemical
toxicity	9	B-Disease
,	9	O
the	5	O
use	5	O
of	5	O
lidocaine	0	B-Chemical
in	5	O
patients	5	O
with	5	O
cocaine	5	B-Chemical
-	7	O
associated	9	O
MI	9	B-Disease
was	9	O
not	5	O
associated	9	O
with	5	O
significant	9	O
cardiovascular	5	B-Disease
or	5	I-Disease
central	5	I-Disease
nervous	5	I-Disease
system	5	I-Disease
toxicity	9	I-Disease
.	9	O

Experimental	9	O
progressive	5	O
muscular	5	B-Disease
dystrophy	9	I-Disease
and	5	O
its	9	O
treatment	9	O
with	5	O
high	9	O
doses	0	O
anabolizing	_	O
agents	5	O
.	9	O

We	9	O
are	5	O
still	5	O
a	5	O
long	5	O
way	5	O
from	9	O
discovering	5	O
an	5	O
unequivocal	9	O
pathogenetic	5	O
interpretation	5	O
of	5	O
progressive	5	O
muscular	5	B-Disease
dystrophy	9	I-Disease
in	5	O
man	5	O
.	9	O

Noteworthy	9	O
efforts	5	O
have	5	O
been	9	O
made	5	O
in	5	O
the	5	O
experimental	5	O
field	5	O
;	9	O
a	5	O
recessive	9	O
autosomic	5	O
form	9	O
found	9	O
in	5	O
the	5	O
mouse	3	O
seems	5	O
to	5	O
bear	9	O
the	5	O
closest	9	O
resemblance	9	O
to	5	O
the	5	O
human	3	O
form	9	O
from	9	O
the	5	O
genetic	5	O
point	5	O
of	5	O
view	5	O
.	9	O

Myopathy	7	B-Disease
due	5	O
to	5	O
lack	9	O
of	5	O
vitamin	0	B-Chemical
E	9	I-Chemical
and	5	O
myopathy	9	B-Disease
induced	3	O
by	9	O
certain	5	O
viruses	9	O
have	5	O
much	5	O
in	5	O
common	5	O
anatomically	5	O
and	5	O
pathologically	5	O
with	5	O
the	5	O
human	3	O
form	9	O
.	9	O

The	5	O
authors	5	O
induced	3	O
myodystrophy	9	B-Disease
in	5	O
the	5	O
rat	3	O
by	9	O
giving	5	O
it	5	O
a	5	O
diet	9	O
lacking	1	O
in	5	O
vitamin	0	B-Chemical
E	9	I-Chemical
.	9	O

The	5	O
pharmacological	9	O
characteristics	5	O
of	5	O
vitamin	0	B-Chemical
E	9	I-Chemical
and	5	O
the	5	O
degenerative	5	O
changes	9	O
brought	5	O
about	5	O
by	9	O
its	9	O
deficiency	9	O
,	9	O
especially	5	O
in	5	O
the	5	O
muscles	5	O
,	9	O
are	5	O
illustrated	9	O
.	9	O

It	5	O
is	5	O
thus	9	O
confirmed	9	O
that	5	O
the	5	O
histological	9	O
characteristics	5	O
of	5	O
myopathic	5	B-Disease
rat	3	O
muscle	9	O
induced	3	O
experimentally	9	O
are	5	O
extraordinarily	5	O
similar	9	O
to	5	O
those	5	O
of	5	O
human	3	O
myopathy	9	B-Disease
as	5	O
confirmed	9	O
during	5	O
biopsies	9	O
performed	9	O
at	9	O
the	5	O
Orthopaedic	2	O
Traumatological	9	O
Centre	2	O
,	9	O
Florence	2	O
.	9	O

The	5	O
encouraging	5	O
results	9	O
obtained	9	O
in	5	O
various	9	O
authoratative	_	O
departments	5	O
in	5	O
myopathic	5	B-Disease
patients	5	O
by	9	O
using	9	O
anabolizing	_	O
steroids	9	B-Chemical
have	5	O
encouraged	5	O
the	5	O
authors	5	O
to	5	O
investigate	9	O
the	5	O
beneficial	9	O
effects	9	O
of	5	O
one	5	O
anabolizing	_	O
agent	9	O
(	9	O
Dianabol	9	B-Chemical
,	9	O
CIBA	2	B-Chemical
)	9	O
at	9	O
high	9	O
doses	0	O
in	5	O
rats	9	O
rendered	9	O
myopathic	5	B-Disease
by	9	O
a	5	O
diet	9	O
deficient	3	O
in	5	O
vitamin	0	B-Chemical
E	9	I-Chemical
.	9	O

In	9	O
this	5	O
way	5	O
they	5	O
obtained	9	O
appreciable	9	O
changes	9	O
in	5	O
body	5	O
weight	9	O
(	9	O
increased	9	O
from	9	O
50	0	O
to	5	O
70	9	O
g	0	O
after	9	O
forty	5	O
days	9	O
at	9	O
a	5	O
dose	9	O
of	5	O
5	9	O
mg	0	O
per	9	O
day	9	O
of	5	O
anabolizing	_	O
agent	9	O
)	9	O
,	9	O
but	9	O
most	9	O
of	5	O
all	5	O
they	5	O
found	9	O
histological	9	O
changes	9	O
due	5	O
to	5	O
"	5	O
regenerative	5	O
"	5	O
changes	9	O
in	5	O
the	5	O
muscle	9	O
tissue	9	O
,	9	O
which	5	O
however	9	O
maintained	9	O
its	9	O
myopathic	5	B-Disease
characteristics	5	O
in	5	O
the	5	O
control	9	O
animals	9	O
that	5	O
were	9	O
not	5	O
treated	3	O
with	5	O
the	5	O
anabolizing	_	O
agent	9	O
.	9	O

The	5	O
authors	5	O
conclude	9	O
by	9	O
affirming	5	O
the	5	O
undoubted	5	O
efficacy	9	O
of	5	O
the	5	O
anabolizing	_	O
steroids	9	B-Chemical
in	5	O
experimental	5	O
myopathic	5	B-Disease
disease	5	I-Disease
,	9	O
but	9	O
they	5	O
have	5	O
reservations	5	O
as	5	O
to	5	O
the	5	O
transfer	9	O
of	5	O
the	5	O
results	9	O
into	9	O
the	5	O
human	3	O
field	5	O
,	9	O
where	5	O
high	9	O
dosage	9	O
cannot	5	O
be	5	O
carried	9	O
out	9	O
continuously	5	O
because	5	O
of	5	O
the	5	O
effects	9	O
of	5	O
the	5	O
drug	5	O
on	5	O
virility	5	O
;	9	O
because	5	O
the	5	O
tissue	9	O
injury	9	O
too	5	O
often	5	O
occurs	9	O
at	9	O
an	5	O
irreversible	9	O
stage	9	O
vis	0	O
-	7	O
a	5	O
-	7	O
vis	0	O
the	5	O
"	5	O
regeneration	9	O
"	5	O
of	5	O
the	5	O
muscle	9	O
tissue	9	O
;	9	O
and	5	O
finally	9	O
because	5	O
the	5	O
dystrophic	3	O
injurious	5	O
agent	9	O
is	5	O
certainly	5	O
not	5	O
the	5	O
lack	9	O
of	5	O
vitamin	0	B-Chemical
E	9	I-Chemical
but	9	O
something	5	O
as	5	O
yet	9	O
unknown	9	O
.	9	O

Paclitaxel	0	B-Chemical
3	9	O
-	7	O
hour	0	O
infusion	0	O
given	5	O
alone	9	O
and	5	O
combined	9	O
with	5	O
carboplatin	0	B-Chemical
:	9	O
preliminary	9	O
results	9	O
of	5	O
dose	9	O
-	7	O
escalation	5	O
trials	5	O
.	9	O

Paclitaxel	0	B-Chemical
(	9	O
Taxol	0	B-Chemical
;	9	O
Bristol	2	O
-	7	O
Myers	6	O
Squibb	2	O
Company	2	O
,	9	O
Princeton	2	O
,	9	O
NJ	0	O
)	9	O
by	9	O
3	9	O
-	7	O
hour	0	O
infusion	0	O
was	9	O
combined	9	O
with	5	O
carboplatin	0	B-Chemical
in	5	O
a	5	O
phase	5	O
I	9	O
/	9	O
II	9	O
study	9	O
directed	9	O
to	5	O
patients	5	O
with	5	O
non	9	B-Disease
-	7	I-Disease
small	9	I-Disease
cell	3	I-Disease
lung	9	I-Disease
cancer	3	I-Disease
.	9	O

Carboplatin	0	B-Chemical
was	9	O
given	5	O
at	9	O
a	5	O
fixed	9	O
target	9	O
area	5	O
under	9	O
the	5	O
concentration	0	O
-	7	O
time	5	O
curve	9	O
of	5	O
6	9	O
.	9	O
0	7	O
by	9	O
the	5	O
Calvert	6	O
formula	9	O
,	9	O
whereas	9	O
paclitaxel	0	B-Chemical
was	9	O
escalated	5	O
in	5	O
patient	5	O
cohorts	9	O
from	9	O
150	0	O
mg	0	O
/	9	O
m2	7	O
(	9	O
dose	9	O
level	9	O
I	9	O
)	9	O
to	5	O
175	7	O
,	9	O
200	0	O
,	9	O
225	9	O
,	9	O
and	5	O
250	0	O
mg	0	O
/	9	O
m2	7	O
.	9	O

The	5	O
225	9	O
mg	0	O
/	9	O
m2	7	O
level	9	O
was	9	O
expanded	9	O
for	5	O
the	5	O
phase	5	O
II	9	O
study	9	O
since	9	O
the	5	O
highest	9	O
level	9	O
achieved	5	O
(	9	O
250	0	O
mg	0	O
/	9	O
m2	7	O
)	9	O
required	9	O
modification	9	O
because	5	O
of	5	O
nonhematologic	5	O
toxicities	5	B-Disease
(	9	O
arthralgia	5	B-Disease
and	5	O
sensory	5	B-Disease
neuropathy	5	I-Disease
)	9	O
.	9	O

Therapeutic	5	O
effects	9	O
were	9	O
noted	9	O
at	9	O
all	5	O
dose	9	O
levels	3	O
,	9	O
with	5	O
objective	5	O
responses	5	O
in	5	O
17	7	O
(	9	O
two	5	O
complete	9	O
and	5	O
15	9	O
partial	9	O
regressions	5	O
)	9	O
of	5	O
41	7	O
previously	9	O
untreated	3	O
patients	5	O
.	9	O

Toxicities	5	B-Disease
were	9	O
compared	9	O
with	5	O
a	5	O
cohort	9	O
of	5	O
patients	5	O
in	5	O
a	5	O
phase	5	O
I	9	O
trial	5	O
of	5	O
paclitaxel	0	B-Chemical
alone	9	O
at	9	O
identical	9	O
dose	9	O
levels	3	O
.	9	O

Carboplatin	0	B-Chemical
did	9	O
not	5	O
appear	9	O
to	5	O
add	5	O
to	5	O
the	5	O
hematologic	5	B-Disease
toxicities	5	I-Disease
observed	9	O
,	9	O
and	5	O
the	5	O
paclitaxel	0	B-Chemical
/	9	O
carboplatin	0	B-Chemical
combination	9	O
could	9	O
be	5	O
dosed	0	O
every	5	O
3	9	O
weeks	9	O
.	9	O

The	5	O
dose	9	O
-	7	O
dependent	9	O
effect	9	O
of	5	O
misoprostol	5	B-Chemical
on	5	O
indomethacin	0	B-Chemical
-	7	O
induced	3	O
renal	9	B-Disease
dysfunction	9	I-Disease
in	5	O
well	9	O
compensated	5	O
cirrhosis	5	B-Disease
.	9	O

Misoprostol	5	B-Chemical
(	9	O
200	0	O
micrograms	0	O
)	9	O
has	9	O
been	9	O
shown	9	O
to	5	O
acutely	9	O
counteract	9	O
the	5	O
indomethacin	0	B-Chemical
-	7	O
induced	3	O
renal	9	B-Disease
dysfunction	9	I-Disease
in	5	O
well	9	O
compensated	5	O
cirrhotic	5	B-Disease
patients	5	O
.	9	O

The	5	O
aim	5	O
of	5	O
this	5	O
study	9	O
was	9	O
to	5	O
determine	9	O
if	5	O
the	5	O
prophylactic	5	O
value	9	O
of	5	O
misoprostol	5	B-Chemical
was	9	O
dose	9	O
-	7	O
dependent	9	O
.	9	O

Parameters	9	O
of	5	O
renal	9	O
hemodynamics	5	O
and	5	O
tubular	9	O
sodium	0	B-Chemical
and	5	O
water	0	O
handling	5	O
were	9	O
assessed	9	O
by	9	O
clearance	9	O
techniques	5	O
in	5	O
26	7	O
well	9	O
compensated	5	O
cirrhotic	5	B-Disease
patients	5	O
before	9	O
and	5	O
after	9	O
an	5	O
oral	9	O
combination	9	O
of	5	O
50	0	O
mg	0	O
of	5	O
indomethacin	0	B-Chemical
and	5	O
various	9	O
doses	0	O
of	5	O
misoprostol	5	B-Chemical
.	9	O

The	5	O
200	0	O
-	7	O
micrograms	0	O
dose	9	O
was	9	O
able	9	O
to	5	O
totally	9	O
abolish	9	O
the	5	O
deleterious	9	O
renal	9	O
effects	9	O
of	5	O
indomethacin	0	B-Chemical
,	9	O
whereas	9	O
the	5	O
800	0	O
-	7	O
micrograms	0	O
dose	9	O
resulted	9	O
in	5	O
significant	9	O
worsening	5	O
of	5	O
renal	9	O
hemodynamics	5	O
and	5	O
sodium	0	B-Chemical
retention	9	O
.	9	O

These	5	O
changes	9	O
were	9	O
maximal	9	O
in	5	O
the	5	O
hour	0	O
immediately	9	O
after	9	O
medications	5	O
and	5	O
slowly	5	O
returned	5	O
toward	5	O
base	5	O
-	7	O
line	9	O
levels	3	O
thereafter	9	O
.	9	O

These	5	O
results	9	O
suggest	9	O
that	5	O
the	5	O
renal	9	O
protective	9	O
effects	9	O
of	5	O
misoprostol	5	B-Chemical
is	5	O
dose	9	O
-	7	O
dependent	9	O
.	9	O

However	9	O
,	9	O
until	5	O
this	5	O
apparent	9	O
ability	9	O
of	5	O
200	0	O
micrograms	0	O
of	5	O
misoprostol	5	B-Chemical
to	5	O
prevent	5	O
the	5	O
adverse	5	O
effects	9	O
of	5	O
indomethacin	0	B-Chemical
on	5	O
renal	9	O
function	9	O
is	5	O
confirmed	9	O
with	5	O
chronic	5	O
frequent	5	O
dosing	9	O
,	9	O
it	5	O
would	5	O
be	5	O
prudent	5	O
to	5	O
avoid	5	O
nonsteroidal	5	O
anti	3	O
-	7	O
inflammatory	3	O
therapy	5	O
in	5	O
patients	5	O
with	5	O
cirrhosis	5	B-Disease
.	9	O

Increased	9	O
frequency	5	O
and	5	O
severity	5	O
of	5	O
angio	5	B-Disease
-	7	I-Disease
oedema	5	I-Disease
related	9	O
to	5	O
long	5	O
-	7	O
term	5	O
therapy	5	O
with	5	O
angiotensin	9	B-Chemical
-	7	I-Chemical
converting	9	I-Chemical
enzyme	0	I-Chemical
inhibitor	3	I-Chemical
in	5	O
two	5	O
patients	5	O
.	9	O

Adverse	5	O
reactions	9	O
to	5	O
drugs	5	O
are	5	O
well	9	O
recognized	9	O
as	5	O
a	5	O
cause	5	O
of	5	O
acute	9	O
or	5	O
chronic	5	O
urticaria	5	B-Disease
,	9	O
and	5	O
angio	5	B-Disease
-	7	I-Disease
oedema	5	I-Disease
.	9	O

Angiotensin	0	B-Chemical
-	7	I-Chemical
converting	9	I-Chemical
enzyme	0	I-Chemical
(	9	I-Chemical
ACE	9	I-Chemical
)	9	I-Chemical
inhibitors	3	I-Chemical
,	9	O
used	5	O
to	5	O
treat	5	O
hypertension	5	B-Disease
and	5	O
congestive	5	B-Disease
heart	5	I-Disease
failure	5	I-Disease
,	9	O
were	9	O
introduced	9	O
in	5	O
Europe	4	O
in	5	O
the	5	O
middle	9	O
of	5	O
the	5	O
eighties	5	O
,	9	O
and	5	O
the	5	O
use	5	O
of	5	O
these	5	O
drugs	5	O
has	9	O
increased	9	O
progressively	9	O
.	9	O

Soon	6	O
after	9	O
the	5	O
introduction	9	O
of	5	O
ACE	9	B-Chemical
inhibitors	3	I-Chemical
,	9	O
acute	9	O
bouts	5	O
of	5	O
angio	5	B-Disease
-	7	I-Disease
oedema	5	I-Disease
were	9	O
reported	9	O
in	5	O
association	9	O
with	5	O
the	5	O
use	5	O
of	5	O
these	5	O
drugs	5	O
.	9	O

We	9	O
wish	6	O
to	5	O
draw	5	O
attention	5	O
to	5	O
the	5	O
possibility	9	O
of	5	O
adverse	5	O
reactions	9	O
to	5	O
ACE	9	B-Chemical
inhibitors	3	I-Chemical
after	9	O
long	5	O
-	7	O
term	5	O
use	5	O
and	5	O
in	5	O
patients	5	O
with	5	O
pre	9	O
-	7	O
existing	5	O
angio	5	B-Disease
-	7	I-Disease
oedema	5	I-Disease
.	9	O

Myoclonus	7	B-Disease
associated	9	O
with	5	O
lorazepam	5	B-Chemical
therapy	5	O
in	5	O
very	5	O
-	7	O
low	9	O
-	7	O
birth	5	O
-	7	O
weight	9	O
infants	5	O
.	9	O

Lorazepam	7	B-Chemical
is	5	O
being	5	O
used	5	O
with	5	O
increasing	9	O
frequency	5	O
as	5	O
a	5	O
sedative	5	O
in	5	O
the	5	O
newborn	9	O
and	5	O
the	5	O
young	5	O
infant	5	O
.	9	O

Concern	5	O
has	9	O
been	9	O
raised	9	O
with	5	O
regard	5	O
to	5	O
the	5	O
safety	5	O
of	5	O
lorazepam	5	B-Chemical
in	5	O
this	5	O
age	5	O
group	9	O
,	9	O
especially	5	O
in	5	O
very	5	O
-	7	O
low	9	O
-	7	O
birth	5	O
-	7	O
weight	9	O
(	9	O
VLBW	5	O
;	9	O
<	0	O
1	9	O
,	9	O
500	0	O
g	0	O
)	9	O
infants	5	O
.	9	O

Three	9	O
young	5	O
infants	5	O
,	9	O
all	5	O
of	5	O
birth	5	O
weight	9	O
<	0	O
1	9	O
,	9	O
500	0	O
g	0	O
,	9	O
experienced	5	O
myoclonus	5	B-Disease
following	9	O
the	5	O
intravenous	0	O
administration	9	O
of	5	O
lorazepam	5	B-Chemical
.	9	O

The	5	O
potential	9	O
neurotoxic	9	B-Disease
effects	9	O
of	5	O
the	5	O
drug	5	O
(	9	O
and	5	O
its	9	O
vehicle	3	O
)	9	O
in	5	O
this	5	O
population	5	O
are	5	O
discussed	5	O
.	9	O

Injectable	0	O
lorazepam	5	B-Chemical
should	5	O
be	5	O
used	5	O
with	5	O
caution	5	O
in	5	O
VLBW	5	O
infants	5	O
.	9	O

Transvenous	5	O
right	5	O
ventricular	5	O
pacing	5	O
during	5	O
cardiopulmonary	5	O
resuscitation	5	O
of	5	O
pediatric	5	O
patients	5	O
with	5	O
acute	9	O
cardiomyopathy	5	B-Disease
.	9	O

We	9	O
describe	5	O
the	5	O
cardiopulmonary	5	O
resuscitation	5	O
efforts	5	O
on	5	O
five	9	O
patients	5	O
who	5	O
presented	5	O
in	5	O
acute	9	O
circulatory	5	B-Disease
failure	5	I-Disease
from	9	O
myocardial	9	B-Disease
dysfunction	9	I-Disease
.	9	O

Three	9	O
patients	5	O
had	9	O
acute	9	O
viral	9	O
myocarditis	9	B-Disease
,	9	O
one	5	O
had	9	O
a	5	O
carbamazepine	0	B-Chemical
-	7	O
induced	3	O
acute	9	O
eosinophilic	5	B-Disease
myocarditis	9	I-Disease
,	9	O
and	5	O
one	5	O
had	9	O
cardiac	5	O
hemosiderosis	5	O
resulting	9	O
in	5	O
acute	9	O
cardiogenic	5	B-Disease
shock	9	I-Disease
.	9	O

All	9	O
patients	5	O
were	9	O
continuously	5	O
monitored	9	O
with	5	O
central	5	O
venous	5	O
and	5	O
arterial	5	O
catheters	5	O
in	5	O
addition	9	O
to	5	O
routine	5	O
noninvasive	5	O
monitoring	5	O
.	9	O

An	5	O
introducer	5	O
sheath	9	O
,	9	O
a	5	O
pacemaker	5	O
,	9	O
and	5	O
sterile	0	O
pacing	5	O
wires	5	O
were	9	O
made	5	O
readily	9	O
available	5	O
for	5	O
the	5	O
patients	5	O
,	9	O
should	5	O
the	5	O
need	5	O
arise	5	O
to	5	O
terminate	9	O
resistant	9	O
cardiac	5	O
dysrhythmias	5	B-Disease
.	9	O

All	9	O
patients	5	O
developed	5	O
cardiocirculatory	5	O
arrest	3	O
associated	9	O
with	5	O
extreme	5	O
hypotension	5	B-Disease
and	5	O
dysrhythmias	5	B-Disease
within	9	O
the	5	O
first	9	O
48	9	O
hours	9	O
of	5	O
their	5	O
admission	5	O
to	5	O
the	5	O
pediatric	5	O
intensive	5	O
care	5	O
unit	5	O
(	9	O
PICU	5	O
)	9	O
.	9	O

Right	9	O
ventricular	5	O
pacemaker	5	O
wires	5	O
were	9	O
inserted	9	O
in	5	O
all	5	O
of	5	O
them	5	O
during	5	O
cardiopulmonary	5	O
resuscitation	5	O
(	9	O
CPR	5	O
)	9	O
.	9	O

In	9	O
four	9	O
patients	5	O
,	9	O
cardiac	5	O
pacing	5	O
was	9	O
used	5	O
,	9	O
resulting	9	O
in	5	O
a	5	O
temporary	5	O
captured	5	O
rhythm	5	O
and	5	O
restoration	5	O
of	5	O
their	5	O
cardiac	5	O
output	5	O
.	9	O

These	5	O
patients	5	O
had	9	O
a	5	O
second	9	O
event	5	O
of	5	O
cardiac	5	B-Disease
arrest	3	I-Disease
,	9	O
resulting	9	O
in	5	O
death	9	O
,	9	O
within	9	O
10	9	O
to	5	O
60	9	O
minutes	0	O
.	9	O

In	9	O
one	5	O
patient	5	O
,	9	O
cardiac	5	O
pacing	5	O
was	9	O
not	5	O
used	5	O
,	9	O
because	5	O
he	5	O
converted	9	O
to	5	O
normal	9	O
sinus	5	O
rhythm	5	O
by	9	O
electrical	5	O
defibrillation	5	O
within	9	O
three	9	O
minutes	0	O
of	5	O
initiating	9	O
CPR	5	O
.	9	O

We	9	O
conclude	9	O
that	5	O
cardiac	5	O
pacing	5	O
during	5	O
resuscitative	5	O
efforts	5	O
in	5	O
pediatric	5	O
patients	5	O
suffering	5	O
from	9	O
acute	9	O
myocardial	9	B-Disease
dysfunction	9	I-Disease
may	5	O
not	5	O
have	5	O
long	5	O
-	7	O
term	5	O
value	9	O
in	5	O
and	5	O
of	5	O
itself	9	O
;	9	O
however	9	O
,	9	O
if	5	O
temporary	5	O
hemodynamic	5	O
stability	9	O
is	5	O
achieved	5	O
by	9	O
this	5	O
procedure	5	O
,	9	O
it	5	O
may	5	O
provide	5	O
additional	9	O
time	5	O
needed	5	O
to	5	O
institute	5	O
other	5	O
therapeutic	5	O
modalities	5	O
.	9	O

Efficacy	5	O
and	5	O
safety	5	O
of	5	O
granisetron	0	B-Chemical
,	9	O
a	5	O
selective	9	O
5	9	B-Chemical
-	7	I-Chemical
hydroxytryptamine	0	I-Chemical
-	7	O
3	9	O
receptor	3	O
antagonist	3	O
,	9	O
in	5	O
the	5	O
prevention	5	O
of	5	O
nausea	5	B-Disease
and	5	O
vomiting	5	B-Disease
induced	3	O
by	9	O
high	9	O
-	7	O
dose	9	O
cisplatin	3	B-Chemical
.	9	O

PURPOSE	2	O
:	9	O
To	9	O
assess	5	O
the	5	O
antiemetic	5	O
effects	9	O
and	5	O
safety	5	O
profile	9	O
of	5	O
four	9	O
different	9	O
doses	0	O
of	5	O
granisetron	0	B-Chemical
(	9	O
Kytril	0	B-Chemical
;	9	O
SmithKline	2	O
Beecham	6	O
Pharmaceuticals	2	O
,	9	O
Philadelphia	2	O
,	9	O
PA	9	O
)	9	O
when	5	O
administered	9	O
as	5	O
a	5	O
single	9	O
intravenous	0	O
(	9	O
IV	9	O
)	9	O
dose	9	O
for	5	O
prophylaxis	5	O
of	5	O
cisplatin	3	B-Chemical
-	7	O
induced	3	O
nausea	5	B-Disease
and	5	O
vomiting	5	B-Disease
.	9	O

PATIENTS	2	O
AND	2	O
METHODS	2	O
:	9	O
One	5	O
hundred	5	O
eighty	5	O
-	7	O
four	9	O
chemotherapy	5	O
-	7	O
naive	3	O
patients	5	O
receiving	9	O
high	9	O
-	7	O
dose	9	O
cisplatin	3	B-Chemical
(	9	O
81	7	O
to	5	O
120	9	O
mg	0	O
/	9	O
m2	7	O
)	9	O
were	9	O
randomized	5	O
to	5	O
receive	5	O
one	5	O
of	5	O
four	9	O
granisetron	0	B-Chemical
doses	0	O
(	9	O
5	9	O
,	9	O
10	9	O
,	9	O
20	9	O
,	9	O
or	5	O
40	9	O
micrograms	0	O
/	9	O
kg	0	O
)	9	O
administered	9	O
before	9	O
chemotherapy	5	O
.	9	O

Patients	5	O
were	9	O
observed	9	O
on	5	O
an	5	O
inpatient	5	O
basis	5	O
for	5	O
18	7	O
to	5	O
24	9	O
hours	9	O
,	9	O
and	5	O
vital	5	O
signs	5	O
,	9	O
nausea	5	B-Disease
,	9	O
vomiting	5	B-Disease
,	9	O
retching	5	O
,	9	O
and	5	O
appetite	5	O
were	9	O
assessed	9	O
.	9	O

Safety	5	O
analyses	9	O
included	5	O
incidence	5	O
of	5	O
adverse	5	O
experiences	5	O
and	5	O
laboratory	9	O
parameter	5	O
changes	9	O
.	9	O

RESULTS	9	O
:	9	O
After	9	O
granisetron	0	B-Chemical
doses	0	O
of	5	O
5	9	O
,	9	O
10	9	O
,	9	O
20	9	O
,	9	O
and	5	O
40	9	O
micrograms	0	O
/	9	O
kg	0	O
,	9	O
a	5	O
major	9	O
response	9	O
(	9	O
<	0	O
or	5	O
=	7	O
two	5	O
vomiting	5	B-Disease
or	5	O
retching	5	O
episodes	5	O
,	9	O
and	5	O
no	9	O
antiemetic	5	O
rescue	3	O
)	9	O
was	9	O
recorded	5	O
in	5	O
23	7	O
%	9	O
,	9	O
57	7	O
%	9	O
,	9	O
58	7	O
%	9	O
,	9	O
and	5	O
60	9	O
%	9	O
of	5	O
patients	5	O
,	9	O
respectively	9	O
,	9	O
and	5	O
a	5	O
complete	9	O
response	9	O
(	9	O
no	9	O
vomiting	5	B-Disease
or	5	O
retching	5	O
,	9	O
and	5	O
no	9	O
antiemetic	5	O
rescue	3	O
)	9	O
in	5	O
18	7	O
%	9	O
,	9	O
41	7	O
%	9	O
,	9	O
40	9	O
%	9	O
,	9	O
and	5	O
47	7	O
%	9	O
of	5	O
patients	5	O
,	9	O
respectively	9	O
.	9	O

There	5	O
was	9	O
a	5	O
statistically	9	O
longer	5	O
time	5	O
to	5	O
first	9	O
episode	5	O
of	5	O
nausea	5	B-Disease
(	9	O
P	9	O
=	7	O
.	9	O
0015	7	O
)	9	O
and	5	O
vomiting	5	B-Disease
(	9	O
P	9	O
=	7	O
.	9	O
0001	7	O
)	9	O
,	9	O
and	5	O
fewer	5	O
patients	5	O
were	9	O
administered	9	O
additional	9	O
antiemetic	5	O
medication	5	O
in	5	O
the	5	O
10	9	O
-	7	O
micrograms	0	O
/	9	O
kg	0	O
dosing	9	O
groups	9	O
than	5	O
in	5	O
the	5	O
5	9	O
-	7	O
micrograms	0	O
/	9	O
kg	0	O
dosing	9	O
group	9	O
.	9	O

As	9	O
granisetron	0	B-Chemical
dose	9	O
increased	9	O
,	9	O
appetite	5	O
return	5	O
increased	9	O
(	9	O
P	9	O
=	7	O
.	9	O
040	2	O
)	9	O
.	9	O

Headache	7	B-Disease
was	9	O
the	5	O
most	9	O
frequently	5	O
reported	9	O
adverse	5	O
event	5	O
(	9	O
20	9	O
%	9	O
)	9	O
.	9	O

CONCLUSION	5	O
:	9	O
A	9	O
single	9	O
10	9	O
-	7	O
,	9	O
20	9	O
-	7	O
,	9	O
or	5	O
40	9	O
-	7	O
micrograms	0	O
/	9	O
kg	0	O
dose	9	O
of	5	O
granisetron	0	B-Chemical
was	9	O
effective	5	O
in	5	O
controlling	9	O
vomiting	5	B-Disease
in	5	O
57	7	O
%	9	O
to	5	O
60	9	O
%	9	O
of	5	O
patients	5	O
who	5	O
received	9	O
cisplatin	3	B-Chemical
at	9	O
doses	0	O
greater	5	O
than	5	O
81	7	O
mg	0	O
/	9	O
m2	7	O
and	5	O
totally	9	O
prevented	9	O
vomiting	5	B-Disease
in	5	O
40	9	O
%	9	O
to	5	O
47	7	O
%	9	O
of	5	O
patients	5	O
.	9	O

There	5	O
were	9	O
no	9	O
statistically	9	O
significant	9	O
differences	9	O
in	5	O
efficacy	9	O
between	5	O
the	5	O
10	9	O
-	7	O
micrograms	0	O
/	9	O
kg	0	O
dose	9	O
and	5	O
the	5	O
20	9	O
-	7	O
and	5	O
40	9	O
-	7	O
micrograms	0	O
/	9	O
kg	0	O
doses	0	O
.	9	O

Granisetron	0	B-Chemical
was	9	O
well	9	O
tolerated	9	O
at	9	O
all	5	O
doses	0	O
.	9	O

Adverse	5	O
interaction	9	O
between	5	O
clonidine	0	B-Chemical
and	5	O
verapamil	0	B-Chemical
.	9	O

OBJECTIVE	2	O
:	9	O
To	9	O
report	5	O
two	5	O
cases	5	O
of	5	O
a	5	O
possible	5	O
adverse	5	O
interaction	9	O
between	5	O
clonidine	0	B-Chemical
and	5	O
verapamil	0	B-Chemical
resulting	9	O
in	5	O
atrioventricular	5	B-Disease
(	9	I-Disease
AV	9	I-Disease
)	9	I-Disease
block	9	I-Disease
in	5	O
both	9	O
patients	5	O
and	5	O
severe	5	O
hypotension	5	B-Disease
in	5	O
one	5	O
patient	5	O
.	9	O

CASE	2	O
SUMMARIES	2	O
:	9	O
A	9	O
54	7	O
-	7	O
year	5	O
-	7	O
old	5	O
woman	5	O
with	5	O
hyperaldosteronism	5	B-Disease
was	9	O
treated	3	O
with	5	O
verapamil	0	B-Chemical
480	9	O
mg	0	O
/	9	O
d	9	O
and	5	O
spironolactone	0	B-Chemical
100	0	O
mg	0	O
/	9	O
d	9	O
.	9	O

After	9	O
the	5	O
addition	9	O
of	5	O
a	5	O
minimal	9	O
dose	9	O
of	5	O
clonidine	0	B-Chemical
(	9	O
0	7	O
.	9	O
15	9	O
mg	0	O
bid	5	O
)	9	O
,	9	O
she	5	O
developed	5	O
complete	9	O
AV	9	B-Disease
block	9	I-Disease
and	5	O
severe	5	O
hypotension	5	B-Disease
,	9	O
which	5	O
resolved	9	O
upon	9	O
cessation	5	O
of	5	O
all	5	O
medications	5	O
.	9	O

A	9	O
65	7	O
-	7	O
year	5	O
-	7	O
old	5	O
woman	5	O
was	9	O
treated	3	O
with	5	O
extended	5	O
-	7	O
release	9	O
verapamil	0	B-Chemical
240	9	O
mg	0	O
/	9	O
d	9	O
.	9	O

After	9	O
the	5	O
addition	9	O
of	5	O
clonidine	0	B-Chemical
0	7	O
.	9	O
15	9	O
mg	0	O
bid	5	O
she	5	O
developed	5	O
complete	9	O
AV	9	B-Disease
block	9	I-Disease
,	9	O
which	5	O
resolved	9	O
after	9	O
all	5	O
therapy	5	O
was	9	O
stopped	9	O
.	9	O

DISCUSSION	9	O
:	9	O
An	5	O
adverse	5	O
interaction	9	O
between	5	O
clonidine	0	B-Chemical
and	5	O
verapamil	0	B-Chemical
has	9	O
not	5	O
been	9	O
reported	9	O
previously	9	O
.	9	O

We	9	O
describe	5	O
two	5	O
such	5	O
cases	5	O
and	5	O
discuss	5	O
the	5	O
various	9	O
mechanisms	9	O
that	5	O
might	9	O
cause	5	O
such	5	O
an	5	O
interaction	9	O
.	9	O

Clinicians	5	O
should	5	O
be	5	O
acquainted	5	O
with	5	O
this	5	O
possibly	9	O
fatal	5	O
interaction	9	O
between	5	O
two	5	O
commonly	5	O
used	5	O
antihypertensive	5	O
drugs	5	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Caution	5	O
is	5	O
recommended	5	O
in	5	O
combining	5	O
clonidine	0	B-Chemical
and	5	O
verapamil	0	B-Chemical
therapy	5	O
,	9	O
even	5	O
in	5	O
patients	5	O
who	5	O
do	5	O
not	5	O
have	5	O
sinus	5	O
or	5	O
AV	9	O
node	5	O
dysfunction	9	O
.	9	O

The	5	O
two	5	O
drugs	5	O
may	5	O
act	9	O
synergistically	9	O
on	5	O
both	9	O
the	5	O
AV	9	O
node	5	O
and	5	O
the	5	O
peripheral	9	O
circulation	9	O
.	9	O

Pharmacological	9	O
studies	9	O
on	5	O
a	5	O
new	5	O
dihydrothienopyridine	_	B-Chemical
calcium	0	I-Chemical
antagonist	3	O
,	9	O
S	9	B-Chemical
-	7	I-Chemical
312	7	I-Chemical
-	7	I-Chemical
d	9	I-Chemical
.	9	O

5th	9	O
communication	5	O
:	9	O
anticonvulsant	5	O
effects	9	O
in	5	O
mice	3	O
.	9	O

S	9	B-Chemical
-	7	I-Chemical
312	7	I-Chemical
,	9	O
S	9	B-Chemical
-	7	I-Chemical
312	7	I-Chemical
-	7	I-Chemical
d	9	I-Chemical
,	9	O
but	9	O
not	5	O
S	9	B-Chemical
-	7	I-Chemical
312	7	I-Chemical
-	7	I-Chemical
l	0	I-Chemical
,	9	O
L	0	O
-	7	O
type	9	O
calcium	0	B-Chemical
channel	9	O
antagonists	3	O
,	9	O
showed	9	O
anticonvulsant	5	O
effects	9	O
on	5	O
the	5	O
audiogenic	3	B-Disease
tonic	5	I-Disease
convulsions	5	I-Disease
in	5	O
DBA	3	O
/	9	O
2	9	O
mice	3	O
;	9	O
and	5	O
their	5	O
ED50	0	O
values	5	O
were	9	O
18	7	O
.	9	O
4	9	O
(	9	O
12	9	O
.	9	O
8	9	O
-	7	O
27	7	O
.	9	O
1	9	O
)	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
p	7	O
.	9	O
o	9	O
.	9	O
and	5	O
15	9	O
.	9	O
0	7	O
(	9	O
10	9	O
.	9	O
2	9	O
-	7	O
23	7	O
.	9	O
7	9	O
)	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
p	7	O
.	9	O
o	9	O
.	9	O
,	9	O
respectively	9	O
,	9	O
while	9	O
that	5	O
of	5	O
flunarizine	0	B-Chemical
was	9	O
34	7	O
.	9	O
0	7	O
(	9	O
26	7	O
.	9	O
0	7	O
-	7	O
44	7	O
.	9	O
8	9	O
)	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
p	7	O
.	9	O
o	9	O
.	9	O

Although	9	O
moderate	9	O
anticonvulsant	5	O
effects	9	O
of	5	O
S	9	B-Chemical
-	7	I-Chemical
312	7	I-Chemical
-	7	I-Chemical
d	9	I-Chemical
in	5	O
higher	9	O
doses	0	O
were	9	O
observed	9	O
against	9	O
the	5	O
clonic	5	O
convulsions	5	B-Disease
induced	3	O
by	9	O
pentylenetetrazole	0	B-Chemical
(	9	O
85	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
s	9	O
.	9	O
c	9	O
.	9	O
)	9	O
or	5	O
bemegride	9	B-Chemical
(	9	O
40	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
s	9	O
.	9	O
c	9	O
.	9	O
)	9	O
,	9	O
no	9	O
effects	9	O
were	9	O
observed	9	O
in	5	O
convulsions	5	B-Disease
induced	3	O
by	9	O
N	9	B-Chemical
-	7	I-Chemical
methyl	0	I-Chemical
-	7	I-Chemical
D	9	I-Chemical
-	7	I-Chemical
aspartate	1	I-Chemical
,	9	O
picrotoxin	0	B-Chemical
,	9	O
or	5	O
electroshock	5	O
in	5	O
Slc	3	O
:	9	O
ddY	3	O
mice	3	O
.	9	O

S	9	B-Chemical
-	7	I-Chemical
312	7	I-Chemical
-	7	I-Chemical
d	9	I-Chemical
may	5	O
be	5	O
useful	5	O
in	5	O
the	5	O
therapy	5	O
of	5	O
certain	5	O
types	9	O
of	5	O
human	3	O
epilepsy	5	B-Disease
.	9	O

Transmural	5	O
myocardial	9	B-Disease
infarction	5	I-Disease
with	5	O
sumatriptan	0	B-Chemical
.	9	O

For	9	O
sumatriptan	0	B-Chemical
,	9	O
tightness	5	O
in	5	O
the	5	O
chest	5	O
caused	9	O
by	9	O
an	5	O
unknown	9	O
mechanism	9	O
has	9	O
been	9	O
reported	9	O
in	5	O
3	9	O
-	7	O
5	9	O
%	9	O
of	5	O
users	5	O
.	9	O

We	9	O
describe	5	O
a	5	O
47	7	O
-	7	O
year	5	O
-	7	O
old	5	O
woman	5	O
with	5	O
an	5	O
acute	9	O
myocardial	9	B-Disease
infarction	5	I-Disease
after	9	O
administration	9	O
of	5	O
sumatriptan	0	B-Chemical
6	9	O
mg	0	O
subcutaneously	3	O
for	5	O
cluster	9	B-Disease
headache	5	I-Disease
.	9	O

The	5	O
patient	5	O
had	9	O
no	9	O
history	5	O
of	5	O
underlying	5	O
ischaemic	5	B-Disease
heart	5	I-Disease
disease	5	I-Disease
or	5	O
Prinzmetal	6	B-Disease
'	9	I-Disease
s	9	I-Disease
angina	5	I-Disease
.	9	O

She	5	O
recovered	9	O
without	9	O
complications	5	O
.	9	O

Flumazenil	0	B-Chemical
induces	3	O
seizures	5	B-Disease
and	5	O
death	9	O
in	5	O
mixed	9	O
cocaine	5	B-Chemical
-	7	O
diazepam	0	B-Chemical
intoxications	5	O
.	9	O

STUDY	2	O
HYPOTHESIS	2	O
:	9	O
Administration	2	O
of	5	O
the	5	O
benzodiazepine	5	B-Chemical
antagonist	3	O
flumazenil	0	B-Chemical
may	5	O
unmask	9	O
seizures	5	B-Disease
in	5	O
mixed	9	O
cocaine	5	B-Chemical
-	7	O
benzodiazepine	5	B-Chemical
intoxication	9	O
.	9	O

DESIGN	2	O
:	9	O
Male	7	O
Sprague	9	O
-	7	O
Dawley	0	O
rats	9	O
received	9	O
100	0	O
mg	0	O
/	9	O
kg	0	O
cocaine	5	B-Chemical
IP	9	O
alone	9	O
,	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
diazepam	0	B-Chemical
alone	9	O
,	9	O
or	5	O
a	5	O
combination	9	O
of	5	O
diazepam	0	B-Chemical
and	5	O
cocaine	5	B-Chemical
.	9	O

Three	9	O
minutes	0	O
later	9	O
,	9	O
groups	9	O
were	9	O
challenged	3	O
with	5	O
vehicle	3	O
or	5	O
flumazenil	0	B-Chemical
5	9	O
or	5	O
10	9	O
mg	0	O
/	9	O
kg	0	O
IP	9	O
.	9	O

Animal	2	O
behavior	5	O
,	9	O
seizures	5	B-Disease
(	9	O
time	5	O
to	5	O
and	5	O
incidence	5	O
)	9	O
,	9	O
death	9	O
(	9	O
time	5	O
to	5	O
and	5	O
incidence	5	O
)	9	O
,	9	O
and	5	O
cortical	5	O
EEG	5	O
tracings	5	O
were	9	O
recorded	5	O
.	9	O

INTERVENTIONS	2	O
:	9	O
Administration	2	O
of	5	O
flumazenil	0	B-Chemical
to	5	O
animals	9	O
after	9	O
they	5	O
had	9	O
received	9	O
a	5	O
combination	9	O
dose	9	O
of	5	O
cocaine	5	B-Chemical
and	5	O
diazepam	0	B-Chemical
.	9	O

RESULTS	9	O
:	9	O
In	9	O
group	9	O
1	9	O
,	9	O
animals	9	O
received	9	O
cocaine	5	B-Chemical
followed	9	O
by	9	O
vehicle	3	O
.	9	O

This	5	O
resulted	9	O
in	5	O
100	0	O
%	9	O
developing	5	O
seizures	5	B-Disease
and	5	O
death	9	O
.	9	O

Group	9	O
2	9	O
received	9	O
diazepam	0	B-Chemical
alone	9	O
followed	9	O
by	9	O
vehicle	3	O
.	9	O

Animals	9	O
became	9	O
somnolent	5	O
and	5	O
none	9	O
died	9	O
.	9	O

Group	9	O
3	9	O
received	9	O
diazepam	0	B-Chemical
followed	9	O
by	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
flumazenil	0	B-Chemical
.	9	O

Animals	9	O
became	9	O
somnolent	5	O
after	9	O
diazepam	0	B-Chemical
and	5	O
then	9	O
active	9	O
after	9	O
flumazenil	0	B-Chemical
administration	9	O
.	9	O

In	9	O
group	9	O
4	9	O
,	9	O
a	5	O
combination	9	O
of	5	O
cocaine	5	B-Chemical
and	5	O
diazepam	0	B-Chemical
was	9	O
administered	9	O
simultaneously	5	O
.	9	O

This	5	O
resulted	9	O
in	5	O
no	9	O
overt	5	O
or	5	O
EEG	5	O
-	7	O
detectable	9	O
seizures	5	B-Disease
and	5	O
a	5	O
50	0	O
%	9	O
incidence	5	O
of	5	O
death	9	O
.	9	O

Group	9	O
5	9	O
received	9	O
a	5	O
similar	9	O
combination	9	O
of	5	O
cocaine	5	B-Chemical
and	5	O
diazepam	0	B-Chemical
,	9	O
followed	9	O
later	9	O
by	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
flumazenil	0	B-Chemical
.	9	O

This	5	O
resulted	9	O
in	5	O
an	5	O
increased	9	O
incidence	5	O
of	5	O
seizures	5	B-Disease
,	9	O
90	9	O
%	9	O
(	9	O
P	9	O
<	0	O
.	9	O
01	7	O
)	9	O
,	9	O
and	5	O
death	9	O
,	9	O
100	0	O
%	9	O
(	9	O
P	9	O
<	0	O
or	5	O
=	7	O
.	9	O
01	7	O
)	9	O
,	9	O
compared	9	O
with	5	O
group	9	O
4	9	O
.	9	O

Group	9	O
6	9	O
received	9	O
cocaine	5	B-Chemical
and	5	O
diazepam	0	B-Chemical
followed	9	O
by	9	O
10	9	O
mg	0	O
/	9	O
kg	0	O
flumazenil	0	B-Chemical
.	9	O

This	5	O
also	9	O
resulted	9	O
in	5	O
an	5	O
increased	9	O
incidence	5	O
of	5	O
seizures	5	B-Disease
,	9	O
90	9	O
%	9	O
(	9	O
P	9	O
<	0	O
or	5	O
=	7	O
.	9	O
01	7	O
)	9	O
,	9	O
and	5	O
death	9	O
,	9	O
90	9	O
%	9	O
(	9	O
P	9	O
<	0	O
or	5	O
=	7	O
.	9	O
05	7	O
)	9	O
,	9	O
compared	9	O
with	5	O
group	9	O
4	9	O
.	9	O

CONCLUSION	5	O
:	9	O
Flumazenil	0	B-Chemical
can	5	O
unmask	9	O
seizures	5	B-Disease
and	5	O
increase	9	O
the	5	O
incidence	5	O
of	5	O
death	9	O
in	5	O
a	5	O
model	5	O
of	5	O
combined	9	O
cocaine	5	B-Chemical
-	7	O
diazepam	0	B-Chemical
intoxications	5	O
.	9	O

Mechanisms	9	O
for	5	O
protective	9	O
effects	9	O
of	5	O
free	9	O
radical	0	O
scavengers	0	O
on	5	O
gentamicin	0	B-Chemical
-	7	O
mediated	3	O
nephropathy	9	B-Disease
in	5	O
rats	9	O
.	9	O

Studies	9	O
were	9	O
performed	9	O
to	5	O
examine	9	O
the	5	O
mechanisms	9	O
for	5	O
the	5	O
protective	9	O
effects	9	O
of	5	O
free	9	O
radical	0	O
scavengers	0	O
on	5	O
gentamicin	0	B-Chemical
(	9	O
GM	9	B-Chemical
)	9	O
-	7	O
mediated	3	O
nephropathy	9	B-Disease
.	9	O

Administration	2	O
of	5	O
GM	9	B-Chemical
at	9	O
40	9	O
mg	0	O
/	9	O
kg	0	O
sc	9	O
for	5	O
13	7	O
days	9	O
to	5	O
rats	9	O
induced	3	O
a	5	O
significant	9	O
reduction	9	O
in	5	O
renal	9	O
blood	9	O
flow	5	O
(	9	O
RBF	5	O
)	9	O
and	5	O
inulin	0	O
clearance	9	O
(	9	O
CIn	7	O
)	9	O
as	5	O
well	9	O
as	5	O
marked	9	O
tubular	9	B-Disease
damage	9	I-Disease
.	9	O

A	9	O
significant	9	O
reduction	9	O
in	5	O
urinary	9	O
guanosine	0	B-Chemical
3	9	I-Chemical
'	9	I-Chemical
,	9	I-Chemical
5	9	I-Chemical
'	9	I-Chemical
-	7	I-Chemical
cyclic	0	I-Chemical
monophosphate	0	I-Chemical
(	9	O
cGMP	0	B-Chemical
)	9	O
excretion	0	O
and	5	O
a	5	O
significant	9	O
increase	9	O
in	5	O
renal	9	O
cortical	5	O
renin	9	O
and	5	O
endothelin	3	O
-	7	O
1	9	O
contents	9	O
were	9	O
also	9	O
observed	9	O
in	5	O
GM	9	B-Chemical
-	7	O
mediated	3	O
nephropathy	9	B-Disease
.	9	O

Superoxide	0	B-Chemical
dismutase	0	O
(	9	O
SOD	0	O
)	9	O
or	5	O
dimethylthiourea	0	B-Chemical
(	9	O
DMTU	0	B-Chemical
)	9	O
significantly	9	O
lessened	5	O
the	5	O
GM	9	B-Chemical
-	7	O
induced	3	O
decrement	5	O
in	5	O
CIn	7	O
.	9	O

The	5	O
SOD	0	O
-	7	O
induced	3	O
increase	9	O
in	5	O
glomerular	5	O
filtration	0	O
rate	9	O
was	9	O
associated	9	O
with	5	O
a	5	O
marked	9	O
improvement	5	O
in	5	O
RBF	5	O
,	9	O
an	5	O
increase	9	O
in	5	O
urinary	9	O
cGMP	0	B-Chemical
excretion	0	O
,	9	O
and	5	O
a	5	O
decrease	9	O
in	5	O
renal	9	O
renin	9	O
and	5	O
endothelin	3	O
-	7	O
1	9	O
content	9	O
.	9	O

SOD	0	O
did	9	O
not	5	O
attenuate	9	O
the	5	O
tubular	9	B-Disease
damage	9	I-Disease
.	9	O

In	9	O
contrast	9	O
,	9	O
DMTU	0	B-Chemical
significantly	9	O
reduced	9	O
the	5	O
tubular	9	B-Disease
damage	9	I-Disease
and	5	O
lipid	0	O
peroxidation	0	O
,	9	O
but	9	O
it	5	O
did	9	O
not	5	O
affect	9	O
renal	9	O
hemodynamics	5	O
and	5	O
vasoactive	5	O
substances	0	O
.	9	O

Neither	9	O
SOD	0	O
nor	9	O
DMTU	0	B-Chemical
affected	9	O
the	5	O
renal	9	O
cortical	5	O
GM	9	B-Chemical
content	9	O
in	5	O
GM	9	B-Chemical
-	7	O
treated	3	O
rats	9	O
.	9	O

These	5	O
results	9	O
suggest	9	O
that	5	O
1	9	O
)	9	O
both	9	O
SOD	0	O
and	5	O
DMTU	0	B-Chemical
have	5	O
protective	9	O
effects	9	O
on	5	O
GM	9	B-Chemical
-	7	O
mediated	3	O
nephropathy	9	B-Disease
,	9	O
2	9	O
)	9	O
the	5	O
mechanisms	9	O
for	5	O
the	5	O
protective	9	O
effects	9	O
differ	9	O
for	5	O
SOD	0	O
and	5	O
DMTU	0	B-Chemical
,	9	O
and	5	O
3	9	O
)	9	O
superoxide	0	B-Chemical
anions	0	O
play	9	O
a	5	O
critical	9	O
role	9	O
in	5	O
GM	9	B-Chemical
-	7	O
induced	3	O
renal	9	O
vasoconstriction	9	O
.	9	O

Cephalothin	7	B-Chemical
-	7	O
induced	3	O
immune	3	O
hemolytic	0	B-Disease
anemia	9	I-Disease
.	9	O

A	9	O
patient	5	O
with	5	O
renal	9	B-Disease
disease	5	I-Disease
developed	5	O
Coombs	6	O
-	7	O
positive	9	O
hemolytic	0	B-Disease
anemia	9	I-Disease
while	9	O
receiving	9	O
cephalothin	0	B-Chemical
therapy	5	O
.	9	O

An	5	O
anti	3	O
-	7	O
cephalothin	0	B-Chemical
IgG	3	O
antibody	3	O
was	9	O
detected	9	O
in	5	O
the	5	O
patient	5	O
'	9	O
s	9	O
serum	9	O
and	5	O
in	5	O
the	5	O
eluates	0	O
from	9	O
her	5	O
erythrocytes	9	O
.	9	O

In	9	O
addition	9	O
,	9	O
nonimmunologic	5	O
binding	1	O
of	5	O
normal	9	O
and	5	O
patient	5	O
'	9	O
s	9	O
serum	9	O
proteins	1	O
to	5	O
her	5	O
own	5	O
and	5	O
cephalothin	0	B-Chemical
-	7	O
coated	0	O
normal	9	O
red	9	O
cells	3	O
was	9	O
demonstrated	9	O
.	9	O

Skin	9	O
tests	5	O
and	5	O
in	5	O
vitro	3	O
lymphocyte	3	O
stimulation	3	O
revealed	9	O
that	5	O
the	5	O
patient	5	O
was	9	O
sensitized	3	O
to	5	O
cephalothin	0	B-Chemical
and	5	O
also	9	O
to	5	O
ampicillin	0	B-Chemical
.	9	O

Careful	5	O
investigation	9	O
of	5	O
drug	5	O
-	7	O
induced	3	O
hemolytic	0	B-Disease
anemias	5	I-Disease
reveals	9	O
the	5	O
complexity	5	O
of	5	O
the	5	O
immune	3	O
mechanisms	9	O
involved	9	O
.	9	O

Assessment	5	O
of	5	O
cardiomyocyte	3	O
DNA	9	O
synthesis	9	O
during	5	O
hypertrophy	9	B-Disease
in	5	O
adult	9	O
mice	3	O
.	9	O

The	5	O
ability	9	O
of	5	O
cardiomyocytes	3	O
to	5	O
synthesize	9	O
DNA	9	O
in	5	O
response	9	O
to	5	O
experimentally	9	O
induced	3	O
cardiac	5	B-Disease
hypertrophy	9	I-Disease
was	9	O
assessed	9	O
in	5	O
adult	9	O
mice	3	O
.	9	O

Isoproterenol	0	B-Chemical
delivered	5	O
by	9	O
osmotic	0	O
minipump	0	O
implantation	5	O
in	5	O
adult	9	O
C3Heb	3	O
/	9	O
FeJ	3	O
mice	3	O
resulted	9	O
in	5	O
a	5	O
46	7	O
%	9	O
increase	9	O
in	5	O
heart	5	O
weight	9	O
and	5	O
a	5	O
19	7	O
.	9	O
3	9	O
%	9	O
increase	9	O
in	5	O
cardiomyocyte	3	O
area	5	O
.	9	O

No	9	O
DNA	9	O
synthesis	9	O
,	9	O
as	5	O
assessed	9	O
by	9	O
autoradiographic	0	O
analysis	9	O
of	5	O
isolated	9	O
cardiomyocytes	3	O
,	9	O
was	9	O
observed	9	O
in	5	O
control	9	O
or	5	O
hypertrophic	3	B-Disease
hearts	3	I-Disease
.	9	O

A	9	O
survey	5	O
of	5	O
15	9	O
independent	9	O
inbred	9	O
strains	1	O
of	5	O
mice	3	O
revealed	9	O
that	5	O
ventricular	5	O
cardiomyocyte	3	O
nuclear	3	O
number	9	O
ranged	9	O
from	9	O
3	9	O
to	5	O
13	7	O
%	9	O
mononucleate	3	O
,	9	O
suggesting	9	O
that	5	O
cardiomyocyte	3	O
terminal	9	O
differentiation	3	O
is	5	O
influenced	5	O
directly	9	O
or	5	O
indirectly	9	O
by	9	O
genetic	5	O
background	9	O
.	9	O

To	9	O
determine	9	O
whether	9	O
the	5	O
capacity	9	O
for	5	O
reactive	9	O
DNA	9	O
synthesis	9	O
was	9	O
also	9	O
subject	5	O
to	5	O
genetic	5	O
regulation	9	O
,	9	O
cardiac	5	B-Disease
hypertrophy	9	I-Disease
was	9	O
induced	3	O
in	5	O
the	5	O
strains	1	O
of	5	O
mice	3	O
comprising	9	O
the	5	O
extremes	5	O
of	5	O
the	5	O
nuclear	3	O
number	9	O
survey	5	O
.	9	O

These	5	O
data	5	O
indicate	9	O
that	5	O
adult	9	O
mouse	3	O
atrial	5	O
and	5	O
ventricular	5	O
cardiomyocytes	3	O
do	5	O
not	5	O
synthesize	9	O
DNA	9	O
in	5	O
response	9	O
to	5	O
isoproterenol	0	B-Chemical
-	7	O
induced	3	O
cardiac	5	B-Disease
hypertrophy	9	I-Disease
.	9	O

Central	4	O
cardiovascular	5	O
effects	9	O
of	5	O
AVP	9	B-Chemical
and	5	O
ANP	9	O
in	5	O
normotensive	9	O
and	5	O
spontaneously	5	O
hypertensive	5	B-Disease
rats	9	O
.	9	O

The	5	O
purpose	5	O
of	5	O
the	5	O
present	9	O
study	9	O
was	9	O
to	5	O
compare	9	O
influence	5	O
of	5	O
central	5	O
arginine	0	B-Chemical
vasopressin	9	I-Chemical
(	9	O
AVP	9	B-Chemical
)	9	O
and	5	O
of	5	O
atrial	5	O
natriuretic	9	O
peptide	9	O
(	9	O
ANP	9	O
)	9	O
on	5	O
control	9	O
of	5	O
arterial	5	O
blood	9	O
pressure	5	O
(	9	O
MAP	9	O
)	9	O
and	5	O
heart	5	O
rate	9	O
(	9	O
HR	9	O
)	9	O
in	5	O
normotensive	9	O
(	9	O
WKY	9	O
)	9	O
and	5	O
spontaneously	5	O
hypertensive	5	B-Disease
(	9	O
SHR	9	O
)	9	O
rats	9	O
.	9	O

Three	9	O
series	5	O
of	5	O
experiments	9	O
were	9	O
performed	9	O
on	5	O
30	9	O
WKY	9	O
and	5	O
30	9	O
SHR	9	O
,	9	O
chronically	9	O
instrumented	5	O
with	5	O
guide	5	O
tubes	0	O
in	5	O
the	5	O
lateral	5	O
ventricle	5	O
(	9	O
LV	9	O
)	9	O
and	5	O
arterial	5	O
and	5	O
venous	5	O
catheters	5	O
.	9	O

MAP	9	O
and	5	O
HR	9	O
were	9	O
monitored	9	O
before	9	O
and	5	O
after	9	O
i	9	O
.	9	O
v	0	O
.	9	O
injections	9	O
of	5	O
either	9	O
vehicle	3	O
or	5	O
1	9	O
,	9	O
10	9	O
and	5	O
50	0	O
ng	0	O
of	5	O
AVP	9	B-Chemical
and	5	O
25	9	O
,	9	O
125	9	O
and	5	O
500	0	O
ng	0	O
of	5	O
ANP	9	O
.	9	O

Sensitivity	9	O
of	5	O
cardiac	5	O
component	9	O
of	5	O
baroreflex	5	O
(	9	O
CCB	9	O
)	9	O
,	9	O
expressed	3	O
as	5	O
a	5	O
slope	5	O
of	5	O
the	5	O
regression	5	O
line	9	O
was	9	O
determined	9	O
from	9	O
relationships	5	O
between	5	O
systolic	5	O
arterial	5	O
pressure	5	O
(	9	O
SAP	9	O
)	9	O
and	5	O
HR	9	O
period	5	O
(	9	O
HRp	7	O
)	9	O
during	5	O
phenylephrine	0	B-Chemical
(	9	O
Phe	0	B-Chemical
)	9	O
-	7	O
induced	3	O
hypertension	5	B-Disease
and	5	O
sodium	0	B-Chemical
nitroprusside	0	I-Chemical
(	9	O
SN	9	B-Chemical
)	9	O
-	7	O
induced	3	O
hypotension	5	B-Disease
.	9	O

CCB	9	O
was	9	O
measured	9	O
before	9	O
and	5	O
after	9	O
administration	9	O
of	5	O
either	9	O
vehicle	3	O
,	9	O
AVP	9	B-Chemical
,	9	O
ANP	9	O
,	9	O
or	5	O
both	9	O
peptides	9	O
together	9	O
.	9	O

Increases	9	O
of	5	O
MAP	9	O
occurred	9	O
after	9	O
LV	9	O
administration	9	O
of	5	O
1	9	O
,	9	O
10	9	O
and	5	O
50	0	O
ng	0	O
of	5	O
AVP	9	B-Chemical
in	5	O
WKY	9	O
and	5	O
of	5	O
10	9	O
and	5	O
50	0	O
ng	0	O
in	5	O
SHR	9	O
.	9	O

ANP	9	O
did	9	O
not	5	O
cause	5	O
significant	9	O
changes	9	O
in	5	O
MAP	9	O
in	5	O
both	9	O
strains	1	O
as	5	O
compared	9	O
to	5	O
vehicle	3	O
,	9	O
but	9	O
it	5	O
abolished	3	O
AVP	9	B-Chemical
-	7	O
induced	3	O
MAP	9	O
increase	9	O
in	5	O
WKY	9	O
and	5	O
SHR	9	O
.	9	O

CCB	9	O
was	9	O
reduced	9	O
in	5	O
WKY	9	O
and	5	O
SHR	9	O
after	9	O
LV	9	O
administration	9	O
of	5	O
AVP	9	B-Chemical
during	5	O
SN	9	B-Chemical
-	7	O
induced	3	O
hypotension	5	B-Disease
.	9	O

In	9	O
SHR	9	O
but	9	O
not	5	O
in	5	O
WKY	9	O
administration	9	O
of	5	O
ANP	9	O
,	9	O
AVP	9	B-Chemical
and	5	O
ANP	9	O
+	9	O
AVP	9	B-Chemical
decreased	9	O
CCB	9	O
during	5	O
Phe	0	B-Chemical
-	7	O
induced	3	O
MAP	9	O
elevation	9	O
.	9	O

The	5	O
results	9	O
indicate	9	O
that	5	O
centrally	5	O
applied	5	O
AVP	9	B-Chemical
and	5	O
ANP	9	O
exert	9	O
differential	9	O
effects	9	O
on	5	O
blood	9	O
pressure	5	O
and	5	O
baroreflex	5	O
control	9	O
of	5	O
heart	5	O
rate	9	O
in	5	O
WKY	9	O
and	5	O
SHR	9	O
and	5	O
suggest	9	O
interaction	9	O
of	5	O
these	5	O
two	5	O
peptides	9	O
in	5	O
blood	9	O
pressure	5	O
regulation	9	O
at	9	O
the	5	O
level	9	O
of	5	O
central	5	O
nervous	5	O
system	5	O
.	9	O

Cutaneous	5	O
exposure	9	O
to	5	O
warfarin	5	B-Chemical
-	7	O
like	9	O
anticoagulant	9	O
causing	9	O
an	5	O
intracerebral	5	B-Disease
hemorrhage	5	I-Disease
:	9	O
a	5	O
case	5	O
report	5	O
.	9	O

A	9	O
case	5	O
of	5	O
intercerebral	9	O
hematoma	5	B-Disease
due	5	O
to	5	O
warfarin	5	B-Chemical
-	7	O
induced	3	O
coagulopathy	5	B-Disease
is	5	O
presented	5	O
.	9	O

The	5	O
39	7	O
-	7	O
year	5	O
-	7	O
old	5	O
woman	5	O
had	9	O
spread	5	O
a	5	O
warfarin	5	B-Chemical
-	7	O
type	9	O
rat	3	O
poison	9	O
around	5	O
her	5	O
house	5	O
weekly	5	O
using	9	O
her	5	O
bare	5	O
hands	5	O
,	9	O
with	5	O
no	9	O
washing	0	O
post	9	O
application	5	O
.	9	O

Percutaneous	5	O
absorption	0	O
of	5	O
warfarin	5	B-Chemical
causing	9	O
coagulopathy	5	B-Disease
,	9	O
reported	9	O
three	9	O
times	5	O
in	5	O
the	5	O
past	5	O
,	9	O
is	5	O
a	5	O
significant	9	O
risk	5	O
if	5	O
protective	9	O
measures	5	O
,	9	O
such	5	O
as	5	O
gloves	5	O
,	9	O
are	5	O
not	5	O
used	5	O
.	9	O

An	5	O
adverse	5	O
drug	5	O
interaction	9	O
with	5	O
piroxicam	0	B-Chemical
,	9	O
which	5	O
she	5	O
took	5	O
occasionally	5	O
,	9	O
may	5	O
have	5	O
exacerbated	9	O
the	5	O
coagulopathy	5	B-Disease
.	9	O

Pediatric	2	O
heart	5	O
transplantation	9	O
without	9	O
chronic	5	O
maintenance	9	O
steroids	9	B-Chemical
.	9	O

From	5	O
1986	2	O
to	5	O
February	2	O
1993	2	O
,	9	O
40	9	O
children	5	O
aged	9	O
2	9	O
months	5	O
to	5	O
18	7	O
years	5	O
(	9	O
average	5	O
age	5	O
10	9	O
.	9	O
4	9	O
+	9	O
/	9	O
-	7	O
5	9	O
.	9	O
8	9	O
years	5	O
)	9	O
underwent	5	O
heart	5	O
transplantation	9	O
.	9	O

Indications	5	O
for	5	O
transplantation	9	O
were	9	O
idiopathic	5	B-Disease
cardiomyopathy	5	I-Disease
(	9	O
52	7	O
%	9	O
)	9	O
,	9	O
congenital	5	B-Disease
heart	5	I-Disease
disease	5	I-Disease
(	9	O
35	9	O
%	9	O
)	9	O
with	5	O
and	5	O
without	9	O
prior	9	O
repair	9	O
(	9	O
71	7	O
%	9	O
and	5	O
29	7	O
%	9	O
,	9	O
respectively	9	O
)	9	O
,	9	O
hypertrophic	3	B-Disease
cardiomyopathy	5	I-Disease
(	9	O
5	9	O
%	9	O
)	9	O
,	9	O
valvular	5	B-Disease
heart	5	I-Disease
disease	5	I-Disease
(	9	O
3	9	O
%	9	O
)	9	O
,	9	O
and	5	O
doxorubicin	0	B-Chemical
cardiomyopathy	5	B-Disease
(	9	O
5	9	O
%	9	O
)	9	O
.	9	O

Patients	5	O
were	9	O
managed	5	O
with	5	O
cyclosporine	0	B-Chemical
and	5	O
azathioprine	5	B-Chemical
.	9	O

No	9	O
prophylaxis	5	O
with	5	O
antilymphocyte	3	O
globulin	9	O
was	9	O
used	5	O
.	9	O

Steroids	0	B-Chemical
were	9	O
given	5	O
to	5	O
39	7	O
%	9	O
of	5	O
patients	5	O
for	5	O
refractory	9	O
rejection	5	O
,	9	O
but	9	O
weaning	5	O
was	9	O
always	5	O
attempted	5	O
and	5	O
generally	5	O
successful	5	O
(	9	O
64	7	O
%	9	O
)	9	O
.	9	O

Five	9	O
patients	5	O
(	9	O
14	7	O
%	9	O
)	9	O
received	9	O
maintenance	9	O
steroids	9	B-Chemical
.	9	O

Four	9	O
patients	5	O
died	9	O
in	5	O
the	5	O
perioperative	5	O
period	5	O
and	5	O
one	5	O
died	9	O
4	9	O
months	5	O
later	9	O
.	9	O

There	5	O
have	5	O
been	9	O
no	9	O
deaths	5	O
related	9	O
to	5	O
rejection	5	O
or	5	O
infection	9	B-Disease
.	9	O

Average	9	O
follow	5	O
-	7	O
up	5	O
was	9	O
36	9	O
+	9	O
/	9	O
-	7	O
19	7	O
months	5	O
(	9	O
range	9	O
1	9	O
to	5	O
65	7	O
months	5	O
)	9	O
.	9	O

Cumulative	9	O
survival	9	O
is	5	O
88	7	O
%	9	O
at	9	O
5	9	O
years	5	O
.	9	O

In	9	O
patients	5	O
less	5	O
than	5	O
7	9	O
years	5	O
of	5	O
age	5	O
,	9	O
rejection	5	O
was	9	O
monitored	9	O
noninvasively	5	O
.	9	O

In	9	O
the	5	O
first	9	O
postoperative	5	O
month	5	O
,	9	O
89	7	O
%	9	O
of	5	O
patients	5	O
were	9	O
treated	3	O
for	5	O
rejection	5	O
.	9	O

Freedom	5	O
from	9	O
serious	5	O
infections	5	B-Disease
was	9	O
83	7	O
%	9	O
at	9	O
1	9	O
month	5	O
and	5	O
65	7	O
%	9	O
at	9	O
1	9	O
year	5	O
.	9	O

Cytomegalovirus	2	B-Disease
infections	5	I-Disease
were	9	O
treated	3	O
successfully	5	O
with	5	O
ganciclovir	0	B-Chemical
in	5	O
11	7	O
patients	5	O
.	9	O

No	9	O
impairment	5	O
of	5	O
growth	3	O
was	9	O
observed	9	O
in	5	O
children	5	O
who	5	O
underwent	5	O
transplantation	9	O
compared	9	O
with	5	O
a	5	O
control	9	O
population	5	O
.	9	O

Twenty	9	O
-	7	O
one	5	O
patients	5	O
(	9	O
60	9	O
%	9	O
)	9	O
have	5	O
undergone	5	O
annual	5	O
catheterizations	5	O
and	5	O
no	9	O
sign	5	O
of	5	O
graft	5	O
atherosclerosis	9	B-Disease
has	9	O
been	9	O
observed	9	O
.	9	O

Seizures	5	B-Disease
occurred	9	O
in	5	O
five	9	O
patients	5	O
(	9	O
14	7	O
%	9	O
)	9	O
and	5	O
hypertension	5	B-Disease
was	9	O
treated	3	O
in	5	O
10	9	O
patients	5	O
(	9	O
28	7	O
%	9	O
)	9	O
.	9	O

No	9	O
patient	5	O
was	9	O
disabled	5	O
and	5	O
no	9	O
lymphoproliferative	3	B-Disease
disorder	5	I-Disease
was	9	O
observed	9	O
.	9	O
(	9	O
ABSTRACT	2	O
TRUNCATED	2	O
AT	9	O
250	0	O
WORDS	3	O
)	9	O

Delirium	5	B-Disease
during	5	O
fluoxetine	0	B-Chemical
treatment	9	O
.	9	O

A	9	O
case	5	O
report	5	O
.	9	O

The	5	O
correlation	9	O
between	5	O
high	9	O
serum	9	O
tricyclic	0	O
antidepressant	5	O
concentrations	0	O
and	5	O
central	5	O
nervous	5	O
system	5	O
side	5	O
effects	9	O
has	9	O
been	9	O
well	9	O
established	9	O
.	9	O

Only	9	O
a	5	O
few	5	O
reports	9	O
exist	9	O
,	9	O
however	9	O
,	9	O
on	5	O
the	5	O
relationship	5	O
between	5	O
the	5	O
serum	9	O
concentrations	0	O
of	5	O
selective	9	O
serotonin	9	B-Chemical
reuptake	0	O
inhibitors	3	O
(	9	O
SSRIs	5	O
)	9	O
and	5	O
their	5	O
toxic	0	O
effects	9	O
.	9	O

In	9	O
some	5	O
cases	5	O
,	9	O
a	5	O
high	9	O
serum	9	O
concentration	0	O
of	5	O
citalopram	0	B-Chemical
(	9	O
>	0	O
600	0	O
nmol	0	O
/	9	O
L	0	O
)	9	O
in	5	O
elderly	5	O
patients	5	O
has	9	O
been	9	O
associated	9	O
with	5	O
increased	9	O
somnolence	5	B-Disease
and	5	O
movement	5	B-Disease
difficulties	5	I-Disease
.	9	O

Widespread	9	O
cognitive	5	B-Disease
disorders	5	I-Disease
,	9	O
such	5	O
as	5	O
delirium	5	B-Disease
,	9	O
have	5	O
not	5	O
been	9	O
previously	9	O
linked	9	O
with	5	O
high	9	O
blood	9	O
levels	3	O
of	5	O
SSRIs	5	O
.	9	O

In	9	O
this	5	O
report	5	O
,	9	O
we	5	O
describe	5	O
a	5	O
patient	5	O
with	5	O
acute	9	O
hyperkinetic	5	B-Disease
delirium	5	B-Disease
connected	5	O
with	5	O
a	5	O
high	9	O
serum	9	O
total	9	O
fluoxetine	0	B-Chemical
(	9	O
fluoxetine	0	B-Chemical
plus	9	O
desmethylfluoxetine	_	B-Chemical
)	9	O
concentration	0	O
.	9	O

Pulmonary	9	B-Disease
edema	5	I-Disease
and	5	O
shock	9	B-Disease
after	9	O
high	9	O
-	7	O
dose	9	O
aracytine	9	B-Chemical
-	7	I-Chemical
C	9	I-Chemical
for	5	O
lymphoma	9	B-Disease
;	9	O
possible	5	O
role	9	O
of	5	O
TNF	3	O
-	7	O
alpha	9	O
and	5	O
PAF	9	O
.	9	O

Four	9	O
out	9	O
of	5	O
23	7	O
consecutive	5	O
patients	5	O
treated	3	O
with	5	O
high	9	O
-	7	O
dose	9	O
Ara	0	B-Chemical
-	7	I-Chemical
C	9	I-Chemical
for	5	O
lymphomas	3	B-Disease
in	5	O
our	5	O
institution	5	O
developed	5	O
a	5	O
strikingly	9	O
similar	9	O
syndrome	5	O
during	5	O
the	5	O
perfusion	5	O
.	9	O

It	5	O
was	9	O
characterized	9	O
by	9	O
the	5	O
onset	5	O
of	5	O
fever	5	B-Disease
,	9	O
diarrhea	5	B-Disease
,	9	O
shock	9	B-Disease
,	9	O
pulmonary	5	B-Disease
edema	5	I-Disease
,	9	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
,	9	O
metabolic	9	B-Disease
acidosis	5	I-Disease
,	9	O
weight	9	B-Disease
gain	5	I-Disease
and	5	O
leukocytosis	9	B-Disease
.	9	O

Thorough	5	O
bacteriological	5	O
screening	5	O
failed	9	O
to	5	O
provide	5	O
evidence	9	O
of	5	O
infection	9	B-Disease
.	9	O

Sequential	5	O
biological	5	O
assays	3	O
of	5	O
IL	0	O
-	7	O
1	9	O
,	9	O
IL	0	O
-	7	O
2	9	O
,	9	O
TNF	3	O
and	5	O
PAF	9	O
were	9	O
performed	9	O
during	5	O
Ara	0	B-Chemical
-	7	I-Chemical
C	9	I-Chemical
infusion	0	O
to	5	O
ten	9	O
patients	5	O
,	9	O
including	9	O
the	5	O
four	9	O
who	5	O
developed	5	O
the	5	O
syndrome	5	O
.	9	O

TNF	3	O
and	5	O
PAF	9	O
activity	9	O
was	9	O
found	9	O
in	5	O
the	5	O
serum	9	O
of	5	O
respectively	9	O
two	5	O
and	5	O
four	9	O
of	5	O
the	5	O
cases	5	O
,	9	O
but	9	O
not	5	O
in	5	O
the	5	O
six	9	O
controls	9	O
.	9	O

As	9	O
TNF	3	O
and	5	O
PAF	9	O
are	5	O
thought	5	O
to	5	O
be	5	O
involved	9	O
in	5	O
the	5	O
development	9	O
of	5	O
septic	5	O
shock	9	B-Disease
and	5	O
adult	9	B-Disease
respiratory	5	I-Disease
distress	5	I-Disease
syndrome	5	I-Disease
,	9	O
we	5	O
hypothesize	9	O
that	5	O
high	9	O
-	7	O
dose	9	O
Ara	0	B-Chemical
-	7	I-Chemical
C	9	I-Chemical
may	5	O
be	5	O
associated	9	O
with	5	O
cytokine	3	O
release	9	O
.	9	O

Protective	9	O
effect	9	O
of	5	O
clentiazem	_	B-Chemical
against	9	O
epinephrine	0	B-Chemical
-	7	O
induced	3	O
cardiac	5	B-Disease
injury	9	I-Disease
in	5	O
rats	9	O
.	9	O

We	9	O
investigated	9	O
the	5	O
effects	9	O
of	5	O
clentiazem	_	B-Chemical
,	9	O
a	5	O
1	9	B-Chemical
,	9	I-Chemical
5	9	I-Chemical
-	7	I-Chemical
benzothiazepine	0	I-Chemical
calcium	0	B-Chemical
antagonist	3	O
,	9	O
on	5	O
epinephrine	0	B-Chemical
-	7	O
induced	3	O
cardiomyopathy	5	B-Disease
in	5	O
rats	9	O
.	9	O

With	5	O
2	9	O
-	7	O
week	9	O
chronic	5	O
epinephrine	0	B-Chemical
infusion	0	O
,	9	O
16	9	O
of	5	O
30	9	O
rats	9	O
died	9	O
within	9	O
4	9	O
days	9	O
,	9	O
and	5	O
severe	5	O
ischemic	9	B-Disease
lesions	5	I-Disease
and	5	O
fibrosis	9	B-Disease
of	5	O
the	5	O
left	5	O
ventricles	5	O
were	9	O
observed	9	O
.	9	O

In	9	O
epinephrine	0	B-Chemical
-	7	O
treated	3	O
rats	9	O
,	9	O
left	5	O
atrial	5	O
and	5	O
left	5	O
ventricular	5	O
papillary	5	O
muscle	9	O
contractile	9	O
responses	5	O
to	5	O
isoproterenol	0	B-Chemical
were	9	O
reduced	9	O
,	9	O
but	9	O
responses	5	O
to	5	O
calcium	0	B-Chemical
were	9	O
normal	9	O
or	5	O
enhanced	3	O
compared	9	O
to	5	O
controls	9	O
.	9	O

Left	9	O
ventricular	5	O
alpha	9	O
and	5	O
beta	9	O
adrenoceptor	5	O
densities	9	O
were	9	O
also	9	O
reduced	9	O
compared	9	O
to	5	O
controls	9	O
.	9	O

Treatment	9	O
with	5	O
clentiazem	_	B-Chemical
prevented	9	O
epinephrine	0	B-Chemical
-	7	O
induced	3	O
death	9	O
(	9	O
P	9	O
<	0	O
.	9	O
05	7	O
)	9	O
,	9	O
and	5	O
attenuated	3	O
the	5	O
ventricular	5	O
ischemic	9	B-Disease
lesions	5	I-Disease
and	5	O
fibrosis	9	B-Disease
,	9	O
in	5	O
a	5	O
dose	9	O
-	7	O
dependent	9	O
manner	9	O
.	9	O

Left	9	O
atrial	5	O
and	5	O
left	5	O
ventricular	5	O
papillary	5	O
muscle	9	O
contractile	9	O
responses	5	O
to	5	O
isoproterenol	0	B-Chemical
were	9	O
reduced	9	O
compared	9	O
to	5	O
controls	9	O
in	5	O
groups	9	O
treated	3	O
with	5	O
clentiazem	_	B-Chemical
alone	9	O
,	9	O
but	9	O
combined	9	O
with	5	O
epinephrine	0	B-Chemical
,	9	O
clentiazem	_	B-Chemical
restored	3	O
left	5	O
atrial	5	O
responses	5	O
and	5	O
enhanced	3	O
left	5	O
ventricular	5	O
papillary	5	O
responses	5	O
to	5	O
isoproterenol	0	B-Chemical
.	9	O

On	5	O
the	5	O
other	5	O
hand	5	O
clentiazem	_	B-Chemical
did	9	O
not	5	O
prevent	5	O
epinephrine	0	B-Chemical
-	7	O
induced	3	O
down	9	O
-	7	O
regulation	9	O
of	5	O
alpha	9	O
and	5	O
beta	9	O
adrenoceptors	3	O
.	9	O

Interestingly	9	O
,	9	O
clentiazem	_	B-Chemical
,	9	O
infused	9	O
alone	9	O
,	9	O
resulted	9	O
in	5	O
decreased	9	O
adrenergic	9	O
receptor	3	O
densities	9	O
in	5	O
the	5	O
left	5	O
ventricle	5	O
.	9	O

Clentiazem	_	B-Chemical
also	9	O
did	9	O
not	5	O
prevent	5	O
the	5	O
enhanced	3	O
responses	5	O
to	5	O
calcium	0	B-Chemical
seen	9	O
in	5	O
the	5	O
epinephrine	0	B-Chemical
-	7	O
treated	3	O
animals	9	O
,	9	O
although	9	O
the	5	O
high	9	O
dose	9	O
of	5	O
clentiazem	_	B-Chemical
partially	9	O
attenuated	3	O
the	5	O
maximal	9	O
response	9	O
to	5	O
calcium	0	B-Chemical
compared	9	O
to	5	O
epinephrine	0	B-Chemical
-	7	O
treated	3	O
animals	9	O
.	9	O

In	9	O
conclusion	9	O
,	9	O
clentiazem	_	B-Chemical
attenuated	3	O
epinephrine	0	B-Chemical
-	7	O
induced	3	O
cardiac	5	B-Disease
injury	9	I-Disease
,	9	O
possibly	9	O
through	9	O
its	9	O
effect	9	O
on	5	O
the	5	O
adrenergic	9	O
pathway	3	O
.	9	O

Kaliuretic	9	O
effect	9	O
of	5	O
L	0	B-Chemical
-	7	I-Chemical
dopa	0	I-Chemical
treatment	9	O
in	5	O
parkinsonian	5	B-Disease
patients	5	O
.	9	O

Hypokalemia	7	B-Disease
,	9	O
sometimes	5	O
severe	5	O
,	9	O
was	9	O
observed	9	O
in	5	O
some	5	O
L	0	B-Chemical
-	7	I-Chemical
dopa	0	I-Chemical
-	7	O
treated	3	O
parkinsonian	5	B-Disease
patients	5	O
.	9	O

The	5	O
influence	5	O
of	5	O
L	0	B-Chemical
-	7	I-Chemical
dopa	0	I-Chemical
on	5	O
the	5	O
renal	9	O
excretion	0	O
of	5	O
potassium	0	B-Chemical
was	9	O
studied	9	O
in	5	O
3	9	O
patients	5	O
with	5	O
hypokalemia	5	B-Disease
and	5	O
in	5	O
5	9	O
normokalemic	5	O
patients	5	O
by	9	O
determination	9	O
of	5	O
renal	9	O
plasma	9	O
flow	5	O
,	9	O
glomerular	5	O
filtration	0	O
rate	9	O
,	9	O
plasma	9	O
concentration	0	O
of	5	O
potassium	0	B-Chemical
and	5	O
sodium	0	B-Chemical
as	5	O
well	9	O
as	5	O
urinary	9	O
excretion	0	O
of	5	O
potassium	0	B-Chemical
,	9	O
sodium	0	B-Chemical
and	5	O
aldosterone	9	B-Chemical
.	9	O

L	0	B-Chemical
-	7	I-Chemical
Dopa	0	I-Chemical
intake	5	O
was	9	O
found	9	O
to	5	O
cause	5	O
an	5	O
increased	9	O
excretion	0	O
of	5	O
potassium	0	B-Chemical
,	9	O
and	5	O
sometimes	5	O
also	9	O
of	5	O
sodium	0	B-Chemical
,	9	O
in	5	O
the	5	O
hypokalemic	5	O
but	9	O
not	5	O
in	5	O
the	5	O
normokalemic	5	O
patients	5	O
.	9	O

This	5	O
effect	9	O
on	5	O
the	5	O
renal	9	O
function	9	O
could	9	O
be	5	O
prohibited	5	O
by	9	O
the	5	O
administration	9	O
of	5	O
a	5	O
peripheral	9	O
dopa	0	O
decarbodylase	_	O
inhibitor	3	O
.	9	O

It	5	O
is	5	O
not	5	O
known	9	O
why	5	O
this	5	O
effect	9	O
occurred	9	O
in	5	O
some	5	O
individuals	5	O
but	9	O
not	5	O
in	5	O
others	5	O
,	9	O
but	9	O
our	5	O
results	9	O
indicate	9	O
a	5	O
correlation	9	O
between	5	O
aldosterone	9	B-Chemical
production	9	O
and	5	O
this	5	O
renal	9	O
effect	9	O
of	5	O
L	0	B-Chemical
-	7	I-Chemical
dopa	0	I-Chemical
.	9	O

Cocaine	5	B-Chemical
induced	3	O
myocardial	9	B-Disease
ischemia	9	I-Disease
.	9	O

We	9	O
report	5	O
a	5	O
case	5	O
of	5	O
myocardial	9	B-Disease
ischemia	9	I-Disease
induced	3	O
by	9	O
cocaine	5	B-Chemical
.	9	O

The	5	O
ischemia	9	B-Disease
probably	9	O
induced	3	O
by	9	O
coronary	5	B-Disease
artery	5	I-Disease
spasm	5	I-Disease
was	9	O
reversed	9	O
by	9	O
nitroglycerin	5	B-Chemical
and	5	O
calcium	0	B-Chemical
blocking	3	O
agents	5	O
.	9	O

Doxorubicin	0	B-Chemical
-	7	O
induced	3	O
cardiotoxicity	9	B-Disease
monitored	9	O
by	9	O
ECG	5	O
in	5	O
freely	5	O
moving	5	O
mice	3	O
.	9	O

A	9	O
new	5	O
model	5	O
to	5	O
test	5	O
potential	9	O
protectors	5	O
.	9	O

In	9	O
laboratory	9	O
animals	9	O
,	9	O
histology	9	O
is	5	O
most	9	O
commonly	5	O
used	5	O
to	5	O
study	9	O
doxorubicin	0	B-Chemical
-	7	O
induced	3	O
cardiotoxicity	9	B-Disease
.	9	O

However	9	O
,	9	O
for	5	O
monitoring	5	O
during	5	O
treatment	9	O
,	9	O
large	5	O
numbers	9	O
of	5	O
animals	9	O
are	5	O
needed	5	O
.	9	O

Recently	9	O
we	5	O
developed	5	O
a	5	O
new	5	O
method	5	O
to	5	O
measure	5	O
ECG	5	O
values	5	O
in	5	O
freely	5	O
moving	5	O
mice	3	O
by	9	O
telemetry	5	O
.	9	O

With	5	O
this	5	O
model	5	O
we	5	O
investigated	9	O
the	5	O
effect	9	O
of	5	O
chronic	5	O
doxorubicin	0	B-Chemical
administration	9	O
on	5	O
the	5	O
ECG	5	O
of	5	O
freely	5	O
moving	5	O
BALB	3	O
/	9	O
c	9	O
mice	3	O
and	5	O
the	5	O
efficacy	9	O
of	5	O
ICRF	2	B-Chemical
-	7	I-Chemical
187	7	I-Chemical
as	5	O
a	5	O
protective	9	O
agent	9	O
.	9	O

The	5	O
ST	9	O
interval	5	O
significantly	9	O
widened	5	O
from	9	O
15	9	O
.	9	O
0	7	O
+	9	O
/	9	O
-	7	O
1	9	O
.	9	O
5	9	O
to	5	O
56	7	O
.	9	O
8	9	O
+	9	O
/	9	O
-	7	O
11	7	O
.	9	O
8	9	O
ms	5	O
in	5	O
week	9	O
10	9	O
(	9	O
7	9	O
weekly	5	O
doses	0	O
of	5	O
4	9	O
mg	0	O
/	9	O
kg	0	O
doxorubicin	0	B-Chemical
given	5	O
i	9	O
.	9	O
v	0	O
.	9	O
plus	9	O
3	9	O
weeks	9	O
of	5	O
observation	9	O
)	9	O
.	9	O

The	5	O
ECG	5	O
of	5	O
the	5	O
control	9	O
animals	9	O
did	9	O
not	5	O
change	9	O
during	5	O
the	5	O
entire	9	O
study	9	O
.	9	O

After	9	O
sacrifice	9	O
the	5	O
hearts	3	O
of	5	O
doxorubicin	0	B-Chemical
-	7	O
treated	3	O
animals	9	O
were	9	O
enlarged	9	O
and	5	O
the	5	O
atria	9	O
were	9	O
hypertrophic	3	B-Disease
.	9	O

As	9	O
this	5	O
schedule	5	O
exerted	9	O
more	5	O
toxicity	9	B-Disease
than	5	O
needed	5	O
to	5	O
investigate	9	O
protective	9	O
agents	5	O
,	9	O
the	5	O
protection	9	O
of	5	O
ICRF	2	B-Chemical
-	7	I-Chemical
187	7	I-Chemical
was	9	O
determined	9	O
using	9	O
a	5	O
dose	9	O
schedule	5	O
with	5	O
lower	9	O
general	5	O
toxicity	9	B-Disease
(	9	O
6	9	O
weekly	5	O
doses	0	O
of	5	O
4	9	O
mg	0	O
/	9	O
kg	0	O
doxorubicin	0	B-Chemical
given	5	O
i	9	O
.	9	O
v	0	O
.	9	O
plus	9	O
2	9	O
weeks	9	O
of	5	O
observation	9	O
)	9	O
.	9	O

On	5	O
this	5	O
schedule	5	O
,	9	O
the	5	O
animals	9	O
'	9	O
hearts	3	O
appeared	9	O
normal	9	O
after	9	O
sacrifice	9	O
and	5	O
ICRF	2	B-Chemical
-	7	I-Chemical
187	7	I-Chemical
(	9	O
50	0	O
mg	0	O
/	9	O
kg	0	O
given	5	O
i	9	O
.	9	O
p	7	O
.	9	O
1	9	O
h	0	O
before	9	O
doxorubicin	0	B-Chemical
)	9	O
provided	9	O
almost	9	O
full	5	O
protection	9	O
.	9	O

These	5	O
data	5	O
were	9	O
confirmed	9	O
by	9	O
histology	9	O
.	9	O

The	5	O
results	9	O
indicate	9	O
that	5	O
this	5	O
new	5	O
model	5	O
is	5	O
very	5	O
sensitive	9	O
and	5	O
enables	5	O
monitoring	5	O
of	5	O
the	5	O
development	9	O
of	5	O
cardiotoxicity	9	B-Disease
with	5	O
time	5	O
.	9	O

These	5	O
findings	9	O
result	9	O
in	5	O
a	5	O
model	5	O
that	5	O
allows	5	O
the	5	O
testing	5	O
of	5	O
protectors	5	O
against	9	O
doxorubicin	0	B-Chemical
-	7	O
induced	3	O
cardiotoxicity	9	B-Disease
as	5	O
demonstrated	9	O
by	9	O
the	5	O
protection	9	O
provided	9	O
by	9	O
ICRF	2	B-Chemical
-	7	I-Chemical
187	7	I-Chemical
.	9	O

Epinephrine	0	B-Chemical
dysrhythmogenicity	_	O
is	5	O
not	5	O
enhanced	3	O
by	9	O
subtoxic	3	O
bupivacaine	0	B-Chemical
in	5	O
dogs	5	O
.	9	O

Since	9	O
bupivacaine	0	B-Chemical
and	5	O
epinephrine	0	B-Chemical
may	5	O
both	9	O
precipitate	0	O
dysrhythmias	5	B-Disease
,	9	O
circulating	9	O
bupivacaine	0	B-Chemical
during	5	O
regional	5	O
anesthesia	5	O
could	9	O
potentiate	3	O
dysrhythmogenic	9	O
effects	9	O
of	5	O
epinephrine	0	B-Chemical
.	9	O

We	9	O
therefore	5	O
examined	9	O
whether	9	O
bupivacaine	0	B-Chemical
alters	9	O
the	5	O
dysrhythmogenicity	_	O
of	5	O
subsequent	9	O
administration	9	O
of	5	O
epinephrine	0	B-Chemical
in	5	O
conscious	5	O
,	9	O
healthy	5	O
dogs	5	O
and	5	O
in	5	O
anesthetized	0	O
dogs	5	O
with	5	O
myocardial	9	B-Disease
infarction	5	I-Disease
.	9	O

Forty	9	O
-	7	O
one	5	O
conscious	5	O
dogs	5	O
received	9	O
10	9	O
micrograms	0	O
.	9	O
kg	0	O
-	7	O
1	9	O
.	9	O
min	0	O
-	7	O
1	9	O
epinephrine	0	B-Chemical
.	9	O

Seventeen	9	O
animals	9	O
responded	9	O
with	5	O
ventricular	5	B-Disease
tachycardia	5	I-Disease
(	9	O
VT	9	B-Disease
)	9	O
within	9	O
3	9	O
min	0	O
.	9	O

After	9	O
3	9	O
h	0	O
,	9	O
these	5	O
responders	5	O
randomly	5	O
received	9	O
1	9	O
or	5	O
2	9	O
mg	0	O
/	9	O
kg	0	O
bupivacaine	0	B-Chemical
or	5	O
saline	0	O
over	5	O
5	9	O
min	0	O
,	9	O
followed	9	O
by	9	O
10	9	O
micrograms	0	O
.	9	O
kg	0	O
-	7	O
1	9	O
.	9	O
min	0	O
-	7	O
1	9	O
epinephrine	0	B-Chemical
.	9	O

In	9	O
the	5	O
bupivacaine	0	B-Chemical
groups	9	O
,	9	O
epinephrine	0	B-Chemical
caused	9	O
fewer	5	O
prodysrhythmic	_	O
effects	9	O
than	5	O
without	9	O
bupivacaine	0	B-Chemical
.	9	O

VT	9	B-Disease
appeared	9	O
in	5	O
fewer	5	O
dogs	5	O
and	5	O
at	9	O
a	5	O
later	9	O
time	5	O
,	9	O
and	5	O
there	5	O
were	9	O
more	5	O
sinoatrial	5	O
beats	5	O
and	5	O
less	5	O
ectopies	5	O
.	9	O

Epinephrine	0	B-Chemical
shortened	9	O
QT	5	O
less	5	O
after	9	O
bupivacaine	0	B-Chemical
than	5	O
in	5	O
control	9	O
animals	9	O
.	9	O

One	5	O
day	9	O
after	9	O
experimental	5	O
myocardial	9	B-Disease
infarction	5	I-Disease
,	9	O
six	9	O
additional	9	O
halothane	0	B-Chemical
-	7	O
anesthetized	0	O
dogs	5	O
received	9	O
4	9	O
micrograms	0	O
.	9	O
kg	0	O
-	7	O
1	9	O
.	9	O
min	0	O
-	7	O
1	9	O
epinephrine	0	B-Chemical
until	5	O
VT	9	B-Disease
appeared	9	O
.	9	O

After	9	O
45	9	O
min	0	O
,	9	O
1	9	O
mg	0	O
/	9	O
kg	0	O
bupivacaine	0	B-Chemical
was	9	O
injected	3	O
over	5	O
5	9	O
min	0	O
,	9	O
again	9	O
followed	9	O
by	9	O
4	9	O
micrograms	0	O
.	9	O
kg	0	O
-	7	O
1	9	O
.	9	O
min	0	O
-	7	O
1	9	O
epinephrine	0	B-Chemical
.	9	O

In	9	O
these	5	O
dogs	5	O
,	9	O
the	5	O
prodysrhythmic	_	O
response	9	O
to	5	O
epinephrine	0	B-Chemical
was	9	O
also	9	O
mitigated	9	O
by	9	O
preceding	5	O
bupivacaine	0	B-Chemical
.	9	O

Bupivacaine	0	B-Chemical
antagonizes	3	O
epinephrine	0	B-Chemical
dysrhythmogenicity	_	O
in	5	O
conscious	5	O
dogs	5	O
susceptible	9	O
to	5	O
VT	9	B-Disease
and	5	O
in	5	O
anesthetized	0	O
dogs	5	O
with	5	O
spontaneous	5	O
postinfarct	5	O
dysrhythmias	5	B-Disease
.	9	O

There	5	O
is	5	O
no	9	O
evidence	9	O
that	5	O
systemic	9	O
subtoxic	3	O
bupivacaine	0	B-Chemical
administration	9	O
enhances	3	O
the	5	O
dysrhythmogenicity	_	O
of	5	O
subsequent	9	O
epinephrine	0	B-Chemical
.	9	O

Milk	7	B-Disease
-	7	I-Disease
alkali	0	I-Disease
syndrome	5	I-Disease
induced	3	O
by	9	O
1	9	B-Chemical
,	9	I-Chemical
25	9	I-Chemical
(	9	I-Chemical
OH	0	I-Chemical
)	9	I-Chemical
2D	5	I-Chemical
in	5	O
a	5	O
patient	5	O
with	5	O
hypoparathyroidism	5	B-Disease
.	9	O

Milk	7	B-Disease
-	7	I-Disease
alkali	0	I-Disease
syndrome	5	I-Disease
was	9	O
first	9	O
described	9	O
70	9	O
years	5	O
ago	5	O
in	5	O
the	5	O
context	5	O
of	5	O
the	5	O
treatment	9	O
of	5	O
peptic	5	B-Disease
ulcer	5	I-Disease
disease	5	I-Disease
with	5	O
large	5	O
amounts	9	O
of	5	O
calcium	0	B-Chemical
and	5	O
alkali	0	B-Chemical
.	9	O

Although	9	O
with	5	O
current	5	O
ulcer	5	B-Disease
therapy	5	O
(	9	O
H	9	O
-	7	O
2	9	O
blockers	9	O
,	9	O
omeprazole	0	B-Chemical
,	9	O
and	5	O
sucralfate	0	B-Chemical
)	9	O
,	9	O
the	5	O
frequency	5	O
of	5	O
milk	9	B-Disease
-	7	I-Disease
alkali	0	I-Disease
syndrome	5	I-Disease
has	9	O
decreased	9	O
significantly	9	O
,	9	O
the	5	O
classic	5	O
triad	9	O
of	5	O
hypercalcemia	5	B-Disease
,	9	O
alkalosis	5	B-Disease
,	9	O
and	5	O
renal	9	B-Disease
impairment	5	I-Disease
remains	9	O
the	5	O
hallmark	9	O
of	5	O
the	5	O
syndrome	5	O
.	9	O

Milk	7	B-Disease
-	7	I-Disease
alkali	0	I-Disease
syndrome	5	I-Disease
can	5	O
present	9	O
serious	5	O
and	5	O
occasionally	5	O
life	5	O
-	7	O
threatening	5	O
illness	5	O
unless	9	O
diagnosed	5	O
and	5	O
treated	3	O
appropriately	5	O
.	9	O

This	5	O
article	6	O
presents	5	O
a	5	O
patient	5	O
with	5	O
hypoparathyroidism	5	B-Disease
who	5	O
was	9	O
treated	3	O
with	5	O
calcium	0	B-Chemical
carbonate	0	I-Chemical
and	5	O
calcitriol	3	B-Chemical
resulting	9	O
in	5	O
two	5	O
admissions	5	O
to	5	O
the	5	O
hospital	5	O
for	5	O
milk	9	B-Disease
-	7	I-Disease
alkali	0	I-Disease
syndrome	5	I-Disease
.	9	O

The	5	O
patient	5	O
was	9	O
successfully	5	O
treated	3	O
with	5	O
intravenous	0	O
pamidronate	0	B-Chemical
on	5	O
his	5	O
first	9	O
admission	5	O
and	5	O
with	5	O
hydrocortisone	0	B-Chemical
on	5	O
the	5	O
second	9	O
.	9	O

This	5	O
illustrates	5	O
intravenous	0	O
pamidronate	0	B-Chemical
as	5	O
a	5	O
valuable	5	O
therapeutic	5	O
tool	5	O
when	5	O
milk	9	B-Disease
-	7	I-Disease
alkali	0	I-Disease
syndrome	5	I-Disease
presents	5	O
as	5	O
hypercalcemic	5	B-Disease
emergency	5	I-Disease
.	9	O

Famotidine	0	B-Chemical
-	7	O
associated	9	O
delirium	5	B-Disease
.	9	O

A	9	O
series	5	O
of	5	O
six	9	O
cases	5	O
.	9	O

Famotidine	0	B-Chemical
is	5	O
a	5	O
histamine	0	O
H2	9	O
-	7	O
receptor	3	O
antagonist	3	O
used	5	O
in	5	O
inpatient	5	O
settings	5	O
for	5	O
prevention	5	O
of	5	O
stress	9	O
ulcers	5	B-Disease
and	5	O
is	5	O
showing	9	O
increasing	9	O
popularity	5	O
because	5	O
of	5	O
its	9	O
low	9	O
cost	5	O
.	9	O

Although	9	O
all	5	O
of	5	O
the	5	O
currently	5	O
available	5	O
H2	9	O
-	7	O
receptor	3	O
antagonists	3	O
have	5	O
shown	9	O
the	5	O
propensity	5	O
to	5	O
cause	5	O
delirium	5	B-Disease
,	9	O
only	9	O
two	5	O
previously	9	O
reported	9	O
cases	5	O
have	5	O
been	9	O
associated	9	O
with	5	O
famotidine	0	B-Chemical
.	9	O

The	5	O
authors	5	O
report	5	O
on	5	O
six	9	O
cases	5	O
of	5	O
famotidine	0	B-Chemical
-	7	O
associated	9	O
delirium	5	B-Disease
in	5	O
hospitalized	5	O
patients	5	O
who	5	O
cleared	9	O
completely	9	O
upon	9	O
removal	9	O
of	5	O
famotidine	0	B-Chemical
.	9	O

The	5	O
pharmacokinetics	9	O
of	5	O
famotidine	0	B-Chemical
are	5	O
reviewed	9	O
,	9	O
with	5	O
no	9	O
change	9	O
in	5	O
its	9	O
metabolism	9	O
in	5	O
the	5	O
elderly	5	O
population	5	O
seen	9	O
.	9	O

The	5	O
implications	5	O
of	5	O
using	9	O
famotidine	0	B-Chemical
in	5	O
elderly	5	O
persons	5	O
are	5	O
discussed	5	O
.	9	O

Encephalopathy	5	B-Disease
during	5	O
amitriptyline	0	B-Chemical
therapy	5	O
:	9	O
are	5	O
neuroleptic	5	B-Disease
malignant	3	I-Disease
syndrome	5	I-Disease
and	5	O
serotonin	9	B-Disease
syndrome	5	I-Disease
spectrum	9	O
disorders	5	O
?	5	O

This	5	O
report	5	O
describes	5	O
a	5	O
case	5	O
of	5	O
encephalopathy	5	B-Disease
developed	5	O
in	5	O
the	5	O
course	5	O
of	5	O
amitriptyline	0	B-Chemical
therapy	5	O
,	9	O
during	5	O
a	5	O
remission	5	O
of	5	O
unipolar	5	B-Disease
depression	5	I-Disease
.	9	O

This	5	O
patient	5	O
could	9	O
have	5	O
been	9	O
diagnosed	5	O
as	5	O
having	5	O
either	9	O
neuroleptic	5	B-Disease
malignant	3	I-Disease
syndrome	5	I-Disease
(	9	O
NMS	9	B-Disease
)	9	O
or	5	O
serotonin	9	B-Disease
syndrome	5	I-Disease
(	9	O
SS	9	B-Disease
)	9	O
.	9	O

The	5	O
major	9	O
determinant	9	O
of	5	O
the	5	O
symptoms	5	O
may	5	O
have	5	O
been	9	O
dopamine	5	B-Chemical
/	9	O
serotonin	9	B-Chemical
imbalance	9	O
in	5	O
the	5	O
central	5	O
nervous	5	O
system	5	O
.	9	O

The	5	O
NMS	9	B-Disease
-	7	O
like	9	O
encephalopathy	5	B-Disease
that	5	O
develops	5	O
in	5	O
association	9	O
with	5	O
the	5	O
use	5	O
of	5	O
antidepressants	5	O
indicates	9	O
that	5	O
NMS	9	B-Disease
and	5	O
SS	9	B-Disease
are	5	O
spectrum	9	O
disorders	5	O
induced	3	O
by	9	O
drugs	5	O
with	5	O
both	9	O
antidopaminergic	5	O
and	5	O
serotonergic	5	O
effects	9	O
.	9	O

Genetic	9	O
separation	5	O
of	5	O
tumor	3	B-Disease
growth	3	O
and	5	O
hemorrhagic	5	B-Disease
phenotypes	9	O
in	5	O
an	5	O
estrogen	3	B-Chemical
-	7	O
induced	3	O
tumor	3	B-Disease
.	9	O

Chronic	9	O
administration	9	O
of	5	O
estrogen	3	B-Chemical
to	5	O
the	5	O
Fischer	6	O
344	7	O
(	9	O
F344	3	O
)	9	O
rat	3	O
induces	3	O
growth	3	O
of	5	O
large	5	O
,	9	O
hemorrhagic	5	B-Disease
pituitary	3	B-Disease
tumors	3	I-Disease
.	9	O

Ten	9	O
weeks	9	O
of	5	O
diethylstilbestrol	0	B-Chemical
(	9	O
DES	9	B-Chemical
)	9	O
treatment	9	O
caused	9	O
female	9	O
F344	3	O
rat	3	O
pituitaries	3	O
to	5	O
grow	9	O
to	5	O
an	5	O
average	5	O
of	5	O
109	7	O
.	9	O
2	9	O
+	9	O
/	9	O
-	7	O
6	9	O
.	9	O
3	9	O
mg	0	O
(	9	O
mean	5	O
+	9	O
/	9	O
-	7	O
SE	9	O
)	9	O
versus	9	O
11	7	O
.	9	O
3	9	O
+	9	O
/	9	O
-	7	O
1	9	O
.	9	O
4	9	O
mg	0	O
for	5	O
untreated	3	O
rats	9	O
,	9	O
and	5	O
to	5	O
become	5	O
highly	9	O
hemorrhagic	5	B-Disease
.	9	O

The	5	O
same	9	O
DES	9	B-Chemical
treatment	9	O
produced	9	O
no	9	O
significant	9	O
growth	3	O
(	9	O
8	9	O
.	9	O
9	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
5	9	O
mg	0	O
for	5	O
treated	3	O
females	9	O
versus	9	O
8	9	O
.	9	O
7	9	O
+	9	O
/	9	O
-	7	O
1	9	O
.	9	O
1	9	O
for	5	O
untreated	3	O
females	9	O
)	9	O
or	5	O
morphological	9	O
changes	9	O
in	5	O
Brown	6	O
Norway	2	O
(	9	O
BN	9	O
)	9	O
rat	3	O
pituitaries	3	O
.	9	O

An	5	O
F1	9	O
hybrid	9	O
of	5	O
F344	3	O
and	5	O
BN	9	O
exhibited	9	O
significant	9	O
pituitary	3	O
growth	3	O
after	9	O
10	9	O
weeks	9	O
of	5	O
DES	9	B-Chemical
treatment	9	O
with	5	O
an	5	O
average	5	O
mass	9	O
of	5	O
26	7	O
.	9	O
3	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
7	9	O
mg	0	O
compared	9	O
with	5	O
8	9	O
.	9	O
6	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
9	7	O
mg	0	O
for	5	O
untreated	3	O
rats	9	O
.	9	O

Surprisingly	9	O
,	9	O
the	5	O
F1	9	O
hybrid	9	O
tumors	3	B-Disease
were	9	O
not	5	O
hemorrhagic	5	B-Disease
and	5	O
had	9	O
hemoglobin	0	O
content	9	O
and	5	O
outward	5	O
appearance	9	O
identical	9	O
to	5	O
that	5	O
of	5	O
BN	9	O
.	9	O

Expression	3	O
of	5	O
both	9	O
growth	3	O
and	5	O
morphological	9	O
changes	9	O
is	5	O
due	5	O
to	5	O
multiple	5	O
genes	1	O
.	9	O

However	9	O
,	9	O
while	9	O
DES	9	B-Chemical
-	7	O
induced	3	O
pituitary	3	O
growth	3	O
exhibited	9	O
quantitative	9	O
,	9	O
additive	9	O
inheritance	9	O
,	9	O
the	5	O
hemorrhagic	5	B-Disease
phenotype	3	O
exhibited	9	O
recessive	9	O
,	9	O
epistatic	5	O
inheritance	9	O
.	9	O

Only	9	O
5	9	O
of	5	O
the	5	O
160	9	O
F2	9	O
pituitaries	3	O
exhibited	9	O
the	5	O
hemorrhagic	5	B-Disease
phenotype	3	O
;	9	O
36	9	O
of	5	O
the	5	O
160	9	O
F2	9	O
pituitaries	3	O
were	9	O
in	5	O
the	5	O
F344	3	O
range	9	O
of	5	O
mass	9	O
,	9	O
but	9	O
31	7	O
of	5	O
these	5	O
were	9	O
not	5	O
hemorrhagic	5	B-Disease
,	9	O
indicating	9	O
that	5	O
the	5	O
hemorrhagic	5	B-Disease
phenotype	3	O
is	5	O
not	5	O
merely	5	O
a	5	O
consequence	5	O
of	5	O
extensive	5	O
growth	3	O
.	9	O

The	5	O
hemorrhagic	5	B-Disease
F2	9	O
pituitaries	3	O
were	9	O
all	5	O
among	5	O
the	5	O
most	9	O
massive	9	O
,	9	O
indicating	9	O
that	5	O
some	5	O
of	5	O
the	5	O
genes	1	O
regulate	3	O
both	9	O
phenotypes	9	O
.	9	O

Increased	9	O
expression	3	O
of	5	O
neuronal	3	O
nitric	0	B-Chemical
oxide	0	I-Chemical
synthase	1	O
in	5	O
bladder	9	O
afferent	5	O
pathways	9	O
following	9	O
chronic	5	O
bladder	9	B-Disease
irritation	5	I-Disease
.	9	O

Immunocytochemical	3	O
techniques	5	O
were	9	O
used	5	O
to	5	O
examine	9	O
alterations	9	O
in	5	O
the	5	O
expression	3	O
of	5	O
neuronal	3	O
nitric	0	B-Chemical
oxide	0	I-Chemical
synthase	1	O
(	9	O
NOS	9	O
)	9	O
in	5	O
bladder	9	O
pathways	9	O
following	9	O
acute	9	O
and	5	O
chronic	5	O
irritation	5	B-Disease
of	5	I-Disease
the	5	I-Disease
urinary	9	I-Disease
tract	9	I-Disease
of	5	O
the	5	O
rat	3	O
.	9	O

Chemical	0	O
cystitis	9	B-Disease
was	9	O
induced	3	O
by	9	O
cyclophosphamide	0	B-Chemical
(	9	O
CYP	0	B-Chemical
)	9	O
which	5	O
is	5	O
metabolized	0	O
to	5	O
acrolein	0	B-Chemical
,	9	O
an	5	O
irritant	0	O
eliminated	9	O
in	5	O
the	5	O
urine	9	O
.	9	O

Injection	9	O
of	5	O
CYP	0	B-Chemical
(	9	O
n	9	O
=	7	O
10	9	O
,	9	O
75	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
2	9	O
hours	9	O
prior	9	O
to	5	O
perfusion	5	O
(	9	O
acute	9	O
treatment	9	O
)	9	O
of	5	O
the	5	O
animals	9	O
increased	9	O
Fos	3	O
-	7	O
immunoreactivity	3	O
(	9	O
IR	9	O
)	9	O
in	5	O
neurons	3	O
in	5	O
the	5	O
dorsal	5	O
commissure	5	O
,	9	O
dorsal	5	O
horn	5	O
,	9	O
and	5	O
autonomic	5	O
regions	9	O
of	5	O
spinal	5	O
segments	9	O
(	9	O
L1	9	O
-	7	O
L2	9	O
and	5	O
L6	3	O
-	7	O
S1	9	O
)	9	O
which	5	O
receive	5	O
afferent	5	O
inputs	5	O
from	9	O
the	5	O
bladder	9	O
,	9	O
urethra	5	O
,	9	O
and	5	O
ureter	5	O
.	9	O

Fos	3	O
-	7	O
IR	9	O
in	5	O
the	5	O
spinal	5	O
cord	9	O
was	9	O
not	5	O
changed	9	O
in	5	O
rats	9	O
receiving	9	O
chronic	5	O
CYP	0	B-Chemical
treatment	9	O
(	9	O
n	9	O
=	7	O
15	9	O
,	9	O
75	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
i	9	O
.	9	O
p	7	O
.	9	O
,	9	O
every	5	O
3rd	9	O
day	9	O
for	5	O
2	9	O
weeks	9	O
)	9	O
.	9	O

In	9	O
control	9	O
animals	9	O
and	5	O
in	5	O
animals	9	O
treated	3	O
acutely	9	O
with	5	O
CYP	0	B-Chemical
,	9	O
only	9	O
small	9	O
numbers	9	O
of	5	O
NOS	9	O
-	7	O
IR	9	O
cells	3	O
(	9	O
0	7	O
.	9	O
5	9	O
-	7	O
0	7	O
.	9	O
7	9	O
cell	3	O
profiles	9	O
/	9	O
sections	9	O
)	9	O
were	9	O
detected	9	O
in	5	O
the	5	O
L6	3	O
-	7	O
S1	9	O
dorsal	5	O
root	5	O
ganglia	5	O
(	9	O
DRG	3	O
)	9	O
.	9	O

Chronic	9	O
CYP	0	B-Chemical
administration	9	O
significantly	9	O
(	9	O
P	9	O
<	0	O
or	5	O
=	7	O
.	9	O
002	7	O
)	9	O
increased	9	O
bladder	9	O
weight	9	O
by	9	O
60	9	O
%	9	O
and	5	O
increased	9	O
(	9	O
7	9	O
-	7	O
to	5	O
11	7	O
-	7	O
fold	9	O
)	9	O
the	5	O
numbers	9	O
of	5	O
NOS	9	O
-	7	O
immunoreactive	3	O
(	9	O
IR	9	O
)	9	O
afferent	5	O
neurons	3	O
in	5	O
the	5	O
L6	3	O
-	7	O
S1	9	O
DRG	3	O
.	9	O

A	9	O
small	9	O
increase	9	O
(	9	O
1	9	O
.	9	O
5	9	O
-	7	O
fold	9	O
)	9	O
also	9	O
occurred	9	O
in	5	O
the	5	O
L1	9	O
DRG	3	O
,	9	O
but	9	O
no	9	O
change	9	O
was	9	O
detected	9	O
in	5	O
the	5	O
L2	9	O
and	5	O
L5	9	O
DRG	3	O
.	9	O

Bladder	9	O
afferent	5	O
cells	3	O
in	5	O
the	5	O
L6	3	O
-	7	O
S1	9	O
DRG	3	O
labeled	3	O
by	9	O
Fluorogold	0	O
(	9	O
40	9	O
microliters	0	O
)	9	O
injected	3	O
into	9	O
the	5	O
bladder	9	O
wall	5	O
did	9	O
not	5	O
exhibit	9	O
NOS	9	O
-	7	O
IR	9	O
in	5	O
control	9	O
animals	9	O
;	9	O
however	9	O
,	9	O
following	9	O
chronic	5	O
CYP	0	B-Chemical
administration	9	O
,	9	O
a	5	O
significant	9	O
percentage	9	O
of	5	O
bladder	9	O
afferent	5	O
neurons	3	O
were	9	O
NOS	9	O
-	7	O
IR	9	O
:	9	O
L6	3	O
(	9	O
19	7	O
.	9	O
8	9	O
+	9	O
/	9	O
-	7	O
4	9	O
.	9	O
6	9	O
%	9	O
)	9	O
and	5	O
S1	9	O
(	9	O
25	9	O
.	9	O
3	9	O
+	9	O
/	9	O
-	7	O
2	9	O
.	9	O
9	7	O
%	9	O
)	9	O
.	9	O

These	5	O
results	9	O
indicate	9	O
that	5	O
neuronal	3	O
gene	1	O
expression	3	O
in	5	O
visceral	9	O
sensory	5	O
pathways	9	O
can	5	O
be	5	O
upregulated	3	O
by	9	O
chemical	0	O
irritation	5	O
of	5	O
afferent	5	O
receptors	3	O
in	5	O
the	5	O
urinary	9	O
tract	9	O
and	5	O
/	9	O
or	5	O
that	5	O
pathological	5	O
changes	9	O
in	5	O
the	5	O
urinary	9	O
tract	9	O
can	5	O
initiate	9	O
chemical	0	O
signals	9	O
that	5	O
alter	9	O
the	5	O
chemical	0	O
properties	9	O
of	5	O
visceral	9	O
afferent	5	O
neurons	3	O
.	9	O

Effects	9	O
of	5	O
a	5	O
new	5	O
calcium	0	B-Chemical
antagonist	3	O
,	9	O
CD	9	B-Chemical
-	7	I-Chemical
832	7	I-Chemical
,	9	O
on	5	O
isoproterenol	0	B-Chemical
-	7	O
induced	3	O
myocardial	9	B-Disease
ischemia	9	I-Disease
in	5	O
dogs	5	O
with	5	O
partial	9	O
coronary	5	B-Disease
stenosis	5	I-Disease
.	9	O

Effects	9	O
of	5	O
CD	9	B-Chemical
-	7	I-Chemical
832	7	I-Chemical
on	5	O
isoproterenol	0	B-Chemical
(	9	O
ISO	0	B-Chemical
)	9	O
-	7	O
induced	3	O
myocardial	9	B-Disease
ischemia	9	I-Disease
were	9	O
studied	9	O
in	5	O
dogs	5	O
with	5	O
partial	9	O
coronary	5	B-Disease
stenosis	5	I-Disease
of	5	O
the	5	O
left	5	O
circumflex	5	O
coronary	5	O
artery	5	O
and	5	O
findings	9	O
were	9	O
compared	9	O
with	5	O
those	5	O
for	5	O
nifedipine	0	B-Chemical
or	5	O
diltiazem	0	B-Chemical
.	9	O

In	9	O
the	5	O
presence	9	O
of	5	O
coronary	5	B-Disease
artery	5	I-Disease
stenosis	5	I-Disease
,	9	O
3	9	O
-	7	O
min	0	O
periods	5	O
of	5	O
intracoronary	5	O
ISO	0	B-Chemical
infusion	0	O
(	9	O
10	9	O
ng	0	O
/	9	O
kg	0	O
/	9	O
min	0	O
)	9	O
increased	9	O
heart	5	O
rate	9	O
and	5	O
maximal	9	O
rate	9	O
of	5	O
left	5	O
ventricular	5	O
pressure	5	O
rise	9	O
,	9	O
which	5	O
resulted	9	O
in	5	O
a	5	O
decrease	9	O
in	5	O
percentage	9	O
segmental	5	O
shortening	9	O
and	5	O
ST	9	O
-	7	O
segment	9	O
elevation	9	O
of	5	O
the	5	O
epicardial	5	O
electrocardiogram	5	O
.	9	O

After	9	O
the	5	O
control	9	O
ISO	0	B-Chemical
infusion	0	O
with	5	O
stenosis	5	B-Disease
was	9	O
performed	9	O
,	9	O
equihypotensive	_	O
doses	0	O
of	5	O
CD	9	B-Chemical
-	7	I-Chemical
832	7	I-Chemical
(	9	O
3	9	O
and	5	O
10	9	O
micrograms	0	O
/	9	O
kg	0	O
/	9	O
min	0	O
,	9	O
n	9	O
=	7	O
7	9	O
)	9	O
,	9	O
nifedipine	0	B-Chemical
(	9	O
1	9	O
and	5	O
3	9	O
micrograms	0	O
/	9	O
kg	0	O
/	9	O
min	0	O
,	9	O
n	9	O
=	7	O
9	7	O
)	9	O
or	5	O
diltiazem	0	B-Chemical
(	9	O
10	9	O
and	5	O
30	9	O
micrograms	0	O
/	9	O
kg	0	O
/	9	O
min	0	O
,	9	O
n	9	O
=	7	O
7	9	O
)	9	O
were	9	O
infused	9	O
5	9	O
min	0	O
before	9	O
and	5	O
during	5	O
the	5	O
second	9	O
and	5	O
third	9	O
ISO	0	B-Chemical
infusion	0	O
.	9	O

Both	9	O
CD	9	B-Chemical
-	7	I-Chemical
832	7	I-Chemical
and	5	O
diltiazem	0	B-Chemical
,	9	O
but	9	O
not	5	O
nifedipine	0	B-Chemical
,	9	O
significantly	9	O
reduced	9	O
the	5	O
increase	9	O
in	5	O
heart	5	O
rate	9	O
induced	3	O
by	9	O
ISO	0	B-Chemical
infusion	0	O
.	9	O

In	9	O
contrast	9	O
to	5	O
nifedipine	0	B-Chemical
,	9	O
CD	9	B-Chemical
-	7	I-Chemical
832	7	I-Chemical
(	9	O
10	9	O
micrograms	0	O
/	9	O
kg	0	O
/	9	O
min	0	O
)	9	O
prevented	9	O
the	5	O
decrease	9	O
in	5	O
percentage	9	O
segmental	5	O
shortening	9	O
from	9	O
32	7	O
+	9	O
/	9	O
-	7	O
12	9	O
%	9	O
to	5	O
115	7	O
+	9	O
/	9	O
-	7	O
26	7	O
%	9	O
of	5	O
the	5	O
control	9	O
value	9	O
(	9	O
P	9	O
<	0	O
.	9	O
01	7	O
)	9	O
and	5	O
ST	9	O
-	7	O
segment	9	O
elevation	9	O
from	9	O
5	9	O
.	9	O
6	9	O
+	9	O
/	9	O
-	7	O
1	9	O
.	9	O
0	7	O
mV	0	O
to	5	O
1	9	O
.	9	O
6	9	O
+	9	O
/	9	O
-	7	O
1	9	O
.	9	O
3	9	O
mV	0	O
(	9	O
P	9	O
<	0	O
.	9	O
01	7	O
)	9	O
at	9	O
3	9	O
min	0	O
after	9	O
ISO	0	B-Chemical
infusion	0	O
with	5	O
stenosis	5	B-Disease
.	9	O

Diltiazem	0	B-Chemical
(	9	O
30	9	O
micrograms	0	O
/	9	O
kg	0	O
/	9	O
min	0	O
)	9	O
also	9	O
prevented	9	O
the	5	O
decrease	9	O
in	5	O
percentage	9	O
segmental	5	O
shortening	9	O
from	9	O
34	7	O
+	9	O
/	9	O
-	7	O
14	7	O
%	9	O
to	5	O
63	7	O
+	9	O
/	9	O
-	7	O
18	7	O
%	9	O
of	5	O
the	5	O
control	9	O
value	9	O
(	9	O
P	9	O
<	0	O
.	9	O
05	7	O
)	9	O
and	5	O
ST	9	O
-	7	O
segment	9	O
elevation	9	O
from	9	O
4	9	O
.	9	O
7	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
7	9	O
mV	0	O
to	5	O
2	9	O
.	9	O
1	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
7	9	O
mV	0	O
(	9	O
P	9	O
<	0	O
.	9	O
01	7	O
)	9	O
at	9	O
3	9	O
min	0	O
after	9	O
ISO	0	B-Chemical
infusion	0	O
with	5	O
stenosis	5	B-Disease
.	9	O

These	5	O
data	5	O
show	9	O
that	5	O
CD	9	B-Chemical
-	7	I-Chemical
832	7	I-Chemical
improves	5	O
myocardial	9	B-Disease
ischemia	9	I-Disease
during	5	O
ISO	0	B-Chemical
infusion	0	O
with	5	O
stenosis	5	B-Disease
and	5	O
suggest	9	O
that	5	O
the	5	O
negative	9	O
chronotropic	5	O
property	5	O
of	5	O
CD	9	B-Chemical
-	7	I-Chemical
832	7	I-Chemical
plays	9	O
a	5	O
major	9	O
role	9	O
in	5	O
the	5	O
beneficial	9	O
effects	9	O
of	5	O
CD	9	B-Chemical
-	7	I-Chemical
832	7	I-Chemical
.	9	O

The	5	O
effect	9	O
of	5	O
recombinant	3	O
human	3	O
insulin	3	O
-	7	O
like	9	O
growth	3	O
factor	9	O
-	7	O
I	9	O
on	5	O
chronic	5	O
puromycin	3	B-Chemical
aminonucleoside	0	I-Chemical
nephropathy	9	B-Disease
in	5	O
rats	9	O
.	9	O

We	9	O
recently	9	O
demonstrated	9	O
that	5	O
recombinant	3	O
hGH	1	O
exacerbates	9	O
renal	9	O
functional	9	O
and	5	O
structural	9	O
injury	9	O
in	5	O
chronic	5	O
puromycin	3	B-Chemical
aminonucleoside	0	I-Chemical
(	9	O
PAN	0	B-Chemical
)	9	O
nephropathy	9	B-Disease
,	9	O
an	5	O
experimental	5	O
model	5	O
of	5	O
glomerular	5	B-Disease
disease	5	I-Disease
.	9	O

Therefore	9	O
,	9	O
we	5	O
examined	9	O
whether	9	O
recombinant	3	O
human	3	O
(	9	O
rh	3	O
)	9	O
IGF	3	O
-	7	O
I	9	O
is	5	O
a	5	O
safer	5	O
alternative	5	O
for	5	O
the	5	O
treatment	9	O
of	5	O
growth	3	B-Disease
failure	5	I-Disease
in	5	O
rats	9	O
with	5	O
chronic	5	O
PAN	0	B-Chemical
nephropathy	9	B-Disease
.	9	O

The	5	O
glomerulopathy	5	B-Disease
was	9	O
induced	3	O
by	9	O
seven	9	O
serial	9	O
injections	9	O
of	5	O
PAN	0	B-Chemical
over	5	O
12	9	O
wk	9	O
.	9	O

Experimental	9	O
animals	9	O
(	9	O
n	9	O
=	7	O
6	9	O
)	9	O
received	9	O
rhIGF	9	O
-	7	O
I	9	O
,	9	O
400	0	O
micrograms	0	O
/	9	O
d	9	O
,	9	O
whereas	9	O
control	9	O
rats	9	O
(	9	O
n	9	O
=	7	O
6	9	O
)	9	O
received	9	O
the	5	O
vehicle	3	O
.	9	O

rhIGF	9	O
-	7	O
I	9	O
improved	5	O
weight	9	O
gain	5	O
by	9	O
14	7	O
%	9	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
,	9	O
without	9	O
altering	9	O
hematocrit	9	O
or	5	O
blood	9	O
pressure	5	O
in	5	O
rats	9	O
with	5	O
renal	9	B-Disease
disease	5	I-Disease
.	9	O

Urinary	9	O
protein	1	O
excretion	0	O
was	9	O
unaltered	9	O
by	9	O
rhIGF	9	O
-	7	O
I	9	O
treatment	9	O
in	5	O
rats	9	O
with	5	O
chronic	5	O
PAN	0	B-Chemical
nephropathy	9	B-Disease
.	9	O

After	9	O
12	9	O
wk	9	O
,	9	O
the	5	O
inulin	0	O
clearance	9	O
was	9	O
higher	9	O
in	5	O
rhIGF	9	O
-	7	O
I	9	O
-	7	O
treated	3	O
rats	9	O
,	9	O
0	7	O
.	9	O
48	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
08	7	O
versus	9	O
0	7	O
.	9	O
24	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
06	7	O
mL	0	O
/	9	O
min	0	O
/	9	O
100	0	O
g	0	O
of	5	O
body	5	O
weight	9	O
in	5	O
untreated	3	O
PAN	0	B-Chemical
nephropathy	9	B-Disease
animals	9	O
,	9	O
p	7	O
<	0	O
0	7	O
.	9	O
05	7	O
.	9	O

The	5	O
improvement	5	O
in	5	O
GFR	5	O
was	9	O
not	5	O
associated	9	O
with	5	O
enhanced	3	O
glomerular	5	B-Disease
hypertrophy	9	I-Disease
or	5	O
increased	9	O
segmental	5	O
glomerulosclerosis	3	B-Disease
,	9	O
tubulointerstitial	3	B-Disease
injury	9	I-Disease
,	9	O
or	5	O
renal	9	O
cortical	5	O
malondialdehyde	0	B-Chemical
content	9	O
.	9	O

In	9	O
rats	9	O
with	5	O
PAN	0	B-Chemical
nephropathy	9	B-Disease
,	9	O
administration	9	O
of	5	O
rhIGF	9	O
-	7	O
I	9	O
increased	9	O
IGF	3	O
-	7	O
I	9	O
and	5	O
GH	9	O
receptor	3	O
gene	1	O
expression	3	O
,	9	O
without	9	O
altering	9	O
the	5	O
steady	5	O
state	5	O
level	9	O
of	5	O
IGF	3	O
-	7	O
I	9	O
receptor	3	O
mRNA	3	O
.	9	O

In	9	O
normal	9	O
rats	9	O
with	5	O
intact	9	O
kidneys	9	O
,	9	O
rhIGF	9	O
-	7	O
I	9	O
administration	9	O
(	9	O
n	9	O
=	7	O
4	9	O
)	9	O
did	9	O
not	5	O
alter	9	O
weight	9	O
gain	5	O
,	9	O
blood	9	O
pressure	5	O
,	9	O
proteinuria	9	B-Disease
,	9	O
GFR	5	O
,	9	O
glomerular	5	O
planar	5	O
area	5	O
,	9	O
renal	9	O
cortical	5	O
malondialdehyde	0	B-Chemical
content	9	O
,	9	O
or	5	O
glomerular	5	O
or	5	O
tubulointerstitial	3	B-Disease
damage	9	I-Disease
,	9	O
compared	9	O
with	5	O
untreated	3	O
animals	9	O
(	9	O
n	9	O
=	7	O
4	9	O
)	9	O
.	9	O

rhIGF	9	O
-	7	O
I	9	O
treatment	9	O
reduced	9	O
the	5	O
steady	5	O
state	5	O
renal	9	O
IGF	3	O
-	7	O
I	9	O
mRNA	3	O
level	9	O
but	9	O
did	9	O
not	5	O
modify	9	O
gene	1	O
expression	3	O
of	5	O
the	5	O
IGF	3	O
-	7	O
I	9	O
or	5	O
GH	9	O
receptors	3	O
.	9	O

We	9	O
conclude	9	O
that	5	O
:	9	O
1	9	O
)	9	O
administration	9	O
of	5	O
rhIGF	9	O
-	7	O
I	9	O
improves	5	O
growth	3	O
and	5	O
GFR	5	O
in	5	O
rats	9	O
with	5	O
chronic	5	O
PAN	0	B-Chemical
nephropathy	9	B-Disease
and	5	O
2	9	O
)	9	O
unlike	9	O
rhGH	5	O
,	9	O
long	5	O
-	7	O
term	5	O
use	5	O
of	5	O
rhIGF	9	O
-	7	O
I	9	O
does	9	O
not	5	O
worsen	5	O
renal	9	O
functional	9	O
and	5	O
structural	9	O
injury	9	O
in	5	O
this	5	O
disease	5	O
model	5	O
.	9	O

Nefiracetam	_	B-Chemical
(	9	O
DM	9	B-Chemical
-	7	I-Chemical
9384	7	I-Chemical
)	9	O
reverses	3	O
apomorphine	0	B-Chemical
-	7	O
induced	3	O
amnesia	5	B-Disease
of	5	O
a	5	O
passive	5	O
avoidance	5	O
response	9	O
:	9	O
delayed	9	O
emergence	9	O
of	5	O
the	5	O
memory	5	O
retention	9	O
effects	9	O
.	9	O

Nefiracetam	_	B-Chemical
is	5	O
a	5	O
novel	9	O
pyrrolidone	0	B-Chemical
derivative	0	O
which	5	O
attenuates	3	O
scopolamine	0	B-Chemical
-	7	O
induced	3	O
learning	5	B-Disease
and	5	I-Disease
post	9	I-Disease
-	7	I-Disease
training	5	I-Disease
consolidation	5	I-Disease
deficits	5	I-Disease
.	9	O

Given	9	O
that	5	O
apomorphine	0	B-Chemical
inhibits	3	O
passive	5	O
avoidance	5	O
retention	9	O
when	5	O
given	5	O
during	5	O
training	5	O
or	5	O
in	5	O
a	5	O
defined	5	O
10	9	O
-	7	O
12h	0	O
post	9	O
-	7	O
training	5	O
period	5	O
,	9	O
we	5	O
evaluated	9	O
the	5	O
ability	9	O
of	5	O
nefiracetam	9	B-Chemical
to	5	O
attenuate	9	O
amnesia	5	B-Disease
induced	3	O
by	9	O
dopaminergic	5	O
agonism	3	O
.	9	O

A	9	O
step	9	O
-	7	O
down	9	O
passive	5	O
avoidance	5	O
paradigm	5	O
was	9	O
employed	5	O
and	5	O
nefiracetam	9	B-Chemical
(	9	O
3	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
and	5	O
apomorphine	0	B-Chemical
(	9	O
0	7	O
.	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
were	9	O
given	5	O
alone	9	O
or	5	O
in	5	O
combination	9	O
during	5	O
training	5	O
and	5	O
at	9	O
the	5	O
10	9	O
-	7	O
12h	0	O
post	9	O
-	7	O
training	5	O
period	5	O
of	5	O
consolidation	5	O
.	9	O

Co	0	O
-	7	O
administration	9	O
of	5	O
nefiracetam	9	B-Chemical
and	5	O
apomorphine	0	B-Chemical
during	5	O
training	5	O
or	5	O
10h	0	O
thereafter	9	O
produced	9	O
no	9	O
significant	9	O
anti	3	O
-	7	O
amnesic	5	O
effect	9	O
.	9	O

However	9	O
,	9	O
administration	9	O
of	5	O
nefiracetam	9	B-Chemical
during	5	O
training	5	O
completely	9	O
reversed	9	O
the	5	O
amnesia	5	B-Disease
induced	3	O
by	9	O
apomorphine	0	B-Chemical
at	9	O
the	5	O
10h	0	O
post	9	O
-	7	O
training	5	O
time	5	O
and	5	O
the	5	O
converse	9	O
was	9	O
also	9	O
true	5	O
.	9	O

These	5	O
effects	9	O
were	9	O
not	5	O
mediated	3	O
by	9	O
a	5	O
dopaminergic	5	O
mechanism	9	O
as	5	O
nefiracetam	9	B-Chemical
,	9	O
at	9	O
millimolar	0	O
concentrations	0	O
,	9	O
failed	9	O
to	5	O
displace	9	O
either	9	O
[	9	O
3H	0	O
]	9	O
SCH	9	B-Chemical
23390	0	I-Chemical
or	5	O
[	9	O
3H	0	O
]	9	O
spiperone	0	B-Chemical
binding	1	O
from	9	O
D1	3	O
or	5	O
D2	9	O
dopamine	5	B-Chemical
receptor	3	O
subtypes	9	O
,	9	O
respectively	9	O
.	9	O

It	5	O
is	5	O
suggested	9	O
that	5	O
nefiracetam	9	B-Chemical
augments	3	O
molecular	9	O
processes	5	O
in	5	O
the	5	O
early	9	O
stages	9	O
of	5	O
events	5	O
which	5	O
ultimately	5	O
lead	5	O
to	5	O
consolidation	5	O
of	5	O
memory	5	O
.	9	O

Phenytoin	0	B-Chemical
encephalopathy	5	B-Disease
as	5	O
probable	9	O
idiosyncratic	5	O
reaction	9	O
:	9	O
case	5	O
report	5	O
.	9	O

A	9	O
case	5	O
of	5	O
phenytoin	0	B-Chemical
(	9	O
DPH	0	B-Chemical
)	9	O
encephalopathy	5	B-Disease
with	5	O
increasing	9	O
seizures	5	B-Disease
and	5	O
EEG	5	O
and	5	O
mental	5	O
changes	9	O
is	5	O
described	9	O
.	9	O

Despite	5	O
adequate	5	O
oral	9	O
dosage	9	O
of	5	O
DPH	0	B-Chemical
(	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
/	9	O
daily	5	O
)	9	O
the	5	O
plasma	9	O
level	9	O
was	9	O
very	5	O
low	9	O
(	9	O
2	9	O
.	9	O
8	9	O
microgramg	_	O
/	9	O
ml	0	O
)	9	O
.	9	O

The	5	O
encephalopathy	5	B-Disease
was	9	O
probably	9	O
an	5	O
idiosyncratic	5	O
and	5	O
not	5	O
toxic	0	O
or	5	O
allergic	9	O
reaction	9	O
.	9	O

In	9	O
fact	9	O
the	5	O
concentration	0	O
of	5	O
free	9	O
DPH	0	B-Chemical
was	9	O
normal	9	O
,	9	O
the	5	O
patient	5	O
presented	5	O
a	5	O
retarded	9	O
morbilliform	5	O
rash	5	B-Disease
during	5	O
DPH	0	B-Chemical
treatment	9	O
,	9	O
the	5	O
protidogram	_	O
was	9	O
normal	9	O
,	9	O
and	5	O
an	5	O
intradermic	0	O
DPH	0	B-Chemical
injection	9	O
had	9	O
no	9	O
local	5	O
effect	9	O
.	9	O

The	5	O
authors	5	O
conclude	9	O
that	5	O
in	5	O
a	5	O
patient	5	O
starting	9	O
DPH	0	B-Chemical
treatment	9	O
an	5	O
unexpected	9	O
increase	9	O
in	5	O
seizures	5	B-Disease
,	9	O
with	5	O
EEG	5	O
and	5	O
mental	5	O
changes	9	O
occurring	9	O
simultaneously	5	O
,	9	O
should	5	O
alert	5	O
the	5	O
physician	5	O
to	5	O
the	5	O
possible	5	O
need	5	O
for	5	O
eliminating	5	O
DPH	0	B-Chemical
from	9	O
the	5	O
therapeutic	5	O
regimen	5	O
,	9	O
even	5	O
if	5	O
plasma	9	O
concentrations	0	O
are	5	O
low	9	O
.	9	O

Prevention	2	O
and	5	O
treatment	9	O
of	5	O
endometrial	9	B-Disease
disease	5	I-Disease
in	5	O
climacteric	5	O
women	5	O
receiving	9	O
oestrogen	3	B-Chemical
therapy	5	O
.	9	O

The	5	O
treatment	9	O
regimens	5	O
are	5	O
described	9	O
in	5	O
74	7	O
patients	5	O
with	5	O
endometrial	9	B-Disease
disease	5	I-Disease
among	5	O
850	9	O
climacteric	5	O
women	5	O
receiving	9	O
oestrogen	3	B-Chemical
therapy	5	O
.	9	O

Cystic	2	O
hyperplasia	9	B-Disease
was	9	O
associated	9	O
with	5	O
unopposed	5	O
oestrogen	3	B-Chemical
therapy	5	O
without	9	O
progestagen	0	B-Chemical
.	9	O

Two	9	O
courses	5	O
of	5	O
21	7	O
days	9	O
of	5	O
5	9	O
mg	0	O
norethisterone	0	B-Chemical
daily	5	O
caused	9	O
reversion	9	O
to	5	O
normal	9	O
in	5	O
all	5	O
57	7	O
cases	5	O
of	5	O
cystic	5	O
hyperplasia	9	B-Disease
and	5	O
6	9	O
of	5	O
the	5	O
8	9	O
cases	5	O
of	5	O
atypical	5	O
hyperplasia	9	B-Disease
.	9	O

4	9	O
cases	5	O
of	5	O
endometrial	9	B-Disease
carcinoma	3	I-Disease
referred	5	O
from	9	O
elsewhere	9	O
demonstrated	9	O
the	5	O
problems	5	O
of	5	O
inappropriate	5	O
and	5	O
unsupervised	5	O
unopposed	5	O
oestrogen	3	B-Chemical
therapy	5	O
and	5	O
the	5	O
difficulty	5	O
in	5	O
distinguishing	5	O
severe	5	O
hyperplasia	9	B-Disease
from	9	O
malignancy	5	B-Disease
.	9	O

Cyclical	5	O
low	9	O
-	7	O
dose	9	O
oestrogen	3	B-Chemical
therapy	5	O
with	5	O
7	9	O
-	7	O
-	7	O
13	7	O
days	9	O
of	5	O
progestagen	0	B-Chemical
does	9	O
not	5	O
seem	5	O
to	5	O
increase	9	O
the	5	O
risk	5	O
of	5	O
endometrial	9	B-Disease
hyperplasia	9	I-Disease
or	5	O
carcinoma	3	B-Disease
.	9	O

Effects	9	O
of	5	O
exercise	5	O
on	5	O
the	5	O
severity	5	O
of	5	O
isoproterenol	0	B-Chemical
-	7	O
induced	3	O
myocardial	9	B-Disease
infarction	5	I-Disease
.	9	O

The	5	O
effect	9	O
of	5	O
exercise	5	O
on	5	O
the	5	O
severity	5	O
of	5	O
isoproterenol	0	B-Chemical
-	7	O
induced	3	O
myocardial	9	B-Disease
infarction	5	I-Disease
was	9	O
studied	9	O
in	5	O
male	9	O
rats	9	O
.	9	O

Ninety	5	O
-	7	O
three	9	O
rats	9	O
were	9	O
randomly	5	O
divided	5	O
into	9	O
three	9	O
groups	9	O
.	9	O

The	5	O
exercise	5	O
-	7	O
isoproterenol	0	B-Chemical
(	9	O
E	9	O
-	7	O
1	9	O
)	9	O
and	5	O
exercise	5	O
control	9	O
(	9	O
EC	9	O
)	9	O
groups	9	O
exercised	5	O
daily	5	O
for	5	O
thirty	5	O
days	9	O
on	5	O
a	5	O
treadmill	5	O
at	9	O
1	9	O
mph	5	O
,	9	O
2	9	O
%	9	O
grade	9	O
while	9	O
animals	9	O
of	5	O
the	5	O
sedentary	5	O
-	7	O
isoproterenol	0	B-Chemical
(	9	O
S	9	O
-	7	O
I	9	O
)	9	O
group	9	O
remained	9	O
sedentary	5	O
.	9	O

Eight	9	O
animals	9	O
were	9	O
assigned	5	O
to	5	O
the	5	O
sedentary	5	O
control	9	O
(	9	O
SC	9	O
)	9	O
group	9	O
which	5	O
remained	9	O
sedentary	5	O
throughout	9	O
the	5	O
experimental	5	O
period	5	O
.	9	O

Forty	9	O
-	7	O
eight	9	O
hours	9	O
after	9	O
the	5	O
final	9	O
exercise	5	O
period	5	O
,	9	O
S	9	O
-	7	O
I	9	O
and	5	O
E	9	O
-	7	O
I	9	O
animals	9	O
received	9	O
a	5	O
single	9	O
subcutaneous	9	O
injection	9	O
of	5	O
isoproterenol	0	B-Chemical
(	9	O
250	0	O
mg	0	O
/	9	O
kg	0	O
body	5	O
weight	9	O
)	9	O
.	9	O

Animals	9	O
of	5	O
the	5	O
S	9	O
-	7	O
I	9	O
group	9	O
exhibited	9	O
significantly	9	O
(	9	O
Pp	9	O
less	5	O
than	5	O
0	7	O
.	9	O
05	7	O
)	9	O
greater	5	O
mortality	5	O
from	9	O
the	5	O
effects	9	O
of	5	O
isoproterenol	0	B-Chemical
than	5	O
animals	9	O
of	5	O
the	5	O
E	9	O
-	7	O
I	9	O
group	9	O
.	9	O

Serum	9	O
CPK	9	O
activity	9	O
for	5	O
E	9	O
-	7	O
I	9	O
animals	9	O
was	9	O
significantly	9	O
(	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
05	7	O
)	9	O
greater	5	O
than	5	O
for	5	O
animals	9	O
in	5	O
the	5	O
S	9	O
-	7	O
I	9	O
and	5	O
EC	9	O
groups	9	O
twenty	5	O
hours	9	O
following	9	O
isoproterenol	0	B-Chemical
injection	9	O
.	9	O

No	9	O
statistically	9	O
significant	9	O
differences	9	O
were	9	O
observed	9	O
between	5	O
the	5	O
two	5	O
isoproterenol	0	B-Chemical
treated	3	O
groups	9	O
for	5	O
severity	5	O
of	5	O
the	5	O
induced	3	O
lesions	5	O
,	9	O
changes	9	O
in	5	O
heart	5	O
weight	9	O
,	9	O
or	5	O
heart	5	O
weight	9	O
to	5	O
body	5	O
weight	9	O
ratios	9	O
.	9	O

The	5	O
results	9	O
indicated	9	O
that	5	O
exercise	5	O
reduced	9	O
the	5	O
mortality	5	O
associated	9	O
with	5	O
the	5	O
effects	9	O
of	5	O
large	5	O
dosages	9	O
of	5	O
isoproterenol	0	B-Chemical
but	9	O
had	9	O
little	9	O
on	5	O
the	5	O
severity	5	O
of	5	O
the	5	O
infarction	5	B-Disease
.	9	O

Human	9	O
corticotropin	9	B-Chemical
-	7	O
releasing	9	O
hormone	9	O
and	5	O
thyrotropin	9	B-Chemical
-	7	O
releasing	9	O
hormone	9	O
modulate	9	O
the	5	O
hypercapnic	5	B-Disease
ventilatory	5	O
response	9	O
in	5	O
humans	9	O
.	9	O

Human	9	O
corticotropin	9	B-Chemical
-	7	O
releasing	9	O
hormone	9	O
(	9	O
hCRH	3	O
)	9	O
and	5	O
thyrotropin	9	B-Chemical
-	7	O
releasing	9	O
hormone	9	O
(	9	O
TRH	3	O
)	9	O
are	5	O
known	9	O
to	5	O
stimulate	3	O
ventilation	5	O
after	9	O
i	9	O
.	9	O
v	0	O
.	9	O
administration	9	O
in	5	O
humans	9	O
.	9	O

In	9	O
a	5	O
placebo	9	O
-	7	O
controlled	5	O
,	9	O
single	9	O
-	7	O
blind	5	O
study	9	O
we	5	O
aimed	5	O
to	5	O
clarify	9	O
if	5	O
both	9	O
peptides	9	O
act	9	O
by	9	O
altering	9	O
central	5	O
chemosensitivity	3	O
.	9	O

Two	9	O
subsequent	9	O
CO2	0	B-Chemical
-	7	O
rebreathing	5	O
tests	5	O
were	9	O
performed	9	O
in	5	O
healthy	5	O
young	5	O
volunteers	5	O
.	9	O

During	5	O
the	5	O
first	9	O
test	5	O
0	7	O
.	9	O
9	7	O
%	9	O
NaCl	0	B-Chemical
was	9	O
given	5	O
i	9	O
.	9	O
v	0	O
.	9	O
;	9	O
during	5	O
the	5	O
second	9	O
test	5	O
200	0	O
micrograms	0	O
of	5	O
hCRH	3	O
(	9	O
n	9	O
=	7	O
12	9	O
)	9	O
or	5	O
400	0	O
micrograms	0	O
of	5	O
TRH	3	O
(	9	O
n	9	O
=	7	O
6	9	O
)	9	O
was	9	O
administered	9	O
i	9	O
.	9	O
v	0	O
.	9	O
Nine	9	O
subjects	5	O
received	9	O
0	7	O
.	9	O
9	7	O
%	9	O
NaCl	0	B-Chemical
i	9	O
.	9	O
v	0	O
.	9	O
during	5	O
both	9	O
rebreathing	5	O
manoeuvres	5	O
.	9	O

The	5	O
CO2	0	B-Chemical
-	7	O
response	9	O
curves	5	O
for	5	O
the	5	O
two	5	O
tests	5	O
were	9	O
compared	9	O
within	9	O
the	5	O
same	9	O
subject	5	O
.	9	O

In	9	O
the	5	O
hCRH	3	O
group	9	O
a	5	O
marked	9	O
parallel	5	O
shift	9	O
of	5	O
the	5	O
CO2	0	B-Chemical
-	7	O
response	9	O
curve	9	O
to	5	O
the	5	O
left	5	O
was	9	O
observed	9	O
after	9	O
hCRH	3	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
01	7	O
)	9	O
.	9	O

The	5	O
same	9	O
effect	9	O
occurred	9	O
following	9	O
TRH	3	O
but	9	O
was	9	O
less	5	O
striking	9	O
(	9	O
P	9	O
=	7	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

hCRH	3	O
and	5	O
TRH	3	O
caused	9	O
a	5	O
reduction	9	O
in	5	O
the	5	O
CO2	0	B-Chemical
threshold	5	O
.	9	O

The	5	O
CO2	0	B-Chemical
-	7	O
response	9	O
curves	5	O
in	5	O
the	5	O
control	9	O
group	9	O
were	9	O
nearly	9	O
identical	9	O
.	9	O

The	5	O
results	9	O
indicate	9	O
an	5	O
additive	9	O
effect	9	O
of	5	O
both	9	O
releasing	9	O
hormones	9	O
on	5	O
the	5	O
hypercapnic	5	B-Disease
ventilatory	5	O
response	9	O
in	5	O
humans	9	O
,	9	O
presumably	9	O
independent	9	O
of	5	O
central	5	O
chemosensitivity	3	O
.	9	O

Lamivudine	7	B-Chemical
is	5	O
effective	5	O
in	5	O
suppressing	3	O
hepatitis	9	B-Disease
B	9	I-Disease
virus	9	O
DNA	9	O
in	5	O
Chinese	9	O
hepatitis	9	B-Chemical
B	9	I-Chemical
surface	9	I-Chemical
antigen	3	I-Chemical
carriers	9	O
:	9	O
a	5	O
placebo	9	O
-	7	O
controlled	5	O
trial	5	O
.	9	O

Lamivudine	7	B-Chemical
is	5	O
a	5	O
novel	9	O
2	9	B-Chemical
'	9	I-Chemical
,	9	I-Chemical
3	9	I-Chemical
'	9	I-Chemical
-	7	I-Chemical
dideoxy	9	I-Chemical
cytosine	1	I-Chemical
analogue	0	O
that	5	O
has	9	O
potent	3	O
inhibitory	3	O
effects	9	O
on	5	O
hepatitis	9	B-Disease
B	9	I-Disease
virus	9	O
replication	9	O
in	5	O
vitro	3	O
and	5	O
in	5	O
vivo	3	O
.	9	O

We	9	O
performed	9	O
a	5	O
single	9	O
-	7	O
blind	5	O
,	9	O
placebo	9	O
-	7	O
controlled	5	O
study	9	O
to	5	O
assess	5	O
its	9	O
effectiveness	5	O
and	5	O
safety	5	O
in	5	O
Chinese	9	O
hepatitis	9	B-Chemical
B	9	I-Chemical
surface	9	I-Chemical
antigen	3	I-Chemical
(	9	O
HBsAg	9	B-Chemical
)	9	O
carriers	9	O
.	9	O

Forty	9	O
-	7	O
two	5	O
Chinese	9	O
HBsAg	9	B-Chemical
carriers	9	O
were	9	O
randomized	5	O
to	5	O
receive	5	O
placebo	9	O
(	9	O
6	9	O
patients	5	O
)	9	O
or	5	O
lamivudine	5	B-Chemical
orally	0	O
in	5	O
dosages	9	O
of	5	O
25	9	O
mg	0	O
,	9	O
100	0	O
mg	0	O
,	9	O
or	5	O
300	0	O
mg	0	O
daily	5	O
(	9	O
12	9	O
patients	5	O
for	5	O
each	5	O
dosage	9	O
)	9	O
.	9	O

The	5	O
drug	5	O
was	9	O
given	5	O
for	5	O
4	9	O
weeks	9	O
.	9	O

The	5	O
patients	5	O
were	9	O
closely	9	O
monitored	9	O
clinically	5	O
,	9	O
biochemically	9	O
,	9	O
and	5	O
serologically	9	O
up	5	O
to	5	O
4	9	O
weeks	9	O
after	9	O
drug	5	O
treatment	9	O
.	9	O

All	9	O
36	9	O
patients	5	O
receiving	9	O
lamivudine	5	B-Chemical
had	9	O
a	5	O
decrease	9	O
in	5	O
hepatitis	9	B-Disease
B	9	I-Disease
virus	9	O
(	9	O
HBV	9	O
)	9	O
DNA	9	O
values	5	O
of	5	O
>	0	O
90	9	O
%	9	O
(	9	O
P	9	O
<	0	O
.	9	O
001	9	O
compared	9	O
with	5	O
placebo	9	O
)	9	O
.	9	O

Although	9	O
25	9	O
mg	0	O
of	5	O
lamivudine	5	B-Chemical
was	9	O
slightly	9	O
less	5	O
effective	5	O
than	5	O
100	0	O
mg	0	O
(	9	O
P	9	O
=	7	O
.	9	O
011	2	O
)	9	O
and	5	O
300	0	O
mg	0	O
(	9	O
P	9	O
=	7	O
.	9	O
005	7	O
)	9	O
,	9	O
it	5	O
still	5	O
induced	3	O
94	7	O
%	9	O
suppression	9	O
of	5	O
HBV	9	O
DNA	9	O
after	9	O
the	5	O
fourth	9	O
week	9	O
of	5	O
therapy	5	O
.	9	O

HBV	9	O
DNA	9	O
values	5	O
returned	5	O
to	5	O
pretreatment	0	O
levels	3	O
within	9	O
4	9	O
weeks	9	O
of	5	O
cessation	5	O
of	5	O
therapy	5	O
.	9	O

There	5	O
was	9	O
no	9	O
change	9	O
in	5	O
the	5	O
hepatitis	9	B-Disease
B	9	I-Disease
e	9	O
antigen	3	O
status	9	O
or	5	O
in	5	O
aminotransferase	7	O
levels	3	O
.	9	O

No	9	O
serious	5	O
adverse	5	O
events	5	O
were	9	O
observed	9	O
.	9	O

In	9	O
conclusion	9	O
,	9	O
a	5	O
4	9	O
-	7	O
week	9	O
course	5	O
of	5	O
lamivudine	5	B-Chemical
was	9	O
safe	5	O
and	5	O
effective	5	O
in	5	O
suppression	9	O
of	5	O
HBV	9	O
DNA	9	O
in	5	O
Chinese	9	O
HBsAg	9	B-Chemical
carriers	9	O
.	9	O

The	5	O
suppression	9	O
was	9	O
>	0	O
90	9	O
%	9	O
but	9	O
reversible	9	O
.	9	O

Studies	9	O
with	5	O
long	5	O
-	7	O
term	5	O
lamivudine	5	B-Chemical
administration	9	O
should	5	O
be	5	O
performed	9	O
to	5	O
determine	9	O
if	5	O
prolonged	9	O
suppression	9	O
of	5	O
HBV	9	O
DNA	9	O
can	5	O
be	5	O
achieved	5	O
.	9	O

Population	5	O
-	7	O
based	5	O
study	9	O
of	5	O
risk	5	O
of	5	O
venous	5	B-Disease
thromboembolism	5	I-Disease
associated	9	O
with	5	O
various	9	O
oral	9	B-Chemical
contraceptives	5	I-Chemical
.	9	O

BACKGROUND	2	O
:	9	O
Four	9	O
studies	9	O
published	9	O
since	9	O
December	2	O
,	9	O
1995	2	O
,	9	O
reported	9	O
that	5	O
the	5	O
incidence	5	O
of	5	O
venous	5	B-Disease
thromboembolism	5	I-Disease
(	9	O
VTE	5	B-Disease
)	9	O
was	9	O
higher	9	O
in	5	O
women	5	O
who	5	O
used	5	O
oral	9	B-Chemical
contraceptives	5	I-Chemical
(	9	O
OCs	5	B-Chemical
)	9	O
containing	0	O
the	5	O
third	9	O
-	7	O
generation	9	O
progestagens	0	B-Chemical
gestodene	0	B-Chemical
or	5	O
desogestrel	0	B-Chemical
than	5	O
in	5	O
users	5	O
of	5	O
OCs	5	B-Chemical
containing	0	O
second	9	O
-	7	O
generation	9	O
progestagens	0	B-Chemical
.	9	O

However	9	O
,	9	O
confounding	5	O
and	5	O
bias	5	O
in	5	O
the	5	O
design	5	O
of	5	O
these	5	O
studies	9	O
may	5	O
have	5	O
affected	9	O
the	5	O
findings	9	O
.	9	O

The	5	O
aim	5	O
of	5	O
our	5	O
study	9	O
was	9	O
to	5	O
re	5	O
-	7	O
examine	9	O
the	5	O
association	9	O
between	5	O
risk	5	O
of	5	O
VTE	5	B-Disease
and	5	O
OC	9	B-Chemical
use	5	O
with	5	O
a	5	O
different	9	O
study	9	O
design	5	O
and	5	O
analysis	9	O
to	5	O
avoid	5	O
some	5	O
of	5	O
the	5	O
bias	5	O
and	5	O
confounding	5	O
of	5	O
the	5	O
earlier	9	O
studies	9	O
.	9	O

METHODS	2	O
:	9	O
We	9	O
used	5	O
computer	5	O
records	5	O
of	5	O
patients	5	O
from	9	O
143	7	O
general	5	O
practices	5	O
in	5	O
the	5	O
UK	2	O
.	9	O

The	5	O
study	9	O
was	9	O
based	5	O
on	5	O
the	5	O
medical	5	O
records	5	O
of	5	O
about	5	O
540	9	O
,	9	O
000	9	O
women	5	O
born	5	O
between	5	O
1941	4	O
and	5	O
1981	2	O
.	9	O

All	9	O
women	5	O
who	5	O
had	9	O
a	5	O
recorded	5	O
diagnosis	5	O
of	5	O
deep	5	B-Disease
-	7	I-Disease
vein	5	I-Disease
thrombosis	5	I-Disease
,	9	O
venous	5	B-Disease
thrombosis	5	I-Disease
not	5	O
otherwise	9	O
specified	5	O
,	9	O
or	5	O
pulmonary	5	O
embolus	5	O
during	5	O
the	5	O
study	9	O
period	5	O
,	9	O
and	5	O
who	5	O
had	9	O
been	9	O
treated	3	O
with	5	O
an	5	O
anticoagulant	9	O
were	9	O
identified	9	O
as	5	O
potential	9	O
cases	5	O
of	5	O
VTE	5	B-Disease
.	9	O

We	9	O
did	9	O
a	5	O
cohort	9	O
analysis	9	O
to	5	O
estimate	5	O
and	5	O
compare	9	O
incidence	5	O
of	5	O
VTE	5	B-Disease
in	5	O
users	5	O
of	5	O
the	5	O
main	5	O
OC	9	B-Chemical
preparations	9	O
,	9	O
and	5	O
a	5	O
nested	9	O
case	5	O
-	7	O
control	9	O
study	9	O
to	5	O
calculate	5	O
the	5	O
odds	5	O
ratios	9	O
of	5	O
VTE	5	B-Disease
associated	9	O
with	5	O
use	5	O
of	5	O
different	9	O
types	9	O
of	5	O
OC	9	B-Chemical
,	9	O
after	9	O
adjustment	5	O
for	5	O
potential	9	O
confounding	5	O
factors	9	O
.	9	O

In	9	O
the	5	O
case	5	O
-	7	O
control	9	O
study	9	O
,	9	O
we	5	O
matched	9	O
cases	5	O
to	5	O
controls	9	O
by	9	O
exact	5	O
year	5	O
of	5	O
birth	5	O
,	9	O
practice	5	O
,	9	O
and	5	O
current	5	O
use	5	O
of	5	O
OCs	5	B-Chemical
.	9	O

We	9	O
used	5	O
a	5	O
multiple	5	O
logistic	5	O
regression	5	O
model	5	O
that	5	O
included	5	O
body	5	O
-	7	O
mass	9	O
index	5	O
,	9	O
number	9	O
of	5	O
cycles	9	O
,	9	O
change	9	O
in	5	O
type	9	O
of	5	O
OC	9	B-Chemical
prescribed	5	O
within	9	O
3	9	O
months	5	O
of	5	O
the	5	O
event	5	O
,	9	O
previous	9	O
pregnancy	5	O
,	9	O
and	5	O
concurrent	5	O
disease	5	O
.	9	O

FINDINGS	2	O
:	9	O
85	9	O
women	5	O
met	5	O
the	5	O
inclusion	5	O
criteria	5	O
for	5	O
VTE	5	B-Disease
,	9	O
two	5	O
of	5	O
whom	5	O
were	9	O
users	5	O
of	5	O
progestagen	0	B-Chemical
-	7	O
only	9	O
OCs	5	B-Chemical
.	9	O

Of	9	O
the	5	O
83	7	O
cases	5	O
of	5	O
VTE	5	B-Disease
associated	9	O
with	5	O
use	5	O
of	5	O
combined	9	O
OCs	5	B-Chemical
,	9	O
43	7	O
were	9	O
recorded	5	O
as	5	O
deep	5	B-Disease
-	7	I-Disease
vein	5	I-Disease
thrombosis	5	I-Disease
,	9	O
35	9	O
as	5	O
pulmonary	5	O
thrombosis	5	B-Disease
,	9	O
and	5	O
five	9	O
as	5	O
venous	5	B-Disease
thrombosis	5	I-Disease
not	5	O
otherwise	9	O
specified	5	O
.	9	O

The	5	O
crude	0	O
rate	9	O
of	5	O
VTE	5	B-Disease
per	9	O
10	9	O
,	9	O
000	9	O
woman	5	O
-	7	O
years	5	O
was	9	O
4	9	O
.	9	O
10	9	O
in	5	O
current	5	O
users	5	O
of	5	O
any	5	O
OC	9	B-Chemical
,	9	O
3	9	O
.	9	O
10	9	O
in	5	O
users	5	O
of	5	O
second	9	O
-	7	O
generation	9	O
OCs	5	B-Chemical
,	9	O
and	5	O
4	9	O
.	9	O
96	9	O
in	5	O
users	5	O
of	5	O
third	9	O
-	7	O
generation	9	O
preparations	9	O
.	9	O

After	9	O
adjustment	5	O
for	5	O
age	5	O
,	9	O
the	5	O
rate	9	O
ratio	9	O
of	5	O
VTE	5	B-Disease
in	5	O
users	5	O
of	5	O
third	9	O
-	7	O
generation	9	O
relative	9	O
to	5	O
second	9	O
-	7	O
generation	9	O
OCs	5	B-Chemical
was	9	O
1	9	O
.	9	O
68	7	O
(	9	O
95	7	O
%	9	O
CI	7	O
1	9	O
.	9	O
04	7	O
-	7	O
2	9	O
.	9	O
75	9	O
)	9	O
.	9	O

Logistic	5	O
regression	5	O
showed	9	O
no	9	O
significant	9	O
difference	9	O
in	5	O
the	5	O
risk	5	O
of	5	O
VTE	5	B-Disease
between	5	O
users	5	O
of	5	O
third	9	O
-	7	O
generation	9	O
and	5	O
second	9	O
-	7	O
generation	9	O
OCs	5	B-Chemical
.	9	O

Among	9	O
users	5	O
of	5	O
third	9	O
-	7	O
generation	9	O
progestagens	0	B-Chemical
,	9	O
the	5	O
risk	5	O
of	5	O
VTE	5	B-Disease
was	9	O
higher	9	O
in	5	O
users	5	O
of	5	O
desogestrel	0	B-Chemical
with	5	O
20	9	O
g	0	O
ethinyloestradiol	0	B-Chemical
than	5	O
in	5	O
users	5	O
of	5	O
gestodene	0	B-Chemical
or	5	O
desogestrel	0	B-Chemical
with	5	O
30	9	O
g	0	O
ethinyloestradiol	0	B-Chemical
.	9	O

With	5	O
all	5	O
second	9	O
-	7	O
generation	9	O
OCs	5	B-Chemical
as	5	O
the	5	O
reference	9	O
,	9	O
the	5	O
odds	5	O
ratios	9	O
for	5	O
VTE	5	B-Disease
were	9	O
3	9	O
.	9	O
49	7	O
(	9	O
1	9	O
.	9	O
21	7	O
-	7	O
10	9	O
.	9	O
12	9	O
)	9	O
for	5	O
desogestrel	0	B-Chemical
plus	9	O
20	9	O
g	0	O
ethinyloestradiol	0	B-Chemical
and	5	O
1	9	O
.	9	O
18	7	O
(	9	O
0	7	O
.	9	O
66	7	O
-	7	O
2	9	O
.	9	O
17	7	O
)	9	O
for	5	O
the	5	O
other	5	O
third	9	O
-	7	O
generation	9	O
progestagens	0	B-Chemical
.	9	O

INTERPRETATION	2	O
:	9	O
The	5	O
previously	9	O
reported	9	O
increase	9	O
in	5	O
odds	5	O
ratio	9	O
associated	9	O
with	5	O
third	9	O
-	7	O
generation	9	O
OCs	5	B-Chemical
when	5	O
compared	9	O
with	5	O
second	9	O
-	7	O
generation	9	O
products	9	O
is	5	O
likely	5	O
to	5	O
have	5	O
been	9	O
the	5	O
result	9	O
of	5	O
residual	9	O
confounding	5	O
by	9	O
age	5	O
.	9	O

The	5	O
increased	9	O
odds	5	O
ratio	9	O
associated	9	O
with	5	O
products	9	O
containing	0	O
20	9	O
micrograms	0	O
ethinyloestradiol	0	B-Chemical
and	5	O
desogestrel	0	B-Chemical
compared	9	O
with	5	O
the	5	O
30	9	O
micrograms	0	O
product	9	O
is	5	O
biologically	9	O
implausible	5	O
,	9	O
and	5	O
is	5	O
likely	5	O
to	5	O
be	5	O
the	5	O
result	9	O
of	5	O
preferential	9	O
prescribing	5	O
and	5	O
,	9	O
thus	9	O
,	9	O
confounding	5	O
.	9	O

MK	9	B-Chemical
-	7	I-Chemical
801	7	I-Chemical
augments	3	O
pilocarpine	0	B-Chemical
-	7	O
induced	3	O
electrographic	5	O
seizure	5	B-Disease
but	9	O
protects	3	O
against	9	O
brain	5	B-Disease
damage	9	I-Disease
in	5	O
rats	9	O
.	9	O

1	9	O
.	9	O

The	5	O
authors	5	O
examined	9	O
the	5	O
anticonvulsant	5	O
effects	9	O
of	5	O
MK	9	B-Chemical
-	7	I-Chemical
801	7	I-Chemical
on	5	O
the	5	O
pilocarpine	0	B-Chemical
-	7	O
induced	3	O
seizure	5	B-Disease
model	5	O
.	9	O

Intraperitoneal	0	O
injection	9	O
of	5	O
pilocarpine	0	B-Chemical
(	9	O
400	0	O
mg	0	O
/	9	O
kg	0	O
)	9	O
induced	3	O
tonic	5	B-Disease
and	5	I-Disease
clonic	5	I-Disease
seizure	5	I-Disease
.	9	O

Scopolamine	0	B-Chemical
(	9	O
10	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
and	5	O
pentobarbital	0	B-Chemical
(	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
prevented	9	O
development	9	O
of	5	O
pilocarpine	0	B-Chemical
-	7	O
induced	3	O
behavioral	5	O
seizure	5	B-Disease
but	9	O
MK	9	B-Chemical
-	7	I-Chemical
801	7	I-Chemical
(	9	O
0	7	O
.	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
did	9	O
not	5	O
.	9	O

2	9	O
.	9	O

An	5	O
electrical	5	O
seizure	5	B-Disease
measured	9	O
with	5	O
hippocampal	3	O
EEG	5	O
appeared	9	O
in	5	O
the	5	O
pilocarpine	0	B-Chemical
-	7	O
treated	3	O
group	9	O
.	9	O

Scopolamine	0	B-Chemical
and	5	O
pentobarbital	0	B-Chemical
blocked	3	O
the	5	O
pilocarpine	0	B-Chemical
-	7	O
induced	3	O
electrographic	5	O
seizure	5	B-Disease
,	9	O
MK	9	B-Chemical
-	7	I-Chemical
801	7	I-Chemical
treatment	9	O
augmented	9	O
the	5	O
electrographic	5	O
seizure	5	B-Disease
induced	3	O
by	9	O
pilocarpine	0	B-Chemical
.	9	O

3	9	O
.	9	O

Brain	9	B-Disease
damage	9	I-Disease
was	9	O
assessed	9	O
by	9	O
examining	5	O
the	5	O
hippocampus	9	O
microscopically	9	O
.	9	O

Pilocarpine	0	B-Chemical
produced	9	O
neuronal	3	B-Disease
death	9	I-Disease
in	5	O
the	5	O
hippocampus	9	O
,	9	O
which	5	O
showed	9	O
pyknotic	3	O
changes	9	O
.	9	O

Pentobarbital	0	B-Chemical
,	9	O
scopolamine	0	B-Chemical
and	5	O
MK	9	B-Chemical
-	7	I-Chemical
801	7	I-Chemical
protected	9	O
the	5	O
brain	5	B-Disease
damage	9	I-Disease
by	9	O
pilocarpine	0	B-Chemical
,	9	O
though	9	O
in	5	O
the	5	O
MK	9	B-Chemical
-	7	I-Chemical
801	7	I-Chemical
-	7	O
treated	3	O
group	9	O
,	9	O
the	5	O
pyramidal	3	O
cells	3	O
of	5	O
hippocampus	9	O
appeared	9	O
darker	4	O
than	5	O
normal	9	O
.	9	O

In	9	O
all	5	O
treatments	9	O
,	9	O
granule	3	O
cells	3	O
of	5	O
the	5	O
dentate	3	O
gyrus	5	O
were	9	O
not	5	O
affected	9	O
.	9	O

4	9	O
.	9	O

These	5	O
results	9	O
indicate	9	O
that	5	O
status	9	B-Disease
epilepticus	5	I-Disease
induced	3	O
by	9	O
pilocarpine	0	B-Chemical
is	5	O
initiated	9	O
by	9	O
cholinergic	3	O
overstimulation	5	O
and	5	O
propagated	9	O
by	9	O
glutamatergic	3	O
transmission	5	O
,	9	O
the	5	O
elevation	9	O
of	5	O
which	5	O
may	5	O
cause	5	O
brain	5	B-Disease
damage	9	I-Disease
through	9	O
an	5	O
excitatory	5	O
NMDA	3	B-Chemical
receptor	3	O
-	7	O
mediated	3	O
mechanism	9	O
.	9	O

Paclitaxel	0	B-Chemical
,	9	O
5	9	B-Chemical
-	7	I-Chemical
fluorouracil	0	I-Chemical
,	9	O
and	5	O
folinic	0	B-Chemical
acid	0	I-Chemical
in	5	O
metastatic	3	O
breast	3	B-Disease
cancer	3	I-Disease
:	9	O
BRE	1	O
-	7	O
26	7	O
,	9	O
a	5	O
phase	5	O
II	9	O
trial	5	O
.	9	O

5	9	B-Chemical
-	7	I-Chemical
Fluorouracil	0	I-Chemical
plus	9	O
folinic	0	B-Chemical
acid	0	I-Chemical
and	5	O
paclitaxel	0	B-Chemical
(	9	O
Taxol	0	B-Chemical
;	9	O
Bristol	2	O
-	7	O
Myers	6	O
Squibb	2	O
Company	2	O
,	9	O
Princeton	2	O
,	9	O
NJ	0	O
)	9	O
are	5	O
effective	5	O
salvage	5	O
therapies	5	O
for	5	O
metastatic	3	O
breast	3	B-Disease
cancer	3	I-Disease
patients	5	O
.	9	O

Paclitaxel	0	B-Chemical
and	5	O
5	9	B-Chemical
-	7	I-Chemical
fluorouracil	0	I-Chemical
have	5	O
additive	9	O
cytotoxicity	3	B-Disease
in	5	O
MCF	9	O
-	7	O
7	9	O
cell	3	O
lines	3	O
.	9	O

We	9	O
performed	9	O
a	5	O
phase	5	O
II	9	O
trial	5	O
of	5	O
paclitaxel	0	B-Chemical
175	7	O
mg	0	O
/	9	O
m2	7	O
over	5	O
3	9	O
hours	9	O
on	5	O
day	9	O
I	9	O
followed	9	O
by	9	O
folinic	0	B-Chemical
acid	0	I-Chemical
300	0	O
mg	0	O
over	5	O
1	9	O
hour	0	O
before	9	O
5	9	B-Chemical
-	7	I-Chemical
fluorouracil	0	I-Chemical
350	9	O
mg	0	O
/	9	O
m2	7	O
on	5	O
days	9	O
1	9	O
to	5	O
3	9	O
every	5	O
28	7	O
days	9	O
(	9	O
TFL	5	O
)	9	O
in	5	O
women	5	O
with	5	O
metastatic	3	O
breast	3	B-Disease
cancer	3	I-Disease
.	9	O

Analysis	9	O
is	5	O
reported	9	O
on	5	O
37	9	O
patients	5	O
with	5	O
a	5	O
minimum	5	O
of	5	O
6	9	O
months	5	O
follow	5	O
-	7	O
up	5	O
who	5	O
received	9	O
a	5	O
total	9	O
of	5	O
192	9	O
cycles	9	O
of	5	O
TFL	5	O
:	9	O
nine	9	O
cycles	9	O
(	9	O
5	9	O
%	9	O
)	9	O
were	9	O
associated	9	O
with	5	O
grade	9	O
3	9	O
/	9	O
4	9	O
neutropenia	5	B-Disease
requiring	5	O
hospitalization	5	O
;	9	O
seven	9	O
(	9	O
4	9	O
%	9	O
)	9	O
cycles	9	O
in	5	O
two	5	O
patients	5	O
required	9	O
granulocyte	3	B-Chemical
colony	9	I-Chemical
-	7	I-Chemical
stimulating	9	I-Chemical
factor	9	I-Chemical
due	5	O
to	5	O
neutropenia	5	B-Disease
;	9	O
no	9	O
patient	5	O
required	9	O
platelet	9	O
transfusions	5	O
.	9	O

Grade	9	O
3	9	O
/	9	O
4	9	O
nonhematologic	5	O
toxicities	5	B-Disease
were	9	O
uncommon	5	O
.	9	O

Among	9	O
the	5	O
34	7	O
patients	5	O
evaluable	9	O
for	5	O
response	9	O
,	9	O
there	5	O
were	9	O
three	9	O
complete	9	O
responses	5	O
(	9	O
9	7	O
%	9	O
)	9	O
and	5	O
18	7	O
partial	9	O
responses	5	O
(	9	O
53	7	O
%	9	O
)	9	O
for	5	O
an	5	O
overall	5	O
response	9	O
rate	9	O
of	5	O
62	7	O
%	9	O
.	9	O

Of	9	O
the	5	O
19	7	O
evaluable	9	O
patients	5	O
with	5	O
prior	9	O
doxorubicin	0	B-Chemical
exposure	9	O
,	9	O
11	7	O
(	9	O
58	7	O
%	9	O
)	9	O
responded	9	O
compared	9	O
with	5	O
nine	9	O
of	5	O
15	9	O
(	9	O
60	9	O
%	9	O
)	9	O
without	9	O
prior	9	O
doxorubicin	0	B-Chemical
.	9	O

Plasma	0	O
paclitaxel	0	B-Chemical
concentrations	0	O
were	9	O
measured	9	O
at	9	O
the	5	O
completion	5	O
of	5	O
paclitaxel	0	B-Chemical
infusion	0	O
and	5	O
at	9	O
24	9	O
hours	9	O
in	5	O
19	7	O
patients	5	O
.	9	O

TFL	5	O
is	5	O
an	5	O
active	9	O
,	9	O
well	9	O
-	7	O
tolerated	9	O
regimen	5	O
in	5	O
metastatic	3	O
breast	3	B-Disease
cancer	3	I-Disease
.	9	O

Efficacy	5	O
and	5	O
proarrhythmia	5	B-Disease
with	5	O
the	5	O
use	5	O
of	5	O
d	9	B-Chemical
,	9	I-Chemical
l	0	I-Chemical
-	7	I-Chemical
sotalol	5	I-Chemical
for	5	O
sustained	5	O
ventricular	5	B-Disease
tachyarrhythmias	5	I-Disease
.	9	O

This	5	O
study	9	O
prospectively	5	O
evaluated	9	O
the	5	O
clinical	5	O
efficacy	9	O
,	9	O
the	5	O
incidence	5	O
of	5	O
torsades	5	B-Disease
de	2	I-Disease
pointes	5	I-Disease
,	9	O
and	5	O
the	5	O
presumable	9	O
risk	5	O
factors	9	O
for	5	O
torsades	5	B-Disease
de	2	I-Disease
pointes	5	I-Disease
in	5	O
patients	5	O
treated	3	O
with	5	O
d	9	B-Chemical
,	9	I-Chemical
l	0	I-Chemical
-	7	I-Chemical
sotalol	5	I-Chemical
for	5	O
sustained	5	O
ventricular	5	B-Disease
tachyarrhythmias	5	I-Disease
.	9	O

Eighty	5	O
-	7	O
one	5	O
consecutive	5	O
patients	5	O
(	9	O
54	7	O
with	5	O
coronary	5	B-Disease
artery	5	I-Disease
disease	5	I-Disease
,	9	O
and	5	O
20	9	O
with	5	O
dilated	5	B-Disease
cardiomyopathy	5	I-Disease
)	9	O
with	5	O
inducible	3	O
sustained	5	O
ventricular	5	B-Disease
tachycardia	5	I-Disease
or	5	O
ventricular	5	B-Disease
fibrillation	5	I-Disease
received	9	O
oral	9	O
d	9	B-Chemical
,	9	I-Chemical
l	0	I-Chemical
-	7	I-Chemical
sotalol	5	I-Chemical
to	5	O
prevent	5	O
induction	3	O
of	5	O
the	5	O
ventricular	5	B-Disease
tachyarrhythmia	5	I-Disease
.	9	O

During	5	O
oral	9	O
loading	9	O
with	5	O
d	9	B-Chemical
,	9	I-Chemical
l	0	I-Chemical
-	7	I-Chemical
sotalol	5	I-Chemical
,	9	O
continuous	5	O
electrocardiographic	5	O
(	9	O
ECG	5	O
)	9	O
monitoring	5	O
was	9	O
performed	9	O
.	9	O

Those	5	O
patients	5	O
in	5	O
whom	5	O
d	9	B-Chemical
,	9	I-Chemical
l	0	I-Chemical
-	7	I-Chemical
sotalol	5	I-Chemical
prevented	9	O
induction	3	O
of	5	O
ventricular	5	B-Disease
tachycardia	5	I-Disease
or	5	O
ventricular	5	B-Disease
fibrillation	5	I-Disease
were	9	O
discharged	5	O
with	5	O
the	5	O
drug	5	O
and	5	O
followed	9	O
up	5	O
on	5	O
an	5	O
outpatient	5	O
basis	5	O
for	5	O
21	7	O
+	9	O
/	9	O
-	7	O
18	7	O
months	5	O
.	9	O

Induction	3	O
of	5	O
the	5	O
ventricular	5	B-Disease
tachyarrhythmia	5	I-Disease
was	9	O
prevented	9	O
by	9	O
oral	9	O
d	9	B-Chemical
,	9	I-Chemical
l	0	I-Chemical
-	7	I-Chemical
sotalol	5	I-Chemical
in	5	O
35	9	O
(	9	O
43	7	O
%	9	O
)	9	O
patients	5	O
;	9	O
the	5	O
ventricular	5	B-Disease
tachyarrhythmia	5	I-Disease
remained	9	O
inducible	3	O
in	5	O
40	9	O
(	9	O
49	7	O
%	9	O
)	9	O
patients	5	O
;	9	O
and	5	O
two	5	O
(	9	O
2	9	O
.	9	O
5	9	O
%	9	O
)	9	O
patients	5	O
did	9	O
not	5	O
tolerate	5	O
even	5	O
40	9	O
mg	0	O
of	5	O
d	9	B-Chemical
,	9	I-Chemical
l	0	I-Chemical
-	7	I-Chemical
sotalol	5	I-Chemical
once	5	O
daily	5	O
.	9	O

Four	9	O
(	9	O
5	9	O
%	9	O
)	9	O
patients	5	O
had	9	O
from	9	O
torsades	5	B-Disease
de	2	I-Disease
pointes	5	I-Disease
during	5	O
the	5	O
initial	9	O
oral	9	O
treatment	9	O
with	5	O
d	9	B-Chemical
,	9	I-Chemical
l	0	I-Chemical
-	7	I-Chemical
sotalol	5	I-Chemical
.	9	O

Neither	9	O
ECG	5	O
[	9	O
sinus	5	O
-	7	O
cycle	9	O
length	9	O
(	9	O
SCL	9	O
)	9	O
,	9	O
QT	5	O
or	5	O
QTc	5	O
interval	5	O
,	9	O
or	5	O
U	9	O
wave	5	O
]	9	O
nor	9	O
clinical	5	O
parameters	5	O
identified	9	O
patients	5	O
at	9	O
risk	5	O
for	5	O
torsades	5	B-Disease
de	2	I-Disease
pointes	5	I-Disease
.	9	O

However	9	O
,	9	O
the	5	O
oral	9	O
dose	9	O
of	5	O
d	9	B-Chemical
,	9	I-Chemical
l	0	I-Chemical
-	7	I-Chemical
sotalol	5	I-Chemical
was	9	O
significantly	9	O
lower	9	O
in	5	O
patients	5	O
with	5	O
torsades	5	B-Disease
de	2	I-Disease
pointes	5	I-Disease
(	9	O
200	0	O
+	9	O
/	9	O
-	7	O
46	7	O
vs	7	O
.	9	O
328	7	O
+	9	O
/	9	O
-	7	O
53	7	O
mg	0	O
/	9	O
day	9	O
;	9	O
p	7	O
=	7	O
0	7	O
.	9	O
0017	7	O
)	9	O
.	9	O

Risk	5	O
factors	9	O
associated	9	O
with	5	O
the	5	O
development	9	O
of	5	O
torsades	5	B-Disease
de	2	I-Disease
pointes	5	I-Disease
were	9	O
the	5	O
appearance	9	O
of	5	O
an	5	O
U	9	O
wave	5	O
(	9	O
p	7	O
=	7	O
0	7	O
.	9	O
049	7	O
)	9	O
,	9	O
female	9	O
gender	5	O
(	9	O
p	7	O
=	7	O
0	7	O
.	9	O
015	7	O
)	9	O
,	9	O
and	5	O
significant	9	O
dose	9	O
-	7	O
corrected	5	O
changes	9	O
of	5	O
SCL	9	O
,	9	O
QT	5	O
interval	5	O
,	9	O
and	5	O
QTc	5	O
interval	5	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

During	5	O
follow	5	O
-	7	O
up	5	O
,	9	O
seven	9	O
(	9	O
20	9	O
%	9	O
)	9	O
patients	5	O
had	9	O
a	5	O
nonfatal	5	O
ventricular	5	B-Disease
tachycardia	5	I-Disease
recurrence	5	O
,	9	O
and	5	O
two	5	O
(	9	O
6	9	O
%	9	O
)	9	O
patients	5	O
died	9	O
suddenly	5	O
.	9	O

One	5	O
female	9	O
patient	5	O
with	5	O
stable	9	O
cardiac	5	B-Disease
disease	5	I-Disease
had	9	O
recurrent	5	O
torsades	5	B-Disease
de	2	I-Disease
pointes	5	I-Disease
after	9	O
2	9	O
years	5	O
of	5	O
successful	5	O
treatment	9	O
with	5	O
d	9	B-Chemical
,	9	I-Chemical
l	0	I-Chemical
-	7	I-Chemical
sotalol	5	I-Chemical
.	9	O

Torsades	2	B-Disease
de	2	I-Disease
pointes	5	I-Disease
occurred	9	O
early	9	O
during	5	O
treatment	9	O
even	5	O
with	5	O
low	9	O
doses	0	O
of	5	O
oral	9	O
d	9	B-Chemical
,	9	I-Chemical
l	0	I-Chemical
-	7	I-Chemical
sotalol	5	I-Chemical
.	9	O

Pronounced	5	O
changes	9	O
in	5	O
the	5	O
surface	9	O
ECG	5	O
(	9	O
cycle	9	O
length	9	O
,	9	O
QT	5	O
,	9	O
and	5	O
QTc	5	O
)	9	O
in	5	O
relation	5	O
to	5	O
the	5	O
dose	9	O
of	5	O
oral	9	O
d	9	B-Chemical
,	9	I-Chemical
l	0	I-Chemical
-	7	I-Chemical
sotalol	5	I-Chemical
might	9	O
identify	9	O
a	5	O
subgroup	9	O
of	5	O
patients	5	O
with	5	O
an	5	O
increased	9	O
risk	5	O
for	5	O
torsades	5	B-Disease
de	2	I-Disease
pointes	5	I-Disease
.	9	O

Other	9	O
ECG	5	O
parameters	5	O
before	9	O
the	5	O
application	5	O
of	5	O
d	9	B-Chemical
,	9	I-Chemical
l	0	I-Chemical
-	7	I-Chemical
sotalol	5	I-Chemical
did	9	O
not	5	O
identify	9	O
patients	5	O
at	9	O
increased	9	O
risk	5	O
for	5	O
torsades	5	B-Disease
de	2	I-Disease
pointes	5	I-Disease
.	9	O

Recurrence	5	O
rates	5	O
of	5	O
ventricular	5	B-Disease
tachyarrhythmias	5	I-Disease
are	5	O
high	9	O
despite	9	O
complete	9	O
suppression	9	O
of	5	O
the	5	O
arrhythmia	5	B-Disease
during	5	O
programmed	5	O
stimulation	3	O
.	9	O

Therefore	9	O
programmed	5	O
electrical	5	O
stimulation	3	O
in	5	O
the	5	O
case	5	O
of	5	O
d	9	B-Chemical
,	9	I-Chemical
l	0	I-Chemical
-	7	I-Chemical
sotalol	5	I-Chemical
seems	5	O
to	5	O
be	5	O
of	5	O
limited	5	O
prognostic	5	O
value	9	O
.	9	O

Chronic	9	O
hyperprolactinemia	5	B-Disease
and	5	O
changes	9	O
in	5	O
dopamine	5	B-Chemical
neurons	3	O
.	9	O

The	5	O
tuberoinfundibular	3	O
dopaminergic	5	O
(	9	O
TIDA	3	O
)	9	O
system	5	O
is	5	O
known	9	O
to	5	O
inhibit	3	O
prolactin	3	O
(	9	O
PRL	3	O
)	9	O
secretion	3	O
.	9	O

In	9	O
young	5	O
animals	9	O
this	5	O
system	5	O
responds	9	O
to	5	O
acute	9	O
elevations	9	O
in	5	O
serum	9	O
PRL	3	O
by	9	O
increasing	9	O
its	9	O
activity	9	O
.	9	O

However	9	O
,	9	O
this	5	O
responsiveness	9	O
is	5	O
lost	9	O
in	5	O
aging	5	O
rats	9	O
with	5	O
chronically	9	O
high	9	O
serum	9	O
PRL	3	O
levels	3	O
.	9	O

The	5	O
purpose	5	O
of	5	O
this	5	O
study	9	O
was	9	O
to	5	O
induce	3	O
hyperprolactinemia	5	B-Disease
in	5	O
rats	9	O
for	5	O
extended	5	O
periods	5	O
of	5	O
time	5	O
and	5	O
examine	9	O
its	9	O
effects	9	O
on	5	O
dopaminergic	5	O
systems	5	O
in	5	O
the	5	O
brain	5	O
.	9	O

Hyperprolactinemia	5	B-Disease
was	9	O
induced	3	O
by	9	O
treatment	9	O
with	5	O
haloperidol	5	B-Chemical
,	9	O
a	5	O
dopamine	5	B-Chemical
receptor	3	O
antagonist	3	O
,	9	O
and	5	O
Palkovits	6	O
'	9	O
microdissection	5	O
technique	5	O
in	5	O
combination	9	O
with	5	O
high	9	O
-	7	O
performance	5	O
liquid	0	O
chromatography	0	O
was	9	O
used	5	O
to	5	O
measure	5	O
neurotransmitter	9	O
concentrations	0	O
in	5	O
several	9	O
areas	5	O
of	5	O
the	5	O
brain	5	O
.	9	O

After	9	O
6	9	O
months	5	O
of	5	O
hyperprolactinemia	5	B-Disease
,	9	O
dopamine	5	B-Chemical
(	9	O
DA	9	B-Chemical
)	9	O
concentrations	0	O
in	5	O
the	5	O
median	9	O
eminence	5	O
(	9	O
ME	9	O
)	9	O
increased	9	O
by	9	O
84	7	O
%	9	O
over	5	O
the	5	O
control	9	O
group	9	O
.	9	O

Nine	9	O
months	5	O
of	5	O
hyperprolactinemia	5	B-Disease
produced	9	O
a	5	O
50	0	O
%	9	O
increase	9	O
in	5	O
DA	9	B-Chemical
concentrations	0	O
in	5	O
the	5	O
ME	9	O
over	5	O
the	5	O
control	9	O
group	9	O
.	9	O

However	9	O
,	9	O
DA	9	B-Chemical
response	9	O
was	9	O
lost	9	O
if	5	O
a	5	O
9	7	O
-	7	O
month	5	O
long	5	O
haloperidol	5	B-Chemical
-	7	O
induced	3	O
hyperprolactinemia	5	B-Disease
was	9	O
followed	9	O
by	9	O
a	5	O
1	9	O
1	9	O
/	9	O
2	9	O
month	5	O
-	7	O
long	5	O
extremely	5	O
high	9	O
increase	9	O
in	5	O
serum	9	O
PRL	3	O
levels	3	O
produced	9	O
by	9	O
implantation	5	O
of	5	O
MMQ	3	O
cells	3	O
under	9	O
the	5	O
kidney	9	O
capsule	9	O
.	9	O

There	5	O
was	9	O
no	9	O
change	9	O
in	5	O
the	5	O
levels	3	O
of	5	O
DA	9	B-Chemical
,	9	O
norepinephrine	9	B-Chemical
(	9	O
NE	9	B-Chemical
)	9	O
,	9	O
serotonin	9	B-Chemical
(	9	O
5	9	B-Chemical
-	7	I-Chemical
HT	9	I-Chemical
)	9	O
,	9	O
or	5	O
their	5	O
metabolites	0	O
in	5	O
the	5	O
arcuate	5	O
nucleus	9	O
(	9	O
AN	9	O
)	9	O
,	9	O
medial	5	O
preoptic	5	O
area	5	O
(	9	O
MPA	9	O
)	9	O
,	9	O
caudate	5	O
putamen	5	O
(	9	O
CP	9	O
)	9	O
,	9	O
substantia	9	O
nigra	4	O
(	9	O
SN	9	O
)	9	O
,	9	O
and	5	O
zona	9	O
incerta	4	O
(	9	O
ZI	2	O
)	9	O
,	9	O
except	9	O
for	5	O
a	5	O
decrease	9	O
in	5	O
5	9	B-Chemical
-	7	I-Chemical
hydroxyindoleacetic	0	I-Chemical
acid	0	I-Chemical
(	9	O
5	9	B-Chemical
-	7	I-Chemical
HIAA	0	I-Chemical
)	9	O
in	5	O
the	5	O
AN	9	O
after	9	O
6	9	O
-	7	O
months	5	O
of	5	O
hyperprolactinemia	5	B-Disease
and	5	O
an	5	O
increase	9	O
in	5	O
DA	9	B-Chemical
concentrations	0	O
in	5	O
the	5	O
AN	9	O
after	9	O
9	7	O
-	7	O
months	5	O
of	5	O
hyperprolactinemia	5	B-Disease
.	9	O

These	5	O
results	9	O
demonstrate	9	O
that	5	O
hyperprolactinemia	5	B-Disease
specifically	9	O
affects	9	O
TIDA	3	O
neurons	3	O
and	5	O
these	5	O
effects	9	O
vary	5	O
,	9	O
depending	5	O
on	5	O
the	5	O
duration	5	O
and	5	O
intensity	5	O
of	5	O
hyperprolactinemia	5	B-Disease
.	9	O

The	5	O
age	5	O
-	7	O
related	9	O
decrease	9	O
in	5	O
hypothalamic	3	O
dopamine	5	B-Chemical
function	9	O
may	5	O
be	5	O
associated	9	O
with	5	O
increases	9	O
in	5	O
PRL	3	O
secretion	3	O
.	9	O

Treatment	9	O
-	7	O
related	9	O
disseminated	5	O
necrotizing	5	O
leukoencephalopathy	5	B-Disease
with	5	O
characteristic	9	O
contrast	9	O
enhancement	9	O
of	5	O
the	5	O
white	9	O
matter	5	O
.	9	O

This	5	O
report	5	O
describes	5	O
unique	9	O
contrast	9	O
enhancement	9	O
of	5	O
the	5	O
white	9	O
matter	5	O
on	5	O
T1	9	O
-	7	O
weighted	5	O
magnetic	0	O
resonance	5	O
images	5	O
of	5	O
two	5	O
patients	5	O
with	5	O
disseminated	5	O
necrotizing	5	O
leukoencephalopathy	5	B-Disease
,	9	O
which	5	O
developed	5	O
from	9	O
acute	9	B-Disease
lymphoblastic	3	I-Disease
leukemia	3	I-Disease
treated	3	O
with	5	O
high	9	O
-	7	O
dose	9	O
methotrexate	9	B-Chemical
.	9	O

In	9	O
both	9	O
patients	5	O
,	9	O
the	5	O
enhancement	9	O
was	9	O
more	5	O
pronounced	9	O
near	9	O
the	5	O
base	5	O
of	5	O
the	5	O
brain	5	O
than	5	O
at	9	O
the	5	O
vertex	5	O
.	9	O

Necropsy	9	O
of	5	O
the	5	O
first	9	O
case	5	O
revealed	9	O
loss	9	B-Disease
of	5	I-Disease
myelination	3	I-Disease
and	5	O
necrosis	9	B-Disease
of	5	O
the	5	O
white	9	O
matter	5	O
.	9	O

Possible	9	O
mechanisms	9	O
causing	9	O
such	5	O
a	5	O
leukoencephalopathy	5	B-Disease
are	5	O
discussed	5	O
.	9	O

Thrombotic	5	B-Disease
complications	5	O
in	5	O
acute	9	B-Disease
promyelocytic	3	I-Disease
leukemia	3	I-Disease
during	5	O
all	5	B-Chemical
-	7	I-Chemical
trans	9	I-Chemical
-	7	I-Chemical
retinoic	3	I-Chemical
acid	0	I-Chemical
therapy	5	O
.	9	O

A	9	O
case	5	O
of	5	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
,	9	O
due	5	O
to	5	O
occlusion	5	B-Disease
of	5	I-Disease
renal	9	I-Disease
vessels	5	I-Disease
in	5	O
a	5	O
patient	5	O
with	5	O
acute	9	B-Disease
promyelocytic	3	I-Disease
leukemia	3	I-Disease
(	9	O
APL	3	B-Disease
)	9	O
treated	3	O
with	5	O
all	5	B-Chemical
-	7	I-Chemical
trans	9	I-Chemical
-	7	I-Chemical
retinoic	3	I-Chemical
acid	0	I-Chemical
(	9	O
ATRA	3	B-Chemical
)	9	O
and	5	O
tranexamic	0	B-Chemical
acid	0	I-Chemical
has	9	O
been	9	O
described	9	O
recently	9	O
.	9	O

We	9	O
report	5	O
a	5	O
case	5	O
of	5	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
in	5	O
an	5	O
APL	3	B-Disease
patient	5	O
treated	3	O
with	5	O
ATRA	3	B-Chemical
alone	9	O
.	9	O

This	5	O
case	5	O
further	9	O
supports	9	O
the	5	O
concern	5	O
about	5	O
thromboembolic	5	B-Disease
complications	5	O
associated	9	O
with	5	O
ATRA	3	B-Chemical
therapy	5	O
in	5	O
APL	3	B-Disease
patients	5	O
.	9	O

The	5	O
patients	5	O
,	9	O
a	5	O
43	7	O
-	7	O
year	5	O
-	7	O
old	5	O
man	5	O
,	9	O
presented	5	O
all	5	O
the	5	O
signs	5	O
and	5	O
symptoms	5	O
of	5	O
APL	3	B-Disease
and	5	O
was	9	O
included	5	O
in	5	O
a	5	O
treatment	9	O
protocol	9	O
with	5	O
ATRA	3	B-Chemical
.	9	O

After	9	O
10	9	O
days	9	O
of	5	O
treatment	9	O
,	9	O
he	5	O
developed	5	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
that	5	O
was	9	O
completely	9	O
reversible	9	O
after	9	O
complete	9	O
remission	5	O
of	5	O
APL	3	B-Disease
was	9	O
achieved	5	O
and	5	O
therapy	5	O
discontinued	5	O
.	9	O

We	9	O
conclude	9	O
that	5	O
ATRA	3	B-Chemical
is	5	O
a	5	O
valid	5	O
therapeutic	5	O
choice	5	O
for	5	O
patients	5	O
with	5	O
APL	3	B-Disease
,	9	O
although	9	O
the	5	O
procoagulant	9	O
tendency	5	O
is	5	O
not	5	O
completely	9	O
corrected	5	O
.	9	O

Thrombotic	5	B-Disease
events	5	O
,	9	O
however	9	O
,	9	O
could	9	O
be	5	O
avoided	5	O
by	9	O
using	9	O
low	9	O
-	7	O
dose	9	O
heparin	0	B-Chemical
.	9	O

Pupillary	5	O
changes	9	O
associated	9	O
with	5	O
the	5	O
development	9	O
of	5	O
stimulant	5	O
-	7	O
induced	3	O
mania	5	B-Disease
:	9	O
a	5	O
case	5	O
report	5	O
.	9	O

A	9	O
30	9	O
-	7	O
year	5	O
-	7	O
old	5	O
cocaine	5	B-Chemical
-	7	O
dependent	9	O
man	5	O
who	5	O
was	9	O
a	5	O
subject	5	O
in	5	O
a	5	O
study	9	O
evaluating	5	O
the	5	O
anticraving	5	O
efficacy	9	O
of	5	O
the	5	O
stimulant	5	O
medication	5	O
diethylpropion	0	B-Chemical
(	9	O
DEP	0	B-Chemical
)	9	O
became	9	O
manic	5	B-Disease
during	5	O
his	5	O
second	9	O
week	9	O
on	5	O
the	5	O
study	9	O
drug	5	O
.	9	O

Pupillometric	9	O
changes	9	O
while	9	O
on	5	O
DEP	0	B-Chemical
,	9	O
especially	5	O
changes	9	O
in	5	O
the	5	O
total	9	O
power	5	O
of	5	O
pupillary	5	B-Disease
oscillation	5	I-Disease
,	9	O
were	9	O
dramatically	9	O
different	9	O
than	5	O
those	5	O
observed	9	O
in	5	O
the	5	O
eight	9	O
other	5	O
study	9	O
subjects	5	O
who	5	O
did	9	O
not	5	O
become	5	O
manic	5	B-Disease
.	9	O

The	5	O
large	5	O
changes	9	O
in	5	O
total	9	O
power	5	O
of	5	O
pupillary	5	B-Disease
oscillation	5	I-Disease
occurred	9	O
a	5	O
few	5	O
days	9	O
before	9	O
the	5	O
patient	5	O
became	9	O
fully	9	O
manic	5	B-Disease
.	9	O

Such	5	O
medication	5	O
-	7	O
associated	9	O
changes	9	O
in	5	O
the	5	O
total	9	O
power	5	O
of	5	O
pupillary	5	B-Disease
oscillation	5	I-Disease
might	9	O
be	5	O
of	5	O
utility	5	O
in	5	O
identifying	5	O
persons	5	O
at	9	O
risk	5	O
for	5	O
manic	5	B-Disease
-	7	O
like	9	O
adverse	5	O
effects	9	O
during	5	O
the	5	O
medical	5	O
use	5	O
of	5	O
psychomotor	5	O
stimulants	5	O
or	5	O
sympathomimetic	5	O
agents	5	O
.	9	O

Fetal	9	O
risks	5	O
due	5	O
to	5	O
warfarin	5	B-Chemical
therapy	5	O
during	5	O
pregnancy	5	O
.	9	O

Two	9	O
mothers	5	O
with	5	O
heart	5	O
valve	5	O
prosthesis	5	O
were	9	O
treated	3	O
with	5	O
warfarin	5	B-Chemical
during	5	O
pregnancy	5	O
.	9	O

In	9	O
the	5	O
first	9	O
case	5	O
a	5	O
caesarean	5	O
section	5	O
was	9	O
done	9	O
one	5	O
week	9	O
after	9	O
replacement	9	O
of	5	O
warfarin	5	B-Chemical
with	5	O
heparin	0	B-Chemical
.	9	O

The	5	O
baby	5	O
died	9	O
of	5	O
cerebral	5	B-Disease
and	5	I-Disease
pulmonary	5	I-Disease
hemorrhage	5	I-Disease
.	9	O

The	5	O
second	9	O
mother	5	O
had	9	O
a	5	O
male	9	O
infant	5	O
by	9	O
caesarean	5	O
section	5	O
.	9	O

The	5	O
baby	5	O
showed	9	O
warfarin	5	B-Chemical
-	7	O
induced	3	O
embryopathy	5	B-Disease
with	5	O
nasal	5	B-Disease
hypoplasia	5	I-Disease
and	5	O
stippled	9	B-Disease
epiphyses	5	I-Disease
(	9	O
chondrodysplasia	1	B-Disease
punctata	4	I-Disease
)	9	O
.	9	O

Nasal	5	B-Disease
hypoplasia	5	I-Disease
with	5	O
or	5	O
without	9	O
stippled	9	B-Disease
epiphyses	5	I-Disease
has	9	O
now	5	O
been	9	O
reported	9	O
in	5	O
11	7	O
infants	5	O
born	5	O
to	5	O
mothers	5	O
treated	3	O
with	5	O
warfarin	5	B-Chemical
during	5	O
the	5	O
first	9	O
trimester	5	O
,	9	O
and	5	O
a	5	O
causal	5	O
association	9	O
is	5	O
probable	9	O
.	9	O

In	9	O
view	5	O
of	5	O
the	5	O
risks	5	O
to	5	O
both	9	O
mother	5	O
and	5	O
fetus	5	O
in	5	O
women	5	O
with	5	O
prosthetic	5	O
cardiac	5	O
valves	5	O
it	5	O
is	5	O
recommended	5	O
that	5	O
therapeutic	5	O
abortion	5	O
be	5	O
advised	5	O
as	5	O
the	5	O
first	9	O
alternative	5	O
.	9	O

The	5	O
negative	9	O
mucosal	9	O
potential	9	O
:	9	O
separating	9	O
central	5	O
and	5	O
peripheral	9	O
effects	9	O
of	5	O
NSAIDs	5	O
in	5	O
man	5	O
.	9	O

OBJECTIVE	2	O
:	9	O
We	9	O
wanted	5	O
to	5	O
test	5	O
whether	9	O
assessment	5	O
of	5	O
both	9	O
a	5	O
central	5	O
pain	5	B-Disease
-	7	O
related	9	O
signal	9	O
(	9	O
chemo	9	O
-	7	O
somatosensory	5	O
evoked	5	O
potential	9	O
,	9	O
CSSEP	_	O
)	9	O
and	5	O
a	5	O
concomitantly	9	O
recorded	5	O
peripheral	9	O
signal	9	O
(	9	O
negative	9	O
mucosal	9	O
potential	9	O
,	9	O
NMP	0	O
)	9	O
allows	5	O
for	5	O
separation	5	O
of	5	O
central	5	O
and	5	O
peripheral	9	O
effects	9	O
of	5	O
NSAIDs	5	O
.	9	O

For	9	O
this	5	O
purpose	5	O
,	9	O
experimental	5	O
conditions	9	O
were	9	O
created	5	O
in	5	O
which	5	O
NSAIDs	5	O
had	9	O
previously	9	O
been	9	O
observed	9	O
to	5	O
produce	9	O
effects	9	O
on	5	O
phasic	5	O
and	5	O
tonic	5	O
pain	5	B-Disease
by	9	O
either	9	O
central	5	O
or	5	O
peripheral	9	O
mechanisms	9	O
.	9	O

METHODS	2	O
:	9	O
According	5	O
to	5	O
a	5	O
double	9	O
-	7	O
blind	5	O
,	9	O
randomised	5	O
,	9	O
controlled	5	O
,	9	O
threefold	9	O
cross	5	O
-	7	O
over	5	O
design	5	O
,	9	O
18	7	O
healthy	5	O
subjects	5	O
(	9	O
11	7	O
males	9	O
,	9	O
7	9	O
females	9	O
;	9	O
mean	5	O
age	5	O
26	7	O
years	5	O
)	9	O
received	9	O
either	9	O
placebo	9	O
,	9	O
400	0	O
mg	0	O
ibuprofen	0	B-Chemical
,	9	O
or	5	O
800	0	O
mg	0	O
ibuprofen	0	B-Chemical
.	9	O

Phasic	5	O
pain	5	B-Disease
was	9	O
applied	5	O
by	9	O
means	5	O
of	5	O
short	5	O
pulses	5	O
of	5	O
CO2	0	B-Chemical
to	5	O
the	5	O
nasal	5	O
mucosa	9	O
(	9	O
stimulus	5	O
duration	5	O
500	0	O
ms	5	O
,	9	O
interval	5	O
approximately	9	O
60	9	O
s	9	O
)	9	O
,	9	O
and	5	O
tonic	5	O
pain	5	B-Disease
was	9	O
induced	3	O
in	5	O
the	5	O
nasal	5	O
cavity	5	O
by	9	O
means	5	O
of	5	O
dry	0	O
air	5	O
of	5	O
controlled	5	O
temperature	0	O
,	9	O
humidity	5	O
and	5	O
flow	5	O
rate	9	O
(	9	O
22	7	O
degrees	5	O
C	9	O
,	9	O
0	7	O
%	9	O
relative	9	O
humidity	5	O
,	9	O
145	7	O
ml	0	O
.	9	O
s	9	O
-	7	O
1	9	O
)	9	O
.	9	O

Both	9	O
CSSEPs	_	O
as	5	O
central	5	O
and	5	O
NMPs	5	O
as	5	O
peripheral	9	O
correlates	9	O
of	5	O
pain	5	B-Disease
were	9	O
obtained	9	O
in	5	O
response	9	O
to	5	O
the	5	O
CO2	0	B-Chemical
stimuli	5	O
.	9	O

Additionally	9	O
,	9	O
the	5	O
subjects	5	O
rated	5	O
the	5	O
intensity	5	O
of	5	O
both	9	O
phasic	5	O
and	5	O
tonic	5	O
pain	5	B-Disease
by	9	O
means	5	O
of	5	O
visual	5	O
analogue	0	O
scales	5	O
.	9	O

RESULTS	9	O
:	9	O
As	9	O
described	9	O
earlier	9	O
,	9	O
administration	9	O
of	5	O
ibuprofen	0	B-Chemical
was	9	O
followed	9	O
by	9	O
a	5	O
decrease	9	O
in	5	O
tonic	5	O
pain	5	B-Disease
but	9	O
-	7	O
relative	9	O
to	5	O
placebo	9	O
-	7	O
an	5	O
increase	9	O
in	5	O
correlates	9	O
of	5	O
phasic	5	O
pain	5	B-Disease
,	9	O
indicating	9	O
a	5	O
specific	9	O
effect	9	O
of	5	O
ibuprofen	0	B-Chemical
on	5	O
the	5	O
interaction	9	O
between	5	O
the	5	O
pain	5	B-Disease
stimuli	5	O
under	9	O
these	5	O
special	5	O
experimental	5	O
conditions	9	O
.	9	O

Based	9	O
on	5	O
the	5	O
similar	9	O
behaviour	5	O
of	5	O
CSSEP	_	O
and	5	O
NMP	0	O
,	9	O
it	5	O
was	9	O
concluded	9	O
that	5	O
the	5	O
pharmacological	9	O
process	5	O
underlying	5	O
this	5	O
phenomenon	5	O
was	9	O
localised	9	O
in	5	O
the	5	O
periphery	9	O
.	9	O

By	5	O
means	5	O
of	5	O
the	5	O
simultaneous	5	O
recording	5	O
of	5	O
interrelated	5	O
peripheral	9	O
and	5	O
central	5	O
electrophysiologic	5	O
correlates	9	O
of	5	O
nociception	5	O
,	9	O
it	5	O
was	9	O
possible	5	O
to	5	O
separate	9	O
central	5	O
and	5	O
peripheral	9	O
effects	9	O
of	5	O
an	5	O
NSAID	5	O
.	9	O

The	5	O
major	9	O
advantage	5	O
of	5	O
this	5	O
pain	5	B-Disease
model	5	O
is	5	O
the	5	O
possibility	9	O
of	5	O
obtaining	5	O
peripheral	9	O
pain	5	B-Disease
-	7	O
related	9	O
activity	9	O
directly	9	O
using	9	O
a	5	O
non	9	O
-	7	O
invasive	5	O
technique	5	O
in	5	O
humans	9	O
.	9	O

Effect	0	O
of	5	O
D	9	B-Chemical
-	7	I-Chemical
Glucarates	_	I-Chemical
on	5	O
basic	5	O
antibiotic	5	O
-	7	O
induced	3	O
renal	9	B-Disease
damage	9	I-Disease
in	5	O
rats	9	O
.	9	O

Dehydrated	0	B-Disease
rats	9	O
regularly	5	O
develop	5	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
following	9	O
single	9	O
injection	9	O
of	5	O
aminoglycoside	9	B-Chemical
antibiotics	5	O
combined	9	O
with	5	O
dextran	0	O
or	5	O
of	5	O
antibiotics	5	O
only	9	O
.	9	O

Oral	9	O
administration	9	O
of	5	O
2	9	B-Chemical
,	9	I-Chemical
5	9	I-Chemical
-	7	I-Chemical
di	2	I-Chemical
-	7	I-Chemical
O	9	I-Chemical
-	7	I-Chemical
acetyl	0	I-Chemical
-	7	I-Chemical
D	9	I-Chemical
-	7	I-Chemical
glucaro	_	I-Chemical
-	7	I-Chemical
1	9	I-Chemical
,	9	I-Chemical
4	9	I-Chemical
-	7	I-Chemical
6	9	I-Chemical
,	9	I-Chemical
3	9	I-Chemical
-	7	I-Chemical
dilactone	0	I-Chemical
protected	9	O
rats	9	O
against	9	O
renal	9	B-Disease
failure	5	I-Disease
induced	3	O
by	9	O
kanamycin	1	B-Chemical
-	7	O
dextran	0	O
.	9	O

The	5	O
protective	9	O
effect	9	O
was	9	O
prevalent	9	O
among	5	O
D	9	B-Chemical
-	7	I-Chemical
glucarates	_	I-Chemical
,	9	O
and	5	O
also	9	O
to	5	O
other	5	O
saccharic	0	B-Chemical
acid	0	I-Chemical
,	9	O
hexauronic	_	B-Chemical
acids	0	I-Chemical
and	5	O
hexaaldonic	_	B-Chemical
acids	0	I-Chemical
,	9	O
although	9	O
to	5	O
a	5	O
lesser	9	O
degree	5	O
,	9	O
but	9	O
not	5	O
to	5	O
a	5	O
hexaaldose	_	O
,	9	O
sugar	0	B-Chemical
alcohols	0	I-Chemical
,	9	O
substances	0	O
inthe	9	O
TCA	0	B-Chemical
cycle	9	O
and	5	O
other	5	O
acidic	0	O
compounds	0	O
.	9	O

D	9	B-Chemical
-	7	I-Chemical
Glucarates	_	I-Chemical
were	9	O
effective	5	O
against	9	O
renal	9	B-Disease
damage	9	I-Disease
induced	3	O
by	9	O
peptide	9	O
antibiotics	5	O
as	5	O
well	9	O
as	5	O
various	9	O
aminoglycoside	9	B-Chemical
antibitocis	_	O
.	9	O

Dose	0	O
-	7	O
responses	5	O
were	9	O
observed	9	O
in	5	O
the	5	O
protective	9	O
effect	9	O
of	5	O
D	9	B-Chemical
-	7	I-Chemical
Glucarates	_	I-Chemical
.	9	O

With	5	O
a	5	O
D	9	B-Chemical
-	7	I-Chemical
glucarate	0	I-Chemical
of	5	O
a	5	O
fixed	9	O
size	9	O
of	5	O
dose	9	O
,	9	O
approximately	9	O
the	5	O
same	9	O
degree	5	O
of	5	O
protection	9	O
was	9	O
obtained	9	O
against	9	O
renal	9	B-Disease
damages	9	I-Disease
induced	3	O
by	9	O
different	9	O
basic	5	O
antibiotics	5	O
despite	9	O
large	5	O
disparities	5	O
in	5	O
administration	9	O
doses	0	O
of	5	O
different	9	O
antibiotics	5	O
.	9	O

D	9	B-Chemical
-	7	I-Chemical
Glucarates	_	I-Chemical
had	9	O
the	5	O
ability	9	O
to	5	O
prevent	5	O
renal	9	B-Disease
damage	9	I-Disease
but	9	O
not	5	O
to	5	O
cure	5	O
it	5	O
.	9	O

Rats	9	O
excreted	0	O
acidic	0	O
urine	9	O
when	5	O
they	5	O
were	9	O
spared	5	O
from	9	O
renal	9	B-Disease
lesions	5	I-Disease
by	9	O
monosaccharides	0	B-Chemical
.	9	O

The	5	O
reduction	9	O
effect	9	O
of	5	O
D	9	B-Chemical
-	7	I-Chemical
glucarates	_	I-Chemical
against	9	O
nephrotoxicity	9	B-Disease
of	5	O
basic	5	O
antibiotics	5	O
was	9	O
discussed	5	O
.	9	O

Acute	5	O
severe	5	O
depression	5	B-Disease
following	9	O
peri	5	O
-	7	O
operative	5	O
ondansetron	0	B-Chemical
.	9	O

A	9	O
41	7	O
-	7	O
year	5	O
-	7	O
old	5	O
woman	5	O
with	5	O
a	5	O
strong	9	O
history	5	O
of	5	O
postoperative	5	B-Disease
nausea	5	I-Disease
and	5	I-Disease
vomiting	5	I-Disease
presented	5	O
for	5	O
abdominal	5	O
hysterectomy	5	O
3	9	O
months	5	O
after	9	O
a	5	O
previous	9	O
anaesthetic	5	O
where	5	O
ondansetron	0	B-Chemical
prophylaxis	5	O
had	9	O
been	9	O
used	5	O
.	9	O

She	5	O
had	9	O
developed	5	O
a	5	O
severe	5	O
acute	9	O
major	9	B-Disease
depression	5	I-Disease
disorder	5	I-Disease
almost	9	O
immediately	9	O
thereafter	9	O
,	9	O
possibly	9	O
related	9	O
to	5	O
the	5	O
use	5	O
of	5	O
a	5	O
serotonin	9	B-Chemical
antagonist	3	O
.	9	O

Nine	9	O
years	5	O
before	9	O
she	5	O
had	9	O
experienced	5	O
a	5	O
self	5	O
-	7	O
limited	5	O
puerperal	5	O
depressive	5	B-Disease
episode	5	I-Disease
.	9	O

Anaesthesia	2	O
with	5	O
a	5	O
propofol	0	B-Chemical
infusion	0	O
and	5	O
avoidance	5	O
of	5	O
serotonin	9	B-Chemical
antagonists	3	O
provided	9	O
a	5	O
nausea	5	B-Disease
-	7	O
free	9	O
postoperative	5	O
course	5	O
without	9	O
exacerbation	5	O
of	5	O
the	5	O
depression	5	B-Disease
disorder	5	I-Disease
.	9	O

Hypertensive	7	B-Disease
response	9	O
during	5	O
dobutamine	5	B-Chemical
stress	9	O
echocardiography	5	O
.	9	O

Among	9	O
3	9	O
,	9	O
129	9	O
dobutamine	5	B-Chemical
stress	9	O
echocardiographic	5	O
studies	9	O
,	9	O
a	5	O
hypertensive	5	B-Disease
response	9	O
,	9	O
defined	5	O
as	5	O
systolic	5	O
blood	9	O
pressure	5	O
(	9	O
BP	9	O
)	9	O
>	0	O
or	5	O
=	7	O
220	9	O
mm	9	O
Hg	0	O
and	5	O
/	9	O
or	5	O
diastolic	5	O
BP	9	O
>	0	O
or	5	O
=	7	O
110	9	O
mm	9	O
Hg	0	O
,	9	O
occurred	9	O
in	5	O
30	9	O
patients	5	O
(	9	O
1	9	O
%	9	O
)	9	O
.	9	O

Patients	5	O
with	5	O
this	5	O
response	9	O
more	5	O
often	5	O
had	9	O
a	5	O
history	5	O
of	5	O
hypertension	5	B-Disease
and	5	O
had	9	O
higher	9	O
resting	5	O
systolic	5	O
and	5	O
diastolic	5	O
BP	9	O
before	9	O
dobutamine	5	B-Chemical
infusion	0	O
.	9	O

Continuously	5	O
nebulized	0	O
albuterol	5	B-Chemical
in	5	O
severe	5	O
exacerbations	5	O
of	5	O
asthma	5	B-Disease
in	5	O
adults	5	O
:	9	O
a	5	O
case	5	O
-	7	O
controlled	5	O
study	9	O
.	9	O

A	9	O
retrospective	5	O
,	9	O
case	5	O
-	7	O
controlled	5	O
analysis	9	O
comparing	9	O
patients	5	O
admitted	5	O
to	5	O
a	5	O
medical	5	O
intensive	5	O
care	5	O
unit	5	O
with	5	O
severe	5	O
exacerbations	5	O
of	5	O
asthma	5	B-Disease
who	5	O
received	9	O
continuously	5	O
nebulized	0	O
albuterol	5	B-Chemical
(	9	O
CNA	9	O
)	9	O
versus	9	O
intermittent	5	O
albuterol	5	B-Chemical
(	9	O
INA	0	O
)	9	O
treatments	9	O
is	5	O
reported	9	O
.	9	O

Forty	9	O
matched	9	O
pairs	9	O
of	5	O
patients	5	O
with	5	O
asthma	5	B-Disease
are	5	O
compared	9	O
.	9	O

CNA	9	O
was	9	O
administered	9	O
for	5	O
a	5	O
mean	5	O
of	5	O
11	7	O
+	9	O
/	9	O
-	7	O
10	9	O
hr	0	O
.	9	O

The	5	O
incidence	5	O
of	5	O
cardiac	5	B-Disease
dysrhythmias	5	I-Disease
was	9	O
similar	9	O
between	5	O
groups	9	O
.	9	O

Symptomatic	5	O
hypokalemia	5	B-Disease
did	9	O
not	5	O
occur	5	O
.	9	O

CNA	9	O
patients	5	O
had	9	O
higher	9	O
heart	5	O
rates	5	O
during	5	O
treatment	9	O
,	9	O
which	5	O
may	5	O
reflect	5	O
severity	5	O
of	5	O
illness	5	O
.	9	O

The	5	O
incidence	5	O
of	5	O
intubation	5	O
was	9	O
similar	9	O
.	9	O

We	9	O
conclude	9	O
that	5	O
CNA	9	O
and	5	O
INA	0	O
demonstrated	9	O
similar	9	O
profiles	9	O
with	5	O
regard	5	O
to	5	O
safety	5	O
,	9	O
morbidity	5	O
,	9	O
and	5	O
mortality	5	O
.	9	O

Paraplegia	7	B-Disease
following	9	O
intrathecal	3	O
methotrexate	9	B-Chemical
:	9	O
report	5	O
of	5	O
a	5	O
case	5	O
and	5	O
review	5	O
of	5	O
the	5	O
literature	5	O
.	9	O

A	9	O
patient	5	O
who	5	O
developed	5	O
paraplegia	5	B-Disease
following	9	O
the	5	O
intrathecal	3	O
instillation	0	O
of	5	O
methotrexate	9	B-Chemical
is	5	O
discribed	9	O
.	9	O

The	5	O
ten	9	O
previously	9	O
reported	9	O
cases	5	O
of	5	O
this	5	O
unusual	9	O
complication	5	O
are	5	O
reviewed	9	O
.	9	O

The	5	O
following	9	O
factors	9	O
appear	9	O
to	5	O
predispose	5	O
to	5	O
the	5	O
development	9	O
of	5	O
this	5	O
complication	5	O
:	9	O
abnormal	9	O
cerebrospinal	9	O
dynamics	5	O
related	9	O
to	5	O
the	5	O
presence	9	O
of	5	O
central	5	B-Disease
nervous	5	I-Disease
system	5	I-Disease
leukemia	3	I-Disease
,	9	O
and	5	O
epidural	5	O
cerebrospinal	9	O
leakage	9	O
;	9	O
elevated	9	O
cerebrospinal	9	O
fluid	5	O
methothexate	_	B-Chemical
concentration	0	O
related	9	O
to	5	O
abnormal	9	O
cerebrospinal	9	O
fluid	5	O
dynamics	5	O
and	5	O
to	5	O
inappropriately	5	O
high	9	O
methotrexate	9	B-Chemical
doses	0	O
based	5	O
on	5	O
body	5	O
surface	9	O
area	5	O
calculations	5	O
in	5	O
older	5	O
children	5	O
and	5	O
adults	5	O
;	9	O
the	5	O
presence	9	O
of	5	O
neurotoxic	9	B-Disease
preservatives	0	O
in	5	O
commercially	0	O
available	5	O
methotrexate	9	B-Chemical
preparations	9	O
and	5	O
diluents	0	O
;	9	O
and	5	O
the	5	O
use	5	O
of	5	O
methotrexate	9	B-Chemical
diluents	0	O
of	5	O
unphysiologic	5	O
pH	0	O
,	9	O
ionic	0	O
content	9	O
and	5	O
osmolarity	0	O
.	9	O

The	5	O
role	9	O
of	5	O
methotrexate	9	B-Chemical
contaminants	9	O
,	9	O
local	5	O
folate	9	B-Disease
deficiency	9	I-Disease
,	9	O
and	5	O
cranial	5	O
irradiation	9	O
in	5	O
the	5	O
pathogenesis	9	O
of	5	O
intrathecal	3	O
methotrexate	9	B-Chemical
toxicity	9	B-Disease
is	5	O
unclear	9	O
.	9	O

The	5	O
incidence	5	O
of	5	O
neurotoxicity	9	B-Disease
may	5	O
be	5	O
reduced	9	O
by	9	O
employing	9	O
lower	9	O
doses	0	O
of	5	O
methotrexate	9	B-Chemical
in	5	O
the	5	O
presence	9	O
of	5	O
central	5	B-Disease
nervous	5	I-Disease
system	5	I-Disease
leukemia	3	I-Disease
,	9	O
in	5	O
older	5	O
children	5	O
and	5	O
adults	5	O
,	9	O
and	5	O
in	5	O
the	5	O
presence	9	O
of	5	O
epidural	5	O
leakage	9	O
.	9	O

Only	9	O
preservative	0	O
-	7	O
free	9	O
methotrexate	9	B-Chemical
in	5	O
Elliott	6	O
'	9	O
s	9	O
B	9	O
Solution	0	O
at	9	O
a	5	O
concentration	0	O
of	5	O
not	5	O
more	5	O
than	5	O
1	9	O
mg	0	O
/	9	O
ml	0	O
should	5	O
be	5	O
used	5	O
for	5	O
intrathecal	3	O
administration	9	O
.	9	O

Periodic	5	O
monitoring	5	O
of	5	O
cerebruspinal	_	O
fluid	5	O
methotrexate	9	B-Chemical
levels	3	O
may	5	O
be	5	O
predictive	5	O
of	5	O
the	5	O
development	9	O
of	5	O
serious	5	O
neurotoxicity	9	B-Disease
.	9	O

Hyperosmolar	0	B-Disease
nonketotic	5	I-Disease
coma	5	I-Disease
precipitated	0	O
by	9	O
lithium	0	B-Chemical
-	7	O
induced	3	O
nephrogenic	5	B-Disease
diabetes	5	I-Disease
insipidus	5	I-Disease
.	9	O

A	9	O
45	9	O
-	7	O
year	5	O
-	7	O
old	5	O
man	5	O
,	9	O
with	5	O
a	5	O
10	9	O
-	7	O
year	5	O
history	5	O
of	5	O
manic	5	B-Disease
depression	5	I-Disease
treated	3	O
with	5	O
lithium	0	B-Chemical
,	9	O
was	9	O
admitted	5	O
with	5	O
hyperosmolar	5	B-Disease
,	9	I-Disease
nonketotic	5	I-Disease
coma	5	I-Disease
.	9	O

He	5	O
gave	9	O
a	5	O
five	9	O
-	7	O
year	5	O
history	5	O
of	5	O
polyuria	5	B-Disease
and	5	O
polydipsia	5	B-Disease
,	9	O
during	5	O
which	5	O
time	5	O
urinalysis	5	O
had	9	O
been	9	O
negative	9	O
for	5	O
glucose	0	B-Chemical
.	9	O

After	9	O
recovery	9	O
from	9	O
hyperglycaemia	5	B-Disease
,	9	O
he	5	O
remained	9	O
polyuric	5	B-Disease
despite	9	O
normal	9	O
blood	9	O
glucose	0	B-Chemical
concentrations	0	O
;	9	O
water	0	O
deprivation	9	O
testing	5	O
indicated	9	O
nephrogenic	5	B-Disease
diabetes	5	I-Disease
insipidus	5	I-Disease
,	9	O
likely	5	O
to	5	O
be	5	O
lithium	0	B-Chemical
-	7	O
induced	3	O
.	9	O

We	9	O
hypothesize	9	O
that	5	O
when	5	O
this	5	O
man	5	O
developed	5	O
type	9	B-Disease
2	9	I-Disease
diabetes	5	I-Disease
,	9	O
chronic	5	O
polyuria	5	B-Disease
due	5	O
to	5	O
nephrogenic	5	B-Disease
diabetes	5	I-Disease
insipidus	5	I-Disease
was	9	O
sufficient	9	O
to	5	O
precipitate	0	O
hyperosmolar	5	O
dehydration	9	B-Disease
.	9	O

Effects	9	O
of	5	O
the	5	O
intracoronary	5	O
infusion	0	O
of	5	O
cocaine	5	B-Chemical
on	5	O
left	5	O
ventricular	5	O
systolic	5	O
and	5	O
diastolic	5	O
function	9	O
in	5	O
humans	9	O
.	9	O

BACKGROUND	2	O
:	9	O
In	9	O
dogs	5	O
,	9	O
a	5	O
large	5	O
amount	9	O
of	5	O
intravenous	0	O
cocaine	5	B-Chemical
causes	9	O
a	5	O
profound	9	O
deterioration	5	B-Disease
of	5	I-Disease
left	5	I-Disease
ventricular	5	I-Disease
(	9	I-Disease
LV	9	I-Disease
)	9	I-Disease
systolic	5	I-Disease
function	9	I-Disease
and	5	O
an	5	O
increase	9	O
in	5	O
LV	9	O
end	9	O
-	7	O
diastolic	5	O
pressure	5	O
.	9	O

This	5	O
study	9	O
was	9	O
done	9	O
to	5	O
assess	5	O
the	5	O
influence	5	O
of	5	O
a	5	O
high	9	O
intracoronary	5	O
cocaine	5	B-Chemical
concentration	0	O
on	5	O
LV	9	O
systolic	5	O
and	5	O
diastolic	5	O
function	9	O
in	5	O
humans	9	O
.	9	O

METHODS	2	O
AND	2	O
RESULTS	9	O
:	9	O
In	9	O
20	9	O
patients	5	O
(	9	O
14	7	O
men	5	O
and	5	O
6	9	O
women	5	O
aged	9	O
39	7	O
to	5	O
72	9	O
years	5	O
)	9	O
referred	5	O
for	5	O
cardiac	5	O
catheterization	5	O
for	5	O
the	5	O
evaluation	5	O
of	5	O
chest	5	B-Disease
pain	5	I-Disease
,	9	O
we	5	O
measured	9	O
heart	5	O
rate	9	O
,	9	O
systemic	9	O
arterial	5	O
pressure	5	O
,	9	O
LV	9	O
pressure	5	O
and	5	O
its	9	O
first	9	O
derivative	0	O
(	9	O
dP	5	O
/	9	O
dt	9	O
)	9	O
,	9	O
and	5	O
LV	9	O
volumes	5	O
and	5	O
ejection	5	O
fraction	9	O
before	9	O
and	5	O
during	5	O
the	5	O
final	9	O
2	9	O
to	5	O
3	9	O
minutes	0	O
of	5	O
a	5	O
15	9	O
-	7	O
minute	5	O
intracoronary	5	O
infusion	0	O
of	5	O
saline	0	O
(	9	O
n	9	O
=	7	O
10	9	O
,	9	O
control	9	O
subjects	5	O
)	9	O
or	5	O
cocaine	5	B-Chemical
hydrochloride	0	I-Chemical
1	9	O
mg	0	O
/	9	O
min	0	O
(	9	O
n	9	O
=	7	O
10	9	O
)	9	O
.	9	O

No	9	O
variable	5	O
changed	9	O
with	5	O
saline	0	O
.	9	O

With	5	O
cocaine	5	B-Chemical
,	9	O
the	5	O
drug	5	O
concentration	0	O
in	5	O
blood	9	O
obtained	9	O
from	9	O
the	5	O
coronary	5	O
sinus	5	O
was	9	O
3	9	O
.	9	O
0	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
4	9	O
(	9	O
mean	5	O
+	9	O
/	9	O
-	7	O
SD	7	O
)	9	O
mg	0	O
/	9	O
L	0	O
,	9	O
similar	9	O
in	5	O
magnitude	5	O
to	5	O
the	5	O
blood	9	O
cocaine	5	B-Chemical
concentration	0	O
reported	9	O
in	5	O
abusers	5	O
dying	5	O
of	5	O
cocaine	5	B-Chemical
intoxication	9	O
.	9	O

Cocaine	5	B-Chemical
induced	3	O
no	9	O
significant	9	O
change	9	O
in	5	O
heart	5	O
rate	9	O
,	9	O
LV	9	O
dP	5	O
/	9	O
dt	9	O
(	9	O
positive	9	O
or	5	O
negative	9	O
)	9	O
,	9	O
or	5	O
LV	9	O
end	9	O
-	7	O
diastolic	5	O
volume	9	O
,	9	O
but	9	O
it	5	O
caused	9	O
an	5	O
increase	9	O
in	5	O
systolic	5	O
and	5	O
mean	5	O
arterial	5	O
pressures	5	O
,	9	O
LV	9	O
end	9	O
-	7	O
diastolic	5	O
pressure	5	O
,	9	O
and	5	O
LV	9	O
end	9	O
-	7	O
systolic	5	O
volume	9	O
,	9	O
as	5	O
well	9	O
as	5	O
a	5	O
decrease	9	O
in	5	O
LV	9	O
ejection	5	O
fraction	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
In	9	O
humans	9	O
,	9	O
the	5	O
intracoronary	5	O
infusion	0	O
of	5	O
cocaine	5	B-Chemical
sufficient	9	O
in	5	O
amount	9	O
to	5	O
achieve	5	O
a	5	O
high	9	O
drug	5	O
concentration	0	O
in	5	O
coronary	5	O
sinus	5	O
blood	9	O
causes	9	O
a	5	O
deterioration	5	B-Disease
of	5	I-Disease
LV	9	I-Disease
systolic	5	I-Disease
and	5	I-Disease
diastolic	5	I-Disease
performance	5	I-Disease
.	9	O

Ascending	5	O
dose	9	O
tolerance	9	O
study	9	O
of	5	O
intramuscular	9	O
carbetocin	5	B-Chemical
administered	9	O
after	9	O
normal	9	O
vaginal	9	O
birth	5	O
.	9	O

OBJECTIVE	2	O
:	9	O
To	9	O
determine	9	O
the	5	O
maximum	5	O
tolerated	9	O
dose	9	O
(	9	O
MTD	9	O
)	9	O
of	5	O
carbetocin	5	B-Chemical
(	9	O
a	5	O
long	5	O
-	7	O
acting	9	O
synthetic	0	O
analogue	0	O
of	5	O
oxytocin	5	B-Chemical
)	9	O
,	9	O
when	5	O
administered	9	O
immediately	9	O
after	9	O
vaginal	9	O
delivery	5	O
at	9	O
term	5	O
.	9	O

MATERIALS	2	O
AND	2	O
METHODS	2	O
:	9	O
Carbetocin	7	B-Chemical
was	9	O
given	5	O
as	5	O
an	5	O
intramuscular	9	O
injection	9	O
immediately	9	O
after	9	O
the	5	O
birth	5	O
of	5	O
the	5	O
infant	5	O
in	5	O
45	9	O
healthy	5	O
women	5	O
with	5	O
normal	9	O
singleton	5	O
pregnancies	5	O
who	5	O
delivered	5	O
vaginally	5	O
at	9	O
term	5	O
.	9	O

Dosage	0	O
groups	9	O
of	5	O
15	9	O
,	9	O
30	9	O
,	9	O
50	0	O
,	9	O
75	9	O
,	9	O
100	0	O
,	9	O
125	9	O
,	9	O
150	0	O
,	9	O
175	7	O
or	5	O
200	0	O
microg	0	O
carbetocin	5	B-Chemical
were	9	O
assigned	5	O
to	5	O
blocks	9	O
of	5	O
three	9	O
women	5	O
according	9	O
to	5	O
the	5	O
continual	5	O
reassessment	5	O
method	5	O
(	9	O
CRM	9	O
)	9	O
.	9	O

RESULTS	9	O
:	9	O
All	9	O
dosage	9	O
groups	9	O
consisted	5	O
of	5	O
three	9	O
women	5	O
,	9	O
except	9	O
those	5	O
with	5	O
100	0	O
microg	0	O
(	9	O
n	9	O
=	7	O
6	9	O
)	9	O
and	5	O
200	0	O
microg	0	O
(	9	O
n	9	O
=	7	O
18	7	O
)	9	O
.	9	O

Recorded	5	O
were	9	O
dose	9	O
-	7	O
limiting	9	O
adverse	5	O
events	5	O
:	9	O
hyper	5	B-Disease
-	7	I-Disease
or	5	I-Disease
hypotension	5	I-Disease
(	9	O
three	9	O
)	9	O
,	9	O
severe	5	O
abdominal	5	B-Disease
pain	5	I-Disease
(	9	O
0	7	O
)	9	O
,	9	O
vomiting	5	B-Disease
(	9	O
0	7	O
)	9	O
and	5	O
retained	9	B-Disease
placenta	9	I-Disease
(	9	O
four	9	O
)	9	O
.	9	O

Serious	5	O
adverse	5	O
events	5	O
occurred	9	O
in	5	O
seven	9	O
women	5	O
:	9	O
six	9	O
cases	5	O
with	5	O
blood	9	B-Disease
loss	9	I-Disease
>	0	O
or	5	O
=	7	O
1000	9	O
ml	0	O
,	9	O
four	9	O
cases	5	O
of	5	O
manual	5	O
placenta	9	O
removal	9	O
,	9	O
five	9	O
cases	5	O
of	5	O
additional	9	O
oxytocics	5	O
administration	9	O
and	5	O
five	9	O
cases	5	O
of	5	O
blood	9	O
transfusion	5	O
.	9	O

Maximum	9	O
blood	9	B-Disease
loss	9	I-Disease
was	9	O
greatest	9	O
at	9	O
the	5	O
upper	9	O
and	5	O
lower	9	O
dose	9	O
levels	3	O
,	9	O
and	5	O
lowest	9	O
in	5	O
the	5	O
70	9	O
-	7	O
125	9	O
microg	0	O
dose	9	O
range	9	O
.	9	O

Four	9	O
out	9	O
of	5	O
six	9	O
cases	5	O
with	5	O
blood	9	B-Disease
loss	9	I-Disease
>	0	O
or	5	O
=	7	O
1000	9	O
ml	0	O
occurred	9	O
in	5	O
the	5	O
200	0	O
microg	0	O
group	9	O
.	9	O

The	5	O
majority	9	O
of	5	O
additional	9	O
administration	9	O
of	5	O
oxytocics	5	O
(	9	O
4	9	O
/	9	O
5	9	O
)	9	O
and	5	O
blood	9	O
transfusion	5	O
(	9	O
3	9	O
/	9	O
5	9	O
)	9	O
occurred	9	O
in	5	O
the	5	O
dose	9	O
groups	9	O
of	5	O
200	0	O
microg	0	O
.	9	O

All	9	O
retained	9	O
placentae	9	O
were	9	O
found	9	O
in	5	O
the	5	O
group	9	O
of	5	O
200	0	O
microg	0	O
.	9	O

CONCLUSION	5	O
:	9	O
The	5	O
MTD	9	O
was	9	O
calculated	5	O
to	5	O
be	5	O
at	9	O
200	0	O
microg	0	O
carbetocin	5	B-Chemical
.	9	O

Heparin	0	B-Chemical
-	7	O
induced	3	O
thrombocytopenia	9	B-Disease
,	9	O
paradoxical	5	O
thromboembolism	5	B-Disease
,	9	O
and	5	O
other	5	O
side	5	O
effects	9	O
of	5	O
heparin	0	B-Chemical
therapy	5	O
.	9	O

Although	9	O
several	9	O
new	5	O
anticoagulant	9	O
drugs	5	O
are	5	O
in	5	O
development	9	O
,	9	O
heparin	0	B-Chemical
remains	9	O
the	5	O
drug	5	O
of	5	O
choice	5	O
for	5	O
most	9	O
anticoagulation	5	O
needs	5	O
.	9	O

The	5	O
clinical	5	O
effects	9	O
of	5	O
heparin	0	B-Chemical
are	5	O
meritorious	5	O
,	9	O
but	9	O
side	5	O
effects	9	O
do	5	O
exist	9	O
.	9	O

Important	5	O
untoward	5	O
effects	9	O
of	5	O
heparin	0	B-Chemical
therapy	5	O
including	9	O
heparin	0	B-Chemical
-	7	O
induced	3	O
thrombocytopenia	9	B-Disease
,	9	O
heparin	0	B-Chemical
-	7	O
associated	9	O
osteoporosis	5	B-Disease
,	9	O
eosinophilia	3	B-Disease
,	9	O
skin	5	B-Disease
reactions	9	I-Disease
,	9	O
allergic	9	B-Disease
reactions	9	I-Disease
other	5	O
than	5	O
thrombocytopenia	9	B-Disease
and	5	O
alopecia	5	B-Disease
will	5	O
be	5	O
discussed	5	O
in	5	O
this	5	O
article	6	O
.	9	O

Nonopaque	_	O
crystal	0	O
deposition	9	O
causing	9	O
ureteric	5	B-Disease
obstruction	5	I-Disease
in	5	O
patients	5	O
with	5	O
HIV	5	O
undergoing	9	O
indinavir	0	B-Chemical
therapy	5	O
.	9	O

OBJECTIVE	2	O
:	9	O
We	9	O
describe	5	O
the	5	O
unique	9	O
CT	9	O
features	5	O
of	5	O
ureteric	5	B-Disease
calculi	5	I-Disease
in	5	O
six	9	O
HIV	5	B-Disease
-	7	I-Disease
infected	3	I-Disease
patients	5	O
receiving	9	O
indinavir	0	B-Chemical
,	9	O
the	5	O
most	9	O
commonly	5	O
used	5	O
HIV	5	O
protease	0	O
inhibitor	3	O
,	9	O
which	5	O
is	5	O
associated	9	O
with	5	O
an	5	O
increased	9	O
incidence	5	O
of	5	O
urolithiasis	5	B-Disease
.	9	O

CONCLUSION	5	O
:	9	O
Ureteric	5	B-Disease
obstruction	5	I-Disease
caused	9	O
by	9	O
precipitated	0	O
indinavir	0	B-Chemical
crystals	0	O
may	5	O
be	5	O
difficult	5	O
to	5	O
diagnose	5	O
with	5	O
unenhanced	5	O
CT	9	O
.	9	O

The	5	O
calculi	5	O
are	5	O
not	5	O
opaque	9	O
,	9	O
and	5	O
secondary	9	O
signs	5	O
of	5	O
obstruction	5	O
may	5	O
be	5	O
absent	9	O
or	5	O
minimal	9	O
and	5	O
should	5	O
be	5	O
sought	9	O
carefully	5	O
.	9	O

Images	9	O
may	5	O
need	5	O
to	5	O
be	5	O
obtained	9	O
using	9	O
i	9	O
.	9	O
v	0	O
.	9	O
contrast	9	O
material	5	O
to	5	O
enable	5	O
diagnosis	5	O
of	5	O
ureteric	5	B-Disease
stones	5	I-Disease
or	5	I-Disease
obstruction	5	I-Disease
in	5	O
patients	5	O
with	5	O
HIV	5	B-Disease
infection	9	I-Disease
who	5	O
receive	5	O
indinavir	0	B-Chemical
therapy	5	O
.	9	O

Ischemic	9	B-Disease
colitis	3	I-Disease
and	5	O
sumatriptan	0	B-Chemical
use	5	O
.	9	O

Sumatriptan	0	B-Chemical
succinate	0	I-Chemical
,	9	O
a	5	O
serotonin	9	B-Chemical
-	7	O
1	9	O
(	9	O
5	9	B-Chemical
-	7	I-Chemical
hydroxytryptamine	0	I-Chemical
-	7	O
1	9	O
)	9	O
receptor	3	O
agonist	3	O
,	9	O
is	5	O
an	5	O
antimigraine	5	O
drug	5	O
that	5	O
is	5	O
reported	9	O
to	5	O
act	9	O
by	9	O
selectively	3	O
constricting	5	O
intracranial	5	O
arteries	5	O
.	9	O

Recently	9	O
,	9	O
vasopressor	5	O
responses	5	O
that	5	O
are	5	O
distinct	9	O
from	9	O
the	5	O
cranial	5	O
circulation	9	O
have	5	O
been	9	O
demonstrated	9	O
to	5	O
occur	5	O
in	5	O
the	5	O
systemic	9	O
,	9	O
pulmonary	5	O
,	9	O
and	5	O
coronary	5	O
circulations	5	O
.	9	O

Cases	9	O
have	5	O
been	9	O
published	9	O
of	5	O
coronary	5	B-Disease
vasospasm	5	I-Disease
,	9	O
myocardial	9	B-Disease
ischemia	9	I-Disease
,	9	O
and	5	O
myocardial	9	B-Disease
infarction	5	I-Disease
occurring	9	O
after	9	O
sumatriptan	0	B-Chemical
use	5	O
.	9	O

We	9	O
report	5	O
on	5	O
the	5	O
development	9	O
of	5	O
8	9	O
serious	5	O
cases	5	O
of	5	O
ischemic	9	B-Disease
colitis	3	I-Disease
in	5	O
patients	5	O
with	5	O
migraine	5	B-Disease
treated	3	O
with	5	O
sumatriptan	0	B-Chemical
.	9	O

Pallidotomy	9	O
with	5	O
the	5	O
gamma	9	O
knife	5	O
:	9	O
a	5	O
positive	9	O
experience	5	O
.	9	O

51	7	O
patients	5	O
with	5	O
medically	5	O
refractory	9	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
underwent	5	O
stereotactic	5	O
posteromedial	5	O
pallidotomy	5	O
between	5	O
August	2	O
1993	2	O
and	5	O
February	2	O
1997	2	O
for	5	O
treatment	9	O
of	5	O
bradykinesia	5	B-Disease
,	9	O
rigidity	5	B-Disease
,	9	O
and	5	O
L	0	B-Chemical
-	7	I-Chemical
DOPA	0	I-Chemical
-	7	O
induced	3	O
dyskinesias	5	B-Disease
.	9	O

In	9	O
29	7	O
patients	5	O
,	9	O
the	5	O
pallidotomies	9	O
were	9	O
performed	9	O
with	5	O
the	5	O
Leksell	5	O
Gamma	9	O
Knife	5	O
and	5	O
in	5	O
22	7	O
they	5	O
were	9	O
performed	9	O
with	5	O
the	5	O
standard	5	O
radiofrequency	5	O
(	9	O
RF	5	O
)	9	O
method	5	O
.	9	O

Clinical	5	O
assessment	5	O
as	5	O
well	9	O
as	5	O
blinded	5	O
ratings	5	O
of	5	O
Unified	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
Disease	2	I-Disease
Rating	5	O
Scale	5	O
(	9	O
UPDRS	5	O
)	9	O
scores	5	O
were	9	O
carried	9	O
out	9	O
pre	9	O
-	7	O
and	5	O
postoperatively	5	O
.	9	O

Mean	9	O
follow	5	O
-	7	O
up	5	O
time	5	O
is	5	O
20	9	O
.	9	O
6	9	O
months	5	O
(	9	O
range	9	O
6	9	O
-	7	O
48	9	O
)	9	O
and	5	O
all	5	O
except	9	O
4	9	O
patients	5	O
have	5	O
been	9	O
followed	9	O
more	5	O
than	5	O
one	5	O
year	5	O
.	9	O

85	9	O
percent	5	O
of	5	O
patients	5	O
with	5	O
dyskinesias	5	B-Disease
were	9	O
relieved	5	O
of	5	O
symptoms	5	O
,	9	O
regardless	9	O
of	5	O
whether	9	O
the	5	O
pallidotomies	9	O
were	9	O
performed	9	O
with	5	O
the	5	O
Gamma	9	O
Knife	5	O
or	5	O
radiofrequency	5	O
methods	5	O
.	9	O

About	9	O
2	9	O
/	9	O
3	9	O
of	5	O
the	5	O
patients	5	O
in	5	O
both	9	O
Gamma	9	O
Knife	5	O
and	5	O
radiofrequency	5	O
groups	9	O
showed	9	O
improvements	5	O
in	5	O
bradykinesia	5	B-Disease
and	5	O
rigidity	5	B-Disease
,	9	O
although	9	O
when	5	O
considered	5	O
as	5	O
a	5	O
group	9	O
neither	9	O
the	5	O
Gamma	9	O
Knife	5	O
nor	9	O
the	5	O
radiofrequency	5	O
group	9	O
showed	9	O
statistically	9	O
significant	9	O
improvements	5	O
in	5	O
UPDRS	5	O
scores	5	O
.	9	O

One	5	O
patient	5	O
in	5	O
the	5	O
Gamma	9	O
Knife	5	O
group	9	O
(	9	O
3	9	O
.	9	O
4	9	O
%	9	O
)	9	O
developed	5	O
a	5	O
homonymous	5	B-Disease
hemianopsia	5	I-Disease
9	7	O
months	5	O
following	9	O
treatment	9	O
and	5	O
5	9	O
patients	5	O
(	9	O
27	7	O
.	9	O
7	9	O
%	9	O
)	9	O
in	5	O
the	5	O
radiofrequency	5	O
group	9	O
became	9	O
transiently	3	O
confused	4	O
postoperatively	5	O
.	9	O

No	9	O
other	5	O
complications	5	O
were	9	O
seen	9	O
.	9	O

Gamma	9	O
Knife	5	O
pallidotomy	5	O
is	5	O
as	5	O
effective	5	O
as	5	O
radiofrequency	5	O
pallidotomy	5	O
in	5	O
controlling	9	O
certain	5	O
of	5	O
the	5	O
symptoms	5	O
of	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
.	9	O

It	5	O
may	5	O
be	5	O
the	5	O
only	9	O
practical	5	O
technique	5	O
available	5	O
in	5	O
certain	5	O
patients	5	O
,	9	O
such	5	O
as	5	O
those	5	O
who	5	O
take	5	O
anticoagulants	5	O
,	9	O
have	5	O
bleeding	5	B-Disease
diatheses	5	O
or	5	O
serious	5	O
systemic	9	O
medical	5	O
illnesses	5	O
.	9	O

It	5	O
is	5	O
a	5	O
viable	9	O
option	5	O
for	5	O
other	5	O
patients	5	O
as	5	O
well	9	O
.	9	O

Centrally	5	O
mediated	3	O
cardiovascular	5	O
effects	9	O
of	5	O
intracisternal	0	O
application	5	O
of	5	O
carbachol	0	B-Chemical
in	5	O
anesthetized	0	O
rats	9	O
.	9	O

The	5	O
pressor	5	O
response	9	O
to	5	O
the	5	O
intracisternal	0	O
(	9	O
i	9	O
.	9	O
c	9	O
.	9	O
)	9	O
injection	9	O
of	5	O
carbachol	0	B-Chemical
(	9	O
1	9	O
mug	5	O
)	9	O
in	5	O
anesthetized	0	O
rats	9	O
was	9	O
analyzed	9	O
.	9	O

This	5	O
response	9	O
was	9	O
significantly	9	O
reduced	9	O
by	9	O
the	5	O
intravenous	0	O
(	9	O
i	9	O
.	9	O
v	0	O
.	9	O
)	9	O
injection	9	O
of	5	O
guanethidine	0	B-Chemical
(	9	O
5	9	O
mg	0	O
)	9	O
,	9	O
hexamethonium	0	B-Chemical
(	9	O
10	9	O
mg	0	O
)	9	O
or	5	O
phentolamine	0	B-Chemical
(	9	O
5	9	O
mg	0	O
)	9	O
,	9	O
and	5	O
conversely	9	O
,	9	O
potentiated	3	O
by	9	O
i	9	O
.	9	O
v	0	O
.	9	O
desmethylimipramine	0	B-Chemical
(	9	O
0	7	O
.	9	O
3	9	O
mg	0	O
)	9	O
,	9	O
while	9	O
propranolol	0	B-Chemical
(	9	O
0	7	O
.	9	O
5	9	O
mg	0	O
)	9	O
i	9	O
.	9	O
v	0	O
.	9	O
selectively	3	O
inhibited	3	O
the	5	O
enlargement	5	B-Disease
of	5	I-Disease
pulse	5	I-Disease
pressure	5	I-Disease
and	5	O
the	5	O
tachycardia	5	B-Disease
following	9	O
i	9	O
.	9	O
c	9	O
.	9	O
carbachol	0	B-Chemical
(	9	O
1	9	O
mug	5	O
)	9	O
.	9	O

On	5	O
the	5	O
other	5	O
hand	5	O
,	9	O
the	5	O
pressor	5	O
response	9	O
to	5	O
i	9	O
.	9	O
c	9	O
.	9	O
carbachol	0	B-Chemical
(	9	O
1	9	O
mug	5	O
)	9	O
was	9	O
almost	9	O
completely	9	O
blocked	3	O
by	9	O
i	9	O
.	9	O
c	9	O
.	9	O
atropine	0	B-Chemical
(	9	O
3	9	O
mug	5	O
)	9	O
or	5	O
hexamethonium	0	B-Chemical
(	9	O
500	0	O
mug	5	O
)	9	O
,	9	O
and	5	O
significantly	9	O
reduced	9	O
by	9	O
i	9	O
.	9	O
c	9	O
.	9	O
chlorpromazine	0	B-Chemical
(	9	O
50	0	O
mug	5	O
)	9	O
but	9	O
significantly	9	O
potentiated	3	O
by	9	O
i	9	O
.	9	O
c	9	O
.	9	O
desmethylimipramine	0	B-Chemical
(	9	O
30	9	O
mug	5	O
)	9	O
.	9	O

The	5	O
pressor	5	O
response	9	O
to	5	O
i	9	O
.	9	O
c	9	O
.	9	O
carbachol	0	B-Chemical
(	9	O
1	9	O
mug	5	O
)	9	O
remained	9	O
unchanged	9	O
after	9	O
sectioning	5	O
of	5	O
the	5	O
bilateral	5	O
cervical	5	O
vagal	5	O
nerves	5	O
but	9	O
disappeared	9	O
after	9	O
sectioning	5	O
of	5	O
the	5	O
spinal	5	O
cord	9	O
(	9	O
C7	8	O
-	7	O
C8	8	O
)	9	O
.	9	O

From	5	O
the	5	O
above	9	O
result	9	O
it	5	O
is	5	O
suggested	9	O
that	5	O
the	5	O
pressor	5	O
response	9	O
to	5	O
i	9	O
.	9	O
c	9	O
.	9	O
carbachol	0	B-Chemical
ortral	_	O
and	5	O
peripheral	9	O
adrenergic	9	O
mechanisms	9	O
,	9	O
and	5	O
that	5	O
the	5	O
sympathetic	5	O
trunk	5	O
is	5	O
the	5	O
main	5	O
pathway	3	O
.	9	O

Neuroleptic	2	B-Disease
malignant	3	I-Disease
syndrome	5	I-Disease
and	5	O
methylphenidate	5	B-Chemical
.	9	O

A	9	O
1	9	O
-	7	O
year	5	O
-	7	O
old	5	O
female	9	O
presented	5	O
with	5	O
neuroleptic	5	B-Disease
malignant	3	I-Disease
syndrome	5	I-Disease
probably	9	O
caused	9	O
by	9	O
methylphenidate	5	B-Chemical
.	9	O

She	5	O
had	9	O
defects	9	O
in	5	O
the	5	O
supratentorial	5	O
brain	5	O
including	9	O
the	5	O
basal	3	O
ganglia	5	O
and	5	O
the	5	O
striatum	9	O
(	9	O
multicystic	5	B-Disease
encephalomalacia	5	I-Disease
)	9	O
due	5	O
to	5	O
severe	5	O
perinatal	5	O
hypoxic	3	B-Disease
-	7	I-Disease
ischemic	9	I-Disease
encephalopathy	5	I-Disease
,	9	O
which	5	O
was	9	O
considered	5	O
to	5	O
be	5	O
a	5	O
possible	5	O
predisposing	5	O
factor	9	O
causing	9	O
neuroleptic	5	B-Disease
malignant	3	I-Disease
syndrome	5	I-Disease
.	9	O

A	9	O
dopaminergic	5	O
blockade	3	O
mechanism	9	O
generally	5	O
is	5	O
accepted	5	O
as	5	O
the	5	O
pathogenesis	9	O
of	5	O
this	5	O
syndrome	5	O
.	9	O

However	9	O
,	9	O
methylphenidate	5	B-Chemical
is	5	O
a	5	O
dopamine	5	B-Chemical
agonist	3	O
via	9	O
the	5	O
inhibition	3	O
of	5	O
uptake	0	O
of	5	O
dopamine	5	B-Chemical
,	9	O
and	5	O
therefore	5	O
dopaminergic	5	O
systems	5	O
in	5	O
the	5	O
brainstem	5	O
(	9	O
mainly	9	O
the	5	O
midbrain	9	O
)	9	O
and	5	O
the	5	O
spinal	5	O
cord	9	O
were	9	O
unlikely	9	O
to	5	O
participate	5	O
in	5	O
the	5	O
onset	5	O
of	5	O
this	5	O
syndrome	5	O
.	9	O

A	9	O
relative	9	O
gamma	9	B-Chemical
-	7	I-Chemical
aminobutyric	0	I-Chemical
acid	0	I-Chemical
-	7	O
ergic	0	O
deficiency	9	O
might	9	O
occur	5	O
because	5	O
diazepam	0	B-Chemical
,	9	O
a	5	O
gamma	9	B-Chemical
-	7	I-Chemical
aminobutyric	0	I-Chemical
acid	0	I-Chemical
-	7	O
mimetic	9	O
agent	9	O
,	9	O
was	9	O
strikingly	9	O
effective	5	O
.	9	O

This	5	O
is	5	O
the	5	O
first	9	O
reported	9	O
patient	5	O
with	5	O
neuroleptic	5	B-Disease
malignant	3	I-Disease
syndrome	5	I-Disease
probably	9	O
caused	9	O
by	9	O
methylphenidate	5	B-Chemical
.	9	O

Differential	9	O
effects	9	O
of	5	O
17alpha	0	B-Chemical
-	7	I-Chemical
ethinylestradiol	0	I-Chemical
on	5	O
the	5	O
neutral	5	O
and	5	O
acidic	0	O
pathways	9	O
of	5	O
bile	0	B-Chemical
salt	0	I-Chemical
synthesis	9	O
in	5	O
the	5	O
rat	3	O
.	9	O

Effects	9	O
of	5	O
17alpha	0	B-Chemical
-	7	I-Chemical
ethinylestradiol	0	I-Chemical
(	9	O
EE	9	B-Chemical
)	9	O
on	5	O
the	5	O
neutral	5	O
and	5	O
acidic	0	O
biosynthetic	9	O
pathways	9	O
of	5	O
bile	0	B-Chemical
salt	0	I-Chemical
(	9	O
BS	9	B-Chemical
)	9	O
synthesis	9	O
were	9	O
evaluated	9	O
in	5	O
rats	9	O
with	5	O
an	5	O
intact	9	O
enterohepatic	5	O
circulation	9	O
and	5	O
in	5	O
rats	9	O
with	5	O
long	5	O
-	7	O
term	5	O
bile	0	O
diversion	5	O
to	5	O
induce	3	O
BS	9	B-Chemical
synthesis	9	O
.	9	O

For	9	O
this	5	O
purpose	5	O
,	9	O
bile	0	B-Chemical
salt	0	I-Chemical
pool	9	O
composition	9	O
,	9	O
synthesis	9	O
of	5	O
individual	5	O
BS	9	B-Chemical
in	5	O
vivo	3	O
,	9	O
hepatic	9	O
activities	9	O
,	9	O
and	5	O
expression	3	O
levels	3	O
of	5	O
cholesterol	0	B-Chemical
7alpha	9	O
-	7	O
hydroxylase	1	O
(	9	O
CYP7A	1	O
)	9	O
,	9	O
and	5	O
sterol	0	B-Chemical
27	7	O
-	7	O
hydroxylase	1	O
(	9	O
CYP27	1	O
)	9	O
,	9	O
as	5	O
well	9	O
as	5	O
of	5	O
other	5	O
enzymes	1	O
involved	9	O
in	5	O
BS	9	B-Chemical
synthesis	9	O
,	9	O
were	9	O
analyzed	9	O
in	5	O
rats	9	O
treated	3	O
with	5	O
EE	9	B-Chemical
(	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
3	9	O
days	9	O
)	9	O
or	5	O
its	9	O
vehicle	3	O
.	9	O

BS	9	B-Chemical
pool	9	O
size	9	O
was	9	O
decreased	9	O
by	9	O
27	7	O
%	9	O
but	9	O
total	9	O
BS	9	B-Chemical
synthesis	9	O
was	9	O
not	5	O
affected	9	O
by	9	O
EE	9	B-Chemical
in	5	O
intact	9	O
rats	9	O
.	9	O

Synthesis	0	O
of	5	O
cholate	0	B-Chemical
was	9	O
reduced	9	O
by	9	O
68	7	O
%	9	O
in	5	O
EE	9	B-Chemical
-	7	O
treated	3	O
rats	9	O
,	9	O
while	9	O
that	5	O
of	5	O
chenodeoxycholate	0	B-Chemical
was	9	O
increased	9	O
by	9	O
60	9	O
%	9	O
.	9	O

The	5	O
recently	9	O
identified	9	O
Delta22	9	O
-	7	O
isomer	0	O
of	5	O
beta	9	O
-	7	O
muricholate	_	O
contributed	9	O
for	5	O
5	9	O
.	9	O
4	9	O
%	9	O
and	5	O
18	7	O
.	9	O
3	9	O
%	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
01	7	O
)	9	O
to	5	O
the	5	O
pool	9	O
in	5	O
control	9	O
and	5	O
EE	9	B-Chemical
-	7	O
treated	3	O
rats	9	O
,	9	O
respectively	9	O
,	9	O
but	9	O
could	9	O
not	5	O
be	5	O
detected	9	O
in	5	O
bile	0	O
after	9	O
exhaustion	9	O
of	5	O
the	5	O
pool	9	O
.	9	O

A	9	O
clear	9	O
reduction	9	O
of	5	O
BS	9	B-Chemical
synthesis	9	O
was	9	O
found	9	O
in	5	O
bile	0	O
-	7	O
diverted	5	O
rats	9	O
treated	3	O
with	5	O
EE	9	B-Chemical
,	9	O
yet	9	O
biliary	5	O
BS	9	B-Chemical
composition	9	O
was	9	O
only	9	O
minimally	5	O
affected	9	O
.	9	O

Activity	9	O
of	5	O
CYP7A	1	O
was	9	O
decreased	9	O
by	9	O
EE	9	B-Chemical
in	5	O
both	9	O
intact	9	O
and	5	O
bile	0	O
-	7	O
diverted	5	O
rats	9	O
,	9	O
whereas	9	O
the	5	O
activity	9	O
of	5	O
the	5	O
CYP27	1	O
was	9	O
not	5	O
affected	9	O
.	9	O

Hepatic	9	O
mRNA	3	O
levels	3	O
of	5	O
CYP7A	1	O
were	9	O
significantly	9	O
reduced	9	O
by	9	O
EE	9	B-Chemical
in	5	O
bile	0	O
-	7	O
diverted	5	O
rats	9	O
only	9	O
;	9	O
CYP27	1	O
mRNA	3	O
levels	3	O
were	9	O
not	5	O
affected	9	O
by	9	O
EE	9	B-Chemical
.	9	O

In	9	O
addition	9	O
,	9	O
mRNA	3	O
levels	3	O
of	5	O
sterol	0	B-Chemical
12alpha	_	O
-	7	O
hydroxylase	1	O
and	5	O
lithocholate	0	O
6beta	7	O
-	7	O
hydroxylase	1	O
were	9	O
increased	9	O
by	9	O
bile	0	O
diversion	5	O
and	5	O
suppressed	3	O
by	9	O
EE	9	B-Chemical
.	9	O

This	5	O
study	9	O
shows	9	O
that	5	O
17alpha	0	B-Chemical
-	7	I-Chemical
ethinylestradiol	0	I-Chemical
(	9	O
EE	9	B-Chemical
)	9	O
-	7	O
induced	3	O
intrahepatic	9	B-Disease
cholestasis	5	I-Disease
in	5	O
rats	9	O
is	5	O
associated	9	O
with	5	O
selective	9	O
inhibition	3	O
of	5	O
the	5	O
neutral	5	O
pathway	3	O
of	5	O
bile	0	B-Chemical
salt	0	I-Chemical
(	9	O
BS	9	B-Chemical
)	9	O
synthesis	9	O
.	9	O

Simultaneous	9	O
impairment	5	O
of	5	O
other	5	O
enzymes	1	O
in	5	O
the	5	O
BS	9	B-Chemical
biosynthetic	9	O
pathways	9	O
may	5	O
contribute	9	O
to	5	O
overall	5	O
effects	9	O
of	5	O
EE	9	B-Chemical
on	5	O
BS	9	B-Chemical
synthesis	9	O
.	9	O

Glibenclamide	0	B-Chemical
-	7	O
sensitive	9	O
hypotension	5	B-Disease
produced	9	O
by	9	O
helodermin	9	B-Chemical
assessed	9	O
in	5	O
the	5	O
rat	3	O
.	9	O

The	5	O
effects	9	O
of	5	O
helodermin	9	B-Chemical
,	9	O
a	5	O
basic	5	O
35	9	O
-	7	O
amino	1	B-Chemical
acid	0	I-Chemical
peptide	9	O
isolated	9	O
from	9	O
the	5	O
venom	4	O
of	5	O
a	5	O
lizard	4	O
salivary	9	O
gland	9	O
,	9	O
on	5	O
arterial	5	O
blood	9	O
pressure	5	O
and	5	O
heart	5	O
rate	9	O
were	9	O
examined	9	O
in	5	O
the	5	O
rat	3	O
,	9	O
focusing	5	O
on	5	O
the	5	O
possibility	9	O
that	5	O
activation	3	O
of	5	O
ATP	0	B-Chemical
sensitive	9	O
K	9	B-Chemical
+	9	O
(	9	O
K	9	B-Chemical
(	9	O
ATP	0	B-Chemical
)	9	O
)	9	O
channels	9	O
is	5	O
involved	9	O
in	5	O
the	5	O
responses	5	O
.	9	O

The	5	O
results	9	O
were	9	O
also	9	O
compared	9	O
with	5	O
those	5	O
of	5	O
vasoactive	5	O
intestinal	9	O
polypeptide	1	O
(	9	O
VIP	9	O
)	9	O
.	9	O

Helodermin	9	B-Chemical
produced	9	O
hypotension	5	B-Disease
in	5	O
a	5	O
dose	9	O
-	7	O
dependent	9	O
manner	9	O
with	5	O
approximately	9	O
similar	9	O
potency	9	O
and	5	O
duration	5	O
to	5	O
VIP	9	O
.	9	O

Hypotension	7	B-Disease
induced	3	O
by	9	O
both	9	O
peptides	9	O
was	9	O
significantly	9	O
attenuated	3	O
by	9	O
glibenclamide	0	B-Chemical
,	9	O
which	5	O
abolished	3	O
a	5	O
levcromakalim	0	B-Chemical
-	7	O
produced	9	O
decrease	9	O
in	5	O
arterial	5	O
blood	9	O
pressure	5	O
.	9	O

Oxyhemoglobin	0	O
did	9	O
not	5	O
affect	9	O
helodermin	9	B-Chemical
-	7	O
induced	3	O
hypotension	5	B-Disease
,	9	O
whereas	9	O
it	5	O
shortened	9	O
the	5	O
duration	5	O
of	5	O
acetylcholine	0	B-Chemical
(	9	O
ACh	0	B-Chemical
)	9	O
-	7	O
produced	9	O
hypotension	5	B-Disease
.	9	O

These	5	O
findings	9	O
suggest	9	O
that	5	O
helodermin	9	B-Chemical
-	7	O
produced	9	O
hypotension	5	B-Disease
is	5	O
partly	9	O
attributable	9	O
to	5	O
the	5	O
activation	3	O
of	5	O
glibenclamide	0	B-Chemical
-	7	O
sensitive	9	O
K	9	B-Chemical
+	9	O
channels	9	O
(	9	O
K	9	B-Chemical
(	9	O
ATP	0	B-Chemical
)	9	O
channels	9	O
)	9	O
,	9	O
which	5	O
presumably	9	O
exist	9	O
on	5	O
arterial	5	O
smooth	5	O
muscle	9	O
cells	3	O
.	9	O

EDRF	3	O
(	9	O
endothelium	3	O
-	7	O
derived	9	O
relaxing	5	O
factor	9	O
)	9	O
/	9	O
nitric	0	B-Chemical
oxide	0	I-Chemical
does	9	O
not	5	O
seem	5	O
to	5	O
play	9	O
an	5	O
important	9	O
role	9	O
in	5	O
the	5	O
peptide	9	O
-	7	O
produced	9	O
hypotension	5	B-Disease
.	9	O

Long	9	O
-	7	O
term	5	O
efficacy	9	O
and	5	O
adverse	5	O
event	5	O
of	5	O
nifedipine	0	B-Chemical
sustained	5	O
-	7	O
release	9	O
tablets	0	O
for	5	O
cyclosporin	0	B-Chemical
A	9	I-Chemical
-	7	O
induced	3	O
hypertension	5	B-Disease
in	5	O
patients	5	O
with	5	O
psoriasis	9	B-Disease
.	9	O

Thirteen	9	O
psoriatic	3	B-Disease
patients	5	O
with	5	O
hypertension	5	B-Disease
during	5	O
the	5	O
course	5	O
of	5	O
cyclosporin	0	B-Chemical
A	9	I-Chemical
therapy	5	O
were	9	O
treated	3	O
for	5	O
25	9	O
months	5	O
with	5	O
a	5	O
calcium	0	B-Chemical
channel	9	O
blocker	0	O
,	9	O
sustained	5	O
-	7	O
release	9	O
nifedipine	0	B-Chemical
,	9	O
to	5	O
study	9	O
the	5	O
clinical	5	O
antihypertensive	5	O
effects	9	O
and	5	O
adverse	5	O
events	5	O
during	5	O
treatment	9	O
with	5	O
both	9	O
drugs	5	O
.	9	O

Seven	9	O
of	5	O
the	5	O
13	7	O
patients	5	O
had	9	O
exhibited	9	O
a	5	O
subclinical	5	O
hypertensive	5	B-Disease
state	5	O
before	9	O
cyclosporin	0	B-Chemical
A	9	I-Chemical
therapy	5	O
.	9	O

Both	9	O
systolic	5	O
and	5	O
diastolic	5	O
blood	9	O
pressures	5	O
of	5	O
these	5	O
13	7	O
patients	5	O
were	9	O
decreased	9	O
significantly	9	O
after	9	O
4	9	O
weeks	9	O
of	5	O
nifedipine	0	B-Chemical
therapy	5	O
,	9	O
and	5	O
blood	9	O
pressure	5	O
was	9	O
maintained	9	O
within	9	O
the	5	O
normal	9	O
range	9	O
thereafter	9	O
for	5	O
25	9	O
months	5	O
.	9	O

The	5	O
adverse	5	O
events	5	O
during	5	O
combined	9	O
therapy	5	O
with	5	O
cyclosporin	0	B-Chemical
A	9	I-Chemical
and	5	O
nifedipine	0	B-Chemical
included	5	O
an	5	O
increase	9	O
in	5	O
blood	9	B-Chemical
urea	0	I-Chemical
nitrogen	0	I-Chemical
levels	3	O
in	5	O
9	7	O
of	5	O
the	5	O
13	7	O
patients	5	O
and	5	O
development	9	O
of	5	O
gingival	5	B-Disease
hyperplasia	9	I-Disease
in	5	O
2	9	O
of	5	O
the	5	O
13	7	O
patients	5	O
.	9	O

Our	9	O
findings	9	O
indicate	9	O
that	5	O
sustained	5	O
-	7	O
release	9	O
nifedipine	0	B-Chemical
is	5	O
useful	5	O
for	5	O
hypertensive	5	B-Disease
psoriatic	3	B-Disease
patients	5	O
under	9	O
long	5	O
-	7	O
term	5	O
treatment	9	O
with	5	O
cyclosporin	0	B-Chemical
A	9	I-Chemical
,	9	O
but	9	O
that	5	O
these	5	O
patients	5	O
should	5	O
be	5	O
monitored	9	O
for	5	O
gingival	5	B-Disease
hyperplasia	9	I-Disease
.	9	O

